5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Peripheral neuropathy,AdverseReaction
Monitor,O
patients,O
for,O
neuropathy,O
and,O
institute,O
dose,O
modifications,O
accordingly,O
5,O
1,O
Anaphylaxis,AdverseReaction
and,O
infusion reactions,AdverseReaction
If,O
an,O
infusion,O
reaction,O
occurs,O
interrupt,O
the,O
infusion,O
If,O
anaphylaxis,O
occurs,O
immediately,O
discontinue,O
the,O
infusion,O
5,O
2,O
Hematologic toxicities,AdverseReaction
Monitor,O
complete,O
blood,O
counts,O
prior,O
to,O
each,O
dose,O
of,O
ADCETRIS,O
Closely,O
monitor,O
patients,O
for,O
fever,O
If,O
Grade,O
3,O
or,O
4,O
neutropenia,O
develops,O
consider,O
dose,O
delays,O
reductions,O
discontinuation,O
or,O
G,O
CSF,O
prophylaxis,O
with,O
subsequent,O
doses,O
5,O
3,O
Serious,Severity
infections,AdverseReaction
and,O
opportunistic infections,AdverseReaction
Closely,O
monitor,O
patients,O
for,O
the,O
emergence,O
of,O
bacterial,O
fungal,O
or,O
viral,O
infections,O
5,O
4,O
Tumor lysis syndrome,AdverseReaction
Closely,O
monitor,O
patients,O
with,O
rapidly,O
proliferating,O
tumor,O
or,O
high,O
tumor,O
burden,O
5,O
5,O
Hepatotoxicity,AdverseReaction
Monitor,O
liver,O
enzymes,O
and,O
bilirubin,O
5,O
8,O
Pulmonary Toxicity,AdverseReaction
Monitor,O
patients,O
for,O
new,O
or,O
worsening,O
symptoms,O
5,O
10,O
Serious,Severity
dermatologic reactions,AdverseReaction
Discontinue,O
if,O
Stevens,O
Johnson,O
syndrome,O
or,O
toxic,O
epidermal,O
necrolysis,O
occurs,O
5,O
10,O
Embryo fetal toxicity,AdverseReaction
Fetal harm,AdverseReaction
can,Factor
occur,O
Advise,O
pregnant,O
women,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
5,O
12,O
5,O
1,O
Peripheral,O
Neuropathy,O
ADCETRIS,O
treatment,O
causes,O
a,O
peripheral neuropathy neuropathy,AdverseReaction
that,O
is,O
predominantly,O
sensory,AdverseReaction
Cases,O
of,O
peripheral motor neuropathy,AdverseReaction
have,O
also,O
been,O
reported,O
ADCETRIS,O
induced,O
peripheral neuropathy,AdverseReaction
is,O
cumulative,O
In,O
the,O
relapsed,O
classical,O
HL,O
and,O
sALCL,O
clinical,O
trials,O
54,O
of,O
patients,O
experienced,O
any,O
grade,O
of,O
neuropathy,AdverseReaction
Of,O
these,O
patients,O
49,O
had,O
complete,O
resolution,O
31,O
had,O
partial,O
improvement,O
and,O
20,O
had,O
no,O
improvement,O
Of,O
the,O
patients,O
who,O
reported,O
neuropathy,AdverseReaction
51,O
had,O
residual neuropathy,AdverseReaction
at,O
the,O
time,O
of,O
their,O
last,O
evaluation,O
Monitor,O
patients,O
for,O
symptoms,O
of,O
neuropathy,O
such,O
as,O
hypoesthesia,O
hyperesthesia,O
paresthesia,O
discomfort,O
a,O
burning,O
sensation,O
neuropathic,O
pain,O
or,O
weakness,O
Patients,O
experiencing,O
new,O
or,O
worsening,O
peripheral,O
neuropathy,O
may,O
require,O
a,O
delay,O
change,O
in,O
dose,O
or,O
discontinuation,O
of,O
ADCETRIS,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
1,O
5,O
2,O
Anaphylaxis,O
and,O
Infusion,O
Reactions,O
Infusion related reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
have,O
occurred,O
with,O
ADCETRIS,O
Monitor,O
patients,O
during,O
infusion,O
If,O
anaphylaxis,O
occurs,O
immediately,O
and,O
permanently,O
discontinue,O
administration,O
of,O
ADCETRIS,O
and,O
administer,O
appropriate,O
medical,O
therapy,O
If,O
an,O
infusion,O
related,O
reaction,O
occurs,O
the,O
infusion,O
should,O
be,O
interrupted,O
and,O
appropriate,O
medical,O
management,O
instituted,O
Patients,O
who,O
have,O
experienced,O
a,O
prior,O
infusion,O
related,O
reaction,O
should,O
be,O
premedicated,O
for,O
subsequent,O
infusions,O
Premedication,O
may,O
include,O
acetaminophen,O
an,O
antihistamine,O
and,O
a,O
corticosteroid,O
5,O
3,O
Hematologic,O
Toxicities,O
Prolonged,O
1,O
week,O
severe,Severity
neutropenia,AdverseReaction
and,O
Grade 3,Severity
or,O
Grade 4,Severity
thrombocytopenia,AdverseReaction
or,O
anemia,AdverseReaction
can,Factor
occur,O
with,O
ADCETRIS,O
Febrile neutropenia,AdverseReaction
has,O
been,O
reported,O
with,O
treatment,O
with,O
ADCETRIS,O
Complete,O
blood,O
counts,O
should,O
be,O
monitored,O
prior,O
to,O
each,O
dose,O
of,O
ADCETRIS,O
and,O
more,O
frequent,O
monitoring,O
should,O
be,O
considered,O
for,O
patients,O
with,O
Grade,O
3,O
or,O
4,O
neutropenia,O
Monitor,O
patients,O
for,O
fever,O
If,O
Grade,O
3,O
or,O
4,O
neutropenia,O
develops,O
consider,O
dose,O
delays,O
reductions,O
discontinuation,O
or,O
G,O
CSF,O
prophylaxis,O
with,O
subsequent,O
ADCETRIS,O
doses,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
4,O
Serious,O
Infections,O
and,O
Opportunistic,O
Infections,O
Serious,Severity
infections,AdverseReaction
and,O
opportunistic infections,AdverseReaction
such,O
as,O
pneumonia,AdverseReaction
bacteremia,AdverseReaction
and,O
sepsis,AdverseReaction
or,O
septic shock,AdverseReaction
including,O
fatal,AdverseReaction
outcomes,O
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
ADCETRIS,O
Patients,O
should,O
be,O
closely,O
monitored,O
during,O
treatment,O
for,O
the,O
emergence,O
of,O
possible,O
bacterial,O
fungal,O
or,O
viral,O
infections,O
5,O
5,O
Tumor,O
Lysis,O
Syndrome,O
Patients,O
with,O
rapidly,O
proliferating,O
tumor,O
and,O
high,O
tumor,O
burden,O
may,Factor
be,O
at,O
increased,O
risk,O
of,O
tumor lysis syndrome,AdverseReaction
Monitor,O
closely,O
and,O
take,O
appropriate,O
measures,O
5,O
6,O
Increased,O
Toxicity,O
in,O
the,O
Presence,O
of,O
Severe,O
Renal,O
Impairment,O
The,O
frequency,O
of,O
Grade,O
3,O
adverse,O
reactions,O
and,O
deaths,AdverseReaction
was,O
greater,O
in,O
patients,O
with,O
severe,O
renal,O
impairment,O
compared,O
to,O
patients,O
with,O
normal,O
renal,O
function,O
Due,O
to,O
higher,O
MMAE,O
exposure,O
Grade,O
3,O
adverse,O
reactions,O
may,O
be,O
more,O
frequent,O
in,O
patients,O
with,O
severe,O
renal,O
impairment,O
compared,O
to,O
patients,O
with,O
normal,O
renal,O
function,O
Avoid,O
the,O
use,O
of,O
ADCETRIS,O
in,O
patients,O
with,O
severe,O
renal,O
impairment,O
creatinine,O
clearance,O
CLcr,O
30,O
mL,O
min,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
5,O
7,O
Increased,O
Toxicity,O
in,O
the,O
Presence,O
of,O
Moderate,O
or,O
Severe,O
Hepatic,O
Impairment,O
The,O
frequency,O
of,O
Grade,O
3,O
adverse,O
reactions,O
and,O
deaths,AdverseReaction
was,O
greater,O
in,O
patients,O
with,O
moderate,O
and,O
severe,O
hepatic,O
impairment,O
compared,O
to,O
patients,O
with,O
normal,O
hepatic,O
function,O
Avoid,O
the,O
use,O
of,O
ADCETRIS,O
in,O
patients,O
with,O
moderate,O
Child,O
Pugh,O
B,O
or,O
severe,O
Child,O
Pugh,O
C,O
hepatic,O
impairment,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
7,O
5,O
8,O
Hepatotoxicity,O
Serious,Severity
cases,O
of,O
hepatotoxicity,AdverseReaction
including,O
fatal,AdverseReaction
outcomes,O
have,O
occurred,O
in,O
patients,O
receiving,O
ADCETRIS,O
Cases,O
were,O
consistent,O
with,O
hepatocellular injury,AdverseReaction
including,O
elevations of transaminases of,AdverseReaction
and,O
or,O
bilirubin,AdverseReaction
Cases,O
have,O
occurred,O
after,O
the,O
first,O
dose,O
of,O
ADCETRIS,O
or,O
after,O
ADCETRIS,O
rechallenge,O
Preexisting,O
liver,O
disease,O
elevated,O
baseline,O
liver,O
enzymes,O
and,O
concomitant,O
medications,O
may,O
also,O
increase,O
the,O
risk,O
Monitor,O
liver,O
enzymes,O
and,O
bilirubin,O
Patients,O
experiencing,O
new,O
worsening,O
or,O
recurrent,O
hepatotoxicity,O
may,O
require,O
a,O
delay,O
change,O
in,O
dose,O
or,O
discontinuation,O
of,O
ADCETRIS,O
5,O
9,O
Progressive,O
Multifocal,O
Leukoencephalopathy,O
JC virus infection,AdverseReaction
resulting,O
in,O
PML,AdverseReaction
and,O
death,AdverseReaction
has,O
been,O
reported,O
in,O
ADCETRIS,O
treated,O
patients,O
First,O
onset,O
of,O
symptoms,O
occurred,O
at,O
various,O
times,O
from,O
initiation,O
of,O
ADCETRIS,O
therapy,O
with,O
some,O
cases,O
occurring,O
within,O
3,O
months,O
of,O
initial,O
exposure,O
In,O
addition,O
to,O
ADCETRIS,O
therapy,O
other,O
possible,O
contributory,O
factors,O
include,O
prior,O
therapies,O
and,O
underlying,O
disease,O
that,O
may,O
cause,O
immunosuppression,O
Consider,O
the,O
diagnosis,O
of,O
PML,O
in,O
any,O
patient,O
presenting,O
with,O
new,O
onset,O
signs,O
and,O
symptoms,O
of,O
central,O
nervous,O
system,O
abnormalities,O
Hold,O
ADCETRIS,O
dosing,O
for,O
any,O
suspected,O
case,O
of,O
PML,O
and,O
discontinue,O
ADCETRIS,O
dosing,O
if,O
a,O
diagnosis,O
of,O
PML,O
is,O
confirmed,O
5,O
10,O
Pulmonary,O
Toxicity,O
Events,O
of,O
noninfectious pulmonary toxicity,AdverseReaction
including,O
pneumonitis,AdverseReaction
interstitial lung disease,AdverseReaction
and,O
acute respiratory distress syndrome,AdverseReaction
ARDS,AdverseReaction
some,O
with,O
fatal,AdverseReaction
outcomes,O
have,O
been,O
reported,O
Monitor,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
pulmonary,O
toxicity,O
including,O
cough,O
and,O
dyspnea,O
In,O
the,O
event,O
of,O
new,O
or,O
worsening,O
pulmonary,O
symptoms,O
hold,O
ADCETRIS,O
dosing,O
during,O
evaluation,O
and,O
until,O
symptomatic,O
improvement,O
5,O
11,O
Serious,O
Dermatologic,O
Reactions,O
Stevens Johnson syndrome,AdverseReaction
SJS,AdverseReaction
and,O
toxic epidermal necrolysis,AdverseReaction
TEN,AdverseReaction
including,O
fatal,AdverseReaction
outcomes,O
have,O
been,O
reported,O
with,O
ADCETRIS,O
If,O
SJS,O
or,O
TEN,O
occurs,O
discontinue,O
ADCETRIS,O
and,O
administer,O
appropriate,O
medical,O
therapy,O
5,O
12,O
Embryo,O
Fetal,O
Toxicity,O
There,O
are,O
no,O
adequate,O
and,O
well,O
controlled,O
studies,O
of,O
ADCETRIS,O
in,O
pregnant,O
women,O
However,O
based,O
on,O
its,O
mechanism,O
of,O
action,O
and,O
findings,O
in,O
animals,O
ADCETRIS,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Brentuximab,O
vedotin,O
caused,O
embryo fetal toxicities,AdverseReaction
including,O
significantly,Severity
decreased embryo viability,AdverseReaction
and,O
fetal malformations,AdverseReaction
in,O
animals,Animal
at,O
maternal,O
exposures,O
that,O
were,O
similar,O
to,O
human,O
exposures,O
at,O
the,O
recommended,O
doses,O
for,O
patients,O
with,O
classical,O
HL,O
and,O
sALCL,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
receiving,O
the,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
BOXED,O
WARNING,O
WARNING,O
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,AdverseReaction
PML,AdverseReaction
WARNING,O
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,AdverseReaction
PML,AdverseReaction
JC virus infection,AdverseReaction
resulting,O
in,O
PML,AdverseReaction
and,O
death,AdverseReaction
can,Factor
occur,O
in,O
patients,O
receiving,O
ADCETRIS,O
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
Adverse,O
Reactions,O
6,O
1,O
EXCERPT,O
WARNING,O
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,AdverseReaction
PML,AdverseReaction
See,O
Full,O
Prescribing,O
Information,O
for,O
complete,O
boxed,O
warning,O
JC virus infection,AdverseReaction
resulting,O
in,O
PML,AdverseReaction
and,O
death,AdverseReaction
can,Factor
occur,O
in,O
patients,O
receiving,O
ADCETRIS,O
5,O
9,O
6,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
prescribing,O
information,O
Peripheral Neuropathy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Anaphylaxis,AdverseReaction
and,O
Infusion Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hematologic Toxicities,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Serious,Severity
Infections,AdverseReaction
and,O
Opportunistic Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Tumor Lysis Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Increased Toxicity,AdverseReaction
in,O
the,O
Presence,O
of,O
Severe,O
Renal,O
Impairment,O
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Increased Toxicity,AdverseReaction
in,O
the,O
Presence,O
of,O
Moderate,O
or,O
Severe,O
Hepatic,O
Impairment,O
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Hepatotoxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Progressive Multifocal Leukoencephalopathy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
Pulmonary Toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
10,O
Serious,Severity
Dermatologic Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
11,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
20,O
were,O
Relapsed,O
classical,O
HL,O
and,O
relapsed,O
sALCL,O
neutropenia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
fatigue,AdverseReaction
nausea,AdverseReaction
anemia,AdverseReaction
upper respiratory tract infection,AdverseReaction
diarrhea,AdverseReaction
pyrexia,AdverseReaction
rash,AdverseReaction
thrombocytopenia,AdverseReaction
cough,AdverseReaction
and,O
vomiting,AdverseReaction
6,O
1,O
Classical,O
HL,O
post,O
auto,O
HSCT,O
consolidation,O
neutropenia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
thrombocytopenia,AdverseReaction
anemia,AdverseReaction
upper respiratory tract infection,AdverseReaction
fatigue,AdverseReaction
peripheral motor neuropathy,AdverseReaction
nausea,AdverseReaction
cough,AdverseReaction
and,O
diarrhea,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Seattle,O
Genetics,O
Inc,O
at,O
1,O
855,O
473,O
2436,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
data,O
below,O
reflect,O
exposure,O
to,O
ADCETRIS,O
as,O
monotherapy,O
in,O
327,O
patients,O
with,O
classical,O
Hodgkin,O
lymphoma,O
HL,O
and,O
systemic,O
anaplastic,O
large,O
cell,O
lymphoma,O
sALCL,O
including,O
160,O
patients,O
in,O
two,O
uncontrolled,O
single,O
arm,O
trials,O
Studies,O
1,O
and,O
2,O
and,O
167,O
patients,O
in,O
one,O
placebo,O
controlled,O
randomized,O
trial,O
Study,O
3,O
In,O
Studies,O
1,O
and,O
2,O
the,O
most,O
common,O
adverse,O
reactions,O
20,O
regardless,O
of,O
causality,O
were,O
neutropenia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
fatigue,AdverseReaction
nausea,AdverseReaction
anemia,AdverseReaction
upper respiratory tract infection,AdverseReaction
diarrhea,AdverseReaction
pyrexia,AdverseReaction
rash,AdverseReaction
thrombocytopenia,AdverseReaction
cough,AdverseReaction
and,O
vomiting,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
occurring,O
in,O
at,O
least,O
10,O
of,O
patients,O
in,O
either,O
Study,O
1,O
or,O
2,O
regardless,O
of,O
causality,O
using,O
the,O
NCI,O
Common,O
Toxicity,O
Criteria,O
CTC,O
Version,O
3,O
0,O
are,O
shown,O
in,O
Table,O
2,O
In,O
Study,O
3,O
the,O
most,O
common,O
adverse,O
reactions,O
20,O
in,O
the,O
ADCETRIS,O
treatment,O
arm,O
regardless,O
of,O
causality,O
were,O
neutropenia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
thrombocytopenia,AdverseReaction
anemia,AdverseReaction
upper respiratory tract infection,AdverseReaction
fatigue,AdverseReaction
peripheral motor neuropathy,AdverseReaction
nausea,AdverseReaction
cough,AdverseReaction
and,O
diarrhea,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
occurring,O
in,O
at,O
least,O
10,O
of,O
patients,O
using,O
the,O
NCI,O
CTC,O
Version,O
4,O
are,O
shown,O
in,O
Table,O
3,O
Experience,O
in,O
Classical,O
Hodgkin,O
Lymphoma,O
Summary,O
of,O
Clinical,O
Trial,O
Experience,O
in,O
Relapsed,O
Classical,O
HL,O
Study,O
1,O
ADCETRIS,O
was,O
studied,O
in,O
102,O
patients,O
with,O
classical,O
HL,O
in,O
a,O
single,O
arm,O
clinical,O
trial,O
in,O
which,O
the,O
recommended,O
starting,O
dose,O
and,O
schedule,O
was,O
1,O
8,O
mg,O
kg,O
intravenously,O
every,O
3,O
weeks,O
Median,O
duration,O
of,O
treatment,O
was,O
9,O
cycles,O
range,O
1,O
16,O
see,O
Clinical,O
Studies,O
14,O
1,O
The,O
most,O
common,O
adverse,O
reactions,O
20,O
regardless,O
of,O
causality,O
were,O
neutropenia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
fatigue,AdverseReaction
upper respiratory tract infection,AdverseReaction
nausea,AdverseReaction
diarrhea,AdverseReaction
anemia,AdverseReaction
pyrexia,AdverseReaction
thrombocytopenia,AdverseReaction
rash,AdverseReaction
abdominal pain,AdverseReaction
cough,AdverseReaction
and,O
vomiting,AdverseReaction
Summary,O
of,O
Clinical,O
Trial,O
Experience,O
in,O
Classical,O
HL,O
Post,O
auto,O
HSCT,O
Consolidation,O
Study,O
3,O
ADCETRIS,O
was,O
studied,O
in,O
329,O
patients,O
with,O
classical,O
HL,O
at,O
high,O
risk,O
of,O
relapse,O
or,O
progression,O
post,O
auto,O
HSCT,O
in,O
a,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
clinical,O
trial,O
in,O
which,O
the,O
recommended,O
starting,O
dose,O
and,O
schedule,O
was,O
1,O
8,O
mg,O
kg,O
of,O
ADCETRIS,O
administered,O
intravenously,O
over,O
30,O
minutes,O
every,O
3,O
weeks,O
or,O
placebo,O
for,O
up,O
to,O
16,O
cycles,O
Of,O
the,O
329,O
enrolled,O
patients,O
327,O
167,O
brentuximab,O
vedotin,O
160,O
placebo,O
received,O
at,O
least,O
one,O
dose,O
of,O
study,O
treatment,O
The,O
median,O
number,O
of,O
treatment,O
cycles,O
in,O
each,O
study,O
arm,O
was,O
15,O
range,O
1,O
16,O
and,O
80,O
patients,O
48,O
in,O
the,O
ADCETRIS,O
treatment,O
arm,O
received,O
16,O
cycles,O
see,O
Clinical,O
Studies,O
14,O
1,O
Standard,O
international,O
guidelines,O
were,O
followed,O
for,O
infection,O
prophylaxis,O
for,O
herpes,O
simplex,O
virus,O
HSV,O
varicella,O
zoster,O
virus,O
VZV,O
and,O
Pneumocystis,O
jiroveci,O
pneumonia,O
PCP,O
post,O
auto,O
HSCT,O
Overall,O
312,O
patients,O
95,O
received,O
HSV,O
and,O
VZV,O
prophylaxis,O
with,O
a,O
median,O
duration,O
of,O
11,O
1,O
months,O
range,O
0,O
20,O
and,O
319,O
patients,O
98,O
received,O
PCP,O
prophylaxis,O
with,O
a,O
median,O
duration,O
of,O
6,O
5,O
months,O
range,O
0,O
20,O
Experience,O
in,O
Systemic,O
Anaplastic,O
Large,O
Cell,O
Lymphoma,O
Summary,O
of,O
Clinical,O
Trial,O
Experience,O
in,O
Relapsed,O
sALCL,O
Study,O
2,O
ADCETRIS,O
was,O
studied,O
in,O
58,O
patients,O
with,O
sALCL,O
in,O
a,O
single,O
arm,O
clinical,O
trial,O
in,O
which,O
the,O
recommended,O
starting,O
dose,O
and,O
schedule,O
was,O
1,O
8,O
mg,O
kg,O
intravenously,O
every,O
3,O
weeks,O
Median,O
duration,O
of,O
treatment,O
was,O
7,O
cycles,O
range,O
1,O
16,O
see,O
Clinical,O
Studies,O
14,O
2,O
The,O
most,O
common,O
adverse,O
reactions,O
20,O
regardless,O
of,O
causality,O
were,O
neutropenia,AdverseReaction
anemia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
fatigue,AdverseReaction
nausea,AdverseReaction
pyrexia,AdverseReaction
rash,AdverseReaction
diarrhea,AdverseReaction
and,O
pain,AdverseReaction
Table,O
2,O
Most,O
Commonly,O
Reported,O
10,O
Adverse,O
Reactions,O
in,O
Studies,O
1,O
and,O
2,O
Classical,O
HL,O
sALCL,O
Total,O
N,O
102,O
of,O
patients,O
Total,O
N,O
58,O
of,O
patients,O
Adverse,O
Reaction,O
AnyGrade,O
Grade3,O
Grade4,O
AnyGrade,O
Grade3,O
Grade4,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Neutropenia,AdverseReaction
54,O
15,O
6,O
55,O
12,O
9,O
Anemia,AdverseReaction
33,O
8,O
2,O
52,O
2,O
Thrombocytopenia,AdverseReaction
28,O
7,O
2,O
16,O
5,O
5,O
Lymphadenopathy,AdverseReaction
11,O
10,O
Nervous,O
system,O
disorders,O
Peripheral sensory neuropathy,AdverseReaction
52,O
8,O
53,O
10,O
Peripheral motor neuropathy,AdverseReaction
16,O
4,O
7,O
3,O
Headache,AdverseReaction
19,O
16,O
2,O
Dizziness,AdverseReaction
11,O
16,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
49,O
3,O
41,O
2,O
2,O
Pyrexia,AdverseReaction
29,O
2,O
38,O
2,O
Chills,AdverseReaction
13,O
12,O
Pain,AdverseReaction
7,O
28,O
5,O
Edema peripheral,AdverseReaction
4,O
16,O
Infections,O
and,O
infestations,O
Upper respiratory tract infection,AdverseReaction
47,O
12,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
42,O
38,O
2,O
Diarrhea,AdverseReaction
36,O
1,O
29,O
3,O
Abdominal pain,AdverseReaction
25,O
2,O
1,O
9,O
2,O
Vomiting,AdverseReaction
22,O
17,O
3,O
Constipation,AdverseReaction
16,O
19,O
2,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
27,O
31,O
Pruritus,AdverseReaction
17,O
19,O
Alopecia,AdverseReaction
13,O
14,O
Night sweats,AdverseReaction
12,O
9,O
Dry skin,AdverseReaction
4,O
10,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
25,O
17,O
Dyspnea,AdverseReaction
13,O
1,O
19,O
2,O
Oropharyngeal pain,AdverseReaction
11,O
9,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
19,O
9,O
Myalgia,AdverseReaction
17,O
16,O
2,O
Back pain,AdverseReaction
14,O
10,O
2,O
Pain in extremity,AdverseReaction
10,O
10,O
2,O
2,O
Muscle spasms,AdverseReaction
9,O
10,O
2,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
14,O
16,O
Anxiety,AdverseReaction
11,O
2,O
7,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
11,O
16,O
2,O
Investigations,O
Weight decreased,AdverseReaction
6,O
12,O
3,O
Table,O
3,O
Most,O
Commonly,O
Reported,O
10,O
in,O
the,O
ADCETRIS,O
arm,O
Adverse,O
Reactions,O
in,O
Study,O
3,O
ADCETRIS,O
Placebo,O
Total,O
N,O
167,O
of,O
patients,O
Total,O
N,O
160,O
of,O
patients,O
Adverse,O
Reaction,O
AnyGrade,O
Grade3,O
Grade4,O
AnyGrade,O
Grade3,O
Grade4,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Neutropenia,AdverseReaction
78,O
30,O
9,O
34,O
6,O
4,O
Thrombocytopenia,AdverseReaction
41,O
2,O
4,O
20,O
3,O
2,O
Anemia,AdverseReaction
27,O
4,O
19,O
2,O
Nervous,O
system,O
disorders,O
Peripheral sensory neuropathy,AdverseReaction
56,O
10,O
16,O
1,O
Peripheral motor neuropathy,AdverseReaction
23,O
6,O
2,O
1,O
Headache,AdverseReaction
11,O
2,O
8,O
1,O
Infections,O
and,O
infestations,O
Upper respiratory tract infection,AdverseReaction
26,O
23,O
1,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
24,O
2,O
18,O
3,O
Pyrexia,AdverseReaction
19,O
2,O
16,O
Chills,AdverseReaction
10,O
5,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
22,O
3,O
8,O
Diarrhea,AdverseReaction
20,O
2,O
10,O
1,O
Vomiting,AdverseReaction
16,O
2,O
7,O
Abdominal pain,AdverseReaction
14,O
2,O
3,O
Constipation,AdverseReaction
13,O
2,O
3,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
21,O
16,O
Dyspnea,AdverseReaction
13,O
6,O
1,O
Investigations,O
Weight decreased,AdverseReaction
19,O
1,O
6,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
18,O
1,O
9,O
Muscle spasms,AdverseReaction
11,O
6,O
Myalgia,AdverseReaction
11,O
1,O
4,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Pruritus,AdverseReaction
12,O
1,O
8,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
12,O
1,O
6,O
Additional,O
Important,O
Adverse,O
Reactions,O
Peripheral,O
neuropathy,O
In,O
Studies,O
1,O
and,O
2,O
54,O
of,O
patients,O
experienced,O
any,O
grade,O
of,O
neuropathy,AdverseReaction
Of,O
these,O
patients,O
49,O
had,O
complete,O
resolution,O
31,O
had,O
partial,O
improvement,O
and,O
20,O
had,O
no,O
improvement,O
Of,O
the,O
patients,O
who,O
reported,O
neuropathy,AdverseReaction
51,O
had,O
residual neuropathy,AdverseReaction
at,O
the,O
time,O
of,O
their,O
last,O
evaluation,O
In,O
Study,O
3,O
67,O
of,O
patients,O
treated,O
with,O
ADCETRIS,O
experienced,O
any,O
grade,O
of,O
neuropathy,AdverseReaction
The,O
median,O
time,O
to,O
first,O
onset,O
of,O
any,O
grade,O
was,O
14,O
weeks,O
range,O
0,O
1,O
47,O
of,O
Grade,O
2,O
was,O
27,O
weeks,O
range,O
0,O
4,O
52,O
and,O
of,O
Grade,O
3,O
was,O
34,O
weeks,O
range,O
7,O
106,O
The,O
median,O
time,O
from,O
onset,O
to,O
resolution,O
or,O
improvement,O
of,O
any,O
grade,O
was,O
23,O
weeks,O
range,O
0,O
1,O
138,O
of,O
Grade,O
2,O
was,O
24,O
weeks,O
range,O
1,O
108,O
and,O
of,O
Grade,O
3,O
was,O
25,O
weeks,O
range,O
2,O
98,O
Of,O
the,O
patients,O
who,O
reported,O
neuropathy,AdverseReaction
59,O
had,O
complete,O
resolution,O
and,O
41,O
had,O
residual neuropathy,AdverseReaction
26,O
partial,O
improvement,O
15,O
no,O
improvement,O
at,O
the,O
time,O
of,O
their,O
last,O
evaluation,O
Infusion,O
reactions,O
Two,O
cases,O
of,O
anaphylaxis,AdverseReaction
were,O
reported,O
in,O
the,O
dose,O
finding,O
trials,O
There,O
were,O
no,Negation
Grade 3,Severity
or,O
4,Severity
infusion related reactions,AdverseReaction
reported,O
in,O
Studies,O
1,O
and,O
2,O
however,O
Grade 1,Severity
or,O
2,Severity
infusion related reactions,AdverseReaction
were,O
reported,O
for,O
19,O
patients,O
12,O
In,O
Studies,O
1,O
and,O
2,O
the,O
most,O
common,O
adverse,O
reactions,O
2,O
associated,O
with,O
infusion related reactions,AdverseReaction
were,O
chills,AdverseReaction
4,O
nausea,AdverseReaction
3,O
dyspnea,AdverseReaction
3,O
pruritus,AdverseReaction
3,O
pyrexia,AdverseReaction
2,O
and,O
cough,AdverseReaction
2,O
In,O
Study,O
3,O
infusion related reactions,AdverseReaction
were,O
reported,O
in,O
25,O
patients,O
15,O
in,O
the,O
ADCETRIS,O
treated,O
arm,O
and,O
3,O
patients,O
2,O
in,O
the,O
placebo,O
arm,O
Grade,O
3,O
events,O
were,O
reported,O
in,O
3,O
of,O
the,O
25,O
patients,O
treated,O
with,O
ADCETRIS,O
who,O
experienced,O
infusion related reactions,AdverseReaction
No,Negation
Grade 4,Severity
infusion related reactions,AdverseReaction
were,O
reported,O
The,O
most,O
common,O
adverse,O
reactions,O
2,O
associated,O
with,O
infusion related reactions,AdverseReaction
were,O
nausea,AdverseReaction
4,O
chills,AdverseReaction
4,O
dyspnea,AdverseReaction
2,O
headache,AdverseReaction
2,O
pruritus,AdverseReaction
2,O
rash,AdverseReaction
2,O
back pain,AdverseReaction
2,O
and,O
vomiting,AdverseReaction
2,O
Pulmonary,O
Toxicity,O
In,O
a,O
trial,O
in,O
patients,O
with,O
classical,O
HL,O
that,O
studied,O
ADCETRIS,O
with,O
bleomycin,O
as,O
part,O
of,O
a,O
combination,O
regimen,O
the,O
rate,O
of,O
non infectious pulmonary toxicity,AdverseReaction
was,O
higher,O
than,O
the,O
historical,O
incidence,O
reported,O
with,O
ABVD,O
adriamycin,O
bleomycin,O
vinblastine,O
dacarbazine,O
Patients,O
typically,O
reported,O
cough,AdverseReaction
and,O
dyspnea,AdverseReaction
Interstitial infiltration,AdverseReaction
and,O
or,O
inflammation,AdverseReaction
were,O
observed,O
on,O
radiographs,O
and,O
computed,O
tomographic,O
imaging,O
of the chest the chest,AdverseReaction
Most,O
patients,O
responded,O
to,O
corticosteroids,O
The,O
concomitant,O
use,O
of,O
ADCETRIS,O
with,O
bleomycin,O
is,O
contraindicated,O
see,O
Contraindications,O
4,O
Cases,O
of,O
pulmonary toxicity,AdverseReaction
have,O
also,O
been,O
reported,O
in,O
patients,O
receiving,O
ADCETRIS,O
In,O
Study,O
3,O
pulmonary toxicity,AdverseReaction
was,O
reported,O
in,O
8,O
patients,O
5,O
in,O
the,O
ADCETRIS,O
treated,O
arm,O
and,O
5,O
patients,O
3,O
in,O
the,O
placebo,O
arm,O
A,O
causal,O
association,O
with,O
single,O
agent,O
ADCETRIS,O
has,O
not,O
been,O
established,O
Serious,O
adverse,O
reactions,O
In,O
Studies,O
1,O
and,O
2,O
serious,O
adverse,O
reactions,O
regardless,O
of,O
causality,O
were,O
reported,O
in,O
31,O
of,O
patients,O
receiving,O
ADCETRIS,O
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
experienced,O
by,O
patients,O
with,O
classical,O
HL,O
include,O
peripheral motor neuropathy,AdverseReaction
4,O
abdominal pain,AdverseReaction
3,O
pulmonary embolism,AdverseReaction
2,O
pneumonitis,AdverseReaction
2,O
pneumothorax,AdverseReaction
2,O
pyelonephritis,AdverseReaction
2,O
and,O
pyrexia,AdverseReaction
2,O
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
experienced,O
by,O
patients,O
with,O
sALCL,O
were,O
septic shock,AdverseReaction
3,O
supraventricular arrhythmia,AdverseReaction
3,O
pain in extremity,AdverseReaction
3,O
and,O
urinary tract infection,AdverseReaction
3,O
Other,O
important,O
serious,O
adverse,O
reactions,O
reported,O
include,O
PML,AdverseReaction
Stevens Johnson syndrome,AdverseReaction
and,O
tumor lysis syndrome,AdverseReaction
In,O
Study,O
3,O
serious,O
adverse,O
reactions,O
regardless,O
of,O
causality,O
were,O
reported,O
in,O
25,O
of,O
ADCETRIS,O
treated,O
patients,O
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
were,O
pneumonia,AdverseReaction
4,O
pyrexia,AdverseReaction
4,O
vomiting,AdverseReaction
3,O
nausea,AdverseReaction
2,O
hepatotoxicity,AdverseReaction
2,O
and,O
peripheral sensory neuropathy,AdverseReaction
2,O
Dose,O
modifications,O
Adverse,O
reactions,O
that,O
led,O
to,O
dose,O
delays,O
in,O
more,O
than,O
5,O
of,O
patients,O
in,O
Studies,O
1,O
and,O
2,O
were,O
neutropenia,AdverseReaction
14,O
and,O
peripheral sensory neuropathy,AdverseReaction
11,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Adverse,O
reactions,O
that,O
led,O
to,O
dose,O
delays,O
in,O
more,O
than,O
5,O
of,O
ADCETRIS,O
treated,O
patients,O
in,O
Study,O
3,O
were,O
neutropenia,AdverseReaction
22,O
peripheral sensory neuropathy,AdverseReaction
16,O
upper respiratory tract infection,AdverseReaction
6,O
and,O
peripheral motor neuropathy,AdverseReaction
6,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Discontinuations,O
Adverse,O
reactions,O
led,O
to,O
treatment,O
discontinuation,O
in,O
21,O
of,O
patients,O
in,O
Studies,O
1,O
and,O
2,O
Adverse,O
reactions,O
that,O
led,O
to,O
treatment,O
discontinuation,O
in,O
2,O
or,O
more,O
patients,O
with,O
classical,O
HL,O
or,O
sALCL,O
were,O
peripheral sensory neuropathy,AdverseReaction
8,O
and,O
peripheral motor neuropathy,AdverseReaction
3,O
Adverse,O
reactions,O
led,O
to,O
treatment,O
discontinuation,O
in,O
32,O
of,O
ADCETRIS,O
treated,O
patients,O
in,O
Study,O
3,O
Adverse,O
reactions,O
that,O
led,O
to,O
treatment,O
discontinuation,O
in,O
2,O
or,O
more,O
patients,O
were,O
peripheral sensory neuropathy,AdverseReaction
14,O
peripheral motor neuropathy,AdverseReaction
7,O
acute respiratory distress syndrome,AdverseReaction
1,O
paraesthesia,AdverseReaction
1,O
and,O
vomiting,AdverseReaction
1,O
6,O
2,O
Post,O
Marketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
ADCETRIS,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
febrile neutropenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Hepatobiliary,O
disorders,O
hepatotoxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Infections,O
PML,AdverseReaction
see,O
Boxed,O
Warning,O
Warnings,O
and,O
Precautions,O
5,O
9,O
serious,Severity
infections,AdverseReaction
and,O
opportunistic infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Metabolism,O
and,O
nutrition,O
disorders,O
hyperglycemia,AdverseReaction
Gastrointestinal,O
disorders,O
Pancreatitis,AdverseReaction
including,O
fatal,AdverseReaction
outcomes,O
Consider,O
the,O
diagnosis,O
of,O
pancreatitis,O
for,O
patients,O
presenting,O
with,O
severe,O
abdominal,O
pain,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
noninfectious pulmonary toxicity,AdverseReaction
including,O
pneumonitis,AdverseReaction
interstitial lung disease,AdverseReaction
and,O
ARDS,AdverseReaction
some,O
with,O
fatal,AdverseReaction
outcomes,O
see,O
Warnings,O
and,O
Precautions,O
5,O
10,O
and,O
Adverse,O
Reactions,O
6,O
1,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Toxic epidermal necrolysis,AdverseReaction
including,O
fatal,AdverseReaction
outcomes,O
see,O
Warnings,O
and,O
Precautions,O
5,O
11,O
6,O
3,O
Immunogenicity,O
Patients,O
with,O
classical,O
HL,O
and,O
sALCL,O
in,O
Studies,O
1,O
and,O
2,O
see,O
Clinical,O
Studies,O
14,O
were,O
tested,O
for,O
antibodies,O
to,O
brentuximab,O
vedotin,O
every,O
3,O
weeks,O
using,O
a,O
sensitive,O
electrochemiluminescent,O
immunoassay,O
Approximately,O
7,O
of,O
patients,O
in,O
these,O
trials,O
developed,O
persistently,O
positive,O
antibodies,O
positive,O
test,O
at,O
more,O
than,O
2,O
timepoints,O
and,O
30,O
developed,O
transiently,O
positive,O
antibodies,O
positive,O
in,O
1,O
or,O
2,O
post,O
baseline,O
timepoints,O
The,O
anti,O
brentuximab,O
antibodies,O
were,O
directed,O
against,O
the,O
antibody,O
component,O
of,O
brentuximab,O
vedotin,O
in,O
all,O
patients,O
with,O
transiently,O
or,O
persistently,O
positive,O
antibodies,O
Two,O
of,O
the,O
patients,O
1,O
with,O
persistently,O
positive,O
antibodies,O
experienced,O
adverse,O
reactions,O
consistent,O
with,O
infusion reactions,AdverseReaction
that,O
led,O
to,O
discontinuation,O
of,O
treatment,O
Overall,O
a,O
higher,O
incidence,O
of,O
infusion related reactions,AdverseReaction
was,O
observed,O
in,O
patients,O
who,O
developed,O
persistently,O
positive,O
antibodies,O
A,O
total,O
of,O
58,O
patient,O
samples,O
that,O
were,O
either,O
transiently,O
or,O
persistently,O
positive,O
for,O
anti,O
brentuximab,O
vedotin,O
antibodies,O
were,O
tested,O
for,O
the,O
presence,O
of,O
neutralizing,O
antibodies,O
Sixty,O
two,O
percent,O
of,O
these,O
patients,O
had,O
at,O
least,O
one,O
sample,O
that,O
was,O
positive,O
for,O
the,O
presence,O
of,O
neutralizing,O
antibodies,O
The,O
effect,O
of,O
anti,O
brentuximab,O
vedotin,O
antibodies,O
on,O
safety,O
and,O
efficacy,O
is,O
not,O
known,O
Immunogenicity,O
assay,O
results,O
are,O
highly,O
dependent,O
on,O
several,O
factors,O
including,O
assay,O
sensitivity,O
and,O
specificity,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
incidence,O
of,O
antibodies,O
to,O
ADCETRIS,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypersensitivity reactions,AdverseReaction
have,O
followed,O
AdreView,O
administration,O
Have,O
anaphylactic,O
and,O
hypersensitivity,O
treatment,O
measures,O
available,O
prior,O
to,O
AdreView,O
administration,O
5,O
1,O
Drugs,O
which,O
block,O
norepinephrine,O
uptake,O
or,O
deplete,O
norepinephrine,O
stores,O
may,O
decrease,O
AdreView,O
uptake,O
When,O
medically,O
feasible,O
stop,O
these,O
drugs,O
before,O
AdreView,O
administration,O
and,O
monitor,O
patients,O
for,O
withdrawal,O
signs,O
and,O
symptoms,O
5,O
2,O
AdreView,O
contains,O
benzyl,O
alcohol,O
10,O
3,O
mg,O
mL,O
which,O
may,O
cause,O
serious,O
reactions,O
in,O
premature,O
or,O
low,O
birth,O
weight,O
infants,O
5,O
3,O
Patients,O
with,O
severe,O
renal,O
impairment,O
may,O
have,O
increased,O
radiation,O
exposure,O
and,O
decreased,O
quality,O
of,O
AdreView,O
images,O
5,O
4,O
Failure,O
to,O
block,O
thyroid,O
iodine,O
uptake,O
may,O
result,O
in,O
iodine,O
123,O
accumulation,O
in,O
the,O
thyroid,O
5,O
6,O
5,O
1,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
following,O
AdreView,O
administration,O
Prior,O
to,O
administration,O
question,O
the,O
patient,O
for,O
a,O
history,O
of,O
prior,O
reactions,O
to,O
iodine,O
an,O
iodine,O
containing,O
contrast,O
agent,O
or,O
other,O
products,O
containing,O
iodine,O
If,O
the,O
patient,O
is,O
known,O
or,O
strongly,O
suspected,O
to,O
have,O
hypersensitivity,O
to,O
iodine,O
an,O
iodine,O
containing,O
contrast,O
agent,O
or,O
other,O
products,O
containing,O
iodine,O
the,O
decision,O
to,O
administer,O
AdreView,O
should,O
be,O
based,O
upon,O
an,O
assessment,O
of,O
the,O
expected,O
benefits,O
compared,O
to,O
the,O
potential,O
hypersensitivity,O
risks,O
Have,O
anaphylactic,O
and,O
hypersensitivity,O
treatment,O
measures,O
available,O
prior,O
to,O
AdreView,O
administration,O
see,O
Adverse,O
Reactions,O
6,O
2,O
5,O
2,O
Imaging,O
Errors,O
due,O
to,O
Concomitant,O
Medications,O
and,O
Risks,O
Associated,O
with,O
Withdrawal,O
of,O
Medications,O
Many,O
medications,O
have,O
the,O
potential,O
to,O
interfere,O
with,O
AdreView,O
imaging,O
and,O
review,O
of,O
the,O
patient,O
s,O
medications,O
is,O
required,O
prior,O
to,O
AdreView,O
dosing,O
due,O
to,O
the,O
risk,O
for,O
unreliable,O
imaging,O
results,O
If,O
the,O
AdreView,O
imaging,O
information,O
is,O
essential,O
for,O
clinical,O
care,O
consider,O
the,O
withdrawal,O
of,O
the,O
following,O
categories,O
of,O
medications,O
if,O
the,O
withdrawal,O
can,O
be,O
accomplished,O
safely,O
antihypertensives,O
that,O
deplete,O
norepinephrine,O
stores,O
or,O
inhibit,O
reuptake,O
e,O
g,O
reserpine,O
labetalol,O
antidepressants,O
that,O
inhibit,O
norepinephrine,O
transporter,O
function,O
e,O
g,O
amitriptyline,O
and,O
derivatives,O
imipramine,O
and,O
derivatives,O
selective,O
serotonin,O
reuptake,O
inhibitors,O
and,O
sympathomimetic,O
amines,O
e,O
g,O
phenylephrine,O
phenylpropanolamine,O
pseudoephedrine,O
and,O
ephedrine,O
The,O
period,O
of,O
time,O
necessary,O
to,O
discontinue,O
any,O
specific,O
medication,O
prior,O
to,O
AdreView,O
dosing,O
has,O
not,O
been,O
established,O
see,O
Drug,O
Interactions,O
7,O
Pheochromocytoma,O
and,O
Neuroblastoma,O
Drugs,O
which,O
interfere,O
with,O
norepinephrine,O
uptake,O
in,O
neuroendocrine,O
tumors,O
may,O
lead,O
to,O
false,O
negative,O
imaging,O
results,O
When,O
medically,O
feasible,O
stop,O
these,O
drugs,O
before,O
AdreView,O
administration,O
and,O
monitor,O
patients,O
for,O
the,O
occurrence,O
of,O
clinically,O
significant,O
withdrawal,O
symptoms,O
especially,O
patients,O
with,O
elevated,O
levels,O
of,O
circulating,O
catecholamines,O
and,O
their,O
metabolites,O
Congestive,O
Heart,O
Failure,O
Many,O
commonly,O
used,O
cardiovascular,O
pulmonary,O
and,O
neuropsychiatric,O
medications,O
interfere,O
with,O
AdreView,O
imaging,O
see,O
above,O
AdreView,O
imaging,O
should,O
not,O
be,O
performed,O
if,O
discontinuation,O
of,O
these,O
medications,O
would,O
involve,O
risks,O
which,O
outweigh,O
the,O
value,O
of,O
AdreView,O
imaging,O
In,O
clinical,O
trials,O
patients,O
were,O
not,O
eligible,O
for,O
AdreView,O
imaging,O
if,O
they,O
were,O
receiving,O
medications,O
in,O
the,O
above,O
categories,O
and,O
the,O
risks,O
for,O
medication,O
withdrawal,O
were,O
unacceptable,O
or,O
if,O
they,O
were,O
not,O
clinically,O
stable,O
e,O
g,O
experiencing,O
continuing,O
chest,O
pain,O
hemodynamic,O
instability,O
or,O
clinically,O
significant,O
arrhythmia,O
5,O
3,O
Risks,O
for,O
Benzyl,O
Alcohol,O
Toxicity,O
in,O
Infants,O
AdreView,O
contains,O
benzyl,O
alcohol,O
at,O
a,O
concentration,O
of,O
10,O
3,O
mg,O
mL,O
Benzyl,O
alcohol,O
has,O
been,O
associated,O
with,O
a,O
fatal,AdverseReaction
Gasping Syndrome,AdverseReaction
in,O
premature,O
infants,O
and,O
infants,O
of,O
low,O
birth,O
weight,O
Exposure,O
to,O
excessive,O
amounts,O
of,O
benzyl,O
alcohol,O
has,O
been,O
associated,O
with,O
toxicity,O
hypotension,O
metabolic,O
acidosis,O
particularly,O
in,O
neonates,O
and,O
an,O
increased,O
incidence,O
of,O
kernicterus,O
particularly,O
in,O
small,O
preterm,O
infants,O
There,O
have,O
been,O
rare,O
reports,O
of,O
deaths,O
primarily,O
in,O
preterm,O
infants,O
associated,O
with,O
exposure,O
to,O
excessive,O
amounts,O
of,O
benzyl,O
alcohol,O
see,O
Description,O
11,O
Observe,O
infants,O
for,O
signs,O
or,O
symptoms,O
of,O
benzyl,O
alcohol,O
toxicity,O
following,O
AdreView,O
administration,O
AdreView,O
safety,O
and,O
effectiveness,O
have,O
not,O
been,O
established,O
in,O
neonates,O
pediatric,O
patients,O
below,O
the,O
age,O
of,O
1,O
month,O
5,O
4,O
Increased,O
Radiation,O
Exposure,O
in,O
Patients,O
with,O
Severe,O
Renal,O
Impairment,O
AdreView,O
is,O
cleared,O
by,O
glomerular,O
filtration,O
and,O
is,O
not,O
dialyzable,O
The,O
radiation,O
dose,O
to,O
patients,O
with,O
severe,O
renal,O
impairment,O
may,O
be,O
increased,O
due,O
to,O
the,O
delayed,O
elimination,O
of,O
the,O
drug,O
Delayed,O
AdreView,O
clearance,O
may,O
also,O
reduce,O
the,O
target,O
to,O
background,O
ratios,O
and,O
decrease,O
the,O
quality,O
of,O
scintigraphic,O
images,O
These,O
risks,O
importantly,O
may,O
limit,O
the,O
role,O
of,O
AdreView,O
in,O
the,O
diagnostic,O
evaluation,O
of,O
patients,O
with,O
severe,O
renal,O
impairment,O
AdreView,O
safety,O
and,O
efficacy,O
have,O
not,O
been,O
established,O
in,O
these,O
patients,O
see,O
Clinical,O
Pharmacology,O
12,O
2,O
5,O
5,O
Imaging,O
Errors,O
due,O
to,O
Conditions,O
that,O
Affect,O
the,O
Sympathetic,O
Nervous,O
System,O
Individuals,O
with,O
conditions,O
that,O
affect,O
the,O
sympathetic,O
nervous,O
system,O
e,O
g,O
Parkinsonian,O
syndromes,O
such,O
as,O
Parkinson,O
s,O
disease,O
or,O
multiple,O
system,O
atrophy,O
may,O
show,O
decreased,O
cardiac,O
uptake,O
of,O
AdreView,O
independent,O
of,O
heart,O
disease,O
5,O
6,O
Thyroid,O
Accumulation,O
Failure,O
to,O
block,O
thyroid,O
uptake,O
of,O
iodine,O
123,O
may,O
result,O
in,O
an,O
increased,O
long,O
term,O
risk,O
for,O
thyroid,O
neoplasia,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
7,O
Hypertension,O
Assess,O
the,O
patient,O
s,O
pulse,O
and,O
blood,O
pressure,O
before,O
and,O
intermittently,O
for,O
30,O
minutes,O
after,O
AdreView,O
administration,O
AdreView,O
may,Factor
increase,O
release,O
of,O
norepinephrine,O
from,O
chromaffin,O
granules,O
and,O
produce,O
a,O
transient episode of hypertension,AdverseReaction
although,O
this,O
was,O
not,O
observed,O
in,O
the,O
clinical,O
studies,O
Prior,O
to,O
AdreView,O
administration,O
ensure,O
emergency,O
cardiac,O
and,O
anti,O
hypertensive,O
treatments,O
are,O
readily,O
available,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Serious,Severity
hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
following,O
AdreView,O
administration,O
The,O
most,O
common,O
adverse,O
reactions,O
dizziness,AdverseReaction
rash,AdverseReaction
pruritis,AdverseReaction
flushing,AdverseReaction
headache,AdverseReaction
and,O
injection site hemorrhage,AdverseReaction
occurred,O
in,O
1,O
3,O
of,O
patients,O
6,O
1,O
6,O
2,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GE,O
Healthcare,O
at,O
1,O
800,O
654,O
0118,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Study,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
During,O
clinical,O
development,O
1346,O
patients,O
were,O
exposed,O
to,O
AdreView,O
251,O
patients,O
with,O
known,O
or,O
suspected,O
pheochromocytoma,O
or,O
neuroblastoma,O
985,O
patients,O
with,O
heart,O
failure,O
and,O
110,O
control,O
patients,O
All,O
patients,O
were,O
monitored,O
for,O
adverse,O
reactions,O
over,O
a,O
24,O
hour,O
period,O
following,O
AdreView,O
administration,O
Pheochromocytoma,O
and,O
Neuroblastoma,O
Serious,O
adverse,O
reactions,O
were,O
not,O
observed,O
in,O
the,O
AdreView,O
clinical,O
study,O
Adverse,O
reactions,O
were,O
all,O
mild,Severity
to,O
moderate,Severity
in,O
severity,O
and,O
were,O
predominantly,O
isolated,O
occurrences,O
2,O
patients,O
of,O
one,O
of,O
the,O
following,O
reactions,O
dizziness,AdverseReaction
rash,AdverseReaction
pruritus,AdverseReaction
flushing,AdverseReaction
or,O
injection site hemorrhage,AdverseReaction
Congestive,O
Heart,O
Failure,O
No,O
serious,O
adverse,O
reactions,O
to,O
AdreView,O
were,O
observed,O
in,O
clinical,O
studies,O
Adverse,O
reactions,O
that,O
occurred,O
with,O
a,O
frequency,O
1,O
were,O
associated,O
with,O
the,O
injection site site site,AdverseReaction
1,O
3,O
problems,AdverseReaction
such,O
as,O
hematoma,AdverseReaction
and,O
bruising,AdverseReaction
The,O
other,O
most,O
common,O
reactions,O
were,O
flushing,AdverseReaction
0,O
3,O
and,O
headache,AdverseReaction
0,O
4,O
The,O
adverse,O
reactions,O
were,O
predominantly,O
of,O
mild,O
to,O
moderate,O
intensity,O
6,O
2,O
Postmarketing,O
Experience,O
Because,O
postmarketing,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Hypersensitivity reactions,AdverseReaction
have,O
uncommonly,O
been,O
reported,O
during,O
the,O
postmarketing,O
use,O
of,O
AdreView,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Non infectious pneumonitis,AdverseReaction
Monitor,O
for,O
clinical,O
symptoms,O
or,O
radiological,O
changes,O
fatal,AdverseReaction
cases,O
have,O
occurred,O
Manage,O
by,O
dose,O
reduction,O
or,O
discontinuation,O
until,O
symptoms,O
resolve,O
and,O
consider,O
use,O
of,O
corticosteroids,O
5,O
1,O
Infections,AdverseReaction
Increased,O
risk,Factor
of,O
infections,AdverseReaction
some,O
fatal,AdverseReaction
Monitor,O
for,O
signs,O
and,O
symptoms,O
and,O
treat,O
promptly,O
5,O
2,O
Angioedema,AdverseReaction
Patients,O
taking,O
concomitant,O
ACE,O
inhibitor,O
therapy,O
may,O
be,O
at,O
increased,O
risk,O
for,O
angioedema,O
5,O
3,O
Oral ulceration,AdverseReaction
Mouth ulcers,AdverseReaction
stomatitis,AdverseReaction
and,O
oral mucositis,AdverseReaction
are,O
common,O
Management,O
includes,O
mouthwashes,O
and,O
topical,O
treatments,O
5,O
4,O
Renal failure,AdverseReaction
Cases,O
of,O
renal failure,AdverseReaction
including,O
acute renal failure,AdverseReaction
some,O
with,O
a,O
fatal,AdverseReaction
outcome,O
have,O
been,O
observed,O
5,O
5,O
Impaired wound healing,AdverseReaction
Increased,O
risk,Factor
of,O
wound related complications,AdverseReaction
Monitor,O
signs,O
and,O
symptoms,O
Exercise,O
caution,O
in,O
the,O
peri,O
surgical,O
period,O
5,O
6,O
Laboratory,O
test,O
alterations,O
Elevations of serum creatinine,AdverseReaction
urinary protein,AdverseReaction
blood glucose,AdverseReaction
and,O
lipids,AdverseReaction
may,O
occur,O
Decreases in hemoglobin in in,AdverseReaction
neutrophils,AdverseReaction
and,O
platelets,AdverseReaction
may,Factor
also,O
occur,O
Monitor,O
renal,O
function,O
blood,O
glucose,O
lipids,O
and,O
hematologic,O
parameters,O
prior,O
to,O
treatment,O
and,O
periodically,O
thereafter,O
5,O
8,O
Vaccinations,O
Avoid,O
live,O
vaccines,O
and,O
close,O
contact,O
with,O
those,O
who,O
have,O
received,O
live,O
vaccines,O
5,O
11,O
Embryo fetal toxicity,AdverseReaction
Fetal harm,AdverseReaction
can,Factor
occur,O
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Apprise,O
women,O
of,O
potential,O
harm,O
to,O
the,O
fetus,O
5,O
12,O
8,O
1,O
5,O
1,O
Non,O
infectious,O
Pneumonitis,O
Non infectious pneumonitis,AdverseReaction
is,O
a,O
class,O
effect,O
of,O
rapamycin,O
derivatives,O
including,O
AFINITOR,O
Non infectious pneumonitis,AdverseReaction
was,O
reported,O
in,O
up,O
to,O
19,O
of,O
patients,O
treated,O
with,O
AFINITOR,O
in,O
clinical,O
trials,O
The,O
incidence,O
of,O
Common,O
Terminology,O
Criteria,O
CTC,O
Grade 3,Severity
and,O
4,Severity
non infectious pneumonitis infectious pneumonitis,AdverseReaction
was,O
up,O
to,O
4,O
0,O
and,O
up,O
to,O
0,O
2,O
respectively,O
see,O
Adverse,O
Reactions,O
6,O
1,O
6,O
2,O
6,O
3,O
6,O
4,O
6,O
5,O
Fatal,AdverseReaction
outcomes,O
have,O
been,O
observed,O
Consider,Factor
a,O
diagnosis,O
of,O
non,O
infectious,O
pneumonitis,O
in,O
patients,O
presenting,O
with,O
non,O
specific,O
respiratory,O
signs,O
and,O
symptoms,O
such,O
as,O
hypoxia,O
pleural,O
effusion,O
cough,O
or,O
dyspnea,O
and,O
in,O
whom,O
infectious,O
neoplastic,O
and,O
other,O
causes,O
have,O
been,O
excluded,O
by,O
means,O
of,O
appropriate,O
investigations,O
Opportunistic,O
infections,O
such,O
as,O
pneumocystis,O
jiroveci,O
pneumonia,O
PJP,O
should,O
be,O
considered,O
in,O
the,O
differential,O
diagnosis,O
Advise,O
patients,O
to,O
report,O
promptly,O
any,O
new,O
or,O
worsening,O
respiratory,O
symptoms,O
Patients,O
who,O
develop,O
radiological,O
changes,O
suggestive,O
of,O
non,O
infectious,O
pneumonitis,O
and,O
have,O
few,O
or,O
no,O
symptoms,O
may,O
continue,O
AFINITOR,O
therapy,O
without,O
dose,O
alteration,O
Imaging,O
appears,O
to,O
overestimate,O
the,O
incidence,O
of,O
clinical,O
pneumonitis,O
If,O
symptoms,O
are,O
moderate,O
consider,O
interrupting,O
therapy,O
until,O
symptoms,O
improve,O
The,O
use,O
of,O
corticosteroids,O
may,O
be,O
indicated,Factor
AFINITOR,O
may,O
be,O
reintroduced,O
at,O
a,O
daily,O
dose,O
approximately,O
50,O
lower,O
than,O
the,O
dose,O
previously,O
administered,O
see,O
Table,O
1,O
in,O
Dosage,O
and,O
Administration,O
2,O
2,O
For,O
cases,O
of,O
Grade,O
3,O
non,O
infectious,O
pneumonitis,O
interrupt,O
AFINITOR,O
until,O
resolution,O
to,O
less,O
than,O
or,O
equal,O
to,O
Grade,O
1,O
AFINITOR,O
may,O
be,O
re,O
introduced,O
at,O
a,O
daily,O
dose,O
approximately,O
50,O
lower,O
than,O
the,O
dose,O
previously,O
administered,O
depending,O
on,O
the,O
individual,O
clinical,O
circumstances,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
If,O
toxicity,O
recurs,O
at,O
Grade,O
3,O
consider,O
discontinuation,O
of,O
AFINITOR,O
For,O
cases,O
of,O
Grade,O
4,O
non,O
infectious,O
pneumonitis,O
discontinue,O
AFINITOR,O
Corticosteroids,O
may,O
be,O
indicated,O
until,O
clinical,O
symptoms,O
resolve,O
For,O
patients,O
who,O
require,O
use,O
of,O
corticosteroids,O
for,O
treatment,O
of,O
non,O
infectious,O
pneumonitis,O
prophylaxis,O
for,O
PJP,O
may,O
be,O
considered,O
The,O
development,O
of,O
pneumonitis,AdverseReaction
has,O
been,O
reported,O
even,O
at,O
a,O
reduced,O
dose,O
5,O
2,O
Infections,O
AFINITOR,O
has,O
immunosuppressive,O
properties,O
and,O
may,Factor
predispose,O
patients,O
to,O
bacterial,AdverseReaction
fungal,AdverseReaction
viral,AdverseReaction
or,O
protozoal infections,AdverseReaction
including,O
infections with opportunistic pathogens,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
6,O
2,O
6,O
3,O
6,O
4,O
6,O
5,O
Localized,O
and,O
systemic,O
infections,O
including,O
pneumonia,AdverseReaction
mycobacterial infections,AdverseReaction
other,O
bacterial infections,AdverseReaction
invasive fungal infections,AdverseReaction
such,O
as,O
aspergillosis,AdverseReaction
candidiasis,AdverseReaction
or,O
pneumocystis jiroveci pneumonia,AdverseReaction
PJP,AdverseReaction
and,O
viral infections,AdverseReaction
including,O
reactivation of hepatitis B virus,AdverseReaction
have,O
occurred,O
in,O
patients,O
taking,O
AFINITOR,O
Some,O
of,O
these,O
infections,AdverseReaction
have,O
been,O
severe,Severity
e,O
g,O
leading,O
to,O
sepsis,AdverseReaction
respiratory,AdverseReaction
or,O
hepatic failure,AdverseReaction
or,O
fatal,AdverseReaction
Physicians,O
and,O
patients,O
should,O
be,O
aware,O
of,O
the,O
increased,O
risk,O
of,O
infection,O
with,O
AFINITOR,O
Complete,O
treatment,O
of,O
pre,O
existing,O
invasive,O
fungal,O
infections,O
prior,O
to,O
starting,O
treatment,O
with,O
AFINITOR,O
While,O
taking,O
AFINITOR,O
be,O
vigilant,O
for,O
signs,O
and,O
symptoms,O
of,O
infection,O
if,O
a,O
diagnosis,O
of,O
an,O
infection,O
is,O
made,O
institute,O
appropriate,O
treatment,O
promptly,O
and,O
consider,O
interruption,O
or,O
discontinuation,O
of,O
AFINITOR,O
If,O
a,O
diagnosis,O
of,O
invasive,O
systemic,O
fungal,O
infection,O
is,O
made,O
discontinue,O
AFINITOR,O
and,O
treat,O
with,O
appropriate,O
antifungal,O
therapy,O
Pneumocystis jiroveci pneumonia,AdverseReaction
some,O
with,O
a,O
fatal,AdverseReaction
outcome,O
has,O
been,O
reported,O
in,O
patients,O
who,O
received,O
everolimus,O
This,O
may,O
be,O
associated,O
with,O
concomitant,O
use,O
of,O
corticosteroids,O
or,O
other,O
immunosuppressive,O
agents,O
Prophylaxis,O
for,O
PJP,O
should,O
be,O
considered,O
when,O
concomitant,O
use,O
of,O
corticosteroids,O
or,O
other,O
immunosuppressive,O
agents,O
are,O
required,O
5,O
3,O
Angioedema,O
with,O
Concomitant,O
Use,O
of,O
Angiotensin,O
Converting,O
Enzyme,O
ACE,O
Inhibitors,O
Patients,O
taking,O
concomitant,O
ACE,O
inhibitor,O
therapy,O
may,O
be,O
at,O
increased,O
risk,Factor
for,O
angioedema,AdverseReaction
e,O
g,O
swelling of the airways of the,AdverseReaction
or,O
tongue,AdverseReaction
with,O
or,O
without,O
respiratory impairment,AdverseReaction
In,O
a,O
pooled,O
analysis,O
of,O
randomized,O
double,O
blind,O
oncology,O
clinical,O
trials,O
the,O
incidence,O
of,O
angioedema,AdverseReaction
in,O
patients,O
taking,O
everolimus,O
with,O
an,O
ACE,O
inhibitor,O
was,O
6,O
8,O
compared,O
to,O
1,O
3,O
in,O
the,O
control,O
arm,O
with,O
an,O
ACE,O
inhibitor,O
5,O
4,O
Oral,O
Ulceration,O
Mouth ulcers,AdverseReaction
stomatitis,AdverseReaction
and,O
oral mucositis,AdverseReaction
have,O
occurred,O
in,O
patients,O
treated,O
with,O
AFINITOR,O
at,O
an,O
incidence,O
ranging,O
from,O
44,O
78,O
across,O
the,O
clinical,O
trial,O
experience,O
Grade 3,Severity
or,O
4,Severity
stomatitis,AdverseReaction
was,O
reported,O
in,O
4,O
9,O
of,O
patients,O
see,O
Adverse,O
Reactions,O
6,O
1,O
6,O
2,O
6,O
3,O
6,O
4,O
6,O
5,O
In,O
such,O
cases,O
topical,O
treatments,O
are,O
recommended,O
but,O
alcohol,O
hydrogen,O
peroxide,O
iodine,O
or,O
thyme,O
containing,O
mouthwashes,O
should,O
be,O
avoided,O
as,O
they,O
may,O
exacerbate,O
the,O
condition,O
Antifungal,O
agents,O
should,O
not,O
be,O
used,O
unless,O
fungal,O
infection,O
has,O
been,O
diagnosed,O
see,O
Drug,O
Interactions,O
7,O
1,O
5,O
5,O
Renal,O
Failure,O
Cases,O
of,O
renal failure,AdverseReaction
including,O
acute renal failure,AdverseReaction
some,O
with,O
a,O
fatal,AdverseReaction
outcome,O
have,O
been,O
observed,O
in,O
patients,O
treated,O
with,O
AFINITOR,O
see,O
Laboratory,O
Tests,O
and,O
Monitoring,O
5,O
8,O
5,O
6,O
Impaired,O
Wound,O
Healing,O
Everolimus,O
delays wound healing,AdverseReaction
and,O
increases,O
the,O
occurrence,O
of,O
wound related complications,AdverseReaction
like,O
wound dehiscence,AdverseReaction
wound infection,AdverseReaction
incisional hernia,AdverseReaction
lymphocele,AdverseReaction
and,O
seroma,AdverseReaction
These,O
wound,O
related,O
complications,O
may,O
require,O
surgical,O
intervention,O
Exercise,O
caution,O
with,O
the,O
use,O
of,O
AFINITOR,O
in,O
the,O
peri,O
surgical,O
period,O
5,O
7,O
Geriatric,O
Patients,O
In,O
the,O
randomized,O
advanced,O
hormone,O
receptor,O
positive,O
HER2,O
negative,O
breast,O
cancer,O
study,O
the,O
incidence,O
of,O
deaths,AdverseReaction
due,O
to,O
any,O
cause,O
within,O
28,O
days,O
of,O
the,O
last,O
AFINITOR,O
dose,O
was,O
6,O
in,O
patients,O
65,O
years,O
of,O
age,O
compared,O
to,O
2,O
in,O
patients,O
65,O
years,O
of,O
age,O
Adverse,O
reactions,O
leading,O
to,O
permanent,O
treatment,O
discontinuation,O
occurred,O
in,O
33,O
of,O
patients,O
65,O
years,O
of,O
age,O
compared,O
to,O
17,O
in,O
patients,O
65,O
years,O
of,O
age,O
Careful,O
monitoring,O
and,O
appropriate,O
dose,O
adjustments,O
for,O
adverse,O
reactions,O
are,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
5,O
8,O
Laboratory,O
Tests,O
and,O
Monitoring,O
Renal,O
Function,O
Elevations of serum creatinine,AdverseReaction
and,O
proteinuria,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
taking,O
AFINITOR,O
see,O
Adverse,O
Reactions,O
6,O
1,O
6,O
2,O
6,O
3,O
6,O
4,O
6,O
5,O
Monitoring,O
of,O
renal,O
function,O
including,O
measurement,O
of,O
blood,O
urea,O
nitrogen,O
BUN,O
urinary,O
protein,O
or,O
serum,O
creatinine,O
is,O
recommended,O
prior,O
to,O
the,O
start,O
of,O
AFINITOR,O
therapy,O
and,O
periodically,O
thereafter,O
Renal,O
function,O
of,O
patients,O
should,O
be,O
monitored,O
particularly,O
where,O
patients,O
have,O
additional,O
risk,O
factors,O
that,O
may,O
further,O
impair,O
renal,O
function,O
Blood,O
Glucose,O
and,O
Lipids,O
Hyperglycemia,AdverseReaction
hyperlipidemia,AdverseReaction
and,O
hypertriglyceridemia,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
taking,O
AFINITOR,O
see,O
Adverse,O
Reactions,O
6,O
1,O
6,O
2,O
6,O
3,O
6,O
4,O
6,O
5,O
Monitoring,O
of,O
fasting,O
serum,O
glucose,O
and,O
lipid,O
profile,O
is,O
recommended,O
prior,O
to,O
the,O
start,O
of,O
AFINITOR,O
therapy,O
and,O
periodically,O
thereafter,O
as,O
well,O
as,O
management,O
with,O
appropriate,O
medical,O
therapy,O
More,O
frequent,O
monitoring,O
is,O
recommended,O
when,O
AFINITOR,O
is,O
co,O
administered,O
with,O
other,O
drugs,O
that,O
may,O
induce,O
hyperglycemia,O
When,O
possible,O
optimal,O
glucose,O
and,O
lipid,O
control,O
should,O
be,O
achieved,O
before,O
starting,O
a,O
patient,O
on,O
AFINITOR,O
Hematologic,O
Parameters,O
Decreased hemoglobin,AdverseReaction
lymphocytes,AdverseReaction
neutrophils,AdverseReaction
and,O
platelets,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
taking,O
AFINITOR,O
see,O
Adverse,O
Reactions,O
6,O
1,O
6,O
2,O
6,O
3,O
6,O
4,O
6,O
5,O
Monitoring,O
of,O
complete,O
blood,O
count,O
is,O
recommended,O
prior,O
to,O
the,O
start,O
of,O
AFINITOR,O
therapy,O
and,O
periodically,O
thereafter,O
5,O
9,O
Drug,O
drug,O
Interactions,O
Due,O
to,O
significant,O
increases,O
in,O
exposure,O
of,O
everolimus,O
co,O
administration,O
with,O
strong,O
CYP3A4,O
PgP,O
inhibitors,O
should,O
be,O
avoided,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
2,O
5,O
and,O
Drug,O
Interactions,O
7,O
1,O
A,O
reduction,O
of,O
the,O
AFINITOR,O
dose,O
is,O
recommended,O
when,O
co,O
administered,O
with,O
a,O
moderate,O
CYP3A4,O
PgP,O
inhibitor,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
2,O
5,O
and,O
Drug,O
Interactions,O
7,O
1,O
An,O
increase,O
in,O
the,O
AFINITOR,O
dose,O
is,O
recommended,O
when,O
co,O
administered,O
with,O
a,O
strong,O
CYP3A4,O
PgP,O
inducer,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
2,O
5,O
and,O
Drug,O
Interactions,O
7,O
2,O
5,O
10,O
Hepatic,O
Impairment,O
Exposure,O
to,O
everolimus,O
was,O
increased,O
in,O
patients,O
with,O
hepatic impairment,AdverseReaction
see,O
Clinical,O
Pharmacology,O
12,O
3,O
For,O
advanced,O
HR,O
BC,O
advanced,O
PNET,O
advanced,O
RCC,O
and,O
renal,O
angiomyolipoma,O
with,O
TSC,O
patients,O
with,O
severe,Severity
hepatic impairment,AdverseReaction
Child,O
Pugh,O
class,O
C,O
AFINITOR,O
may,O
be,O
used,O
at,O
a,O
reduced,O
dose,O
if,O
the,O
desired,O
benefit,O
outweighs,O
the,O
risk,O
For,O
patients,O
with,O
mild,O
Child,O
Pugh,O
class,O
A,O
or,O
moderate,O
Child,O
Pugh,O
class,O
B,O
hepatic,O
impairment,O
a,O
dose,O
reduction,O
is,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
For,O
patients,O
with,O
SEGA,O
and,O
mild,O
or,O
moderate,O
hepatic,O
impairment,O
adjust,O
the,O
dose,O
of,O
AFINITOR,O
Tablets,O
or,O
AFINITOR,O
DISPERZ,O
based,O
on,O
therapeutic,O
drug,O
monitoring,O
For,O
patients,O
with,O
SEGA,O
and,O
severe,O
hepatic,O
impairment,O
reduce,O
the,O
starting,O
dose,O
of,O
AFINITOR,O
Tablets,O
or,O
AFINITOR,O
DISPERZ,O
by,O
approximately,O
50,O
and,O
adjust,O
subsequent,O
doses,O
based,O
on,O
therapeutic,O
drug,O
monitoring,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
2,O
5,O
5,O
11,O
Vaccinations,O
During,O
AFINITOR,O
treatment,O
avoid,O
the,O
use,O
of,O
live,O
vaccines,O
and,O
avoid,O
close,O
contact,O
with,O
individuals,O
who,O
have,O
received,O
live,O
vaccines,O
e,O
g,O
intranasal,O
influenza,O
measles,O
mumps,O
rubella,O
oral,O
polio,O
BCG,O
yellow,O
fever,O
varicella,O
and,O
TY21a,O
typhoid,O
vaccines,O
For,O
pediatric,O
patients,O
with,O
SEGA,O
that,O
do,O
not,O
require,O
immediate,O
treatment,O
complete,O
the,O
recommended,O
childhood,O
series,O
of,O
live,O
virus,O
vaccinations,O
according,O
to,O
American,O
Council,O
on,O
Immunization,O
Practices,O
ACIP,O
guidelines,O
prior,O
to,O
the,O
start,O
of,O
therapy,O
An,O
accelerated,O
vaccination,O
schedule,O
may,O
be,O
appropriate,O
5,O
12,O
Embryo,O
fetal,O
Toxicity,O
Based,O
on,O
the,O
mechanism,O
of,O
action,O
AFINITOR,O
can,Factor
cause,O
fetal harm,AdverseReaction
Everolimus,O
caused,O
embryo fetal toxicities,AdverseReaction
in,O
animals,Animal
at,O
maternal,O
exposures,O
that,O
were,O
lower,O
than,O
human,O
exposures,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
a,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
Advise,O
female,O
patients,O
of,O
reproductive,O
potential,O
to,O
avoid,O
becoming,O
pregnant,O
and,O
to,O
use,O
highly,O
effective,O
contraception,O
while,O
using,O
AFINITOR,O
and,O
for,O
up,O
to,O
8,O
weeks,O
after,O
ending,O
treatment,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
another,O
section,O
of,O
the,O
label,O
see,O
Warnings,O
and,O
Precautions,O
5,O
Non infectious pneumonitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Angioedema,AdverseReaction
with,O
concomitant,O
use,O
of,O
ACE,O
inhibitors,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Oral ulceration,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Renal failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Impaired wound healing,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
the,O
adverse,O
reaction,O
rates,O
observed,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
other,O
trials,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
EXCERPT,O
Advanced,O
HR,O
BC,O
advanced,O
PNET,O
advanced,O
RCC,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
30,O
include,O
stomatitis,AdverseReaction
infections,AdverseReaction
rash,AdverseReaction
fatigue,AdverseReaction
diarrhea,AdverseReaction
edema,AdverseReaction
abdominal pain,AdverseReaction
nausea,AdverseReaction
fever,AdverseReaction
asthenia,AdverseReaction
cough,AdverseReaction
headache,AdverseReaction
and,O
decreased appetite,AdverseReaction
6,O
1,O
6,O
2,O
6,O
3,O
Renal,O
angiomyolipoma,O
with,O
TSC,O
Most,O
common,O
adverse,O
reaction,O
incidence,O
30,O
is,O
stomatitis,AdverseReaction
6,O
4,O
SEGA,O
with,O
TSC,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
30,O
are,O
stomatitis,AdverseReaction
and,O
respiratory tract infection,AdverseReaction
6,O
5,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Novartis,O
Pharmaceuticals,O
Corporation,O
at,O
1,O
888,O
669,O
6682,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Study,O
Experience,O
in,O
Advanced,O
Hormone,O
Receptor,O
Positive,O
HER2,O
Negative,O
Breast,O
Cancer,O
The,O
efficacy,O
and,O
safety,O
of,O
AFINITOR,O
10,O
mg,O
day,O
plus,O
exemestane,O
25,O
mg,O
day,O
n,O
485,O
versus,O
placebo,O
plus,O
exemestane,O
25,O
mg,O
day,O
n,O
239,O
was,O
evaluated,O
in,O
a,O
randomized,O
controlled,O
trial,O
in,O
patients,O
with,O
advanced,O
or,O
metastatic,O
hormone,O
receptor,O
positive,O
HER2,O
negative,O
breast,O
cancer,O
The,O
median,O
age,O
of,O
patients,O
was,O
61,O
years,O
range,O
28,O
93,O
years,O
and,O
75,O
were,O
Caucasian,O
Safety,O
results,O
are,O
based,O
on,O
a,O
median,O
follow,O
up,O
of,O
approximately,O
13,O
months,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
30,O
were,O
stomatitis,AdverseReaction
infections,AdverseReaction
rash,AdverseReaction
fatigue,AdverseReaction
diarrhea,AdverseReaction
and,O
decreased appetite,AdverseReaction
The,O
most,O
common,O
Grade,Severity
3,O
4,Severity
adverse,O
reactions,O
incidence,O
2,O
were,O
stomatitis,AdverseReaction
infections,AdverseReaction
hyperglycemia,AdverseReaction
fatigue,AdverseReaction
dyspnea,AdverseReaction
pneumonitis,AdverseReaction
and,O
diarrhea,AdverseReaction
The,O
most,O
common,O
laboratory,O
abnormalities,O
incidence,O
50,O
were,O
hypercholesterolemia,AdverseReaction
hyperglycemia,AdverseReaction
increased aspartate transaminase,AdverseReaction
AST,AdverseReaction
anemia,AdverseReaction
leukopenia,AdverseReaction
thrombocytopenia,AdverseReaction
lymphopenia,AdverseReaction
increased alanine transaminase,AdverseReaction
ALT,AdverseReaction
and,O
hypertriglyceridemia,AdverseReaction
The,O
most,O
common,O
Grade,O
3,O
4,O
laboratory,O
abnormalities,O
incidence,O
3,O
were,O
lymphopenia,AdverseReaction
hyperglycemia,AdverseReaction
anemia,AdverseReaction
decreased potassium,AdverseReaction
increased AST,AdverseReaction
increased ALT,AdverseReaction
and,O
thrombocytopenia,AdverseReaction
Fatal,AdverseReaction
adverse,O
reactions,O
occurred,O
more,O
frequently,O
in,O
patients,O
who,O
received,O
AFINITOR,O
plus,O
exemestane,O
2,O
compared,O
to,O
patients,O
on,O
the,O
placebo,O
plus,O
exemestane,O
arm,O
0,O
4,O
The,O
rates,O
of,O
treatment,O
emergent,O
adverse,O
events,O
resulting,O
in,O
permanent,O
discontinuation,O
were,O
24,O
and,O
5,O
for,O
the,O
AFINITOR,O
plus,O
exemestane,O
and,O
placebo,O
plus,O
exemestane,O
treatment,O
groups,O
respectively,O
Dose,O
adjustments,O
interruptions,O
or,O
reductions,O
were,O
more,O
frequent,O
among,O
patients,O
in,O
the,O
AFINITOR,O
plus,O
exemestane,O
arm,O
than,O
in,O
the,O
placebo,O
plus,O
exemestane,O
arm,O
63,O
versus,O
14,O
Table,O
2,O
compares,O
the,O
incidence,O
of,O
treatment,O
emergent,O
adverse,O
reactions,O
reported,O
with,O
an,O
incidence,O
of,O
10,O
for,O
patients,O
receiving,O
AFINITOR,O
10,O
mg,O
daily,O
versus,O
placebo,O
Table,O
2,O
Adverse,O
Reactions,O
Reported,O
10,O
of,O
Patients,O
with,O
Advanced,O
HR,O
BC,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
160,O
patients,O
33,O
2,O
were,O
exposed,O
to,O
AFINITOR,O
therapy,O
for,O
a,O
period,O
of,O
32,O
weeks,O
a,O
Exemestane,O
25,O
mg,O
day,O
b,O
Includes,O
stomatitis,AdverseReaction
mouth ulceration,AdverseReaction
aphthous stomatitis,AdverseReaction
glossodynia,AdverseReaction
gingival pain,AdverseReaction
glossitis,AdverseReaction
and,O
lip ulceration,AdverseReaction
c,O
Includes,O
all,O
preferred,O
terms,O
within,O
the,O
infections,O
and,O
infestations,O
system,O
organ,O
class,O
the,O
most,O
common,O
being,O
nasopharyngitis,AdverseReaction
10,O
urinary tract infection,AdverseReaction
10,O
upper respiratory tract infection,AdverseReaction
5,O
pneumonia,AdverseReaction
4,O
bronchitis,AdverseReaction
4,O
cystitis,AdverseReaction
3,O
sinusitis,AdverseReaction
3,O
and,O
also,O
including,O
candidiasis,AdverseReaction
1,O
and,O
sepsis,AdverseReaction
1,O
and,O
hepatitis C,AdverseReaction
1,O
d,O
Includes,O
pneumonitis,AdverseReaction
interstitial lung disease,AdverseReaction
lung infiltration,AdverseReaction
and,O
pulmonary fibrosis,AdverseReaction
e,O
Exposure,O
to,O
AFINITOR,O
or,O
placebo,O
AFINITOR,O
10,O
mg,O
day,O
exemestane,O
a,O
N,O
482,O
Placebo,O
exemestane,O
a,O
N,O
238,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Any,O
adverse,O
reaction,O
100,O
41,O
9,O
90,O
22,O
5,O
Gastrointestinal,O
disorders,O
Stomatitis,AdverseReaction
b,O
67,O
8,O
0,O
11,O
0,O
8,O
0,O
Diarrhea,AdverseReaction
33,O
2,O
0,O
2,O
18,O
0,O
8,O
0,O
Nausea,AdverseReaction
29,O
0,O
2,O
0,O
2,O
28,O
1,O
0,O
Vomiting,AdverseReaction
17,O
0,O
8,O
0,O
2,O
12,O
0,O
8,O
0,O
Constipation,AdverseReaction
14,O
0,O
4,O
0,O
13,O
0,O
4,O
0,O
Dry mouth,AdverseReaction
11,O
0,O
0,O
7,O
0,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
36,O
4,O
0,O
4,O
27,O
1,O
0,O
Edema peripheral,AdverseReaction
19,O
1,O
0,O
6,O
0,O
4,O
0,O
Pyrexia,AdverseReaction
15,O
0,O
2,O
0,O
7,O
0,O
4,O
0,O
Asthenia,AdverseReaction
13,O
2,O
0,O
2,O
4,O
0,O
0,O
Infections,O
and,O
infestations,O
Infections,AdverseReaction
c,O
50,O
4,O
1,O
25,O
2,O
0,O
Investigations,O
Weight decreased,AdverseReaction
25,O
1,O
0,O
6,O
0,O
0,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
30,O
1,O
0,O
12,O
0,O
4,O
0,O
Hyperglycemia,AdverseReaction
14,O
5,O
0,O
4,O
2,O
0,O
4,O
0,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
20,O
0,O
8,O
0,O
17,O
0,O
0,O
Back pain,AdverseReaction
14,O
0,O
2,O
0,O
10,O
0,O
8,O
0,O
Pain in extremity,AdverseReaction
9,O
0,O
4,O
0,O
11,O
2,O
0,O
Nervous,O
system,O
disorders,O
Dysgeusia,AdverseReaction
22,O
0,O
2,O
0,O
6,O
0,O
0,O
Headache,AdverseReaction
21,O
0,O
4,O
0,O
14,O
0,O
0,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
13,O
0,O
2,O
0,O
8,O
0,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
24,O
0,O
6,O
0,O
12,O
0,O
0,O
Dyspnea,AdverseReaction
21,O
4,O
0,O
2,O
11,O
0,O
8,O
0,O
4,O
Epistaxis,AdverseReaction
17,O
0,O
0,O
1,O
0,O
0,O
Pneumonitis,AdverseReaction
d,O
19,O
4,O
0,O
2,O
0,O
4,O
0,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
39,O
1,O
0,O
6,O
0,O
0,O
Pruritus,AdverseReaction
13,O
0,O
2,O
0,O
5,O
0,O
0,O
Alopecia,AdverseReaction
10,O
0,O
0,O
5,O
0,O
0,O
Vascular,O
disorders,O
Hot flush,AdverseReaction
6,O
0,O
0,O
14,O
0,O
0,O
Median,O
duration,O
of,O
treatment,O
e,O
23,O
9,O
weeks,O
13,O
4,O
weeks,O
Key,O
observed,O
laboratory,O
abnormalities,O
are,O
presented,O
in,O
Table,O
3,O
Table,O
3,O
Key,O
Laboratory,O
Abnormalities,O
Reported,O
in,O
10,O
of,O
Patients,O
with,O
Advanced,O
HR,O
BC,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
a,O
Exemestane,O
25,O
mg,O
day,O
b,O
Reflects,O
corresponding,O
adverse,O
drug,O
reaction,O
reports,O
of,O
anemia,AdverseReaction
leukopenia,AdverseReaction
lymphopenia,AdverseReaction
neutropenia,AdverseReaction
and,O
thrombocytopenia,AdverseReaction
collectively,O
as,O
pancytopenia,AdverseReaction
which,O
occurred,O
at,O
lower,O
frequency,O
Laboratory,O
parameter,O
AFINITOR,O
10,O
mg,O
day,O
exemestane,O
a,O
N,O
482,O
Placebo,O
exemestane,O
a,O
N,O
238,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Hematology,O
b,O
Hemoglobin decreased,AdverseReaction
68,O
6,O
0,O
6,O
40,O
0,O
8,O
0,O
4,O
WBC decreased,AdverseReaction
58,O
1,O
0,O
28,O
5,O
0,O
8,O
Platelets decreased,AdverseReaction
54,O
3,O
0,O
2,O
5,O
0,O
0,O
4,O
Lymphocytes decreased,AdverseReaction
54,O
11,O
0,O
6,O
37,O
5,O
0,O
8,O
Neutrophils decreased,AdverseReaction
31,O
2,O
0,O
11,O
0,O
8,O
0,O
8,O
Clinical,O
chemistry,O
Glucose increased,AdverseReaction
69,O
9,O
0,O
4,O
44,O
0,O
8,O
0,O
4,O
Cholesterol increased,AdverseReaction
70,O
0,O
6,O
0,O
2,O
38,O
0,O
8,O
0,O
8,O
Aspartate transaminase,AdverseReaction
AST,AdverseReaction
increased,AdverseReaction
69,O
4,O
0,O
2,O
45,O
3,O
0,O
4,O
Alanine transaminase,AdverseReaction
ALT,AdverseReaction
increased,AdverseReaction
51,O
4,O
0,O
2,O
29,O
5,O
0,O
Triglycerides increased,AdverseReaction
50,O
0,O
8,O
0,O
26,O
0,O
0,O
Albumin decreased,AdverseReaction
33,O
0,O
8,O
0,O
16,O
0,O
8,O
0,O
Potassium decreased,AdverseReaction
29,O
4,O
0,O
2,O
7,O
1,O
0,O
Creatinine increased,AdverseReaction
24,O
2,O
0,O
2,O
13,O
0,O
0,O
6,O
2,O
Clinical,O
Study,O
Experience,O
in,O
Advanced,O
Pancreatic,O
Neuroendocrine,O
Tumors,O
In,O
a,O
randomized,O
controlled,O
trial,O
of,O
AFINITOR,O
n,O
204,O
versus,O
placebo,O
n,O
203,O
in,O
patients,O
with,O
advanced,O
PNET,O
the,O
median,O
age,O
of,O
patients,O
was,O
58,O
years,O
range,O
20,O
87,O
79,O
were,O
Caucasian,O
and,O
55,O
were,O
male,O
Patients,O
on,O
the,O
placebo,O
arm,O
could,O
cross,O
over,O
to,O
open,O
label,O
AFINITOR,O
upon,O
disease,O
progression,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
30,O
were,O
stomatitis,AdverseReaction
rash,AdverseReaction
diarrhea,AdverseReaction
fatigue,AdverseReaction
edema,AdverseReaction
abdominal pain,AdverseReaction
nausea,AdverseReaction
fever,AdverseReaction
and,O
headache,AdverseReaction
The,O
most,O
common,O
Grade 3 3 4,Severity
adverse,O
reactions,O
incidence,O
5,O
were,O
stomatitis,AdverseReaction
and,O
diarrhea,AdverseReaction
The,O
most,O
common,O
laboratory,O
abnormalities,O
incidence,O
50,O
were,O
decreased hemoglobin,AdverseReaction
hyperglycemia,AdverseReaction
alkaline phosphatase increased,AdverseReaction
hypercholesterolemia,AdverseReaction
bicarbonate decreased,AdverseReaction
and,O
increased aspartate transaminase,AdverseReaction
AST,AdverseReaction
The,O
most,O
common,O
Grade 3 3 4,Severity
4,Severity
laboratory,O
abnormalities,O
incidence,O
3,O
were,O
hyperglycemia,AdverseReaction
lymphopenia,AdverseReaction
decreased hemoglobin,AdverseReaction
hypophosphatemia,AdverseReaction
increased alkaline phosphatase,AdverseReaction
neutropenia,AdverseReaction
increased aspartate transaminase,AdverseReaction
AST,AdverseReaction
potassium decreased,AdverseReaction
and,O
thrombocytopenia,AdverseReaction
Deaths,AdverseReaction
during,O
double,O
blind,O
treatment,O
where,O
an,O
adverse,O
event,O
was,O
the,O
primary,O
cause,O
occurred,O
in,O
seven,O
patients,O
on,O
AFINITOR,O
and,O
one,O
patient,O
on,O
placebo,O
Causes,O
of,O
death,AdverseReaction
on,O
the,O
AFINITOR,O
arm,O
included,O
one,O
case,O
of,O
each,O
of,O
the,O
following,O
acute renal failure,AdverseReaction
acute respiratory distress,AdverseReaction
cardiac arrest,AdverseReaction
death,AdverseReaction
cause,O
unknown,O
hepatic failure,AdverseReaction
pneumonia,AdverseReaction
and,O
sepsis,AdverseReaction
There,O
was,O
one,O
death,AdverseReaction
due,O
to,O
pulmonary embolism,AdverseReaction
on,O
the,O
placebo,Factor
arm,O
After,O
cross,O
over,O
to,O
open,O
label,O
AFINITOR,O
there,O
were,O
three,O
additional,O
deaths,AdverseReaction
one,O
due,O
to,O
hypoglycemia,AdverseReaction
and,O
cardiac arrest,AdverseReaction
in,O
a,O
patient,O
with,O
insulinoma,O
one,O
due,O
to,O
myocardial infarction,AdverseReaction
with,O
congestive heart failure,AdverseReaction
and,O
the,O
other,O
due,O
to,O
sudden death,AdverseReaction
The,O
rates,O
of,O
treatment,O
emergent,O
adverse,O
events,O
resulting,O
in,O
permanent,O
discontinuation,O
were,O
20,O
and,O
6,O
for,O
the,O
AFINITOR,O
and,O
placebo,O
treatment,O
groups,O
respectively,O
Dose,O
delay,O
or,O
reduction,O
was,O
necessary,O
in,O
61,O
of,O
everolimus,O
patients,O
and,O
29,O
of,O
placebo,O
patients,O
Grade 3,Severity
4,Severity
renal failure,AdverseReaction
occurred,O
in,O
six,O
patients,O
in,O
the,O
everolimus,O
arm,O
and,O
three,O
patients,O
in,O
the,O
placebo,O
arm,O
Thrombotic events,AdverseReaction
included,O
five,O
patients,O
with,O
pulmonary embolus,AdverseReaction
in,O
the,O
everolimus,O
arm,O
and,O
one,O
in,O
the,O
placebo,O
arm,O
as,O
well,O
as,O
three,O
patients,O
with,O
thrombosis,AdverseReaction
in,O
the,O
everolimus,O
arm,O
and,O
two,O
in,O
the,O
placebo,O
arm,O
Table,O
4,O
compares,O
the,O
incidence,O
of,O
treatment,O
emergent,O
adverse,O
reactions,O
reported,O
with,O
an,O
incidence,O
of,O
10,O
for,O
patients,O
receiving,O
AFINITOR,O
10,O
mg,O
daily,O
versus,O
placebo,O
Table,O
4,O
Adverse,O
Reactions,O
Reported,O
10,O
of,O
Patients,O
with,O
Advanced,O
PNET,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
a,O
Includes,O
stomatitis,AdverseReaction
aphthous stomatitis,AdverseReaction
gingival pain,AdverseReaction
swelling,AdverseReaction
ulceration,AdverseReaction
glossitis,AdverseReaction
glossodynia,AdverseReaction
lip ulceration,AdverseReaction
mouth ulceration,AdverseReaction
tongue ulceration,AdverseReaction
and,O
mucosal inflammation,AdverseReaction
b,O
Includes,O
diarrhea,AdverseReaction
enteritis,AdverseReaction
enterocolitis,AdverseReaction
colitis,AdverseReaction
defecation urgency,AdverseReaction
and,O
steatorrhea,AdverseReaction
c,O
Includes,O
pneumonitis,AdverseReaction
interstitial lung disease,AdverseReaction
pulmonary fibrosis,AdverseReaction
and,O
restrictive pulmonary disease,AdverseReaction
AFINITOR,O
N,O
204,O
Placebo,O
N,O
203,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Any,O
adverse,O
reaction,O
100,O
49,O
13,O
98,O
32,O
8,O
Gastrointestinal,O
disorders,O
Stomatitis,AdverseReaction
a,O
70,O
7,O
0,O
20,O
0,O
0,O
Diarrhea,AdverseReaction
b,O
50,O
5,O
0,O
5,O
25,O
3,O
0,O
Abdominal pain,AdverseReaction
36,O
4,O
0,O
32,O
6,O
1,O
Nausea,AdverseReaction
32,O
2,O
0,O
33,O
2,O
0,O
Vomiting,AdverseReaction
29,O
1,O
0,O
21,O
2,O
0,O
Constipation,AdverseReaction
14,O
0,O
0,O
13,O
0,O
5,O
0,O
Dry mouth,AdverseReaction
11,O
0,O
0,O
4,O
0,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
malaise,AdverseReaction
45,O
3,O
0,O
5,O
27,O
2,O
0,O
5,O
Edema,AdverseReaction
general,AdverseReaction
and,O
peripheral,AdverseReaction
39,O
1,O
0,O
5,O
12,O
1,O
0,O
Fever,AdverseReaction
31,O
0,O
5,O
0,O
5,O
13,O
0,O
5,O
0,O
Asthenia,AdverseReaction
19,O
3,O
0,O
20,O
3,O
0,O
Infections,O
and,O
infestations,O
Nasopharyngitis,AdverseReaction
rhinitis,AdverseReaction
URI,AdverseReaction
25,O
0,O
0,O
13,O
0,O
0,O
Urinary tract infection,AdverseReaction
16,O
0,O
0,O
6,O
0,O
5,O
0,O
Investigations,O
Weight decreased,AdverseReaction
28,O
0,O
5,O
0,O
11,O
0,O
0,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
30,O
1,O
0,O
18,O
1,O
0,O
Diabetes mellitus,AdverseReaction
10,O
2,O
0,O
0,O
5,O
0,O
0,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
15,O
1,O
0,O
5,O
7,O
0,O
5,O
0,O
Back pain,AdverseReaction
15,O
1,O
0,O
11,O
1,O
0,O
Pain in extremity,AdverseReaction
14,O
0,O
5,O
0,O
6,O
1,O
0,O
Muscle spasms,AdverseReaction
10,O
0,O
0,O
4,O
0,O
0,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
migraine,AdverseReaction
30,O
0,O
5,O
0,O
15,O
1,O
0,O
Dysgeusia,AdverseReaction
19,O
0,O
0,O
5,O
0,O
0,O
Dizziness,AdverseReaction
12,O
0,O
5,O
0,O
7,O
0,O
0,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
14,O
0,O
0,O
8,O
0,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
productive cough,AdverseReaction
25,O
0,O
5,O
0,O
13,O
0,O
0,O
Epistaxis,AdverseReaction
22,O
0,O
0,O
1,O
0,O
0,O
Dyspnea,AdverseReaction
dyspnea exertional,AdverseReaction
20,O
2,O
0,O
5,O
7,O
0,O
5,O
0,O
Pneumonitis,AdverseReaction
c,O
17,O
3,O
0,O
5,O
0,O
0,O
0,O
Oropharyngeal pain,AdverseReaction
11,O
0,O
0,O
6,O
0,O
0,O
Skin,O
and,O
subcutaneous,O
disorders,O
Rash,AdverseReaction
59,O
0,O
5,O
0,O
19,O
0,O
0,O
Nail disorders,AdverseReaction
22,O
0,O
5,O
0,O
2,O
0,O
0,O
Pruritus,AdverseReaction
pruritus generalized,AdverseReaction
21,O
0,O
0,O
13,O
0,O
0,O
Dry skin,AdverseReaction
xeroderma,AdverseReaction
13,O
0,O
0,O
6,O
0,O
0,O
Vascular,O
disorders,O
Hypertension,AdverseReaction
13,O
1,O
0,O
6,O
1,O
0,O
Median,O
duration,O
of,O
treatment,O
wks,O
37,O
16,O
In,O
female,O
patients,O
aged,O
18,O
to,O
55,O
years,O
irregular menstruation,AdverseReaction
occurred,O
in,O
5,O
of,O
46,O
11,O
AFINITOR,O
treated,O
females,O
and,O
none,O
of,O
the,O
33,O
females,O
in,O
the,O
placebo,O
group,O
Key,O
observed,O
laboratory,O
abnormalities,O
are,O
presented,O
in,O
Table,O
5,O
Table,O
5,O
Key,O
Laboratory,O
Abnormalities,O
Reported,O
in,O
10,O
of,O
Patients,O
with,O
Advanced,O
PNET,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
Laboratory,O
parameter,O
AFINITOR,O
N,O
204,O
Placebo,O
N,O
203,O
All,O
grades,O
Grade,O
3,O
4,O
All,O
grades,O
Grade,O
3,O
4,O
Hematology,O
Hemoglobin decreased,AdverseReaction
86,O
15,O
63,O
1,O
Lymphocytes decreased,AdverseReaction
45,O
16,O
22,O
4,O
Platelets decreased,AdverseReaction
45,O
3,O
11,O
0,O
WBC decreased,AdverseReaction
43,O
2,O
13,O
0,O
Neutrophils decreased,AdverseReaction
30,O
4,O
17,O
2,O
Clinical,O
chemistry,O
Alkaline phosphatase increased,AdverseReaction
74,O
8,O
66,O
8,O
Glucose fasting increased,AdverseReaction
75,O
17,O
53,O
6,O
Cholesterol increased,AdverseReaction
66,O
0,O
5,O
22,O
0,O
Bicarbonate decreased,AdverseReaction
56,O
0,O
40,O
0,O
Aspartate transaminase,AdverseReaction
AST,AdverseReaction
increased,AdverseReaction
56,O
4,O
41,O
4,O
Alanine transaminase,AdverseReaction
ALT,AdverseReaction
increased,AdverseReaction
48,O
2,O
35,O
2,O
Phosphate decreased,AdverseReaction
40,O
10,O
14,O
3,O
Triglycerides increased,AdverseReaction
39,O
0,O
10,O
0,O
Calcium decreased,AdverseReaction
37,O
0,O
5,O
12,O
0,O
Potassium decreased,AdverseReaction
23,O
4,O
5,O
0,O
Creatinine increased,AdverseReaction
19,O
2,O
14,O
0,O
Sodium decreased,AdverseReaction
16,O
1,O
16,O
1,O
Albumin decreased,AdverseReaction
13,O
1,O
8,O
0,O
Bilirubin increased,AdverseReaction
10,O
1,O
14,O
2,O
Potassium increased,AdverseReaction
7,O
0,O
10,O
0,O
5,O
6,O
3,O
Clinical,O
Study,O
Experience,O
in,O
Advanced,O
Renal,O
Cell,O
Carcinoma,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
AFINITOR,O
n,O
274,O
and,O
placebo,O
n,O
137,O
in,O
a,O
randomized,O
controlled,O
trial,O
in,O
patients,O
with,O
metastatic,O
renal,O
cell,O
carcinoma,O
who,O
received,O
prior,O
treatment,O
with,O
sunitinib,O
and,O
or,O
sorafenib,O
The,O
median,O
age,O
of,O
patients,O
was,O
61,O
years,O
range,O
27,O
85,O
88,O
were,O
Caucasian,O
and,O
78,O
were,O
male,O
The,O
median,O
duration,O
of,O
blinded,O
study,O
treatment,O
was,O
141,O
days,O
range,O
19,O
451,O
days,O
for,O
patients,O
receiving,O
AFINITOR,O
and,O
60,O
days,O
range,O
21,O
295,O
days,O
for,O
those,O
receiving,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
30,O
were,O
stomatitis,AdverseReaction
infections,AdverseReaction
asthenia,AdverseReaction
fatigue,AdverseReaction
cough,AdverseReaction
and,O
diarrhea,AdverseReaction
The,O
most,O
common,O
Grade 3 3 4,Severity
4,Severity
adverse,O
reactions,O
incidence,O
3,O
were,O
infections,AdverseReaction
dyspnea,AdverseReaction
fatigue,AdverseReaction
stomatitis,AdverseReaction
dehydration,AdverseReaction
pneumonitis,AdverseReaction
abdominal pain,AdverseReaction
and,O
asthenia,AdverseReaction
The,O
most,O
common,O
laboratory,O
abnormalities,O
incidence,O
50,O
were,O
anemia,AdverseReaction
hypercholesterolemia,AdverseReaction
hypertriglyceridemia,O
hyperglycemia,AdverseReaction
lymphopenia,AdverseReaction
and,O
increased creatinine,AdverseReaction
The,O
most,O
common,O
Grade 3 3 4,Severity
4,Severity
laboratory,O
abnormalities,O
incidence,O
3,O
were,O
lymphopenia,AdverseReaction
hyperglycemia,AdverseReaction
anemia,AdverseReaction
hypophosphatemia,AdverseReaction
and,O
hypercholesterolemia,AdverseReaction
Deaths,AdverseReaction
due,O
to,O
acute respiratory failure,AdverseReaction
0,O
7,O
infection,AdverseReaction
0,O
7,O
and,O
acute renal failure,AdverseReaction
0,O
4,O
were,O
observed,O
on,O
the,O
AFINITOR,O
arm,O
but,O
none,O
on,O
the,O
placebo,O
arm,O
The,O
rates,O
of,O
treatment,O
emergent,O
adverse,O
events,O
irrespective,O
of,O
causality,O
resulting,O
in,O
permanent,O
discontinuation,O
were,O
14,O
and,O
3,O
for,O
the,O
AFINITOR,O
and,O
placebo,O
treatment,O
groups,O
respectively,O
The,O
most,O
common,O
adverse,O
reactions,O
irrespective,O
of,O
causality,O
leading,O
to,O
treatment,O
discontinuation,O
were,O
pneumonitis,AdverseReaction
and,O
dyspnea,AdverseReaction
Infections,AdverseReaction
stomatitis,AdverseReaction
and,O
pneumonitis,AdverseReaction
were,O
the,O
most,O
common,O
reasons,O
for,O
treatment,O
delay,O
or,O
dose,O
reduction,O
The,O
most,O
common,O
medical,O
interventions,O
required,O
during,O
AFINITOR,O
treatment,O
were,O
for,O
infections,AdverseReaction
anemia,AdverseReaction
and,O
stomatitis,AdverseReaction
Table,O
6,O
compares,O
the,O
incidence,O
of,O
treatment,O
emergent,O
adverse,O
reactions,O
reported,O
with,O
an,O
incidence,O
of,O
10,O
for,O
patients,O
receiving,O
AFINITOR,O
10,O
mg,O
daily,O
versus,O
placebo,O
Within,O
each,O
MedDRA,O
system,O
organ,O
class,O
the,O
adverse,O
reactions,O
are,O
presented,O
in,O
order,O
of,O
decreasing,O
frequency,O
Table,O
6,O
Adverse,O
Reactions,O
Reported,O
in,O
at,O
Least,O
10,O
of,O
Patients,O
with,O
RCC,O
and,O
at,O
a,O
Higher,O
Rate,O
in,O
the,O
AFINITOR,O
Arm,O
than,O
in,O
the,O
Placebo,O
Arm,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
a,O
Stomatitis,AdverseReaction
including,O
aphthous stomatitis,AdverseReaction
and,O
mouth,AdverseReaction
and,O
tongue ulceration,AdverseReaction
b,O
Includes,O
all,O
preferred,O
terms,O
within,O
the,O
infections,O
and,O
infestations,O
system,O
organ,O
class,O
the,O
most,O
common,O
being,O
nasopharyngitis,AdverseReaction
6,O
pneumonia,AdverseReaction
6,O
urinary tract infection,AdverseReaction
5,O
bronchitis,AdverseReaction
4,O
and,O
sinusitis,AdverseReaction
3,O
and,O
also,O
including,O
aspergillosis,AdverseReaction
1,O
candidiasis,AdverseReaction
1,O
and,O
sepsis,AdverseReaction
1,O
c,O
Includes,O
pneumonitis,AdverseReaction
interstitial lung disease,AdverseReaction
lung infiltration,AdverseReaction
pulmonary alveolar hemorrhage,AdverseReaction
pulmonary toxicity,AdverseReaction
and,O
alveolitis,AdverseReaction
AFINITOR,O
10,O
mg,O
day,O
N,O
274,O
Placebo,O
N,O
137,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Any,O
a,O
dverse,O
r,O
eaction,O
97,O
52,O
13,O
93,O
23,O
5,O
Gastrointestinal,O
d,O
isorders,O
Stomatitis,AdverseReaction
a,O
44,O
4,O
1,O
8,O
0,O
0,O
Diarrhea,AdverseReaction
30,O
1,O
0,O
7,O
0,O
0,O
Nausea,AdverseReaction
26,O
1,O
0,O
19,O
0,O
0,O
Vomiting,AdverseReaction
20,O
2,O
0,O
12,O
0,O
0,O
Infections,O
and,O
i,O
nfestations,O
b,O
37,O
7,O
3,O
18,O
1,O
0,O
General,O
d,O
isorders,O
and,O
a,O
dministration,O
s,O
ite,O
c,O
onditions,O
Asthenia,AdverseReaction
33,O
3,O
1,O
23,O
4,O
0,O
Fatigue,AdverseReaction
31,O
5,O
0,O
27,O
3,O
1,O
Edema peripheral,AdverseReaction
25,O
1,O
0,O
8,O
1,O
0,O
Pyrexia,AdverseReaction
20,O
1,O
0,O
9,O
0,O
0,O
Mucosal inflammation,AdverseReaction
19,O
1,O
0,O
1,O
0,O
0,O
Respiratory,O
t,O
horacic,O
and,O
m,O
ediastinal,O
d,O
isorders,O
Cough,AdverseReaction
30,O
1,O
0,O
16,O
0,O
0,O
Dyspnea,AdverseReaction
24,O
6,O
1,O
15,O
3,O
0,O
Epistaxis,AdverseReaction
18,O
0,O
0,O
0,O
0,O
0,O
Pneumonitis,AdverseReaction
c,O
14,O
4,O
0,O
0,O
0,O
0,O
Skin,O
and,O
s,O
ubcutaneous,O
t,O
issue,O
d,O
isorders,O
Rash,AdverseReaction
29,O
1,O
0,O
7,O
0,O
0,O
Pruritus,AdverseReaction
14,O
1,O
0,O
7,O
0,O
0,O
Dry skin,AdverseReaction
13,O
1,O
0,O
5,O
0,O
0,O
Metabolism,O
and,O
n,O
utrition,O
d,O
isorders,O
Anorexia,AdverseReaction
25,O
1,O
0,O
14,O
1,O
0,O
Nervous,O
s,O
ystem,O
d,O
isorders,O
Headache,AdverseReaction
19,O
1,O
1,O
9,O
1,O
0,O
Dysgeusia,AdverseReaction
10,O
0,O
0,O
2,O
0,O
0,O
Musculoskeletal,O
and,O
c,O
onnective,O
t,O
issue,O
d,O
isorders,O
Pain in extremity,AdverseReaction
10,O
1,O
0,O
7,O
0,O
0,O
Medi,O
an,O
d,O
uration,O
of,O
t,O
reatment,O
d,O
141,O
60,O
Other,O
notable,O
adverse,O
reactions,O
occurring,O
more,O
frequently,O
with,O
AFINITOR,O
than,O
with,O
placebo,O
but,O
with,O
an,O
incidence,O
of,O
10,O
include,O
Gastrointestinal,O
disorders,O
Abdominal pain,AdverseReaction
9,O
dry mouth,AdverseReaction
8,O
hemorrhoids,AdverseReaction
5,O
dysphagia,AdverseReaction
4,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Weight decreased,AdverseReaction
9,O
chest pain,AdverseReaction
5,O
chills,AdverseReaction
4,O
impaired wound healing,AdverseReaction
1,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Pleural effusion,AdverseReaction
7,O
pharyngolaryngeal pain,AdverseReaction
4,O
rhinorrhea,AdverseReaction
3,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Hand foot syndrome,AdverseReaction
reported,O
as,O
palmar plantar erythrodysesthesia syndrome,AdverseReaction
5,O
nail disorder,AdverseReaction
5,O
erythema,AdverseReaction
4,O
onychoclasis,AdverseReaction
4,O
skin lesion,AdverseReaction
4,O
acneiform dermatitis,AdverseReaction
3,O
angioedema,AdverseReaction
1,O
Metabolism,O
and,O
nutrition,O
disorders,O
Exacerbation,AdverseReaction
of,O
pre,O
existing,O
diabetes mellitus,AdverseReaction
2,O
new onset of diabetes mellitus,AdverseReaction
1,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
9,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
7,O
paresthesia,AdverseReaction
5,O
Eye,O
disorders,O
Eyelid edema,AdverseReaction
4,O
conjunctivitis,AdverseReaction
2,O
Vascular,O
disorders,O
Hypertension,AdverseReaction
4,O
deep vein thrombosis,AdverseReaction
1,O
Renal,O
and,O
urinary,O
disorders,O
Renal failure,AdverseReaction
3,O
Cardiac,O
disorders,O
Tachycardia,AdverseReaction
3,O
congestive cardiac failure,AdverseReaction
1,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Jaw pain,AdverseReaction
3,O
Hematologic,O
disorders,O
Hemorrhage,AdverseReaction
3,O
Key,O
laboratory,O
abnormalities,O
are,O
presented,O
in,O
Table,O
7,O
Table,O
7,O
Key,O
Laboratory,O
Abnormalities,O
Reported,O
in,O
Patients,O
with,O
RCC,O
at,O
a,O
Higher,O
Rate,O
in,O
the,O
AFINITOR,O
Arm,O
than,O
the,O
Placebo,O
Arm,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
a,O
Reflects,O
corresponding,O
adverse,O
drug,O
reaction,O
reports,O
of,O
anemia,AdverseReaction
leukopenia,AdverseReaction
lymphopenia,AdverseReaction
neutropenia,AdverseReaction
and,O
thrombocytopenia,AdverseReaction
collectively,O
pancytopenia,AdverseReaction
which,O
occurred,O
at,O
lower,O
frequency,O
Laboratory,O
p,O
arameter,O
AFINITOR,O
10,O
mg,O
day,O
N,O
274,O
Placebo,O
N,O
137,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Hematology,O
a,O
Hemoglobin decreased,AdverseReaction
92,O
12,O
1,O
79,O
5,O
1,O
Lymphocytes decreased,AdverseReaction
51,O
16,O
2,O
28,O
5,O
0,O
Platelets decreased,AdverseReaction
23,O
1,O
0,O
2,O
0,O
1,O
Neutrophils decreased,AdverseReaction
14,O
0,O
1,O
4,O
0,O
0,O
Clinical,O
c,O
hemistry,O
Cholesterol increased,AdverseReaction
77,O
4,O
0,O
35,O
0,O
0,O
Triglycerides increased,AdverseReaction
73,O
1,O
0,O
34,O
0,O
0,O
Glucose increased,AdverseReaction
57,O
15,O
1,O
25,O
1,O
0,O
Creatinine increased,AdverseReaction
50,O
1,O
0,O
34,O
0,O
0,O
Phosphate decreased,AdverseReaction
37,O
6,O
0,O
8,O
0,O
0,O
Aspartate transaminase,AdverseReaction
AST,AdverseReaction
increased,AdverseReaction
25,O
1,O
1,O
7,O
0,O
0,O
Alanine transaminase,AdverseReaction
ALT,AdverseReaction
increased,AdverseReaction
21,O
1,O
0,O
4,O
0,O
0,O
Bilirubin increased,AdverseReaction
3,O
1,O
1,O
2,O
0,O
0,O
6,O
4,O
Clinical,O
Study,O
Experience,O
in,O
Renal,O
Angiomyolipoma,O
with,O
Tuberous,O
Sclerosis,O
Complex,O
The,O
data,O
described,O
below,O
are,O
based,O
on,O
a,O
randomized,O
2,O
1,O
double,O
blind,O
placebo,O
controlled,O
trial,O
of,O
AFINITOR,O
in,O
118,O
patients,O
with,O
renal,O
angiomyolipoma,O
as,O
a,O
feature,O
of,O
TSC,O
n,O
113,O
or,O
sporadic,O
lymphangioleiomyomatosis,O
n,O
5,O
The,O
median,O
age,O
of,O
patients,O
was,O
31,O
years,O
range,O
18,O
to,O
61,O
years,O
89,O
were,O
Caucasian,O
and,O
34,O
were,O
male,O
The,O
median,O
duration,O
of,O
blinded,O
study,O
treatment,O
was,O
48,O
weeks,O
range,O
2,O
to,O
115,O
weeks,O
for,O
patients,O
receiving,O
AFINITOR,O
and,O
45,O
weeks,O
range,O
9,O
to,O
115,O
weeks,O
for,O
those,O
receiving,O
placebo,O
The,O
most,O
common,O
adverse,O
reaction,O
reported,O
for,O
AFINITOR,O
incidence,O
30,O
was,O
stomatitis,AdverseReaction
The,O
most,O
common,O
Grade,O
3,O
4,O
adverse,O
reactions,O
incidence,O
2,O
were,O
stomatitis,AdverseReaction
and,O
amenorrhea,AdverseReaction
The,O
most,O
common,O
laboratory,O
abnormalities,O
incidence,O
50,O
were,O
hypercholesterolemia,AdverseReaction
hypertriglyceridemia,AdverseReaction
and,O
anemia,AdverseReaction
The,O
most,O
common,O
Grade,O
3,O
4,O
laboratory,O
abnormality,O
incidence,O
3,O
was,O
hypophosphatemia,AdverseReaction
The,O
rate,O
of,O
adverse,O
reactions,O
resulting,O
in,O
permanent,O
discontinuation,O
was,O
3,O
8,O
in,O
the,O
AFINITOR,O
treated,O
patients,O
Adverse,O
reactions,O
leading,O
to,O
permanent,O
discontinuation,O
in,O
the,O
AFINITOR,O
arm,O
were,O
hypersensitivity,AdverseReaction
angioedema,AdverseReaction
bronchospasm,AdverseReaction
convulsion,AdverseReaction
and,O
hypophosphatemia,AdverseReaction
Dose,O
adjustments,O
interruptions,O
or,O
reductions,O
due,O
to,O
adverse,O
reactions,O
occurred,O
in,O
52,O
of,O
AFINITOR,O
treated,O
patients,O
The,O
most,O
common,O
adverse,O
reaction,O
leading,O
to,O
AFINITOR,O
dose,O
adjustment,O
was,O
stomatitis,AdverseReaction
Table,O
8,O
compares,O
the,O
incidence,O
of,O
adverse,O
reactions,O
reported,O
with,O
an,O
incidence,O
of,O
10,O
for,O
patients,O
receiving,O
AFINITOR,O
and,O
occurring,O
more,O
frequently,O
with,O
AFINITOR,O
than,O
with,O
placebo,O
Laboratory,O
abnormalities,O
are,O
described,O
separately,O
in,O
Table,O
9,O
Table,O
8,O
Adverse,O
Reactions,O
Reported,O
in,O
10,O
of,O
AFINITOR,O
treated,O
Patients,O
with,O
Renal,O
Angiomyolipoma,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
a,O
Includes,O
stomatitis,AdverseReaction
aphthous stomatitis,AdverseReaction
mouth ulceration,AdverseReaction
gingival pain,AdverseReaction
glossitis,AdverseReaction
and,O
glossodynia,AdverseReaction
AFINITOR,O
N,O
79,O
Placebo,O
N,O
39,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Any,O
adverse,O
reaction,O
100,O
25,O
5,O
97,O
8,O
5,O
Gastrointestinal,O
disorders,O
Stomatitis,AdverseReaction
a,O
78,O
6,O
0,O
23,O
0,O
0,O
Vomiting,AdverseReaction
15,O
0,O
0,O
5,O
0,O
0,O
Diarrhea,AdverseReaction
14,O
0,O
0,O
5,O
0,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Peripheral edema,AdverseReaction
13,O
0,O
0,O
8,O
0,O
0,O
Infections,O
and,O
infestations,O
Upper respiratory tract infection,AdverseReaction
11,O
0,O
0,O
5,O
0,O
0,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
13,O
0,O
0,O
5,O
0,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
20,O
0,O
0,O
13,O
0,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Acne,AdverseReaction
22,O
0,O
0,O
5,O
0,O
0,O
Amenorrhea,AdverseReaction
occurred,O
in,O
15,O
of,O
AFINITOR,O
treated,O
females,O
8,O
of,O
52,O
and,O
4,O
1,O
of,O
26,O
of,O
females,O
in,O
the,O
placebo,O
group,O
Other,O
adverse,O
reactions,O
involving,O
the,O
female,O
reproductive,O
system,O
were,O
menorrhagia,AdverseReaction
10,O
menstrual irregularities,AdverseReaction
10,O
and,O
vaginal hemorrhage,AdverseReaction
8,O
The,O
following,O
additional,O
adverse,O
reactions,O
occurred,O
in,O
less,O
than,O
10,O
of,O
AFINITOR,O
treated,O
patients,O
epistaxis,AdverseReaction
9,O
decreased appetite,AdverseReaction
6,O
otitis media,AdverseReaction
6,O
depression,AdverseReaction
5,O
abnormal taste,AdverseReaction
5,O
increased blood luteinizing hormone blood,AdverseReaction
LH,AdverseReaction
levels,AdverseReaction
4,O
increased blood follicle stimulating hormone blood,AdverseReaction
FSH,AdverseReaction
levels,AdverseReaction
3,O
hypersensitivity,AdverseReaction
3,O
ovarian cyst,AdverseReaction
3,O
pneumonitis,AdverseReaction
1,O
and,O
angioedema,AdverseReaction
1,O
Table,O
9,O
Key,O
Laboratory,O
Abnormalities,O
Reported,O
in,O
AFINITOR,O
treated,O
Patients,O
with,O
Renal,O
Angiomyolipoma,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
AFINITOR,O
N,O
79,O
Placebo,O
N,O
39,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Hematology,O
Anemia,O
61,O
0,O
0,O
49,O
0,O
0,O
Leucopenia,AdverseReaction
37,O
0,O
0,O
21,O
0,O
0,O
Neutropenia,AdverseReaction
25,O
0,O
1,O
26,O
0,O
0,O
Lymphopenia,AdverseReaction
20,O
1,O
0,O
8,O
0,O
0,O
Thrombocytopenia,AdverseReaction
19,O
0,O
0,O
3,O
0,O
0,O
Clinical,O
chemistry,O
Hypercholesterolemia,AdverseReaction
85,O
1,O
0,O
46,O
0,O
0,O
Hypertriglyceridemia,AdverseReaction
52,O
0,O
0,O
10,O
0,O
0,O
Hypophosphatemia,AdverseReaction
49,O
5,O
0,O
15,O
0,O
0,O
Alkaline phosphatase increased,AdverseReaction
32,O
1,O
0,O
10,O
0,O
0,O
Elevated aspartate transaminase,AdverseReaction
AST,AdverseReaction
23,O
1,O
0,O
8,O
0,O
0,O
Elevated alanine transaminase,AdverseReaction
ALT,AdverseReaction
20,O
1,O
0,O
15,O
0,O
0,O
Fasting hyperglycemia,AdverseReaction
14,O
0,O
0,O
8,O
0,O
0,O
6,O
5,O
Clinical,O
Study,O
Experience,O
in,O
Subependymal,O
Giant,O
Cell,O
Astrocytoma,O
with,O
Tuberous,O
Sclerosis,O
Complex,O
The,O
data,O
described,O
below,O
are,O
based,O
on,O
a,O
randomized,O
2,O
1,O
double,O
blind,O
placebo,O
controlled,O
trial,O
Study,O
1,O
of,O
AFINITOR,O
in,O
117,O
patients,O
with,O
subependymal,O
giant,O
cell,O
astrocytoma,O
SEGA,O
and,O
tuberous,O
sclerosis,O
complex,O
TSC,O
The,O
median,O
age,O
of,O
patients,O
was,O
9,O
5,O
years,O
range,O
0,O
8,O
to,O
26,O
years,O
93,O
were,O
Caucasian,O
and,O
57,O
were,O
male,O
The,O
median,O
duration,O
of,O
blinded,O
study,O
treatment,O
was,O
52,O
weeks,O
range,O
24,O
to,O
89,O
weeks,O
for,O
patients,O
receiving,O
AFINITOR,O
and,O
47,O
weeks,O
range,O
14,O
to,O
88,O
weeks,O
for,O
those,O
receiving,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
reported,O
for,O
AFINITOR,O
incidence,O
30,O
were,O
stomatitis,AdverseReaction
and,O
respiratory tract infection,AdverseReaction
The,O
most,O
common,O
Grade 3 3 4,Severity
4,Severity
adverse,O
reactions,O
incidence,O
2,O
were,O
stomatitis,AdverseReaction
pyrexia,AdverseReaction
pneumonia,AdverseReaction
gastroenteritis,AdverseReaction
aggression,AdverseReaction
agitation,AdverseReaction
and,O
amenorrhea,AdverseReaction
The,O
most,O
common,O
key,O
laboratory,O
abnormalities,O
incidence,O
50,O
were,O
hypercholesterolemia,AdverseReaction
and,O
elevated partial thromboplastin time,AdverseReaction
The,O
most,O
common,O
Grade 3 3 4,Severity
4,Severity
laboratory,O
abnormality,O
incidence,O
3,O
was,O
neutropenia,AdverseReaction
There,O
were,O
no,O
adverse,O
reactions,O
resulting,O
in,O
permanent,O
discontinuation,O
Dose,O
adjustments,O
interruptions,O
or,O
reductions,O
due,O
to,O
adverse,O
reactions,O
occurred,O
in,O
55,O
of,O
AFINITOR,O
treated,O
patients,O
The,O
most,O
common,O
adverse,O
reaction,O
leading,O
to,O
AFINITOR,O
dose,O
adjustment,O
was,O
stomatitis,AdverseReaction
Table,O
10,O
compares,O
the,O
incidence,O
of,O
adverse,O
reactions,O
reported,O
with,O
an,O
incidence,O
of,O
10,O
for,O
patients,O
receiving,O
AFINITOR,O
and,O
occurring,O
more,O
frequently,O
with,O
AFINITOR,O
than,O
with,O
placebo,O
Laboratory,O
abnormalities,O
are,O
described,O
separately,O
in,O
Table,O
11,O
Table,O
10,O
Adverse,O
Reactions,O
Reported,O
in,O
10,O
of,O
AFINITOR,O
treated,O
Patients,O
with,O
SEGA,O
in,O
Study,O
1,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
a,O
Includes,O
mouth ulceration,AdverseReaction
stomatitis,AdverseReaction
and,O
lip ulceration,AdverseReaction
b,O
Includes,O
respiratory tract infection,AdverseReaction
upper respiratory tract infection,AdverseReaction
and,O
respiratory tract infection viral,AdverseReaction
c,O
Includes,O
gastroenteritis,AdverseReaction
gastroenteritis viral,AdverseReaction
and,O
gastrointestinal infection,AdverseReaction
d,O
Includes,O
agitation,AdverseReaction
anxiety,AdverseReaction
panic attack,AdverseReaction
aggression,AdverseReaction
abnormal behavior,AdverseReaction
and,O
obsessive compulsive disorder,AdverseReaction
e,O
Includes,O
rash,AdverseReaction
rash generalized,AdverseReaction
rash macular,AdverseReaction
rash maculo papular,AdverseReaction
rash papular,AdverseReaction
dermatitis allergic,AdverseReaction
and,O
urticaria,AdverseReaction
AFINITOR,O
N,O
78,O
Placebo,O
N,O
39,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Any,O
adverse,O
reaction,O
97,O
36,O
3,O
92,O
23,O
3,O
Gastrointestinal,O
disorders,O
Stomatitis,AdverseReaction
a,O
62,O
9,O
0,O
26,O
3,O
0,O
Vomiting,AdverseReaction
22,O
1,O
0,O
13,O
0,O
0,O
Diarrhea,AdverseReaction
17,O
0,O
0,O
5,O
0,O
0,O
Constipation,AdverseReaction
10,O
0,O
0,O
3,O
0,O
0,O
Infections,O
and,O
infestations,O
Respiratory tract infection,AdverseReaction
b,O
31,O
1,O
1,O
23,O
0,O
0,O
Gastroenteritis,AdverseReaction
c,O
10,O
4,O
1,O
3,O
0,O
0,O
Pharyngitis,O
streptococcal,O
10,O
0,O
0,O
3,O
0,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Pyrexia,AdverseReaction
23,O
6,O
0,O
18,O
3,O
0,O
Fatigue,AdverseReaction
14,O
0,O
0,O
3,O
0,O
0,O
Psychiatric,O
disorders,O
Anxiety,AdverseReaction
aggression,AdverseReaction
or,O
other,O
behavioral disturbance,AdverseReaction
d,O
21,O
5,O
0,O
3,O
0,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
e,O
21,O
0,O
0,O
8,O
0,O
0,O
Acne,AdverseReaction
10,O
0,O
0,O
5,O
0,O
0,O
Amenorrhea,AdverseReaction
occurred,O
in,O
17,O
of,O
AFINITOR,O
treated,O
females,O
aged,O
10,O
to,O
55,O
years,O
3,O
of,O
18,O
and,O
none,O
of,O
the,O
females,O
in,O
the,O
placebo,O
group,O
For,O
this,O
same,O
group,O
of,O
AFINITOR,O
treated,O
females,O
the,O
following,O
menstrual abnormalities,AdverseReaction
were,O
reported,O
dysmenorrhea,AdverseReaction
6,O
menorrhagia,AdverseReaction
6,O
metrorrhagia,AdverseReaction
6,O
and,O
unspecified menstrual irregularity,AdverseReaction
6,O
The,O
following,O
additional,O
adverse,O
reactions,O
occurred,O
in,O
less,O
than,O
10,O
of,O
AFINITOR,O
treated,O
patients,O
nausea,AdverseReaction
8,O
pain in extremity,AdverseReaction
8,O
insomnia,AdverseReaction
6,O
pneumonia,AdverseReaction
6,O
epistaxis,AdverseReaction
5,O
hypersensitivity,AdverseReaction
3,O
increased blood luteinizing hormone blood,AdverseReaction
LH,AdverseReaction
levels,AdverseReaction
1,O
and,O
pneumonitis,AdverseReaction
1,O
Table,O
11,O
Key,O
Laboratory,O
Abnormalities,O
Reported,O
in,O
AFINITOR,O
treated,O
Patients,O
with,O
SEGA,O
in,O
Study,O
1,O
Grading,O
according,O
to,O
CTCAE,O
Version,O
3,O
0,O
AFINITOR,O
N,O
78,O
Placebo,O
N,O
39,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
All,O
grades,O
Grade,O
3,O
Grade,O
4,O
Hematology,O
Elevated partial thromboplastin time,AdverseReaction
72,O
3,O
0,O
44,O
5,O
0,O
Neutropenia,AdverseReaction
46,O
9,O
0,O
41,O
3,O
0,O
Anemia,AdverseReaction
41,O
0,O
0,O
21,O
0,O
0,O
Clinical,O
chemistry,O
Hypercholesterolemia,AdverseReaction
81,O
0,O
0,O
39,O
0,O
0,O
Elevated aspartate transaminase,AdverseReaction
AST,AdverseReaction
33,O
0,O
0,O
0,O
0,O
0,O
Hypertriglyceridemia,AdverseReaction
27,O
0,O
0,O
15,O
0,O
0,O
Elevated alanine transaminase,AdverseReaction
ALT,AdverseReaction
18,O
0,O
0,O
3,O
0,O
0,O
Hypophosphatemia,AdverseReaction
9,O
1,O
0,O
3,O
0,O
0,O
Longer,O
term,O
follow,O
up,O
of,O
34,O
2,O
months,O
range,O
4,O
7,O
to,O
47,O
1,O
months,O
from,O
a,O
non,O
randomized,O
open,O
label,O
28,O
patient,O
trial,O
resulted,O
in,O
the,O
following,O
additional,O
notable,O
adverse,O
reactions,O
and,O
key,O
laboratory,O
abnormalities,O
cellulitis,AdverseReaction
29,O
hyperglycemia,AdverseReaction
25,O
and,O
elevated creatinine,AdverseReaction
14,O
6,O
6,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
AFINITOR,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
acute pancreatitis,AdverseReaction
cholecystitis,AdverseReaction
cholelithiasis,AdverseReaction
arterial thrombotic events,AdverseReaction
and,O
reflex sympathetic dystrophy,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
AMPYRA,O
can,Factor
cause,O
seizures,AdverseReaction
the,O
risk,Factor
of,O
seizures,AdverseReaction
increases,O
with,O
increasing,O
AMPYRA,O
doses,O
discontinue,O
AMPYRA,O
and,O
do,O
not,O
restart,O
if,O
a,O
seizure,O
occurs,O
5,O
1,O
AMPYRA,O
should,O
not,O
be,O
taken,O
with,O
other,O
forms,O
of,O
4,O
aminopyridine,O
4,O
AP,O
fampridine,O
since,O
the,O
active,O
ingredient,O
is,O
the,O
same,O
5,O
3,O
AMPYRA,O
can,Factor
cause,O
anaphylaxis,AdverseReaction
Discontinue,O
and,O
do,O
not,O
restart,O
AMPYRA,O
if,O
this,O
occurs,O
5,O
4,O
5,O
1,O
Seizures,O
AMPYRA,O
can,Factor
cause,O
seizures,AdverseReaction
Increased,O
incidence,O
of,O
seizures,AdverseReaction
has,O
been,O
observed,O
at,O
20,O
mg,O
twice,O
daily,O
in,O
controlled,O
clinical,O
studies,O
of,O
9,O
14,O
weeks,O
duration,O
with,O
dalfampridine,O
in,O
patients,O
with,O
MS,O
In,O
open,O
label,O
extension,O
trials,O
in,O
MS,O
patients,O
the,O
incidence,O
of,O
seizures,AdverseReaction
during,O
treatment,O
with,O
dalfampridine,O
15,O
mg,O
twice,O
daily,O
1,O
7,O
100PY,O
was,O
over,O
4,O
times,O
higher,O
than,O
the,O
incidence,O
during,O
treatment,O
with,O
10,O
mg,O
twice,O
daily,O
0,O
4,O
100PY,O
In,O
the,O
post,O
marketing,O
period,O
seizures,AdverseReaction
have,O
been,O
reported,O
The,O
majority,O
of,O
seizures,AdverseReaction
occurred,O
at,O
the,O
recommended,O
dose,O
and,O
in,O
patients,O
without,O
a,O
history,O
of,O
seizures,O
and,O
generally,O
within,O
days,O
to,O
weeks,O
of,O
starting,O
therapy,O
AMPYRA,O
has,O
not,O
been,O
evaluated,O
in,O
patients,O
with,O
a,O
history,O
of,O
seizures,O
or,O
with,O
evidence,O
of,O
epileptiform,O
activity,O
on,O
an,O
EEG,O
as,O
these,O
patients,O
were,O
excluded,O
from,O
clinical,O
trials,O
The,O
risk,O
of,O
seizures,O
in,O
patients,O
with,O
epileptiform,O
activity,O
on,O
an,O
EEG,O
is,O
unknown,O
and,O
could,O
be,O
substantially,O
higher,O
than,O
that,O
observed,O
in,O
AMPYRA,O
clinical,O
studies,O
AMPYRA,O
should,O
be,O
discontinued,O
and,O
not,O
restarted,O
in,O
patients,O
who,O
experience,O
a,O
seizure,O
while,O
on,O
treatment,O
AMPYRA,O
is,O
contraindicated,O
in,O
patients,O
with,O
a,O
history,O
of,O
seizures,O
see,O
Contraindications,O
4,O
5,O
2,O
Renal,O
Impairment,O
AMPYRA,O
is,O
eliminated,O
through,O
the,O
kidneys,O
primarily,O
as,O
unchanged,O
drug,O
see,O
Clinical,O
Pharmacology,O
12,O
4,O
Because,O
patients,O
with,O
moderate,O
to,O
severe,O
renal,O
impairment,O
CrCl,O
50mL,O
min,O
would,O
require,O
a,O
dose,O
lower,O
than,O
10,O
mg,O
twice,O
daily,O
and,O
no,O
strength,O
smaller,O
than,O
10,O
mg,O
is,O
available,O
AMPYRA,O
is,O
contraindicated,O
in,O
these,O
patients,O
see,O
Contraindications,O
4,O
In,O
patients,O
with,O
mild,O
renal,O
impairment,O
CrCl,O
51,O
80,O
mL,O
min,O
AMPYRA,O
plasma,O
levels,O
may,O
approach,O
those,O
seen,O
at,O
a,O
dose,O
of,O
15,O
mg,O
twice,O
daily,O
a,O
dose,O
that,O
may,Factor
be,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
seizures,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
3,O
Concurrent,O
Treatment,O
with,O
Other,O
Forms,O
of,O
4,O
Aminopyridine,O
AMPYRA,O
should,O
not,O
be,O
taken,O
with,O
other,O
forms,O
of,O
4,O
aminopyridine,O
4,O
AP,O
fampridine,O
since,O
the,O
active,O
ingredient,O
is,O
the,O
same,O
Patients,O
should,O
discontinue,O
use,O
of,O
any,O
product,O
containing,O
4,O
aminopyridine,O
prior,O
to,O
initiating,O
treatment,O
with,O
AMPYRA,O
in,O
order,O
to,O
reduce,O
the,O
potential,O
for,O
dose,O
related,O
adverse,O
reactions,O
5,O
4,O
Anaphylaxis,O
AMPYRA,O
can,Factor
cause,O
anaphylaxis,AdverseReaction
and,O
severe,Severity
allergic reactions,AdverseReaction
Signs,O
and,O
symptoms,O
have,O
included,O
respiratory compromise,AdverseReaction
urticaria,AdverseReaction
and,O
angioedema of the throat of the,AdverseReaction
and,O
or,O
tongue,AdverseReaction
Patients,O
should,O
be,O
informed,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
anaphylaxis,O
and,O
instructed,O
to,O
discontinue,O
AMPYRA,O
and,O
seek,O
immediate,O
medical,O
care,O
should,O
these,O
signs,O
and,O
symptoms,O
occur,O
17,O
3,O
5,O
5,O
Urinary,O
Tract,O
Infections,O
Urinary tract infections,AdverseReaction
UTIs,AdverseReaction
were,O
reported,O
more,O
frequently,O
as,O
adverse,O
reactions,O
in,O
controlled,O
studies,O
in,O
patients,O
receiving,O
AMPYRA,O
10,O
mg,O
twice,O
daily,O
12,O
as,O
compared,O
to,O
placebo,O
8,O
UTIs,O
in,O
AMPYRA,O
treated,O
patients,O
should,O
be,O
evaluated,O
and,O
treated,O
as,O
clinically,O
indicated,O
""
6,O
ADVERSE,O
REACTIONS,O
Because,O
clinical,O
studies,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
studies,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
studies,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
following,O
adverse,O
reactions,O
are,O
described,O
in,O
more,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
of,O
the,O
label,O
Seizures,AdverseReaction
Anaphylaxis,AdverseReaction
and,O
Urinary Tract Infections,AdverseReaction
EXCERPT,O
The,O
most,O
common,O
adverse,O
events,O
incidence,O
2,O
and,O
at,O
a,O
rate,O
greater,O
than,O
the,O
placebo,O
rate,O
for,O
AMPYRA,O
were,O
urinary tract infection,AdverseReaction
insomnia,AdverseReaction
dizziness,AdverseReaction
headache,AdverseReaction
nausea,AdverseReaction
asthenia,AdverseReaction
back pain,AdverseReaction
balance disorder,AdverseReaction
multiple sclerosis relapse,AdverseReaction
paresthesia,AdverseReaction
nasopharyngitis,AdverseReaction
constipation,AdverseReaction
dyspepsia,AdverseReaction
and,O
pharyngolaryngeal pain,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Acorda,O
Therapeutics,O
at,O
1,O
800,O
367,O
5109,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Controlled,O
Clinical,O
Trials,O
Experience,O
In,O
three,O
placebo,O
controlled,O
clinical,O
trials,O
of,O
up,O
to,O
14,O
weeks,O
duration,O
4,O
15,O
400,O
of,O
patients,O
treated,O
with,O
AMPYRA,O
10,O
mg,O
twice,O
daily,O
experienced,O
one,O
or,O
more,O
treatment,O
emergent,O
adverse,O
events,O
leading,O
to,O
discontinuation,O
compared,O
to,O
2,O
5,O
238,O
of,O
placebo,O
treated,O
patients,O
The,O
treatment,O
emergent,O
adverse,O
events,O
leading,O
to,O
discontinuation,O
of,O
at,O
least,O
2,O
patients,O
treated,O
with,O
AMPYRA,O
and,O
that,O
led,O
to,O
discontinuation,O
more,O
frequently,O
compared,O
to,O
placebo,O
were,O
headache,AdverseReaction
AMPYRA,O
0,O
5,O
placebo,O
0,O
balance disorder,AdverseReaction
AMPYRA,O
0,O
5,O
placebo,O
0,O
dizziness,AdverseReaction
AMPYRA,O
0,O
5,O
placebo,O
0,O
and,O
confusional state,AdverseReaction
AMPYRA,O
0,O
3,O
placebo,O
0,O
Table,O
1,O
lists,O
adverse,O
reactions,O
that,O
occurred,O
in,O
2,O
of,O
patients,O
treated,O
with,O
AMPYRA,O
10,O
mg,O
twice,O
daily,O
and,O
more,O
frequently,O
than,O
in,O
placebo,O
treated,O
patients,O
in,O
controlled,O
clinical,O
trials,O
Table,O
1,O
Adverse,O
reactions,O
with,O
an,O
incidence,O
2,O
of,O
AMPYRA,O
treated,O
MS,O
patients,O
and,O
more,O
frequent,O
with,O
AMPYRA,O
compared,O
to,O
placebo,O
in,O
controlled,O
clinical,O
trials,O
Adverse,O
Reaction,O
Placebo,O
N,O
238,O
AMPYRA10,O
mg,O
twice,O
daily,O
N,O
400,O
Urinary tract infection,AdverseReaction
8,O
12,O
Insomnia,AdverseReaction
4,O
9,O
Dizziness,AdverseReaction
4,O
7,O
Headache,AdverseReaction
4,O
7,O
Nausea,AdverseReaction
3,O
7,O
Asthenia,AdverseReaction
4,O
7,O
Back pain,AdverseReaction
2,O
5,O
Balance disorder,AdverseReaction
1,O
5,O
Multiple sclerosis relapse,AdverseReaction
3,O
4,O
Paresthesia,AdverseReaction
3,O
4,O
Nasopharyngitis,AdverseReaction
2,O
4,O
Constipation,AdverseReaction
2,O
3,O
Dyspepsia,AdverseReaction
1,O
2,O
Pharyngolaryngeal pain,AdverseReaction
1,O
2,O
6,O
2,O
Other,O
Adverse,O
Reactions,O
AMPYRA,O
has,O
been,O
evaluated,O
in,O
a,O
total,O
of,O
1,O
952,O
subjects,O
including,O
917,O
MS,O
patients,O
A,O
total,O
of,O
741,O
patients,O
have,O
been,O
treated,O
with,O
AMPYRA,O
for,O
over,O
six,O
months,O
501,O
for,O
over,O
one,O
year,O
and,O
352,O
for,O
over,O
two,O
years,O
The,O
experience,O
in,O
open,O
label,O
clinical,O
trials,O
is,O
consistent,O
with,O
the,O
safety,O
profile,O
observed,O
in,O
the,O
placebo,O
controlled,O
clinical,O
trials,O
As,O
in,O
controlled,O
clinical,O
trials,O
a,O
dose,O
dependent,O
increase,O
in,O
the,O
incidence,O
of,O
seizures,AdverseReaction
has,O
been,O
observed,O
in,O
open,O
label,O
clinical,O
trials,O
with,O
AMPYRA,O
in,O
patients,O
with,O
MS,O
as,O
follows,O
AMPYRA,O
10,O
mg,O
twice,O
daily,O
0,O
41,O
per,O
100,O
person,O
years,O
95,O
confidence,O
interval,O
0,O
13,O
0,O
96,O
dalfampridine,O
15,O
mg,O
twice,O
daily,O
1,O
7,O
per,O
100,O
person,O
years,O
95,O
confidence,O
interval,O
0,O
21,O
6,O
28,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Image,O
interpretation,O
errors,O
especially,O
false,O
negatives,O
have,O
been,O
observed,O
5,O
1,O
Radiation risk,AdverseReaction
Amyvid,O
similar,O
to,O
all,O
radiopharmaceuticals,O
contributes,O
to,O
a,O
patient,O
s,O
long term cumulative radiation exposure,AdverseReaction
Ensure,O
safe,O
handling,O
to,O
protect,O
patients,O
and,O
health,O
care,O
workers,O
from,O
unintentional,O
radiation,O
exposure,O
2,O
1,O
5,O
2,O
5,O
1,O
Risk,O
for,O
Image,O
Misinterpretation,O
and,O
other,O
Errors,O
Errors,O
may,O
occur,O
in,O
the,O
Amyvid,O
estimation,O
of,O
brain,O
neuritic,O
plaque,O
density,O
during,O
image,O
interpretation,O
see,O
Clinical,O
Studies,O
14,O
Image,O
interpretation,O
should,O
be,O
performed,O
independently,O
of,O
the,O
patient,O
s,O
clinical,O
information,O
The,O
use,O
of,O
clinical,O
information,O
in,O
the,O
interpretation,O
of,O
Amyvid,O
images,O
has,O
not,O
been,O
evaluated,O
and,O
may,O
lead,O
to,O
errors,O
Other,O
errors,O
may,O
be,O
due,O
to,O
extensive,O
brain,O
atrophy,O
that,O
limits,O
the,O
ability,O
to,O
distinguish,O
gray,O
and,O
white,O
matter,O
on,O
the,O
Amyvid,O
scan,O
as,O
well,O
as,O
motion,O
artifacts,O
that,O
distort,O
the,O
image,O
Amyvid,O
scan,O
results,O
are,O
indicative,O
of,O
the,O
brain,O
neuritic,O
amyloid,O
plaque,O
content,O
only,O
at,O
the,O
time,O
of,O
image,O
acquisition,O
and,O
a,O
negative,O
scan,O
result,O
does,O
not,O
preclude,O
the,O
development,O
of,O
brain,O
amyloid,O
in,O
the,O
future,O
5,O
2,O
Radiation,O
Risk,O
Amyvid,O
similar,O
to,O
other,O
radiopharmaceuticals,O
contributes,O
to,O
a,O
patient,O
s,O
overall,O
long term cumulative radiation exposure,AdverseReaction
Long term cumulative radiation exposure,AdverseReaction
is,O
associated,O
with,O
an,O
increased,O
risk,Factor
of,O
cancer,AdverseReaction
Ensure,O
safe,O
handling,O
to,O
protect,O
patients,O
and,O
health,O
care,O
workers,O
from,O
unintentional,O
radiation,O
exposure,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
reported,O
adverse,O
reaction,O
was,O
headache,AdverseReaction
occurring,O
in,O
2,O
of,O
patients,O
followed,O
by,O
musculoskeletal pain,AdverseReaction
blood pressure increased,AdverseReaction
fatigue,AdverseReaction
nausea,AdverseReaction
and,O
injection site reaction,AdverseReaction
all,O
occurring,O
in,O
1,O
of,O
patients,O
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Eli,O
Lilly,O
and,O
Company,O
at,O
1,O
800,O
LillyRx,O
1,O
800,O
545,O
5979,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
In,O
clinical,O
studies,O
555,O
patients,O
were,O
exposed,O
to,O
Amyvid,O
Amyvid,O
caused,O
no,O
serious,O
adverse,O
reactions,O
in,O
the,O
studies,O
and,O
the,O
reported,O
adverse,O
reactions,O
were,O
predominantly,O
mild,O
to,O
moderate,O
in,O
severity,O
The,O
adverse,O
reactions,O
reported,O
in,O
more,O
than,O
one,O
subject,O
within,O
the,O
studies,O
are,O
shown,O
in,O
Table,O
2,O
Table,O
2,O
Adverse,O
Reactions,O
Reported,O
in,O
Clinical,O
Trials,O
N,O
555,O
patients,O
a,O
Includes,O
the,O
terms,O
blood pressure increased,AdverseReaction
and,O
hypertension,AdverseReaction
b,O
Includes,O
the,O
terms,O
injection site haemorrhage,AdverseReaction
injection site irritation,AdverseReaction
and,O
injection site pain,AdverseReaction
c,O
Includes,O
the,O
terms,O
feeling cold,AdverseReaction
and,O
chills,AdverseReaction
Adverse,O
Reactions,O
N,O
Percent,O
of,O
patients,O
Headache,AdverseReaction
10,O
1,O
8,O
Musculoskeletal pain,AdverseReaction
4,O
0,O
7,O
Blood pressure increased,AdverseReaction
a,O
4,O
0,O
7,O
Nausea,AdverseReaction
4,O
0,O
7,O
Fatigue,AdverseReaction
3,O
0,O
5,O
Injection site reaction,AdverseReaction
b,O
3,O
0,O
5,O
Anxiety,AdverseReaction
2,O
0,O
4,O
Back pain,AdverseReaction
2,O
0,O
4,O
Claustrophobia,AdverseReaction
2,O
0,O
4,O
Dizziness,AdverseReaction
2,O
0,O
4,O
Feeling cold,AdverseReaction
c,O
2,O
0,O
4,O
Insomnia,AdverseReaction
2,O
0,O
4,O
Neck pain,AdverseReaction
2,O
0,O
4,O
Other,O
adverse,O
reactions,O
occurred,O
at,O
lower,O
frequencies,O
and,O
included,O
infusion site rash,AdverseReaction
dysgeusia,AdverseReaction
pruritis,AdverseReaction
urticaria,AdverseReaction
and,O
flushing,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Suicidal Behavior,AdverseReaction
and,O
Ideation,AdverseReaction
Monitor,O
for,O
suicidal,O
thoughts,O
or,O
behavior,O
5,O
1,O
Serious,Severity
Dermatologic Reactions,AdverseReaction
Drug Reaction with Eosinophilia and Systemic Symptoms,AdverseReaction
DRESS,AdverseReaction
Anaphylactic Reactions,AdverseReaction
and,O
Angioedema,AdverseReaction
Monitor,O
and,O
discontinue,O
if,O
another,O
cause,O
cannot,O
be,O
established,O
5,O
2,O
5,O
3,O
5,O
4,O
Hyponatremia,AdverseReaction
Monitor,O
sodium,O
levels,O
in,O
patients,O
at,O
risk,O
or,O
patients,O
experiencing,O
hyponatremia,O
symptoms,O
5,O
5,O
Neurological Adverse Reactions,AdverseReaction
Monitor,O
for,O
dizziness,O
disturbance,O
in,O
gait,O
and,O
coordination,O
somnolence,O
fatigue,O
cognitive,O
dysfunction,O
and,O
visual,O
changes,O
Use,O
caution,O
when,O
driving,O
or,O
operating,O
machinery,O
5,O
6,O
Withdrawal,O
of,O
APTIOM,O
Withdraw,O
APTIOM,O
gradually,O
to,O
minimize,O
the,O
risk,O
of,O
increased,O
seizure,O
frequency,O
and,O
status,O
epilepticus,O
2,O
6,O
5,O
7,O
Drug Induced Liver Injury,AdverseReaction
Discontinue,O
APTIOM,O
in,O
patients,O
with,O
jaundice,O
or,O
evidence,O
of,O
significant,O
liver,O
injury,O
5,O
8,O
5,O
1,O
Suicidal,O
Behavior,O
and,O
Ideation,O
Antiepileptic,O
drugs,O
AEDs,O
including,O
APTIOM,O
increase,O
the,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
in,O
patients,O
taking,O
these,O
drugs,O
for,O
any,O
indication,O
Patients,O
treated,O
with,O
any,O
AED,O
for,O
any,O
indication,O
should,O
be,O
monitored,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
depression,O
suicidal,O
thoughts,O
or,O
behavior,O
and,O
or,O
any,O
unusual,O
changes,O
in,O
mood,O
or,O
behavior,O
Pooled,O
analyses,O
of,O
199,O
placebo,O
controlled,O
clinical,O
trials,O
mono,O
and,O
adjunctive,O
therapy,O
of,O
11,O
different,O
AEDs,O
showed,O
that,O
patients,O
randomized,O
to,O
one,O
of,O
the,O
AEDs,O
had,O
approximately,O
twice,O
the,O
risk,O
adjusted,O
Relative,O
Risk,O
1,O
8,O
95,O
confidence,O
interval,O
CI,O
1,O
2,O
2,O
7,O
of,O
suicidal thinking,AdverseReaction
or,O
behavior,AdverseReaction
compared,O
to,O
patients,O
randomized,O
to,O
placebo,O
In,O
these,O
trials,O
which,O
had,O
a,O
median,O
treatment,O
duration,O
of,O
12,O
weeks,O
the,O
estimated,O
incidence,O
of,O
suicidal behavior,AdverseReaction
or,O
ideation,AdverseReaction
among,O
27,O
863,O
AED,O
treated,O
patients,O
was,O
0,O
43,O
compared,O
to,O
0,O
24,O
among,O
16,O
029,O
placebo,O
treated,O
patients,O
representing,O
an,O
increase,O
of,O
approximately,O
one,O
case,O
of,O
suicidal thinking,AdverseReaction
or,O
behavior,AdverseReaction
for,O
every,O
530,O
patients,O
treated,O
There,O
were,O
four,O
suicides,AdverseReaction
in,O
drug,O
treated,O
patients,O
in,O
the,O
trials,O
and,O
none,O
in,O
placebo,O
treated,O
patients,O
but,O
the,O
number of events is too small to allow any conclusion,Factor
about,O
drug,O
effect,O
on,O
suicide,AdverseReaction
The,O
increased,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
with,O
AEDs,O
was,O
observed,O
as,O
early,O
as,O
one,O
week,O
after,O
starting,O
treatment,O
with,O
AEDs,O
and,O
persisted,O
for,O
the,O
duration,O
of,O
treatment,O
assessed,O
Because,O
most,O
trials,O
included,O
in,O
the,O
analysis,O
did,O
not,O
extend,O
beyond,O
24,O
weeks,O
the,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
beyond,O
24,O
weeks,O
could,O
not,O
be,O
assessed,O
The,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
was,O
generally,O
consistent,O
among,O
drugs,O
in,O
the,O
data,O
analyzed,O
The,O
finding,O
of,O
increased,O
risk,O
with,O
AEDs,O
of,O
varying,O
mechanisms,O
of,O
action,O
and,O
across,O
a,O
range,O
of,O
indications,O
suggests,O
that,O
the,O
risk,O
applies,O
to,O
all,O
AEDs,O
used,O
for,O
any,O
indication,O
The,O
risk,O
did,O
not,O
vary,O
substantially,O
by,O
age,O
5,O
100,O
years,O
in,O
the,O
clinical,O
trials,O
analyzed,O
Table,O
2,O
shows,O
absolute,O
and,O
relative,O
risk,O
by,O
indication,O
for,O
all,O
evaluated,O
AEDs,O
Table,O
2,O
Risk,Factor
of,O
Suicidal Thoughts,AdverseReaction
or,O
Behaviors,AdverseReaction
by,O
Indication,O
for,O
Antiepileptic,O
Drugs,O
in,O
the,O
Pooled,O
Analysis,O
Indication,O
Placebo,O
Patients,O
with,O
Events,O
Per,O
1000,O
Patients,O
Drug,O
Patients,O
with,O
Events,O
Per,O
1000,O
Patients,O
Relative,O
Risk,O
Incidence,O
of,O
Events,O
in,O
Drug,O
Patients,O
Incidence,O
in,O
Placebo,O
Patients,O
Risk,O
Differences,O
Additional,O
Drug,O
Patients,O
with,O
Events,O
Per,O
1000,O
Patients,O
Epilepsy,O
1,O
0,O
3,O
4,O
3,O
5,O
2,O
4,O
Psychiatric,O
5,O
7,O
8,O
5,O
1,O
5,O
2,O
9,O
Other,O
1,O
0,O
1,O
8,O
1,O
9,O
0,O
9,O
Total,O
2,O
4,O
4,O
3,O
1,O
8,O
1,O
9,O
The,O
relative,O
risk,O
for,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
was,O
higher,O
in,O
clinical,O
trials,O
in,O
patients,O
with,O
epilepsy,O
than,O
in,O
clinical,O
trials,O
in,O
patients,O
with,O
psychiatric,O
or,O
other,O
conditions,O
but,O
the,O
absolute,O
risk,O
differences,O
were,O
similar,O
for,O
epilepsy,O
and,O
psychiatric,O
indications,O
Anyone,O
considering,O
prescribing,O
APTIOM,O
or,O
any,O
other,O
AED,O
must,O
balance,O
this,O
risk,O
with,O
the,O
risk,O
of,O
untreated,O
illness,O
Epilepsy,O
and,O
many,O
other,O
illnesses for which AEDs are prescribed,Negation
are,O
themselves,O
associated,O
with,O
morbidity,AdverseReaction
and,O
mortality,AdverseReaction
and,O
an,O
increased,O
risk,O
of,O
suicidal thoughts,AdverseReaction
and,O
behavior,AdverseReaction
Should,O
suicidal,O
thoughts,O
and,O
behavior,O
emerge,O
during,O
treatment,O
the,O
prescriber,O
needs,O
to,O
consider,O
whether,O
the,O
emergence,O
of,O
these,O
symptoms,O
in,O
any,O
given,O
patient,O
may,O
be,O
related,O
to,O
the,O
illness,O
being,O
treated,O
Patients,O
their,O
caregivers,O
and,O
families,O
should,O
be,O
informed,O
that,O
AEDs,O
increase,O
the,O
risk,O
of,O
suicidal,O
thoughts,O
and,O
behavior,O
and,O
should,O
be,O
advised,O
of,O
the,O
need,O
to,O
be,O
alert,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
depression,O
any,O
unusual,O
changes,O
in,O
mood,O
or,O
behavior,O
or,O
the,O
emergence,O
of,O
suicidal,O
thoughts,O
behavior,O
or,O
thoughts,O
about,O
self,O
harm,O
Behaviors,O
of,O
concern,O
should,O
be,O
reported,O
immediately,O
to,O
healthcare,O
providers,O
5,O
2,O
Serious,O
Dermatologic,O
Reactions,O
Serious,O
dermatologic reactions,AdverseReaction
including,O
Stevens Johnson Syndrome,AdverseReaction
SJS,AdverseReaction
have,O
been,O
reported,O
in,O
association,O
with,O
APTIOM,O
use,O
Serious,Severity
and,O
sometimes,O
fatal,AdverseReaction
dermatologic reactions,AdverseReaction
including,O
toxic epidermal necrolysis,AdverseReaction
TEN,AdverseReaction
and,O
SJS,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
using,O
oxcarbazepine,DrugClass
or,O
carbamazepine,O
which,O
are,O
chemically,O
related,O
to,O
APTIOM,O
The,O
reporting,O
rate,O
of,O
these,O
reactions,O
associated,O
with,O
oxcarbazepine,O
use,O
exceeds,O
the,O
background,O
incidence,O
rate,O
estimates,O
by,O
a,O
factor,O
of,O
3,O
to,O
10,O
fold,O
Risk,O
factors,O
for,O
development,O
of,O
serious,Severity
dermatologic reactions,AdverseReaction
with,O
APTIOM,O
use,O
have,O
not,Negation
been,O
identified,O
If,O
a,O
patient,O
develops,O
a,O
dermatologic,O
reaction,O
while,O
taking,O
APTIOM,O
discontinue,O
APTIOM,O
use,O
unless,O
the,O
reaction,O
is,O
clearly,O
not,O
drug,O
related,O
Patients,O
with,O
a,O
prior,O
dermatologic,O
reaction,O
with,O
either,O
oxcarbazepine,O
or,O
APTIOM,O
should,O
not,O
be,O
treated,O
with,O
APTIOM,O
see,O
Contraindications,O
4,O
5,O
3,O
Drug,O
Reaction,O
with,O
Eosinophilia,O
and,O
Systemic,O
Symptoms,O
DRESS,O
Multiorgan,O
Hypersensitivity,O
Drug Reaction with Eosinophilia and Systemic Symptoms,AdverseReaction
DRESS,AdverseReaction
also,O
known,O
as,O
Multiorgan Hypersensitivity,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
taking,O
APTIOM,O
DRESS,AdverseReaction
may,O
be,O
fatal,AdverseReaction
or,O
life threatening,Severity
DRESS,AdverseReaction
typically,O
although,O
not,O
exclusively,O
presents,O
with,O
fever,AdverseReaction
rash,AdverseReaction
and,O
or,O
lymphadenopathy,AdverseReaction
in,O
association,O
with,O
other,O
organ,O
system,O
involvement,O
such,O
as,O
hepatitis,AdverseReaction
nephritis,AdverseReaction
hematological abnormalities,AdverseReaction
myocarditis,AdverseReaction
or,O
myositis,AdverseReaction
sometimes,O
resembling,O
an,O
acute,O
viral,O
infection,O
Eosinophilia,AdverseReaction
is,O
often,O
present,O
Because,O
this,O
disorder,O
is,O
variable,O
in,O
its,O
expression,O
other,O
organ,O
systems,O
not,O
noted,O
here,O
may,O
be,O
involved,O
It,O
is,O
important,O
to,O
note,O
that,O
early,O
manifestations,O
of,O
hypersensitivity,AdverseReaction
such,O
as,O
fever,AdverseReaction
or,O
lymphadenopathy,AdverseReaction
may,O
be,O
present,O
even,O
though,O
rash,AdverseReaction
is,O
not evident,Negation
If,O
such,O
signs,O
or,O
symptoms,O
are,O
present,O
the,O
patient,O
should,O
be,O
evaluated,O
immediately,O
APTIOM,O
should,O
be,O
discontinued,O
and,O
not,O
be,O
resumed,O
if,O
an,O
alternative,O
etiology,O
for,O
the,O
signs,O
or,O
symptoms,O
cannot,O
be,O
established,O
Patients,O
with,O
a,O
prior,O
DRESS,O
reaction,O
with,O
either,O
oxcarbazepine,O
or,O
APTIOM,O
should,O
not,O
be,O
treated,O
with,O
APTIOM,O
see,O
Contraindications,O
4,O
5,O
4,O
Anaphylactic,O
Reactions,O
and,O
Angioedema,O
Rare,O
cases,O
of,O
anaphylaxis,AdverseReaction
and,O
angioedema,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
taking,O
APTIOM,O
Anaphylaxis,AdverseReaction
and,O
angioedema,AdverseReaction
associated,O
with,O
laryngeal edema,AdverseReaction
can,Factor
be,O
fatal,AdverseReaction
If,O
a,O
patient,O
develops,O
any,O
of,O
these,O
reactions,O
after,O
treatment,O
with,O
APTIOM,O
the,O
drug,O
should,O
be,O
discontinued,O
Patients,O
with,O
a,O
prior,O
anaphylactic,O
type,O
reaction,O
with,O
either,O
oxcarbazepine,O
or,O
APTIOM,O
should,O
not,O
be,O
treated,O
with,O
APTIOM,O
see,O
Contraindications,O
4,O
5,O
5,O
Hyponatremia,O
Clinically,O
significant,O
hyponatremia,AdverseReaction
sodium,O
125,O
mEq,O
L,O
can,O
develop,O
in,O
patients,O
taking,O
APTIOM,O
In,O
the,O
controlled,O
adjunctive,O
epilepsy,O
trials,O
4,O
415,O
patients,O
1,O
0,O
treated,O
with,O
800,O
mg,O
and,O
6,O
410,O
1,O
5,O
patients,O
treated,O
with,O
1200,O
mg,O
of,O
APTIOM,O
had,O
at,O
least,O
one,O
serum,O
sodium,O
value,O
less,O
than,O
125,O
mEq,O
L,O
compared,O
to,O
none,O
of,O
the,O
patients,O
assigned,O
to,O
placebo,O
A,O
higher,O
percentage,O
of,O
APTIOM,O
treated,O
patients,O
5,O
1,O
than,O
placebo,O
treated,O
patients,O
0,O
7,O
experienced,O
decreases in sodium values,AdverseReaction
of,O
more,O
than,O
10 mEq L,Severity
These,O
effects,O
were,O
dose,O
related,O
and,O
generally,O
appeared,O
within,O
the,O
first,O
8,O
weeks,O
of,O
treatment,O
as,O
early,O
as,O
after,O
3,O
days,O
Serious,O
life threatening,Severity
complications,O
were,O
reported,O
with,O
APTIOM,O
associated,O
hyponatremia,AdverseReaction
as,O
low,O
as,O
112 mEq L,Severity
including,O
seizures,AdverseReaction
severe,Severity
nausea,AdverseReaction
vomiting,AdverseReaction
leading,O
to,O
dehydration,AdverseReaction
severe,Severity
gait instability,AdverseReaction
and,O
injury,AdverseReaction
Some,O
patients,O
required,O
hospitalization,O
and,O
discontinuation,O
of,O
APTIOM,O
Concurrent,O
hypochloremia,AdverseReaction
was,O
also,O
present,O
in,O
patients,O
with,O
hyponatremia,AdverseReaction
Depending,O
on,O
the,O
severity,O
of,O
hyponatremia,O
the,O
dose,O
of,O
APTIOM,O
may,O
need,O
to,O
be,O
reduced,O
or,O
discontinued,O
Hyponatremia,AdverseReaction
was,O
also,O
observed,O
in,O
monotherapy,O
trials,O
Measurement,O
of,O
serum,O
sodium,O
and,O
chloride,O
levels,O
should,O
be,O
considered,O
during,O
maintenance,O
treatment,O
with,O
APTIOM,O
particularly,O
if,O
the,O
patient,O
is,O
receiving,O
other,O
medications,O
known,O
to,O
decrease,O
serum,O
sodium,O
levels,O
and,O
should,O
be,O
performed,O
if,O
symptoms,O
of,O
hyponatremia,O
develop,O
e,O
g,O
nausea,O
vomiting,O
malaise,O
headache,O
lethargy,O
confusion,O
irritability,O
muscle,O
weakness,O
spasms,O
obtundation,O
or,O
increase,O
in,O
seizure,O
frequency,O
or,O
severity,O
5,O
6,O
Neurological,O
Adverse,O
Reactions,O
Dizziness,O
and,O
Disturbance,O
in,O
Gait,O
and,O
Coordination,O
APTIOM,O
causes,O
dose,O
related,O
increases,O
in,O
adverse,O
reactions,O
related,O
to,O
dizziness,AdverseReaction
and,O
disturbance in gait in,AdverseReaction
and,O
coordination,AdverseReaction
dizziness,AdverseReaction
ataxia,AdverseReaction
vertigo,AdverseReaction
balance disorder,AdverseReaction
gait disturbance,AdverseReaction
nystagmus,AdverseReaction
and,O
abnormal coordination,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
In,O
controlled,O
adjunctive,O
epilepsy,O
trials,O
these,O
events,O
were,O
reported,O
in,O
26,O
and,O
38,O
of,O
patients,O
randomized,O
to,O
receive,O
APTIOM,O
at,O
doses,O
of,O
800,O
mg,O
and,O
1200,O
mg,O
day,O
respectively,O
compared,O
to,O
12,O
of,O
placebo,O
treated,O
patients,O
Events,O
related,O
to,O
dizziness,AdverseReaction
and,O
disturbance in gait in,AdverseReaction
and,O
coordination,AdverseReaction
were,O
more,O
often,O
serious,O
in,O
APTIOM,O
treated,O
patients,O
than,O
in,O
placebo,O
treated,O
patients,O
2,O
vs,O
0,O
and,O
more,O
often,O
led,O
to,O
study,O
withdrawal,O
in,O
APTIOM,O
treated,O
patients,O
than,O
in,O
placebo,O
treated,O
patients,O
9,O
vs,O
0,O
7,O
There,O
was,O
an,O
increased,O
risk,O
of,O
these,O
adverse,O
reactions,O
during,O
the,O
titration,O
period,O
compared,O
to,O
the,O
maintenance,O
period,O
and,O
there,O
also,O
may,O
be,O
an,O
increased,O
risk,O
of,O
these,O
adverse,O
reactions,O
in,O
patients,O
60,O
years,O
of,O
age,O
and,O
older,O
compared,O
to,O
younger,O
adults,O
Nausea,AdverseReaction
and,O
vomiting,AdverseReaction
also,O
occurred,O
with,O
these,O
events,O
Dizziness,AdverseReaction
and,O
disturbance in gait in,AdverseReaction
and,O
coordination,AdverseReaction
were,O
also,O
observed,O
in,O
monotherapy,O
trials,O
The,O
incidence,O
of,O
dizziness,AdverseReaction
was,O
greater,O
with,O
the,O
concomitant,O
use,O
of,O
APTIOM,O
and,O
carbamazepine,O
compared,O
to,O
the,O
use,O
of,O
APTIOM,O
without,O
carbamazepine,O
up,O
to,O
37,O
vs,O
19,O
respectively,O
Therefore,O
consider,O
dosage,O
modifications,O
of,O
both,O
APTIOM,O
and,O
carbamazepine,O
if,O
these,O
drugs,O
are,O
used,O
concomitantly,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Somnolence,O
and,O
Fatigue,O
APTIOM,O
causes,O
dose,O
dependent,O
increases,O
in,O
somnolence,AdverseReaction
and,O
fatigue,AdverseReaction
related,O
adverse,O
reactions,O
fatigue,AdverseReaction
asthenia,AdverseReaction
malaise,AdverseReaction
hypersomnia,AdverseReaction
sedation,AdverseReaction
and,O
lethargy,AdverseReaction
In,O
the,O
controlled,O
adjunctive,O
epilepsy,O
trials,O
these,O
events,O
were,O
reported,O
in,O
13,O
of,O
placebo,O
patients,O
16,O
of,O
patients,O
randomized,O
to,O
receive,O
800,O
mg,O
day,O
APTIOM,O
and,O
28,O
of,O
patients,O
randomized,O
to,O
receive,O
1200,O
mg,O
day,O
APTIOM,O
Somnolence,AdverseReaction
and,O
fatigue related events,AdverseReaction
were,O
serious,O
in,O
0,O
3,O
of,O
APTIOM,O
treated,O
patients,O
and,O
0,O
placebo,O
patients,O
and,O
led,O
to,O
discontinuation,O
in,O
3,O
of,O
APTIOM,O
treated,O
patients,O
and,O
0,O
7,O
of,O
placebo,O
treated,O
patients,O
Somnolence,AdverseReaction
and,O
fatigue,AdverseReaction
were,O
also,O
observed,O
in,O
monotherapy,O
trials,O
Cognitive,O
Dysfunction,O
APTIOM,O
causes,O
dose,O
dependent,O
increases,O
in,O
cognitive dysfunction,AdverseReaction
related,O
events,O
memory impairment,AdverseReaction
disturbance in attention,AdverseReaction
amnesia,AdverseReaction
confusional state,AdverseReaction
aphasia,AdverseReaction
speech disorder,AdverseReaction
slowness of thought,AdverseReaction
disorientation,AdverseReaction
and,O
psychomotor retardation,AdverseReaction
In,O
the,O
controlled,O
adjunctive,O
epilepsy,O
trials,O
these,O
events,O
were,O
reported,O
in,O
1,O
of,O
placebo,O
patients,O
4,O
of,O
patients,O
randomized,O
to,O
receive,O
800,O
mg,O
day,O
APTIOM,O
and,O
7,O
of,O
patients,O
randomized,O
to,O
receive,O
1200,O
mg,O
day,O
APTIOM,O
Cognitive dysfunction dysfunction,AdverseReaction
related,O
events,O
were,O
serious,Severity
in,O
0,O
2,O
of,O
APTIOM,O
treated,O
patients,O
and,O
0,O
2,O
of,O
placebo,O
patients,O
and,O
led,O
to,O
discontinuation,O
in,O
1,O
of,O
APTIOM,O
treated,O
patients,O
and,O
0,O
5,O
of,O
placebo,O
treated,O
patients,O
Cognitive dysfunction,AdverseReaction
events,O
were,O
also,O
observed,O
in,O
monotherapy,O
trials,O
Visual,O
Changes,O
APTIOM,O
causes,O
dose,O
dependent,O
increases,O
in,O
events,O
related,O
to,O
visual changes,AdverseReaction
including,O
diplopia,AdverseReaction
blurred vision,AdverseReaction
and,O
impaired vision,AdverseReaction
In,O
the,O
controlled,O
adjunctive,O
epilepsy,O
trials,O
these,O
events,O
were,O
reported,O
in,O
16,O
of,O
patients,O
randomized,O
to,O
receive,O
APTIOM,O
compared,O
to,O
6,O
of,O
placebo,O
patients,O
Eye events events,AdverseReaction
were,O
serious,Severity
in,O
0,O
7,O
of,O
APTIOM,O
treated,O
patients,O
and,O
0,O
placebo,O
patients,O
and,O
led,O
to,O
discontinuation,O
in,O
4,O
of,O
APTIOM,O
treated,O
patients,O
and,O
0,O
2,O
of,O
placebo,O
treated,O
patients,O
There,O
was,O
an,O
increased,O
risk,O
of,O
these,O
adverse,O
reactions,O
during,O
the,O
titration,O
period,O
compared,O
to,O
the,O
maintenance,O
period,O
and,O
also,O
in,O
patients,O
60,O
years,O
of,O
age,O
and,O
older,O
compared,O
to,O
younger,O
adults,O
The,O
incidence,O
of,O
diplopia,AdverseReaction
was,O
greater,O
with,O
the,O
concomitant,O
use,O
of,O
APTIOM,O
and,O
carbamazepine,O
compared,O
to,O
the,O
use,O
of,O
APTIOM,O
without,O
carbamazepine,O
up,O
to,O
16,O
vs,O
6,O
respectively,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Events,O
related,O
to,O
visual changes,AdverseReaction
were,O
also,O
observed,O
in,O
monotherapy,O
trials,O
Hazardous,O
Activities,O
Prescribers,O
should,O
advise,O
patients,O
against,O
engaging,O
in,O
hazardous,O
activities,O
requiring,O
mental,O
alertness,O
such,O
as,O
operating,O
motor,O
vehicles,O
or,O
dangerous,O
machinery,O
until,O
the,O
effect,O
of,O
APTIOM,O
is,O
known,O
5,O
7,O
Withdrawal,O
of,O
AEDs,O
As,O
with,O
all,O
antiepileptic,O
drugs,O
APTIOM,O
should,O
be,O
withdrawn,O
gradually,O
because,O
of,O
the,O
risk,O
of,O
increased,O
seizure,O
frequency,O
and,O
status,O
epilepticus,O
5,O
8,O
Drug,O
Induced,O
Liver,O
Injury,O
Hepatic,O
effects,O
ranging,O
from,O
mild to moderate,Severity
moderate,Severity
elevations in transaminases,AdverseReaction
3 times the upper limit of normal,Severity
to,O
rare,O
cases,O
with,O
concomitant,O
elevations of total bilirubin,AdverseReaction
2 times the upper limit of normal,Severity
have,O
been,O
reported,O
with,O
APTIOM,O
use,O
Baseline,O
evaluations,O
of,O
liver,O
laboratory,O
tests,O
are,O
recommended,O
The,O
combination,O
of,O
transaminase elevations,AdverseReaction
and,O
elevated bilirubin,AdverseReaction
without,O
evidence,O
of,O
obstruction,O
is,O
generally,O
recognized,O
as,O
an,O
important,O
predictor,O
of,O
severe,Severity
liver injury,AdverseReaction
APTIOM,O
should,O
be,O
discontinued,O
in,O
patients,O
with,O
jaundice,O
or,O
other,O
evidence,O
of,O
significant,O
liver,O
injury,O
e,O
g,O
laboratory,O
evidence,O
5,O
9,O
Abnormal,O
Thyroid,O
Function,O
Tests,O
Dose,O
dependent,O
decreases in serum T3 in serum in serum in serum T3,AdverseReaction
and,O
T4,AdverseReaction
free,AdverseReaction
and,O
total,AdverseReaction
values,O
have,O
been,O
observed,O
in,O
patients,O
taking,O
APTIOM,O
These,O
changes,O
were,O
not,Negation
associated,O
with,O
other,O
abnormal thyroid function,AdverseReaction
tests,O
suggesting,O
hypothyroidism,AdverseReaction
Abnormal,O
thyroid,O
function,O
tests,O
should,O
be,O
clinically,O
evaluated,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
described,O
in,O
more,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
of,O
the,O
label,O
Suicidal Behavior,AdverseReaction
and,O
Ideation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Serious,Severity
Dermatologic Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Drug Reaction with Eosinophilia and Systemic Symptoms,AdverseReaction
DRESS,AdverseReaction
Multiorgan Hypersensitivity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Anaphylactic Reactions,AdverseReaction
and,O
Angioedema,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Hyponatremia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Neurological Adverse Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Drug Induced Liver Injury,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Abnormal Thyroid Function Tests,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
in,O
patients,O
receiving,O
APTIOM,O
4,O
and,O
2,O
greater,O
than,O
placebo,O
dizziness,AdverseReaction
somnolence,AdverseReaction
nausea,AdverseReaction
headache,AdverseReaction
diplopia,AdverseReaction
vomiting,AdverseReaction
fatigue,AdverseReaction
vertigo,AdverseReaction
ataxia,AdverseReaction
blurred vision,AdverseReaction
and,O
tremor,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Sunovion,O
at,O
1,O
877,O
737,O
7226,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
In,O
monotherapy,O
trials,O
in,O
patients,O
with,O
partial,O
onset,O
seizures,O
Study,O
1,O
and,O
Study,O
2,O
see,O
Clinical,O
Studies,O
14,O
1,O
365,O
patients,O
received,O
APTIOM,O
of,O
whom,O
225,O
were,O
treated,O
for,O
longer,O
than,O
12,O
months,O
and,O
134,O
for,O
longer,O
than,O
24,O
months,O
Of,O
the,O
patients,O
in,O
those,O
trials,O
95,O
were,O
between,O
18,O
and,O
65,O
years,O
old,O
48,O
were,O
male,O
and,O
84,O
were,O
Caucasian,O
Across,O
controlled,O
and,O
uncontrolled,O
trials,O
in,O
patients,O
receiving,O
adjunctive,O
therapy,O
for,O
partial,O
onset,O
seizures,O
1195,O
patients,O
received,O
APTIOM,O
of,O
whom,O
586,O
were,O
treated,O
for,O
longer,O
than,O
6,O
months,O
and,O
462,O
for,O
longer,O
than,O
12,O
months,O
In,O
the,O
placebo,O
controlled,O
adjunctive,O
therapy,O
trials,O
in,O
patients,O
with,O
partial,O
onset,O
seizures,O
Study,O
3,O
Study,O
4,O
and,O
Study,O
5,O
1021,O
patients,O
received,O
APTIOM,O
Of,O
the,O
patients,O
in,O
those,O
trials,O
approximately,O
95,O
were,O
between,O
18,O
and,O
60,O
years,O
old,O
approximately,O
50,O
were,O
male,O
and,O
approximately,O
80,O
were,O
Caucasian,O
Monotherapy,O
Historical,O
Control,O
Trials,O
In,O
the,O
monotherapy,O
epilepsy,O
trials,O
Study,O
1,O
and,O
Study,O
2,O
13,O
of,O
patients,O
randomized,O
to,O
receive,O
APTIOM,O
at,O
the,O
recommended,O
doses,O
of,O
1200,O
mg,O
and,O
1600,O
mg,O
once,O
daily,O
discontinued,O
from,O
the,O
trials,O
as,O
a,O
result,O
of,O
an,O
adverse,O
event,O
The,O
adverse,O
reaction,O
most,O
commonly,O
1,O
on,O
APTIOM,O
leading,O
to,O
discontinuation,O
was,O
hyponatremia,AdverseReaction
Adverse,O
reactions,O
observed,O
in,O
these,O
studies,O
were,O
generally,O
similar,O
to,O
those,O
observed,O
and,O
attributed,O
to,O
drug,O
in,O
adjunctive,O
placebo,O
controlled,O
studies,O
Because,O
these,O
studies,O
did,O
not,O
include,O
a,O
placebo,O
control,O
group,O
causality,O
could,O
not,O
be,O
established,O
Dizziness,AdverseReaction
nausea,AdverseReaction
somnolence,AdverseReaction
and,O
fatigue,AdverseReaction
were,O
all,O
reported,O
at,O
lower,O
incidences,O
during,O
the,O
AED,O
Withdrawal,O
Phase,O
and,O
Monotherapy,O
Phase,O
compared,O
with,O
the,O
Titration,O
Phase,O
Adjunctive,O
Therapy,O
Controlled,O
Trials,O
In,O
the,O
controlled,O
adjunctive,O
therapy,O
epilepsy,O
trials,O
Study,O
3,O
Study,O
4,O
and,O
Study,O
5,O
the,O
rate,O
of,O
discontinuation,O
as,O
a,O
result,O
of,O
any,O
adverse,O
reaction,O
was,O
14,O
for,O
the,O
800,O
mg,O
dose,O
25,O
for,O
the,O
1200,O
mg,O
dose,O
and,O
7,O
in,O
subjects,O
randomized,O
to,O
placebo,O
The,O
adverse,O
reactions,O
most,O
commonly,O
1,O
in,O
any,O
APTIOM,O
treatment,O
group,O
and,O
greater,O
than,O
placebo,O
leading,O
to,O
discontinuation,O
in,O
descending,O
order,O
of,O
frequency,O
were,O
dizziness,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
ataxia,AdverseReaction
diplopia,AdverseReaction
somnolence,AdverseReaction
headache,AdverseReaction
blurred vision,AdverseReaction
vertigo,AdverseReaction
asthenia,AdverseReaction
fatigue,AdverseReaction
rash,AdverseReaction
dysarthria,AdverseReaction
and,O
tremor,AdverseReaction
The,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
in,O
patients,O
receiving,O
APTIOM,O
at,O
doses,O
of,O
800,O
mg,O
or,O
1200,O
mg,O
4,O
and,O
2,O
greater,O
than,O
placebo,O
were,O
dizziness,AdverseReaction
somnolence,AdverseReaction
nausea,AdverseReaction
headache,AdverseReaction
diplopia,AdverseReaction
vomiting,AdverseReaction
fatigue,AdverseReaction
vertigo,AdverseReaction
ataxia,AdverseReaction
blurred vision,AdverseReaction
and,O
tremor,AdverseReaction
Table,O
3,O
gives,O
the,O
incidence,O
of,O
adverse,O
reactions,O
that,O
occurred,O
in,O
2,O
of,O
subjects,O
with,O
partial,O
onset,O
seizures,O
in,O
any,O
APTIOM,O
treatment,O
group,O
and,O
for,O
which,O
the,O
incidence,O
was,O
greater,O
than,O
placebo,O
during,O
the,O
controlled,O
clinical,O
trials,O
Adverse,O
reactions,O
during,O
titration,O
were,O
less,O
frequent,O
for,O
patients,O
who,O
began,O
therapy,O
at,O
an,O
initial,O
dose,O
of,O
400,O
mg,O
for,O
1,O
week,O
and,O
then,O
increased,O
to,O
800,O
mg,O
compared,O
to,O
patients,O
who,O
initiated,O
therapy,O
at,O
800,O
mg,O
Table,O
3,O
Adverse,O
Reactions,O
Incidence,O
in,O
Pooled,O
Controlled,O
Clinical,O
Trials,O
of,O
Adjunctive,O
Therapy,O
in,O
Adults,O
Events,O
2,O
of,O
Patients,O
in,O
the,O
APTIOM,O
800,O
mg,O
or,O
1200,O
mg,O
Dose,O
Group,O
and,O
More,O
Frequent,O
Than,O
in,O
the,O
Placebo,O
Group,O
Placebo,O
APTIOM,O
800,O
mg,O
1200,O
mg,O
N,O
426,O
N,O
415,O
N,O
410,O
Ear,O
and,O
labyrinth,O
disorders,O
Vertigo,AdverseReaction
1,O
2,O
6,O
Eye,O
disorders,O
Diplopia,AdverseReaction
Blurred vision,AdverseReaction
Visual impairment,AdverseReaction
211,O
962,O
1151,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
Vomiting,AdverseReaction
Diarrhea,AdverseReaction
Constipation,AdverseReaction
Abdominal pain,AdverseReaction
Gastritis,AdverseReaction
53311,O
1,O
1064222,O
1610222,O
1,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
Asthenia,AdverseReaction
Gait disturbance,AdverseReaction
Peripheral edema,AdverseReaction
42,O
11,O
4222,O
7321,O
Infections,O
and,O
Infestations,O
Urinary tract infections,AdverseReaction
1,O
2,O
2,O
Injury,O
poisoning,O
and,O
procedural,O
complications,O
Fall,AdverseReaction
1,O
3,O
1,O
Metabolism,O
and,O
nutrition,O
disorders,O
Hyponatremia,AdverseReaction
1,O
2,O
2,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
Somnolence,AdverseReaction
Headache,AdverseReaction
Ataxia,AdverseReaction
Balance disorder,AdverseReaction
Tremor,AdverseReaction
Dysarthria,AdverseReaction
Memory impairment,AdverseReaction
Nystagmus,AdverseReaction
9892,O
110,O
1,O
1,O
201113432111,O
281815634222,O
Psychiatric,O
disorders,O
Depression,AdverseReaction
Insomnia,AdverseReaction
21,O
12,O
32,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
1,O
2,O
1,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
1,O
1,O
3,O
Vascular,O
disorders,O
Hypertension,AdverseReaction
1,O
1,O
2,O
Other,O
Adverse,O
Reactions,O
with,O
APTIOM,O
Use,O
Compared,O
to,O
placebo,O
APTIOM,O
use,O
was,O
associated,O
with,O
slightly,O
higher,O
frequencies,O
of,O
decreases,O
in,O
hemoglobin,O
and,O
hematocrit,O
increases,O
in,O
total,O
cholesterol,O
triglycerides,O
and,O
LDL,O
and,O
increases,O
in,O
creatine,O
phosphokinase,O
Adverse,O
Reactions,O
Based,O
on,O
Gender,O
and,O
Race,O
No,O
significant,O
gender,O
differences,O
were,O
noted,O
in,O
the,O
incidence,O
of,O
adverse,O
reactions,O
Although,O
there,O
were,O
few,O
non,O
Caucasian,O
patients,O
no,O
differences,O
in,O
the,O
incidences,O
of,O
adverse,O
reactions,O
compared,O
to,O
Caucasian,O
patients,O
were,O
observed,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Do,O
not,O
initiate,O
in,O
acutely,O
deteriorating,O
COPD,O
patients,O
5,O
2,O
Do,O
not,O
use,O
for,O
relief,O
of,O
acute,O
symptoms,O
Concomitant,O
short,O
acting,O
beta2,O
agonists,O
can,O
be,O
used,O
as,O
needed,O
for,O
acute,O
relief,O
5,O
2,O
Do,O
not,O
exceed,O
the,O
recommended,O
dose,O
Excessive,O
use,O
or,O
use,O
in,O
conjunction,O
with,O
other,O
medications,O
containing,O
LABA,DrugClass
can,O
result,O
in,O
clinically,O
significant,Severity
cardiovascular effects,AdverseReaction
and,O
may,O
be,O
fatal,AdverseReaction
5,O
3,O
Immediate,O
hypersensitivity reactions,AdverseReaction
may,Factor
occur,O
Discontinue,O
immediately,O
5,O
4,O
Life threatening,Severity
paradoxical bronchospasm,AdverseReaction
can,Factor
occur,O
Discontinue,O
immediately,O
5,O
5,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
cardiovascular,O
or,O
convulsive,O
disorders,O
thyrotoxicosis,O
or,O
sensitivity,O
to,O
sympathomimetic,O
drugs,O
5,O
6,O
5,O
7,O
5,O
1,O
Asthma,O
Related,O
Death,O
See,O
Boxed,O
Warning,O
Data,O
from,O
a,O
large,O
placebo,O
controlled,O
study,O
in,O
asthma,O
patients,O
showed,O
that,O
long acting beta 2 adrenergic agonists,DrugClass
may,O
increase,O
the,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
Data,O
are,O
not,O
available,O
to,O
determine,O
whether,O
the,O
rate,O
of,O
death,O
in,O
patients,O
with,O
COPD,O
is,O
increased,O
by,O
long,O
acting,O
beta,O
2,O
adrenergic,O
agonists,O
A,O
28,O
week,O
placebo,O
controlled,O
US,O
study,O
comparing,O
the,O
safety,O
of,O
another,O
long acting beta 2 adrenergic agonist,DrugClass
salmeterol,O
with,O
placebo,O
each,O
added,O
to,O
usual,O
asthma,O
therapy,O
showed,O
an,O
increase,O
in,O
asthma,O
related,O
deaths,AdverseReaction
in,O
patients,O
receiving,O
salmeterol,O
13,O
13,O
176,O
in,O
patients,O
treated,O
with,O
salmeterol,O
vs,O
3,O
13,O
179,O
in,O
patients,O
treated,O
with,O
placebo,O
RR,O
4,O
37,O
95,O
CI,O
1,O
25,O
15,O
34,O
The,O
increased,O
risk,Factor
of,O
asthma,O
related,O
death,AdverseReaction
is,O
considered,O
a,O
class,O
effect,O
of,O
the,O
long,O
acting,O
beta,O
2,O
adrenergic,O
agonists,O
including,O
ARCAPTA,O
NEOHALER,O
No,O
study,O
adequate,O
to,O
determine,O
whether,O
the,O
rate,O
of,O
asthma,O
related,O
death,O
is,O
increased,O
in,O
patients,O
treated,O
with,O
ARCAPTA,O
NEOHALER,O
has,O
been,O
conducted,O
The,O
safety,O
and,O
efficacy,O
of,O
ARCAPTA,O
NEOHALER,O
in,O
patients,O
with,O
asthma,O
have,O
not,O
been,O
established,O
ARCAPTA,O
NEOHALER,O
is,O
not,O
indicated,O
for,O
the,O
treatment,O
of,O
asthma,O
see,O
Contraindications,O
4,O
Serious,O
asthma,O
related,O
events,O
including,O
death,AdverseReaction
were,O
reported,O
in,O
clinical,O
studies,O
with,O
ARCAPTA,O
NEOHALER,O
The,O
sizes,O
of,O
these,O
studies,O
were,O
not,O
adequate,O
to,O
precisely,O
quantify,O
the,O
differences,O
in,O
serious,O
asthma,O
exacerbation,O
rates,O
between,O
treatment,O
groups,O
see,O
Adverse,O
Reactions,O
6,O
2,O
5,O
2,O
Deterioration,O
of,O
Disease,O
and,O
Acute,O
Episodes,O
ARCAPTA,O
NEOHALER,O
should,O
not,O
be,O
initiated,O
in,O
patients,O
with,O
acutely,O
deteriorating,O
COPD,O
which,O
may,O
be,O
a,O
life,O
threatening,O
condition,O
ARCAPTA,O
NEOHALER,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
acutely,O
deteriorating,O
COPD,O
The,O
use,O
of,O
ARCAPTA,O
NEOHALER,O
in,O
this,O
setting,O
is,O
inappropriate,O
ARCAPTA,O
NEOHALER,O
should,O
not,O
be,O
used,O
for,O
the,O
relief,O
of,O
acute,O
symptoms,O
i,O
e,O
as,O
rescue,O
therapy,O
for,O
the,O
treatment,O
of,O
acute,O
episodes,O
of,O
bronchospasm,O
ARCAPTA,O
NEOHALER,O
has,O
not,O
been,O
studied,O
in,O
the,O
relief,O
of,O
acute,O
symptoms,O
and,O
extra,O
doses,O
should,O
not,O
be,O
used,O
for,O
that,O
purpose,O
Acute,O
symptoms,O
should,O
be,O
treated,O
with,O
an,O
inhaled,O
short,O
acting,O
beta2,O
agonist,O
When,O
beginning,O
ARCAPTA,O
NEOHALER,O
patients,O
who,O
have,O
been,O
taking,O
inhaled,O
short,O
acting,O
beta2,O
agonists,O
on,O
a,O
regular,O
basis,O
e,O
g,O
four,O
times,O
a,O
day,O
should,O
be,O
instructed,O
to,O
discontinue,O
the,O
regular,O
use,O
of,O
these,O
drugs,O
and,O
use,O
them,O
only,O
for,O
symptomatic,O
relief,O
of,O
acute,O
respiratory,O
symptoms,O
When,O
prescribing,O
ARCAPTA,O
NEOHALER,O
the,O
healthcare,O
provider,O
should,O
also,O
prescribe,O
an,O
inhaled,O
short,O
acting,O
beta2,O
agonist,O
and,O
instruct,O
the,O
patient,O
on,O
how,O
it,O
should,O
be,O
used,O
Increasing,O
inhaled,O
beta2,O
agonist,O
use,O
is,O
a,O
signal,O
of,O
deteriorating,O
disease,O
for,O
which,O
prompt,O
medical,O
attention,O
is,O
indicated,O
COPD,O
may,O
deteriorate,O
acutely,O
over,O
a,O
period,O
of,O
hours,O
or,O
chronically,O
over,O
several,O
days,O
or,O
longer,O
If,O
ARCAPTA,O
NEOHALER,O
no,O
longer,O
controls,O
the,O
symptoms,O
of,O
bronchoconstriction,O
or,O
the,O
patient,O
s,O
inhaled,O
short,O
acting,O
beta2,O
agonist,O
becomes,O
less,O
effective,O
or,O
the,O
patient,O
needs,O
more,O
inhalation,O
of,O
short,O
acting,O
beta2,O
agonist,O
than,O
usual,O
these,O
may,O
be,O
markers,O
of,O
deterioration,O
of,O
disease,O
In,O
this,O
setting,O
a,O
re,O
evaluation,O
of,O
the,O
patient,O
and,O
the,O
COPD,O
treatment,O
regimen,O
should,O
be,O
undertaken,O
at,O
once,O
Increasing,O
the,O
daily,O
dosage,O
of,O
ARCAPTA,O
NEOHALER,O
beyond,O
the,O
recommended,O
dose,O
is,O
not,O
appropriate,O
in,O
this,O
situation,O
5,O
3,O
Excessive,O
Use,O
of,O
ARCAPTA,O
NEOHALER,O
and,O
Use,O
with,O
Other,O
Long,O
Acting,O
Beta2,O
Agonists,O
As,O
with,O
other,O
inhaled,O
beta2,O
adrenergic,O
drugs,O
ARCAPTA,O
NEOHALER,O
should,O
not,O
be,O
used,O
more,O
often,O
at,O
higher,O
doses,O
than,O
recommended,O
or,O
in,O
conjunction,O
with,O
other,O
medications,O
containing,O
long,O
acting,O
beta2,O
agonists,O
as,O
an,O
overdose,O
may,O
result,O
Clinically,O
significant,O
cardiovascular,O
effects,O
and,O
fatalities,O
have,O
been,O
reported,O
in,O
association,O
with,O
excessive,O
use,O
of,O
inhaled,O
sympathomimetic,O
drugs,O
5,O
4,O
Immediate,O
Hypersensitivity,O
Reactions,O
Immediate,O
hypersensitivity reactions,AdverseReaction
may,Factor
occur,O
after,O
administration,O
of,O
ARCAPTA,O
NEOHALER,O
If,O
signs,O
suggesting,O
allergic,O
reactions,O
in,O
particular,O
difficulties,O
in,O
breathing,O
or,O
swallowing,O
swelling,O
of,O
tongue,O
lips,O
and,O
face,O
urticaria,O
skin,O
rash,O
occur,O
ARCAPTA,O
NEOHALER,O
should,O
be,O
discontinued,O
immediately,O
and,O
alternative,O
therapy,O
instituted,O
5,O
5,O
Paradoxical,O
Bronchospasm,O
As,O
with,O
other,O
inhaled,O
beta2,O
agonists,O
ARCAPTA,O
NEOHALER,O
may,Factor
produce,O
paradoxical bronchospasm,AdverseReaction
that,O
may,O
be,O
life threatening,Severity
If,O
paradoxical,O
bronchospasm,O
occurs,O
ARCAPTA,O
NEOHALER,O
should,O
be,O
discontinued,O
immediately,O
and,O
alternative,O
therapy,O
instituted,O
5,O
6,O
Cardiovascular,O
Effects,O
ARCAPTA,O
NEOHALER,O
like,O
other,O
beta2,O
agonists,O
can,Factor
produce,O
a,O
clinically,O
significant,Severity
cardiovascular effect,AdverseReaction
in,O
some,O
patients,O
as,O
measured,O
by,O
increases in pulse rate in in,AdverseReaction
systolic,AdverseReaction
or,O
diastolic blood pressure pressure,AdverseReaction
or,O
symptoms,O
If,O
such,O
effects,O
occur,O
ARCAPTA,O
NEOHALER,O
may,O
need,O
to,O
be,O
discontinued,O
In,O
addition,O
beta agonists,DrugClass
have,O
been,O
reported,O
to,O
produce,O
ECG changes,AdverseReaction
such,O
as,O
flattening of the T wave,AdverseReaction
prolongation of the QTc interval,AdverseReaction
and,O
ST segment depression,AdverseReaction
although,O
the,O
clinical,O
significance,O
of,O
these,O
findings,O
is,O
unknown,O
Therefore,O
ARCAPTA,O
NEOHALER,O
like,O
other,O
sympathomimetic,O
amines,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
cardiovascular,O
disorders,O
especially,O
coronary,O
insufficiency,O
cardiac,O
arrhythmias,O
and,O
hypertension,O
5,O
7,O
Coexisting,O
Conditions,O
ARCAPTA,O
NEOHALER,O
like,O
other,O
sympathomimetic,O
amines,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
convulsive,O
disorders,O
or,O
thyrotoxicosis,O
and,O
in,O
patients,O
who,O
are,O
unusually,O
responsive,O
to,O
sympathomimetic,O
amines,O
Doses,O
of,O
the,O
related,O
beta2 agonist,DrugClass
albuterol,O
when,O
administered,O
intravenously,O
have,O
been,O
reported,O
to,O
aggravate pre existing diabetes mellitus,AdverseReaction
and,O
ketoacidosis,AdverseReaction
5,O
8,O
Hypokalemia,O
and,O
Hyperglycemia,O
Beta2 agonist,DrugClass
medications,O
may,O
produce,O
significant,Severity
hypokalemia,AdverseReaction
in,O
some,O
patients,O
possibly,O
through,O
intracellular,O
shunting,O
which,O
has,O
the,O
potential,O
to,O
produce,O
adverse cardiovascular effects,AdverseReaction
see,O
Clinical,O
Pharmacology,O
12,O
2,O
The,O
decrease in serum potassium,AdverseReaction
is,O
usually,O
transient,O
not,O
requiring,O
supplementation,O
Inhalation,O
of,O
high,O
doses,O
of,O
beta2 adrenergic agonists,DrugClass
may,O
produce,O
increases in plasma glucose,AdverseReaction
Clinically,O
notable,O
decreases in serum potassium,AdverseReaction
or,O
changes in blood glucose,AdverseReaction
were,O
infrequent,O
during,O
clinical,O
studies,O
with,O
long,O
term,O
administration,O
of,O
ARCAPTA,O
NEOHALER,O
with,O
the,O
rates,O
similar,O
to,O
those,O
for,O
placebo,O
controls,O
ARCAPTA,O
NEOHALER,O
has,O
not,O
been,O
investigated,O
in,O
patients,O
whose,O
diabetes,O
mellitus,O
is,O
not,O
well,O
controlled,O
""
BOXED,O
WARNING,O
WARNING,O
ASTHMA,O
RELATED,O
DEATH,AdverseReaction
WARNING,O
ASTHMA,O
RELATED,O
DEATH,AdverseReaction
L ong acting beta 2 adrenergic agonist s,DrugClass
LABA,DrugClass
increase,O
the,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
Data,O
from,O
a,O
large,O
placebo,O
controlled,O
US,O
study,O
that,O
compared,O
the,O
safety,O
of,O
another,O
long acting beta 2 adrenergic agonist,DrugClass
salmeterol,O
or,O
placebo,O
added,O
to,O
usual,O
asthma,O
therapy,O
showed,O
an,O
increase,O
in,O
asthma,O
related,O
deaths,AdverseReaction
in,O
patients,O
receiving,O
salmeterol,O
This,O
finding,O
with,O
salmeterol,O
is,O
considered,O
a,O
class,O
effect,O
of,O
LABA,O
including,O
indacaterol,O
the,O
active,O
ingredient,O
in,O
ARCAPTA,O
NEOHALER,O
The,O
safety,O
and,O
efficacy,O
of,O
ARCAPTA,O
NEOHALER,O
in,O
patients,O
with,O
asthma,O
have,O
not,O
been,O
established,O
A,O
RCAPTA,O
NEOHALER,O
is,O
not,O
indicated,O
for,O
the,O
treatment,O
of,O
asthma,O
See,O
C,O
ontraindications,O
4,O
W,O
arnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
ASTHMA,O
RELATED,O
DEATH,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Long acting beta2 adrenergic agonists,DrugClass
LABA,DrugClass
increase,O
the,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
5,O
1,O
A,O
placebo,O
controlled,O
study,O
with,O
another,O
long acting beta2 adrenergic agonist,DrugClass
salmeterol,O
showed,O
an,O
increase,O
in,O
asthma,O
related,O
deaths,AdverseReaction
in,O
patients,O
receiving,O
salmeterol,O
5,O
1,O
This,O
finding,O
of,O
an,O
increased,O
risk,Factor
of,O
asthma,O
related,O
death,AdverseReaction
with,O
salmeterol,O
is,O
considered,O
a,O
class,O
effect,O
of,O
LABA,O
including,O
indacaterol,O
the,O
active,O
ingredient,O
in,O
ARCAPTA,O
NEOHALER,O
The,O
safety,O
and,O
efficacy,O
of,O
ARCAPTA,O
NEOHALER,O
in,O
patients,O
with,O
asthma,O
have,O
not,O
been,O
established,O
ARCAPTA,O
NEOHALER,O
is,O
not,O
indicated,O
for,O
the,O
treatment,O
of,O
asthma,O
4,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
L,O
ong,O
acting,O
beta,O
2,O
adrenergic,O
agonists,O
such,O
as,O
A,O
RCAPTA,O
NEOHALER,O
increase,O
the,O
risk,Factor
of,O
asthma,AdverseReaction
related,O
death,AdverseReaction
ARCAPTA,O
NEOHALER,O
is,O
not,O
indicated,O
for,O
the,O
treatment,O
of,O
asthma,O
See,O
B,O
oxed,O
Warning,O
and,O
W,O
arning,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
2,O
and,O
more,O
common,O
than,O
placebo,O
are,O
cough,AdverseReaction
oropharyngeal pain,AdverseReaction
nasopharyngitis,AdverseReaction
headache,AdverseReaction
and,O
nausea,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Novartis,O
Pharmaceuticals,O
Corporation,O
at,O
1,O
888,O
669,O
6682,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
in,O
Chronic Obstructive Pulmonary Disease Obstructive Pulmonary Disease,AdverseReaction
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
ARCAPTA,O
NEOHALER,O
safety,O
database,O
reflects,O
exposure,O
of,O
2516,O
patients,O
to,O
ARCAPTA,O
NEOHALER,O
at,O
doses,O
of,O
75,O
mcg,O
or,O
greater,O
for,O
at,O
least,O
12,O
weeks,O
in,O
six,O
confirmatory,O
randomized,O
double,O
blind,O
placebo,O
and,O
active,O
controlled,O
clinical,O
trials,O
see,O
Section,O
14,O
In,O
these,O
trials,O
449,O
patients,O
were,O
exposed,O
to,O
the,O
recommended,O
dose,O
of,O
75,O
mcg,O
for,O
up,O
to,O
3,O
months,O
and,O
144,O
583,O
and,O
425,O
COPD,O
patients,O
were,O
exposed,O
to,O
a,O
dose,O
of,O
150,O
300,O
or,O
600,O
mcg,O
for,O
one,O
year,O
respectively,O
Overall,O
patients,O
had,O
a,O
mean,O
pre,O
bronchodilator,O
forced,O
expiratory,O
volume,O
in,O
one,O
second,O
FEV1,O
percent,O
predicted,O
of,O
54,O
The,O
mean,O
age,O
of,O
patients,O
was,O
64,O
years,O
with,O
47,O
of,O
patients,O
aged,O
65,O
years,O
or,O
older,O
and,O
the,O
majority,O
88,O
was,O
Caucasian,O
In,O
these,O
six,O
clinical,O
trials,O
48,O
of,O
patients,O
treated,O
with,O
any,O
dose,O
of,O
ARCAPTA,O
NEOHALER,O
reported,O
an,O
adverse,O
reaction,O
compared,O
with,O
43,O
of,O
patients,O
treated,O
with,O
placebo,O
The,O
proportion,O
of,O
patients,O
who,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reaction,O
was,O
5,O
for,O
ARCAPTA,O
NEOHALER,O
treated,O
patients,O
and,O
5,O
for,O
placebo,O
treated,O
patients,O
The,O
most,O
common,O
adverse,O
reactions,O
that,O
lead,O
to,O
discontinuation,O
of,O
ARCAPTA,O
NEOHALER,O
were,O
COPD,AdverseReaction
and,O
dyspnea,AdverseReaction
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
were,O
COPD exacerbation,AdverseReaction
pneumonia,AdverseReaction
angina pectoris,AdverseReaction
and,O
atrial fibrillation,AdverseReaction
which,O
occurred,O
at,O
similar,O
rates,O
across,O
treatment,O
groups,O
Table,O
1,O
displays,O
adverse,O
drug,O
reactions,O
reported,O
by,O
at,O
least,O
2,O
of,O
patients,O
and,O
higher,O
than,O
placebo,O
during,O
a,O
3,O
month,O
exposure,O
at,O
the,O
recommended,O
75,O
mcg,O
once,O
daily,O
dose,O
Adverse,O
drug,O
reactions,O
are,O
listed,O
according,O
to,O
MedDRA,O
version,O
13,O
0,O
system,O
organ,O
class,O
and,O
sorted,O
in,O
descending,O
order,O
of,O
frequency,O
Table,O
1,O
Number,O
and,O
frequency,O
of,O
adverse,O
drug,O
reactions,O
greater,O
than,O
2,O
and,O
higher,O
than,O
placebo,O
in,O
COPD,O
patients,O
exposed,O
to,O
ARCAPTA,O
NEOHALER,O
75,O
mcg,O
for,O
up,O
to,O
3,O
months,O
in,O
multiple,O
dose,O
controlled,O
trials,O
Indacaterol,O
75,O
mcg,O
once,O
daily,O
Placebo,O
n,O
449,O
n,O
445,O
n,O
n,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
29,O
6,O
5,O
20,O
4,O
5,O
Oropharyngeal pain,AdverseReaction
10,O
2,O
2,O
3,O
0,O
7,O
Infections,O
and,O
infestations,O
Nasopharyngitis,AdverseReaction
24,O
5,O
3,O
12,O
2,O
7,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
23,O
5,O
1,O
11,O
2,O
5,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
11,O
2,O
4,O
4,O
0,O
9,O
In,O
these,O
trials,O
the,O
overall,O
frequency,O
of,O
all,O
cardiovascular adverse reactions,AdverseReaction
was,O
2,O
5,O
for,O
ARCAPTA,O
NEOHALER,O
75,O
mcg,O
and,O
1,O
6,O
for,O
placebo,O
during,O
a,O
3,O
month,O
exposure,O
There,O
were,O
no,O
frequently,O
occurring,O
specific,O
cardiovascular,O
adverse,O
reactions,O
for,O
ARCAPTA,O
NEOHALER,O
75,O
mcg,O
frequency,O
at,O
least,O
1,O
and,O
greater,O
than,O
placebo,O
Additional,O
adverse,O
drug,O
reactions,O
reported,O
in,O
greater,O
than,O
2,O
and,O
higher,O
than,O
on,O
placebo,O
in,O
patients,O
dosed,O
with,O
150,O
300,O
or,O
600,O
mcg,O
for,O
up,O
to,O
12,O
months,O
were,O
as,O
follows,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
muscle spasm,AdverseReaction
musculoskeletal pain,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
edema peripheral,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorder,O
diabetes mellitus,AdverseReaction
hyperglycemia,AdverseReaction
Infections,O
and,O
infestations,O
sinusitis,AdverseReaction
upper respiratory tract infection,AdverseReaction
C,O
ough,O
experienced,O
p,O
ost,O
inhalation,O
In,O
the,O
clinical,O
trials,O
health,O
care,O
providers,O
observed,O
during,O
clinic,O
visits,O
that,O
an,O
average,O
of,O
24,O
of,O
patients,O
experienced,O
a,O
cough,AdverseReaction
on,O
at,O
least,O
20,O
of,O
visits,O
following,O
inhalation,O
of,O
the,O
recommended,O
75,O
mcg,O
dose,O
of,O
ARCAPTA,O
NEOHALER,O
compared,O
to,O
7,O
of,O
patients,O
receiving,O
placebo,O
The,O
cough,AdverseReaction
usually,O
occurred,O
within,O
15,O
seconds,O
following,O
inhalation,O
and,O
lasted,O
for,O
no,O
more,O
than,O
15,O
seconds,O
Cough,AdverseReaction
following,O
inhalation,O
in,O
clinical,O
trials,O
was,O
not,Negation
associated,O
with,O
bronchospasm,AdverseReaction
exacerbations,AdverseReaction
deteriorations of disease,AdverseReaction
or,O
loss of efficacy,AdverseReaction
6,O
2,O
Clinical,O
Trials,O
Experience,O
in,O
Asthma,O
In,O
a,O
6,O
month,O
randomized,O
active,O
controlled,O
asthma,O
safety,O
trial,O
805,O
adult,O
patients,O
with,O
moderate,O
to,O
severe,O
persistent,O
asthma,O
were,O
treated,O
with,O
ARCAPTA,O
NEOHALER,O
300,O
mcg,O
n,O
268,O
ARCAPTA,O
NEOHALER,O
600,O
mcg,O
n,O
268,O
and,O
salmeterol,O
n,O
269,O
all,O
concomitant,O
with,O
inhaled,O
corticosteroids,O
which,O
were,O
not,O
co,O
randomized,O
Of,O
these,O
patients,O
there,O
were,O
2,O
respiratory,O
related,O
deaths,AdverseReaction
in,O
the,O
ARCAPTA,O
NEOHALER,O
300,O
mcg,O
dose,O
group,O
There,O
were,O
no,Negation
deaths,AdverseReaction
in,O
the,O
ARCAPTA,O
NEOHALER,O
600,O
mcg,O
dose,O
group,O
or,O
in,O
the,O
salmeterol,O
active,O
control,O
group,O
Serious,O
adverse,O
reactions,O
related,O
to,O
asthma exacerbation,AdverseReaction
were,O
reported,O
for,O
2,O
patients,O
in,O
the,O
indacaterol,O
300,O
mcg,O
group,O
3,O
patients,O
in,O
the,O
indacaterol,O
600,O
mcg,O
group,O
and,O
no,O
patients,O
in,O
the,O
salmeterol,O
active,O
control,O
group,O
In,O
addition,O
a,O
two,O
week,O
dose,O
ranging,O
trial,O
was,O
conducted,O
in,O
511,O
adult,O
patients,O
with,O
mild,O
persistent,O
asthma,O
taking,O
inhaled,O
corticosteroids,O
No,Negation
deaths,AdverseReaction
intubations,O
or,O
serious,O
adverse,O
reactions,O
related,O
to,O
asthma exacerbation,AdverseReaction
were,O
reported,O
in,O
this,O
trial,O
6,O
3,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
worldwide,O
post,O
approval,O
use,O
of,O
indacaterol,O
the,O
active,O
ingredient,O
in,O
ARCAPTA,O
NEOHALER,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
These,O
adverse,O
reactions,O
are,O
hypersensitivity reactions,AdverseReaction
paradoxical bronchospasm,AdverseReaction
tachycardia,AdverseReaction
heart rate increase,AdverseReaction
palpitations,AdverseReaction
pruritus,AdverseReaction
rash,AdverseReaction
and,O
dizziness,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Thrombocytopenia,AdverseReaction
leukopenia,AdverseReaction
neutropenia,AdverseReaction
and,O
lymphopenia,AdverseReaction
and,O
anemia,AdverseReaction
Monitor,O
blood,O
counts,O
and,O
modify,O
dosage,O
for,O
hematologic,O
toxicities,O
2,O
2,O
5,O
1,O
Infection,AdverseReaction
Serious,Severity
and,O
fatal,AdverseReaction
infections,AdverseReaction
e,O
g,O
pneumonia,AdverseReaction
and,O
sepsis,AdverseReaction
5,O
2,O
Hepatotoxicity,AdverseReaction
Beleodaq,O
may,Factor
cause,O
hepatic toxicity,AdverseReaction
and,O
liver function test abnormalities,AdverseReaction
Monitor,O
liver,O
function,O
tests,O
and,O
omit,O
or,O
modify,O
dosage,O
for,O
hepatic,O
toxicities,O
2,O
2,O
5,O
3,O
Tumor lysis syndrome,AdverseReaction
Monitor,O
patients,O
with,O
advanced,O
stage,O
disease,O
and,O
or,O
high,O
tumor,O
burden,O
and,O
take,O
appropriate,O
precautions,O
5,O
4,O
Embryo fetal toxicity,AdverseReaction
Beleodaq,O
may,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Advise,O
women,O
of,O
potential,O
harm,O
to,O
the,O
fetus,O
and,O
to,O
avoid,O
pregnancy,O
while,O
receiving,O
Beleodaq,O
5,O
6,O
5,O
1,O
Hematologic,O
Toxicity,O
Beleodaq,O
can,Factor
cause,O
thrombocytopenia,AdverseReaction
leukopenia,AdverseReaction
neutropenia,AdverseReaction
and,O
lymphopenia,AdverseReaction
and,O
or,O
anemia,AdverseReaction
monitor,O
blood,O
counts,O
weekly,O
during,O
treatment,O
and,O
modify,O
dosage,O
as,O
necessary,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
1,O
5,O
2,O
Infections,O
Serious,Severity
and,O
sometimes,O
fatal,AdverseReaction
infections,AdverseReaction
including,O
pneumonia,AdverseReaction
and,O
sepsis,AdverseReaction
have,O
occurred,O
with,O
Beleodaq,O
Do,O
not,O
administer,O
Beleodaq,O
to,O
patients,O
with,O
an,O
active,O
infection,O
Patients,O
with,O
a,O
history,O
of,O
extensive,O
or,O
intensive,O
chemotherapy,O
may,O
be,O
at,O
higher,O
risk,O
of,O
life,O
threatening,O
infections,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
3,O
Hepatotoxicity,O
Beleodaq,O
can,Factor
cause,O
fatal,AdverseReaction
hepatotoxicity,AdverseReaction
and,O
liver function test abnormalities,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
liver,O
function,O
tests,O
before,O
treatment,O
and,O
before,O
the,O
start,O
of,O
each,O
cycle,O
Interrupt,O
or,O
adjust,O
dosage,O
until,O
recovery,O
or,O
permanently,O
discontinue,O
Beleodaq,O
based,O
on,O
the,O
severity,O
of,O
the,O
hepatic,O
toxicity,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
4,O
Tumor,O
Lysis,O
Syndrome,O
Tumor lysis syndrome,AdverseReaction
has,O
occurred,O
in,O
Beleodaq,O
treated,O
patients,O
in,O
the,O
clinical,O
trial,O
of,O
patients,O
with,O
relapsed,O
or,O
refractory,O
PTCL,O
see,O
Clinical,O
Studies,O
14,O
Monitor,O
patients,O
with,O
advanced,O
stage,O
disease,O
and,O
or,O
high,O
tumor,O
burden,O
and,O
take,O
appropriate,O
precautions,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
5,O
Gastrointestinal,O
Toxicity,O
Nausea,AdverseReaction
vomiting,AdverseReaction
and,O
diarrhea,AdverseReaction
occur,O
with,O
Beleodaq,O
see,O
Adverse,O
Reactions,O
6,O
1,O
and,O
may,O
require,O
the,O
use,O
of,O
antiemetic,O
and,O
antidiarrheal,O
medications,O
5,O
6,O
Embryo,O
fetal,O
Toxicity,O
Beleodaq,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Beleodaq,O
may,Factor
cause,O
teratogenicity,AdverseReaction
and,O
or,O
embryo fetal lethality,AdverseReaction
because,O
it,O
is,O
genotoxic,AdverseReaction
and,O
targets,O
actively,O
dividing,O
cells,O
see,O
Nonclinical,O
Toxicology,O
13,O
1,O
Women,O
of,O
childbearing,O
potential,O
should,O
be,O
advised,O
to,O
avoid,O
pregnancy,O
while,O
receiving,O
Beleodaq,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
potential,O
hazard,O
to,O
the,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
described,O
in,O
more,O
detail,O
in,O
other,O
sections,O
of,O
the,O
prescribing,O
information,O
Hematologic Toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Infection,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hepatotoxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Tumor Lysis Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Gastrointestinal Toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
The,O
most,O
common,O
adverse,O
reactions,O
observed,O
in,O
the,O
trial,O
of,O
patients,O
with,O
relapsed,O
or,O
refractory,O
PTCL,O
treated,O
with,O
Beleodaq,O
were,O
nausea,AdverseReaction
fatigue,AdverseReaction
pyrexia,AdverseReaction
anemia,AdverseReaction
and,O
vomiting,AdverseReaction
see,O
Clinical,O
Studies,O
14,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
25,O
are,O
nausea,AdverseReaction
fatigue,AdverseReaction
pyrexia,AdverseReaction
anemia,AdverseReaction
and,O
vomiting,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Spectrum,O
Pharmaceuticals,O
Inc,O
at,O
1,O
888,O
292,O
9617,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
Beleodaq,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Adverse,O
Reactions,O
in,O
Patients,O
with,O
Peripheral,O
T,O
Cell,O
Lymphoma,O
The,O
safety,O
of,O
Beleodaq,O
was,O
evaluated,O
in,O
129,O
patients,O
with,O
relapsed,O
or,O
refractory,O
PTCL,O
in,O
the,O
single,O
arm,O
clinical,O
trial,O
in,O
which,O
patients,O
were,O
administered,O
Beleodaq,O
at,O
a,O
dosage,O
of,O
1,O
000,O
mg,O
m2,O
administered,O
over,O
30,O
minutes,O
by,O
IV,O
infusion,O
once,O
daily,O
on,O
Days,O
1,O
5,O
of,O
a,O
21,O
day,O
cycle,O
see,O
Clinical,O
Studies,O
14,O
The,O
median,O
duration,O
of,O
treatment,O
was,O
2,O
cycles,O
range,O
1,O
33,O
cycles,O
Table,O
2,O
summarizes,O
the,O
adverse,O
reactions,O
regardless,O
of,O
causality,O
from,O
the,O
trial,O
in,O
patients,O
with,O
relapsed,O
or,O
refractory,O
PTCL,O
Table,O
2,O
Adverse,O
Reactions,O
Occurring,O
in,O
10,O
of,O
Patients,O
by,O
Preferred,O
Term,O
and,O
Severity,O
in,O
Patients,O
with,O
Relapsed,O
or,O
Refractory,O
PTCL,O
NCI,O
CTC,O
Grade,O
1,O
4,O
MedDRA,O
Preferred,O
Term,O
Percentage,O
of,O
Patients,O
N,O
129,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
All,O
Adverse,O
Reactions,O
97,O
61,O
Nausea,AdverseReaction
42,O
1,O
Fatigue,AdverseReaction
37,O
5,O
Pyrexia,AdverseReaction
35,O
2,O
Anemia,AdverseReaction
32,O
11,O
Vomiting,AdverseReaction
29,O
1,O
Constipation,AdverseReaction
23,O
1,O
Diarrhea,AdverseReaction
23,O
2,O
Dyspnea,AdverseReaction
22,O
6,O
Rash,AdverseReaction
20,O
1,O
Peripheral Edema,AdverseReaction
20,O
0,O
Cough,AdverseReaction
19,O
0,O
Thrombocytopenia,AdverseReaction
16,O
7,O
Pruritus,AdverseReaction
16,O
3,O
Chills,AdverseReaction
16,O
1,O
Increased Blood Lactate Dehydrogenase,AdverseReaction
16,O
2,O
Decreased Appetite,AdverseReaction
15,O
2,O
Headache,AdverseReaction
15,O
0,O
Infusion Site Pain,AdverseReaction
14,O
0,O
Hypokalemia,AdverseReaction
12,O
4,O
Prolonged QT,AdverseReaction
11,O
4,O
Abdominal pain,AdverseReaction
11,O
1,O
Hypotension,AdverseReaction
10,O
3,O
Phlebitis,AdverseReaction
10,O
1,O
Dizziness,AdverseReaction
10,O
0,O
Note,O
Adverse,O
reactions,O
are,O
listed,O
by,O
order,O
of,O
incidence,O
in,O
the,O
All,O
Grades,O
category,O
first,O
then,O
by,O
incidence,O
in,O
the,O
Grade,O
3,O
or,O
4,O
category,O
MedDRA,O
Medical,O
Dictionary,O
for,O
Regulatory,O
Activities,O
Severity,O
measured,O
by,O
National,O
Cancer,O
Institute,O
Common,O
Terminology,O
Criteria,O
for,O
Adverse,O
Events,O
NCI,O
CTCAE,O
version,O
3,O
0,O
Serious,O
Adverse,O
Reactions,O
Sixty,O
one,O
patients,O
47,O
3,O
experienced,O
serious,O
adverse,O
reactions,O
while,O
taking,O
Beleodaq,O
or,O
within,O
30,O
days,O
after,O
their,O
last,O
dose,O
of,O
Beleodaq,O
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
2,O
were,O
pneumonia,AdverseReaction
pyrexia,AdverseReaction
infection,AdverseReaction
anemia,AdverseReaction
increased creatinine,AdverseReaction
thrombocytopenia,AdverseReaction
and,O
multi organ failure,AdverseReaction
One,O
treatment,O
related,O
death,AdverseReaction
associated,O
with,O
hepatic failure,AdverseReaction
was,O
reported,O
in,O
the,O
trial,O
One,O
patient,O
with,O
baseline,O
hyperuricemia,O
and,O
bulky,O
disease,O
experienced,O
Grade 4,Severity
tumor lysis syndrome,AdverseReaction
during,O
the,O
first,O
cycle,O
of,O
treatment,O
and,O
died,AdverseReaction
due,O
to,O
multi organ failure,AdverseReaction
A,O
treatment,O
related,O
death,AdverseReaction
from,O
ventricular fibrillation,AdverseReaction
was,O
reported,O
in,O
another,O
monotherapy,O
clinical,O
trial,O
with,O
Beleodaq,O
ECG,O
analysis,O
did not identify,Negation
QTc prolongation,AdverseReaction
Discontinuations,O
due,O
to,O
Adverse,O
Reactions,O
Twenty,O
five,O
patients,O
19,O
4,O
discontinued,O
treatment,O
with,O
Beleodaq,O
due,O
to,O
adverse,O
reactions,O
The,O
adverse,O
reactions,O
reported,O
most,O
frequently,O
as,O
the,O
reason,O
for,O
discontinuation,O
of,O
treatment,O
included,O
anemia,AdverseReaction
febrile neutropenia,AdverseReaction
fatigue,AdverseReaction
and,O
multi organ failure,AdverseReaction
Dosage,O
Modifications,O
due,O
to,O
Adverse,O
Reactions,O
In,O
the,O
trial,O
dosage,O
adjustments,O
due,O
to,O
adverse,O
reactions,O
occurred,O
in,O
12,O
of,O
Beleodaq,O
treated,O
patients,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Mortality,AdverseReaction
There,O
were,O
more,O
deaths,AdverseReaction
reported,O
with,O
BENLYSTA,O
than,O
with,O
placebo,O
during,O
the,O
controlled,O
period,O
of,O
clinical,O
trials,O
5,O
1,O
Serious,Severity
Infections,AdverseReaction
Serious,Severity
and,O
sometimes,O
fatal,AdverseReaction
infections,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
receiving,O
immunosuppressive,O
agents,O
including,O
BENLYSTA,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
chronic,O
infections,O
Consider,O
interrupting,O
therapy,O
with,O
BENLYSTA,O
if,O
patients,O
develop,O
a,O
new,O
infection,O
during,O
treatment,O
with,O
BENLYSTA,O
5,O
2,O
Progressive Multifocal Leukoencephalopathy,AdverseReaction
PML,AdverseReaction
Patients,O
presenting,O
with,O
new,O
onset,O
or,O
deteriorating,O
neurological,O
signs,O
and,O
symptoms,O
should,O
be,O
evaluated,O
for,O
PML,O
by,O
an,O
appropriate,O
specialist,O
If,O
PML,O
is,O
confirmed,O
consider,O
discontinuation,O
of,O
immunosuppressant,O
therapy,O
including,O
BENLYSTA,O
5,O
2,O
Hypersensitivity Reactions,AdverseReaction
including,O
Anaphylaxis,AdverseReaction
Serious,Severity
and,O
fatal,AdverseReaction
reactions,O
have,O
been,O
reported,O
BENLYSTA,O
should,O
be,O
administered,O
by,O
healthcare,O
providers,O
prepared,O
to,O
manage,O
anaphylaxis,O
Monitor,O
patients,O
during,O
and,O
for,O
an,O
appropriate,O
period,O
of,O
time,O
after,O
administration,O
of,O
BENLYSTA,O
2,O
2,O
5,O
4,O
Depression,AdverseReaction
Depression,AdverseReaction
and,O
suicidality,AdverseReaction
have,O
been,O
reported,O
in,O
trials,O
with,O
BENLYSTA,O
Patients,O
should,O
be,O
instructed,O
to,O
contact,O
their,O
healthcare,O
provider,O
if,O
they,O
experience,O
new,O
or,O
worsening,O
depression,O
suicidal,O
thoughts,O
or,O
other,O
mood,O
changes,O
5,O
6,O
Immunization,O
Live,O
vaccines,O
should,O
not,O
be,O
given,O
concurrently,O
with,O
BENLYSTA,O
5,O
7,O
5,O
1,O
Mortality,O
There,O
were,O
more,O
deaths,AdverseReaction
reported,O
with,O
BENLYSTA,O
than,O
with,O
placebo,O
during,O
the,O
controlled,O
period,O
of,O
the,O
clinical,O
trials,O
Out,O
of,O
2,O
133,O
patients,O
in,O
3,O
clinical,O
trials,O
a,O
total,O
of,O
14,O
deaths,AdverseReaction
occurred,O
during,O
the,O
placebo,O
controlled,O
double,O
blind,O
treatment,O
periods,O
3,O
675,O
0,O
4,O
5,O
673,O
0,O
7,O
0,O
111,O
0,O
and,O
6,O
674,O
0,O
9,O
deaths,AdverseReaction
in,O
the,O
groups,O
receiving,O
placebo,O
BENLYSTA,O
1,O
mg,O
kg,O
BENLYSTA,O
4,O
mg,O
kg,O
and,O
BENLYSTA,O
10,O
mg,O
kg,O
respectively,O
No,O
single,O
cause,O
of,O
death,AdverseReaction
predominated,O
Etiologies,O
included,O
infection,AdverseReaction
cardiovascular disease,AdverseReaction
and,O
suicide,AdverseReaction
5,O
2,O
Serious,O
Infections,O
Serious,Severity
and,O
sometimes,O
fatal,AdverseReaction
infections,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
receiving,O
immunosuppressive,O
agents,O
including,O
BENLYSTA,O
Physicians,O
should,O
exercise,O
caution,O
when,O
considering,O
the,O
use,O
of,O
BENLYSTA,O
in,O
patients,O
with,O
chronic,O
infections,O
Patients,O
receiving,O
any,O
therapy,O
for,O
chronic,O
infection,O
should,O
not,O
begin,O
therapy,O
with,O
BENLYSTA,O
Consider,O
interrupting,O
therapy,O
with,O
BENLYSTA,O
in,O
patients,O
who,O
develop,O
a,O
new,O
infection,O
while,O
undergoing,O
treatment,O
with,O
BENLYSTA,O
and,O
monitor,O
these,O
patients,O
closely,O
In,O
the,O
controlled,O
clinical,O
trials,O
the,O
overall,O
incidence,O
of,O
infections,AdverseReaction
was,O
71,O
in,O
patients,O
treated,O
with,O
BENLYSTA,O
compared,O
with,O
67,O
in,O
patients,O
who,O
received,O
placebo,O
The,O
most,O
frequent,O
infections,AdverseReaction
5,O
of,O
patients,O
receiving,O
BENLYSTA,O
were,O
upper respiratory tract infection,AdverseReaction
urinary tract infection,AdverseReaction
nasopharyngitis,AdverseReaction
sinusitis,AdverseReaction
bronchitis,AdverseReaction
and,O
influenza,AdverseReaction
Serious,Severity
infections,AdverseReaction
occurred,O
in,O
6,O
0,O
of,O
patients,O
treated,O
with,O
BENLYSTA,O
and,O
in,O
5,O
2,O
of,O
patients,O
who,O
received,O
placebo,O
The,O
most,O
frequent,O
serious,Severity
infections,AdverseReaction
included,O
pneumonia,AdverseReaction
urinary tract infection,AdverseReaction
cellulitis,AdverseReaction
and,O
bronchitis,AdverseReaction
Infections,AdverseReaction
leading,O
to,O
discontinuation,O
of,O
treatment,O
occurred,O
in,O
0,O
7,O
of,O
patients,O
receiving,O
BENLYSTA,O
and,O
1,O
0,O
of,O
patients,O
receiving,O
placebo,O
Infections,AdverseReaction
resulting,O
in,O
death,AdverseReaction
occurred,O
in,O
0,O
3,O
4,O
1,O
458,O
of,O
patients,O
treated,O
with,O
BENLYSTA,O
and,O
in,O
0,O
1,O
1,O
675,O
of,O
patients,O
receiving,O
placebo,O
Progressive,O
Multifocal,O
Leukoencephalopathy,O
PML,O
Cases,O
of,O
JC virus,AdverseReaction
associated,O
PML,AdverseReaction
resulting,O
in,O
neurological deficits,AdverseReaction
including,O
fatal,AdverseReaction
cases,O
have,O
been,O
reported,O
in,O
patients,O
with,O
SLE,O
receiving,O
immunosuppressants,O
including,O
BENLYSTA,O
Risk,O
factors,O
for,O
PML,O
include,O
treatment,O
with,O
immunosuppressant,O
therapies,O
and,O
impairment,O
of,O
immune,O
function,O
Consider,O
the,O
diagnosis,O
of,O
PML,O
in,O
any,O
patient,O
presenting,O
with,O
new,O
onset,O
or,O
deteriorating,O
neurological,O
signs,O
and,O
symptoms,O
and,O
consult,O
with,O
a,O
neurologist,O
or,O
other,O
appropriate,O
specialist,O
as,O
clinically,O
indicated,O
In,O
patients,O
with,O
confirmed,O
PML,O
consider,O
stopping,O
immunosuppressant,O
therapy,O
including,O
BENLYSTA,O
5,O
3,O
Malignancy,O
The,O
impact,O
of,O
treatment,O
with,O
BENLYSTA,O
on,O
the,O
development,O
of,O
malignancies,AdverseReaction
is,O
not known,Factor
In,O
the,O
controlled,O
clinical,O
trials,O
malignancies,AdverseReaction
including,O
non melanoma skin cancers,AdverseReaction
were,O
reported,O
in,O
0,O
4,O
of,O
patients,O
receiving,O
BENLYSTA,O
and,O
0,O
4,O
of,O
patients,O
receiving,O
placebo,O
In,O
the,O
controlled,O
clinical,O
trials,O
malignancies,AdverseReaction
excluding,O
non,O
melanoma,O
skin,O
cancers,O
were,O
observed,O
in,O
0,O
2,O
3,O
1,O
458,O
and,O
0,O
3,O
2,O
675,O
of,O
patients,O
receiving,O
BENLYSTA,O
and,O
placebo,O
respectively,O
The,O
mechanism,O
of,O
action,O
of,O
BENLYSTA,O
could,O
increase,O
the,O
risk,Factor
for,O
the,O
development,O
of,O
malignancies,AdverseReaction
5,O
4,O
Hypersensitivity,O
Reactions,O
including,O
Anaphylaxis,O
Acute hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
and,O
death,AdverseReaction
have,O
been,O
reported,O
in,O
association,O
with,O
BENLYSTA,O
These,O
events,O
generally,O
occurred,O
within,O
hours,O
of,O
the,O
infusion,O
however,O
they,O
may,O
occur,O
later,O
Non,O
acute,O
hypersensitivity reactions,AdverseReaction
including,O
rash,AdverseReaction
nausea,AdverseReaction
fatigue,AdverseReaction
myalgia,AdverseReaction
headache,AdverseReaction
and,O
facial edema,AdverseReaction
have,O
been,O
reported,O
and,O
typically,O
occurred,O
up,O
to,O
a,O
week,O
following,O
the,O
most,O
recent,O
infusion,O
Hypersensitivity,AdverseReaction
including,O
serious,Severity
reactions,O
has,O
occurred,O
in,O
patients,O
who,O
have,O
previously,O
tolerated,O
infusions,O
of,O
BENLYSTA,O
Limited,O
data,O
suggest,O
that,O
patients,O
with,O
a,O
history,O
of,O
multiple,O
drug,O
allergies,O
or,O
significant,O
hypersensitivity,O
may,O
be,O
at,O
increased,O
risk,O
In,O
the,O
controlled,O
clinical,O
trials,O
hypersensitivity reactions,AdverseReaction
occurring,O
on,O
the,O
same,O
day,O
of,O
infusion,O
were,O
reported,O
in,O
13,O
191,O
1,O
458,O
of,O
patients,O
receiving,O
BENLYSTA,O
and,O
11,O
76,O
675,O
of,O
patients,O
receiving,O
placebo,O
Anaphylaxis,AdverseReaction
was,O
observed,O
in,O
0,O
6,O
9,O
1,O
458,O
of,O
patients,O
receiving,O
BENLYSTA,O
and,O
0,O
4,O
3,O
675,O
of,O
patients,O
receiving,O
placebo,O
Manifestations,O
included,O
hypotension,AdverseReaction
angioedema,AdverseReaction
urticaria,AdverseReaction
or,O
other,O
rash,AdverseReaction
pruritus,AdverseReaction
and,O
dyspnea,AdverseReaction
Due,O
to,O
overlap,O
in,O
signs,O
and,O
symptoms,O
it,O
was,O
not,O
possible,O
to,O
distinguish,O
between,O
hypersensitivity reactions,AdverseReaction
and,O
infusion reactions,AdverseReaction
in,O
all,O
cases,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Some,O
patients,O
13,O
received,O
premedication,O
which,O
may,O
have,O
mitigated,O
or,O
masked,O
a,O
hypersensitivity,O
response,O
however,O
there,O
is,O
insufficient,O
evidence,O
to,O
determine,O
whether,O
premedication,O
diminishes,O
the,O
frequency,O
or,O
severity,O
of,O
hypersensitivity,O
reactions,O
BENLYSTA,O
should,O
be,O
administered,O
by,O
healthcare,O
providers,O
prepared,O
to,O
manage,O
anaphylaxis,O
In,O
the,O
event,O
of,O
a,O
serious,O
reaction,O
administration,O
of,O
BENLYSTA,O
must,O
be,O
discontinued,O
immediately,O
and,O
appropriate,O
medical,O
therapy,O
administered,O
Patients,O
should,O
be,O
monitored,O
during,O
and,O
for,O
an,O
appropriate,O
period,O
of,O
time,O
after,O
administration,O
of,O
BENLYSTA,O
Patients,O
should,O
be,O
informed,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
an,O
acute,O
hypersensitivity,O
reaction,O
and,O
be,O
instructed,O
to,O
seek,O
immediate,O
medical,O
care,O
should,O
a,O
reaction,O
occur,O
5,O
5,O
Infusion,O
Reactions,O
In,O
the,O
controlled,O
clinical,O
trials,O
adverse events associated with the infusion,AdverseReaction
occurring,O
on,O
the,O
same,O
day,O
of,O
the,O
infusion,O
were,O
reported,O
in,O
17,O
251,O
1,O
458,O
of,O
patients,O
receiving,O
BENLYSTA,O
and,O
15,O
99,O
675,O
of,O
patients,O
receiving,O
placebo,O
Serious,Severity
infusion reactions,AdverseReaction
excluding,Negation
hypersensitivity reactions,AdverseReaction
were,O
reported,O
in,O
0,O
5,O
of,O
patients,O
receiving,O
BENLYSTA,O
and,O
0,O
4,O
of,O
patients,O
receiving,O
placebo,O
and,O
included,O
bradycardia,AdverseReaction
myalgia,AdverseReaction
headache,AdverseReaction
rash,AdverseReaction
urticaria,AdverseReaction
and,O
hypotension,AdverseReaction
The,O
most,O
common,O
infusion reactions,AdverseReaction
3,O
of,O
patients,O
receiving,O
BENLYSTA,O
were,O
headache,AdverseReaction
nausea,AdverseReaction
and,O
skin reactions,AdverseReaction
Due,O
to,O
overlap,O
in,O
signs,O
and,O
symptoms,O
it,O
was,O
not,O
possible,O
to,O
distinguish,O
between,O
hypersensitivity reactions,AdverseReaction
and,O
infusion reactions,AdverseReaction
in,O
all,O
cases,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Some,O
patients,O
13,O
received,O
premedication,O
which,O
may,O
have,O
mitigated,O
or,O
masked,O
an,O
infusion,O
reaction,O
however,O
there,O
is,O
insufficient,O
evidence,O
to,O
determine,O
whether,O
premedication,O
diminishes,O
the,O
frequency,O
or,O
severity,O
of,O
infusion,O
reactions,O
see,O
Adverse,O
Reactions,O
6,O
1,O
BENLYSTA,O
should,O
be,O
administered,O
by,O
healthcare,O
providers,O
prepared,O
to,O
manage,O
infusion,O
reactions,O
The,O
infusion,O
rate,O
may,O
be,O
slowed,O
or,O
interrupted,O
if,O
the,O
patient,O
develops,O
an,O
infusion,O
reaction,O
Healthcare,O
providers,O
should,O
be,O
aware,O
of,O
the,O
risk,O
of,O
hypersensitivity,O
reactions,O
which,O
may,O
present,O
as,O
infusion,O
reactions,O
and,O
monitor,O
patients,O
closely,O
5,O
6,O
Depression,O
In,O
the,O
controlled,O
clinical,O
trials,O
psychiatric events,AdverseReaction
were,O
reported,O
more,O
frequently,O
with,O
BENLYSTA,O
16,O
than,O
with,O
placebo,O
12,O
related,O
primarily,O
to,O
depression,AdverseReaction
related,O
events,O
6,O
3,O
BENLYSTA,O
and,O
4,O
7,O
placebo,O
insomnia,AdverseReaction
6,O
0,O
BENLYSTA,O
and,O
5,O
3,O
placebo,O
and,O
anxiety,AdverseReaction
3,O
9,O
BENLYSTA,O
and,O
2,O
8,O
placebo,O
Serious,Severity
psychiatric events,AdverseReaction
were,O
reported,O
in,O
0,O
8,O
of,O
patients,O
receiving,O
BENLYSTA,O
0,O
6,O
and,O
1,O
2,O
with,O
1,O
and,O
10,O
mg,O
kg,O
respectively,O
and,O
0,O
4,O
of,O
patients,O
receiving,O
placebo,O
Serious,Severity
depression,AdverseReaction
was,O
reported,O
in,O
0,O
4,O
6,O
1,O
458,O
of,O
patients,O
receiving,O
BENLYSTA,O
and,O
0,O
1,O
1,O
675,O
of,O
patients,O
receiving,O
placebo,O
Two,O
suicides,AdverseReaction
0,O
1,O
were,O
reported,O
in,O
patients,O
receiving,O
BENLYSTA,O
The,O
majority,O
of,O
patients,O
who,O
reported,O
serious,Severity
depression,AdverseReaction
or,O
suicidal behavior,AdverseReaction
had,O
a,O
history,O
of,O
depression,O
or,O
other,O
serious,O
psychiatric,O
disorders,O
and,O
most,O
were,O
receiving,O
psychoactive,O
medications,O
It,O
is,O
unknown,O
if,O
treatment,O
with,O
BENLYSTA,O
is,O
associated,O
with,O
increased,O
risk,O
for,O
these,O
events,O
Patients,O
receiving,O
BENLYSTA,O
should,O
be,O
instructed,O
to,O
contact,O
their,O
healthcare,O
provider,O
if,O
they,O
experience,O
new,O
or,O
worsening,O
depression,O
suicidal,O
thoughts,O
or,O
other,O
mood,O
changes,O
5,O
7,O
Immunization,O
Live,O
vaccines,O
should,O
not,O
be,O
given,O
for,O
30,O
days,O
before,O
or,O
concurrently,O
with,O
BENLYSTA,O
as,O
clinical,O
safety,O
has,O
not,O
been,O
established,O
No,O
data,O
are,O
available,O
on,O
the,O
secondary,O
transmission,O
of,O
infection,O
from,O
persons,O
receiving,O
live,O
vaccines,O
to,O
patients,O
receiving,O
BENLYSTA,O
or,O
the,O
effect,O
of,O
BENLYSTA,O
on,O
new,O
immunizations,O
Because,O
of,O
its,O
mechanism,O
of,O
action,O
BENLYSTA,O
may,O
interfere,O
with,O
the,O
response,O
to,O
immunizations,O
5,O
8,O
Concomitant,O
Use,O
with,O
Other,O
Biologic,O
Therapies,O
or,O
Intravenous,O
Cyclophosphamide,O
BENLYSTA,O
has,O
not,O
been,O
studied,O
in,O
combination,O
with,O
other,O
biologic,O
therapies,O
including,O
B,O
cell,O
targeted,O
therapies,O
or,O
intravenous,O
cyclophosphamide,O
Therefore,O
use,O
of,O
BENLYSTA,O
is,O
not,O
recommended,O
in,O
combination,O
with,O
biologic,O
therapies,O
or,O
intravenous,O
cyclophosphamide,O
""
6,O
ADVERSE,O
REACTIONS,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
following,O
have,O
been,O
observed,O
with,O
BENLYSTA,O
and,O
are,O
discussed,O
in,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
Mortality,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Serious,Severity
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Malignancy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Hypersensitivity Reactions,AdverseReaction
including,O
Anaphylaxis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Infusion Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Depression,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
EXCERPT,O
Common,O
adverse,O
reactions,O
5,O
in,O
clinical,O
trials,O
were,O
nausea,AdverseReaction
diarrhea,AdverseReaction
pyrexia,AdverseReaction
nasopharyngitis,AdverseReaction
bronchitis,AdverseReaction
insomnia,AdverseReaction
pain in extremity,AdverseReaction
depression,AdverseReaction
migraine,AdverseReaction
and,O
pharyngitis,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GlaxoSmithKline,O
at,O
1,O
877,O
423,O
6597,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
BENLYSTA,O
plus,O
standard,O
of,O
care,O
compared,O
with,O
placebo,O
plus,O
standard,O
of,O
care,O
in,O
2,O
133,O
patients,O
in,O
3,O
controlled,O
trials,O
Patients,O
received,O
BENLYSTA,O
at,O
doses,O
of,O
1,O
mg,O
kg,O
N,O
673,O
4,O
mg,O
kg,O
N,O
111,O
Trial,O
1,O
only,O
or,O
10,O
mg,O
kg,O
N,O
674,O
or,O
placebo,O
N,O
675,O
intravenously,O
over,O
a,O
1,O
hour,O
period,O
on,O
Days,O
0,O
14,O
28,O
and,O
then,O
every,O
28,O
days,O
In,O
2,O
of,O
the,O
trials,O
Trial,O
1,O
and,O
Trial,O
3,O
treatment,O
was,O
given,O
for,O
48,O
weeks,O
while,O
in,O
the,O
other,O
trial,O
Trial,O
2,O
treatment,O
was,O
given,O
for,O
72,O
weeks,O
see,O
Clinical,O
Studies,O
14,O
Because,O
there,O
was,O
no,O
apparent,O
dose,O
related,O
increase,O
in,O
the,O
majority,O
of,O
adverse,O
events,O
observed,O
with,O
BENLYSTA,O
the,O
safety,O
data,O
summarized,O
below,O
are,O
presented,O
for,O
the,O
3,O
doses,O
pooled,O
unless,O
otherwise,O
indicated,O
the,O
adverse,O
reaction,O
table,O
displays,O
the,O
results,O
for,O
the,O
recommended,O
dose,O
of,O
10,O
mg,O
kg,O
compared,O
with,O
placebo,O
The,O
population,O
had,O
a,O
mean,O
age,O
of,O
39,O
range,O
18,O
to,O
75,O
94,O
were,O
female,O
and,O
52,O
were,O
Caucasian,O
In,O
these,O
trials,O
93,O
of,O
patients,O
treated,O
with,O
BENLYSTA,O
reported,O
an,O
adverse,O
reaction,O
compared,O
with,O
92,O
treated,O
with,O
placebo,O
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
were,O
serious,Severity
infections,AdverseReaction
6,O
0,O
and,O
5,O
2,O
in,O
the,O
groups,O
receiving,O
BENLYSTA,O
and,O
placebo,O
respectively,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
occurring,O
in,O
5,O
of,O
patients,O
in,O
clinical,O
trials,O
were,O
nausea,AdverseReaction
diarrhea,AdverseReaction
pyrexia,AdverseReaction
nasopharyngitis,AdverseReaction
bronchitis,AdverseReaction
insomnia,AdverseReaction
pain in extremity,AdverseReaction
depression,AdverseReaction
migraine,AdverseReaction
and,O
pharyngitis,AdverseReaction
The,O
proportion,O
of,O
patients,O
who,O
discontinued,O
treatment,O
due,O
to,O
any,O
adverse,O
reaction,O
during,O
the,O
controlled,O
clinical,O
trials,O
was,O
6,O
2,O
for,O
patients,O
receiving,O
BENLYSTA,O
and,O
7,O
1,O
for,O
patients,O
receiving,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
resulting,O
in,O
discontinuation,O
of,O
treatment,O
1,O
of,O
patients,O
receiving,O
BENLYSTA,O
or,O
placebo,O
were,O
infusion reactions,AdverseReaction
1,O
6,O
BENLYSTA,O
and,O
0,O
9,O
placebo,O
lupus nephritis,AdverseReaction
0,O
7,O
BENLYSTA,O
and,O
1,O
2,O
placebo,O
and,O
infections,AdverseReaction
0,O
7,O
BENLYSTA,O
and,O
1,O
0,O
placebo,O
Table,O
1,O
lists,O
adverse,O
reactions,O
regardless,O
of,O
causality,O
occurring,O
in,O
at,O
least,O
3,O
of,O
patients,O
with,O
SLE,O
who,O
received,O
BENLYSTA,O
10,O
mg,O
kg,O
and,O
at,O
an,O
incidence,O
at,O
least,O
1,O
greater,O
than,O
that,O
observed,O
with,O
placebo,O
in,O
the,O
3,O
controlled,O
studies,O
Table,O
1,O
Incidence,O
of,O
Adverse,O
Reactions,O
occurring,O
in,O
at,O
Least,O
3,O
of,O
Patients,O
Treated,O
with,O
BENLYSTA,O
10,O
mg,O
kg,O
plus,O
Standard,O
of,O
Care,O
and,O
at,O
Least,O
1,O
More,O
Frequently,O
than,O
in,O
Patients,O
receiving,O
Placebo,O
plus,O
Standard,O
of,O
Care,O
in,O
3,O
Controlled,O
SLE,O
Studies,O
Preferred,O
Term,O
BENLYSTA,O
10,O
mg,O
kg,O
Standard,O
of,O
Care,O
n,O
674,O
Placebo,O
Standard,O
of,O
Care,O
n,O
675,O
Nausea,AdverseReaction
15,O
12,O
Diarrhea,AdverseReaction
12,O
9,O
Pyrexia,AdverseReaction
10,O
8,O
Nasopharyngitis,AdverseReaction
9,O
7,O
Bronchitis,AdverseReaction
9,O
5,O
Insomnia,AdverseReaction
7,O
5,O
Pain in extremity,AdverseReaction
6,O
4,O
Depression,AdverseReaction
5,O
4,O
Migraine,AdverseReaction
5,O
4,O
Pharyngitis,AdverseReaction
5,O
3,O
Cystitis,AdverseReaction
4,O
3,O
Leukopenia,AdverseReaction
4,O
2,O
Gastroenteritis viral,AdverseReaction
3,O
1,O
6,O
2,O
Immunogenicity,O
In,O
Trials,O
2,O
and,O
3,O
anti,O
belimumab,O
antibodies,O
were,O
detected,O
in,O
4,O
of,O
563,O
0,O
7,O
patients,O
receiving,O
BENLYSTA,O
10,O
mg,O
kg,O
and,O
in,O
27,O
of,O
559,O
4,O
8,O
patients,O
receiving,O
BENLYSTA,O
1,O
mg,O
kg,O
The,O
reported,O
frequency,O
for,O
the,O
group,O
receiving,O
10,O
mg,O
kg,O
may,O
underestimate,O
the,O
actual,O
frequency,O
due,O
to,O
lower,O
assay,O
sensitivity,O
in,O
the,O
presence,O
of,O
high,O
drug,O
concentrations,O
Neutralizing,O
antibodies,O
were,O
detected,O
in,O
3,O
patients,O
receiving,O
BENLYSTA,O
1,O
mg,O
kg,O
Three,O
patients,O
with,O
anti,O
belimumab,O
antibodies,O
experienced,O
mild,Severity
infusion reactions,AdverseReaction
of,O
nausea,AdverseReaction
erythematous rash,AdverseReaction
pruritus,AdverseReaction
eyelid edema,AdverseReaction
headache,AdverseReaction
and,O
dyspnea,AdverseReaction
none,O
of,O
the,O
reactions,O
was,O
life,O
threatening,O
The,O
clinical,O
relevance,O
of,O
the,O
presence,O
of,O
anti,O
belimumab,O
antibodies,O
is,O
not,O
known,O
The,O
data,O
reflect,O
the,O
percentage,O
of,O
patients,O
whose,O
test,O
results,O
were,O
positive,O
for,O
antibodies,O
to,O
belimumab,O
in,O
specific,O
assays,O
The,O
observed,O
incidence,O
of,O
antibody,O
positivity,O
in,O
an,O
assay,O
is,O
highly,O
dependent,O
on,O
several,O
factors,O
including,O
assay,O
sensitivity,O
and,O
specificity,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
belimumab,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
6,O
3,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
postapproval,O
use,O
of,O
BENLYSTA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Fatal,AdverseReaction
anaphylaxis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
To,O
minimize,O
the,O
risk,O
of,O
contamination,O
do,O
not,O
touch,O
dropper,O
tip,O
to,O
any,O
surface,O
Keep,O
bottle,O
tightly,O
closed,O
when,O
not,O
in,O
use,O
5,O
1,O
BEPREVE,O
should,O
not,O
be,O
used,O
to,O
treat,O
contact,O
lens,O
related,O
irritation,O
5,O
2,O
Remove,O
contact,O
lenses,O
prior,O
to,O
instillation,O
of,O
BEPREVE,O
5,O
2,O
5,O
1,O
Contamination,O
of,O
Tip,O
and,O
Solution,O
To,O
minimize,O
contaminating,O
the,O
dropper,O
tip,O
and,O
solution,O
care,O
should,O
be,O
taken,O
not,O
to,O
touch,O
the,O
eyelids,O
or,O
surrounding,O
areas,O
with,O
the,O
dropper,O
tip,O
of,O
the,O
bottle,O
Keep,O
bottle,O
tightly,O
closed,O
when,O
not,O
in,O
use,O
5,O
2,O
Contact,O
Lens,O
Use,O
Patients,O
should,O
be,O
advised,O
not,O
to,O
wear,O
a,O
contact,O
lens,O
if,O
their,O
eye,O
is,O
red,O
BEPREVE,O
should,O
not,O
be,O
used,O
to,O
treat,O
contact,O
lens,O
related,O
irritation,O
BEPREVE,O
should,O
not,O
be,O
instilled,O
while,O
wearing,O
contact,O
lenses,O
Remove,O
contact,O
lenses,O
prior,O
to,O
instillation,O
of,O
BEPREVE,O
The,O
preservative,O
in,O
BEPREVE,O
benzalkonium,O
chloride,O
may,O
be,O
absorbed,O
by,O
soft,O
contact,O
lenses,O
Lenses,O
may,O
be,O
reinserted,O
after,O
10,O
minutes,O
following,O
administration,O
of,O
BEPREVE,O
5,O
3,O
Topical,O
Ophthalmic,O
Use,O
Only,O
BEPREVE,O
is,O
for,O
topical,O
ophthalmic,O
use,O
only,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reaction,O
occurring,O
in,O
approximately,O
25,O
of,O
patients,O
was,O
a,O
mild,Severity
taste following instillation,AdverseReaction
Other,O
adverse,O
reactions,O
which,O
occurred,O
in,O
2,O
5,O
of,O
subjects,O
were,O
eye irritation,AdverseReaction
headache,AdverseReaction
and,O
nasopharyngitis,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Bausch,O
Lomb,O
Incorporated,O
at,O
1,O
800,O
323,O
0000,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
most,O
common,O
reported,O
adverse,O
reaction,O
occurring,O
in,O
approximately,O
25,O
of,O
subjects,O
was,O
a,O
mild,Severity
taste following instillation,AdverseReaction
Other,O
adverse,O
reactions,O
occurring,O
in,O
2,O
5,O
of,O
subjects,O
were,O
eye irritation,AdverseReaction
headache,AdverseReaction
and,O
nasopharyngitis,AdverseReaction
6,O
2,O
Post,O
Marketing,O
Experience,O
Hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
rarely,O
during,O
the,O
post,O
marketing,O
use,O
of,O
BEPREVE,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
unknown,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
casual,O
relationship,O
to,O
drug,O
exposure,O
The,O
hypersensitivity reactions,AdverseReaction
include,O
itching,AdverseReaction
body rash,AdverseReaction
and,O
swelling of lips of of,AdverseReaction
tongue,AdverseReaction
and,O
or,O
throat,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Topical,O
Ophthalmic,O
Use,O
Only,O
5,O
1,O
Growth,O
of,O
Resistant,O
Organisms,O
with,O
Prolonged,O
Use,O
5,O
2,O
Avoidance,O
of,O
Contact,O
Lenses,O
Patients,O
should,O
not,O
wear,O
contact,O
lenses,O
if,O
they,O
have,O
signs,O
or,O
symptoms,O
of,O
bacterial,O
conjunctivitis,O
or,O
during,O
the,O
course,O
of,O
therapy,O
with,O
Besivance,O
5,O
3,O
5,O
1,O
Topical,O
Ophthalmic,O
Use,O
Only,O
NOT,O
FOR,O
INJECTION,O
INTO,O
THE,O
EYE,O
Besivance,O
is,O
for,O
topical,O
ophthalmic,O
use,O
only,O
and,O
should,O
not,O
be,O
injected,O
subconjunctivally,O
nor,O
should,O
it,O
be,O
introduced,O
directly,O
into,O
the,O
anterior,O
chamber,O
of,O
the,O
eye,O
5,O
2,O
Growth,O
of,O
Resistant,O
Organisms,O
with,O
Prolonged,O
Use,O
As,O
with,O
other,O
anti,O
infectives,O
prolonged,O
use,O
of,O
Besivance,O
besifloxacin,O
ophthalmic,O
suspension,O
0,O
6,O
may,Factor
result,O
in,O
overgrowth of non susceptible organisms of,AdverseReaction
including,O
fungi,AdverseReaction
If,O
super,O
infection,O
occurs,O
discontinue,O
use,O
and,O
institute,O
alternative,O
therapy,O
Whenever,O
clinical,O
judgment,O
dictates,O
the,O
patient,O
should,O
be,O
examined,O
with,O
the,O
aid,O
of,O
magnification,O
such,O
as,O
slit,O
lamp,O
biomicroscopy,O
and,O
where,O
appropriate,O
fluorescein,O
staining,O
5,O
3,O
Avoidance,O
of,O
Contact,O
Lenses,O
Patients,O
should,O
not,O
wear,O
contact,O
lenses,O
if,O
they,O
have,O
signs,O
or,O
symptoms,O
of,O
bacterial,O
conjunctivitis,O
or,O
during,O
the,O
course,O
of,O
therapy,O
with,O
Besivance,O
""
6,O
ADVERSE,O
REACTIONS,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
one,O
clinical,O
trial,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
the,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
the,O
same,O
or,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
Besivance,O
in,O
approximately,O
1,O
000,O
patients,O
between,O
1,O
and,O
98,O
years,O
old,O
with,O
clinical,O
signs,O
and,O
symptoms,O
of,O
bacterial,O
conjunctivitis,O
The,O
most,O
frequently,O
reported,O
ocular adverse reaction,AdverseReaction
was,O
conjunctival redness,AdverseReaction
reported,O
in,O
approximately,O
2,O
of,O
patients,O
Other,O
adverse,O
reactions,O
reported,O
in,O
patients,O
receiving,O
Besivance,O
occurring,O
in,O
approximately,O
1,O
2,O
of,O
patients,O
included,O
blurred vision,AdverseReaction
eye pain,AdverseReaction
eye irritation,AdverseReaction
eye pruritus,AdverseReaction
and,O
headache,AdverseReaction
EXCERPT,O
The,O
most,O
common,O
adverse,O
reaction,O
reported,O
in,O
2,O
of,O
patients,O
treated,O
with,O
Besivance,O
was,O
conjunctival redness,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Bausch,O
Lomb,O
Incorporated,O
at,O
1,O
800,O
323,O
0000,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Infections,AdverseReaction
Monitor,O
patients,O
for,O
signs,O
or,O
symptoms,O
and,O
treat,O
appropriately,O
5,O
3,O
Effects on Ability to Drive on Ability to,AdverseReaction
and,O
Use Machines,AdverseReaction
Advise,O
patients,O
to,O
refrain,O
from,O
driving,O
and,O
engaging,O
in,O
hazardous,O
occupations,O
or,O
activities,O
such,O
as,O
operating,O
heavy,O
or,O
potentially,O
dangerous,O
machinery,O
while,O
BLINCYTO,O
is,O
being,O
administered,O
5,O
6,O
Preparation,O
and,O
Administration,O
Errors,O
Strictly,O
follow,O
instructions,O
for,O
preparation,O
including,O
admixing,O
and,O
administration,O
5,O
9,O
5,O
1,O
Cytokine,O
Release,O
Syndrome,O
Cytokine Release Syndrome Release Syndrome,AdverseReaction
CRS,AdverseReaction
which,O
may,Factor
be,O
life threatening,Severity
or,O
fatal,AdverseReaction
occurred,O
in,O
patients,O
receiving,O
BLINCYTO,O
Infusion reactions,AdverseReaction
have,O
occurred,O
with,O
the,O
BLINCYTO,O
infusion,O
and,O
may,O
be,O
clinically,O
indistinguishable,O
from,O
manifestations,O
of,O
CRS,O
Serious,O
adverse,O
events,O
that,O
may,O
be,O
associated,O
with,O
CRS,AdverseReaction
included,O
pyrexia,AdverseReaction
headache,AdverseReaction
nausea,AdverseReaction
asthenia,AdverseReaction
hypotension,AdverseReaction
increased alanine aminotransferase,AdverseReaction
increased aspartate aminotransferase,AdverseReaction
and,O
increased total bilirubin,AdverseReaction
these,O
events,O
infrequently,O
led,O
to,O
BLINCYTO,O
discontinuation,O
Life threatening,Severity
or,O
fatal,AdverseReaction
CRS,AdverseReaction
was,O
infrequently,O
reported,O
in,O
patients,O
receiving,O
BLINCYTO,O
In,O
some,O
cases,O
disseminated intravascular coagulation,AdverseReaction
DIC,AdverseReaction
capillary leak syndrome,AdverseReaction
CLS,AdverseReaction
and,O
hemophagocytic lymphohistiocytosis,AdverseReaction
macrophage activation syndrome,AdverseReaction
HLH,AdverseReaction
MAS,AdverseReaction
have,O
been,O
reported,O
in,O
the,O
setting,O
of,O
CRS,AdverseReaction
Patients,O
should,O
be,O
closely,O
monitored,O
for,O
signs,O
or,O
symptoms,O
of,O
these,O
events,O
Management,O
of,O
these,O
events,O
may,O
require,O
either,O
temporary,O
interruption,O
or,O
discontinuation,O
of,O
BLINCYTO,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
2,O
Neurological,O
Toxicities,O
In,O
patients,O
receiving,O
BLINCYTO,O
in,O
clinical,O
trials,O
neurological toxicities,AdverseReaction
have,O
occurred,O
in,O
approximately,O
50,O
of,O
patients,O
The,O
median,O
time,O
to,O
onset,O
of,O
any,O
neurological,O
toxicity,O
was,O
7,O
days,O
Grade 3,Severity
or,O
higher,O
severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
neurological toxicities,AdverseReaction
following,O
initiation,O
of,O
BLINCYTO,O
administration,O
occurred,O
in,O
approximately,O
15,O
of,O
patients,O
and,O
included,O
encephalopathy,AdverseReaction
convulsions,AdverseReaction
speech disorders,AdverseReaction
disturbances in consciousness,AdverseReaction
confusion,AdverseReaction
and,O
disorientation,AdverseReaction
and,O
coordination,AdverseReaction
and,O
balance disorders,AdverseReaction
The,O
majority,O
of,O
events,O
resolved,O
following,O
interruption,O
of,O
BLINCYTO,O
but,O
some,O
resulted,O
in,O
treatment,O
discontinuation,O
Monitor,O
patients,O
receiving,O
BLINCYTO,O
for,O
signs,O
and,O
symptoms,O
of,O
neurological,O
toxicities,O
and,O
interrupt,O
or,O
discontinue,O
BLINCYTO,O
as,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
3,O
Infections,O
In,O
patients,O
receiving,O
BLINCYTO,O
in,O
clinical,O
trials,O
serious,Severity
infections,AdverseReaction
such,O
as,O
sepsis,AdverseReaction
pneumonia,AdverseReaction
bacteremia,AdverseReaction
opportunistic infections infections,AdverseReaction
and,O
catheter site infections site infections,AdverseReaction
were,O
observed,O
in,O
approximately,O
25,O
of,O
patients,O
some,O
of,O
which,O
were,O
life threatening,Severity
or,O
fatal,AdverseReaction
As,O
appropriate,O
administer,O
prophylactic,O
antibiotics,O
and,O
employ,O
surveillance,O
testing,O
during,O
treatment,O
with,O
BLINCYTO,O
Monitor,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
infection,O
and,O
treat,O
appropriately,O
5,O
4,O
Tumor,O
Lysis,O
Syndrome,O
Tumor lysis syndrome lysis syndrome,AdverseReaction
TLS,AdverseReaction
which,O
may,Factor
be,O
life threatening,Severity
or,O
fatal,AdverseReaction
has,O
been,O
observed,O
in,O
patients,O
receiving,O
BLINCYTO,O
Appropriate,O
prophylactic,O
measures,O
including,O
pretreatment,O
nontoxic,O
cytoreduction,O
and,O
on,O
treatment,O
hydration,O
should,O
be,O
used,O
for,O
the,O
prevention,O
of,O
TLS,O
during,O
BLINCYTO,O
treatment,O
Monitor,O
for,O
signs,O
or,O
symptoms,O
of,O
TLS,O
Management,O
of,O
these,O
events,O
may,O
require,O
either,O
temporary,O
interruption,O
or,O
discontinuation,O
of,O
BLINCYTO,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
5,O
Neutropenia,O
and,O
Febrile,O
Neutropenia,O
Neutropenia,AdverseReaction
and,O
febrile neutropenia neutropenia,AdverseReaction
including,O
life threatening,Severity
cases,O
have,O
been,O
observed,O
in,O
patients,O
receiving,O
BLINCYTO,O
Monitor,O
laboratory,O
parameters,O
including,O
but,O
not,O
limited,O
to,O
white,O
blood,O
cell,O
count,O
and,O
absolute,O
neutrophil,O
count,O
during,O
BLINCYTO,O
infusion,O
Interrupt,O
BLINCYTO,O
if,O
prolonged,O
neutropenia,O
occurs,O
5,O
6,O
Effects,O
on,O
Ability,O
to,O
Drive,O
and,O
Use,O
Machines,O
Due,O
to,O
the,O
potential,Factor
for,O
neurologic events,AdverseReaction
including,O
seizures,AdverseReaction
patients,O
receiving,O
BLINCYTO,O
are,O
at,O
risk,Factor
for,O
loss of consciousness,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Advise,O
patients,O
to,O
refrain,O
from,O
driving,O
and,O
engaging,O
in,O
hazardous,O
occupations,O
or,O
activities,O
such,O
as,O
operating,O
heavy,O
or,O
potentially,O
dangerous,O
machinery,O
while,O
BLINCYTO,O
is,O
being,O
administered,O
5,O
7,O
Elevated,O
Liver,O
Enzymes,O
Treatment,O
with,O
BLINCYTO,O
was,O
associated,O
with,O
transient,Severity
elevations in liver enzymes,AdverseReaction
Although,O
the,O
majority,O
of,O
these,O
events,O
were,O
observed,O
in,O
the,O
setting,O
of,O
CRS,AdverseReaction
some,O
were,O
observed,O
outside,O
of,O
this,O
setting,O
For,O
these,O
events,O
the,O
median,O
time,O
to,O
onset,O
was,O
15,O
days,O
In,O
patients,O
receiving,O
BLINCYTO,O
in,O
clinical,O
trials,O
Grade 3,Severity
or,O
greater,O
elevations in liver enzymes,AdverseReaction
occurred,O
in,O
approximately,O
6,O
of,O
patients,O
outside,Negation
the,O
setting,O
of,O
CRS,AdverseReaction
and,O
resulted,O
in,O
treatment,O
discontinuation,O
in,O
less,O
than,O
1,O
of,O
patients,O
Monitor,O
alanine,O
aminotransferase,O
ALT,O
aspartate,O
aminotransferase,O
AST,O
gamma,O
glutamyl,O
transferase,O
GGT,O
and,O
total,O
blood,O
bilirubin,O
prior,O
to,O
the,O
start,O
of,O
and,O
during,O
BLINCYTO,O
treatment,O
Interrupt,O
BLINCYTO,O
if,O
the,O
transaminases,O
rise,O
to,O
greater,O
than,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
or,O
if,O
bilirubin,O
rises,O
to,O
more,O
than,O
3,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
5,O
8,O
Leukoencephalopathy,O
Cranial,O
magnetic,O
resonance,O
imaging,O
MRI,O
changes,O
showing,O
leukoencephalopathy,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
receiving,O
BLINCYTO,O
especially,O
in,O
patients,O
with,O
prior,O
treatment,O
with,O
cranial,O
irradiation,O
and,O
antileukemic,O
chemotherapy,O
including,O
systemic,O
high,O
dose,O
methotrexate,O
or,O
intrathecal,O
cytarabine,O
The,O
clinical,O
significance,O
of,O
these,O
imaging,O
changes,O
is,O
unknown,O
5,O
9,O
Preparation,O
and,O
Administration,O
Errors,O
Preparation,O
and,O
administration,O
errors,O
have,O
occurred,O
with,O
BLINCYTO,O
treatment,O
Follow,O
instructions,O
for,O
preparation,O
including,O
admixing,O
and,O
administration,O
strictly,O
to,O
minimize,O
medication,O
errors,O
including,O
underdose,O
and,O
overdose,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
2,O
4,O
""
BOXED,O
WARNING,O
WARNING,O
CYTOKINE RELEASE SYNDROME,AdverseReaction
and,O
NEUROLOGICAL TOXICITIES,AdverseReaction
WARNING,O
CYTOKINE RELEASE SYNDROME,AdverseReaction
and,O
NEUROLOGICAL TOXICITIES,AdverseReaction
Cytokine Release Syndrome Release Syndrome,AdverseReaction
CRS,AdverseReaction
which,O
may,Factor
be,O
life threatening,Severity
or,O
fatal,AdverseReaction
occurred,O
in,O
patients,O
receiving,O
BLINCYTO,O
Interrupt,O
or,O
discontinue,O
BLINCYTO,O
as,O
recommended,O
See,O
Dosage,O
and,O
Administration,O
2,O
3,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Neurological toxicities toxicities,AdverseReaction
which,O
may,Factor
be,O
severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
occurred,O
in,O
patients,O
receiving,O
BLINCYTO,O
Interrupt,O
or,O
discontinue,O
BLINCYTO,O
as,O
recommended,O
See,O
Dosage,O
and,O
Administration,O
2,O
3,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
WARNING,O
CYTOKINE RELEASE SYNDROME,AdverseReaction
and,O
NEUROLOGICAL TOXICITIES,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Cytokine Release Syndrome Release Syndrome,AdverseReaction
CRS,AdverseReaction
which,O
may,Factor
be,O
life threatening,Severity
or,O
fatal,AdverseReaction
occurred,O
in,O
patients,O
receiving,O
BLINCYTO,O
Interrupt,O
or,O
discontinue,O
BLINCYTO,O
as,O
recommended,O
2,O
3,O
5,O
1,O
Neurological toxicities toxicities,AdverseReaction
which,O
may,Factor
be,O
severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
occurred,O
in,O
patients,O
receiving,O
BLINCYTO,O
Interrupt,O
or,O
discontinue,O
BLINCYTO,O
as,O
recommended,O
2,O
3,O
5,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
label,O
Cytokine Release Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Neurological Toxicities,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Tumor Lysis Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Neutropenia,AdverseReaction
and,O
Febrile Neutropenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Effects on Ability to Drive on Ability to,AdverseReaction
and,O
Use Machines,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Elevated Liver Enzymes,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Leukoencephalopathy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Preparation,O
and,O
Administration,O
Errors,O
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
The,O
most,O
common,O
adverse,O
reactions,O
20,O
were,O
pyrexia,AdverseReaction
headache,AdverseReaction
peripheral edema,AdverseReaction
febrile neutropenia,AdverseReaction
nausea,AdverseReaction
hypokalemia,AdverseReaction
tremor,AdverseReaction
rash,AdverseReaction
and,O
constipation,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Amgen,O
Inc,O
at,O
1,O
800,O
77,O
AMGEN,O
1,O
800,O
772,O
6436,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
safety,O
data,O
described,O
in,O
this,O
section,O
reflect,O
exposure,O
to,O
BLINCYTO,O
in,O
clinical,O
trials,O
in,O
which,O
212,O
patients,O
with,O
relapsed,O
or,O
refractory,O
ALL,O
received,O
up,O
to,O
28,O
mcg,O
day,O
All,O
patients,O
received,O
at,O
least,O
one,O
dose,O
of,O
BLINCYTO,O
The,O
median,O
age,O
of,O
the,O
study,O
population,O
was,O
37,O
years,O
range,O
18,O
to,O
79,O
years,O
63,O
were,O
male,O
79,O
were,O
White,O
3,O
were,O
Asian,O
and,O
3,O
were,O
Black,O
or,O
African,O
American,O
The,O
most,O
common,O
adverse,O
reactions,O
20,O
were,O
pyrexia,AdverseReaction
62,O
headache,AdverseReaction
36,O
peripheral edema,AdverseReaction
25,O
febrile neutropenia,AdverseReaction
25,O
nausea,AdverseReaction
25,O
hypokalemia,AdverseReaction
23,O
and,O
constipation,AdverseReaction
20,O
Serious,O
adverse,O
reactions,O
were,O
reported,O
in,O
65,O
of,O
patients,O
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
2,O
included,O
febrile neutropenia,AdverseReaction
pyrexia,AdverseReaction
pneumonia,AdverseReaction
sepsis,AdverseReaction
neutropenia,AdverseReaction
device related infection,AdverseReaction
tremor,AdverseReaction
encephalopathy,AdverseReaction
infection,AdverseReaction
overdose,AdverseReaction
confusion,AdverseReaction
Staphylococcal bacteremia,AdverseReaction
and,O
headache,AdverseReaction
Adverse,O
reactions,O
of,O
Grade,O
3,O
or,O
higher,O
were,O
reported,O
in,O
80,O
of,O
patients,O
Discontinuation,O
of,O
therapy,O
due,O
to,O
adverse,O
reactions,O
occurred,O
in,O
18,O
of,O
patients,O
treated,O
with,O
BLINCYTO,O
The,O
adverse,O
reactions,O
reported,O
most,O
frequently,O
as,O
the,O
reason,O
for,O
discontinuation,O
of,O
treatment,O
included,O
encephalopathy,AdverseReaction
and,O
sepsis,AdverseReaction
Fatal,AdverseReaction
adverse,O
events,O
occurred,O
in,O
15,O
of,O
patients,O
The,O
majority,O
of,O
these,O
events,O
were,O
infections,AdverseReaction
No,Negation
fatal,AdverseReaction
adverse,O
events,O
occurred,O
on,O
treatment,O
among,O
patients,O
in,O
remission,O
The,O
adverse,O
reactions,O
with,O
10,O
incidence,O
for,O
any,O
grade,O
or,O
5,O
incidence,O
for,O
Grade,O
3,O
or,O
higher,O
are,O
summarized,O
in,O
Table,O
2,O
Table,O
2,O
Adverse,O
Reactions,O
With,O
10,O
Incidence,O
for,O
Any,O
Grade,O
or,O
5,O
Incidence,O
for,O
Grade,O
3,O
or,O
Higher,O
N,O
212,O
Adverse,O
Reaction,O
Any,O
GradeGrading,O
based,O
on,O
NCI,O
Common,O
Terminology,O
Criteria,O
for,O
Adverse,O
Events,O
CTCAE,O
version,O
4,O
0,O
Grade,O
3,O
or,O
Higher,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Febrile neutropenia,AdverseReaction
Anemia,AdverseReaction
Neutropenia,AdverseReaction
Thrombocytopenia,AdverseReaction
Leukopenia,AdverseReaction
251816119,O
23131588,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
Constipation,AdverseReaction
DiarrheaDiarrhea,O
includes,O
the,O
following,O
terms,O
colitis,AdverseReaction
diarrhea,AdverseReaction
enteritis,AdverseReaction
and,O
neutropenic colitis,AdverseReaction
Abdominal pain,AdverseReaction
Vomiting,AdverseReaction
2520201513,O
0,O
1120,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Pyrexia,AdverseReaction
Peripheral edema,AdverseReaction
Fatigue,AdverseReaction
Chills,AdverseReaction
Chest pain,AdverseReaction
6225171511,O
7,O
1101,O
Immune,O
system,O
disorders,O
Cytokine release syndrome,AdverseReaction
11,O
1,O
Infections,O
and,O
infestations,O
Other,O
pathogen,O
infections,AdverseReaction
Bacterial infections,AdverseReaction
Fungal infections,AdverseReaction
Viral infections,AdverseReaction
Pneumonia,AdverseReaction
Sepsis,AdverseReaction
4419151397,O
25127486,O
Investigations,O
Increased alanine aminotransferase,AdverseReaction
Increased aspartate aminotransferase,AdverseReaction
Increased weight,AdverseReaction
121111,O
640,O
Metabolism,O
and,O
nutrition,O
disorders,O
Hypokalemia,AdverseReaction
Hypomagnesemia,AdverseReaction
Hyperglycemia,AdverseReaction
Decreased appetite,AdverseReaction
Hypophosphatemia,AdverseReaction
231211106,O
60735,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Back pain,AdverseReaction
Pain in extremity,AdverseReaction
Bone pain,AdverseReaction
Arthralgia,AdverseReaction
14121110,O
2132,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
TremorTremor,O
includes,O
the,O
following,O
terms,O
resting tremor,AdverseReaction
and,O
tremor,AdverseReaction
Dizziness,AdverseReaction
362014,O
31,O
1,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
15,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
DyspneaDyspnea,O
includes,O
the,O
following,O
terms,O
acute respiratory failure,AdverseReaction
bronchial hyperactivity,AdverseReaction
bronchospasm,AdverseReaction
dyspnea,AdverseReaction
dyspnea exertional,AdverseReaction
respiratory distress,AdverseReaction
respiratory failure,AdverseReaction
and,O
wheezing,AdverseReaction
1915,O
05,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
RashRash,O
includes,O
the,O
following,O
terms,O
erythema,AdverseReaction
rash,AdverseReaction
erythematous rash,AdverseReaction
generalized rash,AdverseReaction
macular rash,AdverseReaction
maculo papular rash,AdverseReaction
papular rash,AdverseReaction
and,O
vesicular rash,AdverseReaction
21,O
2,O
Vascular,O
disorders,O
Hypotension,AdverseReaction
Hypertension,AdverseReaction
118,O
25,O
Additional,O
important,O
adverse,O
reactions,O
that,O
did,O
not,O
meet,O
the,O
threshold,O
criteria,O
for,O
inclusion,O
in,O
Table,O
2,O
were,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
leukocytosis,AdverseReaction
2,O
lymphopenia,AdverseReaction
1,O
Cardiac,O
disorders,O
tachycardia,AdverseReaction
8,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
edema,AdverseReaction
5,O
Immune,O
system,O
disorders,O
cytokine storm,AdverseReaction
1,O
Investigations,O
decreased immunoglobulins,AdverseReaction
9,O
increased blood bilirubin,AdverseReaction
8,O
increased gamma glutamyl transferase,AdverseReaction
6,O
increased liver enzymes,AdverseReaction
1,O
Metabolism,O
and,O
nutrition,O
disorders,O
tumor lysis syndrome,AdverseReaction
4,O
hypoalbuminemia,AdverseReaction
4,O
Nervous,O
system,O
disorders,O
encephalopathy,AdverseReaction
5,O
paresthesia,AdverseReaction
5,O
aphasia,AdverseReaction
4,O
convulsion,AdverseReaction
2,O
memory impairment,AdverseReaction
2,O
cognitive disorder,AdverseReaction
1,O
speech disorder,AdverseReaction
1,O
Psychiatric,O
disorders,O
confusion,AdverseReaction
7,O
disorientation,AdverseReaction
3,O
Vascular,O
disorders,O
capillary leak syndrome,AdverseReaction
1,O
Hypersensitivity reactions,AdverseReaction
related,O
to,O
BLINCYTO,O
treatment,O
were,O
hypersensitivity,AdverseReaction
1,O
and,O
bronchospasm,AdverseReaction
1,O
6,O
2,O
Immunogenicity,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
potential,O
for,O
immunogenicity,O
The,O
immunogenicity,O
of,O
BLINCYTO,O
has,O
been,O
evaluated,O
using,O
either,O
an,O
electrochemiluminescence,O
detection,O
technology,O
ECL,O
or,O
an,O
enzyme,O
linked,O
immunosorbent,O
assay,O
ELISA,O
screening,O
immunoassay,O
for,O
the,O
detection,O
of,O
binding,O
anti,O
blinatumomab,O
antibodies,O
For,O
patients,O
whose,O
sera,O
tested,O
positive,O
in,O
the,O
screening,O
immunoassay,O
an,O
in,O
vitro,O
biological,O
assay,O
was,O
performed,O
to,O
detect,O
neutralizing,O
antibodies,O
In,O
clinical,O
studies,O
less,O
than,O
1,O
of,O
patients,O
treated,O
with,O
BLINCYTO,O
tested,O
positive,O
for,O
binding,O
anti,O
blinatumomab,O
antibodies,O
All,O
patients,O
who,O
tested,O
positive,O
for,O
binding,O
antibodies,O
also,O
tested,O
positive,O
for,O
neutralizing,O
anti,O
blinatumomab,O
antibodies,O
Anti,O
blinatumomab,O
antibody,O
formation,O
may,O
affect,O
pharmacokinetics,O
of,O
BLINCYTO,O
No,O
association,O
was,O
seen,O
between,O
antibody,O
development,O
and,O
development,O
of,O
adverse,O
events,O
If,O
formation,O
of,O
anti,O
blinatumomab,O
antibodies,O
with,O
a,O
clinically,O
significant,O
effect,O
is,O
suspected,O
contact,O
Amgen,O
at,O
1,O
800,O
77,O
AMGEN,O
1,O
800,O
772,O
6436,O
to,O
discuss,O
antibody,O
testing,O
The,O
detection,O
of,O
anti,O
blinatumomab,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
blinatumomab,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Gastrointestinal Toxicity,AdverseReaction
Monitor,O
and,O
manage,O
as,O
necessary,O
Withhold,O
dose,O
reduce,O
or,O
discontinue,O
BOSULIF,O
2,O
3,O
5,O
1,O
Myelosuppression,AdverseReaction
Monitor,O
blood,O
counts,O
and,O
manage,O
as,O
necessary,O
2,O
4,O
5,O
2,O
Hepatic Toxicity,AdverseReaction
Monitor,O
liver,O
enzymes,O
at,O
least,O
monthly,O
for,O
the,O
first,O
three,O
months,O
and,O
as,O
needed,O
Withhold,O
dose,O
reduce,O
or,O
discontinue,O
BOSULIF,O
2,O
3,O
5,O
3,O
Fluid Retention,AdverseReaction
Monitor,O
patients,O
and,O
manage,O
using,O
standard,O
of,O
care,O
treatment,O
Withhold,O
dose,O
reduce,O
or,O
discontinue,O
BOSULIF,O
2,O
3,O
5,O
4,O
Renal Toxicity,AdverseReaction
Monitor,O
patients,O
for,O
renal,O
function,O
at,O
baseline,O
and,O
during,O
therapy,O
with,O
BOSULIF,O
5,O
5,O
Embryofetal Toxicity,AdverseReaction
May,Factor
cause,O
fetal harm,AdverseReaction
Females,O
of,O
reproductive,O
potential,O
should,O
avoid,O
becoming,O
pregnant,O
while,O
being,O
treated,O
with,O
BOSULIF,O
5,O
6,O
5,O
1,O
Gastrointestinal,O
Toxicity,O
Diarrhea,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
and,O
abdominal pain,AdverseReaction
occur,O
with,O
BOSULIF,O
treatment,O
Monitor,O
and,O
manage,O
patients,O
using,O
standards,O
of,O
care,O
including,O
antidiarrheals,O
antiemetics,O
and,O
fluid,O
replacement,O
In,O
the,O
single,O
arm,O
Phase,O
1,O
2,O
clinical,O
trial,O
the,O
median,O
time,O
to,O
onset,O
for,O
diarrhea,O
all,O
grades,O
was,O
2,O
days,O
and,O
the,O
median,O
duration,O
per,O
event,O
was,O
1,O
day,O
Among,O
the,O
patients,O
who,O
experienced,O
diarrhea,O
the,O
median,O
number,O
of,O
episodes,O
of,O
diarrhea,O
per,O
patient,O
during,O
treatment,O
with,O
BOSULIF,O
was,O
3,O
range,O
1,O
221,O
To,O
manage,O
gastrointestinal,O
toxicity,O
withhold,O
dose,O
reduce,O
or,O
discontinue,O
BOSULIF,O
as,O
necessary,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Adverse,O
Reactions,O
6,O
5,O
2,O
Myelosuppression,O
Thrombocytopenia,AdverseReaction
anemia,AdverseReaction
and,O
neutropenia,AdverseReaction
occur,O
with,O
BOSULIF,O
treatment,O
Perform,O
complete,O
blood,O
counts,O
weekly,O
for,O
the,O
first,O
month,O
of,O
therapy,O
and,O
then,O
monthly,O
thereafter,O
or,O
as,O
clinically,O
indicated,O
To,O
manage,O
myelosuppression,O
withhold,O
dose,O
reduce,O
or,O
discontinue,O
BOSULIF,O
as,O
necessary,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
and,O
Adverse,O
Reactions,O
6,O
5,O
3,O
Hepatic,O
Toxicity,O
One,O
case,O
consistent,O
with,O
drug induced liver injury,AdverseReaction
defined,O
as,O
concurrent,O
elevations in ALT in,AdverseReaction
or,O
AST,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
3 ULN,Severity
with,O
total bilirubin greater than 2 ULN,AdverseReaction
and,O
alkaline phosphatase less than 2 ULN,AdverseReaction
occurred,O
in,O
a,O
trial,O
of,O
BOSULIF,O
in,O
combination,O
with,O
letrozole,O
The,O
patient,O
recovered,O
fully,O
following,O
discontinuation,O
of,O
BOSULIF,O
This,O
case,O
represented,O
1,O
out,O
of,O
1209,O
patients,O
in,O
BOSULIF,O
clinical,O
trials,O
In,O
the,O
546,O
patients,O
from,O
the,O
safety,O
population,O
the,O
incidence,O
of,O
ALT elevation,AdverseReaction
was,O
17,O
and,O
AST elevation,AdverseReaction
was,O
14,O
Twenty,O
percent,O
of,O
the,O
patients,O
experienced,O
an,O
increase in in,AdverseReaction
either,O
ALT,AdverseReaction
or,O
AST,AdverseReaction
Most,O
cases,O
of,O
transaminase elevations,AdverseReaction
occurred,O
early,O
in,O
treatment,O
of,O
patients,O
who,O
experienced,O
transaminase elevations,AdverseReaction
of,O
any,O
grade,O
more,O
than,O
80,O
experienced,O
their,O
first,O
event,O
within,O
the,O
first,O
3,O
months,O
The,O
median,O
time,O
to,O
onset,O
of,O
increased ALT,AdverseReaction
and,O
AST,AdverseReaction
was,O
30,O
and,O
33,O
days,O
respectively,O
and,O
the,O
median,O
duration,O
for,O
each,O
was,O
21,O
days,O
Perform,O
hepatic,O
enzyme,O
tests,O
monthly,O
for,O
the,O
first,O
three,O
months,O
of,O
BOSULIF,O
treatment,O
and,O
as,O
clinically,O
indicated,O
In,O
patients,O
with,O
transaminase,O
elevations,O
monitor,O
liver,O
enzymes,O
more,O
frequently,O
Withhold,O
dose,O
reduce,O
or,O
discontinue,O
BOSULIF,O
as,O
necessary,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Adverse,O
Reactions,O
6,O
5,O
4,O
Fluid,O
Retention,O
Fluid retention,AdverseReaction
occurs,O
with,O
BOSULIF,O
and,O
may,Factor
manifest,O
as,O
pericardial effusion,AdverseReaction
pleural effusion,AdverseReaction
pulmonary edema,AdverseReaction
and,O
or,O
peripheral edema,AdverseReaction
In,O
the,O
single,O
arm,O
Phase,O
1,O
2,O
clinical,O
trial,O
in,O
546,O
patients,O
with,O
CML,O
treated,O
with,O
prior,O
therapy,O
severe,Severity
fluid retention,AdverseReaction
was,O
reported,O
in,O
14,O
patients,O
3,O
Specifically,O
9,O
patients,O
had,O
a,O
Grade 3,Severity
or,O
4,Severity
pleural effusion,AdverseReaction
3,O
patients,O
experienced,O
both,O
Grade 3,Severity
or,O
Grade 4,Severity
pleural,AdverseReaction
and,O
pericardial effusions,AdverseReaction
1,O
patient,O
experienced,O
Grade 3,Severity
peripheral,AdverseReaction
and,O
pulmonary edema,AdverseReaction
and,O
1,O
patient,O
had,O
a,O
Grade 3,Severity
edema,AdverseReaction
Monitor,O
and,O
manage,O
patients,O
using,O
standards,O
of,O
care,O
Interrupt,O
dose,O
reduce,O
or,O
discontinue,O
BOSULIF,O
as,O
necessary,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Adverse,O
Reactions,O
6,O
5,O
5,O
Renal,O
Toxicity,O
An,O
on,O
treatment,O
decline in estimated glomerular filtration rate,AdverseReaction
eGFR,O
has,O
occurred,O
in,O
patients,O
treated,O
with,O
BOSULIF,O
Table,O
2,O
identifies,O
the,O
shift,O
from,O
baseline,O
to,O
lowest,O
observed,O
estimated,O
glomerular,O
filtration,O
rate,O
eGFR,O
during,O
BOSULIF,O
therapy,O
for,O
patients,O
in,O
the,O
global,O
Ph,O
Leukemia,O
studies,O
The,O
median,O
duration,O
of,O
therapy,O
with,O
BOSULIF,O
was,O
approximately,O
17,O
months,O
range,O
0,O
03,O
to,O
95,O
for,O
patients,O
in,O
these,O
studies,O
Table,O
2,O
Shift,O
from,O
Baseline,O
to,O
Lowest,O
Observed,O
eGFR,O
Group,O
During,O
Treatment,O
Safety,O
Population,O
in,O
Clinical,O
Studies,O
n,O
818,O
Among,O
the,O
818,O
patients,O
eGFR,O
was,O
missing,O
in,O
5,O
patients,O
at,O
baseline,O
or,O
on,O
therapy,O
There,O
were,O
no,O
patients,O
with,O
kidney,O
failure,O
at,O
baseline,O
Baseline,O
Follow,O
Up,O
Renal,O
Function,O
Status,O
n,O
Normaln,O
Mildn,O
Mild,O
to,O
Moderaten,O
Moderate,O
to,O
Severen,O
Severen,O
Kidney,O
Failuren,O
Notes,O
Grading,O
is,O
based,O
on,O
Modification,O
in,O
Diet,O
in,O
Renal,O
Disease,O
method,O
MDRD,O
KDIGO,O
Classification,O
by,O
eGFR,O
Normal,O
greater,O
than,O
or,O
equal,O
to,O
90,O
Mild,O
60,O
to,O
less,O
than,O
90,O
Mild,O
to,O
Moderate,O
45,O
to,O
less,O
than,O
60,O
Moderate,O
to,O
Severe,O
30,O
to,O
less,O
than,O
45,O
Severe,O
15,O
to,O
less,O
than,O
30,O
Kidney,O
Failure,O
less,O
than,O
15,O
ml,O
min,O
1,O
73,O
m,O
2,O
Normal,O
274,O
53,O
19,O
174,O
64,O
30,O
11,O
14,O
5,O
1,O
1,O
1,O
1,O
Mild,O
438,O
10,O
2,O
170,O
39,O
177,O
40,O
63,O
14,O
14,O
3,O
2,O
1,O
Mild,O
to,O
Moderate,O
79,O
0,O
4,O
5,O
28,O
35,O
37,O
47,O
10,O
13,O
0,O
Moderate,O
to,O
Severe,O
24,O
0,O
1,O
4,O
1,O
4,O
6,O
25,O
15,O
63,O
1,O
4,O
Severe,O
1,O
0,O
0,O
0,O
0,O
0,O
1,O
100,O
Total,O
816,O
63,O
8,O
349,O
43,O
236,O
29,O
120,O
15,O
40,O
5,O
5,O
1,O
Monitor,O
renal,O
function,O
at,O
baseline,O
and,O
during,O
therapy,O
with,O
BOSULIF,O
with,O
particular,O
attention,O
to,O
those,O
patients,O
who,O
have,O
preexisting,O
renal,O
impairment,O
or,O
risk,O
factors,O
for,O
renal,O
dysfunction,O
Consider,O
dose,O
adjustment,O
in,O
patients,O
with,O
baseline,O
and,O
treatment,O
emergent,O
renal,O
impairment,O
see,O
Dosage,O
and,O
Administration,O
2,O
7,O
5,O
6,O
Embryofetal,O
Toxicity,O
There,O
are,O
no,O
adequate,O
and,O
well,O
controlled,O
studies,O
of,O
BOSULIF,O
in,O
pregnant,O
women,O
BOSULIF,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Bosutinib,O
caused,O
embryofetal toxicities,AdverseReaction
in,O
rabbits,Animal
at,O
maternal,O
exposures,O
that,O
were,O
greater,O
than,O
the,O
clinical,O
exposure,O
at,O
the,O
recommended,O
bosutinib,O
dose,O
of,O
500,O
mg,O
day,O
Females,O
of,O
reproductive,O
potential,O
should,O
be,O
advised,O
to,O
avoid,O
pregnancy,O
while,O
being,O
treated,O
with,O
BOSULIF,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Gastrointestinal toxicity,AdverseReaction
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Myelosuppression,AdverseReaction
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hepatic toxicity,AdverseReaction
see,O
Dosage,O
and,O
Administration,O
2,O
5,O
and,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Fluid retention,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Renal toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
greater,O
than,O
20,O
are,O
diarrhea,AdverseReaction
nausea,AdverseReaction
thrombocytopenia,AdverseReaction
vomiting,AdverseReaction
abdominal pain,AdverseReaction
rash,AdverseReaction
anemia,AdverseReaction
pyrexia,AdverseReaction
and,O
fatigue,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Pfizer,O
Inc,O
at,O
1,O
800,O
438,O
1985,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Serious,O
adverse,O
reactions,O
reported,O
include,O
anaphylactic shock,AdverseReaction
see,O
Contraindications,O
4,O
myelosuppression,AdverseReaction
gastrointestinal toxicity,AdverseReaction
diarrhea,AdverseReaction
fluid retention,AdverseReaction
hepatotoxicity,AdverseReaction
and,O
rash,AdverseReaction
Adverse,O
reactions,O
of,O
any,O
toxicity,O
grade,O
reported,O
for,O
greater,O
than,O
20,O
of,O
patients,O
in,O
the,O
Phase,O
1,O
2,O
safety,O
population,O
n,O
546,O
were,O
diarrhea,AdverseReaction
82,O
nausea,AdverseReaction
46,O
thrombocytopenia,AdverseReaction
41,O
vomiting,AdverseReaction
39,O
abdominal pain,AdverseReaction
37,O
rash,AdverseReaction
35,O
anemia,AdverseReaction
27,O
pyrexia,AdverseReaction
26,O
and,O
fatigue,AdverseReaction
24,O
see,O
Clinical,O
Studies,O
14,O
Adverse,O
Reactions,O
in,O
Patients,O
with,O
Imatinib,O
Resistant,O
or,O
Intolerant,O
Ph,O
Chronic,O
Phase,O
CP,O
Accelerated,O
Phase,O
AP,O
and,O
Blast,O
Phase,O
BP,O
CML,O
The,O
single,O
arm,O
Phase,O
1,O
2,O
clinical,O
trial,O
Study,O
1,O
enrolled,O
patients,O
with,O
Ph,O
chronic,O
accelerated,O
or,O
blast,O
phase,O
chronic,O
myelogenous,O
leukemia,O
CML,O
and,O
with,O
resistance,O
or,O
intolerance,O
to,O
prior,O
therapy,O
see,O
Clinical,O
Studies,O
14,O
The,O
safety,O
population,O
received,O
at,O
least,O
1,O
dose,O
of,O
BOSULIF,O
included,O
546,O
CML,O
patients,O
287,O
patients,O
with,O
CP,O
CML,O
previously,O
treated,O
with,O
imatinib,O
only,O
who,O
had,O
a,O
median,O
duration,O
of,O
BOSULIF,O
treatment,O
of,O
24,O
months,O
and,O
a,O
median,O
dose,O
intensity,O
of,O
484,O
mg,O
day,O
119,O
patients,O
with,O
CP,O
CML,O
previously,O
treated,O
with,O
both,O
imatinib,O
and,O
at,O
least,O
1,O
additional,O
TKI,O
who,O
had,O
a,O
median,O
duration,O
of,O
BOSULIF,O
treatment,O
of,O
9,O
months,O
and,O
a,O
median,O
dose,O
intensity,O
of,O
475,O
mg,O
day,O
140,O
patients,O
with,O
advanced,O
phase,O
CML,O
including,O
76,O
patients,O
with,O
AP,O
CML,O
and,O
64,O
patients,O
with,O
BP,O
CML,O
In,O
the,O
patients,O
with,O
AP,O
CML,O
and,O
BP,O
CML,O
the,O
median,O
duration,O
of,O
BOSULIF,O
treatment,O
was,O
10,O
months,O
and,O
3,O
months,O
respectively,O
The,O
median,O
dose,O
intensity,O
was,O
483,O
mg,O
day,O
and,O
500,O
mg,O
day,O
in,O
the,O
AP,O
CML,O
and,O
BP,O
CML,O
cohorts,O
respectively,O
Table,O
3,O
identifies,O
adverse,O
reactions,O
greater,O
than,O
or,O
equal,O
to,O
10,O
for,O
all,O
grades,O
and,O
grades,O
3,O
or,O
4,O
for,O
the,O
Phase,O
1,O
2,O
CML,O
safety,O
population,O
Table,O
3,O
Adverse,O
Reactions,O
10,O
or,O
Greater,O
in,O
Patients,O
with,O
CML,O
in,O
Study,O
1,O
Chronic,O
Phase,O
CMLN,O
406,O
Advanced,O
Phase,O
CMLN,O
140,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
Advanced,O
Phase,O
CML,O
includes,O
patients,O
with,O
Accelerated,O
Phase,O
and,O
Blast,O
Phase,O
CML,O
Diarrhea,AdverseReaction
84,O
9,O
76,O
5,O
Nausea,AdverseReaction
46,O
1,O
47,O
2,O
Abdominal Pain,AdverseReaction
40,O
1,O
29,O
5,O
Thrombocytopenia,AdverseReaction
40,O
26,O
42,O
37,O
Vomiting,AdverseReaction
37,O
3,O
42,O
4,O
Rash,AdverseReaction
34,O
8,O
35,O
4,O
Fatigue,AdverseReaction
26,O
1,O
20,O
4,O
Anemia,AdverseReaction
23,O
9,O
37,O
26,O
Pyrexia,AdverseReaction
22,O
1,O
36,O
3,O
Increased alanine aminotransferase,AdverseReaction
20,O
7,O
10,O
5,O
Headache,AdverseReaction
20,O
1,O
18,O
4,O
Cough,AdverseReaction
20,O
0,O
21,O
0,O
Increased aspartate aminotransferase,AdverseReaction
16,O
4,O
11,O
3,O
Neutropenia,AdverseReaction
16,O
11,O
19,O
18,O
Edema,AdverseReaction
14,O
1,O
14,O
1,O
Arthralgia,AdverseReaction
14,O
1,O
13,O
0,O
Decreased appetite,AdverseReaction
13,O
1,O
14,O
0,O
Respiratory tract infection,AdverseReaction
12,O
1,O
10,O
0,O
Nasopharyngitis,AdverseReaction
12,O
0,O
5,O
0,O
Back pain,AdverseReaction
12,O
1,O
7,O
1,O
Asthenia,AdverseReaction
11,O
1,O
10,O
1,O
Pruritus,AdverseReaction
11,O
1,O
8,O
0,O
Dizziness,AdverseReaction
10,O
0,O
13,O
1,O
Dyspnea,AdverseReaction
10,O
1,O
19,O
6,O
In,O
the,O
single,O
arm,O
Phase,O
1,O
2,O
clinical,O
trial,O
one,O
patient,O
0,O
2,O
experienced,O
QTcF interval of greater than 500 milliseconds,AdverseReaction
Patients,O
with,O
uncontrolled,O
or,O
significant,O
cardiovascular,O
disease,O
including,O
QT,O
interval,O
prolongation,O
were,O
excluded,O
by,O
protocol,O
Table,O
4,O
identifies,O
the,O
clinically,O
relevant,O
or,O
severe,O
Grade,O
3,O
4,O
laboratory,O
test,O
abnormalities,O
for,O
the,O
Phase,O
1,O
2,O
CML,O
safety,O
population,O
Table,O
4,O
Number,O
of,O
Patients,O
with,O
Clinically,O
Relevant,O
or,O
Severe,O
Grade,O
3,O
4,O
Laboratory,O
Test,O
Abnormalities,O
in,O
Patients,O
with,O
CML,O
in,O
Study,O
1,O
Safety,O
Population,O
Chronic,O
Phase,O
CML,O
Advanced,O
Phase,O
CML,O
All,O
CP,O
and,O
AdvP,O
CML,O
N,O
406,O
N,O
140,O
N,O
546,O
n,O
n,O
n,O
Hematology,O
Parameters,O
Platelet Count,AdverseReaction
Low,AdverseReaction
less,O
than,O
50 10 9 L,Severity
102,O
25,O
80,O
57,O
182,O
33,O
Absolute Neutrophil Count less than 1 10 9 L,AdverseReaction
74,O
18,O
52,O
37,O
126,O
23,O
Hemoglobin,AdverseReaction
Low,AdverseReaction
less,O
than,O
80 g L,Severity
53,O
13,O
49,O
35,O
102,O
19,O
Biochemistry,O
Parameters,O
SGPT,AdverseReaction
ALT greater than 5 0 ULN than 5 0 ULN,AdverseReaction
39,O
10,O
8,O
6,O
47,O
9,O
SGOT,AdverseReaction
AST greater than 5 0 ULN than 5 0 ULN,AdverseReaction
17,O
4,O
4,O
3,O
21,O
4,O
Lipase greater than 2 ULN,AdverseReaction
33,O
8,O
4,O
3,O
37,O
7,O
Phosphorus,AdverseReaction
Low,AdverseReaction
less,O
than,O
0 6 mmol L,Severity
30,O
7,O
10,O
7,O
40,O
7,O
Total Bilirubin greater than 3 0 ULN,AdverseReaction
3,O
1,O
2,O
1,O
5,O
1,O
Additional,O
Adverse,O
Reactions,O
from,O
Multiple,O
Clinical,O
Trials,O
The,O
following,O
adverse,O
reactions,O
were,O
reported,O
in,O
patients,O
in,O
clinical,O
trials,O
with,O
BOSULIF,O
less,O
than,O
10,O
of,O
BOSULIF,O
treated,O
patients,O
They,O
represent,O
an,O
evaluation,O
of,O
the,O
adverse,O
reaction,O
data,O
from,O
870,O
patients,O
with,O
Ph,O
leukemia,O
who,O
received,O
at,O
least,O
1,O
dose,O
of,O
single,O
agent,O
BOSULIF,O
These,O
adverse,O
reactions,O
are,O
presented,O
by,O
system,O
organ,O
class,O
and,O
are,O
ranked,O
by,O
frequency,O
These,O
adverse,O
reactions,O
are,O
included,O
based,O
on,O
clinical,O
relevance,O
and,O
ranked,O
in,O
order,O
of,O
decreasing,O
seriousness,O
within,O
each,O
category,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
febrile neutropenia,AdverseReaction
Cardiac,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
pericardial effusion,AdverseReaction
0,O
1,O
and,O
less,O
than,O
1,O
pericarditis,AdverseReaction
Ear,O
and,O
Labyrinth,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
tinnitus,AdverseReaction
Gastrointestinal,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
gastritis,AdverseReaction
0,O
1,O
and,O
less,O
than,O
1,O
acute pancreatitis,AdverseReaction
gastrointestinal hemorrhage,AdverseReaction
includes,O
gastrointestinal hemorrhage,AdverseReaction
gastric hemorrhage,AdverseReaction
upper gastrointestinal hemorrhage,AdverseReaction
General,O
Disorders,O
and,O
Administrative,O
Site,O
Conditions,O
1,O
and,O
less,O
than,O
10,O
chest pain,AdverseReaction
includes,O
chest pain,AdverseReaction
and,O
chest discomfort,AdverseReaction
pain,AdverseReaction
Hepatobiliary,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
hepatotoxicity,AdverseReaction
includes,O
hepatotoxicity,AdverseReaction
toxic hepatitis,AdverseReaction
and,O
cytolytic hepatitis,AdverseReaction
abnormal hepatic function,AdverseReaction
includes,O
abnormal hepatic function,AdverseReaction
liver disorder,AdverseReaction
0,O
1,O
and,O
less,O
than,O
1,O
liver injury,AdverseReaction
Immune,O
System,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
drug hypersensitivity,AdverseReaction
0,O
1,O
and,O
less,O
than,O
1,O
anaphylactic shock,AdverseReaction
Infections,O
and,O
Infestations,O
1,O
and,O
less,O
than,O
10,O
pneumonia,AdverseReaction
includes,O
pneumonia,AdverseReaction
bronchopneumonia,AdverseReaction
lobar pneumonia,AdverseReaction
primary atypical pneumonia,AdverseReaction
influenza,AdverseReaction
bronchitis,AdverseReaction
Investigations,O
1,O
and,O
less,O
than,O
10,O
electrocardiogram QT prolonged,AdverseReaction
increased blood creatine phosphokinase,AdverseReaction
increased blood creatinine,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorder,O
1,O
and,O
less,O
than,O
10,O
hyperkalemia,AdverseReaction
dehydration,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorder,O
1,O
and,O
less,O
than,O
10,O
myalgia,AdverseReaction
Nervous,O
System,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
dysgeusia,AdverseReaction
Renal,O
and,O
Urinary,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
acute renal failure,AdverseReaction
renal failure,AdverseReaction
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
pleural effusion,AdverseReaction
0,O
1,O
and,O
less,O
than,O
1,O
acute pulmonary edema,AdverseReaction
respiratory failure,AdverseReaction
pulmonary hypertension,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Disorders,O
1,O
and,O
less,O
than,O
10,O
urticaria,AdverseReaction
pruritus,AdverseReaction
acne,AdverseReaction
0,O
1,O
and,O
less,O
than,O
1,O
erythema multiforme,AdverseReaction
exfoliative rash,AdverseReaction
drug eruption,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
LABA,DrugClass
increase,O
the,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
and,O
asthma,O
related,O
hospitalizations,O
Prescribe,O
only,O
for,O
recommended,O
patient,O
populations,O
5,O
1,O
Do,O
not,O
initiate,O
in,O
acutely,O
deteriorating,O
COPD,O
or,O
asthma,O
Do,O
not,O
use,O
to,O
treat,O
acute,O
symptoms,O
5,O
2,O
Do,O
not,O
use,O
in,O
combination,O
with,O
an,O
additional,O
medicine,O
containing,O
a,O
LABA,O
because,O
of,O
risk,O
of,O
overdose,O
5,O
3,O
Candida albicans infection of the mouth albicans infection of the,AdverseReaction
and,O
pharynx,AdverseReaction
may,Factor
occur,O
Monitor,O
patients,O
periodically,O
Advise,O
the,O
patient,O
to,O
rinse,O
his,O
her,O
mouth,O
with,O
water,O
without,O
swallowing,O
after,O
inhalation,O
to,O
help,O
reduce,O
the,O
risk,O
5,O
4,O
Increased,O
risk,Factor
of,O
pneumonia,AdverseReaction
in,O
patients,O
with,O
COPD,O
Monitor,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
pneumonia,O
5,O
5,O
Potential,Factor
worsening of infections,AdverseReaction
e,O
g,O
existing tuberculosis,AdverseReaction
fungal,AdverseReaction
bacterial,AdverseReaction
viral,AdverseReaction
or,O
parasitic infections,AdverseReaction
ocular herpes simplex,AdverseReaction
Use,O
with,O
caution,O
in,O
patients,O
with,O
these,O
infections,O
More,O
serious,Severity
or,O
even,O
fatal,AdverseReaction
course,O
of,O
chickenpox,AdverseReaction
or,O
measles,AdverseReaction
can,Factor
occur,O
in,O
susceptible,O
patients,O
5,O
6,O
Risk,Factor
of,O
impaired adrenal function,AdverseReaction
when,O
transferring,O
from,O
systemic,O
corticosteroids,O
Taper,O
patients,O
slowly,O
from,O
systemic,O
corticosteroids,O
if,O
transferring,O
to,O
BREO,O
ELLIPTA,O
5,O
7,O
Hypercorticism,AdverseReaction
and,O
adrenal suppression,AdverseReaction
may,Factor
occur,O
with,O
very,O
high,O
dosages,O
or,O
at,O
the,O
regular,O
dosage,O
in,O
susceptible,O
individuals,O
If,O
such,O
changes,O
occur,O
discontinue,O
BREO,O
ELLIPTA,O
slowly,O
5,O
8,O
If,O
paradoxical,O
bronchospasm,O
occurs,O
discontinue,O
BREO,O
ELLIPTA,O
and,O
institute,O
alternative,O
therapy,O
5,O
10,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
cardiovascular,O
disorders,O
because,O
of,O
beta,O
adrenergic,O
stimulation,O
5,O
12,O
Assess,O
for,O
decrease,O
in,O
bone,O
mineral,O
density,O
initially,O
and,O
periodically,O
thereafter,O
5,O
13,O
Close,O
monitoring,O
for,O
glaucoma,O
and,O
cataracts,O
is,O
warranted,O
5,O
14,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
convulsive,O
disorders,O
thyrotoxicosis,O
diabetes,O
mellitus,O
and,O
ketoacidosis,O
5,O
15,O
Be,O
alert,O
to,O
hypokalemia,O
and,O
hyperglycemia,O
5,O
16,O
5,O
1,O
Asthma,O
Related,O
Death,O
LABA,DrugClass
such,O
as,O
vilanterol,O
one,O
of,O
the,O
active,O
ingredients,O
in,O
BREO,O
ELLIPTA,O
increase,O
the,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
Currently,O
available,O
data,O
are,O
inadequate,O
to,O
determine,O
whether,O
concurrent,O
use,O
of,O
inhaled,O
corticosteroids,O
or,O
other,O
long,O
term,O
asthma,O
control,O
drugs,O
mitigates,O
the,O
increased,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
from,O
LABA,DrugClass
Available,O
data,O
from,O
controlled,O
clinical,O
trials,O
suggest,O
that,O
LABA,O
increase,O
the,O
risk,O
of,O
asthma,O
related,O
hospitalization,O
in,O
pediatric,O
and,O
adolescent,O
patients,O
Therefore,O
when,O
treating,O
patients,O
with,O
asthma,O
physicians,O
should,O
only,O
prescribe,O
BREO,O
ELLIPTA,O
for,O
patients,O
not,O
adequately,O
controlled,O
on,O
a,O
long,O
term,O
asthma,O
control,O
medication,O
such,O
as,O
an,O
inhaled,O
corticosteroid,O
or,O
whose,O
disease,O
severity,O
clearly,O
warrants,O
initiation,O
of,O
treatment,O
with,O
both,O
an,O
inhaled,O
corticosteroid,O
and,O
a,O
LABA,O
Once,O
asthma,O
control,O
is,O
achieved,O
and,O
maintained,O
assess,O
the,O
patient,O
at,O
regular,O
intervals,O
and,O
step,O
down,O
therapy,O
e,O
g,O
discontinue,O
BREO,O
ELLIPTA,O
if,O
possible,O
without,O
loss,O
of,O
asthma,O
control,O
and,O
maintain,O
the,O
patient,O
on,O
a,O
long,O
term,O
asthma,O
control,O
medication,O
such,O
as,O
an,O
inhaled,O
corticosteroid,O
Do,O
not,O
use,O
BREO,O
ELLIPTA,O
for,O
patients,O
whose,O
asthma,O
is,O
adequately,O
controlled,O
on,O
low,O
or,O
medium,O
dose,O
inhaled,O
corticosteroids,O
A,O
28,O
week,O
placebo,O
controlled,O
US,O
trial,O
that,O
compared,O
the,O
safety,O
of,O
another,O
LABA,DrugClass
salmeterol,O
with,O
placebo,O
each,O
added,O
to,O
usual,O
asthma,O
therapy,O
showed,O
an,O
increase,O
in,O
asthma,O
related,O
deaths,AdverseReaction
in,O
subjects,O
receiving,O
salmeterol,O
13,O
13,O
176,O
in,O
subjects,O
treated,O
with,O
salmeterol,O
vs,O
3,O
13,O
179,O
in,O
subjects,O
treated,O
with,O
placebo,O
relative,O
risk,O
4,O
37,O
95,O
CI,O
1,O
25,O
15,O
34,O
The,O
increased,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
is,O
considered,O
a,O
class,O
effect,O
of,O
LABA,DrugClass
including,O
vilanterol,O
one,O
of,O
the,O
active,O
ingredients,O
in,O
BREO,O
ELLIPTA,O
No trial adequate,Factor
to,O
determine,O
whether,O
the,O
rate,O
of,O
asthma,O
related,O
death,AdverseReaction
is,O
increased,O
in,O
subjects,O
treated,O
with,O
BREO,O
ELLIPTA,O
has,O
been,O
conducted,O
Data,O
are,O
not available,Factor
to,O
determine,O
whether,O
the,O
rate,O
of,O
death,AdverseReaction
in,O
patients,O
with,O
COPD,O
is,O
increased,O
by,O
LABA,O
5,O
2,O
Deterioration,O
of,O
Disease,O
and,O
Acute,O
Episodes,O
BREO,O
ELLIPTA,O
should,O
not,O
be,O
initiated,O
in,O
patients,O
during,O
rapidly,O
deteriorating,O
or,O
potentially,O
life,O
threatening,O
episodes,O
of,O
COPD,O
or,O
asthma,O
BREO,O
ELLIPTA,O
has,O
not,O
been,O
studied,O
in,O
subjects,O
with,O
acutely,O
deteriorating,O
COPD,O
or,O
asthma,O
The,O
initiation,O
of,O
BREO,O
ELLIPTA,O
in,O
this,O
setting,O
is,O
not,O
appropriate,O
COPD,O
may,O
deteriorate,O
acutely,O
over,O
a,O
period,O
of,O
hours,O
or,O
chronically,O
over,O
several,O
days,O
or,O
longer,O
If,O
BREO,O
ELLIPTA,O
100,O
25,O
no,O
longer,O
controls,O
symptoms,O
of,O
bronchoconstriction,O
the,O
patient,O
s,O
inhaled,O
short,O
acting,O
beta2,O
agonist,O
becomes,O
less,O
effective,O
or,O
the,O
patient,O
needs,O
more,O
short,O
acting,O
beta2,O
agonist,O
than,O
usual,O
these,O
may,O
be,O
markers,O
of,O
deterioration,O
of,O
disease,O
In,O
this,O
setting,O
a,O
reevaluation,O
of,O
the,O
patient,O
and,O
the,O
COPD,O
treatment,O
regimen,O
should,O
be,O
undertaken,O
at,O
once,O
For,O
COPD,O
increasing,O
the,O
daily,O
dose,O
of,O
BREO,O
ELLIPTA,O
100,O
25,O
is,O
not,O
appropriate,O
in,O
this,O
situation,O
Increasing,O
use,O
of,O
inhaled,O
short,O
acting,O
beta2,O
agonists,O
is,O
a,O
marker,O
of,O
deteriorating,O
asthma,O
In,O
this,O
situation,O
the,O
patient,O
requires,O
immediate,O
reevaluation,O
with,O
reassessment,O
of,O
the,O
treatment,O
regimen,O
giving,O
special,O
consideration,O
to,O
the,O
possible,O
need,O
for,O
replacing,O
the,O
current,O
strength,O
of,O
BREO,O
ELLIPTA,O
with,O
a,O
higher,O
strength,O
adding,O
additional,O
inhaled,O
corticosteroid,O
or,O
initiating,O
systemic,O
corticosteroids,O
Patients,O
should,O
not,O
use,O
more,O
than,O
1,O
inhalation,O
once,O
daily,O
of,O
BREO,O
ELLIPTA,O
BREO,O
ELLIPTA,O
should,O
not,O
be,O
used,O
for,O
the,O
relief,O
of,O
acute,O
symptoms,O
i,O
e,O
as,O
rescue,O
therapy,O
for,O
the,O
treatment,O
of,O
acute,O
episodes,O
of,O
bronchospasm,O
BREO,O
ELLIPTA,O
has,O
not,O
been,O
studied,O
in,O
the,O
relief,O
of,O
acute,O
symptoms,O
and,O
extra,O
doses,O
should,O
not,O
be,O
used,O
for,O
that,O
purpose,O
Acute,O
symptoms,O
should,O
be,O
treated,O
with,O
an,O
inhaled,O
short,O
acting,O
beta2,O
agonist,O
When,O
beginning,O
treatment,O
with,O
BREO,O
ELLIPTA,O
patients,O
who,O
have,O
been,O
taking,O
oral,O
or,O
inhaled,O
short,O
acting,O
beta2,O
agonists,O
on,O
a,O
regular,O
basis,O
e,O
g,O
4,O
times,O
a,O
day,O
should,O
be,O
instructed,O
to,O
discontinue,O
the,O
regular,O
use,O
of,O
these,O
drugs,O
and,O
to,O
use,O
them,O
only,O
for,O
symptomatic,O
relief,O
of,O
acute,O
respiratory,O
symptoms,O
When,O
prescribing,O
BREO,O
ELLIPTA,O
the,O
healthcare,O
provider,O
should,O
also,O
prescribe,O
an,O
inhaled,O
short,O
acting,O
beta2,O
agonist,O
and,O
instruct,O
the,O
patient,O
on,O
how,O
it,O
should,O
be,O
used,O
5,O
3,O
Excessive,O
Use,O
of,O
BREO,O
ELLIPTA,O
and,O
Use,O
with,O
Other,O
Long,O
Acting,O
Beta2,O
Agonists,O
BREO,O
ELLIPTA,O
should,O
not,O
be,O
used,O
more,O
often,O
than,O
recommended,O
at,O
higher,O
doses,O
than,O
recommended,O
or,O
in,O
conjunction,O
with,O
other,O
medicines,O
containing,O
LABA,O
as,O
an,O
overdose,O
may,O
result,O
Clinically,O
significant,O
cardiovascular,O
effects,O
and,O
fatalities,AdverseReaction
have,O
been,O
reported,O
in,O
association,O
with,O
excessive,O
use,O
of,O
inhaled sympathomimetic drugs,DrugClass
Patients,O
using,O
BREO,O
ELLIPTA,O
should,O
not,O
use,O
another,O
medicine,O
containing,O
a,O
LABA,O
e,O
g,O
salmeterol,O
formoterol,O
fumarate,O
arformoterol,O
tartrate,O
indacaterol,O
for,O
any,O
reason,O
5,O
4,O
Local,O
Effects,O
of,O
Inhaled,O
Corticosteroids,O
In,O
clinical,O
trials,O
the,O
development,O
of,O
localized,O
infections of the mouth of the,AdverseReaction
and,O
pharynx with Candida albicans Candida albicans,AdverseReaction
has,O
occurred,O
in,O
subjects,O
treated,O
with,O
BREO,O
ELLIPTA,O
When,O
such,O
an,O
infection,O
develops,O
it,O
should,O
be,O
treated,O
with,O
appropriate,O
local,O
or,O
systemic,O
i,O
e,O
oral,O
antifungal,O
therapy,O
while,O
treatment,O
with,O
BREO,O
ELLIPTA,O
continues,O
but,O
at,O
times,O
therapy,O
with,O
BREO,O
ELLIPTA,O
may,O
need,O
to,O
be,O
interrupted,O
Advise,O
the,O
patient,O
to,O
rinse,O
his,O
her,O
mouth,O
with,O
water,O
without,O
swallowing,O
following,O
inhalation,O
to,O
help,O
reduce,O
the,O
risk,O
of,O
oropharyngeal,O
candidiasis,O
5,O
5,O
Pneumonia,O
An,O
increase,O
in,O
the,O
incidence,O
of,O
pneumonia,AdverseReaction
has,O
been,O
observed,O
in,O
subjects,O
with,O
COPD,O
receiving,O
BREO,O
ELLIPTA,O
100,O
25,O
in,O
clinical,O
trials,O
There,O
was,O
also,O
an,O
increased,O
incidence,O
of,O
pneumonias,AdverseReaction
resulting,O
in,O
hospitalization,O
In,O
some,O
incidences,O
these,O
pneumonia,AdverseReaction
events,O
were,O
fatal,AdverseReaction
Physicians,O
should,O
remain,O
vigilant,O
for,O
the,O
possible,O
development,O
of,O
pneumonia,O
in,O
patients,O
with,O
COPD,O
as,O
the,O
clinical,O
features,O
of,O
such,O
infections,O
overlap,O
with,O
the,O
symptoms,O
of,O
COPD,O
exacerbations,O
In,O
replicate,O
12,O
month,O
trials,O
in,O
3,O
255,O
subjects,O
with,O
COPD,O
who,O
had,O
experienced,O
a,O
COPD,O
exacerbation,O
in,O
the,O
previous,O
year,O
there,O
was,O
a,O
higher,O
incidence,O
of,O
pneumonia,AdverseReaction
reported,O
in,O
subjects,O
receiving,O
fluticasone,O
furoate,O
vilanterol,O
50,O
mcg,O
25,O
mcg,O
6,O
48,O
of,O
820,O
subjects,O
BREO,O
ELLIPTA,O
100,O
25,O
6,O
51,O
of,O
806,O
subjects,O
or,O
BREO,O
ELLIPTA,O
200,O
25,O
7,O
55,O
of,O
811,O
subjects,O
than,O
in,O
subjects,O
receiving,O
vilanterol,O
25,O
mcg,O
3,O
27,O
of,O
818,O
subjects,O
There,O
was,O
no,Negation
fatal,AdverseReaction
pneumonia,AdverseReaction
in,O
subjects,O
receiving,O
vilanterol,O
or,O
fluticasone,O
furoate,O
vilanterol,O
50,O
mcg,O
25,O
mcg,O
There,O
was,O
fatal,AdverseReaction
pneumonia,AdverseReaction
in,O
1,O
subject,O
receiving,O
BREO,O
ELLIPTA,O
100,O
25,O
and,O
in,O
7,O
subjects,O
receiving,O
BREO,O
ELLIPTA,O
200,O
25,O
less,O
than,O
1,O
for,O
each,O
treatment,O
group,O
5,O
6,O
Immunosuppression,O
Persons,O
who,O
are,O
using,O
drugs that suppress the immune system,DrugClass
are,O
more,O
susceptible,O
to,O
infections,AdverseReaction
than,O
healthy,O
individuals,O
Chickenpox,AdverseReaction
and,O
measles,AdverseReaction
for,O
example,O
can,O
have,O
a,O
more,O
serious,Severity
or,O
even,O
fatal,AdverseReaction
course,O
in,O
susceptible,O
children,O
or,O
adults,O
using,O
corticosteroids,DrugClass
In,O
such,O
children,O
or,O
adults,O
who,O
have,O
not,O
had,O
these,O
diseases,O
or,O
been,O
properly,O
immunized,O
particular,O
care,O
should,O
be,O
taken,O
to,O
avoid,O
exposure,O
How,O
the,O
dose,O
route,O
and,O
duration,O
of,O
corticosteroid,O
administration,O
affect,O
the,O
risk,O
of,O
developing,O
a,O
disseminated,O
infection,O
is,O
not,O
known,O
The,O
contribution,O
of,O
the,O
underlying,O
disease,O
and,O
or,O
prior,O
corticosteroid,O
treatment,O
to,O
the,O
risk,O
is,O
also,O
not,O
known,O
If,O
a,O
patient,O
is,O
exposed,O
to,O
chickenpox,O
prophylaxis,O
with,O
varicella,O
zoster,O
immune,O
globulin,O
VZIG,O
may,O
be,O
indicated,O
If,O
a,O
patient,O
is,O
exposed,O
to,O
measles,O
prophylaxis,O
with,O
pooled,O
intramuscular,O
immunoglobulin,O
IG,O
may,O
be,O
indicated,O
See,O
the,O
respective,O
package,O
inserts,O
for,O
complete,O
VZIG,O
and,O
IG,O
prescribing,O
information,O
If,O
chickenpox,O
develops,O
treatment,O
with,O
antiviral,O
agents,O
may,O
be,O
considered,O
Inhaled,O
corticosteroids,O
should,O
be,O
used,O
with,O
caution,O
if,O
at,O
all,O
in,O
patients,O
with,O
active,O
or,O
quiescent,O
tuberculosis,O
infections,O
of,O
the,O
respiratory,O
tract,O
systemic,O
fungal,O
bacterial,O
viral,O
or,O
parasitic,O
infections,O
or,O
ocular,O
herpes,O
simplex,O
5,O
7,O
Transferring,O
Patients,O
from,O
Systemic,O
Corticosteroid,O
Therapy,O
Particular,O
care,O
is,O
needed,O
for,O
patients,O
who,O
have,O
been,O
transferred,O
from,O
systemically,O
active,O
corticosteroids,O
to,O
inhaled,O
corticosteroids,O
because,O
deaths,O
due,O
to,O
adrenal,O
insufficiency,O
have,O
occurred,O
in,O
patients,O
with,O
asthma,O
during,O
and,O
after,O
transfer,O
from,O
systemic,O
corticosteroids,O
to,O
less,O
systemically,O
available,O
inhaled,O
corticosteroids,O
After,O
withdrawal,O
from,O
systemic,O
corticosteroids,O
a,O
number,O
of,O
months,O
are,O
required,O
for,O
recovery,O
of,O
hypothalamic,O
pituitary,O
adrenal,O
HPA,O
function,O
Patients,O
who,O
have,O
been,O
previously,O
maintained,O
on,O
20,O
mg,O
or,O
more,O
of,O
prednisone,O
or,O
its,O
equivalent,O
may,O
be,O
most,O
susceptible,O
particularly,O
when,O
their,O
systemic,O
corticosteroids,O
have,O
been,O
almost,O
completely,O
withdrawn,O
During,O
this,O
period,O
of,O
HPA,O
suppression,O
patients,O
may,O
exhibit,O
signs,O
and,O
symptoms,O
of,O
adrenal,O
insufficiency,O
when,O
exposed,O
to,O
trauma,O
surgery,O
or,O
infection,O
particularly,O
gastroenteritis,O
or,O
other,O
conditions,O
associated,O
with,O
severe,O
electrolyte,O
loss,O
Although,O
BREO,O
ELLIPTA,O
may,O
control,O
COPD,O
or,O
asthma,O
symptoms,O
during,O
these,O
episodes,O
in,O
recommended,O
doses,O
it,O
supplies,O
less,O
than,O
normal,O
physiological,O
amounts,O
of,O
glucocorticoid,O
systemically,O
and,O
does,O
NOT,O
provide,O
the,O
mineralocorticoid,O
activity,O
that,O
is,O
necessary,O
for,O
coping,O
with,O
these,O
emergencies,O
During,O
periods,O
of,O
stress,O
a,O
severe,O
COPD,O
exacerbation,O
or,O
a,O
severe,O
asthma,O
attack,O
patients,O
who,O
have,O
been,O
withdrawn,O
from,O
systemic,O
corticosteroids,O
should,O
be,O
instructed,O
to,O
resume,O
oral,O
corticosteroids,O
in,O
large,O
doses,O
immediately,O
and,O
to,O
contact,O
their,O
physicians,O
for,O
further,O
instruction,O
These,O
patients,O
should,O
also,O
be,O
instructed,O
to,O
carry,O
a,O
warning,O
card,O
indicating,O
that,O
they,O
may,O
need,O
supplementary,O
systemic,O
corticosteroids,O
during,O
periods,O
of,O
stress,O
a,O
severe,O
COPD,O
exacerbation,O
or,O
a,O
severe,O
asthma,O
attack,O
Patients,O
requiring,O
oral,O
corticosteroids,O
should,O
be,O
weaned,O
slowly,O
from,O
systemic,O
corticosteroid,O
use,O
after,O
transferring,O
to,O
BREO,O
ELLIPTA,O
Prednisone,O
reduction,O
can,O
be,O
accomplished,O
by,O
reducing,O
the,O
daily,O
prednisone,O
dose,O
by,O
2,O
5,O
mg,O
on,O
a,O
weekly,O
basis,O
during,O
therapy,O
with,O
BREO,O
ELLIPTA,O
Lung,O
function,O
FEV1or,O
peak,O
expiratory,O
flow,O
beta,O
agonist,O
use,O
and,O
COPD,O
or,O
asthma,O
symptoms,O
should,O
be,O
carefully,O
monitored,O
during,O
withdrawal,O
of,O
oral,O
corticosteroids,O
In,O
addition,O
patients,O
should,O
be,O
observed,O
for,O
signs,O
and,O
symptoms,O
of,O
adrenal,O
insufficiency,O
such,O
as,O
fatigue,O
lassitude,O
weakness,O
nausea,O
and,O
vomiting,O
and,O
hypotension,O
Transfer,O
of,O
patients,O
from,O
systemic,O
corticosteroid,O
therapy,O
to,O
BREO,O
ELLIPTA,O
may,O
unmask,O
allergic,O
conditions,O
previously,O
suppressed,O
by,O
the,O
systemic,O
corticosteroid,O
therapy,O
e,O
g,O
rhinitis,O
conjunctivitis,O
eczema,O
arthritis,O
eosinophilic,O
conditions,O
During,O
withdrawal,O
from,O
oral,O
corticosteroids,O
some,O
patients,O
may,O
experience,O
symptoms,O
of,O
systemically,O
active,O
corticosteroid,O
withdrawal,O
e,O
g,O
joint,O
and,O
or,O
muscular,O
pain,O
lassitude,O
depression,O
despite,O
maintenance,O
or,O
even,O
improvement,O
of,O
respiratory,O
function,O
5,O
8,O
Hypercorticism,O
and,O
Adrenal,O
Suppression,O
Inhaled,O
fluticasone,O
furoate,O
is,O
absorbed,O
into,O
the,O
circulation,O
and,O
can,O
be,O
systemically,O
active,O
Effects,O
of,O
fluticasone,O
furoate,O
on,O
the,O
HPA,O
axis,O
are,O
not,O
observed,O
with,O
the,O
therapeutic,O
doses,O
of,O
BREO,O
ELLIPTA,O
However,O
exceeding,O
the,O
recommended,O
dosage,O
or,O
coadministration,O
with,O
a,O
strong,O
cytochrome,O
P450,O
3A4,O
CYP3A4,O
inhibitor,O
may,Factor
result,O
in,O
HPA dysfunction,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
Drug,O
Interactions,O
7,O
1,O
Because,O
of,O
the,O
possibility,O
of,O
significant,O
systemic,O
absorption,O
of,O
inhaled,O
corticosteroids,O
in,O
sensitive,O
patients,O
patients,O
treated,O
with,O
BREO,O
ELLIPTA,O
should,O
be,O
observed,O
carefully,O
for,O
any,O
evidence,O
of,O
systemic,O
corticosteroid,O
effects,O
Particular,O
care,O
should,O
be,O
taken,O
in,O
observing,O
patients,O
postoperatively,O
or,O
during,O
periods,O
of,O
stress,O
for,O
evidence,O
of,O
inadequate,O
adrenal,O
response,O
It,O
is,O
possible,O
that,O
systemic,O
corticosteroid,O
effects,O
such,O
as,O
hypercorticism,AdverseReaction
and,O
adrenal suppression,AdverseReaction
including,O
adrenal crisis,AdverseReaction
may,Factor
appear,O
in,O
a,O
small,O
number,O
of,O
patients,O
who,O
are,O
sensitive,O
to,O
these,O
effects,O
If,O
such,O
effects,O
occur,O
BREO,O
ELLIPTA,O
should,O
be,O
reduced,O
slowly,O
consistent,O
with,O
accepted,O
procedures,O
for,O
reducing,O
systemic,O
corticosteroids,O
and,O
other,O
treatments,O
for,O
management,O
of,O
COPD,O
or,O
asthma,O
symptoms,O
should,O
be,O
considered,O
5,O
9,O
Drug,O
Interactions,O
with,O
Strong,O
Cytochrome,O
P450,O
3A4,O
Inhibitors,O
Caution,O
should,O
be,O
exercised,O
when,O
considering,O
the,O
coadministration,O
of,O
BREO,O
ELLIPTA,O
with,O
long,O
term,O
ketoconazole,O
and,O
other,O
known,O
strong,O
CYP3A4,O
inhibitors,O
e,O
g,O
ritonavir,O
clarithromycin,O
conivaptan,O
indinavir,O
itraconazole,O
lopinavir,O
nefazodone,O
nelfinavir,O
saquinavir,O
telithromycin,O
troleandomycin,O
voriconazole,O
because,O
increased,O
systemic,O
corticosteroid,O
and,O
increased,O
cardiovascular,O
adverse,O
effects,O
may,O
occur,O
see,O
Drug,O
Interactions,O
7,O
1,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
10,O
Paradoxical,O
Bronchospasm,O
As,O
with,O
other,O
inhaled,O
medicines,O
BREO,O
ELLIPTA,O
can,Factor
produce,O
paradoxical bronchospasm bronchospasm,AdverseReaction
which,O
may,Factor
be,O
life threatening,Severity
If,O
paradoxical,O
bronchospasm,O
occurs,O
following,O
dosing,O
with,O
BREO,O
ELLIPTA,O
it,O
should,O
be,O
treated,O
immediately,O
with,O
an,O
inhaled,O
short,O
acting,O
bronchodilator,O
BREO,O
ELLIPTA,O
should,O
be,O
discontinued,O
immediately,O
and,O
alternative,O
therapy,O
should,O
be,O
instituted,O
5,O
11,O
Hypersensitivity,O
Reactions,O
Including,O
Anaphylaxis,O
Hypersensitivity reactions,AdverseReaction
such,O
as,O
anaphylaxis,AdverseReaction
angioedema,AdverseReaction
rash,AdverseReaction
and,O
urticaria,AdverseReaction
may,Factor
occur,O
after,O
administration,O
of,O
BREO,O
ELLIPTA,O
Discontinue,O
BREO,O
ELLIPTA,O
if,O
such,O
reactions,O
occur,O
There,O
have,O
been,O
reports,O
of,O
anaphylactic reactions,AdverseReaction
in,O
patients,O
with,O
severe,O
milk,O
protein,O
allergy,O
after,O
inhalation,O
of,O
other,O
powder medications containing lactose,DrugClass
therefore,O
patients,O
with,O
severe,O
milk,O
protein,O
allergy,O
should,O
not,O
use,O
BREO,O
ELLIPTA,O
see,O
Contraindications,O
4,O
5,O
12,O
Cardiovascular,O
Effects,O
Vilanterol,O
like,O
other,O
beta2,O
agonists,O
can,Factor
produce,O
a,O
clinically,O
significant,O
cardiovascular,O
effect,O
in,O
some,O
patients,O
as,O
measured,O
by,O
increases in pulse rate,AdverseReaction
systolic,AdverseReaction
or,O
diastolic blood pressure pressure,AdverseReaction
and,O
also,O
cardiac arrhythmias,AdverseReaction
such,O
as,O
supraventricular tachycardia,AdverseReaction
and,O
extrasystoles,AdverseReaction
If,O
such,O
effects,O
occur,O
BREO,O
ELLIPTA,O
may,O
need,O
to,O
be,O
discontinued,O
In,O
addition,O
beta agonists,DrugClass
have,O
been,O
reported,O
to,O
produce,O
electrocardiographic changes,AdverseReaction
such,O
as,O
flattening of the T wave,AdverseReaction
prolongation of the QTc interval,AdverseReaction
and,O
ST segment depression,AdverseReaction
although,O
the,O
clinical,O
significance,O
of,O
these,O
findings,O
is,O
unknown,O
Fatalities,AdverseReaction
have,O
been,O
reported,O
in,O
association,O
with,O
excessive,O
use,O
of,O
inhaled,O
sympathomimetic,O
drugs,O
In,O
healthy,O
subjects,O
large,O
doses,O
of,O
inhaled,O
fluticasone,O
furoate,O
vilanterol,O
4,O
times,O
the,O
recommended,O
dose,O
of,O
vilanterol,O
representing,O
a,O
12,O
or,O
10,O
fold,O
higher,O
systemic,O
exposure,O
than,O
seen,O
in,O
subjects,O
with,O
COPD,O
or,O
asthma,O
respectively,O
have,O
been,O
associated,O
with,O
clinically significant,Severity
prolongation of the QTc interval,AdverseReaction
which,O
has,O
the,O
potential,Factor
for,O
producing,O
ventricular arrhythmias,AdverseReaction
Therefore,O
BREO,O
ELLIPTA,O
like,O
other,O
sympathomimetic,O
amines,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
cardiovascular,O
disorders,O
especially,O
coronary,O
insufficiency,O
cardiac,O
arrhythmias,O
and,O
hypertension,O
5,O
13,O
Reduction,O
in,O
Bone,O
Mineral,O
Density,O
Decreases in bone mineral density in,AdverseReaction
BMD,AdverseReaction
have,O
been,O
observed,O
with,O
long,O
term,O
administration,O
of,O
products,O
containing,O
inhaled,O
corticosteroids,DrugClass
The,O
clinical,O
significance,O
of,O
small,O
changes,O
in,O
BMD,O
with,O
regard,O
to,O
long,O
term,O
consequences,O
such,O
as,O
fracture,O
is,O
unknown,O
Patients,O
with,O
major,O
risk,O
factors,O
for,O
decreased,O
bone,O
mineral,O
content,O
such,O
as,O
prolonged,O
immobilization,O
family,O
history,O
of,O
osteoporosis,O
postmenopausal,O
status,O
tobacco,O
use,O
advanced,O
age,O
poor,O
nutrition,O
or,O
chronic,O
use,O
of,O
drugs,O
that,O
can,O
reduce,O
bone,O
mass,O
e,O
g,O
anticonvulsants,O
oral,O
corticosteroids,O
should,O
be,O
monitored,O
and,O
treated,O
with,O
established,O
standards,O
of,O
care,O
Since,O
patients,O
with,O
COPD,O
often,O
have,O
multiple,O
risk,O
factors,O
for,O
reduced,O
BMD,O
assessment,O
of,O
BMD,O
is,O
recommended,O
prior,O
to,O
initiating,O
BREO,O
ELLIPTA,O
and,O
periodically,O
thereafter,O
If,O
significant,O
reductions,O
in,O
BMD,O
are,O
seen,O
and,O
BREO,O
ELLIPTA,O
is,O
still,O
considered,O
medically,O
important,O
for,O
that,O
patient,O
s,O
COPD,O
therapy,O
use,O
of,O
medicine,O
to,O
treat,O
or,O
prevent,O
osteoporosis,O
should,O
be,O
strongly,O
considered,O
5,O
14,O
Glaucoma,O
and,O
Cataracts,O
Glaucoma,AdverseReaction
increased intraocular pressure,AdverseReaction
and,O
cataracts,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
with,O
COPD,O
or,O
asthma,O
following,O
the,O
long,O
term,O
administration,O
of,O
inhaled,O
corticosteroids,DrugClass
Therefore,O
close,O
monitoring,O
is,O
warranted,O
in,O
patients,O
with,O
a,O
change,O
in,O
vision,O
or,O
with,O
a,O
history,O
of,O
increased,O
intraocular,O
pressure,O
glaucoma,O
and,O
or,O
cataracts,O
5,O
15,O
Coexisting,O
Conditions,O
BREO,O
ELLIPTA,O
like,O
all,O
medicines,O
containing,O
sympathomimetic,O
amines,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
convulsive,O
disorders,O
or,O
thyrotoxicosis,O
and,O
in,O
those,O
who,O
are,O
unusually,O
responsive,O
to,O
sympathomimetic,O
amines,O
Doses,O
of,O
the,O
related,O
beta2 adrenoceptor agonist,DrugClass
albuterol,O
when,O
administered,O
intravenously,O
have,O
been,O
reported,O
to,O
aggravate preexisting diabetes mellitus preexisting,AdverseReaction
and,O
ketoacidosis,AdverseReaction
5,O
16,O
Hypokalemia,O
and,O
Hyperglycemia,O
Beta,O
adrenergic,O
agonist,O
medicines,O
may,Factor
produce,O
significant,Severity
hypokalemia,AdverseReaction
in,O
some,O
patients,O
possibly,O
through,O
intracellular,O
shunting,O
which,O
has,O
the,O
potential,O
to,O
produce,O
adverse,O
cardiovascular,O
effects,O
The,O
decrease in serum potassium,AdverseReaction
is,O
usually,O
transient,O
not,O
requiring,O
supplementation,O
Beta agonist medications,DrugClass
may,O
produce,O
transient,Severity
hyperglycemia,AdverseReaction
in,O
some,O
patients,O
In,O
clinical,O
trials,O
evaluating,O
BREO,O
ELLIPTA,O
in,O
subjects,O
with,O
COPD,O
or,O
asthma,O
there,O
was,O
no,O
evidence,O
of,O
a,O
treatment,O
effect,O
on,O
serum,O
glucose,O
or,O
potassium,O
5,O
17,O
Effect,O
on,O
Growth,O
Orally inhaled corticosteroids,DrugClass
may,O
cause,O
a,O
reduction in growth velocity,AdverseReaction
when,O
administered,O
to,O
children,O
and,O
adolescents,O
See,O
Use,O
in,O
Specific,O
Populations,O
8,O
4,O
""
BOXED,O
WARNING,O
WARNING,O
ASTHMA,O
RELATED,O
DEATH,AdverseReaction
WARNING,O
ASTHMA,O
RELATED,O
DEATH,AdverseReaction
Long,O
acting,O
beta2,O
adrenergic,O
agonists,O
LABA,DrugClass
such,O
as,O
vilanterol,O
one,O
of,O
the,O
active,O
ingredients,O
in,O
BREO,O
ELLIPTA,O
increase,O
the,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
Data,O
from,O
a,O
large,O
placebo,O
controlled,O
US,O
trial,O
that,O
compared,O
the,O
safety,O
of,O
another,O
LABA,DrugClass
salmeterol,O
with,O
placebo,O
added,O
to,O
usual,O
asthma,O
therapy,O
showed,O
an,O
increase,O
in,O
asthma,O
related,O
deaths,AdverseReaction
in,O
subjects,O
receiving,O
salmeterol,O
This,O
finding,O
with,O
salmeterol,O
is,O
considered,O
a,O
class,O
effect,O
of,O
LABA,O
Currently,O
available,O
data,O
are,O
inadequate,O
to,O
determine,O
whether,O
concurrent,O
use,O
of,O
inhaled,O
corticosteroids,O
ICS,O
or,O
other,O
long,O
term,O
asthma,O
control,O
drugs,O
mitigates,O
the,O
increased,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
from,O
LABA,DrugClass
Available,O
data,O
from,O
controlled,O
clinical,O
trials,O
suggest,O
that,O
LABA,O
increase,O
the,O
risk,O
of,O
asthma,O
related,O
hospitalization,O
in,O
pediatric,O
and,O
adolescent,O
patients,O
Therefore,O
when,O
treating,O
patients,O
with,O
asthma,O
physicians,O
should,O
only,O
prescribe,O
BREO,O
ELLIPTA,O
for,O
patients,O
not,O
adequately,O
controlled,O
on,O
a,O
long,O
term,O
asthma,O
control,O
medication,O
such,O
as,O
an,O
inhaled,O
corticosteroid,O
or,O
whose,O
disease,O
severity,O
clearly,O
warrants,O
initiation,O
of,O
treatment,O
with,O
both,O
an,O
inhaled,O
corticosteroid,O
and,O
a,O
LABA,O
Once,O
asthma,O
control,O
is,O
achieved,O
and,O
maintained,O
assess,O
the,O
patient,O
at,O
regular,O
intervals,O
and,O
step,O
down,O
therapy,O
e,O
g,O
discontinue,O
BREO,O
ELLIPTA,O
if,O
possible,O
without,O
loss,O
of,O
asthma,O
control,O
and,O
maintain,O
the,O
patient,O
on,O
a,O
long,O
term,O
asthma,O
control,O
medication,O
such,O
as,O
an,O
inhaled,O
corticosteroid,O
Do,O
not,O
use,O
BREO,O
ELLIPTA,O
for,O
patients,O
whose,O
asthma,O
is,O
adequately,O
controlled,O
on,O
low,O
or,O
medium,O
dose,O
inhaled,O
corticosteroids,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
ASTHMA,O
RELATED,O
DEATH,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Long,O
acting,O
beta2,O
adrenergic,O
agonists,O
LABA,DrugClass
such,O
as,O
vilanterol,O
increase,O
the,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
A,O
placebo,O
controlled,O
trial,O
with,O
another,O
LABA,DrugClass
salmeterol,O
showed,O
an,O
increase,O
in,O
asthma,O
related,O
deaths,AdverseReaction
This,O
finding,O
with,O
salmeterol,O
is,O
considered,O
a,O
class,O
effect,O
of,O
all,O
LABA,O
Currently,O
available,O
data,O
are,O
inadequate,O
to,O
determine,O
whether,O
concurrent,O
use,O
of,O
inhaled,O
corticosteroids,O
ICS,O
or,O
other,O
long,O
term,O
asthma,O
control,O
drugs,O
mitigates,O
the,O
increased,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
from,O
LABA,DrugClass
Available,O
data,O
from,O
controlled,O
clinical,O
trials,O
suggest,O
that,O
LABA,O
increase,O
the,O
risk,O
of,O
asthma,O
related,O
hospitalization,O
in,O
pediatric,O
and,O
adolescent,O
patients,O
5,O
1,O
When,O
treating,O
patients,O
with,O
asthma,O
only,O
prescribe,O
BREO,O
ELLIPTA,O
for,O
patients,O
not,O
adequately,O
controlled,O
on,O
a,O
long,O
term,O
asthma,O
control,O
medication,O
such,O
as,O
an,O
ICS,O
or,O
whose,O
disease,O
severity,O
clearly,O
warrants,O
initiation,O
of,O
treatment,O
with,O
both,O
an,O
ICS,O
and,O
a,O
LABA,O
Once,O
asthma,O
control,O
is,O
achieved,O
and,O
maintained,O
assess,O
the,O
patient,O
at,O
regular,O
intervals,O
and,O
step,O
down,O
therapy,O
e,O
g,O
discontinue,O
BREO,O
ELLIPTA,O
if,O
possible,O
without,O
loss,O
of,O
asthma,O
control,O
and,O
maintain,O
the,O
patient,O
on,O
a,O
long,O
term,O
asthma,O
control,O
medication,O
such,O
as,O
an,O
ICS,O
Do,O
not,O
use,O
BREO,O
ELLIPTA,O
for,O
patients,O
whose,O
asthma,O
is,O
adequately,O
controlled,O
on,O
low,O
or,O
medium,O
dose,O
ICS,O
1,O
2,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
LABA,O
such,O
as,O
vilanterol,O
one,O
of,O
the,O
active,O
ingredients,O
in,O
BREO,O
ELLIPTA,O
increase,O
the,O
risk,Factor
of,O
asthma,O
related,O
death,AdverseReaction
Currently,O
available,O
data,O
are,O
inadequate,O
to,O
determine,O
whether,O
concurrent,O
use,O
of,O
inhaled,O
corticosteroids,O
or,O
other,O
long,O
term,O
asthma,O
control,O
drugs,O
mitigates,O
the,O
increased,O
risk,O
of,O
asthma,O
related,O
death,AdverseReaction
from,O
LABA,DrugClass
Available,O
data,O
from,O
controlled,O
clinical,O
trials,O
suggest,O
that,O
LABA,O
increase,O
the,O
risk,O
of,O
asthma,O
related,O
hospitalization,O
in,O
pediatric,O
and,O
adolescent,O
patients,O
Data,O
from,O
a,O
large,O
placebo,O
controlled,O
US,O
trial,O
that,O
compared,O
the,O
safety,O
of,O
another,O
LABA,DrugClass
salmeterol,O
or,O
placebo,O
added,O
to,O
usual,O
asthma,O
therapy,O
showed,O
an,O
increase,O
in,O
asthma,O
related,O
deaths,AdverseReaction
in,O
subjects,O
receiving,O
salmeterol,O
See,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Systemic,O
and,O
local,O
corticosteroid,O
use,O
may,O
result,O
in,O
the,O
following,O
Candida albicans infection,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Increased,O
risk,Factor
of,O
pneumonia,AdverseReaction
in,O
COPD,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Immunosuppression,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Hypercorticism,AdverseReaction
and,O
adrenal suppression,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Reduction in bone mineral density,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
13,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
EXCERPT,O
COPD,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
greater,O
than,O
or,O
equal,O
to,O
3,O
are,O
nasopharyngitis,AdverseReaction
upper respiratory tract infection,AdverseReaction
headache,AdverseReaction
and,O
oral candidiasis,AdverseReaction
6,O
1,O
Asthma,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
greater,O
than,O
or,O
equal,O
to,O
2,O
are,O
nasopharyngitis,AdverseReaction
oral candidiasis,AdverseReaction
headache,AdverseReaction
influenza,AdverseReaction
upper respiratory tract infection,AdverseReaction
bronchitis,AdverseReaction
sinusitis,AdverseReaction
oropharyngeal pain,AdverseReaction
dysphonia,AdverseReaction
and,O
cough,AdverseReaction
6,O
2,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GlaxoSmithKline,O
at,O
1,O
888,O
825,O
5249,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
in,O
Chronic,O
Obstructive,O
Pulmonary,O
Disease,O
The,O
clinical,O
program,O
for,O
BREO,O
ELLIPTA,O
included,O
7,O
700,O
subjects,O
with,O
COPD,O
in,O
two,O
6,O
month,O
lung,O
function,O
trials,O
two,O
12,O
month,O
exacerbation,O
trials,O
and,O
6,O
other,O
trials,O
of,O
shorter,O
duration,O
A,O
total,O
of,O
2,O
034,O
subjects,O
with,O
COPD,O
received,O
at,O
least,O
1,O
dose,O
of,O
BREO,O
ELLIPTA,O
100,O
25,O
and,O
1,O
087,O
subjects,O
received,O
a,O
higher,O
strength,O
of,O
fluticasone,O
furoate,O
vilanterol,O
The,O
safety,O
data,O
described,O
below,O
are,O
based,O
on,O
the,O
confirmatory,O
6,O
and,O
12,O
month,O
trials,O
Adverse,O
reactions,O
observed,O
in,O
the,O
other,O
trials,O
were,O
similar,O
to,O
those,O
observed,O
in,O
the,O
confirmatory,O
trials,O
6,O
Month,O
Trials,O
The,O
incidence,O
of,O
adverse,O
reactions,O
associated,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
in,O
Table,O
1,O
is,O
based,O
on,O
2,O
placebo,O
controlled,O
6,O
month,O
clinical,O
trials,O
Trials,O
1,O
and,O
2,O
n,O
1,O
224,O
and,O
n,O
1,O
030,O
respectively,O
Of,O
the,O
2,O
254,O
subjects,O
70,O
were,O
male,O
and,O
84,O
were,O
white,O
They,O
had,O
a,O
mean,O
age,O
of,O
62,O
years,O
and,O
an,O
average,O
smoking,O
history,O
of,O
44,O
pack,O
years,O
with,O
54,O
identified,O
as,O
current,O
smokers,O
At,O
screening,O
the,O
mean,O
postbronchodilator,O
percent,O
predicted,O
FEV1was,O
48,O
range,O
14,O
to,O
87,O
the,O
mean,O
postbronchodilator,O
FEV1,O
forced,O
vital,O
capacity,O
FVC,O
ratio,O
was,O
47,O
range,O
17,O
to,O
88,O
and,O
the,O
mean,O
percent,O
reversibility,O
was,O
14,O
range,O
41,O
to,O
152,O
Subjects,O
received,O
1,O
inhalation,O
once,O
daily,O
of,O
the,O
following,O
BREO,O
ELLIPTA,O
100,O
25,O
BREO,O
ELLIPTA,O
200,O
25,O
fluticasone,O
furoate,O
vilanterol,O
50,O
mcg,O
25,O
mcg,O
fluticasone,O
furoate,O
100,O
mcg,O
fluticasone,O
furoate,O
200,O
mcg,O
vilanterol,O
25,O
mcg,O
or,O
placebo,O
Table,O
1,O
Adverse,O
Reactions,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
with,O
3,O
Incidence,O
and,O
More,O
Common,O
than,O
Placebo,O
in,O
Subjects,O
with,O
Chronic,O
Obstructive,O
Pulmonary,O
Disease,O
Adverse,O
Reaction,O
BREO,O
ELLIPTA,O
100,O
25,O
n,O
410,O
Vilanterol,O
25,O
mcg,O
n,O
408,O
Fluticasone,O
Furoate,O
100,O
mcg,O
n,O
410,O
Placebo,O
n,O
412,O
Infections,O
and,O
infestations,O
Nasopharyngitis,AdverseReaction
9,O
10,O
8,O
8,O
Upper respiratory tract infection,AdverseReaction
7,O
5,O
4,O
3,O
Oropharyngeal candidiasis,AdverseReaction
a,O
5,O
2,O
3,O
2,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
7,O
9,O
7,O
5,O
a,O
Includes,O
oral candidiasis,AdverseReaction
oropharyngeal candidiasis,AdverseReaction
candidiasis,AdverseReaction
and,O
fungal oropharyngitis,AdverseReaction
12,O
Month,O
Trials,O
Long,O
term,O
safety,O
data,O
is,O
based,O
on,O
two,O
12,O
month,O
trials,O
Trials,O
3,O
and,O
4,O
n,O
1,O
633,O
and,O
n,O
1,O
622,O
respectively,O
Trials,O
3,O
and,O
4,O
included,O
3,O
255,O
subjects,O
of,O
which,O
57,O
were,O
male,O
and,O
85,O
were,O
white,O
They,O
had,O
a,O
mean,O
age,O
of,O
64,O
years,O
and,O
an,O
average,O
smoking,O
history,O
of,O
46,O
pack,O
years,O
with,O
44,O
identified,O
as,O
current,O
smokers,O
At,O
screening,O
the,O
mean,O
postbronchodilator,O
percent,O
predicted,O
FEV1was,O
45,O
range,O
12,O
to,O
91,O
and,O
the,O
mean,O
postbronchodilator,O
FEV1,O
FVC,O
ratio,O
was,O
46,O
range,O
17,O
to,O
81,O
indicating,O
that,O
the,O
subject,O
population,O
had,O
moderate,O
to,O
very,O
severely,O
impaired,O
airflow,O
obstruction,O
Subjects,O
received,O
1,O
inhalation,O
once,O
daily,O
of,O
the,O
following,O
BREO,O
ELLIPTA,O
100,O
25,O
BREO,O
ELLIPTA,O
200,O
25,O
fluticasone,O
furoate,O
vilanterol,O
50,O
mcg,O
25,O
mcg,O
or,O
vilanterol,O
25,O
mcg,O
In,O
addition,O
to,O
the,O
reactions,O
shown,O
in,O
Table,O
1,O
adverse,O
reactions,O
occurring,O
in,O
greater,O
than,O
or,O
equal,O
to,O
3,O
of,O
the,O
subjects,O
treated,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
n,O
806,O
for,O
12,O
months,O
included,O
back pain,AdverseReaction
pneumonia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
bronchitis,AdverseReaction
sinusitis,AdverseReaction
cough,AdverseReaction
oropharyngeal pain,AdverseReaction
arthralgia,AdverseReaction
influenza,AdverseReaction
pharyngitis,AdverseReaction
and,O
pyrexia,AdverseReaction
6,O
2,O
Clinical,O
Trials,O
Experience,O
in,O
Asthma,O
BREO,O
ELLIPTA,O
for,O
the,O
treatment,O
of,O
asthma,O
was,O
studied,O
in,O
18,O
double,O
blind,O
parallel,O
group,O
controlled,O
trials,O
11,O
with,O
placebo,O
of,O
4,O
to,O
76,O
weeks,O
duration,O
which,O
enrolled,O
9,O
969,O
subjects,O
with,O
asthma,O
BREO,O
ELLIPTA,O
100,O
25,O
was,O
studied,O
in,O
2,O
369,O
subjects,O
and,O
BREO,O
ELLIPTA,O
200,O
25,O
was,O
studied,O
in,O
956,O
subjects,O
While,O
subjects,O
aged,O
12,O
to,O
17,O
years,O
were,O
included,O
in,O
these,O
trials,O
BREO,O
ELLIPTA,O
is,O
not,O
approved,O
for,O
use,O
in,O
this,O
age,O
group,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
4,O
The,O
safety,O
data,O
described,O
below,O
are,O
based,O
on,O
two,O
12,O
week,O
efficacy,O
trials,O
one,O
24,O
week,O
efficacy,O
trial,O
and,O
two,O
long,O
term,O
trials,O
12,O
Week,O
Trials,O
Trial,O
1,O
was,O
a,O
12,O
week,O
trial,O
that,O
evaluated,O
the,O
efficacy,O
of,O
BREO,O
ELLIPTA,O
100,O
25,O
in,O
adolescent,O
and,O
adult,O
subjects,O
with,O
asthma,O
compared,O
with,O
fluticasone,O
furoate,O
100,O
mcg,O
and,O
placebo,O
Of,O
the,O
609,O
subjects,O
58,O
were,O
female,O
and,O
84,O
were,O
white,O
the,O
mean,O
age,O
was,O
40,O
years,O
The,O
incidence,O
of,O
adverse,O
reactions,O
associated,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
is,O
shown,O
in,O
Table,O
2,O
Table,O
2,O
Adverse,O
Reactions,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
with,O
2,O
Incidence,O
and,O
More,O
Common,O
than,O
Placebo,O
in,O
Subjects,O
with,O
Asthma,O
Trial,O
1,O
Adverse,O
Reaction,O
BREO,O
ELLIPTA,O
100,O
25,O
n,O
201,O
Fluticasone,O
Furoate,O
100,O
mcg,O
n,O
205,O
Placebo,O
n,O
203,O
Infections,O
and,O
infestations,O
Nasopharyngitis,AdverseReaction
10,O
7,O
7,O
Oral candidiasis,AdverseReaction
a,O
2,O
2,O
0,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
5,O
4,O
4,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Oropharyngeal pain,AdverseReaction
2,O
2,O
1,O
Dysphonia,AdverseReaction
2,O
1,O
0,O
a,O
Includes,O
oral candidiasis,AdverseReaction
and,O
oropharyngeal candidiasis,AdverseReaction
Trial,O
2,O
was,O
a,O
12,O
week,O
trial,O
that,O
evaluated,O
the,O
efficacy,O
of,O
BREO,O
ELLIPTA,O
100,O
25,O
BREO,O
ELLIPTA,O
200,O
25,O
and,O
fluticasone,O
furoate,O
100,O
mcg,O
in,O
adolescent,O
and,O
adult,O
subjects,O
with,O
asthma,O
This,O
trial,O
did,O
not,O
have,O
a,O
placebo,O
arm,O
Of,O
the,O
1,O
039,O
subjects,O
60,O
were,O
female,O
and,O
88,O
were,O
white,O
the,O
mean,O
age,O
was,O
46,O
years,O
The,O
incidence,O
of,O
adverse,O
reactions,O
associated,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
and,O
BREO,O
ELLIPTA,O
200,O
25,O
is,O
shown,O
in,O
Table,O
3,O
Table,O
3,O
Adverse,O
Reactions,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
and,O
BREO,O
ELLIPTA,O
200,O
25,O
with,O
2,O
Incidence,O
in,O
Subjects,O
with,O
Asthma,O
Trial,O
2,O
Adverse,O
Reaction,O
BREO,O
ELLIPTA,O
200,O
25,O
n,O
346,O
BREO,O
ELLIPTA,O
100,O
25,O
n,O
346,O
Fluticasone,O
Furoate,O
100,O
mcg,O
n,O
347,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
8,O
8,O
9,O
Infections,O
and,O
infestations,O
Nasopharyngitis,AdverseReaction
7,O
6,O
7,O
Influenza,AdverseReaction
3,O
3,O
1,O
Upper respiratory tract infection,AdverseReaction
2,O
2,O
3,O
Sinusitis,AdverseReaction
2,O
1,O
1,O
Bronchitis,AdverseReaction
2,O
1,O
2,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Oropharyngeal pain,AdverseReaction
2,O
2,O
1,O
Cough,AdverseReaction
1,O
2,O
1,O
24,O
Week,O
Trial,O
Trial,O
3,O
was,O
a,O
24,O
week,O
trial,O
that,O
evaluated,O
the,O
efficacy,O
of,O
BREO,O
ELLIPTA,O
200,O
25,O
once,O
daily,O
fluticasone,O
furoate,O
200,O
mcg,O
once,O
daily,O
and,O
fluticasone,O
propionate,O
500,O
mcg,O
twice,O
daily,O
in,O
adolescent,O
and,O
adult,O
subjects,O
with,O
asthma,O
Of,O
the,O
586,O
subjects,O
59,O
were,O
female,O
and,O
84,O
were,O
white,O
the,O
mean,O
age,O
was,O
46,O
years,O
This,O
trial,O
did,O
not,O
have,O
a,O
placebo,O
arm,O
In,O
addition,O
to,O
the,O
reactions,O
shown,O
in,O
Tables,O
2,O
and,O
3,O
adverse,O
reactions,O
occurring,O
in,O
greater,O
than,O
or,O
equal,O
to,O
2,O
of,O
subjects,O
treated,O
with,O
BREO,O
ELLIPTA,O
200,O
25,O
included,O
viral respiratory tract infection,AdverseReaction
pharyngitis,AdverseReaction
pyrexia,AdverseReaction
and,O
arthralgia,AdverseReaction
12,O
Month,O
Trial,O
Long,O
term,O
safety,O
data,O
is,O
based,O
on,O
a,O
12,O
month,O
trial,O
that,O
evaluated,O
the,O
safety,O
of,O
BREO,O
ELLIPTA,O
100,O
25,O
once,O
daily,O
n,O
201,O
BREO,O
ELLIPTA,O
200,O
25,O
once,O
daily,O
n,O
202,O
and,O
fluticasone,O
propionate,O
500,O
mcg,O
twice,O
daily,O
n,O
100,O
in,O
adolescent,O
and,O
adult,O
subjects,O
with,O
asthma,O
Trial,O
4,O
Overall,O
63,O
were,O
female,O
and,O
67,O
were,O
white,O
The,O
mean,O
age,O
was,O
39,O
years,O
adolescents,O
aged,O
12,O
to,O
17,O
years,O
made,O
up,O
16,O
of,O
the,O
population,O
In,O
addition,O
to,O
the,O
reactions,O
shown,O
in,O
Tables,O
2,O
and,O
3,O
adverse,O
reactions,O
occurring,O
in,O
greater,O
than,O
or,O
equal,O
to,O
2,O
of,O
the,O
subjects,O
treated,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
or,O
BREO,O
ELLIPTA,O
200,O
25,O
for,O
12,O
months,O
included,O
pyrexia,AdverseReaction
back pain,AdverseReaction
extrasystoles,AdverseReaction
upper abdominal pain,AdverseReaction
respiratory tract infection,AdverseReaction
allergic rhinitis,AdverseReaction
pharyngitis,AdverseReaction
rhinitis,AdverseReaction
arthralgia,AdverseReaction
supraventricular extrasystoles,AdverseReaction
ventricular extrasystoles,AdverseReaction
acute sinusitis,AdverseReaction
and,O
pneumonia,AdverseReaction
Exacerbation,O
Trial,O
In,O
a,O
24,O
to,O
76,O
week,O
trial,O
subjects,O
received,O
BREO,O
ELLIPTA,O
100,O
25,O
n,O
1,O
009,O
or,O
fluticasone,O
furoate,O
100,O
mcg,O
n,O
1,O
010,O
Trial,O
5,O
Subjects,O
participating,O
in,O
this,O
trial,O
had,O
a,O
history,O
of,O
one,O
or,O
more,O
asthma,O
exacerbations,O
that,O
required,O
treatment,O
with,O
oral,O
systemic,O
corticosteroids,O
or,O
emergency,O
department,O
visit,O
or,O
in,O
patient,O
hospitalization,O
for,O
the,O
treatment,O
of,O
asthma,O
in,O
the,O
year,O
prior,O
to,O
trial,O
entry,O
Overall,O
67,O
were,O
female,O
and,O
73,O
were,O
white,O
the,O
mean,O
age,O
was,O
42,O
years,O
adolescents,O
aged,O
12,O
to,O
17,O
years,O
made,O
up,O
14,O
of,O
the,O
population,O
While,O
subjects,O
aged,O
12,O
to,O
17,O
years,O
were,O
included,O
in,O
this,O
trial,O
BREO,O
ELLIPTA,O
is,O
not,O
approved,O
for,O
use,O
in,O
this,O
age,O
group,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
4,O
Asthma,O
related,O
hospitalizations,O
occurred,O
in,O
10,O
subjects,O
1,O
treated,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
compared,O
with,O
7,O
subjects,O
0,O
7,O
treated,O
with,O
fluticasone,O
furoate,O
100,O
mcg,O
Among,O
subjects,O
aged,O
12,O
to,O
17,O
years,O
asthma,O
related,O
hospitalizations,O
occurred,O
in,O
4,O
subjects,O
2,O
6,O
treated,O
with,O
BREO,O
ELLIPTA,O
100,O
25,O
n,O
151,O
compared,O
with,O
0,O
subjects,O
treated,O
with,O
fluticasone,O
furoate,O
100,O
mcg,O
n,O
130,O
There,O
were,O
no,Negation
asthma,O
related,O
deaths,AdverseReaction
or,O
asthma,O
related,O
intubations,O
observed,O
in,O
this,O
trial,O
6,O
3,O
Postmarketing,O
Experience,O
In,O
addition,O
to,O
adverse,O
reactions,O
reported,O
from,O
clinical,O
trials,O
the,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
postapproval,O
use,O
of,O
BREO,O
ELLIPTA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
These,O
events,O
have,O
been,O
chosen,O
for,O
inclusion,O
due,O
to,O
either,O
their,O
seriousness,O
frequency,O
of,O
reporting,O
or,O
causal,O
connection,O
to,O
BREO,O
ELLIPTA,O
or,O
a,O
combination,O
of,O
these,O
factors,O
Cardiac,O
Disorders,O
Palpitations,AdverseReaction
tachycardia,AdverseReaction
Immune,O
System,O
Disorders,O
Hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
angioedema,AdverseReaction
rash,AdverseReaction
and,O
urticaria,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Muscle spasms,AdverseReaction
Nervous,O
System,O
Disorders,O
Tremor,AdverseReaction
Psychiatric,O
Disorders,O
Nervousness,AdverseReaction
""
EXCERPT,O
Hyperammonemia,AdverseReaction
Monitor,O
plasma,O
ammonia,O
levels,O
during,O
treatment,O
Prolonged,O
exposure,O
to,O
elevated,O
plasma,O
ammonia,O
levels,O
can,O
rapidly,O
result,O
in,O
injury,O
to,O
the,O
brain,O
or,O
death,O
Prompt,O
use,O
of,O
all,O
therapies,O
necessary,O
to,O
reduce,O
plasma,O
ammonia,O
levels,O
is,O
essential,O
5,O
1,O
Therapeutic,O
Monitoring,O
Plasma,O
ammonia,O
levels,O
should,O
be,O
maintained,O
within,O
normal,O
range,O
for,O
age,O
via,O
individual,O
dose,O
adjustment,O
5,O
2,O
Nutritional,O
Management,O
In,O
the,O
initial,O
treatment,O
of,O
NAGS,O
deficiency,O
protein,O
restriction,O
is,O
recommended,O
When,O
plasma,O
ammonia,O
level,O
is,O
normalized,O
dietary,O
protein,O
intake,O
can,O
usually,O
be,O
reintroduced,O
5,O
3,O
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
5,O
1,O
Hyperammonemia,O
Any,O
episode,O
of,O
acute,O
symptomatic,O
hyperammonemia,O
should,O
be,O
treated,O
as,O
a,O
life,O
threatening,O
emergency,O
Treatment,O
of,O
hyperammonemia,O
may,O
require,O
dialysis,O
preferably,O
hemodialysis,O
to,O
remove,O
a,O
large,O
burden,O
of,O
ammonia,O
Uncontrolled,O
hyperammonemia,O
can,O
rapidly,O
result,O
in,O
brain,O
injury,O
damage,O
or,O
death,O
and,O
prompt,O
use,O
of,O
all,O
therapies,O
necessary,O
to,O
reduce,O
plasma,O
ammonia,O
levels,O
is,O
essential,O
Management,O
of,O
hyperammonemia,O
due,O
to,O
NAGS,O
deficiency,O
should,O
be,O
done,O
in,O
coordination,O
with,O
medical,O
personnel,O
experienced,O
in,O
metabolic,O
disorders,O
Ongoing,O
monitoring,O
of,O
plasma,O
ammonia,O
levels,O
neurological,O
status,O
laboratory,O
tests,O
and,O
clinical,O
responses,O
in,O
patients,O
receiving,O
Carbaglu,O
is,O
crucial,O
to,O
assess,O
patient,O
response,O
to,O
treatment,O
5,O
2,O
Therapeutic,O
Monitoring,O
Plasma,O
ammonia,O
levels,O
should,O
be,O
maintained,O
within,O
normal,O
range,O
for,O
age,O
via,O
individual,O
dose,O
adjustment,O
5,O
3,O
Nutritional,O
Management,O
Since,O
hyperammonemia,O
is,O
the,O
result,O
of,O
protein,O
catabolism,O
complete,O
protein,O
restriction,O
is,O
recommended,O
to,O
be,O
maintained,O
for,O
24,O
to,O
48,O
hours,O
and,O
caloric,O
supplementation,O
should,O
be,O
maximized,O
to,O
reverse,O
catabolism,O
and,O
nitrogen,O
turnover,O
""
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
in,O
13,O
of,O
patients,O
are,O
Infections,AdverseReaction
vomiting,AdverseReaction
abdominal pain,AdverseReaction
pyrexia,AdverseReaction
tonsilitis,AdverseReaction
anemia,AdverseReaction
ear infection,AdverseReaction
diarrhea,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
headache,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Accredo,O
Health,O
Group,O
Inc,O
at,O
1,O
888,O
454,O
8860,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
ADVERSE,O
REACTIONS,O
6,O
1,O
Retrospective,O
Case,O
Series,O
Experience,O
The,O
most,O
common,O
adverse,O
reactions,O
occurring,O
in,O
13,O
of,O
patients,O
regardless,O
of,O
causality,O
are,O
Infections,AdverseReaction
vomiting,AdverseReaction
abdominal pain,AdverseReaction
pyrexia,AdverseReaction
tonsilitis,AdverseReaction
anemia,AdverseReaction
ear infection,AdverseReaction
diarrhea,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
headache,AdverseReaction
Table,O
1,O
summarizes,O
adverse,O
reactions,O
occurring,O
in,O
2,O
or,O
more,O
patients,O
treated,O
with,O
Carbaglu,O
in,O
the,O
retrospective,O
case,O
series,O
Because,O
these,O
reactions,O
were,O
reported,O
retrospectively,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Table,O
1,O
Adverse,O
Reactions,O
Reported,O
in,O
2,O
Patients,O
in,O
the,O
Retrospective,O
Case,O
Series,O
treated,O
with,O
Carbaglu,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
Number,O
of,O
Patients,O
N,O
TOTAL,O
23,O
100,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Anemia,AdverseReaction
3,O
13,O
Ear,O
and,O
labyrinth,O
disorders,O
Ear infection,AdverseReaction
3,O
13,O
Gastrointestinal,O
disorders,O
Abdominal pain,AdverseReaction
4,O
17,O
Diarrhea,AdverseReaction
3,O
13,O
Vomiting,AdverseReaction
6,O
26,O
Dysgeusia,AdverseReaction
2,O
9,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Asthenia,AdverseReaction
2,O
9,O
Hyperhidrosis,AdverseReaction
2,O
9,O
Pyrexia,AdverseReaction
4,O
17,O
Infections,O
and,O
infestations,O
Infection,AdverseReaction
3,O
13,O
Influenza,AdverseReaction
2,O
9,O
Nasopharyngitis,AdverseReaction
3,O
13,O
Pneumonia,AdverseReaction
2,O
9,O
Tonsillitis,AdverseReaction
4,O
17,O
Investigations,O
Hemoglobin decreased,AdverseReaction
3,O
13,O
Weight decreased,AdverseReaction
2,O
9,O
Metabolism,O
and,O
nutrition,O
disorders,O
Anorexia,AdverseReaction
2,O
9,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
3,O
13,O
Somnolence,AdverseReaction
2,O
9,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
2,O
9,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
ECG Changes,AdverseReaction
and,O
Potential,Factor
for,O
Cardiac Arrhythmias,AdverseReaction
Not,O
recommended,O
in,O
patients,O
with,O
pre,O
existing,O
cardiac,O
disease,O
long,O
QT,O
syndrome,O
and,O
concomitant,O
use,O
of,O
Class,O
IA,O
and,O
Class,O
III,O
antiarrhythmics,O
5,O
2,O
5,O
1,O
Drug,O
Drug,O
Interactions,O
Eliglustat,O
is,O
a,O
CYP2D6,O
and,O
CYP3A,O
substrate,O
Drugs,O
that,O
inhibit,O
CYP2D6,O
and,O
CYP3A,O
metabolism,O
pathways,O
may,O
significantly,O
increase,O
the,O
exposure,O
to,O
eliglustat,O
and,O
result,O
in,O
prolongation,AdverseReaction
of,O
the,O
PR,AdverseReaction
QTc,AdverseReaction
and,O
or,O
QRS cardiac intervals intervals intervals,AdverseReaction
that,O
could,Factor
result,O
in,O
cardiac arrhythmias,AdverseReaction
see,O
Clinical,O
Pharmacology,O
12,O
2,O
Some,O
drugs,O
that,O
are,O
inhibitors,O
of,O
CYP2D6,O
and,O
CYP3A,O
are,O
contraindicated,O
with,O
CERDELGA,O
depending,O
on,O
the,O
patient,O
s,O
CYP2D6,O
metabolizer,O
status,O
see,O
Contraindications,O
4,O
See,O
Table,O
3,O
and,O
Table,O
4,O
for,O
other,O
potentially,O
significant,O
drug,O
interactions,O
see,O
Drug,O
Interactions,O
7,O
1,O
5,O
2,O
ECG,O
Changes,O
and,O
Potential,O
for,O
Cardiac,O
Arrhythmias,O
Use,O
of,O
CERDELGA,O
in,O
patients,O
with,O
pre,O
existing,O
cardiac,O
conditions,O
has,O
not,O
been,O
studied,O
during,O
clinical,O
trials,O
Because,O
CERDELGA,O
is,O
predicted,O
to,O
cause,O
increases in ECG intervals in ECG intervals in ECG intervals,AdverseReaction
PR,AdverseReaction
QTc,AdverseReaction
and,O
QRS,AdverseReaction
at,O
substantially,O
elevated,O
eliglustat,O
plasma,O
concentrations,O
use,O
of,O
CERDELGA,O
is,O
not,O
recommended,O
in,O
patients,O
with,O
pre,O
existing,O
cardiac,O
disease,O
congestive,O
heart,O
failure,O
recent,O
acute,O
myocardial,O
infarction,O
bradycardia,O
heart,O
block,O
ventricular,O
arrhythmia,O
long,O
QT,O
syndrome,O
and,O
in,O
combination,O
with,O
Class,O
IA,O
e,O
g,O
quinidine,O
procainamide,O
and,O
Class,O
III,O
e,O
g,O
amiodarone,O
sotalol,O
antiarrhythmic,O
medications,O
see,O
Clinical,O
Pharmacology,O
12,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
10,O
are,O
fatigue,AdverseReaction
headache,AdverseReaction
nausea,AdverseReaction
diarrhea,AdverseReaction
back pain,AdverseReaction
pain in extremities,AdverseReaction
and,O
upper abdominal pain,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Genzyme,O
Corporation,O
at,O
1,O
800,O
745,O
4447,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
most,O
common,O
adverse,O
reactions,O
to,O
CERDELGA,O
occurring,O
in,O
10,O
of,O
the,O
126,O
GD1,O
patients,O
treated,O
with,O
CERDELGA,O
across,O
Trials,O
1,O
and,O
2,O
were,O
fatigue,AdverseReaction
headache,AdverseReaction
nausea,AdverseReaction
diarrhea,AdverseReaction
back pain,AdverseReaction
pain in extremities,AdverseReaction
and,O
upper abdominal pain,AdverseReaction
The,O
adverse,O
reaction,O
profile,O
of,O
CERDELGA,O
is,O
based,O
on,O
two,O
controlled,O
studies,O
Trials,O
1,O
and,O
2,O
Table,O
1,O
presents,O
the,O
profile,O
from,O
the,O
9,O
month,O
double,O
blind,O
randomized,O
placebo,O
controlled,O
trial,O
of,O
40,O
treatment,O
naive,O
patients,O
Trial,O
1,O
Patients,O
were,O
between,O
the,O
ages,O
of,O
16,O
and,O
63,O
on,O
the,O
date,O
of,O
the,O
first,O
dose,O
of,O
study,O
drug,O
and,O
included,O
20,O
males,O
and,O
20,O
females,O
Table,O
1,O
Adverse,O
Reactions,O
Occurring,O
in,O
10,O
of,O
Treatment,O
Naive,O
GD1,O
Patients,O
and,O
More,O
Frequently,O
than,O
Placebo,O
Trial,O
1,O
CERDELGA,O
N,O
20,O
Placebo,O
N,O
20,O
Adverse,O
Reaction,O
Patientsn,O
Patientsn,O
Arthralgia,AdverseReaction
9,O
45,O
2,O
10,O
Headache,AdverseReaction
8,O
40,O
6,O
30,O
Migraine,AdverseReaction
2,O
10,O
0,O
0,O
Flatulence,AdverseReaction
2,O
10,O
1,O
5,O
Nausea,AdverseReaction
2,O
10,O
1,O
5,O
Oropharyngeal pain,AdverseReaction
2,O
10,O
1,O
5,O
Table,O
2,O
presents,O
the,O
profile,O
from,O
the,O
12,O
month,O
open,O
label,O
randomized,O
imiglucerase,O
controlled,O
trial,O
of,O
159,O
treated,O
patients,O
switching,O
from,O
enzyme,O
replacement,O
therapy,O
ERT,O
Trial,O
2,O
Patients,O
were,O
between,O
the,O
ages,O
of,O
18,O
and,O
69,O
on,O
the,O
date,O
of,O
the,O
first,O
dose,O
of,O
CERDELGA,O
and,O
included,O
87,O
females,O
and,O
72,O
males,O
Table,O
2,O
Adverse,O
Reactions,O
Occurring,O
in,O
5,O
of,O
GD1,O
Patients,O
Switching,O
from,O
Enzyme,O
Replacement,O
Therapy,O
to,O
CERDELGA,O
and,O
More,O
Frequently,O
than,O
Imiglucerase,O
Trial,O
2,O
Trial,O
2,O
was,O
not,O
designed,O
to,O
support,O
comparative,O
claims,O
for,O
CERDELGA,O
for,O
the,O
adverse,O
reactions,O
reported,O
in,O
this,O
table,O
CERDELGA,O
N,O
106,O
Imiglucerase,O
N,O
53,O
Adverse,O
Reaction,O
Patientsn,O
Patientsn,O
Fatigue,AdverseReaction
15,O
14,O
1,O
2,O
Headache,AdverseReaction
14,O
13,O
1,O
2,O
Nausea,AdverseReaction
13,O
12,O
0,O
0,O
Diarrhea,AdverseReaction
13,O
12,O
2,O
4,O
Back pain,AdverseReaction
13,O
12,O
3,O
6,O
Pain,O
in,O
extremity,O
12,O
11,O
1,O
2,O
Upper abdominal pain,AdverseReaction
11,O
10,O
0,O
0,O
Dizziness,AdverseReaction
9,O
8,O
0,O
0,O
Asthenia,AdverseReaction
9,O
8,O
0,O
0,O
Cough,AdverseReaction
7,O
7,O
2,O
4,O
Dyspepsia,AdverseReaction
7,O
7,O
1,O
2,O
Gastroesophageal reflux disease,AdverseReaction
7,O
7,O
0,O
0,O
Constipation,AdverseReaction
5,O
5,O
0,O
0,O
Palpitations,AdverseReaction
5,O
5,O
0,O
0,O
Rash,AdverseReaction
5,O
5,O
0,O
0,O
In,O
an,O
uncontrolled,O
study,O
with,O
up,O
to,O
4,O
years,O
of,O
treatment,O
in,O
26,O
patients,O
the,O
types,O
and,O
incidences,O
of,O
adverse,O
reactions,O
were,O
similar,O
to,O
Trials,O
1,O
and,O
2,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Imaging,O
errors,O
have,O
been,O
reported,O
blood,O
PSA,O
levels,O
2,O
ng,O
mL,O
have,O
been,O
associated,O
with,O
poor,O
imaging,O
performance,O
5,O
1,O
Allergic reactions,AdverseReaction
have,O
emergency,O
resuscitation,O
equipment,O
and,O
personnel,O
readily,O
available,O
5,O
2,O
Radiation risk,AdverseReaction
Choline,O
C,O
11,O
Injection,O
contributes,O
to,O
a,O
patient,O
s,O
long,O
term,O
cumulative,O
radiation,O
exposure,O
Ensure,O
safe,O
handling,O
to,O
protect,O
the,O
patient,O
and,O
health,O
care,O
worker,O
5,O
3,O
5,O
1,O
Imaging,O
Errors,O
Imaging,O
errors,O
have,O
been,O
reported,O
with,O
11,O
C,O
choline,O
PET,O
and,O
PET,O
CT,O
imaging,O
A,O
negative,O
image,O
does,O
not,O
rule,O
out,O
the,O
presence,O
of,O
recurrent,O
prostate,O
cancer,O
and,O
a,O
positive,O
image,O
does,O
not,O
confirm,O
the,O
presence,O
of,O
recurrent,O
cancer,O
11,O
C,O
choline,O
uptake,O
is,O
not,O
specific,O
for,O
prostate,O
cancer,O
and,O
may,O
occur,O
with,O
other,O
types,O
of,O
cancer,O
such,O
as,O
lung,O
carcinoma,O
and,O
brain,O
tumors,O
Clinical,O
correlation,O
including,O
histopathological,O
evaluation,O
of,O
the,O
suspected,O
recurrence,O
site,O
is,O
essential,O
to,O
proper,O
use,O
of,O
the,O
PET,O
imaging,O
information,O
Blood,O
PSA,O
levels,O
2,O
ng,O
mL,O
have,O
been,O
associated,O
with,O
poor,O
performance,O
of,O
11,O
C,O
choline,O
PET,O
imaging,O
higher,O
numbers,O
of,O
false,O
positive,O
and,O
false,O
negative,O
results,O
see,O
Clinical,O
Studies,O
14,O
Tissue,O
inflammation,O
as,O
well,O
as,O
prostatic,O
hyperplasia,O
have,O
been,O
associated,O
with,O
false,O
positive,O
11,O
C,O
choline,O
PET,O
images,O
Concomitant,O
colchicine,O
or,O
androgen,O
deprivation,O
therapeutic,O
drugs,O
such,O
as,O
luteinizing,O
hormone,O
releasing,O
analogs,O
and,O
anti,O
androgen,O
drugs,O
may,O
interfere,O
with,O
11,O
C,O
choline,O
PET,O
imaging,O
One,O
published,O
report,O
of,O
18,O
F,O
methylcholine,O
PET,O
imaging,O
indicated,O
that,O
discontinuation,O
of,O
colchicine,O
for,O
two,O
weeks,O
resolved,O
the,O
colchicine,O
effect,O
The,O
impact,O
of,O
discontinuation,O
of,O
androgen,O
deprivation,O
therapy,O
upon,O
11,O
C,O
choline,O
PET,O
imaging,O
has,O
not,O
been,O
established,O
see,O
Drug,O
Interactions,O
7,O
5,O
2,O
Allergic,O
Reactions,O
As,O
with,O
any,O
injectable,O
drug,O
product,O
allergic reactions,AdverseReaction
and,O
anaphylaxis,AdverseReaction
may,Factor
occur,O
Emergency,O
resuscitation,O
equipment,O
and,O
personnel,O
should,O
be,O
immediately,O
available,O
5,O
3,O
Radiation,O
Risks,O
Choline,O
C,O
11,O
Injection,O
contributes,O
to,O
a,O
patient,O
s,O
overall,O
long,O
term,O
cumulative,O
radiation,O
exposure,O
Long,O
term,O
cumulative,O
radiation,O
exposure,O
is,O
associated,O
with,O
an,O
increased,O
risk,Factor
for,O
cancer,AdverseReaction
Safe,O
handling,O
should,O
be,O
ensured,O
to,O
minimize,O
radiation,O
exposure,O
to,O
the,O
patient,O
and,O
health,O
care,O
workers,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
Exclusive,O
of,O
an,O
uncommon,O
mild,Severity
injection site reaction,AdverseReaction
no,O
adverse,O
reactions,O
to,O
11,O
C,O
choline,O
have,O
been,O
reported,O
EXCERPT,O
Exclusive,O
of,O
an,O
uncommon,O
mild,Severity
injection site reaction,AdverseReaction
no,O
other,O
adverse,O
reactions,O
have,O
been,O
reported,O
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Division,O
of,O
Nuclear,O
Medicine,O
Department,O
of,O
Radiology,O
Mayo,O
Clinic,O
at,O
507,O
284,O
2511,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Serious,Severity
infections,AdverseReaction
do,O
not,O
start,O
CIMZIA,O
during,O
an,O
active,O
infection,O
If,O
an,O
infection,O
develops,O
monitor,O
carefully,O
and,O
stop,O
CIMZIA,O
if,O
infection,O
becomes,O
serious,O
5,O
1,O
Invasive fungal infections,AdverseReaction
for,O
patients,O
who,O
develop,O
a,O
systemic,O
illness,O
on,O
CIMZIA,O
consider,O
empiric,O
antifungal,O
therapy,O
for,O
those,O
who,O
reside,O
or,O
travel,O
to,O
regions,O
where,O
mycoses,O
are,O
endemic,O
5,O
1,O
Cases,O
of,O
lymphoma,AdverseReaction
and,O
other,O
malignancies,AdverseReaction
have,O
been,O
observed,O
among,O
patients,O
receiving,O
TNF blockers,DrugClass
5,O
2,O
Heart failure worsening failure,AdverseReaction
or,O
new onset,AdverseReaction
may,Factor
occur,O
5,O
3,O
Anaphylaxis,AdverseReaction
or,O
serious,Severity
allergic reactions,AdverseReaction
may,Factor
occur,O
5,O
4,O
Hepatitis B virus reactivation,AdverseReaction
test,O
for,O
HBV,O
infection,O
before,O
starting,O
CIMZIA,O
Monitor,O
HBV,O
carriers,O
during,O
and,O
several,O
months,O
after,O
therapy,O
If,O
reactivation,O
occurs,O
stop,O
CIMZIA,O
and,O
begin,O
anti,O
viral,O
therapy,O
5,O
5,O
Demyelinating disease,AdverseReaction
exacerbation,O
or,O
new,O
onset,O
may,Factor
occur,O
5,O
6,O
Cytopenias,AdverseReaction
pancytopenia,AdverseReaction
advise,O
patients,O
to,O
seek,O
immediate,O
medical,O
attention,O
if,O
symptoms,O
develop,O
and,O
consider,O
stopping,O
CIMZIA,O
5,O
7,O
Lupus like syndrome,AdverseReaction
stop,O
CIMZIA,O
if,O
syndrome,O
develops,O
5,O
9,O
5,O
1,O
Risk,O
of,O
Serious,O
Infections,O
see,O
Boxed,O
Warning,O
Patients,O
treated,O
with,O
CIMZIA,O
are,O
at,O
an,O
increased,O
risk,Factor
for,O
developing,O
serious,Severity
infections,AdverseReaction
involving,O
various,O
organ,O
systems,O
and,O
sites,O
that,O
may,Factor
lead,O
to,O
hospitalization,O
or,O
death,AdverseReaction
Opportunistic infections,AdverseReaction
infections,AdverseReaction
due,O
to,O
bacterial,AdverseReaction
mycobacterial,AdverseReaction
invasive fungal,AdverseReaction
viral,AdverseReaction
parasitic,AdverseReaction
or,O
other,O
opportunistic,O
pathogens,O
including,O
aspergillosis,AdverseReaction
blastomycosis,AdverseReaction
candidiasis,AdverseReaction
coccidioidomycosis,AdverseReaction
histoplasmosis,AdverseReaction
legionellosis,AdverseReaction
listeriosis,AdverseReaction
pneumocystosis,AdverseReaction
and,O
tuberculosis,AdverseReaction
have,O
been,O
reported,O
with,O
TNF blockers,DrugClass
Patients,O
have,O
frequently,O
presented,O
with,O
disseminated,O
rather,O
than,O
localized,O
disease,O
Treatment,O
with,O
CIMZIA,O
should,O
not,O
be,O
initiated,O
in,O
patients,O
with,O
an,O
active,O
infection,O
including,O
clinically,O
important,O
localized,O
infections,O
Patients,O
greater,O
than,O
65,O
years,O
of,O
age,O
patients,O
with,O
co,O
morbid,O
conditions,O
and,O
or,O
patients,O
taking,O
concomitant,O
immunosuppressants,O
e,O
g,O
corticosteroids,O
or,O
methotrexate,O
may,O
be,O
at,O
a,O
greater,O
risk,Factor
of,O
infection,AdverseReaction
The,O
risks,O
and,O
benefits,O
of,O
treatment,O
should,O
be,O
considered,O
prior,O
to,O
initiating,O
therapy,O
in,O
patients,O
with,O
chronic,O
or,O
recurrent,O
infection,O
who,O
have,O
been,O
exposed,O
to,O
tuberculosis,O
with,O
a,O
history,O
of,O
an,O
opportunistic,O
infection,O
who,O
have,O
resided,O
or,O
traveled,O
in,O
areas,O
of,O
endemic,O
tuberculosis,O
or,O
endemic,O
mycoses,O
such,O
as,O
histoplasmosis,O
coccidioidomycosis,O
or,O
blastomycosis,O
with,O
underlying,O
conditions,O
that,O
may,O
predispose,O
them,O
to,O
infection,O
Tuberculosis,O
Cases,O
of,O
reactivation of tuberculosis,AdverseReaction
or,O
new,O
tuberculosis infections,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
receiving,O
CIMZIA,O
including,O
patients,O
who,O
have,O
previously,O
received,O
treatment,O
for,O
latent,O
or,O
active,O
tuberculosis,O
Patients,O
should,O
be,O
evaluated,O
for,O
tuberculosis,O
risk,O
factors,O
and,O
tested,O
for,O
latent,O
infection,O
prior,O
to,O
initiating,O
CIMZIA,O
and,O
periodically,O
during,O
therapy,O
Treatment,O
of,O
latent,O
tuberculosis,O
infection,O
prior,O
to,O
therapy,O
with,O
TNF,O
blocking,O
agents,O
has,O
been,O
shown,O
to,O
reduce,O
the,O
risk,O
of,O
tuberculosis,O
reactivation,O
during,O
therapy,O
Induration,O
of,O
5,O
mm,O
or,O
greater,O
with,O
tuberculin,O
skin,O
testing,O
should,O
be,O
considered,O
a,O
positive,O
test,O
result,O
when,O
assessing,O
if,O
treatment,O
for,O
latent,O
tuberculosis,O
is,O
needed,O
prior,O
to,O
initiating,O
CIMZIA,O
even,O
for,O
patients,O
previously,O
vaccinated,O
with,O
Bacille,O
Calmette,O
Guerin,O
BCG,O
Anti,O
tuberculosis,O
therapy,O
should,O
also,O
be,O
considered,O
prior,O
to,O
initiation,O
of,O
CIMZIA,O
in,O
patients,O
with,O
a,O
past,O
history,O
of,O
latent,O
or,O
active,O
tuberculosis,O
in,O
whom,O
an,O
adequate,O
course,O
of,O
treatment,O
cannot,O
be,O
confirmed,O
and,O
for,O
patients,O
with,O
a,O
negative,O
test,O
for,O
latent,O
tuberculosis,O
but,O
having,O
risk,O
factors,O
for,O
tuberculosis,O
infection,O
Consultation,O
with,O
a,O
physician,O
with,O
expertise,O
in,O
the,O
treatment,O
of,O
tuberculosis,O
is,O
recommended,O
to,O
aid,O
in,O
the,O
decision,O
of,O
whether,O
initiating,O
anti,O
tuberculosis,O
therapy,O
is,O
appropriate,O
for,O
an,O
individual,O
patient,O
Tuberculosis,O
should,O
be,O
strongly,O
considered,O
in,O
patients,O
who,O
develop,O
a,O
new,O
infection,O
during,O
CIMZIA,O
treatment,O
especially,O
in,O
patients,O
who,O
have,O
previously,O
or,O
recently,O
traveled,O
to,O
countries,O
with,O
a,O
high,O
prevalence,O
of,O
tuberculosis,O
or,O
who,O
have,O
had,O
close,O
contact,O
with,O
a,O
person,O
with,O
active,O
tuberculosis,O
Monitoring,O
Patients,O
should,O
be,O
closely,O
monitored,O
for,O
the,O
development,O
of,O
signs,O
and,O
symptoms,O
of,O
infection,O
during,O
and,O
after,O
treatment,O
with,O
CIMZIA,O
including,O
the,O
development,O
of,O
tuberculosis,O
in,O
patients,O
who,O
tested,O
negative,O
for,O
latent,O
tuberculosis,O
infection,O
prior,O
to,O
initiating,O
therapy,O
Tests,O
for,O
latent,O
tuberculosis,O
infection,O
may,O
also,O
be,O
falsely,O
negative,O
while,O
on,O
therapy,O
with,O
CIMZIA,O
CIMZIA,O
should,O
be,O
discontinued,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
or,O
sepsis,O
A,O
patient,O
who,O
develops,O
a,O
new,O
infection,O
during,O
treatment,O
with,O
CIMZIA,O
should,O
be,O
closely,O
monitored,O
undergo,O
a,O
prompt,O
and,O
complete,O
diagnostic,O
workup,O
appropriate,O
for,O
an,O
immunocompromised,O
patient,O
and,O
appropriate,O
antimicrobial,O
therapy,O
should,O
be,O
initiated,O
Invasive,O
Fungal,O
Infections,O
For,O
patients,O
who,O
reside,O
or,O
travel,O
in,O
regions,O
where,O
mycoses,O
are,O
endemic,O
invasive,O
fungal,O
infection,O
should,O
be,O
suspected,O
if,O
they,O
develop,O
a,O
serious,O
systemic,O
illness,O
Appropriate,O
empiric,O
antifungal,O
therapy,O
should,O
be,O
considered,O
while,O
a,O
diagnostic,O
workup,O
is,O
being,O
performed,O
Antigen,O
and,O
antibody,O
testing,O
for,O
histoplasmosis,O
may,O
be,O
negative,O
in,O
some,O
patients,O
with,O
active,O
infection,O
When,O
feasible,O
the,O
decision,O
to,O
administer,O
empiric,O
antifungal,O
therapy,O
in,O
these,O
patients,O
should,O
be,O
made,O
in,O
consultation,O
with,O
a,O
physician,O
with,O
expertise,O
in,O
the,O
diagnosis,O
and,O
treatment,O
of,O
invasive,O
fungal,O
infections,O
and,O
should,O
take,O
into,O
account,O
both,O
the,O
risk,O
for,O
severe,O
fungal,O
infection,O
and,O
risks,O
of,O
antifungal,O
therapy,O
5,O
2,O
Malignancies,O
In,O
the,O
controlled,O
portions,O
of,O
clinical,O
studies,O
of,O
some,O
TNF,O
blockers,O
more,O
cases,O
of,O
malignancies,AdverseReaction
have,O
been,O
observed,O
among,O
patients,O
receiving,O
TNF blockers,DrugClass
compared,O
to,O
control,O
patients,O
During,O
controlled,O
and,O
open,O
labeled,O
portions,O
of,O
CIMZIA,O
studies,O
of,O
Crohn,O
s,O
disease,O
and,O
other,O
diseases,O
malignancies,AdverseReaction
excluding,Negation
non melanoma skin cancer,AdverseReaction
were,O
observed,O
at,O
a,O
rate,O
95,O
confidence,O
interval,O
of,O
0,O
5,O
0,O
4,O
0,O
7,O
per,O
100,O
patient,O
years,O
among,O
4,O
650,O
CIMZIA,O
treated,O
patients,O
versus,O
a,O
rate,O
of,O
0,O
6,O
0,O
1,O
1,O
7,O
per,O
100,O
patient,O
years,O
among,O
1,O
319,O
placebo,O
treated,O
patients,O
The,O
size,O
of,O
the,O
control,O
group,O
and,O
limited,O
duration,O
of,O
the,O
controlled,O
portions,O
of,O
the,O
studies,O
precludes,O
the,O
ability,O
to,O
draw,O
firm,O
conclusions,O
Malignancies,AdverseReaction
some,O
fatal,AdverseReaction
have,O
been,O
reported,O
among,O
children,O
adolescents,O
and,O
young,O
adults,O
who,O
received,O
treatment,O
with,O
TNF blocking agents,DrugClass
initiation,O
of,O
therapy,O
18,O
years,O
of,O
age,O
of,O
which,O
CIMZIA,O
is,O
a,O
member,O
Approximately,O
half,O
the,O
cases,O
were,O
lymphomas,AdverseReaction
including,O
Hodgkin,AdverseReaction
s,O
and,O
non Hodgkin s lymphoma,AdverseReaction
The,O
other,O
cases,O
represented,O
a,O
variety,O
of,O
different,O
malignancies,AdverseReaction
and,O
included,O
rare malignancies,AdverseReaction
usually,O
associated,O
with,O
immunosuppression,O
and,O
malignancies,AdverseReaction
that,O
are,O
not,O
usually,O
observed,O
in,O
children,O
and,O
adolescents,O
The,O
malignancies,AdverseReaction
occurred,O
after,O
a,O
median,O
of,O
30,O
months,O
of,O
therapy,O
range,O
1,O
to,O
84,O
months,O
Most,O
of,O
the,O
patients,O
were,O
receiving,O
concomitant,O
immunosuppressants,O
These,O
cases,O
were,O
reported,O
post,O
marketing,O
and,O
are,O
derived,O
from,O
a,O
variety,O
of,O
sources,O
including,O
registries,O
and,O
spontaneous,O
post,O
marketing,O
reports,O
CIMZIA,O
is,O
not,O
indicated,O
for,O
use,O
in,O
pediatric,O
patients,O
In,O
the,O
controlled,O
portions,O
of,O
clinical,O
trials,O
of,O
all,O
the,O
TNF,O
blockers,O
more,O
cases,O
of,O
lymphoma,AdverseReaction
have,O
been,O
observed,O
among,O
patients,O
receiving,O
TNF blockers,DrugClass
compared,O
to,O
control,O
patients,O
In,O
controlled,O
studies,O
of,O
CIMZIA,O
for,O
Crohn,O
s,O
disease,O
and,O
other,O
investigational,O
uses,O
there,O
was,O
one,O
case,O
of,O
lymphoma,AdverseReaction
among,O
2,O
657,O
Cimzia,O
treated,O
patients,O
and,O
one,O
case,O
of,O
Hodgkin s lymphoma,AdverseReaction
among,O
1,O
319,O
placebo,Factor
treated,O
patients,O
In,O
the,O
CIMZIA,O
RA,O
clinical,O
trials,O
placebo,O
controlled,O
and,O
open,O
label,O
a,O
total,O
of,O
three,O
cases,O
of,O
lymphoma,AdverseReaction
were,O
observed,O
among,O
2,O
367,O
patients,O
This,O
is,O
approximately,O
2,O
fold,O
higher,O
than,O
expected,O
in,O
the,O
general,O
population,O
Patients,O
with,O
RA,O
particularly,O
those,O
with,O
highly,O
active,O
disease,O
are,O
at,O
a,O
higher,O
risk,O
for,O
the,O
development,O
of,O
lymphoma,O
Rates,O
in,O
clinical,O
studies,O
for,O
CIMZIA,O
cannot,O
be,O
compared,O
to,O
the,O
rates,O
of,O
clinical,O
trials,O
of,O
other,O
TNF,O
blockers,O
and,O
may,O
not,O
predict,O
the,O
rates,O
observed,O
when,O
CIMZIA,O
is,O
used,O
in,O
a,O
broader,O
patient,O
population,O
Patients,O
with,O
Crohn,O
s,O
disease,O
that,O
require,O
chronic,O
exposure,O
to,O
immunosuppressant therapies,DrugClass
may,O
be,O
at,O
higher,O
risk,O
than,O
the,O
general,O
population,O
for,O
the,O
development,O
of,O
lymphoma,AdverseReaction
even,O
in,O
the,O
absence,O
of,O
TNF,O
blocker,O
therapy,O
see,O
Adverse,O
Reactions,O
6,O
1,O
The,O
potential,O
role,O
of,O
TNF,O
blocker,O
therapy,O
in,O
the,O
development,O
of,O
malignancies,O
in,O
adults,O
is,O
not,O
known,O
Postmarketing,O
cases,O
of,O
hepatosplenic T cell lymphoma,AdverseReaction
HSTCL,AdverseReaction
a,O
rare,O
type,O
of,O
T,O
cell,O
lymphoma,O
that,O
has,O
a,O
very,O
aggressive,O
disease,O
course,O
and,O
is,O
usually,O
fatal,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
TNF,O
blockers,O
including,O
CIMZIA,O
The,O
majority,O
of,O
reported,O
TNF,O
blocker,O
cases,O
occurred,O
in,O
adolescent,O
and,O
young,O
adult,O
males,O
with,O
Crohn,O
s,O
disease,O
or,O
ulcerative,O
colitis,O
Almost,O
all,O
of,O
these,O
patients,O
had,O
received,O
treatment,O
with,O
the,O
immunosuppressants,O
azathioprine,O
and,O
or,O
6,O
mercaptopurine,O
6,O
MP,O
concomitantly,O
with,O
a,O
TNF,O
blocker,O
at,O
or,O
prior,O
to,O
diagnosis,O
It,O
is,O
uncertain,O
whether,O
the,O
occurrence,O
of,O
HSTCL,O
is,O
related,O
to,O
use,O
of,O
a,O
TNF,O
blocker,O
or,O
a,O
TNF,O
blocker,O
in,O
combination,O
with,O
these,O
other,O
immunosuppressants,O
The,O
potential,O
risk,O
of,O
using,O
a,O
TNF,O
blocker,O
in,O
combination,O
with,O
azathioprine,O
or,O
6,O
MP,O
should,O
be,O
carefully,O
considered,O
Cases,O
of,O
acute,AdverseReaction
and,O
chronic leukemia,AdverseReaction
have,O
been,O
reported,O
in,O
association,O
with,O
post,O
marketing,O
TNF blocker,DrugClass
use,O
in,O
RA,O
and,O
other,O
indications,O
Even,O
in,O
the,O
absence,O
of,O
TNF,O
blocker,O
therapy,O
patients,O
with,O
RA,O
may,O
be,O
at,O
a,O
higher,O
risk,O
approximately,O
2,O
fold,O
than,O
the,O
general,O
population,O
for,O
the,O
development,O
of,O
leukemia,O
Periodic,O
skin,O
examinations,O
are,O
recommended,O
for,O
all,O
patients,O
particularly,O
those,O
with,O
risk,O
factors,O
for,O
skin,O
cancer,O
5,O
3,O
Heart,O
Failure,O
Cases,O
of,O
worsening congestive heart failure,AdverseReaction
CHF,AdverseReaction
and,O
new onset CHF,AdverseReaction
have,O
been,O
reported,O
with,O
TNF,O
blockers,O
including,O
CIMZIA,O
CIMZIA,O
has,O
not,O
been,O
formally,O
studied,O
in,O
patients,O
with,O
CHF,O
however,O
in,O
clinical,O
studies,O
in,O
patients,O
with,O
CHF,O
with,O
another,O
TNF blocker,DrugClass
worsening congestive heart failure,AdverseReaction
CHF,AdverseReaction
and,O
increased mortality,AdverseReaction
due,O
to,O
CHF,AdverseReaction
were,O
observed,O
Exercise,O
caution,O
in,O
patients,O
with,O
heart,O
failure,O
and,O
monitor,O
them,O
carefully,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
4,O
Hypersensitivity,O
Reactions,O
The,O
following,O
symptoms,O
that,O
could,Factor
be,O
compatible,O
with,O
hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
rarely,O
following,O
CIMZIA,O
administration,O
to,O
patients,O
angioedema,AdverseReaction
dyspnea,AdverseReaction
hypotension,AdverseReaction
rash,AdverseReaction
serum sickness,AdverseReaction
and,O
urticaria,AdverseReaction
Some,O
of,O
these,O
reactions,O
occurred,O
after,O
the,O
first,O
administration,O
of,O
CIMZIA,O
If,O
such,O
reactions,O
occur,O
discontinue,O
further,O
administration,O
of,O
CIMZIA,O
and,O
institute,O
appropriate,O
therapy,O
There,O
are,O
no,O
data,O
on,O
the,O
risks,O
of,O
using,O
CIMZIA,O
in,O
patients,O
who,O
have,O
experienced,O
a,O
severe,O
hypersensitivity,O
reaction,O
towards,O
another,O
TNF,O
blocker,O
in,O
these,O
patients,O
caution,O
is,O
needed,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
5,O
Hepatitis,O
B,O
Virus,O
Reactivation,O
Use,O
of,O
TNF,O
blockers,O
including,O
CIMZIA,O
has,O
been,O
associated,O
with,O
reactivation of hepatitis B virus of,AdverseReaction
HBV,AdverseReaction
in,O
patients,O
who,O
are,O
chronic,O
carriers,O
of,O
this,O
virus,O
In,O
some,O
instances,O
HBV reactivation,AdverseReaction
occurring,O
in,O
conjunction,O
with,O
TNF blocker,DrugClass
therapy,O
has,O
been,O
fatal,AdverseReaction
The,O
majority,O
of,O
reports,O
have,O
occurred,O
in,O
patients,O
concomitantly,O
receiving,O
other,O
medications,O
that,O
suppress,O
the,O
immune,O
system,O
which,O
may,O
also,O
contribute,O
to,O
HBV reactivation,AdverseReaction
Test,O
patients,O
for,O
HBV,O
infection,O
before,O
initiating,O
treatment,O
with,O
CIMZIA,O
For,O
patients,O
who,O
test,O
positive,O
for,O
HBV,O
infection,O
consultation,O
with,O
a,O
physician,O
with,O
expertise,O
in,O
the,O
treatment,O
of,O
hepatitis,O
B,O
is,O
recommended,O
Adequate,O
data,O
are,O
not,O
available,O
on,O
the,O
safety,O
or,O
efficacy,O
of,O
treating,O
patients,O
who,O
are,O
carriers,O
of,O
HBV,O
with,O
anti,O
viral,O
therapy,O
in,O
conjunction,O
with,O
TNF,O
blocker,O
therapy,O
to,O
prevent,O
HBV,O
reactivation,O
Patients,O
who,O
are,O
carriers,O
of,O
HBV,O
and,O
require,O
treatment,O
with,O
CIMZIA,O
should,O
be,O
closely,O
monitored,O
for,O
clinical,O
and,O
laboratory,O
signs,O
of,O
active,O
HBV,O
infection,O
throughout,O
therapy,O
and,O
for,O
several,O
months,O
following,O
termination,O
of,O
therapy,O
In,O
patients,O
who,O
develop,O
HBV,O
reactivation,O
discontinue,O
CIMZIA,O
and,O
initiate,O
effective,O
anti,O
viral,O
therapy,O
with,O
appropriate,O
supportive,O
treatment,O
The,O
safety,O
of,O
resuming,O
TNF,O
blocker,O
therapy,O
after,O
HBV,O
reactivation,O
is,O
controlled,O
is,O
not,O
known,O
Therefore,O
exercise,O
caution,O
when,O
considering,O
resumption,O
of,O
CIMZIA,O
therapy,O
in,O
this,O
situation,O
and,O
monitor,O
patients,O
closely,O
5,O
6,O
Neurologic,O
Reactions,O
Use,O
of,O
TNF blockers,DrugClass
of,O
which,O
CIMZIA,O
is,O
a,O
member,O
has,O
been,O
associated,O
with,O
rare,O
cases,O
of,O
new,O
onset,O
or,O
exacerbation,O
of,O
clinical,O
symptoms,O
and,O
or,O
radiographic,O
evidence,O
of,O
central nervous system demyelinating disease,AdverseReaction
including,O
multiple sclerosis,AdverseReaction
and,O
with,O
peripheral demyelinating disease,AdverseReaction
including,O
Guillain Barre syndrome,AdverseReaction
Exercise,O
caution,O
in,O
considering,O
the,O
use,O
of,O
CIMZIA,O
in,O
patients,O
with,O
pre,O
existing,O
or,O
recent,O
onset,O
central,O
or,O
peripheral,O
nervous,O
system,O
demyelinating,O
disorders,O
Rare,O
cases,O
of,O
neurological disorders,AdverseReaction
including,O
seizure disorder,AdverseReaction
optic neuritis,AdverseReaction
and,O
peripheral neuropathy,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
CIMZIA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
7,O
Hematological,O
Reactions,O
Rare,O
reports,O
of,O
pancytopenia,AdverseReaction
including,O
aplastic anemia,AdverseReaction
have,O
been,O
reported,O
with,O
TNF blockers,DrugClass
Adverse reactions of the hematologic system,AdverseReaction
including,O
medically significant,Severity
cytopenia,AdverseReaction
e,O
g,O
leukopenia,AdverseReaction
pancytopenia,AdverseReaction
thrombocytopenia,AdverseReaction
have,O
been,O
infrequently,O
reported,O
with,O
CIMZIA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
The,O
causal,O
relationship,O
of,O
these,O
events,O
to,O
CIMZIA,O
remains,O
unclear,O
Although,O
no,O
high,O
risk,O
group,O
has,O
been,O
identified,O
exercise,O
caution,O
in,O
patients,O
being,O
treated,O
with,O
CIMZIA,O
who,O
have,O
ongoing,O
or,O
a,O
history,O
of,O
significant,O
hematologic,O
abnormalities,O
Advise,O
all,O
patients,O
to,O
seek,O
immediate,O
medical,O
attention,O
if,O
they,O
develop,O
signs,O
and,O
symptoms,O
suggestive,O
of,O
blood,O
dyscrasias,O
or,O
infection,O
e,O
g,O
persistent,O
fever,O
bruising,O
bleeding,O
pallor,O
while,O
on,O
CIMZIA,O
Consider,O
discontinuation,O
of,O
CIMZIA,O
therapy,O
in,O
patients,O
with,O
confirmed,O
significant,O
hematologic,O
abnormalities,O
5,O
8,O
Use,O
with,O
Biological,O
Disease,O
Modifying,O
Antirheumatic,O
Drugs,O
Biological,O
DMARDs,O
Serious,Severity
infections,AdverseReaction
were,O
seen,O
in,O
clinical,O
studies,O
with,O
concurrent,O
use,O
of,O
anakinra,O
an,O
interleukin,O
1,O
antagonist,O
and,O
another,O
TNF,O
blocker,O
etanercept,DrugClass
with,O
no,O
added,O
benefit,O
compared,O
to,O
etanercept,O
alone,O
A,O
higher,O
risk,Factor
of,O
serious,Severity
infections,AdverseReaction
was,O
also,O
observed,O
in,O
combination,O
use,O
of,O
TNF blockers,DrugClass
with,O
abatacept,O
and,O
rituximab,O
Because,O
of,O
the,O
nature,O
of,O
the,O
adverse,O
events,O
seen,O
with,O
this,O
combination,O
therapy,O
similar,O
toxicities,O
may,O
also,O
result,O
from,O
the,O
use,O
of,O
CIMZIA,O
in,O
this,O
combination,O
Therefore,O
the,O
use,O
of,O
CIMZIA,O
in,O
combination,O
with,O
other,O
biological,O
DMARDs,O
is,O
not,O
recommended,O
see,O
Drug,O
Interactions,O
7,O
1,O
5,O
9,O
Autoimmunity,O
Treatment,O
with,O
CIMZIA,O
may,Factor
result,O
in,O
the,O
formation of autoantibodies,AdverseReaction
and,O
rarely,O
in,O
the,O
development,O
of,O
a,O
lupus like syndrome,AdverseReaction
If,O
a,O
patient,O
develops,O
symptoms,O
suggestive,O
of,O
a,O
lupus,O
like,O
syndrome,O
following,O
treatment,O
with,O
CIMZIA,O
discontinue,O
treatment,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
10,O
Immunizations,O
Patients,O
treated,O
with,O
CIMZIA,O
may,O
receive,O
vaccinations,O
except,O
for,O
live,O
or,O
live,O
attenuated,O
vaccines,O
No,O
data,O
are,O
available,O
on,O
the,O
response,O
to,O
live,O
vaccinations,O
or,O
the,O
secondary,O
transmission,O
of,O
infection,O
by,O
live,O
vaccines,O
in,O
patients,O
receiving,O
CIMZIA,O
In,O
a,O
placebo,O
controlled,O
clinical,O
trial,O
of,O
patients,O
with,O
rheumatoid,O
arthritis,O
no,O
difference,O
was,O
detected,O
in,O
antibody,O
response,O
to,O
vaccine,O
between,O
CIMZIA,O
and,O
placebo,O
treatment,O
groups,O
when,O
the,O
pneumococcal,O
polysaccharide,O
vaccine,O
and,O
influenza,O
vaccine,O
were,O
administered,O
concurrently,O
with,O
CIMZIA,O
Similar,O
proportions,O
of,O
patients,O
developed,O
protective,O
levels,O
of,O
anti,O
vaccine,O
antibodies,O
between,O
CIMZIA,O
and,O
placebo,O
treatment,O
groups,O
however,O
patients,O
receiving,O
CIMZIA,O
and,O
concomitant,O
methotrexate,O
had,O
a,O
lower,O
humoral,O
response,O
compared,O
with,O
patients,O
receiving,O
CIMZIA,O
alone,O
The,O
clinical,O
significance,O
of,O
this,O
is,O
unknown,O
5,O
11,O
Immunosuppression,O
Since,O
TNF,O
mediates,O
inflammation,O
and,O
modulates,O
cellular,O
immune,O
responses,O
the,O
possibility,O
exists,O
for,O
TNF,O
blockers,O
including,O
CIMZIA,O
to,O
affect,O
host,O
defenses,O
against,O
infections,O
and,O
malignancies,O
The,O
impact,O
of,O
treatment,O
with,O
CIMZIA,O
on,O
the,O
development,O
and,O
course,O
of,O
malignancies,O
as,O
well,O
as,O
active,O
and,O
or,O
chronic,O
infections,O
is,O
not,O
fully,O
understood,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
2,O
5,O
5,O
and,O
Adverse,O
Reactions,O
6,O
1,O
The,O
safety,O
and,O
efficacy,O
of,O
CIMZIA,O
in,O
patients,O
with,O
immunosuppression,O
has,O
not,O
been,O
formally,O
evaluated,O
""
BOXED,O
WARNING,O
WARNING,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
AND,O
MALIGNANCY,AdverseReaction
WARNING,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
AND,O
MALIGNANCY,AdverseReaction
SERIOUS,O
INFECTIONS,O
Patients,O
treated,O
with,O
CIMZIA,O
are,O
at,O
increased,O
risk,Factor
for,O
developing,O
serious,Severity
infections,AdverseReaction
that,O
may,Factor
lead,O
to,O
hospitalization,O
or,O
death,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Adverse,O
Reactions,O
6,O
1,O
Most,O
patients,O
who,O
developed,O
these,O
infections,AdverseReaction
were,O
taking,O
concomitant,O
immunosuppressants,O
such,O
as,O
methotrexate,O
or,O
corticosteroids,O
CIMZIA,O
should,O
be,O
discontinued,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
or,O
sepsis,O
Reported,O
infections,O
include,O
Active tuberculosis,AdverseReaction
including,O
reactivation of latent tuberculosis,AdverseReaction
Patients,O
with,O
tuberculosis,AdverseReaction
have,O
frequently,O
presented,O
with,O
disseminated,AdverseReaction
or,O
extrapulmonary,AdverseReaction
disease,O
Patients,O
should,O
be,O
tested,O
for,O
latent,O
tuberculosis,O
before,O
CIMZIA,O
use,O
and,O
during,O
therapy,O
Treatment,O
for,O
latent,O
infection,O
should,O
be,O
initiated,O
prior,O
to,O
CIMZIA,O
use,O
Invasive fungal infections,AdverseReaction
including,O
histoplasmosis,AdverseReaction
coccidioidomycosis,AdverseReaction
candidiasis,AdverseReaction
aspergillosis,AdverseReaction
blastomycosis,AdverseReaction
and,O
pneumocystosis,AdverseReaction
Patients,O
with,O
histoplasmosis,AdverseReaction
or,O
other,O
invasive fungal infections fungal infections,AdverseReaction
may,Factor
present,O
with,O
disseminated,AdverseReaction
rather,O
than,O
localized,O
disease,O
Antigen,O
and,O
antibody,O
testing,O
for,O
histoplasmosis,O
may,O
be,O
negative,O
in,O
some,O
patients,O
with,O
active,O
infection,O
Empiric,O
anti,O
fungal,O
therapy,O
should,O
be,O
considered,O
in,O
patients,O
at,O
risk,O
for,O
invasive,O
fungal,O
infections,O
who,O
develop,O
severe,O
systemic,O
illness,O
Bacterial,AdverseReaction
viral,AdverseReaction
and,O
other,O
infections,AdverseReaction
due,O
to,O
opportunistic,O
pathogens,O
including,O
Legionella,AdverseReaction
and,O
Listeria,AdverseReaction
The,O
risks,O
and,O
benefits,O
of,O
treatment,O
with,O
CIMZIA,O
should,O
be,O
carefully,O
considered,O
prior,O
to,O
initiating,O
therapy,O
in,O
patients,O
with,O
chronic,O
or,O
recurrent,O
infection,O
Patients,O
should,O
be,O
closely,O
monitored,O
for,O
the,O
development,O
of,O
signs,O
and,O
symptoms,O
of,O
infection,O
during,O
and,O
after,O
treatment,O
with,O
CIMZIA,O
including,O
the,O
possible,O
development,O
of,O
tuberculosis,O
in,O
patients,O
who,O
tested,O
negative,O
for,O
latent,O
tuberculosis,O
infection,O
prior,O
to,O
initiating,O
therapy,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Adverse,O
Reactions,O
6,O
1,O
MALIGNANCY,O
Lymphoma,AdverseReaction
and,O
other,O
malignancies,AdverseReaction
some,O
fatal,AdverseReaction
have,O
been,O
reported,O
in,O
children,O
and,O
adolescent,O
patients,O
treated,O
with,O
TNF blockers,DrugClass
of,O
which,O
CIMZIA,O
is,O
a,O
member,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
CIMZIA,O
is,O
not,O
indicated,O
for,O
use,O
in,O
pediatric,O
patients,O
EXCERPT,O
WARNING,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
AND,O
MALIGNANCY,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Increased,O
risk,Factor
of,O
serious,Severity
infections,AdverseReaction
leading,O
to,O
hospitalization,O
or,O
death,AdverseReaction
including,O
tuberculosis,AdverseReaction
TB,AdverseReaction
bacterial sepsis,AdverseReaction
invasive fungal infections,AdverseReaction
such,O
as,O
histoplasmosis,AdverseReaction
and,O
infections due to other opportunistic pathogens,AdverseReaction
5,O
1,O
CIMZIA,O
should,O
be,O
discontinued,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
or,O
sepsis,O
5,O
1,O
Perform,O
test,O
for,O
latent,O
TB,O
if,O
positive,O
start,O
treatment,O
for,O
TB,O
prior,O
to,O
starting,O
CIMZIA,O
5,O
1,O
Monitor,O
all,O
patients,O
for,O
active,O
TB,O
during,O
treatment,O
even,O
if,O
initial,O
latent,O
TB,O
test,O
is,O
negative,O
5,O
1,O
Lymphoma,AdverseReaction
and,O
other,O
malignancies,AdverseReaction
some,O
fatal,AdverseReaction
have,O
been,O
reported,O
in,O
children,O
and,O
adolescent,O
patients,O
treated,O
with,O
TNF blockers,DrugClass
of,O
which,O
CIMZIA,O
is,O
a,O
member,O
5,O
2,O
CIMZIA,O
is,O
not,O
indicated,O
for,O
use,O
in,O
pediatric,O
patients,O
8,O
4,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
7,O
and,O
higher,O
than,O
placebo,O
upper respiratory tract infection,AdverseReaction
rash,AdverseReaction
and,O
urinary tract infection,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
UCB,O
Inc,O
at,O
1,O
866,O
822,O
0068,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
The,O
most,O
serious,O
adverse,O
reactions,O
were,O
Serious,Severity
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Malignancies,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Heart Failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Because,O
clinical,O
studies,O
are,O
conducted,O
under,O
widely,O
varying,O
and,O
controlled,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
clinical,O
studies,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
studies,O
of,O
another,O
drug,O
and,O
may,O
not,O
predict,O
the,O
rates,O
observed,O
in,O
a,O
broader,O
patient,O
population,O
in,O
clinical,O
practice,O
In,O
premarketing,O
controlled,O
trials,O
of,O
all,O
patient,O
populations,O
combined,O
the,O
most,O
common,O
adverse,O
reactions,O
8,O
were,O
upper respiratory infections,AdverseReaction
18,O
rash,AdverseReaction
9,O
and,O
urinary tract infections,AdverseReaction
8,O
Adverse,O
Reactions,O
Most,O
Commonly,O
Leading,O
to,O
Discontinuation,O
of,O
Treatment,O
in,O
Premarketing,O
Controlled,O
Trials,O
The,O
proportion,O
of,O
patients,O
with,O
Crohn,O
s,O
disease,O
who,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reactions,O
in,O
the,O
controlled,O
clinical,O
studies,O
was,O
8,O
for,O
CIMZIA,O
and,O
7,O
for,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
the,O
discontinuation,O
of,O
CIMZIA,O
for,O
at,O
least,O
2,O
patients,O
and,O
with,O
a,O
higher,O
incidence,O
than,O
placebo,O
were,O
abdominal pain,AdverseReaction
0,O
4,O
CIMZIA,O
0,O
2,O
placebo,O
diarrhea,AdverseReaction
0,O
4,O
CIMZIA,O
0,O
placebo,O
and,O
intestinal obstruction,AdverseReaction
0,O
4,O
CIMZIA,O
0,O
placebo,O
The,O
proportion,O
of,O
patients,O
with,O
rheumatoid,O
arthritis,O
who,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reactions,O
in,O
the,O
controlled,O
clinical,O
studies,O
was,O
5,O
for,O
CIMZIA,O
and,O
2,O
5,O
for,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
of,O
CIMZIA,O
were,O
tuberculosis infections,AdverseReaction
0,O
5,O
and,O
pyrexia,AdverseReaction
urticaria,AdverseReaction
pneumonia,AdverseReaction
and,O
rash,AdverseReaction
0,O
3,O
Controlled,O
Studies,O
with,O
Crohn,O
s,O
Disease,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
CIMZIA,O
at,O
400,O
mg,O
subcutaneous,O
dosing,O
in,O
studies,O
of,O
patients,O
with,O
Crohn,O
s,O
disease,O
In,O
the,O
safety,O
population,O
in,O
controlled,O
studies,O
a,O
total,O
of,O
620,O
patients,O
with,O
Crohn,O
s,O
disease,O
received,O
CIMZIA,O
at,O
a,O
dose,O
of,O
400,O
mg,O
and,O
614,O
subjects,O
received,O
placebo,O
including,O
subjects,O
randomized,O
to,O
placebo,O
in,O
Study,O
CD2,O
following,O
open,O
label,O
dosing,O
of,O
CIMZIA,O
at,O
Weeks,O
0,O
2,O
4,O
In,O
controlled,O
and,O
uncontrolled,O
studies,O
1,O
564,O
patients,O
received,O
CIMZIA,O
at,O
some,O
dose,O
level,O
of,O
whom,O
1,O
350,O
patients,O
received,O
400,O
mg,O
CIMZIA,O
Approximately,O
55,O
of,O
subjects,O
were,O
female,O
45,O
were,O
male,O
and,O
94,O
were,O
Caucasian,O
The,O
majority,O
of,O
patients,O
in,O
the,O
active,O
group,O
were,O
between,O
the,O
ages,O
of,O
18,O
and,O
64,O
During,O
controlled,O
clinical,O
studies,O
the,O
proportion,O
of,O
patients,O
with,O
serious,O
adverse,O
reactions,O
was,O
10,O
for,O
CIMZIA,O
and,O
9,O
for,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
occurring,O
in,O
5,O
of,O
CIMZIA,O
treated,O
patients,O
and,O
with,O
a,O
higher,O
incidence,O
compared,O
to,O
placebo,O
in,O
controlled,O
clinical,O
studies,O
with,O
CIMZIA,O
were,O
upper respiratory infections,AdverseReaction
e,O
g,O
nasopharyngitis,AdverseReaction
laryngitis,AdverseReaction
viral infection,AdverseReaction
in,O
20,O
of,O
CIMZIA,O
treated,O
patients,O
and,O
13,O
of,O
placebo,O
treated,O
patients,O
urinary tract infections,AdverseReaction
e,O
g,O
bladder infection,AdverseReaction
bacteriuria,AdverseReaction
cystitis,AdverseReaction
in,O
7,O
of,O
CIMZIA,O
treated,O
patients,O
and,O
in,O
6,O
of,O
placebo,O
treated,O
patients,O
and,O
arthralgia,AdverseReaction
6,O
CIMZIA,O
4,O
placebo,O
Other,O
Adverse,O
Reactions,O
The,O
most,O
commonly,O
occurring,O
adverse,O
reactions,O
in,O
controlled,O
trials,O
of,O
Crohn,O
s,O
disease,O
were,O
described,O
above,O
Other,O
serious,O
or,O
significant,O
adverse,O
reactions,O
reported,O
in,O
controlled,O
and,O
uncontrolled,O
studies,O
in,O
Crohn,O
s,O
disease,O
and,O
other,O
diseases,O
occurring,O
in,O
patients,O
receiving,O
CIMZIA,O
at,O
doses,O
of,O
400,O
mg,O
or,O
other,O
doses,O
include,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Anemia,AdverseReaction
leukopenia,AdverseReaction
lymphadenopathy,AdverseReaction
pancytopenia,AdverseReaction
and,O
thrombophilia,AdverseReaction
Cardiac,O
disorders,O
Angina pectoris,AdverseReaction
arrhythmias,AdverseReaction
atrial fibrillation,AdverseReaction
cardiac failure,AdverseReaction
hypertensive heart disease,AdverseReaction
myocardial infarction,AdverseReaction
myocardial ischemia,AdverseReaction
pericardial effusion,AdverseReaction
pericarditis,AdverseReaction
stroke,AdverseReaction
and,O
transient ischemic attack,AdverseReaction
Eye,O
disorders,O
Optic neuritis,AdverseReaction
retinal hemorrhage,AdverseReaction
and,O
uveitis,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Bleeding,AdverseReaction
and,O
injection site reactions,AdverseReaction
Hepatobiliary,O
disorders,O
Elevated liver enzymes,AdverseReaction
and,O
hepatitis,AdverseReaction
Immune,O
system,O
disorders,O
Alopecia totalis,AdverseReaction
Psychiatric,O
disorders,O
Anxiety,AdverseReaction
bipolar disorder,AdverseReaction
and,O
suicide attempt,AdverseReaction
Renal,O
and,O
urinary,O
disorders,O
Nephrotic syndrome,AdverseReaction
and,O
renal failure,AdverseReaction
Reproductive,O
system,O
and,O
breast,O
disorders,O
Menstrual disorder,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Dermatitis,AdverseReaction
erythema nodosum,AdverseReaction
and,O
urticaria,AdverseReaction
Vascular,O
disorders,O
Thrombophlebitis,AdverseReaction
vasculitis,AdverseReaction
Controlled,O
Studies,O
with,O
Rheumatoid,O
Arthritis,O
CIMZIA,O
was,O
studied,O
primarily,O
in,O
placebo,O
controlled,O
trials,O
and,O
in,O
long,O
term,O
follow,O
up,O
studies,O
The,O
data,O
described,O
below,O
reflect,O
the,O
exposure,O
to,O
CIMZIA,O
in,O
2,O
367,O
RA,O
patients,O
including,O
2,O
030,O
exposed,O
for,O
at,O
least,O
6,O
months,O
1,O
663,O
exposed,O
for,O
at,O
least,O
one,O
year,O
and,O
282,O
for,O
at,O
least,O
2,O
years,O
and,O
1,O
774,O
in,O
adequate,O
and,O
well,O
controlled,O
studies,O
In,O
placebo,O
controlled,O
studies,O
the,O
population,O
had,O
a,O
median,O
age,O
of,O
53,O
years,O
at,O
entry,O
approximately,O
80,O
were,O
females,O
93,O
were,O
Caucasian,O
and,O
all,O
patients,O
were,O
suffering,O
from,O
active,O
rheumatoid,O
arthritis,O
with,O
a,O
median,O
disease,O
duration,O
of,O
6,O
2,O
years,O
Most,O
patients,O
received,O
the,O
recommended,O
dose,O
of,O
CIMZIA,O
or,O
higher,O
Table,O
1,O
summarizes,O
the,O
reactions,O
reported,O
at,O
a,O
rate,O
of,O
at,O
least,O
3,O
in,O
patients,O
treated,O
with,O
CIMZIA,O
200,O
mg,O
every,O
other,O
week,O
compared,O
to,O
placebo,O
saline,O
formulation,O
given,O
concomitantly,O
with,O
methotrexate,O
Table,O
1,O
Adverse,O
Reactions,O
Reported,O
by,O
3,O
of,O
Patients,O
Treated,O
with,O
CIMZIA,O
Dosed,O
Every,O
Other,O
Week,O
during,O
Placebo,O
Controlled,O
Period,O
of,O
Rheumatoid,O
Arthritis,O
Studies,O
with,O
Concomitant,O
Methotrexate,O
Adverse,O
Reaction,O
Preferred,O
Term,O
Placebo,O
MTX,O
N,O
324,O
CIMZIA,O
200,O
mg,O
EOW,O
MTX,O
N,O
640,O
Upper respiratory tract infection,AdverseReaction
2,O
6,O
Headache,AdverseReaction
4,O
5,O
Hypertension,AdverseReaction
2,O
5,O
Nasopharyngitis,AdverseReaction
1,O
5,O
Back pain,AdverseReaction
1,O
4,O
Pyrexia,AdverseReaction
2,O
3,O
Pharyngitis,AdverseReaction
1,O
3,O
Rash,AdverseReaction
1,O
3,O
Acute bronchitis,AdverseReaction
1,O
3,O
Fatigue,AdverseReaction
2,O
3,O
Hypertensive adverse reactions,AdverseReaction
were,O
observed,O
more,O
frequently,O
in,O
patients,O
receiving,O
CIMZIA,O
than,O
in,O
controls,O
These,O
adverse,O
reactions,O
occurred,O
more,O
frequently,O
among,O
patients,O
with,O
a,O
baseline,O
history,O
of,O
hypertension,O
and,O
among,O
patients,O
receiving,O
concomitant,O
corticosteroids,O
and,O
non,O
steroidal,O
anti,O
inflammatory,O
drugs,O
Patients,O
receiving,O
CIMZIA,O
400,O
mg,O
as,O
monotherapy,O
every,O
4,O
weeks,O
in,O
rheumatoid,O
arthritis,O
controlled,O
clinical,O
trials,O
had,O
similar,O
adverse,O
reactions,O
to,O
those,O
patients,O
receiving,O
CIMZIA,O
200,O
mg,O
every,O
other,O
week,O
Other,O
Adverse,O
Reactions,O
Other,O
infrequent,O
adverse,O
reactions,O
occurring,O
in,O
less,O
than,O
3,O
of,O
RA,O
patients,O
were,O
similar,O
to,O
those,O
seen,O
in,O
Crohn,O
s,O
disease,O
patients,O
Psoriatic,O
Arthritis,O
Clinical,O
Study,O
CIMZIA,O
has,O
been,O
studied,O
in,O
409,O
patients,O
with,O
psoriatic,O
arthritis,O
PsA,O
in,O
a,O
placebo,O
controlled,O
trial,O
The,O
safety,O
profile,O
for,O
patients,O
with,O
PsA,O
treated,O
with,O
CIMZIA,O
was,O
similar,O
to,O
the,O
safety,O
profile,O
seen,O
in,O
patients,O
with,O
RA,O
and,O
previous,O
experience,O
with,O
CIMZIA,O
Ankylosing,O
Spondylitis,O
Clinical,O
Study,O
CIMZIA,O
has,O
been,O
studied,O
in,O
325,O
patients,O
with,O
axial,O
spondyloarthritis,O
of,O
whom,O
the,O
majority,O
had,O
ankylosing,O
spondylitis,O
AS,O
in,O
a,O
placebo,O
controlled,O
study,O
AS,O
1,O
The,O
safety,O
profile,O
for,O
patients,O
in,O
study,O
AS,O
1,O
treated,O
with,O
CIMZIA,O
was,O
similar,O
to,O
the,O
safety,O
profile,O
seen,O
in,O
patients,O
with,O
RA,O
Infections,O
The,O
incidence,O
of,O
infections,AdverseReaction
in,O
controlled,O
studies,O
in,O
Crohn,O
s,O
disease,O
was,O
38,O
for,O
CIMZIA,O
treated,O
patients,O
and,O
30,O
for,O
placebo,O
treated,O
patients,O
The,O
infections,AdverseReaction
consisted,O
primarily,O
of,O
upper respiratory infections,AdverseReaction
20,O
for,O
CIMZIA,O
13,O
for,O
placebo,O
The,O
incidence,O
of,O
serious,Severity
infections,AdverseReaction
during,O
the,O
controlled,O
clinical,O
studies,O
was,O
3,O
per,O
patient,O
year,O
for,O
CIMZIA,O
treated,O
patients,O
and,O
1,O
for,O
placebo,O
treated,O
patients,O
Serious,Severity
infections,AdverseReaction
observed,O
included,O
bacterial,AdverseReaction
and,O
viral infections,AdverseReaction
pneumonia,AdverseReaction
and,O
pyelonephritis,AdverseReaction
The,O
incidence,O
of,O
new,O
cases,O
of,O
infections,AdverseReaction
in,O
controlled,O
clinical,O
studies,O
in,O
rheumatoid,O
arthritis,O
was,O
0,O
91,O
per,O
patient,O
year,O
for,O
all,O
CIMZIA,O
treated,O
patients,O
and,O
0,O
72,O
per,O
patient,O
year,O
for,O
placebo,O
treated,O
patients,O
The,O
infections,AdverseReaction
consisted,O
primarily,O
of,O
upper respiratory tract infections,AdverseReaction
herpes infections,AdverseReaction
urinary tract infections,AdverseReaction
and,O
lower respiratory tract infections,AdverseReaction
In,O
the,O
controlled,O
rheumatoid,O
arthritis,O
studies,O
there,O
were,O
more,O
new,O
cases,O
of,O
serious,Severity
infection,AdverseReaction
adverse,O
reactions,O
in,O
the,O
CIMZIA,O
treatment,O
groups,O
compared,O
to,O
the,O
placebo,O
groups,O
0,O
06,O
per,O
patient,O
year,O
for,O
all,O
CIMZIA,O
doses,O
vs,O
0,O
02,O
per,O
patient,O
year,O
for,O
placebo,O
Rates,O
of,O
serious,Severity
infections,AdverseReaction
in,O
the,O
200,O
mg,O
every,O
other,O
week,O
dose,O
group,O
were,O
0,O
06,O
per,O
patient,O
year,O
and,O
in,O
the,O
400,O
mg,O
every,O
4,O
weeks,O
dose,O
group,O
were,O
0,O
04,O
per,O
patient,O
year,O
Serious,Severity
infections,AdverseReaction
included,O
tuberculosis,AdverseReaction
pneumonia,AdverseReaction
cellulitis,AdverseReaction
and,O
pyelonephritis,AdverseReaction
In,O
the,O
placebo,Factor
group,O
no,O
serious,Severity
infection,AdverseReaction
occurred,O
in,O
more,O
than,O
one,O
subject,O
There,O
is,O
no,O
evidence,O
of,O
increased,O
risk,O
of,O
infections,O
with,O
continued,O
exposure,O
over,O
time,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Tuberculosis,O
and,O
Opportunistic,O
Infections,O
In,O
completed,O
and,O
ongoing,O
global,O
clinical,O
studies,O
in,O
all,O
indications,O
including,O
5,O
118,O
CIMZIA,O
treated,O
patients,O
the,O
overall,O
rate,O
of,O
tuberculosis,AdverseReaction
is,O
approximately,O
0,O
61,O
per,O
100,O
patient,O
years,O
across,O
all,O
indications,O
The,O
majority,O
of,O
cases,O
occurred,O
in,O
countries,O
with,O
high,O
endemic,O
rates,O
of,O
TB,AdverseReaction
Reports,O
include,O
cases,O
of,O
miliary,AdverseReaction
lymphatic,AdverseReaction
peritoneal,AdverseReaction
as,O
well,O
as,O
pulmonary TB,AdverseReaction
The,O
median,O
time,O
to,O
onset,O
of,O
TB,AdverseReaction
for,O
all,O
patients,O
exposed,O
to,O
CIMZIA,O
across,O
all,O
indications,O
was,O
345,O
days,O
In,O
the,O
studies,O
with,O
CIMZIA,O
in,O
RA,O
there,O
were,O
36,O
cases,O
of,O
TB,AdverseReaction
among,O
2,O
367,O
exposed,O
patients,O
including,O
some,O
fatal,AdverseReaction
cases,O
Rare,O
cases,O
of,O
opportunistic infections,AdverseReaction
have,O
also,O
been,O
reported,O
in,O
these,O
clinical,O
trials,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Malignancies,O
In,O
clinical,O
studies,O
of,O
CIMZIA,O
the,O
overall,O
incidence,O
rate,O
of,O
malignancies,AdverseReaction
was,O
similar,O
for,O
CIMZIA,O
treated,O
and,O
control,O
patients,O
For,O
some,O
TNF,O
blockers,O
more,O
cases,O
of,O
malignancies,AdverseReaction
have,O
been,O
observed,O
among,O
patients,O
receiving,O
those,O
TNF blockers,DrugClass
compared,O
to,O
control,O
patients,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Heart,O
Failure,O
In,O
placebo,O
controlled,O
and,O
open,O
label,O
rheumatoid,O
arthritis,O
studies,O
cases,O
of,O
new,AdverseReaction
or,O
worsening heart failure failure,AdverseReaction
have,O
been,O
reported,O
for,O
CIMZIA,O
treated,O
patients,O
The,O
majority,O
of,O
these,O
cases,O
were,O
mild,O
to,O
moderate,O
and,O
occurred,O
during,O
the,O
first,O
year,O
of,O
exposure,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Autoantibodies,O
In,O
clinical,O
studies,O
in,O
Crohn,O
s,O
disease,O
4,O
of,O
patients,O
treated,O
with,O
CIMZIA,O
and,O
2,O
of,O
patients,O
treated,O
with,O
placebo,O
that,O
had,O
negative,O
baseline,O
ANA titers,AdverseReaction
developed,O
positive,AdverseReaction
titers,O
during,O
the,O
studies,O
One,O
of,O
the,O
1,O
564,O
Crohn,O
s,O
disease,O
patients,O
treated,O
with,O
CIMZIA,O
developed,O
symptoms,O
of,O
a,O
lupus like syndrome,AdverseReaction
In,O
clinical,O
trials,O
of,O
TNF,O
blockers,O
including,O
CIMZIA,O
in,O
patients,O
with,O
RA,O
some,O
patients,O
have,O
developed,O
ANA,AdverseReaction
Four,O
patients,O
out,O
of,O
2,O
367,O
patients,O
treated,O
with,O
CIMZIA,O
in,O
RA,O
clinical,O
studies,O
developed,O
clinical,O
signs,O
suggestive,O
of,O
a,O
lupus like syndrome,AdverseReaction
The,O
impact,O
of,O
long,O
term,O
treatment,O
with,O
CIMZIA,O
on,O
the,O
development,O
of,O
autoimmune,O
diseases,O
is,O
unknown,O
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
Immunogenicity,O
Patients,O
were,O
tested,O
at,O
multiple,O
time,O
points,O
for,O
antibodies,O
to,O
certolizumab,O
pegol,O
during,O
Studies,O
CD1,O
and,O
CD2,O
The,O
overall,O
percentage,O
of,O
antibody,O
positive,O
patients,O
was,O
8,O
in,O
patients,O
continuously,O
exposed,O
to,O
CIMZIA,O
approximately,O
6,O
were,O
neutralizing,O
in,O
vitro,O
No,O
apparent,O
correlation,O
of,O
antibody,O
development,O
to,O
adverse,O
events,O
or,O
efficacy,O
was,O
observed,O
Patients,O
treated,O
with,O
concomitant,O
immunosuppressants,O
had,O
a,O
lower,O
rate,O
of,O
antibody,O
development,O
than,O
patients,O
not,O
taking,O
immunosuppressants,O
at,O
baseline,O
3,O
and,O
11,O
respectively,O
The,O
following,O
adverse,O
events,O
were,O
reported,O
in,O
Crohn,O
s,O
disease,O
patients,O
who,O
were,O
antibody,O
positive,O
N,O
100,O
at,O
an,O
incidence,O
at,O
least,O
3,O
higher,O
compared,O
to,O
antibody,O
negative,O
patients,O
N,O
1,O
242,O
abdominal pain,AdverseReaction
arthralgia,AdverseReaction
edema peripheral,AdverseReaction
erythema nodosum,AdverseReaction
injection site erythema,AdverseReaction
injection site pain,AdverseReaction
pain in extremity,AdverseReaction
and,O
upper respiratory tract infection,AdverseReaction
The,O
overall,O
percentage,O
of,O
patients,O
with,O
antibodies,O
to,O
certolizumab,O
pegol,O
detectable,O
on,O
at,O
least,O
one,O
occasion,O
was,O
7,O
105,O
of,O
1,O
509,O
in,O
the,O
rheumatoid,O
arthritis,O
placebo,O
controlled,O
trials,O
Approximately,O
one,O
third,O
3,O
39,O
of,O
1,O
509,O
of,O
these,O
patients,O
had,O
antibodies,O
with,O
neutralizing,O
activity,O
in,O
vitro,O
Patients,O
treated,O
with,O
concomitant,O
immunosuppressants,O
MTX,O
had,O
a,O
lower,O
rate,O
of,O
antibody,O
development,O
than,O
patients,O
not,O
taking,O
immunosuppressants,O
at,O
baseline,O
Patients,O
treated,O
with,O
concomitant,O
immunosuppressant,O
therapy,O
MTX,O
in,O
RA,O
I,O
RA,O
II,O
RA,O
III,O
had,O
a,O
lower,O
rate,O
of,O
neutralizing,O
antibody,O
formation,O
overall,O
than,O
patients,O
treated,O
with,O
CIMZIA,O
monotherapy,O
in,O
RA,O
IV,O
2,O
vs,O
8,O
Both,O
the,O
loading,O
dose,O
of,O
400,O
mg,O
every,O
other,O
week,O
at,O
Weeks,O
0,O
2,O
and,O
4,O
and,O
concomitant,O
use,O
of,O
MTX,O
were,O
associated,O
with,O
reduced,O
immunogenicity,O
Antibody,O
formation,O
was,O
associated,O
with,O
lowered,O
drug,O
plasma,O
concentration,O
and,O
reduced,O
efficacy,O
In,O
patients,O
receiving,O
the,O
recommended,O
CIMZIA,O
dosage,O
of,O
200,O
mg,O
every,O
other,O
week,O
with,O
concomitant,O
MTX,O
the,O
ACR20,O
response,O
was,O
lower,O
among,O
antibody,O
positive,O
patients,O
than,O
among,O
antibody,O
negative,O
patients,O
Study,O
RA,O
I,O
48,O
versus,O
60,O
Study,O
RA,O
II,O
35,O
versus,O
59,O
respectively,O
In,O
Study,O
RA,O
III,O
too,O
few,O
patients,O
developed,O
antibodies,O
to,O
allow,O
for,O
meaningful,O
analysis,O
of,O
ACR20,O
response,O
by,O
antibody,O
status,O
In,O
Study,O
RA,O
IV,O
monotherapy,O
the,O
ACR20,O
response,O
was,O
33,O
versus,O
56,O
antibody,O
positive,O
versus,O
antibody,O
negative,O
status,O
respectively,O
see,O
Clinical,O
Pharmacology,O
12,O
3,O
No,O
association,O
was,O
seen,O
between,O
antibody,O
development,O
and,O
the,O
development,O
of,O
adverse,O
events,O
The,O
data,O
reflect,O
the,O
percentage,O
of,O
patients,O
whose,O
test,O
results,O
were,O
considered,O
positive,O
for,O
antibodies,O
to,O
certolizumab,O
pegol,O
in,O
an,O
ELISA,O
and,O
are,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
The,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
is,O
highly,O
dependent,O
on,O
several,O
factors,O
including,O
assay,O
sensitivity,O
and,O
specificity,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
certolizumab,O
pegol,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
Hypersensitivity,O
Reactions,O
The,O
following,O
symptoms,O
that,O
could,O
be,O
compatible,O
with,O
hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
rarely,O
following,O
CIMZIA,O
administration,O
to,O
patients,O
angioedema,AdverseReaction
dermatitis allergic,AdverseReaction
dizziness,AdverseReaction
postural,AdverseReaction
dyspnea,AdverseReaction
hot flush,AdverseReaction
hypotension,AdverseReaction
injection site reactions,AdverseReaction
malaise,AdverseReaction
pyrexia,AdverseReaction
rash,AdverseReaction
serum sickness,AdverseReaction
and,O
vasovagal,AdverseReaction
syncope,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
CIMZIA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
estimate,O
reliably,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Vascular,O
disorder,O
systemic vasculitis,AdverseReaction
has,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
TNF blockers,DrugClass
Skin,O
case,O
of,O
severe,Severity
skin reactions,AdverseReaction
including,O
Stevens Johnson syndrome,AdverseReaction
toxic epidermal necrolysis,AdverseReaction
erythema multiforme,AdverseReaction
and,O
new,O
or,O
worsening,O
psoriasis,AdverseReaction
all,O
sub,O
types,O
including,O
pustular,AdverseReaction
and,O
palmoplantar,AdverseReaction
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
TNF blockers,DrugClass
Immune,O
System,O
Disorders,O
sarcoidosis,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Maintain,O
aseptic,O
technique,O
Discard,O
unused,O
portion,O
12,O
hours,O
after,O
stopper,O
puncture,O
5,O
1,O
Hypotension,AdverseReaction
and,O
reflex tachycardia,AdverseReaction
are,O
potential,Factor
consequences,O
of,O
rapid,O
upward,O
titration,O
of,O
Cleviprex,O
5,O
2,O
Dihydropyridine calcium channel blockers,DrugClass
can,O
produce,O
negative inotropic effects,AdverseReaction
and,O
exacerbate heart failure,AdverseReaction
Monitor,O
heart,O
failure,O
patients,O
carefully,O
5,O
4,O
Cleviprex,O
gives,O
no,O
protection,O
against,O
the,O
effects,O
of,O
abrupt,O
beta,O
blocker,O
withdrawal,O
5,O
5,O
Patients,O
who,O
receive,O
prolonged,O
Cleviprex,O
infusions,O
and,O
are,O
not,O
transitioned,O
to,O
other,O
antihypertensive,O
therapies,O
should,O
be,O
monitored,O
for,O
the,O
possibility,O
of,O
rebound,O
hypertension,O
for,O
at,O
least,O
8,O
hours,O
after,O
the,O
infusion,O
is,O
stopped,O
5,O
6,O
5,O
1,O
Need,O
for,O
Aseptic,O
Technique,O
Use,O
aseptic,O
technique,O
and,O
discard,O
any,O
unused,O
product,O
within,O
12,O
hours,O
of,O
stopper,O
puncture,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
2,O
Hypotension,O
and,O
Reflex,O
Tachycardia,O
Cleviprex,O
may,Factor
produce,O
systemic hypotension,AdverseReaction
and,O
reflex tachycardia,AdverseReaction
If,O
either,O
occurs,O
decrease,O
the,O
dose,O
of,O
Cleviprex,O
There,O
is,O
limited,O
experience,O
with,O
short,O
duration,O
therapy,O
with,O
beta,O
blockers,O
as,O
a,O
treatment,O
for,O
Cleviprex,O
induced,O
tachycardia,O
Beta,O
blocker,O
use,O
for,O
this,O
purpose,O
is,O
not,O
recommended,O
5,O
3,O
Lipid,O
Intake,O
Cleviprex,O
contains,O
approximately,O
0,O
2,O
g,O
of,O
lipid,O
per,O
mL,O
2,O
0,O
kcal,O
Lipid,O
intake,O
restrictions,O
may,O
be,O
necessary,O
for,O
patients,O
with,O
significant,O
disorders,O
of,O
lipid,O
metabolism,O
For,O
these,O
patients,O
a,O
reduction,O
in,O
the,O
quantity,O
of,O
concurrently,O
administered,O
lipids,O
may,O
be,O
necessary,O
to,O
compensate,O
for,O
the,O
amount,O
of,O
lipid,O
infused,O
as,O
part,O
of,O
the,O
Cleviprex,O
formulation,O
5,O
4,O
Negative,O
Inotropy,O
Dihydropyridine calcium channel blockers,DrugClass
can,O
produce,O
negative inotropic effects,AdverseReaction
and,O
exacerbate heart failure,AdverseReaction
Monitor,O
heart,O
failure,O
patients,O
carefully,O
5,O
5,O
Beta,O
Blocker,O
Withdrawal,O
Cleviprex,O
is,O
not,O
a,O
beta,O
blocker,O
does,O
not,O
reduce,O
heart,O
rate,O
and,O
gives,O
no,O
protection,O
against,O
the,O
effects,O
of,O
abrupt,O
beta,O
blocker,O
withdrawal,O
Beta,O
blockers,O
should,O
be,O
withdrawn,O
only,O
after,O
a,O
gradual,O
reduction,O
in,O
dose,O
5,O
6,O
Rebound,O
Hypertension,O
Patients,O
who,O
receive,O
prolonged,O
Cleviprex,O
infusions,O
and,O
are,O
not,O
transitioned,O
to,O
other,O
antihypertensive,O
therapies,O
should,O
be,O
monitored,O
for,O
the,O
possibility,O
of,O
rebound,O
hypertension,O
for,O
at,O
least,O
8,O
hours,O
after,O
the,O
infusion,O
is,O
stopped,O
5,O
7,O
Pheochromocytoma,O
There,O
is,O
no,O
information,O
to,O
guide,O
use,O
of,O
Cleviprex,O
in,O
treating,O
hypertension,O
associated,O
with,O
pheochromocytoma,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
risk,O
is,O
discussed,O
elsewhere,O
in,O
the,O
labeling,O
Hypotension,AdverseReaction
and,O
Reflex Tachycardia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
2,O
are,O
headache,AdverseReaction
nausea,AdverseReaction
and,O
vomiting,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
The,O
Medicines,O
Company,O
at,O
1,O
888,O
977,O
MDCO,O
6326,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Cleviprex,O
clinical,O
development,O
included,O
19,O
studies,O
with,O
99,O
healthy,O
subjects,O
and,O
1307,O
hypertensive,O
patients,O
who,O
received,O
at,O
least,O
one,O
dose,O
of,O
clevidipine,O
1406,O
total,O
exposures,O
Clevidipine,O
was,O
evaluated,O
in,O
15,O
studies,O
in,O
hypertensive,O
patients,O
1099,O
patients,O
with,O
perioperative,O
hypertension,O
126,O
with,O
severe,O
hypertension,O
and,O
82,O
patients,O
with,O
essential,O
hypertension,O
The,O
desired,O
therapeutic,O
response,O
was,O
achieved,O
at,O
doses,O
of,O
4,O
6,O
mg,O
hour,O
Cleviprex,O
was,O
infused,O
for,O
24,O
hours,O
in,O
the,O
majority,O
of,O
patients,O
n,O
1199,O
it,O
was,O
infused,O
as,O
a,O
continuous,O
infusion,O
in,O
an,O
additional,O
93,O
patients,O
for,O
durations,O
between,O
24,O
and,O
72,O
hours,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Perioperative,O
Hypertension,O
The,O
placebo,O
controlled,O
experience,O
with,O
Cleviprex,O
in,O
the,O
perioperative,O
setting,O
was,O
both,O
small,O
and,O
brief,O
about,O
30,O
minutes,O
Table,O
2,O
shows,O
treatment,O
emergent,O
adverse,O
reactions,O
and,O
the,O
category,O
of,O
any,O
common,O
adverse,O
event,O
in,O
ESCAPE,O
1,O
and,O
ESCAPE,O
2,O
where,O
the,O
rate,O
on,O
Cleviprex,O
exceeded,O
the,O
rate,O
on,O
placebo,O
by,O
at,O
least,O
5,O
common,O
adverse,O
reactions,O
Table,O
2,O
Common,O
adverse,O
reactions,O
in,O
placebo,O
controlled,O
perioperative,O
studies,O
ESCAPE,O
1,O
ESCAPE,O
2,O
CLVN,O
53,O
PBON,O
51,O
CLVN,O
61,O
PBON,O
49,O
Any,O
common,O
adverse,O
event,O
27,O
51,O
21,O
41,O
32,O
53,O
24,O
49,O
Acute renal failure,AdverseReaction
5,O
9,O
1,O
2,O
Atrial fibrillation,AdverseReaction
13,O
21,O
6,O
12,O
Nausea,AdverseReaction
13,O
21,O
6,O
12,O
Three,O
randomized,O
parallel,O
open,O
label,O
studies,O
called,O
ECLIPSE,O
with,O
longer,O
exposure,O
in,O
cardiac,O
surgery,O
patients,O
define,O
the,O
adverse,O
reactions,O
for,O
patients,O
with,O
perioperative,O
hypertension,O
Each,O
ECLIPSE,O
study,O
compared,O
Cleviprex,O
n,O
752,O
to,O
an,O
active,O
comparator,O
nitroglycerin,O
NTG,O
n,O
278,O
sodium,O
nitroprusside,O
SNP,O
n,O
283,O
or,O
nicardipine,O
NIC,O
n,O
193,O
The,O
pooled,O
mean,O
maximum,O
dose,O
in,O
these,O
studies,O
was,O
10,O
mg,O
hour,O
and,O
the,O
mean,O
duration,O
of,O
treatment,O
was,O
8,O
hours,O
There,O
were,O
many,O
adverse,O
events,O
associated,O
with,O
the,O
operative,O
procedure,O
in,O
the,O
clinical,O
studies,O
of,O
Cleviprex,O
and,O
relatively,O
few,O
plausibly,O
related,O
to,O
the,O
drugs,O
used,O
to,O
lower,O
blood,O
pressure,O
Thus,O
the,O
ability,O
to,O
differentiate,O
the,O
adverse,O
event,O
profile,O
between,O
treatments,O
is,O
limited,O
The,O
adverse,O
events,O
observed,O
within,O
one,O
hour,O
of,O
the,O
end,O
of,O
the,O
infusion,O
were,O
similar,O
in,O
patients,O
who,O
received,O
Cleviprex,O
and,O
in,O
those,O
who,O
received,O
comparator,O
agents,O
There,O
was,O
no,O
adverse,O
reaction,O
that,O
was,O
more,O
than,O
2,O
more,O
common,O
on,O
Cleviprex,O
than,O
on,O
the,O
average,O
of,O
all,O
comparators,O
Serious,O
Adverse,O
Events,O
and,O
Discontinuation,O
Perioperative,O
Hypertension,O
Studies,O
The,O
incidence,O
of,O
adverse,O
events,O
leading,O
to,O
study,O
drug,O
discontinuation,O
in,O
patients,O
with,O
perioperative,O
hypertension,O
receiving,O
Cleviprex,O
was,O
5,O
9,O
versus,O
3,O
2,O
for,O
all,O
active,O
comparators,O
For,O
patients,O
receiving,O
Cleviprex,O
and,O
all,O
active,O
comparators,O
the,O
incidence,O
of,O
serious,O
adverse,O
events,O
within,O
one,O
hour,O
of,O
drug,O
infusion,O
discontinuation,O
was,O
similar,O
Severe,O
Hypertension,O
The,O
adverse,O
events,O
for,O
patients,O
with,O
severe,O
hypertension,O
are,O
based,O
on,O
an,O
uncontrolled,O
study,O
in,O
patients,O
with,O
severe,O
hypertension,O
VELOCITY,O
n,O
126,O
The,O
common,O
adverse,O
reactions,O
for,O
Cleviprex,O
in,O
severe,O
hypertension,O
included,O
headache,AdverseReaction
6,O
3,O
nausea,AdverseReaction
4,O
8,O
and,O
vomiting,AdverseReaction
3,O
2,O
The,O
incidence,O
of,O
adverse,O
events,O
leading,O
to,O
study,O
drug,O
discontinuation,O
for,O
Cleviprex,O
in,O
severe,O
hypertension,O
was,O
4,O
8,O
Less,O
Common,O
Adverse,O
Reactions,O
in,O
Patients,O
with,O
Severe,O
or,O
Essential,O
Hypertension,O
Adverse,O
reactions,O
that,O
were,O
reported,O
in,O
1,O
of,O
patients,O
with,O
severe,O
or,O
essential,O
hypertension,O
included,O
Cardiac,O
myocardial infarction,AdverseReaction
cardiac,O
arrestNervous,O
system,O
syncopeRespiratory,O
dyspnea,AdverseReaction
6,O
2,O
Post,O
Marketing,O
and,O
Other,O
Clinical,O
Experience,O
Because,O
adverse,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
estimate,O
reliably,O
their,O
frequency,O
or,O
to,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
Cleviprex,O
increased blood triglycerides,AdverseReaction
ileus,AdverseReaction
hypersensitivity,AdverseReaction
hypotension,AdverseReaction
nausea,AdverseReaction
decreased oxygen saturation,AdverseReaction
possible,Factor
pulmonary shunting,AdverseReaction
and,O
reflex tachycardia,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Avoid,O
use,O
in,O
patients,O
with,O
known,O
QT,O
prolongation,O
those,O
with,O
hypokalemia,O
or,O
hypomagnesemia,O
and,O
those,O
taking,O
other,O
drugs,O
that,O
prolong,O
the,O
QT,O
interval,O
5,O
1,O
12,O
6,O
Halofantrine,O
and,O
Coartem,O
Tablets,O
should,O
not,O
be,O
administered,O
within,O
one,O
month,O
of,O
each,O
other,O
due,O
to,O
potential,O
additive,O
effects,O
on,O
the,O
QT,O
interval,O
5,O
1,O
5,O
2,O
12,O
3,O
Antimalarials,O
should,O
not,O
be,O
given,O
concomitantly,O
unless,O
there,O
is,O
no,O
other,O
treatment,O
option,O
due,O
to,O
limited,O
safety,O
data,O
5,O
2,O
QT,O
prolonging,O
drugs,O
including,O
quinine,O
and,O
quinidine,O
should,O
be,O
used,O
cautiously,O
following,O
Coartem,O
Tablets,O
5,O
1,O
5,O
2,O
7,O
7,O
12,O
3,O
Substrates,O
inhibitors,O
or,O
inducers,O
of,O
CYP3A4,O
including,O
antiretroviral,O
medications,O
should,O
be,O
used,O
cautiously,O
with,O
Coartem,O
Tablets,O
due,O
to,O
a,O
potential,O
loss,O
of,O
efficacy,O
of,O
the,O
concomitant,O
drug,O
or,O
additive,O
QT,O
prolongation,O
5,O
3,O
7,O
2,O
7,O
3,O
5,O
1,O
Prolongation,O
of,O
the,O
QT,O
Interval,O
Some,O
antimalarials,O
e,O
g,O
halofantrine,O
quinine,O
quinidine,O
including,O
Coartem,O
Tablets,O
have,O
been,O
associated,O
with,O
prolongation of the QT interval,AdverseReaction
on,O
the,O
electrocardiogram,O
Coartem,O
Tablets,O
should,O
be,O
avoided,O
in,O
patients,O
with,O
congenital,O
prolongation,O
of,O
the,O
QT,O
interval,O
e,O
g,O
long,O
QT,O
syndrome,O
or,O
any,O
other,O
clinical,O
condition,O
known,O
to,O
prolong,O
the,O
QTc,O
interval,O
such,O
as,O
patients,O
with,O
a,O
history,O
of,O
symptomatic,O
cardiac,O
arrhythmias,O
with,O
clinically,O
relevant,O
bradycardia,O
or,O
with,O
severe,O
cardiac,O
disease,O
with,O
a,O
family,O
history,O
of,O
congenital,O
prolongation,O
of,O
the,O
QT,O
interval,O
or,O
sudden,O
death,O
with,O
known,O
disturbances,O
of,O
electrolyte,O
balance,O
e,O
g,O
hypokalemia,O
or,O
hypomagnesemia,O
receiving,O
other,O
medications,O
that,O
prolong,O
the,O
QT,O
interval,O
such,O
as,O
class,O
IA,O
quinidine,O
procainamide,O
disopyramide,O
or,O
class,O
III,O
amiodarone,O
sotalol,O
antiarrhythmic,O
agents,O
antipsychotics,O
pimozide,O
ziprasidone,O
antidepressants,O
certain,O
antibiotics,O
macrolide,O
antibiotics,O
fluoroquinolone,O
antibiotics,O
imidazole,O
and,O
triazole,O
antifungal,O
agents,O
see,O
Clinical,O
Pharmacology,O
12,O
6,O
receiving,O
medications,O
that,O
are,O
metabolized,O
by,O
the,O
cytochrome,O
enzyme,O
CYP2D6,O
which,O
also,O
have,O
cardiac,O
effects,O
e,O
g,O
flecainide,O
imipramine,O
amitriptyline,O
clomipramine,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Drug,O
Interactions,O
7,O
6,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
2,O
Use,O
of,O
QT,O
Prolonging,O
Drugs,O
and,O
Other,O
Antimalarials,O
Halofantrine,O
and,O
Coartem,O
Tablets,O
should,O
not,O
be,O
administered,O
within,O
1,O
month,O
of,O
each,O
other,O
due,O
to,O
the,O
long,O
elimination,O
half,O
life,O
of,O
lumefantrine,O
3,O
to,O
6,O
days,O
and,O
potential,O
additive,O
effects,O
on,O
the,O
QT,O
interval,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
Antimalarials,O
should,O
not,O
be,O
given,O
concomitantly,O
with,O
Coartem,O
Tablets,O
unless,O
there,O
is,O
no,O
other,O
treatment,O
option,O
due,O
to,O
limited,O
safety,O
data,O
Drugs,O
that,O
prolong,O
the,O
QT,O
interval,O
including,O
antimalarials,O
such,O
as,O
quinine,O
and,O
quinidine,O
should,O
be,O
used,O
cautiously,O
following,O
Coartem,O
Tablets,O
due,O
to,O
the,O
long,O
elimination,O
half,O
life,O
of,O
lumefantrine,O
3,O
to,O
6,O
days,O
and,O
the,O
potential,O
for,O
additive,O
effects,O
on,O
the,O
QT,O
interval,O
ECG,O
monitoring,O
is,O
advised,O
if,O
use,O
of,O
drugs,O
that,O
prolong,O
the,O
QT,O
interval,O
is,O
medically,O
required,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Drug,O
Interactions,O
7,O
7,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
If,O
mefloquine,O
is,O
administered,O
immediately,O
prior,O
to,O
Coartem,O
Tablets,O
there,O
may,O
be,O
a,O
decreased,O
exposure,O
to,O
lumefantrine,O
possibly,O
due,O
to,O
a,O
mefloquine,O
induced,O
decrease,O
in,O
bile,O
production,O
Therefore,O
patients,O
should,O
be,O
monitored,O
for,O
decreased,O
efficacy,O
and,O
food,O
consumption,O
should,O
be,O
encouraged,O
while,O
taking,O
Coartem,O
Tablets,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
Drug,O
Interactions,O
7,O
4,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
3,O
Drug,O
Interactions,O
with,O
CYP3A4,O
When,O
Coartem,O
Tablets,O
are,O
coadministered,O
with,O
substrates,O
of,O
CYP3A4,O
it,O
may,O
result,O
in,O
decreased,O
concentrations,O
of,O
the,O
substrate,O
and,O
potential,O
loss,O
of,O
substrate,O
efficacy,O
When,O
Coartem,O
Tablets,O
are,O
coadministered,O
with,O
an,O
inhibitor,O
of,O
CYP3A4,O
including,O
grapefruit,O
juice,O
it,O
may,Factor
result,O
in,O
increased,O
concentrations,O
of,O
artemether,O
and,O
or,O
lumefantrine,O
and,O
potentiate,O
QT prolongation,AdverseReaction
When,O
Coartem,O
Tablets,O
are,O
coadministered,O
with,O
inducers,O
of,O
CYP3A4,O
it,O
may,O
result,O
in,O
decreased,O
concentrations,O
of,O
artemether,O
and,O
or,O
lumefantrine,O
and,O
loss,O
of,O
antimalarial,O
efficacy,O
see,O
Contraindications,O
4,O
and,O
Drug,O
Interactions,O
7,O
Drugs,O
that,O
have,O
a,O
mixed,O
effect,O
on,O
CYP3A4,O
especially,O
antiretroviral,O
drugs,O
such,O
as,O
HIV,O
protease,O
inhibitors,O
and,O
non,O
nucleoside,O
reverse,O
transcriptase,O
inhibitors,O
and,O
those,O
that,O
have,O
an,O
effect,O
on,O
the,O
QT,O
interval,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
taking,O
Coartem,O
Tablets,O
see,O
Drug,O
Interactions,O
7,O
3,O
7,O
7,O
Coartem,O
Tablets,O
may,O
reduce,O
the,O
effectiveness,O
of,O
hormonal,O
contraceptives,O
Therefore,O
patients,O
using,O
oral,O
transdermal,O
patch,O
or,O
other,O
systemic,O
hormonal,O
contraceptives,O
should,O
be,O
advised,O
to,O
use,O
an,O
additional,O
non,O
hormonal,O
method,O
of,O
birth,O
control,O
see,O
Drug,O
Interactions,O
7,O
5,O
5,O
4,O
Drug,O
Interactions,O
with,O
CYP2D6,O
Administration,O
of,O
Coartem,O
Tablets,O
with,O
drugs,O
that,O
are,O
metabolized,O
by,O
CYP2D6,O
may,O
significantly,O
increase,O
plasma,O
concentrations,O
of,O
the,O
coadministered,O
drug,O
and,O
increase,O
the,O
risk,O
of,O
adverse,O
effects,O
Many,O
of,O
the,O
drugs,O
metabolized,O
by,O
CYP2D6,O
can,O
prolong,O
the,O
QT,O
interval,O
and,O
should,O
not,O
be,O
administered,O
with,O
Coartem,O
Tablets,O
due,O
to,O
the,O
potential,O
additive,O
effect,O
on,O
the,O
QT,O
interval,O
e,O
g,O
flecainide,O
imipramine,O
amitriptyline,O
clomipramine,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Drug,O
Interactions,O
7,O
6,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
5,O
Recrudescence,O
Food,O
enhances,O
absorption,O
of,O
artemether,O
and,O
lumefantrine,O
following,O
administration,O
of,O
Coartem,O
Tablets,O
Patients,O
who,O
remain,O
averse,O
to,O
food,O
during,O
treatment,O
should,O
be,O
closely,O
monitored,O
as,O
the,O
risk,O
of,O
recrudescence,O
may,O
be,O
greater,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
In,O
the,O
event,O
of,O
recrudescent,O
P,O
falciparum,O
infection,O
after,O
treatment,O
with,O
Coartem,O
Tablets,O
patients,O
should,O
be,O
treated,O
with,O
a,O
different,O
antimalarial,O
drug,O
5,O
6,O
Hepatic,O
and,O
Renal,O
Impairment,O
Coartem,O
Tablets,O
have,O
not,O
been,O
studied,O
for,O
efficacy,O
and,O
safety,O
in,O
patients,O
with,O
severe,O
hepatic,O
and,O
or,O
renal,O
impairment,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
5,O
7,O
Plasmodium,O
vivax,O
Infection,O
Coartem,O
Tablets,O
have,O
been,O
shown,O
in,O
limited,O
data,O
43,O
patients,O
to,O
be,O
effective,O
in,O
treating,O
the,O
erythrocytic,O
stage,O
of,O
P,O
vivax,O
infection,O
However,O
relapsing,O
malaria,O
caused,O
by,O
P,O
vivax,O
requires,O
additional,O
treatment,O
with,O
other,O
antimalarial,O
agents,O
to,O
achieve,O
radical,O
cure,O
i,O
e,O
eradicate,O
any,O
hypnozoites,O
forms,O
that,O
may,O
remain,O
dormant,O
in,O
the,O
liver,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
in,O
adults,O
30,O
are,O
headache,AdverseReaction
anorexia,AdverseReaction
dizziness,AdverseReaction
asthenia,AdverseReaction
arthralgia,AdverseReaction
and,O
myalgia,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
in,O
children,O
12,O
are,O
pyrexia,AdverseReaction
cough,AdverseReaction
vomiting,AdverseReaction
anorexia,AdverseReaction
and,O
headache,AdverseReaction
6,O
2,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Novartis,O
Pharmaceuticals,O
Corporation,O
at,O
1,O
888,O
669,O
6682,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Serious,O
Adverse,O
Reactions,O
The,O
following,O
serious,O
and,O
otherwise,O
important,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
labeling,O
Hypersensitivity Reactions,AdverseReaction
see,O
Contraindications,O
4,O
and,O
Adverse,O
Reactions,O
6,O
3,O
6,O
2,O
Clinical,O
Studies,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rate,O
observed,O
in,O
practice,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
a,O
6,O
dose,O
regimen,O
of,O
Coartem,O
Tablets,O
in,O
1,O
979,O
patients,O
including,O
647,O
adults,O
older,O
than,O
16,O
years,O
and,O
1,O
332,O
children,O
16,O
years,O
and,O
younger,O
For,O
the,O
6,O
dose,O
regimen,O
Coartem,O
Tablets,O
was,O
studied,O
in,O
active,O
controlled,O
366,O
patients,O
and,O
non,O
controlled,O
open,O
label,O
trials,O
1,O
613,O
patients,O
The,O
6,O
dose,O
Coartem,O
Tablets,O
population,O
was,O
patients,O
with,O
malaria,O
between,O
ages,O
2,O
months,O
and,O
71,O
years,O
67,O
1,O
332,O
were,O
16,O
years,O
and,O
younger,O
and,O
33,O
647,O
were,O
older,O
than,O
16,O
years,O
Males,O
represented,O
73,O
and,O
53,O
of,O
the,O
adult,O
and,O
pediatric,O
populations,O
respectively,O
The,O
majority,O
of,O
adult,O
patients,O
were,O
enrolled,O
in,O
studies,O
in,O
Thailand,O
while,O
the,O
majority,O
of,O
pediatric,O
patients,O
were,O
enrolled,O
in,O
Africa,O
Tables,O
1,O
and,O
2,O
show,O
the,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
3,O
in,O
adults,O
and,O
children,O
respectively,O
who,O
received,O
the,O
6,O
dose,O
regimen,O
of,O
Coartem,O
Tablets,O
Adverse,O
reactions,O
collected,O
in,O
clinical,O
trials,O
included,O
signs,O
and,O
symptoms,O
at,O
baseline,O
but,O
only,O
treatment,O
emergent,O
adverse,O
events,O
defined,O
as,O
events,O
that,O
appeared,O
or,O
worsened,O
after,O
the,O
start,O
of,O
treatment,O
are,O
presented,O
below,O
In,O
adults,O
the,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
were,O
headache,AdverseReaction
anorexia,AdverseReaction
dizziness,AdverseReaction
and,O
asthenia,AdverseReaction
In,O
children,O
the,O
adverse,O
reactions,O
were,O
pyrexia,AdverseReaction
cough,AdverseReaction
vomiting,AdverseReaction
anorexia,AdverseReaction
and,O
headache,AdverseReaction
Most,O
adverse,O
reactions,O
were,O
mild,O
did,O
not,O
lead,O
to,O
discontinuation,O
of,O
study,O
medication,O
and,O
resolved,O
In,O
limited,O
comparative,O
studies,O
the,O
adverse,O
reaction,O
profile,O
of,O
Coartem,O
Tablets,O
appeared,O
similar,O
to,O
that,O
of,O
another,O
antimalarial,O
regimen,O
Discontinuation,O
of,O
Coartem,O
Tablets,O
due,O
to,O
adverse,O
drug,O
reactions,O
occurred,O
in,O
1,O
1,O
of,O
patients,O
treated,O
with,O
the,O
6,O
dose,O
regimen,O
overall,O
0,O
2,O
1,O
647,O
in,O
adults,O
and,O
1,O
6,O
21,O
1,O
332,O
in,O
children,O
Table,O
1,O
Adverse,O
Reactions,O
Occurring,O
in,O
3,O
or,O
More,O
of,O
Adult,O
Patients,O
Treated,O
in,O
Clinical,O
Trials,O
with,O
the,O
6,O
dose,O
Regimen,O
of,O
Coartem,O
Tablets,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
Adults,O
N,O
647,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
360,O
56,O
Dizziness,AdverseReaction
253,O
39,O
Metabolism,O
and,O
nutrition,O
disorders,O
Anorexia,AdverseReaction
260,O
40,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Asthenia,AdverseReaction
243,O
38,O
Pyrexia,AdverseReaction
159,O
25,O
Chills,AdverseReaction
147,O
23,O
Fatigue,AdverseReaction
111,O
17,O
Malaise,AdverseReaction
20,O
3,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
219,O
34,O
Myalgia,AdverseReaction
206,O
32,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
169,O
26,O
Vomiting,AdverseReaction
113,O
17,O
Abdominal pain,AdverseReaction
112,O
17,O
Diarrhea,AdverseReaction
46,O
7,O
Psychiatric,O
disorders,O
Sleep disorder,AdverseReaction
144,O
22,O
Insomnia,AdverseReaction
32,O
5,O
Cardiac,O
disorders,O
Palpitations,AdverseReaction
115,O
18,O
Hepatobiliary,O
disorders,O
Hepatomegaly,AdverseReaction
59,O
9,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Splenomegaly,AdverseReaction
57,O
9,O
Anemia,AdverseReaction
23,O
4,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
37,O
6,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Pruritus,AdverseReaction
24,O
4,O
Rash,AdverseReaction
21,O
3,O
Ear,O
and,O
labyrinth,O
disorders,O
Vertigo,AdverseReaction
21,O
3,O
Infections,O
and,O
infestations,O
Malaria,AdverseReaction
18,O
3,O
Nasopharyngitis,AdverseReaction
17,O
3,O
Adult,O
patients,O
defined,O
as,O
16,O
years,O
of,O
age,O
Table,O
2,O
Adverse,O
Reactions,O
Occurring,O
in,O
3,O
or,O
More,O
of,O
Pediatric,O
Patients,O
Treated,O
in,O
Clinical,O
Trials,O
with,O
the,O
6,O
dose,O
Regimen,O
of,O
Coartem,O
Tablets,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
Children,O
N,O
1,O
332,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Pyrexia,AdverseReaction
381,O
29,O
Chills,AdverseReaction
72,O
5,O
Asthenia,AdverseReaction
63,O
5,O
Fatigue,AdverseReaction
46,O
3,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
302,O
23,O
Gastrointestinal,O
disorders,O
Vomiting,AdverseReaction
242,O
18,O
Abdominal pain,AdverseReaction
112,O
8,O
Diarrhea,AdverseReaction
100,O
8,O
Nausea,AdverseReaction
61,O
5,O
Infections,O
and,O
infestations,O
Plasmodium falciparum infection,AdverseReaction
224,O
17,O
Rhinitis,AdverseReaction
51,O
4,O
Metabolism,O
and,O
nutrition,O
disorders,O
Anorexia,AdverseReaction
175,O
13,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
168,O
13,O
Dizziness,AdverseReaction
56,O
4,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Splenomegaly,AdverseReaction
124,O
9,O
Anemia,AdverseReaction
115,O
9,O
Hepatobiliary,O
disorders,O
Hepatomegaly,AdverseReaction
75,O
6,O
Investigations,O
Aspartate aminotransferase increased,AdverseReaction
51,O
4,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
39,O
3,O
Myalgia,AdverseReaction
39,O
3,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
38,O
3,O
Children,O
defined,O
as,O
patients,O
16,O
years,O
of,O
age,O
Clinically,O
significant,O
adverse,O
reactions,O
reported,O
in,O
adults,O
and,O
or,O
children,O
treated,O
with,O
the,O
6,O
dose,O
regimen,O
of,O
Coartem,O
Tablets,O
which,O
occurred,O
in,O
clinical,O
studies,O
at,O
3,O
regardless,O
of,O
causality,O
are,O
listed,O
below,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
eosinophilia,AdverseReaction
Ear,O
and,O
labyrinth,O
disorders,O
tinnitus,AdverseReaction
Eye,O
disorders,O
conjunctivitis,AdverseReaction
Gastrointestinal,O
disorders,O
constipation,AdverseReaction
dyspepsia,AdverseReaction
dysphagia,AdverseReaction
peptic ulcer,AdverseReaction
General,O
disorders,O
gait disturbance,AdverseReaction
Infections,O
and,O
infestations,O
abscess,AdverseReaction
acrodermatitis,AdverseReaction
bronchitis,AdverseReaction
ear infection,AdverseReaction
gastroenteritis,AdverseReaction
helminthic infection,AdverseReaction
hookworm infection,AdverseReaction
impetigo,AdverseReaction
influenza,AdverseReaction
lower respiratory tract infection,AdverseReaction
malaria,AdverseReaction
nasopharyngitis,AdverseReaction
oral herpes,AdverseReaction
pneumonia,AdverseReaction
respiratory tract infection,AdverseReaction
subcutaneous abscess,AdverseReaction
upper respiratory tract infection,AdverseReaction
urinary tract infection,AdverseReaction
Investigations,O
alanine aminotransferase increased,AdverseReaction
aspartate aminotransferase increased,AdverseReaction
hematocrit decreased,AdverseReaction
lymphocyte morphology abnormal,AdverseReaction
platelet count decreased,AdverseReaction
platelet count increased,AdverseReaction
white blood cell count decreased,AdverseReaction
white blood cell count increased,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorders,O
hypokalemia,AdverseReaction
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
back pain,AdverseReaction
Nervous,O
system,O
disorders,O
ataxia,AdverseReaction
clonus,AdverseReaction
fine motor delay,AdverseReaction
hyperreflexia,AdverseReaction
hypoesthesia,AdverseReaction
nystagmus,AdverseReaction
tremor,AdverseReaction
Psychiatric,O
disorders,O
agitation,AdverseReaction
mood swings,AdverseReaction
Renal,O
and,O
urinary,O
disorders,O
hematuria,AdverseReaction
proteinuria,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
asthma,AdverseReaction
pharyngo laryngeal pain,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
urticaria,AdverseReaction
6,O
3,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
Coartem,O
Tablets,O
Because,O
these,O
events,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Hypersensitivity,O
reactions,O
anaphylaxis,AdverseReaction
urticaria,AdverseReaction
angioedema,AdverseReaction
and,O
serious,Severity
skin reactions,AdverseReaction
bullous eruption,AdverseReaction
have,O
been,O
reported,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Thrombotic Events,AdverseReaction
Discontinue,O
COMETRIQ,O
for,O
myocardial,O
infarction,O
cerebral,O
infarction,O
or,O
other,O
serious,O
arterial,O
thromboembolic,O
events,O
5,O
3,O
Wound Complications,AdverseReaction
Withhold,O
COMETRIQ,O
for,O
dehiscence,O
or,O
complications,O
requiring,O
medical,O
intervention,O
5,O
4,O
Hypertension,AdverseReaction
Monitor,O
blood,O
pressure,O
regularly,O
Discontinue,O
COMETRIQ,O
for,O
hypertensive,O
crisis,O
5,O
5,O
Osteonecrosis of the jaw,AdverseReaction
Discontinue,O
COMETRIQ,O
5,O
6,O
Palmar plantar Erythrodysesthesia syndrome,AdverseReaction
PPES,AdverseReaction
Interrupt,O
COMETRIQ,O
decrease,O
dose,O
5,O
7,O
Proteinuria,AdverseReaction
Monitor,O
urine,O
protein,O
Discontinue,O
for,O
nephrotic,O
syndrome,O
5,O
8,O
Reversible posterior leukoencephalopathy syndrome,AdverseReaction
RPLS,AdverseReaction
Discontinue,O
COMETRIQ,O
5,O
9,O
Embryofetal toxicity,AdverseReaction
Can,Factor
cause,O
fetal harm,AdverseReaction
Advise,O
women,O
of,O
potential,O
risk,O
to,O
a,O
fetus,O
5,O
11,O
8,O
1,O
5,O
1,O
Perforations,O
and,O
Fistulas,O
Gastrointestinal,AdverseReaction
GI,AdverseReaction
perforations,AdverseReaction
and,O
fistulas,AdverseReaction
were,O
reported,O
in,O
3,O
and,O
1,O
of,O
COMETRIQ,O
treated,O
patients,O
respectively,O
All,O
were,O
serious,Severity
and,O
one,O
GI fistula,AdverseReaction
was,O
fatal,AdverseReaction
1,O
Non GI fistulas,AdverseReaction
fistulas,AdverseReaction
including,O
tracheal,AdverseReaction
esophageal,AdverseReaction
were,O
reported,O
in,O
4,O
of,O
COMETRIQ,O
treated,O
patients,O
Two,O
1,O
of,O
these,O
were,O
fatal,AdverseReaction
Monitor,O
patients,O
for,O
symptoms,O
of,O
perforations,O
and,O
fistulas,O
Discontinue,O
COMETRIQ,O
in,O
patients,O
who,O
experience,O
a,O
perforation,O
or,O
a,O
fistula,O
5,O
2,O
Hemorrhage,O
Serious,Severity
and,O
sometimes,O
fatal,AdverseReaction
hemorrhage,AdverseReaction
occurred,O
with,O
COMETRIQ,O
The,O
incidence,O
of,O
Grade,Severity
3,Severity
hemorrhagic events,AdverseReaction
was,O
higher,O
in,O
COMETRIQ,O
treated,O
patients,O
compared,O
with,O
placebo,O
3,O
vs,O
1,O
Do,O
not,O
administer,O
COMETRIQ,O
to,O
patients,O
with,O
a,O
recent,O
history,O
of,O
hemorrhage,O
or,O
hemoptysis,O
5,O
3,O
Thrombotic,O
Events,O
COMETRIQ,O
treatment,O
results,O
in,O
an,O
increased,O
incidence,O
of,O
thrombotic events,AdverseReaction
venous thromboembolism,AdverseReaction
6,O
vs,O
3,O
and,O
arterial thromboembolism,AdverseReaction
2,O
vs,O
0,O
in,O
COMETRIQ,O
treated,O
and,O
placebo,O
treated,O
patients,O
respectively,O
Discontinue,O
COMETRIQ,O
in,O
patients,O
who,O
develop,O
an,O
acute,O
myocardial,O
infarction,O
or,O
any,O
other,O
clinically,O
significant,O
arterial,O
thromboembolic,O
complication,O
5,O
4,O
Wound,O
Complications,O
Wound complications,AdverseReaction
have,O
been,O
reported,O
with,O
COMETRIQ,O
Stop,O
treatment,O
with,O
COMETRIQ,O
at,O
least,O
28,O
days,O
prior,O
to,O
scheduled,O
surgery,O
Resume,O
COMETRIQ,O
therapy,O
after,O
surgery,O
based,O
on,O
clinical,O
judgment,O
of,O
adequate,O
wound,O
healing,O
Withhold,O
COMETRIQ,O
in,O
patients,O
with,O
dehiscence,O
or,O
wound,O
healing,O
complications,O
requiring,O
medical,O
intervention,O
5,O
5,O
Hypertension,O
COMETRIQ,O
treatment,O
results,O
in,O
an,O
increased,O
incidence,O
of,O
treatment,O
emergent,O
hypertension,AdverseReaction
with,O
Joint,O
National,O
Committee,O
on,O
Prevention,O
Detection,O
Evaluation,O
and,O
Treatment,O
of,O
High,O
Blood,O
Pressure,O
modified,O
JNC,O
criteria,O
stage 1,Severity
or,O
2,Severity
hypertension,AdverseReaction
identified,O
in,O
61,O
in,O
COMETRIQ,O
treated,O
patients,O
compared,O
with,O
30,O
of,O
placebo,O
treated,O
patients,O
in,O
the,O
randomized,O
trial,O
Monitor,O
blood,O
pressure,O
prior,O
to,O
initiation,O
and,O
regularly,O
during,O
COMETRIQ,O
treatment,O
Withhold,O
COMETRIQ,O
for,O
hypertension,O
that,O
is,O
not,O
adequately,O
controlled,O
with,O
medical,O
management,O
when,O
controlled,O
resume,O
COMETRIQ,O
at,O
a,O
reduced,O
dose,O
Discontinue,O
COMETRIQ,O
for,O
severe,O
hypertension,O
that,O
cannot,O
be,O
controlled,O
with,O
anti,O
hypertensive,O
therapy,O
5,O
6,O
Osteonecrosis,O
of,O
the,O
Jaw,O
Osteonecrosis of the jaw,AdverseReaction
ONJ,AdverseReaction
occurred,O
in,O
1,O
of,O
COMETRIQ,O
treated,O
patients,O
ONJ,AdverseReaction
can,Factor
manifest,O
as,O
jaw pain,AdverseReaction
osteomyelitis,AdverseReaction
osteitis,AdverseReaction
bone erosion,AdverseReaction
tooth,AdverseReaction
or,O
periodontal infection,AdverseReaction
toothache,AdverseReaction
gingival ulceration,AdverseReaction
or,O
erosion,AdverseReaction
persistent jaw pain,AdverseReaction
or,O
slow healing of the mouth healing of the,AdverseReaction
or,O
jaw after dental surgery dental surgery,AdverseReaction
Perform,O
an,O
oral,O
examination,O
prior,O
to,O
initiation,O
of,O
COMETRIQ,O
and,O
periodically,O
during,O
COMETRIQ,O
therapy,O
Advise,O
patients,O
regarding,O
good,O
oral,O
hygiene,O
practices,O
For,O
invasive,O
dental,O
procedures,O
withhold,O
COMETRIQ,O
treatment,O
for,O
at,O
least,O
28,O
days,O
prior,O
to,O
scheduled,O
surgery,O
if,O
possible,O
5,O
7,O
Palmar,O
Plantar,O
Erythrodysesthesia,O
Syndrome,O
Palmar plantar erythrodysesthesia syndrome plantar erythrodysesthesia syndrome,AdverseReaction
PPES,AdverseReaction
occurred,O
in,O
50,O
of,O
patients,O
treated,O
with,O
COMETRIQ,O
and,O
was,O
severe,Severity
Grade 3,Severity
in,O
13,O
of,O
patients,O
Withhold,O
COMETRIQ,O
in,O
patients,O
who,O
develop,O
intolerable,O
Grade,O
2,O
PPES,O
or,O
Grade,O
3,O
4,O
PPES,O
until,O
improvement,O
to,O
Grade,O
1,O
resume,O
COMETRIQ,O
at,O
a,O
reduced,O
dose,O
5,O
8,O
Proteinuria,O
Proteinuria,AdverseReaction
was,O
observed,O
in,O
4,O
2,O
of,O
patients,O
receiving,O
COMETRIQ,O
including,O
one,O
with,O
nephrotic syndrome,AdverseReaction
as,O
compared,O
to,O
none,O
of,O
the,O
patients,O
receiving,O
placebo,O
Monitor,O
urine,O
protein,O
regularly,O
during,O
COMETRIQ,O
treatment,O
Discontinue,O
COMETRIQ,O
in,O
patients,O
who,O
develop,O
nephrotic,O
syndrome,O
5,O
9,O
Reversible,O
Posterior,O
Leukoencephalopathy,O
Syndrome,O
Reversible Posterior Leukoencephalopathy Syndrome,AdverseReaction
RPLS,AdverseReaction
a,O
syndrome,O
of,O
subcortical vasogenic edema,AdverseReaction
diagnosed,O
by,O
characteristic,O
finding,O
on,O
MRI,O
occurred,O
in,O
one,O
1,O
patient,O
Perform,O
an,O
evaluation,O
for,O
RPLS,O
in,O
any,O
patient,O
presenting,O
with,O
seizures,O
headache,O
visual,O
disturbances,O
confusion,O
or,O
altered,O
mental,O
function,O
Discontinue,O
COMETRIQ,O
in,O
patients,O
who,O
develop,O
RPLS,O
5,O
10,O
Drug,O
Interactions,O
Avoid,O
administration,O
of,O
COMETRIQ,O
with,O
agents,O
that,O
are,O
strong,O
CYP3A4,O
inducers,O
or,O
inhibitors,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
and,O
Drug,O
Interactions,O
7,O
1,O
7,O
2,O
5,O
11,O
Hepatic,O
Impairment,O
COMETRIQ,O
is,O
not,O
recommended,O
for,O
use,O
in,O
patients,O
with,O
moderate,O
or,O
severe,O
hepatic,O
impairment,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
5,O
12,O
Embryo,O
fetal,O
Toxicity,O
COMETRIQ,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Cabozantinib,O
was,O
embryolethal,AdverseReaction
in,O
rats,Animal
at,O
exposures,O
below,O
the,O
recommended,O
human,O
dose,O
with,O
increased,O
incidences,O
of,O
skeletal variations,AdverseReaction
in,O
rats,Animal
and,O
visceral variations,AdverseReaction
and,O
malformations,AdverseReaction
in,O
rabbits,Animal
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
See,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
BOXED,O
WARNING,O
WARNING,O
PERFORATIONS,AdverseReaction
AND,O
FISTULAS,AdverseReaction
and,O
HEMORRHAGE,AdverseReaction
WARNING,O
PERFORATIONS,AdverseReaction
AND,O
FISTULAS,AdverseReaction
and,O
HEMORRHAGE,AdverseReaction
Perforations,AdverseReaction
and,O
fistulas,AdverseReaction
Gastrointestinal perforations,AdverseReaction
occurred,O
in,O
3,O
and,O
fistula formation,AdverseReaction
in,O
1,O
of,O
COMETRIQTM,O
treated,O
patients,O
Discontinue,O
COMETRIQ,O
for,O
perforation,O
or,O
for,O
fistula,O
formation,O
See,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hemorrhage,AdverseReaction
Severe,Severity
sometimes,O
fatal,AdverseReaction
hemorrhage,AdverseReaction
including,O
hemoptysis,AdverseReaction
and,O
gastrointestinal hemorrhage,AdverseReaction
occurred,O
in,O
3,O
of,O
COMETRIQ,O
treated,O
patients,O
Monitor,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
bleeding,O
Do,O
not,O
administer,O
COMETRIQ,O
to,O
patients,O
with,O
severe,O
hemorrhage,O
See,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
WARNING,O
PERFORATIONS,AdverseReaction
AND,O
FISTULAS,AdverseReaction
andHEMORRHAGE,O
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Perforations,AdverseReaction
and,O
Fistulas,AdverseReaction
Gastrointestinal perforations,AdverseReaction
occurred,O
in,O
3,O
and,O
fistula formation,AdverseReaction
in,O
1,O
of,O
COMETRIQ,O
treated,O
patients,O
Discontinue,O
COMETRIQ,O
in,O
patients,O
with,O
perforation,O
or,O
fistula,O
5,O
1,O
Hemorrhage,AdverseReaction
Severe,Severity
sometimes,O
fatal,AdverseReaction
hemorrhage,AdverseReaction
including,O
hemoptysis,AdverseReaction
and,O
gastrointestinal hemorrhage,AdverseReaction
occurred,O
in,O
3,O
of,O
COMETRIQ,O
treated,O
patients,O
Monitor,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
bleeding,O
Do,O
not,O
administer,O
COMETRIQ,O
to,O
patients,O
with,O
severe,O
hemorrhage,O
5,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
elsewhere,O
in,O
the,O
label,O
Perforations,AdverseReaction
and,O
Fistula,AdverseReaction
see,O
Boxed,O
Warning,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hemorrhage,AdverseReaction
see,O
Boxed,O
Warning,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Thromboembolic Events,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Wound Complications,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Hypertension,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Osteonecrosis of the Jaw,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Palmar plantar erythrodysesthesia syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Proteinuria,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Reversible Posterior Leukoencephalopathy Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
EXCERPT,O
The,O
most,O
commonly,O
reported,O
adverse,O
drug,O
reactions,O
25,O
are,O
diarrhea,AdverseReaction
stomatitis,AdverseReaction
palmar plantar erythrodysesthesia syndrome,AdverseReaction
PPES,AdverseReaction
decreased weight,AdverseReaction
decreased appetite,AdverseReaction
nausea,AdverseReaction
fatigue,AdverseReaction
oral pain,AdverseReaction
hair color changes,AdverseReaction
dysgeusia,AdverseReaction
hypertension,AdverseReaction
abdominal pain,AdverseReaction
and,O
constipation,AdverseReaction
The,O
most,O
common,O
laboratory,O
abnormalities,O
25,O
are,O
increased AST,AdverseReaction
increased ALT,AdverseReaction
lymphopenia,AdverseReaction
increased alkaline phosphatase,AdverseReaction
hypocalcemia,AdverseReaction
neutropenia,AdverseReaction
thrombocytopenia,AdverseReaction
hypophosphatemia,AdverseReaction
and,O
hyperbilirubinemia,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Exelixis,O
Inc,O
at,O
1,O
855,O
500,O
3935,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
safety,O
of,O
COMETRIQ,O
was,O
evaluated,O
in,O
330,O
patients,O
with,O
progressive,O
metastatic,O
medullary,O
thyroid,O
cancer,O
randomized,O
to,O
receive,O
140,O
mg,O
COMETRIQ,O
n,O
214,O
or,O
placebo,O
n,O
109,O
administered,O
daily,O
until,O
disease,O
progression,O
or,O
intolerable,O
toxicity,O
in,O
a,O
randomized,O
doubleblind,O
controlled,O
trial,O
See,O
Clinical,O
Studies,O
14,O
The,O
data,O
described,O
below,O
reflect,O
a,O
median,O
exposure,O
to,O
COMETRIQ,O
for,O
204,O
days,O
The,O
population,O
exposed,O
to,O
COMETRIQ,O
was,O
70,O
male,O
90,O
white,O
and,O
had,O
a,O
median,O
age,O
of,O
55,O
years,O
Adverse,O
reactions,O
which,O
occurred,O
in,O
25,O
of,O
COMETRIQ,O
treated,O
patients,O
occurring,O
more,O
frequently,O
in,O
the,O
COMETRIQ,O
arm,O
with,O
a,O
between,O
arm,O
difference,O
of,O
5,O
included,O
in,O
order,O
of,O
decreasing,O
frequency,O
diarrhea,AdverseReaction
stomatitis,AdverseReaction
palmar plantar erythrodysesthesia syndrome,AdverseReaction
PPES,AdverseReaction
decreased weight,AdverseReaction
decreased appetite,AdverseReaction
nausea,AdverseReaction
fatigue,AdverseReaction
oral pain,AdverseReaction
hair color changes,AdverseReaction
dysgeusia,AdverseReaction
hypertension,AdverseReaction
abdominal pain,AdverseReaction
and,O
constipation,AdverseReaction
The,O
most,O
common,O
laboratory,O
abnormalities,O
25,O
were,O
increased AST,AdverseReaction
increased ALT,AdverseReaction
lymphopenia,AdverseReaction
increased ALP,AdverseReaction
hypocalcemia,AdverseReaction
neutropenia,AdverseReaction
thrombocytopenia,AdverseReaction
hypophosphatemia,AdverseReaction
and,O
hyperbilirubinemia,AdverseReaction
Grade 3 3 4,Severity
4,Severity
adverse,O
reactions,O
and,O
laboratory,O
abnormalities,O
which,O
occurred,O
in,O
5,O
of,O
COMETRIQ,O
treated,O
patients,O
occurring,O
more,O
frequently,O
in,O
the,O
COMETRIQ,O
arm,O
with,O
a,O
between,O
arm,O
difference,O
of,O
2,O
included,O
in,O
order,O
of,O
decreasing,O
frequency,O
diarrhea,AdverseReaction
PPES,AdverseReaction
lymphopenia,AdverseReaction
hypocalcemia,AdverseReaction
fatigue,AdverseReaction
hypertension,AdverseReaction
asthenia,AdverseReaction
increased ALT,AdverseReaction
decreased weight,AdverseReaction
stomatitis,AdverseReaction
and,O
decreased appetite,AdverseReaction
see,O
Table,O
1,O
Table,O
2,O
Fatal,AdverseReaction
adverse,O
reactions,O
occurred,O
in,O
6,O
of,O
patients,O
receiving,O
COMETRIQ,O
and,O
resulted,O
from,O
hemorrhage,AdverseReaction
pneumonia,AdverseReaction
septicemia,AdverseReaction
fistulas,AdverseReaction
cardiac arrest,AdverseReaction
respiratory failure,AdverseReaction
and,O
unspecified,O
death,AdverseReaction
Fatal,AdverseReaction
adverse,O
reactions,O
occurred,O
in,O
5,O
of,O
patients,O
receiving,O
placebo,Factor
and,O
resulted,O
from,O
septicemia,AdverseReaction
pneumonia,AdverseReaction
and,O
general deterioration,AdverseReaction
The,O
dose,O
was,O
reduced,O
in,O
79,O
of,O
patients,O
receiving,O
COMETRIQ,O
compared,O
to,O
9,O
of,O
patients,O
receiving,O
placebo,O
The,O
median,O
number,O
of,O
dosing,O
delays,O
was,O
one,O
in,O
patients,O
receiving,O
COMETRIQ,O
compared,O
to,O
none,O
in,O
patients,O
receiving,O
placebo,O
Adverse,O
reactions,O
led,O
to,O
study,O
treatment,O
discontinuation,O
in,O
16,O
of,O
patients,O
receiving,O
COMETRIQ,O
and,O
in,O
8,O
of,O
patients,O
receiving,O
placebo,O
The,O
most,O
frequent,O
adverse,O
reactions,O
leading,O
to,O
permanent,O
discontinuation,O
in,O
patients,O
treated,O
with,O
COMETRIQ,O
were,O
hypocalcemia,AdverseReaction
increased lipase,AdverseReaction
PPES,AdverseReaction
diarrhea,AdverseReaction
fatigue,AdverseReaction
hypertension,AdverseReaction
nausea,AdverseReaction
pancreatitis,AdverseReaction
tracheal fistula formation,AdverseReaction
and,O
vomiting,AdverseReaction
Increased levels of thyroid stimulating hormone,AdverseReaction
TSH,O
were,O
observed,O
in,O
57,O
of,O
patients,O
receiving,O
COMETRIQ,O
after,O
the,O
first,O
dose,O
compared,O
to,O
19,O
of,O
patients,O
receiving,O
placebo,O
regardless,O
of,O
baseline,O
value,O
Ninety,O
two,O
percent,O
92,O
of,O
patients,O
on,O
the,O
COMETRIQ,O
arm,O
had,O
a,O
prior,O
thyroidectomy,O
and,O
89,O
were,O
taking,O
thyroid,O
hormone,O
replacement,O
prior,O
to,O
the,O
first,O
dose,O
Table,O
1,O
Per,O
Patient,O
Incidence,O
of,O
Selected,O
Adverse,O
Reactions,O
in,O
Protocol,O
XL184,O
301,O
Occurring,O
at,O
a,O
Higher,O
Incidence,O
in,O
COMETRIQ,O
Treated,O
Patients,O
Between,O
Arm,O
Difference,O
of,O
5,O
All,O
Grades,O
National,O
Cancer,O
Institute,O
Common,O
Terminology,O
Criteria,O
for,O
Adverse,O
Events,O
Version,O
3,O
0,O
or,O
2,O
Grades,O
3,O
4,O
MedDRA,O
System,O
Organ,O
Class,O
Preferred,O
Terms,O
COMETRIQ,O
n,O
214,O
Placebo,O
n,O
109,O
AllGrades,O
Grades3,O
4,O
AllGrades,O
Grades3,O
4,O
GASTROINTESTINAL,O
DISORDERS,O
Diarrhea,AdverseReaction
63,O
16,O
33,O
2,O
Stomatitis,AdverseReaction
51,O
5,O
6,O
0,O
Nausea,AdverseReaction
43,O
1,O
21,O
0,O
Oral pain,AdverseReaction
36,O
2,O
6,O
0,O
Constipation,AdverseReaction
27,O
0,O
6,O
0,O
Abdominal pain,AdverseReaction
27,O
3,O
13,O
1,O
Vomiting,AdverseReaction
24,O
2,O
2,O
1,O
Dysphagia,AdverseReaction
13,O
4,O
6,O
1,O
Dyspepsia,AdverseReaction
11,O
0,O
0,O
0,O
Hemorrhoids,AdverseReaction
9,O
0,O
3,O
0,O
GENERAL,O
DISORDERS,O
AND,O
ADMINISTRATION,O
SITE,O
CONDITIONS,O
Fatigue,AdverseReaction
41,O
9,O
28,O
3,O
Asthenia,AdverseReaction
21,O
6,O
15,O
1,O
INVESTIGATIONS,O
Decreased weight,AdverseReaction
48,O
5,O
10,O
0,O
METABOLISM,O
AND,O
NUTRITION,O
DISORDERS,O
Decreased appetite,AdverseReaction
46,O
5,O
16,O
1,O
Dehydration,AdverseReaction
7,O
2,O
2,O
1,O
MUSCULOSKELETAL,O
AND,O
CONNECTIVE,O
TISSUE,O
DISORDERS,O
Arthralgia,AdverseReaction
14,O
1,O
7,O
0,O
Muscle spasms,AdverseReaction
12,O
0,O
5,O
0,O
Musculoskeletal chest pain,AdverseReaction
9,O
1,O
4,O
0,O
NERVOUS,O
SYSTEM,O
DISORDERS,O
Dysgeusia,AdverseReaction
34,O
0,O
6,O
0,O
Headache,AdverseReaction
18,O
0,O
8,O
0,O
Dizziness,AdverseReaction
14,O
0,O
7,O
0,O
Paresthesia,AdverseReaction
7,O
0,O
2,O
0,O
Peripheral sensory neuropathy,AdverseReaction
7,O
0,O
0,O
0,O
Peripheral neuropathy,AdverseReaction
5,O
0,O
0,O
0,O
PSYCHIATRIC,O
DISORDERS,O
Anxiety,AdverseReaction
9,O
0,O
2,O
0,O
RESPIRATORY,O
THORACIC,O
AND,O
MEDIASTINAL,O
DISORDERS,O
Dysphonia,AdverseReaction
20,O
0,O
9,O
0,O
SKIN,O
AND,O
SUBCUTANEOUS,O
TISSUE,O
DISORDERS,O
PPES,AdverseReaction
50,O
13,O
2,O
0,O
Hair color changes color color,AdverseReaction
depigmentation,AdverseReaction
graying,AdverseReaction
34,O
0,O
1,O
0,O
Rash,AdverseReaction
19,O
1,O
10,O
0,O
Dry skin,AdverseReaction
19,O
0,O
3,O
0,O
Alopecia,AdverseReaction
16,O
0,O
2,O
0,O
Erythema,AdverseReaction
11,O
1,O
2,O
0,O
Hyperkeratosis,AdverseReaction
7,O
0,O
0,O
0,O
VASCULAR,O
DISORDERS,O
Hypertension,AdverseReaction
33,O
8,O
4,O
0,O
Hypotension,AdverseReaction
7,O
1,O
0,O
0,O
Table,O
2,O
Percent,O
Patient,O
Incidence,O
of,O
Laboratory,O
Abnormalities,O
Occurring,O
at,O
a,O
Higher,O
Incidence,O
in,O
COMETRIQ,O
Treated,O
Patients,O
in,O
Protocol,O
XL184,O
301,O
Between,O
Arm,O
Difference,O
of,O
5,O
All,O
Grades,O
or,O
2,O
Grades,O
3,O
4,O
Adverse,O
Event,O
COMETRIQ,O
n,O
214,O
Placebo,O
N,O
109,O
AllGrades,O
Grade3,O
4,O
AllGrades,O
Grade3,O
4,O
Chemistries,O
Increased AST,AdverseReaction
86,O
3,O
35,O
2,O
Increased ALT,AdverseReaction
86,O
6,O
41,O
2,O
Increased ALP,AdverseReaction
52,O
3,O
35,O
3,O
Hypocalcemia,AdverseReaction
52,O
12,O
27,O
3,O
Hypophosphatemia,AdverseReaction
28,O
3,O
10,O
1,O
Hyperbilirubinemia,AdverseReaction
25,O
2,O
14,O
5,O
Hypomagnesemia,AdverseReaction
19,O
1,O
4,O
0,O
Hypokalemia,AdverseReaction
18,O
4,O
9,O
3,O
Hyponatremia,AdverseReaction
10,O
2,O
5,O
0,O
Hematologic,O
Lymphopenia,AdverseReaction
53,O
16,O
51,O
11,O
Neutropenia,AdverseReaction
35,O
3,O
15,O
2,O
Thrombocytopenia,AdverseReaction
35,O
0,O
4,O
3,O
ALT,O
alanine,O
aminotransferase,O
ALP,O
alkaline,O
phosphatase,O
AST,O
aspartate,O
aminotransferase,O
Nearly,O
all,O
COMETRIQ,O
treated,O
patients,O
96,O
vs,O
84,O
placebo,O
experienced,O
elevated blood pressure,AdverseReaction
and,O
there,O
was,O
a,O
doubling,O
in,O
the,O
incidence,O
of,O
overt,O
hypertension,AdverseReaction
in,O
COMETRIQ,O
treated,O
patients,O
over,O
placebo,O
treated,O
patients,O
61,O
vs,O
30,O
according,O
to,O
modified,O
Joint,O
National,O
Committee,O
on,O
Prevention,O
Detection,O
Evaluation,O
and,O
Treatment,O
of,O
High,O
Blood,O
Pressure,O
JNC,O
staging,O
criteria,O
No,Negation
patients,O
developed,O
malignant hypertension,AdverseReaction
Table,O
3,O
Per,O
Patient,O
Incidence,O
of,O
Hypertension,AdverseReaction
in,O
Protocol,O
XL184,O
301,O
Hypertension,AdverseReaction
JNCStage,O
COMETRIQN,O
211,O
PlaceboN,O
107,O
Normal,O
Grade,O
0,O
Systolic,O
120,O
mmHg,O
and,O
Diastolic,O
80,O
mmHg,O
4,O
15,O
Pre hypertension,AdverseReaction
Systolic,Severity
120 mmHg,Severity
or,O
Diastolic,Severity
80 mmHg,Severity
34,O
54,O
Stage,O
1,O
Systolic,O
140,O
mmHg,O
or,O
Diastolic,O
90,O
mmHg,O
46,O
25,O
Stage,O
2,O
Systolic,O
160,O
mmHg,O
or,O
Diastolic,O
100,O
mmHg,O
15,O
5,O
Malignant,O
Diastolic,O
120,O
mmHg,O
0,O
0,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Serious,Severity
hypersensitivity,AdverseReaction
anaphylactic,AdverseReaction
and,O
skin reactions,AdverseReaction
have,O
been,O
reported,O
with,O
glycopeptide,O
antibacterial,O
agents,O
including,O
DALVANCE,O
exercise,O
caution,O
in,O
patients,O
with,O
known,O
hypersensitivity,O
to,O
glycopeptides,O
5,O
1,O
Rapid,O
intravenous,O
infusion,AdverseReaction
of,O
glycopeptide,O
antibacterial,O
agents,O
can,Factor
cause,O
reactions,AdverseReaction
5,O
2,O
ALT elevations,AdverseReaction
with,O
DALVANCE,O
treatment,O
were,O
reported,O
in,O
clinical,O
trials,O
5,O
3,O
Clostridium difficile associated diarrhea,AdverseReaction
CDAD,AdverseReaction
has,O
been,O
reported,O
with,O
nearly,O
all,O
systemic,O
antibacterial,O
agents,O
including,O
DALVANCE,O
Evaluate,O
if,O
diarrhea,O
occurs,O
5,O
4,O
5,O
1,O
Hypersensitivity,O
Reactions,O
Serious,Severity
hypersensitivity,AdverseReaction
anaphylactic,AdverseReaction
and,O
skin reactions,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
DALVANCE,O
If,O
an,O
allergic,O
reaction,O
occurs,O
treatment,O
with,O
DALVANCE,O
should,O
be,O
discontinued,O
Before,O
using,O
DALVANCE,O
inquire,O
carefully,O
about,O
previous,O
hypersensitivity,O
reactions,O
to,O
glycopeptides,O
and,O
due,O
to,O
the,O
possibility,O
of,O
cross,O
sensitivity,O
exercise,O
caution,O
in,O
patients,O
with,O
a,O
history,O
of,O
glycopeptide,O
allergy,O
see,O
Patient,O
Counseling,O
Information,O
17,O
5,O
2,O
Infusion,O
Related,O
Reactions,O
DALVANCE,O
is,O
administered,O
via,O
intravenous,O
infusion,O
using,O
a,O
total,O
infusion,O
time,O
of,O
30,O
minutes,O
to,O
minimize,O
the,O
risk,O
of,O
infusion,O
related,O
reactions,O
Rapid,O
intravenous,O
infusions,O
of,O
DALVANCE,O
can,Factor
cause,O
reactions,O
that,O
resemble,O
Red Man Syndrome,AdverseReaction
including,O
flushing of the upper body,AdverseReaction
urticaria,AdverseReaction
pruritus,AdverseReaction
and,O
or,O
rash,AdverseReaction
Stopping,O
or,O
slowing,O
the,O
infusion,O
may,O
result,O
in,O
cessation,O
of,O
these,O
reactions,O
5,O
3,O
Hepatic,O
Effects,O
In,O
Phase,O
2,O
and,O
3,O
clinical,O
trials,O
more,O
DALVANCE,O
than,O
comparator,O
treated,O
subjects,O
with,O
normal,O
baseline,O
transaminase,O
levels,O
had,O
post,O
baseline,O
alanine aminotransferase,AdverseReaction
ALT,AdverseReaction
elevation,AdverseReaction
greater,O
than,O
3 times the upper limit of normal,Severity
ULN,O
Overall,O
abnormalities in in in,AdverseReaction
liver,O
tests,O
ALT,AdverseReaction
AST,AdverseReaction
bilirubin,AdverseReaction
were,O
reported,O
with,O
similar,O
frequency,O
in,O
the,O
DALVANCE,O
and,O
comparator,O
arms,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
4,O
Clostridium,O
difficile,O
Associated,O
Diarrhea,O
Clostridium difficile associated diarrhea,AdverseReaction
CDAD,AdverseReaction
has,O
been,O
reported,O
in,O
users,O
of,O
nearly,O
all,O
systemic,O
antibacterial,O
drugs,O
including,O
DALVANCE,O
with,O
severity,O
ranging,O
from,O
mild,Severity
diarrhea,AdverseReaction
to,O
fatal,AdverseReaction
colitis,AdverseReaction
Treatment,O
with,O
antibacterial,O
agents,O
can,O
alter,O
the,O
normal,O
flora,O
of,O
the,O
colon,O
and,O
may,O
permit,O
overgrowth,O
of,O
C,O
difficile,O
C,O
difficile,O
produces,O
toxins,O
A,O
and,O
B,O
which,O
contribute,O
to,O
the,O
development,O
of,O
CDAD,O
Hypertoxin,O
producing,O
strains,O
of,O
C,O
difficile,O
cause,O
increased,O
morbidity,O
and,O
mortality,O
as,O
these,O
infections,O
can,O
be,O
refractory,O
to,O
antibacterial,O
therapy,O
and,O
may,O
require,O
colectomy,O
CDAD,O
must,O
be,O
considered,O
in,O
all,O
patients,O
who,O
present,O
with,O
diarrhea,O
following,O
antibacterial,O
use,O
Careful,O
medical,O
history,O
is,O
necessary,O
because,O
CDAD,O
has,O
been,O
reported,O
to,O
occur,O
more,O
than,O
2,O
months,O
after,O
the,O
administration,O
of,O
antibacterial,O
agents,O
If,O
CDAD,O
is,O
suspected,O
or,O
confirmed,O
ongoing,O
antibacterial,O
use,O
not,O
directed,O
against,O
C,O
difficile,O
should,O
be,O
discontinued,O
if,O
possible,O
Appropriate,O
measures,O
such,O
as,O
fluid,O
and,O
electrolyte,O
management,O
protein,O
supplementation,O
antibacterial,O
treatment,O
of,O
C,O
difficile,O
and,O
surgical,O
evaluation,O
should,O
be,O
instituted,O
as,O
clinically,O
indicated,O
5,O
5,O
Development,O
of,O
Drug,O
Resistant,O
Bacteria,O
Prescribing,O
DALVANCE,O
in,O
the,O
absence,O
of,O
a,O
proven,O
or,O
strongly,O
suspected,O
bacterial,O
infection,O
is,O
unlikely,O
to,O
provide,O
benefit,O
to,O
the,O
patient,O
and,O
increases,O
the,O
risk,O
of,O
the,O
development,O
of,O
drug,O
resistant,O
bacteria,O
""
6,O
ADVERSE,O
REACTIONS,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
clinical,O
trials,O
of,O
DALVANCE,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
rates,O
observed,O
in,O
practice,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
in,O
patients,O
treated,O
with,O
DALVANCE,O
were,O
nausea,AdverseReaction
5,O
5,O
headache,AdverseReaction
4,O
7,O
and,O
diarrhea,AdverseReaction
4,O
4,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Durata,O
Therapeutics,O
Inc,O
at,O
1,O
855,O
387,O
2825,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Adverse,O
Reactions,O
in,O
Clinical,O
Trials,O
Adverse,O
reactions,O
were,O
evaluated,O
for,O
1778,O
patients,O
treated,O
with,O
DALVANCE,O
and,O
1224,O
patients,O
treated,O
with,O
comparator,O
antibacterial,O
drugs,O
in,O
seven,O
Phase,O
2,O
and,O
Phase,O
3,O
clinical,O
trials,O
A,O
causal,O
relationship,O
between,O
study,O
drug,O
and,O
adverse,O
reactions,O
was,O
not,O
always,O
established,O
The,O
median,O
age,O
of,O
patients,O
treated,O
with,O
DALVANCE,O
was,O
47,O
years,O
ranging,O
between,O
16,O
and,O
93,O
years,O
old,O
Patients,O
treated,O
with,O
DALVANCE,O
were,O
predominantly,O
male,O
60,O
and,O
Caucasian,O
78,O
Serious,O
Adverse,O
Reactions,O
and,O
Adverse,O
Reactions,O
Leading,O
to,O
Discontinuation,O
Serious,O
adverse,O
reactions,O
occurred,O
in,O
109,O
1778,O
6,O
1,O
of,O
patients,O
treated,O
with,O
DALVANCE,O
and,O
in,O
80,O
1224,O
6,O
5,O
of,O
patients,O
treated,O
with,O
comparator,O
DALVANCE,O
was,O
discontinued,O
due,O
to,O
an,O
adverse,O
reaction,O
in,O
53,O
1778,O
3,O
patients,O
and,O
the,O
comparator,O
was,O
discontinued,O
due,O
to,O
an,O
adverse,O
reaction,O
in,O
35,O
1224,O
2,O
8,O
patients,O
Most,O
Common,O
Adverse,O
Reactions,O
The,O
most,O
common,O
adverse,O
reactions,O
in,O
patients,O
treated,O
with,O
DALVANCE,O
were,O
nausea,AdverseReaction
5,O
5,O
headache,AdverseReaction
4,O
7,O
and,O
diarrhea,AdverseReaction
4,O
4,O
The,O
median,O
duration,O
of,O
adverse,O
reactions,O
was,O
4,O
0,O
days,O
in,O
both,O
treatment,O
groups,O
Table,O
1,O
lists,O
selected,O
adverse,O
reactions,O
occurring,O
in,O
more,O
than,O
2,O
of,O
patients,O
treated,O
with,O
DALVANCE,O
in,O
clinical,O
trials,O
Table1,O
Selected,O
Adverse,O
Reactions,O
in,O
Phase,O
2,O
3,O
Trials,O
Number,O
of,O
Patients,O
Dalbavancin,O
Comparator,O
N,O
1778,O
N,O
1224,O
Nausea,AdverseReaction
98,O
5,O
5,O
78,O
6,O
4,O
Vomiting,AdverseReaction
50,O
2,O
8,O
37,O
3,O
Diarrhea,AdverseReaction
79,O
4,O
4,O
72,O
5,O
9,O
Headache,AdverseReaction
83,O
4,O
7,O
59,O
4,O
8,O
Rash,AdverseReaction
48,O
2,O
7,O
30,O
2,O
4,O
Pruritus,AdverseReaction
38,O
2,O
1,O
41,O
3,O
3,O
Comparators,O
included,O
linezolid,O
cefazolin,O
cephalexin,O
and,O
vancomycin,O
The,O
following,O
selected,O
adverse,O
reactions,O
were,O
reported,O
in,O
DALVANCE,O
treated,O
patients,O
at,O
a,O
rate,O
of,O
less,O
than,O
2,O
in,O
these,O
clinical,O
trials,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
anemia,AdverseReaction
hemorrhagic anemia,AdverseReaction
leucopenia,AdverseReaction
neutropenia,AdverseReaction
thrombocytopenia,AdverseReaction
petechiae,AdverseReaction
eosinophilia,AdverseReaction
thrombocytosis,AdverseReaction
Gastrointestinal,O
disorders,O
gastrointestinal hemorrhage,AdverseReaction
melena,AdverseReaction
hematochezia,AdverseReaction
abdominal pain,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
infusion related reactions,AdverseReaction
Hepatobiliary,O
disorders,O
hepatotoxicity,AdverseReaction
Immune,O
system,O
disorders,O
anaphylactoid reaction,AdverseReaction
Infections,O
and,O
infestations,O
Clostridium difficile colitis,AdverseReaction
oral candidiasis,AdverseReaction
vulvovaginal mycotic infection,AdverseReaction
Investigations,O
hepatic transaminases increased,AdverseReaction
blood alkaline phosphatase increased,AdverseReaction
international normalized ratio increased,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorders,O
hypoglycemia,AdverseReaction
Nervous,O
System,O
disorders,O
dizziness,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
bronchospasm,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
disorders,O
urticaria,AdverseReaction
Vascular,O
disorders,O
flushing,AdverseReaction
phlebitis,AdverseReaction
wound hemorrhage,AdverseReaction
spontaneous hematoma,AdverseReaction
Alanine,O
Aminotransferase,O
ALT,O
Elevations,O
Among,O
patients,O
with,O
normal,O
baseline,O
ALT,O
levels,O
more,O
DALVANCE,O
than,O
comparator,O
treated,O
patients,O
had,O
post,O
baseline,O
ALT elevations,AdverseReaction
greater,O
than,O
3 times the upper limit of normal,Severity
ULN,O
12,O
0,O
8,O
vs,O
2,O
0,O
2,O
respectively,O
including,O
three,O
subjects,O
with,O
post,O
baseline,O
ALT values greater than 10 times ULN,AdverseReaction
Eight,O
of,O
12,O
patients,O
treated,O
with,O
DALVANCE,O
and,O
one,O
comparator,O
patient,O
had,O
underlying,O
conditions,O
which,O
could,O
affect,O
liver,O
enzymes,O
including,O
chronic,O
viral,O
hepatitis,O
and,O
a,O
history,O
of,O
alcohol,O
abuse,O
In,O
addition,O
one,O
DALVANCE,O
treated,O
subject,O
in,O
a,O
Phase,O
1,O
trial,O
had,O
post,O
baseline,O
ALT elevations,AdverseReaction
greater,O
than,O
20 times ULN,Severity
ALT elevations,AdverseReaction
were,O
reversible,O
in,O
all,O
subjects,O
No,Negation
comparator,O
treated,O
subject,O
with,O
normal,O
baseline,O
transaminases,O
had,O
post,O
baseline,O
ALT elevation,AdverseReaction
greater,O
than,O
10 times ULN,Severity
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
following,O
DaTscan,O
administration,O
Have,O
anaphylactic,O
and,O
hypersensitivity,O
treatment,O
measures,O
available,O
prior,O
to,O
DaTscan,O
administration,O
5,O
1,O
Administer,O
a,O
thyroid,O
blocking,O
agent,O
before,O
DaTscan,O
administration,O
5,O
2,O
5,O
1,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
following,O
DaTscan,O
administration,O
see,O
Adverse,O
Reactions,O
6,O
2,O
The,O
reactions,O
have,O
generally,O
consisted,O
of,O
skin erythema,AdverseReaction
and,O
pruritis,AdverseReaction
and,O
have,O
either,O
resolved,O
spontaneously,O
or,O
following,O
the,O
administration,O
of,O
corticosteroids,O
and,O
anti,O
histamines,O
Prior,O
to,O
administration,O
question,O
the,O
patient,O
for,O
a,O
history,O
of,O
prior,O
reactions,O
to,O
DaTscan,O
If,O
the,O
patient,O
is,O
known,O
or,O
strongly,O
suspected,O
of,O
having,O
had,O
a,O
hypersensitivity,O
reaction,O
to,O
DaTscan,O
the,O
decision,O
to,O
administer,O
DaTscan,O
should,O
be,O
based,O
upon,O
an,O
assessment,O
of,O
the,O
expected,O
benefits,O
compared,O
to,O
the,O
potential,O
hypersensitivity,O
risks,O
Have,O
anaphylactic,O
and,O
hypersensitivity,O
treatment,O
measures,O
available,O
prior,O
to,O
DaTscan,O
administration,O
and,O
following,O
administration,O
observe,O
patients,O
for,O
symptoms,O
or,O
signs,O
of,O
a,O
hypersensitivity,O
reaction,O
5,O
2,O
Thyroid,O
Accumulation,O
The,O
DaTscan,O
injection,O
may,O
contain,O
up,O
to,O
6,O
of,O
free,O
iodide,O
iodine,O
123,O
To,O
decrease,O
thyroid,O
accumulation,O
of,O
iodine,O
123,O
block,O
the,O
thyroid,O
gland,O
before,O
administration,O
of,O
DaTscan,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Avoid,O
the,O
use,O
of,O
Potassium,O
Iodide,O
Oral,O
Solution,O
or,O
Lugol,O
s,O
Solution,O
in,O
patients,O
who,O
are,O
sensitive,O
to,O
such,O
products,O
Failure,O
to,O
block,O
thyroid,O
uptake,O
of,O
iodine,O
123,O
may,O
result,O
in,O
an,O
increased,O
long,O
term,O
risk,O
for,O
thyroid,O
neoplasia,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Hypersensitivity,AdverseReaction
and,O
injection site reactions,AdverseReaction
have,O
been,O
reported,O
following,O
DaTscan,O
administration,O
6,O
2,O
In,O
clinical,O
trials,O
the,O
most,O
common,O
adverse,O
reactions,O
headache,AdverseReaction
nausea,AdverseReaction
vertigo,AdverseReaction
dry mouth,AdverseReaction
or,O
dizziness,AdverseReaction
occurred,O
in,O
1,O
of,O
subjects,O
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GE,O
Healthcare,O
at,O
1,O
800,O
654,O
0118,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Study,O
Experience,O
The,O
data,O
from,O
clinical,O
studies,O
reflect,O
exposure,O
to,O
DaTscan,O
in,O
942,O
subjects,O
with,O
a,O
mean,O
age,O
of,O
66,O
years,O
range,O
25,O
to,O
90,O
years,O
Among,O
these,O
subjects,O
42,O
were,O
women,O
and,O
99,O
Caucasian,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
DaTscan,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
In,O
clinical,O
trials,O
no,O
serious,O
adverse,O
reactions,O
were,O
reported,O
Other,O
adverse,O
reactions,O
occurred,O
at,O
a,O
rate,O
of,O
1,O
or,O
less,O
and,O
the,O
reported,O
events,O
consisted,O
of,O
headache,AdverseReaction
nausea,AdverseReaction
vertigo,AdverseReaction
dry mouth,AdverseReaction
or,O
dizziness,AdverseReaction
These,O
reactions,O
were,O
of,O
mild,O
to,O
moderate,O
severity,O
6,O
2,O
Postmarketing,O
Experience,O
Because,O
postmarketing,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
In,O
the,O
postmarketing,O
experience,O
hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
The,O
reactions,O
generally,O
related,O
to,O
rash,AdverseReaction
and,O
pruritis,AdverseReaction
within,O
minutes,O
of,O
DaTscan,O
administration,O
The,O
reactions,O
either,O
resolved,O
spontaneously,O
or,O
following,O
the,O
administration,O
of,O
corticosteroids,O
and,O
antihistamines,O
Injection site pain,AdverseReaction
has,O
also,O
been,O
reported,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
DIFICID,O
should,O
not,O
be,O
used,O
for,O
systemic,O
infections,O
5,O
1,O
Acute hypersensitivity reactions,AdverseReaction
angioedema,AdverseReaction
dyspnea,AdverseReaction
pruritus,AdverseReaction
and,O
rash,AdverseReaction
have,O
been,O
reported,O
In,O
the,O
event,O
of,O
a,O
severe,O
reaction,O
discontinue,O
DIFICID,O
5,O
2,O
Development,O
of,O
drug,O
resistant,O
bacteria,O
Only,O
use,O
DIFICID,O
for,O
infection,O
proven,O
or,O
strongly,O
suspected,O
to,O
be,O
caused,O
by,O
C,O
difficile,O
5,O
3,O
5,O
1,O
Not,O
for,O
Systemic,O
Infections,O
Since,O
there,O
is,O
minimal,O
systemic,O
absorption,O
of,O
fidaxomicin,O
DIFICID,O
is,O
not,O
effective,O
for,O
treatment,O
of,O
systemic,O
infections,O
5,O
2,O
Hypersensitivity,O
Reactions,O
Acute hypersensitivity reactions,AdverseReaction
including,O
dyspnea,AdverseReaction
rash,AdverseReaction
pruritus,AdverseReaction
and,O
angioedema of the mouth of the of the,AdverseReaction
throat,AdverseReaction
and,O
face,AdverseReaction
have,O
been,O
reported,O
with,O
fidaxomicin,O
If,O
a,O
severe,O
hypersensitivity,O
reaction,O
occurs,O
DIFICID,O
r,O
should,O
be,O
discontinued,O
and,O
appropriate,O
therapy,O
should,O
be,O
instituted,O
Some,O
patients,O
with,O
hypersensitivity reactions,AdverseReaction
also,O
reported,O
a,O
history,O
of,O
allergy,O
to,O
other,O
macrolides,O
Physicians,O
prescribing,O
DIFICID,O
to,O
patients,O
with,O
a,O
known,O
macrolide,O
allergy,O
should,O
be,O
aware,O
of,O
the,O
possibility,O
of,O
hypersensitivity,O
reactions,O
5,O
3,O
Development,O
of,O
Drug,O
Resistant,O
Bacteria,O
Prescribing,O
DIFICID,O
in,O
the,O
absence,O
of,O
a,O
proven,O
or,O
strongly,O
suspected,O
C,O
difficile,O
infection,O
is,O
unlikely,O
to,O
provide,O
benefit,O
to,O
the,O
patient,O
and,O
increases,O
the,O
risk,O
of,O
the,O
development,O
of,O
drug,O
resistant,O
bacteria,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
are,O
nausea,AdverseReaction
11,O
vomiting,AdverseReaction
7,O
abdominal pain,AdverseReaction
6,O
gastrointestinal hemorrhage,AdverseReaction
4,O
anemia,AdverseReaction
2,O
and,O
neutropenia,AdverseReaction
2,O
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Cubist,O
Pharmaceuticals,O
at,O
1,O
877,O
CUBIST,O
6,O
1,O
877,O
282,O
4786,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
event,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
any,O
other,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
safety,O
of,O
DIFICID,O
200,O
mg,O
tablets,O
taken,O
twice,O
a,O
day,O
for,O
10,O
days,O
was,O
evaluated,O
in,O
564,O
patients,O
with,O
CDAD,O
in,O
two,O
active,O
comparator,O
controlled,O
trials,O
with,O
86,O
7,O
of,O
patients,O
receiving,O
a,O
full,O
course,O
of,O
treatment,O
Thirty,O
three,O
patients,O
receiving,O
DIFICID,O
5,O
9,O
withdrew,O
from,O
trials,O
as,O
a,O
result,O
of,O
adverse,O
reactions,O
AR,O
The,O
types,O
of,O
AR,O
resulting,O
in,O
withdrawal,O
from,O
the,O
study,O
varied,O
considerably,O
Vomiting,AdverseReaction
was,O
the,O
primary,O
adverse,O
reaction,O
leading,O
to,O
discontinuation,O
of,O
dosing,O
this,O
occurred,O
at,O
an,O
incidence,O
of,O
0,O
5,O
in,O
both,O
the,O
fidaxomicin,O
and,O
vancomycin,O
patients,O
in,O
Phase,O
3,O
studies,O
Table,O
1,O
Selected,O
Adverse,O
Reactions,O
with,O
an,O
Incidence,O
of,O
2,O
Reported,O
in,O
DIFICID,O
Patients,O
in,O
Controlled,O
Trials,O
DIFICID,O
N,O
564,O
Vancomycin,O
N,O
583,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
n,O
n,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
Anemia,AdverseReaction
14,O
2,O
12,O
2,O
Neutropenia,AdverseReaction
14,O
2,O
6,O
1,O
Gastrointestinal,O
Disorders,O
Nausea,AdverseReaction
62,O
11,O
66,O
11,O
Vomiting,AdverseReaction
41,O
7,O
37,O
6,O
Abdominal Pain,AdverseReaction
33,O
6,O
23,O
4,O
Gastrointestinal Hemorrhage,AdverseReaction
20,O
4,O
12,O
2,O
The,O
following,O
adverse,O
reactions,O
were,O
reported,O
in,O
2,O
of,O
patients,O
taking,O
DIFICID,O
tablets,O
in,O
controlled,O
trials,O
Gastrointestinal,O
Disorders,O
abdominal distension,AdverseReaction
abdominal tenderness,AdverseReaction
dyspepsia,AdverseReaction
dysphagia,AdverseReaction
flatulence,AdverseReaction
intestinal obstruction,AdverseReaction
megacolon,AdverseReaction
Investigations,O
increased blood alkaline phosphatase,AdverseReaction
decreased blood bicarbonate,AdverseReaction
increased hepatic enzymes,AdverseReaction
decreased platelet count,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorders,O
hyperglycemia,AdverseReaction
metabolic acidosis,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
drug eruption,AdverseReaction
pruritus,AdverseReaction
rash,AdverseReaction
6,O
2,O
Post,O
Marketing,O
Experience,O
Adverse,O
reactions,O
reported,O
in,O
the,O
post,O
marketing,O
setting,O
arise,O
from,O
a,O
population,O
of,O
unknown,O
size,O
and,O
are,O
voluntary,O
in,O
nature,O
As,O
such,O
reliability,O
in,O
estimating,O
their,O
frequency,O
or,O
in,O
establishing,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
is,O
not,O
always,O
possible,O
Hypersensitivity reactions,AdverseReaction
dyspnea,AdverseReaction
angioedema,AdverseReaction
rash,AdverseReaction
and,O
pruritus,AdverseReaction
have,O
been,O
reported,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Nephrogenic Systemic Fibrosis,AdverseReaction
has,O
occurred,O
in,O
patients,O
with,O
impaired,O
elimination,O
of,O
GBCAs,O
Higher,O
than,O
recommended,O
dosing,O
or,O
repeat,O
dosing,O
appear,O
to,O
increase,O
the,O
risk,O
5,O
1,O
Hypersensitivity,AdverseReaction
Anaphylactoid,AdverseReaction
anaphylactic reactions,AdverseReaction
with,O
cardiovascular,AdverseReaction
respiratory,AdverseReaction
or,O
cutaneous manifestations,AdverseReaction
ranging,O
from,O
mild,Severity
to,O
severe,Severity
including,O
death,AdverseReaction
have,O
uncommonly,O
occurred,O
Monitor,O
patients,O
closely,O
for,O
need,O
of,O
emergency,O
cardiorespiratory,O
support,O
5,O
2,O
5,O
1,O
Nephrogenic,O
Systemic,O
Fibrosis,O
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,O
for,O
nephrogenic systemic fibrosis,AdverseReaction
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
among,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrast,O
MRI,O
or,O
other,O
modalities,O
The,O
GBCA,DrugClass
associated,O
NSF,AdverseReaction
risk,O
appears,O
highest,O
for,O
patients,O
with,O
chronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73m,O
2,O
as,O
well,O
as,O
patients,O
with,O
acute,O
kidney,O
injury,O
The,O
risk,O
appears,O
lower,O
for,O
patients,O
with,O
chronic,O
moderate,O
kidney,O
disease,O
GFR,O
30,O
59,O
mL,O
min,O
1,O
73,O
m,O
2,O
and,O
little,O
if,O
any,O
for,O
patients,O
with,O
chronic,O
mild,O
kidney,O
disease,O
GFR,O
60,O
89,O
mL,O
min,O
1,O
73,O
m,O
2,O
NSF,AdverseReaction
may,Factor
result,O
in,O
fatal,AdverseReaction
or,O
debilitating,Severity
fibrosis,AdverseReaction
affecting,O
the,O
skin,O
muscle,O
and,O
internal,O
organs,O
Report,O
any,O
diagnosis,O
of,O
NSF,O
following,O
DOTAREM,O
administration,O
to,O
Guerbet,O
LLC,O
1,O
877,O
729,O
6679,O
or,O
FDA,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
Features,O
of,O
acute,O
kidney,O
injury,O
consist,O
of,O
rapid,O
over,O
hours,O
to,O
days,O
and,O
usually,O
reversible,O
decrease,O
in,O
kidney,O
function,O
commonly,O
in,O
the,O
setting,O
of,O
surgery,O
severe,O
infection,O
injury,O
or,O
drug,O
induced,O
kidney,O
toxicity,O
Serum,O
creatinine,O
levels,O
and,O
estimated,O
GFR,O
may,O
not,O
reliably,O
assess,O
renal,O
function,O
in,O
the,O
setting,O
of,O
acute,O
kidney,O
injury,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
e,O
g,O
age,O
60,O
years,O
diabetes,O
mellitus,O
or,O
chronic,O
hypertension,O
estimate,O
the,O
GFR,O
through,O
laboratory,O
testing,O
Among,O
the,O
factors,O
that,O
may,O
increase,O
the,O
risk,O
for,O
NSF,O
are,O
repeated,O
or,O
higher,O
than,O
recommended,O
doses,O
of,O
a,O
GBCA,O
and,O
the,O
degree,O
of,O
renal,O
impairment,O
at,O
the,O
time,O
of,O
exposure,O
Record,O
the,O
specific,O
GBCA,O
and,O
the,O
dose,O
administered,O
to,O
a,O
patient,O
For,O
patients,O
at,O
highest,O
risk,O
for,O
NSF,O
do,O
not,O
exceed,O
the,O
recommended,O
DOTAREM,O
dose,O
and,O
allow,O
a,O
sufficient,O
period,O
of,O
time,O
for,O
elimination,O
of,O
the,O
drug,O
prior,O
to,O
re,O
administration,O
For,O
patients,O
receiving,O
hemodialysis,O
physicians,O
may,O
consider,O
the,O
prompt,O
initiation,O
of,O
hemodialysis,O
following,O
the,O
administration,O
of,O
a,O
GBCA,O
in,O
order,O
to,O
enhance,O
the,O
contrast,O
agent,O
s,O
elimination,O
The,O
usefulness,O
of,O
hemodialysis,O
in,O
the,O
prevention,O
of,O
NSF,O
is,O
unknown,O
see,O
Dosage,O
and,O
Administration,O
2,O
and,O
Clinical,O
Pharmacology,O
12,O
5,O
2,O
Hypersensitivity,O
Reactions,O
Anaphylactic,AdverseReaction
and,O
anaphylactoid reactions,AdverseReaction
have,O
been,O
reported,O
with,O
DOTAREM,O
involving,O
cardiovascular,O
respiratory,O
and,O
or,O
cutaneous,O
manifestations,O
Some,O
patients,O
experienced,O
circulatory collapse,AdverseReaction
and,O
died,AdverseReaction
In,O
most,O
cases,O
initial,O
symptoms,O
occurred,O
within,O
minutes,O
of,O
DOTAREM,O
administration,O
and,O
resolved,O
with,O
prompt,O
emergency,O
treatment,O
see,O
Adverse,O
Reactions,O
6,O
Before,O
DOTAREM,O
administration,O
assess,O
all,O
patients,O
for,O
any,O
history,O
of,O
a,O
reaction,O
to,O
contrast,O
media,O
bronchial,O
asthma,O
and,O
or,O
allergic,O
disorders,O
These,O
patients,O
may,Factor
have,O
an,O
increased,O
risk,O
for,O
a,O
hypersensitivity reaction,AdverseReaction
to,O
DOTAREM,O
Administer,O
DOTAREM,O
only,O
in,O
situations,O
where,O
trained,O
personnel,O
and,O
therapies,O
are,O
promptly,O
available,O
for,O
the,O
treatment,O
of,O
hypersensitivity,O
reactions,O
including,O
personnel,O
trained,O
in,O
resuscitation,O
During,O
and,O
following,O
DOTAREM,O
administration,O
observe,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
hypersensitivity,O
reactions,O
5,O
3,O
Acute,O
Kidney,O
Injury,O
In,O
patients,O
with,O
chronically,O
reduced,O
renal,O
function,O
acute kidney injury,AdverseReaction
requiring,O
dialysis,O
has,O
occurred,O
with,O
the,O
use,O
of,O
GBCAs,DrugClass
The,O
risk,O
of,O
acute,O
kidney,O
injury,O
may,O
increase,O
with,O
increasing,O
dose,O
of,O
the,O
contrast,O
agent,O
administer,O
the,O
lowest,O
dose,O
necessary,O
for,O
adequate,O
imaging,O
Screen,O
all,O
patients,O
for,O
renal,O
impairment,O
by,O
obtaining,O
a,O
history,O
and,O
or,O
laboratory,O
tests,O
Consider,O
follow,O
up,O
renal,O
function,O
assessments,O
for,O
patients,O
with,O
a,O
history,O
of,O
renal,O
dysfunction,O
5,O
4,O
Extravasation,O
and,O
Injection,O
Site,O
Reactions,O
Ensure,O
catheter,O
and,O
venous,O
patency,O
before,O
the,O
injection,O
of,O
DOTAREM,O
Extravasation,O
into,O
tissues,O
during,O
DOTAREM,O
administration,AdverseReaction
may,Factor
result,O
in,O
tissue irritation,AdverseReaction
see,O
Nonclinical,O
Toxicology,O
13,O
2,O
""
BOXED,O
WARNING,O
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
NSF,AdverseReaction
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
NSF,AdverseReaction
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,O
for,O
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
in,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrasted,O
MRI,O
or,O
other,O
modalities,O
NSF,AdverseReaction
may,Factor
result,O
in,O
fatal,AdverseReaction
or,O
debilitating,Severity
fibrosis,AdverseReaction
affecting,O
the,O
skin,O
muscle,O
and,O
internal,O
organs,O
The,O
risk,Factor
for,O
NSF,AdverseReaction
appears,O
highest,O
among,O
patients,O
with,O
Chronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73,O
m2,O
orAcute,O
kidney,O
injury,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
e,O
g,O
age,O
60,O
years,O
hypertension,O
diabetes,O
estimate,O
the,O
glomerular,O
filtration,O
rate,O
GFR,O
through,O
laboratory,O
testing,O
5,O
1,O
For,O
patients,O
at,O
highest,O
risk,O
for,O
NSF,O
do,O
not,O
exceed,O
the,O
recommended,O
DOTAREM,O
dose,O
and,O
allow,O
a,O
sufficient,O
period,O
of,O
time,O
for,O
elimination,O
of,O
the,O
drug,O
from,O
the,O
body,O
prior,O
to,O
any,O
re,O
administration,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
NSF,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,O
for,O
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
in,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrasted,O
MRI,O
or,O
other,O
modalities,O
The,O
risk,Factor
for,O
NSF,AdverseReaction
appears,O
highest,O
among,O
patients,O
with,O
Chronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73,O
m2,O
orAcute,O
kidney,O
injury,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
for,O
example,O
age,O
60,O
years,O
hypertension,O
or,O
diabetes,O
estimate,O
the,O
glomerular,O
filtration,O
rate,O
GFR,O
through,O
laboratory,O
testing,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
GBCAs,DrugClass
have,O
been,O
associated,O
with,O
a,O
risk,O
for,O
NSF,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
NSF,AdverseReaction
has,O
not,Negation
been,O
reported,O
in,O
patients,O
with,O
a,O
clear,O
history,O
of,O
exposure,O
to,O
DOTAREM,O
alone,O
Hypersensitivity reactions,AdverseReaction
and,O
acute kidney injury,AdverseReaction
are,O
described,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
and,O
5,O
3,O
EXCERPT,O
The,O
most,O
frequent,O
0,O
2,O
adverse,O
reactions,O
in,O
clinical,O
studies,O
were,O
nausea,AdverseReaction
headache,AdverseReaction
injection site pain,AdverseReaction
injection site coldness,AdverseReaction
and,O
burning sensation,AdverseReaction
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GUERBET,O
LLC,O
at,O
1,O
877,O
729,O
6679,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
data,O
described,O
below,O
reflect,O
DOTAREM,O
exposure,O
in,O
2813,O
patients,O
representing,O
2672,O
adults,O
and,O
141,O
pediatric,O
patients,O
Overall,O
55,O
of,O
the,O
patients,O
were,O
men,O
In,O
clinical,O
trials,O
where,O
ethnicity,O
was,O
recorded,O
the,O
ethnic,O
distribution,O
was,O
74,O
Caucasian,O
12,O
Asian,O
4,O
Black,O
and,O
10,O
others,O
The,O
average,O
age,O
was,O
53,O
years,O
range,O
from,O
0,O
1,O
to,O
97,O
years,O
Overall,O
3,O
9,O
of,O
patients,O
reported,O
at,O
least,O
one,O
adverse,O
reaction,O
primarily,O
occurring,O
immediately,O
or,O
several,O
days,O
following,O
DOTAREM,O
administration,O
Most,O
adverse,O
reactions,O
were,O
mild,O
or,O
moderate,O
in,O
severity,O
and,O
transient,O
in,O
nature,O
Table,O
2,O
lists,O
adverse,O
reactions,O
that,O
occurred,O
in,O
0,O
2,O
patients,O
who,O
received,O
DOTAREM,O
Table,O
2,O
Adverse,O
Reactions,O
in,O
Clinical,O
Trials,O
Reaction,O
Rate,O
n,O
2813,O
Nausea,AdverseReaction
0,O
6,O
Headache,AdverseReaction
0,O
5,O
Injection Site Pain,AdverseReaction
0,O
4,O
Injection Site Coldness,AdverseReaction
0,O
2,O
Burning Sensation,AdverseReaction
0,O
2,O
Adverse,O
reactions,O
that,O
occurred,O
with,O
a,O
frequency,O
0,O
2,O
in,O
patients,O
who,O
received,O
DOTAREM,O
include,O
feeling cold,AdverseReaction
rash,AdverseReaction
somnolence,AdverseReaction
fatigue,AdverseReaction
dizziness,AdverseReaction
vomiting,AdverseReaction
pruritus,AdverseReaction
paresthesia,AdverseReaction
dysgeusia,AdverseReaction
pain in extremity,AdverseReaction
anxiety,AdverseReaction
hypertension,AdverseReaction
palpitations,AdverseReaction
oropharyngeal discomfort,AdverseReaction
serum creatinine increased,AdverseReaction
and,O
injection site reactions site site site,AdverseReaction
including,O
site inflammation,AdverseReaction
extravasation,AdverseReaction
pruritus,AdverseReaction
and,O
warmth,AdverseReaction
Adverse,O
Reactions,O
in,O
Pediatric,O
Patients,O
During,O
clinical,O
trials,O
141,O
pediatric,O
patients,O
7,O
aged,O
24,O
months,O
33,O
aged,O
2,O
5,O
years,O
58,O
aged,O
6,O
11,O
years,O
and,O
43,O
aged,O
12,O
17,O
received,O
DOTAREM,O
Overall,O
6,O
pediatric,O
patients,O
4,O
3,O
reported,O
at,O
least,O
one,O
adverse,O
reaction,O
following,O
DOTAREM,O
administration,O
The,O
most,O
frequently,O
reported,O
adverse,O
reaction,O
was,O
headache,AdverseReaction
1,O
5,O
Most,O
adverse,O
events,O
were,O
mild,O
in,O
severity,O
and,O
transient,O
in,O
nature,O
and,O
all,O
patients,O
recovered,O
without,O
treatment,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
additional,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
postmarketing,O
use,O
of,O
DOTAREM,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Table,O
3,O
Adverse,O
Reactions,O
in,O
the,O
Postmarketing,O
Experience,O
System,O
Organ,O
Class,O
Adverse,O
Reaction,O
Cardiac,O
Disorders,O
bradycardia,AdverseReaction
tachycardia,AdverseReaction
arrhythmia,AdverseReaction
Immune,O
System,O
Disorders,O
hypersensitivity,AdverseReaction
anaphylactoid reactions,AdverseReaction
including,O
cardiac arrest,AdverseReaction
respiratory arrest,AdverseReaction
cyanosis,AdverseReaction
pharyngeal edema,AdverseReaction
laryngospasm,AdverseReaction
bronchospasm,AdverseReaction
angioedema,AdverseReaction
conjunctivitis,AdverseReaction
ocular hyperemia,AdverseReaction
eyelid edema,AdverseReaction
lacrimation increased,AdverseReaction
hyperhidrosis,AdverseReaction
urticaria,AdverseReaction
Nervous,O
System,O
Disorders,O
coma,AdverseReaction
convulsion,AdverseReaction
syncope,AdverseReaction
presyncope,AdverseReaction
parosmia,AdverseReaction
tremor,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
muscle contracture,AdverseReaction
muscle weakness,AdverseReaction
Gastrointestinal,O
Disorders,O
diarrhea,AdverseReaction
salivary hypersecretion,AdverseReaction
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
malaise,AdverseReaction
fever,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
NSF,AdverseReaction
in,O
patients,O
whose,O
reports,O
were,O
confounded,O
by,O
the,O
receipt,O
of,O
other,O
GBCAs,DrugClass
or,O
in,O
situations,O
where,O
receipt,O
of,O
other,O
GBCAs,O
could,O
not,O
be,O
ruled,O
out,O
No,Negation
unconfounded,O
cases,O
of,O
NSF,AdverseReaction
have,O
been,O
reported,O
with,O
DOTAREM,O
Vascular,O
Disorders,O
superficial phlebitis,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Women,O
taking,O
DUAVEE,O
should,O
not,O
take,O
progestins,O
additional,O
estrogens,O
or,O
additional,O
estrogen,O
agonist,O
antagonists,O
5,O
1,O
Cardiovascular disorders,AdverseReaction
including,O
venous thromboembolism,AdverseReaction
pulmonary embolism,AdverseReaction
stroke,AdverseReaction
and,O
retinal vascular thrombosis,AdverseReaction
5,O
2,O
5,O
6,O
Malignant neoplasms,AdverseReaction
including,O
endometrial cancer,AdverseReaction
breast cancer,AdverseReaction
and,O
ovarian cancer,AdverseReaction
5,O
3,O
Estrogens,O
increase,O
the,O
risk,Factor
of,O
gallbladder disease,AdverseReaction
5,O
5,O
Discontinue,O
estrogen,O
if,O
loss,O
of,O
vision,O
severe,O
hypertriglyceridemia,O
or,O
cholestatic,O
jaundice,O
occurs,O
5,O
6,O
5,O
8,O
5,O
9,O
Monitor,O
thyroid,O
function,O
in,O
women,O
on,O
thyroid,O
replacement,O
therapy,O
5,O
10,O
5,O
17,O
5,O
1,O
Drugs,O
Containing,O
Progestins,O
Estrogens,O
or,O
Estrogen,O
Agonist,O
Antagonists,O
DUAVEE,O
contains,O
conjugated,O
estrogens,O
and,O
bazedoxifene,O
an,O
estrogen,O
agonist,O
antagonist,O
Women,O
taking,O
DUAVEE,O
should,O
not,O
take,O
progestins,O
additional,O
estrogens,O
or,O
additional,O
estrogen,O
agonist,O
antagonists,O
5,O
2,O
Cardiovascular,O
Disorders,O
Estrogen,O
agonist,O
antagonists,O
including,O
bazedoxifene,O
a,O
component,O
of,O
DUAVEE,O
and,O
estrogens,O
individually,O
are,O
known,O
to,O
increase,O
the,O
risk,Factor
of,O
VTE,AdverseReaction
An,O
increased,O
risk,O
of,O
stroke,AdverseReaction
and,O
DVT,AdverseReaction
has,O
been,O
reported,O
with,O
estrogen,DrugClass
alone,O
therapy,O
Should,O
any,O
of,O
these,O
occur,O
or,O
be,O
suspected,O
DUAVEE,O
should,O
be,O
discontinued,O
immediately,O
Risk,O
factors,O
for,O
arterial,O
vascular,O
disease,O
for,O
example,O
hypertension,O
diabetes,O
mellitus,O
tobacco,O
use,O
hypercholesterolemia,O
and,O
obesity,O
and,O
or,O
VTE,O
for,O
example,O
personal,O
history,O
or,O
family,O
history,O
of,O
VTE,O
obesity,O
and,O
systemic,O
lupus,O
erythematosus,O
should,O
be,O
managed,O
appropriately,O
Stroke,O
In,O
the,O
WHI,O
estrogen,O
alone,O
substudy,O
a,O
statistically,O
significant,O
increased,O
risk,O
of,O
stroke,AdverseReaction
was,O
reported,O
in,O
women,O
50,O
to,O
79,O
years,O
of,O
age,O
receiving,O
daily,O
conjugated estrogens,DrugClass
CE,O
0,O
625,O
mg,O
alone,O
compared,O
to,O
women,O
in,O
the,O
same,O
age,O
group,O
receiving,O
placebo,O
45,O
versus,O
33,O
per,O
10,O
000,O
women,O
years,O
The,O
increase,O
in,O
risk,O
was,O
demonstrated,O
in,O
year,O
1,O
and,O
persisted,O
see,O
Clinical,O
Studies,O
14,O
5,O
Subgroup,O
analyses,O
of,O
women,O
50,O
to,O
59,O
years,O
of,O
age,O
suggest,O
no,Negation
increased,O
risk,O
of,O
stroke,AdverseReaction
for,O
those,O
women,O
receiving,O
conjugated estrogens,DrugClass
0,O
625,O
mg,O
alone,O
versus,O
those,O
receiving,O
placebo,O
18,O
versus,O
21,O
per,O
10,O
000,O
women,O
years,O
Should,O
a,O
stroke,O
occur,O
or,O
be,O
suspected,O
DUAVEE,O
should,O
be,O
discontinued,O
immediately,O
see,O
Contraindications,O
4,O
Coronary,O
Heart,O
Disease,O
In,O
the,O
WHI,O
estrogen,O
alone,O
substudy,O
no,O
overall,O
effect,O
on,O
coronary heart disease,AdverseReaction
CHD,AdverseReaction
events,O
defined,O
as,O
nonfatal,Severity
myocardial infarction,AdverseReaction
silent myocardial infarction,AdverseReaction
or,O
CHD death,AdverseReaction
was,O
reported,O
in,O
women,O
receiving,O
estrogen,DrugClass
alone,O
compared,O
to,O
placebo,O
see,O
Clinical,O
Studies,O
14,O
5,O
Subgroup,O
analyses,O
of,O
women,O
50,O
to,O
59,O
years,O
of,O
age,O
suggest,O
a,O
statistically,O
non,O
significant,O
reduction,Negation
in,O
CHD,AdverseReaction
events,O
CE,O
0,O
625,O
mg,O
alone,O
compared,O
to,O
placebo,O
in,O
women,O
with,O
less,O
than,O
10,O
years,O
since,O
menopause,O
8,O
versus,O
16,O
per,O
10,O
000,O
women,O
years,O
Venous,O
Thromboembolism,O
VTE,O
In,O
the,O
WHI,O
estrogen,O
alone,O
substudy,O
the,O
risk,O
of,O
VTE,AdverseReaction
DVT,AdverseReaction
and,O
pulmonary embolism,AdverseReaction
PE,AdverseReaction
was,O
increased,O
for,O
women,O
receiving,O
daily,O
conjugated estrogens,DrugClass
0,O
625,O
mg,O
alone,O
compared,O
to,O
placebo,O
30,O
versus,O
22,O
per,O
10,O
000,O
women,O
years,O
although,O
only,O
the,O
increased,O
risk,O
of,O
DVT,AdverseReaction
reached,O
statistical,O
significance,O
23,O
versus,O
15,O
per,O
10,O
000,O
women,O
years,O
The,O
increase,O
in,O
VTE,AdverseReaction
risk,Factor
was,O
demonstrated,O
during,O
the,O
first,O
2,O
years,O
see,O
Clinical,O
Studies,O
14,O
5,O
If,O
feasible,O
DUAVEE,O
should,O
be,O
discontinued,O
at,O
least,O
4,O
to,O
6,O
weeks,O
before,O
surgery,O
of,O
the,O
type,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
thromboembolism,O
or,O
during,O
periods,O
of,O
prolonged,O
immobilization,O
Because,O
immobilization,O
increases,O
the,O
risk,O
for,O
venous,O
thromboembolic,O
events,O
independent,O
of,O
therapy,O
DUAVEE,O
should,O
be,O
discontinued,O
prior,O
to,O
and,O
during,O
prolonged,O
immobilization,O
e,O
g,O
post,O
surgical,O
recovery,O
prolonged,O
bed,O
rest,O
and,O
DUAVEE,O
therapy,O
should,O
be,O
resumed,O
only,O
after,O
the,O
patient,O
is,O
fully,O
ambulatory,O
In,O
addition,O
women,O
taking,O
DUAVEE,O
should,O
be,O
advised,O
to,O
move,O
about,O
periodically,O
during,O
travel,O
involving,O
prolonged,O
immobilization,O
5,O
3,O
Malignant,O
Neoplasms,O
Endometrial,O
Cancer,O
An,O
increased,O
risk,O
of,O
endometrial cancer,AdverseReaction
has,O
been,O
reported,O
with,O
the,O
use,O
of,O
unopposed,O
estrogen,DrugClass
therapy,O
in,O
women,O
with,O
a,O
uterus,O
The,O
reported,O
endometrial cancer,AdverseReaction
risk,O
among,O
unopposed,O
estrogen,DrugClass
users,O
is,O
about,O
2,O
to,O
12,O
times,O
greater,O
than,O
in,O
non,O
users,O
and,O
appears,O
dependent,O
on,O
duration,O
of,O
treatment,O
and,O
on,O
estrogen,O
dose,O
Most,O
studies,O
show,O
no,O
significant,O
increased,O
risk,O
associated,O
with,O
use,O
of,O
estrogens,O
for,O
less,O
than,O
1,O
year,O
The,O
greatest,O
risk,O
appears,O
associated,O
with,O
prolonged,O
use,O
with,O
increased,O
risks,O
of,O
15,O
to,O
24,O
fold,O
for,O
5,O
to,O
10,O
years,O
or,O
more,O
of,O
treatment,O
This,O
risk,O
has,O
been,O
shown,O
to,O
persist,O
for,O
at,O
least,O
8,O
to,O
15,O
years,O
after,O
estrogen,O
therapy,O
is,O
discontinued,O
DUAVEE,O
contains,O
an,O
estrogen,O
agonist,O
antagonist,O
This,O
component,O
reduces,O
the,O
risk,O
of,O
endometrial,O
hyperplasia,O
that,O
can,O
occur,O
with,O
the,O
conjugated,O
estrogens,O
component,O
Endometrial,O
hyperplasia,O
may,O
be,O
a,O
precursor,O
to,O
endometrial,O
cancer,O
Women,O
taking,O
DUAVEE,O
should,O
not,O
take,O
additional,O
estrogens,O
as,O
this,O
may,O
increase,O
the,O
risk,O
of,O
endometrial,O
hyperplasia,O
Clinical,O
surveillance,O
of,O
all,O
women,O
taking,O
DUAVEE,O
is,O
important,O
Adequate,O
diagnostic,O
measures,O
including,O
directed,O
or,O
random,O
endometrial,O
sampling,O
when,O
indicated,O
should,O
be,O
undertaken,O
to,O
rule,O
out,O
malignancy,O
in,O
postmenopausal,O
women,O
with,O
undiagnosed,O
persistent,O
or,O
recurring,O
abnormal,O
genital,O
bleeding,O
Breast,O
Cancer,O
The,O
most,O
important,O
randomized,O
clinical,O
study,O
providing,O
information,O
about,O
breast,O
cancer,O
in,O
estrogen,O
alone,O
users,O
is,O
the,O
WHI,O
substudy,O
of,O
daily,O
conjugated,O
estrogens,O
0,O
625,O
mg,O
alone,O
In,O
the,O
WHI,O
estrogen,O
alone,O
substudy,O
after,O
an,O
average,O
follow,O
up,O
of,O
7,O
1,O
years,O
daily,O
conjugated estrogen,DrugClass
0,O
625,O
mg,O
alone,O
was,O
not,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
invasive breast cancer,AdverseReaction
relative,O
risk,O
RR,O
0,O
80,O
The,O
use,O
of,O
estrogen,O
alone,O
has,O
been,O
reported,O
to,O
result,O
in,O
an,O
increase,O
in,O
abnormal,O
mammograms,O
requiring,O
further,O
evaluation,O
The,O
effect,O
of,O
treatment,O
with,O
DUAVEE,O
on,O
the,O
risk,O
of,O
breast,O
cancer,O
is,O
unknown,O
All,O
women,O
should,O
receive,O
yearly,O
breast,O
examinations,O
by,O
a,O
healthcare,O
provider,O
and,O
perform,O
monthly,O
breast,O
self,O
examinations,O
In,O
addition,O
mammography,O
examinations,O
should,O
be,O
scheduled,O
based,O
on,O
patient,O
age,O
risk,O
factors,O
and,O
prior,O
mammogram,O
results,O
Ovarian,O
Cancer,O
In,O
some,O
epidemiological,O
studies,O
the,O
use,O
of,O
estrogen,DrugClass
only,O
products,O
in,O
particular,O
for,O
5,O
or,O
more,O
years,O
has,O
been,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
ovarian cancer,AdverseReaction
However,O
the,O
duration,O
of,O
exposure,O
associated,O
with,O
increased,O
risk,O
is,O
not,O
consistent,O
across,O
all,O
epidemiologic,O
studies,O
and,O
some,O
report,O
no,O
association,O
The,O
effect,O
of,O
treatment,O
with,O
DUAVEE,O
on,O
the,O
risk,O
of,O
ovarian,O
cancer,O
is,O
unknown,O
5,O
4,O
Probable,O
Dementia,O
In,O
the,O
WHIMS,O
estrogen,O
alone,O
ancillary,O
study,O
of,O
WHI,O
a,O
population,O
of,O
2,O
947,O
hysterectomized,O
women,O
65,O
to,O
79,O
years,O
of,O
age,O
was,O
randomized,O
to,O
daily,O
CE,O
0,O
625,O
mg,O
alone,O
or,O
placebo,O
After,O
an,O
average,O
follow,O
up,O
of,O
5,O
2,O
years,O
28,O
women,O
in,O
the,O
estrogen,DrugClass
alone,O
group,O
and,O
19,O
women,O
in,O
the,O
placebo,O
group,O
were,O
diagnosed,O
with,O
probable,O
dementia,AdverseReaction
The,O
relative,O
risk,O
of,O
probable,O
dementia,AdverseReaction
for,O
CE,DrugClass
alone,O
versus,O
placebo,O
was,O
1,O
49,O
95,O
percent,O
CI,O
0,O
83,O
2,O
66,O
The,O
absolute,O
risk,O
of,O
probable,O
dementia,AdverseReaction
for,O
CE,DrugClass
alone,O
versus,O
placebo,O
was,O
37,O
versus,O
25,O
cases,O
per,O
10,O
000,O
women,O
years,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
and,O
Clinical,O
Studies,O
14,O
6,O
5,O
5,O
Gallbladder,O
Disease,O
A,O
2,O
to,O
4,O
fold,O
increase,O
in,O
the,O
risk,Factor
of,O
gallbladder disease,AdverseReaction
requiring,O
surgery,O
in,O
postmenopausal,O
women,O
receiving,O
estrogens,O
has,O
been,O
reported,O
5,O
6,O
Visual,O
Abnormalities,O
Retinal vascular thrombosis,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
receiving,O
estrogens,O
Discontinue,O
medication,O
pending,O
examination,O
if,O
there,O
is,O
sudden,O
partial,O
or,O
complete,O
loss,O
of,O
vision,O
or,O
a,O
sudden,O
onset,O
of,O
proptosis,O
diplopia,O
or,O
migraine,O
If,O
examination,O
reveals,O
papilledema,O
or,O
retinal,O
vascular,O
lesions,O
DUAVEE,O
should,O
be,O
permanently,O
discontinued,O
5,O
7,O
Elevated,O
Blood,O
Pressure,O
In,O
a,O
small,O
number,O
of,O
case,O
reports,O
in,O
women,O
receiving,O
estrogens,O
substantial,Severity
increases in blood pressure,AdverseReaction
have,O
been,O
attributed,O
to,O
idiosyncratic,O
reactions,O
to,O
estrogens,O
In,O
a,O
large,O
randomized,O
placebo,O
controlled,O
clinical,O
study,O
a,O
generalized,O
effect,AdverseReaction
of,O
estrogens,O
on blood pressure,AdverseReaction
was,O
not,Negation
seen,O
5,O
8,O
Hypertriglyceridemia,O
In,O
women,O
with,O
pre,O
existing,O
hypertriglyceridemia,O
treatment,O
with,O
estrogens,O
may,Factor
be,O
associated,O
with,O
elevations of plasma triglycerides,AdverseReaction
leading,O
to,O
pancreatitis,AdverseReaction
Consider,O
discontinuation,O
of,O
DUAVEE,O
if,O
pancreatitis,O
occurs,O
5,O
9,O
Hepatic,O
Impairment,O
and,O
Past,O
History,O
of,O
Cholestatic,O
Jaundice,O
DUAVEE,O
has,O
not,O
been,O
studied,O
in,O
women,O
with,O
impaired,O
liver,O
function,O
or,O
past,O
history,O
of,O
cholestatic,O
jaundice,O
Estrogens,O
may,O
be,O
poorly,O
metabolized,O
in,O
women,O
with,O
impaired,O
liver,O
function,O
On,O
average,O
women,O
with,O
hepatic,O
impairment,O
treated,O
with,O
bazedoxifene,O
alone,O
showed,O
a,O
4,O
3,O
fold,O
increase,O
in,O
overall,O
exposures,O
compared,O
with,O
controls,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
7,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
For,O
women,O
with,O
a,O
history,O
of,O
cholestatic,O
jaundice,O
associated,O
with,O
past,O
estrogen,O
use,O
or,O
with,O
pregnancy,O
caution,O
should,O
be,O
exercised,O
and,O
in,O
the,O
case,O
of,O
recurrence,O
DUAVEE,O
should,O
be,O
discontinued,O
Use,O
of,O
DUAVEE,O
in,O
patients,O
with,O
hepatic,O
impairment,O
is,O
contraindicated,O
see,O
Contraindications,O
4,O
5,O
10,O
Hypothyroidism,O
Estrogen,O
administration,O
leads,O
to,O
increased thyroid binding globulin,AdverseReaction
TBG,AdverseReaction
levels,AdverseReaction
Women,O
with,O
normal,O
thyroid,O
function,O
can,O
compensate,O
for,O
the,O
increased TBG,AdverseReaction
by,O
making,O
more,O
thyroid,O
hormone,O
thus,O
maintaining,O
free,O
T4,O
and,O
T3,O
serum,O
concentrations,O
in,O
the,O
normal,O
range,O
Women,O
dependent,O
on,O
thyroid,O
hormone,O
replacement,O
therapy,O
who,O
are,O
also,O
receiving,O
estrogens,O
may,O
require,O
increased,O
doses,O
of,O
their,O
thyroid,O
replacement,O
therapy,O
These,O
women,O
should,O
have,O
their,O
thyroid,O
function,O
monitored,O
in,O
order,O
to,O
maintain,O
their,O
free,O
thyroid,O
hormone,O
levels,O
in,O
an,O
acceptable,O
range,O
5,O
11,O
Fluid,O
Retention,O
Estrogens,O
may,Factor
cause,O
some,O
degree,O
of,O
fluid retention,AdverseReaction
Because,O
of,O
this,O
patients,O
who,O
have,O
conditions,O
that,O
might,O
be,O
influenced,O
by,O
this,O
factor,O
such,O
as,O
cardiac,O
dysfunction,O
or,O
renal,O
impairment,O
warrant,O
careful,O
observation,O
when,O
estrogens,O
are,O
prescribed,O
Use,O
of,O
DUAVEE,O
in,O
patients,O
with,O
renal,O
impairment,O
is,O
not,O
recommended,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
5,O
12,O
Hypocalcemia,O
Estrogen,O
therapy,O
should,O
be,O
used,O
with,O
caution,O
in,O
women,O
with,O
hypoparathyroidism,O
as,O
estrogen,O
induced,O
hypocalcemia,O
may,O
occur,O
5,O
13,O
Hereditary,O
Angioedema,O
Exogenous,O
estrogens,O
may,Factor
exacerbate,AdverseReaction
symptoms,O
of,O
angioedema,AdverseReaction
in,O
women,O
with,O
hereditary,O
angioedema,O
5,O
14,O
Exacerbation,O
of,O
Other,O
Conditions,O
Estrogens,O
may,O
cause,O
an,O
exacerbation,O
of,O
asthma,O
diabetes,O
mellitus,O
epilepsy,O
migraine,O
or,O
porphyria,O
systemic,O
lupus,O
erythematosus,O
and,O
hepatic,O
hemangiomas,O
and,O
should,O
be,O
used,O
with,O
caution,O
in,O
women,O
with,O
these,O
conditions,O
5,O
15,O
Premenopausal,O
Women,O
There,O
is,O
no,O
indication,O
for,O
premenopausal,O
use,O
of,O
DUAVEE,O
The,O
efficacy,O
and,O
safety,O
of,O
DUAVEE,O
in,O
premenopausal,O
women,O
have,O
not,O
been,O
established,O
and,O
its,O
use,O
is,O
not,O
recommended,O
5,O
16,O
Laboratory,O
Tests,O
Serum,O
follicle,O
stimulating,O
hormone,O
FSH,O
and,O
estradiol,O
levels,O
have,O
not,O
been,O
shown,O
to,O
be,O
useful,O
in,O
the,O
management,O
of,O
moderate,O
to,O
severe,O
vasomotor,O
symptoms,O
5,O
17,O
Drug,O
Laboratory,O
Test,O
Interactions,O
Accelerated prothrombin time,AdverseReaction
partial thromboplastin time,AdverseReaction
and,O
platelet aggregation time,AdverseReaction
increased platelet count,AdverseReaction
increased factors II factors factors factors factors factors factors factors factors,AdverseReaction
VII antigen,AdverseReaction
VIII antigen,AdverseReaction
VIII coagulant activity,AdverseReaction
IX,AdverseReaction
X,AdverseReaction
XII,AdverseReaction
VII X complex,AdverseReaction
II VII X complex,AdverseReaction
and,O
beta thromboglobulin,AdverseReaction
decreased levels of antifactor Xa levels of,AdverseReaction
and,O
antithrombin III,AdverseReaction
decreased antithrombin III activity,AdverseReaction
increased levels of fibrinogen levels of,AdverseReaction
and,O
fibrinogen activity,AdverseReaction
increased plasminogen antigen plasminogen,AdverseReaction
and,O
activity,AdverseReaction
Increased thyroid binding globulin,AdverseReaction
TBG,AdverseReaction
leading,O
to,O
increased circulating total thyroid hormone,AdverseReaction
as,O
measured,O
by,O
protein,O
bound,O
iodine,O
PBI,O
T4 levels,AdverseReaction
by,O
column,O
or,O
by,O
radioimmunoassay,O
or,O
T3 levels,AdverseReaction
by,O
radioimmunoassay,O
T3 resin uptake,AdverseReaction
is,O
decreased,AdverseReaction
reflecting,O
the,O
elevated TBG,AdverseReaction
Free,O
T4,O
and,O
free,O
T3,O
concentrations,O
are,O
unaltered,O
Women,O
on,O
thyroid,O
replacement,O
therapy,O
may,O
require,O
higher,O
doses,O
of,O
thyroid,O
hormone,O
Other,O
binding,O
proteins,O
may,Factor
be,O
elevated,AdverseReaction
in,O
serum,O
for,O
example,O
corticosteroid binding globulin,AdverseReaction
CBG,AdverseReaction
sex hormone binding globulin,AdverseReaction
SHBG,AdverseReaction
leading,O
to,O
increased total circulating corticosteroids total circulating,AdverseReaction
and,O
sex steroids,AdverseReaction
respectively,O
Free hormone concentrations,AdverseReaction
such,O
as,O
testosterone,AdverseReaction
and,O
estradiol,AdverseReaction
may,Factor
be,O
decreased,AdverseReaction
Other,O
plasma proteins,AdverseReaction
may,Factor
be,O
increased,AdverseReaction
angiotensinogen,AdverseReaction
renin substrate,AdverseReaction
alpha 1 antitrypsin,AdverseReaction
ceruloplasmin,AdverseReaction
Increased plasma high density lipoprotein,AdverseReaction
HDL,AdverseReaction
and,O
HDL2 cholesterol subfraction concentrations,AdverseReaction
reduced low density lipoprotein,AdverseReaction
LDL,AdverseReaction
cholesterol concentrations concentrations,AdverseReaction
increased triglyceride levels,AdverseReaction
Impaired glucose tolerance,AdverseReaction
""
BOXED,O
WARNING,O
WARNING,O
ENDOMETRIAL CANCER,AdverseReaction
CARDIOVASCULAR DISORDERS,AdverseReaction
AND,O
PROBABLE,Factor
DEMENTIA,AdverseReaction
WARNING,O
ENDOMETRIAL CANCER,AdverseReaction
CARDIOVASCULAR DISORDERS,AdverseReaction
AND,O
PROBABLE,Factor
DEMENTIA,AdverseReaction
Women,O
taking,O
DUAVEE,O
should,O
not,O
take,O
additional,O
estrogens,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
There,O
is,O
an,O
increased,O
risk,O
of,O
endometrial cancer,AdverseReaction
in,O
a,O
woman,O
with,O
a,O
uterus,O
who,O
uses,O
unopposed,O
estrogens,DrugClass
DUAVEE,O
has,O
been,O
shown,O
to,O
reduce the risk,Factor
of,O
endometrial hyperplasia,AdverseReaction
which,O
may,O
be,O
a,O
precursor,O
to,O
endometrial,O
cancer,O
Adequate,O
diagnostic,O
measures,O
including,O
directed,O
or,O
random,O
endometrial,O
sampling,O
when,O
indicated,O
should,O
be,O
undertaken,O
to,O
rule,O
out,O
malignancy,O
in,O
postmenopausal,O
women,O
with,O
undiagnosed,O
persistent,O
or,O
recurring,O
abnormal,O
genital,O
bleeding,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Estrogen,O
therapy,O
should,O
not,O
be,O
used,O
for,O
the,O
prevention,O
of,O
cardiovascular,O
disease,O
or,O
dementia,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
5,O
4,O
The,O
Women,O
s,O
Health,O
Initiative,O
WHI,O
estrogen,O
alone,O
substudy,O
reported,O
increased,O
risks,O
of,O
stroke,AdverseReaction
and,O
deep vein thrombosis,AdverseReaction
DVT,AdverseReaction
in,O
postmenopausal,O
women,O
50,O
to,O
79,O
years,O
of,O
age,O
during,O
7,O
1,O
years,O
of,O
treatment,O
with,O
daily,O
oral conjugated estrogens,DrugClass
0,O
625,O
mg,O
alone,O
relative,O
to,O
placebo,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
The,O
WHI,O
Memory,O
Study,O
WHIMS,O
estrogen,O
alone,O
ancillary,O
study,O
of,O
WHI,O
reported,O
an,O
increased,O
risk,O
of,O
probable,O
dementia,AdverseReaction
in,O
postmenopausal,O
women,O
65,O
years,O
of,O
age,O
and,O
older,O
during,O
5,O
2,O
years,O
of,O
treatment,O
with,O
daily,O
conjugated estrogens,DrugClass
0,O
625,O
mg,O
alone,O
relative,O
to,O
placebo,O
It,O
is,O
unknown,O
whether,O
this,O
finding,O
applies,O
to,O
younger,O
postmenopausal,O
women,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
In,O
the,O
absence,O
of,O
comparable,O
data,O
these,O
risks,O
should,O
be,O
assumed,O
to,O
be,O
similar,O
for,O
other,O
doses,O
of,O
conjugated,O
estrogens,O
and,O
other,O
dosage,O
forms,O
of,O
estrogens,O
Estrogens,O
should,O
be,O
prescribed,O
at,O
the,O
lowest,O
effective,O
doses,O
and,O
for,O
the,O
shortest,O
duration,O
consistent,O
with,O
treatment,O
goals,O
and,O
risks,O
for,O
the,O
individual,O
woman,O
EXCERPT,O
WARNING,O
ENDOMETRIAL CANCER,AdverseReaction
CARDIOVASCULAR DISORDERS,AdverseReaction
AND,O
PROBABLE,Factor
DEMENTIA,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
Boxed,O
Warning,O
Women,O
taking,O
DUAVEE,O
should,O
not,O
take,O
additional,O
estrogens,O
5,O
1,O
There,O
is,O
an,O
increased,O
risk,O
of,O
endometrial cancer,AdverseReaction
in,O
a,O
woman,O
with,O
a,O
uterus,O
who,O
uses,O
unopposed,O
estrogens,DrugClass
5,O
1,O
5,O
3,O
Estrogen,O
therapy,O
should,O
not,O
be,O
used,O
for,O
the,O
prevention,O
of,O
cardiovascular,O
disease,O
or,O
dementia,O
5,O
2,O
5,O
4,O
The,O
Women,O
s,O
Health,O
Initiative,O
WHI,O
estrogen,DrugClass
alone,O
substudy,O
reported,O
increased,O
risks,O
of,O
stroke,AdverseReaction
and,O
deep vein thrombosis,AdverseReaction
DVT,AdverseReaction
5,O
2,O
The,O
WHI,O
Memory,O
Study,O
WHIMS,O
estrogen,DrugClass
alone,O
ancillary,O
study,O
of,O
WHI,O
reported,O
an,O
increased,O
risk,O
of,O
probable,O
dementia,AdverseReaction
in,O
postmenopausal,O
women,O
65,O
years,O
of,O
age,O
and,O
older,O
5,O
4,O
BOXED,O
WARNING,O
Patient,O
InformationDUAVEE,O
r,O
DEW,O
ah,O
vee,O
conjugated,O
estrogens,O
bazedoxifene,O
Tablets,O
Read,O
this,O
Patient,O
Information,O
before,O
you,O
start,O
taking,O
DUAVEE,O
and,O
each,O
time,O
you,O
get,O
a,O
refill,O
There,O
may,O
be,O
new,O
information,O
This,O
information,O
does,O
not,O
take,O
the,O
place,O
of,O
talking,O
to,O
your,O
healthcare,O
provider,O
about,O
your,O
medical,O
condition,O
or,O
your,O
treatment,O
What,O
is,O
the,O
most,O
important,O
information,O
I,O
should,O
know,O
about,O
DUAVEE,O
Do,O
not,O
take,O
additional,O
estrogen,O
products,O
while,O
you,O
are,O
taking,O
DUAVEE,O
Using,O
estrogens,O
may,O
increase,O
your,O
chance,O
of,O
getting,O
cancer,O
of,O
the,O
uterus,O
womb,O
Report,O
any,O
unusual,O
vaginal,O
bleeding,O
right,O
away,O
while,O
you,O
are,O
taking,O
DUAVEE,O
Vaginal,O
bleeding,O
after,O
menopause,O
may,O
be,O
a,O
warning,O
sign,O
of,O
cancer,O
of,O
the,O
uterus,O
womb,O
Your,O
healthcare,O
provider,O
should,O
check,O
any,O
unusual,O
vaginal,O
bleeding,O
to,O
find,O
out,O
the,O
cause,O
Do,O
not,O
use,O
estrogens,O
to,O
prevent,O
heart,O
disease,O
heart,O
attacks,O
strokes,O
or,O
dementia,O
decline,O
in,O
brain,O
function,O
Using,O
estrogens,O
may,O
increase,O
your,O
chances,O
of,O
getting,O
strokes,O
or,O
blood,O
clots,O
Using,O
estrogens,O
may,O
increase,O
your,O
chance,O
of,O
getting,O
dementia,O
based,O
on,O
a,O
study,O
of,O
women,O
65,O
years,O
of,O
age,O
or,O
older,O
You,O
and,O
your,O
healthcare,O
provider,O
should,O
talk,O
regularly,O
about,O
whether,O
you,O
still,O
need,O
treatment,O
with,O
DUAVEE,O
What,O
is,O
DUAVEE,O
DUAVEE,O
is,O
a,O
prescription,O
medicine,O
that,O
contains,O
a,O
mixture,O
of,O
estrogens,O
and,O
bazedoxifene,O
What,O
is,O
DUAVEE,O
used,O
for,O
DUAVEE,O
is,O
used,O
after,O
menopause,O
for,O
women,O
with,O
a,O
uterus,O
to,O
reduce,O
moderate,O
to,O
severe,O
hot,O
flushesEstrogens,O
are,O
hormones,O
made,O
by,O
a,O
woman,O
s,O
ovaries,O
The,O
ovaries,O
normally,O
stop,O
making,O
estrogens,O
when,O
a,O
woman,O
is,O
between,O
45,O
and,O
55,O
years,O
old,O
This,O
drop,O
in,O
body,O
estrogen,O
levels,O
causes,O
the,O
change,O
of,O
life,O
or,O
menopause,O
the,O
end,O
of,O
monthly,O
menstrual,O
periods,O
Sometimes,O
both,O
ovaries,O
are,O
removed,O
during,O
an,O
operation,O
before,O
natural,O
menopause,O
takes,O
place,O
The,O
sudden,O
drop,O
in,O
estrogen,O
levels,O
causes,O
surgical,O
menopause,O
When,O
the,O
estrogen,O
levels,O
begin,O
dropping,O
some,O
women,O
get,O
very,O
uncomfortable,O
symptoms,O
such,O
as,O
feelings,O
of,O
warmth,O
in,O
the,O
face,O
neck,O
and,O
chest,O
or,O
sudden,O
intense,O
episodes,O
of,O
heat,O
and,O
sweating,O
hot,O
flashes,O
or,O
hot,O
flushes,O
In,O
some,O
women,O
the,O
symptoms,O
are,O
mild,O
and,O
they,O
will,O
not,O
need,O
to,O
take,O
medicines,O
In,O
other,O
women,O
symptoms,O
can,O
be,O
more,O
severe,O
help,O
reduce,O
your,O
chances,O
of,O
developing,O
osteoporosis,O
thin,O
weak,O
bones,O
If,O
you,O
use,O
DUAVEE,O
only,O
to,O
prevent,O
osteoporosis,O
due,O
to,O
menopause,O
talk,O
with,O
your,O
healthcare,O
provider,O
about,O
whether,O
a,O
different,O
treatment,O
or,O
medicine,O
without,O
estrogens,O
might,O
be,O
better,O
for,O
you,O
DUAVEE,O
should,O
be,O
taken,O
for,O
the,O
shortest,O
time,O
possible,O
and,O
only,O
for,O
as,O
long,O
as,O
treatment,O
is,O
needed,O
You,O
and,O
your,O
healthcare,O
provider,O
should,O
talk,O
regularly,O
about,O
whether,O
you,O
still,O
need,O
treatment,O
with,O
DUAVEE,O
DUAVEE,O
is,O
not,O
for,O
use,O
in,O
children,O
It,O
is,O
not,O
known,O
if,O
DUAVEE,O
is,O
safe,O
and,O
effective,O
in,O
people,O
with,O
kidney,O
problems,O
Who,O
should,O
not,O
take,O
DUAVEE,O
Do,O
not,O
take,O
DUAVEE,O
if,O
you,O
currently,O
have,O
or,O
have,O
had,O
blood,O
clots,O
are,O
allergic,O
to,O
estrogens,O
or,O
bazedoxifene,O
the,O
active,O
ingredients,O
in,O
DUAVEE,O
or,O
any,O
of,O
its,O
ingredients,O
See,O
the,O
list,O
of,O
ingredients,O
in,O
DUAVEE,O
at,O
the,O
end,O
of,O
this,O
leaflet,O
have,O
unusual,O
vaginal,O
bleeding,O
Vaginal,O
bleeding,O
after,O
menopause,O
may,O
be,O
a,O
warning,O
sign,O
of,O
cancer,O
of,O
the,O
uterus,O
womb,O
Your,O
healthcare,O
provider,O
should,O
check,O
any,O
unusual,O
vaginal,O
bleeding,O
to,O
find,O
out,O
the,O
cause,O
currently,O
have,O
or,O
have,O
had,O
certain,O
cancers,O
Estrogens,O
may,O
increase,O
the,O
chances,O
of,O
getting,O
certain,O
types,O
of,O
cancers,O
including,O
cancer,O
of,O
the,O
breast,O
or,O
uterus,O
If,O
you,O
have,O
or,O
have,O
had,O
cancer,O
talk,O
with,O
your,O
healthcare,O
provider,O
about,O
whether,O
you,O
should,O
use,O
DUAVEE,O
currently,O
have,O
or,O
have,O
had,O
liver,O
problems,O
have,O
been,O
diagnosed,O
with,O
a,O
bleeding,O
disorder,O
think,O
you,O
may,O
be,O
pregnant,O
DUAVEE,O
is,O
not,O
for,O
pregnant,O
women,O
If,O
you,O
think,O
you,O
may,O
be,O
pregnant,O
you,O
should,O
have,O
a,O
pregnancy,O
test,O
and,O
know,O
the,O
results,O
Do,O
not,O
take,O
DUAVEE,O
if,O
the,O
test,O
is,O
positive,O
and,O
talk,O
to,O
your,O
healthcare,O
provider,O
are,O
breastfeeding,O
or,O
plan,O
to,O
breastfeed,O
It,O
is,O
not,O
known,O
if,O
DUAVEE,O
passes,O
into,O
your,O
breast,O
milk,O
You,O
and,O
your,O
healthcare,O
provider,O
should,O
decide,O
if,O
you,O
will,O
take,O
DUAVEE,O
or,O
breastfeed,O
You,O
should,O
not,O
do,O
both,O
What,O
should,O
I,O
tell,O
my,O
healthcare,O
provider,O
before,O
taking,O
DUAVEE,O
Before,O
you,O
take,O
DUAVEE,O
tell,O
your,O
healthcare,O
provider,O
if,O
you,O
have,O
any,O
unusual,O
vaginal,O
bleeding,O
have,O
any,O
other,O
medical,O
conditions,O
Your,O
healthcare,O
provider,O
may,O
need,O
to,O
check,O
you,O
more,O
carefully,O
if,O
you,O
have,O
certain,O
conditions,O
such,O
as,O
asthma,O
wheezing,O
epilepsy,O
seizures,O
diabetes,O
migraine,O
endometriosis,O
lupus,O
or,O
problems,O
with,O
your,O
heart,O
liver,O
thyroid,O
kidneys,O
or,O
have,O
high,O
calcium,O
levels,O
in,O
your,O
blood,O
are,O
going,O
to,O
have,O
surgery,O
or,O
will,O
be,O
on,O
bed,O
rest,O
Your,O
healthcare,O
provider,O
will,O
let,O
you,O
know,O
if,O
you,O
need,O
to,O
stop,O
taking,O
DUAVEE,O
Tell,O
your,O
healthcare,O
provider,O
about,O
all,O
the,O
medicines,O
you,O
take,O
including,O
prescription,O
and,O
over,O
the,O
counter,O
medicines,O
vitamins,O
and,O
herbal,O
supplements,O
Especially,O
tell,O
your,O
healthcare,O
provider,O
if,O
you,O
take,O
other,O
hormonal,O
medicines,O
including,O
progestins,O
or,O
other,O
medicines,O
like,O
DUAVEE,O
Ask,O
your,O
healthcare,O
provider,O
if,O
you,O
do,O
not,O
know,O
if,O
you,O
take,O
any,O
of,O
these,O
medicines,O
Some,O
medicines,O
may,O
affect,O
how,O
DUAVEE,O
works,O
DUAVEE,O
may,O
also,O
affect,O
how,O
your,O
other,O
medicines,O
work,O
Keep,O
a,O
list,O
of,O
your,O
medicines,O
and,O
show,O
it,O
to,O
your,O
healthcare,O
provider,O
and,O
pharmacist,O
when,O
you,O
get,O
a,O
new,O
medicine,O
How,O
should,O
I,O
take,O
DUAVEE,O
DUAVEE,O
comes,O
in,O
a,O
blister,O
package,O
Record,O
the,O
date,O
you,O
open,O
the,O
foil,O
pouch,O
in,O
the,O
space,O
provided,O
on,O
the,O
blister,O
package,O
label,O
Do,O
not,O
use,O
if,O
the,O
blister,O
package,O
has,O
been,O
open,O
for,O
more,O
than,O
60,O
days,O
Take,O
DUAVEE,O
exactly,O
as,O
your,O
healthcare,O
provider,O
tells,O
you,O
to,O
take,O
it,O
Take,O
1,O
DUAVEE,O
tablet,O
at,O
the,O
same,O
time,O
each,O
day,O
DUAVEE,O
should,O
be,O
swallowed,O
whole,O
Take,O
DUAVEE,O
with,O
or,O
without,O
food,O
You,O
should,O
not,O
remove,O
DUAVEE,O
from,O
the,O
blister,O
until,O
right,O
before,O
you,O
are,O
ready,O
to,O
take,O
it,O
Remove,O
1,O
tablet,O
at,O
a,O
time,O
from,O
the,O
blister,O
package,O
Do,O
not,O
place,O
DUAVEE,O
in,O
pill,O
boxes,O
or,O
pill,O
organizers,O
If,O
you,O
miss,O
a,O
dose,O
of,O
DUAVEE,O
take,O
it,O
as,O
soon,O
as,O
you,O
remember,O
If,O
it,O
is,O
almost,O
time,O
for,O
your,O
next,O
dose,O
skip,O
the,O
missed,O
dose,O
Take,O
the,O
next,O
dose,O
at,O
your,O
regular,O
time,O
Do,O
not,O
take,O
2,O
doses,O
at,O
the,O
same,O
time,O
unless,O
your,O
healthcare,O
provider,O
tells,O
you,O
to,O
If,O
you,O
are,O
not,O
sure,O
about,O
your,O
dosing,O
call,O
your,O
healthcare,O
provider,O
If,O
you,O
take,O
a,O
calcium,O
or,O
vitamin,O
D,O
supplement,O
you,O
may,O
take,O
it,O
at,O
the,O
same,O
time,O
you,O
take,O
DUAVEE,O
If,O
you,O
take,O
too,O
much,O
DUAVEE,O
call,O
your,O
healthcare,O
provider,O
Symptoms,O
of,O
taking,O
too,O
much,O
DUAVEE,O
include,O
nauseavomitingbreast,O
tendernessdizzinessabdominal,O
painfeeling,O
tiredvaginal,O
bleeding,O
What,O
are,O
the,O
possible,O
side,O
effects,O
of,O
DUAVEE,O
Side,O
effects,O
are,O
grouped,O
by,O
how,O
serious,O
they,O
are,O
and,O
how,O
often,O
they,O
happen,O
when,O
you,O
are,O
treated,O
Serious,O
side,O
effects,O
include,O
blood,O
clots,O
stroke,O
heart,O
attack,O
cancer,O
of,O
the,O
lining,O
of,O
the,O
uterus,O
breast,O
cancer,O
cancer,O
of,O
the,O
ovary,O
dementia,O
gallbladder,O
problems,O
loss,O
of,O
vision,O
high,O
blood,O
pressure,O
increased,O
fats,O
in,O
your,O
blood,O
liver,O
problems,O
thyroid,O
problems,O
fluid,O
retention,O
low,O
calcium,O
swelling,O
of,O
your,O
mouth,O
or,O
tongue,O
worsening,O
of,O
other,O
medical,O
problems,O
such,O
as,O
asthma,O
diabetes,O
epilepsy,O
migraines,O
a,O
genetic,O
problem,O
called,O
porphyria,O
lupus,O
and,O
liver,O
problems,O
Call,O
your,O
healthcare,O
provider,O
right,O
away,O
if,O
you,O
get,O
any,O
of,O
the,O
following,O
warning,O
signs,O
or,O
any,O
other,O
unusual,O
symptoms,O
that,O
concern,O
you,O
new,O
breast,O
lumps,O
unusual,O
vaginal,O
bleeding,O
changes,O
in,O
vision,O
or,O
speech,O
sudden,O
new,O
severe,O
headaches,O
severe,O
pains,O
in,O
your,O
chest,O
or,O
legs,O
with,O
or,O
without,O
shortness,O
of,O
breath,O
weakness,O
and,O
fatigue,O
Less,O
serious,O
but,O
common,O
side,O
effects,O
include,O
muscle,O
spasms,O
nausea,O
diarrhea,O
upset,O
stomach,O
abdominal,O
pain,O
throat,O
pain,O
dizziness,O
neck,O
pain,O
These,O
are,O
not,O
all,O
the,O
possible,O
side,O
effects,O
of,O
DUAVEE,O
For,O
more,O
information,O
ask,O
your,O
healthcare,O
provider,O
or,O
pharmacist,O
Tell,O
your,O
healthcare,O
provider,O
if,O
you,O
have,O
any,O
side,O
effects,O
that,O
bother,O
you,O
or,O
do,O
not,O
go,O
away,O
Call,O
your,O
doctor,O
for,O
medical,O
advice,O
about,O
side,O
effects,O
You,O
may,O
report,O
side,O
effects,O
to,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
What,O
can,O
I,O
do,O
to,O
lower,O
my,O
chances,O
of,O
a,O
serious,O
side,O
effect,O
with,O
DUAVEE,O
Talk,O
with,O
your,O
healthcare,O
provider,O
regularly,O
about,O
whether,O
you,O
should,O
continue,O
taking,O
DUAVEE,O
See,O
you,O
healthcare,O
provider,O
right,O
away,O
if,O
you,O
get,O
vaginal,O
bleeding,O
while,O
taking,O
DUAVEE,O
Have,O
a,O
pelvic,O
exam,O
breast,O
exam,O
and,O
mammogram,O
breast,O
X,O
ray,O
every,O
year,O
unless,O
your,O
healthcare,O
provider,O
tells,O
you,O
something,O
else,O
If,O
members,O
of,O
your,O
family,O
have,O
had,O
breast,O
cancer,O
or,O
if,O
you,O
have,O
ever,O
had,O
breast,O
lumps,O
or,O
an,O
abnormal,O
mammogram,O
you,O
may,O
need,O
to,O
have,O
breast,O
exams,O
more,O
often,O
If,O
you,O
have,O
high,O
blood,O
pressure,O
high,O
cholesterol,O
fat,O
in,O
the,O
blood,O
diabetes,O
are,O
overweight,O
or,O
if,O
you,O
use,O
tobacco,O
you,O
may,O
have,O
higher,O
chances,O
of,O
getting,O
heart,O
disease,O
Ask,O
your,O
healthcare,O
provider,O
for,O
ways,O
to,O
lower,O
your,O
chances,O
of,O
getting,O
heart,O
disease,O
How,O
do,O
I,O
store,O
DUAVEE,O
Store,O
DUAVEE,O
at,O
room,O
temperature,O
between,O
68,O
degrees,O
F,O
to,O
77,O
degrees,O
F,O
20,O
degrees,O
C,O
to,O
25,O
degrees,O
C,O
Keep,O
DUAVEE,O
in,O
the,O
blister,O
until,O
you,O
are,O
ready,O
to,O
take,O
it,O
to,O
protect,O
the,O
tablet,O
from,O
moisture,O
Do,O
not,O
place,O
DUAVEE,O
in,O
pill,O
boxes,O
or,O
pill,O
organizers,O
After,O
opening,O
the,O
foil,O
pouch,O
the,O
DUAVEE,O
blisters,O
come,O
in,O
DUAVEE,O
must,O
be,O
used,O
within,O
60,O
days,O
Keep,O
DUAVEE,O
and,O
all,O
other,O
medicines,O
out,O
of,O
the,O
reach,O
of,O
children,O
General,O
information,O
about,O
the,O
safe,O
and,O
effective,O
use,O
of,O
DUAVEE,O
Medicines,O
are,O
sometimes,O
prescribed,O
for,O
purposes,O
other,O
than,O
those,O
listed,O
in,O
a,O
Patient,O
Information,O
leaflet,O
Do,O
not,O
use,O
DUAVEE,O
for,O
a,O
condition,O
for,O
which,O
it,O
was,O
not,O
prescribed,O
Do,O
not,O
give,O
DUAVEE,O
to,O
other,O
people,O
even,O
if,O
they,O
have,O
the,O
same,O
symptoms,O
you,O
have,O
It,O
may,O
harm,O
them,O
This,O
Patient,O
Information,O
summarizes,O
the,O
most,O
important,O
information,O
about,O
DUAVEE,O
If,O
you,O
would,O
like,O
more,O
information,O
talk,O
with,O
your,O
healthcare,O
provider,O
You,O
can,O
ask,O
your,O
pharmacist,O
or,O
healthcare,O
provider,O
for,O
information,O
about,O
DUAVEE,O
that,O
is,O
written,O
for,O
health,O
professionals,O
For,O
more,O
information,O
go,O
to,O
www,O
DUAVEE,O
com,O
or,O
call,O
1,O
800,O
438,O
1985,O
What,O
are,O
the,O
ingredients,O
in,O
DUAVEE,O
Active,O
Ingredients,O
conjugated,O
estrogens,O
and,O
bazedoxifene,O
Conjugated,O
estrogens,O
are,O
a,O
mixture,O
of,O
sodium,O
estrone,O
sulfate,O
and,O
sodium,O
equilin,O
sulfate,O
and,O
other,O
components,O
including,O
sodium,O
sulfate,O
conjugates,O
17alpha,O
dihydroequilin,O
17alpha,O
estradiol,O
and,O
17beta,O
dihydroequilin,O
Inactive,O
Ingredients,O
calcium,O
phosphate,O
tribasic,O
hydroxypropyl,O
cellulose,O
microcrystalline,O
cellulose,O
powdered,O
cellulose,O
hypromellose,O
lactose,O
monohydrate,O
magnesium,O
stearate,O
polyethylene,O
glycol,O
sucrose,O
ascorbic,O
acid,O
sucrose,O
palmitic,O
acid,O
ester,O
hydroxyethylcellulose,O
titanium,O
dioxide,O
red,O
iron,O
oxide,O
yellow,O
iron,O
oxide,O
black,O
iron,O
oxide,O
povidone,O
polydextrose,O
maltitol,O
poloxamer,O
188,O
propylene,O
glycol,O
isopropyl,O
alcohol,O
This,O
Patient,O
Information,O
has,O
been,O
approved,O
by,O
the,O
U,O
S,O
Food,O
and,O
Drug,O
Administration,O
This,O
product,O
s,O
label,O
may,O
have,O
been,O
updated,O
For,O
current,O
full,O
prescribing,O
information,O
please,O
visit,O
www,O
pfizer,O
com,O
LAB,O
0583,O
1,O
0,O
October,O
2013,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
label,O
Cardiovascular Disorders,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Malignant Neoplasms,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Gallbladder Disease,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Hypertriglyceridemia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
EXCERPT,O
In,O
four,O
prospective,O
randomized,O
placebo,O
controlled,O
trials,O
the,O
common,O
adverse,O
reactions,O
incidence,O
5,O
were,O
muscle spasms,AdverseReaction
nausea,AdverseReaction
diarrhea,AdverseReaction
dyspepsia,AdverseReaction
abdominal pain upper,AdverseReaction
oropharyngeal pain,AdverseReaction
dizziness,AdverseReaction
and,O
neck pain,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Pfizer,O
Inc,O
at,O
1,O
800,O
438,O
1985,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
safety,O
of,O
conjugated,O
estrogens,O
bazedoxifene,O
was,O
evaluated,O
in,O
four,O
Phase,O
3,O
clinical,O
trials,O
ranging,O
from,O
12,O
weeks,O
to,O
24,O
months,O
in,O
duration,O
and,O
enrolling,O
6,O
210,O
postmenopausal,O
women,O
age,O
40,O
to,O
75,O
years,O
mean,O
age,O
55,O
years,O
A,O
total,O
of,O
1,O
224,O
patients,O
were,O
treated,O
with,O
DUAVEE,O
and,O
1,O
069,O
patients,O
received,O
placebo,O
Women,O
enrolled,O
in,O
Studies,O
1,O
and,O
2,O
received,O
calcium,O
600,O
1200,O
mg,O
and,O
vitamin,O
D,O
200,O
400,O
IU,O
daily,O
while,O
women,O
in,O
Studies,O
3,O
and,O
4,O
received,O
no,O
calcium,O
and,O
vitamin,O
D,O
supplementation,O
as,O
part,O
of,O
the,O
protocol,O
The,O
incidence,O
of,O
all,O
cause,O
mortality,AdverseReaction
was,O
0,O
0,O
in,O
the,O
DUAVEE,O
group,O
and,O
0,O
2,O
in,O
the,O
placebo,O
group,O
The,O
incidence,O
of,O
serious,O
adverse,O
reactions,O
was,O
3,O
5,O
in,O
the,O
DUAVEE,O
group,O
and,O
4,O
8,O
in,O
the,O
placebo,O
group,O
The,O
percentage,O
of,O
patients,O
who,O
withdrew,O
from,O
treatment,O
due,O
to,O
adverse,O
reactions,O
was,O
7,O
5,O
in,O
the,O
DUAVEE,O
group,O
and,O
10,O
0,O
in,O
the,O
placebo,O
group,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
were,O
hot flush,AdverseReaction
abdominal pain upper,AdverseReaction
and,O
nausea,AdverseReaction
The,O
most,O
commonly,O
observed,O
adverse,O
reactions,O
incidence,O
5,O
more,O
frequently,O
reported,O
in,O
women,O
treated,O
with,O
DUAVEE,O
than,O
placebo,O
are,O
presented,O
in,O
Table,O
1,O
Table,O
1,O
Adverse,O
Reactions,O
Incidence,O
5,O
More,O
Common,O
in,O
the,O
DUAVEE,O
Treatment,O
Group,O
in,O
Placebo,O
controlled,O
Trials,O
DUAVEE,O
N,O
1224,O
n,O
Placebo,O
N,O
1069,O
n,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
100,O
8,O
58,O
5,O
Diarrhea,AdverseReaction
96,O
8,O
57,O
5,O
Dyspepsia,AdverseReaction
84,O
7,O
59,O
6,O
Abdominal pain upper,AdverseReaction
81,O
7,O
58,O
5,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Muscle spasms,AdverseReaction
110,O
9,O
63,O
6,O
Neck pain,AdverseReaction
62,O
5,O
46,O
4,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
65,O
5,O
37,O
3,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Oropharyngeal pain,AdverseReaction
80,O
7,O
61,O
6,O
Venous,O
thromboembolism,O
In,O
the,O
clinical,O
studies,O
with,O
DUAVEE,O
the,O
reporting,O
rates,O
for,O
venous thromboembolism,AdverseReaction
deep venous thrombosis,AdverseReaction
pulmonary embolism,AdverseReaction
and,O
retinal vein thrombosis,AdverseReaction
were,O
low,O
in,O
all,O
treatment,O
groups,O
Adverse,O
reactions,O
of,O
venous thromboembolism,AdverseReaction
were,O
reported,O
in,O
0,O
0,O
of,O
patients,O
treated,O
with,O
DUAVEE,O
and,O
0,O
1,O
of,O
patients,O
treated,O
with,O
placebo,O
Due,O
to,O
the,O
low,O
rate,O
of,O
events,O
in,O
both,O
groups,O
it,O
is,O
not,O
possible,O
to,O
conclude,O
that,O
the,O
risk,Factor
of,O
venous thromboembolism,AdverseReaction
with,O
DUAVEE,O
is,O
different,O
from,O
that,O
seen,O
with,O
other,O
estrogen,O
therapies,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Intraocular pressure,AdverseReaction
IOP,AdverseReaction
increase,AdverseReaction
Prolonged,O
use,O
of,O
corticosteroids,DrugClass
may,O
result,O
in,O
glaucoma,AdverseReaction
with,O
damage to the optic nerve,AdverseReaction
defects in visual acuity,AdverseReaction
and,O
fields of vision,AdverseReaction
If,O
this,O
product,O
is,O
used,O
for,O
10,O
days,O
or,O
longer,O
IOP,O
should,O
be,O
monitored,O
5,O
1,O
item,O
Cataracts,O
Use,O
of,O
corticosteroids,DrugClass
may,O
result,O
in,O
posterior subcapsular cataract,AdverseReaction
formation,O
5,O
2,O
item,O
Delayed,O
healing,O
The,O
use,O
of,O
steroids,DrugClass
after,O
cataract,O
surgery,O
may,O
delay healing,AdverseReaction
and,O
increase,AdverseReaction
the,O
incidence,O
of,O
bleb formation,AdverseReaction
In,O
those,O
diseases,O
causing,O
thinning,O
of,O
the,O
cornea,O
or,O
sclera,O
perforations,AdverseReaction
have,O
been,O
known,O
to,O
occur,O
with,O
the,O
use,O
of,O
topical,O
steroids,DrugClass
The,O
initial,O
prescription,O
and,O
renewal,O
of,O
the,O
medication,O
order,O
beyond,O
28,O
days,O
should,O
be,O
made,O
by,O
a,O
physician,O
only,O
after,O
examination,O
of,O
the,O
patient,O
with,O
the,O
aid,O
of,O
magnification,O
such,O
as,O
slit,O
lamp,O
biomicroscopy,O
and,O
where,O
appropriate,O
fluorescein,O
staining,O
5,O
3,O
item,O
Bacterial,O
infections,O
Prolonged,O
use,O
of,O
corticosteroids,DrugClass
may,O
suppress the host response,AdverseReaction
and,O
thus,O
increase,O
the,O
hazard,O
of,O
secondary ocular infections,AdverseReaction
In,O
acute,O
purulent,O
conditions,O
steroids,O
may,O
mask,O
infection,O
or,O
enhance,O
existing,O
infection,O
If,O
signs,O
and,O
symptoms,O
fail,O
to,O
improve,O
after,O
2,O
days,O
the,O
patient,O
should,O
be,O
re,O
evaluated,O
5,O
4,O
item,O
Viral,O
infections,O
Employment,O
of,O
a,O
corticosteroid,O
medication,O
in,O
the,O
treatment,O
of,O
patients,O
with,O
a,O
history,O
of,O
herpes,O
simplex,O
requires,O
great,O
caution,O
Use,O
of,O
ocular,O
steroids,DrugClass
may,O
prolong,O
the,O
course,O
and,O
may,O
exacerbate,AdverseReaction
the,O
severity,O
of,O
many,O
viral infections of the eye,AdverseReaction
including,O
herpes simplex,AdverseReaction
5,O
5,O
item,O
Fungal,O
infections,O
Fungal infections of the cornea,AdverseReaction
are,O
particularly,O
prone,O
to,O
develop,O
coincidentally,O
with,O
long,O
term,O
local,O
steroid,DrugClass
application,O
Fungus,O
invasion,O
must,O
be,O
considered,O
in,O
any,O
persistent,O
corneal,O
ulceration,O
where,O
a,O
steroid,O
has,O
been,O
used,O
or,O
is,O
in,O
use,O
5,O
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Alcon,O
Laboratories,O
Inc,O
at,O
1,O
800,O
757,O
9195,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
5,O
1,O
IOP,O
Increase,O
Prolonged,O
use,O
of,O
corticosteroids,DrugClass
may,O
result,O
in,O
glaucoma,AdverseReaction
with,O
damage to the optic nerve,AdverseReaction
defects in visual acuity,AdverseReaction
and,O
fields of vision,AdverseReaction
Steroids,O
should,O
be,O
used,O
with,O
caution,O
in,O
the,O
presence,O
of,O
glaucoma,O
If,O
this,O
product,O
is,O
used,O
for,O
10,O
days,O
or,O
longer,O
intraocular,O
pressure,O
should,O
be,O
monitored,O
5,O
2,O
Cataracts,O
Use,O
of,O
corticosteroids,DrugClass
may,O
result,O
in,O
posterior subcapsular cataract,AdverseReaction
formation,O
5,O
3,O
Delayed,O
Healing,O
The,O
use,O
of,O
steroids,DrugClass
after,O
cataract,O
surgery,O
may,O
delay healing,AdverseReaction
and,O
increase,AdverseReaction
the,O
incidence,O
of,O
bleb formation,AdverseReaction
In,O
those,O
diseases,O
causing,O
thinning,O
of,O
the,O
cornea,O
or,O
sclera,O
perforations,AdverseReaction
have,O
been,O
known,O
to,O
occur,O
with,O
the,O
use,O
of,O
topical,O
steroids,DrugClass
The,O
initial,O
prescription,O
and,O
renewal,O
of,O
the,O
medication,O
order,O
beyond,O
28,O
days,O
should,O
be,O
made,O
by,O
a,O
physician,O
only,O
after,O
examination,O
of,O
the,O
patient,O
with,O
the,O
aid,O
of,O
magnification,O
such,O
as,O
slit,O
lamp,O
biomicroscopy,O
and,O
where,O
appropriate,O
fluorescein,O
staining,O
5,O
4,O
Bacterial,O
Infections,O
Prolonged,O
use,O
of,O
corticosteroids,DrugClass
may,O
suppress the host response,AdverseReaction
and,O
thus,O
increase,O
the,O
hazard,O
of,O
secondary ocular infections,AdverseReaction
In,O
acute,O
purulent,O
conditions,O
steroids,O
may,O
mask,O
infection,O
or,O
enhance,O
existing,O
infection,O
If,O
signs,O
and,O
symptoms,O
fail,O
to,O
improve,O
after,O
2,O
days,O
the,O
patient,O
should,O
be,O
re,O
evaluated,O
5,O
5,O
Viral,O
Infections,O
Employment,O
of,O
a,O
corticosteroid,O
medication,O
in,O
the,O
treatment,O
of,O
patients,O
with,O
a,O
history,O
of,O
herpes,O
simplex,O
requires,O
great,O
caution,O
Use,O
of,O
ocular,O
steroids,DrugClass
may,O
prolong,O
the,O
course,O
and,O
may,O
exacerbate,AdverseReaction
the,O
severity,O
of,O
many,O
viral infections of the eye,AdverseReaction
including,O
herpes simplex,AdverseReaction
5,O
6,O
Fungal,O
Infections,O
Fungal infections of the cornea,AdverseReaction
are,O
particularly,O
prone,O
to,O
develop,O
coincidentally,O
with,O
long,O
term,O
local,O
steroid,DrugClass
application,O
Fungus,O
invasion,O
must,O
be,O
considered,O
in,O
any,O
persistent,O
corneal,O
ulceration,O
where,O
a,O
steroid,O
has,O
been,O
used,O
or,O
is,O
in,O
use,O
Fungal,O
culture,O
should,O
be,O
taken,O
when,O
appropriate,O
5,O
7,O
Topical,O
Ophthalmic,O
Use,O
Only,O
DUREZOL,O
is,O
not,O
indicated,O
for,O
intraocular,O
administration,O
5,O
8,O
Contact,O
Lens,O
Wear,O
DUREZOL,O
should,O
not,O
be,O
instilled,O
while,O
wearing,O
contact,O
lenses,O
Remove,O
contact,O
lenses,O
prior,O
to,O
instillation,O
of,O
DUREZOL,O
The,O
preservative,O
in,O
DUREZOL,O
may,O
be,O
absorbed,O
by,O
soft,O
contact,O
lenses,O
Lenses,O
may,O
be,O
reinserted,O
after,O
10,O
minutes,O
following,O
administration,O
of,O
DUREZOL,O
""
6,O
ADVERSE,O
REACTIONS,O
Adverse,O
reactions,O
associated,O
with,O
ophthalmic steroids,DrugClass
include,O
elevated intraocular pressure,AdverseReaction
which,O
may,O
be,O
associated,O
with,O
optic nerve damage,AdverseReaction
visual acuity,AdverseReaction
and,O
field defects,AdverseReaction
posterior subcapsular cataract formation,AdverseReaction
secondary ocular infection ocular infection,AdverseReaction
from,O
pathogens,O
including,O
herpes simplex,AdverseReaction
and,O
perforation of the globe,AdverseReaction
where,O
there,O
is,O
thinning,O
of,O
the,O
cornea,O
or,O
sclera,O
6,O
1,O
Ocular,O
Surgery,O
Ocular adverse reactions,AdverseReaction
occurring,O
in,O
5,O
15,O
of,O
subjects,O
in,O
clinical,O
studies,O
with,O
DUREZOL,O
included,O
corneal edema,AdverseReaction
ciliary,AdverseReaction
and,O
conjunctival hyperemia,AdverseReaction
eye pain,AdverseReaction
photophobia,AdverseReaction
posterior capsule opacification,AdverseReaction
anterior chamber cells,AdverseReaction
anterior chamber flare,AdverseReaction
conjunctival edema,AdverseReaction
and,O
blepharitis,AdverseReaction
Other,O
ocular,O
adverse,O
reactions,O
occurring,O
in,O
1,O
5,O
of,O
subjects,O
included,O
reduced visual acuity,AdverseReaction
punctate keratitis,AdverseReaction
eye inflammation,AdverseReaction
and,O
iritis,AdverseReaction
Ocular,O
adverse,O
reactions,O
occurring,O
in,O
1,O
of,O
subjects,O
included,O
application site discomfort site,AdverseReaction
or,O
irritation,AdverseReaction
corneal pigmentation,AdverseReaction
and,O
striae,AdverseReaction
episcleritis,AdverseReaction
eye pruritis,AdverseReaction
eyelid irritation,AdverseReaction
and,O
crusting,AdverseReaction
foreign body sensation,AdverseReaction
increased lacrimation,AdverseReaction
macular edema,AdverseReaction
sclera hyperemia,AdverseReaction
and,O
uveitis,AdverseReaction
Most,O
of,O
these,O
reactions,O
may,O
have,O
been,O
the,O
consequence,O
of,O
the,O
surgical,O
procedure,O
6,O
2,O
Endogenous,O
Anterior,O
Uveitis,O
A,O
total,O
of,O
200,O
subjects,O
participated,O
in,O
the,O
clinical,O
trials,O
for,O
endogenous,O
anterior,O
uveitis,O
of,O
which,O
106,O
were,O
exposed,O
to,O
DUREZOL,O
The,O
most,O
common,O
adverse,O
reactions,O
of,O
those,O
exposed,O
to,O
DUREZOL,O
occurring,O
in,O
5,O
10,O
of,O
subjects,O
included,O
blurred vision,AdverseReaction
eye irritation,AdverseReaction
eye pain,AdverseReaction
headache,AdverseReaction
increased IOP,AdverseReaction
iritis,AdverseReaction
limbal,AdverseReaction
and,O
conjunctival hyperemia,AdverseReaction
punctate keratitis,AdverseReaction
and,O
uveitis,AdverseReaction
Adverse,O
reactions,O
occurring,O
in,O
2,O
5,O
of,O
subjects,O
included,O
anterior chamber flare,AdverseReaction
corneal edema,AdverseReaction
dry eye,AdverseReaction
iridocyclitis,AdverseReaction
photophobia,AdverseReaction
and,O
reduced visual acuity,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
The,O
potency,O
Units,O
of,O
DYSPORT,O
r,O
are,O
not,O
interchangeable,O
with,O
other,O
preparations,O
of,O
botulinum,O
toxin,O
products,O
and,O
therefore,O
units,O
of,O
biological,O
activity,O
of,O
DYSPORT,O
r,O
cannot,O
be,O
compared,O
to,O
or,O
converted,O
into,O
units,O
of,O
any,O
other,O
botulinum,O
toxin,O
products,O
5,O
1,O
Recommended,O
dose,O
and,O
frequency,O
of,O
administration,O
should,O
not,O
be,O
exceeded,O
5,O
4,O
Immediate,O
medical,O
attention,O
may,O
be,O
required,O
in,O
cases,O
of,O
respiratory,AdverseReaction
speech,AdverseReaction
or,O
swallowing difficulties,AdverseReaction
5,O
3,O
Concomitant,O
neuromuscular,O
disorder,O
may,O
exacerbate,O
clinical,O
effects,O
of,O
treatment,O
5,O
5,O
DYSPORT,O
r,O
contains,O
human,O
albumin,O
There,O
is,O
a,O
risk,Factor
for,O
transmission,O
of,O
Creutzfeldt Jakob disease,AdverseReaction
CJD,AdverseReaction
however,O
no,Negation
cases,O
of,O
transmission,Negation
of,O
viral diseases,AdverseReaction
or,O
CJD,AdverseReaction
have,O
ever,O
been,O
identified,O
for,O
albumin,O
5,O
6,O
5,O
1,O
Lack,O
of,O
Interchangeability,O
between,O
Botulinum,O
Toxin,O
Products,O
The,O
potency,O
Units,O
of,O
DYSPORT,O
r,O
are,O
specific,O
to,O
the,O
preparation,O
and,O
assay,O
method,O
utilized,O
They,O
are,O
not,O
interchangeable,O
with,O
other,O
preparations,O
of,O
botulinum,O
toxin,O
products,O
and,O
therefore,O
units,O
of,O
biological,O
activity,O
of,O
DYSPORT,O
r,O
cannot,O
be,O
compared,O
to,O
or,O
converted,O
into,O
units,O
of,O
any,O
other,O
botulinum,O
toxin,O
products,O
assessed,O
with,O
any,O
other,O
specific,O
assay,O
method,O
seeDescription,O
11,O
5,O
2,O
Spread,O
of,O
Toxin,O
Effect,O
Post,O
marketing,O
safety,O
data,O
from,O
DYSPORT,O
r,O
and,O
other,O
approved,O
botulinum,O
toxins,O
suggest,O
that,O
botulinum,O
toxin effects,AdverseReaction
may,Factor
in,O
some,O
cases,O
be,O
observed,O
beyond the site of local injection,AdverseReaction
The,O
symptoms,O
are,O
consistent,O
with,O
the,O
mechanism,O
of,O
action,O
of,O
botulinum,O
toxin,O
and,O
may,Factor
include,O
asthenia,AdverseReaction
generalized muscle weakness,AdverseReaction
diplopia,AdverseReaction
blurred vision,AdverseReaction
ptosis,AdverseReaction
dysphagia,AdverseReaction
dysphonia,AdverseReaction
dysarthria,AdverseReaction
urinary incontinence,AdverseReaction
and,O
breathing difficulties,AdverseReaction
These,O
symptoms,O
have,O
been,O
reported,O
hours,O
to,O
weeks,O
after,O
injection,O
Swallowing,AdverseReaction
and,O
breathing difficulties,AdverseReaction
can,O
be,O
life,O
threatening,O
and,O
there,O
have,O
been,O
reports,O
of,O
death,AdverseReaction
related,O
to,O
spread of toxin effects,AdverseReaction
The,O
risk,O
of,O
the,O
symptoms,O
is,O
probably,O
greatest,O
in,O
children,O
treated,O
for,O
spasticity,O
but,O
symptoms,O
can,O
also,O
occur,O
in,O
adults,O
treated,O
for,O
spasticity,O
and,O
other,O
conditions,O
and,O
particularly,O
in,O
those,O
patients,O
who,O
have,O
underlying,O
conditions,O
that,O
would,O
predispose,O
them,O
to,O
these,O
symptoms,O
In,O
unapproved,O
uses,O
including,O
spasticity,O
in,O
children,O
and,O
in,O
approved,O
indications,O
symptoms,O
consistent,O
with,O
spread of toxin effect,AdverseReaction
have,O
been,O
reported,O
at,O
doses,O
comparable,O
to,O
or,O
lower,O
than,O
the,O
maximum,O
recommended,O
total,O
dose,O
5,O
3,O
Dysphagia,O
and,O
Breathing,O
Difficulties,O
Treatment,O
with,O
DYSPORT,O
r,O
and,O
other,O
botulinum,O
toxin,O
products,O
can,Factor
result,O
in,O
swallowing,AdverseReaction
or,O
breathing difficulties,AdverseReaction
Patients,O
with,O
pre,O
existing,O
swallowing,O
or,O
breathing,O
difficulties,O
may,O
be,O
more,O
susceptible,O
to,O
these,O
complications,O
In,O
most,O
cases,O
this,O
is,O
a,O
consequence,O
of,O
weakening,O
of,O
muscles,O
in,O
the,O
area,O
of,O
injection,O
that,O
are,O
involved,O
in,O
breathing,O
or,O
swallowing,O
When,O
distant,O
effects,O
occur,O
additional,O
respiratory,O
muscles,O
may,O
be,O
involved,O
seeWarnings,O
and,O
Precautions,O
5,O
2,O
Deaths,AdverseReaction
as,O
a,O
complication,O
of,O
severe,Severity
dysphagia,AdverseReaction
have,O
been,O
reported,O
after,O
treatment,O
with,O
botulinum,O
toxin,O
Dysphagia,AdverseReaction
may,O
persist,O
for,O
several,O
weeks,O
and,O
require,O
use,O
of,O
a,O
feeding,O
tube,O
to,O
maintain,O
adequate,O
nutrition,O
and,O
hydration,O
Aspiration,AdverseReaction
may,Factor
result,O
from,O
severe,Severity
dysphagia,AdverseReaction
and,O
is,O
a,O
particular,O
risk,O
when,O
treating,O
patients,O
in,O
whom,O
swallowing,O
or,O
respiratory,O
function,O
is,O
already,O
compromised,O
Treatment,O
of,O
cervical,O
dystonia,O
with,O
botulinum,O
toxins,O
may,Factor
weaken neck muscles,AdverseReaction
that,O
serve,O
as,O
accessory,O
muscles,O
of,O
ventilation,O
This,O
may,Factor
result,O
in,O
a,O
critical,Severity
loss of breathing capacity,AdverseReaction
in,O
patients,O
with,O
respiratory,O
disorders,O
who,O
may,O
have,O
become,O
dependent,O
upon,O
these,O
accessory,O
muscles,O
There,O
have,O
been,O
post,O
marketing,O
reports,O
of,O
serious,Severity
breathing difficulties,AdverseReaction
including,O
respiratory failure,AdverseReaction
Patients,Factor
treated,O
with,O
botulinum,O
toxin,O
may,O
require,O
immediate,O
medical,O
attention,O
should,O
they,O
develop,O
problems,O
with,O
swallowing,O
speech,O
or,O
respiratory,O
disorders,O
These,O
reactions,O
can,O
occur,O
within,O
hours,O
to,O
weeks,O
after,O
injection,O
with,O
botulinum,O
toxin,O
seeWarnings,O
and,O
Precautions,O
5,O
2,O
Adverse,O
Reactions,O
6,O
1,O
Clinical,O
Pharmacology,O
12,O
2,O
5,O
4,O
Facial,O
Anatomy,O
in,O
the,O
Treatment,O
of,O
Glabellar,O
Lines,O
Caution,O
should,O
be,O
exercised,O
when,O
administering,O
DYSPORT,O
r,O
to,O
patients,O
with,O
surgical,O
alterations,O
to,O
the,O
facial,O
anatomy,O
excessive,O
weakness,O
or,O
atrophy,O
in,O
the,O
target,O
muscle,O
s,O
marked,O
facial,O
asymmetry,O
inflammation,O
at,O
the,O
injection,O
site,O
s,O
ptosis,O
excessive,O
dermatochalasis,O
deep,O
dermal,O
scarring,O
thick,O
sebaceous,O
skin,O
seeDosage,O
and,O
Administration,O
2,O
3,O
or,O
the,O
inability,O
to,O
substantially,O
lessen,O
glabellar,O
lines,O
by,O
physically,O
spreading,O
them,O
apart,O
seeClinical,O
Studies,O
14,O
2,O
Do,O
not,O
exceed,O
the,O
recommended,O
dosage,O
and,O
frequency,O
of,O
administration,O
of,O
DYSPORT,Factor
r,O
In,O
clinical,O
trials,O
subjects,O
who,O
received,O
a,O
higher,O
dose,O
of,O
DYSPORT,O
r,O
had,O
an,O
increased,O
incidence,O
of,O
eyelid ptosis,AdverseReaction
5,O
5,O
Pre,O
existing,O
Neuromuscular,O
Disorders,O
Individuals,O
with,O
peripheral,O
motor,O
neuropathic,O
diseases,O
amyotrophic,O
lateral,O
sclerosis,O
or,O
neuromuscular,O
junction,O
disorders,O
e,O
g,O
myasthenia,O
gravis,O
or,O
Lambert,O
Eaton,O
syndrome,O
should,O
be,O
monitored,O
particularly,O
closely,O
when,O
given,O
botulinum,O
toxin,O
Patients,O
with,O
neuromuscular,O
disorders,O
may,O
be,O
at,O
increased,O
risk,Factor
of,O
clinically,O
significant,O
effects,O
including,O
severe,Severity
dysphagia,AdverseReaction
and,O
respiratory compromise,AdverseReaction
from,O
typical,O
doses,O
of,O
DYSPORT,O
r,O
seeAdverse,O
Reactions,O
6,O
1,O
5,O
6,O
Human,O
Albumin,O
This,O
product,O
contains,O
albumin,O
a,O
derivative,O
of,O
human,O
blood,O
Based,O
on,O
effective,O
donor,O
screening,O
and,O
product,O
manufacturing,O
processes,O
it,O
carries,O
an,O
extremely,O
remote,O
risk,Factor
for,O
transmission,O
of,O
viral diseases,AdverseReaction
A,O
theoretical,O
risk,Factor
for,O
transmission,O
of,O
Creutzfeldt Jakob disease,AdverseReaction
CJD,AdverseReaction
is,O
also,O
considered,O
extremely,O
remote,O
No,Negation
cases,O
of,O
transmission,Negation
of,O
viral diseases,AdverseReaction
or,O
CJD,AdverseReaction
have,O
ever,O
been,O
reported,O
for,O
albumin,O
5,O
7,O
Intradermal,O
Immune,O
Reaction,O
The,O
possibility,O
of,O
an,O
immune,O
reaction,O
when,O
injected,O
intradermally,O
is,O
unknown,O
The,O
safety,O
of,O
DYSPORT,O
r,O
for,O
the,O
treatment,O
of,O
hyperhidrosis,O
has,O
not,O
been,O
established,O
DYSPORT,O
r,O
is,O
approved,O
only,O
for,O
intramuscular,O
injection,O
""
BOXED,O
WARNING,O
WARNING,O
DISTANT SPREAD OF TOXIN EFFECT,AdverseReaction
WARNING,O
DISTANT SPREAD OF TOXIN EFFECT,AdverseReaction
Postmarketing,O
reports,O
indicate,O
that,O
the,O
effects,O
of,O
DYSPORT,O
r,O
and,O
all,O
botulinum,O
toxin,O
products,O
may,Factor
spread,AdverseReaction
from,O
the,O
area,O
of,O
injection,O
to,O
produce,O
symptoms,O
consistent,O
with,O
botulinum,O
toxin effects,AdverseReaction
These,O
may,Factor
include,O
asthenia,AdverseReaction
generalized muscle weakness,AdverseReaction
diplopia,AdverseReaction
blurred vision,AdverseReaction
ptosis,AdverseReaction
dysphagia,AdverseReaction
dysphonia,AdverseReaction
dysarthria,AdverseReaction
urinary incontinence,AdverseReaction
and,O
breathing difficulties,AdverseReaction
These,O
symptoms,O
have,O
been,O
reported,O
hours,O
to,O
weeks,O
after,O
injection,O
Swallowing,AdverseReaction
and,O
breathing difficulties,AdverseReaction
can,O
be,O
life,O
threatening,O
and,O
there,O
have,O
been,O
reports,O
of,O
death,AdverseReaction
The,O
risk,O
of,O
symptoms,O
is,O
probably,O
greatest,O
in,O
children,O
treated,O
for,O
spasticity,O
but,O
symptoms,O
can,O
also,O
occur,O
in,O
adults,O
treated,O
for,O
spasticity,O
and,O
other,O
conditions,O
particularly,O
in,O
those,O
patients,O
who,O
have,O
underlying,O
conditions,O
that,O
would,O
predispose,O
them,O
to,O
these,O
symptoms,O
In,O
unapproved,O
uses,O
including,O
spasticity,O
in,O
children,O
and,O
in,O
approved,O
indications,O
cases,O
of,O
spread,O
of,O
effect,O
have,O
been,O
reported,O
at,O
doses,O
comparable,O
to,O
or,O
lower,O
than,O
the,O
maximum,O
recommended,O
total,O
dose,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
WARNING,O
DISTANT SPREAD OF TOXIN EFFECT,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
The,O
effects,O
of,O
DYSPORT,O
r,O
and,O
all,O
botulinum,O
toxin,O
products,O
may,Factor
spread,AdverseReaction
from,O
the,O
area,O
of,O
injection,O
to,O
produce,O
symptoms,O
consistent,O
with,O
botulinum,O
toxin effects,AdverseReaction
These,O
symptoms,O
have,O
been,O
reported,O
hours,O
to,O
weeks,O
after,O
injection,O
Swallowing,AdverseReaction
and,O
breathing difficulties,AdverseReaction
can,O
be,O
life,O
threatening,O
and,O
there,O
have,O
been,O
reports,O
of,O
death,AdverseReaction
The,O
risk,O
of,O
symptoms,O
is,O
probably,O
greatest,O
in,O
children,O
treated,O
for,O
spasticity,O
but,O
symptoms,O
can,O
also,O
occur,O
in,O
adults,O
particularly,O
in,O
those,O
patients,O
who,O
have,O
underlying,O
conditions,O
that,O
would,O
predispose,O
them,O
to,O
these,O
symptoms,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
below,O
and,O
elsewhere,O
in,O
labeling,O
Distant Spread of Toxin Effect,AdverseReaction
seeBoxed,O
Warning,O
Lack,O
of,O
Interchangeability,O
between,O
Botulinum,O
Toxin,O
Products,O
seeWarnings,O
and,O
Precautions,O
5,O
1,O
Spread of Effects from Toxin,AdverseReaction
seeWarnings,O
and,O
Precautions,O
5,O
2,O
Dysphagia,AdverseReaction
and,O
Breathing Difficulties,AdverseReaction
seeWarnings,O
and,O
Precautions,O
5,O
3,O
Facial,O
Anatomy,O
in,O
the,O
Treatment,O
of,O
Glabellar,O
Lines,O
seeWarnings,O
and,O
Precautions,O
5,O
4,O
Pre,O
existing,O
Neuromuscular,O
Disorders,O
seeWarnings,O
and,O
Precautions,O
5,O
5,O
Human,O
Albumin,O
seeWarnings,O
and,O
Precautions,O
5,O
6,O
Intradermal Immune Reaction,AdverseReaction
seeWarnings,O
and,O
Precautions,O
5,O
7,O
EXCERPT,O
Cervical,O
Dystonia,O
Most,O
commonly,O
observed,O
adverse,O
reactions,O
5,O
of,O
patients,O
are,O
muscular weakness,AdverseReaction
dysphagia,AdverseReaction
dry mouth,AdverseReaction
injection site discomfort,AdverseReaction
fatigue,AdverseReaction
headache,AdverseReaction
neck pain,AdverseReaction
musculoskeletal pain,AdverseReaction
dysphonia,AdverseReaction
injection site pain,AdverseReaction
and,O
eye disorders,AdverseReaction
6,O
1,O
Glabellar,O
Lines,O
The,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
2,O
are,O
nasopharyngitis,AdverseReaction
headache,AdverseReaction
injection site pain,AdverseReaction
injection site reaction,AdverseReaction
upper respiratory tract infection,AdverseReaction
eyelid edema,AdverseReaction
eyelid ptosis,AdverseReaction
sinusitis,AdverseReaction
and,O
nausea,AdverseReaction
6,O
1,O
Upper,O
Limb,O
Spasticity,O
The,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
2,O
are,O
urinary tract infection,AdverseReaction
nasopharyngitis,AdverseReaction
muscular weakness,AdverseReaction
musculoskeletal pain,AdverseReaction
dizziness,AdverseReaction
fall,AdverseReaction
and,O
depression,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Ipsen,O
Biopharmaceuticals,O
Inc,O
at,O
877,O
397,O
7671,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Cervical,O
Dystonia,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
DYSPORT,O
r,O
in,O
357,O
cervical,O
dystonia,O
patients,O
in,O
6,O
studies,O
Of,O
these,O
two,O
studies,O
were,O
randomized,O
double,O
blind,O
single,O
treatment,O
placebo,O
controlled,O
studies,O
with,O
subsequent,O
optional,O
open,O
label,O
treatment,O
in,O
which,O
dose,O
optimization,O
250,O
to,O
1000,O
Units,O
per,O
treatment,O
over,O
the,O
course,O
of,O
5,O
treatment,O
cycles,O
was,O
allowed,O
The,O
population,O
was,O
almost,O
entirely,O
Caucasian,O
99,O
with,O
a,O
median,O
age,O
of,O
51,O
years,O
range,O
18,O
82,O
years,O
Most,O
patients,O
87,O
were,O
less,O
than,O
65,O
years,O
of,O
age,O
58,O
4,O
were,O
women,O
Common,O
Adverse,O
Reactions,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
occurring,O
in,O
more,O
than,O
5,O
of,O
patients,O
who,O
received,O
500,O
Units,O
of,O
DYSPORT,O
r,O
in,O
the,O
placebo,O
controlled,O
clinical,O
trials,O
in,O
cervical,O
dystonia,O
patients,O
were,O
muscular weakness,AdverseReaction
dysphagia,AdverseReaction
dry mouth,AdverseReaction
injection site discomfort,AdverseReaction
fatigue,AdverseReaction
headache,AdverseReaction
neck pain,AdverseReaction
musculoskeletal pain,AdverseReaction
dysphonia,AdverseReaction
injection site pain,AdverseReaction
and,O
eye disorders,AdverseReaction
consisting,O
of,O
blurred vision,AdverseReaction
diplopia,AdverseReaction
and,O
reduced visual acuity visual,AdverseReaction
and,O
accommodation,AdverseReaction
Other,O
than,O
injection site reactions,AdverseReaction
most,O
adverse,O
reactions,O
became,O
noticeable,O
about,O
one,O
week,O
after,O
treatment,O
and,O
lasted,O
several,O
weeks,O
The,O
rates,O
of,O
adverse,O
reactions,O
were,O
higher,O
in,O
the,O
combined,O
controlled,O
and,O
open,O
label,O
experience,O
than,O
in,O
the,O
placebo,O
controlled,O
trials,O
During,O
the,O
clinical,O
studies,O
two,O
patients,O
1,O
experienced,O
adverse,O
reactions,O
leading,O
to,O
withdrawal,O
One,O
patient,O
experienced,O
disturbance in attention,AdverseReaction
eyelid disorder,AdverseReaction
feeling abnormal,AdverseReaction
and,O
headache,AdverseReaction
and,O
one,O
patient,O
experienced,O
dysphagia,AdverseReaction
Table,O
3,O
compares,O
the,O
incidence,O
of,O
the,O
most,O
frequent,O
adverse,O
reactions,O
from,O
a,O
single,O
treatment,O
cycle,O
of,O
500,O
Units,O
of,O
DYSPORT,O
r,O
compared,O
to,O
placebo,O
seeClinical,O
Studies,O
14,O
1,O
Table,O
3,O
Most,O
Common,O
Adverse,O
Reactions,O
5,O
and,O
Greater,O
than,O
Placebo,O
in,O
the,O
Pooled,O
Double,O
blind,O
Phase,O
of,O
Clinical,O
Trials,O
in,O
Patients,O
with,O
Cervical,O
Dystonia,O
Adverse,O
Reaction,O
Preferred,O
Term,O
DYSPORT,O
r,O
500,O
Units,O
N,O
173,O
Placebo,O
N,O
182,O
Any,O
Adverse,O
Reaction,O
61,O
51,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
30,O
23,O
Injection site discomfort,AdverseReaction
13,O
8,O
Fatigue,AdverseReaction
12,O
10,O
Injection site pain,AdverseReaction
5,O
4,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
30,O
18,O
Muscular weakness,AdverseReaction
16,O
4,O
Musculoskeletal pain,AdverseReaction
7,O
3,O
Gastrointestinal,O
disorders,O
28,O
15,O
Dysphagia,AdverseReaction
15,O
4,O
Dry mouth,AdverseReaction
13,O
7,O
Nervous,O
system,O
disorders,O
16,O
13,O
Headache,AdverseReaction
11,O
9,O
Infections,O
and,O
infestations,O
13,O
9,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
12,O
8,O
Dysphonia,AdverseReaction
6,O
2,O
Eye,O
Disorders,O
7,O
2,O
Dose,O
response,O
relationships,O
for,O
common,O
adverse,O
reactions,O
in,O
a,O
randomized,O
multiple,O
fixed,O
dose,O
study,O
in,O
which,O
the,O
total,O
dose,O
was,O
divided,O
between,O
two,O
muscles,O
the,O
sternocleidomastoid,O
and,O
splenius,O
capitis,O
are,O
shown,O
in,O
Table,O
4,O
Table,O
4,O
Common,O
Adverse,O
Reactions,O
by,O
Dose,O
in,O
Fixed,O
dose,O
Study,O
in,O
Patients,O
with,O
Cervical,O
Dystonia,O
Adverse,O
Reaction,O
Preferred,O
Term,O
DYSPORT,O
r,O
Dose,O
Placebo,O
250,O
Units,O
500,O
Units,O
1000,O
Units,O
Any,O
Adverse,O
Event,O
30,O
37,O
65,O
83,O
Dysphagia,AdverseReaction
5,O
21,O
29,O
39,O
Dry Mouth,AdverseReaction
10,O
21,O
18,O
39,O
Muscular Weakness,AdverseReaction
0,O
11,O
12,O
56,O
Injection Site Discomfort,AdverseReaction
10,O
5,O
18,O
22,O
Dysphonia,AdverseReaction
0,O
0,O
18,O
28,O
Facial Paresis,AdverseReaction
0,O
5,O
0,O
11,O
Eye,O
Disorders,O
0,O
0,O
6,O
17,O
Injection,O
Site,O
Reactions,O
Injection site discomfort,AdverseReaction
and,O
injection site pain,AdverseReaction
were,O
common,O
adverse,O
reactions,O
following,O
DYSPORT,O
r,O
administration,O
Less,O
Common,O
Adverse,O
Reactions,O
The,O
following,O
adverse,O
reactions,O
were,O
reported,O
less,O
frequently,O
5,O
Breathing,O
Difficulty,O
Breathing difficulties,AdverseReaction
were,O
reported,O
by,O
approximately,O
3,O
of,O
patients,O
following,O
DYSPORT,O
r,O
administration,O
and,O
in,O
1,O
of,O
placebo,O
patients,O
in,O
clinical,O
trials,O
during,O
the,O
double,O
blind,O
phase,O
These,O
consisted,O
mainly,O
of,O
dyspnea,AdverseReaction
The,O
median,O
time,O
to,O
onset,O
from,O
last,O
dose,O
of,O
DYSPORT,O
r,O
was,O
approximately,O
one,O
week,O
and,O
the,O
median,O
duration,O
was,O
approximately,O
three,O
weeks,O
Other,O
adverse,O
reactions,O
with,O
incidences,O
of,O
less,O
than,O
5,O
in,O
the,O
DYSPORT,O
r,O
500,O
Units,O
group,O
in,O
the,O
double,O
blind,O
phase,O
of,O
clinical,O
trials,O
included,O
dizziness,AdverseReaction
in,O
3,O
5,O
of,O
DYSPORT,O
r,O
treated,O
patients,O
and,O
1,O
of,O
placebo,O
treated,O
patients,O
and,O
muscle atrophy,AdverseReaction
in,O
1,O
of,O
DYSPORT,O
r,O
treated,O
patients,O
and,O
in,O
none,O
of,O
the,O
placebo,O
treated,O
patients,O
Laboratory,O
Findings,O
Patients,O
treated,O
with,O
DYSPORT,O
r,O
exhibited,O
a,O
small,Severity
increase,AdverseReaction
from,O
baseline,O
0,O
23,O
mol,O
L,O
in mean blood glucose,AdverseReaction
relative,O
to,O
placebo,O
treated,O
patients,O
This,O
was,O
not,O
clinically,O
significant,O
among,O
patients,O
in,O
the,O
development,O
program,O
but,O
could,O
be,O
a,O
factor,O
in,O
patients,O
whose,O
diabetes,O
is,O
difficult,O
to,O
control,O
Electrocardiographic,O
Findings,O
ECG,O
measurements,O
were,O
only,O
recorded,O
in,O
a,O
limited,O
number,O
of,O
patients,O
in,O
an,O
open,O
label,O
study,O
without,O
a,O
placebo,O
or,O
active,O
control,O
This,O
study,O
showed,O
a,O
statistically,O
significant,O
reduction in heart rate,AdverseReaction
compared,O
to,O
baseline,O
averaging,O
about,O
three,O
beats,O
per,O
minute,O
observed,O
thirty,O
minutes,O
after,O
injection,O
Glabellar,O
Lines,O
In,O
placebo,O
controlled,O
clinical,O
trials,O
of,O
DYSPORT,O
r,O
the,O
most,O
common,O
adverse,O
reactions,O
2,O
following,O
injection,O
of,O
DYSPORT,O
r,O
were,O
nasopharyngitis,AdverseReaction
headache,AdverseReaction
injection site pain,AdverseReaction
injection site reaction,AdverseReaction
upper respiratory tract infection,AdverseReaction
eyelid edema,AdverseReaction
eyelid ptosis,AdverseReaction
sinusitis,AdverseReaction
and,O
nausea,AdverseReaction
Table,O
5,O
reflects,O
exposure,O
to,O
DYSPORT,O
r,O
in,O
398,O
patients,O
19,O
to,O
75,O
years,O
of,O
age,O
who,O
were,O
evaluated,O
in,O
the,O
randomized,O
placebo,O
controlled,O
clinical,O
studies,O
that,O
assessed,O
the,O
use,O
of,O
DYSPORT,O
r,O
for,O
the,O
temporary,O
improvement,O
in,O
the,O
appearance,O
of,O
glabellar,O
lines,O
seeClinical,O
Studies,O
14,O
Adverse,O
reactions,O
of,O
any,O
cause,O
occurred,O
in,O
48,O
of,O
the,O
DYSPORT,O
r,O
treated,O
patients,O
and,O
33,O
of,O
the,O
placebo,O
treated,O
patients,O
Table,O
5,O
Most,O
Common,O
Adverse,O
Reactions,O
with,O
1,O
Incidence,O
in,O
Pooled,O
Placebo,O
Controlled,O
Trials,O
for,O
Glabellar,O
Lines,O
Adverse,O
Reactions,O
by,O
Body,O
System,O
DYSPORT,O
r,O
n,O
398,O
Placebon,O
496,O
Any,O
Adverse,O
Reaction,O
48,O
33,O
Eye,O
Disorders,O
Eyelid Edema,AdverseReaction
2,O
0,O
Eyelid Ptosis,AdverseReaction
2,O
1,O
Gastrointestinal,O
Disorders,O
Nausea,AdverseReaction
2,O
1,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Injection Site Pain,AdverseReaction
3,O
2,O
Injection Site Reaction,AdverseReaction
3,O
1,O
Infections,O
and,O
Infestations,O
Nasopharyngitis,AdverseReaction
10,O
4,O
Upper Respiratory Tract Infection,AdverseReaction
3,O
2,O
Sinusitis,AdverseReaction
2,O
1,O
Investigations,O
Blood Present in Urine,AdverseReaction
2,O
1,O
Nervous,O
System,O
Disorders,O
Headache,AdverseReaction
9,O
5,O
In,O
the,O
overall,O
safety,O
database,O
where,O
some,O
patients,O
received,O
up,O
to,O
twelve,O
treatments,O
with,O
DYSPORT,O
r,O
adverse,O
reactions,O
were,O
reported,O
for,O
57,O
1425,O
2491,O
of,O
patients,O
The,O
most,O
frequently,O
reported,O
of,O
these,O
adverse,O
reactions,O
were,O
headache,AdverseReaction
nasopharyngitis,AdverseReaction
injection site pain,AdverseReaction
sinusitis,AdverseReaction
URI,AdverseReaction
injection site bruising,AdverseReaction
and,O
injection site reaction site site site site site site site site site site site,AdverseReaction
numbness,AdverseReaction
discomfort,AdverseReaction
erythema,AdverseReaction
tenderness,AdverseReaction
tingling,AdverseReaction
itching,AdverseReaction
stinging,AdverseReaction
warmth,AdverseReaction
irritation,AdverseReaction
tightness,AdverseReaction
swelling,AdverseReaction
Adverse,O
reactions,O
that,O
occurred,O
after,O
repeated,O
injections,O
in,O
2,O
3,O
of,O
the,O
population,O
included,O
bronchitis,AdverseReaction
influenza,AdverseReaction
pharyngolaryngeal pain,AdverseReaction
cough,AdverseReaction
contact dermatitis,AdverseReaction
injection site swelling,AdverseReaction
and,O
injection site discomfort,AdverseReaction
The,O
incidence,O
of,O
eyelid ptosis,AdverseReaction
did,O
not,O
increase,O
in,O
the,O
long,O
term,O
safety,O
studies,O
with,O
multiple,O
re,O
treatments,O
at,O
intervals,O
three,O
months,O
The,O
majority,O
of,O
the,O
reports,O
of,O
eyelid ptosis ptosis,AdverseReaction
were,O
mild,Severity
to,O
moderate,Severity
in,O
severity,O
and,O
resolved,O
over,O
several,O
weeks,O
seeDosage,O
and,O
Administration,O
2,O
3,O
Upper,O
Limb,O
Spasticity,O
Table,O
6,O
lists,O
the,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
2,O
in,O
any,O
DYSPORT,O
r,O
dose,O
group,O
and,O
more,O
frequent,O
than,O
placebo,O
in,O
double,O
blind,O
studies,O
evaluating,O
the,O
treatment,O
of,O
upper,O
limb,O
spasticity,O
in,O
adults,O
with,O
DYSPORT,O
r,O
Table,O
6,O
Most,O
Common,O
Adverse,O
Reactions,O
Observed,O
in,O
at,O
Least,O
2,O
of,O
Patients,O
Treated,O
in,O
Pooled,O
Double,O
Blind,O
Trials,O
of,O
Patients,O
with,O
Upper,O
Limb,O
Spasticity,O
Reported,O
More,O
Frequently,O
than,O
with,O
Placebo,O
Adverse,O
Reaction,O
Preferred,O
Term,O
DYSPORT,O
r,O
Placebo,O
500,O
Units,O
N,O
197,O
1000,O
Units,O
N,O
194,O
N,O
279,O
Infections,O
and,O
infestations,O
Nasopharyngitis,AdverseReaction
4,O
1,O
1,O
Urinary tract infection,AdverseReaction
3,O
1,O
2,O
Influenza,AdverseReaction
1,O
2,O
1,O
Infection,AdverseReaction
1,O
2,O
1,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Muscular weakness,AdverseReaction
2,O
4,O
1,O
Pain in extremity,AdverseReaction
0,O
2,O
1,O
Musculoskeletal pain,AdverseReaction
3,O
2,O
2,O
Back pain,AdverseReaction
1,O
2,O
1,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
1,O
2,O
1,O
Dizziness,AdverseReaction
3,O
1,O
1,O
Convulsion,AdverseReaction
2,O
2,O
1,O
Syncope,AdverseReaction
1,O
2,O
0,O
Hypoaesthesia,AdverseReaction
0,O
2,O
1,O
Partial seizures,AdverseReaction
0,O
2,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
2,O
2,O
0,O
Asthenia,AdverseReaction
2,O
1,O
1,O
Injury,O
poisoning,O
and,O
procedural,O
complications,O
Fall,AdverseReaction
2,O
3,O
2,O
Injury,AdverseReaction
2,O
2,O
1,O
Contusion,AdverseReaction
1,O
2,O
1,O
Gastrointestinal,O
disorders,O
Diarrhea,AdverseReaction
1,O
2,O
1,O
Nausea,AdverseReaction
2,O
1,O
1,O
Constipation,AdverseReaction
0,O
2,O
1,O
Investigation,O
Blood triglycerides increased,AdverseReaction
2,O
1,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
1,O
2,O
1,O
Vascular,O
disorders,O
Hypertension,AdverseReaction
1,O
2,O
1,O
Psychiatric,O
disorders,O
Depression,AdverseReaction
2,O
3,O
1,O
Injection,O
Site,O
Reactions,O
Injection site reactions site site site,AdverseReaction
e,O
g,O
pain,AdverseReaction
bruising,AdverseReaction
haemorrhage,AdverseReaction
injection site erythema site,AdverseReaction
haematoma,AdverseReaction
etc,O
have,O
occurred,O
following,O
administration,O
of,O
DYSPORT,O
r,O
Less,O
Common,O
Adverse,O
Reactions,O
In,O
a,O
pooled,O
analysis,O
of,O
clinical,O
studies,O
adverse,O
reactions,O
with,O
an,O
incidence,O
of,O
less,O
than,O
2,O
reported,O
in,O
DYSPORT,O
r,O
treatment,O
groups,O
included,O
dysphagia,AdverseReaction
0,O
5,O
gait disturbance,AdverseReaction
0,O
5,O
hypertonia,AdverseReaction
0,O
5,O
and,O
sensation of heaviness,AdverseReaction
0,O
3,O
6,O
2,O
Postmarketing,O
Experience,O
Because,O
adverse,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
DYSPORT,O
r,O
vertigo,AdverseReaction
photophobia,AdverseReaction
influenza like illness,AdverseReaction
amyotrophy,AdverseReaction
burning sensation,AdverseReaction
facial paresis,AdverseReaction
hypoesthesia,AdverseReaction
erythema,AdverseReaction
and,O
excessive granulation tissue,AdverseReaction
6,O
3,O
Immunogenicity,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
a,O
potential,O
for,O
immunogenicity,O
The,O
incidence,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
In,O
addition,O
the,O
observed,O
incidence,O
of,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
across,O
products,O
in,O
this,O
class,O
may,O
be,O
misleading,O
Cervical,O
Dystonia,O
About,O
3,O
of,O
subjects,O
developed,O
antibodies,O
binding,O
or,O
neutralizing,O
over,O
time,O
with,O
DYSPORT,O
r,O
treatment,O
Glabellar,O
Lines,O
Testing,O
for,O
antibodies,O
to,O
DYSPORT,O
r,O
was,O
performed,O
for,O
1554,O
subjects,O
who,O
had,O
up,O
to,O
nine,O
cycles,O
of,O
treatment,O
Two,O
subjects,O
0,O
13,O
tested,O
positive,O
for,O
binding,O
antibodies,O
at,O
baseline,O
Three,O
additional,O
subjects,O
tested,O
positive,O
for,O
binding,O
antibodies,O
after,O
receiving,O
DYSPORT,O
r,O
treatment,O
None,O
of,O
the,O
subjects,O
tested,O
positive,O
for,O
neutralizing,O
antibodies,O
Upper,O
Limb,O
Spasticity,O
From,O
230,O
subjects,O
treated,O
with,O
DYSPORT,O
r,O
and,O
tested,O
for,O
the,O
presence,O
of,O
binding,O
antibodies,O
5,O
subjects,O
were,O
positive,O
at,O
baseline,O
and,O
17,O
developed,O
antibodies,O
after,O
treatment,O
Among,O
those,O
17,O
subjects,O
10,O
subjects,O
developed,O
neutralizing,O
antibodies,O
An,O
additional,O
51,O
subjects,O
from,O
a,O
separate,O
repeat,O
dose,O
study,O
were,O
tested,O
for,O
the,O
presence,O
of,O
neutralizing,O
antibodies,O
only,O
None,O
of,O
the,O
subjects,O
tested,O
positive,O
In,O
total,O
from,O
the,O
281,O
subjects,O
treated,O
in,O
the,O
long,O
term,O
studies,O
and,O
tested,O
for,O
the,O
presence,O
of,O
neutralizing,O
antibodies,O
3,O
6,O
developed,O
neutralizing,O
antibodies,O
after,O
treatment,O
In,O
the,O
presence,O
of,O
binding,O
and,O
neutralizing,O
antibodies,O
to,O
DYSPORT,O
r,O
some,O
patients,O
continue,O
to,O
experience,O
clinical,O
benefit,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Correct,O
volume,O
or,O
salt,O
depletion,O
prior,O
to,O
administration,O
of,O
Edarbi,O
5,O
2,O
Monitor,O
for,O
worsening,O
renal,O
function,O
in,O
patients,O
with,O
renal,O
impairment,O
5,O
3,O
5,O
1,O
Fetal,O
Toxicity,O
Use,O
of,O
drugs that act on the renin angiotensin system,DrugClass
during,O
the,O
second,O
and,O
third,O
trimesters,O
of,O
pregnancy,O
reduces fetal renal function,AdverseReaction
and,O
increases,O
fetal,AdverseReaction
and,O
neonatal morbidity,AdverseReaction
and,O
death,AdverseReaction
Resulting,O
oligohydramnios,AdverseReaction
can,Factor
be,O
associated,O
with,O
fetal lung hypoplasia,AdverseReaction
and,O
skeletal deformations,AdverseReaction
Potential,Factor
neonatal adverse effects,AdverseReaction
include,O
skull hypoplasia,AdverseReaction
anuria,AdverseReaction
hypotension,AdverseReaction
renal failure,AdverseReaction
and,O
death,AdverseReaction
When,O
pregnancy,O
is,O
detected,O
discontinue,O
Edarbi,O
as,O
soon,O
as,O
possible,O
seeUse,O
in,O
Specific,O
Populations,O
8,O
1,O
5,O
2,O
Hypotension,O
in,O
Volume,O
or,O
Salt,O
Depleted,O
Patients,O
In,O
patients,O
with,O
an,O
activated,O
renin,O
angiotensin,O
system,O
such,O
as,O
volume,O
and,O
or,O
salt,O
depleted,O
patients,O
e,O
g,O
those,O
being,O
treated,O
with,O
high,O
doses,O
of,O
diuretics,O
symptomatic hypotension,AdverseReaction
may,Factor
occur,O
after,O
initiation,O
of,O
treatment,O
with,O
Edarbi,O
Correct,O
volume,O
or,O
salt,O
depletion,O
prior,O
to,O
administration,O
of,O
Edarbi,O
or,O
start,O
treatment,O
at,O
40,O
mg,O
If,O
hypotension,O
does,O
occur,O
the,O
patient,O
should,O
be,O
placed,O
in,O
the,O
supine,O
position,O
and,O
if,O
necessary,O
given,O
an,O
intravenous,O
infusion,O
of,O
normal,O
saline,O
A,O
transient,O
hypotensive,O
response,O
is,O
not,O
a,O
contraindication,O
to,O
further,O
treatment,O
which,O
usually,O
can,O
be,O
continued,O
without,O
difficulty,O
once,O
the,O
blood,O
pressure,O
has,O
stabilized,O
5,O
3,O
Impaired,O
Renal,O
Function,O
As,O
a,O
consequence,O
of,O
inhibiting,O
the,O
renin,O
angiotensin,O
system,O
changes in renal function,AdverseReaction
may,Factor
be,O
anticipated,O
in,O
susceptible,O
individuals,O
treated,O
with,O
Edarbi,O
In,O
patients,O
whose,O
renal,O
function,O
may,O
depend,O
on,O
the,O
activity,O
of,O
the,O
renin,O
angiotensin,O
system,O
e,O
g,O
patients,O
with,O
severe,O
congestive,O
heart,O
failure,O
renal,O
artery,O
stenosis,O
or,O
volume,O
depletion,O
treatment,O
with,O
angiotensin converting enzyme inhibitors,DrugClass
and,O
angiotensin receptor blockers,DrugClass
has,O
been,O
associated,O
with,O
oliguria,AdverseReaction
or,O
progressive azotemia,AdverseReaction
and,O
rarely,O
with,O
acute renal failure,AdverseReaction
and,O
death,AdverseReaction
Similar,O
results,O
may,O
be,O
anticipated,O
in,O
patients,O
treated,O
with,O
Edarbi,O
seeDrug,O
Interactions,O
7,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
andClinical,O
Pharmacology,O
12,O
3,O
In,O
studies,O
of,O
ACE inhibitors,DrugClass
in,O
patients,O
with,O
unilateral,O
or,O
bilateral,O
renal,O
artery,O
stenosis,O
increases in serum creatinine in,AdverseReaction
or,O
blood urea nitrogen,AdverseReaction
have,O
been,O
reported,O
There,O
has,O
been,O
no,O
long,O
term,O
use,O
of,O
Edarbi,O
in,O
patients,O
with,O
unilateral,O
or,O
bilateral,O
renal,O
artery,O
stenosis,O
but,O
similar,O
results,O
may,O
be,O
expected,O
""
BOXED,O
WARNING,O
WARNING,O
FETAL TOXICITY,AdverseReaction
WARNING,O
FETAL TOXICITY,AdverseReaction
When,O
pregnancy,O
is,O
detected,O
discontinue,O
Edarbi,O
as,O
soon,O
as,O
possible,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Drugs that act directly on the renin angiotensin system,DrugClass
can,O
cause,O
injury,AdverseReaction
and,O
death to the developing fetus the developing fetus,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
WARNING,O
FETAL TOXICITY,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
When,O
pregnancy,O
is,O
detected,O
discontinue,O
Edarbi,O
as,O
soon,O
as,O
possible,O
5,O
1,O
Drugs that act directly on the renin angiotensin system,DrugClass
can,O
cause,O
injury,AdverseReaction
and,O
death to the developing fetus the developing fetus,AdverseReaction
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reaction,O
in,O
adults,O
was,O
diarrhea,AdverseReaction
2,O
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Arbor,O
Pharmaceuticals,O
LLC,O
at,O
1,O
866,O
516,O
4950,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
A,O
total,O
of,O
4814,O
patients,O
were,O
evaluated,O
for,O
safety,O
when,O
treated,O
with,O
Edarbi,O
at,O
doses,O
of,O
20,O
40,O
or,O
80,O
mg,O
in,O
clinical,O
trials,O
This,O
includes,O
1704,O
patients,O
treated,O
for,O
at,O
least,O
six,O
months,O
of,O
these,O
588,O
were,O
treated,O
for,O
at,O
least,O
one,O
year,O
Treatment,O
with,O
Edarbi,O
was,O
well,O
tolerated,O
with,O
an,O
overall,O
incidence,O
of,O
adverse,O
reactions,O
similar,O
to,O
placebo,O
The,O
rate,O
of,O
withdrawals,O
due,O
to,O
adverse,O
events,O
in,O
placebo,O
controlled,O
monotherapy,O
and,O
combination,O
therapy,O
trials,O
was,O
2,O
4,O
19,O
801,O
for,O
placebo,O
2,O
2,O
24,O
1072,O
for,O
Edarbi,O
40,O
mg,O
and,O
2,O
7,O
29,O
1074,O
for,O
Edarbi,O
80,O
mg,O
The,O
most,O
common,O
adverse,O
event,O
leading,O
to,O
discontinuation,O
hypotension,AdverseReaction
orthostatic hypotension,AdverseReaction
was,O
reported,O
by,O
0,O
4,O
8,O
2146,O
patients,O
randomized,O
to,O
Edarbi,O
40,O
mg,O
or,O
80,O
mg,O
compared,O
to,O
0,O
0,O
801,O
patients,O
randomized,O
to,O
placebo,O
Generally,O
adverse,O
reactions,O
were,O
mild,O
not,O
dose,O
related,O
and,O
similar,O
regardless,O
of,O
age,O
gender,O
and,O
race,O
In,O
placebo,O
controlled,O
monotherapy,O
trials,O
diarrhea,AdverseReaction
was,O
reported,O
up,O
to,O
2,O
in,O
patients,O
treated,O
with,O
Edarbi,O
80,O
mg,O
daily,O
compared,O
with,O
0,O
5,O
of,O
patients,O
on,O
placebo,O
Other,O
adverse,O
reactions,O
with,O
a,O
plausible,O
relationship,O
to,O
treatment,O
that,O
have,O
been,O
reported,O
with,O
an,O
incidence,O
of,O
0,O
3,O
and,O
greater,O
than,O
placebo,O
in,O
more,O
than,O
3300,O
patients,O
treated,O
with,O
Edarbi,O
in,O
controlled,O
trials,O
are,O
listed,O
below,O
Gastrointestinal,O
Disorders,O
nausea,AdverseReaction
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
asthenia,AdverseReaction
fatigue,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
muscle spasm,AdverseReaction
Nervous,O
System,O
Disorders,O
dizziness,AdverseReaction
dizziness postural,AdverseReaction
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
cough,AdverseReaction
6,O
2,O
Clinical,O
Laboratory,O
Findings,O
In,O
controlled,O
clinical,O
trials,O
clinically,O
relevant,O
changes,O
in,O
standard,O
laboratory,O
parameters,O
were,O
uncommon,O
with,O
administration,O
of,O
Edarbi,O
Serum,O
creatinine,O
Small,Severity
reversible,Severity
increases in serum creatinine,AdverseReaction
are,O
seen,O
in,O
patients,O
receiving,O
80,O
mg,O
of,O
Edarbi,O
The,O
increase,O
may,O
be,O
larger,O
when,O
coadministered,O
with,O
chlorthalidone,O
or,O
hydrochlorothiazide,O
In,O
addition,O
patients,O
taking,O
Edarbi,O
who,O
had,O
moderate,O
to,O
severe,O
renal,O
impairment,O
at,O
baseline,O
or,O
who,O
were,O
75,O
years,O
of,O
age,O
were,O
more,O
likely,O
to,O
report,O
serum creatinine increases,AdverseReaction
Hemoglobin,O
Hematocrit,O
Low hemoglobin,AdverseReaction
hematocrit,AdverseReaction
and,O
RBC counts,AdverseReaction
were,O
observed,O
in,O
0,O
2,O
0,O
4,O
and,O
0,O
3,O
of,O
Edarbi,O
treated,O
subjects,O
respectively,O
None,O
of,O
these,O
abnormalities,O
were,O
reported,O
in,O
the,O
placebo,O
group,O
Low,AdverseReaction
and,O
high,AdverseReaction
markedly,Severity
abnormal platelet,AdverseReaction
and,O
WBC counts counts counts,AdverseReaction
were,O
observed,O
in,O
0,O
1,O
of,O
subjects,O
6,O
3,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
the,O
postmarketing,O
use,O
of,O
EDARBI,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Nausea,AdverseReaction
Muscle spasms,AdverseReaction
Rash,AdverseReaction
Pruritus,AdverseReaction
Angioedema,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
ELIQUIS,O
can,Factor
cause,O
serious,Severity
potentially,Factor
fatal,AdverseReaction
bleeding,AdverseReaction
Promptly,O
evaluate,O
signs,O
and,O
symptoms,O
of,O
blood,O
loss,O
5,O
2,O
Prosthetic,O
heart,O
valves,O
ELIQUIS,O
use,O
not,O
recommended,O
5,O
4,O
5,O
1,O
Increased,O
Risk,O
of,O
Thrombotic,O
Events,O
after,O
Premature,O
Discontinuation,O
Premature,O
discontinuation,O
of,O
any,O
oral,O
anticoagulant,O
including,O
ELIQUIS,O
in,O
the,O
absence,O
of,O
adequate,O
alternative,O
anticoagulation,O
increases,O
the,O
risk,Factor
of,O
thrombotic events,AdverseReaction
An,O
increased,O
rate,O
of,O
stroke,AdverseReaction
was,O
observed,O
during,O
the,O
transition,O
from,O
ELIQUIS,O
to,O
warfarin,O
in,O
clinical,O
trials,O
in,O
atrial,O
fibrillation,O
patients,O
If,O
ELIQUIS,O
is,O
discontinued,O
for,O
a,O
reason,O
other,O
than,O
pathological,O
bleeding,O
or,O
completion,O
of,O
a,O
course,O
of,O
therapy,O
consider,O
coverage,O
with,O
another,O
anticoagulant,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
andClinical,O
Studies,O
14,O
1,O
5,O
2,O
Bleeding,O
ELIQUIS,O
increases,O
the,O
risk,Factor
of,O
bleeding,AdverseReaction
and,O
can,Factor
cause,O
serious,Severity
potentially,Factor
fatal,AdverseReaction
bleeding,AdverseReaction
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
andAdverse,O
Reactions,O
6,O
1,O
Concomitant,O
use,O
of,O
drugs,O
affecting,O
hemostasis,O
increases,O
the,O
risk,Factor
of,O
bleeding,AdverseReaction
These,O
include,O
aspirin,O
and,O
other,O
antiplatelet,O
agents,O
other,O
anticoagulants,O
heparin,O
thrombolytic,O
agents,O
selective,O
serotonin,O
reuptake,O
inhibitors,O
serotonin,O
norepinephrine,O
reuptake,O
inhibitors,O
and,O
nonsteroidal,O
anti,O
inflammatory,O
drugs,O
NSAIDs,O
seeDrug,O
Interactions,O
7,O
3,O
Advise,O
patients,O
of,O
signs,O
and,O
symptoms,O
of,O
blood,O
loss,O
and,O
to,O
report,O
them,O
immediately,O
or,O
go,O
to,O
an,O
emergency,O
room,O
Discontinue,O
ELIQUIS,O
in,O
patients,O
with,O
active,O
pathological,O
hemorrhage,O
There,O
is,O
no,O
established,O
way,O
to,O
reverse,O
the,O
anticoagulant,O
effect,O
of,O
apixaban,O
which,O
can,O
be,O
expected,O
to,O
persist,O
for,O
at,O
least,O
24,O
hours,O
after,O
the,O
last,O
dose,O
i,O
e,O
for,O
about,O
two,O
drug,O
half,O
lives,O
A,O
specific,O
antidote,O
for,O
ELIQUIS,O
is,O
not,O
available,O
Hemodialysis,O
does,O
not,O
appear,O
to,O
have,O
a,O
substantial,O
impact,O
on,O
apixaban,O
exposure,O
seeClinical,O
Pharmacology,O
12,O
3,O
Protamine,O
sulfate,O
and,O
vitamin,O
K,O
are,O
not,O
expected,O
to,O
affect,O
the,O
anticoagulant,O
activity,O
of,O
apixaban,O
There,O
is,O
no,O
experience,O
with,O
antifibrinolytic,O
agents,O
tranexamic,O
acid,O
aminocaproic,O
acid,O
in,O
individuals,O
receiving,O
apixaban,O
There,O
is,O
neither,O
scientific,O
rationale,O
for,O
reversal,O
nor,O
experience,O
with,O
systemic,O
hemostatics,O
desmopressin,O
and,O
aprotinin,O
in,O
individuals,O
receiving,O
apixaban,O
Use,O
of,O
procoagulant,O
reversal,O
agents,O
such,O
as,O
prothrombin,O
complex,O
concentrate,O
activated,O
prothrombin,O
complex,O
concentrate,O
or,O
recombinant,O
factor,O
VIIa,O
may,O
be,O
considered,O
but,O
has,O
not,O
been,O
evaluated,O
in,O
clinical,O
studies,O
Activated,O
oral,O
charcoal,O
reduces,O
absorption,O
of,O
apixaban,O
thereby,O
lowering,O
apixaban,O
plasma,O
concentration,O
seeOverdosage,O
10,O
5,O
3,O
Spinal,O
Epidural,O
Anesthesia,O
or,O
Puncture,O
When,O
neuraxial,O
anesthesia,O
spinal,O
epidural,O
anesthesia,O
or,O
spinal,O
epidural,O
puncture,O
is,O
employed,O
patients,O
treated,O
with,O
antithrombotic,O
agents,O
for,O
prevention,O
of,O
thromboembolic,O
complications,O
are,O
at,O
risk,Factor
of,O
developing,O
an,O
epidural,AdverseReaction
or,O
spinal hematoma,AdverseReaction
which,O
can,Factor
result,O
in,O
long term,AdverseReaction
or,O
permanent paralysis,AdverseReaction
The,O
risk,O
of,O
these,O
events,O
may,O
be,O
increased,O
by,O
the,O
postoperative,O
use,O
of,O
indwelling,O
epidural,O
catheters,O
or,O
the,O
concomitant,O
use,O
of,O
medicinal,O
products,O
affecting,O
hemostasis,O
Indwelling,O
epidural,O
or,O
intrathecal,O
catheters,O
should,O
not,O
be,O
removed,O
earlier,O
than,O
24,O
hours,O
after,O
the,O
last,O
administration,O
of,O
ELIQUIS,O
The,O
next,O
dose,O
of,O
ELIQUIS,O
should,O
not,O
be,O
administered,O
earlier,O
than,O
5,O
hours,O
after,O
the,O
removal,O
of,O
the,O
catheter,O
The,O
risk,O
may,O
also,O
be,O
increased,O
by,O
traumatic,O
or,O
repeated,O
epidural,O
or,O
spinal,O
puncture,O
If,O
traumatic,O
puncture,O
occurs,O
delay,O
the,O
administration,O
of,O
ELIQUIS,O
for,O
48,O
hours,O
Monitor,O
patients,O
frequently,O
for,O
signs,O
and,O
symptoms,O
of,O
neurological,O
impairment,O
e,O
g,O
numbness,O
or,O
weakness,O
of,O
the,O
legs,O
bowel,O
or,O
bladder,O
dysfunction,O
If,O
neurological,O
compromise,O
is,O
noted,O
urgent,O
diagnosis,O
and,O
treatment,O
is,O
necessary,O
Prior,O
to,O
neuraxial,O
intervention,O
the,O
physician,O
should,O
consider,O
the,O
potential,O
benefit,O
versus,O
the,O
risk,O
in,O
anticoagulated,O
patients,O
or,O
in,O
patients,O
to,O
be,O
anticoagulated,O
for,O
thromboprophylaxis,O
5,O
4,O
Patients,O
with,O
Prosthetic,O
Heart,O
Valves,O
The,O
safety,O
and,O
efficacy,O
of,O
ELIQUIS,O
have,O
not,O
been,O
studied,O
in,O
patients,O
with,O
prosthetic,O
heart,O
valves,O
Therefore,O
use,O
of,O
ELIQUIS,O
is,O
not,O
recommended,O
in,O
these,O
patients,O
5,O
5,O
Acute,O
PE,O
in,O
Hemodynamically,O
Unstable,O
Patients,O
or,O
Patients,O
who,O
Require,O
Thrombolysis,O
or,O
Pulmonary,O
Embolectomy,O
Initiation,O
of,O
ELIQUIS,O
is,O
not,O
recommended,O
as,O
an,O
alternative,O
to,O
unfractionated,O
heparin,O
for,O
the,O
initial,O
treatment,O
of,O
patients,O
with,O
PE,O
who,O
present,O
with,O
hemodynamic,O
instability,O
or,O
who,O
may,O
receive,O
thrombolysis,O
or,O
pulmonary,O
embolectomy,O
""
BOXED,O
WARNING,O
WARNING,O
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
ELIQUIS,O
INCREASES,O
THE,O
RISK,Factor
OF,O
THROMBOTIC EVENTS,AdverseReaction
B,O
SPINAL,AdverseReaction
EPIDURAL HEMATOMA,AdverseReaction
WARNING,O
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
ELIQUIS,O
INCREASES,O
THE,O
RISK,Factor
OF,O
THROMBOTIC EVENTS,AdverseReaction
B,O
SPINAL,AdverseReaction
EPIDURAL HEMATOMA,AdverseReaction
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
ELIQUIS,O
INCREASES,O
THE,O
RISK,Factor
OF,O
THROMBOTIC EVENTS,AdverseReaction
Premature,O
discontinuation,O
of,O
any,O
oral,O
anticoagulant,O
including,O
ELIQUIS,O
increases,O
the,O
risk,Factor
of,O
thrombotic events,AdverseReaction
If,O
anticoagulation,O
with,O
ELIQUIS,O
is,O
discontinued,O
for,O
a,O
reason,O
other,O
than,O
pathological,O
bleeding,O
or,O
completion,O
of,O
a,O
course,O
of,O
therapy,O
consider,O
coverage,O
with,O
another,O
anticoagulant,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Clinical,O
Studies,O
14,O
1,O
B,O
SPINAL,O
EPIDURAL,O
HEMATOMA,O
Epidural,AdverseReaction
or,O
spinal hematomas,AdverseReaction
may,Factor
occur,O
in,O
patients,O
treated,O
with,O
ELIQUIS,O
who,O
are,O
receiving,O
neuraxial,O
anesthesia,O
or,O
undergoing,O
spinal,O
puncture,O
These,O
hematomas,AdverseReaction
may,Factor
result,O
in,O
long term,AdverseReaction
or,O
permanent paralysis,AdverseReaction
Consider,O
these,O
risks,O
when,O
scheduling,O
patients,O
for,O
spinal,O
procedures,O
Factors,O
that,O
can,O
increase,O
the,O
risk,Factor
of,O
developing,O
epidural,AdverseReaction
or,O
spinal hematomas,AdverseReaction
in,O
these,O
patients,O
include,O
use,O
of,O
indwelling,O
epidural,O
catheters,O
concomitant,O
use,O
of,O
other,O
drugs,O
that,O
affect,O
hemostasis,O
such,O
as,O
nonsteroidal,O
anti,O
inflammatory,O
drugs,O
NSAIDs,O
platelet,O
inhibitors,O
other,O
anticoagulants,O
a,O
history,O
of,O
traumatic,O
or,O
repeated,O
epidural,O
or,O
spinal,O
punctures,O
a,O
history,O
of,O
spinal,O
deformity,O
or,O
spinal,O
surgery,O
optimal,O
timing,O
between,O
the,O
administration,O
of,O
ELIQUIS,O
and,O
neuraxial,O
procedures,O
is,O
not,O
known,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Monitor,O
patients,O
frequently,O
for,O
signs,O
and,O
symptoms,O
of,O
neurological,O
impairment,O
If,O
neurological,O
compromise,O
is,O
noted,O
urgent,O
treatment,O
is,O
necessary,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Consider,O
the,O
benefits,O
and,O
risks,O
before,O
neuraxial,O
intervention,O
in,O
patients,O
anticoagulated,O
or,O
to,O
be,O
anticoagulated,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
WARNING,O
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
ELIQUIS,O
INCREASES,O
THE,O
RISK,Factor
OF,O
THROMBOTIC EVENTS,AdverseReaction
B,O
SPINAL,AdverseReaction
EPIDURAL HEMATOMA,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
ELIQUIS,O
INCREASES,O
THE,O
RISK,Factor
OF,O
THROMBOTIC EVENTS,AdverseReaction
Premature,O
discontinuation,O
of,O
any,O
oral,O
anticoagulant,O
including,O
ELIQUIS,O
increases,O
the,O
risk,Factor
of,O
thrombotic events,AdverseReaction
To,O
reduce,O
this,O
risk,O
consider,O
coverage,O
with,O
another,O
anticoagulant,O
if,O
ELIQUIS,O
is,O
discontinued,O
for,O
a,O
reason,O
other,O
than,O
pathological,O
bleeding,O
or,O
completion,O
of,O
a,O
course,O
of,O
therapy,O
2,O
4,O
5,O
1,O
14,O
1,O
B,O
SPINAL,O
EPIDURAL,O
HEMATOMA,O
Epidural,AdverseReaction
or,O
spinal hematomas,AdverseReaction
may,Factor
occur,O
in,O
patients,O
treated,O
with,O
ELIQUIS,O
who,O
are,O
receiving,O
neuraxial,O
anesthesia,O
or,O
undergoing,O
spinal,O
puncture,O
These,O
hematomas,AdverseReaction
may,Factor
result,O
in,O
long term,AdverseReaction
or,O
permanent paralysis,AdverseReaction
Consider,O
these,O
risks,O
when,O
scheduling,O
patients,O
for,O
spinal,O
procedures,O
5,O
3,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
prescribing,O
information,O
Increased,O
risk,Factor
of,O
thrombotic events,AdverseReaction
after,O
premature,O
discontinuation,O
seeWarnings,O
and,O
Precautions,O
5,O
1,O
Bleeding,AdverseReaction
seeWarnings,O
and,O
Precautions,O
5,O
2,O
Spinal,O
epidural,O
anesthesia,O
or,O
puncture,O
seeWarnings,O
and,O
Precautions,O
5,O
3,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
1,O
are,O
related,O
to,O
bleeding,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Bristol,O
Myers,O
Squibb,O
at,O
1,O
800,O
721,O
5072,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Reduction,O
of,O
Risk,O
of,O
Stroke,O
and,O
Systemic,O
Embolism,O
in,O
Patients,O
with,O
Nonvalvular,O
Atrial,O
Fibrillation,O
The,O
safety,O
of,O
ELIQUIS,O
was,O
evaluated,O
in,O
the,O
ARISTOTLE,O
and,O
AVERROES,O
studies,O
seeClinical,O
Studies,O
14,O
including,O
11,O
284,O
patients,O
exposed,O
to,O
ELIQUIS,O
5,O
mg,O
twice,O
daily,O
and,O
602,O
patients,O
exposed,O
to,O
ELIQUIS,O
2,O
5,O
mg,O
twice,O
daily,O
The,O
duration,O
of,O
ELIQUIS,O
exposure,O
was,O
12,O
months,O
for,O
9375,O
patients,O
and,O
24,O
months,O
for,O
3369,O
patients,O
in,O
the,O
two,O
studies,O
In,O
ARISTOTLE,O
the,O
mean,O
duration,O
of,O
exposure,O
was,O
89,O
weeks,O
15,O
000,O
patient,O
years,O
In,O
AVERROES,O
the,O
mean,O
duration,O
of,O
exposure,O
was,O
approximately,O
59,O
weeks,O
3000,O
patient,O
years,O
The,O
most,O
common,O
reason,O
for,O
treatment,O
discontinuation,O
in,O
both,O
studies,O
was,O
for,O
bleeding related adverse reactions,AdverseReaction
in,O
ARISTOTLE,O
this,O
occurred,O
in,O
1,O
7,O
and,O
2,O
5,O
of,O
patients,O
treated,O
with,O
ELIQUIS,O
and,O
warfarin,O
respectively,O
and,O
in,O
AVERROES,O
in,O
1,O
5,O
and,O
1,O
3,O
on,O
ELIQUIS,O
and,O
aspirin,O
respectively,O
Bleeding,O
in,O
Patients,O
with,O
Nonvalvular,O
Atrial,O
Fibrillation,O
in,O
ARISTOTLE,O
and,O
AVERROES,O
Tables,O
1,O
and,O
2,O
show,O
the,O
number,O
of,O
patients,O
experiencing,O
major,Severity
bleeding,AdverseReaction
during,O
the,O
treatment,O
period,O
and,O
the,O
bleeding,AdverseReaction
rate,O
percentage,O
of,O
subjects,O
with,O
at,O
least,O
one,O
bleeding,AdverseReaction
event,O
per,O
100,O
patient,O
years,O
in,O
ARISTOTLE,O
and,O
AVERROES,O
Table,O
1,O
Bleeding,AdverseReaction
Events,O
in,O
Patients,O
with,O
Nonvalvular,O
Atrial,O
Fibrillation,O
in,O
ARISTOTLE,O
ELIQUISN,O
9088n,O
per,O
100,O
pt,O
year,O
WarfarinN,O
9052n,O
per,O
100,O
pt,O
year,O
Hazard,O
Ratio,O
95,O
CI,O
P,O
value,O
Bleeding,AdverseReaction
events,O
within,O
each,O
subcategory,O
were,O
counted,O
once,O
per,O
subject,O
but,O
subjects,O
may,O
have,O
contributed,O
events,O
to,O
multiple,O
endpoints,O
Bleeding,AdverseReaction
events,O
were,O
counted,O
during,O
treatment,O
or,O
within,O
2,O
days,O
of,O
stopping,O
study,O
treatment,O
on,O
treatment,O
period,O
Defined,O
as,O
clinically,O
overt,O
bleeding,AdverseReaction
accompanied,O
by,O
one,O
or,O
more,O
of,O
the,O
following,O
a,O
decrease in hemoglobin,AdverseReaction
of,O
2 g dL,Severity
a,O
transfusion,O
of,O
2,O
or,O
more,O
units,O
of,O
packed,O
red,O
blood,O
cells,O
bleeding at a critical site,AdverseReaction
intracranial,AdverseReaction
intraspinal,AdverseReaction
intraocular,AdverseReaction
pericardial,AdverseReaction
intra articular,AdverseReaction
intramuscular,AdverseReaction
with,O
compartment syndrome,AdverseReaction
retroperitoneal,AdverseReaction
or,O
with,O
fatal outcome,AdverseReaction
Intracranial bleed,AdverseReaction
includes,O
intracerebral,AdverseReaction
intraventricular,AdverseReaction
subdural,AdverseReaction
and,O
subarachnoid bleeding,AdverseReaction
Any,O
type,O
of,O
hemorrhagic stroke,AdverseReaction
was,O
adjudicated,O
and,O
counted,O
as,O
an,O
intracranial,AdverseReaction
major,Severity
bleed,AdverseReaction
S,O
On,O
treatment,O
analysis,O
based,O
on,O
the,O
safety,O
population,O
compared,O
to,O
ITT,O
analysis,O
presented,O
in,O
Section,O
14,O
GI bleed,AdverseReaction
includes,O
upper GI,AdverseReaction
lower GI,AdverseReaction
and,O
rectal bleeding,AdverseReaction
Fatal,AdverseReaction
bleeding,AdverseReaction
is,O
an,O
adjudicated,O
death,AdverseReaction
with,O
the,O
primary,O
cause,O
of,O
death,AdverseReaction
as,O
intracranial bleeding,AdverseReaction
or,O
non intracranial bleeding,AdverseReaction
during,O
the,O
on,O
treatment,O
period,O
Major,O
327,O
2,O
13,O
462,O
3,O
09,O
0,O
69,O
0,O
60,O
0,O
80,O
0,O
0001,O
Intracranial,O
ICH,AdverseReaction
52,O
0,O
33,O
125,O
0,O
82,O
0,O
41,O
0,O
30,O
0,O
57,O
Hemorrhagic,O
strokeS,O
38,O
0,O
24,O
74,O
0,O
49,O
0,O
51,O
0,O
34,O
0,O
75,O
Other,O
ICH,AdverseReaction
15,O
0,O
10,O
51,O
0,O
34,O
0,O
29,O
0,O
16,O
0,O
51,O
Gastrointestinal,O
GI,O
128,O
0,O
83,O
141,O
0,O
93,O
0,O
89,O
0,O
70,O
1,O
14,O
Fatal,AdverseReaction
10,O
0,O
06,O
37,O
0,O
24,O
0,O
27,O
0,O
13,O
0,O
53,O
Intracranial,O
4,O
0,O
03,O
30,O
0,O
20,O
0,O
13,O
0,O
05,O
0,O
37,O
Non,O
intracranial,O
6,O
0,O
04,O
7,O
0,O
05,O
0,O
84,O
0,O
28,O
2,O
15,O
In,O
ARISTOTLE,O
the,O
results,O
for,O
major,Severity
bleeding,AdverseReaction
were,O
generally,O
consistent,O
across,O
most,O
major,O
subgroups,O
including,O
age,O
weight,O
CHADS2score,O
a,O
scale,O
from,O
0,O
to,O
6,O
used,O
to,O
estimate,O
risk,O
of,O
stroke,O
with,O
higher,O
scores,O
predicting,O
greater,O
risk,O
prior,O
warfarin,O
use,O
geographic,O
region,O
and,O
aspirin,O
use,O
at,O
randomization,O
Figure,O
1,O
Subjects,O
treated,O
with,O
apixaban,O
with,O
diabetes,O
bled,AdverseReaction
more,O
3,O
0,O
per,O
year,O
than,O
did,O
subjects,O
without,O
diabetes,O
1,O
9,O
per,O
year,O
Figure,O
1,O
Major,Severity
Bleeding,AdverseReaction
Hazard,O
Ratios,O
by,O
Baseline,O
Characteristics,O
ARISTOTLE,O
Study,O
Note,O
The,O
figure,O
above,O
presents,O
effects,O
in,O
various,O
subgroups,O
all,O
of,O
which,O
are,O
baseline,O
characteristics,O
and,O
all,O
of,O
which,O
were,O
pre,O
specified,O
if,O
not,O
the,O
groupings,O
The,O
95,O
confidence,O
limits,O
that,O
are,O
shown,O
do,O
not,O
take,O
into,O
account,O
how,O
many,O
comparisons,O
were,O
made,O
nor,O
do,O
they,O
reflect,O
the,O
effect,O
of,O
a,O
particular,O
factor,O
after,O
adjustment,O
for,O
all,O
other,O
factors,O
Apparent,O
homogeneity,O
or,O
heterogeneity,O
among,O
groups,O
should,O
not,O
be,O
over,O
interpreted,O
Table,O
2,O
Bleeding,AdverseReaction
Events,O
in,O
Patients,O
with,O
Nonvalvular,O
Atrial,O
Fibrillation,O
in,O
AVERROES,O
ELIQUISN,O
2798n,O
year,O
AspirinN,O
2780n,O
year,O
Hazard,O
Ratio,O
95,O
CI,O
P,O
value,O
Events,O
associated,O
with,O
each,O
endpoint,O
were,O
counted,O
once,O
per,O
subject,O
but,O
subjects,O
may,O
have,O
contributed,O
events,O
to,O
multiple,O
endpoints,O
Major,O
45,O
1,O
41,O
29,O
0,O
92,O
1,O
54,O
0,O
96,O
2,O
45,O
0,O
07,O
Fatal,AdverseReaction
5,O
0,O
16,O
5,O
0,O
16,O
0,O
99,O
0,O
23,O
4,O
29,O
Intracranial,O
11,O
0,O
34,O
11,O
0,O
35,O
0,O
99,O
0,O
39,O
2,O
51,O
ARISTOTLE,O
Major,Severity
Bleeding,AdverseReaction
Forest,O
Plot,O
Other,O
Adverse,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
including,O
drug hypersensitivity,AdverseReaction
such,O
as,O
skin rash,AdverseReaction
and,O
anaphylactic reactions,AdverseReaction
such,O
as,O
allergic edema,AdverseReaction
and,O
syncope,AdverseReaction
were,O
reported,O
in,O
1,O
of,O
patients,O
receiving,O
ELIQUIS,O
Prophylaxis,O
of,O
Deep,O
Vein,O
Thrombosis,O
Following,O
Hip,O
or,O
Knee,O
Replacement,O
Surgery,O
The,O
safety,O
of,O
ELIQUIS,O
has,O
been,O
evaluated,O
in,O
1,O
Phase,O
II,O
and,O
3,O
Phase,O
III,O
studies,O
including,O
5924,O
patients,O
exposed,O
to,O
ELIQUIS,O
2,O
5,O
mg,O
twice,O
daily,O
undergoing,O
major,O
orthopedic,O
surgery,O
of,O
the,O
lower,O
limbs,O
elective,O
hip,O
replacement,O
or,O
elective,O
knee,O
replacement,O
treated,O
for,O
up,O
to,O
38,O
days,O
In,O
total,O
11,O
of,O
the,O
patients,O
treated,O
with,O
ELIQUIS,O
2,O
5,O
mg,O
twice,O
daily,O
experienced,O
adverse,O
reactions,O
Bleeding,AdverseReaction
results,O
during,O
the,O
treatment,O
period,O
in,O
the,O
Phase,O
III,O
studies,O
are,O
shown,O
in,O
Table,O
3,O
Bleeding,AdverseReaction
was,O
assessed,O
in,O
each,O
study,O
beginning,O
with,O
the,O
first,O
dose,O
of,O
double,O
blind,O
study,O
drug,O
Table,O
3,O
Bleeding,AdverseReaction
During,O
the,O
Treatment,O
Period,O
in,O
Patients,O
Undergoing,O
Elective,O
Hip,O
or,O
Knee,O
Replacement,O
Surgery,O
Bleeding,O
Endpoint,O
ADVANCE,O
3Hip,O
Replacement,O
Surgery,O
ADVANCE,O
2Knee,O
Replacement,O
Surgery,O
ADVANCE,O
1Knee,O
Replacement,O
Surgery,O
All,O
bleeding,AdverseReaction
criteria,O
included,O
surgical site bleeding,AdverseReaction
Includes,O
13,O
subjects,O
with,O
major,Severity
bleeding,AdverseReaction
events,O
that,O
occurred,O
before the first dose,Negation
of,O
apixaban,O
administered,O
12,O
to,O
24,O
hours,O
post,O
surgery,O
Includes,O
5,O
subjects,O
with,O
major,Severity
bleeding,AdverseReaction
events,O
that,O
occurred,O
before the first dose,Negation
of,O
apixaban,O
administered,O
12,O
to,O
24,O
hours,O
post,O
surgery,O
S,O
Intracranial,O
intraspinal,O
intraocular,O
pericardial,O
an,O
operated,O
joint,O
requiring,O
re,O
operation,O
or,O
intervention,O
intramuscular,O
with,O
compartment,O
syndrome,O
or,O
retroperitoneal,O
Bleeding into an operated joint,AdverseReaction
requiring,O
re,O
operation,O
or,O
intervention,O
was,O
present,O
in,O
all,O
patients,O
with,O
this,O
category,O
of,O
bleeding,AdverseReaction
Events,O
and,O
event,O
rates,O
include,O
one,O
enoxaparin,O
treated,O
patient,O
in,O
ADVANCE,O
1,O
who,O
also,O
had,O
intracranial hemorrhage,AdverseReaction
CRNM,O
clinically,O
relevant,O
nonmajor,O
ELIQUIS2,O
5,O
mg,O
po,O
bid35,O
3,O
days,O
Enoxaparin,O
40,O
mg,O
sc,O
qd,O
35,O
3,O
days,O
ELIQUIS,O
2,O
5,O
mg,O
po,O
bid,O
12,O
2,O
days,O
Enoxaparin,O
40,O
mg,O
sc,O
qd,O
12,O
2,O
days,O
ELIQUIS,O
2,O
5,O
mg,O
po,O
bid,O
12,O
2,O
days,O
Enoxaparin,O
30,O
mg,O
sc,O
q12h,O
12,O
2,O
days,O
First,O
dose,O
12,O
to,O
24,O
hours,O
post,O
surgery,O
First,O
dose,O
9,O
to,O
15,O
hours,O
prior,O
to,O
surgery,O
First,O
dose,O
12,O
to,O
24,O
hours,O
post,O
surgery,O
First,O
dose,O
9,O
to,O
15,O
hours,O
prior,O
to,O
surgery,O
First,O
dose,O
12,O
to,O
24,O
hours,O
post,O
surgery,O
First,O
dose,O
12,O
to,O
24,O
hours,O
post,O
surgery,O
All,O
treated,O
N,O
2673,O
N,O
2659,O
N,O
1501,O
N,O
1508,O
N,O
1596,O
N,O
1588,O
Major,O
including,O
surgical,O
site,O
22,O
0,O
82,O
18,O
0,O
68,O
9,O
0,O
60,O
14,O
0,O
93,O
11,O
0,O
69,O
22,O
1,O
39,O
Fatal,AdverseReaction
0,O
0,O
0,O
0,O
0,O
1,O
0,O
06,O
Hgb decrease,AdverseReaction
2 g dL,Severity
13,O
0,O
49,O
10,O
0,O
38,O
8,O
0,O
53,O
9,O
0,O
60,O
10,O
0,O
63,O
16,O
1,O
01,O
Transfusion,O
of,O
2,O
units,O
RBC,O
16,O
0,O
60,O
14,O
0,O
53,O
5,O
0,O
33,O
9,O
0,O
60,O
9,O
0,O
56,O
18,O
1,O
13,O
Bleed,O
at,O
critical,O
siteS,O
1,O
0,O
04,O
1,O
0,O
04,O
1,O
0,O
07,O
2,O
0,O
13,O
1,O
0,O
06,O
4,O
0,O
25,O
Major,O
CRNM,O
129,O
4,O
83,O
134,O
5,O
04,O
53,O
3,O
53,O
72,O
4,O
77,O
46,O
2,O
88,O
68,O
4,O
28,O
All,O
313,O
11,O
71,O
334,O
12,O
56,O
104,O
6,O
93,O
126,O
8,O
36,O
85,O
5,O
33,O
108,O
6,O
80,O
Adverse,O
reactions,O
occurring,O
in,O
1,O
of,O
patients,O
undergoing,O
hip,O
or,O
knee,O
replacement,O
surgery,O
in,O
the,O
1,O
Phase,O
II,O
study,O
and,O
the,O
3,O
Phase,O
III,O
studies,O
are,O
listed,O
in,O
Table,O
4,O
Table,O
4,O
Adverse,O
Reactions,O
Occurring,O
in,O
1,O
of,O
Patients,O
in,O
Either,O
Group,O
Undergoing,O
Hip,O
or,O
Knee,O
Replacement,O
Surgery,O
ELIQUIS,O
n,O
2,O
5,O
mg,O
po,O
bidN,O
5924,O
Enoxaparin,O
n,O
40,O
mg,O
sc,O
qd,O
or30,O
mg,O
sc,O
q12hN,O
5904,O
Nausea,AdverseReaction
153,O
2,O
6,O
159,O
2,O
7,O
Anemia,AdverseReaction
including,O
postoperative,AdverseReaction
and,O
hemorrhagic anemia,AdverseReaction
and,O
respective,O
laboratory,O
parameters,O
153,O
2,O
6,O
178,O
3,O
0,O
Contusion,AdverseReaction
83,O
1,O
4,O
115,O
1,O
9,O
Hemorrhage,AdverseReaction
including,O
hematoma,AdverseReaction
and,O
vaginal,AdverseReaction
and,O
urethral hemorrhage,AdverseReaction
67,O
1,O
1,O
81,O
1,O
4,O
Postprocedural hemorrhage,AdverseReaction
including,O
postprocedural hematoma,AdverseReaction
wound hemorrhage,AdverseReaction
vessel puncture site hematoma,AdverseReaction
and,O
catheter site hemorrhage,AdverseReaction
54,O
0,O
9,O
60,O
1,O
0,O
Transaminases increased,AdverseReaction
including,O
alanine aminotransferase increased,AdverseReaction
and,O
alanine aminotransferase abnormal,AdverseReaction
50,O
0,O
8,O
71,O
1,O
2,O
Aspartate aminotransferase increased,AdverseReaction
47,O
0,O
8,O
69,O
1,O
2,O
Gamma glutamyltransferase increased,AdverseReaction
38,O
0,O
6,O
65,O
1,O
1,O
Less,O
common,O
adverse,O
reactions,O
in,O
apixaban,O
treated,O
patients,O
undergoing,O
hip,O
or,O
knee,O
replacement,O
surgery,O
occurring,O
at,O
a,O
frequency,O
of,O
0,O
1,O
to,O
1,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
thrombocytopenia,AdverseReaction
including,O
platelet count decreases,AdverseReaction
Vascular,O
disorders,O
hypotension,AdverseReaction
including,O
procedural hypotension,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
epistaxis,AdverseReaction
Gastrointestinal,O
disorders,O
gastrointestinal hemorrhage,AdverseReaction
including,O
hematemesis,AdverseReaction
and,O
melena,AdverseReaction
hematochezia,AdverseReaction
Hepatobiliary,O
disorders,O
liver function test abnormal,AdverseReaction
blood alkaline phosphatase increased,AdverseReaction
blood bilirubin increased,AdverseReaction
Renal,O
and,O
urinary,O
disorders,O
hematuria,AdverseReaction
including,O
respective,O
laboratory,O
parameters,O
Injury,O
poisoning,O
and,O
procedural,O
complications,O
wound secretion,AdverseReaction
incision site hemorrhage,AdverseReaction
including,O
incision site hematoma,AdverseReaction
operative hemorrhage,AdverseReaction
Less,O
common,O
adverse,O
reactions,O
in,O
apixaban,O
treated,O
patients,O
undergoing,O
hip,O
or,O
knee,O
replacement,O
surgery,O
occurring,O
at,O
a,O
frequency,O
of,O
0,O
1,O
Gingival bleeding,AdverseReaction
hemoptysis,AdverseReaction
hypersensitivity,AdverseReaction
muscle hemorrhage,AdverseReaction
ocular hemorrhage,AdverseReaction
including,O
conjunctival hemorrhage,AdverseReaction
rectal hemorrhage,AdverseReaction
Treatment,O
of,O
DVT,O
and,O
PE,O
and,O
Reduction,O
in,O
the,O
Risk,O
of,O
Recurrence,O
of,O
DVT,O
or,O
PE,O
The,O
safety,O
of,O
ELIQUIS,O
has,O
been,O
evaluated,O
in,O
the,O
AMPLIFY,O
and,O
AMPLIFY,O
EXT,O
studies,O
including,O
2676,O
patients,O
exposed,O
to,O
ELIQUIS,O
10,O
mg,O
twice,O
daily,O
3359,O
patients,O
exposed,O
to,O
ELIQUIS,O
5,O
mg,O
twice,O
daily,O
and,O
840,O
patients,O
exposed,O
to,O
ELIQUIS,O
2,O
5,O
mg,O
twice,O
daily,O
Common,O
adverse,O
reactions,O
1,O
were,O
gingival bleeding,AdverseReaction
epistaxis,AdverseReaction
contusion,AdverseReaction
hematuria,AdverseReaction
rectal hemorrhage,AdverseReaction
hematoma,AdverseReaction
menorrhagia,AdverseReaction
and,O
hemoptysis,AdverseReaction
AMPLIFY,O
Study,O
The,O
mean,O
duration,O
of,O
exposure,O
to,O
ELIQUIS,O
was,O
154,O
days,O
and,O
to,O
enoxaparin,O
warfarin,O
was,O
152,O
days,O
in,O
the,O
AMPLIFY,O
study,O
Adverse,O
reactions,O
related,O
to,O
bleeding,AdverseReaction
occurred,O
in,O
417,O
15,O
6,O
ELIQUIS,O
treated,O
patients,O
compared,O
to,O
661,O
24,O
6,O
enoxaparin,O
warfarin,O
treated,O
patients,O
The,O
discontinuation,O
rate,O
due,O
to,O
bleeding,AdverseReaction
events,O
was,O
0,O
7,O
in,O
the,O
ELIQUIS,O
treated,O
patients,O
compared,O
to,O
1,O
7,O
in,O
enoxaparin,O
warfarin,O
treated,O
patients,O
in,O
the,O
AMPLIFY,O
study,O
In,O
the,O
AMPLIFY,O
study,O
ELIQUIS,O
was,O
statistically,O
superior,O
to,O
enoxaparin,O
warfarin,O
in,O
the,O
primary,O
safety,O
endpoint,O
of,O
major,Severity
bleeding,AdverseReaction
relative,O
risk,O
0,O
31,O
95,O
CI,O
0,O
17,O
0,O
55,O
P,O
value,O
0,O
0001,O
Bleeding,AdverseReaction
results,O
from,O
the,O
AMPLIFY,O
study,O
are,O
summarized,O
in,O
Table,O
5,O
Table,O
5,O
Bleeding,AdverseReaction
Results,O
in,O
the,O
AMPLIFY,O
Study,O
ELIQUISN,O
2676n,O
Enoxaparin,O
WarfarinN,O
2689n,O
Relative,O
Risk,O
95,O
CI,O
CRNM,AdverseReaction
clinically relevant nonmajor bleeding,AdverseReaction
Events,O
associated,O
with,O
each,O
endpoint,O
were,O
counted,O
once,O
per,O
subject,O
but,O
subjects,O
may,O
have,O
contributed,O
events,O
to,O
multiple,O
endpoints,O
Major,O
15,O
0,O
6,O
49,O
1,O
8,O
0,O
31,O
0,O
17,O
0,O
55,O
p,O
0,O
0001,O
CRNM,AdverseReaction
103,O
3,O
9,O
215,O
8,O
0,O
Major,O
CRNM,AdverseReaction
115,O
4,O
3,O
261,O
9,O
7,O
Minor,O
313,O
11,O
7,O
505,O
18,O
8,O
All,O
402,O
15,O
0,O
676,O
25,O
1,O
Adverse,O
reactions,O
occurring,O
in,O
1,O
of,O
patients,O
in,O
the,O
AMPLIFY,O
study,O
are,O
listed,O
in,O
Table,O
6,O
Table,O
6,O
Adverse,O
Reactions,O
Occurring,O
in,O
1,O
of,O
Patients,O
Treated,O
for,O
DVT,O
and,O
PE,O
in,O
the,O
AMPLIFY,O
Study,O
ELIQUISN,O
2676n,O
Enoxaparin,O
WarfarinN,O
2689n,O
Epistaxis,AdverseReaction
77,O
2,O
9,O
146,O
5,O
4,O
Contusion,AdverseReaction
49,O
1,O
8,O
97,O
3,O
6,O
Hematuria,AdverseReaction
46,O
1,O
7,O
102,O
3,O
8,O
Menorrhagia,AdverseReaction
38,O
1,O
4,O
30,O
1,O
1,O
Hematoma,AdverseReaction
35,O
1,O
3,O
76,O
2,O
8,O
Hemoptysis,AdverseReaction
32,O
1,O
2,O
31,O
1,O
2,O
Rectal hemorrhage,AdverseReaction
26,O
1,O
0,O
39,O
1,O
5,O
Gingival bleeding,AdverseReaction
26,O
1,O
0,O
50,O
1,O
9,O
AMPLIFY,O
EXT,O
Study,O
The,O
mean,O
duration,O
of,O
exposure,O
to,O
ELIQUIS,O
was,O
approximately,O
330,O
days,O
and,O
to,O
placebo,O
was,O
312,O
days,O
in,O
the,O
AMPLIFY,O
EXT,O
study,O
Adverse,O
reactions,O
related,O
to,O
bleeding,AdverseReaction
occurred,O
in,O
219,O
13,O
3,O
ELIQUIS,O
treated,O
patients,O
compared,O
to,O
72,O
8,O
7,O
placebo,O
treated,O
patients,O
The,O
discontinuation,O
rate,O
due,O
to,O
bleeding,AdverseReaction
events,O
was,O
approximately,O
1,O
in,O
the,O
ELIQUIS,O
treated,O
patients,O
compared,O
to,O
0,O
4,O
in,O
those,O
patients,O
in,O
the,O
placebo,O
group,O
in,O
the,O
AMPLIFY,O
EXT,O
study,O
Bleeding,AdverseReaction
results,O
from,O
the,O
AMPLIFY,O
EXT,O
study,O
are,O
summarized,O
in,O
Table,O
7,O
Table,O
7,O
Bleeding,AdverseReaction
Results,O
in,O
the,O
AMPLIFY,O
EXT,O
Study,O
ELIQUIS,O
2,O
5,O
mg,O
bidN,O
840n,O
ELIQUIS,O
5,O
mg,O
bidN,O
811n,O
PlaceboN,O
826n,O
CRNM,AdverseReaction
clinically relevant nonmajor bleeding,AdverseReaction
Events,O
associated,O
with,O
each,O
endpoint,O
were,O
counted,O
once,O
per,O
subject,O
but,O
subjects,O
may,O
have,O
contributed,O
events,O
to,O
multiple,O
endpoints,O
Major,O
2,O
0,O
2,O
1,O
0,O
1,O
4,O
0,O
5,O
CRNM,AdverseReaction
25,O
3,O
0,O
34,O
4,O
2,O
19,O
2,O
3,O
Major,O
CRNM,AdverseReaction
27,O
3,O
2,O
35,O
4,O
3,O
22,O
2,O
7,O
Minor,O
75,O
8,O
9,O
98,O
12,O
1,O
58,O
7,O
0,O
All,O
94,O
11,O
2,O
121,O
14,O
9,O
74,O
9,O
0,O
Adverse,O
reactions,O
occurring,O
in,O
1,O
of,O
patients,O
in,O
the,O
AMPLIFY,O
EXT,O
study,O
are,O
listed,O
in,O
Table,O
8,O
Table,O
8,O
Adverse,O
Reactions,O
Occurring,O
in,O
1,O
of,O
Patients,O
Undergoing,O
Extended,O
Treatment,O
for,O
DVT,O
and,O
PE,O
in,O
the,O
AMPLIFY,O
EXT,O
Study,O
ELIQUIS,O
2,O
5,O
mg,O
bidN,O
840n,O
ELIQUIS,O
5,O
mg,O
bidN,O
811n,O
PlaceboN,O
826n,O
Epistaxis,AdverseReaction
13,O
1,O
5,O
29,O
3,O
6,O
9,O
1,O
1,O
Hematuria,AdverseReaction
12,O
1,O
4,O
17,O
2,O
1,O
9,O
1,O
1,O
Hematoma,AdverseReaction
13,O
1,O
5,O
16,O
2,O
0,O
10,O
1,O
2,O
Contusion,AdverseReaction
18,O
2,O
1,O
18,O
2,O
2,O
18,O
2,O
2,O
Gingival bleeding,AdverseReaction
12,O
1,O
4,O
9,O
1,O
1,O
3,O
0,O
4,O
Other,O
Adverse,O
Reactions,O
Less,O
common,O
adverse,O
reactions,O
in,O
ELIQUIS,O
treated,O
patients,O
in,O
the,O
AMPLIFY,O
or,O
AMPLIFY,O
EXT,O
studies,O
occurring,O
at,O
a,O
frequency,O
of,O
0,O
1,O
to,O
1,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
hemorrhagic anemia,AdverseReaction
Gastrointestinal,O
disorders,O
hematochezia,AdverseReaction
hemorrhoidal hemorrhage,AdverseReaction
gastrointestinal hemorrhage,AdverseReaction
hematemesis,AdverseReaction
melena,AdverseReaction
anal hemorrhage,AdverseReaction
Injury,O
poisoning,O
and,O
procedural,O
complications,O
wound hemorrhage,AdverseReaction
postprocedural hemorrhage,AdverseReaction
traumatic hematoma,AdverseReaction
periorbital hematoma,AdverseReaction
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
muscle hemorrhage,AdverseReaction
Reproductive,O
system,O
and,O
breast,O
disorders,O
vaginal hemorrhage,AdverseReaction
metrorrhagia,AdverseReaction
menometrorrhagia,AdverseReaction
genital hemorrhage,AdverseReaction
Vascular,O
disorders,O
hemorrhage,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
ecchymosis,AdverseReaction
skin hemorrhage,AdverseReaction
petechiae,AdverseReaction
Eye,O
disorders,O
conjunctival hemorrhage,AdverseReaction
retinal hemorrhage,AdverseReaction
eye hemorrhage,AdverseReaction
Investigations,O
blood urine present,AdverseReaction
occult blood positive,AdverseReaction
occult blood,AdverseReaction
red blood cells urine positive,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
injection site hematoma,AdverseReaction
vessel puncture site hematoma,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
A,O
higher,O
number,O
of,O
myocardial infarctions,AdverseReaction
was,O
reported,O
in,O
patients,O
treated,O
with,O
alvimopan,O
0,O
5,O
mg,O
twice,O
daily,O
compared,O
with,O
placebo,O
in,O
a,O
12,O
month,O
study,O
in,O
patients,O
treated,O
with,O
opioids,O
for,O
chronic,O
non,O
cancer,O
pain,O
although,O
a,O
causal,O
relationship,O
with,O
long,O
term,O
use,O
has,O
not,O
been,O
established,O
5,O
1,O
Patients,O
recently,O
exposed,O
to,O
opioids,O
are,O
expected,O
to,O
be,O
more,O
sensitive,O
to,O
the,O
effects,O
of,O
ENTEREG,O
and,O
therefore,O
may,Factor
experience,O
abdominal pain,AdverseReaction
nausea,AdverseReaction
and,O
vomiting,AdverseReaction
and,O
diarrhea,AdverseReaction
5,O
3,O
Not,O
recommended,O
in,O
patients,O
with,O
severe,O
hepatic,O
impairment,O
5,O
4,O
Not,O
recommended,O
in,O
patients,O
with,O
end,O
stage,O
renal,O
disease,O
5,O
5,O
Not,O
recommended,O
in,O
patients,O
with,O
complete,O
gastrointestinal,O
obstruction,O
or,O
in,O
patients,O
who,O
have,O
surgery,O
for,O
correction,O
of,O
complete,O
bowel,O
obstruction,O
5,O
6,O
Not,O
recommended,O
in,O
pancreatic,O
or,O
gastric,O
anastomosis,O
5,O
7,O
5,O
1,O
Potential,O
Risk,O
of,O
Myocardial,O
Infarction,O
with,O
Long,O
term,O
Use,O
There,O
were,O
more,O
reports,O
of,O
myocardial infarctions,AdverseReaction
in,O
patients,O
treated,O
with,O
alvimopan,O
0,O
5,O
mg,O
twice,O
daily,O
compared,O
with,O
placebo,O
treated,O
patients,O
in,O
a,O
12,O
month,O
study,O
of,O
patients,O
treated,O
with,O
opioids,O
for,O
chronic,O
non,O
cancer,O
pain,O
alvimopan,O
0,O
5,O
mg,O
n,O
538,O
placebo,O
n,O
267,O
In,O
this,O
study,O
the,O
majority,O
of,O
myocardial infarctions,AdverseReaction
occurred,O
between,O
1,O
and,O
4,O
months,O
after,O
initiation,O
of,O
treatment,O
This,O
imbalance,O
has,O
not,O
been,O
observed,O
in,O
other,O
studies,O
of,O
ENTEREG,O
in,O
patients,O
treated,O
with,O
opioids,O
for,O
chronic,O
pain,O
nor,O
in,O
patients,O
treated,O
within,O
the,O
surgical,O
setting,O
including,O
patients,O
undergoing,O
surgeries,O
that,O
included,O
bowel,O
resection,O
who,O
received,O
ENTEREG,O
12,O
mg,O
twice,O
daily,O
for,O
up,O
to,O
7,O
days,O
the,O
indicated,O
dose,O
and,O
patient,O
population,O
ENTEREG,O
12,O
mg,O
n,O
1,O
142,O
placebo,O
n,O
1,O
120,O
A,O
causal,O
relationship,O
with,O
alvimopan,O
with,O
long,O
term,O
use,O
has,O
not,O
been,O
established,O
ENTEREG,O
is,O
available,O
only,O
through,O
a,O
program,O
under,O
a,O
REMS,O
that,O
restricts,O
use,O
to,O
enrolled,O
hospitals,O
seeWarnings,O
and,O
Precautions,O
5,O
2,O
5,O
2,O
E,O
A,O
S,O
E,O
ENTEREG,O
REMS,O
Program,O
ENTEREG,O
is,O
available,O
only,O
through,O
a,O
program,O
called,O
the,O
ENTEREG,O
Access,O
Support,O
and,O
Education,O
E,O
A,O
S,O
E,O
ENTEREG,O
REMS,O
Program,O
that,O
restricts,O
use,O
to,O
enrolled,O
hospitals,O
because,O
of,O
the,O
potential,O
risk,O
of,O
myocardial,O
infarction,O
with,O
long,O
term,O
use,O
of,O
ENTEREG,O
seeWarnings,O
and,O
Precautions,O
5,O
1,O
Notable,O
requirements,O
of,O
the,O
E,O
A,O
S,O
E,O
Program,O
include,O
the,O
following,O
ENTEREG,O
is,O
available,O
only,O
for,O
short,O
term,O
15,O
doses,O
use,O
in,O
hospitalized,O
patients,O
Only,O
hospitals,O
that,O
have,O
enrolled,O
in,O
and,O
met,O
all,O
of,O
the,O
requirements,O
for,O
the,O
E,O
A,O
S,O
E,O
program,O
may,O
use,O
ENTEREG,O
To,O
enroll,O
in,O
the,O
E,O
A,O
S,O
E,O
Program,O
an,O
authorized,O
hospital,O
representative,O
must,O
acknowledge,O
that,O
hospital,O
staff,O
who,O
prescribe,O
dispense,O
or,O
administer,O
ENTEREG,O
have,O
been,O
provided,O
the,O
educational,O
materials,O
on,O
the,O
need,O
to,O
limit,O
use,O
of,O
ENTEREG,O
to,O
short,O
term,O
inpatient,O
use,O
patients,O
will,O
not,O
receive,O
more,O
than,O
15,O
doses,O
of,O
ENTEREG,O
and,O
ENTEREG,O
will,O
not,O
be,O
dispensed,O
to,O
patients,O
after,O
they,O
have,O
been,O
discharged,O
from,O
the,O
hospital,O
Further,O
information,O
is,O
available,O
at,O
www,O
ENTEREGREMS,O
com,O
or,O
1,O
800,O
278,O
0340,O
5,O
3,O
Gastrointestinal,O
Related,O
Adverse,O
Reactions,O
in,O
Opioid,O
Tolerant,O
Patients,O
Patients,O
recently,O
exposed,O
to,O
opioids,O
are,O
expected,O
to,O
be,O
more,O
sensitive,O
to,O
the,O
effects,O
of,O
mu,O
opioid,O
receptor,O
antagonists,O
such,O
as,O
ENTEREG,O
Since,O
ENTEREG,O
acts,O
peripherally,O
clinical,O
signs,O
and,O
symptoms,O
of,O
increased sensitivity,AdverseReaction
would,O
be,O
related,O
to the gastrointestinal tract,AdverseReaction
e,O
g,O
abdominal pain,AdverseReaction
nausea,AdverseReaction
and,O
vomiting,AdverseReaction
diarrhea,AdverseReaction
Patients,O
receiving,O
more,O
than,O
3,O
doses,O
of,O
an,O
opioid,O
within,O
the,O
week,O
prior,O
to,O
surgery,O
were,O
not,O
studied,O
in,O
the,O
postoperative,O
ileus,O
clinical,O
trials,O
Therefore,O
if,O
ENTEREG,O
is,O
administered,O
to,O
these,O
patients,O
they,O
should,O
be,O
monitored,O
for,O
gastrointestinal,O
adverse,O
reactions,O
ENTEREG,O
is,O
contraindicated,O
in,O
patients,O
who,O
have,O
taken,O
therapeutic,O
doses,O
of,O
opioids,O
for,O
more,O
than,O
7,O
consecutive,O
days,O
immediately,O
prior,O
to,O
taking,O
ENTEREG,O
5,O
4,O
Risk,O
of,O
Serious,O
Adverse,O
Reactions,O
in,O
Patients,O
with,O
Severe,O
Hepatic,O
Impairment,O
Patients,O
with,O
severe,O
hepatic,O
impairment,O
may,O
be,O
at,O
higher,O
risk,O
of,O
serious,O
adverse,O
reactions,O
including,O
dose,O
related,O
serious,O
adverse,O
reactions,O
because,O
up,O
to,O
10,O
fold,O
higher,O
plasma,O
levels,O
of,O
drug,O
have,O
been,O
observed,O
in,O
such,O
patients,O
compared,O
with,O
patients,O
with,O
normal,O
hepatic,O
function,O
Therefore,O
the,O
use,O
of,O
ENTEREG,O
is,O
not,O
recommended,O
in,O
this,O
population,O
5,O
5,O
End,O
Stage,O
Renal,O
Disease,O
No,O
studies,O
have,O
been,O
conducted,O
in,O
patients,O
with,O
end,O
stage,O
renal,O
disease,O
ENTEREG,O
is,O
not,O
recommended,O
for,O
use,O
in,O
these,O
patients,O
5,O
6,O
Risk,O
of,O
Serious,O
Adverse,O
Reactions,O
in,O
Patients,O
with,O
Complete,O
Gastrointestinal,O
Obstruction,O
No,O
studies,O
have,O
been,O
conducted,O
in,O
patients,O
with,O
complete,O
gastrointestinal,O
obstruction,O
or,O
in,O
patients,O
who,O
have,O
surgery,O
for,O
correction,O
of,O
complete,O
bowel,O
obstruction,O
ENTEREG,O
is,O
not,O
recommended,O
for,O
use,O
in,O
these,O
patients,O
5,O
7,O
Risk,O
of,O
Serious,O
Adverse,O
Reactions,O
in,O
Pancreatic,O
and,O
Gastric,O
Anastomoses,O
ENTEREG,O
has,O
not,O
been,O
studied,O
in,O
patients,O
having,O
pancreatic,O
or,O
gastric,O
anastomosis,O
Therefore,O
ENTEREG,O
is,O
not,O
recommended,O
for,O
use,O
in,O
these,O
patients,O
""
BOXED,O
WARNING,O
WARNING,O
POTENTIAL,O
RISK,Factor
OF,O
MYOCARDIAL INFARCTION,AdverseReaction
WITH,O
LONG,O
TERM,O
USE,O
FOR,O
SHORT,O
TERM,O
HOSPITAL,O
USE,O
ONLY,O
WARNING,O
POTENTIAL,O
RISK,Factor
OF,O
MYOCARDIAL INFARCTION,AdverseReaction
WITH,O
LONG,O
TERM,O
USE,O
FOR,O
SHORT,O
TERM,O
HOSPITAL,O
USE,O
ONLY,O
There,O
was,O
a,O
greater,O
incidence,O
of,O
myocardial infarction,AdverseReaction
in,O
alvimopan,O
treated,O
patients,O
compared,O
to,O
placebo,O
treated,O
patients,O
in,O
a,O
12,O
month,O
clinical,O
trial,O
although,O
a,O
causal,O
relationship,O
has,O
not,O
been,O
established,O
In,O
short,O
term,O
trials,O
with,O
ENTEREG,O
r,O
no,Negation
increased,O
risk,O
of,O
myocardial infarction,AdverseReaction
was,O
observed,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Because,O
of,O
the,O
potential,O
risk,O
of,O
myocardial,O
infarction,O
with,O
long,O
term,O
use,O
ENTEREG,O
is,O
available,O
only,O
through,O
a,O
restricted,O
program,O
for,O
short,O
term,O
use,O
15,O
doses,O
under,O
a,O
Risk,O
Evaluation,O
and,O
Mitigation,O
Strategy,O
REMS,O
called,O
the,O
ENTEREG,O
Access,O
Support,O
and,O
Education,O
E,O
A,O
S,O
E,O
r,O
Program,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
5,O
2,O
WARNING,O
POTENTIAL,O
RISK,Factor
OF,O
MYOCARDIAL INFARCTION,AdverseReaction
WITH,O
LONG,O
TERM,O
USE,O
FOR,O
SHORT,O
TERM,O
HOSPITAL,O
USE,O
ONLY,O
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Increased,O
incidence,O
of,O
myocardial infarction,AdverseReaction
was,O
seen,O
in,O
a,O
clinical,O
trial,O
of,O
patients,O
taking,O
alvimopan,O
for,O
long,O
term,O
use,O
5,O
1,O
ENTEREG,O
is,O
available,O
only,O
through,O
a,O
restricted,O
program,O
for,O
short,O
term,O
use,O
15,O
doses,O
called,O
the,O
ENTEREG,O
Access,O
Support,O
and,O
Education,O
E,O
A,O
S,O
E,O
r,O
Program,O
5,O
1,O
5,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reaction,O
incidence,O
1,O
5,O
occurring,O
with,O
a,O
higher,O
frequency,O
than,O
placebo,O
among,O
ENTEREG,O
treated,O
patients,O
undergoing,O
surgeries,O
that,O
included,O
a,O
bowel,O
resection,O
was,O
dyspepsia,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Merck,O
Sharp,O
Dohme,O
Corp,O
a,O
subsidiary,O
of,O
Merck,O
Co,O
Inc,O
at,O
1,O
877,O
888,O
4231,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
compared,O
directly,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
adverse,O
event,O
information,O
from,O
clinical,O
trials,O
does,O
however,O
provide,O
a,O
basis,O
for,O
identifying,O
the,O
adverse,O
events,O
that,O
appear,O
to,O
be,O
related,O
to,O
drug,O
use,O
and,O
for,O
approximating,O
rates,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
ENTEREG,O
12,O
mg,O
in,O
1,O
793,O
patients,O
in,O
10,O
placebo,O
controlled,O
studies,O
The,O
population,O
was,O
19,O
to,O
97,O
years,O
old,O
64,O
were,O
female,O
and,O
84,O
were,O
Caucasian,O
64,O
were,O
undergoing,O
a,O
surgery,O
that,O
included,O
bowel,O
resection,O
The,O
first,O
dose,O
of,O
ENTEREG,O
was,O
administered,O
30,O
minutes,O
to,O
5,O
hours,O
before,O
the,O
scheduled,O
start,O
of,O
surgery,O
and,O
then,O
twice,O
daily,O
until,O
hospital,O
discharge,O
or,O
for,O
a,O
maximum,O
of,O
7,O
days,O
of,O
postoperative,O
treatment,O
Among,O
ENTEREG,O
treated,O
patients,O
undergoing,O
surgeries,O
that,O
included,O
a,O
bowel,O
resection,O
the,O
most,O
common,O
adverse,O
reaction,O
incidence,O
1,O
5,O
occurring,O
with,O
a,O
higher,O
frequency,O
than,O
placebo,O
was,O
dyspepsia,AdverseReaction
ENTEREG,O
1,O
5,O
placebo,O
0,O
8,O
Adverse,O
reactions,O
are,O
events,O
that,O
occurred,O
after,O
the,O
first,O
dose,O
of,O
study,O
medication,O
treatment,O
and,O
within,O
7,O
days,O
of,O
the,O
last,O
dose,O
of,O
study,O
medication,O
or,O
events,O
present,O
at,O
baseline,O
that,O
increased,O
in,O
severity,O
after,O
the,O
start,O
of,O
study,O
medication,O
treatment,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Nephrogenic Systemic Fibrosis,AdverseReaction
has,O
occurred,O
in,O
patients,O
with,O
impaired,O
elimination,O
of,O
GBCAs,O
Higher,O
than,O
recommended,O
dosing,O
or,O
repeated,O
dosing,O
appears,O
to,O
increase,O
the,O
risk,O
5,O
1,O
Hypersensitivity,O
anaphylactoid,AdverseReaction
hypersensitivity reactions,AdverseReaction
with,O
cardiovascular,AdverseReaction
respiratory,AdverseReaction
and,O
cutaneous manifestations,AdverseReaction
ranging,O
from,O
mild,Severity
to,O
severe,Severity
reactions,O
including,O
shock,AdverseReaction
can,Factor
occur,O
Monitor,O
patients,O
closely,O
for,O
need,O
of,O
emergency,O
cardiorespiratory,O
support,O
5,O
2,O
5,O
1,O
Nephrogenic,O
Systemic,O
Fibrosis,O
NSF,O
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,Factor
for,O
nephrogenic systemic fibrosis,AdverseReaction
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
among,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrast,O
enhanced,O
MRI,O
or,O
other,O
modalities,O
The,O
GBCA,DrugClass
associated,O
NSF,AdverseReaction
risk,O
appears,O
highest,O
for,O
patients,O
with,O
chronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73m,O
2,O
as,O
well,O
as,O
patients,O
with,O
acute,O
kidney,O
injury,O
The,O
risk,O
appears,O
lower,O
for,O
patients,O
with,O
chronic,O
moderate,O
kidney,O
disease,O
GFR,O
30,O
to,O
59,O
mL,O
min,O
1,O
73m,O
2,O
and,O
little,O
if,O
any,O
for,O
patients,O
with,O
chronic,O
mild,O
kidney,O
disease,O
GFR,O
60,O
to,O
89,O
mL,O
min,O
1,O
73m,O
2,O
NSF,AdverseReaction
may,Factor
result,O
in,O
fatal,AdverseReaction
or,O
debilitating,Severity
fibrosis,AdverseReaction
affecting,O
the,O
skin,O
muscle,O
and,O
internal,O
organs,O
Report,O
any,O
diagnosis,O
of,O
NSF,O
following,O
EOVIST,O
administration,O
to,O
Bayer,O
HealthCare,O
1,O
888,O
842,O
2937,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
Features,O
of,O
acute,O
kidney,O
injury,O
consist,O
of,O
rapid,O
over,O
hours,O
to,O
days,O
and,O
usually,O
reversible,O
decrease,O
in,O
kidney,O
function,O
commonly,O
in,O
the,O
setting,O
of,O
surgery,O
severe,O
infection,O
injury,O
or,O
drug,O
induced,O
kidney,O
toxicity,O
Serum,O
creatinine,O
levels,O
and,O
estimated,O
GFR,O
may,O
not,O
reliably,O
assess,O
renal,O
function,O
in,O
the,O
setting,O
of,O
acute,O
kidney,O
injury,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
for,O
example,O
age,O
60,O
years,O
diabetes,O
mellitus,O
or,O
chronic,O
hypertension,O
estimate,O
the,O
GFR,O
through,O
laboratory,O
testing,O
Among,O
the,O
factors,O
that,O
may,O
increase,O
the,O
risk,Factor
for,O
NSF,AdverseReaction
are,O
repeated,O
or,O
higher,O
than,O
recommended,O
doses,O
of,O
a,O
GBCA,O
and,O
degree,O
of,O
renal,O
impairment,O
at,O
the,O
time,O
of,O
exposure,O
Record,O
the,O
specific,O
GBCA,O
and,O
the,O
dose,O
administrated,O
to,O
a,O
patient,O
For,O
patients,O
at,O
highest,O
risk,O
for,O
NSF,O
do,O
not,O
exceed,O
the,O
recommended,O
EOVIST,O
dose,O
and,O
allow,O
a,O
sufficient,O
period,O
of,O
time,O
for,O
elimination,O
of,O
the,O
drug,O
prior,O
to,O
any,O
re,O
administration,O
For,O
patients,O
receiving,O
hemodialysis,O
physicians,O
may,O
consider,O
the,O
prompt,O
initiation,O
of,O
hemodialysis,O
following,O
the,O
administration,O
of,O
a,O
GBCA,O
in,O
order,O
to,O
enhance,O
the,O
contrast,O
agent,O
s,O
elimination,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
The,O
usefulness,O
of,O
hemodialysis,O
in,O
the,O
prevention,O
of,O
NSF,O
is,O
unknown,O
5,O
2,O
Hypersensitivity,O
Reactions,O
Anaphylactic,AdverseReaction
and,O
other,O
hypersensitivity reactions,AdverseReaction
with,O
cardiovascular,AdverseReaction
respiratory,AdverseReaction
and,O
cutaneous manifestations,AdverseReaction
ranging,O
from,O
mild,Severity
to,O
severe,Severity
including,O
shock,AdverseReaction
have,O
uncommonly,O
occurred,O
following,O
EOVIST,O
administration,O
see,O
Adverse,O
Reactions,O
6,O
Before,O
EOVIST,O
administration,O
assess,O
all,O
patients,O
for,O
any,O
history,O
of,O
a,O
reaction,O
to,O
contrast,O
media,O
bronchial,O
asthma,O
and,O
allergic,O
disorders,O
These,O
patients,O
may,O
have,O
an,O
increased,O
risk,Factor
for,O
a,O
hypersensitivity reaction,AdverseReaction
to,O
EOVIST,O
Administer,O
EOVIST,O
only,O
in,O
situations,O
where,O
trained,O
personnel,O
and,O
therapies,O
are,O
promptly,O
available,O
for,O
the,O
treatment,O
of,O
hypersensitivity,O
reactions,O
including,O
personnel,O
trained,O
in,O
resuscitation,O
Most,O
hypersensitivity,AdverseReaction
reactions,O
to,O
EOVIST,O
have,O
occurred,O
within,O
half,O
an,O
hour,O
after,O
administration,O
Delayed reactions,AdverseReaction
can,Factor
occur,O
up,O
to,O
several,O
days,O
after,O
EOVIST,O
administration,O
Observe,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
hypersensitivity,O
reactions,O
during,O
and,O
following,O
EOVIST,O
administration,O
5,O
3,O
Acute,O
Kidney,O
Injury,O
In,O
patients,O
with,O
chronic,O
renal,O
impairment,O
acute kidney injury,AdverseReaction
sometimes,O
requiring,O
dialysis,O
has,O
been,O
observed,O
with,O
the,O
use,O
of,O
some,O
GBCAs,DrugClass
The,O
risk,Factor
of,O
acute kidney injury,AdverseReaction
might,O
be,O
lower,O
with,O
EOVIST,O
due,O
to,O
its,O
dual,O
excretory,O
pathways,O
Do,O
not,O
exceed,O
the,O
recommended,O
dose,O
the,O
risk,O
of,O
acute,O
kidney,O
injury,O
may,O
increase,O
with,O
higher,O
than,O
recommended,O
doses,O
5,O
4,O
Extravasation,O
and,O
Injection Site,AdverseReaction
Reactions,O
Ensure,O
catheter,O
and,O
venous,O
patency,O
before,O
the,O
injection,O
of,O
EOVIST,O
Extravasation,O
into,O
tissues,O
during,O
EOVIST,O
administration,O
may,Factor
result,O
in,O
local tissue reactions,AdverseReaction
Strictly,O
avoid,O
intramuscular,O
administration,O
of,O
EOVIST,O
because,O
it,O
may,O
cause,O
myocyte,O
necrosis,O
and,O
inflammation,O
see,O
Nonclinical,O
Toxicology,O
13,O
2,O
5,O
5,O
Interference,O
with,O
Laboratory,O
Tests,O
Serum,O
iron,O
determination,O
using,O
complexometric,O
methods,O
for,O
example,O
ferrocene,O
complexation,O
method,O
may,O
result,O
in,O
falsely,O
high,O
or,O
low,O
values,O
for,O
up,O
to,O
24,O
hours,O
after,O
the,O
examination,O
with,O
EOVIST,O
because,O
of,O
the,O
caloxetate,O
trisodium,O
excipients,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
6,O
Interference,O
with,O
Visualization,O
of,O
Liver,O
Lesions,O
Severe,O
renal,O
or,O
hepatic,O
failure,O
may,O
impair,O
EOVIST,O
imaging,O
performance,O
In,O
patients,O
with,O
end,O
stage,O
renal,O
failure,O
hepatic,O
contrast,O
was,O
markedly,O
reduced,O
and,O
was,O
attributed,O
to,O
elevated,O
serum,O
ferritin,O
levels,O
In,O
patients,O
with,O
abnormally,O
high,O
3,O
mg,O
dL,O
serum,O
bilirubin,O
reduced,O
hepatic,O
contrast,O
was,O
observed,O
If,O
EOVIST,O
is,O
used,O
in,O
these,O
patients,O
complete,O
MRI,O
no,O
later,O
than,O
60,O
minutes,O
after,O
EOVIST,O
administration,O
and,O
use,O
a,O
paired,O
non,O
contrast,O
and,O
contrast,O
MRI,O
set,O
for,O
diagnosis,O
""
BOXED,O
WARNING,O
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
NSF,AdverseReaction
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
NSF,AdverseReaction
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,O
for,O
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
in,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrasted,O
MRI,O
or,O
other,O
modalities,O
NSF,AdverseReaction
may,Factor
result,O
in,O
fatal,AdverseReaction
or,O
debilitating,Severity
fibrosis,AdverseReaction
affecting,O
the,O
skin,O
muscle,O
and,O
internal,O
organs,O
The,O
risk,Factor
for,O
NSF,AdverseReaction
appears,O
highest,O
among,O
patients,O
with,O
oChronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73m2,O
oroAcute,O
kidney,O
injury,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
for,O
example,O
age,O
60,O
years,O
hypertension,O
or,O
diabetes,O
estimate,O
the,O
glomerular,O
filtration,O
rate,O
GFR,O
through,O
laboratory,O
testing,O
For,O
patients,O
at,O
highest,O
risk,O
for,O
NSF,O
do,O
not,O
exceed,O
the,O
recommended,O
EOVIST,O
dose,O
and,O
allow,O
a,O
sufficient,O
period,O
of,O
time,O
for,O
elimination,O
of,O
the,O
drug,O
from,O
the,O
body,O
prior,O
to,O
any,O
re,O
administration,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
NSF,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,O
for,O
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
in,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrasted,O
MRI,O
or,O
other,O
modalities,O
The,O
risk,Factor
for,O
NSF,AdverseReaction
appears,O
highest,O
among,O
patients,O
with,O
oChronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73m2,O
oroAcute,O
kidney,O
injury,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
for,O
example,O
age,O
60,O
years,O
hypertension,O
or,O
diabetes,O
estimate,O
the,O
glomerular,O
filtration,O
rate,O
GFR,O
through,O
laboratory,O
testing,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactionsare,O
discussed,O
elsewhere,O
in,O
the,O
labeling,O
Nephrogenic systemic fibrosis,AdverseReaction
NSF,AdverseReaction
see,O
Boxed,O
Warning,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hypersensitivity reactions,AdverseReaction
see,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
0,O
5,O
are,O
nausea,AdverseReaction
headache,AdverseReaction
feeling hot,AdverseReaction
dizziness,AdverseReaction
and,O
back pain,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Bayer,O
HealthCare,O
Pharmaceuticals,O
Inc,O
at,O
1,O
888,O
84,O
BAYER,O
1,O
888,O
842,O
2937,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
adverse,O
reactions,O
described,O
in,O
this,O
section,O
reflect,O
EOVIST,O
exposure,O
in,O
1,O
989,O
subjects,O
with,O
the,O
majority,O
1,O
581,O
subjects,O
receiving,O
the,O
recommended,O
dose,O
Overall,O
59,O
of,O
the,O
subjects,O
were,O
men,O
and,O
the,O
ethnic,O
distribution,O
was,O
64,O
Caucasian,O
22,O
Asian,O
3,O
Hispanic,O
2,O
Black,O
and,O
0,O
5,O
of,O
subjects,O
consisted,O
of,O
other,O
ethnic,O
groups,O
The,O
average,O
age,O
was,O
57,O
years,O
age,O
range,O
from,O
19,O
to,O
84,O
years,O
Overall,O
4,O
of,O
subjects,O
reported,O
one,O
or,O
more,O
adverse,O
reactions,O
following,O
EOVIST,O
administration,O
The,O
most,O
frequent,O
0,O
5,O
adverse,O
reactions,O
associated,O
with,O
the,O
use,O
of,O
EOVIST,O
were,O
nausea,AdverseReaction
headache,AdverseReaction
feeling hot,AdverseReaction
dizziness,AdverseReaction
and,O
back pain,AdverseReaction
Adverse,O
reactions,O
were,O
predominantly,O
of,O
mild,O
to,O
moderate,O
severity,O
Table,O
1,O
lists,O
adverse,O
reactions,O
that,O
occurred,O
in,O
0,O
1,O
of,O
subjects,O
treated,O
with,O
EOVIST,O
Table,O
1,O
Adverse,O
Reactions,O
Reaction,O
Rate,O
n,O
1581,O
Nausea,AdverseReaction
1,O
1,O
Headache,AdverseReaction
1,O
1,O
Feeling hot,AdverseReaction
0,O
8,O
Dizziness,AdverseReaction
0,O
6,O
Back pain,AdverseReaction
0,O
6,O
Vomiting,AdverseReaction
0,O
4,O
Blood pressure increased,AdverseReaction
0,O
4,O
Injection site reactions site site site site site,AdverseReaction
pain,AdverseReaction
burning,AdverseReaction
coldness,AdverseReaction
extravasation,AdverseReaction
irritation,AdverseReaction
0,O
4,O
Dysgeusia,AdverseReaction
0,O
4,O
Paresthesia,AdverseReaction
0,O
3,O
Flushing,AdverseReaction
0,O
3,O
Parosmia,AdverseReaction
0,O
3,O
Pruritus,AdverseReaction
generalized,AdverseReaction
eye,AdverseReaction
0,O
3,O
Rash,AdverseReaction
0,O
3,O
Respiratory disorders,AdverseReaction
dyspnea,AdverseReaction
respiratory distress,AdverseReaction
0,O
2,O
Fatigue,AdverseReaction
0,O
2,O
Chest pain,AdverseReaction
0,O
1,O
Vertigo,AdverseReaction
0,O
1,O
Dry mouth,AdverseReaction
0,O
1,O
Chills,AdverseReaction
0,O
1,O
Feeling abnormal,AdverseReaction
0,O
1,O
Adverse,O
reactions,O
that,O
occurred,O
with,O
a,O
frequency,O
of,O
0,O
1,O
in,O
subjects,O
who,O
received,O
EOVIST,O
include,O
tremor,AdverseReaction
akathisia,AdverseReaction
bundle branch block,AdverseReaction
palpitation,AdverseReaction
oral discomfort,AdverseReaction
salivary hypersecretion,AdverseReaction
maculopapular rash,AdverseReaction
hyperhidrosis,AdverseReaction
discomfort,AdverseReaction
and,O
malaise,AdverseReaction
Elevation of serum iron of,AdverseReaction
values,O
and,O
serum bilirubin,AdverseReaction
laboratory,O
values,O
were,O
reported,O
in,O
less,O
than,O
1,O
of,O
patients,O
after,O
administration,O
of,O
EOVIST,O
The,O
values,O
did,O
not,O
exceed,O
more,O
than,O
3,O
times,O
the,O
baseline,O
values,O
and,O
returned,O
to,O
baseline,O
within,O
1,O
to,O
4,O
days,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
additional,O
adverse,O
reactions,O
have,O
been,O
reported,O
during,O
the,O
postmarketing,O
use,O
of,O
EOVIST,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Hypersensitivity reactions,AdverseReaction
anaphylacticshock,AdverseReaction
hypotension,AdverseReaction
pharyngolaryngeal edema,AdverseReaction
urticaria,AdverseReaction
face edema,AdverseReaction
rhinitis,AdverseReaction
conjunctivitis,AdverseReaction
abdominal pain,AdverseReaction
hypoesthesia,AdverseReaction
sneezing,AdverseReaction
cough,AdverseReaction
and,O
pallor,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Tachycardia,AdverseReaction
Restlessness,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
If,O
the,O
following,O
occur,O
discontinue,O
ERWINAZE,O
Serious,Severity
hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
5,O
1,O
Severe,Severity
or,O
hemorrhagic pancreatitis,AdverseReaction
pancreatitis,AdverseReaction
5,O
2,O
Glucose intolerance intolerance,AdverseReaction
can,Factor
occur,O
and,O
in,O
some,O
cases,O
may,O
be,O
irreversible,Severity
Perform,O
appropriate,O
monitoring,O
and,O
treat,O
hyperglycemia,O
with,O
insulin,O
as,O
necessary,O
5,O
3,O
Thrombosis,AdverseReaction
hemorrhage,AdverseReaction
discontinue,O
ERWINAZE,O
until,O
resolved,O
5,O
4,O
5,O
1,O
Hypersensitivity,O
Reactions,O
Grade 3,Severity
and,O
4,Severity
hypersensitivity reactions,AdverseReaction
after,O
the,O
use,O
of,O
ERWINAZE,O
have,O
occurred,O
in,O
5,O
of,O
patients,O
in,O
clinical,O
trials,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Administer,O
this,O
product,O
in,O
a,O
setting,O
with,O
resuscitation,O
equipment,O
and,O
other,O
agents,O
necessary,O
to,O
treat,O
anaphylaxis,O
If,O
a,O
serious,O
hypersensitivity,O
reaction,O
occurs,O
discontinue,O
ERWINAZE,O
and,O
initiate,O
appropriate,O
therapy,O
5,O
2,O
Pancreatitis,O
Pancreatitis,AdverseReaction
has,O
been,O
reported,O
in,O
4,O
of,O
patients,O
in,O
clinical,O
trials,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Evaluate,O
patients,O
with,O
symptoms,O
compatible,O
with,O
pancreatitis,O
to,O
establish,O
a,O
diagnosis,O
Discontinue,O
ERWINAZE,O
for,O
severe,O
or,O
hemorrhagic,O
pancreatitis,O
manifested,O
by,O
abdominal,O
pain,O
72,O
hours,O
and,O
amylase,O
elevation,O
2,O
0,O
x,O
ULN,O
Severe,O
pancreatitis,O
is,O
a,O
contraindication,O
to,O
additional,O
asparaginase,O
administration,O
In,O
the,O
case,O
of,O
mild,O
pancreatitis,O
hold,O
ERWINAZE,O
until,O
the,O
signs,O
and,O
symptoms,O
subside,O
and,O
amylase,O
levels,O
return,O
to,O
normal,O
After,O
resolution,O
treatment,O
with,O
ERWINAZE,O
may,O
be,O
resumed,O
5,O
3,O
Glucose,O
Intolerance,O
Glucose,O
intolerance,O
has,O
been,O
reported,O
in,O
5,O
of,O
patients,O
receiving,O
ERWINAZE,O
in,O
clinical,O
trials,O
see,O
Adverse,O
Reactions,O
6,O
1,O
In,O
some,O
cases,O
glucose intolerance intolerance,AdverseReaction
may,O
be,O
irreversible,Severity
Monitor,O
glucose,O
levels,O
in,O
patients,O
at,O
baseline,O
and,O
periodically,O
during,O
treatment,O
Administer,O
insulin,O
therapy,O
as,O
necessary,O
in,O
patients,O
with,O
hyperglycemia,O
5,O
4,O
Thrombosis,O
and,O
Hemorrhage,O
Serious,Severity
thrombotic events,AdverseReaction
including,O
sagittal sinus thrombosis,AdverseReaction
and,O
pulmonary embolism,AdverseReaction
have,O
been,O
reported,O
with,O
both,O
E,O
coli,O
and,O
Erwinia,O
derived,O
L,O
asparaginase,O
therapy,O
The,O
following,O
coagulation proteins,AdverseReaction
were,O
decreased,AdverseReaction
in,O
the,O
majority,O
of,O
patients,O
after,O
a,O
2,O
week,O
course,O
of,O
ERWINAZE,O
by,O
intramuscular,O
administration,O
fibrinogen,AdverseReaction
protein C activity,AdverseReaction
protein S activity,AdverseReaction
and,O
anti thrombin III,AdverseReaction
Discontinue,O
ERWINAZE,O
for,O
a,O
thrombotic,O
or,O
hemorrhagic,O
event,O
until,O
symptoms,O
resolve,O
after,O
resolution,O
treatment,O
with,O
ERWINAZE,O
may,O
be,O
resumed,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
label,O
Hypersensitivity reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Pancreatitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Glucose intolerance,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Thrombosis,AdverseReaction
and,O
hemorrhage,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
1,O
or,O
greater,O
with,O
ERWINAZE,O
treatment,O
are,O
systemic hypersensitivity,AdverseReaction
hyperglycemia,AdverseReaction
transaminases abnormal,AdverseReaction
fever,AdverseReaction
pancreatitis,AdverseReaction
local reactions,AdverseReaction
vomiting,AdverseReaction
nausea,AdverseReaction
thrombosis,AdverseReaction
hyperbilirubinemia,AdverseReaction
abdominal pain,AdverseReaction
discomfort,AdverseReaction
and,O
diarrhea,AdverseReaction
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
1,O
or,O
greater,O
are,O
systemic hypersensitivity,AdverseReaction
hyperglycemia,AdverseReaction
transaminases abnormal,AdverseReaction
fever,AdverseReaction
pancreatitis,AdverseReaction
local reactions,AdverseReaction
vomiting,AdverseReaction
nausea,AdverseReaction
thrombosis,AdverseReaction
hyperbilirubinemia,AdverseReaction
abdominal pain,AdverseReaction
discomfort,AdverseReaction
and,O
diarrhea,AdverseReaction
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Jazz,O
Pharmaceuticals,O
Inc,O
at,O
1,O
800,O
520,O
5568,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
controlled,O
but,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
clinical,O
trials,O
of,O
ERWINAZE,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
other,O
drugs,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
data,O
presented,O
below,O
are,O
based,O
on,O
information,O
collected,O
from,O
Study,O
1,O
a,O
single,O
arm,O
multi,O
center,O
open,O
label,O
safety,O
and,O
clinical,O
pharmacology,O
trial,O
intramuscular,O
administration,O
the,O
ERWINAZE,O
Master,O
Treatment,O
Protocol,O
EMTP,O
an,O
expanded,O
access,O
program,O
both,O
intramuscular,O
intravenous,O
and,O
other,O
or,O
unknown,O
administration,O
and,O
Study,O
2,O
a,O
single,O
arm,O
multi,O
center,O
open,O
label,O
pharmacokinetic,O
PK,O
study,O
trial,O
of,O
intravenous,O
administration,O
of,O
ERWINAZE,O
Study,O
1,O
enrolled,O
58,O
patients,O
treated,O
on,O
National,O
Cancer,O
Institute,O
NCI,O
sponsored,O
cooperative,O
group,O
ALL,O
protocols,O
who,O
were,O
unable,O
to,O
continue,O
to,O
receive,O
pegaspargase,O
due,O
to,O
hypersensitivity,O
reactions,O
Patients,O
received,O
6,O
doses,O
of,O
ERWINAZE,O
25,O
000,O
International,O
Units,O
m,O
2,O
intramuscularly,O
on,O
a,O
Monday,O
Wednesday,O
and,O
Friday,O
schedule,O
as,O
a,O
replacement,O
for,O
each,O
scheduled,O
dose,O
of,O
pegaspargase,O
remaining,O
on,O
their,O
original,O
treatment,O
protocol,O
The,O
Study,O
1,O
population,O
included,O
patients,O
with,O
a,O
median,O
age,O
of,O
11,O
years,O
2,O
to,O
18,O
years,O
59,O
were,O
male,O
78,O
were,O
White,O
10,O
were,O
Black,O
African,O
American,O
5,O
were,O
Asian,O
and,O
7,O
were,O
other,O
or,O
unknown,O
A,O
total,O
of,O
35,O
were,O
Hispanic,O
or,O
Latino,O
In,O
Study,O
1,O
the,O
number,O
of,O
ERWINAZE,O
courses,O
ranged,O
from,O
1,O
to,O
9,O
In,O
this,O
study,O
76,O
44,O
of,O
58,O
completed,O
all,O
planned,O
therapy,O
Fourteen,O
24,O
patients,O
stopped,O
therapy,O
prior,O
to,O
completion,O
seven,O
due,O
to,O
allergic reactions,AdverseReaction
five,O
due,O
to,O
physician,O
or,O
patient,O
choice,O
one,O
due,O
to,O
disease,O
progression,O
and,O
one,O
due,O
to,O
discontinuation,O
during,O
frontline,O
protocol,O
All,O
other,O
chemotherapy,O
was,O
continued,O
according,O
to,O
the,O
patient,O
s,O
prescribed,O
treatment,O
regimen,O
see,O
Clinical,O
Studies,O
14,O
Study,O
2,O
enrolled,O
30,O
patients,O
29,O
were,O
being,O
treated,O
for,O
ALL,O
and,O
one,O
for,O
lymphoblastic,O
lymphoma,O
LBL,O
following,O
allergy,O
to,O
native,O
E,O
coli,O
asparaginase,O
or,O
pegaspargase,O
Patients,O
received,O
ERWINAZE,O
25,O
000,O
International,O
Unit,O
m,O
2,O
dose,O
administered,O
by,O
intravenous,O
infusion,O
on,O
a,O
Monday,O
Wednesday,O
and,O
Friday,O
schedule,O
6,O
doses,O
as,O
a,O
replacement,O
for,O
doses,O
remaining,O
on,O
their,O
original,O
treatment,O
plan,O
The,O
Study,O
2,O
population,O
included,O
patients,O
with,O
a,O
median,O
age,O
of,O
7,O
years,O
1,O
to,O
17,O
years,O
63,O
were,O
male,O
27,O
were,O
Hispanic,O
or,O
Latino,O
83,O
were,O
White,O
3,O
were,O
Black,O
African,O
American,O
7,O
were,O
Asian,O
and,O
7,O
were,O
other,O
American,O
Indian,O
Alaska,O
Native,O
or,O
Indian,O
see,O
Clinical,O
Studies,O
14,O
The,O
EMTP,O
trial,O
enrolled,O
1368,O
patients,O
with,O
ALL,O
or,O
lymphoblastic,O
lymphoma,O
who,O
received,O
ERWINAZE,O
after,O
developing,O
systemic,O
hypersensitivity,O
to,O
an,O
E,O
coli,O
derived,O
asparaginase,O
Of,O
these,O
1368,O
patients,O
safety,O
data,O
were,O
received,O
for,O
940,O
patients,O
with,O
a,O
median,O
age,O
of,O
9,O
years,O
0,O
to,O
76,O
years,O
63,O
were,O
male,O
91,O
with,O
leukemia,O
3,O
with,O
lymphoma,O
and,O
6,O
with,O
unknown,O
disease,O
information,O
Patients,O
received,O
ERWINAZE,O
according,O
to,O
several,O
schedules,O
and,O
treatment,O
center,O
specifications,O
with,O
doses,O
that,O
ranged,O
from,O
20,O
000,O
to,O
25,O
000,O
International,O
Units,O
m,O
2,O
The,O
route,O
of,O
administration,O
was,O
intramuscular,O
n,O
852,O
intravenous,O
n,O
29,O
other,O
or,O
unknown,O
n,O
59,O
In,O
the,O
EMTP,O
trial,O
the,O
planned,O
number,O
of,O
doses,O
of,O
ERWINAZE,O
ranged,O
from,O
3,O
to,O
48,O
doses,O
Seventy,O
eight,O
percent,O
of,O
patients,O
693,O
of,O
893,O
were,O
able,O
to,O
receive,O
all,O
planned,O
doses,O
to,O
complete,O
their,O
prescribed,O
treatment,O
regimen,O
In,O
Study,O
1,O
and,O
Study,O
2,O
safety,O
information,O
was,O
prospectively,O
and,O
systematically,O
collected,O
In,O
Study,O
1,O
all,O
Grades,O
of,O
adverse,O
events,O
were,O
reported,O
for,O
the,O
following,O
adverse,O
events,O
of,O
special,O
interest,O
allergy,AdverseReaction
pancreatitis,AdverseReaction
coagulopathy,AdverseReaction
hemorrhage,AdverseReaction
thrombosis,AdverseReaction
or,O
infarct,AdverseReaction
hyperbilirubinemia,AdverseReaction
hyperglycemia,AdverseReaction
hyperlipidemia,AdverseReaction
ketoacidosis,AdverseReaction
and,O
CNS events,AdverseReaction
hemorrhage,AdverseReaction
thrombosis,AdverseReaction
or,O
infarction,AdverseReaction
and,O
cerebral venous thrombosis,AdverseReaction
and,O
only,O
Grade,O
3,O
and,O
4,O
events,O
were,O
reported,O
for,O
other,O
adverse,O
events,O
In,O
Study,O
2,O
all,O
adverse,O
events,O
of,O
all,O
Grades,O
were,O
prospectively,O
collected,O
In,O
the,O
EMTP,O
trial,O
safety,O
data,O
were,O
derived,O
from,O
case,O
report,O
forms,O
that,O
collected,O
adverse,O
event,O
information,O
The,O
forms specifically requested information,Factor
on,O
occurrence,O
of,O
allergic reactions,AdverseReaction
thrombotic events,AdverseReaction
hemorrhagic events,AdverseReaction
hepatobiliary disorders,AdverseReaction
pancreatic disorders,AdverseReaction
and,O
hyperglycemia,AdverseReaction
The,O
incidence,O
of,O
non,O
hematologic,O
non,O
infectious,O
adverse,O
events,O
all,O
Grades,O
in,O
Study,O
1,O
Study,O
2,O
and,O
the,O
EMTP,O
trial,O
is,O
provided,O
in,O
Table,O
1,O
The,O
incidence,O
of,O
Grade,O
3,O
or,O
greater,O
non,O
hematologic,O
non,O
infectious,O
adverse,O
reactions,O
occurring,O
with,O
ERWINAZE,O
in,O
Study,O
1,O
Study,O
2,O
and,O
EMTP,O
trial,O
is,O
provided,O
in,O
Table,O
2,O
Table,O
1,O
Table,O
2,O
6,O
2,O
Immunogenicity,O
As,O
with,O
most,O
therapeutic,O
proteins,O
patients,O
may,O
develop,O
anti,O
drug,O
antibodies,O
ADA,O
to,O
ERWINAZE,O
In,O
a,O
study,O
with,O
ERWINAZE,O
treatment,O
by,O
intramuscular,O
administration,O
Study,O
1,O
6,O
of,O
56,O
11,O
patients,O
treated,O
with,O
ERWINAZE,O
developed,O
antibodies,O
to,O
ERWINAZE,O
Of,O
these,O
6,O
ADA,O
positive,O
patients,O
one,O
experienced,O
a,O
hypersensitivity reaction,AdverseReaction
during,O
Study,O
1,O
2,O
1,O
of,O
56,O
None,O
of,O
these,O
6,O
patients,O
had,O
neutralizing,O
antibodies,O
In,O
a,O
study,O
with,O
ERWINAZE,O
treatment,O
by,O
intravenous,O
administration,O
Study,O
2,O
4,O
of,O
30,O
13,O
3,O
patients,O
treated,O
with,O
ERWINAZE,O
developed,O
anti,O
ERWINAZE,O
antibodies,O
Of,O
these,O
4,O
patients,O
who,O
developed,O
anti,O
ERWINAZE,O
antibodies,O
3,O
experienced,O
hypersensitivity reactions,AdverseReaction
10,O
3,O
of,O
30,O
during,O
the,O
study,O
None,O
of,O
these,O
4,O
patients,O
had,O
neutralizing,O
antibodies,O
The,O
presence,O
of,O
ADA,O
to,O
ERWINAZE,O
is,O
associated,O
with,O
a,O
higher,O
risk,Factor
of,O
hypersensitivity reactions,AdverseReaction
in,O
patients,O
who,O
received,O
ERWINAZE,O
through,O
intravenous,O
infusion,O
compared,O
to,O
intramuscular,O
administration,O
of,O
ERWINAZE,O
Immunogenicity,O
assay,O
are,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
and,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
such,O
as,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
ERWINAZE,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Endophthalmitis,AdverseReaction
and,O
retinal detachments,AdverseReaction
may,Factor
occur,O
following,O
intravitreal,O
injections,O
Patients,O
should,O
be,O
instructed,O
to,O
report,O
any,O
symptoms,O
suggestive,O
of,O
endophthalmitis,O
or,O
retinal,O
detachment,O
without,O
delay,O
and,O
should,O
be,O
managed,O
appropriately,O
5,O
1,O
Increases in intraocular pressure,AdverseReaction
have,O
been,O
seen,O
within,O
60,O
minutes,O
of,O
an,O
intravitreal,O
injection,O
5,O
2,O
There,O
is,O
a,O
potential,O
risk,O
of,O
arterial thromboembolic events,AdverseReaction
following,O
intravitreal,O
use,O
of,O
VEGF inhibitors,DrugClass
5,O
3,O
5,O
1,O
Endophthalmitis,O
and,O
Retinal,O
Detachments,O
Intravitreal,O
injections,O
including,O
those,O
with,O
EYLEA,O
have,O
been,O
associated,O
with,O
endophthalmitis,AdverseReaction
and,O
retinal detachments,AdverseReaction
seeAdverse,O
Reactions,O
6,O
1,O
Proper,O
aseptic,O
injection,O
technique,O
must,O
always,O
be,O
used,O
when,O
administering,O
EYLEA,O
Patients,O
should,O
be,O
instructed,O
to,O
report,O
any,O
symptoms,O
suggestive,O
of,O
endophthalmitis,O
or,O
retinal,O
detachment,O
without,O
delay,O
and,O
should,O
be,O
managed,O
appropriately,O
seeDosage,O
and,O
Administration,O
2,O
7,O
andPatient,O
Counseling,O
Information,O
17,O
5,O
2,O
Increase,O
in,O
Intraocular,O
Pressure,O
Acute increases in intraocular pressure,AdverseReaction
have,O
been,O
seen,O
within,O
60,O
minutes,O
of,O
intravitreal,O
injection,O
including,O
with,O
EYLEA,O
seeAdverse,O
Reactions,O
6,O
1,O
Sustained increases in intraocular pressure,AdverseReaction
have,O
also,O
been,O
reported,O
after,O
repeated,O
intravitreal,O
dosing,O
with,O
vascular endothelial growth factor,DrugClass
VEGF,O
inhibitors,DrugClass
Intraocular,O
pressure,O
and,O
the,O
perfusion,O
of,O
the,O
optic,O
nerve,O
head,O
should,O
be,O
monitored,O
and,O
managed,O
appropriately,O
seeDosage,O
and,O
Administration,O
2,O
7,O
5,O
3,O
Thromboembolic,O
Events,O
There,O
is,O
a,O
potential,O
risk,Factor
of,O
arterial thromboembolic events,AdverseReaction
ATEs,AdverseReaction
following,O
intravitreal,O
use,O
of,O
VEGF,O
inhibitors,O
including,O
EYLEA,O
ATEs,O
are,O
defined,O
as,O
nonfatal,O
stroke,O
nonfatal,O
myocardial,O
infarction,O
or,O
vascular,O
death,O
including,O
deaths,O
of,O
unknown,O
cause,O
The,O
incidence,O
of,O
reported,O
thromboembolic events,AdverseReaction
in,O
wet,O
AMD,O
studies,O
during,O
the,O
first,O
year,O
was,O
1,O
8,O
32,O
out,O
of,O
1824,O
in,O
the,O
combined,O
group,O
of,O
patients,O
treated,O
with,O
EYLEA,O
The,O
incidence,O
in,O
the,O
DME,O
studies,O
from,O
baseline,O
to,O
week,O
52,O
was,O
3,O
3,O
19,O
out,O
of,O
578,O
in,O
the,O
combined,O
group,O
of,O
patients,O
treated,O
with,O
EYLEA,O
compared,O
with,O
2,O
8,O
8,O
out,O
of,O
287,O
in,O
the,O
control,O
group,O
from,O
baseline,O
to,O
week,O
100,O
the,O
incidence,O
was,O
6,O
4,O
37,O
out,O
of,O
578,O
in,O
the,O
combined,O
group,O
of,O
patients,O
treated,O
with,O
EYLEA,O
compared,O
with,O
4,O
2,O
12,O
out,O
of,O
287,O
in,O
the,O
control,O
group,O
There,O
were,O
no,Negation
reported,O
thromboembolic events,AdverseReaction
in,O
the,O
patients,O
treated,O
with,O
EYLEA,O
in,O
the,O
first,O
six,O
months,O
of,O
the,O
RVO,O
studies,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
5,O
section,O
of,O
the,O
labeling,O
Endophthalmitis,AdverseReaction
and,O
retinal detachments,AdverseReaction
Increased intraocular pressure,AdverseReaction
Thromboembolic events,AdverseReaction
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
reported,O
in,O
patients,O
receiving,O
EYLEA,O
were,O
conjunctival hemorrhage,AdverseReaction
eye pain,AdverseReaction
cataract,AdverseReaction
vitreous floaters,AdverseReaction
intraocular pressure increased,AdverseReaction
and,O
vitreous detachment,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Regeneron,O
at,O
1,O
855,O
395,O
3248,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
other,O
clinical,O
trials,O
of,O
the,O
same,O
or,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
A,O
total,O
of,O
2711,O
patients,O
treated,O
with,O
EYLEA,O
constituted,O
the,O
safety,O
population,O
in,O
seven,O
phase,O
3,O
studies,O
Among,O
those,O
2110,O
patients,O
were,O
treated,O
with,O
the,O
recommended,O
dose,O
of,O
2,O
mg,O
Serious,O
adverse,O
reactions,O
related,O
to,O
the,O
injection,O
procedure,O
have,O
occurred,O
in,O
0,O
1,O
of,O
intravitreal,O
injections,O
with,O
EYLEA,O
including,O
endophthalmitis,AdverseReaction
and,O
retinal detachment,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
5,O
reported,O
in,O
patients,O
receiving,O
EYLEA,O
were,O
conjunctival hemorrhage,AdverseReaction
eye pain,AdverseReaction
cataract,AdverseReaction
vitreous floaters,AdverseReaction
intraocular pressure increased,AdverseReaction
and,O
vitreous detachment,AdverseReaction
Neovascular,O
Wet,O
Age,O
Related,O
Macular,O
Degeneration,O
AMD,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
EYLEA,O
in,O
1824,O
patients,O
with,O
wet,O
AMD,O
including,O
1223,O
patients,O
treated,O
with,O
the,O
2,O
mg,O
dose,O
in,O
2,O
double,O
masked,O
active,O
controlled,O
clinical,O
studies,O
VIEW1,O
and,O
VIEW2,O
for,O
12,O
months,O
seeClinical,O
Studies,O
14,O
1,O
Table,O
1,O
Most,O
Common,O
Adverse,O
Reactions,O
1,O
in,O
Wet,O
AMD,O
Studies,O
Adverse,O
Reactions,O
EYLEA,O
N,O
1824,O
Active,O
Control,O
ranibizumab,O
N,O
595,O
Conjunctival hemorrhage,AdverseReaction
25,O
28,O
Eye pain,AdverseReaction
9,O
9,O
Cataract,AdverseReaction
7,O
7,O
Vitreous detachment,AdverseReaction
6,O
6,O
Vitreous floaters,AdverseReaction
6,O
7,O
Intraocular pressure increased,AdverseReaction
5,O
7,O
Ocular hyperemia,AdverseReaction
4,O
8,O
Corneal epithelium defect,AdverseReaction
4,O
5,O
Detachment of the retinal pigment epithelium,AdverseReaction
3,O
3,O
Injection site pain,AdverseReaction
3,O
3,O
Foreign body sensation in eyes,AdverseReaction
3,O
4,O
Lacrimation increased,AdverseReaction
3,O
1,O
Vision blurred,AdverseReaction
2,O
2,O
Intraocular inflammation,AdverseReaction
2,O
3,O
Retinal pigment epithelium tear,AdverseReaction
2,O
1,O
Injection site hemorrhage,AdverseReaction
1,O
2,O
Eyelid edema,AdverseReaction
1,O
2,O
Corneal edema,AdverseReaction
1,O
1,O
Less,O
common,O
serious,O
adverse,O
reactions,O
reported,O
in,O
1,O
of,O
the,O
patients,O
treated,O
with,O
EYLEA,O
were,O
hypersensitivity,AdverseReaction
retinal detachment,AdverseReaction
retinal tear,AdverseReaction
and,O
endophthalmitis,AdverseReaction
Macular,O
Edema,O
Following,O
Retinal,O
Vein,O
Occlusion,O
RVO,O
The,O
data,O
described,O
below,O
reflect,O
6,O
months,O
exposure,O
to,O
EYLEA,O
with,O
a,O
monthly,O
2,O
mg,O
dose,O
in,O
218,O
patients,O
following,O
CRVO,O
in,O
2,O
clinical,O
studies,O
COPERNICUS,O
and,O
GALILEO,O
and,O
91,O
patients,O
following,O
BRVO,O
in,O
one,O
clinical,O
study,O
VIBRANT,O
seeClinical,O
Studies,O
14,O
2,O
14,O
3,O
Table,O
2,O
Most,O
Common,O
Adverse,O
Reactions,O
1,O
in,O
RVO,O
Studies,O
Adverse,O
Reactions,O
CRVO,O
BRVO,O
EYLEA,O
N,O
218,O
Control,O
N,O
142,O
EYLEA,O
N,O
91,O
Control,O
N,O
92,O
Eye pain,AdverseReaction
13,O
5,O
4,O
5,O
Conjunctival hemorrhage,AdverseReaction
12,O
11,O
20,O
4,O
Intraocular pressure increased,AdverseReaction
8,O
6,O
2,O
0,O
Corneal epithelium defect,AdverseReaction
5,O
4,O
2,O
0,O
Vitreous floaters,AdverseReaction
5,O
1,O
1,O
0,O
Ocular hyperemia,AdverseReaction
5,O
3,O
2,O
2,O
Foreign body sensation in eyes,AdverseReaction
3,O
5,O
3,O
0,O
Vitreous detachment,AdverseReaction
3,O
4,O
2,O
0,O
Lacrimation increased,AdverseReaction
3,O
4,O
3,O
0,O
Injection site pain,AdverseReaction
3,O
1,O
1,O
0,O
Vision blurred,AdverseReaction
1,O
1,O
1,O
1,O
Intraocular inflammation,AdverseReaction
1,O
1,O
0,O
0,O
Cataract,AdverseReaction
1,O
1,O
5,O
0,O
Eyelid edema,AdverseReaction
1,O
1,O
1,O
0,O
Less,O
common,O
adverse,O
reactions,O
reported,O
in,O
1,O
of,O
the,O
patients,O
treated,O
with,O
EYLEA,O
in,O
the,O
CRVO,O
studies,O
were,O
corneal edema,AdverseReaction
retinal tear,AdverseReaction
hypersensitivity,AdverseReaction
and,O
endophthalmitis,AdverseReaction
Diabetic,O
Macular,O
Edema,O
DME,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
EYLEA,O
in,O
578,O
patients,O
with,O
DME,O
treated,O
with,O
the,O
2,O
mg,O
dose,O
in,O
2,O
double,O
masked,O
controlled,O
clinical,O
studies,O
VIVID,O
and,O
VISTA,O
from,O
baseline,O
to,O
week,O
52,O
and,O
from,O
baseline,O
to,O
week,O
100,O
seeClinical,O
Studies,O
14,O
4,O
Table,O
3,O
Most,O
Common,O
Adverse,O
Reactions,O
1,O
in,O
DME,O
Studies,O
Adverse,O
Reactions,O
Baseline,O
to,O
Week,O
52,O
Baseline,O
to,O
Week,O
100,O
EYLEA,O
N,O
578,O
Control,O
N,O
287,O
EYLEA,O
N,O
578,O
Control,O
N,O
287,O
Conjunctival hemorrhage,AdverseReaction
28,O
17,O
31,O
21,O
Eye pain,AdverseReaction
9,O
6,O
11,O
9,O
Cataract,AdverseReaction
8,O
9,O
19,O
17,O
Vitreous floaters,AdverseReaction
6,O
3,O
8,O
6,O
Corneal epithelium defect,AdverseReaction
5,O
3,O
7,O
5,O
Intraocular pressure increased,AdverseReaction
5,O
3,O
9,O
5,O
Ocular hyperemia,AdverseReaction
5,O
6,O
5,O
6,O
Vitreous detachment,AdverseReaction
3,O
3,O
8,O
6,O
Foreign body sensation in eyes,AdverseReaction
3,O
3,O
3,O
3,O
Lacrimation increased,AdverseReaction
3,O
2,O
4,O
2,O
Vision blurred,AdverseReaction
2,O
2,O
3,O
4,O
Intraocular inflammation,AdverseReaction
2,O
1,O
3,O
1,O
Injection site pain,AdverseReaction
2,O
1,O
2,O
1,O
Eyelid edema,AdverseReaction
1,O
1,O
2,O
1,O
Less,O
common,O
adverse,O
reactions,O
reported,O
in,O
1,O
of,O
the,O
patients,O
treated,O
with,O
EYLEA,O
were,O
hypersensitivity,AdverseReaction
retinal detachment,AdverseReaction
retinal tear,AdverseReaction
corneal edema,AdverseReaction
and,O
injection site hemorrhage,AdverseReaction
6,O
2,O
Immunogenicity,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
a,O
potential,O
for,O
an,O
immune,O
response,O
in,O
patients,O
treated,O
with,O
EYLEA,O
The,O
immunogenicity,O
of,O
EYLEA,O
was,O
evaluated,O
in,O
serum,O
samples,O
The,O
immunogenicity,O
data,O
reflect,O
the,O
percentage,O
of,O
patients,O
whose,O
test,O
results,O
were,O
considered,O
positive,O
for,O
antibodies,O
to,O
EYLEA,O
in,O
immunoassays,O
The,O
detection,O
of,O
an,O
immune,O
response,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assays,O
used,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
EYLEA,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
In,O
the,O
wet,O
AMD,O
RVO,O
and,O
DME,O
studies,O
the,O
pre,O
treatment,O
incidence,O
of,O
immunoreactivity,O
to,O
EYLEA,O
was,O
approximately,O
1,O
to,O
3,O
across,O
treatment,O
groups,O
After,O
dosing,O
with,O
EYLEA,O
for,O
24,O
100,O
weeks,O
antibodies,O
to,O
EYLEA,O
were,O
detected,O
in,O
a,O
similar,O
percentage,O
range,O
of,O
patients,O
There,O
were,O
no,O
differences,O
in,O
efficacy,O
or,O
safety,O
between,O
patients,O
with,O
or,O
without,O
immunoreactivity,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Elderly,O
patients,O
with,O
dementia,O
related,O
psychosis,O
who,O
are,O
treated,O
with,O
atypical antipsychotic drugs,DrugClass
are,O
at,O
an,O
increased,O
risk,O
of,O
death,AdverseReaction
and,O
cerebrovascular related adverse events,AdverseReaction
including,O
stroke,AdverseReaction
5,O
1,O
QT prolongation,AdverseReaction
Prolongs QT interval,AdverseReaction
and,O
may,Factor
be,O
associated,O
with,O
arrhythmia,AdverseReaction
and,O
sudden death,AdverseReaction
consider,O
using,O
other,O
antipsychotics,O
first,O
Avoid,O
use,O
of,O
FANAPT,O
in,O
combination,O
with,O
other,O
drugs,O
that,O
are,O
known,O
to,O
prolong,O
QTc,O
use,O
caution,O
and,O
consider,O
dose,O
modification,O
when,O
prescribing,O
FANAPT,O
with,O
other,O
drugs,O
that,O
inhibit,O
FANAPT,O
metabolism,O
Monitor,O
serum,O
potassium,O
and,O
magnesium,O
in,O
patients,O
at,O
risk,O
for,O
electrolyte,O
disturbances,O
1,O
5,O
2,O
7,O
1,O
7,O
3,O
12,O
3,O
Neuroleptic Malignant Syndrome,AdverseReaction
Manage,O
with,O
immediate,O
discontinuation,O
of,O
drug,O
and,O
close,O
monitoring,O
5,O
3,O
Tardive dyskinesia,AdverseReaction
Discontinue,O
if,O
clinically,O
appropriate,O
5,O
4,O
Hyperglycemia,AdverseReaction
and,O
diabetes mellitus,AdverseReaction
Monitor,O
patients,O
for,O
symptoms,O
of,O
hyperglycemia,O
including,O
polydipsia,O
polyuria,O
polyphagia,O
and,O
weakness,O
Monitor,O
glucose,O
regularly,O
in,O
patients,O
at,O
risk,O
for,O
diabetes,O
5,O
5,O
Dyslipidemia,AdverseReaction
Undesirable,O
alterations,O
have,O
been,O
observed,O
in,O
patients,O
treated,O
with,O
atypical,O
antipsychotics,O
5,O
5,O
Weight Gain,AdverseReaction
Weight,O
gain,O
has,O
been,O
reported,O
Monitor,O
weight,O
5,O
5,O
Metabolic Changes,AdverseReaction
Atypical antipsychotic drugs,DrugClass
have,O
been,O
associated,O
with,O
metabolic,O
changes,O
that,O
may,O
increase,O
cardiovascular,AdverseReaction
cerebrovascular risk,AdverseReaction
These,O
metabolic changes,AdverseReaction
include,O
hyperglycemia,AdverseReaction
dyslipidemia,AdverseReaction
and,O
weight gain,AdverseReaction
5,O
5,O
Seizures,AdverseReaction
Use,O
cautiously,O
in,O
patients,O
with,O
a,O
history,O
of,O
seizures,O
or,O
with,O
conditions,O
that,O
lower,O
seizure,O
threshold,O
5,O
6,O
Orthostatic hypotension,AdverseReaction
Dizziness,AdverseReaction
tachycardia,AdverseReaction
and,O
syncope,AdverseReaction
can,Factor
occur,O
with,O
standing,O
5,O
7,O
Leukopenia,AdverseReaction
Neutropenia,AdverseReaction
and,O
Agranulocytosis,AdverseReaction
have,O
been,O
reported,O
with,O
antipsychotics,DrugClass
Patients,O
with,O
a,O
pre,O
existing,O
low,O
white,O
blood,O
cell,O
count,O
WBC,O
or,O
a,O
history,O
of,O
leukopenia,O
neutropenia,O
should,O
have,O
their,O
complete,O
blood,O
count,O
CBC,O
monitored,O
frequently,O
during,O
the,O
first,O
few,O
months,O
of,O
therapy,O
and,O
should,O
discontinue,O
FANAPT,O
at,O
the,O
first,O
sign,O
of,O
a,O
decline,O
in,O
WBC,O
in,O
the,O
absence,O
of,O
other,O
causative,O
factors,O
5,O
8,O
Suicide,AdverseReaction
Close,O
supervision,O
of,O
high,O
risk,O
patients,O
5,O
12,O
Priapism,AdverseReaction
Cases,O
have,O
been,O
reported,O
in,O
association,O
with,O
FANAPT,O
treatment,O
5,O
13,O
Potential,Factor
for,O
cognitive,AdverseReaction
and,O
motor impairment,AdverseReaction
Use,O
caution,O
when,O
operating,O
machinery,O
5,O
14,O
See,O
Full,O
Prescribing,O
Information,O
for,O
additional,O
WARNINGS,O
and,O
PRECAUTIONS,O
5,O
1,O
Increased,O
Risks,O
in,O
Elderly,O
Patients,O
with,O
Dementia,O
Related,O
Psychosis,O
Increased,O
Mortality,O
Elderly,O
patients,O
with,O
dementia,O
related,O
psychosis,O
treated,O
with,O
atypical antipsychotic drugs,DrugClass
are,O
at,O
an,O
increased,O
risk,O
of,O
death,AdverseReaction
compared,O
to,O
placebo,O
FANAPT,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
dementia,O
related,O
psychosis,O
s,O
ee,O
Boxed,O
Warning,O
Cerebrovascular,O
Adverse,O
Events,O
Including,O
Stroke,O
In,O
placebo,O
controlled,O
trials,O
with,O
risperidone,O
aripiprazole,O
and,O
olanzapine,O
in,O
elderly,O
patients,O
with,O
dementia,O
there,O
was,O
a,O
higher,O
incidence,O
of,O
cerebrovascular adverse events,AdverseReaction
cerebrovascular accidents,AdverseReaction
and,O
transient ischemic attacks,AdverseReaction
including,O
fatalities,AdverseReaction
compared,O
to,O
placebo,O
treated,O
patients,O
FANAPT,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
dementia,O
related,O
psychosis,O
s,O
ee,O
Boxed,O
Warning,O
5,O
2,O
QT,O
Prolongation,O
In,O
an,O
open,O
label,O
QTc,O
study,O
in,O
patients,O
with,O
schizophrenia,O
or,O
schizoaffective,O
disorder,O
n,O
160,O
FANAPT,O
was,O
associated,O
with,O
QTc prolongation,AdverseReaction
of,O
9,O
msec,O
at,O
an,O
iloperidone,O
dose,O
of,O
12,O
mg,O
twice,O
daily,O
The,O
effect,O
of,O
FANAPT,O
on,O
the,O
QT,O
interval,O
was,O
augmented,O
by,O
the,O
presence,O
of,O
CYP450,O
2D6,O
or,O
3A4,O
metabolic,O
inhibition,O
paroxetine,O
20,O
mg,O
once,O
daily,O
and,O
ketoconazole,O
200,O
mg,O
twice,O
daily,O
respectively,O
Under,O
conditions,O
of,O
metabolic,O
inhibition,O
for,O
both,O
2D6,O
and,O
3A4,O
FANAPT,O
12,O
mg,O
twice,O
daily,O
was,O
associated,O
with,O
a,O
mean,O
QTcF increase,AdverseReaction
from,O
baseline,O
of,O
about,O
19,O
msec,O
No,Negation
cases,O
of,O
torsade de pointes,AdverseReaction
or,O
other,O
severe,Severity
cardiac arrhythmias,AdverseReaction
were,O
observed,O
during,O
the,O
pre,O
marketing,O
clinical,O
program,O
The,O
use,O
of,O
FANAPT,O
should,O
be,O
avoided,O
in,O
combination,O
with,O
other,O
drugs,O
that,O
are,O
known,O
to,O
prolong,O
QTc,O
including,O
Class,O
1A,O
e,O
g,O
quinidine,O
procainamide,O
or,O
Class,O
III,O
e,O
g,O
amiodarone,O
sotalol,O
antiarrhythmic,O
medications,O
antipsychotic,O
medications,O
e,O
g,O
chlorpromazine,O
thioridazine,O
antibiotics,O
e,O
g,O
gatifloxacin,O
moxifloxacin,O
or,O
any,O
other,O
class,O
of,O
medications,O
known,O
to,O
prolong,O
the,O
QTc,O
interval,O
e,O
g,O
pentamidine,O
levomethadyl,O
acetate,O
methadone,O
FANAPT,O
should,O
also,O
be,O
avoided,O
in,O
patients,O
with,O
congenital,O
long,O
QT,O
syndrome,O
and,O
in,O
patients,O
with,O
a,O
history,O
of,O
cardiac,O
arrhythmias,O
Certain,O
circumstances,O
may,O
increase,O
the,O
risk,O
of,O
torsade,O
de,O
pointes,O
and,O
or,O
sudden,O
death,O
in,O
association,O
with,O
the,O
use,O
of,O
drugs,O
that,O
prolong,O
the,O
QTc,O
interval,O
including,O
1,O
bradycardia,O
2,O
hypokalemia,O
or,O
hypomagnesemia,O
3,O
concomitant,O
use,O
of,O
other,O
drugs,O
that,O
prolong,O
the,O
QTc,O
interval,O
and,O
4,O
presence,O
of,O
congenital,O
prolongation,O
of,O
the,O
QT,O
interval,O
5,O
recent,O
acute,O
myocardial,O
infarction,O
and,O
or,O
6,O
uncompensated,O
heart,O
failure,O
Caution,O
is,O
warranted,O
when,O
prescribing,O
FANAPT,O
with,O
drugs,O
that,O
inhibit,O
FANAPT,O
metabolism,O
see,O
Drug,O
Interaction,O
s,O
7,O
1,O
and,O
in,O
patients,O
with,O
reduced,O
activity,O
of,O
CYP2D6,O
see,O
Clinical,O
Pharmacology,O
12,O
3,O
It,O
is,O
recommended,O
that,O
patients,O
being,O
considered,O
for,O
FANAPT,O
treatment,O
who,O
are,O
at,O
risk,O
for,O
significant,O
electrolyte,O
disturbances,O
have,O
baseline,O
serum,O
potassium,O
and,O
magnesium,O
measurements,O
with,O
periodic,O
monitoring,O
Hypokalemia,O
and,O
or,O
hypomagnesemia,O
may,O
increase,O
the,O
risk,O
of,O
QT,O
prolongation,O
and,O
arrhythmia,O
FANAPT,O
should,O
be,O
avoided,O
in,O
patients,O
with,O
histories,O
of,O
significant,O
cardiovascular,O
illness,O
e,O
g,O
QT,O
prolongation,O
recent,O
acute,O
myocardial,O
infarction,O
uncompensated,O
heart,O
failure,O
or,O
cardiac,O
arrhythmia,O
FANAPT,O
should,O
be,O
discontinued,O
in,O
patients,O
who,O
are,O
found,O
to,O
have,O
persistent,O
QTc,O
measurements,O
500,O
msec,O
If,O
patients,O
taking,O
FANAPT,O
experience,O
symptoms,O
that,O
could,O
indicate,O
the,O
occurrence,O
of,O
cardiac,O
arrhythmias,O
e,O
g,O
dizziness,O
palpitations,O
or,O
syncope,O
the,O
prescriber,O
should,O
initiate,O
further,O
evaluation,O
including,O
cardiac,O
monitoring,O
5,O
3,O
Neuroleptic,O
Malignant,O
Syndrome,O
NMS,O
A,O
potentially,O
fatal,O
symptom,O
complex,O
sometimes,O
referred,O
to,O
as,O
Neuroleptic Malignant Syndrome,AdverseReaction
NMS,AdverseReaction
has,O
been,O
reported,O
in,O
association,O
with,O
administration,O
of,O
antipsychotic,O
drugs,O
including,O
FANAPT,O
Clinical,O
manifestations,O
include,O
hyperpyrexia,AdverseReaction
muscle rigidity,AdverseReaction
altered mental status,AdverseReaction
including,O
catatonic signs,AdverseReaction
and,O
evidence,O
of,O
autonomic instability,AdverseReaction
irregular pulse,AdverseReaction
or,O
blood pressure,AdverseReaction
tachycardia,AdverseReaction
diaphoresis,AdverseReaction
and,O
cardiac dysrhythmia,AdverseReaction
Additional,O
signs,O
may,Factor
include,O
elevated creatine phosphokinase,AdverseReaction
myoglobinuria,AdverseReaction
rhabdomyolysis,AdverseReaction
and,O
acute renal failure,AdverseReaction
The,O
diagnostic,O
evaluation,O
of,O
patients,O
with,O
this,O
syndrome,O
is,O
complicated,O
In,O
arriving,O
at,O
a,O
diagnosis,O
it,O
is,O
important,O
to,O
identify,O
cases,O
in,O
which,O
the,O
clinical,O
presentation,O
includes,O
both,O
serious,O
medical,O
illness,O
e,O
g,O
pneumonia,O
systemic,O
infection,O
etc,O
and,O
untreated,O
or,O
inadequately,O
treated,O
extrapyramidal,O
signs,O
and,O
symptoms,O
EPS,O
Other,O
important,O
considerations,O
in,O
the,O
differential,O
diagnosis,O
include,O
central,O
anticholinergic,O
toxicity,O
heat,O
stroke,O
drug,O
fever,O
and,O
primary,O
central,O
nervous,O
system,O
CNS,O
pathology,O
The,O
management,O
of,O
this,O
syndrome,O
should,O
include,O
1,O
immediate,O
discontinuation,O
of,O
the,O
antipsychotic,O
drugs,O
and,O
other,O
drugs,O
not,O
essential,O
to,O
concurrent,O
therapy,O
2,O
intensive,O
symptomatic,O
treatment,O
and,O
medical,O
monitoring,O
and,O
3,O
treatment,O
of,O
any,O
concomitant,O
serious,O
medical,O
problems,O
for,O
which,O
specific,O
treatments,O
are,O
available,O
There,O
is,O
no,O
general,O
agreement,O
about,O
specific,O
pharmacological,O
treatment,O
regimens,O
for,O
NMS,O
If,O
a,O
patient,O
requires,O
antipsychotic,O
drug,O
treatment,O
after,O
recovery,O
from,O
NMS,O
the,O
potential,O
reintroduction,O
of,O
drug,O
therapy,O
should,O
be,O
carefully,O
considered,O
The,O
patient,O
should,O
be,O
carefully,O
monitored,O
since,O
recurrences,O
of,O
NMS,O
have,O
been,O
reported,O
5,O
4,O
Tardive,O
Dyskinesia,O
Tardive dyskinesia,AdverseReaction
is,O
a,O
syndrome,O
consisting,O
of,O
potentially,O
irreversible,O
involuntary dyskinetic movements,AdverseReaction
which,O
may,O
develop,O
in,O
patients,O
treated,O
with,O
antipsychotic drugs,DrugClass
Although,O
the,O
prevalence,O
of,O
the,O
syndrome,O
appears,O
to,O
be,O
highest,O
among,O
the,O
elderly,O
especially,O
elderly,O
women,O
it,O
is,O
impossible,O
to,O
rely,O
on,O
prevalence,O
estimates,O
to,O
predict,O
at,O
the,O
inception,O
of,O
antipsychotic,O
treatment,O
which,O
patients,O
are,O
likely,O
to,O
develop,O
the,O
syndrome,O
Whether,O
antipsychotic,O
drug,O
products,O
differ,O
in,O
their,O
potential,O
to,O
cause,O
tardive,O
dyskinesia,O
is,O
unknown,O
The,O
risk,O
of,O
developing,O
tardive,O
dyskinesia,O
and,O
the,O
likelihood,O
that,O
it,O
will,O
become,O
irreversible,O
are,O
believed,O
to,O
increase,O
as,O
the,O
duration,O
of,O
treatment,O
and,O
the,O
total,O
cumulative,O
dose,O
of,O
antipsychotic,O
administered,O
increases,O
However,O
the,O
syndrome,O
can,O
develop,O
although,O
much,O
less,O
commonly,O
after,O
relatively,O
brief,O
treatment,O
periods,O
at,O
low,O
doses,O
There,O
is,O
no,O
known,O
treatment,O
for,O
established,O
cases,O
of,O
tardive,O
dyskinesia,O
although,O
the,O
syndrome,O
may,O
remit,O
partially,O
or,O
completely,O
if,O
antipsychotic,O
treatment,O
is,O
withdrawn,O
Antipsychotic,O
treatment,O
itself,O
however,O
may,O
suppress,O
or,O
partially,O
suppress,O
the,O
signs,O
and,O
symptoms,O
of,O
the,O
syndrome,O
and,O
thereby,O
may,O
possibly,O
mask,O
the,O
underlying,O
process,O
The,O
effect,O
that,O
symptomatic,O
suppression,O
has,O
upon,O
the,O
long,O
term,O
course,O
of,O
the,O
syndrome,O
is,O
unknown,O
Given,O
these,O
considerations,O
FANAPT,O
should,O
be,O
prescribed,O
in,O
a,O
manner,O
that,O
is,O
most,O
likely,O
to,O
minimize,O
the,O
occurrence,O
of,O
tardive,O
dyskinesia,O
Chronic,O
antipsychotic,O
treatment,O
should,O
generally,O
be,O
reserved,O
for,O
patients,O
who,O
suffer,O
from,O
a,O
chronic,O
illness,O
that,O
1,O
is,O
known,O
to,O
respond,O
to,O
antipsychotic,O
drugs,O
and,O
2,O
for,O
whom,O
alternative,O
equally,O
effective,O
but,O
potentially,O
less,O
harmful,O
treatments,O
are,O
not,O
available,O
or,O
appropriate,O
In,O
patients,O
who,O
do,O
require,O
chronic,O
treatment,O
the,O
smallest,O
dose,O
and,O
the,O
shortest,O
duration,O
of,O
treatment,O
producing,O
a,O
satisfactory,O
clinical,O
response,O
should,O
be,O
sought,O
The,O
need,O
for,O
continued,O
treatment,O
should,O
be,O
reassessed,O
periodically,O
If,O
signs,O
and,O
symptoms,O
of,O
tardive,O
dyskinesia,O
appear,O
in,O
a,O
patient,O
on,O
FANAPT,O
drug,O
discontinuation,O
should,O
be,O
considered,O
However,O
some,O
patients,O
may,O
require,O
treatment,O
with,O
FANAPT,O
despite,O
the,O
presence,O
of,O
the,O
syndrome,O
5,O
5,O
Metabolic,O
Changes,O
Atypical antipsychotic drugs,DrugClass
have,O
been,O
associated,O
with,O
metabolic,O
changes,O
that,O
may,O
increase cardiovascular,AdverseReaction
cerebrovascular risk,AdverseReaction
These,O
metabolic,O
changes,O
include,O
hyperglycemia,AdverseReaction
dyslipidemia,AdverseReaction
and,O
body weight gain,AdverseReaction
see,O
Patient,O
Counseling,O
Information,O
17,O
3,O
While,O
all,O
atypical,O
antipsychotic,O
drugs,O
have,O
been,O
shown,O
to,O
produce,O
some,O
metabolic,O
changes,O
each,O
drug,O
in,O
the,O
class,O
has,O
its,O
own,O
specific,O
risk,O
profile,O
Hyperglycemia,O
and,O
Diabetes,O
Mellitus,O
Hyperglycemia,AdverseReaction
in,O
some,O
cases,O
extreme,Severity
and,O
associated,O
with,O
ketoacidosis,AdverseReaction
or,O
hyperosmolar coma,AdverseReaction
or,O
death,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
atypical,O
antipsychotics,O
including,O
FANAPT,O
Assessment,O
of,O
the,O
relationship,O
between,O
atypical,O
antipsychotic,O
use,O
and,O
glucose,O
abnormalities,O
is,O
complicated,O
by,O
the,O
possibility,O
of,O
an,O
increased,O
background,O
risk,O
of,O
diabetes,O
mellitus,O
in,O
patients,O
with,O
schizophrenia,O
and,O
the,O
increasing,O
incidence,O
of,O
diabetes,O
mellitus,O
in,O
the,O
general,O
population,O
Given,O
these,O
confounders,O
the,O
relationship,O
between,O
atypical,O
antipsychotic,O
use,O
and,O
hyperglycemia,O
related,O
adverse,O
events,O
is,O
not,O
completely,O
understood,O
However,O
epidemiological,O
studies,O
suggest,O
an,O
increased,O
risk,O
of,O
treatment,O
emergent,O
hyperglycemia related adverse events,AdverseReaction
in,O
patients,O
treated,O
with,O
the,O
atypical antipsychotics,DrugClass
included,O
in,O
these,O
studies,O
Because,O
FANAPT,O
was,O
not,O
marketed,O
at,O
the,O
time,O
these,O
studies,O
were,O
performed,O
it,O
is,O
not,O
known,O
if,O
FANAPT,O
is,O
associated,O
with,O
this,O
increased,O
risk,O
Patients,O
with,O
an,O
established,O
diagnosis,O
of,O
diabetes,O
mellitus,O
who,O
are,O
started,O
on,O
atypical,O
antipsychotics,O
should,O
be,O
monitored,O
regularly,O
for,O
worsening,O
of,O
glucose,O
control,O
Patients,O
with,O
risk,O
factors,O
for,O
diabetes,O
mellitus,O
e,O
g,O
obesity,O
family,O
history,O
of,O
diabetes,O
who,O
are,O
starting,O
treatment,O
with,O
atypical,O
antipsychotics,O
should,O
undergo,O
fasting,O
blood,O
glucose,O
testing,O
at,O
the,O
beginning,O
of,O
treatment,O
and,O
periodically,O
during,O
treatment,O
Any,O
patient,O
treated,O
with,O
atypical,O
antipsychotics,O
should,O
be,O
monitored,O
for,O
symptoms,O
of,O
hyperglycemia,O
including,O
polydipsia,O
polyuria,O
polyphagia,O
and,O
weakness,O
Patients,O
who,O
develop,O
symptoms,O
of,O
hyperglycemia,O
during,O
treatment,O
with,O
atypical,O
antipsychotics,O
should,O
undergo,O
fasting,O
blood,O
glucose,O
testing,O
In,O
some,O
cases,O
hyperglycemia,O
has,O
resolved,O
when,O
the,O
atypical,O
antipsychotic,O
was,O
discontinued,O
however,O
some,O
patients,O
required,O
continuation,O
of,O
antidiabetic,O
treatment,O
despite,O
discontinuation,O
of,O
the,O
suspect,O
drug,O
Data,O
from,O
a,O
4,O
week,O
fixed,O
dose,O
study,O
in,O
adult,O
subjects,O
with,O
schizophrenia,O
in,O
which,O
fasting,O
blood,O
samples,O
were,O
drawn,O
are,O
presented,O
in,O
Table,O
1,O
Table,O
1,O
Change,O
in,O
Fasting,O
Glucose,O
FANAPT,O
Placebo,O
24,O
mg,O
day,O
Mean,O
Change,O
from,O
Baseline,O
mg,O
dL,O
n,O
114,O
n,O
228,O
Serum,O
Glucose,O
Change,O
from,O
Baseline,O
0,O
5,O
6,O
6,O
Proportion,O
of,O
Patients,O
with,O
Shifts,O
Serum,O
Glucose,O
Normal,O
to,O
High,O
2,O
5,O
10,O
7,O
100,O
mg,O
dL,O
to,O
126,O
mg,O
dL,O
2,O
80,O
18,O
169,O
Pooled,O
analyses,O
of,O
glucose,O
data,O
from,O
clinical,O
studies,O
including,O
longer,O
term,O
trials,O
are,O
shown,O
in,O
Table,O
2,O
Table,O
2,O
Change,O
in,O
Glucose,O
Mean,O
Change,O
from,O
Baseline,O
mg,O
dL,O
3,O
6,O
months,O
6,O
12,O
months,O
12,O
months,O
FANAPT,O
10,O
16,O
mg,O
day,O
1,O
8,O
N,O
773,O
5,O
4,O
N,O
723,O
5,O
4,O
N,O
425,O
FANAPT,O
20,O
24,O
mg,O
day,O
3,O
6,O
N,O
34,O
9,O
0,O
N,O
31,O
18,O
0,O
N,O
20,O
Dyslipidemia,O
Undesirable alterations in lipids,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
treated,O
with,O
atypical antipsychotics,DrugClass
Data,O
from,O
a,O
placebo,O
controlled,O
4,O
week,O
fixed,O
dose,O
study,O
in,O
which,O
fasting,O
blood,O
samples,O
were,O
drawn,O
in,O
adult,O
subjects,O
with,O
schizophrenia,O
are,O
presented,O
in,O
Table,O
3,O
Table,O
3,O
Change,O
in,O
Fasting,O
Lipids,O
FANAPT,O
Placebo,O
24,O
mg,O
day,O
Mean,O
Change,O
from,O
Baseline,O
mg,O
dL,O
Cholesterol,O
n,O
114,O
n,O
228,O
Change,O
from,O
baseline,O
2,O
17,O
8,O
18,O
LDL,O
n,O
109,O
n,O
217,O
Change,O
from,O
baseline,O
1,O
41,O
9,O
03,O
HDL,O
n,O
114,O
n,O
228,O
Change,O
from,O
baseline,O
3,O
35,O
0,O
55,O
Triglycerides,O
n,O
114,O
n,O
228,O
Change,O
from,O
baseline,O
16,O
47,O
0,O
83,O
Proportion,O
of,O
Patients,O
with,O
Shifts,O
Cholesterol,O
Normal,O
to,O
High,O
1,O
4,O
3,O
6,O
200,O
mg,O
dL,O
to,O
240,O
mg,O
dL,O
1,O
72,O
5,O
141,O
LDL,O
Normal,O
to,O
High,O
2,O
4,O
1,O
1,O
100,O
mg,O
dL,O
to,O
160,O
mg,O
dL,O
1,O
42,O
1,O
90,O
HDL,O
Normal,O
to,O
Low,O
23,O
8,O
12,O
1,O
40,O
mg,O
dL,O
to,O
40,O
mg,O
dL,O
19,O
80,O
20,O
166,O
Triglycerides,O
Normal,O
to,O
High,O
8,O
3,O
10,O
1,O
150,O
mg,O
dL,O
to,O
200,O
mg,O
dL,O
6,O
72,O
15,O
148,O
Pooled,O
analyses,O
of,O
cholesterol,O
and,O
triglyceride,O
data,O
from,O
clinical,O
studies,O
including,O
longer,O
term,O
trials,O
are,O
shown,O
in,O
Tables,O
4,O
and,O
5,O
Table,O
4,O
Change,O
in,O
Cholesterol,O
Mean,O
Change,O
from,O
Baseline,O
mg,O
dL,O
3,O
6,O
months,O
6,O
12,O
months,O
12,O
months,O
FANAPT,O
10,O
16,O
mg,O
day,O
3,O
9,O
N,O
783,O
3,O
9,O
N,O
726,O
7,O
7,O
N,O
428,O
FANAPT,O
20,O
24,O
mg,O
day,O
19,O
4,O
N,O
34,O
23,O
2,O
N,O
31,O
19,O
4,O
N,O
20,O
Table,O
5,O
Change,O
in,O
Triglycerides,O
Mean,O
Change,O
from,O
Baseline,O
mg,O
dL,O
3,O
6,O
months,O
6,O
12,O
months,O
12,O
months,O
FANAPT,O
10,O
16,O
mg,O
day,O
8,O
9,O
N,O
783,O
8,O
9,O
N,O
726,O
17,O
7,O
N,O
428,O
FANAPT,O
20,O
24,O
mg,O
day,O
26,O
6,O
N,O
34,O
35,O
4,O
N,O
31,O
17,O
7,O
N,O
20,O
Weight,O
Gain,O
Weight gain,AdverseReaction
has,O
been,O
observed,O
with,O
atypical antipsychotic,DrugClass
use,O
Clinical,O
monitoring,O
of,O
weight,O
is,O
recommended,O
Across,O
all,O
short,O
and,O
long,O
term,O
studies,O
the,O
overall,O
mean,O
change,O
from,O
baseline,O
at,O
endpoint,O
was,O
2,O
1,O
kg,O
Changes,O
in,O
body,O
weight,O
kg,O
and,O
the,O
proportion,O
of,O
subjects,O
with,O
7,O
gain in body weight,AdverseReaction
from,O
4,O
placebo,O
controlled,O
4,O
or,O
6,O
week,O
fixed,O
or,O
flexible,O
dose,O
studies,O
in,O
adult,O
subjects,O
are,O
presented,O
in,O
Table,O
6,O
Table,O
6,O
Change,O
in,O
Body,O
Weight,O
FANAPT,O
FANAPT,O
Placebo,O
10,O
16,O
mg,O
day,O
20,O
24,O
mg,O
day,O
n,O
576,O
n,O
481,O
n,O
391,O
Weight,O
kg,O
Change,O
from,O
Baseline,O
0,O
1,O
2,O
0,O
2,O
7,O
Weight,O
Gain,O
7,O
increase,O
from,O
Baseline,O
4,O
12,O
18,O
5,O
6,O
Seizures,O
In,O
short,O
term,O
placebo,O
controlled,O
trials,O
4,O
to,O
6,O
weeks,O
seizures,AdverseReaction
occurred,O
in,O
0,O
1,O
1,O
1344,O
of,O
patients,O
treated,O
with,O
FANAPT,O
compared,O
to,O
0,O
3,O
2,O
587,O
on,O
placebo,O
As,O
with,O
other,O
antipsychotics,O
FANAPT,O
should,O
be,O
used,O
cautiously,O
in,O
patients,O
with,O
a,O
history,O
of,O
seizures,O
or,O
with,O
conditions,O
that,O
potentially,O
lower,O
the,O
seizure,O
threshold,O
e,O
g,O
Alzheimer,O
s,O
dementia,O
Conditions,O
that,O
lower,O
the,O
seizure,O
threshold,O
may,O
be,O
more,O
prevalent,O
in,O
a,O
population,O
of,O
65,O
years,O
or,O
older,O
5,O
7,O
Orthostatic,O
Hypotension,O
and,O
Syncope,O
FANAPT,O
can,Factor
induce,O
orthostatic hypotension,AdverseReaction
associated,O
with,O
dizziness,AdverseReaction
tachycardia,AdverseReaction
and,O
syncope,AdverseReaction
This,O
reflects,O
its,O
alpha1,O
adrenergic,O
antagonist,O
properties,O
In,O
double,O
blind,O
placebo,O
controlled,O
short,O
term,O
studies,O
where,O
the,O
dose,O
was,O
increased,O
slowly,O
as,O
recommended,O
above,O
syncope,AdverseReaction
was,O
reported,O
in,O
0,O
4,O
5,O
1344,O
of,O
patients,O
treated,O
with,O
FANAPT,O
compared,O
with,O
0,O
2,O
1,O
587,O
on,O
placebo,O
Orthostatic hypotension,AdverseReaction
was,O
reported,O
in,O
5,O
of,O
patients,O
given,O
20,O
to,O
24,O
mg,O
day,O
3,O
of,O
patients,O
given,O
10,O
to,O
16,O
mg,O
day,O
and,O
1,O
of,O
patients,O
given,O
placebo,O
More,O
rapid,O
titration,O
would,O
be,O
expected,O
to,O
increase,O
the,O
rate,O
of,O
orthostatic,O
hypotension,O
and,O
syncope,O
FANAPT,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
known,O
cardiovascular,O
disease,O
e,O
g,O
heart,O
failure,O
history,O
of,O
myocardial,O
infarction,O
ischemia,O
or,O
conduction,O
abnormalities,O
cerebrovascular,O
disease,O
or,O
conditions,O
that,O
predispose,O
the,O
patient,O
to,O
hypotension,O
dehydration,O
hypovolemia,O
and,O
treatment,O
with,O
antihypertensive,O
medications,O
Monitoring,O
of,O
orthostatic,O
vital,O
signs,O
should,O
be,O
considered,O
in,O
patients,O
who,O
are,O
vulnerable,O
to,O
hypotension,O
5,O
8,O
Leukopenia,O
Neutropenia,O
and,O
Agranulocytosis,O
In,O
clinical,O
trial,O
and,O
postmarketing,O
experience,O
events,O
of,O
leukopenia,AdverseReaction
neutropenia,AdverseReaction
have,O
been,O
reported,O
temporally,O
related,O
to,O
antipsychotic agents,DrugClass
Agranulocytosis,AdverseReaction
including,O
fatal,AdverseReaction
cases,O
has,O
also,O
been,O
reported,O
Possible,O
risk,O
factors,O
for,O
leukopenia,AdverseReaction
neutropenia,AdverseReaction
include,O
preexisting,O
low,O
white,O
blood,O
cell,O
count,O
WBC,O
and,O
history,O
of,O
drug,O
induced,O
leukopenia,O
neutropenia,O
Patients,O
with,O
a,O
pre,O
existing,O
low,O
WBC,O
or,O
a,O
history,O
of,O
drug,O
induced,O
leukopenia,O
neutropenia,O
should,O
have,O
their,O
complete,O
blood,O
count,O
CBC,O
monitored,O
frequently,O
during,O
the,O
first,O
few,O
months,O
of,O
therapy,O
and,O
should,O
discontinue,O
FANAPT,O
at,O
the,O
first,O
sign,O
of,O
a,O
decline,O
in,O
WBC,O
in,O
the,O
absence,O
of,O
other,O
causative,O
factors,O
Patients,O
with,O
neutropenia,O
should,O
be,O
carefully,O
monitored,O
for,O
fever,O
or,O
other,O
symptoms,O
or,O
signs,O
of,O
infection,O
and,O
treated,O
promptly,O
if,O
such,O
symptoms,O
or,O
signs,O
occur,O
Patients,O
with,O
severe,O
neutropenia,O
absolute,O
neutrophil,O
count,O
1000,O
mm,O
3,O
should,O
discontinue,O
FANAPT,O
and,O
have,O
their,O
WBC,O
followed,O
until,O
recovery,O
5,O
9,O
Hyperprolactinemia,O
As,O
with,O
other,O
drugs,O
that,O
antagonize,O
dopamine,O
D2,O
receptors,O
FANAPT,O
elevates prolactin levels,AdverseReaction
Hyperprolactinemia,AdverseReaction
may,Factor
suppress hypothalamic GnRH,AdverseReaction
resulting,O
in,O
reduced pituitary gonadotropin secretion,AdverseReaction
This,O
in,O
turn,O
may,Factor
inhibit reproductive function,AdverseReaction
by,O
impairing gonadalsteroidogenesis,AdverseReaction
in,O
both,O
female,O
and,O
male,O
patients,O
Galactorrhea,AdverseReaction
amenorrhea,AdverseReaction
gynecomastia,AdverseReaction
and,O
impotence,AdverseReaction
have,O
been,O
reported,O
with,O
prolactin elevating compounds,DrugClass
Long standing hyperprolactinemia,AdverseReaction
when,O
associated,O
with,O
hypogonadism,AdverseReaction
may,Factor
lead,O
to,O
decreased bone density,AdverseReaction
in,O
both,O
female,O
and,O
male,O
patients,O
Tissue,O
culture,O
experiments,O
indicate,O
that,O
approximately,O
one,O
third,O
of,O
human,O
breast,O
cancers,O
are,O
prolactin,O
dependent,O
in,O
vitro,O
a,O
factor,O
of,O
potential,O
importance,O
if,O
the,O
prescription,O
of,O
these,O
drugs,O
is,O
contemplated,O
in,O
a,O
patient,O
with,O
previously,O
detected,O
breast,O
cancer,O
Mammary gland proliferative changes,AdverseReaction
and,O
increases in serum prolactin,AdverseReaction
were,O
seen,O
in,O
mice,Animal
and,O
rats,Animal
treated,O
with,O
FANAPT,O
see,O
Nonclinical,O
Toxicology,O
13,O
1,O
Neither,O
clinical,O
studies,O
nor,O
epidemiologic,O
studies,O
conducted,O
to,O
date,O
have,O
shown,O
an,O
association,O
between,O
chronic,O
administration,O
of,O
this,O
class,O
of,O
drugs,O
and,O
tumorigenesis,O
in,O
humans,O
the,O
available,O
evidence,O
is,O
considered,O
too,O
limited,O
to,O
be,O
conclusive,O
at,O
this,O
time,O
In,O
a,O
short,O
term,O
placebo,O
controlled,O
trial,O
4,O
weeks,O
the,O
mean,O
change,O
from,O
baseline,O
to,O
endpoint,O
in,O
plasma prolactin levels,AdverseReaction
for,O
the,O
FANAPT,O
24,O
mg,O
day,O
treated,O
group,O
was,O
an,O
increase,AdverseReaction
of,O
2 6 ng mL,Severity
compared,O
to,O
a,O
decrease,O
of,O
6,O
3,O
ng,O
mL,O
in,O
the,O
placebo,O
group,O
In,O
this,O
trial,O
elevated plasma prolactin levels,AdverseReaction
were,O
observed,O
in,O
26,O
of,O
adults,O
treated,O
with,O
FANAPT,O
compared,O
to,O
12,O
in,O
the,O
placebo,O
group,O
In,O
the,O
short,O
term,O
trials,O
FANAPT,O
was,O
associated,O
with,O
modest levels,Severity
of,O
prolactin elevation,AdverseReaction
compared,O
to,O
greater,Severity
prolactin elevations,AdverseReaction
observed,O
with,O
some,O
other antipsychotic agents,DrugClass
In,O
pooled,O
analysis,O
from,O
clinical,O
studies,O
including,O
longer,O
term,O
trials,O
in,O
3210,O
adults,O
treated,O
with,O
iloperidone,O
gynecomastia,AdverseReaction
was,O
reported,O
in,O
2,O
male,O
subjects,O
0,O
1,O
compared,O
to,O
0,O
in,O
placebo,O
treated,O
patients,O
and,O
galactorrhea,AdverseReaction
was,O
reported,O
in,O
8,O
female,O
subjects,O
0,O
2,O
compared,O
to,O
3,O
female,O
subjects,O
0,O
5,O
in,O
placebo,O
treated,O
patients,O
5,O
10,O
Body,O
Temperature,O
Regulation,O
Disruption of the body s ability to reduce core body temperature,AdverseReaction
has,O
been,O
attributed,O
to,O
antipsychotic agents,DrugClass
Appropriate,O
care,O
is,O
advised,O
when,O
prescribing,O
FANAPT,O
for,O
patients,O
who,O
will,O
be,O
experiencing,O
conditions,O
which,O
may,O
contribute,O
to,O
an,O
elevation,O
in,O
core,O
body,O
temperature,O
e,O
g,O
exercising,O
strenuously,O
exposure,O
to,O
extreme,O
heat,O
receiving,O
concomitant,O
medication,O
with,O
anticholinergic,O
activity,O
or,O
being,O
subject,O
to,O
dehydration,O
5,O
11,O
Dysphagia,O
Esophageal dysmotility,AdverseReaction
and,O
aspiration,AdverseReaction
have,O
been,O
associated,O
with,O
antipsychotic drug,DrugClass
use,O
Aspiration,O
pneumonia,O
is,O
a,O
common,O
cause,O
of,O
morbidity,O
and,O
mortality,O
in,O
elderly,O
patients,O
in,O
particular,O
those,O
with,O
advanced,O
Alzheimer,O
s,O
dementia,O
FANAPT,O
and,O
other,O
antipsychotic,O
drugs,O
should,O
be,O
used,O
cautiously,O
in,O
patients,O
at,O
risk,O
for,O
aspiration,O
pneumonia,O
see,O
Boxed,O
Warning,O
5,O
12,O
Suicide,O
The,O
possibility,O
of,O
a,O
suicide,O
attempt,O
is,O
inherent,O
in,O
psychotic,O
illness,O
and,O
close,O
supervision,O
of,O
high,O
risk,O
patients,O
should,O
accompany,O
drug,O
therapy,O
Prescriptions,O
for,O
FANAPT,O
should,O
be,O
written,O
for,O
the,O
smallest,O
quantity,O
of,O
tablets,O
consistent,O
with,O
good,O
patient,O
management,O
in,O
order,O
to,O
reduce,O
the,O
risk,O
of,O
overdose,O
5,O
13,O
Priapism,O
Three,O
cases,O
of,O
priapism,AdverseReaction
were,O
reported,O
in,O
the,O
premarketing,O
FANAPT,O
program,O
Drugs with alpha adrenergic blocking effects,DrugClass
have,O
been,O
reported,O
to,O
induce,O
priapism,AdverseReaction
FANAPT,O
shares,O
this,O
pharmacologic,O
activity,O
Severe,Severity
priapism,AdverseReaction
may,O
require,O
surgical,O
intervention,O
5,O
14,O
Potential,O
for,O
Cognitive,O
and,O
Motor,O
Impairment,O
FANAPT,O
like,O
other,O
antipsychotics,O
has,O
the,O
potential,Factor
to,O
impair judgment,AdverseReaction
thinking,AdverseReaction
or,O
motor skills,AdverseReaction
In,O
short,O
term,O
placebo,O
controlled,O
trials,O
somnolence,AdverseReaction
including,O
sedation,AdverseReaction
was,O
reported,O
in,O
11,O
9,O
104,O
874,O
of,O
adult,O
patients,O
treated,O
with,O
FANAPT,O
at,O
doses,O
of,O
10,O
mg,O
day,O
or,O
greater,O
versus,O
5,O
3,O
31,O
587,O
treated,O
with,O
placebo,O
Patients,O
should,O
be,O
cautioned,O
about,O
operating,O
hazardous,O
machinery,O
including,O
automobiles,O
until,O
they,O
are,O
reasonably,O
certain,O
that,O
therapy,O
with,O
FANAPT,O
does,O
not,O
affect,O
them,O
adversely,O
""
BOXED,O
WARNING,O
WARNING,O
INCREASED,O
MORTALITY,AdverseReaction
IN,O
ELDERLY,O
PATIENTS,O
WITH,O
DEMENTIA,O
RELATED,O
PSYCHOSIS,O
WARNING,O
INCREASED,O
MORTALITY,AdverseReaction
IN,O
ELDERLY,O
PATIENTS,O
WITH,O
DEMENTIA,O
RELATED,O
PSYCHOSIS,O
Elderly,O
patients,O
with,O
dementia,O
related,O
psychosis,O
treated,O
with,O
antipsychotic drugs,DrugClass
are,O
at,O
an,O
increased,O
risk,O
of,O
death,AdverseReaction
Analysis,O
of,O
seventeen,O
placebo,O
controlled,O
trials,O
modal,O
duration,O
10,O
weeks,O
largely,O
in,O
patients,O
taking,O
atypical,O
antipsychotic,O
drugs,O
revealed,O
a,O
risk,Factor
of,O
death,AdverseReaction
in,O
the,O
drug,O
treated,O
patients,O
of,O
between,O
1,O
6,O
to,O
1,O
7,O
times,O
the,O
risk,O
of,O
death,O
in,O
placebo,O
treated,O
patients,O
Over,O
the,O
course,O
of,O
a,O
typical,O
10,O
week,O
controlled,O
trial,O
the,O
rate,O
of,O
death,AdverseReaction
in,O
drug,O
treated,O
patients,O
was,O
about,O
4,O
5,O
compared,O
to,O
a,O
rate,O
of,O
about,O
2,O
6,O
in,O
the,O
placebo,O
group,O
Although,O
the,O
causes,O
of,O
death,AdverseReaction
were,O
varied,O
most,O
of,O
the,O
deaths,AdverseReaction
appeared,O
to,O
be,O
either,O
cardiovascular,O
e,O
g,O
heart failure,AdverseReaction
sudden death,AdverseReaction
or,O
infectious,O
e,O
g,O
pneumonia,AdverseReaction
in,O
nature,O
Observational,O
studies,O
suggest,O
that,O
similar,O
to,O
atypical,O
antipsychotic,O
drugs,O
treatment,O
with,O
conventional,O
antipsychotic,O
drugs,O
may,O
increase,O
mortality,O
The,O
extent,O
to,O
which,O
the,O
findings,O
of,O
increased,O
mortality,O
in,O
observational,O
studies,O
may,O
be,O
attributed,O
to,O
the,O
antipsychotic,O
drug,O
as,O
opposed,O
to,O
some,O
characteristic,O
s,O
of,O
the,O
patients,O
is,O
not,O
clear,O
FANAPT,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
Dementia,O
Related,O
Psychosis,O
See,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
INCREASED,O
MORTALITY,AdverseReaction
IN,O
ELDERLY,O
PATIENTS,O
WITH,O
DEMENTIA,O
RELATED,O
PSYCHOSIS,O
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Elderly,O
patients,O
with,O
dementia,O
related,O
psychosis,O
treated,O
with,O
antipsychotic drugs,DrugClass
are,O
at,O
an,O
increased,O
risk,O
of,O
death,AdverseReaction
FANAPT,O
is,O
not,O
approved,O
for,O
use,O
in,O
patients,O
with,O
dementia,O
related,O
psychosis,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Commonly,O
observed,O
adverse,O
reactions,O
incidence,O
5,O
and,O
2,O
fold,O
greater,O
than,O
placebo,O
were,O
dizziness,AdverseReaction
dry mouth,AdverseReaction
fatigue,AdverseReaction
nasal congestion,AdverseReaction
orthostatic hypotension,AdverseReaction
somnolence,AdverseReaction
tachycardia,AdverseReaction
and,O
weight increased,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Novartis,O
Pharmaceuticals,O
Corporation,O
at,O
1,O
888,O
669,O
6682,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trial,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
information,O
below,O
is,O
derived,O
from,O
a,O
clinical,O
trial,O
database,O
for,O
FANAPT,O
consisting,O
of,O
2070,O
patients,O
exposed,O
to,O
FANAPT,O
at,O
doses,O
of,O
10,O
mg,O
day,O
or,O
greater,O
for,O
the,O
treatment,O
of,O
schizophrenia,O
Of,O
these,O
806,O
received,O
FANAPT,O
for,O
at,O
least,O
6,O
months,O
with,O
463,O
exposed,O
to,O
FANAPT,O
for,O
at,O
least,O
12,O
months,O
All,O
of,O
these,O
patients,O
who,O
received,O
FANAPT,O
were,O
participating,O
in,O
multiple,O
dose,O
clinical,O
trials,O
The,O
conditions,O
and,O
duration,O
of,O
treatment,O
with,O
FANAPT,O
varied,O
greatly,O
and,O
included,O
in,O
overlapping,O
categories,O
open,O
label,O
and,O
double,O
blind,O
phases,O
of,O
studies,O
inpatients,O
and,O
outpatients,O
fixed,O
dose,O
and,O
flexible,O
dose,O
studies,O
and,O
short,O
term,O
and,O
longer,O
term,O
exposure,O
Adverse,O
reactions,O
during,O
exposure,O
were,O
obtained,O
by,O
general,O
inquiry,O
and,O
recorded,O
by,O
clinical,O
investigators,O
using,O
their,O
own,O
terminology,O
Consequently,O
to,O
provide,O
a,O
meaningful,O
estimate,O
of,O
the,O
proportion,O
of,O
individuals,O
experiencing,O
adverse,O
reactions,O
reactions,O
were,O
grouped,O
in,O
standardized,O
categories,O
using,O
MedDRA,O
terminology,O
The,O
stated,O
frequencies,O
of,O
adverse,O
reactions,O
represent,O
the,O
proportions,O
of,O
individuals,O
who,O
experienced,O
a,O
treatment,O
emergent,O
adverse,O
reaction,O
of,O
the,O
type,O
listed,O
A,O
reaction,O
was,O
considered,O
treatment,O
emergent,O
if,O
it,O
occurred,O
for,O
the,O
first,O
time,O
or,O
worsened,O
while,O
receiving,O
therapy,O
following,O
baseline,O
evaluation,O
The,O
information,O
presented,O
in,O
these,O
sections,O
was,O
derived,O
from,O
pooled,O
data,O
from,O
4,O
placebo,O
controlled,O
4,O
or,O
6,O
week,O
fixed,O
or,O
flexible,O
dose,O
studies,O
in,O
patients,O
who,O
received,O
FANAPT,O
at,O
daily,O
doses,O
within,O
a,O
range,O
of,O
10,O
to,O
24,O
mg,O
n,O
874,O
Adverse,O
Reactions,O
Occurring,O
at,O
an,O
Incidence,O
of,O
2,O
or,O
More,O
among,O
FANAPT,O
Treated,O
Patients,O
and,O
More,O
Frequent,O
than,O
Placebo,O
Table,O
7,O
enumerates,O
the,O
pooled,O
incidences,O
of,O
treatment,O
emergent,O
adverse,O
reactions,O
that,O
were,O
spontaneously,O
reported,O
in,O
four,O
placebo,O
controlled,O
4,O
or,O
6,O
week,O
fixed,O
or,O
flexible,O
dose,O
studies,O
listing,O
those,O
reactions,O
that,O
occurred,O
in,O
2,O
or,O
more,O
of,O
patients,O
treated,O
with,O
FANAPT,O
in,O
any,O
of,O
the,O
dose,O
groups,O
and,O
for,O
which,O
the,O
incidence,O
in,O
FANAPT,O
treated,O
patients,O
in,O
any,O
dose,O
group,O
was,O
greater,O
than,O
the,O
incidence,O
in,O
patients,O
treated,O
with,O
placebo,O
Table,O
7,O
Percentage,O
of,O
Treatment,O
Emergent,O
Adverse,O
Reactions,O
in,O
Short,O
Term,O
Fixed,O
or,O
Flexible,O
Dose,O
Placebo,O
Controlled,O
Trials,O
in,O
Adult,O
Patients,O
Body,O
System,O
or,O
Organ,O
Class,O
Placebo,O
FANAPT,O
10,O
16,O
mg,O
day,O
FANAPT,O
20,O
24,O
mg,O
day,O
Dictionary,O
derived,O
Term,O
N,O
587,O
N,O
483,O
N,O
391,O
Body,O
as,O
a,O
Whole,O
Arthralgia,AdverseReaction
2,O
3,O
3,O
Fatigue,AdverseReaction
3,O
4,O
6,O
Musculoskeletal Stiffness,AdverseReaction
1,O
1,O
3,O
Weight Increased,AdverseReaction
1,O
1,O
9,O
Cardiac,O
Disorders,O
Tachycardia,AdverseReaction
1,O
3,O
12,O
Eye,O
Disorders,O
Vision Blurred,AdverseReaction
2,O
3,O
1,O
Gastrointestinal,O
Disorders,O
Nausea,AdverseReaction
8,O
7,O
10,O
Dry Mouth,AdverseReaction
1,O
8,O
10,O
Diarrhea,AdverseReaction
4,O
5,O
7,O
Abdominal Discomfort,AdverseReaction
1,O
1,O
3,O
Infections,O
Nasopharyngitis,AdverseReaction
3,O
4,O
3,O
Upper Respiratory Tract Infection,AdverseReaction
1,O
2,O
3,O
Nervous,O
System,O
Disorders,O
Dizziness,AdverseReaction
7,O
10,O
20,O
Somnolence,AdverseReaction
5,O
9,O
15,O
Extrapyramidal Disorder,AdverseReaction
4,O
5,O
4,O
Tremor,AdverseReaction
2,O
3,O
3,O
Lethargy,AdverseReaction
1,O
3,O
1,O
Reproductive,O
System,O
Ejaculation Failure,AdverseReaction
1,O
2,O
2,O
Respiratory,O
Nasal Congestion,AdverseReaction
2,O
5,O
8,O
Dyspnea,AdverseReaction
1,O
2,O
2,O
Skin,O
Rash,AdverseReaction
2,O
3,O
2,O
Vascular,O
Disorders,O
Orthostatic Hypotension,AdverseReaction
1,O
3,O
5,O
Hypotension,AdverseReaction
1,O
1,O
3,O
Table,O
includes,O
adverse,O
reactions,O
that,O
were,O
reported,O
in,O
2,O
or,O
more,O
of,O
patients,O
in,O
any,O
of,O
the,O
FANAPT,O
dose,O
groups,O
and,O
which,O
occurred,O
at,O
greater,O
incidence,O
than,O
in,O
the,O
placebo,O
group,O
Figures,O
rounded,O
to,O
the,O
nearest,O
integer,O
Dose,O
Related,O
Adverse,O
Reactions,O
in,O
Clinical,O
Trials,O
Based,O
on,O
the,O
pooled,O
data,O
from,O
4,O
placebo,O
controlled,O
4,O
or,O
6,O
week,O
fixed,O
or,O
flexible,O
dose,O
studies,O
adverse,O
reactions,O
that,O
occurred,O
with,O
a,O
greater,O
than,O
2,O
incidence,O
in,O
the,O
patients,O
treated,O
with,O
FANAPT,O
and,O
for,O
which,O
the,O
incidence,O
in,O
patients,O
treated,O
with,O
FANAPT,O
20,O
to,O
24,O
mg,O
day,O
were,O
twice,O
than,O
the,O
incidence,O
in,O
patients,O
treated,O
with,O
FANAPT,O
10,O
to,O
16,O
mg,O
day,O
were,O
abdominal discomfort,AdverseReaction
dizziness,AdverseReaction
hypotension,AdverseReaction
musculoskeletal stiffness,AdverseReaction
tachycardia,AdverseReaction
and,O
weight increased,AdverseReaction
Common,O
and,O
Drug,O
Related,O
Adverse,O
Reactions,O
in,O
Clinical,O
Trials,O
Based,O
on,O
the,O
pooled,O
data,O
from,O
4,O
placebo,O
controlled,O
4,O
or,O
6,O
week,O
fixed,O
or,O
flexible,O
dose,O
studies,O
the,O
following,O
adverse,O
reactions,O
occurred,O
in,O
5,O
incidence,O
in,O
the,O
patients,O
treated,O
with,O
FANAPT,O
and,O
at,O
least,O
twice,O
the,O
placebo,O
rate,O
for,O
at,O
least,O
1,O
dose,O
dizziness,AdverseReaction
dry mouth,AdverseReaction
fatigue,AdverseReaction
nasal congestion,AdverseReaction
somnolence,AdverseReaction
tachycardia,AdverseReaction
orthostatic hypotension,AdverseReaction
and,O
weight increased,AdverseReaction
Dizziness,AdverseReaction
tachycardia,AdverseReaction
and,O
weight increased,AdverseReaction
were,O
at,O
least,O
twice,O
as,O
common,O
on,O
20,O
to,O
24,O
mg,O
day,O
as,O
on,O
10,O
to,O
16,O
mg,O
day,O
Extrapyramidal,O
Symptoms,O
EPS,O
in,O
Clinical,O
Trials,O
Pooled,O
data,O
from,O
the,O
4,O
placebo,O
controlled,O
4,O
or,O
6,O
week,O
fixed,O
or,O
flexible,O
dose,O
studies,O
provided,O
information,O
regarding,O
treatment,O
emergent,O
EPS,AdverseReaction
Adverse,O
event,O
data,O
collected,O
from,O
those,O
trials,O
showed,O
the,O
following,O
rates,O
of,O
EPS related adverse events,AdverseReaction
as,O
shown,O
in,O
Table,O
8,O
Table,O
8,O
Percentage,O
of,O
EPS,AdverseReaction
Compared,O
to,O
Placebo,O
Placebo,O
FANAPT,O
10,O
16,O
mg,O
day,O
FANAPT,O
20,O
24,O
mg,O
day,O
Adverse,O
Event,O
Term,O
N,O
587,O
N,O
483,O
N,O
391,O
All,O
EPS,O
events,O
11,O
6,O
13,O
5,O
15,O
1,O
Akathisia,AdverseReaction
2,O
7,O
1,O
7,O
2,O
3,O
Bradykinesia,AdverseReaction
0,O
0,O
6,O
0,O
5,O
Dyskinesia,AdverseReaction
1,O
5,O
1,O
7,O
1,O
0,O
Dystonia,AdverseReaction
0,O
7,O
1,O
0,O
0,O
8,O
Parkinsonism,AdverseReaction
0,O
0,O
2,O
0,O
3,O
Tremor,AdverseReaction
1,O
9,O
2,O
5,O
3,O
1,O
Adverse,O
Reactions,O
Associated,O
with,O
Discontinuation,O
of,O
Treatment,O
in,O
Clinical,O
Trials,O
Based,O
on,O
the,O
pooled,O
data,O
from,O
4,O
placebo,O
controlled,O
4,O
or,O
6,O
week,O
fixed,O
or,O
flexible,O
dose,O
studies,O
there,O
was,O
no,O
difference,O
in,O
the,O
incidence,O
of,O
discontinuation,O
due,O
to,O
adverse,O
events,O
between,O
FANAPT,O
treated,O
5,O
and,O
placebo,O
treated,O
5,O
patients,O
The,O
types,O
of,O
adverse,O
events,O
that,O
led,O
to,O
discontinuation,O
were,O
similar,O
for,O
the,O
FANAPT,O
and,O
placebo,O
treated,O
patients,O
Demographic,O
Differences,O
in,O
Adverse,O
Reactions,O
in,O
Clinical,O
Trials,O
An,O
examination,O
of,O
population,O
subgroups,O
in,O
the,O
4,O
placebo,O
controlled,O
4,O
or,O
6,O
week,O
fixed,O
or,O
flexible,O
dose,O
studies,O
did,O
not,O
reveal,O
any,O
evidence,O
of,O
differences,O
in,O
safety,O
on,O
the,O
basis,O
of,O
age,O
gender,O
or,O
race,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Laboratory,O
Test,O
Abnormalities,O
in,O
Clinical,O
Trials,O
There,O
were,O
no,O
differences,O
between,O
FANAPT,O
and,O
placebo,O
in,O
the,O
incidence,O
of,O
discontinuation,O
due,O
to,O
changes,O
in,O
hematology,O
urinalysis,O
or,O
serum,O
chemistry,O
In,O
short,O
term,O
placebo,O
controlled,O
trials,O
4,O
to,O
6,O
weeks,O
there,O
were,O
1,O
0,O
13,O
1342,O
iloperidone,O
treated,O
patients,O
with,O
hematocrit,AdverseReaction
at,O
least,O
one,O
time,O
below the extended normal range,AdverseReaction
during,O
post,O
randomization,O
treatment,O
compared,O
to,O
0,O
3,O
2,O
585,O
on,O
placebo,O
The,O
extended,O
normal,O
range,O
for,O
lowered,O
hematocrit,O
was,O
defined,O
in,O
each,O
of,O
these,O
trials,O
as,O
the,O
value,O
15,O
below,O
the,O
normal,O
range,O
for,O
the,O
centralized,O
laboratory,O
that,O
was,O
used,O
in,O
the,O
trial,O
Other,O
Reactions,O
During,O
the,O
Premarketing,O
Evaluation,O
of,O
FANAPT,O
The,O
following,O
is,O
a,O
list,O
of,O
MedDRA,O
terms,O
that,O
reflect,O
treatment,O
emergent,O
adverse,O
reactions,O
in,O
patients,O
treated,O
with,O
FANAPT,O
at,O
multiple,O
doses,O
4,O
mg,O
day,O
during,O
any,O
phase,O
of,O
a,O
trial,O
with,O
the,O
database,O
of,O
3210,O
FANAPT,O
treated,O
patients,O
All,O
reported,O
reactions,O
are,O
included,O
except,O
those,O
already,O
listed,O
in,O
Table,O
7,O
or,O
other,O
parts,O
of,O
the,O
Adverse,O
Reactions,O
6,O
section,O
those,O
considered,O
in,O
the,O
Warnings,O
and,O
Precautions,O
5,O
those,O
reaction,O
terms,O
which,O
were,O
so,O
general,O
as,O
to,O
be,O
uninformative,O
reactions,O
reported,O
in,O
fewer,O
than,O
3,O
patients,O
and,O
which,O
were,O
neither,O
serious,O
nor,O
life,O
threatening,O
reactions,O
that,O
are,O
otherwise,O
common,O
as,O
background,O
reactions,O
and,O
reactions,O
considered,O
unlikely,O
to,O
be,O
drug,O
related,O
It,O
is,O
important,O
to,O
emphasize,O
that,O
although,O
the,O
reactions,O
reported,O
occurred,O
during,O
treatment,O
with,O
FANAPT,O
they,O
were,O
not,O
necessarily,O
caused,O
by,O
it,O
Reactions,O
are,O
further,O
categorized,O
by,O
MedDRA,O
system,O
organ,O
class,O
and,O
listed,O
in,O
order,O
of,O
decreasing,O
frequency,O
according,O
to,O
the,O
following,O
definitions,O
frequent,O
adverse,O
events,O
are,O
those,O
occurring,O
in,O
at,O
least,O
1,O
100,O
patients,O
only,O
those,O
not,O
listed,O
in,O
Table,O
7,O
appear,O
in,O
this,O
listing,O
infrequent,O
adverse,O
reactions,O
are,O
those,O
occurring,O
in,O
1,O
100,O
to,O
1,O
1000,O
patients,O
rare,O
events,O
are,O
those,O
occurring,O
in,O
fewer,O
than,O
1,O
1000,O
patients,O
Blood,O
and,O
Lymphatic,O
Disorders,O
Infrequent,O
anemia,AdverseReaction
iron deficiency anemia,AdverseReaction
Rare,O
leukopenia,AdverseReaction
Cardiac,O
Disorders,O
Frequent,O
palpitations,AdverseReaction
Rare,O
arrhythmia,AdverseReaction
atrioventricular block,AdverseReaction
first degree,Severity
cardiac failure failure failure,AdverseReaction
including,O
congestive,AdverseReaction
and,O
acute,AdverseReaction
Ear,O
and,O
Labyrinth,O
Disorders,O
Infrequent,O
vertigo,AdverseReaction
tinnitus,AdverseReaction
Endocrine,O
Disorders,O
Infrequent,O
hypothyroidism,AdverseReaction
Eye,O
Disorders,O
Frequent,O
conjunctivitis,AdverseReaction
including,O
allergic,AdverseReaction
Infrequent,O
dry eye,AdverseReaction
blepharitis,AdverseReaction
eyelid edema,AdverseReaction
eye swelling,AdverseReaction
lenticular opacities,AdverseReaction
cataract,AdverseReaction
hyperemia,AdverseReaction
including,O
conjunctival,AdverseReaction
Gastrointestinal,O
Disorders,O
Infrequent,O
gastritis,AdverseReaction
salivary hypersecretion,AdverseReaction
fecal incontinence,AdverseReaction
mouth ulceration,AdverseReaction
Rare,O
aphthous stomatitis,AdverseReaction
duodenal ulcer,AdverseReaction
hiatus hernia,AdverseReaction
hyperchlorhydria,AdverseReaction
lip ulceration,AdverseReaction
reflux esophagitis,AdverseReaction
stomatitis,AdverseReaction
General,O
Disorders,O
and,O
Administrative,O
Site,O
Conditions,O
Infrequent,O
edema,AdverseReaction
general,AdverseReaction
pitting,AdverseReaction
due,O
to,O
cardiac,O
disease,O
difficulty in walking,AdverseReaction
thirst,AdverseReaction
Rare,O
hyperthermia,AdverseReaction
Hepatobiliary,O
Disorders,O
Infrequent,O
cholelithiasis,AdverseReaction
Investigations,O
Frequent,O
weight decreased,AdverseReaction
Infrequent,O
hemoglobin decreased,AdverseReaction
neutrophil count increased,AdverseReaction
hematocrit decreased,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorders,O
Infrequent,O
increased appetite,AdverseReaction
dehydration,AdverseReaction
hypokalemia,AdverseReaction
fluid retention,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Frequent,O
myalgia,AdverseReaction
muscle spasms,AdverseReaction
Rare,O
torticollis,AdverseReaction
Nervous,O
System,O
Disorders,O
Infrequent,O
paresthesia,AdverseReaction
psychomotor hyperactivity,AdverseReaction
restlessness,AdverseReaction
amnesia,AdverseReaction
nystagmus,AdverseReaction
Rare,O
restless legs syndrome,AdverseReaction
Psychiatric,O
Disorders,O
Frequent,O
restlessness,AdverseReaction
aggression,AdverseReaction
delusion,AdverseReaction
Infrequent,O
hostility,AdverseReaction
libido decreased,AdverseReaction
paranoia,AdverseReaction
anorgasmia,AdverseReaction
confusional state,AdverseReaction
mania,AdverseReaction
catatonia,AdverseReaction
mood swings,AdverseReaction
panic attack,AdverseReaction
obsessive compulsive disorder,AdverseReaction
bulimia nervosa,AdverseReaction
delirium,AdverseReaction
polydipsia psychogenic,AdverseReaction
impulse control disorder,AdverseReaction
major depression,AdverseReaction
Renal,O
and,O
Urinary,O
Disorders,O
Frequent,O
urinary incontinence,AdverseReaction
Infrequent,O
dysuria,AdverseReaction
pollakiuria,AdverseReaction
enuresis,AdverseReaction
nephrolithiasis,AdverseReaction
Rare,O
urinary retention,AdverseReaction
renal failure acute,AdverseReaction
Reproductive,O
System,O
and,O
Breast,O
Disorders,O
Frequent,O
erectile dysfunction,AdverseReaction
Infrequent,O
testicular pain,AdverseReaction
amenorrhea,AdverseReaction
breast pain,AdverseReaction
Rare,O
menstruation irregular,AdverseReaction
gynecomastia,AdverseReaction
menorrhagia,AdverseReaction
metrorrhagia,AdverseReaction
postmenopausal hemorrhage,AdverseReaction
prostatitis,AdverseReaction
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Infrequent,O
epistaxis,AdverseReaction
asthma,AdverseReaction
rhinorrhea,AdverseReaction
sinus congestion,AdverseReaction
nasal dryness,AdverseReaction
Rare,O
dry throat,AdverseReaction
sleep apnea syndrome,AdverseReaction
dyspnea exertional,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
FANAPT,O
retrograde ejaculation,AdverseReaction
Because,O
these,O
reactions,O
were,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypotension,AdverseReaction
Before,O
initiating,O
FARXIGA,O
assess,O
volume,O
status,O
and,O
correct,O
hypovolemia,O
in,O
the,O
elderly,O
in,O
patients,O
with,O
renal,O
impairment,O
or,O
low,O
systolic,O
blood,O
pressure,O
and,O
in,O
patients,O
on,O
diuretics,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
during,O
therapy,O
5,O
1,O
6,O
1,O
Impairment in renal function,AdverseReaction
Monitor,O
renal,O
function,O
during,O
therapy,O
5,O
2,O
Hypoglycemia,AdverseReaction
In,O
patients,O
taking,O
insulin,O
or,O
an,O
insulin,O
secretagogue,O
with,O
FARXIGA,O
consider,O
a,O
lower,O
dose,O
of,O
insulin,O
or,O
the,O
insulin,O
secretagogue,O
to,O
reduce,O
the,O
risk,O
of,O
hypoglycemia,O
5,O
3,O
Genital mycotic infections,AdverseReaction
Monitor,O
and,O
treat,O
if,O
indicated,O
5,O
4,O
Increased LDL C,AdverseReaction
Monitor,O
and,O
treat,O
per,O
standard,O
of,O
care,O
5,O
5,O
Bladder Cancer,AdverseReaction
An,O
imbalance,O
in,O
bladder cancers,AdverseReaction
was,O
observed,O
in,O
clinical,O
trials,O
FARXIGA,O
should,O
not,O
be,O
used,O
in,O
patients,O
with,O
active,O
bladder,O
cancer,O
and,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
a,O
prior,O
history,O
of,O
bladder,O
cancer,O
5,O
6,O
Macrovascular,O
outcomes,O
There,O
have,O
been,O
no,O
clinical,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
FARXIGA,O
or,O
any,O
other,O
antidiabetic,O
drug,O
5,O
7,O
5,O
1,O
Hypotension,O
FARXIGA,O
causes,O
intravascular volume contraction,AdverseReaction
Symptomatic hypotension,AdverseReaction
can,Factor
occur,O
after,O
initiating,O
FARXIGA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
particularly,O
in,O
patients,O
with,O
impaired,O
renal,O
function,O
eGFR,O
less,O
than,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
elderly,O
patients,O
or,O
patients,O
on,O
loop,O
diuretics,O
Before,O
initiating,O
FARXIGA,O
in,O
patients,O
with,O
one,O
or,O
more,O
of,O
these,O
characteristics,O
volume,O
status,O
should,O
be,O
assessed,O
and,O
corrected,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
of,O
hypotension,O
after,O
initiating,O
therapy,O
5,O
2,O
Impairment,O
in,O
Renal,O
Function,O
FARXIGA,O
increases serum creatinine,AdverseReaction
and,O
decreases eGFR,AdverseReaction
Elderly,O
patients,O
and,O
patients,O
with,O
impaired,O
renal,O
function,O
may,O
be,O
more,O
susceptible,O
to,O
these,O
changes,O
Adverse,AdverseReaction
reactions,O
related,O
to,O
renal function,AdverseReaction
can,Factor
occur,O
after,O
initiating,O
FARXIGA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Renal,O
function,O
should,O
be,O
evaluated,O
prior,O
to,O
initiation,O
of,O
FARXIGA,O
and,O
monitored,O
periodically,O
thereafter,O
5,O
3,O
Hypoglycemia,O
with,O
Concomitant,O
Use,O
with,O
Insulin,O
and,O
Insulin,O
Secretagogues,O
Insulin,O
and,O
insulin,O
secretagogues,O
are,O
known,O
to,O
cause,O
hypoglycemia,O
FARXIGA,O
can,Factor
increase,O
the,O
risk,O
of,O
hypoglycemia,AdverseReaction
when,O
combined,O
with,O
insulin,O
or,O
an,O
insulin,O
secretagogue,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Therefore,O
a,O
lower,O
dose,O
of,O
insulin,O
or,O
insulin,O
secretagogue,O
may,O
be,O
required,O
to,O
minimize,O
the,O
risk,O
of,O
hypoglycemia,O
when,O
these,O
agents,O
are,O
used,O
in,O
combination,O
with,O
FARXIGA,O
5,O
4,O
Genital,O
Mycotic,O
Infections,O
FARXIGA,O
increases,O
the,O
risk,Factor
of,O
genital mycotic infections,AdverseReaction
Patients,O
with,O
a,O
history,O
of,O
genital,O
mycotic,O
infections,O
were,O
more,O
likely,O
to,O
develop,O
genital mycotic infections,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
and,O
treat,O
appropriately,O
5,O
5,O
Increases,O
in,O
Low,O
Density,O
Lipoprotein,O
Cholesterol,O
LDL,O
C,O
Increases in LDL C,AdverseReaction
occur,O
with,O
FARXIGA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
LDL,O
C,O
and,O
treat,O
per,O
standard,O
of,O
care,O
after,O
initiating,O
FARXIGA,O
5,O
6,O
Bladder,O
Cancer,O
Across,O
22,O
clinical,O
studies,O
newly,O
diagnosed,O
cases,O
of,O
bladder cancer,AdverseReaction
were,O
reported,O
in,O
10,O
6045,O
patients,O
0,O
17,O
treated,O
with,O
FARXIGA,O
and,O
1,O
3512,O
patient,O
0,O
03,O
treated,O
with,O
placebo,O
comparator,O
After,O
excluding,O
patients,O
in,O
whom,O
exposure,O
to,O
study,O
drug,O
was,O
less,O
than,O
one,O
year,O
at,O
the,O
time,O
of,O
diagnosis,O
of,O
bladder cancer,AdverseReaction
there,O
were,O
4,O
cases,O
with,O
FARXIGA,O
and,O
no,O
cases,O
with,O
placebo,O
comparator,O
Bladder,O
cancer,O
risk,O
factors,O
and,O
hematuria,O
a,O
potential,O
indicator,O
of,O
pre,O
existing,O
tumors,O
were,O
balanced,O
between,O
treatment,O
arms,O
at,O
baseline,O
There,O
were,O
too,O
few,O
cases,O
to,O
determine,O
whether,O
the,O
emergence,O
of,O
these,O
events,O
is,O
related,O
to,O
FARXIGA,O
There,O
are,O
insufficient,O
data,O
to,O
determine,O
whether,O
FARXIGA,O
has,O
an,O
effect,O
on,O
pre,O
existing,O
bladder,O
tumors,O
Consequently,O
FARXIGA,O
should,O
not,O
be,O
used,O
in,O
patients,O
with,O
active,O
bladder,O
cancer,O
In,O
patients,O
with,O
prior,O
history,O
of,O
bladder,O
cancer,O
the,O
benefits,O
of,O
glycemic,O
control,O
versus,O
unknown,O
risks,O
for,O
cancer,O
recurrence,O
with,O
FARXIGA,O
should,O
be,O
considered,O
5,O
7,O
Macrovascular,O
Outcomes,O
There,O
have,O
been,O
no,O
clinical,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
FARXIGA,O
or,O
any,O
other,O
antidiabetic,O
drug,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
important,O
adverse,O
reactions,O
are,O
described,O
below,O
and,O
elsewhere,O
in,O
the,O
labeling,O
Hypotension,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Impairment in Renal Function,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hypoglycemia,AdverseReaction
with,O
Concomitant,O
Use,O
with,O
Insulin,O
and,O
Insulin,O
Secretagogues,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Genital Mycotic Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Increases in Low Density Lipoprotein Cholesterol,AdverseReaction
LDL,O
C,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Bladder Cancer,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
The,O
most,O
common,O
adverse,O
reactions,O
associated,O
with,O
FARXIGA,O
5,O
or,O
greater,O
incidence,O
were,O
female genital mycotic infections,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
urinary tract infections,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
AstraZeneca,O
at,O
1,O
800,O
236,O
9933,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Pool,O
of,O
12,O
Placebo,O
Controlled,O
Studies,O
for,O
FARXIGA,O
5,O
and,O
10,O
mg,O
The,O
data,O
in,O
Table,O
1,O
is,O
derived,O
from,O
12,O
placebo,O
controlled,O
studies,O
ranging,O
from,O
12,O
to,O
24,O
weeks,O
In,O
4,O
studies,O
FARXIGA,O
was,O
used,O
as,O
monotherapy,O
and,O
in,O
8,O
studies,O
FARXIGA,O
was,O
used,O
as,O
add,O
on,O
to,O
background,O
antidiabetic,O
therapy,O
or,O
as,O
combination,O
therapy,O
with,O
metformin,O
see,O
Clinical,O
Studies,O
14,O
These,O
data,O
reflect,O
exposure,O
of,O
2338,O
patients,O
to,O
FARXIGA,O
with,O
a,O
mean,O
exposure,O
duration,O
of,O
21,O
weeks,O
Patients,O
received,O
placebo,O
N,O
1393,O
FARXIGA,O
5,O
mg,O
N,O
1145,O
or,O
FARXIGA,O
10,O
mg,O
N,O
1193,O
once,O
daily,O
The,O
mean,O
age,O
of,O
the,O
population,O
was,O
55,O
years,O
and,O
2,O
were,O
older,O
than,O
75,O
years,O
of,O
age,O
Fifty,O
percent,O
50,O
of,O
the,O
population,O
were,O
male,O
81,O
were,O
White,O
14,O
were,O
Asian,O
and,O
3,O
were,O
Black,O
or,O
African,O
American,O
At,O
baseline,O
the,O
population,O
had,O
diabetes,O
for,O
an,O
average,O
of,O
6,O
years,O
had,O
a,O
mean,O
hemoglobin,O
A1c,O
HbA1c,O
of,O
8,O
3,O
and,O
21,O
had,O
established,O
microvascular,O
complications,O
of,O
diabetes,O
Baseline,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
in,O
92,O
of,O
patients,O
and,O
moderately,O
impaired,O
in,O
8,O
of,O
patients,O
mean,O
eGFR,O
86,O
mL,O
min,O
1,O
73,O
m,O
2,O
Table,O
1,O
shows,O
common,O
adverse,O
reactions,O
associated,O
with,O
the,O
use,O
of,O
FARXIGA,O
These,O
adverse,O
reactions,O
were,O
not,O
present,O
at,O
baseline,O
occurred,O
more,O
commonly,O
on,O
FARXIGA,O
than,O
on,O
placebo,O
and,O
occurred,O
in,O
at,O
least,O
2,O
of,O
patients,O
treated,O
with,O
either,O
FARXIGA,O
5,O
mg,O
or,O
FARXIGA,O
10,O
mg,O
Table,O
1,O
Adverse,O
Reactions,O
in,O
Placebo,O
Controlled,O
Studies,O
Reported,O
in,O
2,O
of,O
Patients,O
Treated,O
with,O
FARXIGA,O
Adverse,O
Reaction,O
of,O
Patients,O
Pool,O
of,O
12,O
Placebo,O
Controlled,O
Studies,O
Placebo,O
N,O
1393,O
FARXIGA,O
5,O
mg,O
N,O
1145,O
FARXIGA,O
10,O
mg,O
N,O
1193,O
Female,O
genital,O
mycotic,O
infectionsGenital,O
mycotic,O
infections,O
include,O
the,O
following,O
adverse,O
reactions,O
listed,O
in,O
order,O
of,O
frequency,O
reported,O
for,O
females,AdverseReaction
vulvovaginal mycotic infection,AdverseReaction
vaginal infection,AdverseReaction
vulvovaginal candidiasis,AdverseReaction
vulvovaginitis,AdverseReaction
genital infection,AdverseReaction
genital candidiasis,AdverseReaction
fungal genital infection,AdverseReaction
vulvitis,AdverseReaction
genitourinary tract infection,AdverseReaction
vulval abscess,AdverseReaction
and,O
vaginitis bacterial,AdverseReaction
N,O
for,O
females,O
Placebo,O
677,O
FARXIGA,O
5,O
mg,O
581,O
FARXIGA,O
10,O
mg,O
598,O
1,O
5,O
8,O
4,O
6,O
9,O
Nasopharyngitis,AdverseReaction
6,O
2,O
6,O
6,O
6,O
3,O
Urinary,O
tract,O
infectionsUrinary,O
tract,O
infections,O
include,O
the,O
following,O
adverse,O
reactions,O
listed,O
in,O
order,O
of,O
frequency,O
reported,O
urinary tract infection,AdverseReaction
cystitis,AdverseReaction
Escherichia urinary tract infection,AdverseReaction
genitourinary tract infection,AdverseReaction
pyelonephritis,AdverseReaction
trigonitis,AdverseReaction
urethritis,AdverseReaction
kidney infection,AdverseReaction
and,O
prostatitis,AdverseReaction
3,O
7,O
5,O
7,O
4,O
3,O
Back pain,AdverseReaction
3,O
2,O
3,O
1,O
4,O
2,O
Increased,O
urinationIncreased,O
urination,O
includes,O
the,O
following,O
adverse,O
reactions,O
listed,O
in,O
order,O
of,O
frequency,O
reported,O
pollakiuria,AdverseReaction
polyuria,AdverseReaction
and,O
urine output increased,AdverseReaction
1,O
7,O
2,O
9,O
3,O
8,O
Male,O
genital,O
mycotic,O
infectionsGenital,O
mycotic,O
infections,O
include,O
the,O
following,O
adverse,O
reactions,O
listed,O
in,O
order,O
of,O
frequency,O
reported,O
for,O
males,AdverseReaction
balanitis,AdverseReaction
fungal genital infection,AdverseReaction
balanitis candida,AdverseReaction
genital candidiasis,AdverseReaction
genital infection male,AdverseReaction
penile infection,AdverseReaction
balanoposthitis,AdverseReaction
balanoposthitis infective,AdverseReaction
genital infection,AdverseReaction
posthitis,AdverseReaction
N,O
for,O
males,O
Placebo,O
716,O
FARXIGA,O
5,O
mg,O
564,O
FARXIGA,O
10,O
mg,O
595,O
0,O
3,O
2,O
8,O
2,O
7,O
Nausea,AdverseReaction
2,O
4,O
2,O
8,O
2,O
5,O
Influenza,AdverseReaction
2,O
3,O
2,O
7,O
2,O
3,O
Dyslipidemia,AdverseReaction
1,O
5,O
2,O
1,O
2,O
5,O
Constipation,AdverseReaction
1,O
5,O
2,O
2,O
1,O
9,O
Discomfort with urination,AdverseReaction
0,O
7,O
1,O
6,O
2,O
1,O
Pain in extremity,AdverseReaction
1,O
4,O
2,O
0,O
1,O
7,O
Pool,O
of,O
13,O
Placebo,O
Controlled,O
Studies,O
for,O
FARXIGA,O
10,O
mg,O
The,O
safety,O
and,O
tolerability,O
of,O
FARXIGA,O
10,O
mg,O
was,O
also,O
evaluated,O
in,O
a,O
larger,O
placebo,O
controlled,O
study,O
pool,O
This,O
pool,O
combined,O
13,O
placebo,O
controlled,O
studies,O
including,O
3,O
monotherapy,O
studies,O
9,O
add,O
on,O
to,O
background,O
antidiabetic,O
therapy,O
studies,O
and,O
an,O
initial,O
combination,O
with,O
metformin,O
study,O
Across,O
these,O
13,O
studies,O
2360,O
patients,O
were,O
treated,O
once,O
daily,O
with,O
FARXIGA,O
10,O
mg,O
for,O
a,O
mean,O
duration,O
of,O
exposure,O
of,O
22,O
weeks,O
The,O
mean,O
age,O
of,O
the,O
population,O
was,O
59,O
years,O
and,O
4,O
were,O
older,O
than,O
75,O
years,O
Fifty,O
eight,O
percent,O
58,O
of,O
the,O
population,O
were,O
male,O
84,O
were,O
White,O
9,O
were,O
Asian,O
and,O
3,O
were,O
Black,O
or,O
African,O
American,O
At,O
baseline,O
the,O
population,O
had,O
diabetes,O
for,O
an,O
average,O
of,O
9,O
years,O
had,O
a,O
mean,O
HbA1c,O
of,O
8,O
2,O
and,O
30,O
had,O
established,O
microvascular,O
disease,O
Baseline,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
in,O
88,O
of,O
patients,O
and,O
moderately,O
impaired,O
in,O
11,O
of,O
patients,O
mean,O
eGFR,O
82,O
mL,O
min,O
1,O
73,O
m,O
2,O
Volume,O
Depletion,O
FARXIGA,O
causes,O
an,O
osmotic diuresis,AdverseReaction
which,O
may,Factor
lead,O
to,O
reductions in intravascular volume,AdverseReaction
Adverse,O
reactions,O
related,O
to,O
volume depletion,AdverseReaction
including,O
reports,O
of,O
dehydration,AdverseReaction
hypovolemia,AdverseReaction
orthostatic hypotension,AdverseReaction
or,O
hypotension,AdverseReaction
are,O
shown,O
in,O
Table,O
2,O
for,O
the,O
12,O
study,O
and,O
13,O
study,O
short,O
term,O
placebo,O
controlled,O
pools,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Table,O
2,O
Adverse,O
Reactions,O
of,O
Volume,O
DepletionVolume,O
depletion,O
includes,O
reports,O
of,O
dehydration,AdverseReaction
hypovolemia,AdverseReaction
orthostatic hypotension,AdverseReaction
or,O
hypotension,AdverseReaction
in,O
Clinical,O
Studies,O
with,O
FARXIGA,O
Pool,O
of,O
12,O
Placebo,O
Controlled,O
Studies,O
Pool,O
of,O
13,O
Placebo,O
Controlled,O
Studies,O
Placebo,O
FARXIGA,O
5,O
mg,O
FARXIGA,O
10,O
mg,O
Placebo,O
FARXIGA,O
10,O
mg,O
Overall,O
population,O
N,O
N,O
1393,O
5,O
0,O
4,O
N,O
1145,O
7,O
0,O
6,O
N,O
1193,O
9,O
0,O
8,O
N,O
2295,O
17,O
0,O
7,O
N,O
2360,O
27,O
1,O
1,O
Patient,O
Subgroup,O
n,O
Patients,O
on,O
loop,O
diuretics,O
n,O
551,O
1,O
8,O
n,O
400,O
n,O
313,O
9,O
7,O
n,O
2674,O
1,O
5,O
n,O
2366,O
2,O
5,O
Patients,O
with,O
moderate,O
renal,O
impairment,O
with,O
eGFR,O
30,O
and,O
60,O
mL,O
min,O
1,O
73,O
m2,O
n,O
1072,O
1,O
9,O
n,O
1071,O
0,O
9,O
n,O
891,O
1,O
1,O
n,O
2684,O
1,O
5,O
n,O
2655,O
1,O
9,O
Patients,O
65,O
years,O
of,O
age,O
n,O
2761,O
0,O
4,O
n,O
2161,O
0,O
5,O
n,O
2043,O
1,O
5,O
n,O
7116,O
0,O
8,O
n,O
66511,O
1,O
7,O
Impairment,O
of,O
Renal,O
Function,O
Use,O
of,O
FARXIGA,O
was,O
associated,O
with,O
increases in serum creatinine,AdverseReaction
and,O
decreases in eGFR,AdverseReaction
see,O
Table,O
3,O
In,O
patients,O
with,O
normal,O
or,O
mildly,O
impaired,O
renal,O
function,O
at,O
baseline,O
serum,O
creatinine,O
and,O
eGFR,O
returned,O
to,O
baseline,O
values,O
at,O
Week,O
24,O
Renal related adverse reactions,AdverseReaction
including,O
renal failure,AdverseReaction
and,O
blood creatinine increase,AdverseReaction
were,O
more,O
frequent,O
in,O
patients,O
treated,O
with,O
FARXIGA,O
see,O
Table,O
4,O
Elderly,O
patients,O
and,O
patients,O
with,O
impaired,O
renal,O
function,O
were,O
more,O
susceptible,O
to,O
these,O
adverse,O
reactions,O
see,O
Table,O
4,O
Sustained,O
decreases,O
in,O
eGFR,O
were,O
seen,O
in,O
patients,O
with,O
moderate,O
renal,O
impairment,O
eGFR,O
30,O
to,O
less,O
than,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
Table,O
3,O
Changes,O
in,O
Serum,O
Creatinine,O
and,O
eGFR,O
Associated,O
with,O
FARXIGA,O
in,O
the,O
Pool,O
of,O
12,O
Placebo,O
Controlled,O
Studies,O
and,O
Moderate,O
Renal,O
Impairment,O
Study,O
Pool,O
of,O
12,O
Placebo,O
Controlled,O
Studies,O
PlaceboN,O
1393,O
FARXIGA,O
5,O
mgN,O
1145,O
FARXIGA,O
10,O
mgN,O
1193,O
Baseline,O
Mean,O
Serum,O
Creatinine,O
mg,O
dL,O
0,O
853,O
0,O
860,O
0,O
847,O
eGFR,O
mL,O
min,O
1,O
73,O
m2,O
86,O
0,O
85,O
3,O
86,O
7,O
Week,O
1,O
Change,O
Serum,O
Creatinine,O
mg,O
dL,O
0,O
003,O
0,O
029,O
0,O
041,O
eGFR,O
mL,O
min,O
1,O
73,O
m2,O
0,O
4,O
2,O
9,O
4,O
1,O
Week,O
24,O
Change,O
Serum,O
Creatinine,O
mg,O
dL,O
0,O
005,O
0,O
001,O
0,O
001,O
eGFR,O
mL,O
min,O
1,O
73,O
m2,O
0,O
8,O
0,O
8,O
0,O
3,O
Moderate,O
Renal,O
Impairment,O
Study,O
PlaceboN,O
84,O
FARXIGA,O
5,O
mgN,O
83,O
FARXIGA,O
10,O
mgN,O
85,O
Baseline,O
Mean,O
Serum,O
Creatinine,O
mg,O
dL,O
1,O
46,O
1,O
53,O
1,O
52,O
eGFR,O
mL,O
min,O
1,O
73,O
m2,O
45,O
6,O
44,O
2,O
43,O
9,O
Week,O
1,O
Change,O
Serum,O
Creatinine,O
mg,O
dL,O
0,O
01,O
0,O
13,O
0,O
18,O
eGFR,O
mL,O
min,O
1,O
73,O
m2,O
0,O
5,O
3,O
8,O
5,O
5,O
Week,O
24,O
Change,O
Serum,O
Creatinine,O
mg,O
dL,O
0,O
02,O
0,O
08,O
0,O
16,O
eGFR,O
mL,O
min,O
1,O
73,O
m2,O
0,O
03,O
4,O
0,O
7,O
4,O
Week,O
52,O
Change,O
Serum,O
Creatinine,O
mg,O
dL,O
0,O
10,O
0,O
06,O
0,O
15,O
eGFR,O
mL,O
min,O
1,O
73,O
m2,O
2,O
6,O
4,O
2,O
7,O
3,O
Table,O
4,O
Proportion,O
of,O
Patients,O
with,O
at,O
Least,O
One,O
Renal Impairment Related Adverse Reaction,AdverseReaction
Pool,O
of,O
6,O
Placebo,O
Controlled,O
Studies,O
up,O
to,O
104,O
weeks,O
Pool,O
of,O
9,O
Placebo,O
Controlled,O
Studies,O
up,O
to,O
104,O
weeks,O
Baseline,O
Characteristic,O
Placebo,O
FARXIGA,O
5,O
mg,O
FARXIGA,O
10,O
mg,O
Placebo,O
FARXIGA,O
10,O
mg,O
Overall,O
populationPatients,O
with,O
at,O
least,O
one,O
event,O
n,O
78513,O
1,O
7,O
n,O
76714,O
1,O
8,O
n,O
85916,O
1,O
9,O
n,O
195682,O
4,O
2,O
n,O
2026136,O
6,O
7,O
65,O
years,O
of,O
age,O
and,O
older,O
Patients,O
with,O
at,O
least,O
one,O
event,O
n,O
1904,O
2,O
1,O
n,O
1625,O
3,O
1,O
n,O
1596,O
3,O
8,O
n,O
65552,O
7,O
9,O
n,O
62087,O
14,O
0,O
eGFR,O
30,O
and,O
60,O
mL,O
min,O
1,O
73,O
m2Patients,O
with,O
at,O
least,O
one,O
event,O
n,O
775,O
6,O
5,O
n,O
887,O
8,O
0,O
n,O
75,O
9,O
12,O
0,O
n,O
24940,O
16,O
1,O
n,O
25171,O
28,O
3,O
65,O
years,O
of,O
age,O
and,O
older,O
and,O
eGFR,O
30,O
and,O
60,O
mL,O
min,O
1,O
73,O
m2Patients,O
with,O
at,O
least,O
one,O
event,O
n,O
412,O
4,O
9,O
n,O
433,O
7,O
0,O
n,O
354,O
11,O
4,O
n,O
14127,O
19,O
1,O
n,O
13447,O
35,O
1,O
The,O
safety,O
of,O
FARXIGA,O
was,O
evaluated,O
in,O
a,O
study,O
of,O
patients,O
with,O
moderate,O
renal,O
impairment,O
eGFR,O
30,O
to,O
less,O
than,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
see,O
Clinical,O
Studies,O
14,O
In,O
this,O
study,O
13,O
patients,O
experienced,O
bone fractures,AdverseReaction
for,O
treatment,O
durations,O
up,O
to,O
104,O
weeks,O
No,O
fractures,AdverseReaction
occurred,O
in,O
the,O
placebo,O
group,O
5,O
occurred,O
in,O
the,O
FARXIGA,O
5,O
mg,O
group,O
and,O
8,O
occurred,O
in,O
the,O
FARXIGA,O
10,O
mg,O
group,O
Eight,O
of,O
these,O
13,O
fractures,AdverseReaction
were,O
in,O
patients,O
who,O
had,O
a,O
baseline,O
eGFR,O
of,O
30,O
to,O
45,O
mL,O
min,O
1,O
73,O
m,O
2,O
Eleven,O
of,O
the,O
13,O
fractures,AdverseReaction
were,O
reported,O
within,O
the,O
first,O
52,O
weeks,O
There,O
was,O
no,O
apparent,O
pattern,O
with,O
respect,O
to,O
the,O
anatomic,O
site,O
of,O
fracture,AdverseReaction
Hypoglycemia,O
The,O
frequency,O
of,O
hypoglycemia,AdverseReaction
by,O
study,O
see,O
Clinical,O
Studies,O
14,O
is,O
shown,O
in,O
Table,O
5,O
Hypoglycemia,AdverseReaction
was,O
more,O
frequent,O
when,O
FARXIGA,O
was,O
added,O
to,O
sulfonylurea,O
or,O
insulin,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Table,O
5,O
Incidence,O
of,O
MajorMajor,O
episodes,O
of,O
hypoglycemia,AdverseReaction
were,O
defined,O
as,O
symptomatic,O
episodes,O
requiring,O
external,O
third,O
party,O
assistance,O
due,O
to,O
severe,Severity
impairment in consciousness in,AdverseReaction
or,O
behavior,AdverseReaction
with,O
a,O
capillary,AdverseReaction
or,O
plasma glucose value 54 mg dL value 54 mg dL,AdverseReaction
and,O
prompt,O
recovery,O
after,O
glucose,O
or,O
glucagon,O
administration,O
and,O
MinorMinor,O
episodes,O
of,O
hypoglycemia,AdverseReaction
were,O
defined,O
as,O
either,O
a,O
symptomatic,O
episode,O
with,O
a,O
capillary,AdverseReaction
or,O
plasma glucose measurement 63 mg dL measurement 63 mg dL,AdverseReaction
regardless,O
of,O
need,O
for,O
external,O
assistance,O
or,O
an,O
asymptomatic,O
capillary,AdverseReaction
or,O
plasma glucose measurement 63 mg dL measurement 63 mg dL,AdverseReaction
that,O
does,O
not,O
qualify,O
as,O
a,O
major,O
episode,O
Hypoglycemia,AdverseReaction
in,O
Controlled,O
Clinical,O
Studies,O
Placebo,O
Active,O
Control,O
FARXIGA,O
5,O
mg,O
FARXIGA,O
10,O
mg,O
Monotherapy,O
24,O
weeks,O
N,O
75,O
N,O
64,O
N,O
70,O
Major,O
n,O
0,O
0,O
0,O
Minor,O
n,O
0,O
0,O
0,O
Add,O
on,O
to,O
Metformin,O
24,O
weeks,O
N,O
137,O
N,O
137,O
N,O
135,O
Major,O
n,O
0,O
0,O
0,O
Minor,O
n,O
0,O
2,O
1,O
5,O
1,O
0,O
7,O
Active,O
Control,O
Add,O
on,O
to,O
Metformin,O
versus,O
Glipizide,O
52,O
weeks,O
N,O
408,O
N,O
406,O
Major,O
n,O
3,O
0,O
7,O
0,O
Minor,O
n,O
147,O
36,O
0,O
7,O
1,O
7,O
Add,O
on,O
to,O
Glimepiride,O
24,O
weeks,O
N,O
146,O
N,O
145,O
N,O
151,O
Major,O
n,O
0,O
0,O
0,O
Minor,O
n,O
3,O
2,O
1,O
8,O
5,O
5,O
9,O
6,O
0,O
Add,O
on,O
to,O
Metformin,O
and,O
a,O
Sulfonylurea,O
24,O
Weeks,O
N,O
109,O
N,O
109,O
Major,O
n,O
0,O
0,O
Minor,O
n,O
4,O
3,O
7,O
14,O
12,O
8,O
Add,O
on,O
to,O
Pioglitazone,O
24,O
weeks,O
N,O
139,O
N,O
141,O
N,O
140,O
Major,O
n,O
0,O
0,O
0,O
Minor,O
n,O
0,O
3,O
2,O
1,O
0,O
Add,O
on,O
to,O
DPP4,O
inhibitor,O
24,O
weeks,O
N,O
226,O
N,O
225,O
Major,O
n,O
0,O
1,O
0,O
4,O
Minor,O
n,O
3,O
1,O
3,O
4,O
1,O
8,O
Add,O
on,O
to,O
Insulin,O
with,O
or,O
without,O
other,O
OADsOAD,O
oral,O
antidiabetic,O
therapy,O
24,O
weeks,O
N,O
197,O
N,O
212,O
N,O
196,O
Major,O
n,O
1,O
0,O
5,O
1,O
0,O
5,O
1,O
0,O
5,O
Minor,O
n,O
67,O
34,O
0,O
92,O
43,O
4,O
79,O
40,O
3,O
Genital,O
Mycotic,O
Infections,O
Genital mycotic infections,AdverseReaction
were,O
more,O
frequent,O
with,O
FARXIGA,O
treatment,O
Genital mycotic infections,AdverseReaction
were,O
reported,O
in,O
0,O
9,O
of,O
patients,O
on,O
placebo,O
5,O
7,O
on,O
FARXIGA,O
5,O
mg,O
and,O
4,O
8,O
on,O
FARXIGA,O
10,O
mg,O
in,O
the,O
12,O
study,O
placebo,O
controlled,O
pool,O
Discontinuation,O
from,O
study,O
due,O
to,O
genital infection,AdverseReaction
occurred,O
in,O
0,O
of,O
placebo,O
treated,O
patients,O
and,O
0,O
2,O
of,O
patients,O
treated,O
with,O
FARXIGA,O
10,O
mg,O
Infections,AdverseReaction
were,O
more,O
frequently,O
reported,O
in,O
females,O
than,O
in,O
males,O
see,O
Table,O
1,O
The,O
most,O
frequently,O
reported,O
genital mycotic infections,AdverseReaction
were,O
vulvovaginal mycotic infections,AdverseReaction
in,O
females,O
and,O
balanitis,AdverseReaction
in,O
males,O
Patients,O
with,O
a,O
history,O
of,O
genital,O
mycotic,O
infections,O
were,O
more,O
likely,O
to,O
have,O
a,O
genital mycotic infection,AdverseReaction
during,O
the,O
study,O
than,O
those,O
with,O
no,O
prior,O
history,O
10,O
0,O
23,O
1,O
and,O
25,O
0,O
versus,O
0,O
8,O
5,O
9,O
and,O
5,O
0,O
on,O
placebo,O
FARXIGA,O
5,O
mg,O
and,O
FARXIGA,O
10,O
mg,O
respectively,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
e,O
g,O
angioedema,AdverseReaction
urticaria,AdverseReaction
hypersensitivity,AdverseReaction
were,O
reported,O
with,O
FARXIGA,O
treatment,O
Across,O
the,O
clinical,O
program,O
serious,Severity
anaphylactic reactions,AdverseReaction
and,O
severe,Severity
cutaneous adverse reactions,AdverseReaction
and,O
angioedema,AdverseReaction
were,O
reported,O
in,O
0,O
2,O
of,O
comparator,O
treated,O
patients,O
and,O
0,O
3,O
of,O
FARXIGA,O
treated,O
patients,O
If,O
hypersensitivity,O
reactions,O
occur,O
discontinue,O
use,O
of,O
FARXIGA,O
treat,O
per,O
standard,O
of,O
care,O
and,O
monitor,O
until,O
signs,O
and,O
symptoms,O
resolve,O
Laboratory,O
Tests,O
Increase,O
in,O
Hematocrit,O
In,O
the,O
pool,O
of,O
13,O
placebo,O
controlled,O
studies,O
increases,AdverseReaction
from,O
baseline,O
in mean hematocrit values,AdverseReaction
were,O
observed,O
in,O
FARXIGA,O
treated,O
patients,O
starting,O
at,O
Week,O
1,O
and,O
continuing,O
up,O
to,O
Week,O
16,O
when,O
the,O
maximum,O
mean,O
difference,O
from,O
baseline,O
was,O
observed,O
At,O
Week,O
24,O
the,O
mean,O
changes,AdverseReaction
from,O
baseline,O
in hematocrit,AdverseReaction
were,O
0,O
33,O
in,O
the,O
placebo,O
group,O
and,O
2,O
30,O
in,O
the,O
FARXIGA,O
10,O
mg,O
group,O
By,O
Week,O
24,O
hematocrit,O
values,O
55,O
were,O
reported,O
in,O
0,O
4,O
of,O
placebo,O
treated,O
patients,O
and,O
1,O
3,O
of,O
FARXIGA,O
10,O
mg,O
treated,O
patients,O
Increase,O
in,O
Serum,O
Inorganic,O
Phosphorus,O
In,O
the,O
pool,O
of,O
13,O
placebo,O
controlled,O
studies,O
increases,AdverseReaction
from,O
baseline,O
in mean serum phosphorus levels,AdverseReaction
were,O
reported,O
at,O
Week,O
24,O
in,O
FARXIGA,O
treated,O
patients,O
compared,O
with,O
placebo,O
treated,O
patients,O
mean,O
increase,O
of,O
0,O
13,O
versus,O
0,O
04,O
mg,O
dL,O
respectively,O
Higher,O
proportions,O
of,O
patients,O
with,O
marked,O
laboratory,O
abnormalities,O
of,O
hyperphosphatemia,AdverseReaction
5,O
6,O
mg,O
dL,O
for,O
age,O
17,O
65,O
years,O
or,O
5,O
1,O
mg,O
dL,O
for,O
age,O
66,O
years,O
were,O
reported,O
on,O
FARXIGA,O
at,O
Week,O
24,O
0,O
9,O
versus,O
1,O
7,O
for,O
placebo,O
and,O
FARXIGA,O
10,O
mg,O
respectively,O
Increase,O
in,O
Low,O
Density,O
Lipoprotein,O
Cholesterol,O
In,O
the,O
pool,O
of,O
13,O
placebo,O
controlled,O
studies,O
changes,AdverseReaction
from,O
baseline,O
in mean lipid values,AdverseReaction
were,O
reported,O
in,O
FARXIGA,O
treated,O
patients,O
compared,O
to,O
placebo,O
treated,O
patients,O
Mean,O
percent,O
changes,AdverseReaction
from,O
baseline,O
at,O
Week,O
24,O
were,O
0,O
0,O
versus,O
2,O
5,O
for total cholesterol,AdverseReaction
and,O
1,O
0,O
versus,O
2,O
9,O
for LDL cholesterol,AdverseReaction
in,O
the,O
placebo,O
and,O
FARXIGA,O
10,O
mg,O
groups,O
respectively,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
If,O
infection,O
occurs,O
while,O
on,O
Ferriprox,O
interrupt,O
therapy,O
and,O
monitor,O
the,O
ANC,O
more,O
frequently,O
5,O
1,O
Ferriprox,O
can,Factor
cause,O
fetal harm,AdverseReaction
Women,O
should,O
be,O
advised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
and,O
to,O
avoid,O
pregnancy,O
while,O
on,O
this,O
drug,O
5,O
2,O
5,O
1,O
Agranulocytosis,O
Neutropenia,O
Fatal,AdverseReaction
agranulocytosis,AdverseReaction
can,Factor
occur,O
with,O
Ferriprox,O
use,O
Ferriprox,O
can,Factor
also,O
cause,O
neutropenia,AdverseReaction
which,O
may,Factor
foreshadow,O
agranulocytosis,AdverseReaction
Measure,O
the,O
absolute,O
neutrophil,O
count,O
ANC,O
before,O
starting,O
Ferriprox,O
therapy,O
and,O
monitor,O
the,O
ANC,O
weekly,O
on,O
therapy,O
Interrupt,O
Ferriprox,O
therapy,O
if,O
neutropenia,O
develops,O
ANC,O
1,O
5,O
x,O
10,O
9,O
L,O
Interrupt,O
Ferriprox,O
if,O
infection,O
develops,O
and,O
monitor,O
the,O
ANC,O
more,O
frequently,O
Advise,O
patients,O
taking,O
Ferriprox,O
to,O
immediately,O
interrupt,O
therapy,O
and,O
report,O
to,O
their,O
physician,O
if,O
they,O
experience,O
any,O
symptoms,O
indicative,O
of,O
infection,O
In,O
pooled,O
clinical,O
trials,O
the,O
incidence,O
of,O
agranulocytosis,AdverseReaction
was,O
1,O
7,O
of,O
patients,O
The,O
mechanism,O
of,O
Ferriprox,O
associated,O
agranulocytosis,AdverseReaction
is,O
unknown,O
Agranulocytosis,AdverseReaction
and,O
neutropenia,AdverseReaction
usually,O
resolve,O
upon,O
discontinuation,O
of,O
Ferriprox,O
but,O
there,O
have,O
been,O
reports,O
of,O
agranulocytosis,AdverseReaction
leading,O
to,O
death,AdverseReaction
Implement,O
a,O
plan,O
to,O
monitor,O
for,O
and,O
to,O
manage,O
agranulocytosis,O
neutropenia,O
prior,O
to,O
initiating,O
Ferriprox,O
treatment,O
For,O
neutropenia,O
ANC,O
1,O
5,O
x,O
10,O
9,O
L,O
and,O
0,O
5,O
x,O
10,O
9,O
L,O
Instruct,O
the,O
patient,O
to,O
immediately,O
discontinue,O
Ferriprox,O
and,O
all,O
other,O
medications,O
with,O
a,O
potential,O
to,O
cause,O
neutropenia,O
Obtain,O
a,O
complete,O
blood,O
cell,O
CBC,O
count,O
including,O
a,O
white,O
blood,O
cell,O
WBC,O
count,O
corrected,O
for,O
the,O
presence,O
of,O
nucleated,O
red,O
blood,O
cells,O
an,O
absolute,O
neutrophil,O
count,O
ANC,O
and,O
a,O
platelet,O
count,O
daily,O
until,O
recovery,O
ANC,O
1,O
5,O
x,O
10,O
9,O
L,O
For,O
agranulocytosis,O
ANC,O
0,O
5,O
x,O
10,O
9,O
L,O
Consider,O
hospitalization,O
and,O
other,O
management,O
as,O
clinically,O
appropriate,O
Do,O
not,O
resume,O
Ferriprox,O
in,O
patients,O
who,O
have,O
developed,O
agranulocytosis,O
unless,O
potential,O
benefits,O
outweigh,O
potential,O
risks,O
Do,O
not,O
rechallenge,O
patients,O
who,O
develop,O
neutropenia,O
with,O
Ferriprox,O
unless,O
potential,O
benefits,O
outweigh,O
potential,O
risks,O
5,O
2,O
Embryofetal,AdverseReaction
Toxicity,O
Based,O
on,O
evidence,O
of,O
genotoxicity,AdverseReaction
and,O
developmental toxicity,AdverseReaction
in,O
animal,Animal
studies,O
Ferriprox,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
In,O
animal,Animal
studies,O
administration,O
of,O
deferiprone,O
during,O
the,O
period,O
of,O
organogenesis,O
resulted,O
in,O
embryofetal death,AdverseReaction
and,O
malformations,AdverseReaction
at,O
doses,O
lower,O
than,O
equivalent,O
human,O
clinical,O
doses,O
If,O
Ferriprox,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
Ferriprox,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
Women,O
of,O
reproductive,O
potential,O
should,O
be,O
advised,O
to,O
avoid,O
pregnancy,O
when,O
taking,O
Ferriprox,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
and,O
Nonclinical,O
Toxicology,O
13,O
1,O
5,O
3,O
Laboratory,O
Tests,O
Serum,O
Liver,O
Enzyme,O
Activities,O
In,O
clinical,O
studies,O
7,O
5,O
of,O
642,O
subjects,O
treated,O
with,O
Ferriprox,O
developed,O
increased ALT values,AdverseReaction
Four,O
0,O
62,O
Ferriprox,O
treated,O
subjects,O
discontinued,O
the,O
drug,O
due,O
to,O
increased serum ALT,AdverseReaction
levels,O
and,O
1,O
0,O
16,O
due,O
to,O
an,O
increase in in,AdverseReaction
both,O
ALT,AdverseReaction
and,O
AST,AdverseReaction
Monitor,O
serum,O
ALT,O
values,O
monthly,O
during,O
therapy,O
with,O
Ferriprox,O
and,O
consider,O
interruption,O
of,O
therapy,O
if,O
there,O
is,O
a,O
persistent,O
increase,O
in,O
the,O
serum,O
transaminase,O
levels,O
Plasma,O
Zinc,O
Concentration,O
Decreased plasma zinc concentrations,AdverseReaction
have,O
been,O
observed,O
on,O
Ferriprox,O
therapy,O
Monitor,O
plasma,O
zinc,O
and,O
supplement,O
in,O
the,O
event,O
of,O
a,O
deficiency,O
""
BOXED,O
WARNING,O
WARNING,O
AGRANULOCYTOSIS,AdverseReaction
NEUTROPENIA,AdverseReaction
WARNING,O
AGRANULOCYTOSIS,AdverseReaction
NEUTROPENIA,AdverseReaction
Ferriprox,O
can,Factor
cause,O
agranulocytosis,AdverseReaction
that,O
can,Factor
lead,O
to,O
serious,Severity
infections,AdverseReaction
and,O
death,AdverseReaction
Neutropenia,AdverseReaction
may,Factor
precede,O
the,O
development,O
of,O
agranulocytosis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Measure,O
the,O
absolute,O
neutrophil,O
count,O
ANC,O
before,O
starting,O
Ferriprox,O
therapy,O
and,O
monitor,O
the,O
ANC,O
weekly,O
on,O
therapy,O
Interrupt,O
Ferriprox,O
therapy,O
if,O
neutropenia,O
develops,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Interrupt,O
Ferriprox,O
if,O
infection,O
develops,O
and,O
monitor,O
the,O
ANC,O
more,O
frequently,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Advise,O
patients,O
taking,O
Ferriprox,O
to,O
report,O
immediately,O
any,O
symptoms,O
indicative,O
of,O
infection,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
AGRANULOCYTOSIS,AdverseReaction
NEUTROPENIA,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Ferriprox,O
can,Factor
cause,O
agranulocytosis,AdverseReaction
that,O
can,Factor
lead,O
to,O
serious,Severity
infections,AdverseReaction
and,O
death,AdverseReaction
Neutropenia,AdverseReaction
may,Factor
precede,O
the,O
development,O
of,O
agranulocytosis,AdverseReaction
5,O
1,O
Measure,O
the,O
absolute,O
neutrophil,O
count,O
ANC,O
before,O
starting,O
Ferriprox,O
and,O
monitor,O
the,O
ANC,O
weekly,O
on,O
therapy,O
5,O
1,O
Interrupt,O
Ferriprox,O
if,O
infection,O
develops,O
and,O
monitor,O
the,O
ANC,O
more,O
frequently,O
5,O
1,O
Advise,O
patients,O
taking,O
Ferriprox,O
to,O
report,O
immediately,O
any,O
symptoms,O
indicative,O
of,O
infection,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
are,O
incidence,O
5,O
chromaturia,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
and,O
abdominal pain,AdverseReaction
alanine aminotransferase increased,AdverseReaction
arthralgia,AdverseReaction
and,O
neutropenia,AdverseReaction
5,O
1,O
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
ApoPharma,O
Inc,O
at,O
Telephone,O
1,O
866,O
949,O
0995,O
Email,O
medicalsafety,O
apopharma,O
com,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
The,O
following,O
adverse,O
reactions,O
are,O
also,O
discussed,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Agranulocytosis,AdverseReaction
Neutropenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Elevated ALT,AdverseReaction
5,O
3,O
Decreased plasma zinc concentrations,AdverseReaction
5,O
3,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Adverse,O
reaction,O
information,O
for,O
Ferriprox,O
represents,O
the,O
pooled,O
data,O
collected,O
from,O
642,O
patients,O
who,O
participated,O
in,O
single,O
arm,O
or,O
active,O
controlled,O
clinical,O
studies,O
The,O
most,O
serious,O
adverse,O
reaction,O
reported,O
in,O
clinical,O
trials,O
with,O
Ferriprox,O
was,O
agranulocytosis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
The,O
most,O
common,O
adverse,O
reactions,O
reported,O
during,O
clinical,O
trials,O
were,O
chromaturia,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
abdominal pain,AdverseReaction
alanine aminotransferase increased,AdverseReaction
arthralgia,AdverseReaction
and,O
neutropenia,AdverseReaction
The,O
table,O
below,O
lists,O
the,O
adverse,O
drug,O
reactions,O
that,O
occurred,O
in,O
at,O
least,O
1,O
of,O
patients,O
treated,O
with,O
Ferriprox,O
in,O
clinical,O
trials,O
Table,O
2,O
Adverse,O
drug,O
reactions,O
occurring,O
in,O
1,O
of,O
642,O
Ferriprox,O
treated,O
patients,O
Body,O
System,O
Subjects,O
Preferred,O
Term,O
BLOOD,O
AND,O
LYMPHATIC,O
SYSTEM,O
DISORDERS,O
Neutropenia,AdverseReaction
6,O
2,O
Agranulocytosis,AdverseReaction
1,O
7,O
GASTROINTESTINAL,O
DISORDERS,O
Nausea,AdverseReaction
12,O
6,O
Abdominal pain,AdverseReaction
discomfort,AdverseReaction
10,O
4,O
Vomiting,AdverseReaction
9,O
8,O
Diarrhea,AdverseReaction
3,O
0,O
Dyspepsia,AdverseReaction
2,O
0,O
INVESTIGATIONS,O
Alanine Aminotransferase increased,AdverseReaction
7,O
5,O
Neutrophil count decreased,AdverseReaction
7,O
3,O
Weight increased,AdverseReaction
1,O
9,O
Aspartate Aminotransferase increased,AdverseReaction
1,O
2,O
METABOLISM,O
AND,O
NUTRITION,O
DISORDERS,O
Increased appetite,AdverseReaction
4,O
0,O
Decreased appetite,AdverseReaction
1,O
1,O
MUSCULOSKELETAL,O
AND,O
CONNECTIVE,O
TISSUE,O
DISORDERS,O
Arthralgia,AdverseReaction
9,O
8,O
Back pain,AdverseReaction
2,O
0,O
Pain in extremity,AdverseReaction
1,O
9,O
Arthropathy,AdverseReaction
1,O
4,O
NERVOUS,O
SYSTEM,O
DISORDERS,O
Headache,AdverseReaction
2,O
5,O
URINARY,O
DISORDERS,O
Chromaturia,AdverseReaction
14,O
6,O
Gastrointestinal,O
symptoms,O
such,O
as,O
nausea,AdverseReaction
vomiting,AdverseReaction
and,O
abdominal pain,AdverseReaction
were,O
the,O
most,O
frequent,O
adverse,O
reactions,O
reported,O
by,O
patients,O
participating,O
in,O
clinical,O
trials,O
and,O
led,O
to,O
the,O
discontinuation,O
of,O
Ferriprox,O
therapy,O
in,O
1,O
6,O
of,O
patients,O
Chromaturia,AdverseReaction
reddish,O
brown,O
discoloration,O
of,O
the,O
urine,O
is,O
a,O
result,O
of,O
the,O
excretion,O
of,O
the,O
iron,O
in,O
the,O
urine,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
additional,O
adverse,O
reactions,O
have,O
been,O
reported,O
in,O
patients,O
receiving,O
Ferriprox,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
to,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
thrombocytosis,AdverseReaction
pancytopenia,AdverseReaction
Cardiac,O
disorders,O
atrial fibrillation,AdverseReaction
cardiac failure,AdverseReaction
Congenital,O
familial,O
and,O
genetic,O
disorders,O
hypospadias,AdverseReaction
Eye,O
disorders,O
diplopia,AdverseReaction
papilledema,AdverseReaction
retinal toxicity,AdverseReaction
Gastrointestinal,O
disorders,O
enterocolitis,AdverseReaction
rectal hemorrhage,AdverseReaction
gastric ulcer,AdverseReaction
pancreatitis,AdverseReaction
parotid gland enlargement,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
chills,AdverseReaction
pyrexia,AdverseReaction
edema peripheral,AdverseReaction
multi organ failure,AdverseReaction
Hepatobiliary,O
disorders,O
jaundice,AdverseReaction
hepatomegaly,AdverseReaction
Immune,O
system,O
disorders,O
anaphylactic shock,AdverseReaction
hypersensitivity,AdverseReaction
I,O
nfections,O
and,O
infestations,O
cryptococcal cutaneous infection,AdverseReaction
enteroviral encephalitis,AdverseReaction
pharyngitis,AdverseReaction
pneumonia,AdverseReaction
sepsis,AdverseReaction
furuncle,AdverseReaction
infectious hepatitis,AdverseReaction
rash pustular,AdverseReaction
subcutaneous abscess,AdverseReaction
Investigations,O
blood bilirubin increased,AdverseReaction
blood creatinine phosphokinase increased,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorders,O
metabolic acidosis,AdverseReaction
dehydration,AdverseReaction
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
myositis,AdverseReaction
chondropathy,AdverseReaction
trismus,AdverseReaction
Nervous,O
system,O
disorders,O
cerebellar syndrome,AdverseReaction
cerebral hemorrhage,AdverseReaction
convulsion,AdverseReaction
gait disturbance,AdverseReaction
intracranial pressure increased,AdverseReaction
psychomotor skills impaired,AdverseReaction
pyramidal tract syndrome,AdverseReaction
somnolence,AdverseReaction
Psychiatric,O
disorders,O
bruxism,AdverseReaction
depression,AdverseReaction
obsessive compulsive disorder,AdverseReaction
Renal,O
disorders,O
glycosuria,AdverseReaction
hemoglobinuria,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
acute respiratory distress syndrome,AdverseReaction
epistaxis,AdverseReaction
hemoptysis,AdverseReaction
pulmonary embolism,AdverseReaction
Skin,O
subcutaneous,O
tissue,O
disorders,O
hyperhidrosis,AdverseReaction
periorbital edema,AdverseReaction
photosensitivity reaction,AdverseReaction
pruritis,AdverseReaction
urticaria,AdverseReaction
rash,AdverseReaction
Henoch Schonlein purpura,AdverseReaction
Vascular,O
disorders,O
hypotension,AdverseReaction
hypertension,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Laryngeal,O
attacks,O
Following,O
treatment,O
of,O
laryngeal,O
attacks,O
with,O
FIRAZYR,O
advise,O
patients,O
to,O
seek,O
immediate,O
medical,O
attention,O
5,O
1,O
5,O
1,O
Laryngeal,O
Attacks,O
Given,O
the,O
potential,O
for,O
airway,O
obstruction,O
during,O
acute,O
laryngeal,O
HAE,O
attacks,O
patients,O
should,O
be,O
advised,O
to,O
seek,O
medical,O
attention,O
in,O
an,O
appropriate,O
healthcare,O
facility,O
immediately,O
in,O
addition,O
to,O
treatment,O
with,O
FIRAZYR,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
were,O
injection site reactions,AdverseReaction
which,O
occurred,O
in,O
almost,O
all,O
patients,O
97,O
in,O
clinical,O
trials,O
Other,O
common,O
adverse,O
reactions,O
occurring,O
in,O
greater,O
than,O
1,O
of,O
patients,O
included,O
pyrexia,AdverseReaction
transaminase increase,AdverseReaction
dizziness,AdverseReaction
and,O
rash,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Shire,O
Human,O
Genetic,O
Therapies,O
at,O
the,O
OnePath,O
r,O
phone,O
1,O
866,O
888,O
0660,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
The,O
safety,O
of,O
icatibant,O
was,O
evaluated,O
in,O
three,O
controlled,O
trials,O
that,O
included,O
223,O
patients,O
who,O
received,O
FIRAZYR,O
30,O
mg,O
n,O
113,O
placebo,O
n,O
75,O
or,O
comparator,O
n,O
38,O
The,O
mean,O
age,O
at,O
study,O
entry,O
was,O
38,O
years,O
range,O
18,O
to,O
83,O
years,O
64,O
were,O
female,O
and,O
95,O
were,O
white,O
The,O
data,O
described,O
below,O
represent,O
adverse,O
reactions,O
observed,O
from,O
the,O
two,O
placebo,O
controlled,O
trials,O
consisting,O
of,O
77,O
patients,O
who,O
received,O
FIRAZYR,O
at,O
a,O
dose,O
of,O
30,O
mg,O
SC,O
and,O
75,O
who,O
received,O
placebo,O
The,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
occurring,O
in,O
greater,O
than,O
1,O
of,O
patients,O
and,O
at,O
a,O
higher,O
rate,O
with,O
FIRAZYR,O
versus,O
placebo,O
are,O
shown,O
in,O
Table,O
1,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Table,O
1,O
Adverse,O
reactions,O
observed,O
in,O
1,O
of,O
patients,O
with,O
acute,O
attacks,O
of,O
HAE,O
and,O
at,O
a,O
higher,O
rate,O
with,O
FIRAZYR,O
versus,O
placebo,O
in,O
the,O
placebo,O
controlled,O
trialsEvents,O
occurring,O
within,O
14,O
days,O
of,O
study,O
drug,O
administration,O
FIRAZYR,O
N,O
77,O
Placebo,O
N,O
75,O
System,O
Organ,O
ClassPreferred,O
Term,O
Subjects,O
Subjects,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Injection site reaction,AdverseReaction
75,O
97,O
25,O
33,O
Pyrexia,AdverseReaction
3,O
4,O
0,O
Investigations,O
Transaminase increased,AdverseReaction
3,O
4,O
0,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
2,O
3,O
1,O
1,O
The,O
third,O
trial,O
was,O
active,O
controlled,O
and,O
was,O
comprised,O
of,O
35,O
patients,O
who,O
received,O
FIRAZYR,O
30,O
mg,O
and,O
38,O
patients,O
who,O
received,O
the,O
comparator,O
Adverse,O
reactions,O
for,O
FIRAZYR,O
were,O
similar,O
in,O
nature,O
and,O
frequency,O
to,O
those,O
reported,O
in,O
Table,O
1,O
In,O
all,O
three,O
controlled,O
trials,O
patients,O
were,O
eligible,O
for,O
treatment,O
of,O
subsequent,O
attacks,O
in,O
an,O
open,O
label,O
extension,O
Patients,O
were,O
treated,O
with,O
FIRAZYR,O
30,O
mg,O
and,O
could,O
receive,O
up,O
to,O
3,O
doses,O
of,O
FIRAZYR,O
30,O
mg,O
administered,O
at,O
least,O
6,O
hours,O
apart,O
for,O
each,O
attack,O
A,O
total,O
of,O
225,O
patients,O
were,O
treated,O
with,O
1,O
076,O
doses,O
of,O
30,O
mg,O
FIRAZYR,O
for,O
987,O
attacks,O
of,O
acute,O
HAE,O
Adverse,O
reactions,O
similar,O
in,O
nature,O
and,O
frequency,O
were,O
observed,O
to,O
those,O
seen,O
in,O
the,O
controlled,O
phase,O
of,O
the,O
trials,O
Other,O
adverse,O
reactions,O
reported,O
included,O
rash,AdverseReaction
nausea,AdverseReaction
and,O
headache,AdverseReaction
in,O
patients,O
exposed,O
to,O
FIRAZYR,O
The,O
safety,O
of,O
self,O
administration,O
was,O
evaluated,O
in,O
a,O
separate,O
open,O
label,O
trial,O
in,O
56,O
patients,O
with,O
HAE,O
In,O
this,O
trial,O
the,O
safety,O
profile,O
of,O
FIRAZYR,O
in,O
patients,O
who,O
self,O
administered,O
FIRAZYR,O
was,O
similar,O
in,O
nature,O
and,O
frequency,O
to,O
that,O
of,O
patients,O
whose,O
therapy,O
was,O
administered,O
by,O
healthcare,O
professionals,O
6,O
2,O
Immunogenicity,O
Across,O
repeated,O
treatment,O
in,O
the,O
controlled,O
trials,O
4,O
patients,O
tested,O
positive,O
for,O
anti,O
icatibant,O
antibodies,O
Three,O
of,O
these,O
patients,O
had,O
subsequent,O
tests,O
which,O
were,O
negative,O
No,Negation
hypersensitivity,AdverseReaction
or,O
anaphylactic reactions,AdverseReaction
were,O
reported,O
with,O
FIRAZYR,O
No,O
association,O
between,O
anti,O
icatibant,O
antibodies,O
and,O
efficacy,O
was,O
observed,O
6,O
3,O
Postmarketing,O
Experience,O
Similar,O
adverse,O
reactions,O
have,O
been,O
observed,O
in,O
postmarketing,O
use,O
as,O
compared,O
to,O
the,O
clinical,O
trials,O
Because,O
these,O
events,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
5,O
1,O
Risks,O
of,O
Treatment,O
in,O
Patients,O
with,O
Infectious,O
Diarrhea,O
If,O
infectious,O
etiologies,O
are,O
not,O
considered,O
and,O
FULYZAQ,O
is,O
initiated,O
based,O
on,O
a,O
presumptive,O
diagnosis,O
of,O
non,O
infectious,O
diarrhea,O
then,O
there,O
is,O
a,O
risk,O
that,O
patients,O
with,O
infectious,O
etiologies,O
will,O
not,O
receive,O
the,O
appropriate,O
treatments,O
and,O
their,O
disease,O
may,O
worsen,O
Before,O
starting,O
FULYZAQ,O
rule,O
out,O
infectious,O
etiologies,O
of,O
diarrhea,O
FULYZAQ,O
is,O
not,O
indicated,O
for,O
the,O
treatment,O
of,O
infectious,O
diarrhea,O
EXCERPT,O
Rule,O
out,O
infectious,O
etiologies,O
of,O
diarrhea,O
before,O
starting,O
crofelemer,O
If,O
infectious,O
etiologies,O
are,O
not,O
considered,O
there,O
is,O
a,O
risk,O
that,O
patients,O
with,O
infectious,O
etiologies,O
will,O
not,O
receive,O
the,O
appropriate,O
therapy,O
and,O
their,O
disease,O
may,O
worsen,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
A,O
total,O
of,O
696,O
HIV,O
positive,O
patients,O
in,O
three,O
placebo,O
controlled,O
trials,O
received,O
FULYZAQ,O
for,O
a,O
mean,O
duration,O
of,O
78,O
days,O
Of,O
the,O
total,O
population,O
across,O
the,O
three,O
trials,O
229,O
patients,O
received,O
a,O
dose,O
of,O
125,O
mg,O
twice,O
a,O
day,O
for,O
a,O
mean,O
duration,O
of,O
141,O
days,O
69,O
patients,O
received,O
a,O
dose,O
of,O
250,O
mg,O
twice,O
a,O
day,O
for,O
a,O
mean,O
duration,O
of,O
139,O
days,O
102,O
patients,O
received,O
a,O
dose,O
of,O
250,O
mg,O
four,O
times,O
a,O
day,O
for,O
a,O
mean,O
duration,O
of,O
14,O
days,O
54,O
patients,O
received,O
a,O
dose,O
of,O
500,O
mg,O
twice,O
a,O
day,O
for,O
a,O
mean,O
duration,O
of,O
146,O
days,O
and,O
242,O
patients,O
received,O
a,O
dose,O
of,O
500,O
mg,O
four,O
times,O
a,O
day,O
for,O
a,O
mean,O
duration,O
of,O
14,O
days,O
Adverse,O
reactions,O
for,O
FULYZAQ,O
that,O
occurred,O
in,O
at,O
least,O
2,O
of,O
patients,O
and,O
at,O
a,O
higher,O
incidence,O
than,O
placebo,O
are,O
provided,O
in,O
Table,O
1,O
Table,O
1,O
Adverse,O
Reactions,O
Occurring,O
in,O
at,O
Least,O
2,O
of,O
Patients,O
in,O
the,O
125,O
mg,O
Twice,O
Daily,O
Group,O
Adverse,O
Reaction,O
Crofelemer,O
125,O
mg,O
BID,O
N,O
229n,O
PlaceboN,O
274n,O
Upper respiratory tract infection,AdverseReaction
13,O
5,O
7,O
4,O
1,O
5,O
Bronchitis,AdverseReaction
9,O
3,O
9,O
0,O
Cough,AdverseReaction
8,O
3,O
5,O
3,O
1,O
1,O
Flatulence,AdverseReaction
7,O
3,O
1,O
3,O
1,O
1,O
Increased bilirubin,AdverseReaction
7,O
3,O
1,O
3,O
1,O
1,O
Nausea,AdverseReaction
6,O
2,O
6,O
4,O
1,O
5,O
Back pain,AdverseReaction
6,O
2,O
6,O
4,O
1,O
5,O
Arthralgia,AdverseReaction
6,O
2,O
6,O
0,O
Urinary tract infection,AdverseReaction
5,O
2,O
2,O
2,O
0,O
7,O
Nasopharyngitis,AdverseReaction
5,O
2,O
2,O
2,O
0,O
7,O
Musculoskeletal pain,AdverseReaction
5,O
2,O
2,O
1,O
0,O
4,O
Hemorrhoids,AdverseReaction
5,O
2,O
2,O
0,O
Giardiasis,AdverseReaction
5,O
2,O
2,O
0,O
Anxiety,AdverseReaction
5,O
2,O
2,O
1,O
0,O
4,O
Increased alanine aminotransferase,AdverseReaction
5,O
2,O
2,O
3,O
1,O
1,O
Abdominal distension,AdverseReaction
5,O
2,O
2,O
1,O
0,O
4,O
Twice,O
daily,O
Adverse,O
reactions,O
that,O
occurred,O
in,O
between,O
1,O
and,O
2,O
of,O
patients,O
taking,O
a,O
250,O
mg,O
daily,O
dose,O
of,O
FULYZAQ,O
were,O
abdominal pain,AdverseReaction
acne,AdverseReaction
increased aspartate aminotransferase,AdverseReaction
increased conjugated bilirubin,AdverseReaction
increased unconjugated blood bilirubin,AdverseReaction
constipation,AdverseReaction
depression,AdverseReaction
dermatitis,AdverseReaction
dizziness,AdverseReaction
dry mouth,AdverseReaction
dyspepsia,AdverseReaction
gastroenteritis,AdverseReaction
herpes zoster,AdverseReaction
nephrolithiasis,AdverseReaction
pain in extremity,AdverseReaction
pollakiuria,AdverseReaction
procedural pain,AdverseReaction
seasonal allergy,AdverseReaction
sinusitis,AdverseReaction
and,O
decreased white blood cell count,AdverseReaction
Adverse,O
reactions,O
were,O
similar,O
in,O
patients,O
who,O
received,O
doses,O
greater,O
than,O
250,O
mg,O
daily,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
3,O
are,O
upper respiratory tract infection,AdverseReaction
bronchitis,AdverseReaction
cough,AdverseReaction
flatulence,AdverseReaction
and,O
increased bilirubin,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Salix,O
Pharmaceuticals,O
at,O
1,O
800,O
508,O
0024,O
or,O
www,O
Salix,O
com,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Nephrogenic Systemic Fibrosis,AdverseReaction
has,O
occurred,O
in,O
patients,O
with,O
impaired,O
elimination,O
of,O
GBCAs,O
Higher,O
than,O
recommended,O
dosing,O
or,O
repeated,O
dosing,O
appears,O
to,O
increase,O
the,O
risk,O
5,O
1,O
Anaphylactic,AdverseReaction
and,O
other,O
hypersensitivity reactions,AdverseReaction
with,O
cardiovascular,AdverseReaction
respiratory,AdverseReaction
or,O
cutaneous manifestations,AdverseReaction
ranging,O
from,O
mild,Severity
to,O
severe,Severity
including,O
death,AdverseReaction
have,O
occurred,O
Monitor,O
patients,O
closely,O
during,O
and,O
after,O
administration,O
of,O
Gadavist,O
5,O
2,O
5,O
1,O
Nephrogenic,O
Systemic,O
Fibrosis,O
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,O
for,O
nephrogenic systemic fibrosis,AdverseReaction
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
among,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrast,O
MRI,O
or,O
other,O
modalities,O
The,O
GBCA,DrugClass
associated,O
NSF,AdverseReaction
risk,O
appears,O
highest,O
for,O
patients,O
with,O
chronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73m,O
2,O
as,O
well,O
as,O
patients,O
with,O
acute,O
kidney,O
injury,O
The,O
risk,O
appears,O
lower,O
for,O
patients,O
with,O
chronic,O
moderate,O
kidney,O
disease,O
GFR,O
30,O
to,O
59,O
mL,O
min,O
1,O
73m,O
2,O
and,O
little,O
if,O
any,O
for,O
patients,O
with,O
chronic,O
mild,O
kidney,O
disease,O
GFR,O
60,O
to,O
89,O
mL,O
min,O
1,O
73m,O
2,O
NSF,AdverseReaction
may,Factor
result,O
in,O
fatal,AdverseReaction
or,O
debilitating,Severity
fibrosis,AdverseReaction
affecting,O
the,O
skin,O
muscle,O
and,O
internal,O
organs,O
Report,O
any,O
diagnosis,O
of,O
NSF,O
following,O
Gadavist,O
administration,O
to,O
Bayer,O
Healthcare,O
1,O
888,O
842,O
2937,O
or,O
FDA,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
Features,O
of,O
acute,O
kidney,O
injury,O
consist,O
of,O
rapid,O
over,O
hours,O
to,O
days,O
and,O
usually,O
reversible,O
decrease,O
in,O
kidney,O
function,O
commonly,O
in,O
the,O
setting,O
of,O
surgery,O
severe,O
infection,O
injury,O
or,O
drug,O
induced,O
kidney,O
toxicity,O
Serum,O
creatinine,O
levels,O
and,O
estimated,O
GFR,O
may,O
not,O
reliably,O
assess,O
renal,O
function,O
in,O
the,O
setting,O
of,O
acute,O
kidney,O
injury,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
for,O
example,O
age,O
60,O
years,O
diabetes,O
mellitus,O
or,O
chronic,O
hypertension,O
estimate,O
the,O
GFR,O
through,O
laboratory,O
testing,O
Among,O
the,O
factors,O
that,O
may,O
increase,O
the,O
risk,O
for,O
NSF,O
are,O
repeated,O
or,O
higher,O
than,O
recommended,O
doses,O
of,O
a,O
GBCA,O
and,O
degree,O
of,O
renal,O
impairment,O
at,O
the,O
time,O
of,O
exposure,O
Record,O
the,O
specific,O
GBCA,O
and,O
the,O
dose,O
administered,O
to,O
a,O
patient,O
For,O
patients,O
at,O
highest,O
risk,O
for,O
NSF,O
do,O
not,O
exceed,O
the,O
recommended,O
Gadavist,O
dose,O
and,O
allow,O
a,O
sufficient,O
period,O
of,O
time,O
for,O
elimination,O
of,O
the,O
drug,O
prior,O
to,O
re,O
administration,O
For,O
patients,O
receiving,O
hemodialysis,O
consider,O
the,O
prompt,O
initiation,O
of,O
hemodialysis,O
following,O
the,O
administration,O
of,O
a,O
GBCA,O
in,O
order,O
to,O
enhance,O
the,O
contrast,O
agent,O
s,O
elimination,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
The,O
usefulness,O
of,O
hemodialysis,O
in,O
the,O
prevention,O
of,O
NSF,O
is,O
unknown,O
see,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
2,O
Hypersensitivity,O
Reactions,O
Anaphylactic,AdverseReaction
and,O
other,O
hypersensitivity reactions,AdverseReaction
with,O
cardiovascular,O
respiratory,O
or,O
cutaneous,O
manifestations,O
ranging,O
from,O
mild,Severity
to,O
severe,Severity
including,O
death,AdverseReaction
have,O
uncommonly,O
occurred,O
following,O
Gadavist,O
administration,O
see,O
Adverse,O
Reactions,O
6,O
Before,O
Gadavist,O
administration,O
assess,O
all,O
patients,O
for,O
any,O
history,O
of,O
a,O
reaction,O
to,O
contrast,O
media,O
bronchial,O
asthma,O
and,O
or,O
allergic,O
disorders,O
These,O
patients,O
may,O
have,O
an,O
increased,O
risk,O
for,O
a,O
hypersensitivity,O
reaction,O
to,O
Gadavist,O
Administer,O
Gadavist,O
only,O
in,O
situations,O
where,O
trained,O
personnel,O
and,O
therapies,O
are,O
promptly,O
available,O
for,O
the,O
treatment,O
of,O
hypersensitivity,O
reactions,O
including,O
personnel,O
trained,O
in,O
resuscitation,O
Most,O
hypersensitivity,O
reactions,O
to,O
Gadavist,O
have,O
occurred,O
within,O
half,O
an,O
hour,O
after,O
administration,O
Delayed,O
reactions,O
can,O
occur,O
up,O
to,O
several,O
days,O
after,O
administration,O
Observe,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
hypersensitivity,O
reactions,O
during,O
and,O
following,O
Gadavist,O
administration,O
5,O
3,O
Acute,O
Kidney,O
Injury,O
In,O
patients,O
with,O
chronic,O
renal,O
impairment,O
acute kidney injury,AdverseReaction
sometimes,O
requiring,O
dialysis,O
has,O
been,O
observed,O
with,O
the,O
use,O
of,O
some,O
GBCAs,DrugClass
Do,O
not,O
exceed,O
the,O
recommended,O
dose,O
the,O
risk,O
of,O
acute,O
kidney,O
injury,O
may,O
increase,O
with,O
higher,O
than,O
recommended,O
doses,O
5,O
4,O
Extravasation,O
and,O
Injection,O
Site,O
Reactions,O
Ensure,O
catheter,O
and,O
venous,O
patency,O
before,O
the,O
injection,O
of,O
Gadavist,O
Extravasation,O
into,O
tissues,O
during,O
Gadavist,O
administration,AdverseReaction
may,Factor
result,O
in,O
moderate,Severity
irritation,AdverseReaction
see,O
Nonclinical,O
Toxicology,O
13,O
2,O
5,O
5,O
Overestimation,O
of,O
Extent,O
of,O
Malignant,O
Disease,O
in,O
MRI,O
of,O
the,O
Breast,O
Gadavist,O
MRI,O
of,O
the,O
breast,O
overestimated,O
the,O
histologically,O
confirmed,O
extent,O
of,O
malignancy,O
in,O
the,O
diseased,O
breast,O
in,O
up,O
to,O
50,O
of,O
the,O
patients,O
see,O
Clinical,O
Studies,O
14,O
2,O
""
BOXED,O
WARNING,O
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,Factor
for,O
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
in,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrasted,O
MRI,O
or,O
other,O
modalities,O
NSF,AdverseReaction
may,Factor
result,O
in,O
fatal,AdverseReaction
or,O
debilitating,Severity
fibrosis,AdverseReaction
affecting,O
the,O
skin,O
muscle,O
and,O
internal,O
organs,O
The,O
risk,Factor
for,O
NSF,AdverseReaction
appears,O
highest,O
among,O
patients,O
with,O
Chronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73m2,O
orAcute,O
kidney,O
injury,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
for,O
example,O
age,O
60,O
years,O
hypertension,O
or,O
diabetes,O
estimate,O
the,O
glomerular,O
filtration,O
rate,O
GFR,O
through,O
laboratory,O
testing,O
For,O
patients,O
at,O
highest,O
risk,O
for,O
NSF,O
do,O
not,O
exceed,O
the,O
recommended,O
Gadavist,O
dose,O
and,O
allow,O
a,O
sufficient,O
period,O
of,O
time,O
for,O
elimination,O
of,O
the,O
drug,O
from,O
the,O
body,O
prior,O
to,O
any,O
re,O
administration,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
NEPHROGENIC SYSTEMIC FIBROSIS,AdverseReaction
NSF,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Gadolinium based contrast agents,DrugClass
GBCAs,O
increase,O
the,O
risk,O
for,O
NSF,AdverseReaction
among,O
patients,O
with,O
impaired,O
elimination,O
of,O
the,O
drugs,O
Avoid,O
use,O
of,O
GBCAs,O
in,O
these,O
patients,O
unless,O
the,O
diagnostic,O
information,O
is,O
essential,O
and,O
not,O
available,O
with,O
non,O
contrasted,O
MRI,O
or,O
other,O
modalities,O
The,O
risk,Factor
for,O
NSF,AdverseReaction
appears,O
highest,O
among,O
patients,O
with,O
Chronic,O
severe,O
kidney,O
disease,O
GFR,O
30,O
mL,O
min,O
1,O
73m2,O
orAcute,O
kidney,O
injury,O
Screen,O
patients,O
for,O
acute,O
kidney,O
injury,O
and,O
other,O
conditions,O
that,O
may,O
reduce,O
renal,O
function,O
For,O
patients,O
at,O
risk,O
for,O
chronically,O
reduced,O
renal,O
function,O
for,O
example,O
age,O
60,O
years,O
hypertension,O
or,O
diabetes,O
estimate,O
the,O
glomerular,O
filtration,O
rate,O
GFR,O
through,O
laboratory,O
testing,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
elsewhere,O
in,O
labeling,O
Nephrogenic Systemic Fibrosis,AdverseReaction
NSF,AdverseReaction
see,O
Boxed,O
Warning,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hypersensitivity reactions,AdverseReaction
see,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
0,O
5,O
are,O
headache,AdverseReaction
nausea,AdverseReaction
and,O
dizziness,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Bayer,O
HealthCare,O
Pharmaceuticals,O
Inc,O
at,O
1,O
888,O
842,O
2937,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
adverse,O
reactions,O
described,O
in,O
this,O
section,O
reflect,O
Gadavist,O
exposure,O
in,O
6,O
330,O
subjects,O
including,O
184,O
pediatric,O
patients,O
ages,O
0,O
to,O
17,O
years,O
with,O
the,O
majority,O
receiving,O
the,O
recommended,O
dose,O
Approximately,O
50,O
of,O
the,O
subjects,O
were,O
male,O
and,O
the,O
ethnic,O
distribution,O
was,O
60,O
Caucasian,O
30,O
Asian,O
6,O
Hispanic,O
2,O
Black,O
and,O
3,O
patients,O
of,O
other,O
ethnic,O
groups,O
The,O
average,O
age,O
was,O
55,O
years,O
range,O
from1,O
week,O
to,O
93,O
years,O
Overall,O
approximately,O
4,O
of,O
subjects,O
reported,O
one,O
or,O
more,O
adverse,O
reactions,O
during,O
a,O
follow,O
up,O
period,O
that,O
ranged,O
from,O
24,O
hours,O
to,O
7,O
days,O
after,O
Gadavist,O
administration,O
Adverse,O
reactions,O
associated,O
with,O
the,O
use,O
of,O
Gadavist,O
were,O
usually,O
mild,O
to,O
moderate,O
in,O
severity,O
and,O
transient,O
in,O
nature,O
Table,O
2,O
lists,O
adverse,O
reactions,O
that,O
occurred,O
in,O
0,O
1,O
subjects,O
who,O
received,O
Gadavist,O
Table,O
2,O
Adverse,O
Reactions,O
Reaction,O
Rate,O
n,O
6330,O
Headache,AdverseReaction
1,O
5,O
Nausea,AdverseReaction
1,O
2,O
Dizziness,AdverseReaction
0,O
5,O
Dysgeusia,AdverseReaction
0,O
4,O
Feeling Hot,AdverseReaction
0,O
4,O
Injection site reactions,AdverseReaction
0,O
4,O
Vomiting,AdverseReaction
0,O
4,O
Rash,AdverseReaction
includes,O
generalized,AdverseReaction
macular,AdverseReaction
papular,AdverseReaction
pruritic,AdverseReaction
0,O
3,O
Pruritus,AdverseReaction
includes,O
generalized,AdverseReaction
0,O
2,O
Erythema,AdverseReaction
0,O
2,O
Hypersensitivity,AdverseReaction
Anaphylactoid,AdverseReaction
0,O
1,O
Dyspnea,AdverseReaction
0,O
1,O
Paresthesia,AdverseReaction
0,O
1,O
Hypersensitivity,AdverseReaction
anaphylactoid reaction,AdverseReaction
may,O
occur,O
with,O
one,O
or,O
more,O
of,O
the,O
following,O
adverse,O
reactions,O
for,O
example,O
hypotension,AdverseReaction
urticaria,AdverseReaction
face edema,AdverseReaction
eyelid edema,AdverseReaction
flushing,AdverseReaction
Adverse,O
reactions,O
that,O
occurred,O
with,O
a,O
frequency,O
of,O
0,O
1,O
in,O
subjects,O
who,O
received,O
Gadavist,O
include,O
loss of consciousness,AdverseReaction
convulsion,AdverseReaction
parosmia,AdverseReaction
tachycardia,AdverseReaction
palpitation,AdverseReaction
dry mouth,AdverseReaction
malaise,AdverseReaction
and,O
feeling cold,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
additional,O
adverse,O
reactions,O
have,O
been,O
reported,O
during,O
postmarketing,O
use,O
of,O
Gadavist,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Cardiac arrest,AdverseReaction
Nephrogenic Systemic Fibrosis,AdverseReaction
NSF,AdverseReaction
Hypersensitivity reactions,AdverseReaction
anaphylactic shock,AdverseReaction
circulatory collapse,AdverseReaction
respiratory arrest,AdverseReaction
pulmonary edema,AdverseReaction
bronchospasm,AdverseReaction
cyanosis,AdverseReaction
oropharyngeal swelling,AdverseReaction
laryngeal edema,AdverseReaction
blood pressure increased,AdverseReaction
chest pain,AdverseReaction
angioedema,AdverseReaction
conjunctivitis,AdverseReaction
hyperhidrosis,AdverseReaction
cough,AdverseReaction
sneezing,AdverseReaction
burning sensation,AdverseReaction
and,O
pallor,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Bradycardia,AdverseReaction
and,O
or,O
atrioventricular conduction,AdverseReaction
after,O
first,O
dose,O
Monitor,O
patients,O
2,O
5,O
1,O
Infections,AdverseReaction
GILENYA,O
may,O
increase,O
the,O
risk,Factor
of,O
infections,AdverseReaction
A,O
recent,O
CBC,O
should,O
be,O
available,O
before,O
initiating,O
treatment,O
Monitor,O
for,O
infection,O
during,O
treatment,O
and,O
for,O
2,O
months,O
after,O
discontinuation,O
Do,O
not,O
start,O
in,O
patients,O
with,O
active,O
infections,O
5,O
2,O
Progressive multifocal leukoencephalopathy,AdverseReaction
PML,AdverseReaction
Withhold,O
GILENYA,O
at,O
the,O
first,O
sign,O
or,O
symptom,O
suggestive,O
of,O
PML,O
5,O
3,O
Macular edema,AdverseReaction
Perform,O
an,O
examination,O
of,O
the,O
fundus,O
including,O
the,O
macula,O
before,O
and,O
3,O
4,O
months,O
after,O
treatment,O
initiation,O
Patients,O
with,O
diabetes,O
mellitus,O
or,O
a,O
history,O
of,O
uveitis,O
are,O
at,O
increased,O
risk,O
5,O
4,O
Posterior reversible encephalopathy syndrome,AdverseReaction
PRES,AdverseReaction
If,O
suspected,O
discontinue,O
GILENYA,O
5,O
5,O
Decrease in pulmonary function tests in,AdverseReaction
PFT,AdverseReaction
Obtain,O
PFT,O
when,O
clinically,O
indicated,O
5,O
6,O
Liver injury,AdverseReaction
liver,O
enzyme,O
results,O
should,O
be,O
available,O
before,O
initiation,O
Discontinue,O
if,O
significant,O
liver,O
injury,O
occurs,O
5,O
7,O
Women,O
of,O
childbearing,O
potential,O
should,O
use,O
effective,O
contraception,O
during,O
and,O
for,O
2,O
months,O
after,O
stopping,O
GILENYA,O
5,O
8,O
Blood,O
pressure,O
BP,O
Monitor,O
BP,O
during,O
treatment,O
5,O
9,O
5,O
1,O
Bradyarrhythmia,O
and,O
Atrioventricular,O
Blocks,O
Because,O
of,O
a,O
risk,O
for,O
bradyarrhythmia,O
and,O
atrioventricular,O
AV,O
blocks,O
patients,O
should,O
be,O
monitored,O
during,O
GILENYA,O
treatment,O
initiation,O
see,O
Dosage,O
and,O
Administration,O
2,O
Reduction,O
in,O
Heart,O
Rate,O
After,O
the,O
first,O
dose,O
of,O
GILENYA,O
the,O
heart rate decrease,AdverseReaction
starts,O
within,O
an,O
hour,O
On,O
Day,O
1,O
the,O
maximum,O
decline in heart rate,AdverseReaction
generally,O
occurs,O
within,O
6,O
hours,O
and,O
recovers,O
although,O
not,O
to,O
baseline,O
levels,O
by,O
8,O
to,O
10,O
hours,O
postdose,O
Because,O
of,O
physiological,O
diurnal,O
variation,O
there,O
is,O
a,O
second,O
period,O
of,O
heart rate decrease,AdverseReaction
within,O
24,O
hours,O
after,O
the,O
first,O
dose,O
In,O
some,O
patients,O
heart rate decrease,AdverseReaction
during,O
the,O
second,O
period,O
is,O
more,O
pronounced,O
than,O
the,O
decrease,O
observed,O
in,O
the,O
first,O
6,O
hours,O
Heart rates below 40 beats per minute,AdverseReaction
were,O
rarely,O
observed,O
In,O
controlled,O
clinical,O
trials,O
adverse,O
reactions,O
of,O
symptomatic bradycardia,AdverseReaction
following,O
the,O
first,O
dose,O
were,O
reported,O
in,O
0,O
6,O
of,O
patients,O
receiving,O
GILENYA,O
0,O
5,O
mg,O
and,O
in,O
0,O
1,O
of,O
patients,O
on,O
placebo,O
Patients,O
who,O
experienced,O
bradycardia,AdverseReaction
were,O
generally,O
asymptomatic,O
but,O
some,O
patients,O
experienced,O
hypotension,AdverseReaction
dizziness,AdverseReaction
fatigue,AdverseReaction
palpitations,AdverseReaction
and,O
or,O
chest pain,AdverseReaction
that,O
usually,O
resolved,O
within,O
the,O
first,O
24,O
hours,O
on,O
treatment,O
Following,O
the,O
second,O
dose,O
a,O
further,O
decrease in heart rate,AdverseReaction
may,O
occur,O
when,O
compared,O
to,O
the,O
heart,O
rate,O
prior,O
to,O
the,O
second,O
dose,O
but,O
this,O
change,O
is,O
of,O
a,O
smaller,O
magnitude,O
than,O
that,O
observed,O
following,O
the,O
first,O
dose,O
With,O
continued,O
dosing,O
the,O
heart,O
rate,O
returns,O
to,O
baseline,O
within,O
1,O
month,O
of,O
chronic,O
treatment,O
Atrioventricular,O
Blocks,O
Initiation,O
of,O
GILENYA,O
treatment,O
has,O
resulted,O
in,O
transient,Severity
AV conduction delays,AdverseReaction
In,O
controlled,O
clinical,O
trials,O
first degree AV block,AdverseReaction
after,O
the,O
first,O
dose,O
occurred,O
in,O
4,O
7,O
of,O
patients,O
receiving,O
GILENYA,O
and,O
1,O
6,O
of,O
patients,O
on,O
placebo,O
In,O
a,O
study,O
of,O
697,O
patients,O
with,O
available,O
24,O
hour,O
Holter,O
monitoring,O
data,O
after,O
their,O
first,O
dose,O
N,O
351,O
receiving,O
GILENYA,O
and,O
N,O
346,O
on,O
placebo,O
second degree AV blocks,AdverseReaction
AV blocks blocks,AdverseReaction
Mobitz Types I,AdverseReaction
Wenckebach,AdverseReaction
or,O
2 1 AV blocks,AdverseReaction
occurred,O
in,O
4,O
N,O
14,O
of,O
patients,O
receiving,O
GILENYA,O
and,O
2,O
N,O
7,O
of,O
patients,O
on,O
placebo,O
Of,O
the,O
14,O
patients,O
receiving,O
GILENYA,O
7,O
patients,O
had,O
2 1 AV block,AdverseReaction
5,O
patients,O
within,O
the,O
first,O
6,O
hours,O
postdose,O
and,O
2,O
patients,O
after,O
6,O
hours,O
postdose,O
All,O
second degree AV blocks,AdverseReaction
on,O
placebo,Factor
were,O
Mobitz Type I,AdverseReaction
and,O
occurred,O
after,O
the,O
first,O
12,O
hours,O
postdose,O
The,O
conduction abnormalities,AdverseReaction
were,O
usually,O
transient,Severity
and,O
asymptomatic,O
and,O
resolved,O
within,O
the,O
first,O
24,O
hours,O
on,O
treatment,O
but,O
they,O
occasionally,O
required,O
treatment,O
with,O
atropine,O
or,O
isoproterenol,O
Postmarketing,O
Experience,O
In,O
the,O
postmarketing,O
setting,O
third degree AV block,AdverseReaction
and,O
AV block,AdverseReaction
with,O
junctional escape,AdverseReaction
have,O
been,O
observed,O
during,O
the,O
first,O
dose,O
6,O
hour,O
observation,O
period,O
with,O
GILENYA,O
Isolated,O
delayed,O
onset,O
events,O
including,O
transient,Severity
asystole,AdverseReaction
and,O
unexplained,O
death,AdverseReaction
have,O
occurred,O
within,O
24,O
hours,O
of,O
the,O
first,O
dose,O
These,O
events,O
were,O
confounded,O
by,O
concomitant,O
medications,O
and,O
or,O
preexisting,O
disease,O
and,O
the,O
relationship,O
to,O
GILENYA,O
is,O
uncertain,O
Cases,O
of,O
syncope,AdverseReaction
were,O
also,O
reported,O
after,O
the,O
first,O
dose,O
of,O
GILENYA,O
5,O
2,O
Infections,O
Risk,O
of,O
Infections,O
GILENYA,O
causes,O
a,O
dose,O
dependent,O
reduction in peripheral lymphocyte count,AdverseReaction
to,O
20 30 of baseline,Severity
values,O
because,O
of,O
reversible,Severity
sequestration of lymphocytes in lymphoid tissues,AdverseReaction
GILENYA,O
may,O
therefore,O
increase,O
the,O
risk,Factor
of,O
infections,AdverseReaction
some,O
serious,Severity
in,O
nature,O
see,O
Clinical,O
Pharmacology,O
12,O
2,O
Before,O
initiating,O
treatment,O
with,O
GILENYA,O
a,O
recent,O
CBC,O
i,O
e,O
within,O
6,O
months,O
or,O
after,O
discontinuation,O
of,O
prior,O
therapy,O
should,O
be,O
available,O
Consider,O
suspending,O
treatment,O
with,O
GILENYA,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
and,O
reassess,O
the,O
benefits,O
and,O
risks,O
prior,O
to,O
reinitiation,O
of,O
therapy,O
Because,O
the,O
elimination,O
of,O
fingolimod,O
after,O
discontinuation,O
may,O
take,O
up,O
to,O
2,O
months,O
continue,O
monitoring,O
for,O
infections,O
throughout,O
this,O
period,O
Instruct,O
patients,O
receiving,O
GILENYA,O
to,O
report,O
symptoms,O
of,O
infections,O
to,O
a,O
physician,O
Patients,O
with,O
active,O
acute,O
or,O
chronic,O
infections,O
should,O
not,O
start,O
treatment,O
until,O
the,O
infection,O
s,O
is,O
resolved,O
In,O
MS,O
placebo,O
controlled,O
trials,O
the,O
overall,O
rate,O
of,O
infections,AdverseReaction
72,O
with,O
GILENYA,O
was,O
similar,O
to,O
placebo,O
However,O
bronchitis,AdverseReaction
herpes zoster,AdverseReaction
influenza,AdverseReaction
sinusitis,AdverseReaction
and,O
pneumonia,AdverseReaction
were,O
more,O
common,O
in,O
GILENYA,O
treated,O
patients,O
Serious,Severity
infections,AdverseReaction
occurred,O
at,O
a,O
rate,O
of,O
2,O
3,O
in,O
the,O
GILENYA,O
group,O
versus,O
1,O
6,O
in,O
the,O
placebo,O
group,O
Herpes,O
Viral,O
Infections,O
In,O
placebo,O
controlled,O
trials,O
the,O
rate,O
of,O
herpetic infections,AdverseReaction
was,O
9,O
in,O
patients,O
receiving,O
GILENYA,O
0,O
5,O
mg,O
and,O
7,O
on,O
placebo,O
Two,O
patients,O
died,AdverseReaction
of,O
herpetic infections,AdverseReaction
during,O
controlled,O
trials,O
One,O
death,AdverseReaction
was,O
due,O
to,O
disseminated primary herpes zoster,AdverseReaction
and,O
the,O
other,O
to,O
herpes simplex encephalitis,AdverseReaction
In,O
both,O
cases,O
the,O
patients,O
were,O
taking,O
a,O
1,O
25,O
mg,O
dose,O
of,O
fingolimod,O
higher,O
than,O
the,O
recommended,O
0,O
5,O
mg,O
dose,O
and,O
had,O
received,O
high,O
dose,O
corticosteroid,O
therapy,O
to,O
treat,O
suspected,O
MS,O
relapses,O
Serious,Severity
life threatening,Severity
events,O
of,O
disseminated varicella zoster,AdverseReaction
and,O
herpes simplex infections,AdverseReaction
including,O
cases,O
of,O
encephalitis,AdverseReaction
and,O
multiorgan failure,AdverseReaction
have,O
occurred,O
with,O
GILENYA,O
0,O
5,O
mg,O
in,O
the,O
postmarketing,O
setting,O
One,O
of,O
these,O
events,O
was,O
fatal,AdverseReaction
Include,O
disseminated,O
herpetic,O
infections,O
in,O
the,O
differential,O
diagnosis,O
of,O
patients,O
who,O
are,O
receiving,O
GILENYA,O
and,O
present,O
with,O
an,O
atypical,O
MS,O
relapse,O
or,O
multiorgan,O
failure,O
Cryptococcal,O
infections,O
Cryptococcal infections,AdverseReaction
including,O
cases,O
of,O
cryptococcal meningitis,AdverseReaction
have,O
been,O
reported,O
with,O
GILENYA,O
in,O
the,O
postmarketing,O
setting,O
Patients,O
with,O
symptoms,O
and,O
signs,O
consistent,O
with,O
cryptococcal,O
meningitis,O
should,O
undergo,O
prompt,O
diagnostic,O
evaluation,O
and,O
treatment,O
Prior,O
and,O
Concomitant,O
Treatment,O
with,O
Antineoplastic,O
Immunosuppressive,O
or,O
Immune,O
Modulating,O
Therapies,O
In,O
clinical,O
studies,O
patients,O
who,O
received,O
GILENYA,O
did,O
not,O
receive,O
concomitant,O
treatment,O
with,O
antineoplastic,O
non,O
corticosteroid,O
immunosuppressive,O
or,O
immune,O
modulating,O
therapies,O
used,O
for,O
treatment,O
of,O
MS,O
Concomitant,O
use,O
of,O
GILENYA,O
with,O
any,O
of,O
these,O
therapies,O
and,O
also,O
with,O
corticosteroids,O
would,O
be,O
expected,O
to,O
increase,O
the,O
risk,Factor
of,O
immunosuppression,AdverseReaction
see,O
Drug,O
Interactions,O
7,O
When,O
switching,O
to,O
GILENYA,O
from,O
immune,O
modulating,O
or,O
immunosuppressive,O
medications,O
consider,O
the,O
duration,O
of,O
their,O
effects,O
and,O
their,O
mode,O
of,O
action,O
to,O
avoid,O
unintended,O
additive,O
immunosuppressive,O
effects,O
Varicella,O
Zoster,O
Virus,O
Antibody,O
Testing,O
Vaccination,O
Patients,O
without,O
a,O
healthcare,O
professional,O
confirmed,O
history,O
of,O
chickenpox,O
or,O
without,O
documentation,O
of,O
a,O
full,O
course,O
of,O
vaccination,O
against,O
varicella,O
zoster,O
virus,O
VZV,O
should,O
be,O
tested,O
for,O
antibodies,O
to,O
VZV,O
before,O
initiating,O
GILENYA,O
VZV,O
vaccination,O
of,O
antibody,O
negative,O
patients,O
is,O
recommended,O
prior,O
to,O
commencing,O
treatment,O
with,O
GILENYA,O
following,O
which,O
initiation,O
of,O
treatment,O
with,O
GILENYA,O
should,O
be,O
postponed,O
for,O
1,O
month,O
to,O
allow,O
the,O
full,O
effect,O
of,O
vaccination,O
to,O
occur,O
5,O
3,O
Progressive,O
Multifocal,O
Leukoencephalopathy,O
A,O
case,O
of,O
progressive multifocal leukoencephalopathy,AdverseReaction
PML,AdverseReaction
and,O
a,O
case,O
of,O
probable,Factor
PML,AdverseReaction
occurred,O
in,O
patients,O
with,O
MS,O
who,O
received,O
GILENYA,O
in,O
the,O
post,O
marketing,O
setting,O
PML,AdverseReaction
is,O
an,O
opportunistic viral infection of the brain,AdverseReaction
caused,O
by,O
the,O
JC virus,AdverseReaction
JCV,AdverseReaction
that,O
typically,Factor
only,O
occurs,O
in,O
patients,O
who,O
are,O
immunocompromised,O
and,O
that,O
usually,Factor
leads,O
to,O
death,AdverseReaction
or,O
severe,Severity
disability,AdverseReaction
One,O
patient,O
developed,O
PML,AdverseReaction
after,O
taking,O
GILENYA,O
for,O
approximately,O
2,O
5,O
years,O
The,O
other,O
patient,O
developed,O
probable,Factor
PML,AdverseReaction
after,O
taking,O
GILENYA,O
for,O
approximately,O
4,O
years,O
The,O
diagnosis,O
of,O
probable,Factor
PML,AdverseReaction
was,O
based,O
on,O
MRI,O
findings,O
and,O
the,O
detection,O
of,O
JCV,AdverseReaction
DNA,O
in the CSF,AdverseReaction
in,O
the,O
absence,Negation
of,O
clinical,O
signs,O
or,O
symptoms,O
specific,O
to,O
PML,AdverseReaction
The,O
patients,O
had,O
no,O
other,O
identified,O
systemic,O
medical,O
conditions,O
resulting,O
in,O
compromised immune system,AdverseReaction
function,O
and,O
had,O
not,O
previously,O
been,O
treated,O
with,O
natalizumab,Negation
which,O
has,O
a,O
known,O
association,O
with,O
PML,AdverseReaction
The,O
patients,O
were,O
also,O
not,O
taking,O
any,O
immunosuppressive,O
or,O
immunomodulatory,O
medications,O
concomitantly,O
At,O
the,O
first,O
sign,O
or,O
symptom,O
suggestive,O
of,O
PML,O
withhold,O
GILENYA,O
and,O
perform,O
an,O
appropriate,O
diagnostic,O
evaluation,O
MRI,O
signs,O
may,O
be,O
apparent,O
before,O
clinical,O
symptoms,O
Typical,Factor
symptoms,O
associated,O
with,O
PML,AdverseReaction
are,O
diverse,O
progress,O
over,O
days,O
to,O
weeks,O
and,O
include,O
progressive weakness on one side of the body,AdverseReaction
or,O
clumsiness of limbs,AdverseReaction
disturbance of vision,AdverseReaction
and,O
changes in thinking in in,AdverseReaction
memory,AdverseReaction
and,O
orientation,AdverseReaction
leading,O
to,O
confusion,AdverseReaction
and,O
personality changes,AdverseReaction
5,O
4,O
Macular,O
Edema,O
Fingolimod,O
increases,O
the,O
risk,Factor
of,O
macular edema,AdverseReaction
Perform,O
an,O
examination,O
of,O
the,O
fundus,O
including,O
the,O
macula,O
in,O
all,O
patients,O
before,O
starting,O
treatment,O
again,O
3,O
4,O
months,O
after,O
starting,O
treatment,O
and,O
again,O
at,O
any,O
time,O
after,O
a,O
patient,O
reports,O
visual,O
disturbances,O
while,O
on,O
GILENYA,O
therapy,O
A,O
dose,O
dependent,O
increase,O
in,O
the,O
risk,Factor
of,O
macular edema,AdverseReaction
occurred,O
in,O
the,O
GILENYA,O
clinical,O
development,O
program,O
In,O
2,O
year,O
double,O
blind,O
placebo,O
controlled,O
studies,O
in,O
patients,O
with,O
multiple,O
sclerosis,O
macular edema,AdverseReaction
with,O
or,O
without,O
visual symptoms,AdverseReaction
occurred,O
in,O
1,O
5,O
of,O
patients,O
11,O
799,O
treated,O
with,O
fingolimod,O
1,O
25,O
mg,O
0,O
5,O
of,O
patients,O
4,O
783,O
treated,O
with,O
GILENYA,O
0,O
5,O
mg,O
and,O
0,O
4,O
of,O
patients,O
3,O
773,O
treated,O
with,O
placebo,O
Macular edema,AdverseReaction
occurred,O
predominantly,O
during,O
the,O
first,O
3,O
to,O
4,O
months,O
of,O
therapy,O
These,O
clinical,O
trials,O
excluded,O
patients,O
with,O
diabetes,O
mellitus,O
a,O
known,O
risk,O
factor,O
for,O
macular,O
edema,O
see,O
below,O
Macular,O
Edema,O
in,O
Patients,O
with,O
History,O
of,O
Uveitis,O
or,O
Diabetes,O
Mellitus,O
Symptoms,O
of,O
macular edema,AdverseReaction
included,O
blurred vision,AdverseReaction
and,O
decreased visual acuity,AdverseReaction
Routine,O
ophthalmological,O
examination,O
detected,O
macular edema,AdverseReaction
in,O
some,O
patients,O
with,O
no,Negation
visual symptoms,AdverseReaction
Macular edema,AdverseReaction
generally,O
partially,O
or,O
completely,O
resolved,O
with,O
or,O
without,O
treatment,O
after,O
drug,O
discontinuation,O
Some,O
patients,O
had,O
residual,O
visual acuity loss,AdverseReaction
even,O
after,O
resolution,O
of,O
macular edema,AdverseReaction
Macular edema,AdverseReaction
has,O
also,O
been,O
reported,O
in,O
patients,O
taking,O
GILENYA,O
0,O
5,O
mg,O
in,O
the,O
postmarketing,O
setting,O
usually,O
within,O
the,O
first,O
6,O
months,O
of,O
treatment,O
Continuation,O
of,O
GILENYA,O
in,O
patients,O
who,O
develop,O
macular edema,AdverseReaction
has,O
not,O
been,O
evaluated,O
A,O
decision,O
on,O
whether,O
or,O
not,O
to,O
discontinue,O
GILENYA,O
therapy,O
should,O
include,O
an,O
assessment,O
of,O
the,O
potential,O
benefits,O
and,O
risks,O
for,O
the,O
individual,O
patient,O
The,O
risk,O
of,O
recurrence,O
after,O
rechallenge,O
has,O
not,O
been,O
evaluated,O
Macular,O
Edema,O
in,O
Patients,O
with,O
History,O
of,O
Uveitis,O
or,O
Diabetes,O
Mellitus,O
Patients,O
with,O
a,O
history,O
of,O
uveitis,O
and,O
patients,O
with,O
diabetes,O
mellitus,O
are,O
at,O
increased,O
risk,Factor
of,O
macular edema,AdverseReaction
during,O
GILENYA,O
therapy,O
The,O
incidence,O
of,O
macular edema,AdverseReaction
is,O
also,O
increased,O
in,O
MS,O
patients,O
with,O
a,O
history,O
of,O
uveitis,O
In,O
the,O
combined,O
clinical,O
trial,O
experience,O
with,O
all,O
doses,O
of,O
fingolimod,O
the,O
rate,O
of,O
macular edema,AdverseReaction
was,O
approximately,O
20,O
in,O
MS,O
patients,O
with,O
a,O
history,O
of,O
uveitis,O
versus,O
0,O
6,O
in,O
those,O
without,O
a,O
history,O
of,O
uveitis,O
GILENYA,O
has,O
not,O
been,O
tested,O
in,O
MS,O
patients,O
with,O
diabetes,O
mellitus,O
In,O
addition,O
to,O
the,O
examination,O
of,O
the,O
fundus,O
including,O
the,O
macula,O
prior,O
to,O
treatment,O
and,O
at,O
3,O
4,O
months,O
after,O
starting,O
treatment,O
MS,O
patients,O
with,O
diabetes,O
mellitus,O
or,O
a,O
history,O
of,O
uveitis,O
should,O
have,O
regular,O
follow,O
up,O
examinations,O
5,O
5,O
Posterior,O
Reversible,O
Encephalopathy,O
Syndrome,O
There,O
have,O
been,O
rare,O
cases,O
of,O
posterior reversible encephalopathy syndrome,AdverseReaction
PRES,AdverseReaction
reported,O
in,O
patients,O
receiving,O
GILENYA,O
Symptoms,O
reported,O
included,O
sudden,O
onset,O
of,O
severe,Severity
headache,AdverseReaction
altered mental status,AdverseReaction
visual disturbances,AdverseReaction
and,O
seizure,AdverseReaction
Symptoms,O
of,O
PRES,AdverseReaction
are,O
usually,O
reversible,O
but,O
may,Factor
evolve,O
into,O
ischemic stroke,AdverseReaction
or,O
cerebral hemorrhage,AdverseReaction
Delay,O
in,O
diagnosis,O
and,O
treatment,O
may,O
lead,O
to,O
permanent,O
neurological,O
sequelae,O
If,O
PRES,O
is,O
suspected,O
GILENYA,O
should,O
be,O
discontinued,O
5,O
6,O
Respiratory,O
Effects,O
Dose,O
dependent,O
reductions in forced expiratory volume over 1 second in in in,AdverseReaction
FEV1,AdverseReaction
and,O
diffusion lung capacity for carbon monoxide,AdverseReaction
DLCO,AdverseReaction
were,O
observed,O
in,O
patients,O
treated,O
with,O
GILENYA,O
as,O
early,O
as,O
1,O
month,O
after,O
treatment,O
initiation,O
In,O
2,O
year,O
placebo,O
controlled,O
trials,O
the,O
reduction,AdverseReaction
from,O
baseline,O
in,O
the,O
percent,O
of,O
predicted,O
values,O
for FEV1,AdverseReaction
at,O
the,O
time,O
of,O
last,O
assessment,O
on,O
drug,O
was,O
2,O
8,O
for,O
GILENYA,O
0,O
5,O
mg,O
and,O
1,O
0,O
for,O
placebo,O
For,O
DLCO,AdverseReaction
the,O
reduction,AdverseReaction
from,O
baseline,O
in,O
percent,O
of,O
predicted,O
values,O
at,O
the,O
time,O
of,O
last,O
assessment,O
on,O
drug,O
was,O
3,O
3,O
for,O
GILENYA,O
0,O
5,O
mg,O
and,O
0,O
5,O
for,O
placebo,O
The,O
changes in FEV1,AdverseReaction
appear,O
to,O
be,O
reversible,Severity
after,O
treatment,O
discontinuation,O
There,O
is,O
insufficient,O
information,O
to,O
determine,O
the,O
reversibility,O
of,O
the,O
decrease of DLCO,AdverseReaction
after,O
drug,O
discontinuation,O
In,O
MS,O
placebo,O
controlled,O
trials,O
dyspnea,AdverseReaction
was,O
reported,O
in,O
9,O
of,O
patients,O
receiving,O
GILENYA,O
0,O
5,O
mg,O
and,O
7,O
of,O
patients,O
receiving,O
placebo,O
Several,O
patients,O
discontinued,O
GILENYA,O
because,O
of,O
unexplained,O
dyspnea,AdverseReaction
during,O
the,O
extension,O
uncontrolled,O
studies,O
GILENYA,O
has,O
not,O
been,O
tested,O
in,O
MS,O
patients,O
with,O
compromised,O
respiratory,O
function,O
Spirometric,O
evaluation,O
of,O
respiratory,O
function,O
and,O
evaluation,O
of,O
DLCO,O
should,O
be,O
performed,O
during,O
therapy,O
with,O
GILENYA,O
if,O
clinically,O
indicated,O
5,O
7,O
Liver,O
Injury,O
Elevations of liver enzymes,AdverseReaction
may,Factor
occur,O
in,O
patients,O
receiving,O
GILENYA,O
Recent,O
i,O
e,O
within,O
last,O
6,O
months,O
transaminase,O
and,O
bilirubin,O
levels,O
should,O
be,O
available,O
before,O
initiation,O
of,O
GILENYA,O
therapy,O
In,O
2,O
year,O
placebo,O
controlled,O
clinical,O
trials,O
elevation of liver transaminases,AdverseReaction
to,O
3,O
fold,O
the,O
upper,O
limit,O
of,O
normal,O
ULN,O
or,O
greater,O
occurred,O
in,O
14,O
of,O
patients,O
treated,O
with,O
GILENYA,O
0,O
5,O
mg,O
and,O
3,O
of,O
patients,O
on,O
placebo,O
Elevations,O
5,O
fold,O
the,O
ULN,O
or,O
greater,O
occurred,O
in,O
4,O
5,O
of,O
patients,O
on,O
GILENYA,O
and,O
1,O
of,O
patients,O
on,O
placebo,O
The,O
majority,O
of,O
elevations,O
occurred,O
within,O
6,O
to,O
9,O
months,O
In,O
clinical,O
trials,O
GILENYA,O
was,O
discontinued,O
if,O
the,O
elevation,O
exceeded,O
5,O
times,O
the,O
ULN,O
Serum,O
transaminase,O
levels,O
returned,O
to,O
normal,O
within,O
approximately,O
2,O
months,O
after,O
discontinuation,O
of,O
GILENYA,O
Recurrence,O
of,O
liver transaminase elevations,AdverseReaction
occurred,O
with,O
rechallenge,O
in,O
some,O
patients,O
Liver,O
enzymes,O
should,O
be,O
monitored,O
in,O
patients,O
who,O
develop,O
symptoms,O
suggestive,O
of,O
hepatic,O
dysfunction,O
such,O
as,O
unexplained,O
nausea,O
vomiting,O
abdominal,O
pain,O
fatigue,O
anorexia,O
or,O
jaundice,O
and,O
or,O
dark,O
urine,O
GILENYA,O
should,O
be,O
discontinued,O
if,O
significant,O
liver,O
injury,O
is,O
confirmed,O
Patients,O
with,O
preexisting,O
liver,O
disease,O
may,O
be,O
at,O
increased,O
risk,Factor
of,O
developing,O
elevated liver enzymes,AdverseReaction
when,O
taking,O
GILENYA,O
Because,O
GILENYA,O
exposure,O
is,O
doubled,O
in,O
patients,O
with,O
severe,O
hepatic,O
impairment,O
these,O
patients,O
should,O
be,O
closely,O
monitored,O
as,O
the,O
risk,O
of,O
adverse,O
reactions,O
is,O
greater,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
8,O
Fetal,O
Risk,O
Based,O
on,O
animal,Animal
studies,O
GILENYA,O
may,O
cause,O
fetal harm,AdverseReaction
Because,O
it,O
takes,O
approximately,O
2,O
months,O
to,O
eliminate,O
GILENYA,O
from,O
the,O
body,O
women,O
of,O
childbearing,O
potential,O
should,O
use,O
effective,O
contraception,O
to,O
avoid,O
pregnancy,O
during,O
and,O
for,O
2,O
months,O
after,O
stopping,O
GILENYA,O
treatment,O
5,O
9,O
Blood,O
Pressure,O
Effects,O
In,O
MS,O
controlled,O
clinical,O
trials,O
patients,O
treated,O
with,O
GILENYA,O
0,O
5,O
mg,O
had,O
an,O
average,O
increase,AdverseReaction
over,O
placebo,O
of,O
approximately,O
3 mmHg,Severity
in,O
systolic pressure,AdverseReaction
and,O
approximately,O
2 mmHg,Severity
in,O
diastolic pressure,AdverseReaction
first,O
detected,O
after,O
approximately,O
1,O
month,O
of,O
treatment,O
initiation,O
and,O
persisting,O
with,O
continued,O
treatment,O
Hypertension,AdverseReaction
was,O
reported,O
as,O
an,O
adverse,O
reaction,O
in,O
8,O
of,O
patients,O
on,O
GILENYA,O
0,O
5,O
mg,O
and,O
in,O
4,O
of,O
patients,O
on,O
placebo,O
Blood,O
pressure,O
should,O
be,O
monitored,O
during,O
treatment,O
with,O
GILENYA,O
5,O
10,O
Immune,O
System,O
Effects,O
Following,O
GILENYA,O
Discontinuation,O
Fingolimod,O
remains,O
in,O
the,O
blood,O
and,O
has,O
pharmacodynamic,O
effects,O
including,O
decreased lymphocyte counts,AdverseReaction
for,O
up,O
to,O
2,O
months,O
following,O
the,O
last,O
dose,O
of,O
GILENYA,O
Lymphocyte,O
counts,O
generally,O
return,O
to,O
the,O
normal,O
range,O
within,O
1,O
2,O
months,O
of,O
stopping,O
therapy,O
see,O
Clinical,O
Pharmacology,O
12,O
2,O
Because,O
of,O
the,O
continuing,O
pharmacodynamic,O
effects,O
of,O
fingolimod,O
initiating,O
other,O
drugs,O
during,O
this,O
period,O
warrants,O
the,O
same,O
considerations,O
needed,O
for,O
concomitant,O
administration,O
e,O
g,O
risk,Factor
of,O
additive,O
immunosuppressant effects,AdverseReaction
see,O
Drug,O
Interactions,O
7,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
described,O
elsewhere,O
in,O
labeling,O
Bradyarrhythmia,AdverseReaction
and,O
Atrioventricular Blocks,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Progressive multifocal leukoencephalopathy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Macular Edema,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Posterior Reversible Encephalopathy Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Respiratory Effects,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Liver Injury,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
10,O
and,O
placebo,O
Headache,AdverseReaction
liver transaminase elevation,AdverseReaction
diarrhea,AdverseReaction
cough,AdverseReaction
influenza,AdverseReaction
sinusitis,AdverseReaction
back pain,AdverseReaction
abdominal pain,AdverseReaction
and,O
pain in extremity,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Novartis,O
Pharmaceuticals,O
Corporation,O
at,O
1,O
888,O
669,O
6682,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
In,O
clinical,O
trials,O
Studies,O
1,O
2,O
and,O
3,O
a,O
total,O
of,O
1212,O
patients,O
with,O
relapsing,O
forms,O
of,O
multiple,O
sclerosis,O
received,O
GILENYA,O
0,O
5,O
mg,O
This,O
included,O
783,O
patients,O
who,O
received,O
GILENYA,O
0,O
5,O
mg,O
in,O
the,O
2,O
year,O
placebo,O
controlled,O
trials,O
Studies,O
1,O
and,O
3,O
and,O
429,O
patients,O
who,O
received,O
GILENYA,O
0,O
5,O
mg,O
in,O
the,O
1,O
year,O
active,O
controlled,O
trial,O
Study,O
2,O
The,O
overall,O
exposure,O
in,O
the,O
controlled,O
trials,O
was,O
equivalent,O
to,O
1716,O
person,O
years,O
Approximately,O
1000,O
patients,O
received,O
at,O
least,O
2,O
years,O
of,O
treatment,O
with,O
GILENYA,O
0,O
5,O
mg,O
In,O
all,O
clinical,O
studies,O
including,O
uncontrolled,O
extension,O
studies,O
the,O
exposure,O
to,O
GILENYA,O
0,O
5,O
mg,O
was,O
approximately,O
4119,O
person,O
years,O
In,O
placebo,O
controlled,O
trials,O
the,O
most,O
frequent,O
adverse,O
reactions,O
incidence,O
10,O
and,O
placebo,O
for,O
GILENYA,O
0,O
5,O
mg,O
were,O
headache,AdverseReaction
liver transaminase elevation,AdverseReaction
diarrhea,AdverseReaction
cough,AdverseReaction
influenza,AdverseReaction
sinusitis,AdverseReaction
back pain,AdverseReaction
abdominal pain,AdverseReaction
and,O
pain in extremity,AdverseReaction
Adverse,O
events,O
that,O
led,O
to,O
treatment,O
discontinuation,O
and,O
occurred,O
in,O
more,O
than,O
1,O
of,O
patients,O
taking,O
GILENYA,O
0,O
5,O
mg,O
were,O
serum transaminase elevations,AdverseReaction
4,O
7,O
compared,O
to,O
1,O
on,O
placebo,O
and,O
basal cell carcinoma,AdverseReaction
1,O
compared,O
to,O
0,O
5,O
on,O
placebo,O
Table,O
1,O
lists,O
adverse,O
reactions,O
that,O
occurred,O
in,O
1,O
of,O
GILENYA,O
treated,O
patients,O
and,O
1,O
higher,O
rate,O
than,O
for,O
placebo,O
Table,O
1,O
Adverse,O
Reactions,O
Reported,O
in,O
Studies,O
1,O
and,O
3,O
Occurring,O
in,O
1,O
of,O
Patients,O
and,O
Reported,O
for,O
GILENYA,O
0,O
5,O
mg,O
at,O
1,O
Higher,O
Rate,O
than,O
for,O
Placebo,O
Primary,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
GILENYA,O
0,O
5,O
mg,O
N,O
783,O
Placebo,O
N,O
773,O
Infections,O
Influenza,AdverseReaction
11,O
8,O
Sinusitis,AdverseReaction
11,O
8,O
Bronchitis,AdverseReaction
8,O
5,O
Herpes zoster,AdverseReaction
2,O
1,O
Tinea versicolor,AdverseReaction
2,O
1,O
Cardiac,O
Disorders,O
Bradycardia,AdverseReaction
3,O
1,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
25,O
24,O
Migraine,AdverseReaction
6,O
4,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
13,O
12,O
Diarrhea,AdverseReaction
13,O
10,O
Abdominal pain,AdverseReaction
11,O
10,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Asthenia,AdverseReaction
2,O
1,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Back pain,AdverseReaction
10,O
9,O
Pain in extremity,AdverseReaction
10,O
7,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Alopecia,AdverseReaction
3,O
2,O
Actinic keratosis,AdverseReaction
2,O
1,O
Investigations,O
Liver transaminase elevations,AdverseReaction
elevations,AdverseReaction
ALT,AdverseReaction
GGT,AdverseReaction
AST,AdverseReaction
15,O
4,O
Blood triglycerides increased,AdverseReaction
3,O
1,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
12,O
11,O
Dyspnea,AdverseReaction
9,O
7,O
Eye,O
disorders,O
Vision blurred,AdverseReaction
4,O
2,O
Vascular,O
disorders,O
Hypertension,AdverseReaction
8,O
4,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Lymphopenia,AdverseReaction
7,O
1,O
Leukopenia,AdverseReaction
2,O
1,O
Neoplasms,O
benign,O
malignant,O
and,O
unspecified,O
including,O
cysts,O
and,O
polyps,O
Skin papilloma,AdverseReaction
3,O
2,O
Basal cell carcinoma,AdverseReaction
2,O
1,O
Adverse,O
reactions,O
of,O
dizziness,AdverseReaction
pneumonia,AdverseReaction
eczema,AdverseReaction
and,O
pruritus,AdverseReaction
were,O
also,O
reported,O
in,O
Studies,O
1,O
and,O
3,O
but,O
did,O
not,O
meet,O
the,O
reporting,O
rate,O
criteria,O
for,O
inclusion,O
in,O
Table,O
1,O
difference,O
was,O
less,O
than,O
1,O
Adverse,O
reactions,O
with,O
GILENYA,O
0,O
5,O
mg,O
in,O
Study,O
2,O
the,O
1,O
year,O
active,O
controlled,O
versus,O
interferon,O
beta,O
1a,O
study,O
were,O
generally,O
similar,O
to,O
those,O
in,O
Studies,O
1,O
and,O
3,O
Vascular,O
Events,O
Vascular events,AdverseReaction
including,O
ischemic,AdverseReaction
and,O
hemorrhagic strokes,AdverseReaction
and,O
peripheral arterial occlusive disease,AdverseReaction
were,O
reported,O
in,O
premarketing,O
clinical,O
trials,O
in,O
patients,O
who,O
received,O
GILENYA,O
doses,O
1,O
25,O
5,O
mg,O
higher,O
than,O
recommended,O
for,O
use,O
in,O
MS,O
Similar,O
events,O
have,O
been,O
reported,O
with,O
GILENYA,O
0,O
5,O
mg,O
in,O
the,O
postmarketing,O
setting,O
although,O
a,O
causal,O
relationship,O
has,O
not,O
been,O
established,O
Lymphomas,O
Cases,O
of,O
lymphoma,AdverseReaction
have,O
occurred,O
in,O
premarketing,O
clinical,O
trials,O
and,O
in,O
the,O
postmarketing,O
setting,O
The,O
relationship,O
to,O
GILENYA,O
remains,O
uncertain,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Diarrhea,O
Diarrhea,AdverseReaction
may,Factor
result,O
in,O
dehydration,AdverseReaction
and,O
renal failure,AdverseReaction
Withhold,O
GILOTRIF,O
for,O
severe,O
and,O
prolonged,O
diarrhea,O
not,O
responsive,O
to,O
anti,O
diarrheal,O
agents,O
2,O
3,O
5,O
1,O
Bullous,O
and,O
Exfoliative,O
Skin,AdverseReaction
Disorders,O
Severe,Severity
bullous,AdverseReaction
blistering,AdverseReaction
and,O
exfoliating lesions,AdverseReaction
occurred,O
in,O
0,O
15,O
of,O
patients,O
Discontinue,O
for,O
life,O
threatening,O
cutaneous,O
reactions,O
Withhold,O
GILOTRIF,O
for,O
severe,O
and,O
prolonged,O
cutaneous,O
reactions,O
2,O
3,O
5,O
2,O
Interstitial lung disease,AdverseReaction
ILD,AdverseReaction
Occurs,O
in,O
1,O
5,O
of,O
patients,O
Withhold,O
GILOTRIF,O
for,O
acute,O
onset,O
or,O
worsening,O
of,O
pulmonary,O
symptoms,O
Discontinue,O
GILOTRIF,O
if,O
ILD,O
is,O
diagnosed,O
2,O
3,O
5,O
3,O
Hepatic toxicity,AdverseReaction
Fatal,AdverseReaction
hepatic impairment,AdverseReaction
occurs,O
in,O
0,O
18,O
of,O
patients,O
Monitor,O
with,O
periodic,O
liver,O
testing,O
Withhold,O
or,O
discontinue,O
GILOTRIF,O
for,O
severe,O
or,O
worsening,O
liver,O
tests,O
2,O
3,O
5,O
4,O
Keratitis,AdverseReaction
Occurs,O
in,O
0,O
8,O
of,O
patients,O
Withhold,O
GILOTRIF,O
for,O
keratitis,O
evaluation,O
Withhold,O
or,O
discontinue,O
GILOTRIF,O
for,O
confirmed,O
ulcerative,O
keratitis,O
2,O
3,O
5,O
5,O
Embryofetal toxicity,AdverseReaction
Can,Factor
cause,O
fetal harm,AdverseReaction
Advise,O
females,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
and,O
to,O
use,O
highly,O
effective,O
contraception,O
5,O
6,O
5,O
1,O
Diarrhea,O
Diarrhea,AdverseReaction
has,O
resulted,O
in,O
dehydration,AdverseReaction
with,O
or,O
without,O
renal impairment,AdverseReaction
some,O
of,O
these,O
cases,O
were,O
fatal,AdverseReaction
In,O
Study,O
1,O
diarrhea,AdverseReaction
occurred,O
in,O
96,O
of,O
patients,O
treated,O
with,O
GILOTRIF,O
n,O
229,O
of,O
which,O
15,O
was,O
Grade 3,Severity
in,O
severity,O
and,O
occurred,O
within,O
the,O
first,O
6,O
weeks,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Renal impairment impairment,AdverseReaction
as,O
a,O
consequence,O
of,O
diarrhea,AdverseReaction
occurred,O
in,O
6,O
1,O
of,O
patients,O
treated,O
with,O
GILOTRIF,O
out,O
of,O
which,O
3,O
1,O
3,O
were,O
Grade 3,Severity
For,O
patients,O
who,O
develop,O
prolonged,O
Grade,O
2,O
diarrhea,O
lasting,O
more,O
than,O
48,O
hours,O
or,O
greater,O
than,O
or,O
equal,O
to,O
Grade,O
3,O
diarrhea,O
withhold,O
GILOTRIF,O
until,O
diarrhea,O
resolves,O
to,O
Grade,O
1,O
or,O
less,O
and,O
resume,O
GILOTRIF,O
with,O
appropriate,O
dose,O
reduction,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Provide,O
patients,O
with,O
an,O
anti,O
diarrheal,O
agent,O
e,O
g,O
loperamide,O
for,O
self,O
administration,O
at,O
the,O
onset,O
of,O
diarrhea,O
and,O
instruct,O
patients,O
to,O
continue,O
anti,O
diarrheal,O
therapy,O
until,O
loose,O
bowel,O
movements,O
cease,O
for,O
12,O
hours,O
5,O
2,O
Bullous,O
and,O
Exfoliative,O
Skin,O
Disorders,O
Grade 3,Severity
cutaneous reactions,AdverseReaction
characterized,O
by,O
bullous,AdverseReaction
blistering,AdverseReaction
and,O
exfoliating lesions,AdverseReaction
occurred,O
in,O
6,O
0,O
15,O
of,O
the,O
3865,O
patients,O
who,O
received,O
GILOTRIF,O
across,O
clinical,O
trials,O
see,O
Adverse,O
Reactions,O
6,O
1,O
In,O
Study,O
1,O
the,O
overall,O
incidence,O
of,O
cutaneous reactions,AdverseReaction
consisting,O
of,O
rash,AdverseReaction
erythema,AdverseReaction
and,O
acneiform rash,AdverseReaction
was,O
90,O
and,O
the,O
incidence,O
of,O
Grade 3,Severity
cutaneous reactions,AdverseReaction
was,O
16,O
In,O
addition,O
the,O
incidence,O
of,O
Grade 1 1 3,Severity
3,Severity
palmar plantar erythrodysesthesia syndrome,AdverseReaction
was,O
7,O
Discontinue,O
GILOTRIF,O
in,O
patients,O
who,O
develop,O
life,O
threatening,O
bullous,O
blistering,O
or,O
exfoliating,O
lesions,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
For,O
patients,O
who,O
develop,O
prolonged,O
Grade,O
2,O
cutaneous,O
adverse,O
reactions,O
lasting,O
more,O
than,O
7,O
days,O
intolerable,O
Grade,O
2,O
or,O
Grade,O
3,O
cutaneous,O
reactions,O
withhold,O
GILOTRIF,O
until,O
the,O
adverse,O
reaction,O
resolves,O
to,O
Grade,O
1,O
or,O
less,O
and,O
resume,O
GILOTRIF,O
with,O
appropriate,O
dose,O
reduction,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
3,O
Interstitial,O
Lung,O
Disease,O
ILD,O
ILD,AdverseReaction
or,O
ILD like adverse reactions,AdverseReaction
e,O
g,O
lung infiltration,AdverseReaction
pneumonitis,AdverseReaction
acute respiratory distress syndrome,AdverseReaction
or,O
alveolitis allergic,AdverseReaction
occurred,O
in,O
1,O
5,O
of,O
the,O
3865,O
patients,O
who,O
received,O
GILOTRIF,O
across,O
clinical,O
trials,O
of,O
these,O
0,O
4,O
were,O
fatal,AdverseReaction
The,O
incidence,O
of,O
ILD,AdverseReaction
appeared,O
to,O
be,O
higher,O
in,O
patients,O
of,O
Asian,O
ethnicity,O
2,O
1,O
as,O
compared,O
to,O
non,O
Asians,O
1,O
2,O
In,O
Study,O
1,O
the,O
incidence,O
of,O
Grade,Severity
3,Severity
ILD,AdverseReaction
was,O
1,O
3,O
and,O
resulted,O
in,O
death,AdverseReaction
in,O
1,O
of,O
GILOTRIF,O
treated,O
patients,O
Withhold,O
GILOTRIF,O
during,O
evaluation,O
of,O
patients,O
with,O
suspected,O
ILD,O
and,O
discontinue,O
GILOTRIF,O
in,O
patients,O
with,O
confirmed,O
ILD,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
4,O
Hepatic,O
Toxicity,O
In,O
3865,O
patients,O
who,O
received,O
GILOTRIF,O
across,O
clinical,O
trials,O
10,O
1,O
had,O
liver test abnormalities,AdverseReaction
of,O
which,O
7,O
0,O
18,O
were,O
fatal,AdverseReaction
In,O
Study,O
1,O
liver test abnormalities,AdverseReaction
of,O
any,O
grade,O
occurred,O
in,O
17,O
5,O
of,O
the,O
patients,O
treated,O
with,O
GILOTRIF,O
Obtain,O
periodic,O
liver,O
testing,O
in,O
patients,O
during,O
treatment,O
with,O
GILOTRIF,O
Withhold,O
GILOTRIF,O
in,O
patients,O
who,O
develop,O
worsening,O
of,O
liver,O
function,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
In,O
patients,O
who,O
develop,O
severe,O
hepatic,O
impairment,O
while,O
taking,O
GILOTRIF,O
treatment,O
should,O
be,O
discontinued,O
5,O
5,O
Keratitis,O
Keratitis,AdverseReaction
characterized,O
as,O
acute,AdverseReaction
or,O
worsening eye inflammation inflammation,AdverseReaction
lacrimation,AdverseReaction
light sensitivity,AdverseReaction
blurred vision,AdverseReaction
eye pain,AdverseReaction
and,O
or,O
red eye,AdverseReaction
occurred,O
in,O
0,O
8,O
of,O
patients,O
treated,O
with,O
GILOTRIF,O
among,O
3865,O
patients,O
across,O
clinical,O
trials,O
Keratitis,AdverseReaction
was,O
reported,O
in,O
5,O
2,O
2,O
patients,O
in,O
Study,O
1,O
with,O
Grade 3,Severity
in,O
1,O
0,O
4,O
Withhold,O
GILOTRIF,O
during,O
evaluation,O
of,O
patients,O
with,O
suspected,O
keratitis,O
and,O
if,O
diagnosis,O
of,O
ulcerative,O
keratitis,O
is,O
confirmed,O
treatment,O
with,O
GILOTRIF,O
should,O
be,O
interrupted,O
or,O
discontinued,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
If,O
keratitis,O
is,O
diagnosed,O
the,O
benefits,O
and,O
risks,O
of,O
continuing,O
treatment,O
should,O
be,O
carefully,O
considered,O
GILOTRIF,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
a,O
history,O
of,O
keratitis,O
ulcerative,O
keratitis,O
or,O
severe,O
dry,O
eye,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Contact,O
lens,O
use,O
is,O
also,O
a,O
risk,O
factor,O
for,O
keratitis,O
and,O
ulceration,O
5,O
6,O
Embryofetal,O
Toxicity,O
Based,O
on,O
its,O
mechanism,O
of,O
action,O
GILOTRIF,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Afatinib,O
was,O
embryotoxic,AdverseReaction
and,O
in,O
animals,O
with,O
maternal,O
toxicity,O
led,O
to,O
abortions at late gestational stages,AdverseReaction
in,O
rabbits,Animal
at,O
doses,O
of,O
5,O
mg,O
kg,O
approximately,O
0,O
2,O
times,O
the,O
human,O
exposure,O
at,O
the,O
recommended,O
dose,O
of,O
40,O
mg,O
daily,O
or,O
greater,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
Advise,O
females,O
of,O
reproductive,O
potential,O
to,O
use,O
highly,O
effective,O
contraception,O
during,O
treatment,O
and,O
for,O
at,O
least,O
2,O
weeks,O
after,O
the,O
last,O
dose,O
of,O
GILOTRIF,O
Advise,O
patients,O
to,O
contact,O
their,O
healthcare,O
provider,O
if,O
they,O
become,O
pregnant,O
or,O
if,O
pregnancy,O
is,O
suspected,O
while,O
taking,O
GILOTRIF,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1and8,O
6,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Diarrhea,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Bullous,AdverseReaction
and,O
Exfoliative Skin Disorders Disorders,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Interstitial Lung Disease,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Hepatic Toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Keratitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
20,O
are,O
diarrhea,AdverseReaction
rash,AdverseReaction
dermatitis acneiform,AdverseReaction
stomatitis,AdverseReaction
paronychia,AdverseReaction
dry skin,AdverseReaction
decreased appetite,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
pruritus,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Boehringer,O
Ingelheim,O
Pharmaceuticals,O
Inc,O
at,O
800,O
542,O
6257,O
or,O
800,O
459,O
9906,O
TTY,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
orwww,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
safety,O
evaluation,O
of,O
GILOTRIF,O
is,O
based,O
on,O
the,O
data,O
from,O
more,O
than,O
3800,O
patients,O
including,O
2135,O
NSCLC,O
patients,O
receiving,O
GILOTRIF,O
monotherapy,O
at,O
or,O
above,O
the,O
recommended,O
dose,O
Controlled,O
Study,O
The,O
data,O
in,O
Tables,O
1,O
and,O
2,O
below,O
reflect,O
exposure,O
of,O
229,O
EGFR,O
TKI,O
naive,O
GILOTRIF,O
treated,O
patients,O
with,O
EGFR,O
mutation,O
positive,O
metastatic,O
non,O
squamous,O
NSCLC,O
enrolled,O
in,O
a,O
randomized,O
multicenter,O
open,O
label,O
trial,O
Study,O
1,O
Patients,O
received,O
GILOTRIF,O
40,O
mg,O
daily,O
until,O
documented,O
disease,O
progression,O
or,O
intolerance,O
to,O
the,O
therapy,O
A,O
total,O
of,O
111,O
patients,O
were,O
treated,O
with,O
pemetrexed,O
cisplatin,O
Patients,O
were,O
treated,O
with,O
pemetrexed,O
500,O
mg,O
m2,O
followed,O
after,O
30,O
minutes,O
by,O
cisplatin,O
75,O
mg,O
m2,O
every,O
three,O
weeks,O
for,O
a,O
maximum,O
of,O
six,O
treatment,O
courses,O
The,O
median,O
exposure,O
was,O
11,O
0,O
months,O
for,O
patients,O
treated,O
with,O
GILOTRIF,O
and,O
3,O
4,O
months,O
for,O
patients,O
treated,O
with,O
pemetrexed,O
cisplatin,O
The,O
overall,O
trial,O
population,O
had,O
a,O
median,O
age,O
of,O
61,O
years,O
61,O
of,O
patients,O
in,O
the,O
GILOTRIF,O
arm,O
and,O
60,O
of,O
patients,O
in,O
the,O
pemetrexed,O
cisplatin,O
arm,O
were,O
younger,O
than,O
65,O
years,O
A,O
total,O
of,O
64,O
of,O
patients,O
on,O
GILOTRIF,O
and,O
67,O
of,O
pemetrexed,O
cisplatin,O
patients,O
were,O
female,O
More,O
than,O
two,O
thirds,O
of,O
patients,O
were,O
from,O
Asia,O
GILOTRIF,O
70,O
pemetrexed,O
cisplatin,O
72,O
Serious,O
adverse,O
reactions,O
were,O
reported,O
in,O
29,O
of,O
patients,O
treated,O
with,O
GILOTRIF,O
The,O
most,O
frequent,O
serious,O
adverse,O
reactions,O
reported,O
in,O
patients,O
treated,O
with,O
GILOTRIF,O
were,O
diarrhea,AdverseReaction
6,O
6,O
vomiting,AdverseReaction
4,O
8,O
and,O
dyspnea,AdverseReaction
fatigue,AdverseReaction
and,O
hypokalemia,AdverseReaction
1,O
7,O
each,O
Fatal,AdverseReaction
adverse,O
reactions,O
in,O
GILOTRIF,O
treated,O
patients,O
in,O
Study,O
1,O
included,O
pulmonary toxicity,AdverseReaction
ILD like adverse reactions,AdverseReaction
1,O
3,O
sepsis,AdverseReaction
0,O
43,O
and,O
pneumonia,AdverseReaction
0,O
43,O
Dose,O
reductions,O
due,O
to,O
adverse,O
reactions,O
were,O
required,O
in,O
57,O
of,O
GILOTRIF,O
treated,O
patients,O
The,O
most,O
frequent,O
adverse,O
reactions,O
that,O
led,O
to,O
dose,O
reduction,O
in,O
the,O
patients,O
treated,O
with,O
GILOTRIF,O
were,O
diarrhea,AdverseReaction
20,O
rash,AdverseReaction
acne,AdverseReaction
19,O
paronychia,AdverseReaction
14,O
and,O
stomatitis,AdverseReaction
10,O
Discontinuation,O
of,O
therapy,O
in,O
GILOTRIF,O
treated,O
patients,O
for,O
adverse,O
reactions,O
was,O
14,O
0,O
The,O
most,O
frequent,O
adverse,O
reactions,O
that,O
led,O
to,O
discontinuation,O
in,O
GILOTRIF,O
treated,O
patients,O
were,O
diarrhea,AdverseReaction
1,O
3,O
ILD,AdverseReaction
0,O
9,O
and,O
paronychia,AdverseReaction
0,O
9,O
Clinical,O
trials,O
of,O
GILOTRIF,O
excluded,O
patients,O
with,O
an,O
abnormal,O
left,O
ventricular,O
ejection,O
fraction,O
LVEF,O
i,O
e,O
below,O
the,O
institutional,O
lower,O
limit,O
of,O
normal,O
In,O
Study,O
1,O
all,O
patients,O
were,O
evaluated,O
for,O
LVEF,O
at,O
screening,O
and,O
every,O
9,O
weeks,O
thereafter,O
in,O
the,O
GILOTRIF,O
treated,O
group,O
and,O
as,O
needed,O
in,O
the,O
pemetrexed,O
cisplatin,O
group,O
More,O
GILOTRIF,O
treated,O
patients,O
2,O
2,O
n,O
5,O
experienced,O
ventricular dysfunction,AdverseReaction
defined,O
as,O
diastolic dysfunction,AdverseReaction
left ventricular dysfunction,AdverseReaction
or,O
ventricular dilation,AdverseReaction
all,O
Grade,O
3,O
compared,O
to,O
chemotherapy,O
treated,O
patients,O
0,O
9,O
n,O
1,O
Table,O
1,O
Adverse,O
Reactions,O
Reported,O
in,O
10,O
of,O
GILOTRIF,O
Treated,O
Patients,O
in,O
Study,O
1,O
None,O
of,O
the,O
adverse,O
reactions,O
in,O
this,O
table,O
except,O
stomatitis,AdverseReaction
one,O
patient,O
on,O
GILOTRIF,O
0,O
4,O
were,O
Grade 4,Severity
in,O
severity,O
1,O
Includes,O
stomatitis,AdverseReaction
aphthous stomatitis,AdverseReaction
mucosal inflammation,AdverseReaction
mouth ulceration,AdverseReaction
oral mucosa erosion,AdverseReaction
mucosal erosion,AdverseReaction
mucosal ulceration,AdverseReaction
2,O
Includes,O
group,O
of,O
rash,AdverseReaction
preferred,O
terms,O
acne,AdverseReaction
acne pustular,AdverseReaction
dermatitis acneiform,AdverseReaction
3,O
Includes,O
paronychia,AdverseReaction
nail infection,AdverseReaction
nail bed infection,AdverseReaction
GILOTRIFn,O
229,O
Pemetrexed,O
Cisplatinn,O
111,O
Adverse,O
Reaction,O
All,O
Grades,O
Grade,O
3,O
All,O
Grades,O
Grade,O
3,O
Gastrointestinal,O
disorders,O
Diarrhea,AdverseReaction
96,O
15,O
23,O
2,O
Stomatitis,AdverseReaction
1,O
71,O
9,O
15,O
1,O
Nausea,AdverseReaction
25,O
4,O
68,O
4,O
Vomiting,AdverseReaction
23,O
4,O
47,O
3,O
Cheilitis,AdverseReaction
12,O
0,O
1,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
Dermatitis acneiform,AdverseReaction
2,O
90,O
16,O
11,O
0,O
Pruritus,AdverseReaction
21,O
0,O
1,O
0,O
Dry skin,AdverseReaction
31,O
0,O
2,O
0,O
Infections,O
and,O
infestations,O
Paronychia,AdverseReaction
3,O
58,O
11,O
0,O
0,O
Cystitis,AdverseReaction
13,O
1,O
5,O
0,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
29,O
4,O
55,O
4,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Epistaxis,AdverseReaction
17,O
0,O
2,O
1,O
Rhinorrhea,AdverseReaction
11,O
0,O
6,O
0,O
Investigations,O
Weight Decreased,AdverseReaction
17,O
1,O
14,O
1,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Pyrexia,AdverseReaction
12,O
0,O
6,O
0,O
Eye,O
disorders,O
Conjunctivitis,AdverseReaction
11,O
0,O
3,O
0,O
Table,O
2,O
Adverse,O
Reactions,O
of,O
Laboratory,O
Abnormalities,O
from,O
the,O
Investigations,O
SOC,O
Reported,O
in,O
5,O
of,O
GILOTRIF,O
Treated,O
Patients,O
in,O
Study,O
1,O
1,O
Includes,O
hypokalemia,AdverseReaction
blood,O
potassium,O
decreasedSOC,O
system,O
organ,O
class,O
GILOTRIFn,O
229,O
Pemetrexed,O
Cisplatinn,O
111,O
Adverse,O
Reaction,O
All,O
Grades,O
Grades,O
3,O
4,O
All,O
Grades,O
Grades,O
3,O
4,O
Alanine aminotransferase increased,AdverseReaction
11,O
2,O
4,O
0,O
Hypokalemia,AdverseReaction
1,O
11,O
4,O
5,O
4,O
Aspartate aminotransferase increased,AdverseReaction
8,O
2,O
2,O
1,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
GILOTRIF,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Pancreatitis,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Splenic Rupture,AdverseReaction
Discontinue,O
GRANIX,O
if,O
suspected,O
5,O
1,O
Acute Respiratory Distress Syndrome,AdverseReaction
ARDS,AdverseReaction
Monitor,O
for,O
and,O
manage,O
immediately,O
Discontinue,O
GRANIX,O
if,O
suspected,O
5,O
2,O
Allergic reactions,AdverseReaction
angioneurotic edema,AdverseReaction
dermatitis allergic,AdverseReaction
drug hypersensitivity,AdverseReaction
hypersensitivity,AdverseReaction
rash,AdverseReaction
pruritic rash,AdverseReaction
and,O
urticaria,AdverseReaction
5,O
3,O
Sickle cell crisis,AdverseReaction
Severe,Severity
and,O
sometimes,O
fatal,AdverseReaction
crisis,O
can,Factor
occur,O
Discontinue,O
GRANIX,O
if,O
suspected,O
5,O
4,O
Capillary Leak Syndrome,AdverseReaction
Monitor,O
if,O
symptoms,O
develop,O
and,O
administer,O
standard,O
symptomatic,O
treatment,O
5,O
5,O
5,O
1,O
Splenic,O
Rupture,O
Splenic rupture,AdverseReaction
including,O
fatal,AdverseReaction
cases,O
can,Factor
occur,O
following,O
administration,O
of,O
human,O
granulocyte,O
colony,O
stimulating,O
factors,O
In,O
patients,O
who,O
report,O
upper,O
abdominal,O
or,O
shoulder,O
pain,O
after,O
receiving,O
GRANIX,O
discontinue,O
GRANIX,O
and,O
evaluate,O
for,O
an,O
enlarged,O
spleen,O
or,O
splenic,O
rupture,O
5,O
2,O
Acute,O
Respiratory,O
Distress,O
Syndrome,O
ARDS,O
Acute respiratory distress syndrome,AdverseReaction
ARDS,AdverseReaction
can,O
occur,O
in,O
patients,O
receiving,O
human granulocyte colony stimulating factors,DrugClass
Evaluate,O
patients,O
who,O
develop,O
fever,O
and,O
lung,O
infiltrates,O
or,O
respiratory,O
distress,O
after,O
receiving,O
GRANIX,O
for,O
ARDS,O
Discontinue,O
GRANIX,O
in,O
patients,O
with,O
ARDS,O
5,O
3,O
Allergic,O
Reactions,O
Serious,Severity
allergic reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
can,O
occur,O
in,O
patients,O
receiving,O
human granulocyte colony stimulating factors,DrugClass
Reactions,O
can,O
occur,O
on,O
initial,O
exposure,O
The,O
administration,O
of,O
antihistamines,O
steroids,O
bronchodilators,O
and,O
or,O
epinephrine,O
may,O
reduce,O
the,O
severity,O
of,O
the,O
reactions,O
Permanently,O
discontinue,O
GRANIX,O
in,O
patients,O
with,O
serious,O
allergic,O
reactions,O
Do,O
not,O
administer,O
GRANIX,O
to,O
patients,O
with,O
a,O
history,O
of,O
serious,O
allergic,O
reactions,O
to,O
filgrastim,O
or,O
pegfilgrastim,O
5,O
4,O
Use,O
in,O
Patients,O
with,O
Sickle,O
Cell,O
Disease,O
Severe,O
and,O
sometimes,O
fatal,AdverseReaction
sickle cell crises,AdverseReaction
can,Factor
occur,O
in,O
patients,O
with,O
sickle,O
cell,O
disease,O
receiving,O
human,O
granulocyte,O
colony,O
stimulating,O
factors,O
Consider,O
the,O
potential,O
risks,O
and,O
benefits,O
prior,O
to,O
the,O
administration,O
of,O
human,O
granulocyte,O
colony,O
stimulating,O
factors,O
in,O
patients,O
with,O
sickle,O
cell,O
disease,O
Discontinue,O
GRANIX,O
in,O
patients,O
undergoing,O
a,O
sickle,O
cell,O
crisis,O
5,O
5,O
Capillary,O
Leak,O
Syndrome,O
Capillary leak syndrome,AdverseReaction
CLS,AdverseReaction
can,O
occur,O
in,O
patients,O
receiving,O
human granulocyte colony stimulating factors,DrugClass
and,O
is,O
characterized,O
by,O
hypotension,AdverseReaction
hypoalbuminemia,AdverseReaction
edema,AdverseReaction
and,O
hemoconcentration,AdverseReaction
Episodes,O
vary,O
in,O
frequency,O
severity,O
and,O
may,O
be,O
life,O
threatening,O
if,O
treatment,O
is,O
delayed,O
Patients,O
who,O
develop,O
symptoms,O
of,O
capillary,O
leak,O
syndrome,O
should,O
be,O
closely,O
monitored,O
and,O
receive,O
standard,O
symptomatic,O
treatment,O
which,O
may,O
include,O
a,O
need,O
for,O
intensive,O
care,O
5,O
6,O
Potential,O
for,O
Tumor,O
Growth,O
Stimulatory,O
Effects,O
on,O
Malignant,O
Cells,O
The,O
granulocyte,O
colony,O
stimulating,O
factor,O
G,O
CSF,O
receptor,O
through,O
which,O
GRANIX,O
acts,O
has,O
been,O
found,O
on,O
tumor,O
cell,O
lines,O
The,O
possibility,Factor
that,O
GRANIX,O
acts,O
as,O
a,O
growth factor for,AdverseReaction
any,O
tumor,AdverseReaction
type,O
including,O
myeloid malignancies,AdverseReaction
and,O
myelodysplasia,AdverseReaction
diseases,O
for,O
which,O
GRANIX,O
is,O
not,O
approved,O
cannot,O
be,O
excluded,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
potential,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Splenic Rupture,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Acute Respiratory Distress Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Serious,Severity
Allergic Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Use,O
in,O
Patients,O
with,O
Sickle,O
Cell,O
Disease,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Capillary Leak Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Potential,Factor
for,O
Tumor Growth Stimulatory Effects on Malignant Cells,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
The,O
most,O
common,O
treatment,O
emergent,O
adverse,O
reaction,O
that,O
occurred,O
at,O
an,O
incidence,O
of,O
at,O
least,O
1,O
or,O
greater,O
in,O
patients,O
treated,O
with,O
GRANIX,O
at,O
the,O
recommended,O
dose,O
and,O
was,O
numerically,O
two,O
times,O
more,O
frequent,O
than,O
in,O
the,O
placebo,O
group,O
was,O
bone pain,AdverseReaction
EXCERPT,O
Most,O
common,O
adverse,O
reaction,O
to,O
GRANIX,O
is,O
bone pain,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
TEVA,O
at,O
1,O
866,O
832,O
8537,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
GRANIX,O
clinical,O
trials,O
safety,O
data,O
are,O
based,O
upon,O
the,O
results,O
of,O
three,O
randomized,O
clinical,O
trials,O
in,O
patients,O
receiving,O
myeloablative,O
chemotherapy,O
for,O
breast,O
cancer,O
N,O
348,O
lung,O
cancer,O
N,O
240,O
and,O
non,O
Hodgkin,O
s,O
lymphoma,O
N,O
92,O
In,O
the,O
breast,O
cancer,O
study,O
99,O
of,O
patients,O
were,O
female,O
the,O
median,O
age,O
was,O
50,O
years,O
and,O
86,O
of,O
patients,O
were,O
Caucasian,O
In,O
the,O
lung,O
cancer,O
study,O
80,O
of,O
patients,O
were,O
male,O
the,O
median,O
age,O
was,O
58,O
years,O
and,O
95,O
of,O
patients,O
were,O
Caucasian,O
In,O
the,O
non,O
Hodgkin,O
s,O
lymphoma,O
study,O
52,O
of,O
patients,O
were,O
male,O
the,O
median,O
age,O
was,O
55,O
years,O
and,O
88,O
of,O
patients,O
were,O
Caucasian,O
In,O
all,O
three,O
studies,O
a,O
placebo,O
Cycle,O
1,O
of,O
the,O
breast,O
cancer,O
study,O
only,O
or,O
a,O
non,O
US,O
approved,O
filgrastim,O
product,O
were,O
used,O
as,O
controls,O
Both,O
GRANIX,O
and,O
the,O
non,O
US,O
approved,O
filgrastim,O
product,O
were,O
administered,O
at,O
5,O
mcg,O
kg,O
subcutaneously,O
once,O
daily,O
beginning,O
one,O
day,O
after,O
chemotherapy,O
for,O
at,O
least,O
five,O
days,O
and,O
continued,O
to,O
a,O
maximum,O
of,O
14,O
days,O
or,O
until,O
an,O
ANC,O
of,O
10,O
000,O
x,O
10,O
6,O
L,O
after,O
nadir,O
was,O
reached,O
Bone pain,AdverseReaction
was,O
the,O
most,O
frequent,O
treatment,O
emergent,O
adverse,O
reaction,O
that,O
occurred,O
in,O
at,O
least,O
1,O
or,O
greater,O
in,O
patients,O
treated,O
with,O
GRANIX,O
at,O
the,O
recommended,O
dose,O
and,O
was,O
numerically,O
two,O
times,O
more,O
frequent,O
than,O
in,O
the,O
placebo,O
group,O
The,O
overall,O
incidence,O
of,O
bone pain,AdverseReaction
in,O
Cycle,O
1,O
of,O
treatment,O
was,O
3,O
4,O
3,O
4,O
GRANIX,O
1,O
4,O
placebo,O
7,O
5,O
non,O
US,O
approved,O
filgrastim,O
product,O
Leukocytosis,O
In,O
clinical,O
studies,O
leukocytosis,AdverseReaction
WBC counts 100 000 x 10 6 L,AdverseReaction
was,O
observed,O
in,O
less,O
than,O
1,O
patients,O
with,O
non,O
myeloid,O
malignancies,O
receiving,O
GRANIX,O
No,O
complications,O
attributable,O
to,O
leukocytosis,AdverseReaction
were,O
reported,O
in,O
clinical,O
studies,O
Additional,O
Adverse,O
Reactions,O
Other,O
adverse,O
reactions,O
known,O
to,O
occur,O
following,O
administration,O
of,O
human granulocyte colony stimulating factors,DrugClass
include,O
myalgia,AdverseReaction
headache,AdverseReaction
vomiting,AdverseReaction
Sweet s syndrome,AdverseReaction
acute febrile neutrophilic dermatosis,AdverseReaction
cutaneous vasculitis,AdverseReaction
and,O
thrombocytopenia,AdverseReaction
6,O
2,O
Immunogenicity,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
a,O
potential,O
for,O
immunogenicity,O
The,O
incidence,O
of,O
antibody,O
development,O
in,O
patients,O
receiving,O
GRANIX,O
has,O
not,O
been,O
adequately,O
determined,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Neutropenia,AdverseReaction
Monitor,O
peripheral,O
blood,O
cell,O
counts,O
and,O
adjust,O
dose,O
as,O
appropriate,O
2,O
2,O
5,O
1,O
6,O
Peripheral Neuropathy,AdverseReaction
Monitor,O
for,O
signs,O
of,O
neuropathy,O
Manage,O
with,O
dose,O
delay,O
and,O
adjustment,O
2,O
2,O
5,O
2,O
6,O
Embryo Fetal Toxicity,AdverseReaction
Fetal harm,AdverseReaction
can,Factor
occur,O
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
5,O
3,O
8,O
1,O
QT Prolongation,AdverseReaction
Monitor,O
for,O
prolonged,O
QT,O
intervals,O
in,O
patients,O
with,O
congestive,O
heart,O
failure,O
bradyarrhythmias,O
drugs,O
known,O
to,O
prolong,O
the,O
QT,O
interval,O
and,O
electrolyte,O
abnormalities,O
Avoid,O
in,O
patients,O
with,O
congenital,O
long,O
QT,O
syndrome,O
5,O
4,O
5,O
1,O
Neutropenia,O
Severe,Severity
neutropenia,AdverseReaction
ANC,O
500,O
mm,O
3,O
lasting,O
more,O
than,O
one,O
week,O
occurred,O
in,O
12,O
62,O
503,O
of,O
patients,O
in,O
Study,O
1,O
leading,O
to,O
discontinuation,O
in,O
1,O
of,O
patients,O
see,O
Adverse,O
Reactions,O
6,O
Patients,O
with,O
alanine,O
aminotransferase,O
or,O
aspartate,O
aminotransferase,O
3,O
ULN,O
upper,O
limit,O
of,O
normal,O
experienced,O
a,O
higher,O
incidence,O
of,O
Grade 4,Severity
neutropenia,AdverseReaction
and,O
febrile neutropenia,AdverseReaction
than,O
patients,O
with,O
normal,O
aminotransferase,O
levels,O
Patients,O
with,O
bilirubin,O
1,O
5,O
ULN,O
also,O
had,O
a,O
higher,O
incidence,O
of,O
Grade 4,Severity
neutropenia,AdverseReaction
and,O
febrile neutropenia,AdverseReaction
Monitor,O
complete,O
blood,O
counts,O
prior,O
to,O
each,O
dose,O
increase,O
the,O
frequency,O
of,O
monitoring,O
in,O
patients,O
who,O
develop,O
Grade,O
3,O
or,O
4,O
cytopenias,O
Delay,O
administration,O
of,O
HALAVEN,O
and,O
reduce,O
subsequent,O
doses,O
in,O
patients,O
who,O
experience,O
febrile,O
neutropenia,O
or,O
Grade,O
4,O
neutropenia,O
lasting,O
longer,O
than,O
7,O
days,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Clinical,O
studies,O
of,O
HALAVEN,O
did,O
not,O
include,O
patients,O
with,O
baseline,O
neutrophil,O
counts,O
below,O
1,O
500,O
mm,O
3,O
5,O
2,O
Peripheral,O
Neuropathy,O
Grade 3,Severity
peripheral neuropathy neuropathy,AdverseReaction
occurred,O
in,O
8,O
40,O
503,O
of,O
patients,O
and,O
Grade 4,Severity
in,O
0,O
4,O
2,O
503,O
of,O
patients,O
in,O
Study,O
1,O
Peripheral neuropathy,AdverseReaction
was,O
the,O
most,O
common,O
toxicity,O
leading,O
to,O
discontinuation,O
of,O
HALAVEN,O
5,O
of,O
patients,O
24,O
503,O
Neuropathy,AdverseReaction
lasting,O
more,O
than,O
one,O
year,O
occurred,O
in,O
5,O
26,O
503,O
of,O
patients,O
Twenty,O
two,O
percent,O
109,O
503,O
of,O
patients,O
developed,O
a,O
new,O
or,O
worsening,O
neuropathy,AdverseReaction
that,O
had,O
not,O
recovered,O
within,O
a,O
median,O
follow,O
up,O
duration,O
of,O
269,O
days,O
range,O
25,O
662,O
days,O
Monitor,O
patients,O
closely,O
for,O
signs,O
of,O
peripheral,O
motor,O
and,O
sensory,O
neuropathy,O
Withhold,O
HALAVEN,O
in,O
patients,O
who,O
experience,O
Grade,O
3,O
or,O
4,O
peripheral,O
neuropathy,O
until,O
resolution,O
to,O
Grade,O
2,O
or,O
less,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
3,O
Embryo,O
Fetal,O
Toxicity,O
There,O
are,O
no,O
adequate,O
and,O
well,O
controlled,O
studies,O
of,O
HALAVEN,O
in,O
pregnant,O
women,O
HALAVEN,O
is,O
a,O
microtubule inhibitor,DrugClass
therefore,O
it,O
is,O
expected,O
to,O
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Embryo fetal toxicity,AdverseReaction
and,O
teratogenicity,AdverseReaction
occurred,O
in,O
rats,Animal
that,O
received,O
eribulin,O
mesylate,O
at,O
approximately,O
half,O
of,O
the,O
recommended,O
human,O
dose,O
based,O
on,O
body,O
surface,O
area,O
If,Factor
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
a,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
she,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,Factor
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
5,O
4,O
QT,O
Prolongation,O
In,O
an,O
uncontrolled,O
open,O
label,O
ECG,O
study,O
in,O
26,O
patients,O
QT prolongation,AdverseReaction
was,O
observed,O
on,O
Day,O
8,O
independent,O
of,O
eribulin,O
concentration,O
with,O
no,Negation
QT prolongation,AdverseReaction
observed,O
on,O
Day,O
1,O
ECG,O
monitoring,O
is,O
recommended,O
if,O
therapy,O
is,O
initiated,O
in,O
patients,O
with,O
congestive,O
heart,O
failure,O
bradyarrhythmias,O
drugs,O
known,O
to,O
prolong,O
the,O
QT,O
interval,O
including,O
Class,O
Ia,O
and,O
III,O
antiarrhythmics,O
and,O
electrolyte,O
abnormalities,O
Correct,O
hypokalemia,O
or,O
hypomagnesemia,O
prior,O
to,O
initiating,O
HALAVEN,O
and,O
monitor,O
these,O
electrolytes,O
periodically,O
during,O
therapy,O
Avoid,O
HALAVEN,O
in,O
patients,O
with,O
congenital,O
long,O
QT,O
syndrome,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
25,O
were,O
neutropenia,AdverseReaction
anemia,AdverseReaction
asthenia,AdverseReaction
fatigue,AdverseReaction
alopecia,AdverseReaction
peripheral neuropathy,AdverseReaction
nausea,AdverseReaction
and,O
constipation,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Eisai,O
Inc,O
at,O
1,O
877,O
873,O
4724,O
or,O
contact,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
the,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
other,O
clinical,O
trials,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Neutropenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Peripheral neuropathy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
QT interval prolongation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
The,O
most,O
common,O
adverse,O
reactions,O
25,O
reported,O
in,O
patients,O
receiving,O
HALAVEN,O
were,O
neutropenia,AdverseReaction
anemia,AdverseReaction
asthenia,AdverseReaction
fatigue,AdverseReaction
alopecia,AdverseReaction
peripheral neuropathy,AdverseReaction
nausea,AdverseReaction
and,O
constipation,AdverseReaction
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
reported,O
in,O
patients,O
receiving,O
HALAVEN,O
were,O
febrile neutropenia,AdverseReaction
4,O
and,O
neutropenia,AdverseReaction
2,O
The,O
most,O
common,O
adverse,O
reaction,O
resulting,O
in,O
discontinuation,O
of,O
HALAVEN,O
was,O
peripheral neuropathy,AdverseReaction
5,O
In,O
clinical,O
trials,O
HALAVEN,O
has,O
been,O
administered,O
to,O
1,O
222,O
patients,O
with,O
multiple,O
tumor,O
types,O
including,O
240,O
patients,O
exposed,O
to,O
HALAVEN,O
for,O
6,O
months,O
or,O
longer,O
The,O
majority,O
of,O
the,O
1,O
222,O
patients,O
were,O
women,O
82,O
with,O
a,O
median,O
age,O
of,O
58,O
years,O
range,O
26,O
to,O
91,O
years,O
The,O
racial,O
and,O
ethnic,O
distribution,O
was,O
Caucasian,O
83,O
Black,O
5,O
Asian,O
2,O
and,O
other,O
5,O
The,O
adverse,O
reactions,O
described,O
in,O
Table,O
2,O
were,O
identified,O
in,O
750,O
patients,O
treated,O
in,O
Study,O
1,O
see,O
Clinical,O
Studies,O
14,O
In,O
Study,O
1,O
patients,O
were,O
randomized,O
2,O
1,O
to,O
receive,O
either,O
HALAVEN,O
1,O
4,O
mg,O
m,O
2,O
on,O
Days,O
1,O
and,O
8,O
of,O
a,O
21,O
day,O
cycle,O
or,O
single,O
agent,O
treatment,O
chosen,O
by,O
their,O
physician,O
control,O
group,O
A,O
total,O
of,O
503,O
patients,O
received,O
HALAVEN,O
and,O
247,O
patients,O
in,O
the,O
control,O
group,O
received,O
therapy,O
consisting,O
of,O
chemotherapy,O
total,O
97,O
anthracyclines,O
10,O
capecitabine,O
18,O
gemcitabine,O
19,O
taxanes,O
15,O
vinorelbine,O
25,O
other,O
chemotherapies,O
10,O
or,O
hormonal,O
therapy,O
3,O
The,O
median,O
duration,O
of,O
exposure,O
was,O
118,O
days,O
for,O
patients,O
receiving,O
HALAVEN,O
and,O
63,O
days,O
for,O
patients,O
receiving,O
control,O
therapy,O
Table,O
2,O
reports,O
the,O
most,O
common,O
adverse,O
reactions,O
occurring,O
in,O
at,O
least,O
10,O
of,O
patients,O
in,O
either,O
group,O
Table,O
2,O
Adverse,O
Reactions,O
with,O
a,O
Per,O
Patient,O
Incidence,O
of,O
at,O
Least,O
10,O
in,O
Study,O
1,O
MedDRA,O
ver,O
10,O
0,O
HALAVEN,O
n,O
503,O
Control,O
Group,O
n,O
247,O
All,O
Grades,O
Grade,O
3,O
All,O
Grades,O
Grade,O
3,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
a,O
Neutropenia,AdverseReaction
82,O
57,O
53,O
23,O
Anemia,AdverseReaction
58,O
2,O
55,O
4,O
Nervous,O
system,O
disorders,O
Peripheral neuropathy,AdverseReaction
b,O
35,O
8,O
16,O
2,O
Headache,AdverseReaction
19,O
1,O
12,O
1,O
General,O
disorders,O
and,O
administrative,O
site,O
conditions,O
Asthenia,AdverseReaction
Fatigue,AdverseReaction
54,O
10,O
40,O
11,O
Mucosal inflammation,AdverseReaction
9,O
1,O
10,O
2,O
Pyrexia,AdverseReaction
21,O
1,O
13,O
1,O
Gastrointestinal,O
disorders,O
Constipation,AdverseReaction
25,O
1,O
21,O
1,O
Diarrhea,AdverseReaction
18,O
0,O
18,O
0,O
Nausea,AdverseReaction
35,O
1,O
28,O
3,O
Vomiting,AdverseReaction
18,O
1,O
18,O
1,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
Myalgia,AdverseReaction
22,O
1,O
12,O
1,O
Back pain,AdverseReaction
16,O
1,O
7,O
2,O
Bone pain,AdverseReaction
12,O
2,O
9,O
2,O
Pain in extremity,AdverseReaction
11,O
1,O
10,O
1,O
Investigations,O
Weight decreased,AdverseReaction
21,O
1,O
14,O
1,O
Metabolism,O
and,O
nutrition,O
disorders,O
Anorexia,AdverseReaction
20,O
1,O
13,O
1,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
14,O
0,O
9,O
0,O
Dyspnea,AdverseReaction
16,O
4,O
13,O
4,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Alopecia,AdverseReaction
45,O
NA,O
c,O
10,O
NA,O
c,O
Infections,O
and,O
Infestations,O
Urinary Tract Infection,AdverseReaction
10,O
1,O
5,O
0,O
a,O
based,O
upon,O
laboratory,O
data,O
b,O
includes,O
neuropathy peripheral,AdverseReaction
neuropathy,AdverseReaction
peripheral motor neuropathy,AdverseReaction
polyneuropathy,AdverseReaction
peripheral sensoryneuropathy,AdverseReaction
and,O
paraesthesia,AdverseReaction
c,O
not,O
applicable,O
grading,O
system,O
does,O
not,O
specify,O
Grade,O
2,O
for,O
alopecia,AdverseReaction
Cytopenias,O
Grade 3,Severity
neutropenia,AdverseReaction
occurred,O
in,O
28,O
143,O
503,O
of,O
patients,O
who,O
received,O
HALAVEN,O
in,O
Study,O
1,O
and,O
29,O
144,O
503,O
of,O
patients,O
experienced,O
Grade 4,Severity
neutropenia,AdverseReaction
Febrile neutropenia,AdverseReaction
occurred,O
in,O
5,O
23,O
503,O
of,O
patients,O
two,O
patients,O
0,O
4,O
died,AdverseReaction
from,O
complications,O
of,O
febrile neutropenia,AdverseReaction
Dose,O
reduction,O
due,O
to,O
neutropenia,AdverseReaction
was,O
required,O
in,O
12,O
62,O
503,O
of,O
patients,O
and,O
discontinuation,O
was,O
required,O
in,O
1,O
of,O
patients,O
The,O
mean,O
time,O
to,O
nadir,O
was,O
13,O
days,O
and,O
the,O
mean,O
time,O
to,O
recovery,O
from,O
severe,Severity
neutropenia,AdverseReaction
500,O
mm,O
3,O
was,O
8,O
days,O
Grade 3,Severity
or,O
greater,O
thrombocytopenia,AdverseReaction
occurred,O
in,O
1,O
7,O
503,O
of,O
patients,O
G,O
CSF,O
granulocyte,O
colony,O
stimulating,O
factor,O
or,O
GM,O
CSF,O
granulocyte,O
macrophage,O
colony,O
stimulating,O
factor,O
was,O
used,O
in,O
19,O
of,O
patients,O
who,O
received,O
HALAVEN,O
Peripheral,O
Neuropathy,O
In,O
Study,O
1,O
17,O
of,O
enrolled,O
patients,O
had,O
Grade 1,Severity
peripheral neuropathy,AdverseReaction
and,O
3,O
of,O
patients,O
had,O
Grade 2,Severity
peripheral neuropathy,AdverseReaction
at,O
baseline,O
Dose,O
reduction,O
due,O
to,O
peripheral neuropathy,AdverseReaction
was,O
required,O
by,O
3,O
14,O
503,O
of,O
patients,O
who,O
received,O
HALAVEN,O
Four,O
percent,O
20,O
503,O
of,O
patients,O
experienced,O
peripheral motor neuropathy,AdverseReaction
of,O
any,O
grade,O
and,O
2,O
8,O
503,O
of,O
patients,O
developed,O
Grade 3,Severity
peripheral motor neuropathy,AdverseReaction
Liver,O
Function,O
Test,O
Abnormalities,O
Among,O
patients,O
with,O
Grade,O
0,O
or,O
1,O
ALT,O
levels,O
at,O
baseline,O
18,O
of,O
HALAVEN,O
treated,O
patients,O
experienced,O
Grade 2,Severity
or,O
greater,O
ALT elevation,AdverseReaction
One,O
HALAVEN,O
treated,O
patient,O
without,O
documented,O
liver,O
metastases,O
had,O
concomitant,O
Grade 2,Severity
elevations in bilirubin in,AdverseReaction
and,O
ALT,AdverseReaction
these,O
abnormalities,O
resolved,O
and,O
did,O
not,O
recur,O
with,O
re,O
exposure,O
to,O
HALAVEN,O
Less,O
Common,O
Adverse,O
Reactions,O
The,O
following,O
additional,O
adverse,O
reactions,O
were,O
reported,O
in,O
5,O
to,O
10,O
of,O
the,O
HALAVEN,O
treated,O
group,O
Eye,O
Disorders,O
increased lacrimation,AdverseReaction
Gastrointestinal,O
Disorders,O
dyspepsia,AdverseReaction
abdominal pain,AdverseReaction
stomatitis,AdverseReaction
dry mouth,AdverseReaction
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
peripheral edema,AdverseReaction
Infections,O
and,O
Infestations,O
upper respiratory tract infection,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorders,O
hypokalemia,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
muscle spasms,AdverseReaction
muscular weakness,AdverseReaction
Nervous,O
System,O
Disorders,O
dysgeusia,AdverseReaction
dizziness,AdverseReaction
Psychiatric,O
Disorders,O
insomnia,AdverseReaction
depression,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
rash,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
drug,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
of,O
HALAVEN,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
lymphopenia,AdverseReaction
Gastrointestinal,O
Disorders,O
pancreatitis,AdverseReaction
Hepatobiliary,O
Disorders,O
hepatotoxicity,AdverseReaction
Immune,O
System,O
Disorders,O
drug,O
hypersensitivity,AdverseReaction
Infections,O
and,O
Infestations,O
pneumonia,AdverseReaction
sepsis,AdverseReaction
neutropenic sepsis,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorders,O
hypomagnesemia,AdverseReaction
dehydration,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
interstitial lung disease,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
pruritus,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Driving impairment,AdverseReaction
Warn,O
patients,O
not,O
to,O
drive,O
until,O
they,O
have,O
gained,O
sufficient,O
experience,O
with,O
HORIZANT,O
to,O
assess,O
whether,O
it,O
will,O
impair,O
their,O
ability,O
to,O
drive,O
5,O
1,O
Somnolence,AdverseReaction
sedation,AdverseReaction
and,O
dizziness,AdverseReaction
May,Factor
impair,AdverseReaction
the,O
patient,O
s,O
ability to operate complex machinery,AdverseReaction
5,O
2,O
HORIZANT,O
is,O
not,O
interchangeable,O
with,O
other,O
gabapentin,O
products,O
5,O
3,O
Suicidal thoughts,AdverseReaction
or,O
behaviors,AdverseReaction
HORIZANT,O
is,O
a,O
prodrug,O
of,O
gabapentin,O
an,O
antiepileptic,O
drug,O
AED,O
AEDs,DrugClass
increase,O
the,O
risk,O
of,O
suicidal thoughts,AdverseReaction
or,O
behaviors,AdverseReaction
Monitor,O
for,O
suicidal,O
thoughts,O
or,O
behaviors,O
5,O
4,O
5,O
1,O
Effects,O
on,O
Driving,O
HORIZANT,O
may,Factor
cause,O
significant,Severity
driving impairment,AdverseReaction
see,O
Clinical,O
Studies,O
14,O
3,O
The,O
duration,O
of,O
driving impairment,AdverseReaction
after,O
starting,O
therapy,O
with,O
HORIZANT,O
is,O
unknown,O
Patients,O
taking,O
HORIZANT,O
should,O
not,O
drive,O
until,O
they,O
have,O
gained,O
sufficient,O
experience,O
to,O
assess,O
whether,O
HORIZANT,O
impairs,O
their,O
ability,O
to,O
drive,O
However,O
prescribers,O
and,O
patients,O
should,O
be,O
aware,O
that,O
patients,O
ability,O
to,O
assess,O
their,O
own,O
driving,O
competence,O
as,O
well,O
as,O
their,O
ability,O
to,O
assess,O
the,O
degree,O
of,O
somnolence,O
caused,O
by,O
HORIZANT,O
can,O
be,O
imperfect,O
Whether,O
the,O
impairment,O
is,O
related,O
to,O
somnolence,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
or,O
other,O
effects,O
of,O
HORIZANT,O
is,O
unknown,O
5,O
2,O
Somnolence,O
Sedation,O
and,O
Dizziness,O
HORIZANT,O
causes,O
somnolence,AdverseReaction
sedation,AdverseReaction
and,O
dizziness,AdverseReaction
see,O
Tables,O
4,O
and,O
5,O
Patients,O
should,O
be,O
advised,O
not,O
to,O
drive,O
a,O
car,O
or,O
operate,O
other,O
complex,O
machinery,O
until,O
they,O
have,O
gained,O
sufficient,O
experience,O
on,O
HORIZANT,O
to,O
assess,O
whether,O
HORIZANT,O
impairs,O
their,O
ability,O
to,O
perform,O
these,O
tasks,O
During,O
the,O
controlled,O
trials,O
in,O
patients,O
with,O
RLS,O
somnolence,AdverseReaction
sedation,AdverseReaction
was,O
reported,O
in,O
20,O
of,O
patients,O
treated,O
with,O
600,O
mg,O
of,O
HORIZANT,O
per,O
day,O
compared,O
with,O
6,O
of,O
patients,O
receiving,O
placebo,O
In,O
those,O
patients,O
treated,O
with,O
HORIZANT,O
who,O
reported,O
somnolence,AdverseReaction
the,O
somnolence,AdverseReaction
persisted,O
during,O
treatment,O
in,O
about,O
30,O
In,O
the,O
remaining,O
patients,O
symptoms,O
resolved,O
within,O
3,O
to,O
4,O
weeks,O
Dizziness,AdverseReaction
was,O
reported,O
in,O
13,O
of,O
patients,O
receiving,O
600,O
mg,O
of,O
HORIZANT,O
per,O
day,O
compared,O
with,O
4,O
of,O
patients,O
receiving,O
placebo,O
In,O
those,O
patients,O
treated,O
with,O
HORIZANT,O
who,O
reported,O
dizziness,AdverseReaction
symptoms,O
persisted,O
during,O
treatment,O
in,O
about,O
20,O
Somnolence,AdverseReaction
sedation,AdverseReaction
led,O
to,O
withdrawal,O
in,O
2,O
of,O
patients,O
receiving,O
600,O
mg,O
of,O
HORIZANT,O
per,O
day,O
Dizziness,AdverseReaction
led,O
to,O
withdrawal,O
in,O
1,O
of,O
patients,O
receiving,O
600,O
mg,O
of,O
HORIZANT,O
per,O
day,O
The,O
incidence,O
of,O
these,O
adverse,O
reactions,O
was,O
greater,O
in,O
the,O
patients,O
receiving,O
1,O
200,O
mg,O
per,O
day,O
During,O
the,O
12,O
week,O
controlled,O
study,O
in,O
patients,O
with,O
PHN,O
somnolence,AdverseReaction
was,O
reported,O
in,O
10,O
of,O
patients,O
treated,O
with,O
1,O
200,O
mg,O
of,O
HORIZANT,O
per,O
day,O
compared,O
with,O
8,O
of,O
patients,O
receiving,O
placebo,O
Fatigue,AdverseReaction
asthenia,AdverseReaction
was,O
reported,O
in,O
6,O
of,O
patients,O
treated,O
with,O
1,O
200,O
mg,O
of,O
HORIZANT,O
per,O
day,O
compared,O
with,O
1,O
of,O
patients,O
receiving,O
placebo,O
In,O
those,O
patients,O
treated,O
with,O
1,O
200,O
mg,O
of,O
HORIZANT,O
per,O
day,O
who,O
reported,O
somnolence,AdverseReaction
10,O
the,O
somnolence,AdverseReaction
persisted,O
during,O
treatment,O
in,O
about,O
27,O
In,O
the,O
remaining,O
patients,O
symptoms,O
resolved,O
within,O
4,O
to,O
5,O
weeks,O
Dizziness,AdverseReaction
was,O
reported,O
in,O
17,O
of,O
patients,O
receiving,O
1,O
200,O
mg,O
of,O
HORIZANT,O
per,O
day,O
compared,O
with,O
15,O
of,O
patients,O
receiving,O
placebo,O
In,O
those,O
patients,O
treated,O
with,O
1,O
200,O
mg,O
of,O
HORIZANT,O
per,O
day,O
who,O
reported,O
dizziness,AdverseReaction
symptoms,O
persisted,O
during,O
treatment,O
in,O
about,O
6,O
Somnolence,AdverseReaction
led,O
to,O
withdrawal,O
in,O
1,O
of,O
patients,O
receiving,O
1,O
200,O
mg,O
of,O
HORIZANT,O
per,O
day,O
compared,O
with,O
2,O
of,O
patients,O
receiving,O
placebo,O
Dizziness,AdverseReaction
led,O
to,O
withdrawal,O
in,O
2,O
of,O
patients,O
receiving,O
1,O
200,O
mg,O
of,O
HORIZANT,O
per,O
day,O
compared,O
with,O
3,O
of,O
patients,O
receiving,O
placebo,O
5,O
3,O
Lack,O
of,O
Interchangeability,O
With,O
Gabapentin,O
HORIZANT,O
is,O
not,O
interchangeable,O
with,O
other,O
gabapentin,O
products,O
because,O
of,O
differing,O
pharmacokinetic,O
profiles,O
The,O
same,O
dose,O
of,O
HORIZANT,O
results,O
in,O
different,O
plasma,O
concentrations,O
of,O
gabapentin,O
relative,O
to,O
other,O
gabapentin,O
products,O
See,O
Clinical,O
Pharmacology,O
12,O
3,O
The,O
safety,O
and,O
effectiveness,O
of,O
HORIZANT,O
in,O
patients,O
with,O
epilepsy,O
have,O
not,O
been,O
studied,O
5,O
4,O
Suicidal,O
Behavior,O
and,O
Ideation,O
HORIZANT,O
gabapentin,O
enacarbil,O
is,O
a,O
prodrug,O
of,O
gabapentin,O
an,O
antiepileptic,O
drug,O
AED,O
AEDs,DrugClass
increase,O
the,O
risk,O
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
in,O
patients,O
taking,O
these,O
drugs,O
for,O
any,O
indication,O
Because,O
HORIZANT,O
is,O
a,O
prodrug,O
of,O
gabapentin,O
HORIZANT,O
also,O
increases,O
this,O
risk,O
Patients,O
treated,O
with,O
any,O
AED,O
for,O
any,O
indication,O
should,O
be,O
monitored,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
depression,O
suicidal,O
thoughts,O
or,O
behavior,O
and,O
or,O
any,O
unusual,O
changes,O
in,O
mood,O
or,O
behavior,O
Pooled,O
analyses,O
of,O
199,O
placebo,O
controlled,O
clinical,O
trials,O
monotherapy,O
and,O
adjunctive,O
therapy,O
of,O
11,O
different,O
AEDs,O
showed,O
that,O
patients,O
randomized,O
to,O
1,O
of,O
the,O
AEDs,DrugClass
had,O
approximately,O
twice,O
the,O
risk,O
adjusted,O
relative,O
risk,O
1,O
8,O
95,O
confidence,O
interval,O
CI,O
1,O
2,O
2,O
7,O
of,O
suicidal thinking,AdverseReaction
or,O
behavior,AdverseReaction
compared,O
with,O
patients,O
randomized,O
to,O
placebo,O
In,O
these,O
trials,O
which,O
had,O
a,O
median,O
treatment,O
duration,O
of,O
12,O
weeks,O
the,O
estimated,O
incidence,O
rate,O
of,O
suicidal behavior,AdverseReaction
or,O
ideation,AdverseReaction
among,O
27,O
863,O
AED,O
treated,O
patients,O
was,O
0,O
43,O
compared,O
with,O
0,O
24,O
among,O
16,O
029,O
placebo,O
treated,O
patients,O
representing,O
an,O
increase,O
of,O
approximately,O
1,O
case,O
of,O
suicidal thinking,AdverseReaction
or,O
behavior,AdverseReaction
for,O
every,O
530,O
patients,O
treated,O
There,O
were,O
4,O
suicides,AdverseReaction
in,O
drug,O
treated,O
patients,O
in,O
the,O
trials,O
and,O
none,O
in,O
placebo,O
treated,O
patients,O
but,O
the,O
number is too small,Factor
to,O
allow,O
any,O
conclusion,O
about,O
drug,O
effect,O
on,O
suicide,AdverseReaction
The,O
increased,O
risk,O
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
with,O
AEDs,DrugClass
was,O
observed,O
as,O
early,O
as,O
1,O
week,O
after,O
starting,O
drug,O
treatment,O
with,O
AEDs,O
and,O
persisted,O
for,O
the,O
duration,O
of,O
treatment,O
assessed,O
Because,O
most,O
trials,O
included,O
in,O
the,O
analysis,O
did,O
not,O
extend,O
beyond,O
24,O
weeks,O
the,O
risk,O
of,O
suicidal,O
thoughts,O
or,O
behavior,O
beyond,O
24,O
weeks,O
could,O
not,O
be,O
assessed,O
The,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
was,O
generally,O
consistent,O
among,O
drugs,O
in,O
the,O
data,O
analyzed,O
The,O
finding,O
of,O
increased,O
risk,O
with,O
AEDs,O
of,O
varying,O
mechanisms,O
of,O
action,O
and,O
across,O
a,O
range,O
of,O
indications,O
suggests,O
that,O
the,O
risk,O
applies,O
to,O
all,O
AEDs,O
used,O
for,O
any,O
indication,O
The,O
risk,O
did,O
not,O
vary,O
substantially,O
by,O
age,O
5,O
to,O
100,O
years,O
in,O
the,O
clinical,O
trials,O
analyzed,O
Table,O
3,O
shows,O
absolute,O
and,O
relative,O
risk,O
by,O
indication,O
for,O
all,O
evaluated,O
AEDs,O
Table,O
3,O
Risk,O
by,O
Indication,O
for,O
Antiepileptic,O
Drugs,O
in,O
the,O
Pooled,O
Analysis,O
Indication,O
PlaceboPatients,O
WithEvents,O
Per1,O
000,O
Patients,O
Drug,O
PatientsWith,O
Events,O
Per1,O
000,O
Patients,O
Relative,O
Risk,O
Incidence,O
of,O
Eventsin,O
DrugPatients,O
Incidencein,O
Placebo,O
Patients,O
Risk,O
Difference,O
Additional,O
DrugPatients,O
WithEvents,O
Per,O
1,O
000Patients,O
Epilepsy,O
1,O
0,O
3,O
4,O
3,O
5,O
2,O
4,O
Psychiatric,O
5,O
7,O
8,O
5,O
1,O
5,O
2,O
9,O
Other,O
1,O
0,O
1,O
8,O
1,O
9,O
0,O
9,O
Total,O
2,O
4,O
4,O
3,O
1,O
8,O
1,O
9,O
The,O
relative,O
risk,Factor
for,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
was,O
higher,O
in,O
clinical,O
trials,O
for,O
epilepsy,O
than,O
in,O
clinical,O
trials,O
for,O
psychiatric,O
or,O
other,O
conditions,O
but,O
the,O
absolute,O
risk,O
differences,O
were,O
similar,O
for,O
the,O
epilepsy,O
and,O
psychiatric,O
indications,O
Anyone,O
considering,O
prescribing,O
HORIZANT,O
must,O
balance,O
the,O
risk,O
of,O
suicidal,O
thoughts,O
or,O
behavior,O
with,O
the,O
risk,O
of,O
untreated,O
illness,O
Epilepsy,O
and,O
many,O
other,O
illnesses,O
for,O
which,O
AEDs,O
are,O
prescribed,O
are,O
themselves,O
associated,O
with,O
morbidity,O
and,O
mortality,O
and,O
an,O
increased,O
risk,O
of,O
suicidal,O
thoughts,O
and,O
behavior,O
Should,O
suicidal,O
thoughts,O
and,O
behavior,O
emerge,O
during,O
treatment,O
the,O
prescriber,O
needs,O
to,O
consider,O
whether,O
the,O
emergence,O
of,O
these,O
symptoms,O
in,O
any,O
given,O
patient,O
may,O
be,O
related,O
to,O
the,O
illness,O
being,O
treated,O
Patients,O
their,O
caregivers,O
and,O
families,O
should,O
be,O
informed,O
that,O
HORIZANT,O
increases,O
the,O
risk,O
of,O
suicidal,O
thoughts,O
and,O
behavior,O
and,O
should,O
be,O
advised,O
of,O
the,O
need,O
to,O
be,O
alert,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
depression,O
any,O
unusual,O
changes,O
in,O
mood,O
or,O
behavior,O
or,O
the,O
emergence,O
of,O
suicidal,O
thoughts,O
behavior,O
or,O
thoughts,O
about,O
self,O
harm,O
Behaviors,O
of,O
concern,O
should,O
be,O
reported,O
immediately,O
to,O
healthcare,O
providers,O
5,O
5,O
Drug,O
Reaction,O
With,O
Eosinophilia,O
and,O
Systemic,O
Symptoms,O
DRESS,O
Multiorgan,O
Hypersensitivity,O
Drug Reaction with Eosinophilia and Systemic Symptoms,AdverseReaction
DRESS,AdverseReaction
also,O
known,O
as,O
multiorgan hypersensitivity,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
taking,O
antiepileptic drugs,DrugClass
including,O
gabapentin,O
HORIZANT,O
is,O
a,O
prodrug,O
of,O
gabapentin,O
Some,O
of,O
these,O
events,O
have,O
been,O
fatal,AdverseReaction
or,O
life,O
threatening,O
DRESS,AdverseReaction
typically,O
although,O
not,O
exclusively,O
presents,O
with,O
fever,AdverseReaction
rash,AdverseReaction
and,O
or,O
lymphadenopathy,AdverseReaction
in,O
association,O
with,O
other,O
organ,O
system,O
involvement,O
such,O
as,O
hepatitis,AdverseReaction
nephritis,AdverseReaction
hematological abnormalities,AdverseReaction
myocarditis,AdverseReaction
or,O
myositis,AdverseReaction
sometimes,O
resembling,O
an,O
acute,O
viral,O
infection,O
Eosinophilia,AdverseReaction
is,O
often,O
present,O
Because,O
this,O
disorder,O
is,O
variable,O
in,O
its,O
expression,O
other,O
organ,O
systems,O
not,O
noted,O
here,O
may,O
be,O
involved,O
It,O
is,O
important,O
to,O
note,O
that,O
early,O
manifestations,O
of,O
hypersensitivity,AdverseReaction
such,O
as,O
fever,AdverseReaction
or,O
lymphadenopathy,AdverseReaction
may,Factor
be,O
present,O
even,O
though,O
rash,AdverseReaction
is,O
not evident,Negation
If,O
such,O
signs,O
or,O
symptoms,O
are,O
present,O
the,O
patient,O
should,O
be,O
evaluated,O
immediately,O
HORIZANT,O
should,O
be,O
discontinued,O
if,O
an,O
alternative,O
etiology,O
for,O
the,O
signs,O
or,O
symptoms,O
cannot,O
be,O
established,O
5,O
6,O
Discontinuation,O
of,O
HORIZANT,O
When,O
discontinuing,O
HORIZANT,O
patients,O
with,O
RLS,O
receiving,O
600,O
mg,O
or,O
less,O
once,O
daily,O
can,O
discontinue,O
the,O
drug,O
without,O
tapering,O
If,O
the,O
recommended,O
dose,O
is,O
exceeded,O
the,O
dose,O
should,O
be,O
reduced,O
to,O
600,O
mg,O
daily,O
for,O
1,O
week,O
prior,O
to,O
discontinuation,O
to,O
minimize,O
the,O
potential,O
of,O
withdrawal,O
seizure,O
In,O
patients,O
with,O
PHN,O
receiving,O
HORIZANT,O
twice,O
daily,O
the,O
dose,O
should,O
be,O
reduced,O
to,O
once,O
daily,O
for,O
1,O
week,O
prior,O
to,O
discontinuation,O
to,O
minimize,O
the,O
potential,O
of,O
withdrawal,O
seizure,O
see,O
Table,O
2,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
7,O
Tumorigenic,O
Potential,O
In,O
an,O
oral,O
carcinogenicity,O
study,O
gabapentin,O
enacarbil,O
increased,O
the,O
incidence,O
of,O
pancreatic acinar cell adenoma acinar cell,AdverseReaction
and,O
carcinoma,AdverseReaction
in,O
male,O
and,O
female,O
rats,Animal
see,O
Nonclinical,O
Toxicology,O
13,O
1,O
The,O
clinical,O
significance,O
of,O
this,O
finding,O
is,O
unknown,O
In,O
clinical,O
studies,O
of,O
gabapentin,O
as,O
adjunctive,O
therapy,O
in,O
epilepsy,O
comprising,O
2,O
085,O
patient,O
years,O
of,O
exposure,O
in,O
patients,O
12,O
years,O
of,O
age,O
new,O
tumors,AdverseReaction
were,O
reported,O
in,O
10,O
patients,O
2,O
breast,AdverseReaction
3,O
brain,AdverseReaction
2,O
lung,AdverseReaction
1,O
adrenal,AdverseReaction
1,O
non Hodgkin s lymphoma,AdverseReaction
1,O
endometrial carcinoma in situ,AdverseReaction
and,O
preexisting,O
tumors worsened worsened worsened,AdverseReaction
in,O
11,O
patients,O
9,O
brain,AdverseReaction
1,O
breast,AdverseReaction
1,O
prostate,AdverseReaction
during,O
or,O
up,O
to,O
2,O
years,O
following,O
discontinuation,O
of,O
gabapentin,O
Without,O
knowledge,O
of,O
the,O
background,O
incidence,O
and,O
recurrence,O
in,O
a,O
similar,O
population,O
not,O
treated,O
with,O
gabapentin,O
it,O
is,O
impossible,O
to,O
know,O
whether,O
the,O
incidence,O
reported,O
in,O
this,O
cohort,O
is,O
or,O
is,O
not,O
affected,O
by,O
treatment,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
described,O
in,O
more,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
of,O
the,O
label,O
Somnolence,AdverseReaction
sedation,AdverseReaction
and,O
dizziness,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
RLS,O
Most,O
common,O
adverse,O
reactions,O
10,O
and,O
at,O
least,O
2,O
times,O
the,O
rate,O
of,O
placebo,O
were,O
somnolence,AdverseReaction
sedation,AdverseReaction
and,O
dizziness,AdverseReaction
6,O
1,O
PHN,O
Most,O
common,O
adverse,O
reactions,O
10,O
and,O
greater,O
than,O
placebo,O
were,O
dizziness,AdverseReaction
somnolence,AdverseReaction
and,O
headache,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
XenoPort,O
at,O
1,O
877,O
XENOPRT,O
1,O
877,O
936,O
6778,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
In,O
all,O
controlled,O
and,O
uncontrolled,O
trials,O
across,O
various,O
patient,O
populations,O
more,O
than,O
2,O
300,O
patients,O
have,O
received,O
HORIZANT,O
orally,O
in,O
daily,O
doses,O
ranging,O
from,O
600,O
to,O
3,O
600,O
mg,O
Restless,O
Legs,O
Syndrome,O
The,O
exposure,O
to,O
HORIZANT,O
in,O
1,O
201,O
patients,O
with,O
RLS,O
included,O
613,O
exposed,O
for,O
at,O
least,O
6,O
months,O
and,O
371,O
exposed,O
for,O
at,O
least,O
1,O
year,O
HORIZANT,O
in,O
the,O
treatment,O
of,O
RLS,O
was,O
studied,O
primarily,O
in,O
placebo,O
controlled,O
trials,O
n,O
642,O
and,O
in,O
long,O
term,O
follow,O
up,O
studies,O
The,O
population,O
with,O
RLS,O
ranged,O
from,O
18,O
to,O
82,O
years,O
of,O
age,O
with,O
60,O
being,O
female,O
and,O
95,O
being,O
Caucasian,O
The,O
safety,O
of,O
HORIZANT,O
in,O
doses,O
ranging,O
from,O
600,O
to,O
2,O
400,O
mg,O
has,O
been,O
evaluated,O
in,O
515,O
patients,O
with,O
RLS,O
in,O
3,O
double,O
blind,O
placebo,O
controlled,O
12,O
week,O
clinical,O
trials,O
The,O
600,O
mg,O
dose,O
was,O
studied,O
in,O
2,O
of,O
the,O
3,O
studies,O
Eleven,O
out,O
of,O
163,O
7,O
patients,O
treated,O
with,O
600,O
mg,O
of,O
HORIZANT,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reactions,O
compared,O
with,O
10,O
of,O
the,O
245,O
4,O
patients,O
who,O
received,O
placebo,O
The,O
most,O
commonly,O
observed,O
adverse,O
reactions,O
5,O
and,O
at,O
least,O
2,O
times,O
the,O
rate,O
of,O
placebo,O
in,O
these,O
trials,O
for,O
the,O
600,O
mg,O
dose,O
of,O
HORIZANT,O
were,O
somnolence,AdverseReaction
sedation,AdverseReaction
and,O
dizziness,AdverseReaction
see,O
Table,O
4,O
Table,O
4,O
lists,O
treatment,O
emergent,O
adverse,O
reactions,O
that,O
occurred,O
in,O
2,O
of,O
patients,O
with,O
RLS,O
treated,O
with,O
HORIZANT,O
and,O
numerically,O
greater,O
than,O
placebo,O
Table,O
4,O
Incidence,O
of,O
Adverse,O
Reactions,O
in,O
12,O
Week,O
RLS,O
Studies,O
Reported,O
in,O
2,O
of,O
Patients,O
Treated,O
With,O
600,O
or,O
1,O
200,O
mg,O
of,O
HORIZANT,O
and,O
Numerically,O
Greater,O
Than,O
Placebo,O
Body,O
System,O
Adverse,O
Reaction,O
Placebo,O
a,O
N,O
245,O
HORIZANT600,O
mg,O
day,O
b,O
N,O
163,O
HORIZANT1,O
200,O
mg,O
day,O
c,O
N,O
269,O
Nervous,O
system,O
disorders,O
Somnolence,AdverseReaction
sedation,AdverseReaction
6,O
20,O
27,O
Dizziness,AdverseReaction
4,O
13,O
22,O
Headache,AdverseReaction
11,O
12,O
15,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
5,O
6,O
7,O
Dry mouth,AdverseReaction
2,O
3,O
4,O
Flatulence,AdverseReaction
1,O
3,O
2,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
4,O
6,O
7,O
Irritability,AdverseReaction
1,O
4,O
4,O
Feeling drunk,AdverseReaction
0,O
1,O
3,O
Feeling abnormal,AdverseReaction
1,O
1,O
3,O
Peripheral edema,AdverseReaction
1,O
1,O
3,O
Metabolism,O
and,O
nutritional,O
disorders,O
Weight increased,AdverseReaction
2,O
2,O
3,O
Increased appetite,AdverseReaction
1,O
2,O
2,O
Ear,O
and,O
labyrinth,O
disorders,O
Vertigo,AdverseReaction
0,O
1,O
3,O
Psychiatric,O
disorders,O
Depression,AdverseReaction
1,O
1,O
3,O
Libido decreased,AdverseReaction
1,O
1,O
2,O
a,O
Placebo,O
was,O
a,O
treatment,O
arm,O
in,O
each,O
of,O
the,O
3,O
double,O
blind,O
placebo,O
controlled,O
12,O
week,O
clinical,O
trials,O
b,O
The,O
600,O
mg,O
dose,O
of,O
HORIZANT,O
was,O
a,O
treatment,O
arm,O
in,O
2,O
of,O
the,O
3,O
double,O
blind,O
placebo,O
controlled,O
12,O
week,O
clinical,O
trials,O
c,O
The,O
1,O
200,O
mg,O
dose,O
of,O
HORIZANT,O
was,O
a,O
treatment,O
arm,O
in,O
each,O
of,O
the,O
3,O
double,O
blind,O
placebo,O
controlled,O
12,O
week,O
clinical,O
trials,O
Adverse,O
reactions,O
reported,O
in,O
these,O
three,O
12,O
week,O
studies,O
in,O
2,O
of,O
patients,O
treated,O
with,O
600,O
mg,O
of,O
HORIZANT,O
and,O
numerically,O
greater,O
than,O
placebo,O
were,O
balance disorder,AdverseReaction
blurred vision,AdverseReaction
disorientation,AdverseReaction
feeling drunk,AdverseReaction
lethargy,AdverseReaction
and,O
vertigo,AdverseReaction
The,O
following,O
adverse,O
reactions,O
were,O
dose,O
related,O
somnolence,AdverseReaction
sedation,AdverseReaction
dizziness,AdverseReaction
feeling drunk,AdverseReaction
libido decreased,AdverseReaction
depression,AdverseReaction
headache,AdverseReaction
peripheral edema,AdverseReaction
and,O
vertigo,AdverseReaction
Postherpetic,O
Neuralgia,O
The,O
exposure,O
to,O
HORIZANT,O
in,O
417,O
patients,O
with,O
PHN,O
included,O
207,O
patients,O
exposed,O
for,O
at,O
least,O
3,O
months,O
Overall,O
the,O
mean,O
age,O
of,O
patients,O
in,O
the,O
PHN,O
studies,O
ranged,O
from,O
61,O
to,O
64,O
years,O
of,O
age,O
across,O
dose,O
groups,O
the,O
majority,O
of,O
patients,O
were,O
male,O
45,O
to,O
61,O
and,O
Caucasian,O
80,O
to,O
98,O
The,O
safety,O
of,O
HORIZANT,O
in,O
doses,O
ranging,O
from,O
1,O
200,O
to,O
3,O
600,O
mg,O
has,O
been,O
evaluated,O
in,O
417,O
patients,O
with,O
PHN,O
in,O
3,O
clinical,O
studies,O
The,O
principal,O
efficacy,O
study,O
evaluating,O
the,O
efficacy,O
and,O
safety,O
of,O
HORIZANT,O
in,O
the,O
management,O
of,O
PHN,O
was,O
a,O
12,O
week,O
double,O
blind,O
multicenter,O
study,O
comparing,O
1,O
200,O
mg,O
day,O
2,O
400,O
mg,O
day,O
and,O
3,O
600,O
mg,O
day,O
to,O
placebo,O
Six,O
out,O
of,O
107,O
6,O
patients,O
treated,O
with,O
1,O
200,O
mg,O
of,O
HORIZANT,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
events,O
compared,O
with,O
12,O
of,O
the,O
95,O
13,O
patients,O
who,O
received,O
placebo,O
The,O
most,O
commonly,O
observed,O
adverse,O
reactions,O
10,O
and,O
greater,O
than,O
placebo,O
in,O
this,O
trial,O
for,O
the,O
1,O
200,O
mg,O
dose,O
of,O
HORIZANT,O
were,O
dizziness,AdverseReaction
somnolence,AdverseReaction
and,O
headache,AdverseReaction
see,O
Table,O
5,O
Table,O
5,O
lists,O
treatment,O
emergent,O
adverse,O
reactions,O
that,O
occurred,O
in,O
2,O
of,O
patients,O
with,O
PHN,O
treated,O
with,O
HORIZANT,O
1,O
200,O
mg,O
day,O
and,O
numerically,O
greater,O
than,O
placebo,O
Table,O
5,O
Incidence,O
of,O
Adverse,O
Reactions,O
in,O
At,O
Least,O
2,O
of,O
Patients,O
Treated,O
With,O
1,O
200,O
mg,O
day,O
of,O
HORIZANT,O
and,O
Numerically,O
Greater,O
Than,O
the,O
Placebo,O
Rate,O
Reported,O
in,O
All,O
Patients,O
in,O
the,O
12,O
Week,O
PHN,O
Study,O
Body,O
System,O
Adverse,O
Reaction,O
Placebo,O
N,O
95,O
HORIZANT1,O
200,O
mg,O
day,O
N,O
107,O
HORIZANT2,O
400,O
mg,O
day,O
N,O
82,O
HORIZANT3,O
600,O
mg,O
day,O
N,O
87,O
Nervous,O
System,O
Dizziness,AdverseReaction
15,O
17,O
26,O
30,O
Somnolence,AdverseReaction
8,O
10,O
11,O
14,O
Headache,AdverseReaction
9,O
10,O
10,O
7,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
5,O
8,O
4,O
9,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
Asthenia,AdverseReaction
1,O
6,O
4,O
10,O
Peripheral edema,AdverseReaction
0,O
6,O
7,O
6,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
2,O
3,O
5,O
7,O
Metabolism,O
and,O
nutritional,O
disorders,O
Weight increased,AdverseReaction
1,O
3,O
5,O
5,O
Eye,O
disorders,O
Blurred vision,AdverseReaction
0,O
2,O
5,O
2,O
The,O
following,O
adverse,O
reactions,O
were,O
also,O
reported,O
as,O
2,O
at,O
2,O
400,O
mg,O
day,O
and,O
or,O
3,O
600,O
mg,O
day,O
and,O
appeared,O
to,O
be,O
dose,O
related,O
but,O
were,O
2,O
at,O
1,O
200,O
mg,O
day,O
balance disorder,AdverseReaction
confusional state,AdverseReaction
depression,AdverseReaction
dry mouth,AdverseReaction
flatulence,AdverseReaction
increased appetite,AdverseReaction
irritability,AdverseReaction
and,O
vertigo,AdverseReaction
Dizziness,AdverseReaction
somnolence,AdverseReaction
fatigue,AdverseReaction
and,O
insomnia,AdverseReaction
appeared,O
to,O
show,O
a,O
dose,O
relationship,O
6,O
2,O
Adverse,O
Events,O
Associated,O
With,O
Gabapentin,O
The,O
following,O
adverse,O
events,O
have,O
been,O
reported,O
in,O
patients,O
receiving,O
gabapentin,O
either,O
in,O
clinical,O
trials,O
or,O
postmarketing,O
breast enlargement,AdverseReaction
gynecomastia,AdverseReaction
and,O
elevated creatine kinase,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Interleukin,O
1,O
blockade,O
may,O
interfere,O
with,O
immune,O
response,O
to,O
infections,O
Treatment,O
with,O
medications that work through inhibition of IL 1,DrugClass
has,O
been,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
serious,Severity
infections,AdverseReaction
ILARIS,O
has,O
been,O
associated,O
with,O
an,O
increased,O
incidence,O
of,O
serious,Severity
infections,AdverseReaction
Physicians,O
should,O
exercise,O
caution,O
when,O
administering,O
ILARIS,O
to,O
patients,O
with,O
infections,O
a,O
history,O
of,O
recurring,O
infections,O
or,O
underlying,O
conditions,O
which,O
may,O
predispose,O
them,O
to,O
infections,O
Discontinue,O
treatment,O
with,O
ILARIS,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
Do,O
not,O
administer,O
ILARIS,O
to,O
patients,O
during,O
an,O
active,O
infection,O
requiring,O
medical,O
intervention,O
5,O
1,O
Live,O
vaccines,O
should,O
not,O
be,O
given,O
concurrently,O
with,O
ILARIS,O
Prior,O
to,O
initiation,O
of,O
therapy,O
with,O
ILARIS,O
patients,O
should,O
receive,O
all,O
recommended,O
vaccinations,O
5,O
4,O
5,O
1,O
Serious,O
Infections,O
ILARIS,O
has,O
been,O
associated,O
with,O
an,O
increased,O
risk,Factor
of,O
serious,Severity
infections,AdverseReaction
Physicians,O
should,O
exercise,O
caution,O
when,O
administering,O
ILARIS,O
to,O
patients,O
with,O
infections,O
a,O
history,O
of,O
recurring,O
infections,O
or,O
underlying,O
conditions,O
which,O
may,O
predispose,O
them,O
to,O
infections,O
ILARIS,O
should,O
not,O
be,O
administered,O
to,O
patients,O
during,O
an,O
active,O
infection,O
requiring,O
medical,O
intervention,O
Administration,O
of,O
ILARIS,O
should,O
be,O
discontinued,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
Infections,AdverseReaction
predominantly,O
of the upper respiratory tract the upper respiratory tract,AdverseReaction
in,O
some,O
instances,O
serious,Severity
have,O
been,O
reported,O
with,O
ILARIS,O
Generally,O
the,O
observed,O
infections,AdverseReaction
responded,O
to,O
standard,O
therapy,O
Isolated,O
cases,O
of,O
unusual,AdverseReaction
or,O
opportunistic infections,AdverseReaction
infections,AdverseReaction
e,O
g,O
aspergillosis,AdverseReaction
atypical mycobacterial infections,AdverseReaction
cytomegalovirus,AdverseReaction
herpes zoster,AdverseReaction
were,O
reported,O
during,O
ILARIS,O
treatment,O
A,O
causal,O
relationship,O
of,O
ILARIS,O
to,O
these,O
events,O
cannot,O
be,O
excluded,O
In,O
clinical,O
trials,O
ILARIS,O
has,O
not,O
been,O
administered,O
concomitantly,O
with,O
tumor,O
necrosis,O
factor,O
TNF,O
inhibitors,O
An,O
increased,O
incidence,O
of,O
serious,Severity
infections,AdverseReaction
has,O
been,O
associated,O
with,O
administration,O
of,O
another,O
IL 1 blocker,DrugClass
in,O
combination,O
with,O
TNF,O
inhibitors,O
Coadministration,O
of,O
ILARIS,O
with,O
TNF,O
inhibitors,O
is,O
not,O
recommended,O
because,O
this,O
may,O
increase,O
the,O
risk,O
of,O
serious,O
infections,O
see,O
Drug,O
Interactions,O
7,O
1,O
Drugs,O
that,O
affect,O
the,O
immune,O
system,O
by,O
blocking,O
TNF,O
have,O
been,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
new,O
tuberculosis,O
and,O
reactivation,O
of,O
latent,O
tuberculosis,O
TB,O
It,O
is,O
possible,O
that,O
use,O
of,O
IL,O
1,O
inhibitors,O
such,O
as,O
ILARIS,O
increases,O
the,O
risk,Factor
of,O
reactivation of tuberculosis,AdverseReaction
or,O
of,O
opportunistic infections,AdverseReaction
Prior,O
to,O
initiating,O
immunomodulatory,O
therapies,O
including,O
ILARIS,O
patients,O
should,O
be,O
evaluated,O
for,O
active,O
and,O
latent,O
tuberculosis,O
infection,O
Appropriate,O
screening,O
tests,O
should,O
be,O
performed,O
in,O
all,O
patients,O
ILARIS,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
a,O
positive,O
tuberculosis,O
screen,O
and,O
the,O
safety,O
of,O
ILARIS,O
in,O
individuals,O
with,O
latent,O
tuberculosis,O
infection,O
is,O
unknown,O
Patients,O
testing,O
positive,O
in,O
tuberculosis,O
screening,O
should,O
be,O
treated,O
according,O
to,O
standard,O
medical,O
practice,O
prior,O
to,O
therapy,O
with,O
ILARIS,O
All,O
patients,O
should,O
be,O
instructed,O
to,O
seek,O
medical,O
advice,O
if,O
signs,O
symptoms,O
or,O
high,O
risk,O
exposure,O
suggestive,O
of,O
tuberculosis,O
e,O
g,O
persistent,O
cough,O
weight,O
loss,O
subfebrile,O
temperature,O
appear,O
during,O
or,O
after,O
ILARIS,O
therapy,O
Healthcare,O
providers,O
should,O
follow,O
current,O
CDC,O
guidelines,O
both,O
to,O
evaluate,O
for,O
and,O
to,O
treat,O
possible,O
latent,O
tuberculosis,O
infections,O
before,O
initiating,O
therapy,O
with,O
ILARIS,O
5,O
2,O
Immunosuppression,O
The,O
impact,O
of,O
treatment,O
with,O
anti,O
interleukin,O
1,O
IL,O
1,O
therapy,O
on,O
the,O
development,O
of,O
malignancies,O
is,O
not,O
known,O
However,O
treatment,O
with,O
immunosuppressants,O
including,O
ILARIS,O
may,O
result,O
in,O
an,O
increase,O
in,O
the,O
risk,Factor
of,O
malignancies,AdverseReaction
5,O
3,O
Hypersensitivity,O
Hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
with,O
ILARIS,O
therapy,O
During,O
clinical,O
trials,O
no,Negation
anaphylactic reactions,AdverseReaction
have,O
been,O
reported,O
It,O
should,O
be,O
recognized,O
that,O
symptoms,O
of,O
the,O
underlying,O
disease,O
being,O
treated,O
may,O
be,O
similar,O
to,O
symptoms,O
of,O
hypersensitivity,O
ILARIS,O
should,O
not,O
be,O
administered,O
to,O
any,O
patients,O
with,O
known,O
clinical,O
hypersensitivity,O
to,O
ILARIS,O
see,O
Contraindications,O
4,O
and,O
Adverse,O
Reactions,O
6,O
2,O
5,O
4,O
Immunizations,O
Live,O
vaccines,O
should,O
not,O
be,O
given,O
concurrently,O
with,O
ILARIS,O
see,O
Drug,O
Interactions,O
7,O
2,O
Since,O
no,O
data,O
are,O
available,O
on,O
either,O
the,O
efficacy,O
or,O
on,O
the,O
risks,O
of,O
secondary,O
transmission,O
of,O
infection,O
by,O
live,O
vaccines,O
in,O
patients,O
receiving,O
ILARIS,O
live,O
vaccines,O
should,O
not,O
be,O
given,O
concurrently,O
with,O
ILARIS,O
In,O
addition,O
because,O
ILARIS,O
may,Factor
interfere with normal immune response,AdverseReaction
to,O
new,O
antigens,O
vaccinations,O
may,O
not,O
be,O
effective,O
in,O
patients,O
receiving,O
ILARIS,O
No,O
data,O
are,O
available,O
on,O
the,O
effectiveness,O
of,O
vaccinations,O
with,O
inactivated,O
killed,O
antigens,O
in,O
patients,O
receiving,O
ILARIS,O
see,O
Drug,O
Interactions,O
7,O
2,O
Because,O
IL,O
1,O
blockade,O
may,O
interfere,O
with,O
immune,O
response,O
to,O
infections,O
it,O
is,O
recommended,O
that,O
prior,O
to,O
initiation,O
of,O
therapy,O
with,O
ILARIS,O
adult,O
and,O
pediatric,O
patients,O
receive,O
all,O
recommended,O
vaccinations,O
as,O
appropriate,O
including,O
pneumococcal,O
vaccine,O
and,O
inactivated,O
influenza,O
vaccine,O
See,O
current,O
recommended,O
immunization,O
schedules,O
at,O
the,O
website,O
of,O
the,O
Centers,O
for,O
Disease,O
Control,O
http,O
www,O
cdc,O
gov,O
vaccines,O
schedules,O
index,O
html,O
5,O
5,O
Macrophage,O
Activation,O
Syndrome,O
Macrophage,O
activation,O
syndrome,O
MAS,O
is,O
a,O
known,O
life,O
threatening,O
disorder,O
that,O
may,O
develop,O
in,O
patients,O
with,O
rheumatic,O
conditions,O
in,O
particular,O
SJIA,O
and,O
should,O
be,O
aggressively,O
treated,O
Physicians,O
should,O
be,O
attentive,O
to,O
symptoms,O
of,O
infection,O
or,O
worsening,O
of,O
SJIA,O
as,O
these,O
are,O
known,O
triggers,O
for,O
MAS,O
Eleven,O
cases,O
of,O
MAS,AdverseReaction
were,O
observed,O
in,O
201,O
SJIA,O
patients,O
treated,O
with,O
canakinumab,O
in,O
clinical,O
trials,O
Based,O
on,O
the,O
clinical,O
trial,O
experience,O
ILARIS,O
does,O
not,O
appear,O
to,O
increase,O
the,O
incidence,O
of,O
MAS,AdverseReaction
in,O
SJIA,O
patients,O
but,O
no definitive conclusion,Factor
can,O
be,O
made,O
""
6,O
ADVERSE,O
REACTIONS,O
Three,O
hundred,O
ninety,O
five,O
patients,O
including,O
approximately,O
250,O
children,O
aged,O
2,O
to,O
17,O
years,O
have,O
been,O
treated,O
with,O
ILARIS,O
in,O
interventional,O
trials,O
in,O
CAPS,O
or,O
SJIA,O
The,O
most,O
frequently,O
reported,O
adverse,O
drug,O
reactions,O
were,O
infections,AdverseReaction
predominantly,O
of the upper respiratory tract,AdverseReaction
The,O
majority,O
of,O
the,O
events,O
were,O
mild to moderate,Severity
moderate,Severity
although,O
serious,Severity
infections,AdverseReaction
were,O
observed,O
The,O
type,O
and,O
frequency,O
of,O
adverse,O
drug,O
reactions,O
appeared,O
to,O
be,O
consistent,O
over,O
time,O
Opportunistic infections,AdverseReaction
have,O
also,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
ILARIS,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
CAPS,O
The,O
most,O
common,O
adverse,O
reactions,O
greater,O
than,O
10,O
reported,O
by,O
patients,O
with,O
CAPS,O
treated,O
with,O
ILARIS,O
are,O
nasopharyngitis,AdverseReaction
diarrhea,AdverseReaction
influenza,AdverseReaction
headache,AdverseReaction
and,O
nausea,AdverseReaction
6,O
SJIA,O
The,O
most,O
common,O
adverse,O
drug,O
reactions,O
greater,O
than,O
10,O
reported,O
by,O
patients,O
with,O
SJIA,O
treated,O
with,O
ILARIS,O
are,O
infections,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
upper respiratory tract infections,AdverseReaction
abdominal pain,AdverseReaction
and,O
injection site reactions,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Novartis,O
Pharmaceuticals,O
Corporation,O
at,O
1,O
888,O
669,O
6682,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Treatment,O
of,O
CAPS,O
The,O
data,O
described,O
herein,O
reflect,O
exposure,O
to,O
ILARIS,O
in,O
104,O
adult,O
and,O
pediatric,O
CAPS,O
patients,O
including,O
20,O
FCAS,O
72,O
MWS,O
10,O
MWS,O
NOMID,O
Neonatal,O
Onset,O
Multisystem,O
Inflammatory,O
Disorder,O
overlap,O
1,O
non,O
FCAS,O
non,O
MWS,O
and,O
1,O
misdiagnosed,O
in,O
placebo,O
controlled,O
35,O
patients,O
and,O
uncontrolled,O
trials,O
Sixty,O
two,O
patients,O
were,O
exposed,O
to,O
ILARIS,O
for,O
at,O
least,O
6,O
months,O
56,O
for,O
at,O
least,O
1,O
year,O
and,O
4,O
for,O
at,O
least,O
3,O
years,O
A,O
total,O
of,O
9,O
serious,O
adverse,O
reactions,O
were,O
reported,O
for,O
CAPS,O
patients,O
Among,O
these,O
were,O
vertigo,AdverseReaction
2,O
patients,O
infections,AdverseReaction
3,O
patients,O
including,O
intra abdominal abscess,AdverseReaction
following,O
appendectomy,O
1,O
patient,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
associated,O
with,O
ILARIS,O
treatment,O
in,O
the,O
CAPS,O
patients,O
were,O
nasopharyngitis,AdverseReaction
diarrhea,AdverseReaction
influenza,AdverseReaction
headache,AdverseReaction
and,O
nausea,AdverseReaction
One,O
patient,O
discontinued,O
treatment,O
due,O
to,O
potential,Factor
infection,AdverseReaction
CAPS,O
Study,O
1,O
investigated,O
the,O
safety,O
of,O
ILARIS,O
in,O
an,O
8,O
week,O
open,O
label,O
period,O
Part,O
1,O
followed,O
by,O
a,O
24,O
week,O
randomized,O
withdrawal,O
period,O
Part,O
2,O
followed,O
by,O
a,O
16,O
week,O
open,O
label,O
period,O
Part,O
3,O
All,O
patients,O
were,O
treated,O
with,O
ILARIS,O
150,O
mg,O
subcutaneously,O
or,O
2,O
mg,O
kg,O
if,O
body,O
weight,O
was,O
greater,O
than,O
or,O
equal,O
to,O
15,O
kg,O
and,O
less,O
than,O
or,O
equal,O
to,O
40,O
kg,O
see,O
Table,O
1,O
Since,O
all,O
CAPS,O
patients,O
received,O
ILARIS,O
in,O
Part,O
1,O
there,O
are,O
no,O
controlled,O
data,O
on,O
adverse,O
events,O
AEs,O
Data,O
in,O
Table,O
1,O
are,O
for,O
all,O
AEs,O
for,O
all,O
CAPS,O
patients,O
receiving,O
canakinumab,O
In,O
CAPS,O
Study,O
1,O
no,O
pattern,O
was,O
observed,O
for,O
any,O
type,O
or,O
frequency,O
of,O
adverse,O
events,O
throughout,O
the,O
three,O
study,O
periods,O
Table,O
1,O
Number,O
of,O
Patients,O
with,O
AEs,O
by,O
Preferred,O
Terms,O
in,O
10,O
of,O
Patients,O
in,O
Parts,O
1,O
to,O
3,O
of,O
the,O
Phase,O
3,O
Trial,O
for,O
CAPS,O
Patients,O
Preferred,O
Term,O
ILARISN,O
35n,O
n,O
of,O
Patients,O
with,O
Adverse,O
Events,O
35,O
100,O
Nasopharyngitis,AdverseReaction
12,O
34,O
Diarrhea,AdverseReaction
7,O
20,O
Influenza,AdverseReaction
6,O
17,O
Rhinitis,AdverseReaction
6,O
17,O
Nausea,AdverseReaction
5,O
14,O
Headache,AdverseReaction
5,O
14,O
Bronchitis,AdverseReaction
4,O
11,O
Gastroenteritis,AdverseReaction
4,O
11,O
Pharyngitis,AdverseReaction
4,O
11,O
Weight increased,AdverseReaction
4,O
11,O
Musculoskeletal pain,AdverseReaction
4,O
11,O
Vertigo,AdverseReaction
4,O
11,O
Vertigo,O
Vertigo,AdverseReaction
has,O
been,O
reported,O
in,O
9,O
to,O
14,O
of,O
patients,O
in,O
CAPS,O
studies,O
exclusively,O
in,O
MWS,O
patients,O
and,O
reported,O
as,O
a,O
serious,Severity
adverse,O
event,O
in,O
two,O
cases,O
All,O
events,O
resolved,O
with,O
continued,O
treatment,O
with,O
ILARIS,O
Injection,O
Site,O
Reactions,O
In,O
CAPS,O
Study,O
1,O
subcutaneous injection site reactions,AdverseReaction
were,O
observed,O
in,O
9,O
of,O
patients,O
in,O
Part,O
1,O
with,O
mild,O
tolerability,O
reactions,O
in,O
Part,O
2,O
one,O
patient,O
each,O
7,O
had,O
a,O
mild,O
or,O
a,O
moderate,O
tolerability,O
reaction,O
and,O
in,O
Part,O
3,O
one,O
patient,O
had,O
a,O
mild,Severity
local tolerability reaction,AdverseReaction
No,Negation
severe,Severity
injection site reactions,AdverseReaction
were,O
reported,O
and,O
none,O
led,O
to,O
discontinuation,O
of,O
treatment,O
Treatment,O
of,O
SJIA,O
A,O
total,O
of,O
201,O
SJIA,O
patients,O
aged,O
2,O
to,O
less,O
than,O
20,O
years,O
have,O
received,O
ILARIS,O
in,O
clinical,O
trials,O
The,O
safety,O
of,O
ILARIS,O
compared,O
to,O
placebo,O
was,O
investigated,O
in,O
two,O
phase,O
3,O
studies,O
see,O
Clinical,O
Studies,O
14,O
2,O
Patients,O
in,O
SJIA,O
Study,O
1,O
received,O
a,O
single,O
dose,O
of,O
ILARIS,O
4,O
mg,O
kg,O
n,O
43,O
or,O
placebo,O
n,O
41,O
via,O
subcutaneous,O
injection,O
and,O
were,O
assessed,O
at,O
Day,O
15,O
for,O
the,O
efficacy,O
endpoints,O
and,O
had,O
a,O
safety,O
analysis,O
up,O
to,O
Day,O
29,O
SJIA,O
Study,O
2,O
was,O
a,O
two,O
part,O
study,O
with,O
an,O
open,O
label,O
single,O
arm,O
active,O
treatment,O
period,O
Part,O
I,O
followed,O
by,O
a,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
event,O
driven,O
withdrawal,O
design,O
Part,O
II,O
Overall,O
177,O
patients,O
were,O
enrolled,O
into,O
the,O
study,O
and,O
received,O
ILARIS,O
4,O
mg,O
kg,O
up,O
to,O
300,O
mg,O
maximum,O
in,O
Part,O
I,O
and,O
100,O
patients,O
received,O
ILARIS,O
4,O
mg,O
kg,O
up,O
to,O
300,O
mg,O
maximum,O
every,O
4,O
weeks,O
or,O
placebo,O
in,O
Part,O
II,O
Adverse,O
drug,O
reactions,O
listed,O
in,O
Table,O
2,O
showed,O
higher,O
rates,O
than,O
placebo,O
from,O
both,O
trials,O
The,O
adverse,O
drug,O
reactions,O
associated,O
with,O
ILARIS,O
treatment,O
in,O
SJIA,O
patients,O
were,O
infections,AdverseReaction
abdominal pain,AdverseReaction
and,O
injection site reactions,AdverseReaction
Serious,Severity
infections,AdverseReaction
e,O
g,O
pneumonia,AdverseReaction
varicella,AdverseReaction
gastroenteritis,AdverseReaction
measles,AdverseReaction
sepsis,AdverseReaction
otitis media,AdverseReaction
sinusitis,AdverseReaction
adenovirus,AdverseReaction
lymph node abscess,AdverseReaction
pharyngitis,AdverseReaction
were,O
observed,O
in,O
approximately,O
4,O
to,O
5,O
0,O
02,O
to,O
0,O
17,O
per,O
100,O
patient,O
days,O
of,O
patients,O
receiving,O
ILARIS,O
in,O
both,O
studies,O
Adverse,O
reactions,O
are,O
listed,O
according,O
to,O
MedDRA,O
version,O
15,O
0,O
system,O
organ,O
class,O
Table,O
2,O
Tabulated,O
Summary,O
of,O
Adverse,O
Drug,O
Reactions,O
from,O
Pivotal,O
SJIA,O
Clinical,O
Trials,O
n,O
number,O
of,O
patients,O
IR,O
Exposure,O
adjusted,O
incidence,O
rate,O
per,O
100,O
patient,O
days,O
No,O
injection,O
site,O
reaction,O
led,O
to,O
study,O
discontinuation,O
SJIA,O
Study,O
2,O
SJIA,O
Study,O
1,O
Part,O
I,O
Part,O
II,O
ILARISN,O
177n,O
IR,O
ILARISN,O
50n,O
IR,O
PlaceboN,O
50n,O
IR,O
ILARISN,O
43n,O
IR,O
PlaceboN,O
41n,O
IR,O
Infections,O
and,O
infestations,O
All,O
Infections,AdverseReaction
e,O
g,O
nasopharyngitis,AdverseReaction
viral,AdverseReaction
upper respiratory tract infection,AdverseReaction
pneumonia,AdverseReaction
rhinitis,AdverseReaction
pharyngitis,AdverseReaction
tonsillitis,AdverseReaction
sinusitis,AdverseReaction
urinary tract infection,AdverseReaction
gastroenteritis,AdverseReaction
viral infection,AdverseReaction
97,O
54,O
8,O
0,O
91,O
27,O
54,O
0,O
59,O
19,O
38,O
0,O
63,O
13,O
30,O
2,O
1,O
26,O
5,O
12,O
2,O
1,O
37,O
Gastrointestinal,O
disorders,O
Abdominal pain,AdverseReaction
upper,AdverseReaction
25,O
14,O
1,O
0,O
16,O
8,O
16,O
0,O
15,O
6,O
12,O
0,O
08,O
3,O
7,O
0,O
25,O
1,O
2,O
4,O
0,O
23,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Injection site reaction,AdverseReaction
mild,O
19,O
10,O
7,O
6,O
12,O
0,O
2,O
4,O
0,O
0,O
3,O
7,O
3,O
moderate,O
2,O
1,O
1,O
1,O
2,O
0,O
0,O
0,O
0,O
6,O
2,O
Hypersensitivity,O
During,O
clinical,O
trials,O
no,Negation
anaphylactic reactions,AdverseReaction
have,O
been,O
reported,O
In,O
CAPS,O
trials,O
one,O
patient,O
discontinued,O
and,O
in,O
SJIA,O
trials,O
no,O
patients,O
discontinued,O
due,O
to,O
hypersensitivity reactions,AdverseReaction
ILARIS,O
should,O
not,O
be,O
administered,O
to,O
any,O
patients,O
with,O
known,O
clinical,O
hypersensitivity,O
to,O
ILARIS,O
see,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
3,O
6,O
3,O
Immunogenicity,O
A,O
biosensor,O
binding,O
assay,O
or,O
a,O
bridging,O
immunoassay,O
was,O
used,O
to,O
detect,O
antibodies,O
directed,O
against,O
canakinumab,O
in,O
patients,O
who,O
received,O
ILARIS,O
Antibodies,O
against,O
ILARIS,O
were,O
observed,O
in,O
approximately,O
1,O
5,O
and,O
3,O
1,O
of,O
the,O
patients,O
treated,O
with,O
ILARIS,O
for,O
CAPS,O
and,O
SJIA,O
respectively,O
No,O
neutralizing,O
antibodies,O
were,O
detected,O
No,O
apparent,O
correlation,O
of,O
antibody,O
development,O
to,O
clinical,O
response,O
or,O
adverse,O
events,O
was,O
observed,O
The,O
CAPS,O
clinical,O
studies,O
employed,O
the,O
biosensor,O
binding,O
assay,O
and,O
most,O
of,O
the,O
SJIA,O
clinical,O
studies,O
employed,O
the,O
bridging,O
assay,O
The,O
data,O
obtained,O
in,O
an,O
assay,O
are,O
highly,O
dependent,O
on,O
several,O
factors,O
including,O
assay,O
sensitivity,O
and,O
specificity,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
underlying,O
disease,O
and,O
the,O
number,O
of,O
patients,O
tested,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
canakinumab,O
between,O
the,O
CAPS,O
and,O
SJIA,O
clinical,O
studies,O
or,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
6,O
4,O
Laboratory,O
Findings,O
Hematology,O
During,O
clinical,O
trials,O
with,O
ILARIS,O
mean,O
values,O
decreased,AdverseReaction
for,O
white blood cells,AdverseReaction
neutrophils,AdverseReaction
and,O
platelets,AdverseReaction
In,O
the,O
randomized,O
placebo,O
controlled,O
portion,O
of,O
SJIA,O
Study,O
2,O
decreased white blood cell counts,AdverseReaction
WBC,AdverseReaction
less,O
than,O
or,O
equal,O
to,O
0 8 times lower limit of normal,Severity
LLN,O
were,O
reported,O
in,O
5,O
patients,O
10,O
4,O
in,O
the,O
ILARIS,O
group,O
compared,O
to,O
2,O
4,O
0,O
in,O
the,O
placebo,O
group,O
Transient,Severity
decreases in absolute neutrophil count in,AdverseReaction
ANC,AdverseReaction
to,O
less,O
than,O
1x10 9 L,Severity
were,O
reported,O
in,O
3,O
patients,O
6,O
0,O
in,O
the,O
ILARIS,O
group,O
compared,O
to1,O
patient,O
2,O
0,O
in,O
the,O
placebo,O
group,O
One,O
case,O
of,O
ANC less than 0 5x10 9 L,AdverseReaction
was,O
observed,O
in,O
the,O
ILARIS,O
group,O
and,O
none,O
in,O
the,O
placebo,O
group,O
Mild,Severity
less,O
than,O
LLN,Severity
and,O
greater,O
than,O
75x10 9 L,Severity
and,O
transient,Severity
decreases in platelet counts,AdverseReaction
were,O
observed,O
in,O
3,O
6,O
3,O
ILARIS,O
treated,O
patients,O
versus,O
1,O
2,O
0,O
placebo,O
treated,O
patient,O
Hepatic,O
Transaminases,O
Elevations of transaminases,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
treated,O
with,O
ILARIS,O
In,O
the,O
randomized,O
placebo,O
controlled,O
portion,O
of,O
SJIA,O
Study,O
2,O
high ALT,AdverseReaction
and,O
or,O
AST,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
3 times upper limit of normal,Severity
ULN,O
were,O
reported,O
in,O
2,O
4,O
1,O
ILARIS,O
treated,O
patients,O
and,O
1,O
2,O
0,O
placebo,O
patient,O
All,O
patients,O
had,O
normal,O
values,O
at,O
the,O
next,O
visit,O
Bilirubin,O
Asymptomatic,O
and,O
mild,Severity
elevations of serum bilirubin,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
treated,O
with,O
ILARIS,O
without,Negation
concomitant,O
elevations of transaminases,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hemorrhage,AdverseReaction
Monitor,O
for,O
bleeding,O
5,O
1,O
Infections,AdverseReaction
Monitor,O
patients,O
for,O
fever,O
and,O
infections,O
and,O
evaluate,O
promptly,O
5,O
2,O
Cytopenias,AdverseReaction
Check,O
complete,O
blood,O
counts,O
monthly,O
5,O
3,O
Atrial Fibrillation,AdverseReaction
Monitor,O
patients,O
for,O
atrial,O
fibrillation,O
5,O
4,O
Second Primary Malignancies,AdverseReaction
Other,O
malignancies,AdverseReaction
have,O
occurred,O
in,O
patients,O
including,O
skin cancers,AdverseReaction
and,O
other,O
carcinomas,AdverseReaction
5,O
5,O
Tumor Lysis Syndrome,AdverseReaction
TLS,AdverseReaction
Monitor,O
patients,O
at,O
risk,O
for,O
TLS,O
e,O
g,O
high,O
tumor,O
burden,O
5,O
6,O
Embryo Fetal Toxicity,AdverseReaction
Can,Factor
cause,O
fetal harm,AdverseReaction
Advise,O
women,O
of,O
the,O
potential,O
risk,O
to,O
a,O
fetus,O
and,O
to,O
avoid,O
pregnancy,O
while,O
taking,O
the,O
drug,O
5,O
7,O
5,O
1,O
Hemorrhage,O
Fatal,AdverseReaction
bleeding events,AdverseReaction
have,O
occurred,O
in,O
patients,O
treated,O
with,O
IMBRUVICA,O
Grade 3,Severity
or,O
higher,O
bleeding events,AdverseReaction
subdural hematoma,AdverseReaction
gastrointestinal bleeding,AdverseReaction
hematuria,AdverseReaction
and,O
post procedural hemorrhage,AdverseReaction
have,O
occurred,O
in,O
up,O
to,O
6,O
of,O
patients,O
Bleeding,AdverseReaction
events,O
of,O
any,O
grade,O
including,O
bruising,AdverseReaction
and,O
petechiae,AdverseReaction
occurred,O
in,O
approximately,O
half,O
of,O
patients,O
treated,O
with,O
IMBRUVICA,O
The,O
mechanism,O
for,O
the,O
bleeding,O
events,O
is,O
not,O
well,O
understood,O
IMBRUVICA,O
may,Factor
increase,O
the,O
risk,O
of,O
hemorrhage,AdverseReaction
in,O
patients,O
receiving,O
antiplatelet,O
or,O
anticoagulant,O
therapies,O
Consider,O
the,O
benefit,O
risk,O
of,O
withholding,O
IMBRUVICA,O
for,O
at,O
least,O
3,O
to,O
7,O
days,O
pre,O
and,O
post,O
surgery,O
depending,O
upon,O
the,O
type,O
of,O
surgery,O
and,O
the,O
risk,O
of,O
bleeding,O
see,O
Clinical,O
Studies,O
14,O
5,O
2,O
Infections,O
Fatal,AdverseReaction
and,O
non fatal,Severity
infections,AdverseReaction
have,O
occurred,O
with,O
IMBRUVICA,O
therapy,O
Grade 3,Severity
or,O
greater,O
infections,AdverseReaction
occurred,O
in,O
14,O
to,O
26,O
of,O
patients,O
See,O
Adverse,O
Reactions,O
6,O
1,O
Cases,O
of,O
progressive multifocal leukoencephalopathy,AdverseReaction
PML,AdverseReaction
have,O
occurred,O
in,O
patients,O
treated,O
with,O
IMBRUVICA,O
Monitor,O
patients,O
for,O
fever,O
and,O
infections,O
and,O
evaluate,O
promptly,O
5,O
3,O
Cytopenias,O
Treatment,O
emergent,O
Grade 3,Severity
or,O
4,Severity
cytopenias,AdverseReaction
including,O
neutropenia,AdverseReaction
range,O
19,O
to,O
29,O
thrombocytopenia,AdverseReaction
range,O
5,O
to,O
17,O
and,O
anemia,AdverseReaction
range,O
0,O
to,O
9,O
occurred,O
in,O
patients,O
treated,O
with,O
IMBRUVICA,O
Monitor,O
complete,O
blood,O
counts,O
monthly,O
5,O
4,O
Atrial,O
Fibrillation,O
Atrial fibrillation,AdverseReaction
and,O
atrial flutter,AdverseReaction
range,O
6,O
to,O
9,O
have,O
occurred,O
in,O
patients,O
treated,O
with,O
IMBRUVICA,O
particularly,O
in,O
patients,O
with,O
cardiac,O
risk,O
factors,O
acute,O
infections,O
and,O
a,O
previous,O
history,O
of,O
atrial,O
fibrillation,O
Periodically,O
monitor,O
patients,O
clinically,O
for,O
atrial,O
fibrillation,O
Patients,O
who,O
develop,O
arrhythmic,O
symptoms,O
e,O
g,O
palpitations,O
lightheadedness,O
or,O
new,O
onset,O
dyspnea,O
should,O
have,O
an,O
ECG,O
performed,O
If,O
atrial,O
fibrillation,O
persists,O
consider,O
the,O
risks,O
and,O
benefits,O
of,O
IMBRUVICA,O
treatment,O
and,O
dose,O
modification,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
5,O
Second,O
Primary,O
Malignancies,O
Other,O
malignancies,AdverseReaction
range,O
5,O
to,O
14,O
including,O
non skin carcinomas,AdverseReaction
range,O
1,O
to,O
3,O
have,O
occurred,O
in,O
patients,O
treated,O
with,O
IMBRUVICA,O
The,O
most,O
frequent,O
second primary malignancy,AdverseReaction
was,O
non melanoma skin cancer,AdverseReaction
range,O
4,O
to,O
11,O
5,O
6,O
Tumor,O
Lysis,O
Syndrome,O
Tumor lysis syndrome,AdverseReaction
has,O
been,O
reported,O
with,O
IMBRUVICA,O
therapy,O
Monitor,O
patients,O
closely,O
and,O
take,O
appropriate,O
precautions,O
in,O
patients,O
at,O
risk,O
for,O
tumor,O
lysis,O
syndrome,O
e,O
g,O
high,O
tumor,O
burden,O
5,O
7,O
Embryo,O
Fetal,O
Toxicity,O
Based,O
on,O
findings,O
in,O
animals,Animal
IMBRUVICA,O
can,O
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Ibrutinib,O
caused,O
malformations,AdverseReaction
in,O
rats,Animal
at,O
exposures,O
14,O
times,O
those,O
reported,O
in,O
patients,O
with,O
MCL,O
and,O
20,O
times,O
those,O
reported,O
in,O
patients,O
with,O
CLL,O
or,O
WM,O
receiving,O
the,O
ibrutinib,O
dose,O
of,O
560,O
mg,O
per,O
day,O
and,O
420,O
mg,O
per,O
day,O
respectively,O
Reduced fetal weights,AdverseReaction
were,O
observed,O
at,O
lower,O
exposures,O
Advise,O
women,O
to,O
avoid,O
becoming,O
pregnant,O
while,O
taking,O
IMBRUVICA,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
a,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
more,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Hemorrhage,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Cytopenias,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Atrial Fibrillation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Second Primary Malignancies,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Tumor Lysis Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
variable,O
conditions,O
adverse,O
event,O
rates,O
observed,O
in,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
of,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
25,O
in,O
patients,O
with,O
B,O
cell,O
malignancies,O
MCL,O
CLL,O
WM,O
were,O
thrombocytopenia,AdverseReaction
neutropenia,AdverseReaction
diarrhea,AdverseReaction
anemia,AdverseReaction
fatigue,AdverseReaction
musculoskeletal pain,AdverseReaction
bruising,AdverseReaction
nausea,AdverseReaction
upper respiratory tract infection,AdverseReaction
and,O
rash,AdverseReaction
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Pharmacyclics,O
at,O
1,O
877,O
877,O
3536,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Mantle,O
Cell,O
Lymphoma,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
IMBRUVICA,O
in,O
a,O
clinical,O
trial,O
that,O
included,O
111,O
patients,O
with,O
previously,O
treated,O
MCL,O
treated,O
with,O
560,O
mg,O
daily,O
with,O
a,O
median,O
treatment,O
duration,O
of,O
8,O
3,O
months,O
The,O
most,O
commonly,O
occurring,O
adverse,O
reactions,O
20,O
were,O
thrombocytopenia,AdverseReaction
diarrhea,AdverseReaction
neutropenia,AdverseReaction
anemia,AdverseReaction
fatigue,AdverseReaction
musculoskeletal pain,AdverseReaction
peripheral edema,AdverseReaction
upper respiratory tract infection,AdverseReaction
nausea,AdverseReaction
bruising,AdverseReaction
dyspnea,AdverseReaction
constipation,AdverseReaction
rash,AdverseReaction
abdominal pain,AdverseReaction
vomiting,AdverseReaction
and,O
decreased appetite,AdverseReaction
see,O
Tables,O
1,O
and,O
2,O
The,O
most,O
common,O
Grade 3,Severity
or,O
4,Severity
non,O
hematological,O
adverse,O
reactions,O
5,O
were,O
pneumonia,AdverseReaction
abdominal pain,AdverseReaction
atrial fibrillation,AdverseReaction
diarrhea,AdverseReaction
fatigue,AdverseReaction
and,O
skin infections,AdverseReaction
Fatal,AdverseReaction
and,O
serious,Severity
cases,O
of,O
renal failure,AdverseReaction
have,O
occurred,O
with,O
IMBRUVICA,O
therapy,O
Increases in creatinine,AdverseReaction
1 5 to 3 times the upper limit of normal,Severity
occurred,O
in,O
9,O
of,O
patients,O
Adverse,O
reactions,O
from,O
the,O
MCL,O
trial,O
N,O
111,O
using,O
single,O
agent,O
IMBRUVICA,O
560,O
mg,O
daily,O
occurring,O
at,O
a,O
rate,O
of,O
10,O
are,O
presented,O
in,O
Table,O
1,O
Table,O
1,O
Non,O
Hematologic,O
Adverse,O
Reactions,O
in,O
10,O
of,O
Patients,O
with,O
MCL,O
N,O
111,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
Gastrointestinal,O
disorders,O
Diarrhea,AdverseReaction
51,O
5,O
Nausea,AdverseReaction
31,O
0,O
Constipation,AdverseReaction
25,O
0,O
Abdominal pain,AdverseReaction
24,O
5,O
Vomiting,AdverseReaction
23,O
0,O
Stomatitis,AdverseReaction
17,O
1,O
Dyspepsia,AdverseReaction
11,O
0,O
Infections,O
and,O
infestations,O
Upper respiratory tract infection,AdverseReaction
34,O
0,O
Urinary tract infection,AdverseReaction
14,O
3,O
Pneumonia,AdverseReaction
14,O
7,O
Skin infections,AdverseReaction
14,O
5,O
Sinusitis,AdverseReaction
13,O
1,O
General,O
disorders,O
and,O
administrative,O
site,O
conditions,O
Fatigue,AdverseReaction
41,O
5,O
Peripheral edema,AdverseReaction
35,O
3,O
Pyrexia,AdverseReaction
18,O
1,O
Asthenia,AdverseReaction
14,O
3,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Bruising,AdverseReaction
30,O
0,O
Rash,AdverseReaction
25,O
3,O
Petechiae,AdverseReaction
11,O
0,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Musculoskeletal pain,AdverseReaction
37,O
1,O
Muscle spasms,AdverseReaction
14,O
0,O
Arthralgia,AdverseReaction
11,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Dyspnea,AdverseReaction
27,O
4,O
Cough,AdverseReaction
19,O
0,O
Epistaxis,AdverseReaction
11,O
0,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
21,O
2,O
Dehydration,AdverseReaction
12,O
4,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
14,O
0,O
Headache,AdverseReaction
13,O
0,O
Table,O
2,O
Treatment,O
EmergentBased,O
on,O
laboratory,O
measurements,O
and,O
adverse,O
reactions,O
Decrease of Hemoglobin of of,AdverseReaction
Platelets,AdverseReaction
or,O
Neutrophils,AdverseReaction
in,O
Patients,O
with,O
MCL,O
N,O
111,O
Percent,O
of,O
Patients,O
N,O
111,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
Platelets Decreased,AdverseReaction
57,O
17,O
Neutrophils Decreased,AdverseReaction
47,O
29,O
Hemoglobin Decreased,AdverseReaction
41,O
9,O
Ten,O
patients,O
9,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reactions,O
in,O
the,O
trial,O
N,O
111,O
The,O
most,O
frequent,O
adverse,O
reaction,O
leading,O
to,O
treatment,O
discontinuation,O
was,O
subdural hematoma,AdverseReaction
1,O
8,O
Adverse,O
reactions,O
leading,O
to,O
dose,O
reduction,O
occurred,O
in,O
14,O
of,O
patients,O
Patients,O
with,O
MCL,O
who,O
develop,O
lymphocytosis,O
greater,O
than,O
400,O
000,O
mcL,O
have,O
developed,O
intracranial,O
hemorrhage,O
lethargy,O
gait,O
instability,O
and,O
headache,O
However,O
some,O
of,O
these,O
cases,O
were,O
in,O
the,O
setting,O
of,O
disease,O
progression,O
Forty,O
percent,O
of,O
patients,O
had,O
elevated uric acid levels uric acid levels,AdverseReaction
on,O
study,O
including,O
13,O
with,O
values,O
above 10 mg dL,Severity
Adverse,O
reaction,O
of,O
hyperuricemia,AdverseReaction
was,O
reported,O
for,O
15,O
of,O
patients,O
Chronic,O
Lymphocytic,O
Leukemia,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
IMBRUVICA,O
in,O
an,O
open,O
label,O
clinical,O
trial,O
Study,O
1,O
that,O
included,O
48,O
patients,O
with,O
previously,O
treated,O
CLL,O
and,O
a,O
randomized,O
clinical,O
trial,O
Study,O
2,O
that,O
included,O
391,O
randomized,O
patients,O
with,O
previously,O
treated,O
CLL,O
or,O
SLL,O
The,O
most,O
commonly,O
occurring,O
adverse,O
reactions,O
in,O
Study,O
1,O
and,O
Study,O
2,O
20,O
were,O
thrombocytopenia,AdverseReaction
neutropenia,AdverseReaction
diarrhea,AdverseReaction
anemia,AdverseReaction
fatigue,AdverseReaction
musculoskeletal pain,AdverseReaction
upper respiratory tract infection,AdverseReaction
rash,AdverseReaction
nausea,AdverseReaction
and,O
pyrexia,AdverseReaction
Approximately,O
five,O
percent,O
of,O
patients,O
receiving,O
IMBRUVICA,O
in,O
Study,O
1,O
and,O
Study,O
2,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
events,O
These,O
included,O
infections,AdverseReaction
subdural hematomas,AdverseReaction
and,O
diarrhea,AdverseReaction
Adverse,O
events,O
leading,O
to,O
dose,O
reduction,O
occurred,O
in,O
approximately,O
6,O
of,O
patients,O
Study,O
1,O
Adverse,O
reactions,O
and,O
laboratory,O
abnormalities,O
from,O
the,O
CLL,O
trial,O
N,O
48,O
using,O
single,O
agent,O
IMBRUVICA,O
420,O
mg,O
daily,O
occurring,O
at,O
a,O
rate,O
of,O
10,O
are,O
presented,O
in,O
Tables,O
3,O
and,O
4,O
Table,O
3,O
Non,O
Hematologic,O
Adverse,O
Reactions,O
in,O
10,O
of,O
Patients,O
with,O
CLL,O
N,O
48,O
in,O
Study,O
1,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
Gastrointestinal,O
disorders,O
Diarrhea,AdverseReaction
63,O
4,O
Constipation,AdverseReaction
23,O
2,O
Nausea,AdverseReaction
21,O
2,O
Stomatitis,AdverseReaction
21,O
0,O
Vomiting,AdverseReaction
19,O
2,O
Abdominal pain,AdverseReaction
15,O
0,O
Dyspepsia,AdverseReaction
13,O
0,O
Infections,O
and,O
infestations,O
Upper respiratory tract infection,AdverseReaction
48,O
2,O
Sinusitis,AdverseReaction
21,O
6,O
Skin infection,AdverseReaction
17,O
6,O
Pneumonia,AdverseReaction
10,O
8,O
Urinary tract infection,AdverseReaction
10,O
0,O
General,O
disorders,O
and,O
administrative,O
site,O
conditions,O
Fatigue,AdverseReaction
31,O
4,O
Pyrexia,AdverseReaction
25,O
2,O
Peripheral edema,AdverseReaction
23,O
0,O
Asthenia,AdverseReaction
13,O
4,O
Chills,AdverseReaction
13,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Bruising,AdverseReaction
54,O
2,O
Rash,AdverseReaction
27,O
0,O
Petechiae,AdverseReaction
17,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
19,O
0,O
Oropharyngeal pain,AdverseReaction
15,O
0,O
Dyspnea,AdverseReaction
10,O
0,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Musculoskeletal pain,AdverseReaction
27,O
6,O
Arthralgia,AdverseReaction
23,O
0,O
Muscle spasms,AdverseReaction
19,O
2,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
21,O
0,O
Headache,AdverseReaction
19,O
2,O
Peripheral neuropathy,AdverseReaction
10,O
0,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
17,O
2,O
Neoplasms,O
benign,O
malignant,O
unspecified,O
Second malignancies,AdverseReaction
10,O
0,O
Injury,O
poisoning,O
and,O
procedural,O
complications,O
Laceration,AdverseReaction
10,O
2,O
Psychiatric,O
disorders,O
Anxiety,AdverseReaction
10,O
0,O
Insomnia,AdverseReaction
10,O
0,O
Vascular,O
disorders,O
Hypertension,AdverseReaction
17,O
8,O
Table,O
4,O
Treatment,O
EmergentBased,O
on,O
laboratory,O
measurements,O
per,O
IWCLL,O
criteria,O
and,O
adverse,O
reactions,O
Decrease of Hemoglobin of of,AdverseReaction
Platelets,AdverseReaction
or,O
Neutrophils,AdverseReaction
in,O
Patients,O
with,O
CLL,O
N,O
48,O
in,O
Study,O
1,O
Percent,O
of,O
Patients,O
N,O
48,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
Platelets Decreased,AdverseReaction
71,O
10,O
Neutrophils Decreased,AdverseReaction
54,O
27,O
Hemoglobin Decreased,AdverseReaction
44,O
0,O
Study,O
2,O
Adverse,O
reactions,O
and,O
laboratory,O
abnormalities,O
described,O
below,O
in,O
Tables,O
5,O
and,O
6,O
reflect,O
exposure,O
to,O
IMBRUVICA,O
with,O
a,O
median,O
duration,O
of,O
8,O
6,O
months,O
and,O
exposure,O
to,O
ofatumumab,O
with,O
a,O
median,O
of,O
5,O
3,O
months,O
in,O
Study,O
2,O
Table,O
5,O
Non,O
Hematologic,O
Adverse,O
Reactions,O
10,O
Reported,O
in,O
Study,O
2,O
IMBRUVICA,O
N,O
195,O
Ofatumumab,O
N,O
191,O
System,O
Organ,O
Class,O
ADR,O
Term,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
Subjects,O
with,O
multiple,O
events,O
for,O
a,O
given,O
ADR,O
term,O
are,O
counted,O
once,O
only,O
for,O
each,O
ADR,O
term,O
The,O
system,O
organ,O
class,O
and,O
individual,O
ADR,O
terms,O
are,O
sorted,O
in,O
descending,O
frequency,O
order,O
in,O
the,O
IMBRUVICA,O
arm,O
Gastrointestinal,O
disorders,O
Diarrhea,AdverseReaction
48,O
4,O
18,O
2,O
Nausea,AdverseReaction
26,O
2,O
18,O
0,O
Stomatitis,AdverseReaction
17,O
1,O
6,O
1,O
Constipation,AdverseReaction
15,O
0,O
9,O
0,O
Vomiting,AdverseReaction
14,O
0,O
6,O
1,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
28,O
2,O
30,O
2,O
Pyrexia,AdverseReaction
24,O
2,O
15,O
1,O
Infections,O
and,O
infestations,O
Upper respiratory tract infection,AdverseReaction
16,O
1,O
11,O
2,O
Pneumonia,AdverseReaction
15,O
10,O
13,O
9,O
Sinusitis,AdverseReaction
11,O
1,O
6,O
0,O
Urinary tract infection,AdverseReaction
10,O
4,O
5,O
1,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
24,O
3,O
13,O
0,O
Petechiae,AdverseReaction
14,O
0,O
1,O
0,O
Bruising,AdverseReaction
12,O
0,O
1,O
0,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Musculoskeletal Pain,AdverseReaction
28,O
2,O
18,O
1,O
Arthralgia,AdverseReaction
17,O
1,O
7,O
0,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
14,O
1,O
6,O
0,O
Dizziness,AdverseReaction
11,O
0,O
5,O
0,O
Injury,O
poisoning,O
and,O
procedural,O
complications,O
Contusion,AdverseReaction
11,O
0,O
3,O
0,O
Eye,O
disorders,O
Vision blurred,AdverseReaction
10,O
0,O
3,O
0,O
Table,O
6,O
Treatment,O
EmergentBased,O
on,O
laboratory,O
measurements,O
per,O
IWCLL,O
criteria,O
Decrease of Hemoglobin of of,AdverseReaction
Platelets,AdverseReaction
or,O
Neutrophils,AdverseReaction
in,O
Study,O
2,O
IMBRUVICA,O
N,O
195,O
Ofatumumab,O
N,O
191,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
Neutrophils Decreased,AdverseReaction
51,O
23,O
57,O
26,O
Platelets Decreased,AdverseReaction
52,O
5,O
45,O
10,O
Hemoglobin Decreased,AdverseReaction
36,O
0,O
21,O
0,O
Waldenstrom,O
s,O
Macroglobulinemia,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
IMBRUVICA,O
in,O
an,O
open,O
label,O
clinical,O
trial,O
that,O
included,O
63,O
patients,O
with,O
previously,O
treated,O
WM,O
The,O
most,O
commonly,O
occurring,O
adverse,O
reactions,O
in,O
the,O
WM,O
trial,O
20,O
were,O
neutropenia,AdverseReaction
thrombocytopenia,AdverseReaction
diarrhea,AdverseReaction
rash,AdverseReaction
nausea,AdverseReaction
muscle spasms,AdverseReaction
and,O
fatigue,AdverseReaction
Six,O
percent,O
of,O
patients,O
receiving,O
IMBRUVICA,O
in,O
the,O
WM,O
trial,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
events,O
Adverse,O
events,O
leading,O
to,O
dose,O
reduction,O
occurred,O
in,O
11,O
of,O
patients,O
Adverse,O
reactions,O
and,O
laboratory,O
abnormalities,O
described,O
below,O
in,O
Tables,O
7,O
and,O
8,O
reflect,O
exposure,O
to,O
IMBRUVICA,O
with,O
a,O
median,O
duration,O
of,O
11,O
7,O
months,O
in,O
the,O
WM,O
trial,O
Table,O
7,O
Non,O
Hematologic,O
Adverse,O
Reactions,O
in,O
10,O
of,O
Patients,O
with,O
Waldenstrom,O
s,O
Macroglobulinemia,O
N,O
63,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
The,O
system,O
organ,O
class,O
and,O
individual,O
ADR,O
terms,O
are,O
sorted,O
in,O
descending,O
frequency,O
order,O
Gastrointestinal,O
disorders,O
Diarrhea,AdverseReaction
37,O
0,O
Nausea,AdverseReaction
21,O
0,O
Stomatitis,AdverseReaction
16,O
0,O
Gastroesophageal reflux disease,AdverseReaction
13,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
22,O
0,O
Bruising,AdverseReaction
16,O
0,O
Pruritus,AdverseReaction
11,O
0,O
General,O
disorders,O
and,O
administrative,O
site,O
conditions,O
Fatigue,AdverseReaction
21,O
0,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Muscle spasms,AdverseReaction
21,O
0,O
Arthropathy,AdverseReaction
13,O
0,O
Infections,O
and,O
infestations,O
Upper respiratory tract infection,AdverseReaction
19,O
0,O
Sinusitis,AdverseReaction
19,O
0,O
Pneumonia,AdverseReaction
14,O
6,O
Skin infection,AdverseReaction
14,O
2,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Epistaxis,AdverseReaction
19,O
0,O
Cough,AdverseReaction
13,O
0,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
14,O
0,O
Headache,AdverseReaction
13,O
0,O
Neoplasms,O
benign,O
malignant,O
and,O
unspecified,O
including,O
cysts,O
and,O
polyps,O
Skin cancer,AdverseReaction
11,O
0,O
Table,O
8,O
Treatment,O
EmergentBased,O
on,O
laboratory,O
measurements,O
Decrease of Hemoglobin of of,AdverseReaction
Platelets,AdverseReaction
or,O
Neutrophils,AdverseReaction
in,O
Patients,O
with,O
WM,O
N,O
63,O
Percent,O
of,O
Patients,O
N,O
63,O
All,O
Grades,O
Grade,O
3,O
or,O
4,O
Platelets Decreased,AdverseReaction
43,O
13,O
Neutrophils Decreased,AdverseReaction
44,O
19,O
Hemoglobin Decreased,AdverseReaction
13,O
8,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
IMBRUVICA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Hypersensitivity reactions,AdverseReaction
including,O
anaphylactic shock,AdverseReaction
fatal,AdverseReaction
urticaria,AdverseReaction
and,O
angioedema,AdverseReaction
have,O
been,O
reported,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypertension,AdverseReaction
including,O
hypertensive crisis,AdverseReaction
has,O
been,O
observed,O
Blood,O
pressure,O
should,O
be,O
well,O
controlled,O
prior,O
to,O
initiating,O
INLYTA,O
Monitor,O
for,O
hypertension,O
and,O
treat,O
as,O
needed,O
For,O
persistent,O
hypertension,O
despite,O
use,O
of,O
anti,O
hypertensive,O
medications,O
reduce,O
the,O
INLYTA,O
dose,O
5,O
1,O
Arterial,AdverseReaction
and,O
venous thrombotic events events,AdverseReaction
have,O
been,O
observed,O
and,O
can,Factor
be,O
fatal,AdverseReaction
Use,O
with,O
caution,O
in,O
patients,O
who,O
are,O
at,O
increased,O
risk,O
for,O
these,O
events,O
5,O
2,O
5,O
3,O
Hemorrhagic events,AdverseReaction
including,O
fatal,AdverseReaction
events,O
have,O
been,O
reported,O
INLYTA,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
evidence,O
of,O
untreated,O
brain,O
metastasis,O
or,O
recent,O
active,O
gastrointestinal,O
bleeding,O
and,O
should,O
not,O
be,O
used,O
in,O
those,O
patients,O
5,O
4,O
Cardiac failure,AdverseReaction
has,O
been,O
observed,O
and,O
can,Factor
be,O
fatal,AdverseReaction
Monitor,O
for,O
signs,O
or,O
symptoms,O
of,O
cardiac,O
failure,O
throughout,O
treatment,O
with,O
INLYTA,O
5,O
5,O
Gastrointestinal perforation,AdverseReaction
and,O
fistula,AdverseReaction
including,O
death,AdverseReaction
have,O
occurred,O
Use,O
with,O
caution,O
in,O
patients,O
at,O
risk,O
for,O
gastrointestinal,O
perforation,O
or,O
fistula,O
5,O
6,O
Hypothyroidism,AdverseReaction
requiring,O
thyroid,O
hormone,O
replacement,O
has,O
been,O
reported,O
Monitor,O
thyroid,O
function,O
before,O
initiation,O
of,O
and,O
periodically,O
throughout,O
treatment,O
with,O
INLYTA,O
5,O
7,O
Stop,O
INLYTA,O
at,O
least,O
24,O
hours,O
prior,O
to,O
scheduled,O
surgery,O
5,O
8,O
Reversible Posterior Leukoencephalopathy Syndrome,AdverseReaction
RPLS,AdverseReaction
has,O
been,O
observed,O
Permanently,O
discontinue,O
INLYTA,O
if,O
signs,O
or,O
symptoms,O
of,O
RPLS,O
occur,O
5,O
9,O
Monitor,O
for,O
proteinuria,O
before,O
initiation,O
of,O
and,O
periodically,O
throughout,O
treatment,O
with,O
INLYTA,O
For,O
moderate,O
to,O
severe,O
proteinuria,O
reduce,O
the,O
dose,O
or,O
temporarily,O
interrupt,O
treatment,O
with,O
INLYTA,O
5,O
10,O
Liver enzyme elevation,AdverseReaction
has,O
been,O
observed,O
during,O
treatment,O
with,O
INLYTA,O
Monitor,O
ALT,O
AST,O
and,O
bilirubin,O
before,O
initiation,O
of,O
and,O
periodically,O
throughout,O
treatment,O
with,O
INLYTA,O
5,O
11,O
The,O
starting,O
dose,O
of,O
INLYTA,O
should,O
be,O
decreased,O
if,O
used,O
in,O
patients,O
with,O
moderate,O
hepatic,O
impairment,O
INLYTA,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
severe,O
hepatic,O
impairment,O
2,O
2,O
5,O
12,O
INLYTA,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
based,O
on,O
its,O
mechanism,O
of,O
action,O
Women,O
of,O
childbearing,O
potential,O
should,O
be,O
advised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
and,O
to,O
avoid,O
becoming,O
pregnant,O
while,O
receiving,O
INLYTA,O
5,O
13,O
8,O
1,O
5,O
1,O
Hypertension,O
and,O
Hypertensive,O
Crisis,O
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
hypertension,AdverseReaction
was,O
reported,O
in,O
145,O
359,O
patients,O
40,O
receiving,O
INLYTA,O
and,O
103,O
355,O
patients,O
29,O
receiving,O
sorafenib,O
Grade 3,Severity
4,Severity
hypertension,AdverseReaction
was,O
observed,O
in,O
56,O
359,O
patients,O
16,O
receiving,O
INLYTA,O
and,O
39,O
355,O
patients,O
11,O
receiving,O
sorafenib,O
Hypertensive crisis,AdverseReaction
was,O
reported,O
in,O
2,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
none,O
of,O
the,O
patients,O
receiving,O
sorafenib,O
The,O
median,O
onset,O
time,O
for,O
hypertension,AdverseReaction
systolic blood pressure 150 mmHg,AdverseReaction
or,O
diastolic blood pressure 100 mmHg,AdverseReaction
was,O
within,O
the,O
first,O
month,O
of,O
the,O
start,O
of,O
INLYTA,O
treatment,O
and,O
blood pressure increases,AdverseReaction
have,O
been,O
observed,O
as,O
early,O
as,O
4,O
days,O
after,O
starting,O
INLYTA,O
Hypertension,AdverseReaction
was,O
managed,O
with,O
standard,O
antihypertensive,O
therapy,O
Discontinuation,O
of,O
INLYTA,O
treatment,O
due,O
to,O
hypertension,AdverseReaction
occurred,O
in,O
1,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
none,O
of,O
the,O
patients,O
receiving,O
sorafenib,O
seeAdverse,O
Reactions,O
6,O
1,O
Blood,O
pressure,O
should,O
be,O
well,O
controlled,O
prior,O
to,O
initiating,O
INLYTA,O
Patients,O
should,O
be,O
monitored,O
for,O
hypertension,O
and,O
treated,O
as,O
needed,O
with,O
standard,O
anti,O
hypertensive,O
therapy,O
In,O
the,O
case,O
of,O
persistent,O
hypertension,O
despite,O
use,O
of,O
anti,O
hypertensive,O
medications,O
reduce,O
the,O
INLYTA,O
dose,O
Discontinue,O
INLYTA,O
if,O
hypertension,O
is,O
severe,O
and,O
persistent,O
despite,O
anti,O
hypertensive,O
therapy,O
and,O
dose,O
reduction,O
of,O
INLYTA,O
and,O
discontinuation,O
should,O
be,O
considered,O
if,O
there,O
is,O
evidence,O
of,O
hypertensive,O
crisis,O
If,O
INLYTA,O
is,O
interrupted,O
patients,O
receiving,O
antihypertensive,O
medications,O
should,O
be,O
monitored,O
for,O
hypotension,O
seeDosage,O
and,O
Administration,O
2,O
2,O
5,O
2,O
Arterial,O
Thromboembolic,O
Events,O
In,O
clinical,O
trials,O
arterial thromboembolic events,AdverseReaction
have,O
been,O
reported,O
including,O
deaths,AdverseReaction
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
Grade 3,Severity
4,Severity
arterial thromboembolic events,AdverseReaction
were,O
reported,O
in,O
4,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
4,O
355,O
patients,O
1,O
receiving,O
sorafenib,O
Fatal,AdverseReaction
cerebrovascular accident,AdverseReaction
was,O
reported,O
in,O
1,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
none,O
of,O
the,O
patients,O
receiving,O
sorafenib,O
seeAdverse,O
Reactions,O
6,O
1,O
In,O
clinical,O
trials,O
with,O
INLYTA,O
arterial thromboembolic events,AdverseReaction
including,O
transient ischemic attack,AdverseReaction
cerebrovascular accident,AdverseReaction
myocardial infarction,AdverseReaction
and,O
retinal artery occlusion,AdverseReaction
were,O
reported,O
in,O
17,O
715,O
patients,O
2,O
with,O
two,O
deaths,AdverseReaction
secondary,O
to,O
cerebrovascular accident,AdverseReaction
Use,O
INLYTA,O
with,O
caution,O
in,O
patients,O
who,O
are,O
at,O
risk,O
for,O
or,O
who,O
have,O
a,O
history,O
of,O
these,O
events,O
INLYTA,O
has,O
not,O
been,O
studied,O
in,O
patients,O
who,O
had,O
an,O
arterial,O
thromboembolic,O
event,O
within,O
the,O
previous,O
12,O
months,O
5,O
3,O
Venous,O
Thromboembolic,O
Events,O
In,O
clinical,O
trials,O
venous thromboembolic events,AdverseReaction
have,O
been,O
reported,O
including,O
deaths,AdverseReaction
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
venous thromboembolic events,AdverseReaction
were,O
reported,O
in,O
11,O
359,O
patients,O
3,O
receiving,O
INLYTA,O
and,O
2,O
355,O
patients,O
1,O
receiving,O
sorafenib,O
Grade 3,Severity
4,Severity
venous thromboembolic events,AdverseReaction
were,O
reported,O
in,O
9,O
359,O
patients,O
3,O
receiving,O
INLYTA,O
including,O
pulmonary embolism,AdverseReaction
deep vein thrombosis,AdverseReaction
retinal vein occlusion,AdverseReaction
and,O
retinal vein thrombosis,AdverseReaction
and,O
2,O
355,O
patients,O
1,O
receiving,O
sorafenib,O
Fatal,AdverseReaction
pulmonary embolism,AdverseReaction
was,O
reported,O
in,O
1,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
none,O
of,O
the,O
patients,O
receiving,O
sorafenib,O
In,O
clinical,O
trials,O
with,O
INLYTA,O
venous thromboembolic events,AdverseReaction
were,O
reported,O
in,O
22,O
715,O
patients,O
3,O
with,O
two,O
deaths,AdverseReaction
secondary,O
to,O
pulmonary embolism,AdverseReaction
Use,O
INLYTA,O
with,O
caution,O
in,O
patients,O
who,O
are,O
at,O
risk,O
for,O
or,O
who,O
have,O
a,O
history,O
of,O
these,O
events,O
INLYTA,O
has,O
not,O
been,O
studied,O
in,O
patients,O
who,O
had,O
a,O
venous,O
thromboembolic,O
event,O
within,O
the,O
previous,O
6,O
months,O
5,O
4,O
Hemorrhage,O
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
hemorrhagic events,AdverseReaction
were,O
reported,O
in,O
58,O
359,O
patients,O
16,O
receiving,O
INLYTA,O
and,O
64,O
355,O
patients,O
18,O
receiving,O
sorafenib,O
Grade 3,Severity
4,Severity
hemorrhagic events,AdverseReaction
were,O
reported,O
in,O
5,O
359,O
1,O
patients,O
receiving,O
INLYTA,O
including,O
cerebral hemorrhage,AdverseReaction
hematuria,AdverseReaction
hemoptysis,AdverseReaction
lower gastrointestinal hemorrhage,AdverseReaction
and,O
melena,AdverseReaction
and,O
11,O
355,O
3,O
patients,O
receiving,O
sorafenib,O
Fatal,AdverseReaction
hemorrhage,AdverseReaction
was,O
reported,O
in,O
1,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
gastric hemorrhage,AdverseReaction
and,O
3,O
355,O
patients,O
1,O
receiving,O
sorafenib,O
INLYTA,O
has,O
not,O
been,O
studied,O
in,O
patients,O
who,O
have,O
evidence,O
of,O
untreated,O
brain,O
metastasis,O
or,O
recent,O
active,O
gastrointestinal,O
bleeding,O
and,O
should,O
not,O
be,O
used,O
in,O
those,O
patients,O
If,O
any,O
bleeding,O
requires,O
medical,O
intervention,O
temporarily,O
interrupt,O
the,O
INLYTA,O
dose,O
5,O
5,O
Cardiac,O
Failure,O
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
cardiac failure,AdverseReaction
was,O
reported,O
in,O
6,O
359,O
patients,O
2,O
receiving,O
INLYTA,O
and,O
3,O
355,O
patients,O
1,O
receiving,O
sorafenib,O
Grade 3,Severity
4,Severity
cardiac failure,AdverseReaction
was,O
observed,O
in,O
2,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
1,O
355,O
patients,O
1,O
receiving,O
sorafenib,O
Fatal,AdverseReaction
cardiac failure,AdverseReaction
was,O
reported,O
in,O
2,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
1,O
355,O
patients,O
1,O
receiving,O
sorafenib,O
Monitor,O
for,O
signs,O
or,O
symptoms,O
of,O
cardiac,O
failure,O
throughout,O
treatment,O
with,O
INLYTA,O
Management,O
of,O
cardiac,O
failure,O
may,O
require,O
permanent,O
discontinuation,O
of,O
INLYTA,O
5,O
6,O
Gastrointestinal,O
Perforation,O
and,O
Fistula,O
Formation,O
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
gastrointestinal perforation,AdverseReaction
was,O
reported,O
in,O
1,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
none,O
of,O
the,O
patients,O
receiving,O
sorafenib,O
In,O
clinical,O
trials,O
with,O
INLYTA,O
gastrointestinal perforation,AdverseReaction
was,O
reported,O
in,O
5,O
715,O
patients,O
1,O
including,O
one,O
death,AdverseReaction
In,O
addition,O
to,O
cases,O
of,O
gastrointestinal perforation,AdverseReaction
fistulas,AdverseReaction
were,O
reported,O
in,O
4,O
715,O
patients,O
1,O
Monitor,O
for,O
symptoms,O
of,O
gastrointestinal,O
perforation,O
or,O
fistula,O
periodically,O
throughout,O
treatment,O
with,O
INLYTA,O
5,O
7,O
Thyroid,O
Dysfunction,O
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
hypothyroidism,AdverseReaction
was,O
reported,O
in,O
69,O
359,O
patients,O
19,O
receiving,O
INLYTA,O
and,O
29,O
355,O
patients,O
8,O
receiving,O
sorafenib,O
Hyperthyroidism,AdverseReaction
was,O
reported,O
in,O
4,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
4,O
355,O
patients,O
1,O
receiving,O
sorafenib,O
In,O
patients,O
who,O
had,O
thyroid,O
stimulating,O
hormone,O
TSH,O
5,O
muU,O
mL,O
before,O
treatment,O
elevations of TSH,AdverseReaction
to,O
10,O
muU,O
mL,O
occurred,O
in,O
79,O
245,O
patients,O
32,O
receiving,O
INLYTA,O
and,O
25,O
232,O
patients,O
11,O
receiving,O
sorafenib,O
seeAdverse,O
Reactions,O
6,O
1,O
Monitor,O
thyroid,O
function,O
before,O
initiation,O
of,O
and,O
periodically,O
throughout,O
treatment,O
with,O
INLYTA,O
Treat,O
hypothyroidism,O
and,O
hyperthyroidism,O
according,O
to,O
standard,O
medical,O
practice,O
to,O
maintain,O
euthyroid,O
state,O
5,O
8,O
Wound,O
Healing,O
Complications,O
No,O
formal,O
studies,O
of,O
the,O
effect,O
of,O
INLYTA,O
on,O
wound,O
healing,O
have,O
been,O
conducted,O
Stop,O
treatment,O
with,O
INLYTA,O
at,O
least,O
24,O
hours,O
prior,O
to,O
scheduled,O
surgery,O
The,O
decision,O
to,O
resume,O
INLYTA,O
therapy,O
after,O
surgery,O
should,O
be,O
based,O
on,O
clinical,O
judgment,O
of,O
adequate,O
wound,O
healing,O
5,O
9,O
Reversible,O
Posterior,O
Leukoencephalopathy,O
Syndrome,O
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
reversible posterior leukoencephalopathy syndrome,AdverseReaction
RPLS,AdverseReaction
was,O
reported,O
in,O
1,O
359,O
patients,O
1,O
receiving,O
INLYTA,O
and,O
none,O
of,O
the,O
patients,O
receiving,O
sorafenib,O
seeAdverse,O
Reactions,O
6,O
1,O
There,O
were,O
two,O
additional,O
reports,O
of,O
RPLS,AdverseReaction
in,O
other,O
clinical,O
trials,O
with,O
INLYTA,O
RPLS,AdverseReaction
is,O
a,O
neurological,O
disorder,O
which,O
can,Factor
present,O
with,O
headache,AdverseReaction
seizure,AdverseReaction
lethargy,AdverseReaction
confusion,AdverseReaction
blindness,AdverseReaction
and,O
other,O
visual,AdverseReaction
and,O
neurologic disturbances,AdverseReaction
Mild to severe,Severity
severe,Severity
hypertension,AdverseReaction
may,Factor
be,O
present,O
Magnetic,O
resonance,O
imaging,O
is,O
necessary,O
to,O
confirm,O
the,O
diagnosis,O
of,O
RPLS,O
Discontinue,O
INLYTA,O
in,O
patients,O
developing,O
RPLS,O
The,O
safety,O
of,O
reinitiating,O
INLYTA,O
therapy,O
in,O
patients,O
previously,O
experiencing,O
RPLS,O
is,O
not,O
known,O
5,O
10,O
Proteinuria,O
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
proteinuria,AdverseReaction
was,O
reported,O
in,O
39,O
359,O
patients,O
11,O
receiving,O
INLYTA,O
and,O
26,O
355,O
patients,O
7,O
receiving,O
sorafenib,O
Grade 3,Severity
proteinuria,AdverseReaction
was,O
reported,O
in,O
11,O
359,O
patients,O
3,O
receiving,O
INLYTA,O
and,O
6,O
355,O
patients,O
2,O
receiving,O
sorafenib,O
seeAdverse,O
Reactions,O
6,O
1,O
Monitoring,O
for,O
proteinuria,O
before,O
initiation,O
of,O
and,O
periodically,O
throughout,O
treatment,O
with,O
INLYTA,O
is,O
recommended,O
For,O
patients,O
who,O
develop,O
moderate,O
to,O
severe,O
proteinuria,O
reduce,O
the,O
dose,O
or,O
temporarily,O
interrupt,O
INLYTA,O
treatment,O
5,O
11,O
Elevation,O
of,O
Liver,O
Enzymes,O
In,O
a,O
controlled,O
clinical,O
study,O
with,O
INLYTA,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
RCC,O
alanine aminotransferase aminotransferase,AdverseReaction
ALT,AdverseReaction
elevations,AdverseReaction
of,O
all,O
grades,O
occurred,O
in,O
22,O
of,O
patients,O
on,O
both,O
arms,O
with,O
Grade 3,Severity
4,Severity
events,O
in,O
1,O
of,O
patients,O
on,O
the,O
INLYTA,O
arm,O
and,O
2,O
of,O
patients,O
on,O
the,O
sorafenib,O
arm,O
Monitor,O
ALT,O
aspartate,O
aminotransferase,O
AST,O
and,O
bilirubin,O
before,O
initiation,O
of,O
and,O
periodically,O
throughout,O
treatment,O
with,O
INLYTA,O
5,O
12,O
Hepatic,O
Impairment,O
The,O
systemic,O
exposure,O
to,O
axitinib,O
was,O
higher,O
in,O
subjects,O
with,O
moderate,O
hepatic,O
impairment,O
Child,O
Pugh,O
class,O
B,O
compared,O
to,O
subjects,O
with,O
normal,O
hepatic,O
function,O
A,O
dose,O
decrease,O
is,O
recommended,O
when,O
administering,O
INLYTA,O
to,O
patients,O
with,O
moderate,O
hepatic,O
impairment,O
Child,O
Pugh,O
class,O
B,O
INLYTA,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
severe,O
hepatic,O
impairment,O
Child,O
Pugh,O
class,O
C,O
seeDosage,O
and,O
Administration,O
2,O
2,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
andClinical,O
Pharmacology,O
12,O
3,O
5,O
13,O
Pregnancy,O
INLYTA,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
based,O
on,O
its,O
mechanism,O
of,O
action,O
There,O
are,O
no,O
adequate,O
and,O
well,O
controlled,O
studies,O
in,O
pregnant,O
women,O
using,O
INLYTA,O
In,O
developmental,O
toxicity,O
studies,O
in,O
mice,Animal
axitinib,O
was,O
teratogenic,AdverseReaction
embryotoxic,AdverseReaction
and,O
fetotoxic,AdverseReaction
at,O
maternal,O
exposures,O
that,O
were,O
lower,O
than,O
human,O
exposures,O
at,O
the,O
recommended,O
clinical,O
dose,O
Women,O
of,O
childbearing,O
potential,O
should,O
be,O
advised,O
to,O
avoid,O
becoming,O
pregnant,O
while,O
receiving,O
INLYTA,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
a,O
patient,O
becomes,O
pregnant,O
while,O
receiving,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
seeUse,O
in,O
Specific,O
Populations,O
8,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
safety,O
of,O
INLYTA,O
has,O
been,O
evaluated,O
in,O
715,O
patients,O
in,O
monotherapy,O
studies,O
which,O
included,O
537,O
patients,O
with,O
advanced,O
RCC,O
The,O
data,O
described,O
seeAdverse,O
Reactions,O
6,O
1,O
reflect,O
exposure,O
to,O
INLYTA,O
in,O
359,O
patients,O
with,O
advanced,O
RCC,O
who,O
participated,O
in,O
a,O
randomized,O
clinical,O
study,O
versus,O
sorafenib,O
seeClinical,O
Studies,O
14,O
The,O
following,O
risks,Factor
including,O
appropriate,O
action,O
to,O
be,O
taken,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
label,O
seeWarnings,O
and,O
Precautions,O
5,O
1,O
5,O
13,O
hypertension,AdverseReaction
arterial thromboembolic events,AdverseReaction
venous thromboembolic events,AdverseReaction
hemorrhage,AdverseReaction
cardiac failure,AdverseReaction
gastrointestinal perforation,AdverseReaction
and,O
fistula formation,AdverseReaction
thyroid dysfunction,AdverseReaction
wound healing complications,AdverseReaction
RPLS,AdverseReaction
proteinuria,AdverseReaction
elevation of liver enzymes,AdverseReaction
hepatic impairment,AdverseReaction
and,O
fetal,O
development,O
EXCERPT,O
The,O
most,O
common,O
20,O
adverse,O
reactions,O
are,O
diarrhea,AdverseReaction
hypertension,AdverseReaction
fatigue,AdverseReaction
decreased appetite,AdverseReaction
nausea,AdverseReaction
dysphonia,AdverseReaction
palmar plantar erythrodysesthesia,AdverseReaction
hand foot,AdverseReaction
syndrome,AdverseReaction
weight decreased,AdverseReaction
vomiting,AdverseReaction
asthenia,AdverseReaction
and,O
constipation,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Pfizer,O
Inc,O
at,O
1,O
800,O
438,O
1985,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
The,O
median,O
duration,O
of,O
treatment,O
was,O
6,O
4,O
months,O
range,O
0,O
03,O
to,O
22,O
0,O
for,O
patients,O
who,O
received,O
INLYTA,O
and,O
5,O
0,O
months,O
range,O
0,O
03,O
to,O
20,O
1,O
for,O
patients,O
who,O
received,O
sorafenib,O
Dose,O
modifications,O
or,O
temporary,O
delay,O
of,O
treatment,O
due,O
to,O
an,O
adverse,O
reaction,O
occurred,O
in,O
199,O
359,O
patients,O
55,O
receiving,O
INLYTA,O
and,O
220,O
355,O
patients,O
62,O
receiving,O
sorafenib,O
Permanent,O
discontinuation,O
due,O
to,O
an,O
adverse,O
reaction,O
occurred,O
in,O
34,O
359,O
patients,O
9,O
receiving,O
INLYTA,O
and,O
46,O
355,O
patients,O
13,O
receiving,O
sorafenib,O
The,O
most,O
common,O
20,O
adverse,O
reactions,O
observed,O
following,O
treatment,O
with,O
INLYTA,O
were,O
diarrhea,AdverseReaction
hypertension,AdverseReaction
fatigue,AdverseReaction
decreased appetite,AdverseReaction
nausea,AdverseReaction
dysphonia,AdverseReaction
palmar plantar erythrodysesthesia,AdverseReaction
hand foot,AdverseReaction
syndrome,AdverseReaction
weight decreased,AdverseReaction
vomiting,AdverseReaction
asthenia,AdverseReaction
and,O
constipation,AdverseReaction
Table,O
1,O
presents,O
adverse,O
reactions,O
reported,O
in,O
10,O
patients,O
who,O
received,O
INLYTA,O
or,O
sorafenib,O
Table,O
1,O
Adverse,O
Reactions,O
Occurring,O
in,O
10,O
of,O
Patients,O
Who,O
Received,O
INLYTA,O
or,O
Sorafenib,O
Adverse,O
Reaction,O
INLYTA,O
Sorafenib,O
N,O
359,O
N,O
355,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
Diarrhea,AdverseReaction
55,O
11,O
53,O
7,O
Hypertension,AdverseReaction
40,O
16,O
29,O
11,O
Fatigue,AdverseReaction
39,O
11,O
32,O
5,O
Decreased appetite,AdverseReaction
34,O
5,O
29,O
4,O
Nausea,AdverseReaction
32,O
3,O
22,O
1,O
Dysphonia,AdverseReaction
31,O
0,O
14,O
0,O
Palmar plantar erythrodysesthesia syndrome,AdverseReaction
27,O
5,O
51,O
16,O
Weight decreased,AdverseReaction
25,O
2,O
21,O
1,O
Vomiting,AdverseReaction
24,O
3,O
17,O
1,O
Asthenia,AdverseReaction
21,O
5,O
14,O
3,O
Constipation,AdverseReaction
20,O
1,O
20,O
1,O
Hypothyroidism,AdverseReaction
19,O
1,O
8,O
0,O
Cough,AdverseReaction
15,O
1,O
17,O
1,O
Mucosal inflammation,AdverseReaction
15,O
1,O
12,O
1,O
Arthralgia,AdverseReaction
15,O
2,O
11,O
1,O
Stomatitis,AdverseReaction
15,O
1,O
12,O
1,O
Dyspnea,AdverseReaction
15,O
3,O
12,O
3,O
Abdominal pain,AdverseReaction
14,O
2,O
11,O
1,O
Headache,AdverseReaction
14,O
1,O
11,O
0,O
Pain in extremity,AdverseReaction
13,O
1,O
14,O
1,O
Rash,AdverseReaction
13,O
1,O
32,O
4,O
Proteinuria,AdverseReaction
11,O
3,O
7,O
2,O
Dysgeusia,AdverseReaction
11,O
0,O
8,O
0,O
Dry skin,AdverseReaction
10,O
0,O
11,O
0,O
Dyspepsia,AdverseReaction
10,O
0,O
2,O
0,O
Pruritus,AdverseReaction
7,O
0,O
12,O
0,O
Alopecia,AdverseReaction
4,O
0,O
32,O
0,O
Erythema,AdverseReaction
2,O
0,O
10,O
1,O
Selected,O
adverse,O
reactions,O
all,O
grades,O
that,O
were,O
reported,O
in,O
10,O
of,O
patients,O
treated,O
with,O
INLYTA,O
included,O
dizziness,AdverseReaction
9,O
upper abdominal pain,AdverseReaction
8,O
myalgia,AdverseReaction
7,O
dehydration,AdverseReaction
6,O
epistaxis,AdverseReaction
6,O
anemia,AdverseReaction
4,O
hemorrhoids,AdverseReaction
4,O
hematuria,AdverseReaction
3,O
tinnitus,AdverseReaction
3,O
lipase increased,AdverseReaction
3,O
glossodynia,AdverseReaction
3,O
pulmonary embolism,AdverseReaction
2,O
rectal hemorrhage,AdverseReaction
2,O
hemoptysis,AdverseReaction
2,O
deep vein thrombosis,AdverseReaction
1,O
retinal vein occlusion vein,AdverseReaction
thrombosis,AdverseReaction
1,O
polycythemia,AdverseReaction
1,O
and,O
transient ischemic attack,AdverseReaction
1,O
Table,O
2,O
presents,O
the,O
most,O
common,O
laboratory,O
abnormalities,O
reported,O
in,O
10,O
patients,O
who,O
received,O
INLYTA,O
or,O
sorafenib,O
Table,O
2,O
Laboratory,O
Abnormalities,O
Occurring,O
in,O
10,O
of,O
Patients,O
Who,O
Received,O
INLYTA,O
or,O
Sorafenib,O
Laboratory,O
Abnormality,O
N,O
INLYTA,O
N,O
Sorafenib,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
ALP,O
alkaline,O
phosphatase,O
ALT,O
alanine,O
aminotransferase,O
AST,O
aspartate,O
aminotransferase,O
Hematology,O
Hemoglobin decreased,AdverseReaction
320,O
35,O
1,O
316,O
52,O
4,O
Lymphocytes absolute decreased,AdverseReaction
317,O
33,O
3,O
309,O
36,O
4,O
Platelets decreased,AdverseReaction
312,O
15,O
1,O
310,O
14,O
0,O
White blood cells decreased,AdverseReaction
320,O
11,O
0,O
315,O
16,O
1,O
Chemistry,O
Creatinine increased,AdverseReaction
336,O
55,O
0,O
318,O
41,O
1,O
Bicarbonate decreased,AdverseReaction
314,O
44,O
1,O
291,O
43,O
0,O
Hypocalcemia,AdverseReaction
336,O
39,O
1,O
319,O
59,O
2,O
ALP increased,AdverseReaction
336,O
30,O
1,O
319,O
34,O
1,O
Hyperglycemia,AdverseReaction
336,O
28,O
2,O
319,O
23,O
2,O
Lipase increased,AdverseReaction
338,O
27,O
5,O
319,O
46,O
15,O
Amylase increased,AdverseReaction
338,O
25,O
2,O
319,O
33,O
2,O
ALT increased,AdverseReaction
331,O
22,O
1,O
313,O
22,O
2,O
AST increased,AdverseReaction
331,O
20,O
1,O
311,O
25,O
1,O
Hypernatremia,AdverseReaction
338,O
17,O
1,O
319,O
13,O
1,O
Hypoalbuminemia,AdverseReaction
337,O
15,O
1,O
319,O
18,O
1,O
Hyperkalemia,AdverseReaction
333,O
15,O
3,O
314,O
10,O
3,O
Hypoglycemia,AdverseReaction
336,O
11,O
1,O
319,O
8,O
1,O
Hyponatremia,AdverseReaction
338,O
13,O
4,O
319,O
11,O
2,O
Hypophosphatemia,AdverseReaction
336,O
13,O
2,O
318,O
49,O
16,O
Selected,O
laboratory,O
abnormalities,O
all,O
grades,O
that,O
were,O
reported,O
in,O
10,O
of,O
patients,O
treated,O
with,O
INLYTA,O
included,O
hemoglobin increased,AdverseReaction
above,O
the,O
upper,O
limit,O
of,O
normal,O
9,O
for,O
INLYTA,O
versus,O
1,O
for,O
sorafenib,O
and,O
hypercalcemia,AdverseReaction
6,O
for,O
INLYTA,O
versus,O
2,O
for,O
sorafenib,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Severe,Severity
potentially,O
life threatening,Severity
and,O
fatal,AdverseReaction
skin reactions,AdverseReaction
have,O
been,O
reported,O
This,O
includes,O
cases,O
of,O
Stevens Johnson syndrome,AdverseReaction
hypersensitivity reaction,AdverseReaction
toxic epidermal necrolysis,AdverseReaction
and,O
erythema multiforme,AdverseReaction
Immediately,O
discontinue,O
treatment,O
if,O
severe,O
hypersensitivity,O
severe,O
rash,O
or,O
rash,O
with,O
systemic,O
symptoms,O
or,O
liver,O
transaminase,O
elevations,O
develops,O
and,O
monitor,O
clinical,O
status,O
including,O
liver,O
transaminases,O
closely,O
5,O
1,O
5,O
1,O
Severe,O
Skin,O
and,O
Hypersensitivity,O
Reactions,O
Severe,Severity
potentially,Factor
life threatening,Severity
and,O
fatal,AdverseReaction
skin reactions,AdverseReaction
have,O
been,O
reported,O
These,O
include,O
cases,O
of,O
Stevens Johnson syndrome,AdverseReaction
toxic epidermal necrolysis,AdverseReaction
and,O
erythema multiforme,AdverseReaction
Hypersensitivity reactions,AdverseReaction
including,O
Drug Rash with Eosinophilia and Systemic Symptoms,AdverseReaction
DRESS,AdverseReaction
have,O
also,O
been,O
reported,O
and,O
were,O
characterized,O
by,O
rash,AdverseReaction
constitutional,O
findings,O
and,O
sometimes,O
organ dysfunction,AdverseReaction
including,O
hepatic failure,AdverseReaction
In,O
Phase,O
3,O
clinical,O
trials,O
Grade 3,Severity
and,O
4,Severity
rashes,AdverseReaction
were,O
reported,O
in,O
1,O
3,O
of,O
subjects,O
receiving,O
INTELENCE,O
r,O
compared,O
to,O
0,O
2,O
of,O
placebo,O
subjects,O
A,O
total,O
of,O
2,O
2,O
of,O
HIV,O
1,O
infected,O
subjects,O
receiving,O
INTELENCE,O
r,O
discontinued,O
from,O
Phase,O
3,O
trials,O
due,O
to,O
rash,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
Rash,AdverseReaction
occurred,O
most,O
commonly,O
during,O
the,O
first,O
6,O
weeks,O
of,O
therapy,O
The,O
incidence,O
of,O
rash,AdverseReaction
was,O
higher,O
in,O
females,O
see,O
Adverse,O
Reactions,O
6,O
Discontinue,O
INTELENCE,O
r,O
immediately,O
if,O
signs,O
or,O
symptoms,O
of,O
severe,O
skin,O
reactions,O
or,O
hypersensitivity,O
reactions,O
develop,O
including,O
but,O
not,O
limited,O
to,O
severe,O
rash,O
or,O
rash,O
accompanied,O
by,O
fever,O
general,O
malaise,O
fatigue,O
muscle,O
or,O
joint,O
aches,O
blisters,O
oral,O
lesions,O
conjunctivitis,O
facial,O
edema,O
hepatitis,O
eosinophilia,O
angioedema,O
Clinical,O
status,O
including,O
liver,O
transaminases,O
should,O
be,O
monitored,O
and,O
appropriate,O
therapy,O
initiated,O
Delay,O
in,O
stopping,O
INTELENCE,O
r,O
treatment,O
after,O
the,O
onset,O
of,O
severe,O
rash,O
may,O
result,O
in,O
a,O
life,O
threatening,O
reaction,O
5,O
2,O
Fat,O
Redistribution,O
Redistribution,AdverseReaction
accumulation of body fat body fat,AdverseReaction
body fat,AdverseReaction
including,O
central obesity,AdverseReaction
dorsocervical fat enlargement,AdverseReaction
buffalo hump,AdverseReaction
peripheral wasting,AdverseReaction
facial wasting,AdverseReaction
breast enlargement,AdverseReaction
and,O
cushingoid appearance,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
receiving,O
antiretroviral,O
therapy,O
The,O
mechanism,O
and,O
long,O
term,O
consequences,O
of,O
these,O
events,O
are,O
currently,O
unknown,O
A,O
causal,O
relationship,O
has,O
not,O
been,O
established,O
5,O
3,O
Immune,O
Reconstitution,O
Syndrome,O
Immune reconstitution syndrome,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
combination,O
antiretroviral,DrugClass
therapy,O
including,O
INTELENCE,O
r,O
During,O
the,O
initial,O
phase,O
of,O
combination,O
antiretroviral,O
treatment,O
patients,O
whose,O
immune,O
system,O
responds,O
may,O
develop,O
an,O
inflammatory response,AdverseReaction
to,O
indolent,O
or,O
residual,O
opportunistic infections,AdverseReaction
such,O
as,O
Mycobacterium avium infection,AdverseReaction
cytomegalovirus,AdverseReaction
Pneumocystis jiroveci pneumonia,AdverseReaction
PCP,AdverseReaction
or,O
tuberculosis,AdverseReaction
which,O
may,O
necessitate,O
further,O
evaluation,O
and,O
treatment,O
Autoimmune disorders,AdverseReaction
such,O
as,O
Graves disease,AdverseReaction
polymyositis,AdverseReaction
and,O
Guillain Barre syndrome,AdverseReaction
have,O
also,O
been,O
reported,O
to,O
occur,O
in,O
the,O
setting,O
of,O
immune,O
reconstitution,O
however,O
the,O
time,O
to,O
onset,O
is,O
more,O
variable,O
and,O
can,O
occur,O
many,O
months,O
after,O
initiation,O
of,O
treatment,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
described,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
Severe,Severity
skin,AdverseReaction
and,O
hypersensitivity reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
drug,O
reactions,O
of,O
moderate to severe,Severity
severe,Severity
intensity,O
at,O
least,O
2,O
which,O
occurred,O
at,O
a,O
higher,O
rate,O
than,O
placebo,O
in,O
adults,O
are,O
rash,AdverseReaction
and,O
peripheral neuropathy,AdverseReaction
6,O
1,O
The,O
most,O
common,O
adverse,O
drug,O
reactions,O
in,O
at,O
least,O
2,O
of,O
pediatric,O
patients,O
are,O
rash,AdverseReaction
and,O
diarrhea,AdverseReaction
6,O
2,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Janssen,O
Products,O
LP,O
at,O
1,O
800,O
JANSSEN,O
1,O
800,O
526,O
7736,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Adults,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
safety,O
assessment,O
is,O
based,O
on,O
all,O
data,O
from,O
1203,O
subjects,O
in,O
the,O
Phase,O
3,O
placebo,O
controlled,O
trials,O
TMC125,O
C206,O
and,O
TMC125,O
C216,O
conducted,O
in,O
antiretroviral,O
treatment,O
experienced,O
HIV,O
1,O
infected,O
adult,O
subjects,O
599,O
of,O
whom,O
received,O
INTELENCE,O
r,O
200,O
mg,O
twice,O
daily,O
In,O
these,O
pooled,O
trials,O
the,O
median,O
exposure,O
for,O
subjects,O
in,O
the,O
INTELENCE,O
r,O
arm,O
and,O
placebo,O
arm,O
was,O
52,O
3,O
and,O
51,O
0,O
weeks,O
respectively,O
Discontinuations,O
due,O
to,O
adverse,O
drug,O
reactions,O
ADRs,O
were,O
5,O
2,O
in,O
the,O
INTELENCE,O
r,O
arm,O
and,O
2,O
6,O
in,O
the,O
placebo,O
arm,O
The,O
most,O
frequently,O
reported,O
ADR,O
at,O
least,O
Grade 2,Severity
in,O
severity,O
was,O
rash,AdverseReaction
10,O
0,O
Stevens Johnson syndrome,AdverseReaction
drug,O
hypersensitivity,AdverseReaction
reaction,O
and,O
erythema multiforme,AdverseReaction
were,O
reported,O
in,O
less,O
than,O
0,O
1,O
of,O
subjects,O
during,O
clinical,O
development,O
with,O
INTELENCE,O
r,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
A,O
total,O
of,O
2,O
2,O
of,O
HIV,O
1,O
infected,O
subjects,O
in,O
Phase,O
3,O
trials,O
receiving,O
INTELENCE,O
r,O
discontinued,O
due,O
to,O
rash,AdverseReaction
In,O
general,O
in,O
clinical,O
trials,O
rash,AdverseReaction
was,O
mild to moderate,Severity
moderate,Severity
occurred,O
primarily,O
in,O
the,O
second,O
week,O
of,O
therapy,O
and,O
was,O
infrequent,O
after,O
Week,O
4,O
Rash,AdverseReaction
generally,O
resolved,O
within,O
1,O
to,O
2,O
weeks,O
on,O
continued,O
therapy,O
The,O
incidence,O
of,O
rash,AdverseReaction
was,O
higher,O
in,O
women,O
compared,O
to,O
men,O
in,O
the,O
INTELENCE,O
r,O
arm,O
in,O
the,O
Phase,O
3,O
trials,O
rash,AdverseReaction
Grade 2,Severity
was,O
reported,O
in,O
9,O
60,O
15,O
0,O
women,O
versus,O
51,O
539,O
9,O
5,O
men,O
discontinuations,O
due,O
to,O
rash,AdverseReaction
were,O
reported,O
in,O
3,O
60,O
5,O
0,O
women,O
versus,O
10,O
539,O
1,O
9,O
men,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Patients,O
with,O
a,O
history,O
of,O
NNRTI,DrugClass
related,O
rash,AdverseReaction
did,O
not,O
appear,O
to,O
be,O
at,O
increased,O
risk,O
for,O
the,O
development,O
of,O
INTELENCE,O
r,O
related,O
rash,AdverseReaction
compared,O
to,O
patients,O
without,O
a,O
history,O
of,O
NNRTI,DrugClass
related,O
rash,AdverseReaction
Common,O
Adverse,O
Reactions,O
Clinical,O
ADRs,O
of,O
moderate,O
intensity,O
or,O
greater,O
greater,O
than,O
or,O
equal,O
to,O
Grade,O
2,O
and,O
reported,O
in,O
at,O
least,O
2,O
of,O
subjects,O
treated,O
with,O
INTELENCE,O
r,O
and,O
occurring,O
at,O
a,O
higher,O
rate,O
compared,O
to,O
placebo,O
excess,O
of,O
1,O
are,O
presented,O
in,O
Table,O
1,O
Laboratory,O
abnormalities,O
considered,O
ADRs,O
are,O
included,O
in,O
Table,O
2,O
Table,O
1,O
Treatment,O
Emergent,O
Adverse,O
ReactionsIncludes,O
adverse,O
reactions,O
at,O
least,O
possibly,O
probably,O
or,O
very,O
likely,O
related,O
to,O
the,O
drug,O
of,O
at,O
least,O
Moderate,O
IntensityIntensities,O
are,O
defined,O
as,O
follows,O
Moderate,O
discomfort,O
enough,O
to,O
cause,O
interference,O
with,O
usual,O
activity,O
Severe,O
incapacitating,O
with,O
inability,O
to,O
work,O
or,O
do,O
usual,O
activity,O
Grades,O
2,O
to,O
4,O
in,O
at,O
least,O
2,O
of,O
Adult,O
Subjects,O
in,O
the,O
INTELENCE,O
r,O
Treatment,O
Groups,O
and,O
at,O
a,O
higher,O
rate,O
compared,O
to,O
placebo,O
excess,O
of,O
1,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
Pooled,O
TMC125,O
C206,O
and,O
TMC125,O
C216,O
Trials,O
INTELENCE,O
r,O
BRN,O
599,O
Placebo,O
BRN,O
604,O
N,O
total,O
number,O
of,O
subjects,O
per,O
treatment,O
group,O
BR,O
background,O
regimen,O
Nervous,O
System,O
Disorders,O
Peripheral neuropathy,AdverseReaction
4,O
2,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Rash,AdverseReaction
10,O
3,O
Less,O
Common,O
Adverse,O
Reactions,O
Treatment,O
emergent,O
ADRs,O
occurring,O
in,O
less,O
than,O
2,O
of,O
subjects,O
599,O
subjects,O
receiving,O
INTELENCE,O
r,O
and,O
of,O
at,O
least,O
moderate,O
intensity,O
greater,O
than,O
or,O
equal,O
to,O
Grade,O
2,O
are,O
listed,O
below,O
by,O
body,O
system,O
Cardiac,O
Disorders,O
myocardial infarction,AdverseReaction
angina pectoris,AdverseReaction
atrial fibrillation,AdverseReaction
Ear,O
and,O
Labyrinth,O
Disorders,O
vertigo,AdverseReaction
Eye,O
Disorders,O
blurred vision,AdverseReaction
Gastrointestinal,O
Disorders,O
gastroesophageal reflux disease,AdverseReaction
flatulence,AdverseReaction
gastritis,AdverseReaction
abdominal distension,AdverseReaction
pancreatitis,AdverseReaction
constipation,AdverseReaction
dry mouth,AdverseReaction
hematemesis,AdverseReaction
retching,AdverseReaction
stomatitis,AdverseReaction
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
sluggishness,AdverseReaction
Hematologic,O
Disorders,O
hemolytic anemia,AdverseReaction
Hepatobiliary,O
Disorders,O
hepatic failure,AdverseReaction
hepatomegaly,AdverseReaction
cytolytic hepatitis,AdverseReaction
hepatic steatosis,AdverseReaction
hepatitis,AdverseReaction
Immune,O
System,O
Disorders,O
drug hypersensitivity,AdverseReaction
immune reconstitution syndrome,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorders,O
diabetes mellitus,AdverseReaction
anorexia,AdverseReaction
dyslipidemia,AdverseReaction
Nervous,O
System,O
Disorders,O
paraesthesia,AdverseReaction
somnolence,AdverseReaction
convulsion,AdverseReaction
hypoesthesia,AdverseReaction
amnesia,AdverseReaction
syncope,AdverseReaction
disturbance in attention,AdverseReaction
hypersomnia,AdverseReaction
tremor,AdverseReaction
Psychiatric,O
Disorders,O
anxiety,AdverseReaction
sleep disorders,AdverseReaction
abnormal dreams,AdverseReaction
confusional state,AdverseReaction
disorientation,AdverseReaction
nervousness,AdverseReaction
nightmares,AdverseReaction
Renal,O
and,O
Urinary,O
Disorders,O
acute renal failure,AdverseReaction
Reproductive,O
System,O
and,O
Breast,O
Disorders,O
gynecomastia,AdverseReaction
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
exertional dyspnea,AdverseReaction
bronchospasm,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
night sweats,AdverseReaction
lipohypertrophy,AdverseReaction
prurigo,AdverseReaction
hyperhidrosis,AdverseReaction
dry skin,AdverseReaction
swelling face,AdverseReaction
Additional,O
ADRs,O
of,O
at,O
least,O
moderate,O
intensity,O
observed,O
in,O
other,O
trials,O
were,O
acquired lipodystrophy,AdverseReaction
angioneurotic edema,AdverseReaction
erythema multiforme,AdverseReaction
and,O
haemorrhagic stroke,AdverseReaction
each,O
reported,O
in,O
no,O
more,O
than,O
0,O
5,O
of,O
subjects,O
Laboratory,O
Abnormalities,O
in,O
Treatment,O
Experienced,O
Patients,O
Selected,O
Grade,O
2,O
to,O
Grade,O
4,O
laboratory,O
abnormalities,O
that,O
represent,O
a,O
worsening,O
from,O
baseline,O
observed,O
in,O
adult,O
subjects,O
treated,O
with,O
INTELENCE,O
r,O
are,O
presented,O
in,O
Table,O
2,O
Table,O
2,O
Selected,O
Grade,O
2,O
to,O
4,O
Laboratory,O
Abnormalities,O
Observed,O
in,O
Treatment,O
Experienced,O
Subjects,O
Pooled,O
TMC125,O
C206,O
and,O
TMC125,O
C216,O
Trials,O
Laboratory,O
ParameterPreferred,O
Term,O
DAIDS,O
Toxicity,O
Range,O
INTELENCE,O
r,O
BRN,O
599,O
Placebo,O
BRN,O
604,O
ULN,O
Upper,O
Limit,O
of,O
Normal,O
BR,O
background,O
regimen,O
GENERAL,O
BIOCHEMISTRY,O
Pancreatic,O
amylase,O
Grade,O
2,O
1,O
5,O
2,O
ULN,O
7,O
8,O
Grade,O
3,O
2,O
5,O
ULN,O
7,O
8,O
Grade,O
4,O
5,O
ULN,O
2,O
1,O
Lipase,O
Grade,O
2,O
1,O
5,O
3,O
ULN,O
4,O
6,O
Grade,O
3,O
3,O
5,O
ULN,O
2,O
2,O
Grade,O
4,O
5,O
ULN,O
1,O
1,O
Creatinine,O
Grade,O
2,O
1,O
4,O
1,O
8,O
ULN,O
6,O
5,O
Grade,O
3,O
1,O
9,O
3,O
4,O
ULN,O
2,O
1,O
Grade,O
4,O
3,O
4,O
ULN,O
0,O
1,O
HEMATOLOGY,O
Decreased hemoglobin,AdverseReaction
Grade,O
2,O
90,O
99,O
g,O
L,O
2,O
4,O
Grade,O
3,O
70,O
89,O
g,O
L,O
1,O
1,O
Grade,O
4,O
70,O
g,O
L,O
1,O
1,O
White,O
blood,O
cell,O
count,O
Grade,O
2,O
1,O
500,O
1,O
999,O
mm,O
3,O
2,O
3,O
Grade,O
3,O
1,O
000,O
1,O
499,O
mm,O
3,O
1,O
4,O
Grade,O
4,O
1,O
000,O
mm,O
3,O
1,O
1,O
Neutrophils,O
Grade,O
2,O
750,O
999,O
mm,O
3,O
5,O
6,O
Grade,O
3,O
500,O
749,O
mm,O
3,O
4,O
4,O
Grade,O
4,O
500,O
mm,O
3,O
2,O
3,O
Platelet,O
count,O
Grade,O
2,O
50,O
000,O
99,O
999,O
mm,O
3,O
3,O
5,O
Grade,O
3,O
25,O
000,O
49,O
999,O
mm,O
3,O
1,O
1,O
Grade,O
4,O
25,O
000,O
mm,O
3,O
1,O
1,O
LIPIDS,O
AND,O
GLUCOSE,O
Total,O
cholesterol,O
Grade,O
2,O
6,O
20,O
7,O
77,O
mmol,O
L240,O
300,O
mg,O
dL,O
20,O
17,O
Grade,O
3,O
7,O
77,O
mmol,O
L,O
300,O
mg,O
dL,O
8,O
5,O
Low,O
density,O
lipoprotein,O
Grade,O
2,O
4,O
13,O
4,O
9,O
mmol,O
L160,O
190,O
mg,O
dL,O
13,O
12,O
Grade,O
3,O
4,O
9,O
mmol,O
L,O
190,O
mg,O
dL,O
7,O
7,O
Triglycerides,O
Grade,O
2,O
5,O
65,O
8,O
48,O
mmol,O
L500,O
750,O
mg,O
dL,O
9,O
7,O
Grade,O
3,O
8,O
49,O
13,O
56,O
mmol,O
L751,O
1200,O
mg,O
dL,O
6,O
4,O
Grade,O
4,O
13,O
56,O
mmol,O
L,O
1200,O
mg,O
dL,O
4,O
2,O
Elevated glucose levels,AdverseReaction
Grade,O
2,O
6,O
95,O
13,O
88,O
mmol,O
L161,O
250,O
mg,O
dL,O
15,O
13,O
Grade,O
3,O
13,O
89,O
27,O
75,O
mmol,O
L251,O
500,O
mg,O
dL,O
4,O
2,O
Grade,O
4,O
27,O
75,O
mmol,O
L,O
500,O
mg,O
dL,O
0,O
1,O
HEPATIC,O
PARAMETERS,O
Alanine,O
amino,O
transferase,O
Grade,O
2,O
2,O
6,O
5,O
ULN,O
6,O
5,O
Grade,O
3,O
5,O
1,O
10,O
ULN,O
3,O
2,O
Grade,O
4,O
10,O
ULN,O
1,O
1,O
Aspartate,O
amino,O
transferase,O
Grade,O
2,O
2,O
6,O
5,O
ULN,O
6,O
8,O
Grade,O
3,O
5,O
1,O
10,O
ULN,O
3,O
2,O
Grade,O
4,O
10,O
ULN,O
1,O
1,O
Patients,O
co,O
infected,O
with,O
hepatitis,O
B,O
and,O
or,O
hepatitis,O
C,O
virus,O
In,O
Phase,O
3,O
trials,O
TMC125,O
C206,O
and,O
TMC125,O
C216,O
139,O
subjects,O
12,O
3,O
with,O
chronic,O
hepatitis,O
B,O
and,O
or,O
hepatitis,O
C,O
virus,O
co,O
infection,O
out,O
of,O
1129,O
subjects,O
were,O
permitted,O
to,O
enroll,O
AST,AdverseReaction
and,O
ALT abnormalities,AdverseReaction
occurred,O
more,O
frequently,O
in,O
hepatitis,O
B,O
and,O
or,O
hepatitis,O
C,O
virus,O
co,O
infected,O
subjects,O
for,O
both,O
treatment,O
groups,O
Grade 2,Severity
or,O
higher,O
laboratory,O
abnormalities,AdverseReaction
that,O
represent,O
a,O
worsening,O
from,O
baseline,O
of AST,AdverseReaction
ALT,AdverseReaction
or,O
total bilirubin,AdverseReaction
occurred,O
in,O
27,O
8,O
25,O
0,O
and,O
7,O
1,O
respectively,O
of,O
INTELENCE,O
r,O
treated,O
co,O
infected,O
subjects,O
as,O
compared,O
to,O
6,O
7,O
7,O
5,O
and,O
1,O
8,O
of,O
non,O
co,O
infected,O
INTELENCE,O
r,O
treated,O
subjects,O
In,O
general,O
adverse,O
events,O
reported,O
by,O
INTELENCE,O
r,O
treated,O
subjects,O
with,O
hepatitis,O
B,O
and,O
or,O
hepatitis,O
C,O
virus,O
co,O
infection,O
were,O
similar,O
to,O
INTELENCE,O
r,O
treated,O
subjects,O
without,O
hepatitis,O
B,O
and,O
or,O
hepatitis,O
C,O
virus,O
co,O
infection,O
6,O
2,O
Clinical,O
Trials,O
Experience,O
Pediatric,O
Subjects,O
6,O
years,O
to,O
less,O
than,O
18,O
years,O
of,O
age,O
The,O
safety,O
assessment,O
in,O
children,O
and,O
adolescents,O
is,O
based,O
on,O
the,O
Week,O
24,O
analysis,O
of,O
the,O
single,O
arm,O
Phase,O
2,O
trial,O
TMC125,O
C213,O
in,O
which,O
101,O
antiretroviral,O
treatment,O
experienced,O
HIV,O
1,O
infected,O
subjects,O
6,O
years,O
to,O
less,O
than,O
18,O
years,O
of,O
age,O
and,O
weighing,O
at,O
least,O
16,O
kg,O
received,O
INTELENCE,O
r,O
in,O
combination,O
with,O
other,O
antiretroviral,O
agents,O
see,O
Clinical,O
Studies,O
14,O
2,O
The,O
frequency,O
type,O
and,O
severity,O
of,O
adverse,O
drug,O
reactions,O
in,O
pediatric,O
subjects,O
were,O
comparable,O
to,O
those,O
observed,O
in,O
adult,O
subjects,O
except,O
for,O
rash,AdverseReaction
which,O
was,O
observed,O
more,O
frequently,O
in,O
pediatric,O
subjects,O
The,O
most,O
common,O
adverse,O
drug,O
reactions,O
in,O
at,O
least,O
2,O
of,O
pediatric,O
subjects,O
were,O
rash,AdverseReaction
and,O
diarrhea,AdverseReaction
Rash,AdverseReaction
was,O
reported,O
more,O
frequently,O
in,O
female,O
subjects,O
than,O
in,O
male,O
subjects,O
rash,AdverseReaction
Grade 2,Severity
was,O
reported,O
in,O
13,O
64,O
20,O
3,O
females,O
versus,O
2,O
37,O
5,O
4,O
males,O
discontinuations,O
due,O
to,O
rash,AdverseReaction
were,O
reported,O
in,O
4,O
64,O
6,O
3,O
females,O
versus,O
0,O
37,O
0,O
males,O
Rash,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
Grade 2,Severity
occurred,O
in,O
15,O
of,O
pediatric,O
subjects,O
In,O
the,O
majority,O
of,O
cases,O
rash,AdverseReaction
was,O
mild to moderate,Severity
moderate,Severity
of,O
macular,AdverseReaction
papular,AdverseReaction
type,O
and,O
occurred,O
in,O
the,O
second,O
week,O
of,O
therapy,O
Rash,AdverseReaction
was,O
self,O
limiting,O
and,O
generally,O
resolved,O
within,O
1,O
week,O
on,O
continued,O
therapy,O
The,O
safety,O
profile,O
for,O
subjects,O
who,O
completed,O
48,O
weeks,O
of,O
treatment,O
was,O
similar,O
to,O
the,O
safety,O
profile,O
for,O
subjects,O
who,O
completed,O
24,O
weeks,O
of,O
treatment,O
6,O
3,O
Postmarketing,O
Experience,O
The,O
following,O
events,O
have,O
been,O
identified,O
during,O
postmarketing,O
use,O
of,O
INTELENCE,O
r,O
Because,O
these,O
events,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
unknown,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Immune,O
System,O
Disorders,O
Severe,Severity
hypersensitivity,AdverseReaction
reactions,O
including,O
DRESS,AdverseReaction
and,O
cases,O
of,O
hepatic failure,AdverseReaction
have,O
been,O
reported,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
rhabdomyolysis,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Fatal,AdverseReaction
cases,O
of,O
toxic epidermal necrolysis,AdverseReaction
have,O
been,O
reported,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypotension,AdverseReaction
Before,O
initiating,O
INVOKANA,O
assess,O
volume,O
status,O
and,O
correct,O
hypovolemia,O
in,O
patients,O
with,O
renal,O
impairment,O
the,O
elderly,O
in,O
patients,O
with,O
low,O
systolic,O
blood,O
pressure,O
or,O
if,O
on,O
diuretics,O
ACEi,O
or,O
ARB,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
during,O
therapy,O
5,O
1,O
Impairment in Renal Function,AdverseReaction
Monitor,O
renal,O
function,O
during,O
therapy,O
More,O
frequent,O
monitoring,O
is,O
recommended,O
in,O
patients,O
with,O
eGFR,O
below,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
5,O
2,O
Hyperkalemia,AdverseReaction
Monitor,O
potassium,O
levels,O
in,O
patients,O
with,O
impaired,O
renal,O
function,O
and,O
in,O
patients,O
predisposed,O
to,O
hyperkalemia,O
2,O
2,O
5,O
3,O
6,O
1,O
8,O
6,O
Hypoglycemia,AdverseReaction
Consider,O
a,O
lower,O
dose,O
of,O
insulin,O
or,O
the,O
insulin,O
secretagogue,O
to,O
reduce,O
the,O
risk,O
of,O
hypoglycemia,O
when,O
used,O
in,O
combination,O
with,O
INVOKANA,O
5,O
4,O
Genital mycotic infections,AdverseReaction
Monitor,O
and,O
treat,O
if,O
indicated,O
5,O
5,O
Hypersensitivity reactions,AdverseReaction
Discontinue,O
INVOKANA,O
and,O
monitor,O
until,O
signs,O
and,O
symptoms,O
resolve,O
5,O
6,O
Bone fracture,AdverseReaction
Consider,O
factors,O
that,O
contribute,O
to,O
fracture,O
risk,O
before,O
initiating,O
INVOKANA,O
5,O
7,O
Increased LDL C,AdverseReaction
Monitor,O
LDL,O
C,O
and,O
treat,O
if,O
appropriate,O
5,O
8,O
5,O
1,O
Hypotension,O
INVOKANA,O
causes,O
intravascular volume contraction,AdverseReaction
Symptomatic hypotension,AdverseReaction
can,Factor
occur,O
after,O
initiating,O
INVOKANA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
particularly,O
in,O
patients,O
with,O
impaired,O
renal,O
function,O
eGFR,O
less,O
than,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
elderly,O
patients,O
patients,O
on,O
either,O
diuretics,O
or,O
medications,O
that,O
interfere,O
with,O
the,O
renin,O
angiotensin,O
aldosterone,O
system,O
e,O
g,O
angiotensin,O
converting,O
enzyme,O
ACE,O
inhibitors,O
angiotensin,O
receptor,O
blockers,O
ARBs,O
or,O
patients,O
with,O
low,O
systolic,O
blood,O
pressure,O
Before,O
initiating,O
INVOKANA,O
in,O
patients,O
with,O
one,O
or,O
more,O
of,O
these,O
characteristics,O
volume,O
status,O
should,O
be,O
assessed,O
and,O
corrected,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
after,O
initiating,O
therapy,O
5,O
2,O
Impairment,O
in,O
Renal,O
Function,O
INVOKANA,O
increases serum creatinine,AdverseReaction
and,O
decreases eGFR,AdverseReaction
Patients,O
with,O
hypovolemia,O
may,O
be,O
more,O
susceptible,O
to,O
these,O
changes,O
Renal function abnormalities,AdverseReaction
can,Factor
occur,O
after,O
initiating,O
INVOKANA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
More,O
frequent,O
renal,O
function,O
monitoring,O
is,O
recommended,O
in,O
patients,O
with,O
an,O
eGFR,O
below,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
5,O
3,O
Hyperkalemia,O
INVOKANA,O
can,Factor
lead,O
to,O
hyperkalemia,AdverseReaction
Patients,O
with,O
moderate,O
renal,O
impairment,O
who,O
are,O
taking,O
medications,O
that,O
interfere,O
with,O
potassium,O
excretion,O
such,O
as,O
potassium,O
sparing,O
diuretics,O
or,O
medications,O
that,O
interfere,O
with,O
the,O
renin,O
angiotensin,O
aldosterone,O
system,O
are,O
at,O
an,O
increased,O
risk,Factor
of,O
developing,O
hyperkalemia,AdverseReaction
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
serum,O
potassium,O
levels,O
periodically,O
after,O
initiating,O
INVOKANA,O
in,O
patients,O
with,O
impaired,O
renal,O
function,O
and,O
in,O
patients,O
predisposed,O
to,O
hyperkalemia,O
due,O
to,O
medications,O
or,O
other,O
medical,O
conditions,O
5,O
4,O
Hypoglycemia,O
with,O
Concomitant,O
Use,O
with,O
Insulin,O
and,O
Insulin,O
Secretagogues,O
Insulin,O
and,O
insulin,O
secretagogues,O
are,O
known,O
to,O
cause,O
hypoglycemia,O
INVOKANA,O
can,O
increase,O
the,O
risk,Factor
of,O
hypoglycemia,AdverseReaction
when,O
combined,O
with,O
insulin,O
or,O
an,O
insulin,O
secretagogue,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Therefore,O
a,O
lower,O
dose,O
of,O
insulin,O
or,O
insulin,O
secretagogue,O
may,O
be,O
required,O
to,O
minimize,O
the,O
risk,O
of,O
hypoglycemia,O
when,O
used,O
in,O
combination,O
with,O
INVOKANA,O
5,O
5,O
Genital,O
Mycotic,O
Infections,O
INVOKANA,O
increases,O
the,O
risk,Factor
of,O
genital mycotic infections,AdverseReaction
Patients,O
with,O
a,O
history,O
of,O
genital,O
mycotic,O
infections,O
and,O
uncircumcised,O
males,O
were,O
more,O
likely,O
to,O
develop,O
genital mycotic infections,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
and,O
treat,O
appropriately,O
5,O
6,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions reactions,AdverseReaction
e,O
g,O
generalized urticaria,AdverseReaction
some,O
serious,Severity
were,O
reported,O
with,O
INVOKANA,O
treatment,O
these,O
reactions,O
generally,O
occurred,O
within,O
hours,O
to,O
days,O
after,O
initiating,O
INVOKANA,O
If,O
hypersensitivity,O
reactions,O
occur,O
discontinue,O
use,O
of,O
INVOKANA,O
treat,O
and,O
monitor,O
until,O
signs,O
and,O
symptoms,O
resolve,O
see,O
Contraindications,O
4,O
and,O
Adverse,O
Reactions,O
6,O
1,O
5,O
7,O
Bone,O
Fracture,O
An,O
increased,O
risk,Factor
of,O
bone fracture,AdverseReaction
occurring,O
as,O
early,O
as,O
12,O
weeks,O
after,O
treatment,O
initiation,O
was,O
observed,O
in,O
patients,O
using,O
INVOKANA,O
Consider,O
factors,O
that,O
contribute,O
to,O
fracture,O
risk,O
prior,O
to,O
initiating,O
INVOKANA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
8,O
Increases,O
in,O
Low,O
Density,O
Lipoprotein,O
LDL,O
C,O
Dose,O
related,O
increases in LDL C,AdverseReaction
occur,O
with,O
INVOKANA,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
LDL,O
C,O
and,O
treat,O
if,O
appropriate,O
after,O
initiating,O
INVOKANA,O
5,O
9,O
Macrovascular,O
Outcomes,O
There,O
have,O
been,O
no,O
clinical,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
INVOKANA,O
or,O
any,O
other,O
antidiabetic,O
drug,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
important,O
adverse,O
reactions,O
are,O
described,O
below,O
and,O
elsewhere,O
in,O
the,O
labeling,O
Hypotension,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Impairment in Renal Function,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hyperkalemia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Hypoglycemia,AdverseReaction
with,O
Concomitant,O
Use,O
with,O
Insulin,O
and,O
Insulin,O
Secretagogues,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Genital Mycotic Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Hypersensitivity Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Bone Fracture,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Increases in Low Density Lipoprotein,AdverseReaction
LDL,O
C,O
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Most,O
common,O
adverse,O
reactions,O
associated,O
with,O
INVOKANA,O
5,O
or,O
greater,O
incidence,O
female genital mycotic infections,AdverseReaction
urinary tract infection,AdverseReaction
and,O
increased urination,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Janssen,O
Pharmaceuticals,O
Inc,O
at,O
1,O
800,O
526,O
7736,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
the,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Pool,O
of,O
Placebo,O
Controlled,O
Trials,O
The,O
data,O
in,O
Table,O
1,O
is,O
derived,O
from,O
four,O
26,O
week,O
placebo,O
controlled,O
trials,O
In,O
one,O
trial,O
INVOKANA,O
was,O
used,O
as,O
monotherapy,O
and,O
in,O
three,O
trials,O
INVOKANA,O
was,O
used,O
as,O
add,O
on,O
therapy,O
see,O
Clinical,O
Studies,O
14,O
These,O
data,O
reflect,O
exposure,O
of,O
1667,O
patients,O
to,O
INVOKANA,O
and,O
a,O
mean,O
duration,O
of,O
exposure,O
to,O
INVOKANA,O
of,O
24,O
weeks,O
Patients,O
received,O
INVOKANA,O
100,O
mg,O
N,O
833,O
INVOKANA,O
300,O
mg,O
N,O
834,O
or,O
placebo,O
N,O
646,O
once,O
daily,O
The,O
mean,O
age,O
of,O
the,O
population,O
was,O
56,O
years,O
and,O
2,O
were,O
older,O
than,O
75,O
years,O
of,O
age,O
Fifty,O
percent,O
50,O
of,O
the,O
population,O
was,O
male,O
and,O
72,O
were,O
Caucasian,O
12,O
were,O
Asian,O
and,O
5,O
were,O
Black,O
or,O
African,O
American,O
At,O
baseline,O
the,O
population,O
had,O
diabetes,O
for,O
an,O
average,O
of,O
7,O
3,O
years,O
had,O
a,O
mean,O
HbA1C,O
of,O
8,O
0,O
and,O
20,O
had,O
established,O
microvascular,O
complications,O
of,O
diabetes,O
Baseline,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
mean,O
eGFR,O
88,O
mL,O
min,O
1,O
73,O
m,O
2,O
Table,O
1,O
shows,O
common,O
adverse,O
reactions,O
associated,O
with,O
the,O
use,O
of,O
INVOKANA,O
These,O
adverse,O
reactions,O
were,O
not,O
present,O
at,O
baseline,O
occurred,O
more,O
commonly,O
on,O
INVOKANA,O
than,O
on,O
placebo,O
and,O
occurred,O
in,O
at,O
least,O
2,O
of,O
patients,O
treated,O
with,O
either,O
INVOKANA,O
100,O
mg,O
or,O
INVOKANA,O
300,O
mg,O
Table,O
1,O
Adverse,O
Reactions,O
From,O
Pool,O
of,O
Four,O
26,O
Week,O
Placebo,O
Controlled,O
Studies,O
Reported,O
in,O
2,O
of,O
INVOKANA,O
Treated,O
PatientsThe,O
four,O
placebo,O
controlled,O
trials,O
included,O
one,O
monotherapy,O
trial,O
and,O
three,O
add,O
on,O
combination,O
trials,O
with,O
metformin,O
metformin,O
and,O
sulfonylurea,O
or,O
metformin,O
and,O
pioglitazone,O
Adverse,O
Reaction,O
PlaceboN,O
646,O
INVOKANA,O
100,O
mgN,O
833,O
INVOKANA,O
300,O
mgN,O
834,O
Female genital mycotic infections,AdverseReaction
3,O
2,O
10,O
4,O
11,O
4,O
Urinary tract infections,AdverseReaction
4,O
0,O
5,O
9,O
4,O
3,O
Increased urination,AdverseReaction
0,O
8,O
5,O
3,O
4,O
6,O
Male genital mycotic infections,AdverseReaction
0,O
6,O
4,O
2,O
3,O
7,O
Vulvovaginal pruritus,AdverseReaction
0,O
0,O
1,O
6,O
3,O
0,O
Thirst,AdverseReaction
0,O
2,O
2,O
8,O
2,O
3,O
Constipation,AdverseReaction
0,O
9,O
1,O
8,O
2,O
3,O
Nausea,AdverseReaction
1,O
5,O
2,O
2,O
2,O
3,O
Abdominal pain,AdverseReaction
was,O
also,O
more,O
commonly,O
reported,O
in,O
patients,O
taking,O
INVOKANA,O
100,O
mg,O
1,O
8,O
300,O
mg,O
1,O
7,O
than,O
in,O
patients,O
taking,O
placebo,O
0,O
8,O
Pool,O
of,O
Placebo,O
and,O
Active,O
Controlled,O
Trials,O
The,O
occurrence,O
of,O
adverse,O
reactions,O
for,O
canagliflozin,O
was,O
evaluated,O
in,O
a,O
larger,O
pool,O
of,O
patients,O
participating,O
in,O
placebo,O
and,O
active,O
controlled,O
trials,O
The,O
data,O
combined,O
eight,O
clinical,O
trials,O
see,O
Clinical,O
Studies,O
14,O
and,O
reflect,O
exposure,O
of,O
6177,O
patients,O
to,O
INVOKANA,O
The,O
mean,O
duration,O
of,O
exposure,O
to,O
INVOKANA,O
was,O
38,O
weeks,O
with,O
1832,O
individuals,O
exposed,O
to,O
INVOKANA,O
for,O
greater,O
than,O
50,O
weeks,O
Patients,O
received,O
INVOKANA,O
100,O
mg,O
N,O
3092,O
INVOKANA,O
300,O
mg,O
N,O
3085,O
or,O
comparator,O
N,O
3262,O
once,O
daily,O
The,O
mean,O
age,O
of,O
the,O
population,O
was,O
60,O
years,O
and,O
5,O
were,O
older,O
than,O
75,O
years,O
of,O
age,O
Fifty,O
eight,O
percent,O
58,O
of,O
the,O
population,O
was,O
male,O
and,O
73,O
were,O
Caucasian,O
16,O
were,O
Asian,O
and,O
4,O
were,O
Black,O
or,O
African,O
American,O
At,O
baseline,O
the,O
population,O
had,O
diabetes,O
for,O
an,O
average,O
of,O
11,O
years,O
had,O
a,O
mean,O
HbA1C,O
of,O
8,O
0,O
and,O
33,O
had,O
established,O
microvascular,O
complications,O
of,O
diabetes,O
Baseline,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
mean,O
eGFR,O
81,O
mL,O
min,O
1,O
73,O
m,O
2,O
The,O
types,O
and,O
frequency,O
of,O
common,O
adverse,O
reactions,O
observed,O
in,O
the,O
pool,O
of,O
eight,O
clinical,O
trials,O
were,O
consistent,O
with,O
those,O
listed,O
in,O
Table,O
1,O
In,O
this,O
pool,O
INVOKANA,O
was,O
also,O
associated,O
with,O
the,O
adverse,O
reactions,O
of,O
fatigue,AdverseReaction
1,O
7,O
with,O
comparator,O
2,O
2,O
with,O
INVOKANA,O
100,O
mg,O
and,O
2,O
0,O
with,O
INVOKANA,O
300,O
mg,O
and,O
loss of strength of,AdverseReaction
or,O
energy,AdverseReaction
i,O
e,O
asthenia,AdverseReaction
0,O
6,O
with,O
comparator,O
0,O
7,O
with,O
INVOKANA,O
100,O
mg,O
and,O
1,O
1,O
with,O
INVOKANA,O
300,O
mg,O
In,O
the,O
pool,O
of,O
eight,O
clinical,O
trials,O
the,O
incidence,O
rate,O
of,O
pancreatitis,AdverseReaction
acute,AdverseReaction
or,O
chronic,AdverseReaction
was,O
0,O
9,O
2,O
7,O
and,O
0,O
9,O
per,O
1000,O
patient,O
years,O
of,O
exposure,O
to,O
comparator,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
In,O
the,O
pool,O
of,O
eight,O
clinical,O
trials,O
hypersensitivity related adverse reactions,AdverseReaction
including,O
erythema,AdverseReaction
rash,AdverseReaction
pruritus,AdverseReaction
urticaria,AdverseReaction
and,O
angioedema,AdverseReaction
occurred,O
in,O
3,O
0,O
3,O
8,O
and,O
4,O
2,O
of,O
patients,O
receiving,O
comparator,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
Five,O
patients,O
experienced,O
serious,Severity
adverse,O
reactions,O
of,O
hypersensitivity,AdverseReaction
with,O
INVOKANA,O
which,O
included,O
4,O
patients,O
with,O
urticaria,AdverseReaction
and,O
1,O
patient,O
with,O
a,O
diffuse rash,AdverseReaction
and,O
urticaria,AdverseReaction
occurring,O
within,O
hours,O
of,O
exposure,O
to,O
INVOKANA,O
Among,O
these,O
patients,O
2,O
patients,O
discontinued,O
INVOKANA,O
One,O
patient,O
with,O
urticaria,AdverseReaction
had,O
recurrence,O
when,O
INVOKANA,O
was,O
re,O
initiated,O
Photosensitivity related adverse reactions,AdverseReaction
including,O
photosensitivity reaction,AdverseReaction
polymorphic light eruption,AdverseReaction
and,O
sunburn,AdverseReaction
occurred,O
in,O
0,O
1,O
0,O
2,O
and,O
0,O
2,O
of,O
patients,O
receiving,O
comparator,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
Other,O
adverse,O
reactions,O
occurring,O
more,O
frequently,O
on,O
INVOKANA,O
than,O
on,O
comparator,O
were,O
Volume,O
Depletion,O
Related,O
Adverse,O
Reactions,O
INVOKANA,O
results,O
in,O
an,O
osmotic diuresis,AdverseReaction
which,O
may,Factor
lead,O
to,O
reductions in intravascular volume,AdverseReaction
In,O
clinical,O
studies,O
treatment,O
with,O
INVOKANA,O
was,O
associated,O
with,O
a,O
dose,O
dependent,O
increase,O
in,O
the,O
incidence,O
of,O
volume depletion related adverse reactions,AdverseReaction
e,O
g,O
hypotension,AdverseReaction
postural dizziness,AdverseReaction
orthostatic hypotension,AdverseReaction
syncope,AdverseReaction
and,O
dehydration,AdverseReaction
An,O
increased,O
incidence,O
was,O
observed,O
in,O
patients,O
on,O
the,O
300,O
mg,O
dose,O
The,O
three,O
factors,O
associated,O
with,O
the,O
largest,O
increase,O
in,O
volume depletion related adverse reactions,AdverseReaction
were,O
the,O
use,O
of,O
loop,O
diuretics,O
moderate,O
renal,O
impairment,O
eGFR,O
30,O
to,O
less,O
than,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
and,O
age,O
75,O
years,O
and,O
older,O
Table,O
2,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
and,O
8,O
6,O
Table,O
2,O
Proportion,O
of,O
Patients,O
With,O
at,O
Least,O
One,O
Volume Depletion Related Adverse Reaction,AdverseReaction
Pooled,O
Results,O
from,O
8,O
Clinical,O
Trials,O
Baseline,O
Characteristic,O
Comparator,O
Group,O
INVOKANA,O
100,O
mg,O
INVOKANA,O
300,O
mg,O
Overall,O
population,O
1,O
5,O
2,O
3,O
3,O
4,O
75,O
years,O
of,O
age,O
and,O
older,O
2,O
6,O
4,O
9,O
8,O
7,O
eGFR less than 60 mL min 1 73 m 2,AdverseReaction
2,O
5,O
4,O
7,O
8,O
1,O
Use,O
of,O
loop,O
diuretic,O
4,O
7,O
3,O
2,O
8,O
8,O
Falls,O
In,O
a,O
pool,O
of,O
nine,O
clinical,O
trials,O
with,O
mean,O
duration,O
of,O
exposure,O
to,O
INVOKANA,O
of,O
85,O
weeks,O
the,O
proportion,O
of,O
patients,O
who,O
experienced,O
falls,AdverseReaction
was,O
1,O
3,O
1,O
5,O
and,O
2,O
1,O
with,O
comparator,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
The,O
higher,O
risk,Factor
of,O
falls,AdverseReaction
for,O
patients,O
treated,O
with,O
INVOKANA,O
was,O
observed,O
within,O
the,O
first,O
few,O
weeks,O
of,O
treatment,O
Impairment,O
in,O
Renal,O
Function,O
INVOKANA,O
is,O
associated,O
with,O
a,O
dose,O
dependent,O
increase in serum creatinine,AdverseReaction
and,O
a,O
concomitant,O
fall in estimated GFR,AdverseReaction
Table,O
3,O
Patients,O
with,O
moderate,O
renal,O
impairment,O
at,O
baseline,O
had,O
larger,O
mean,O
changes,O
Table,O
3,O
Changes in Serum Creatinine in,AdverseReaction
and,O
eGFR,AdverseReaction
Associated,O
with,O
INVOKANA,O
in,O
the,O
Pool,O
of,O
Four,O
Placebo,O
Controlled,O
Trials,O
and,O
Moderate,O
Renal,O
Impairment,O
Trial,O
PlaceboN,O
646,O
INVOKANA,O
100,O
mgN,O
833,O
INVOKANA,O
300,O
mgN,O
834,O
Pool,O
of,O
Four,O
Placebo,O
Controlled,O
Trials,O
Baseline,O
Creatinine,O
mg,O
dL,O
0,O
84,O
0,O
82,O
0,O
82,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
87,O
0,O
88,O
3,O
88,O
8,O
Week,O
6,O
Change,O
Creatinine,O
mg,O
dL,O
0,O
01,O
0,O
03,O
0,O
05,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
1,O
6,O
3,O
8,O
5,O
0,O
End,O
of,O
Treatment,O
Change,O
Creatinine,O
mg,O
dL,O
0,O
01,O
0,O
02,O
0,O
03,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
1,O
6,O
2,O
3,O
3,O
4,O
PlaceboN,O
90,O
INVOKANA,O
100,O
mgN,O
90,O
INVOKANA,O
300,O
mgN,O
89,O
Moderate,O
Renal,O
Impairment,O
Trial,O
Baseline,O
Creatinine,O
mg,O
dL,O
1,O
61,O
1,O
62,O
1,O
63,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
40,O
1,O
39,O
7,O
38,O
5,O
Week,O
3,O
Change,O
Creatinine,O
mg,O
dL,O
0,O
03,O
0,O
18,O
0,O
28,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
0,O
7,O
4,O
6,O
6,O
2,O
End,O
of,O
Treatment,O
Change,O
Creatinine,O
mg,O
dL,O
0,O
07,O
0,O
16,O
0,O
18,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
1,O
5,O
3,O
6,O
4,O
0,O
In,O
the,O
pool,O
of,O
four,O
placebo,O
controlled,O
trials,O
where,O
patients,O
had,O
normal,O
or,O
mildly,O
impaired,O
baseline,O
renal,O
function,O
the,O
proportion,O
of,O
patients,O
who,O
experienced,O
at,O
least,O
one,O
event,O
of,O
significant,Severity
renal function decline,AdverseReaction
defined,O
as,O
an,O
eGFR below 80 mL min 1 73 m 2,AdverseReaction
and,O
30 lower than baseline,AdverseReaction
was,O
2,O
1,O
with,O
placebo,O
2,O
0,O
with,O
INVOKANA,O
100,O
mg,O
and,O
4,O
1,O
with,O
INVOKANA,O
300,O
mg,O
At,O
the,O
end,O
of,O
treatment,O
0,O
5,O
with,O
placebo,O
0,O
7,O
with,O
INVOKANA,O
100,O
mg,O
and,O
1,O
4,O
with,O
INVOKANA,O
300,O
mg,O
had,O
a,O
significant,Severity
renal function decline,AdverseReaction
In,O
a,O
trial,O
carried,O
out,O
in,O
patients,O
with,O
moderate,O
renal,O
impairment,O
with,O
a,O
baseline,O
eGFR,O
of,O
30,O
to,O
less,O
than,O
50,O
mL,O
min,O
1,O
73,O
m,O
2,O
mean,O
baseline,O
eGFR,O
39,O
mL,O
min,O
1,O
73,O
m,O
2,O
see,O
Clinical,O
Studies,O
14,O
3,O
the,O
proportion,O
of,O
patients,O
who,O
experienced,O
at,O
least,O
one,O
event,O
of,O
significant,Severity
renal function decline,AdverseReaction
defined,O
as,O
an,O
eGFR 30 lower than baseline,AdverseReaction
was,O
6,O
9,O
with,O
placebo,O
18,O
with,O
INVOKANA,O
100,O
mg,O
and,O
22,O
5,O
with,O
INVOKANA,O
300,O
mg,O
At,O
the,O
end,O
of,O
treatment,O
4,O
6,O
with,O
placebo,O
3,O
4,O
with,O
INVOKANA,O
100,O
mg,O
and,O
2,O
2,O
with,O
INVOKANA,O
300,O
mg,O
had,O
a,O
significant,Severity
renal function decline,AdverseReaction
In,O
a,O
pooled,O
population,O
of,O
patients,O
with,O
moderate,O
renal,O
impairment,O
N,O
1085,O
with,O
baseline,O
eGFR,O
of,O
30,O
to,O
less,O
than,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
mean,O
baseline,O
eGFR,O
48,O
mL,O
min,O
1,O
73,O
m,O
2,O
the,O
overall,O
incidence,O
of,O
these,O
events,O
was,O
lower,O
than,O
in,O
the,O
dedicated,O
trial,O
but,O
a,O
dose,O
dependent,O
increase,O
in,O
incident,O
episodes,O
of,O
significant,Severity
renal function decline,AdverseReaction
compared,O
to,O
placebo,O
was,O
still,O
observed,O
Use,O
of,O
INVOKANA,O
has,O
been,O
associated,O
with,O
an,O
increased,O
incidence,O
of,O
renal related adverse reactions,AdverseReaction
e,O
g,O
increased blood creatinine,AdverseReaction
decreased glomerular filtration rate,AdverseReaction
renal impairment,AdverseReaction
and,O
acute renal failure,AdverseReaction
particularly,O
in,O
patients,O
with,O
moderate,O
renal,O
impairment,O
In,O
the,O
pooled,O
analysis,O
of,O
patients,O
with,O
moderate,O
renal,O
impairment,O
the,O
incidence,O
of,O
renal related adverse reactions,AdverseReaction
was,O
3,O
7,O
with,O
placebo,O
8,O
9,O
with,O
INVOKANA,O
100,O
mg,O
and,O
9,O
3,O
with,O
INVOKANA,O
300,O
mg,O
Discontinuations,O
due,O
to,O
renal related adverse events,AdverseReaction
occurred,O
in,O
1,O
0,O
with,O
placebo,O
1,O
2,O
with,O
INVOKANA,O
100,O
mg,O
and,O
1,O
6,O
with,O
INVOKANA,O
300,O
mg,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Genital,O
Mycotic,O
Infections,O
In,O
the,O
pool,O
of,O
four,O
placebo,O
controlled,O
clinical,O
trials,O
female genital mycotic infections,AdverseReaction
e,O
g,O
vulvovaginal mycotic infection,AdverseReaction
vulvovaginal candidiasis,AdverseReaction
and,O
vulvovaginitis,AdverseReaction
occurred,O
in,O
3,O
2,O
10,O
4,O
and,O
11,O
4,O
of,O
females,O
treated,O
with,O
placebo,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
Patients,O
with,O
a,O
history,O
of,O
genital,O
mycotic,O
infections,O
were,O
more,O
likely,O
to,O
develop,O
genital mycotic infections,AdverseReaction
on,O
INVOKANA,O
Female,AdverseReaction
patients,O
who,O
developed,O
genital mycotic infections,AdverseReaction
on,O
INVOKANA,O
were,O
more,O
likely,O
to,O
experience,O
recurrence,O
and,O
require,O
treatment,O
with,O
oral,O
or,O
topical,O
antifungal,O
agents,O
and,O
anti,O
microbial,O
agents,O
In,O
females,AdverseReaction
discontinuation,O
due,O
to,O
genital mycotic infections,AdverseReaction
occurred,O
in,O
0,O
and,O
0,O
7,O
of,O
patients,O
treated,O
with,O
placebo,O
and,O
INVOKANA,O
respectively,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
In,O
the,O
pool,O
of,O
four,O
placebo,O
controlled,O
clinical,O
trials,O
male genital mycotic infections,AdverseReaction
e,O
g,O
candidal balanitis,AdverseReaction
balanoposthitis,AdverseReaction
occurred,O
in,O
0,O
6,O
4,O
2,O
and,O
3,O
7,O
of,O
males,O
treated,O
with,O
placebo,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
Male genital mycotic infections,AdverseReaction
occurred,O
more,O
commonly,O
in,O
uncircumcised,O
males,O
and,O
in,O
males,O
with,O
a,O
prior,O
history,O
of,O
balanitis,O
or,O
balanoposthitis,O
Male,AdverseReaction
patients,O
who,O
developed,O
genital mycotic infections,AdverseReaction
on,O
INVOKANA,O
were,O
more,O
likely,O
to,O
experience,O
recurrent,O
infections,O
22,O
on,O
INVOKANA,O
versus,O
none,O
on,O
placebo,O
and,O
require,O
treatment,O
with,O
oral,O
or,O
topical,O
antifungal,O
agents,O
and,O
anti,O
microbial,O
agents,O
than,O
patients,O
on,O
comparators,O
In,O
males,AdverseReaction
discontinuations,O
due,O
to,O
genital mycotic infections,AdverseReaction
occurred,O
in,O
0,O
and,O
0,O
5,O
of,O
patients,O
treated,O
with,O
placebo,O
and,O
INVOKANA,O
respectively,O
In,O
the,O
pooled,O
analysis,O
of,O
8,O
controlled,O
trials,O
phimosis,AdverseReaction
was,O
reported,O
in,O
0,O
3,O
of,O
uncircumcised,O
male,O
patients,O
treated,O
with,O
INVOKANA,O
and,O
0,O
2,O
required,O
circumcision,O
to,O
treat,O
the,O
phimosis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Hypoglycemia,O
In,O
all,O
clinical,O
trials,O
hypoglycemia,O
was,O
defined,O
as,O
any,O
event,O
regardless,O
of,O
symptoms,O
where,O
biochemical,O
hypoglycemia,O
was,O
documented,O
any,O
glucose,O
value,O
below,O
or,O
equal,O
to,O
70,O
mg,O
dL,O
Severe,O
hypoglycemia,O
was,O
defined,O
as,O
an,O
event,O
consistent,O
with,O
hypoglycemia,O
where,O
the,O
patient,O
required,O
the,O
assistance,O
of,O
another,O
person,O
to,O
recover,O
lost,O
consciousness,O
or,O
experienced,O
a,O
seizure,O
regardless,O
of,O
whether,O
biochemical,O
documentation,O
of,O
a,O
low,O
glucose,O
value,O
was,O
obtained,O
In,O
individual,O
clinical,O
trials,O
see,O
Clinical,O
Studies,O
14,O
episodes,O
of,O
hypoglycemia,AdverseReaction
occurred,O
at,O
a,O
higher,O
rate,O
when,O
INVOKANA,O
was,O
co,O
administered,O
with,O
insulin,O
or,O
sulfonylureas,O
Table,O
4,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Table,O
4,O
Incidence,O
of,O
HypoglycemiaNumber,O
of,O
patients,O
experiencing,O
at,O
least,O
one,O
event,O
of,O
hypoglycemia,AdverseReaction
based,O
on,O
either,O
biochemically,O
documented,O
episodes,O
or,O
severe,Severity
hypoglycemic events,AdverseReaction
in,O
the,O
intent,O
to,O
treat,O
population,O
in,O
Controlled,O
Clinical,O
Studies,O
Monotherapy,O
26,O
weeks,O
Placebo,O
N,O
192,O
INVOKANA,O
100,O
mg,O
N,O
195,O
INVOKANA,O
300,O
mg,O
N,O
197,O
Overall,O
N,O
5,O
2,O
6,O
7,O
3,O
6,O
6,O
3,O
0,O
In,O
Combination,O
with,O
Metformin,O
26,O
weeks,O
Placebo,O
Metformin,O
N,O
183,O
INVOKANA,O
100,O
mg,O
Metformin,O
N,O
368,O
INVOKANA,O
300,O
mg,O
Metformin,O
N,O
367,O
Overall,O
N,O
3,O
1,O
6,O
16,O
4,O
3,O
17,O
4,O
6,O
Severe,O
N,O
0,O
0,O
1,O
0,O
3,O
1,O
0,O
3,O
In,O
Combination,O
with,O
Metformin,O
52,O
weeks,O
Glimepiride,O
Metformin,O
N,O
482,O
INVOKANA,O
100,O
mg,O
Metformin,O
N,O
483,O
INVOKANA,O
300,O
mg,O
Metformin,O
N,O
485,O
Overall,O
N,O
165,O
34,O
2,O
27,O
5,O
6,O
24,O
4,O
9,O
Severe,O
N,O
15,O
3,O
1,O
2,O
0,O
4,O
3,O
0,O
6,O
In,O
Combination,O
with,O
Sulfonylurea,O
18,O
weeks,O
Placebo,O
Sulfonylurea,O
N,O
69,O
INVOKANA,O
100,O
mg,O
Sulfonylurea,O
N,O
74,O
INVOKANA,O
300,O
mg,O
Sulfonylurea,O
N,O
72,O
Overall,O
N,O
4,O
5,O
8,O
3,O
4,O
1,O
9,O
12,O
5,O
In,O
Combination,O
with,O
Metformin,O
Sulfonylurea,O
26,O
weeks,O
Placebo,O
Metformin,O
Sulfonylurea,O
N,O
156,O
INVOKANA,O
100,O
mg,O
Metformin,O
Sulfonylurea,O
N,O
157,O
INVOKANA,O
300,O
mg,O
Metformin,O
Sulfonylurea,O
N,O
156,O
Overall,O
N,O
24,O
15,O
4,O
43,O
27,O
4,O
47,O
30,O
1,O
Severe,O
N,O
1,O
0,O
6,O
1,O
0,O
6,O
0,O
In,O
Combination,O
with,O
Metformin,O
Sulfonylurea,O
52,O
weeks,O
Sitagliptin,O
Metformin,O
Sulfonylurea,O
N,O
378,O
INVOKANA,O
300,O
mg,O
Metformin,O
Sulfonylurea,O
N,O
377,O
Overall,O
N,O
154,O
40,O
7,O
163,O
43,O
2,O
Severe,O
N,O
13,O
3,O
4,O
15,O
4,O
0,O
In,O
Combination,O
with,O
Metformin,O
Pioglitazone,O
26,O
weeks,O
Placebo,O
Metformin,O
Pioglitazone,O
N,O
115,O
INVOKANA,O
100,O
mg,O
Metformin,O
Pioglitazone,O
N,O
113,O
INVOKANA,O
300,O
mg,O
Metformin,O
Pioglitazone,O
N,O
114,O
Overall,O
N,O
3,O
2,O
6,O
3,O
2,O
7,O
6,O
5,O
3,O
In,O
Combination,O
with,O
Insulin,O
18,O
weeks,O
Placebo,O
N,O
565,O
INVOKANA,O
100,O
mg,O
N,O
566,O
INVOKANA,O
300,O
mg,O
N,O
587,O
Overall,O
N,O
208,O
36,O
8,O
279,O
49,O
3,O
285,O
48,O
6,O
Severe,O
N,O
14,O
2,O
5,O
10,O
1,O
8,O
16,O
2,O
7,O
Bone,O
Fracture,O
The,O
occurrence,O
of,O
bone fractures,AdverseReaction
was,O
evaluated,O
in,O
a,O
pool,O
of,O
nine,O
clinical,O
trials,O
with,O
a,O
mean,O
duration,O
of,O
exposure,O
to,O
INVOKANA,O
of,O
85,O
weeks,O
The,O
incidence,O
rates,O
of,O
adjudicated,O
bone fractures,AdverseReaction
were,O
1,O
1,O
1,O
4,O
and,O
1,O
5,O
per,O
100,O
patient,O
years,O
of,O
exposure,O
in,O
the,O
comparator,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
groups,O
respectively,O
Fractures,AdverseReaction
were,O
observed,O
as,O
early,O
as,O
12,O
weeks,O
after,O
treatment,O
initiation,O
and,O
were,O
more,O
likely,O
to,O
be,O
low trauma,Severity
e,O
g,O
fall,O
from,O
no,O
more,O
than,O
standing,O
height,O
and,O
affect,O
the,O
upper extremities,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Laboratory,O
and,O
Imaging,O
Tests,O
Increases,O
in,O
Serum,O
Potassium,O
In,O
a,O
pooled,O
population,O
of,O
patients,O
N,O
723,O
with,O
moderate,O
renal,O
impairment,O
eGFR,O
45,O
to,O
less,O
than,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
increases in serum potassium in serum potassium,AdverseReaction
to,O
greater,O
than,O
5 4 mEq L,Severity
and,O
15 above baseline,Severity
occurred,O
in,O
5,O
3,O
5,O
0,O
and,O
8,O
8,O
of,O
patients,O
treated,O
with,O
placebo,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
Severe,O
elevations,O
greater,O
than,O
or,O
equal,O
to,O
6,O
5,O
mEq,O
L,O
occurred,O
in,O
0,O
4,O
of,O
patients,O
treated,O
with,O
placebo,O
no,O
patients,O
treated,O
with,O
INVOKANA,O
100,O
mg,O
and,O
1,O
3,O
of,O
patients,O
treated,O
with,O
INVOKANA,O
300,O
mg,O
In,O
these,O
patients,O
increases in potassium,AdverseReaction
were,O
more,O
commonly,O
seen,O
in,O
those,O
with,O
elevated,O
potassium,O
at,O
baseline,O
Among,O
patients,O
with,O
moderate,O
renal,O
impairment,O
approximately,O
84,O
were,O
taking,O
medications,O
that,O
interfere,O
with,O
potassium,O
excretion,O
such,O
as,O
potassium,O
sparing,O
diuretics,O
angiotensin,O
converting,O
enzyme,O
inhibitors,O
and,O
angiotensin,O
receptor,O
blockers,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
and,O
5,O
3,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
Increases,O
in,O
Serum,O
Magnesium,O
Dose,O
related,O
increases in serum magnesium,AdverseReaction
were,O
observed,O
early,O
after,O
initiation,O
of,O
INVOKANA,O
within,O
6,O
weeks,O
and,O
remained,O
elevated,O
throughout,O
treatment,O
In,O
the,O
pool,O
of,O
four,O
placebo,O
controlled,O
trials,O
the,O
mean,O
percent,O
change in serum magnesium levels,AdverseReaction
was,O
8,O
1,O
and,O
9,O
3,O
with,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
compared,O
to,O
0,O
6,O
with,O
placebo,O
In,O
a,O
trial,O
of,O
patients,O
with,O
moderate,O
renal,O
impairment,O
see,O
Clinical,O
Studies,O
14,O
3,O
serum magnesium levels increased,AdverseReaction
by,O
0,O
2,O
9,O
2,O
and,O
14,O
8,O
with,O
placebo,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
Increases,O
in,O
Serum,O
Phosphate,O
Dose,O
related,O
increases in serum phosphate,AdverseReaction
levels,O
were,O
observed,O
with,O
INVOKANA,O
In,O
the,O
pool,O
of,O
four,O
placebo,O
controlled,O
trials,O
the,O
mean,O
percent,O
change in serum phosphate levels,AdverseReaction
were,O
3,O
6,O
and,O
5,O
1,O
with,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
compared,O
to,O
1,O
5,O
with,O
placebo,O
In,O
a,O
trial,O
of,O
patients,O
with,O
moderate,O
renal,O
impairment,O
see,O
Clinical,O
Studies,O
14,O
3,O
the,O
mean,O
serum phosphate levels increased,AdverseReaction
by,O
1,O
2,O
5,O
0,O
and,O
9,O
3,O
with,O
placebo,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
Increases,O
in,O
Low,O
Density,O
Lipoprotein,O
Cholesterol,O
LDL,O
C,O
and,O
non,O
High,O
Density,O
Lipoprotein,O
Cholesterol,O
non,O
HDL,O
C,O
In,O
the,O
pool,O
of,O
four,O
placebo,O
controlled,O
trials,O
dose,O
related,O
increases in LDL C,AdverseReaction
with,O
INVOKANA,O
were,O
observed,O
Mean,O
changes,AdverseReaction
percent,O
changes,O
from,O
baseline,O
in LDL C,AdverseReaction
relative,O
to,O
placebo,O
were,O
4 4 mg dL,Severity
4,O
5,O
and,O
8 2 mg dL,Severity
8,O
0,O
with,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
The,O
mean,O
baseline,O
LDL,O
C,O
levels,O
were,O
104,O
to,O
110,O
mg,O
dL,O
across,O
treatment,O
groups,O
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Dose,O
related,O
increases in non HDL C,AdverseReaction
with,O
INVOKANA,O
were,O
observed,O
Mean,O
changes,AdverseReaction
percent,O
changes,O
from,O
baseline,O
in non HDL C,AdverseReaction
relative,O
to,O
placebo,O
were,O
2 1 mg dL,Severity
1,O
5,O
and,O
5 1 mg dL,Severity
3,O
6,O
with,O
INVOKANA,O
100,O
mg,O
and,O
300,O
mg,O
respectively,O
The,O
mean,O
baseline,O
non,O
HDL,O
C,O
levels,O
were,O
140,O
to,O
147,O
mg,O
dL,O
across,O
treatment,O
groups,O
Increases,O
in,O
Hemoglobin,O
In,O
the,O
pool,O
of,O
four,O
placebo,O
controlled,O
trials,O
mean,O
changes,AdverseReaction
percent,O
changes,O
from,O
baseline,O
in hemoglobin,AdverseReaction
were,O
0,O
18,O
g,O
dL,O
1,O
1,O
with,O
placebo,O
0 47 g dL,Severity
3,O
5,O
with,O
INVOKANA,O
100,O
mg,O
and,O
0 51 g dL,Severity
3,O
8,O
with,O
INVOKANA,O
300,O
mg,O
The,O
mean,O
baseline,O
hemoglobin,O
value,O
was,O
approximately,O
14,O
1,O
g,O
dL,O
across,O
treatment,O
groups,O
At,O
the,O
end,O
of,O
treatment,O
0,O
8,O
4,O
0,O
and,O
2,O
7,O
of,O
patients,O
treated,O
with,O
placebo,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
respectively,O
had,O
hemoglobin above the upper limit of normal,AdverseReaction
Decreases,O
in,O
Bone,O
Mineral,O
Density,O
Bone,O
mineral,O
density,O
BMD,O
was,O
measured,O
by,O
dual,O
energy,O
X,O
ray,O
absorptiometry,O
in,O
a,O
clinical,O
trial,O
of,O
714,O
older,O
adults,O
mean,O
age,O
64,O
years,O
see,O
Clinical,O
Studies,O
14,O
3,O
At,O
2,O
years,O
patients,O
randomized,O
to,O
INVOKANA,O
100,O
mg,O
and,O
INVOKANA,O
300,O
mg,O
had,O
placebo,O
corrected,O
declines in BMD at the total hip in BMD,AdverseReaction
of,O
0,O
9,O
and,O
1,O
2,O
respectively,O
and,O
at the lumbar spine,AdverseReaction
of,O
0,O
3,O
and,O
0,O
7,O
respectively,O
Additionally,O
placebo,O
adjusted,O
BMD declines declines,AdverseReaction
were,O
0,O
1,O
at the femoral neck,AdverseReaction
for,O
both,O
INVOKANA,O
doses,O
and,O
0,O
4,O
at the distal forearm,AdverseReaction
for,O
patients,O
randomized,O
to,O
INVOKANA,O
300,O
mg,O
The,O
placebo,O
adjusted,O
change,O
at,O
the,O
distal,O
forearm,O
for,O
patients,O
randomized,O
to,O
INVOKANA,O
100,O
mg,O
was,O
0,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypotension,AdverseReaction
Before,O
initiating,O
JARDIANCE,O
assess,O
and,O
correct,O
volume,O
status,O
in,O
patients,O
with,O
renal,O
impairment,O
the,O
elderly,O
in,O
patients,O
with,O
low,O
systolic,O
blood,O
pressure,O
and,O
in,O
patients,O
on,O
diuretics,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
during,O
therapy,O
5,O
1,O
Impairment in renal function,AdverseReaction
Monitor,O
renal,O
function,O
during,O
therapy,O
More,O
frequent,O
monitoring,O
is,O
recommended,O
in,O
patients,O
with,O
eGFR,O
below,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
5,O
2,O
Hypoglycemia,AdverseReaction
Consider,O
lowering,O
the,O
dose,O
of,O
insulin,O
secretagogue,O
or,O
insulin,O
to,O
reduce,O
the,O
risk,O
of,O
hypoglycemia,O
when,O
initiating,O
JARDIANCE,O
5,O
3,O
Genital mycotic infections,AdverseReaction
Monitor,O
and,O
treat,O
as,O
appropriate,O
5,O
4,O
Urinary tract infections,AdverseReaction
Monitor,O
and,O
treat,O
as,O
appropriate,O
5,O
5,O
Increased LDL C,AdverseReaction
Monitor,O
and,O
treat,O
as,O
appropriate,O
5,O
6,O
Macrovascular,O
outcomes,O
There,O
have,O
been,O
no,O
clinical,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
JARDIANCE,O
5,O
7,O
5,O
1,O
Hypotension,O
JARDIANCE,O
causes,O
intravascular volume contraction,AdverseReaction
Symptomatic hypotension,AdverseReaction
may,Factor
occur,O
after,O
initiating,O
JARDIANCE,O
see,O
Adverse,O
Reactions,O
6,O
1,O
particularly,O
in,O
patients,O
with,O
renal,O
impairment,O
the,O
elderly,O
in,O
patients,O
with,O
low,O
systolic,O
blood,O
pressure,O
and,O
in,O
patients,O
on,O
diuretics,O
Before,O
initiating,O
JARDIANCE,O
assess,O
for,O
volume,O
contraction,O
and,O
correct,O
volume,O
status,O
if,O
indicated,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
of,O
hypotension,O
after,O
initiating,O
therapy,O
and,O
increase,O
monitoring,O
in,O
clinical,O
situations,O
where,O
volume,O
contraction,O
is,O
expected,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
5,O
2,O
Impairment,O
in,O
Renal,O
Function,O
JARDIANCE,O
increases serum creatinine,AdverseReaction
and,O
decreases eGFR,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
The,O
risk,Factor
of,O
impaired renal function,AdverseReaction
with,O
JARDIANCE,O
is,O
increased,O
in,O
elderly,O
patients,O
and,O
patients,O
with,O
moderate,O
renal,O
impairment,O
More,O
frequent,O
monitoring,O
of,O
renal,O
function,O
is,O
recommended,O
in,O
these,O
patients,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
8,O
6,O
Renal,O
function,O
should,O
be,O
evaluated,O
prior,O
to,O
initiating,O
JARDIANCE,O
and,O
periodically,O
thereafter,O
5,O
3,O
Hypoglycemia,O
with,O
Concomitant,O
Use,O
with,O
Insulin,O
and,O
Insulin,O
Secretagogues,O
Insulin,O
and,O
insulin,O
secretagogues,O
are,O
known,O
to,O
cause,O
hypoglycemia,O
The,O
risk,Factor
of,O
hypoglycemia,AdverseReaction
is,O
increased,O
when,O
JARDIANCE,O
is,O
used,O
in,O
combination,O
with,O
insulin,O
secretagogues,O
e,O
g,O
sulfonylurea,O
or,O
insulin,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Therefore,O
a,O
lower,O
dose,O
of,O
the,O
insulin,O
secretagogue,O
or,O
insulin,O
may,O
be,O
required,O
to,O
reduce,O
the,O
risk,O
of,O
hypoglycemia,O
when,O
used,O
in,O
combination,O
with,O
JARDIANCE,O
5,O
4,O
Genital,O
Mycotic,O
Infections,O
JARDIANCE,O
increases,O
the,O
risk,Factor
for,O
genital mycotic infections,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
Patients,O
with,O
a,O
history,O
of,O
chronic,O
or,O
recurrent,O
genital,O
mycotic,O
infections,O
were,O
more,O
likely,O
to,O
develop,O
mycotic genital infections,AdverseReaction
Monitor,O
and,O
treat,O
as,O
appropriate,O
5,O
5,O
Urinary,O
Tract,O
Infections,O
JARDIANCE,O
increases,O
the,O
risk,Factor
for,O
urinary tract infections,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
and,O
treat,O
as,O
appropriate,O
5,O
6,O
Increased,O
Low,O
Density,O
Lipoprotein,O
Cholesterol,O
LDL,O
C,O
Increases in LDL C,AdverseReaction
can,Factor
occur,O
with,O
JARDIANCE,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
and,O
treat,O
as,O
appropriate,O
5,O
7,O
Macrovascular,O
Outcomes,O
There,O
have,O
been,O
no,O
clinical,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
JARDIANCE,O
or,O
any,O
other,O
antidiabetic,O
drug,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
important,O
adverse,O
reactions,O
are,O
described,O
below,O
and,O
elsewhere,O
in,O
the,O
labeling,O
Hypotension,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Impairment in Renal Function,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hypoglycemia,AdverseReaction
with,O
Concomitant,O
Use,O
with,O
Insulin,O
and,O
Insulin,O
Secretagogues,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Genital Mycotic Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Urinary Tract Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Increased Low Density Lipoprotein Cholesterol,AdverseReaction
LDL,O
C,O
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
The,O
most,O
common,O
adverse,O
reactions,O
associated,O
with,O
JARDIANCE,O
5,O
or,O
greater,O
incidence,O
were,O
urinary tract infections,AdverseReaction
and,O
female,O
genital mycotic infections,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Boehringer,O
Ingelheim,O
Pharmaceuticals,O
Inc,O
at,O
1,O
800,O
542,O
6257,O
or,O
1,O
800,O
459,O
9906,O
TTY,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Pool,O
of,O
Placebo,O
Controlled,O
Trials,O
evaluating,O
JARDIANCE,O
10,O
and,O
25,O
mg,O
The,O
data,O
in,O
Table,O
1,O
are,O
derived,O
from,O
a,O
pool,O
of,O
four,O
24,O
week,O
placebo,O
controlled,O
trials,O
and,O
18,O
week,O
data,O
from,O
a,O
placebo,O
controlled,O
trial,O
with,O
insulin,O
JARDIANCE,O
was,O
used,O
as,O
monotherapy,O
in,O
one,O
trial,O
and,O
as,O
add,O
on,O
therapy,O
in,O
four,O
trials,O
see,O
Clinical,O
Studies,O
14,O
These,O
data,O
reflect,O
exposure,O
of,O
1976,O
patients,O
to,O
JARDIANCE,O
with,O
a,O
mean,O
exposure,O
duration,O
of,O
approximately,O
23,O
weeks,O
Patients,O
received,O
placebo,O
N,O
995,O
JARDIANCE,O
10,O
mg,O
N,O
999,O
or,O
JARDIANCE,O
25,O
mg,O
N,O
977,O
once,O
daily,O
The,O
mean,O
age,O
of,O
the,O
population,O
was,O
56,O
years,O
and,O
3,O
were,O
older,O
than,O
75,O
years,O
of,O
age,O
More,O
than,O
half,O
55,O
of,O
the,O
population,O
was,O
male,O
46,O
were,O
White,O
50,O
were,O
Asian,O
and,O
3,O
were,O
Black,O
or,O
African,O
American,O
At,O
baseline,O
57,O
of,O
the,O
population,O
had,O
diabetes,O
more,O
than,O
5,O
years,O
and,O
had,O
a,O
mean,O
hemoglobin,O
A1c,O
HbA1c,O
of,O
8,O
Established,O
microvascular,O
complications,O
of,O
diabetes,O
at,O
baseline,O
included,O
diabetic,O
nephropathy,O
7,O
retinopathy,O
8,O
or,O
neuropathy,O
16,O
Baseline,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
in,O
91,O
of,O
patients,O
and,O
moderately,O
impaired,O
in,O
9,O
of,O
patients,O
mean,O
eGFR,O
86,O
8,O
mL,O
min,O
1,O
73,O
m,O
2,O
Table,O
1,O
shows,O
common,O
adverse,O
reactions,O
excluding,O
hypoglycemia,AdverseReaction
associated,O
with,O
the,O
use,O
of,O
JARDIANCE,O
The,O
adverse,O
reactions,O
were,O
not,O
present,O
at,O
baseline,O
occurred,O
more,O
commonly,O
on,O
JARDIANCE,O
than,O
on,O
placebo,O
and,O
occurred,O
in,O
greater,O
than,O
or,O
equal,O
to,O
2,O
of,O
patients,O
treated,O
with,O
JARDIANCE,O
10,O
mg,O
or,O
JARDIANCE,O
25,O
mg,O
Table,O
1,O
Adverse,O
Reactions,O
Reported,O
in,O
2,O
of,O
Patients,O
Treated,O
with,O
JARDIANCE,O
and,O
Greater,O
than,O
Placebo,O
in,O
Pooled,O
Placebo,O
Controlled,O
Clinical,O
Studies,O
of,O
JARDIANCE,O
Monotherapy,O
or,O
Combination,O
Therapy,O
a,O
Predefined,O
adverse,O
event,O
grouping,O
including,O
but,O
not,O
limited,O
to,O
urinary tract infection,AdverseReaction
asymptomatic bacteriuria,AdverseReaction
cystitis,AdverseReaction
b,O
Female genital mycotic infections,AdverseReaction
include,O
the,O
following,O
adverse,O
reactions,O
vulvovaginal mycotic infection,AdverseReaction
vaginal infection,AdverseReaction
vulvitis,AdverseReaction
vulvovaginal candidiasis,AdverseReaction
genital infection,AdverseReaction
genital candidiasis,AdverseReaction
genital infection fungal,AdverseReaction
genitourinary tract infection,AdverseReaction
vulvovaginitis,AdverseReaction
cervicitis,AdverseReaction
urogenital infection fungal,AdverseReaction
vaginitis bacterial,AdverseReaction
Percentages,O
calculated,O
with,O
the,O
number,O
of,O
female,O
subjects,O
in,O
each,O
group,O
as,O
denominator,O
placebo,O
N,O
481,O
JARDIANCE,O
10,O
mg,O
N,O
443,O
JARDIANCE,O
25,O
mg,O
N,O
420,O
c,O
Predefined,O
adverse,O
event,O
grouping,O
including,O
but,O
not,O
limited,O
to,O
polyuria,AdverseReaction
pollakiuria,AdverseReaction
and,O
nocturia,AdverseReaction
d,O
Male,O
genital,O
mycotic,O
infections,O
include,O
the,O
following,O
adverse,O
reactions,O
balanoposthitis,AdverseReaction
balanitis,AdverseReaction
genital infections fungal,AdverseReaction
genitourinary tract infection,AdverseReaction
balanitis candida,AdverseReaction
scrotal abscess,AdverseReaction
penile infection,AdverseReaction
Percentages,O
calculated,O
with,O
the,O
number,O
of,O
male,O
subjects,O
in,O
each,O
group,O
as,O
denominator,O
placebo,O
N,O
514,O
JARDIANCE,O
10,O
mg,O
N,O
556,O
JARDIANCE,O
25,O
mg,O
N,O
557,O
Number,O
of,O
Patients,O
PlaceboN,O
995,O
JARDIANCE,O
10,O
mgN,O
999,O
JARDIANCE,O
25,O
mgN,O
977,O
Urinary tract infection,AdverseReaction
a,O
7,O
6,O
9,O
3,O
7,O
6,O
Female genital mycotic infections,AdverseReaction
b,O
1,O
5,O
5,O
4,O
6,O
4,O
Upper respiratory tract infection,AdverseReaction
3,O
8,O
3,O
1,O
4,O
0,O
Increased urination,AdverseReaction
c,O
1,O
0,O
3,O
4,O
3,O
2,O
Dyslipidemia,AdverseReaction
3,O
4,O
3,O
9,O
2,O
9,O
Arthralgia,AdverseReaction
2,O
2,O
2,O
4,O
2,O
3,O
Male genital mycotic infections,AdverseReaction
d,O
0,O
4,O
3,O
1,O
1,O
6,O
Nausea,AdverseReaction
1,O
4,O
2,O
3,O
1,O
1,O
Thirst,AdverseReaction
including,O
polydipsia,AdverseReaction
was,O
reported,O
in,O
0,O
1,O
7,O
and,O
1,O
5,O
for,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
respectively,O
Volume,O
Depletion,O
JARDIANCE,O
causes,O
an,O
osmotic diuresis,AdverseReaction
which,O
may,Factor
lead,O
to,O
intravascular volume contraction,AdverseReaction
and,O
adverse,O
reactions,O
related,O
to,O
volume depletion,AdverseReaction
In,O
the,O
pool,O
of,O
five,O
placebo,O
controlled,O
clinical,O
trials,O
adverse,O
reactions,O
related,O
to,O
volume depletion,AdverseReaction
e,O
g,O
blood pressure,AdverseReaction
ambulatory,O
decreased,AdverseReaction
blood pressure systolic decreased,AdverseReaction
dehydration,AdverseReaction
hypotension,AdverseReaction
hypovolemia,AdverseReaction
orthostatic hypotension,AdverseReaction
and,O
syncope,AdverseReaction
were,O
reported,O
by,O
0,O
3,O
0,O
5,O
and,O
0,O
3,O
of,O
patients,O
treated,O
with,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
respectively,O
JARDIANCE,O
may,O
increase,O
the,O
risk,Factor
of,O
hypotension,AdverseReaction
in,O
patients,O
at,O
risk,O
for,O
volume,O
contraction,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
8,O
6,O
Increased Urination,AdverseReaction
In,O
the,O
pool,O
of,O
five,O
placebo,O
controlled,O
clinical,O
trials,O
adverse,O
reactions,O
of,O
increased urination,AdverseReaction
e,O
g,O
polyuria,AdverseReaction
pollakiuria,AdverseReaction
and,O
nocturia,AdverseReaction
occurred,O
more,O
frequently,O
on,O
JARDIANCE,O
than,O
on,O
placebo,O
see,O
Table,O
1,O
Specifically,O
nocturia,AdverseReaction
was,O
reported,O
by,O
0,O
4,O
0,O
3,O
and,O
0,O
8,O
of,O
patients,O
treated,O
with,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
respectively,O
Impairment in Renal Function,AdverseReaction
Use,O
of,O
JARDIANCE,O
was,O
associated,O
with,O
increases in serum creatinine,AdverseReaction
and,O
decreases in eGFR,AdverseReaction
see,O
Table,O
2,O
Patients,O
with,O
moderate,O
renal,O
impairment,O
at,O
baseline,O
had,O
larger,O
mean,O
changes,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
8,O
6,O
Table,O
2,O
Changes,O
from,O
Baseline,O
in,O
Serum,O
Creatinine,O
and,O
eGFR,O
in,O
the,O
Pool,O
of,O
Four,O
24,O
week,O
Placebo,O
Controlled,O
Studies,O
and,O
Renal,O
Impairment,O
Study,O
a,O
Subset,O
of,O
patients,O
from,O
renal,O
impairment,O
study,O
with,O
eGFR 30 to less than 60 mL min 1 73 m 2,AdverseReaction
Pool,O
of,O
24,O
Week,O
Placebo,O
Controlled,O
Studies,O
Placebo,O
JARDIANCE,O
10,O
mg,O
JARDIANCE,O
25,O
mg,O
Baseline,O
Mean,O
N,O
825,O
830,O
822,O
Creatinine,O
mg,O
dL,O
0,O
84,O
0,O
85,O
0,O
85,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
87,O
3,O
87,O
1,O
87,O
8,O
Week,O
12,O
Change,O
N,O
771,O
797,O
783,O
Creatinine,O
mg,O
dL,O
0,O
00,O
0,O
02,O
0,O
01,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
0,O
3,O
1,O
3,O
1,O
4,O
Week,O
24,O
Change,O
N,O
708,O
769,O
754,O
Creatinine,O
mg,O
dL,O
0,O
00,O
0,O
01,O
0,O
01,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
0,O
3,O
0,O
6,O
1,O
4,O
Moderate,O
Renal,O
Impairment,O
a,O
Placebo,O
JARDIANCE,O
25,O
mg,O
Baseline,O
N,O
187,O
187,O
Creatinine,O
mg,O
dL,O
1,O
49,O
1,O
46,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
44,O
3,O
45,O
4,O
Week,O
12,O
Change,O
N,O
176,O
179,O
Creatinine,O
mg,O
dL,O
0,O
01,O
0,O
12,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
0,O
1,O
3,O
8,O
Week,O
24,O
Change,O
N,O
170,O
171,O
Creatinine,O
mg,O
dL,O
0,O
01,O
0,O
10,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
0,O
2,O
3,O
2,O
Week,O
52,O
Change,O
N,O
164,O
162,O
Creatinine,O
mg,O
dL,O
0,O
02,O
0,O
11,O
eGFR,O
mL,O
min,O
1,O
73,O
m,O
2,O
0,O
3,O
2,O
8,O
Hypoglycemia,AdverseReaction
The,O
incidence,O
of,O
hypoglycemia,AdverseReaction
by,O
study,O
is,O
shown,O
in,O
Table,O
3,O
The,O
incidence,O
of,O
hypoglycemia,AdverseReaction
increased,O
when,O
JARDIANCE,O
was,O
administered,O
with,O
insulin,O
or,O
sulfonylurea,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Table,O
3,O
Incidence,O
of,O
Overalla,O
and,O
Severeb,O
Hypoglycemic Events Events,AdverseReaction
in,O
Placebo,O
Controlled,O
Clinical,O
Studies,O
a,O
Overall,O
hypoglycemic events,AdverseReaction
plasma,AdverseReaction
or,O
capillary glucose of less than or equal to 70 mg dL of less than or equal to 70 mg dL,AdverseReaction
b,O
Severe,Severity
hypoglycemic events,AdverseReaction
requiring,O
assistance,O
regardless,O
of,O
blood,O
glucose,O
c,O
Insulin,O
dose,O
could,O
not,O
be,O
adjusted,O
during,O
the,O
initial,O
18,O
week,O
treatment,O
period,O
Monotherapy,O
24,O
weeks,O
Placebo,O
n,O
229,O
JARDIANCE,O
10,O
mg,O
n,O
224,O
JARDIANCE,O
25,O
mg,O
n,O
223,O
Overall,O
0,O
4,O
0,O
4,O
0,O
4,O
Severe,O
0,O
0,O
0,O
In,O
Combination,O
withMetformin,O
24,O
weeks,O
Placebo,O
Metformin,O
n,O
206,O
JARDIANCE,O
10,O
mg,O
Metformin,O
n,O
217,O
JARDIANCE,O
25,O
mg,O
Metformin,O
n,O
214,O
Overall,O
0,O
5,O
1,O
8,O
1,O
4,O
Severe,O
0,O
0,O
0,O
In,O
Combination,O
withMetformin,O
Sulfonylurea,O
24,O
weeks,O
Placebo,O
n,O
225,O
JARDIANCE,O
10,O
mg,O
Metformin,O
Sulfonylurea,O
n,O
224,O
JARDIANCE,O
25,O
mg,O
Metformin,O
Sulfonylurea,O
n,O
217,O
Overall,O
8,O
4,O
16,O
1,O
11,O
5,O
Severe,O
0,O
0,O
0,O
In,O
Combination,O
withPioglitazone,O
Metformin,O
24,O
weeks,O
Placebo,O
n,O
165,O
JARDIANCE,O
10,O
mg,O
Pioglitazone,O
Metformin,O
n,O
165,O
JARDIANCE,O
25,O
mg,O
Pioglitazone,O
Metformin,O
n,O
168,O
Overall,O
1,O
8,O
1,O
2,O
2,O
4,O
Severe,O
0,O
0,O
0,O
In,O
Combination,O
with,O
Basal,O
Insulin,O
18,O
weeks,O
c,O
Placebo,O
n,O
170,O
JARDIANCE,O
10,O
mg,O
n,O
169,O
JARDIANCE,O
25,O
mg,O
n,O
155,O
Overall,O
20,O
6,O
19,O
5,O
28,O
4,O
Severe,O
0,O
0,O
1,O
3,O
In,O
Combination,O
with,O
MDI,O
Insulin,O
Metformin,O
18,O
weeks,O
c,O
Placebo,O
n,O
188,O
JARDIANCE,O
10,O
mg,O
n,O
186,O
JARDIANCE,O
25,O
mg,O
n,O
189,O
Overall,O
37,O
2,O
39,O
8,O
41,O
3,O
Severe,O
0,O
5,O
0,O
5,O
0,O
5,O
Genital Mycotic Infections,AdverseReaction
In,O
the,O
pool,O
of,O
five,O
placebo,O
controlled,O
clinical,O
trials,O
the,O
incidence,O
of,O
genital mycotic infections,AdverseReaction
e,O
g,O
vaginal mycotic infection,AdverseReaction
vaginal infection,AdverseReaction
genital infection fungal,AdverseReaction
vulvovaginal candidiasis,AdverseReaction
and,O
vulvitis,AdverseReaction
was,O
increased,O
in,O
patients,O
treated,O
with,O
JARDIANCE,O
compared,O
to,O
placebo,O
occurring,O
in,O
0,O
9,O
4,O
1,O
and,O
3,O
7,O
of,O
patients,O
randomized,O
to,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
respectively,O
Discontinuation,O
from,O
study,O
due,O
to,O
genital infection,AdverseReaction
occurred,O
in,O
0,O
of,O
placebo,O
treated,O
patients,O
and,O
0,O
2,O
of,O
patients,O
treated,O
with,O
either,O
JARDIANCE,O
10,O
or,O
25,O
mg,O
Genital mycotic infections,AdverseReaction
occurred,O
more,O
frequently,O
in,O
female,O
than,O
male,O
patients,O
see,O
Table,O
1,O
Phimosis,AdverseReaction
occurred,O
more,O
frequently,O
in,O
male,O
patients,O
treated,O
with,O
JARDIANCE,O
10,O
mg,O
less,O
than,O
0,O
1,O
and,O
JARDIANCE,O
25,O
mg,O
0,O
1,O
than,O
placebo,O
0,O
Urinary Tract Infections,AdverseReaction
In,O
the,O
pool,O
of,O
five,O
placebo,O
controlled,O
clinical,O
trials,O
the,O
incidence,O
of,O
urinary tract infections,AdverseReaction
e,O
g,O
urinary tract infection,AdverseReaction
asymptomatic bacteriuria,AdverseReaction
and,O
cystitis,AdverseReaction
was,O
increased,O
in,O
patients,O
treated,O
with,O
JARDIANCE,O
compared,O
to,O
placebo,O
see,O
Table,O
1,O
Patients,O
with,O
a,O
history,O
of,O
chronic,O
or,O
recurrent,O
urinary,O
tract,O
infections,O
were,O
more,O
likely,O
to,O
experience,O
a,O
urinary tract infection,AdverseReaction
The,O
rate,O
of,O
treatment,O
discontinuation,O
due,O
to,O
urinary tract infections,AdverseReaction
was,O
0,O
1,O
0,O
2,O
and,O
0,O
1,O
for,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
respectively,O
Urinary tract infections,AdverseReaction
occurred,O
more,O
frequently,O
in,O
female,O
patients,O
The,O
incidence,O
of,O
urinary tract infections,AdverseReaction
in,O
female,O
patients,O
randomized,O
to,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
was,O
16,O
6,O
18,O
4,O
and,O
17,O
0,O
respectively,O
The,O
incidence,O
of,O
urinary tract infections,AdverseReaction
in,O
male,O
patients,O
randomized,O
to,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
was,O
3,O
2,O
3,O
6,O
and,O
4,O
1,O
respectively,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
Laboratory,O
Tests,O
Increase in Low Density Lipoprotein Cholesterol,AdverseReaction
LDL,O
C,O
Dose,O
related,O
increases in low density lipoprotein cholesterol,AdverseReaction
LDL,O
C,O
were,O
observed,O
in,O
patients,O
treated,O
with,O
JARDIANCE,O
LDL C increased,AdverseReaction
by,O
2,O
3,O
4,O
6,O
and,O
6,O
5,O
in,O
patients,O
treated,O
with,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
respectively,O
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
The,O
range,O
of,O
mean,O
baseline,O
LDL,O
C,O
levels,O
was,O
90,O
3,O
to,O
90,O
6,O
mg,O
dL,O
across,O
treatment,O
groups,O
Increase in Hematocrit,AdverseReaction
In,O
a,O
pool,O
of,O
four,O
placebo,O
controlled,O
studies,O
median,O
hematocrit decreased,AdverseReaction
by,O
1,O
3,O
in,O
placebo,Factor
and,O
increased,AdverseReaction
by,O
2,O
8,O
in,O
JARDIANCE,O
10,O
mg,O
and,O
2,O
8,O
in,O
JARDIANCE,O
25,O
mg,O
treated,O
patients,O
At,O
the,O
end,O
of,O
treatment,O
0,O
6,O
2,O
7,O
and,O
3,O
5,O
of,O
patients,O
with,O
hematocrits,O
initially,O
within,O
the,O
reference,O
range,O
had,O
values,O
above,O
the,O
upper,O
limit,O
of,O
the,O
reference,O
range,O
with,O
placebo,O
JARDIANCE,O
10,O
mg,O
and,O
JARDIANCE,O
25,O
mg,O
respectively,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Bone marrow suppression,AdverseReaction
particularly,O
neutropenia,AdverseReaction
and,O
its,O
clinical,O
consequences,O
febrile neutropenia,AdverseReaction
neutropenic infections,AdverseReaction
Monitor,O
blood,O
counts,O
frequently,O
to,O
determine,O
if,O
dosage,O
modification,O
or,O
initiation,O
of,O
G,O
CSF,O
is,O
needed,O
Primary,O
prophylaxis,O
with,O
G,O
CSF,O
should,O
be,O
considered,O
in,O
patients,O
with,O
high,O
risk,O
clinical,O
features,O
Use,O
caution,O
in,O
patients,O
with,O
hemoglobin,O
10,O
g,O
dL,O
2,O
2,O
4,O
5,O
1,O
Hypersensitivity,AdverseReaction
Severe,Severity
hypersensitivity reactions,AdverseReaction
can,Factor
occur,O
Premedicate,O
with,O
corticosteroids,O
and,O
H2,O
antagonists,O
Discontinue,O
infusion,O
immediately,O
if,O
hypersensitivity,O
is,O
observed,O
and,O
treat,O
as,O
indicated,O
4,O
5,O
2,O
Gastrointestinal disorders,AdverseReaction
Nausea,AdverseReaction
vomiting,AdverseReaction
and,O
diarrhea,AdverseReaction
may,Factor
occur,O
Mortality,AdverseReaction
related,O
to,O
diarrhea,AdverseReaction
has,O
been,O
reported,O
Rehydrate,O
and,O
treat,O
with,O
anti,O
emetics,O
and,O
anti,O
diarrheals,O
as,O
needed,O
If,O
experiencing,O
Grade,O
3,O
diarrhea,O
dosage,O
should,O
be,O
modified,O
2,O
2,O
Deaths,AdverseReaction
have,O
occurred,O
due,O
to,O
gastrointestinal hemorrhage,AdverseReaction
perforation,AdverseReaction
and,O
neutropenic enterocolitis,AdverseReaction
Delay,O
or,O
discontinue,O
JEVTANA,O
5,O
3,O
Renal failure,AdverseReaction
including,O
cases,O
with,O
fatal,AdverseReaction
outcomes,O
has,O
been,O
reported,O
Identify,O
cause,O
and,O
manage,O
aggressively,O
5,O
4,O
Elderly,O
patients,O
Patients,O
65,O
years,O
of,O
age,O
were,O
more,O
likely,O
to,O
experience,O
fatal,AdverseReaction
outcomes,O
not,O
related,O
to,O
disease,O
progression,O
and,O
certain,O
adverse,O
reactions,O
including,O
neutropenia,AdverseReaction
and,O
febrile neutropenia,AdverseReaction
Monitor,O
closely,O
5,O
5,O
6,O
8,O
5,O
Hepatic impairment,AdverseReaction
Reduce,O
the,O
JEVTANA,O
dose,O
to,O
20,O
mg,O
m,O
2,O
in,O
patients,O
with,O
mild,O
hepatic,O
impairment,O
and,O
to,O
15,O
mg,O
m,O
2,O
in,O
patients,O
with,O
moderate,O
hepatic,O
impairment,O
2,O
3,O
JEVTANA,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
5,O
7,O
8,O
1,O
5,O
1,O
Bone,O
Marrow,O
Suppression,O
Bone marrow suppression,AdverseReaction
manifested,O
as,O
neutropenia,AdverseReaction
anemia,AdverseReaction
thrombocytopenia,AdverseReaction
and,O
or,O
pancytopenia,AdverseReaction
may,Factor
occur,O
Neutropenic,AdverseReaction
deaths,AdverseReaction
have,O
been,O
reported,O
In,O
the,O
randomized,O
trial,O
five,O
patients,O
1,O
3,O
experienced,O
fatal,AdverseReaction
infectious adverse events,AdverseReaction
sepsis,AdverseReaction
or,O
septic shock,AdverseReaction
All,O
had,O
grade 4,Severity
neutropenia,AdverseReaction
and,O
one,O
had,O
febrile neutropenia,AdverseReaction
One,O
additional,O
patient,O
s,O
death,AdverseReaction
was,O
attributed,O
to,O
neutropenia,AdverseReaction
without,Negation
a,O
documented,O
infection,AdverseReaction
Grade 3 3 4,Severity
4,Severity
neutropenia,AdverseReaction
has,O
been,O
observed,O
in,O
82,O
of,O
patients,O
treated,O
with,O
JEVTANA,O
in,O
the,O
randomized,O
trial,O
G,O
CSF,O
may,O
be,O
administered,O
to,O
reduce,O
the,O
risks,O
of,O
neutropenia,O
complications,O
associated,O
with,O
JEVTANA,O
use,O
Primary,O
prophylaxis,O
with,O
G,O
CSF,O
should,O
be,O
considered,O
in,O
patients,O
with,O
high,O
risk,O
clinical,O
features,O
age,O
65,O
years,O
poor,O
performance,O
status,O
previous,O
episodes,O
of,O
febrile,O
neutropenia,O
extensive,O
prior,O
radiation,O
ports,O
poor,O
nutritional,O
status,O
or,O
other,O
serious,O
comorbidities,O
that,O
predispose,O
them,O
to,O
increased,O
complications,O
from,O
prolonged,O
neutropenia,O
Therapeutic,O
use,O
of,O
G,O
CSF,O
and,O
secondary,O
prophylaxis,O
should,O
be,O
considered,O
in,O
all,O
patients,O
considered,O
to,O
be,O
at,O
increased,O
risk,O
for,O
neutropenia,O
complications,O
Monitoring,O
of,O
complete,O
blood,O
counts,O
is,O
essential,O
on,O
a,O
weekly,O
basis,O
during,O
cycle,O
1,O
and,O
before,O
each,O
treatment,O
cycle,O
thereafter,O
so,O
that,O
the,O
dose,O
can,O
be,O
adjusted,O
if,O
needed,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
JEVTANA,O
is,O
contraindicated,O
in,O
patients,O
with,O
neutrophils,O
1,O
500,O
mm,O
3,O
see,O
Contraindications,O
4,O
Caution,O
is,O
recommended,O
in,O
patients,O
with,O
hemoglobin,O
10,O
g,O
dl,O
5,O
2,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
may,Factor
occur,O
within,O
a,O
few,O
minutes,O
following,O
the,O
initiation,O
of,O
the,O
infusion,O
of,O
JEVTANA,O
thus,O
facilities,O
and,O
equipment,O
for,O
the,O
treatment,O
of,O
hypotension,O
and,O
bronchospasm,O
should,O
be,O
available,O
Severe,Severity
hypersensitivity reactions,AdverseReaction
can,Factor
occur,O
and,O
may,Factor
include,O
generalized rash,AdverseReaction
erythema,AdverseReaction
hypotension,AdverseReaction
and,O
bronchospasm,AdverseReaction
Premedicate,O
all,O
patients,O
prior,O
to,O
the,O
initiation,O
of,O
the,O
infusion,O
of,O
JEVTANA,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
Observe,O
patients,O
closely,O
for,O
hypersensitivity,O
reactions,O
especially,O
during,O
the,O
first,O
and,O
second,O
infusions,O
Severe,Severity
hypersensitivity reactions,AdverseReaction
require,O
immediate,O
discontinuation,O
of,O
the,O
JEVTANA,O
infusion,O
and,O
appropriate,O
therapy,O
JEVTANA,O
is,O
contraindicated,O
in,O
patients,O
with,O
a,O
history,O
of,O
severe,O
hypersensitivity,O
reactions,O
to,O
cabazitaxel,O
or,O
to,O
other,O
drugs,O
formulated,O
with,O
polysorbate,O
80,O
see,O
Contraindications,O
4,O
5,O
3,O
Gastrointestinal,O
Adverse,O
Reactions,O
Nausea,AdverseReaction
vomiting,AdverseReaction
and,O
severe,Severity
diarrhea,AdverseReaction
at,O
times,O
may,Factor
occur,O
Death,AdverseReaction
related,O
to,O
diarrhea,AdverseReaction
and,O
electrolyte imbalance,AdverseReaction
occurred,O
in,O
the,O
randomized,O
clinical,O
trial,O
Intensive,O
measures,O
may,O
be,O
required,O
for,O
severe,O
diarrhea,O
and,O
electrolyte,O
imbalance,O
Antiemetic,O
prophylaxis,O
is,O
recommended,O
Treat,O
patients,O
with,O
rehydration,O
anti,O
diarrheal,O
or,O
anti,O
emetic,O
medications,O
as,O
needed,O
Treatment,O
delay,O
or,O
dosage,O
reduction,O
may,O
be,O
necessary,O
if,O
patients,O
experience,O
Grade,O
3,O
diarrhea,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Gastrointestinal,AdverseReaction
GI,O
hemorrhage,AdverseReaction
and,O
perforation,AdverseReaction
ileus,AdverseReaction
enterocolitis,AdverseReaction
neutropenic enterocolitis,AdverseReaction
including,O
fatal,AdverseReaction
outcome,O
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
JEVTANA,O
see,O
Adverse,O
Reactions,O
6,O
2,O
Risk,O
may,O
be,O
increased,O
with,O
neutropenia,O
age,O
steroid,O
use,O
concomitant,O
use,O
of,O
NSAIDs,O
anti,O
platelet,O
therapy,O
or,O
anti,O
coagulants,O
and,O
patients,O
with,O
a,O
prior,O
history,O
of,O
pelvic,O
radiotherapy,O
adhesions,O
ulceration,O
and,O
GI,O
bleeding,O
Abdominal,O
pain,O
and,O
tenderness,O
fever,O
persistent,O
constipation,O
diarrhea,O
with,O
or,O
without,O
neutropenia,O
may,O
be,O
early,O
manifestations,O
of,O
serious,O
gastrointestinal,O
toxicity,O
and,O
should,O
be,O
evaluated,O
and,O
treated,O
promptly,O
JEVTANA,O
treatment,O
delay,O
or,O
discontinuation,O
may,O
be,O
necessary,O
5,O
4,O
Renal,O
Failure,O
In,O
the,O
randomized,O
clinical,O
trial,O
renal failure,AdverseReaction
of,O
any,O
grade,O
occurred,O
in,O
4,O
of,O
the,O
patients,O
being,O
treated,O
with,O
JEVTANA,O
including,O
four,O
cases,O
with,O
fatal,AdverseReaction
outcome,O
Most,O
cases,O
occurred,O
in,O
association,O
with,O
sepsis,AdverseReaction
dehydration,AdverseReaction
or,O
obstructive uropathy,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
Some,O
deaths,AdverseReaction
due,O
to,O
renal failure,AdverseReaction
did,O
not,O
have,O
a,O
clear,O
etiology,O
Appropriate,O
measures,O
should,O
be,O
taken,O
to,O
identify,O
causes,O
of,O
renal,O
failure,O
and,O
treat,O
aggressively,O
5,O
5,O
Use,O
in,O
Elderly,O
Patients,O
In,O
the,O
randomized,O
clinical,O
trial,O
3,O
of,O
131,O
2,O
patients,O
65,O
years,O
of,O
age,O
and,O
15,O
of,O
240,O
6,O
65,O
years,O
of,O
age,O
died,AdverseReaction
of,O
causes,O
other,O
than,O
disease,O
progression,O
within,O
30,O
days,O
of,O
the,O
last,O
cabazitaxel,O
dose,O
Patients,O
65,O
years,O
of,O
age,O
are,O
more,O
likely,O
to,O
experience,O
certain,O
adverse,O
reactions,O
including,O
neutropenia,AdverseReaction
and,O
febrile neutropenia,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
5,O
6,O
Use,O
in,O
Patients,O
with,O
Hepatic,O
Impairment,O
Cabazitaxel,O
is,O
extensively,O
metabolized,O
in,O
the,O
liver,O
JEVTANA,O
is,O
contraindicated,O
in,O
patients,O
with,O
severe,O
hepatic,O
impairment,O
total,O
bilirubin,O
3,O
ULN,O
see,O
Contraindications,O
4,O
Dose,O
should,O
be,O
reduced,O
for,O
patients,O
with,O
mild,O
total,O
bilirubin,O
1,O
to,O
1,O
5,O
ULN,O
or,O
AST,O
1,O
5,O
ULN,O
and,O
moderate,O
total,O
bilirubin,O
1,O
5,O
to,O
3,O
0,O
ULN,O
and,O
any,O
AST,O
hepatic,O
impairment,O
based,O
on,O
tolerability,O
data,O
in,O
these,O
patients,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
7,O
Administration,O
of,O
cabazitaxel,O
to,O
patients,O
with,O
mild,O
and,O
moderate,O
hepatic,O
impairment,O
should,O
be,O
undertaken,O
with,O
caution,O
and,O
close,O
monitoring,O
of,O
safety,O
5,O
7,O
Embryo,O
Fetal,O
Toxicity,O
JEVTANA,O
is,O
not,O
indicated,O
for,O
use,O
in,O
female,O
patients,O
JEVTANA,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
In,O
non,O
clinical,O
studies,O
in,O
rats,Animal
and,O
rabbits,Animal
cabazitaxel,O
was,O
embryotoxic,AdverseReaction
fetotoxic,AdverseReaction
and,O
abortifacient,AdverseReaction
at,O
exposures,O
significantly,O
lower,O
than,O
those,O
expected,O
at,O
the,O
recommended,O
human,O
dose,O
level,O
There,O
are,O
no,O
adequate,O
and,O
well,O
controlled,O
studies,O
in,O
pregnant,O
women,O
using,O
JEVTANA,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
Females,O
of,O
childbearing,O
potential,O
should,O
be,O
advised,O
to,O
avoid,O
becoming,O
pregnant,O
during,O
treatment,O
with,O
JEVTANA,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
BOXED,O
WARNING,O
WARNING,O
NEUTROPENIA,AdverseReaction
AND,O
HYPERSENSITIVITY,AdverseReaction
WARNING,O
NEUTROPENIA,AdverseReaction
AND,O
HYPERSENSITIVITY,AdverseReaction
EXCERPT,O
WARNING,O
NEUTROPENIA,AdverseReaction
AND,O
HYPERSENSITIVITY,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Neutropenic,AdverseReaction
deaths,AdverseReaction
have,O
been,O
reported,O
Obtain,O
frequent,O
blood,O
counts,O
to,O
monitor,O
for,O
neutropenia,O
Do,O
not,O
give,O
JEVTANA,O
if,O
neutrophil,O
counts,O
are,O
1,O
500,O
cells,O
mm3,O
2,O
2,O
4,O
Severe,Severity
hypersensitivity,AdverseReaction
can,Factor
occur,O
and,O
may,Factor
include,O
generalized rash,AdverseReaction
erythema,AdverseReaction
hypotension,AdverseReaction
and,O
bronchospasm,AdverseReaction
Discontinue,O
JEVTANA,O
immediately,O
if,O
severe,O
reactions,O
occur,O
and,O
administer,O
appropriate,O
therapy,O
2,O
1,O
5,O
2,O
Contraindicated,O
if,O
history,O
of,O
severe,O
hypersensitivity,O
reactions,O
to,O
JEVTANA,O
or,O
to,O
drugs,O
formulated,O
with,O
polysorbate,O
80,O
4,O
Neutropenia,O
Neutropenic,AdverseReaction
deaths,AdverseReaction
have,O
been,O
reported,O
In,O
order,O
to,O
monitor,O
the,O
occurrence,O
of,O
neutropenia,O
frequent,O
blood,O
cell,O
counts,O
should,O
be,O
performed,O
on,O
all,O
patients,O
receiving,O
JEVTANA,O
JEVTANA,O
is,O
contraindicated,O
in,O
patients,O
with,O
neutrophil,O
counts,O
of,O
1,O
500,O
cells,O
mm,O
3,O
see,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Severe,O
hypersensitivity,O
Severe,Severity
hypersensitivity reactions,AdverseReaction
can,Factor
occur,O
and,O
may,Factor
include,O
generalized rash,AdverseReaction
erythema,AdverseReaction
hypotension,AdverseReaction
and,O
bronchospasm,AdverseReaction
Severe,Severity
hypersensitivity reactions,AdverseReaction
require,O
immediate,O
discontinuation,O
of,O
the,O
JEVTANA,O
infusion,O
and,O
administration,O
of,O
appropriate,O
therapy,O
Patients,O
should,O
receive,O
premedication,O
JEVTANA,O
is,O
contraindicated,O
in,O
patients,O
who,O
have,O
a,O
history,O
of,O
severe,O
hypersensitivity,O
reactions,O
to,O
cabazitaxel,O
or,O
to,O
other,O
drugs,O
formulated,O
with,O
polysorbate,O
80,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
another,O
section,O
of,O
the,O
label,O
Bone Marrow Suppression,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hypersensitivity Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Gastrointestinal Adverse Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Renal Failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Use,O
in,O
Elderly,O
Patients,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Use,O
in,O
Patients,O
with,O
Hepatic,O
Impairment,O
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Embryo Fetal Toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
EXCERPT,O
Most,O
common,O
all,O
grades,O
adverse,O
reactions,O
10,O
are,O
neutropenia,AdverseReaction
anemia,AdverseReaction
leukopenia,AdverseReaction
thrombocytopenia,AdverseReaction
diarrhea,AdverseReaction
fatigue,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
constipation,AdverseReaction
asthenia,AdverseReaction
abdominal pain,AdverseReaction
hematuria,AdverseReaction
back pain,AdverseReaction
anorexia,AdverseReaction
peripheral neuropathy,AdverseReaction
pyrexia,AdverseReaction
dyspnea,AdverseReaction
dysgeusia,AdverseReaction
cough,AdverseReaction
arthralgia,AdverseReaction
and,O
alopecia,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
sanofi,O
aventis,O
U,O
S,O
LLC,O
at,O
1,O
800,O
633,O
1610,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
the,O
adverse,O
reaction,O
rates,O
observed,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
other,O
trials,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
safety,O
of,O
JEVTANA,O
in,O
combination,O
with,O
prednisone,O
was,O
evaluated,O
in,O
371,O
patients,O
with,O
hormone,O
refractory,O
metastatic,O
prostate,O
cancer,O
treated,O
in,O
a,O
single,O
randomized,O
trial,O
compared,O
to,O
mitoxantrone,O
plus,O
prednisone,O
Deaths,AdverseReaction
due,O
to,O
causes,O
other,O
than,O
disease,O
progression,O
within,O
30,O
days,O
of,O
last,O
study,O
drug,O
dose,O
were,O
reported,O
in,O
18,O
5,O
JEVTANA,O
treated,O
patients,O
and,O
3,O
1,O
mitoxantrone,O
treated,O
patients,O
The,O
most,O
common,O
fatal,AdverseReaction
adverse,O
reactions,O
in,O
JEVTANA,O
treated,O
patients,O
were,O
infections,AdverseReaction
n,O
5,O
and,O
renal failure,AdverseReaction
n,O
4,O
The,O
majority,O
4,O
of,O
5,O
patients,O
of,O
fatal,AdverseReaction
infection related adverse reactions,AdverseReaction
occurred,O
after,O
a,O
single,O
dose,O
of,O
JEVTANA,O
Other,O
fatal,AdverseReaction
adverse,O
reactions,O
in,O
JEVTANA,O
treated,O
patients,O
included,O
ventricular fibrillation,AdverseReaction
cerebral hemorrhage,AdverseReaction
and,O
dyspnea,AdverseReaction
The,O
most,O
common,O
10,O
grade 1 1 4,Severity
4,Severity
adverse,O
reactions,O
were,O
anemia,AdverseReaction
leukopenia,AdverseReaction
neutropenia,AdverseReaction
thrombocytopenia,AdverseReaction
diarrhea,AdverseReaction
fatigue,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
constipation,AdverseReaction
asthenia,AdverseReaction
abdominal pain,AdverseReaction
hematuria,AdverseReaction
back pain,AdverseReaction
anorexia,AdverseReaction
peripheral neuropathy,AdverseReaction
pyrexia,AdverseReaction
dyspnea,AdverseReaction
dysguesia,AdverseReaction
cough,AdverseReaction
arthralgia,AdverseReaction
and,O
alopecia,AdverseReaction
The,O
most,O
common,O
5,O
grade 3 3 4,Severity
4,Severity
adverse,O
reactions,O
in,O
patients,O
who,O
received,O
JEVTANA,O
were,O
neutropenia,AdverseReaction
leukopenia,AdverseReaction
anemia,AdverseReaction
febrile neutropenia,AdverseReaction
diarrhea,AdverseReaction
fatigue,AdverseReaction
and,O
asthenia,AdverseReaction
Treatment,O
discontinuations,O
due,O
to,O
adverse,O
drug,O
reactions,O
occurred,O
in,O
18,O
of,O
patients,O
who,O
received,O
JEVTANA,O
and,O
8,O
of,O
patients,O
who,O
received,O
mitoxantrone,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
treatment,O
discontinuation,O
in,O
the,O
JEVTANA,O
group,O
were,O
neutropenia,AdverseReaction
and,O
renal failure,AdverseReaction
Dose,O
reductions,O
were,O
reported,O
in,O
12,O
of,O
JEVTANA,O
treated,O
patients,O
and,O
4,O
of,O
mitoxantrone,O
treated,O
patients,O
Dose,O
delays,O
were,O
reported,O
in,O
28,O
of,O
JEVTANA,O
treated,O
patients,O
and,O
15,O
of,O
mitoxantrone,O
treated,O
patients,O
Table,O
2,O
Incidence,O
of,O
Reported,O
Adverse,O
ReactionsGraded,O
using,O
NCI,O
CTCAE,O
version,O
3,O
and,O
Hematologic Abnormalities,AdverseReaction
in,O
5,O
of,O
Patients,O
Receiving,O
JEVTANA,O
in,O
Combination,O
with,O
Prednisone,O
or,O
Mitoxantrone,O
in,O
Combination,O
with,O
Prednisone,O
JEVTANA,O
25,O
mg,O
m,O
2,O
every,O
3,O
weeks,O
with,O
prednisone,O
10,O
mg,O
dailyn,O
371,O
Mitoxantrone,O
12,O
mg,O
m,O
2,O
every,O
3,O
weeks,O
with,O
prednisone,O
10,O
mg,O
dailyn,O
371,O
Grade,O
1,O
4n,O
Grade,O
3,O
4n,O
Grade,O
1,O
4n,O
Grade,O
3,O
4n,O
Any,O
Adverse,O
Reaction,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
Neutropenia,AdverseReaction
347,O
94,O
303,O
82,O
325,O
87,O
215,O
58,O
Febrile Neutropenia,AdverseReaction
27,O
7,O
27,O
7,O
5,O
1,O
5,O
1,O
Anemia,AdverseReaction
361,O
98,O
39,O
11,O
302,O
82,O
18,O
5,O
Leukopenia,AdverseReaction
355,O
96,O
253,O
69,O
343,O
93,O
157,O
42,O
Thrombocytopenia,AdverseReaction
176,O
48,O
15,O
4,O
160,O
43,O
6,O
2,O
Cardiac,O
Disorders,O
Arrhythmia,AdverseReaction
18,O
5,O
4,O
1,O
6,O
2,O
1,O
1,O
Gastrointestinal,O
Disorders,O
Diarrhea,AdverseReaction
173,O
47,O
23,O
6,O
39,O
11,O
1,O
1,O
Nausea,AdverseReaction
127,O
34,O
7,O
2,O
85,O
23,O
1,O
1,O
Vomiting,AdverseReaction
83,O
22,O
6,O
2,O
38,O
10,O
0,O
Constipation,AdverseReaction
76,O
20,O
4,O
1,O
57,O
15,O
2,O
1,O
Abdominal Pain,AdverseReaction
64,O
17,O
7,O
2,O
23,O
6,O
0,O
Dyspepsia,AdverseReaction
36,O
10,O
0,O
9,O
2,O
0,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Fatigue,AdverseReaction
136,O
37,O
18,O
5,O
102,O
27,O
11,O
3,O
Asthenia,AdverseReaction
76,O
20,O
17,O
5,O
46,O
12,O
9,O
2,O
Pyrexia,AdverseReaction
45,O
12,O
4,O
1,O
23,O
6,O
1,O
1,O
Peripheral Edema,AdverseReaction
34,O
9,O
2,O
1,O
34,O
9,O
2,O
1,O
Mucosal Inflammation,AdverseReaction
22,O
6,O
1,O
1,O
10,O
3,O
1,O
1,O
Pain,AdverseReaction
20,O
5,O
4,O
1,O
18,O
5,O
7,O
2,O
Infections,O
and,O
Infestations,O
Urinary Tract Infection,AdverseReaction
29,O
8,O
6,O
2,O
12,O
3,O
4,O
1,O
Investigations,O
Weight Decreased,AdverseReaction
32,O
9,O
0,O
28,O
8,O
1,O
1,O
Metabolism,O
and,O
Nutrition,O
Disorders,O
Anorexia,AdverseReaction
59,O
16,O
3,O
1,O
39,O
11,O
3,O
1,O
Dehydration,AdverseReaction
18,O
5,O
8,O
2,O
10,O
3,O
3,O
1,O
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Back Pain,AdverseReaction
60,O
16,O
14,O
4,O
45,O
12,O
11,O
3,O
Arthralgia,AdverseReaction
39,O
11,O
4,O
1,O
31,O
8,O
4,O
1,O
Muscle Spasms,AdverseReaction
27,O
7,O
0,O
10,O
3,O
0,O
Nervous,O
System,O
Disorders,O
Peripheral Neuropathy,AdverseReaction
50,O
13,O
3,O
1,O
12,O
3,O
2,O
3,O
1,O
Dysgeusia,AdverseReaction
41,O
11,O
0,O
15,O
4,O
0,O
Dizziness,AdverseReaction
30,O
8,O
0,O
21,O
6,O
2,O
1,O
Headache,AdverseReaction
28,O
8,O
0,O
19,O
5,O
0,O
Renal,O
and,O
Urinary,O
Tract,O
Disorders,O
Hematuria,AdverseReaction
62,O
17,O
7,O
2,O
13,O
4,O
1,O
1,O
Dysuria,AdverseReaction
25,O
7,O
0,O
5,O
1,O
0,O
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Dyspnea,AdverseReaction
43,O
12,O
4,O
1,O
16,O
4,O
2,O
1,O
Cough,AdverseReaction
40,O
11,O
0,O
22,O
6,O
0,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Alopecia,AdverseReaction
37,O
10,O
0,O
18,O
5,O
0,O
Vascular,O
Disorders,O
Hypotension,AdverseReaction
20,O
5,O
2,O
1,O
9,O
2,O
1,O
1,O
Median,O
Duration,O
of,O
Treatment,O
6,O
cycles,O
4,O
cycles,O
Neutropenia,O
and,O
Associated,O
Clinical,O
Events,O
Five,O
patients,O
experienced,O
fatal,AdverseReaction
infectious adverse events,AdverseReaction
sepsis,AdverseReaction
or,O
septic shock,AdverseReaction
All,O
had,O
grade 4,Severity
neutropenia,AdverseReaction
and,O
one,O
had,O
febrile neutropenia,AdverseReaction
One,O
additional,O
patient,O
s,O
death,AdverseReaction
was,O
attributed,O
to,O
neutropenia,AdverseReaction
without,Negation
a,O
documented,O
infection,AdverseReaction
Twenty,O
two,O
6,O
patients,O
discontinued,O
JEVTANA,O
treatment,O
due,O
to,O
neutropenia,AdverseReaction
febrile neutropenia,AdverseReaction
infection,AdverseReaction
or,O
sepsis,AdverseReaction
The,O
most,O
common,O
adverse,O
reaction,O
leading,O
to,O
treatment,O
discontinuation,O
in,O
the,O
JEVTANA,O
group,O
was,O
neutropenia,AdverseReaction
2,O
Hematuria,O
Adverse,O
events,O
of,O
hematuria,AdverseReaction
including,O
those,O
requiring,O
medical,O
intervention,O
were,O
more,O
common,O
in,O
JEVTANA,O
treated,O
patients,O
The,O
incidence,O
of,O
grade,Severity
2,Severity
hematuria,AdverseReaction
was,O
6,O
in,O
JEVTANA,O
treated,O
patients,O
and,O
2,O
in,O
mitoxantrone,O
treated,O
patients,O
Other,O
factors,O
associated,O
with,O
hematuria,AdverseReaction
were,O
well,O
balanced,O
between,O
arms,O
and,O
do,O
not,O
account,O
for,O
the,O
increased,O
rate,O
of,O
hematuria,AdverseReaction
on,O
the,O
JEVTANA,O
arm,O
Hepatic,O
Laboratory,O
Abnormalities,O
The,O
incidences,O
of,O
grade 3 3 4,Severity
increased AST,AdverseReaction
increased ALT,AdverseReaction
and,O
increased bilirubin,AdverseReaction
were,O
each,O
1,O
Elderly,O
Population,O
The,O
following,O
grade 1 1 4,Severity
adverse,O
reactions,O
were,O
reported,O
at,O
rates,O
5,O
higher,O
in,O
patients,O
65,O
years,O
of,O
age,O
or,O
greater,O
compared,O
to,O
younger,O
patients,O
fatigue,AdverseReaction
40,O
vs,O
30,O
neutropenia,AdverseReaction
97,O
vs,O
89,O
asthenia,AdverseReaction
24,O
vs,O
15,O
pyrexia,AdverseReaction
15,O
vs,O
8,O
dizziness,AdverseReaction
10,O
vs,O
5,O
urinary tract infection,AdverseReaction
10,O
vs,O
3,O
and,O
dehydration,AdverseReaction
7,O
vs,O
2,O
respectively,O
The,O
incidence,O
of,O
the,O
following,O
grade 3 3 4,Severity
adverse,O
reactions,O
were,O
higher,O
in,O
patients,O
65,O
years,O
of,O
age,O
compared,O
to,O
younger,O
patients,O
neutropenia,AdverseReaction
87,O
vs,O
74,O
and,O
febrile neutropenia,AdverseReaction
8,O
vs,O
6,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
from,O
clinical,O
trials,O
and,O
or,O
post,O
marketing,O
surveillance,O
Because,O
they,O
are,O
reported,O
from,O
a,O
population,O
of,O
unknown,O
size,O
precise,O
estimates,O
of,O
frequency,O
cannot,O
be,O
made,O
Gastrointestinal,O
Gastritis,AdverseReaction
intestinal obstruction,AdverseReaction
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
1,O
were,O
ingrown toenails,AdverseReaction
application site dermatitis,AdverseReaction
application site vesicles,AdverseReaction
and,O
application site pain,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Valeant,O
Pharmaceuticals,O
North,O
America,O
LLC,O
at,O
1,O
800,O
321,O
4576,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
In,O
two,O
clinical,O
trials,O
1227,O
subjects,O
were,O
treated,O
with,O
JUBLIA,O
1161,O
for,O
at,O
least,O
24,O
weeks,O
and,O
780,O
for,O
48,O
weeks,O
Adverse,O
reactions,O
reported,O
within,O
48,O
weeks,O
of,O
treatment,O
and,O
in,O
at,O
least,O
1,O
of,O
subjects,O
treated,O
with,O
JUBLIA,O
and,O
those,O
reported,O
in,O
subjects,O
treated,O
with,O
the,O
vehicle,O
are,O
presented,O
in,O
Table,O
1,O
Table,O
1,O
Adverse,O
Reactions,O
Reported,O
by,O
at,O
Least,O
1,O
of,O
Subjects,O
Treated,O
for,O
up,O
to,O
48,O
Weeks,O
Adverse,O
Event,O
n,O
JUBLIAN,O
1227,O
VehicleN,O
413,O
Ingrown toenail,AdverseReaction
28,O
2,O
3,O
3,O
0,O
7,O
Application site dermatitis,AdverseReaction
27,O
2,O
2,O
1,O
0,O
2,O
Application site vesicles,AdverseReaction
20,O
1,O
6,O
0,O
0,O
0,O
Application site pain,AdverseReaction
13,O
1,O
1,O
1,O
0,O
2,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypersensitivity Reactions,AdverseReaction
Including,O
Anaphylaxis,AdverseReaction
Anaphylaxis,AdverseReaction
has,O
occurred,O
in,O
4,O
of,O
treated,O
patients,O
Administer,O
KALBITOR,O
in,O
a,O
setting,O
equipped,O
to,O
manage,O
anaphylaxis,O
and,O
hereditary,O
angioedema,O
Given,O
the,O
similarity,O
in,O
hypersensitivity,O
symptoms,O
and,O
acute,O
HAE,O
symptoms,O
monitor,O
patients,O
closely,O
for,O
hypersensitivity,O
reactions,O
5,O
5,O
1,O
Hypersensitivity,O
Reactions,O
Including,O
Anaphylaxis,O
Potentially,Factor
serious,Severity
hypersensitivity,AdverseReaction
reactions,O
including,O
anaphylaxis,AdverseReaction
have,O
occurred,O
in,O
patients,O
treated,O
with,O
KALBITOR,O
In,O
255,O
HAE,O
patients,O
treated,O
with,O
intravenous,O
or,O
subcutaneous,O
KALBITOR,O
in,O
clinical,O
studies,O
10,O
patients,O
4,O
experienced,O
anaphylaxis,AdverseReaction
For,O
the,O
subgroup,O
of,O
187,O
patients,O
treated,O
with,O
subcutaneous,O
KALBITOR,O
5,O
patients,O
3,O
experienced,O
anaphylaxis,AdverseReaction
Symptoms,O
associated,O
with,O
these,O
reactions,O
have,O
included,O
chest discomfort,AdverseReaction
flushing,AdverseReaction
pharyngeal edema,AdverseReaction
pruritus,AdverseReaction
rhinorrhea,AdverseReaction
sneezing,AdverseReaction
nasal congestion,AdverseReaction
throat irritation,AdverseReaction
urticaria,AdverseReaction
wheezing,AdverseReaction
and,O
hypotension,AdverseReaction
These,O
reactions,O
occurred,O
within,O
the,O
first,O
hour,O
after,O
dosing,O
Other,O
adverse,O
reactions,O
indicative,O
of,O
hypersensitivity,AdverseReaction
reactions,O
included,O
the,O
following,O
pruritus,AdverseReaction
5,O
rash,AdverseReaction
3,O
and,O
urticaria,AdverseReaction
2,O
Patients,O
should,O
be,O
observed,O
for,O
an,O
appropriate,O
period,O
of,O
time,O
after,O
administration,O
of,O
KALBITOR,O
taking,O
into,O
account,O
the,O
time,O
to,O
onset,O
of,O
anaphylaxis,O
seen,O
in,O
clinical,O
trials,O
Given,O
the,O
similarity,O
in,O
hypersensitivity,O
symptoms,O
and,O
acute,O
HAE,O
symptoms,O
patients,O
should,O
be,O
monitored,O
closely,O
in,O
the,O
event,O
of,O
a,O
hypersensitivity,O
reaction,O
KALBITOR,O
should,O
not,O
be,O
administered,O
to,O
any,O
patients,O
with,O
known,O
clinical,O
hypersensitivity,O
to,O
KALBITOR,O
see,O
Contraindications,O
4,O
""
BOXED,O
WARNING,O
WARNING,O
ANAPHYLAXIS,AdverseReaction
WARNING,O
ANAPHYLAXIS,AdverseReaction
Anaphylaxis,AdverseReaction
has,O
been,O
reported,O
after,O
administration,O
of,O
KALBITOR,O
Because,O
of,O
the,O
risk,O
of,O
anaphylaxis,O
KALBITOR,O
should,O
only,O
be,O
administered,O
by,O
a,O
healthcare,O
professional,O
with,O
appropriate,O
medical,O
support,O
to,O
manage,O
anaphylaxis,O
and,O
hereditary,O
angioedema,O
Healthcare,O
professionals,O
should,O
be,O
aware,O
of,O
the,O
similarity,O
of,O
symptoms,O
between,O
hypersensitivity,O
reactions,O
and,O
hereditary,O
angioedema,O
and,O
patients,O
should,O
be,O
monitored,O
closely,O
Do,O
not,O
administer,O
KALBITOR,O
to,O
patients,O
with,O
known,O
clinical,O
hypersensitivity,O
to,O
KALBITOR,O
see,O
Contraindications,O
4,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Adverse,O
Reactions,O
6,O
EXCERPT,O
WARNING,O
ANAPHYLAXIS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Anaphylaxis,AdverseReaction
has,O
been,O
reported,O
after,O
administration,O
of,O
KALBITOR,O
r,O
Because,O
of,O
the,O
risk,O
of,O
anaphylaxis,O
KALBITOR,O
should,O
only,O
be,O
administered,O
by,O
a,O
healthcare,O
professional,O
with,O
appropriate,O
medical,O
support,O
to,O
manage,O
anaphylaxis,O
and,O
hereditary,O
angioedema,O
Healthcare,O
professionals,O
should,O
be,O
aware,O
of,O
the,O
similarity,O
of,O
symptoms,O
between,O
hypersensitivity,O
reactions,O
and,O
hereditary,O
angioedema,O
and,O
patients,O
should,O
be,O
monitored,O
closely,O
Do,O
not,O
administer,O
KALBITOR,O
to,O
patients,O
with,O
known,O
clinical,O
hypersensitivity,O
to,O
KALBITOR,O
see,O
Contraindications,O
4,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Adverse,O
Reactions,O
6,O
""
6,O
ADVERSE,O
REACTIONS,O
Hypersensitivity,AdverseReaction
reactions,O
including,O
anaphylaxis,AdverseReaction
have,O
occurred,O
in,O
patients,O
treated,O
with,O
KALBITOR,O
see,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
occurring,O
in,O
3,O
of,O
KALBITOR,O
treated,O
patients,O
and,O
greater,O
than,O
placebo,O
are,O
headache,AdverseReaction
nausea,AdverseReaction
diarrhea,AdverseReaction
pyrexia,AdverseReaction
injection site reactions,AdverseReaction
and,O
nasopharyngitis,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Dyax,O
Corp,O
at,O
1,O
888,O
452,O
5248,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
safety,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
KALBITOR,O
in,O
255,O
patients,O
with,O
HAE,O
treated,O
with,O
either,O
intravenous,O
or,O
subcutaneous,O
KALBITOR,O
Of,O
the,O
255,O
patients,O
66,O
of,O
patients,O
were,O
female,O
and,O
86,O
were,O
Caucasian,O
Patients,O
treated,O
with,O
KALBITOR,O
were,O
between,O
the,O
ages,O
of,O
10,O
and,O
78,O
years,O
Overall,O
the,O
most,O
common,O
adverse,O
reactions,O
in,O
255,O
patients,O
with,O
HAE,O
were,O
headache,AdverseReaction
16,O
nausea,AdverseReaction
13,O
fatigue,AdverseReaction
12,O
diarrhea,AdverseReaction
11,O
upper respiratory tract infection,AdverseReaction
8,O
injection site reactions,AdverseReaction
7,O
nasopharyngitis,AdverseReaction
6,O
vomiting,AdverseReaction
6,O
pruritus,AdverseReaction
5,O
upper abdominal pain,AdverseReaction
5,O
and,O
pyrexia,AdverseReaction
5,O
Anaphylaxis,AdverseReaction
was,O
reported,O
in,O
4,O
of,O
patients,O
with,O
HAE,O
Injection site reactions site site site site site site,AdverseReaction
were,O
characterized,O
by,O
local,O
pruritus,AdverseReaction
erythema,AdverseReaction
pain,AdverseReaction
irritation,AdverseReaction
urticaria,AdverseReaction
and,O
or,O
bruising,AdverseReaction
The,O
incidence,O
of,O
adverse,O
reactions,O
below,O
is,O
based,O
upon,O
2,O
placebo,O
controlled,O
clinical,O
trials,O
EDEMA3,O
r,O
and,O
EDEMA4,O
r,O
in,O
a,O
total,O
of,O
143,O
unique,O
patients,O
with,O
HAE,O
Patients,O
were,O
treated,O
with,O
KALBITOR,O
30,O
mg,O
subcutaneous,O
or,O
placebo,O
Patients,O
were,O
permitted,O
to,O
participate,O
sequentially,O
in,O
both,O
placebo,O
controlled,O
trials,O
safety,O
data,O
collected,O
during,O
exposure,O
to,O
KALBITOR,O
was,O
attributed,O
to,O
treatment,O
with,O
KALBITOR,O
and,O
safety,O
data,O
collected,O
during,O
exposure,O
to,O
placebo,O
was,O
attributed,O
to,O
treatment,O
with,O
placebo,O
Table,O
1,O
shows,O
adverse,O
reactions,O
occurring,O
in,O
3,O
of,O
KALBITOR,O
treated,O
patients,O
that,O
also,O
occurred,O
at,O
a,O
higher,O
rate,O
than,O
in,O
the,O
placebo,O
treated,O
patients,O
in,O
the,O
two,O
controlled,O
trials,O
EDEMA3,O
and,O
EDEMA4,O
of,O
the,O
30,O
mg,O
subcutaneous,O
dose,O
Table,O
1,O
Adverse,O
Reactions,O
Occurring,O
at,O
3,O
and,O
Higher,O
than,O
Placebo,O
in,O
2,O
Placebo,O
Controlled,O
Clinical,O
Trials,O
in,O
Patients,O
with,O
HAE,O
Treated,O
with,O
KALBITOR,O
a,O
Patients,O
experiencing,O
more,O
than,O
1,O
event,O
with,O
the,O
same,O
preferred,O
term,O
are,O
counted,O
only,O
once,O
for,O
that,O
preferred,O
term,O
KALIBITORN,O
100,O
PlaceboN,O
81,O
Adverse,O
Reactions,O
n,O
a,O
n,O
a,O
Headache,AdverseReaction
8,O
8,O
6,O
7,O
Nausea,AdverseReaction
5,O
5,O
1,O
1,O
Diarrhea,AdverseReaction
4,O
4,O
3,O
4,O
Pyrexia,AdverseReaction
4,O
4,O
0,O
Injection site reactions,AdverseReaction
3,O
3,O
1,O
1,O
Nasopharyngitis,AdverseReaction
3,O
3,O
0,O
Some,O
patients,O
in,O
EDEMA3,O
and,O
EDEMA4,O
received,O
a,O
second,O
open,O
label,O
30,O
mg,O
subcutaneous,O
dose,O
of,O
KALBITOR,O
within,O
24,O
hours,O
following,O
the,O
initial,O
dose,O
Adverse,O
reactions,O
reported,O
by,O
these,O
patients,O
who,O
received,O
the,O
additional,O
30,O
mg,O
subcutaneous,O
dose,O
of,O
KALBITOR,O
were,O
consistent,O
with,O
those,O
reported,O
in,O
the,O
patients,O
receiving,O
a,O
single,O
dose,O
6,O
2,O
Immunogenicity,O
In,O
the,O
KALBITOR,O
HAE,O
program,O
patients,O
developed,O
antibodies,O
to,O
KALBITOR,O
Rates,O
of,O
seroconversion,O
increased,O
with,O
exposure,O
to,O
KALBITOR,O
over,O
time,O
Overall,O
20,O
2,O
of,O
patients,O
seroconverted,O
to,O
anti,O
ecallantide,O
antibodies,O
Neutralizing,O
antibodies,O
to,O
ecallantide,O
were,O
determined,O
in,O
vitro,O
to,O
be,O
present,O
in,O
8,O
8,O
of,O
patients,O
and,O
were,O
not,O
associated,O
with,O
loss,O
of,O
efficacy,O
Anti,O
ecallantide,O
IgE,O
antibodies,O
were,O
detected,O
at,O
a,O
rate,O
of,O
4,O
7,O
for,O
tested,O
patients,O
and,O
anti,O
P,O
pastoris,O
IgE,O
antibodies,O
were,O
also,O
detected,O
at,O
a,O
rate,O
of,O
20,O
2,O
Patients,O
who,O
seroconvert,O
may,O
be,O
at,O
a,O
higher,O
risk,O
of,O
a,O
hypersensitivity,O
reaction,O
The,O
long,O
term,O
effects,O
of,O
antibodies,O
to,O
KALBITOR,O
are,O
not,O
known,O
The,O
test,O
results,O
for,O
the,O
ecallantide,O
program,O
were,O
determined,O
using,O
one,O
of,O
two,O
assay,O
formats,O
ELISA,O
and,O
bridging,O
electrochemiluminescence,O
ECL,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
a,O
potential,O
for,O
immunogenicity,O
with,O
the,O
use,O
of,O
KALBITOR,O
The,O
incidence,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
KALBITOR,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
6,O
3,O
Postmarketing,O
Experience,O
Similar,O
adverse,O
reactions,O
have,O
been,O
observed,O
postmarketing,O
as,O
described,O
for,O
clinical,O
trial,O
experience,O
Because,O
these,O
events,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
frequency,O
or,O
to,O
establish,O
a,O
causal,O
relationship,O
with,O
drug,O
exposure,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Elevated transaminases,AdverseReaction
ALT,AdverseReaction
or,O
AST,AdverseReaction
Transaminases,O
ALT,O
and,O
AST,O
should,O
be,O
assessed,O
prior,O
to,O
initiating,O
KALYDECO,O
every,O
3,O
months,O
during,O
the,O
first,O
year,O
of,O
treatment,O
and,O
annually,O
thereafter,O
In,O
patients,O
with,O
a,O
history,O
of,O
transaminase,O
elevations,O
more,O
frequent,O
monitoring,O
of,O
liver,O
function,O
tests,O
should,O
be,O
considered,O
Patients,O
who,O
develop,O
increased,O
transaminase,O
levels,O
should,O
be,O
closely,O
monitored,O
until,O
the,O
abnormalities,O
resolve,O
Dosing,O
should,O
be,O
interrupted,O
in,O
patients,O
with,O
ALT,O
or,O
AST,O
of,O
greater,O
than,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
ULN,O
Following,O
resolution,O
of,O
transaminase,O
elevations,O
consider,O
the,O
benefits,O
and,O
risks,O
of,O
resuming,O
KALYDECO,O
dosing,O
5,O
1,O
6,O
Use,O
with,O
CYP3A,O
inducers,O
Concomitant,O
use,O
with,O
strong,O
CYP3A,O
inducers,O
e,O
g,O
rifampin,O
St,O
John,O
s,O
wort,O
substantially,O
decreases,O
exposure,O
of,O
ivacaftor,O
which,O
may,O
diminish,O
effectiveness,O
Therefore,O
co,O
administration,O
is,O
not,O
recommended,O
5,O
2,O
7,O
2,O
12,O
3,O
Cataracts,AdverseReaction
Non congenital lens opacities congenital,AdverseReaction
cataracts,AdverseReaction
have,O
been,O
reported,O
in,O
pediatric,O
patients,O
treated,O
with,O
KALYDECO,O
Baseline,O
and,O
follow,O
up,O
examinations,O
are,O
recommended,O
in,O
pediatric,O
patients,O
initiating,O
KALYDECO,O
treatment,O
5,O
3,O
5,O
1,O
Transaminase,O
ALT,O
or,O
AST,O
Elevations,O
Elevated transaminases,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
with,O
CF,O
receiving,O
KALYDECO,O
It,O
is,O
recommended,O
that,O
ALT,O
and,O
AST,O
be,O
assessed,O
prior,O
to,O
initiating,O
KALYDECO,O
every,O
3,O
months,O
during,O
the,O
first,O
year,O
of,O
treatment,O
and,O
annually,O
thereafter,O
For,O
patients,O
with,O
a,O
history,O
of,O
transaminase,O
elevations,O
more,O
frequent,O
monitoring,O
of,O
liver,O
function,O
tests,O
should,O
be,O
considered,O
Patients,O
who,O
develop,O
increased,O
transaminase,O
levels,O
should,O
be,O
closely,O
monitored,O
until,O
the,O
abnormalities,O
resolve,O
Dosing,O
should,O
be,O
interrupted,O
in,O
patients,O
with,O
ALT,O
or,O
AST,O
of,O
greater,O
than,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
ULN,O
Following,O
resolution,O
of,O
transaminase,O
elevations,O
consider,O
the,O
benefits,O
and,O
risks,O
of,O
resuming,O
KALYDECO,O
dosing,O
see,O
Adverse,O
Reactions,O
6,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
5,O
2,O
Concomitant,O
Use,O
with,O
CYP3A,O
Inducers,O
Use,O
of,O
KALYDECO,O
with,O
strong,O
CYP3A,O
inducers,O
such,O
as,O
rifampin,O
substantially,O
decreases,O
the,O
exposure,O
of,O
ivacaftor,O
which,O
may,O
reduce,O
the,O
therapeutic,O
effectiveness,O
of,O
KALYDECO,O
Therefore,O
co,O
administration,O
of,O
KALYDECO,O
with,O
strong,O
CYP3A,O
inducers,O
e,O
g,O
rifampin,O
St,O
John,O
s,O
wort,O
is,O
not,O
recommended,O
see,O
Drug,O
Interactions,O
7,O
2,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
3,O
Cataracts,O
Cases,O
of,O
non congenital lens opacities congenital,AdverseReaction
cataracts,AdverseReaction
have,O
been,O
reported,O
in,O
pediatric,O
patients,O
treated,O
with,O
KALYDECO,O
Although,O
other,O
risk,O
factors,O
were,O
present,O
in,O
some,O
cases,O
such,O
as,O
corticosteroid,O
use,O
and,O
or,O
exposure,O
to,O
radiation,O
a,O
possible,O
risk,O
attributable,O
to,O
KALYDECO,O
cannot,O
be,O
excluded,O
Baseline,O
and,O
follow,O
up,O
ophthalmological,O
examinations,O
are,O
recommended,O
in,O
pediatric,O
patients,O
initiating,O
KALYDECO,O
treatment,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reaction,O
is,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
label,O
Transaminase Elevations,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
drug,O
reactions,O
to,O
KALYDECO,O
occurring,O
in,O
8,O
of,O
patients,O
with,O
CF,O
who,O
have,O
a,O
G551D,O
mutation,O
in,O
the,O
CFTR,O
gene,O
were,O
headache,AdverseReaction
oropharyngeal pain,AdverseReaction
upper respiratory tract infection,AdverseReaction
nasal congestion,AdverseReaction
abdominal pain,AdverseReaction
nasopharyngitis,AdverseReaction
diarrhea,AdverseReaction
rash,AdverseReaction
nausea,AdverseReaction
and,O
dizziness,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Vertex,O
Pharmaceuticals,O
Incorporated,O
at,O
1,O
877,O
634,O
8789,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
overall,O
safety,O
profile,O
of,O
KALYDECO,O
is,O
based,O
on,O
pooled,O
data,O
from,O
three,O
placebo,O
controlled,O
clinical,O
trials,O
conducted,O
in,O
353,O
patients,O
6,O
years,O
of,O
age,O
and,O
older,O
with,O
CF,O
who,O
had,O
a,O
G551D,O
mutation,O
in,O
the,O
CFTR,O
gene,O
Trials,O
1,O
and,O
2,O
or,O
were,O
homozygous,O
for,O
the,O
F508del,O
mutation,O
Trial,O
3,O
In,O
addition,O
the,O
following,O
clinical,O
trials,O
have,O
also,O
been,O
conducted,O
see,O
Clinical,O
Pharmacology,O
12,O
and,O
Clinical,O
Studies,O
14,O
An,O
8,O
week,O
crossover,O
design,O
trial,O
Trial,O
4,O
involving,O
39,O
patients,O
between,O
the,O
ages,O
of,O
6,O
and,O
57,O
years,O
with,O
a,O
G1244E,O
G1349D,O
G178R,O
G551S,O
G970R,O
S1251N,O
S1255P,O
S549N,O
or,O
S549R,O
mutation,O
in,O
the,O
CFTR,O
gene,O
A,O
24,O
week,O
placebo,O
controlled,O
trial,O
Trial,O
5,O
involving,O
69,O
patients,O
between,O
the,O
ages,O
of,O
6,O
and,O
68,O
years,O
with,O
an,O
R117H,O
mutation,O
in,O
the,O
CFTR,O
gene,O
A,O
24,O
week,O
open,O
label,O
trial,O
Trial,O
6,O
in,O
34,O
patients,O
2,O
to,O
less,O
than,O
6,O
years,O
of,O
age,O
Patients,O
eligible,O
for,O
Trial,O
6,O
were,O
those,O
with,O
the,O
G551D,O
G1244E,O
G1349D,O
G178R,O
G551S,O
G970R,O
S1251N,O
S1255P,O
S549N,O
or,O
S549R,O
mutation,O
in,O
the,O
CFTR,O
gene,O
Of,O
34,O
patients,O
enrolled,O
32,O
had,O
the,O
G551D,O
mutation,O
and,O
2,O
had,O
the,O
S549N,O
mutation,O
Of,O
the,O
353,O
patients,O
included,O
in,O
the,O
pooled,O
analyses,O
of,O
patients,O
with,O
CF,O
who,O
had,O
either,O
a,O
G551D,O
mutation,O
or,O
were,O
homozygous,O
for,O
the,O
F508del,O
mutation,O
in,O
the,O
CFTR,O
gene,O
50,O
of,O
patients,O
were,O
female,O
and,O
97,O
were,O
Caucasian,O
221,O
received,O
KALYDECO,O
and,O
132,O
received,O
placebo,O
from,O
16,O
to,O
48,O
weeks,O
The,O
proportion,O
of,O
patients,O
who,O
prematurely,O
discontinued,O
study,O
drug,O
due,O
to,O
adverse,O
reactions,O
was,O
2,O
for,O
KALYDECO,O
treated,O
patients,O
and,O
5,O
for,O
placebo,O
treated,O
patients,O
Serious,O
adverse,O
reactions,O
whether,O
considered,O
drug,O
related,O
or,O
not,O
by,O
the,O
investigators,O
that,O
occurred,O
more,O
frequently,O
in,O
KALYDECO,O
treated,O
patients,O
included,O
abdominal pain,AdverseReaction
increased hepatic enzymes,AdverseReaction
and,O
hypoglycemia,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
in,O
the,O
221,O
patients,O
treated,O
with,O
KALYDECO,O
were,O
headache,AdverseReaction
17,O
upper respiratory tract infection,AdverseReaction
16,O
nasal congestion,AdverseReaction
16,O
nausea,AdverseReaction
10,O
rash,AdverseReaction
10,O
rhinitis,AdverseReaction
6,O
dizziness,AdverseReaction
5,O
arthralgia,AdverseReaction
5,O
and,O
bacteria in sputum,AdverseReaction
5,O
The,O
incidence,O
of,O
adverse,O
reactions,O
below,O
is,O
based,O
upon,O
two,O
double,O
blind,O
placebo,O
controlled,O
48,O
week,O
clinical,O
trials,O
Trials,O
1,O
and,O
2,O
in,O
a,O
total,O
of,O
213,O
patients,O
with,O
CF,O
ages,O
6,O
to,O
53,O
who,O
have,O
a,O
G551D,O
mutation,O
in,O
the,O
CFTR,O
gene,O
and,O
who,O
were,O
treated,O
with,O
KALYDECO,O
150,O
mg,O
orally,O
or,O
placebo,O
twice,O
daily,O
Table,O
2,O
shows,O
adverse,O
reactions,O
occurring,O
in,O
8,O
of,O
KALYDECO,O
treated,O
patients,O
with,O
CF,O
who,O
have,O
a,O
G551D,O
mutation,O
in,O
the,O
CFTR,O
gene,O
that,O
also,O
occurred,O
at,O
a,O
higher,O
rate,O
than,O
in,O
the,O
placebo,O
treated,O
patients,O
in,O
the,O
two,O
double,O
blind,O
placebo,O
controlled,O
trials,O
Table,O
2,O
Incidence,O
of,O
Adverse,O
Drug,O
Reactions,O
in,O
8,O
of,O
KALYDECO,O
Treated,O
Patients,O
with,O
a,O
G551D,O
Mutation,O
in,O
the,O
CFTR,O
Gene,O
and,O
Greater,O
than,O
Placebo,O
in,O
2,O
Placebo,O
Controlled,O
Phase,O
3,O
Clinical,O
Trials,O
of,O
48,O
Weeks,O
Duration,O
Adverse,O
Reaction,O
Preferred,O
Term,O
Incidence,O
Pooled,O
48,O
Week,O
Trials,O
KALYDECON,O
109n,O
PlaceboN,O
104n,O
Headache,AdverseReaction
26,O
24,O
17,O
16,O
Oropharyngeal pain,AdverseReaction
24,O
22,O
19,O
18,O
Upper respiratory tract infection,AdverseReaction
24,O
22,O
14,O
14,O
Nasal congestion,AdverseReaction
22,O
20,O
16,O
15,O
Abdominal pain,AdverseReaction
17,O
16,O
13,O
13,O
Nasopharyngitis,AdverseReaction
16,O
15,O
12,O
12,O
Diarrhea,AdverseReaction
14,O
13,O
10,O
10,O
Rash,AdverseReaction
14,O
13,O
7,O
7,O
Nausea,AdverseReaction
13,O
12,O
11,O
11,O
Dizziness,AdverseReaction
10,O
9,O
1,O
1,O
Adverse,O
reactions,O
in,O
the,O
48,O
week,O
clinical,O
trials,O
that,O
occurred,O
in,O
the,O
KALYDECO,O
group,O
at,O
a,O
frequency,O
of,O
4,O
to,O
7,O
where,O
rates,O
exceeded,O
that,O
in,O
the,O
placebo,O
group,O
include,O
Infections,O
and,O
infestations,O
rhinitis,AdverseReaction
Investigations,O
aspartate aminotransferase increased,AdverseReaction
bacteria in sputum,AdverseReaction
blood glucose increased,AdverseReaction
hepatic enzyme increased,AdverseReaction
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
arthralgia,AdverseReaction
musculoskeletal chest pain,AdverseReaction
myalgia,AdverseReaction
Nervous,O
system,O
disorders,O
sinus headache,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
pharyngeal erythema,AdverseReaction
pleuritic pain,AdverseReaction
sinus congestion,AdverseReaction
wheezing,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
acne,AdverseReaction
The,O
safety,O
profile,O
for,O
the,O
CF,O
patients,O
enrolled,O
in,O
the,O
other,O
clinical,O
trials,O
Trials,O
3,O
6,O
was,O
similar,O
to,O
that,O
observed,O
in,O
the,O
48,O
week,O
placebo,O
controlled,O
trials,O
Trials,O
1,O
and,O
2,O
Laboratory,O
Abnormalities,O
Transaminase,O
Elevations,O
In,O
Trials,O
1,O
2,O
and,O
3,O
the,O
incidence,O
of,O
maximum,O
transaminase,AdverseReaction
ALT,AdverseReaction
or,O
AST,AdverseReaction
8,O
5,O
or,O
3,O
ULN,O
was,O
2,O
2,O
and,O
6,O
in,O
KALYDECO,O
treated,O
patients,O
and,O
2,O
2,O
and,O
8,O
in,O
placebo,O
treated,O
patients,O
respectively,O
Two,O
patients,O
2,O
on,O
placebo,O
and,O
1,O
patient,O
0,O
5,O
on,O
KALYDECO,O
permanently,O
discontinued,O
treatment,O
for,O
elevated transaminases,AdverseReaction
all,O
8,O
ULN,O
Two,O
patients,O
treated,O
with,O
KALYDECO,O
were,O
reported,O
to,O
have,O
serious,Severity
adverse,O
reactions,O
of,O
elevated liver transaminases,AdverseReaction
compared,O
to,O
none,O
on,O
placebo,O
Transaminase,O
elevations,O
were,O
more,O
common,O
in,O
patients,O
with,O
a,O
history,O
of,O
transaminase,O
elevations,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
During,O
the,O
24,O
week,O
open,O
label,O
clinical,O
trial,O
in,O
34,O
patients,O
ages,O
2,O
to,O
less,O
than,O
6,O
years,O
Trial,O
6,O
where,O
patients,O
received,O
either,O
50,O
mg,O
less,O
than,O
14,O
kg,O
or,O
75,O
mg,O
14,O
kg,O
or,O
greater,O
ivacaftor,O
granules,O
twice,O
daily,O
the,O
incidence,O
of,O
patients,O
experiencing,O
transaminase elevations,AdverseReaction
ALT,AdverseReaction
or,O
AST,AdverseReaction
3,O
ULN,O
was,O
14,O
7,O
5,O
34,O
All,O
5,O
patients,O
had,O
maximum,O
ALT,AdverseReaction
or,O
AST levels 8 ULN 8 ULN,AdverseReaction
which,O
returned,O
to,O
baseline,O
levels,O
following,O
interruption,O
of,O
KALYDECO,O
dosing,O
Transaminase,O
elevations,O
were,O
more,O
common,O
in,O
patients,O
who,O
had,O
abnormal,O
transaminases,O
at,O
baseline,O
KALYDECO,O
was,O
permanently,O
discontinued,O
in,O
one,O
patient,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Cardiac toxicities,AdverseReaction
include,O
cardiac failure,AdverseReaction
and,O
myocardial infarction,AdverseReaction
with,O
fatal,AdverseReaction
outcome,O
and,O
myocardial ischemia,AdverseReaction
Withhold,O
Kyprolis,O
and,O
evaluate,O
promptly,O
5,O
1,O
Acute Renal Failure,AdverseReaction
Monitor,O
serum,O
creatinine,O
regularly,O
5,O
2,O
Tumor Lysis Syndrome,AdverseReaction
TLS,AdverseReaction
Administer,O
pre,O
treatment,O
hydration,O
2,O
1,O
Monitor,O
for,O
TLS,O
including,O
uric,O
acid,O
levels,O
and,O
treat,O
promptly,O
5,O
3,O
Pulmonary Toxicity,AdverseReaction
including,O
Acute Respiratory Distress Syndrome,AdverseReaction
acute respiratory failure,AdverseReaction
and,O
acute diffuse infiltrative pulmonary disease,AdverseReaction
Withhold,O
Kyprolis,O
and,O
evaluate,O
promptly,O
5,O
4,O
Pulmonary Hypertension,AdverseReaction
Withhold,O
Kyprolis,O
and,O
evaluate,O
5,O
5,O
Dyspnea,AdverseReaction
For,O
severe,O
or,O
life,O
threatening,O
dyspnea,O
withhold,O
Kyprolis,O
and,O
evaluate,O
5,O
6,O
Hypertension,AdverseReaction
including,O
hypertensive crisis,AdverseReaction
Monitor,O
blood,O
pressure,O
regularly,O
If,O
hypertension,O
cannot,O
be,O
adequately,O
controlled,O
a,O
risk,O
benefit,O
decision,O
on,O
continued,O
Kyprolis,O
therapy,O
is,O
needed,O
5,O
7,O
Venous Thrombosis,AdverseReaction
Thromboprophylaxis,O
is,O
recommended,O
5,O
8,O
Infusion Reactions,AdverseReaction
Pre,O
medicate,O
with,O
dexamethasone,O
2,O
1,O
5,O
9,O
Thrombocytopenia,AdverseReaction
Monitor,O
platelet,O
counts,O
interrupt,O
or,O
reduce,O
Kyprolis,O
dosing,O
as,O
clinically,O
indicated,O
2,O
4,O
5,O
10,O
Hepatic Toxicity,AdverseReaction
and,O
Hepatic Failure,AdverseReaction
Monitor,O
liver,O
enzymes,O
Withhold,O
Kyprolis,O
if,O
suspected,O
5,O
11,O
Thrombotic thrombocytopenic purpura,AdverseReaction
hemolytic uremic syndrome,AdverseReaction
TTP,AdverseReaction
HUS,AdverseReaction
Monitor,O
for,O
signs,O
and,O
symptoms,O
of,O
TTP,O
HUS,O
Discontinue,O
Kyprolis,O
if,O
suspected,O
5,O
12,O
Posterior reversible encephalopathy syndrome,AdverseReaction
PRES,AdverseReaction
Consider,O
neuro,O
radiological,O
imaging,O
MRI,O
for,O
onset,O
of,O
visual,O
or,O
neurological,O
symptoms,O
discontinue,O
Kyprolis,O
if,O
suspected,O
5,O
13,O
Embryo fetal Toxicity,AdverseReaction
Kyprolis,O
can,Factor
cause,O
fetal harm,AdverseReaction
Females,O
of,O
reproductive,O
potential,O
should,O
avoid,O
becoming,O
pregnant,O
while,O
being,O
treated,O
5,O
14,O
8,O
1,O
5,O
1,O
Cardiac,O
Toxicities,O
New onset,AdverseReaction
or,O
worsening of pre existing cardiac failure failure,AdverseReaction
e,O
g,O
congestive heart failure,AdverseReaction
pulmonary edema,AdverseReaction
decreased ejection fraction,AdverseReaction
restrictive cardiomyopathy,AdverseReaction
myocardial ischemia,AdverseReaction
and,O
myocardial infarction,AdverseReaction
including,O
fatalities,AdverseReaction
have,O
occurred,O
following,O
administration,O
of,O
Kyprolis,O
In,O
clinical,O
studies,O
with,O
Kyprolis,O
these,O
events,O
typically,O
occurred,O
early,O
in,O
the,O
course,O
of,O
Kyprolis,O
therapy,O
5,O
cycles,O
Death,AdverseReaction
due,O
to,O
cardiac arrest,AdverseReaction
has,O
occurred,O
within,O
a,O
day,O
of,O
Kyprolis,O
administration,O
Withhold,O
Kyprolis,O
for,O
Grade,O
3,O
or,O
4,O
cardiac,O
adverse,O
events,O
until,O
recovery,O
and,O
consider,O
whether,O
to,O
restart,O
Kyprolis,O
at,O
1,O
dose,O
level,O
reduction,O
based,O
on,O
a,O
benefit,O
risk,O
assessment,O
see,O
Dosage,O
and,O
Administration,O
2,O
While,O
adequate,O
hydration,O
is,O
required,O
prior,O
to,O
each,O
dose,O
in,O
Cycle,O
1,O
all,O
patients,O
should,O
also,O
be,O
monitored,O
for,O
evidence,O
of,O
volume,O
overload,O
especially,O
patients,O
at,O
risk,O
for,O
cardiac,O
failure,O
Adjust,O
total,O
fluid,O
intake,O
as,O
clinically,O
appropriate,O
in,O
patients,O
with,O
baseline,O
cardiac,O
failure,O
or,O
who,O
are,O
at,O
risk,O
for,O
cardiac,O
failure,O
see,O
Dosage,O
and,O
Administration,O
2,O
In,O
patients,O
75,O
years,O
of,O
age,O
the,O
risk,O
of,O
cardiac,O
failure,O
is,O
increased,O
Patients,O
with,O
New,O
York,O
Heart,O
Association,O
Class,O
III,O
and,O
IV,O
heart,O
failure,O
recent,O
myocardial,O
infarction,O
and,O
conduction,O
abnormalities,O
uncontrolled,O
by,O
medications,O
were,O
not,O
eligible,O
for,O
the,O
clinical,O
trials,O
These,O
patients,O
may,O
be,O
at,O
greater,O
risk,O
for,O
cardiac,O
complications,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
2,O
Acute,O
Renal,O
Failure,O
Cases,O
of,O
acute renal failure,AdverseReaction
have,O
occurred,O
in,O
patients,O
receiving,O
Kyprolis,O
Renal insufficiency adverse events,AdverseReaction
renal impairment,AdverseReaction
acute renal failure,AdverseReaction
renal failure,AdverseReaction
have,O
occurred,O
with,O
an,O
incidence,O
of,O
approximately,O
8,O
in,O
a,O
randomized,O
controlled,O
trial,O
Acute renal failure,AdverseReaction
was,O
reported,O
more,O
frequently,O
in,O
patients,O
with,O
advanced,O
relapsed,O
and,O
refractory,O
multiple,O
myeloma,O
who,O
received,O
Kyprolis,O
monotherapy,O
This,O
risk,O
was,O
greater,O
in,O
patients,O
with,O
a,O
baseline,O
reduced,O
estimated,O
creatinine,O
clearance,O
calculated,O
using,O
Cockcroft,O
and,O
Gault,O
equation,O
Monitor,O
renal,O
function,O
with,O
regular,O
measurement,O
of,O
the,O
serum,O
creatinine,O
and,O
or,O
estimated,O
creatinine,O
clearance,O
Reduce,O
or,O
withhold,O
dose,O
as,O
appropriate,O
see,O
Dosage,O
and,O
Administration,O
2,O
5,O
3,O
Tumor,O
Lysis,O
Syndrome,O
Cases,O
of,O
tumor lysis syndrome,AdverseReaction
TLS,AdverseReaction
including,O
fatal,AdverseReaction
outcomes,O
have,O
been,O
reported,O
in,O
patients,O
who,O
received,O
Kyprolis,O
Patients,O
with,O
multiple,O
myeloma,O
and,O
a,O
high,O
tumor,O
burden,O
should,O
be,O
considered,O
to,O
be,O
at,O
greater,O
risk,O
for,O
TLS,O
Ensure,O
that,O
patients,O
are,O
well,O
hydrated,O
before,O
administration,O
of,O
Kyprolis,O
in,O
Cycle,O
1,O
and,O
in,O
subsequent,O
cycles,O
as,O
needed,O
see,O
Dosage,O
and,O
Administration,O
2,O
Consider,O
uric,O
acid,O
lowering,O
drugs,O
in,O
patients,O
at,O
risk,O
for,O
TLS,O
Monitor,O
for,O
evidence,O
of,O
TLS,O
during,O
treatment,O
and,O
manage,O
promptly,O
including,O
interruption,O
of,O
Kyprolis,O
until,O
TLS,O
is,O
resolved,O
see,O
Dosage,O
and,O
Administration,O
2,O
5,O
4,O
Pulmonary,O
Toxicity,O
Acute Respiratory Distress Syndrome,AdverseReaction
ARDS,AdverseReaction
acute respiratory failure,AdverseReaction
and,O
acute diffuse infiltrative pulmonary disease,AdverseReaction
such,O
as,O
pneumonitis,AdverseReaction
and,O
interstitial lung disease,AdverseReaction
have,O
occurred,O
in,O
less,O
than,O
1,O
of,O
patients,O
receiving,O
Kyprolis,O
Some,O
events,O
have,O
been,O
fatal,AdverseReaction
In,O
the,O
event,O
of,O
drug,O
induced,O
pulmonary,O
toxicity,O
discontinue,O
Kyprolis,O
see,O
Dosage,O
and,O
Administration,O
2,O
5,O
5,O
Pulmonary,O
Hypertension,O
Pulmonary arterial hypertension arterial hypertension,AdverseReaction
PAH,AdverseReaction
was,O
reported,O
in,O
approximately,O
1,O
of,O
patients,O
treated,O
with,O
Kyprolis,O
and,O
was,O
Grade 3,Severity
or,O
greater,O
in,O
less,O
than,O
1,O
of,O
patients,O
Evaluate,O
with,O
cardiac,O
imaging,O
and,O
or,O
other,O
tests,O
as,O
indicated,O
Withhold,O
Kyprolis,O
for,O
pulmonary,O
hypertension,O
until,O
resolved,O
or,O
returned,O
to,O
baseline,O
and,O
consider,O
whether,O
to,O
restart,O
Kyprolis,O
based,O
on,O
a,O
benefit,O
risk,O
assessment,O
see,O
Dosage,O
and,O
Administration,O
2,O
5,O
6,O
Dyspnea,O
Dyspnea,AdverseReaction
was,O
reported,O
in,O
28,O
of,O
patients,O
treated,O
with,O
Kyprolis,O
and,O
was,O
Grade 3,Severity
or,O
greater,O
in,O
4,O
of,O
patients,O
Evaluate,O
dyspnea,O
to,O
exclude,O
cardiopulmonary,O
conditions,O
including,O
cardiac,O
failure,O
and,O
pulmonary,O
syndromes,O
Stop,O
Kyprolis,O
for,O
Grade,O
3,O
or,O
4,O
dyspnea,O
until,O
resolved,O
or,O
returned,O
to,O
baseline,O
Consider,O
whether,O
to,O
restart,O
Kyprolis,O
based,O
on,O
a,O
benefit,O
risk,O
assessment,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Warnings,O
and,O
Precautions,O
Cardiac,O
Toxicities,O
5,O
1,O
Pulmonary,O
Toxicity,O
5,O
4,O
and,O
Adverse,O
Reactions,O
6,O
5,O
7,O
Hypertension,O
Hypertension,AdverseReaction
including,O
hypertensive crisis,AdverseReaction
and,O
hypertensive emergency,AdverseReaction
has,O
been,O
observed,O
with,O
Kyprolis,O
Some,O
of,O
these,O
events,O
have,O
been,O
fatal,AdverseReaction
Monitor,O
blood,O
pressure,O
regularly,O
in,O
all,O
patients,O
If,O
hypertension,O
cannot,O
be,O
adequately,O
controlled,O
withhold,O
Kyprolis,O
and,O
evaluate,O
Consider,O
whether,O
to,O
restart,O
Kyprolis,O
based,O
on,O
a,O
benefit,O
risk,O
assessment,O
see,O
Dosage,O
and,O
Administration,O
2,O
5,O
8,O
Venous,O
Thrombosis,O
Venous thromboembolic events,AdverseReaction
including,O
deep venous thrombosis,AdverseReaction
and,O
pulmonary embolism,AdverseReaction
have,O
been,O
observed,O
with,O
Kyprolis,O
In,O
the,O
combination,O
study,O
the,O
incidence,O
of,O
venous thromboembolic events,AdverseReaction
in,O
the,O
first,O
12,O
cycles,O
was,O
13,O
in,O
the,O
Kyprolis,O
combination,O
arm,O
versus,O
6,O
in,O
the,O
control,O
arm,O
With,O
Kyprolis,O
monotherapy,O
the,O
incidence,O
of,O
venous thromboembolic events,AdverseReaction
was,O
2,O
Thromboprophylaxis,O
is,O
recommended,O
and,O
should,O
be,O
based,O
on,O
an,O
assessment,O
of,O
the,O
patient,O
s,O
underlying,O
risks,O
treatment,O
regimen,O
and,O
clinical,O
status,O
5,O
9,O
Infusion,O
Reactions,O
Infusion reactions reactions,AdverseReaction
including,O
life threatening,Severity
reactions,O
have,O
occurred,O
in,O
patients,O
receiving,O
Kyprolis,O
Symptoms,O
include,O
fever,AdverseReaction
chills,AdverseReaction
arthralgia,AdverseReaction
myalgia,AdverseReaction
facial flushing,AdverseReaction
facial edema,AdverseReaction
vomiting,AdverseReaction
weakness,AdverseReaction
shortness of breath,AdverseReaction
hypotension,AdverseReaction
syncope,AdverseReaction
chest tightness,AdverseReaction
or,O
angina,AdverseReaction
These,O
reactions,O
can,O
occur,O
immediately,O
following,O
or,O
up,O
to,O
24,O
hours,O
after,O
administration,O
of,O
Kyprolis,O
Administer,O
dexamethasone,O
prior,O
to,O
Kyprolis,O
to,O
reduce,O
the,O
incidence,O
and,O
severity,O
of,O
infusion,O
reactions,O
see,O
Dosage,O
and,O
Administration,O
2,O
Inform,O
patients,O
of,O
the,O
risk,O
and,O
of,O
symptoms,O
and,O
to,O
contact,O
a,O
physician,O
immediately,O
if,O
symptoms,O
of,O
an,O
infusion,O
reaction,O
occur,O
see,O
Patient,O
Counseling,O
Information,O
17,O
5,O
10,O
Thrombocytopenia,O
Kyprolis,O
causes,O
thrombocytopenia,AdverseReaction
with,O
platelet nadirs,AdverseReaction
observed,O
between,O
Day,O
8,O
and,O
Day,O
15,O
of,O
each,O
28,O
day,O
cycle,O
with,O
recovery,O
to,O
baseline,O
platelet,O
count,O
usually,O
by,O
the,O
start,O
of,O
the,O
next,O
cycle,O
see,O
Adverse,O
Reactions,O
6,O
Thrombocytopenia,AdverseReaction
was,O
reported,O
in,O
approximately,O
40,O
of,O
patients,O
in,O
clinical,O
trials,O
with,O
Kyprolis,O
Monitor,O
platelet,O
counts,O
frequently,O
during,O
treatment,O
with,O
Kyprolis,O
Reduce,O
or,O
withhold,O
dose,O
as,O
appropriate,O
see,O
Dosage,O
and,O
Administration,O
2,O
5,O
11,O
Hepatic,O
Toxicity,O
and,O
Hepatic,O
Failure,O
Cases,O
of,O
hepatic failure,AdverseReaction
including,O
fatal,AdverseReaction
cases,O
have,O
been,O
reported,O
1,O
during,O
treatment,O
with,O
Kyprolis,O
Kyprolis,O
can,Factor
cause,O
increased serum transaminases,AdverseReaction
Monitor,O
liver,O
enzymes,O
regularly,O
Reduce,O
or,O
withhold,O
dose,O
as,O
appropriate,O
see,O
Dosage,O
and,O
Administration,O
2,O
and,O
Adverse,O
Reactions,O
6,O
5,O
12,O
Thrombotic,O
Thrombocytopenic,O
Purpura,O
Hemolytic,O
Uremic,O
Syndrome,O
Cases,O
of,O
thrombotic thrombocytopenic purpura,AdverseReaction
hemolytic uremic syndrome,AdverseReaction
TTP,AdverseReaction
HUS,AdverseReaction
including,O
fatal,AdverseReaction
outcome,O
have,O
been,O
reported,O
in,O
patients,O
who,O
received,O
Kyprolis,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
of,O
TTP,O
HUS,O
If,O
the,O
diagnosis,O
is,O
suspected,O
stop,O
Kyprolis,O
and,O
evaluate,O
If,O
the,O
diagnosis,O
of,O
TTP,O
HUS,O
is,O
excluded,O
Kyprolis,O
may,O
be,O
restarted,O
The,O
safety,O
of,O
reinitiating,O
Kyprolis,O
therapy,O
in,O
patients,O
previously,O
experiencing,O
TTP,O
HUS,O
is,O
not,O
known,O
5,O
13,O
Posterior,O
Reversible,O
Encephalopathy,O
Syndrome,O
PRES,O
Cases,O
of,O
PRES,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
receiving,O
Kyprolis,O
Posterior,O
reversible,O
encephalopathy,O
syndrome,O
PRES,O
formerly,O
termed,O
Reversible,O
Posterior,O
Leukoencephalopathy,O
Syndrome,O
RPLS,O
is,O
a,O
neurological,O
disorder,O
which,O
can,O
present,O
with,O
seizure,O
headache,O
lethargy,O
confusion,O
blindness,O
altered,O
consciousness,O
and,O
other,O
visual,O
and,O
neurological,O
disturbances,O
along,O
with,O
hypertension,O
and,O
the,O
diagnosis,O
is,O
confirmed,O
by,O
neuro,O
radiological,O
imaging,O
MRI,O
Discontinue,O
Kyprolis,O
if,O
PRES,O
is,O
suspected,O
and,O
evaluate,O
The,O
safety,O
of,O
reinitiating,O
Kyprolis,O
therapy,O
in,O
patients,O
previously,O
experiencing,O
PRES,O
is,O
not,O
known,O
5,O
14,O
Embryo,O
fetal,O
Toxicity,O
Kyprolis,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
based,O
on,O
its,O
mechanism,O
of,O
action,O
and,O
findings,O
in,O
animals,O
There,O
are,O
no,O
adequate,O
and,O
well,O
controlled,O
studies,O
in,O
pregnant,O
women,O
using,O
Kyprolis,O
Carfilzomib,O
caused,O
embryo fetal toxicity,AdverseReaction
in,O
pregnant,O
rabbits,Animal
at,O
doses,O
that,O
were,O
lower,O
than,O
in,O
patients,O
receiving,O
the,O
recommended,O
dose,O
Females,O
of,O
reproductive,O
potential,O
should,O
be,O
advised,O
to,O
avoid,O
becoming,O
pregnant,O
while,O
being,O
treated,O
with,O
Kyprolis,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
the,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Cardiac Toxicities,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Acute Renal Failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Tumor Lysis Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Pulmonary Toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Pulmonary Hypertension,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Dyspnea,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Hypertension,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Venous Thrombosis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Infusion Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
Thrombocytopenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
10,O
Hepatic Toxicity,AdverseReaction
and,O
Hepatic Failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
11,O
Thrombotic Thrombocytopenic Purpura,AdverseReaction
Hemolytic Uremic Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
12,O
Posterior Reversible Encephalopathy Syndrome,AdverseReaction
PRES,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
13,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
events,O
occurring,O
in,O
at,O
least,O
20,O
of,O
patients,O
treated,O
with,O
Kyprolis,O
in,O
monotherapy,O
trials,O
anemia,AdverseReaction
fatigue,AdverseReaction
thrombocytopenia,AdverseReaction
nausea,AdverseReaction
pyrexia,AdverseReaction
decreased platelets,AdverseReaction
dyspnea,AdverseReaction
diarrhea,AdverseReaction
decreased lymphocyte,AdverseReaction
headache,AdverseReaction
decreased hemoglobin,AdverseReaction
cough,AdverseReaction
edema peripheral,AdverseReaction
6,O
The,O
most,O
common,O
adverse,O
events,O
occurring,O
in,O
at,O
least,O
20,O
of,O
patients,O
treated,O
with,O
Kyprolis,O
in,O
the,O
combination,O
therapy,O
trial,O
decreased lymphocytes,AdverseReaction
decreased absolute neutrophil count,AdverseReaction
decreased phosphorus,AdverseReaction
anemia,AdverseReaction
neutropenia,AdverseReaction
decreased total white blood cell count,AdverseReaction
decreased platelets,AdverseReaction
diarrhea,AdverseReaction
fatigue,AdverseReaction
thrombocytopenia,AdverseReaction
pyrexia,AdverseReaction
muscle spasm,AdverseReaction
cough,AdverseReaction
upper respiratory tract infection,AdverseReaction
decreased hemoglobin,AdverseReaction
hypokalemia,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Amgen,O
Medical,O
Information,O
at,O
1,O
800,O
77,O
AMGEN,O
1,O
800,O
772,O
6436,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
medical,O
practice,O
6,O
1,O
1,O
Safety,O
Experience,O
with,O
Kyprolis,O
in,O
Combination,O
with,O
Lenalidomide,O
and,O
Dexamethasone,O
in,O
Patients,O
with,O
Multiple,O
Myeloma,O
The,O
safety,O
of,O
Kyprolis,O
in,O
combination,O
with,O
lenalidomide,O
and,O
dexamethasone,O
KRd,O
was,O
evaluated,O
in,O
an,O
open,O
label,O
randomized,O
study,O
in,O
patients,O
with,O
relapsed,O
multiple,O
myeloma,O
Details,O
of,O
the,O
study,O
treatment,O
are,O
described,O
in,O
Section,O
14,O
1,O
The,O
median,O
number,O
of,O
cycles,O
initiated,O
was,O
22,O
cycles,O
for,O
the,O
KRd,O
arm,O
and,O
14,O
cycles,O
for,O
the,O
Rd,O
arm,O
Deaths,AdverseReaction
due,O
to,O
adverse,O
events,O
within,O
30,O
days,O
of,O
the,O
last,O
dose,O
of,O
any,O
therapy,O
in,O
the,O
KRd,O
arm,O
occurred,O
in,O
27,O
392,O
7,O
patients,O
compared,O
with,O
27,O
389,O
7,O
patients,O
who,O
died,AdverseReaction
due,O
to,O
adverse,O
events,O
within,O
30,O
days,O
of,O
the,O
last,O
dose,O
of,O
any,O
Rd,O
therapy,O
The,O
most,O
common,O
cause,O
of,O
deaths,AdverseReaction
occurring,O
in,O
patients,O
in,O
the,O
two,O
arms,O
KRd,O
versus,O
Rd,O
included,O
cardiac,AdverseReaction
10,O
3,O
versus,O
7,O
2,O
infection,AdverseReaction
9,O
2,O
versus,O
10,O
3,O
renal,AdverseReaction
0,O
0,O
versus,O
1,O
1,O
and,O
other,O
adverse events events events,AdverseReaction
9,O
2,O
versus,O
10,O
3,O
Serious,O
adverse,O
events,O
were,O
reported,O
in,O
60,O
of,O
the,O
patients,O
in,O
the,O
KRd,O
arm,O
and,O
54,O
of,O
the,O
patients,O
in,O
the,O
Rd,O
arm,O
The,O
most,O
common,O
serious,O
adverse,O
events,O
reported,O
in,O
the,O
KRd,O
arm,O
as,O
compared,O
with,O
the,O
Rd,O
arm,O
were,O
pneumonia,AdverseReaction
14,O
versus,O
11,O
respiratory tract infection,AdverseReaction
4,O
versus,O
1,O
5,O
pyrexia,AdverseReaction
4,O
versus,O
2,O
and,O
pulmonary embolism,AdverseReaction
3,O
versus,O
2,O
Discontinuation,O
due,O
to,O
any,O
adverse,O
event,O
occurred,O
in,O
26,O
in,O
the,O
KRd,O
arm,O
versus,O
25,O
in,O
the,O
Rd,O
arm,O
Adverse,O
events,O
leading,O
to,O
discontinuation,O
of,O
Kyprolis,O
occurred,O
in,O
12,O
of,O
patients,O
and,O
the,O
most,O
common,O
events,O
included,O
pneumonia,AdverseReaction
1,O
myocardial infarction,AdverseReaction
0,O
8,O
and,O
upper respiratory tract infection,AdverseReaction
0,O
8,O
Common,O
Adverse,O
Events,O
10,O
The,O
adverse,O
events,O
in,O
the,O
first,O
12,O
cycles,O
of,O
therapy,O
that,O
occurred,O
at,O
a,O
rate,O
of,O
10,O
or,O
greater,O
in,O
the,O
KRd,O
arm,O
are,O
presented,O
in,O
Table,O
5,O
Table,O
5,O
Common,O
Adverse,O
Events,O
10,O
in,O
the,O
KRd,O
Arm,O
Occurring,O
in,O
Cycles,O
1,O
12,O
Combination,O
Therapy,O
KRd,O
Kyprolis,O
lenalidomide,O
and,O
low,O
dose,O
dexamethasone,O
Rd,O
lenalidomide,O
and,O
low,O
dose,O
dexamethasone,O
a,O
Pneumonia,AdverseReaction
includes,O
preferred,O
terms,O
of,O
pneumonia,AdverseReaction
bronchopneumonia,AdverseReaction
b,O
Peripheral neuropathies NEC,AdverseReaction
includes,O
preferred,O
terms,O
under,O
HLT,O
peripheral neuropathies NEC,AdverseReaction
c,O
Dyspnea,AdverseReaction
includes,O
preferred,O
terms,O
of,O
dyspnea,AdverseReaction
dyspnea exertional,AdverseReaction
d,O
Embolic and thrombotic events venous,AdverseReaction
include,O
preferred,O
terms,O
in,O
MedDRA,O
SMQ,O
narrow,O
scope,O
search,O
of,O
embolic and thrombotic events venous,AdverseReaction
e,O
Hypertension,AdverseReaction
includes,O
preferred,O
terms,O
of,O
hypertension,AdverseReaction
hypertensive crisis,AdverseReaction
hypertensive emergency,AdverseReaction
System,O
Organ,O
Class,O
KRd,O
Arm,O
N,O
392,O
Rd,O
Arm,O
N,O
389,O
Preferred,O
Term,O
Any,O
Grade,O
Grade,O
3,O
Any,O
Grade,O
Grade,O
3,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
Anemia,AdverseReaction
138,O
35,O
53,O
14,O
127,O
33,O
47,O
12,O
Neutropenia,AdverseReaction
124,O
32,O
104,O
27,O
115,O
30,O
89,O
23,O
Thrombocytopenia,AdverseReaction
100,O
26,O
58,O
15,O
75,O
19,O
39,O
10,O
Gastrointestinal,O
Disorders,O
Diarrhea,AdverseReaction
115,O
29,O
7,O
2,O
105,O
27,O
12,O
3,O
Constipation,AdverseReaction
68,O
17,O
0,O
53,O
14,O
1,O
0,O
Nausea,AdverseReaction
60,O
15,O
1,O
0,O
39,O
10,O
3,O
1,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Fatigue,AdverseReaction
109,O
28,O
21,O
5,O
104,O
27,O
20,O
5,O
Pyrexia,AdverseReaction
93,O
24,O
5,O
1,O
64,O
17,O
1,O
0,O
Edema Peripheral,AdverseReaction
63,O
16,O
2,O
1,O
57,O
15,O
2,O
1,O
Asthenia,AdverseReaction
53,O
14,O
11,O
3,O
46,O
12,O
7,O
2,O
Infections,O
and,O
Infestations,O
Upper Respiratory Tract Infection,AdverseReaction
85,O
22,O
7,O
2,O
52,O
13,O
3,O
1,O
Nasopharyngitis,AdverseReaction
63,O
16,O
0,O
43,O
11,O
0,O
Bronchitis,AdverseReaction
54,O
14,O
5,O
1,O
39,O
10,O
2,O
1,O
Pneumoniaa,O
54,O
14,O
35,O
9,O
43,O
11,O
27,O
7,O
Metabolism,O
and,O
Nutrition,O
Disorders,O
Hypokalemia,AdverseReaction
78,O
20,O
22,O
6,O
35,O
9,O
12,O
3,O
Hypocalcemia,AdverseReaction
55,O
14,O
10,O
3,O
39,O
10,O
5,O
1,O
Hyperglycemia,AdverseReaction
43,O
11,O
18,O
5,O
33,O
9,O
15,O
4,O
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Muscle Spasms,AdverseReaction
88,O
22,O
3,O
1,O
73,O
19,O
3,O
1,O
Nervous,O
System,O
Disorders,O
Peripheral,O
Neuropathies,O
NECb,O
43,O
11,O
7,O
2,O
37,O
10,O
4,O
1,O
Psychiatric,O
Disorders,O
Insomnia,AdverseReaction
63,O
16,O
6,O
2,O
50,O
13,O
8,O
2,O
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Cough,AdverseReaction
85,O
22,O
1,O
0,O
46,O
12,O
0,O
Dyspneac,O
70,O
18,O
9,O
2,O
58,O
15,O
6,O
2,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Rash,AdverseReaction
45,O
12,O
5,O
1,O
53,O
14,O
5,O
1,O
Vascular,O
Disorders,O
Embolic,O
and,O
Thrombotic,O
Events,O
Venousd,O
49,O
13,O
16,O
4,O
22,O
6,O
9,O
2,O
Hypertensione,O
41,O
11,O
12,O
3,O
15,O
4,O
4,O
1,O
There,O
were,O
274,O
70,O
patients,O
in,O
the,O
KRd,O
arm,O
who,O
received,O
treatment,O
beyond,O
Cycle,O
12,O
There,O
were,O
no,O
new,O
clinically,O
relevant,O
AEs,O
that,O
emerged,O
in,O
the,O
later,O
treatment,O
cycles,O
Adverse,O
Reactions,O
Occurring,O
at,O
a,O
Frequency,O
of,O
10,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
febrile neutropenia,AdverseReaction
lymphopenia,AdverseReaction
Cardiac,O
disorders,O
cardiac arrest,AdverseReaction
cardiac failure,AdverseReaction
cardiac failure congestive,AdverseReaction
myocardial infarction,AdverseReaction
myocardial ischemia,AdverseReaction
Eye,O
disorders,O
cataract,AdverseReaction
vision blurred,AdverseReaction
Gastrointestinal,O
disorders,O
abdominal pain,AdverseReaction
abdominal pain upper,AdverseReaction
dyspepsia,AdverseReaction
toothache,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
chills,AdverseReaction
infusion site reaction,AdverseReaction
multi organ failure,AdverseReaction
pain,AdverseReaction
Infections,O
and,O
infestations,O
influenza,AdverseReaction
sepsis,AdverseReaction
urinary tract infection,AdverseReaction
viral infection,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorders,O
dehydration,AdverseReaction
hyperkalemia,AdverseReaction
hyperuricemia,AdverseReaction
hypoalbuminemia,AdverseReaction
hyponatremia,AdverseReaction
tumor lysis syndrome,AdverseReaction
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
muscular weakness,AdverseReaction
myalgia,AdverseReaction
Nervous,O
system,O
disorders,O
hypoesthesia,AdverseReaction
paresthesia,AdverseReaction
deafness,AdverseReaction
Psychiatric,O
disorders,O
anxiety,AdverseReaction
delirium,AdverseReaction
Renal,O
and,O
urinary,O
disorders,O
renal failure,AdverseReaction
renal failure acute,AdverseReaction
renal impairment,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
dysphonia,AdverseReaction
epistaxis,AdverseReaction
oropharyngeal pain,AdverseReaction
pulmonary embolism,AdverseReaction
pulmonary edema,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
erythema,AdverseReaction
hyperhidrosis,AdverseReaction
pruritus,AdverseReaction
Vascular,O
disorders,O
deep vein thrombosis,AdverseReaction
hypotension,AdverseReaction
Grade 3,Severity
and,O
higher,O
adverse,O
reactions,O
that,O
occurred,O
during,O
Cycles,O
1,O
12,O
with,O
a,O
substantial,O
difference,O
2,O
between,O
the,O
two,O
arms,O
were,O
neutropenia,AdverseReaction
thrombocytopenia,AdverseReaction
hypokalemia,AdverseReaction
and,O
hypophosphatemia,AdverseReaction
Laboratory,O
Abnormalities,O
Table,O
6,O
describes,O
Grade,O
3,O
4,O
laboratory,O
abnormalities,O
reported,O
at,O
a,O
rate,O
of,O
10,O
in,O
the,O
KRd,O
arm,O
for,O
patients,O
who,O
received,O
combination,O
therapy,O
Table,O
6,O
Grade,O
3,O
4,O
Laboratory,O
Abnormalities,O
10,O
in,O
Cycles,O
1,O
12,O
Combination,O
Therapy,O
KRd,O
Kyprolis,O
lenalidomide,O
and,O
low,O
dose,O
dexamethasone,O
Rd,O
lenalidomide,O
and,O
low,O
dose,O
dexamethasone,O
Laboratory,O
Abnormality,O
KRd,O
N,O
392,O
Rd,O
N,O
389,O
Decreased Lymphocytes,AdverseReaction
182,O
46,O
119,O
31,O
Decreased Absolute Neutrophil Count,AdverseReaction
152,O
39,O
140,O
36,O
Decreased Phosphorus,AdverseReaction
122,O
31,O
106,O
27,O
Decreased Platelets,AdverseReaction
101,O
26,O
59,O
15,O
Decreased Total White Blood Cell Count,AdverseReaction
97,O
25,O
71,O
18,O
Decreased Hemoglobin,AdverseReaction
58,O
15,O
68,O
18,O
Decreased Potassium,AdverseReaction
41,O
11,O
23,O
6,O
6,O
1,O
2,O
Safety,O
Experience,O
with,O
Kyprolis,O
in,O
Patients,O
with,O
Multiple,O
Myeloma,O
who,O
Received,O
Monotherapy,O
The,O
safety,O
of,O
Kyprolis,O
was,O
evaluated,O
in,O
clinical,O
trials,O
in,O
which,O
598,O
patients,O
with,O
relapsed,O
and,O
or,O
refractory,O
myeloma,O
received,O
Kyprolis,O
monotherapy,O
starting,O
with,O
the,O
20,O
mg,O
m,O
2,O
dose,O
in,O
Cycle,O
1,O
Day,O
1,O
and,O
escalating,O
to,O
27,O
mg,O
m,O
2,O
on,O
Cycle,O
1,O
Day,O
8,O
or,O
Cycle,O
2,O
Day,O
1,O
The,O
median,O
age,O
of,O
these,O
patients,O
was,O
64,O
years,O
range,O
32,O
87,O
The,O
patients,O
received,O
a,O
median,O
of,O
5,O
range,O
1,O
20,O
prior,O
regimens,O
Approximately,O
57,O
of,O
the,O
patients,O
were,O
male,O
The,O
median,O
number,O
of,O
cycles,O
initiated,O
was,O
4,O
range,O
1,O
35,O
Serious,O
adverse,O
events,O
were,O
reported,O
regardless,O
of,O
causality,O
in,O
50,O
of,O
patients,O
in,O
the,O
pooled,O
Kyprolis,O
monotherapy,O
studies,O
n,O
598,O
The,O
most,O
common,O
serious,O
adverse,O
events,O
were,O
pneumonia,AdverseReaction
8,O
acute renal failure,AdverseReaction
5,O
disease progression,AdverseReaction
4,O
pyrexia,AdverseReaction
3,O
hypercalcemia,AdverseReaction
3,O
congestive heart failure,AdverseReaction
3,O
multiple myeloma,AdverseReaction
3,O
anemia,AdverseReaction
2,O
and,O
dyspnea,AdverseReaction
2,O
In,O
patients,O
treated,O
with,O
Kyprolis,O
the,O
incidence,O
of,O
serious,O
adverse,O
events,O
was,O
higher,O
in,O
those,O
65,O
years,O
old,O
and,O
in,O
those,O
75,O
years,O
old,O
see,O
Geriatric,O
Use,O
8,O
5,O
Deaths,AdverseReaction
due,O
to,O
adverse,O
events,O
within,O
30,O
days,O
of,O
the,O
last,O
dose,O
of,O
Kyprolis,O
occurred,O
in,O
30,O
598,O
5,O
patients,O
receiving,O
Kyprolis,O
monotherapy,O
These,O
adverse,O
events,O
were,O
related,O
to,O
cardiac disorders,AdverseReaction
in,O
10,O
2,O
patients,O
infections,AdverseReaction
in,O
8,O
1,O
patients,O
renal disorders,AdverseReaction
in,O
4,O
1,O
patients,O
and,O
other,O
adverse,O
events,O
in,O
8,O
1,O
patients,O
In,O
a,O
randomized,O
trial,O
comparing,O
Kyprolis,O
as,O
a,O
single,O
agent,O
versus,O
corticosteroids,O
with,O
optional,O
oral,O
cyclophosphamide,O
for,O
patients,O
with,O
relapsed,O
and,O
refractory,O
multiple,O
myeloma,O
mortality,AdverseReaction
was,O
higher,O
in,O
the,O
patients,O
treated,O
with,O
Kyprolis,O
in,O
comparison,O
to,O
the,O
control,O
arm,O
in,O
the,O
subgroup,O
of,O
48,O
patients,O
75,O
years,O
of,O
age,O
The,O
most,O
common,O
cause,O
of,O
discontinuation,O
due,O
to,O
an,O
adverse,O
event,O
was,O
acute renal failure,AdverseReaction
2,O
The,O
common,O
adverse,O
events,O
occurring,O
at,O
a,O
rate,O
of,O
10,O
or,O
greater,O
with,O
Kyprolis,O
monotherapy,O
are,O
presented,O
in,O
Table,O
7,O
Table,O
7,O
Most,O
Commonly,O
Reported,O
Adverse,O
Events,O
10,O
with,O
Kyprolis,O
Monotherapy,O
a,O
Pneumonia,AdverseReaction
includes,O
the,O
preferred,O
terms,O
of,O
pneumonia,AdverseReaction
bronchopneumonia,AdverseReaction
b,O
Peripheral neuropathies NEC,AdverseReaction
includes,O
the,O
preferred,O
terms,O
under,O
HLT,O
peripheral neuropathies NEC,AdverseReaction
c,O
Dyspnea,AdverseReaction
includes,O
the,O
preferred,O
terms,O
of,O
dyspnea,AdverseReaction
dyspnea exertional,AdverseReaction
d,O
Hypertension,AdverseReaction
includes,O
the,O
preferred,O
terms,O
of,O
hypertension,AdverseReaction
hypertensive crisis,AdverseReaction
and,O
hypertensive emergency,AdverseReaction
Kyprolis,O
Monotherapy20,O
27,O
mg,O
m2,O
N,O
598,O
System,O
Organ,O
Class,O
Any,O
Grade,O
Grade3,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
Anemia,AdverseReaction
291,O
49,O
141,O
24,O
Thrombocytopenia,AdverseReaction
220,O
37,O
152,O
25,O
Neutropenia,AdverseReaction
113,O
19,O
63,O
11,O
Lymphopenia,AdverseReaction
85,O
14,O
73,O
12,O
Leukopenia,AdverseReaction
61,O
10,O
26,O
4,O
Gastrointestinal,O
Disorders,O
Nausea,AdverseReaction
211,O
35,O
7,O
1,O
Diarrhea,AdverseReaction
160,O
27,O
8,O
1,O
Vomiting,AdverseReaction
104,O
17,O
4,O
1,O
Constipation,AdverseReaction
90,O
15,O
1,O
0,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Fatigue,AdverseReaction
238,O
40,O
25,O
4,O
Pyrexia,AdverseReaction
177,O
30,O
11,O
2,O
Edema Peripheral,AdverseReaction
118,O
20,O
1,O
0,O
Chills,AdverseReaction
73,O
12,O
1,O
0,O
Asthenia,AdverseReaction
71,O
12,O
9,O
2,O
Infections,O
and,O
Infestations,O
Upper Respiratory Tract Infection,AdverseReaction
112,O
19,O
15,O
3,O
Pneumoniaa,O
71,O
12,O
54,O
9,O
Metabolism,O
and,O
Nutrition,O
Disorders,O
Decreased Appetite,AdverseReaction
89,O
15,O
2,O
0,O
Hypercalcemia,AdverseReaction
68,O
11,O
26,O
4,O
Hypokalemia,AdverseReaction
61,O
10,O
17,O
3,O
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Back Pain,AdverseReaction
115,O
19,O
19,O
3,O
Arthralgia,AdverseReaction
83,O
14,O
5,O
1,O
Pain in Extremity,AdverseReaction
69,O
12,O
7,O
1,O
Muscle Spasms,AdverseReaction
62,O
10,O
2,O
0,O
Musculoskeletal Pain,AdverseReaction
60,O
10,O
12,O
2,O
Nervous,O
System,O
Disorders,O
Headache,AdverseReaction
141,O
24,O
7,O
1,O
Dizziness,AdverseReaction
64,O
11,O
5,O
1,O
Peripheral,O
Neuropathies,O
NECb,O
62,O
10,O
5,O
1,O
Psychiatric,O
Disorders,O
Insomnia,AdverseReaction
75,O
13,O
0,O
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Dyspneac,O
202,O
34,O
21,O
4,O
Cough,AdverseReaction
120,O
20,O
2,O
0,O
Epistaxis,AdverseReaction
60,O
10,O
5,O
1,O
Renal,O
Disorders,O
Renal Failure,AdverseReaction
76,O
13,O
49,O
8,O
Vascular,O
Disorders,O
Hypertensiond,O
90,O
15,O
22,O
4,O
Adverse,O
Reactions,O
Occurring,O
at,O
a,O
Frequency,O
of,O
10,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
febrile neutropenia,AdverseReaction
Cardiac,O
disorders,O
cardiac arrest,AdverseReaction
cardiac failure congestive,AdverseReaction
myocardial infarction,AdverseReaction
myocardial ischemia,AdverseReaction
Eye,O
disorders,O
cataract,AdverseReaction
blurred vision,AdverseReaction
Gastrointestinal,O
disorders,O
abdominal pain,AdverseReaction
abdominal pain upper,AdverseReaction
dyspepsia,AdverseReaction
toothache,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
infusion site reaction,AdverseReaction
multi organ failure,AdverseReaction
pain,AdverseReaction
Hepatobiliary,O
disorders,O
hepatic failure,AdverseReaction
Infections,O
and,O
infestations,O
bronchitis,AdverseReaction
influenza,AdverseReaction
nasopharyngitis,AdverseReaction
respiratory tract infection,AdverseReaction
sepsis,AdverseReaction
urinary tract infection,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorders,O
hyperglycemia,AdverseReaction
hyperkalemia,AdverseReaction
hyperuricemia,AdverseReaction
hypoalbuminemia,AdverseReaction
hypocalcemia,AdverseReaction
hypomagnesemia,AdverseReaction
hyponatremia,AdverseReaction
hypophosphatemia,AdverseReaction
tumor lysis syndrome,AdverseReaction
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
musculoskeletal chest pain,AdverseReaction
myalgia,AdverseReaction
Nervous,O
system,O
disorders,O
hypoesthesia,AdverseReaction
paresthesia,AdverseReaction
Psychiatric,O
disorders,O
anxiety,AdverseReaction
Renal,O
and,O
urinary,O
disorders,O
renal impairment,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
dysphonia,AdverseReaction
oropharyngeal pain,AdverseReaction
pulmonary edema,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
erythema,AdverseReaction
hyperhidrosis,AdverseReaction
pruritus,AdverseReaction
rash,AdverseReaction
Vascular,O
disorders,O
embolic and thrombotic events venous,AdverseReaction
including,O
deep vein thrombosis,AdverseReaction
and,O
pulmonary embolism,AdverseReaction
hypotension,AdverseReaction
Grade 3,Severity
and,O
higher,O
adverse,O
reactions,O
occurring,O
at,O
an,O
incidence,O
of,O
1,O
include,O
febrile neutropenia,AdverseReaction
cardiac arrest,AdverseReaction
cardiac failure congestive,AdverseReaction
pain,AdverseReaction
sepsis,AdverseReaction
urinary tract infection,AdverseReaction
hyperglycemia,AdverseReaction
hyperkalemia,AdverseReaction
hyperuricemia,AdverseReaction
hypoalbuminemia,AdverseReaction
hypocalcemia,AdverseReaction
hyponatremia,AdverseReaction
hypophosphatemia,AdverseReaction
renal failure,AdverseReaction
renal failure acute,AdverseReaction
renal impairment,AdverseReaction
pulmonary edema,AdverseReaction
and,O
hypotension,AdverseReaction
Laboratory,O
Abnormalities,O
Table,O
8,O
describes,O
Grade,O
3,O
4,O
laboratory,O
abnormalities,O
reported,O
at,O
a,O
rate,O
of,O
10,O
for,O
patients,O
who,O
received,O
Kyprolis,O
monotherapy,O
Table,O
8,O
Grade,O
3,O
4,O
Laboratory,O
Abnormalities,O
10,O
Monotherapy,O
Adverse,O
Reaction,O
Kyprolis,O
N,O
598,O
Decreased Platelets,AdverseReaction
184,O
31,O
Decreased Lymphocytes,AdverseReaction
151,O
25,O
Decreased Hemoglobin,AdverseReaction
132,O
22,O
Decreased Total White Blood Cell Count,AdverseReaction
71,O
12,O
Decreased Sodium,AdverseReaction
69,O
12,O
Decreased Absolute Neutrophil Count,AdverseReaction
67,O
11,O
6,O
2,O
Post,O
marketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
were,O
reported,O
in,O
the,O
post,O
marketing,O
experience,O
with,O
Kyprolis,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
dehydration,AdverseReaction
thrombotic thrombocytopenic purpura,AdverseReaction
hemolytic uremic syndrome,AdverseReaction
TTP,AdverseReaction
HUS,AdverseReaction
tumor lysis syndrome,AdverseReaction
including,O
fatal,AdverseReaction
outcomes,O
and,O
posterior reversible encephalopathy syndrome,AdverseReaction
PRES,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Anaphylaxis,AdverseReaction
and,O
Hypersensitivity Reactions,AdverseReaction
Life threatening,Severity
anaphylaxis,AdverseReaction
and,O
hypersensitivity reactions,AdverseReaction
have,O
been,O
observed,O
in,O
some,O
patients,O
during,O
and,O
after,O
treatment,O
with,O
alglucosidase,O
alfa,O
Ensure,O
that,O
appropriate,O
medical,O
support,O
measures,O
including,O
cardiopulmonary,O
resuscitation,O
equipment,O
are,O
readily,O
available,O
If,O
anaphylaxis,O
or,O
severe,O
hypersensitivity,O
reactions,O
occur,O
immediately,O
discontinue,O
infusion,O
and,O
initiate,O
appropriate,O
medical,O
treatment,O
5,O
1,O
Immune Mediated Reactions,AdverseReaction
Monitor,O
patients,O
for,O
the,O
development,O
of,O
systemic,O
immune,O
mediated,O
reactions,O
involving,O
skin,O
and,O
other,O
organs,O
5,O
2,O
Risk,Factor
of,O
Acute Cardiorespiratory Failure,AdverseReaction
Patients,O
with,O
compromised,O
cardiac,O
or,O
respiratory,O
function,O
may,Factor
be,O
at,O
risk,O
of,O
acute cardiorespiratory failure,AdverseReaction
Caution,O
should,O
be,O
exercised,O
when,O
administering,O
alglucosidase,O
alfa,O
to,O
patients,O
susceptible,O
to,O
fluid,O
volume,O
overload,O
Appropriate,O
medical,O
support,O
and,O
monitoring,O
measures,O
should,O
be,O
available,O
during,O
infusion,O
5,O
3,O
Risk,Factor
of,O
Cardiac Arrhythmia,AdverseReaction
and,O
Sudden Cardiac Death,AdverseReaction
during,O
General,O
Anesthesia,O
for,O
Central,O
Venous,O
Catheter,O
Placement,O
Caution,O
should,O
be,O
used,O
when,O
administering,O
general,O
anesthesia,O
for,O
the,O
placement,O
of,O
a,O
central,O
venous,O
catheter,O
intended,O
for,O
alglucosidase,O
alfa,O
infusion,O
5,O
4,O
5,O
1,O
Anaphylaxis,O
and,O
Hypersensitivity,O
Reactions,O
Anaphylaxis,AdverseReaction
and,O
hypersensitivity reactions,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
during,O
and,O
up,O
to,O
3,O
hours,O
after,O
alglucosidase,O
alfa,O
infusion,O
Some,O
of,O
the,O
reactions,O
were,O
life threatening,Severity
and,O
included,O
anaphylactic shock shock,AdverseReaction
cardiac arrest arrest,AdverseReaction
respiratory arrest arrest,AdverseReaction
respiratory distress distress,AdverseReaction
hypoxia,AdverseReaction
apnea,AdverseReaction
dyspnea,AdverseReaction
bradycardia,AdverseReaction
tachycardia,AdverseReaction
bronchospasm,AdverseReaction
throat tightness tightness,AdverseReaction
hypotension,AdverseReaction
angioedema,AdverseReaction
including,O
tongue,AdverseReaction
or,O
lip swelling swelling,AdverseReaction
periorbital edema edema,AdverseReaction
and,O
face edema edema,AdverseReaction
and,O
urticaria,AdverseReaction
Other,O
accompanying,O
reactions,O
included,O
chest discomfort,AdverseReaction
pain,AdverseReaction
wheezing,AdverseReaction
tachypnea,AdverseReaction
cyanosis,AdverseReaction
decreased oxygen saturation,AdverseReaction
convulsions,AdverseReaction
pruritus,AdverseReaction
rash,AdverseReaction
hyperhidrosis,AdverseReaction
nausea,AdverseReaction
dizziness,AdverseReaction
hypertension,AdverseReaction
increased blood pressure,AdverseReaction
flushing,AdverseReaction
feeling hot,AdverseReaction
erythema,AdverseReaction
pyrexia,AdverseReaction
pallor,AdverseReaction
peripheral coldness,AdverseReaction
restlessness,AdverseReaction
nervousness,AdverseReaction
headache,AdverseReaction
back pain,AdverseReaction
and,O
paresthesia,AdverseReaction
Some,O
of,O
these,O
reactions,O
were,O
IgE,O
mediated,O
If,O
anaphylaxis,O
or,O
severe,O
hypersensitivity,O
reactions,O
occur,O
immediately,O
discontinue,O
administration,O
of,O
alglucosidase,O
alfa,O
and,O
initiate,O
appropriate,O
medical,O
treatment,O
Severe,O
reactions,O
are,O
generally,O
managed,O
with,O
infusion,O
interruption,O
administration,O
of,O
antihistamines,O
corticosteroids,O
intravenous,O
fluids,O
and,O
or,O
oxygen,O
when,O
clinically,O
indicated,O
In,O
some,O
cases,O
of,O
anaphylaxis,O
epinephrine,O
has,O
been,O
administered,O
Appropriate,O
medical,O
support,O
including,O
cardiopulmonary,O
resuscitation,O
equipment,O
should,O
be,O
readily,O
available,O
when,O
alglucosidase,O
alfa,O
is,O
administered,O
The,O
risks,O
and,O
benefits,O
of,O
re,O
administering,O
alglucosidase,O
alfa,O
following,O
an,O
anaphylactic,O
or,O
hypersensitivity,O
reaction,O
should,O
be,O
considered,O
Some,O
patients,O
have,O
been,O
rechallenged,O
and,O
have,O
continued,O
to,O
receive,O
alglucosidase,O
alfa,O
under,O
close,O
clinical,O
supervision,O
Extreme,O
care,O
should,O
be,O
exercised,O
with,O
appropriate,O
resuscitation,O
measures,O
available,O
if,O
the,O
decision,O
is,O
made,O
to,O
re,O
administer,O
the,O
product,O
seeAdverse,O
Reactions,O
6,O
2,O
5,O
2,O
Immune,O
Mediated,O
Reactions,O
Immune mediated cutaneous reactions,AdverseReaction
have,O
been,O
reported,O
with,O
alglucosidase,O
alfa,O
including,O
necrotizing skin lesions,AdverseReaction
seeAdverse,O
Reactions,O
6,O
3,O
Systemic immune mediated reactions,AdverseReaction
including,O
possible,Factor
type III immune mediated reactions,AdverseReaction
have,O
been,O
observed,O
with,O
alglucosidase,O
alfa,O
These,O
reactions,O
occurred,O
several,O
weeks,O
to,O
3,O
years,O
after,O
initiation,O
of,O
alglucosidase,O
alfa,O
infusions,O
Skin,O
biopsy,O
in,O
one,O
patient,O
demonstrated,O
deposition of anti rhGAA antibodies,AdverseReaction
in,O
the,O
lesion,O
Another,O
patient,O
developed,O
severe,Severity
inflammatory arthropathy,AdverseReaction
in,O
association,O
with,O
pyrexia,AdverseReaction
and,O
elevated erythrocyte sedimentation rate,AdverseReaction
Nephrotic syndrome,AdverseReaction
secondary,O
to,O
membranous glomerulonephritis,AdverseReaction
was,O
observed,O
in,O
some,O
Pompe,O
disease,O
patients,O
treated,O
with,O
alglucosidase,O
alfa,O
who,O
had,O
persistently,O
positive anti rhGAA IgG antibody titers,AdverseReaction
In,O
these,O
patients,O
renal,O
biopsy,O
was,O
consistent,O
with,O
immune complex deposition,AdverseReaction
Patients,O
improved,O
following,O
treatment,O
interruption,O
Therefore,O
patients,O
receiving,O
alglucosidase,O
alfa,O
should,O
undergo,O
periodic,O
urinalysis,O
seeAdverse,O
Reactions,O
6,O
3,O
Patients,O
should,O
be,O
monitored,O
for,O
the,O
development,O
of,O
systemic,O
immune,O
mediated,O
reactions,O
involving,O
skin,O
and,O
other,O
organs,O
while,O
receiving,O
alglucosidase,O
alfa,O
If,O
immune,O
mediated,O
reactions,O
occur,O
consider,O
discontinuation,O
of,O
the,O
administration,O
of,O
alglucosidase,O
alfa,O
and,O
initiate,O
appropriate,O
medical,O
treatment,O
The,O
risks,O
and,O
benefits,O
of,O
re,O
administering,O
alglucosidase,O
alfa,O
following,O
an,O
immune,O
mediated,O
reaction,O
should,O
be,O
considered,O
Some,O
patients,O
have,O
been,O
able,O
to,O
be,O
rechallenged,O
and,O
have,O
continued,O
to,O
receive,O
alglucosidase,O
alfa,O
under,O
close,O
clinical,O
supervision,O
5,O
3,O
Risk,O
of,O
Acute,O
Cardiorespiratory,O
Failure,O
Patients,O
with,O
acute,O
underlying,O
respiratory,O
illness,O
or,O
compromised,O
cardiac,O
and,O
or,O
respiratory,O
function,O
may,Factor
be,O
at,O
risk,O
of,O
serious,Severity
exacerbation of of,AdverseReaction
their,O
cardiac,AdverseReaction
or,O
respiratory compromise,AdverseReaction
compromise,AdverseReaction
during,O
infusions,O
Appropriate,O
medical,O
support,O
and,O
monitoring,O
measures,O
should,O
be,O
readily,O
available,O
during,O
alglucosidase,O
alfa,O
infusion,O
and,O
some,O
patients,O
may,O
require,O
prolonged,O
observation,O
times,O
that,O
should,O
be,O
individualized,O
based,O
on,O
the,O
needs,O
of,O
the,O
patient,O
Acute cardiorespiratory failure,AdverseReaction
has,O
been,O
observed,O
in,O
infantile,O
onset,O
Pompe,O
disease,O
patients,O
with,O
underlying,O
cardiac,O
hypertrophy,O
possibly,O
associated,O
with,O
fluid overload,AdverseReaction
with,O
intravenous,O
administration,O
of,O
alglucosidase,O
alfa,O
seeDosage,O
and,O
Administration,O
2,O
2,O
5,O
4,O
Risk,O
of,O
Cardiac,O
Arrhythmia,O
and,O
Sudden,O
Cardiac,O
Death,O
During,O
General,O
Anesthesia,O
for,O
Central,O
Venous,O
Catheter,O
Placement,O
Administration,O
of,O
general,O
anesthesia,O
can,O
be,O
complicated,O
by,O
the,O
presence,O
of,O
severe,O
cardiac,O
and,O
skeletal,O
including,O
respiratory,O
muscle,O
weakness,O
Therefore,O
caution,O
should,O
be,O
used,O
when,O
administering,O
general,O
anesthesia,O
Ventricular arrhythmias,AdverseReaction
and,O
bradycardia,AdverseReaction
resulting,O
in,O
cardiac arrest,AdverseReaction
or,O
death,AdverseReaction
or,O
requiring,O
cardiac,O
resuscitation,O
or,O
defibrillation,O
have,O
been,O
observed,O
in,O
infantile,O
onset,O
Pompe,O
disease,O
patients,O
with,O
cardiac,O
hypertrophy,O
during,O
general,O
anesthesia,O
for,O
central,O
venous,O
catheter,O
placement,O
5,O
5,O
Risk,O
of,O
Antibody,O
Development,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
potential,O
for,O
immunogenicity,O
In,O
clinical,O
studies,O
the,O
majority,O
of,O
patients,O
developed,O
IgG,O
antibodies,O
to,O
alglucosidase,O
alfa,O
typically,O
within,O
3,O
months,O
of,O
treatment,O
There,O
is,O
evidence,O
to,O
suggest,O
that,O
some,O
patients,O
who,O
develop,O
high,O
and,O
sustained,O
IgG,O
antibody,O
titers,O
may,Factor
experience,O
reduced clinical efficacy,AdverseReaction
to,O
alglucosidase,O
alfa,O
treatment,O
such,O
as,O
loss of motor function,AdverseReaction
ventilator,O
dependence,O
or,O
death,AdverseReaction
The,O
effect,O
of,O
antibody,O
development,O
on,O
the,O
long,O
term,O
efficacy,O
of,O
alglucosidase,O
alfa,O
is,O
not,O
fully,O
understood,O
Patients,O
should,O
be,O
monitored,O
for,O
IgG,O
antibody,O
formation,O
every,O
3,O
months,O
for,O
2,O
years,O
and,O
then,O
annually,O
thereafter,O
Testing,O
for,O
IgG,O
titers,O
may,O
also,O
be,O
considered,O
if,O
patients,O
develop,O
hypersensitivity,O
reactions,O
other,O
immune,O
mediated,O
reactions,O
or,O
lose,O
clinical,O
response,O
Patients,O
who,O
experience,O
reduced,O
clinical,O
response,O
may,O
also,O
be,O
tested,O
for,O
inhibitory,O
antibody,O
activity,O
Patients,O
who,O
experience,O
anaphylactic,O
or,O
hypersensitivity,O
reactions,O
may,O
also,O
be,O
tested,O
for,O
IgE,O
antibodies,O
to,O
alglucosidase,O
alfa,O
and,O
other,O
mediators,O
of,O
anaphylaxis,O
seeAdverse,O
Reactions,O
6,O
2,O
There,O
are,O
currently,O
no,O
marketed,O
tests,O
for,O
antibodies,O
against,O
alglucosidase,O
alfa,O
however,O
a,O
testing,O
service,O
is,O
provided,O
by,O
Genzyme,O
Contact,O
your,O
local,O
Genzyme,O
representative,O
or,O
Genzyme,O
Corporation,O
at,O
1,O
800,O
745,O
4447,O
for,O
information,O
on,O
testing,O
and,O
to,O
obtain,O
a,O
sample,O
collection,O
box,O
""
BOXED,O
WARNING,O
WARNING,O
RISK,Factor
OF,O
ANAPHYLAXIS,AdverseReaction
HYPERSENSITIVITY,AdverseReaction
AND,O
IMMUNE MEDIATED REACTIONS,AdverseReaction
AND,O
RISK,Factor
OF,O
CARDIORESPIRATORY FAILURE,AdverseReaction
WARNING,O
RISK,Factor
OF,O
ANAPHYLAXIS,AdverseReaction
HYPERSENSITIVITY,AdverseReaction
AND,O
IMMUNE MEDIATED REACTIONS,AdverseReaction
AND,O
RISK,Factor
OF,O
CARDIORESPIRATORY FAILURE,AdverseReaction
Life threatening,Severity
anaphylactic reactions,AdverseReaction
and,O
severe,Severity
hypersensitivity reactions,AdverseReaction
presenting,O
as,O
respiratory distress,AdverseReaction
hypoxia,AdverseReaction
apnea,AdverseReaction
dyspnea,AdverseReaction
bradycardia,AdverseReaction
tachycardia,AdverseReaction
bronchospasm,AdverseReaction
throat tightness,AdverseReaction
hypotension,AdverseReaction
angioedema,AdverseReaction
including,O
tongue,AdverseReaction
or,O
lip swelling,AdverseReaction
periorbital edema,AdverseReaction
and,O
face edema,AdverseReaction
and,O
urticaria,AdverseReaction
have,O
occurred,O
in,O
some,O
patients,O
during,O
and,O
after,O
alglucosidase,O
alfa,O
infusions,O
Immune mediated reactions,AdverseReaction
presenting,O
as,O
proteinuria,AdverseReaction
nephrotic syndrome,AdverseReaction
and,O
necrotizing skin lesions,AdverseReaction
have,O
occurred,O
in,O
some,O
patients,O
following,O
alglucosidase,O
alfa,O
treatment,O
Closely,O
observe,O
patients,O
during,O
and,O
after,O
alglucosidase,O
alfa,O
administration,O
and,O
be,O
prepared,O
to,O
manage,O
anaphylaxis,O
and,O
hypersensitivity,O
reactions,O
Inform,O
patients,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
anaphylaxis,O
hypersensitivity,O
reactions,O
and,O
immune,O
mediated,O
reactions,O
and,O
have,O
them,O
seek,O
immediate,O
medical,O
care,O
should,O
signs,O
and,O
symptoms,O
occur,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
2,O
Infantile,O
onset,O
Pompe,O
disease,O
patients,O
with,O
compromised,O
cardiac,O
or,O
respiratory,O
function,O
may,Factor
be,O
at,O
risk,O
of,O
serious,Severity
acute exacerbation of exacerbation of,AdverseReaction
their,O
cardiac,AdverseReaction
or,O
respiratory compromise,AdverseReaction
due,O
to,O
fluid overload,AdverseReaction
and,O
require,O
additional,O
monitoring,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
WARNING,O
RISK,Factor
OF,O
ANAPHYLAXIS,AdverseReaction
HYPERSENSITIVITY,AdverseReaction
AND,O
IMMUNE MEDIATED REACTIONS,AdverseReaction
and,O
RISK,Factor
OF,O
CARDIORESPIRATORY FAILURE,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Life threatening,Severity
anaphylactic reactions,AdverseReaction
and,O
severe,Severity
hypersensitivity reactions,AdverseReaction
have,O
occurred,O
in,O
some,O
patients,O
during,O
and,O
after,O
alglucosidase,O
alfa,O
infusions,O
Immune mediated reactions,AdverseReaction
presenting,O
as,O
proteinuria,AdverseReaction
nephrotic syndrome,AdverseReaction
and,O
necrotizing skin lesions,AdverseReaction
have,O
occurred,O
in,O
some,O
patients,O
following,O
alglucosidase,O
alfa,O
treatment,O
Closely,O
observe,O
patients,O
during,O
and,O
after,O
alglucosidase,O
alfa,O
administration,O
and,O
be,O
prepared,O
to,O
manage,O
anaphylaxis,O
and,O
hypersensitivity,O
reactions,O
Inform,O
patients,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
anaphylaxis,O
hypersensitivity,O
reactions,O
and,O
immune,O
mediated,O
reactions,O
and,O
have,O
them,O
seek,O
immediate,O
medical,O
care,O
should,O
signs,O
and,O
symptoms,O
occur,O
5,O
1,O
5,O
2,O
Infantile,O
onset,O
Pompe,O
disease,O
patients,O
with,O
compromised,O
cardiac,O
or,O
respiratory,O
function,O
may,Factor
be,O
at,O
risk,O
of,O
serious,Severity
acute exacerbation of exacerbation of,AdverseReaction
their,O
cardiac,AdverseReaction
or,O
respiratory compromise,AdverseReaction
compromise,AdverseReaction
due,O
to,O
fluid overload,AdverseReaction
and,O
require,O
additional,O
monitoring,O
5,O
3,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
5,O
in,O
clinical,O
trials,O
were,O
hypersensitivity reactions,AdverseReaction
and,O
included,O
anaphylaxis,AdverseReaction
rash,AdverseReaction
pyrexia,AdverseReaction
flushing,AdverseReaction
feeling hot,AdverseReaction
urticaria,AdverseReaction
headache,AdverseReaction
hyperhidrosis,AdverseReaction
nausea,AdverseReaction
cough,AdverseReaction
decreased oxygen saturation,AdverseReaction
tachycardia,AdverseReaction
tachypnea,AdverseReaction
chest discomfort,AdverseReaction
dizziness,AdverseReaction
muscle twitching,AdverseReaction
agitation,AdverseReaction
cyanosis,AdverseReaction
erythema,AdverseReaction
hypertension,AdverseReaction
increased blood pressure,AdverseReaction
pallor,AdverseReaction
rigors,AdverseReaction
tremor,AdverseReaction
vomiting,AdverseReaction
fatigue,AdverseReaction
and,O
myalgia,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Genzyme,O
at,O
1,O
800,O
745,O
4447,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
described,O
below,O
and,O
elsewhere,O
in,O
the,O
labeling,O
Anaphylaxis,O
and,O
hypersensitivity,O
reactions,O
seeWarnings,O
and,O
Precautions,O
5,O
1,O
In,O
clinical,O
trials,O
the,O
most,O
common,O
adverse,O
reactions,O
5,O
following,O
alglucosidase,O
alfa,O
treatment,O
were,O
hypersensitivity reactions,AdverseReaction
and,O
included,O
anaphylaxis,AdverseReaction
rash,AdverseReaction
pyrexia,AdverseReaction
flushing,AdverseReaction
feeling hot,AdverseReaction
urticaria,AdverseReaction
headache,AdverseReaction
hyperhidrosis,AdverseReaction
nausea,AdverseReaction
cough,AdverseReaction
decreased oxygen saturation,AdverseReaction
tachycardia,AdverseReaction
tachypnea,AdverseReaction
chest discomfort,AdverseReaction
dizziness,AdverseReaction
muscle twitching,AdverseReaction
agitation,AdverseReaction
cyanosis,AdverseReaction
erythema,AdverseReaction
hypertension,AdverseReaction
increased blood pressure,AdverseReaction
pallor,AdverseReaction
rigors,AdverseReaction
tremor,AdverseReaction
vomiting,AdverseReaction
fatigue,AdverseReaction
and,O
myalgia,AdverseReaction
Clinical,O
Trials,O
in,O
Infantile,O
Onset,O
and,O
Juvenile,O
Onset,O
Pompe,O
Disease,O
Two,O
multicenter,O
open,O
label,O
clinical,O
trials,O
were,O
conducted,O
in,O
39,O
infantile,O
onset,O
Pompe,O
disease,O
patients,O
ages,O
1,O
month,O
to,O
3,O
5,O
years,O
old,O
Approximately,O
half,O
of,O
the,O
patients,O
54,O
were,O
male,O
Patients,O
were,O
treated,O
with,O
alglucosidase,O
alfa,O
20,O
or,O
40,O
mg,O
kg,O
every,O
other,O
week,O
for,O
periods,O
ranging,O
from,O
1,O
to,O
106,O
weeks,O
mean,O
61,O
weeks,O
The,O
most,O
serious,O
adverse,O
reactions,O
reported,O
with,O
alglucosidase,O
alfa,O
treatment,O
included,O
anaphylaxis,AdverseReaction
and,O
acute cardiorespiratory failure,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
requiring,O
intervention,O
in,O
clinical,O
trials,O
were,O
hypersensitivity reactions,AdverseReaction
occurring,O
in,O
20,O
of,O
39,O
51,O
patients,O
treated,O
with,O
alglucosidase,O
alfa,O
and,O
included,O
rash,AdverseReaction
pyrexia,AdverseReaction
urticaria,AdverseReaction
flushing,AdverseReaction
decreased oxygen saturation,AdverseReaction
cough,AdverseReaction
tachypnea,AdverseReaction
tachycardia,AdverseReaction
hypertension,AdverseReaction
increased blood pressure,AdverseReaction
pallor,AdverseReaction
rigors,AdverseReaction
vomiting,AdverseReaction
cyanosis,AdverseReaction
agitation,AdverseReaction
and,O
tremor,AdverseReaction
These,O
reactions,O
were,O
more,O
likely,O
to,O
occur,O
with,O
higher,O
infusion,O
rates,O
Some,O
patients,O
who,O
were,O
pre,O
treated,O
with,O
antihistamines,O
antipyretics,O
and,O
or,O
corticosteroids,O
still,O
experienced,O
hypersensitivity reactions,AdverseReaction
Table,O
2,O
summarizes,O
all,O
adverse,O
reactions,O
occurring,O
in,O
5,O
of,O
patients,O
2,O
or,O
more,O
patients,O
treated,O
with,O
alglucosidase,O
alfa,O
in,O
clinical,O
trials,O
described,O
above,O
Table,O
2,O
Adverse,O
Reactions,O
that,O
Occurred,O
in,O
At,O
Least,O
5,O
of,O
Infantile,O
Onset,O
Patients,O
Treated,O
with,O
Alglucosidase,O
Alfa,O
in,O
Clinical,O
Trials,O
Number,O
of,O
Patients,O
N,O
39,O
n,O
Adverse,O
Reaction,O
20,O
51,O
Rash,AdverseReaction
including,O
rash erythematous,AdverseReaction
rash macular,AdverseReaction
and,O
maculo papular,AdverseReaction
7,O
18,O
Pyrexia,AdverseReaction
6,O
15,O
Urticaria,AdverseReaction
5,O
13,O
Flushing,AdverseReaction
5,O
13,O
Hypertension,AdverseReaction
Increased Blood Pressure,AdverseReaction
4,O
10,O
Decreased Oxygen Saturation,AdverseReaction
3,O
8,O
Cough,AdverseReaction
3,O
8,O
Tachypnea,AdverseReaction
3,O
8,O
Tachycardia,AdverseReaction
3,O
8,O
Erythema,AdverseReaction
2,O
5,O
Vomiting,AdverseReaction
2,O
5,O
Rigors,AdverseReaction
2,O
5,O
Pallor,AdverseReaction
2,O
5,O
Cyanosis,AdverseReaction
2,O
5,O
Agitation,AdverseReaction
2,O
5,O
Tremor,AdverseReaction
2,O
5,O
An,O
open,O
label,O
single,O
center,O
trial,O
was,O
conducted,O
in,O
18,O
treatment,O
naive,O
infantile,O
onset,O
Pompe,O
disease,O
patients,O
who,O
were,O
treated,O
exclusively,O
with,O
alglucosidase,O
alfa,O
Adverse,O
reactions,O
observed,O
in,O
these,O
patients,O
were,O
similar,O
to,O
infantile,O
onset,O
Pompe,O
disease,O
patients,O
who,O
received,O
alglucosidase,O
alfa,O
in,O
other,O
clinical,O
trials,O
Additional,O
hypersensitivity reactions,AdverseReaction
observed,O
in,O
infantile,O
onset,O
Pompe,O
disease,O
patients,O
treated,O
in,O
other,O
clinical,O
trials,O
and,O
expanded,O
access,O
programs,O
with,O
alglucosidase,O
alfa,O
included,O
livedo reticularis,AdverseReaction
irritability,AdverseReaction
retching,AdverseReaction
increased lacrimation,AdverseReaction
ventricular extrasystoles,AdverseReaction
nodal rhythm,AdverseReaction
rales,AdverseReaction
respiratory tract irritation,AdverseReaction
and,O
cold sweat,AdverseReaction
Safety,O
was,O
also,O
evaluated,O
in,O
99,O
patients,O
51,O
male,O
48,O
females,O
with,O
Pompe,O
disease,O
in,O
an,O
ongoing,O
open,O
label,O
prospective,O
study,O
in,O
patients,O
12,O
months,O
of,O
age,O
and,O
older,O
who,O
were,O
previously,O
treated,O
with,O
the,O
160,O
L,O
scale,O
of,O
alglucosidase,O
alfa,O
and,O
switched,O
to,O
the,O
4000,O
L,O
scale,O
of,O
alglucosidase,O
alfa,O
Patients,O
were,O
aged,O
1,O
to,O
18,O
years,O
with,O
a,O
median,O
duration,O
of,O
treatment,O
of,O
437,O
days,O
range,O
13,O
to,O
466,O
days,O
No,O
new,O
safety,O
findings,O
were,O
observed,O
following,O
the,O
switch,O
to,O
4000,O
L,O
scale,O
of,O
alglucosidase,O
alfa,O
Clinical,O
Trials,O
in,O
Late,O
Onset,O
Pompe,O
Disease,O
Assessment,O
of,O
adverse,O
reactions,O
in,O
patients,O
with,O
late,O
onset,O
Pompe,O
disease,O
is,O
based,O
on,O
the,O
exposure,O
of,O
90,O
patients,O
45,O
male,O
45,O
female,O
aged,O
10,O
to,O
70,O
years,O
to,O
20,O
mg,O
kg,O
alglucosidase,O
alfa,O
or,O
placebo,O
in,O
a,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
trial,O
The,O
youngest,O
alglucosidase,O
alfa,O
treated,O
patient,O
was,O
16,O
years,O
of,O
age,O
and,O
the,O
youngest,O
placebo,O
treated,O
patient,O
was,O
10,O
years,O
of,O
age,O
All,O
patients,O
were,O
naive,O
to,O
enzyme,O
replacement,O
therapy,O
Patients,O
were,O
randomized,O
in,O
a,O
2,O
1,O
ratio,O
and,O
received,O
alglucosidase,O
alfa,O
or,O
placebo,O
every,O
other,O
week,O
for,O
78,O
weeks,O
18,O
months,O
The,O
study,O
population,O
included,O
34,O
males,O
and,O
26,O
females,O
n,O
60,O
in,O
the,O
alglucosidase,O
alfa,O
group,O
and,O
11,O
males,O
and,O
19,O
females,O
n,O
30,O
in,O
the,O
placebo,O
group,O
Two,O
patients,O
receiving,O
alglucosidase,O
alfa,O
discontinued,O
the,O
trial,O
due,O
to,O
anaphylactic reactions,AdverseReaction
Serious,O
adverse,O
reactions,O
reported,O
with,O
alglucosidase,O
alfa,O
included,O
anaphylaxis,AdverseReaction
which,O
presented,O
as,O
angioedema,AdverseReaction
throat tightness,AdverseReaction
and,O
chest pain,AdverseReaction
discomfort,AdverseReaction
One,O
patient,O
with,O
a,O
history,O
of,O
Wolff,O
Parkinson,O
White,O
syndrome,O
experienced,O
a,O
serious,O
adverse,O
reaction,O
of,O
supraventricular tachycardia,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
3,O
2,O
or,O
more,O
patients,O
observed,O
in,O
alglucosidase,O
alfa,O
treated,O
patients,O
were,O
hypersensitivity reactions,AdverseReaction
and,O
included,O
anaphylaxis,AdverseReaction
headache,AdverseReaction
nausea,AdverseReaction
urticaria,AdverseReaction
dizziness,AdverseReaction
chest discomfort,AdverseReaction
vomiting,AdverseReaction
hyperhidrosis,AdverseReaction
flushing,AdverseReaction
feeling hot,AdverseReaction
increased blood pressure,AdverseReaction
paresthesia,AdverseReaction
pyrexia,AdverseReaction
local swelling,AdverseReaction
diarrhea,AdverseReaction
pruritus,AdverseReaction
rash,AdverseReaction
and,O
throat tightness,AdverseReaction
Delayed,O
onset,O
reactions,O
defined,O
as,O
adverse,O
reactions,O
occurring,O
2,O
48,O
hours,O
after,O
completion,O
of,O
alglucosidase,O
alfa,O
infusion,O
that,O
were,O
observed,O
in,O
3,O
more,O
patients,O
in,O
the,O
alglucosidase,O
alfa,O
treated,O
group,O
compared,O
to,O
patients,O
in,O
the,O
placebo,O
treated,O
group,O
in,O
the,O
controlled,O
trial,O
included,O
hyperhidrosis,AdverseReaction
Additional,O
delayed,O
onset,O
reactions,O
occurring,O
in,O
alglucosidase,O
alfa,O
treated,O
patients,O
included,O
fatigue,AdverseReaction
myalgia,AdverseReaction
and,O
nausea,AdverseReaction
Patients,O
should,O
be,O
counseled,O
about,O
the,O
possibility,O
of,O
delayed,O
onset,O
hypersensitivity,O
reactions,O
and,O
given,O
proper,O
follow,O
up,O
instructions,O
Table,O
3,O
summarizes,O
the,O
most,O
common,O
adverse,O
reactions,O
that,O
occurred,O
in,O
at,O
least,O
3,O
of,O
alglucosidase,O
alfa,O
treated,O
patients,O
and,O
with,O
a,O
higher,O
incidence,O
than,O
the,O
placebo,O
treated,O
patients,O
during,O
the,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
study,O
described,O
above,O
Table,O
3,O
Adverse,O
Reactions,O
Occurring,O
in,O
at,O
Least,O
3,O
of,O
Alglucosidase,O
Alfa,O
Treated,O
Late,O
Onset,O
Patients,O
and,O
with,O
a,O
Higher,O
Incidence,O
than,O
the,O
Placebo,O
Treated,O
Patients,O
Adverse,O
Reaction,O
Alglucosidase,O
Alfan,O
60N,O
Placebon,O
30N,O
Hyperhidrosis,AdverseReaction
5,O
8,O
3,O
0,O
0,O
Urticaria,AdverseReaction
5,O
8,O
3,O
0,O
0,O
Anaphylaxis,AdverseReaction
4,O
6,O
7,O
0,O
0,O
Chest Discomfort,AdverseReaction
4,O
6,O
7,O
1,O
3,O
3,O
Muscle Twitching,AdverseReaction
4,O
6,O
7,O
1,O
3,O
3,O
Myalgia,AdverseReaction
3,O
5,O
0,O
1,O
3,O
3,O
Flushing,AdverseReaction
Feeling Hot,AdverseReaction
3,O
5,O
0,O
0,O
0,O
Increased Blood Pressure,AdverseReaction
3,O
5,O
0,O
0,O
0,O
Vomiting,AdverseReaction
3,O
5,O
0,O
0,O
0,O
Edema Peripheral,AdverseReaction
2,O
3,O
3,O
0,O
0,O
Pruritus,AdverseReaction
2,O
3,O
3,O
0,O
0,O
Rash Papular,AdverseReaction
2,O
3,O
3,O
0,O
0,O
Throat Tightness,AdverseReaction
2,O
3,O
3,O
0,O
0,O
In,O
clinical,O
trials,O
anaphylaxis,AdverseReaction
and,O
hypersensitivity reactions,AdverseReaction
were,O
managed,O
with,O
infusion,O
interruption,O
decreased,O
infusion,O
rate,O
administration,O
of,O
antihistamines,O
corticosteroids,O
intravenous,O
fluids,O
and,O
or,O
oxygen,O
when,O
clinically,O
indicated,O
In,O
some,O
cases,O
of,O
anaphylactic reactions,AdverseReaction
epinephrine,O
was,O
administered,O
Patients,O
who,O
have,O
experienced,O
anaphylaxis,O
or,O
hypersensitivity,O
reactions,O
should,O
be,O
treated,O
with,O
caution,O
when,O
they,O
are,O
re,O
administered,O
alglucosidase,O
alfa,O
6,O
2,O
Immunogenicity,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
potential,O
for,O
immunogenicity,O
The,O
data,O
reflect,O
the,O
percentage,O
of,O
patients,O
whose,O
test,O
results,O
were,O
considered,O
positive,O
for,O
antibodies,O
to,O
alglucosidase,O
alfa,O
using,O
an,O
enzyme,O
linked,O
immunosorbent,O
assay,O
ELISA,O
and,O
confirmed,O
by,O
a,O
radioimmunoprecipitation,O
RIP,O
assay,O
for,O
alglucosidase,O
alfa,O
specific,O
IgG,O
antibodies,O
In,O
the,O
two,O
clinical,O
trials,O
in,O
infantile,O
onset,O
patients,O
the,O
majority,O
of,O
patients,O
34,O
of,O
38,O
89,O
tested,O
positive,O
for,O
IgG,O
antibodies,O
to,O
alglucosidase,O
alfa,O
There,O
is,O
evidence,O
to,O
suggest,O
that,O
some,O
patients,O
who,O
develop,O
high,O
sustained,O
titers,O
of,O
anti,O
alglucosidase,O
alfa,O
antibodies,O
may,O
experience,O
reduced,O
clinical,O
efficacy,O
to,O
alglucosidase,O
alfa,O
treatment,O
seeWarnings,O
and,O
Precautions,O
5,O
5,O
Some,O
IgG,O
positive,O
patients,O
in,O
clinical,O
trials,O
who,O
were,O
retrospectively,O
evaluated,O
for,O
the,O
presence,O
of,O
inhibitory,O
antibodies,O
tested,O
positive,O
for,O
inhibition,O
of,O
enzyme,O
activity,O
and,O
or,O
uptake,O
in,O
in,O
vitro,O
assays,O
Furthermore,O
CRIM,O
negative,O
infants,O
have,O
shown,O
reduced,O
clinical,O
effect,O
in,O
the,O
presence,O
of,O
high sustained,Severity
IgG antibody titers with inhibitory activity,AdverseReaction
Alglucosidase,O
alfa,O
treated,O
patients,O
who,O
experience,O
a,O
decrease,O
in,O
motor,O
function,O
should,O
be,O
tested,O
for,O
the,O
presence,O
of,O
inhibitory,O
antibodies,O
that,O
neutralize,O
enzyme,O
uptake,O
or,O
activity,O
In,O
the,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
trial,O
in,O
late,O
onset,O
patients,O
all,O
alglucosidase,O
alfa,O
treated,O
patients,O
with,O
available,O
samples,O
N,O
59,O
100,O
developed,O
IgG,O
antibodies,O
to,O
alglucosidase,O
alfa,O
Most,O
patients,O
who,O
developed,O
IgG,O
antibodies,O
did,O
so,O
within,O
the,O
first,O
3,O
months,O
of,O
exposure,O
median,O
time,O
to,O
seroconversion,O
was,O
4,O
weeks,O
There,O
was,O
no,O
apparent,O
association,O
between,O
mean,O
or,O
peak,O
IgG,O
antibody,O
titers,O
and,O
the,O
occurrence,O
of,O
adverse,O
reactions,O
None,O
of,O
the,O
59,O
evaluable,O
patients,O
tested,O
positive,O
for,O
inhibition,O
of,O
enzyme,O
activity,O
Antibody,O
titers,O
for,O
cellular,O
uptake,O
inhibition,O
were,O
present,O
in,O
18,O
of,O
59,O
31,O
patients,O
by,O
Week,O
78,O
All,O
other,O
patients,O
tested,O
negative,O
for,O
inhibition,O
of,O
cellular,O
uptake,O
Patients,O
who,O
tested,O
positive,O
for,O
uptake,O
inhibition,O
tended,O
to,O
have,O
higher,O
IgG,O
titers,O
than,O
patients,O
who,O
tested,O
negative,O
for,O
uptake,O
inhibition,O
Among,O
the,O
32,O
patients,O
with,O
evaluable,O
pharmacokinetic,O
PK,O
samples,O
5,O
patients,O
tested,O
positive,O
for,O
uptake,O
inhibition,O
The,O
clinical,O
relevance,O
of,O
this,O
in,O
vitro,O
inhibition,O
is,O
not,O
fully,O
understood,O
The,O
clearance,O
values,O
for,O
4,O
of,O
these,O
5,O
patients,O
were,O
approximately,O
1,O
2,O
to,O
1,O
8,O
fold,O
greater,O
in,O
the,O
presence,O
of,O
inhibitory,O
antibodies,O
Week,O
52,O
as,O
compared,O
to,O
in,O
the,O
absence,O
of,O
inhibitory,O
antibodies,O
Week,O
0,O
seeClinical,O
Pharmacology,O
12,O
3,O
Some,O
patients,O
in,O
the,O
clinical,O
studies,O
or,O
in,O
the,O
postmarketing,O
setting,O
have,O
undergone,O
testing,O
for,O
alglucosidase,O
alfa,O
specific,O
IgE,O
antibodies,O
Testing,O
was,O
performed,O
in,O
patients,O
who,O
experienced,O
moderate to severe,Severity
severe,Severity
or,O
recurrent hypersensitivity reactions,AdverseReaction
hypersensitivity reactions,AdverseReaction
for,O
which,O
mast,O
cell,O
activation,O
was,O
suspected,O
Some,O
of,O
the,O
patients,O
who,O
tested,O
positive,O
for,O
alglucosidase,O
alfa,O
specific,O
IgE,O
antibodies,O
experienced,O
anaphylactic reactions,AdverseReaction
seeBoxed,O
WarningandWarnings,O
and,O
Precautions,O
5,O
1,O
Some,O
patients,O
who,O
tested,O
positive,O
for,O
alglucosidase,O
alfa,O
specific,O
IgE,O
antibodies,O
and,O
experienced,O
hypersensitivity reactions,AdverseReaction
were,O
able,O
to,O
be,O
rechallenged,O
with,O
alglucosidase,O
alfa,O
using,O
a,O
slower,O
infusion,O
rate,O
at,O
lower,O
starting,O
doses,O
and,O
have,O
continued,O
to,O
receive,O
treatment,O
under,O
close,O
clinical,O
supervision,O
seeWarnings,O
and,O
Precautions,O
5,O
1,O
Since,O
patients,O
who,O
develop,O
IgE,O
antibodies,O
to,O
alglucosidase,O
alfa,O
appear,O
to,O
be,O
at,O
a,O
higher,O
risk,O
for,O
developing,O
anaphylaxis,O
and,O
hypersensitivity,O
reactions,O
these,O
patients,O
should,O
be,O
monitored,O
more,O
closely,O
during,O
administration,O
of,O
alglucosidase,O
alfa,O
The,O
detection,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
alglucosidase,O
alfa,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
6,O
3,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
alglucosidase,O
alfa,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
In,O
postmarketing,O
experience,O
with,O
alglucosidase,O
alfa,O
serious,O
adverse,O
reactions,O
have,O
been,O
reported,O
including,O
anaphylaxis,AdverseReaction
seeBoxed,O
WarningandWarnings,O
and,O
Precautions,O
5,O
1,O
Acute cardiorespiratory failure,AdverseReaction
possibly,O
associated,O
with,O
fluid overload,AdverseReaction
has,O
been,O
reported,O
in,O
infantile,O
onset,O
Pompe,O
disease,O
patients,O
with,O
pre,O
existing,O
hypertrophic,O
cardiomyopathy,O
seeBoxed,O
WarningandWarning,O
and,O
Precautions,O
5,O
3,O
Recurrent,O
reactions,O
consisting,O
of,O
flu like illness,AdverseReaction
or,O
a,O
combination,O
of,O
events,O
such,O
as,O
pyrexia,AdverseReaction
chills,AdverseReaction
myalgia,AdverseReaction
arthralgia,AdverseReaction
pain,AdverseReaction
or,O
fatigue,AdverseReaction
occurring,O
after,O
completion,O
of,O
infusions,O
and,O
lasting,O
usually,O
for,O
1,O
3,O
days,O
have,O
been,O
observed,O
in,O
some,O
patients,O
treated,O
with,O
alglucosidase,O
alfa,O
The,O
majority,O
of,O
patients,O
were,O
able,O
to,O
be,O
rechallenged,O
with,O
alglucosidase,O
alfa,O
using,O
lower,O
doses,O
and,O
or,O
pretreatment,O
with,O
anti,O
inflammatory,O
drugs,O
and,O
or,O
corticosteroids,O
and,O
were,O
able,O
to,O
continue,O
treatment,O
under,O
close,O
clinical,O
supervision,O
In,O
addition,O
to,O
the,O
hypersensitivity reactions,AdverseReaction
reported,O
in,O
clinical,O
trials,O
seeAdverse,O
Reactions,O
6,O
1,O
the,O
following,O
hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
in,O
at,O
least,O
2,O
patients,O
and,O
included,O
anaphylactic shock,AdverseReaction
respiratory failure,AdverseReaction
respiratory arrest,AdverseReaction
cardiac arrest,AdverseReaction
hypoxia,AdverseReaction
dyspnea,AdverseReaction
wheezing,AdverseReaction
convulsions,AdverseReaction
peripheral coldness,AdverseReaction
restlessness,AdverseReaction
nervousness,AdverseReaction
back pain,AdverseReaction
stridor,AdverseReaction
pharyngeal edema,AdverseReaction
abdominal pain,AdverseReaction
apnea,AdverseReaction
muscle spasm,AdverseReaction
and,O
conjunctivitis,AdverseReaction
In,O
addition,O
one,O
case,O
of,O
hyperparathyroidism,AdverseReaction
has,O
been,O
reported,O
Systemic,AdverseReaction
and,O
cutaneous immune mediated reactions mediated reactions,AdverseReaction
including,O
proteinuria,AdverseReaction
and,O
nephrotic syndrome,AdverseReaction
secondary,O
to,O
membranous glomerulonephritis,AdverseReaction
and,O
necrotizing skin lesions,AdverseReaction
have,O
been,O
reported,O
in,O
postmarketing,O
safety,O
experience,O
with,O
alglucosidase,O
alfa,O
seeWarnings,O
and,O
Precautions,O
5,O
2,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Determine,O
cardiac,O
rhythm,O
at,O
least,O
once,O
every,O
3,O
months,O
If,O
AF,O
is,O
detected,O
discontinue,O
MULTAQ,O
or,O
cardiovert,O
5,O
2,O
Ensure,O
appropriate,O
antithrombotic,O
therapy,O
prior,O
to,O
and,O
throughout,O
MULTAQ,O
use,O
5,O
3,O
Liver injury,AdverseReaction
if,O
hepatic,O
injury,O
is,O
suspected,O
discontinue,O
MULTAQ,O
5,O
5,O
If,O
pulmonary,O
toxicity,O
is,O
confirmed,O
discontinue,O
treatment,O
5,O
6,O
Hypokalemia,AdverseReaction
and,O
hypomagnesemia,AdverseReaction
Maintain,O
potassium,O
and,O
magnesium,O
levels,O
within,O
the,O
normal,O
range,O
5,O
7,O
Renal Impairment,AdverseReaction
Monitor,O
renal,O
function,O
periodically,O
5,O
9,O
Teratogen,AdverseReaction
Women,O
of,O
childbearing,O
potential,O
should,O
use,O
effective,O
contraception,O
while,O
using,O
MULTAQ,O
5,O
10,O
5,O
1,O
Cardiovascular,O
Death,O
in,O
NYHA,O
Class,O
IV,O
or,O
Decompensated,O
Heart,O
Failure,O
MULTAQ,O
is,O
contraindicated,O
in,O
patients,O
with,O
NYHA,O
Class,O
IV,O
heart,O
failure,O
or,O
symptomatic,O
heart,O
failure,O
with,O
recent,O
decompensation,O
requiring,O
hospitalization,O
because,O
it,O
doubles,O
the,O
risk,Factor
of,O
death,AdverseReaction
5,O
2,O
Cardiovascular,O
Death,O
and,O
Heart,O
Failure,O
in,O
Permanent,O
AF,O
MULTAQ,O
doubles,O
the,O
risk,Factor
of,O
cardiovascular death death,AdverseReaction
largely,O
arrhythmic,AdverseReaction
and,O
heart failure events,AdverseReaction
in,O
patients,O
with,O
permanent,O
AF,O
Patients,O
treated,O
with,O
dronedarone,O
should,O
undergo,O
monitoring,O
of,O
cardiac,O
rhythm,O
no,O
less,O
often,O
than,O
every,O
3,O
months,O
Cardiovert,O
patients,O
who,O
are,O
in,O
atrial,O
fibrillation,O
if,O
clinically,O
indicated,O
or,O
discontinue,O
MULTAQ,O
MULTAQ,O
offers,O
no,O
benefit,O
in,O
subjects,O
in,O
permanent,O
AF,O
5,O
3,O
Increased,O
Risk,O
of,O
Stroke,O
in,O
Permanent,O
AF,O
In,O
a,O
placebo,O
controlled,O
study,O
in,O
patients,O
with,O
permanent,O
atrial,O
fibrillation,O
dronedarone,O
was,O
associated,O
with,O
an,O
increased,O
risk,Factor
of,O
stroke,AdverseReaction
particularly,O
in,O
the,O
first,O
two,O
weeks,O
of,O
therapy,O
see,O
Clinical,O
Studies,O
14,O
4,O
MULTAQ,O
should,O
only,O
be,O
initiated,O
in,O
patients,O
in,O
sinus,O
rhythm,O
who,O
are,O
receiving,O
appropriate,O
antithrombotic,O
therapy,O
see,O
Drug,O
interactions,O
7,O
3,O
5,O
4,O
New,O
Onset,O
or,O
Worsening,O
Heart,O
Failure,O
New onset,AdverseReaction
or,O
worsening of heart failure failure,AdverseReaction
has,O
been,O
reported,O
during,O
treatment,O
with,O
MULTAQ,O
in,O
the,O
postmarketing,O
setting,O
In,O
a,O
placebo,O
controlled,O
study,O
in,O
patients,O
with,O
permanent,O
AF,O
increased,O
rates,O
of,O
heart failure,AdverseReaction
were,O
observed,O
in,O
patients,O
with,O
normal,O
left,O
ventricular,O
function,O
and,O
no,O
history,O
of,O
symptomatic,O
heart,O
failure,O
as,O
well,O
as,O
those,O
with,O
a,O
history,O
of,O
heart,O
failure,O
or,O
left,O
ventricular,O
dysfunction,O
Advise,O
patients,O
to,O
consult,O
a,O
physician,O
if,O
they,O
develop,O
signs,O
or,O
symptoms,O
of,O
heart,O
failure,O
such,O
as,O
weight,O
gain,O
dependent,O
edema,O
or,O
increasing,O
shortness,O
of,O
breath,O
If,O
heart,O
failure,O
develops,O
or,O
worsens,O
and,O
requires,O
hospitalization,O
discontinue,O
MULTAQ,O
5,O
5,O
Liver,O
Injury,O
Hepatocellular liver injury,AdverseReaction
including,O
acute liver failure,AdverseReaction
requiring,O
transplant,O
has,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
MULTAQ,O
in,O
the,O
postmarketing,O
setting,O
Advise,O
patients,O
treated,O
with,O
MULTAQ,O
to,O
report,O
immediately,O
symptoms,O
suggesting,O
hepatic,O
injury,O
such,O
as,O
anorexia,O
nausea,O
vomiting,O
fever,O
malaise,O
fatigue,O
right,O
upper,O
quadrant,O
pain,O
jaundice,O
dark,O
urine,O
or,O
itching,O
Consider,O
obtaining,O
periodic,O
hepatic,O
serum,O
enzymes,O
especially,O
during,O
the,O
first,O
6,O
months,O
of,O
treatment,O
but,O
it,O
is,O
not,O
known,O
whether,O
routine,O
periodic,O
monitoring,O
of,O
serum,O
enzymes,O
will,O
prevent,O
the,O
development,O
of,O
severe,O
liver,O
injury,O
If,O
hepatic,O
injury,O
is,O
suspected,O
promptly,O
discontinue,O
MULTAQ,O
and,O
test,O
serum,O
enzymes,O
aspartate,O
aminotransferase,O
AST,O
alanine,O
aminotransferase,O
ALT,O
and,O
alkaline,O
phosphatase,O
as,O
well,O
as,O
serum,O
bilirubin,O
to,O
establish,O
whether,O
there,O
is,O
liver,O
injury,O
If,O
liver,O
injury,O
is,O
found,O
institute,O
appropriate,O
treatment,O
and,O
investigate,O
the,O
probable,O
cause,O
Do,O
not,O
restart,O
MULTAQ,O
in,O
patients,O
without,O
another,O
explanation,O
for,O
the,O
observed,O
liver,O
injury,O
5,O
6,O
Pulmonary,O
Toxicity,O
Cases,O
of,O
interstitial lung disease,AdverseReaction
including,O
pneumonitis,AdverseReaction
and,O
pulmonary fibrosis,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
MULTAQ,O
in,O
the,O
post,O
marketing,O
setting,O
see,O
Adverse,O
Reactions,O
6,O
2,O
Onset,O
of,O
dyspnea,O
or,O
non,O
productive,O
cough,O
may,O
be,O
related,O
to,O
pulmonary,O
toxicity,O
and,O
patients,O
should,O
be,O
carefully,O
evaluated,O
clinically,O
If,O
pulmonary,O
toxicity,O
is,O
confirmed,O
MULTAQ,O
should,O
be,O
discontinued,O
5,O
7,O
Hypokalemia,O
and,O
Hypomagnesemia,O
with,O
Potassium,O
Depleting,O
Diuretics,O
Hypokalemia,AdverseReaction
or,O
hypomagnesemia,AdverseReaction
may,Factor
occur,O
with,O
concomitant,O
administration,O
of,O
potassium,O
depleting,O
diuretics,O
Potassium,O
levels,O
should,O
be,O
within,O
the,O
normal,O
range,O
prior,O
to,O
administration,O
of,O
MULTAQ,O
and,O
maintained,O
in,O
the,O
normal,O
range,O
during,O
administration,O
of,O
MULTAQ,O
5,O
8,O
QT,O
Interval,O
Prolongation,O
Dronedarone,O
induces,O
a,O
moderate,Severity
average,O
of,O
about,O
10,O
ms,O
but,O
much,O
greater,O
effects,O
have,O
been,O
observed,O
QTc,AdverseReaction
Bazett,O
prolongation,AdverseReaction
see,O
Clinical,O
Pharmacology,O
12,O
2,O
and,O
Clinical,O
Studies,O
14,O
1,O
If,O
the,O
QTc,O
Bazett,O
interval,O
is,O
500,O
ms,O
discontinue,O
MULTAQ,O
see,O
Contraindications,O
4,O
5,O
9,O
Renal,O
Impairment,O
and,O
Failure,O
Marked,O
increase in serum creatinine,AdverseReaction
pre renal azotemia,AdverseReaction
and,O
acute renal failure,AdverseReaction
often,O
in,O
the,O
setting,O
of,O
heart failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
or,O
hypovolemia,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
taking,O
MULTAQ,O
In,O
most,O
cases,O
these,O
effects,O
appear,O
to,O
be,O
reversible,O
upon,O
drug,O
discontinuation,O
and,O
with,O
appropriate,O
medical,O
treatment,O
Monitor,O
renal,O
function,O
periodically,O
Small,O
increases in creatinine levels,AdverseReaction
about,O
0 1 mg dL,Severity
following,O
dronedarone,O
treatment,O
initiation,O
have,O
been,O
shown,O
to,O
be,O
a,O
result,O
of,O
inhibition,O
of,O
creatinine,O
s,O
tubular,O
secretion,O
The,O
elevation,O
has,O
a,O
rapid,O
onset,O
reaches,O
a,O
plateau,O
after,O
7,O
days,O
and,O
is,O
reversible,O
after,O
discontinuation,O
5,O
10,O
Women,O
of,O
Childbearing,O
Potential,O
Premenopausal,O
women,O
who,O
have,O
not,O
undergone,O
a,O
hysterectomy,O
or,O
oophorectomy,O
must,O
use,O
effective,O
contraception,O
while,O
using,O
MULTAQ,O
Dronedarone,O
caused,O
fetal harm,AdverseReaction
in,O
animal,Animal
studies,O
at,O
doses,O
equivalent,O
to,O
recommended,O
human,O
doses,O
Counsel,O
women,O
of,O
childbearing,O
potential,O
regarding,O
appropriate,O
contraceptive,O
choices,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
BOXED,O
WARNING,O
WARNING,O
INCREASED,O
RISK,Factor
OF,O
DEATH,AdverseReaction
STROKE,AdverseReaction
AND,O
HEART FAILURE,AdverseReaction
IN,O
PATIENTS,O
WITH,O
DECOMPENSATED,O
HEART,O
FAILURE,O
OR,O
PERMANENT,O
ATRIAL,O
FIBRILLATION,O
WARNING,O
INCREASED,O
RISK,Factor
OF,O
DEATH,AdverseReaction
STROKE,AdverseReaction
AND,O
HEART FAILURE,AdverseReaction
IN,O
PATIENTS,O
WITH,O
DECOMPENSATED,O
HEART,O
FAILURE,O
OR,O
PERMANENT,O
ATRIAL,O
FIBRILLATION,O
In,O
patients,O
with,O
symptomatic,O
heart,O
failure,O
and,O
recent,O
decompensation,O
requiring,O
hospitalization,O
or,O
NYHA,O
Class,O
IV,O
heart,O
failure,O
MULTAQ,O
doubles,O
the,O
risk,Factor
of,O
death,AdverseReaction
14,O
3,O
MULTAQ,O
is,O
contraindicated,O
in,O
patients,O
with,O
symptomatic,O
heart,O
failure,O
with,O
recent,O
decompensation,O
requiring,O
hospitalization,O
or,O
NYHA,O
Class,O
IV,O
heart,O
failure,O
4,O
5,O
1,O
In,O
patients,O
with,O
permanent,O
atrial,O
fibrillation,O
MULTAQ,O
doubles,O
the,O
risk,Factor
of,O
death,AdverseReaction
stroke,AdverseReaction
and,O
hospitalization,O
for,O
heart failure,AdverseReaction
14,O
4,O
MULTAQ,O
is,O
contraindicated,O
in,O
patients,O
in,O
atrial,O
fibrillation,O
AF,O
who,O
will,O
not,O
or,O
cannot,O
be,O
cardioverted,O
into,O
normal,O
sinus,O
rhythm,O
4,O
5,O
2,O
EXCERPT,O
WARNING,O
INCREASED,O
RISK,Factor
OF,O
DEATH,AdverseReaction
STROKE,AdverseReaction
AND,O
HEART FAILURE,AdverseReaction
IN,O
PATIENTS,O
WITH,O
DECOMPENSATED,O
HEART,O
FAILURE,O
OR,O
PERMANENT,O
ATRIAL,O
FIBRILLATION,O
MULTAQ,O
is,O
contraindicated,O
in,O
patients,O
with,O
symptomatic,O
heart,O
failure,O
with,O
recent,O
decompensation,O
requiring,O
hospitalization,O
or,O
NYHA,O
Class,O
IV,O
heart,O
failure,O
MULTAQ,O
doubles,O
the,O
risk,Factor
of,O
death,AdverseReaction
in,O
these,O
patients,O
4,O
5,O
1,O
14,O
3,O
MULTAQ,O
is,O
contraindicated,O
in,O
patients,O
in,O
atrial,O
fibrillation,O
AF,O
who,O
will,O
not,O
or,O
cannot,O
be,O
cardioverted,O
into,O
normal,O
sinus,O
rhythm,O
In,O
patients,O
with,O
permanent,O
AF,O
MULTAQ,O
doubles,O
the,O
risk,Factor
of,O
death,AdverseReaction
stroke,AdverseReaction
and,O
hospitalization,O
for,O
heart failure,AdverseReaction
4,O
5,O
2,O
14,O
4,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
safety,O
concerns,O
are,O
described,O
elsewhere,O
in,O
the,O
label,O
New,AdverseReaction
or,O
worsening heart failure failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Liver Injury,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Pulmonary toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Hypokalemia,AdverseReaction
and,O
hypomagnesemia,AdverseReaction
with,O
potassium,O
depleting,O
diuretics,O
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
QT prolongation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
2,O
are,O
diarrhea,AdverseReaction
nausea,AdverseReaction
abdominal pain,AdverseReaction
vomiting,AdverseReaction
and,O
asthenia,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
sanofi,O
aventis,O
U,O
S,O
LLC,O
at,O
1,O
800,O
633,O
1610,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
The,O
safety,O
evaluation,O
of,O
dronedarone,O
400,O
mg,O
twice,O
daily,O
in,O
patients,O
with,O
AF,O
or,O
AFL,O
is,O
based,O
on,O
5,O
placebo,O
controlled,O
studies,O
ATHENA,O
EURIDIS,O
ADONIS,O
ERATO,O
and,O
DAFNE,O
In,O
these,O
studies,O
a,O
total,O
of,O
6285,O
patients,O
were,O
randomized,O
and,O
treated,O
3282,O
patients,O
with,O
MULTAQ,O
400,O
mg,O
twice,O
daily,O
and,O
2875,O
with,O
placebo,O
The,O
mean,O
exposure,O
across,O
studies,O
was,O
12,O
months,O
In,O
ATHENA,O
the,O
maximum,O
follow,O
up,O
was,O
30,O
months,O
In,O
clinical,O
trials,O
premature,O
discontinuation,O
because,O
of,O
adverse,O
reactions,O
occurred,O
in,O
11,O
8,O
of,O
the,O
dronedarone,O
treated,O
patients,O
and,O
in,O
7,O
7,O
of,O
the,O
placebo,O
treated,O
group,O
The,O
most,O
common,O
reasons,O
for,O
discontinuation,O
of,O
therapy,O
with,O
MULTAQ,O
were,O
gastrointestinal disorders,AdverseReaction
3,O
2,O
versus,O
1,O
8,O
in,O
the,O
placebo,O
group,O
and,O
QT prolongation,AdverseReaction
1,O
5,O
versus,O
0,O
5,O
in,O
the,O
placebo,O
group,O
The,O
most,O
frequent,O
adverse,O
reactions,O
observed,O
with,O
MULTAQ,O
400,O
mg,O
twice,O
daily,O
in,O
the,O
5,O
studies,O
were,O
diarrhea,AdverseReaction
nausea,AdverseReaction
abdominal pain,AdverseReaction
vomiting,AdverseReaction
and,O
asthenia,AdverseReaction
Table,O
1,O
displays,O
adverse,O
reactions,O
more,O
common,O
with,O
dronedarone,O
400,O
mg,O
twice,O
daily,O
than,O
with,O
placebo,O
in,O
AF,O
or,O
AFL,O
patients,O
presented,O
by,O
system,O
organ,O
class,O
and,O
by,O
decreasing,O
order,O
of,O
frequency,O
Adverse,O
laboratory,O
and,O
ECG,O
effects,O
are,O
presented,O
separately,O
in,O
Table,O
2,O
Table,O
1,O
Adverse,O
Drug,O
Reactions,O
that,O
Occurred,O
in,O
at,O
Least,O
1,O
of,O
Patients,O
and,O
Were,O
More,O
Frequent,O
than,O
Placebo,O
Placebo,O
Dronedarone,O
400,O
mg,O
twice,O
daily,O
N,O
2875,O
N,O
3282,O
Gastrointestinal,O
Diarrhea,AdverseReaction
6,O
9,O
Nausea,AdverseReaction
3,O
5,O
Abdominal pain,AdverseReaction
3,O
4,O
Vomiting,AdverseReaction
1,O
2,O
Dyspeptic signs and symptoms,AdverseReaction
1,O
2,O
General,O
Asthenic conditions,AdverseReaction
5,O
7,O
Cardiac,O
Bradycardia,AdverseReaction
1,O
3,O
Skin,O
and,O
subcutaneous,O
tissue,O
Including,O
rashes,AdverseReaction
generalized,AdverseReaction
macular,AdverseReaction
maculo papular,AdverseReaction
erythematous,AdverseReaction
pruritus,AdverseReaction
eczema,AdverseReaction
dermatitis,AdverseReaction
dermatitis allergic,AdverseReaction
3,O
5,O
Photosensitivity reaction,AdverseReaction
and,O
dysgeusia,AdverseReaction
have,O
also,O
been,O
reported,O
at,O
an,O
incidence,O
less,O
than,O
1,O
in,O
patients,O
treated,O
with,O
MULTAQ,O
The,O
following,O
laboratory,O
data,O
ECG,O
parameters,O
were,O
reported,O
with,O
MULTAQ,O
400,O
mg,O
twice,O
daily,O
Table,O
2,O
Laboratory,O
data,O
ECG,O
parameters,O
not,O
necessarily,O
reported,O
as,O
adverse,O
events,O
Placebo,O
MULTAQ,O
400,O
mg,O
twice,O
daily,O
N,O
2875,O
N,O
3282,O
Early,O
increases in creatinine,AdverseReaction
10,O
21,O
51,O
N,O
2237,O
N,O
2701,O
QTc prolonged,AdverseReaction
19,O
28,O
Assessment,O
of,O
demographic,O
factors,O
such,O
as,O
gender,O
or,O
age,O
on,O
the,O
incidence,O
of,O
treatment,O
emergent,O
adverse,O
events,O
did,O
not,O
suggest,O
an,O
excess,O
of,O
adverse,O
events,O
in,O
any,O
particular,O
sub,O
group,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
MULTAQ,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
an,O
unknown,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Cardiac,O
New,O
or,O
worsening,O
heart failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Atrial flutter flutter with 1 1 atrioventricular conduction,AdverseReaction
has,O
been,O
reported,O
very,O
rarely,O
Hepatic,O
Liver Injury,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Respiratory,O
Interstitial lung disease,AdverseReaction
including,O
pneumonitis,AdverseReaction
and,O
pulmonary fibrosis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Immune,O
Anaphylactic reactions,AdverseReaction
including,O
angioedema,AdverseReaction
Vascular,O
Vasculitis,AdverseReaction
including,O
leukocytoclastic vasculitis,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Vascular risks,AdverseReaction
Stop,O
Natazia,O
if,O
a,O
thrombotic,AdverseReaction
event,O
occurs,O
Stop,O
Natazia,O
at,O
least,O
4,O
weeks,O
before,O
and,O
through,O
2,O
weeks,O
after,O
major,O
surgery,O
Start,O
Natazia,O
no,O
earlier,O
than,O
4,O
weeks,O
after,O
delivery,O
in,O
women,O
who,O
are,O
not,O
breastfeeding,O
5,O
1,O
Liver disease,AdverseReaction
Discontinue,O
Natazia,O
if,O
jaundice,O
occurs,O
5,O
3,O
High blood pressure,AdverseReaction
Do,O
not,O
prescribe,O
Natazia,O
for,O
women,O
with,O
uncontrolled,O
hypertension,O
or,O
hypertension,O
with,O
vascular,O
disease,O
5,O
4,O
Carbohydrate,AdverseReaction
and,O
lipid metabolic effects effects,AdverseReaction
Monitor,O
prediabetic,O
and,O
diabetic,O
women,O
taking,O
Natazia,O
Consider,O
an,O
alternate,O
contraceptive,O
method,O
for,O
women,O
with,O
uncontrolled,O
dyslipidemia,O
5,O
6,O
Headache,AdverseReaction
Evaluate,O
significant,O
change,O
in,O
headaches,O
and,O
discontinue,O
Natazia,O
if,O
indicated,O
5,O
7,O
Uterine bleeding,AdverseReaction
Evaluate,O
irregular,O
bleeding,O
or,O
amenorrhea,O
5,O
8,O
CYP3A4,O
induction,O
Women,O
taking,O
strong,O
CYP3A4,O
inducers,O
for,O
example,O
carbamazepine,O
phenytoin,O
rifampicin,O
and,O
St,O
John,O
s,O
wort,O
should,O
not,O
choose,O
Natazia,O
as,O
their,O
oral,O
contraceptive,O
due,O
to,O
the,O
possibility,O
of,O
decreased,O
contraceptive,O
efficacy,O
5,O
13,O
7,O
1,O
5,O
1,O
Thromboembolic,O
Disorders,O
and,O
Other,O
Vascular,O
Problems,O
Stop,O
Natazia,O
if,O
an,O
arterial,O
or,O
venous,O
thrombotic,O
event,O
VTE,O
occurs,O
The,O
use,O
of,O
COCs,DrugClass
increases,O
the,O
risk,O
of,O
venous thromboembolism,AdverseReaction
However,O
pregnancy,Factor
increases,O
the,O
risk,O
of,O
venous thromboembolism,AdverseReaction
as,O
much,O
or,O
more,O
than,O
the,O
use,O
of,O
COCs,O
The,O
risk,O
of,O
VTE,AdverseReaction
in,O
women,O
using,O
COCs,DrugClass
has,O
been,O
estimated,O
to,O
be,O
3,O
to,O
9,O
per,O
10,O
000,O
woman,O
years,O
The,O
risk,Factor
of,O
VTE,AdverseReaction
is,O
highest,O
during,O
the,O
first,O
year,O
of,O
use,O
Data,O
from,O
a,O
large,O
prospective,O
cohort,O
safety,O
study,O
of,O
various,O
COCs,O
suggest,O
that,O
this,O
increased,O
risk,O
as,O
compared,O
to,O
that,O
in,O
non,O
COC,O
users,O
is,O
greatest,O
during,O
the,O
first,O
6,O
months,O
of,O
COC,O
use,O
Data,O
from,O
this,O
safety,O
study,O
indicate,O
that,O
the,O
greatest,O
risk,O
of,O
VTE,AdverseReaction
is,O
present,O
after,O
initially,O
starting,O
a,O
COC,DrugClass
or,O
restarting,O
following,O
a,O
4,O
week,O
or,O
greater,O
pill,O
free,O
interval,O
the,O
same,O
or,O
a,O
different,O
COC,O
Use,O
of,O
COCs,DrugClass
also,O
increases,O
the,O
risk,O
of,O
arterial thromboses,AdverseReaction
such,O
as,O
strokes,AdverseReaction
and,O
myocardial infarctions,AdverseReaction
especially,O
in,O
women,O
with,O
other,O
risk,O
factors,O
for,O
these,O
events,O
The,O
risk,O
of,O
thromboembolic disease,AdverseReaction
due,O
to,O
oral contraceptives,DrugClass
gradually,O
disappears,O
after,O
COC,O
use,O
is,O
discontinued,O
If,O
feasible,O
stop,O
Natazia,O
at,O
least,O
4,O
weeks,O
before,O
and,O
through,O
2,O
weeks,O
after,O
major,O
surgery,O
or,O
other,O
surgeries,O
known,O
to,O
have,O
an,O
elevated,O
risk,O
of,O
thromboembolism,O
Start,O
Natazia,O
no,O
earlier,O
than,O
4,O
weeks,O
after,O
delivery,O
in,O
women,O
who,O
are,O
not,O
breastfeeding,O
The,O
risk,O
of,O
postpartum,O
thromboembolism,O
decreases,O
after,O
the,O
third,O
postpartum,O
week,O
whereas,O
the,O
risk,O
of,O
ovulation,O
increases,O
after,O
the,O
third,O
postpartum,O
week,O
COCs,DrugClass
have,O
been,O
shown,O
to,O
increase,O
both,O
the,O
relative,O
and,O
attributable,O
risks,O
of,O
cerebrovascular events,AdverseReaction
thrombotic,AdverseReaction
and,O
hemorrhagic strokes,AdverseReaction
although,O
in,O
general,O
the,O
risk,O
is,O
greatest,O
among,O
older,O
35,O
years,O
of,O
age,O
hypertensive,O
women,O
who,O
also,O
smoke,O
COCs,DrugClass
also,O
increase,O
the,O
risk,O
for,O
stroke,AdverseReaction
in,O
women,O
with,O
other,O
underlying,O
risk,O
factors,O
Oral,O
contraceptives,O
must,O
be,O
used,O
with,O
caution,O
in,O
women,O
with,O
cardiovascular,O
disease,O
risk,O
factors,O
Stop,O
Natazia,O
if,O
there,O
is,O
unexplained,O
loss,O
of,O
vision,O
proptosis,O
diplopia,O
papilledema,O
or,O
retinal,O
vascular,O
lesions,O
Evaluate,O
for,O
retinal,O
vein,O
thrombosis,O
immediately,O
See,O
Adverse,O
Reactions,O
6,O
5,O
2,O
Carcinoma,O
of,O
the,O
Breasts,O
and,O
Reproductive,O
Organs,O
Women,O
who,O
currently,O
have,O
or,O
have,O
had,O
breast,O
cancer,O
should,O
not,O
use,O
Natazia,O
because,O
breast,O
cancer,O
is,O
a,O
hormonally,O
sensitive,O
tumor,O
There,O
is,O
substantial,O
evidence,O
that,O
COCs,O
do,O
not,Negation
increase,O
the,O
incidence,O
of,O
breast cancer,AdverseReaction
Although,O
some,O
past,O
studies,O
have,O
suggested,O
that,O
COCs,O
might,O
increase,O
the,O
incidence,O
of,O
breast cancer,AdverseReaction
more,O
recent,O
studies,O
have,O
not confirmed,Negation
such,O
findings,O
Some,O
studies,O
suggest,O
that,O
COCs,DrugClass
are,O
associated,O
with,O
an,O
increase,O
in,O
the,O
risk,O
of,O
cervical cancer,AdverseReaction
or,O
intraepithelial neoplasia,AdverseReaction
However,O
there,O
is,O
controversy,O
about,O
the,O
extent,O
to,O
which,O
these,O
findings,O
may,O
be,O
due,O
to,O
differences,O
in,O
sexual,O
behavior,O
and,O
other,O
factors,O
Endometrial,O
biopsies,O
performed,O
in,O
a,O
subset,O
of,O
subjects,O
in,O
a,O
Phase,O
3,O
Natazia,O
clinical,O
trial,O
did,O
not,O
reveal,O
any,O
unexpected,O
or,O
concerning,O
findings,O
for,O
subjects,O
taking,O
COCs,O
See,O
Adverse,O
Reactions,O
6,O
1,O
5,O
3,O
Liver,O
Disease,O
Discontinue,O
Natazia,O
if,O
jaundice,O
develops,O
Steroid,O
hormones,O
may,O
be,O
poorly,O
metabolized,O
in,O
patients,O
with,O
impaired,O
liver,O
function,O
Acute,O
or,O
chronic,O
disturbances,O
of,O
liver,O
function,O
may,O
necessitate,O
the,O
discontinuation,O
of,O
COC,O
use,O
until,O
markers,O
of,O
liver,O
function,O
return,O
to,O
normal,O
and,O
COC,O
causation,O
has,O
been,O
excluded,O
Hepatic adenomas,AdverseReaction
are,O
associated,O
with,O
COC,DrugClass
use,O
An,O
estimate,O
of,O
the,O
attributable,O
risk,O
is,O
3,O
3,O
cases,O
100,O
000,O
COC,O
users,O
Rupture of hepatic adenomas,AdverseReaction
may,Factor
cause,O
death,AdverseReaction
through,O
intra abdominal hemorrhage,AdverseReaction
Studies,O
have,O
shown,O
an,O
increased,O
risk,O
of,O
developing,O
hepatocellular carcinoma,AdverseReaction
in,O
long,O
term,O
8,O
years,O
COC,DrugClass
users,O
However,O
the,O
attributable,O
risk,O
of,O
liver cancers,AdverseReaction
in,O
COC,DrugClass
users,O
is,O
less,O
than,O
one,O
case,O
per,O
million,O
users,O
Oral contraceptive,DrugClass
related,O
cholestasis,AdverseReaction
may,O
occur,O
in,O
women,O
with,O
a,O
history,O
of,O
pregnancy,O
related,O
cholestasis,O
Women,O
with,O
a,O
history,O
of,O
COC,DrugClass
related,O
cholestasis,AdverseReaction
may,O
have,O
the,O
condition,O
recur,O
with,O
subsequent,O
COC,O
use,O
5,O
4,O
High,O
Blood,O
Pressure,O
For,O
women,O
with,O
well,O
controlled,O
hypertension,O
monitor,O
blood,O
pressure,O
and,O
stop,O
Natazia,O
if,O
blood,O
pressure,O
rises,O
significantly,O
Women,O
with,O
uncontrolled,O
hypertension,O
or,O
hypertension,O
with,O
vascular,O
disease,O
should,O
not,O
use,O
COCs,O
An,O
increase in blood pressure,AdverseReaction
has,O
been,O
reported,O
in,O
women,O
taking,O
COCs,DrugClass
and,O
this,O
increase,O
is,O
more,O
likely,O
in,O
older,O
women,O
and,O
with,O
extended,O
duration,O
of,O
use,O
The,O
incidence,O
of,O
hypertension,AdverseReaction
increases,O
with,O
increasing,O
concentration,O
of,O
progestin,O
5,O
5,O
Gallbladder,O
Disease,O
Studies,O
suggest,O
a,O
small,O
increased,O
relative,O
risk,O
of,O
developing,O
gallbladder disease,AdverseReaction
among,O
COC,DrugClass
users,O
5,O
6,O
Carbohydrate,O
and,O
Lipid,O
Metabolic,O
Effects,O
Carefully,O
monitor,O
prediabetic,O
and,O
diabetic,O
women,O
who,O
are,O
taking,O
Natazia,O
COCs,DrugClass
may,O
decrease glucose tolerance,AdverseReaction
in,O
a,O
dose,O
related,O
fashion,O
Consider,O
alternative,O
contraception,O
for,O
women,O
with,O
uncontrolled,O
dyslipidemia,O
A,O
small,O
proportion,O
of,O
women,O
will,O
have,O
adverse lipid changes,AdverseReaction
while,O
on,O
COCs,DrugClass
Women,O
with,O
hypertriglyceridemia,O
or,O
a,O
family,O
history,O
thereof,O
may,O
be,O
at,O
an,O
increased,O
risk,O
of,O
pancreatitis,AdverseReaction
when,O
using,O
COCs,DrugClass
5,O
7,O
Headache,O
If,O
a,O
woman,O
taking,O
Natazia,O
develops,O
new,O
headaches,AdverseReaction
that,O
are,O
recurrent,AdverseReaction
persistent,AdverseReaction
or,O
severe,Severity
evaluate,O
the,O
cause,O
and,O
discontinue,O
Natazia,O
if,O
indicated,O
An,O
increase,O
in,O
frequency,O
or,O
severity,O
of,O
migraine,AdverseReaction
during,O
COC,DrugClass
use,O
which,O
may,Factor
be,O
prodromal,O
of,O
a,O
cerebrovascular event,AdverseReaction
may,O
be,O
a,O
reason,O
for,O
immediate,O
discontinuation,O
of,O
the,O
COC,O
5,O
8,O
Bleeding,O
Irregularities,O
Breakthrough bleeding,AdverseReaction
and,O
spotting,AdverseReaction
sometimes,O
occur,O
in,O
patients,O
on,O
COCs,DrugClass
especially,O
during,O
the,O
first,O
three,O
months,O
of,O
use,O
If,O
bleeding,O
persists,O
or,O
occurs,O
after,O
previously,O
regular,O
cycles,O
check,O
for,O
causes,O
such,O
as,O
pregnancy,O
or,O
malignancy,O
If,O
pathology,O
and,O
pregnancy,O
are,O
excluded,O
bleeding,O
irregularities,O
may,O
resolve,O
over,O
time,O
or,O
with,O
a,O
change,O
to,O
a,O
different,O
COC,O
Women,O
who,O
are,O
not,O
pregnant,O
and,O
use,O
Natazia,O
may,Factor
experience,O
amenorrhea,AdverseReaction
Based,O
on,O
patient,O
diaries,O
amenorrhea,O
occurs,O
in,O
approximately,O
16,O
of,O
cycles,O
in,O
women,O
using,O
Natazia,O
Pregnancy,O
should,O
be,O
ruled,O
out,O
in,O
the,O
event,O
of,O
amenorrhea,O
occurring,O
in,O
two,O
or,O
more,O
consecutive,O
cycles,O
Some,O
women,O
may,Factor
encounter,O
amenorrhea,AdverseReaction
or,O
oligomenorrhea,AdverseReaction
after,O
stopping,O
COCs,O
especially,O
when,O
such,O
a,O
condition,O
was,O
pre,O
existent,O
Based,O
on,O
patient,O
diaries,O
from,O
three,O
clinical,O
trials,O
evaluating,O
the,O
safety,O
and,O
efficacy,O
of,O
Natazia,O
for,O
contraception,O
10,O
23,O
of,O
women,O
experienced,O
intracyclic bleeding,AdverseReaction
per,O
cycle,O
5,O
9,O
COC,O
Use,O
Before,O
or,O
During,O
Early,O
Pregnancy,O
Extensive,O
epidemiological,O
studies,O
have,O
revealed,O
no,Negation
increased,O
risk,O
of,O
birth defects,AdverseReaction
in,O
women,O
who,O
have,O
used,O
oral,O
contraceptives,O
prior,O
to,O
pregnancy,O
Studies,O
also,O
do,O
not,Negation
suggest,O
a,O
teratogenic effect,AdverseReaction
particularly,O
in,O
so,O
far,O
as,O
cardiac anomalies,AdverseReaction
and,O
limb reduction defects,AdverseReaction
are,O
concerned,O
when,O
taken,O
inadvertently,O
during,O
early,O
pregnancy,O
Oral,O
contraceptive,O
use,O
should,O
be,O
discontinued,O
if,O
pregnancy,O
is,O
confirmed,O
The,O
administration,O
of,O
oral,O
contraceptives,O
to,O
induce,O
withdrawal,O
bleeding,O
should,O
not,O
be,O
used,O
as,O
a,O
test,O
for,O
pregnancy,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
5,O
10,O
Depression,O
Women,O
with,O
a,O
history,O
of,O
depression,O
should,O
be,O
carefully,O
observed,O
and,O
Natazia,O
discontinued,O
if,O
depression,O
recurs,O
to,O
a,O
serious,O
degree,O
5,O
11,O
Interference,O
with,O
Laboratory,O
Tests,O
The,O
use,O
of,O
COCs,O
may,O
change,O
the,O
results,O
of,O
some,O
laboratory,O
tests,O
such,O
as,O
coagulation,O
factors,O
lipids,O
glucose,O
tolerance,O
and,O
binding,O
proteins,O
Women,O
on,O
thyroid,O
hormone,O
replacement,O
therapy,O
may,O
need,O
increased,O
doses,O
of,O
thyroid,O
hormone,O
because,O
serum,O
concentrations,O
of,O
thyroid binding globulin increase,AdverseReaction
with,O
use,O
of,O
COCs,DrugClass
see,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
12,O
Monitoring,O
A,O
woman,O
who,O
is,O
taking,O
COCs,O
should,O
have,O
a,O
yearly,O
visit,O
with,O
her,O
healthcare,O
provider,O
for,O
a,O
blood,O
pressure,O
check,O
and,O
for,O
other,O
indicated,O
healthcare,O
5,O
13,O
Drug,O
Interactions,O
Women,O
who,O
take,O
medications,O
that,O
are,O
strong,O
cytochrome,O
P450,O
3A4,O
CYP3A4,O
inducers,O
for,O
example,O
carbamazepine,O
phenytoin,O
rifampicin,O
and,O
St,O
John,O
s,O
wort,O
should,O
not,O
choose,O
Natazia,O
as,O
their,O
oral,O
contraceptive,O
while,O
using,O
these,O
inducers,O
and,O
for,O
at,O
least,O
28,O
days,O
after,O
discontinuation,O
of,O
these,O
inducers,O
due,O
to,O
the,O
possibility,O
of,O
decreased,O
contraceptive,O
efficacy,O
See,O
Drug,O
Interactions,O
7,O
1,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
5,O
14,O
Other,O
Conditions,O
In,O
women,O
with,O
hereditary,O
angioedema,O
exogenous,O
estrogens,O
may,Factor
induce,O
or,O
exacerbate,O
symptoms,O
of,O
angioedema,AdverseReaction
Chloasma,AdverseReaction
may,Factor
occasionally,O
occur,O
especially,O
in,O
women,O
with,O
a,O
history,O
of,O
chloasma,O
gravidarum,O
Women,O
with,O
a,O
tendency,O
to,O
chloasma,O
should,O
avoid,O
exposure,O
to,O
the,O
sun,O
or,O
ultraviolet,O
radiation,O
while,O
taking,O
COCs,O
""
BOXED,O
WARNING,O
WARNING,O
CIGARETTE,O
SMOKING,O
AND,O
SERIOUS,Severity
CARDIOVASCULAR EVENTS,AdverseReaction
WARNING,O
CIGARETTE,O
SMOKING,O
AND,O
SERIOUS,Severity
CARDIOVASCULAR EVENTS,AdverseReaction
Cigarette,O
smoking,O
increases,O
the,O
risk,O
of,O
serious,O
cardiovascular events,AdverseReaction
from,O
combination oral contraceptives,DrugClass
COC,O
use,O
This,O
risk,O
increases,O
with,O
age,O
particularly,O
in,O
women,O
over,O
35,O
years,O
of,O
age,O
and,O
with,O
the,O
number,O
of,O
cigarettes,O
smoked,O
For,O
this,O
reason,O
COCs,O
should,O
not,O
be,O
used,O
by,O
women,O
who,O
are,O
over,O
35,O
years,O
of,O
age,O
and,O
smoke,O
See,O
Contraindications,O
4,O
EXCERPT,O
WARNING,O
CIGARETTE,O
SMOKING,O
AND,O
SERIOUS,Severity
CARDIOVASCULAR EVENTS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Women,O
over,O
35,O
years,O
old,O
who,O
smoke,O
should,O
not,O
use,O
Natazia,O
4,O
Cigarette,O
smoking,O
increases,O
the,O
risk,O
of,O
serious,O
cardiovascular events,AdverseReaction
from,O
combination oral contraceptive,DrugClass
COC,O
use,O
4,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
with,O
the,O
use,O
of,O
COCs,O
are,O
discussed,O
elsewhere,O
in,O
the,O
labeling,O
Serious,Severity
cardiovascular events,AdverseReaction
and,O
stroke,AdverseReaction
see,O
Boxed,O
Warning,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Vascular events,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Liver disease,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Adverse,O
reactions,O
commonly,O
reported,O
by,O
COC,O
users,O
are,O
Irregular uterine bleeding,AdverseReaction
Nausea,AdverseReaction
Breast tenderness,AdverseReaction
Headache,AdverseReaction
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
2,O
in,O
clinical,O
trials,O
for,O
Natazia,O
are,O
headaches,AdverseReaction
irregular uterine bleeding,AdverseReaction
headache,AdverseReaction
including,O
migraines,AdverseReaction
13,O
breast tenderness,AdverseReaction
pain,AdverseReaction
7,O
menstrual disorders,AdverseReaction
7,O
nausea,AdverseReaction
or,O
vomiting,AdverseReaction
6,O
acne,AdverseReaction
4,O
mood changes,AdverseReaction
3,O
and,O
increased weight,AdverseReaction
3,O
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Bayer,O
HealthCare,O
Pharmaceuticals,O
Inc,O
at,O
1,O
888,O
842,O
2937,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Contraception,O
and,O
Heavy,O
Menstrual,O
Bleeding,O
Studies,O
A,O
total,O
of,O
2,O
131,O
women,O
18,O
to,O
54,O
years,O
of,O
age,O
who,O
took,O
at,O
least,O
one,O
dose,O
of,O
Natazia,O
were,O
enrolled,O
in,O
four,O
clinical,O
phase,O
3,O
trials,O
A,O
total,O
of,O
1,O
867,O
subjects,O
were,O
included,O
in,O
two,O
clinical,O
phase,O
3,O
studies,O
with,O
a,O
treatment,O
duration,O
up,O
to,O
28,O
cycles,O
with,O
Natazia,O
as,O
an,O
oral,O
contraceptive,O
and,O
264,O
subjects,O
in,O
the,O
two,O
phase,O
3,O
clinical,O
trials,O
with,O
a,O
treatment,O
duration,O
of,O
7,O
cycles,O
evaluating,O
Natazia,O
in,O
the,O
treatment,O
of,O
heavy,O
prolonged,O
and,O
or,O
frequent,O
menstrual,O
bleeding,O
in,O
women,O
without,O
organic,O
pathology,O
See,O
Clinical,O
Studies,O
14,O
1,O
14,O
2,O
Adverse,O
Reactions,O
Leading,O
to,O
Study,O
Discontinuation,O
11,O
4,O
of,O
the,O
women,O
discontinued,O
from,O
the,O
clinical,O
trials,O
due,O
to,O
an,O
adverse,O
reaction,O
the,O
most,O
frequent,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
were,O
menstrual disorder,AdverseReaction
metrorrhagia,AdverseReaction
menorrhagia,AdverseReaction
menstruation irregular,AdverseReaction
genital hemorrhage,AdverseReaction
vaginal hemorrhage,AdverseReaction
dysfunctional uterine bleeding,AdverseReaction
2,O
3,O
mood changes,AdverseReaction
depression,AdverseReaction
mood swings,AdverseReaction
mood altered,AdverseReaction
depressed mood,AdverseReaction
dysthymic disorder,AdverseReaction
crying,AdverseReaction
1,O
2,O
acne,AdverseReaction
1,O
1,O
headache,AdverseReaction
including,O
migraines,AdverseReaction
1,O
1,O
and,O
weight increased,AdverseReaction
0,O
7,O
Common,O
Adverse,O
Reactions,O
2,O
headache,AdverseReaction
including,O
migraines,AdverseReaction
12,O
7,O
breast pain,AdverseReaction
discomfort,AdverseReaction
or,O
tenderness,AdverseReaction
7,O
0,O
menstrual disorders,AdverseReaction
metrorrhagia,AdverseReaction
menstruation irregular,AdverseReaction
menorrhagia,AdverseReaction
vaginal hemorrhage,AdverseReaction
dysfunctional uterine bleeding,AdverseReaction
genital hemorrhage,AdverseReaction
abnormal withdrawal bleeding,AdverseReaction
uterine hemorrhage,AdverseReaction
6,O
9,O
nausea,AdverseReaction
or,O
vomiting,AdverseReaction
6,O
0,O
acne,AdverseReaction
3,O
9,O
mood changes,AdverseReaction
depression,AdverseReaction
mood swings,AdverseReaction
depressed mood,AdverseReaction
mood altered,AdverseReaction
affect lability,AdverseReaction
dysthymic disorder,AdverseReaction
crying,AdverseReaction
3,O
0,O
and,O
increased weight,AdverseReaction
2,O
9,O
Serious,O
Adverse,O
Reactions,O
myocardial infarction,AdverseReaction
2,O
cases,O
ruptured ovarian cyst,AdverseReaction
2,O
cases,O
deep vein thrombosis,AdverseReaction
focal nodular hyperplasia of the liver,AdverseReaction
uterine leiomyoma,AdverseReaction
acute cholecystitis,AdverseReaction
and,O
chronic acalculous cholecystitis,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
Natazia,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Vascular,O
disorders,O
Venous,AdverseReaction
and,O
arterial thromboembolic events events,AdverseReaction
including,O
pulmonary emboli,AdverseReaction
deep vein thrombosis,AdverseReaction
cerebral thrombosis,AdverseReaction
myocardial infarction,AdverseReaction
and,O
stroke,AdverseReaction
hypertension,AdverseReaction
Hepatobiliary,O
disorders,O
Gallbladder disease,AdverseReaction
hepatitis,AdverseReaction
Immune,O
system,O
disorders,O
Hypersensitivity,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorders,O
Fluid retention,AdverseReaction
hypertriglyceridemia,AdverseReaction
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Chloasma,AdverseReaction
angioedema,AdverseReaction
erythema nodosum,AdverseReaction
erythema multiforme,AdverseReaction
Gastrointestinal,O
disorders,O
Gastrointestinal symptoms,AdverseReaction
for,O
example,O
abdominal pain,AdverseReaction
Infections,O
and,O
infestations,O
Vulvovaginal candidiasis,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Acute pancreatitis,AdverseReaction
There,O
have,O
been,O
postmarketing,O
reports,O
of,O
acute pancreatitis,AdverseReaction
If,O
pancreatitis,O
is,O
suspected,O
promptly,O
discontinue,O
NESINA,O
5,O
1,O
Hypersensitivity,AdverseReaction
There,O
have,O
been,O
postmarketing,O
reports,O
of,O
serious,Severity
hypersensitivity reactions,AdverseReaction
in,O
patients,O
treated,O
with,O
NESINA,O
such,O
as,O
anaphylaxis,AdverseReaction
angioedema,AdverseReaction
and,O
severe,Severity
cutaneous adverse reactions,AdverseReaction
In,O
such,O
cases,O
promptly,O
discontinue,O
NESINA,O
assess,O
for,O
other,O
potential,O
causes,O
institute,O
appropriate,O
monitoring,O
and,O
treatment,O
and,O
initiate,O
alternative,O
treatment,O
for,O
diabetes,O
5,O
2,O
Hepatic effects,AdverseReaction
Postmarketing,O
reports,O
of,O
hepatic failure,AdverseReaction
sometimes,O
fatal,AdverseReaction
Causality,O
cannot,O
be,O
excluded,O
If,O
liver,O
injury,O
is,O
detected,O
promptly,O
interrupt,O
NESINA,O
and,O
assess,O
patient,O
for,O
probable,O
cause,O
then,O
treat,O
cause,O
if,O
possible,O
to,O
resolution,O
or,O
stabilization,O
Do,O
not,O
restart,O
NESINA,O
if,O
liver,O
injury,O
is,O
confirmed,O
and,O
no,O
alternative,O
etiology,O
can,O
be,O
found,O
5,O
3,O
Hypoglycemia,AdverseReaction
When,O
an,O
insulin,O
secretagogue,O
e,O
g,O
sulfonylurea,O
or,O
insulin,O
is,O
used,O
in,O
combination,O
with,O
NESINA,O
a,O
lower,O
dose,O
of,O
the,O
insulin,O
secretagogue,O
or,O
insulin,O
may,O
be,O
required,O
to,O
minimize,O
the,O
risk,O
of,O
hypoglycemia,O
5,O
4,O
Arthralgia,AdverseReaction
Severe,Severity
and,O
disabling,Severity
arthralgia,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
taking,O
DPP 4 inhibitors,DrugClass
Consider,O
as,O
a,O
possible,O
cause,O
for,O
severe,O
joint,O
pain,O
and,O
discontinue,O
drug,O
if,O
appropriate,O
5,O
5,O
Macrovascular,O
outcomes,O
There,O
have,O
been,O
no,O
clinical,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
NESINA,O
or,O
any,O
other,O
antidiabetic,O
drug,O
5,O
6,O
5,O
1,O
Pancreatitis,O
There,O
have,O
been,O
postmarketing,O
reports,O
of,O
acute pancreatitis,AdverseReaction
in,O
patients,O
taking,O
NESINA,O
After,O
initiation,O
of,O
NESINA,O
patients,O
should,O
be,O
observed,O
carefully,O
for,O
signs,O
and,O
symptoms,O
of,O
pancreatitis,O
If,O
pancreatitis,O
is,O
suspected,O
NESINA,O
should,O
promptly,O
be,O
discontinued,O
and,O
appropriate,O
management,O
should,O
be,O
initiated,O
It,O
is,O
unknown,O
whether,O
patients,O
with,O
a,O
history,O
of,O
pancreatitis,O
are,O
at,O
increased,O
risk,O
for,O
the,O
development,O
of,O
pancreatitis,O
while,O
using,O
NESINA,O
5,O
2,O
Hypersensitivity,O
Reactions,O
There,O
have,O
been,O
postmarketing,O
reports,O
of,O
serious,Severity
hypersensitivity reactions,AdverseReaction
in,O
patients,O
treated,O
with,O
NESINA,O
These,O
reactions,O
include,O
anaphylaxis,AdverseReaction
angioedema,AdverseReaction
and,O
severe,Severity
cutaneous adverse reactions,AdverseReaction
including,O
Stevens Johnson syndrome,AdverseReaction
If,O
a,O
serious,O
hypersensitivity,O
reaction,O
is,O
suspected,O
discontinue,O
NESINA,O
assess,O
for,O
other,O
potential,O
causes,O
for,O
the,O
event,O
and,O
institute,O
alternative,O
treatment,O
for,O
diabetes,O
seeAdverse,O
Reactions,O
6,O
2,O
Use,O
caution,O
in,O
a,O
patient,O
with,O
a,O
history,O
of,O
angioedema,O
with,O
another,O
DPP,O
4,O
inhibitor,O
because,O
it,O
is,O
unknown,O
whether,O
such,O
patients,O
will,O
be,O
predisposed,O
to,O
angioedema,O
with,O
NESINA,O
5,O
3,O
Hepatic,O
Effects,O
There,O
have,O
been,O
postmarketing,O
reports,O
of,O
fatal,AdverseReaction
and,O
nonfatal,Severity
hepatic failure failure,AdverseReaction
in,O
patients,O
taking,O
NESINA,O
although,O
some,O
of,O
the,O
reports,O
contain,O
insufficient,O
information,O
necessary,O
to,O
establish,O
the,O
probable,O
cause,O
seeAdverse,O
Reactions,O
6,O
2,O
In,O
randomized,O
controlled,O
studies,O
serum alanine aminotransferase,AdverseReaction
ALT,AdverseReaction
elevations,AdverseReaction
greater,O
than,O
three,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
ULN,O
were,O
observed,O
1,O
3,O
in,O
alogliptin,O
treated,O
patients,O
and,O
1,O
5,O
in,O
all,O
comparator,O
treated,O
patients,O
Patients,O
with,O
type,O
2,O
diabetes,O
may,O
have,O
fatty,O
liver,O
disease,O
which,O
may,O
cause,O
liver,O
test,O
abnormalities,O
and,O
they,O
may,O
also,O
have,O
other,O
forms,O
of,O
liver,O
disease,O
many,O
of,O
which,O
can,O
be,O
treated,O
or,O
managed,O
Therefore,O
obtaining,O
a,O
liver,O
test,O
panel,O
and,O
assessing,O
the,O
patient,O
before,O
initiating,O
NESINA,O
therapy,O
is,O
recommended,O
In,O
patients,O
with,O
abnormal,O
liver,O
tests,O
NESINA,O
should,O
be,O
initiated,O
with,O
caution,O
Measure,O
liver,O
tests,O
promptly,O
in,O
patients,O
who,O
report,O
symptoms,O
that,O
may,O
indicate,O
liver,O
injury,O
including,O
fatigue,O
anorexia,O
right,O
upper,O
abdominal,O
discomfort,O
dark,O
urine,O
or,O
jaundice,O
In,O
this,O
clinical,O
context,O
if,O
the,O
patient,O
is,O
found,O
to,O
have,O
clinically,O
significant,O
liver,O
enzyme,O
elevations,O
and,O
if,O
abnormal,O
liver,O
tests,O
persist,O
or,O
worsen,O
NESINA,O
should,O
be,O
interrupted,O
and,O
investigation,O
done,O
to,O
establish,O
the,O
probable,O
cause,O
NESINA,O
should,O
not,O
be,O
restarted,O
in,O
these,O
patients,O
without,O
another,O
explanation,O
for,O
the,O
liver,O
test,O
abnormalities,O
5,O
4,O
Use,O
with,O
Medications,O
Known,O
to,O
Cause,O
Hypoglycemia,O
Insulin,O
and,O
insulin,O
secretagogues,O
such,O
as,O
sulfonylureas,O
are,O
known,O
to,O
cause,O
hypoglycemia,O
Therefore,O
a,O
lower,O
dose,O
of,O
insulin,O
or,O
insulin,O
secretagogue,O
may,O
be,O
required,O
to,O
minimize,O
the,O
risk,O
of,O
hypoglycemia,O
when,O
used,O
in,O
combination,O
with,O
NESINA,O
5,O
5,O
Severe,O
and,O
Disabling,O
Arthralgia,O
There,O
have,O
been,O
postmarketing,O
reports,O
of,O
severe,Severity
and,O
disabling,Severity
arthralgia,AdverseReaction
in,O
patients,O
taking,O
DPP 4 inhibitors,DrugClass
The,O
time,O
to,O
onset,O
of,O
symptoms,O
following,O
initiation,O
of,O
drug,O
therapy,O
varied,O
from,O
one,O
day,O
to,O
years,O
Patients,O
experienced,O
relief,O
of,O
symptoms,O
upon,O
discontinuation,O
of,O
the,O
medication,O
A,O
subset,O
of,O
patients,O
experienced,O
a,O
recurrence,O
of,O
symptoms,O
when,O
restarting,O
the,O
same,O
drug,O
or,O
a,O
different,O
DPP,O
4,O
inhibitor,O
Consider,O
DPP,O
4,O
inhibitors,O
as,O
a,O
possible,O
cause,O
for,O
severe,O
joint,O
pain,O
and,O
discontinue,O
drug,O
if,O
appropriate,O
5,O
6,O
Macrovascular,O
Outcomes,O
There,O
have,O
been,O
no,O
clinical,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
NESINA,O
or,O
any,O
other,O
antidiabetic,O
drug,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Common,O
adverse,O
reactions,O
reported,O
in,O
4,O
of,O
patients,O
treated,O
with,O
NESINA,O
25,O
mg,O
and,O
more,O
frequently,O
than,O
in,O
patients,O
who,O
received,O
placebo,O
are,O
nasopharyngitis,AdverseReaction
headache,AdverseReaction
and,O
upper respiratory tract infection,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Takeda,O
Pharmaceuticals,O
at,O
1,O
877,O
TAKEDA,O
7,O
1,O
877,O
825,O
3327,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Approximately,O
8500,O
patients,O
with,O
type,O
2,O
diabetes,O
have,O
been,O
treated,O
with,O
NESINA,O
in,O
14,O
randomized,O
double,O
blind,O
controlled,O
clinical,O
trials,O
with,O
approximately,O
2900,O
subjects,O
randomized,O
to,O
placebo,O
and,O
approximately,O
2200,O
to,O
an,O
active,O
comparator,O
The,O
mean,O
exposure,O
to,O
NESINA,O
was,O
40,O
weeks,O
with,O
more,O
than,O
2400,O
subjects,O
treated,O
for,O
more,O
than,O
one,O
year,O
Among,O
these,O
patients,O
63,O
had,O
a,O
history,O
of,O
hypertension,O
51,O
had,O
a,O
history,O
of,O
dyslipidemia,O
25,O
had,O
a,O
history,O
of,O
myocardial,O
infarction,O
8,O
had,O
a,O
history,O
of,O
unstable,O
angina,O
and,O
7,O
had,O
a,O
history,O
of,O
congestive,O
heart,O
failure,O
The,O
mean,O
duration,O
of,O
diabetes,O
was,O
seven,O
years,O
the,O
mean,O
body,O
mass,O
index,O
BMI,O
was,O
31,O
kg,O
m,O
2,O
51,O
of,O
patients,O
had,O
a,O
BMI,O
30,O
kg,O
m,O
2,O
and,O
the,O
mean,O
age,O
was,O
57,O
years,O
24,O
of,O
patients,O
65,O
years,O
of,O
age,O
Two,O
placebo,O
controlled,O
monotherapy,O
trials,O
of,O
12,O
and,O
26,O
weeks,O
of,O
duration,O
were,O
conducted,O
in,O
patients,O
treated,O
with,O
NESINA,O
12,O
5,O
mg,O
daily,O
NESINA,O
25,O
mg,O
daily,O
and,O
placebo,O
Four,O
placebo,O
controlled,O
add,O
on,O
combination,O
therapy,O
trials,O
of,O
26,O
weeks,O
duration,O
were,O
also,O
conducted,O
with,O
metformin,O
with,O
a,O
sulfonylurea,O
with,O
a,O
thiazolidinedione,O
and,O
with,O
insulin,O
Four,O
placebo,O
controlled,O
and,O
one,O
active,O
controlled,O
trials,O
of,O
16,O
weeks,O
up,O
through,O
two,O
years,O
in,O
duration,O
were,O
conducted,O
in,O
combination,O
with,O
metformin,O
in,O
combination,O
with,O
pioglitazone,O
and,O
with,O
pioglitazone,O
added,O
to,O
a,O
background,O
of,O
metformin,O
therapy,O
Three,O
active,O
controlled,O
trials,O
of,O
52,O
weeks,O
in,O
duration,O
were,O
conducted,O
in,O
patients,O
treated,O
with,O
pioglitazone,O
and,O
metformin,O
in,O
combination,O
with,O
metformin,O
and,O
as,O
monotherapy,O
compared,O
to,O
glipizide,O
In,O
a,O
pooled,O
analysis,O
of,O
these,O
14,O
controlled,O
clinical,O
trials,O
the,O
overall,O
incidence,O
of,O
adverse,O
events,O
was,O
66,O
in,O
patients,O
treated,O
with,O
NESINA,O
25,O
mg,O
compared,O
to,O
62,O
with,O
placebo,O
and,O
70,O
with,O
active,O
comparator,O
Overall,O
discontinuation,O
of,O
therapy,O
due,O
to,O
adverse,O
events,O
was,O
4,O
7,O
with,O
NESINA,O
25,O
mg,O
compared,O
to,O
4,O
5,O
with,O
placebo,O
or,O
6,O
2,O
with,O
active,O
comparator,O
Adverse,O
reactions,O
reported,O
in,O
4,O
of,O
patients,O
treated,O
with,O
NESINA,O
25,O
mg,O
and,O
more,O
frequently,O
than,O
in,O
patients,O
who,O
received,O
placebo,O
are,O
summarized,O
in,O
Table,O
1,O
Table,O
1,O
Adverse,O
Reactions,O
Reported,O
in,O
4,O
Patients,O
Treated,O
with,O
NESINA,O
25,O
mg,O
and,O
More,O
Frequently,O
Than,O
in,O
Patients,O
Given,O
Placebo,O
in,O
Pooled,O
Studies,O
Number,O
of,O
Patients,O
NESINA25,O
mg,O
Placebo,O
Active,O
Comparator,O
N,O
5902,O
N,O
2926,O
N,O
2257,O
Nasopharyngitis,AdverseReaction
257,O
4,O
4,O
89,O
3,O
0,O
113,O
5,O
0,O
Headache,AdverseReaction
247,O
4,O
2,O
72,O
2,O
5,O
121,O
5,O
4,O
Upper Respiratory Tract Infection,AdverseReaction
247,O
4,O
2,O
61,O
2,O
1,O
113,O
5,O
0,O
Pancreatitis,O
In,O
the,O
clinical,O
trial,O
program,O
pancreatitis,AdverseReaction
was,O
reported,O
in,O
11,O
of,O
5902,O
0,O
2,O
patients,O
receiving,O
NESINA,O
25,O
mg,O
daily,O
compared,O
to,O
five,O
of,O
5183,O
0,O
1,O
patients,O
receiving,O
all,O
comparators,O
Hypersensitivity,O
Reactions,O
In,O
a,O
pooled,O
analysis,O
the,O
overall,O
incidence,O
of,O
hypersensitivity reactions,AdverseReaction
was,O
0,O
6,O
with,O
NESINA,O
25,O
mg,O
compared,O
to,O
0,O
8,O
with,O
all,O
comparators,O
A,O
single,O
event,O
of,O
serum sickness,AdverseReaction
was,O
reported,O
in,O
a,O
patient,O
treated,O
with,O
NESINA,O
25,O
mg,O
Hypoglycemia,O
Hypoglycemic events,AdverseReaction
were,O
documented,O
based,O
upon,O
a,O
blood,O
glucose,O
value,O
and,O
or,O
clinical,O
signs,O
and,O
symptoms,O
of,O
hypoglycemia,AdverseReaction
In,O
the,O
monotherapy,O
study,O
the,O
incidence,O
of,O
hypoglycemia,AdverseReaction
was,O
1,O
5,O
in,O
patients,O
treated,O
with,O
NESINA,O
compared,O
to,O
1,O
6,O
with,O
placebo,O
The,O
use,O
of,O
NESINA,O
as,O
add,O
on,O
therapy,O
to,O
glyburide,O
or,O
insulin,O
did,O
not,O
increase,O
the,O
incidence,O
of,O
hypoglycemia,AdverseReaction
compared,O
to,O
placebo,O
In,O
a,O
monotherapy,O
study,O
comparing,O
NESINA,O
to,O
a,O
sulfonylurea,O
in,O
elderly,O
patients,O
the,O
incidence,O
of,O
hypoglycemia,AdverseReaction
was,O
5,O
4,O
with,O
NESINA,O
compared,O
to,O
26,O
with,O
glipizide,O
Table,O
2,O
Table,O
2,O
Incidence,O
and,O
Rate,O
of,O
HypoglycemiaAdverse,O
reactions,O
of,O
hypoglycemia,AdverseReaction
were,O
based,O
on,O
all,O
reports,O
of,O
symptomatic,Severity
and,O
asymptomatic,O
hypoglycemia,AdverseReaction
a,O
concurrent,O
glucose,O
measurement,O
was,O
not,O
required,O
intent,O
to,O
treat,O
population,O
in,O
Placebo,O
and,O
Active,O
Controlled,O
Studies,O
when,O
NESINA,O
Was,O
Used,O
as,O
Add,O
On,O
Therapy,O
to,O
Glyburide,O
Insulin,O
Metformin,O
Pioglitazone,O
or,O
Compared,O
to,O
Glipizide,O
Add,O
On,O
to,O
Glyburide,O
26,O
Weeks,O
NESINA,O
25,O
mg,O
Glyburide,O
Placebo,O
Glyburide,O
N,O
198,O
N,O
99,O
Overall,O
19,O
9,O
6,O
11,O
11,O
1,O
Severe,O
Severe,Severity
events,O
of,O
hypoglycemia,AdverseReaction
were,O
defined,O
as,O
those,O
events,O
requiring,O
medical,O
assistance,O
or,O
exhibiting,O
depressed,O
level,O
or,O
loss,O
of,O
consciousness,O
or,O
seizure,O
0,O
1,O
1,O
Add,O
On,O
to,O
Insulin,O
Metformin,O
26,O
Weeks,O
NESINA,O
25,O
mg,O
Insulin,O
Metformin,O
Placebo,O
Insulin,O
Metformin,O
N,O
129,O
N,O
129,O
Overall,O
35,O
27,O
31,O
24,O
Severe,O
1,O
0,O
8,O
2,O
1,O
6,O
Add,O
On,O
to,O
Metformin,O
26,O
Weeks,O
NESINA,O
25,O
mg,O
Metformin,O
Placebo,O
Metformin,O
N,O
207,O
N,O
104,O
Overall,O
0,O
3,O
2,O
9,O
Severe,O
0,O
0,O
Add,O
On,O
to,O
Pioglitazone,O
Metformin,O
or,O
Sulfonylurea,O
26,O
Weeks,O
NESINA,O
25,O
mg,O
Pioglitazone,O
Placebo,O
Pioglitazone,O
N,O
199,O
N,O
97,O
Overall,O
14,O
7,O
0,O
5,O
5,O
2,O
Severe,O
0,O
1,O
1,O
Compared,O
to,O
Glipizide,O
52,O
Weeks,O
NESINA,O
25,O
mg,O
Glipizide,O
N,O
222,O
N,O
219,O
Overall,O
12,O
5,O
4,O
57,O
26,O
Severe,O
0,O
3,O
1,O
4,O
Add,O
On,O
to,O
Metformin,O
26,O
Weeks,O
NESINA,O
25,O
mg,O
Metformin,O
500,O
mg,O
twice,O
daily,O
N,O
112,O
N,O
109,O
Overall,O
2,O
1,O
8,O
2,O
1,O
8,O
Severe,O
0,O
0,O
Add,O
On,O
to,O
Metformin,O
Compared,O
to,O
Glipizide,O
52,O
Weeks,O
NESINA,O
25,O
mg,O
Metformin,O
Glipizide,O
Metformin,O
N,O
877,O
N,O
869,O
Overall,O
12,O
1,O
4,O
207,O
23,O
8,O
Severe,O
0,O
4,O
0,O
5,O
Vital,O
Signs,O
No,Negation
clinically,O
meaningful,O
changes in vital signs,AdverseReaction
or,O
in,O
electrocardiograms,O
were,O
observed,O
in,O
patients,O
treated,O
with,O
NESINA,O
Laboratory,O
Tests,O
No,O
clinically,O
meaningful,O
changes,O
in,O
hematology,O
serum,O
chemistry,O
or,O
urinalysis,O
were,O
observed,O
in,O
patients,O
treated,O
with,O
NESINA,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
the,O
postmarketing,O
use,O
of,O
NESINA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
angioedema,AdverseReaction
rash,AdverseReaction
urticaria,AdverseReaction
and,O
severe,Severity
cutaneous adverse reactions,AdverseReaction
including,O
Stevens Johnson syndrome,AdverseReaction
hepatic enzyme elevations,AdverseReaction
fulminant hepatic failure,AdverseReaction
severe,Severity
and,O
disabling,Severity
arthralgia,AdverseReaction
and,O
acute pancreatitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
2,O
5,O
3,O
5,O
5,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Image,O
interpretation,O
errors,O
especially,O
false,O
positives,O
have,O
been,O
observed,O
5,O
1,O
Neuraceq,O
like,O
all,O
radiopharmaceuticals,O
contributes,O
to,O
a,O
patient,O
s,O
long term cumulative radiation exposure,AdverseReaction
Ensure,O
safe,O
handling,O
to,O
protect,O
patients,O
and,O
health,O
care,O
workers,O
from,O
unintentional,O
radiation,O
exposure,O
5,O
2,O
5,O
1,O
Risk,O
for,O
Image,O
Misinterpretation,O
and,O
Other,O
Errors,O
Errors,O
may,O
occur,O
in,O
the,O
Neuraceq,O
estimation,O
of,O
brain,O
neuritic,O
beta,O
amyloid,O
plaque,O
density,O
during,O
image,O
interpretation,O
see,O
Clinical,O
Studies,O
14,O
Image,O
interpretation,O
should,O
be,O
performed,O
independently,O
of,O
the,O
patient,O
s,O
clinical,O
information,O
The,O
use,O
of,O
clinical,O
information,O
in,O
the,O
interpretation,O
of,O
Neuraceq,O
images,O
has,O
not,O
been,O
evaluated,O
and,O
may,O
lead,O
to,O
errors,O
Errors,O
may,O
also,O
occur,O
in,O
cases,O
with,O
severe,O
brain,O
atrophy,O
that,O
limits,O
the,O
ability,O
to,O
distinguish,O
gray,O
and,O
white,O
matter,O
on,O
the,O
Neuraceq,O
scan,O
Errors,O
may,O
also,O
occur,O
due,O
to,O
motion,O
artifacts,O
that,O
result,O
in,O
image,O
distortion,O
Neuraceq,O
scan,O
results,O
are,O
indicative,O
of,O
the,O
presence,O
of,O
brain,O
neuritic,O
beta,O
amyloid,O
plaques,O
only,O
at,O
the,O
time,O
of,O
image,O
acquisition,O
and,O
a,O
negative,O
scan,O
result,O
does,O
not,O
preclude,O
the,O
development,O
of,O
brain,O
neuritic,O
beta,O
amyloid,O
plaques,O
in,O
the,O
future,O
5,O
2,O
Radiation,O
Risk,O
Neuraceq,O
similar,O
to,O
other,O
radiopharmaceuticals,O
contributes,O
to,O
a,O
patient,O
s,O
overall,O
long term cumulative radiation exposure,AdverseReaction
Long term cumulative radiation exposure,AdverseReaction
is,O
associated,O
with,O
an,O
increased,O
risk,Factor
of,O
cancer,AdverseReaction
Ensure,O
safe,O
handling,O
to,O
protect,O
patients,O
and,O
health,O
care,O
workers,O
from,O
unintentional,O
radiation,O
exposure,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
were,O
injection site reaction site site site,AdverseReaction
consisting,O
of,O
erythema,AdverseReaction
1,O
7,O
irritation,AdverseReaction
1,O
2,O
and,O
pain,AdverseReaction
3,O
9,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Piramal,O
at,O
1,O
855,O
545,O
5245,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rate,O
observed,O
in,O
clinical,O
practice,O
The,O
overall,O
safety,O
profile,O
of,O
Neuraceq,O
is,O
based,O
on,O
data,O
from,O
978,O
administrations,O
of,O
Neuraceq,O
to,O
872,O
subjects,O
and,O
12,O
subjects,O
who,O
received,O
vehicle,O
only,O
No,O
serious,O
adverse,O
reactions,O
related,O
to,O
Neuraceq,O
administration,O
have,O
been,O
reported,O
The,O
most,O
frequently,O
observed,O
adverse,O
drug,O
reactions,O
in,O
subjects,O
receiving,O
Neuraceq,O
were,O
injection site reactions site site site,AdverseReaction
consisting,O
of,O
erythema,AdverseReaction
irritation,AdverseReaction
and,O
pain,AdverseReaction
All,O
adverse,O
reactions,O
were,O
mild,O
to,O
moderate,O
in,O
severity,O
and,O
of,O
short,O
duration,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
occurring,O
in,O
at,O
least,O
0,O
5,O
of,O
subjects,O
during,O
Neuraceq,O
clinical,O
trials,O
are,O
shown,O
in,O
Table,O
2,O
Table,O
2,O
Adverse,O
Reactions,O
with,O
a,O
Frequency,O
0,O
5,O
Reported,O
in,O
Clinical,O
Trials,O
n,O
978,O
Administrations,O
in,O
872,O
Subjects,O
Adverse,O
drug,O
reaction,O
n,O
Injection,AdverseReaction
application site erythema erythema,AdverseReaction
17,O
1,O
7,O
Injection site irritation,AdverseReaction
12,O
1,O
2,O
Injection site pain,AdverseReaction
38,O
3,O
9,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
NORTHERA,O
can,Factor
cause,O
supine hypertension,AdverseReaction
and,O
may,Factor
increase,O
cardiovascular risk,AdverseReaction
if,O
supine hypertension,AdverseReaction
is,O
not,O
well,O
managed,O
5,O
1,O
Hyperpyrexia,AdverseReaction
and,O
confusion,AdverseReaction
5,O
2,O
May,Factor
exacerbate,AdverseReaction
symptoms,O
in,O
patients,O
with,O
existing,O
ischemic heart disease,AdverseReaction
arrhythmias,AdverseReaction
and,O
congestive heart failure,AdverseReaction
5,O
3,O
Allergic reactions,AdverseReaction
5,O
4,O
5,O
1,O
Supine,O
Hypertension,O
NORTHERA,O
therapy,O
may,Factor
cause,O
or,O
exacerbate,O
supine hypertension,AdverseReaction
in,O
patients,O
with,O
NOH,O
Patients,O
should,O
be,O
advised,O
to,O
elevate,O
the,O
head,O
of,O
the,O
bed,O
when,O
resting,O
or,O
sleeping,O
Monitor,O
blood,O
pressure,O
both,O
in,O
the,O
supine,O
position,O
and,O
in,O
the,O
recommended,O
head,O
elevated,O
sleeping,O
position,O
Reduce,O
or,O
discontinue,O
NORTHERA,O
if,O
supine,O
hypertension,O
persists,O
If,O
supine,O
hypertension,O
is,O
not,O
well,O
managed,O
NORTHERA,O
may,O
increase,O
the,O
risk,O
of,O
cardiovascular,O
events,O
5,O
2,O
Hyperpyrexia,O
and,O
Confusion,O
Post,O
marketing,O
cases,O
of,O
a,O
symptom,O
complex,O
resembling,O
neuroleptic malignant syndrome,AdverseReaction
NMS,AdverseReaction
have,O
been,O
reported,O
with,O
NORTHERA,O
use,O
during,O
post,O
marketing,O
surveillance,O
in,O
Japan,O
Observe,O
patients,O
carefully,O
when,O
the,O
dosage,O
of,O
NORTHERA,O
is,O
changed,O
or,O
when,O
concomitant,O
levodopa,O
is,O
reduced,O
abruptly,O
or,O
discontinued,O
especially,O
if,O
the,O
patient,O
is,O
receiving,O
neuroleptics,O
NMS,AdverseReaction
is,O
an,O
uncommon,O
but,O
life threatening,Severity
syndrome,O
characterized,O
by,O
fever,AdverseReaction
or,O
hyperthermia,AdverseReaction
muscle rigidity,AdverseReaction
involuntary movements,AdverseReaction
altered consciousness,AdverseReaction
and,O
mental status changes,AdverseReaction
The,O
early,O
diagnosis,O
of,O
this,O
condition,O
is,O
important,O
for,O
the,O
appropriate,O
management,O
of,O
these,O
patients,O
5,O
3,O
Ischemic,O
Heart,O
Disease,O
Arrhythmias,O
and,O
Congestive,O
Heart,O
Failure,O
NORTHERA,O
may,Factor
exacerbate,AdverseReaction
existing,O
ischemic heart disease,AdverseReaction
arrhythmias,AdverseReaction
and,O
congestive heart failure,AdverseReaction
Careful,O
consideration,O
should,O
be,O
given,O
to,O
this,O
potential,O
risk,O
prior,O
to,O
initiating,O
therapy,O
in,O
patients,O
with,O
these,O
conditions,O
5,O
4,O
Allergic,O
Reactions,O
This,O
product,O
contains,O
FD,O
C,O
Yellow,O
No,O
5,O
tartrazine,O
which,O
may,Factor
cause,O
allergic type reactions,AdverseReaction
including,O
bronchial asthma,AdverseReaction
in,O
certain,O
susceptible,O
persons,O
Although,O
the,O
overall,O
incidence,O
of,O
FD,O
C,O
Yellow,O
No,O
5,O
tartrazine,O
sensitivity,O
in,O
the,O
general,O
population,O
is,O
low,O
it,O
is,O
frequently,O
seen,O
in,O
patients,O
who,O
also,O
have,O
aspirin,O
hypersensitivity,O
""
BOXED,O
WARNING,O
WARNING,O
SUPINE HYPERTENSION,AdverseReaction
WARNING,O
SUPINE HYPERTENSION,AdverseReaction
Monitor,O
supine,O
blood,O
pressure,O
prior,O
to,O
and,O
during,O
treatment,O
and,O
more,O
frequently,O
when,O
increasing,O
doses,O
Elevating,O
the,O
head,O
of,O
the,O
bed,O
lessens,O
the,O
risk,O
of,O
supine,O
hypertension,O
and,O
blood,O
pressure,O
should,O
be,O
measured,O
in,O
this,O
position,O
If,O
supine,O
hypertension,O
cannot,O
be,O
managed,O
by,O
elevation,O
of,O
the,O
head,O
of,O
the,O
bed,O
reduce,O
or,O
discontinue,O
NORTHERA,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
SUPINE HYPERTENSION,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Monitor,O
supine,O
blood,O
pressure,O
prior,O
to,O
and,O
during,O
treatment,O
and,O
more,O
frequently,O
when,O
increasing,O
doses,O
Elevating,O
the,O
head,O
of,O
the,O
bed,O
lessens,O
the,O
risk,O
of,O
supine,O
hypertension,O
and,O
blood,O
pressure,O
should,O
be,O
measured,O
in,O
this,O
position,O
If,O
supine,O
hypertension,O
cannot,O
be,O
managed,O
by,O
elevation,O
of,O
the,O
head,O
of,O
the,O
bed,O
reduce,O
or,O
discontinue,O
NORTHERA,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
with,O
NORTHERA,O
are,O
included,O
in,O
more,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
of,O
the,O
label,O
Supine Hypertension,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hyperpyrexia,AdverseReaction
and,O
Confusion,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
May,Factor
exacerbate,AdverseReaction
existing,O
ischemic heart disease,AdverseReaction
arrhythmias,AdverseReaction
and,O
congestive heart failure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
EXCERPT,O
Headache,AdverseReaction
dizziness,AdverseReaction
nausea,AdverseReaction
hypertension,AdverseReaction
and,O
fatigue,AdverseReaction
greater,O
than,O
5,O
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Lundbeck,O
at,O
1,O
800,O
455,O
1141,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
safety,O
evaluation,O
of,O
NORTHERA,O
is,O
based,O
on,O
two,O
placebo,O
controlled,O
studies,O
1,O
to,O
2,O
weeks,O
in,O
duration,O
Studies,O
301,O
and,O
302,O
one,O
8,O
week,O
placebo,O
controlled,O
study,O
Study,O
306,O
and,O
two,O
long,O
term,O
open,O
label,O
extension,O
studies,O
Studies,O
303,O
and,O
304,O
In,O
the,O
placebo,O
controlled,O
studies,O
a,O
total,O
of,O
485,O
patients,O
with,O
Parkinson,O
s,O
disease,O
multiple,O
system,O
atrophy,O
pure,O
autonomic,O
failure,O
dopamine,O
beta,O
hydroxylase,O
deficiency,O
or,O
non,O
diabetic,O
autonomic,O
neuropathy,O
were,O
randomized,O
and,O
treated,O
245,O
with,O
NORTHERA,O
and,O
240,O
with,O
placebo,O
see,O
Clinical,O
Studies,O
14,O
Placebo,O
Controlled,O
Experience,O
The,O
most,O
commonly,O
observed,O
adverse,O
reactions,O
those,O
occurring,O
at,O
an,O
incidence,O
of,O
greater,O
than,O
5,O
in,O
the,O
NORTHERA,O
group,O
and,O
with,O
at,O
least,O
a,O
3,O
greater,O
incidence,O
in,O
the,O
NORTHERA,O
group,O
than,O
in,O
the,O
placebo,O
group,O
in,O
NORTHERA,O
treated,O
patients,O
during,O
the,O
three,O
placebo,O
controlled,O
trials,O
were,O
headache,AdverseReaction
dizziness,AdverseReaction
nausea,AdverseReaction
hypertension,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
from,O
NORTHERA,O
were,O
hypertension,AdverseReaction
or,O
increased blood pressure,AdverseReaction
and,O
nausea,AdverseReaction
Table,O
1,O
Most,O
Common,O
Adverse,O
Reactions,O
Occurring,O
More,O
Frequently,O
in,O
the,O
NORTHERA,O
Group,O
Study,O
301,O
and,O
Study,O
302,O
1,O
to,O
2,O
Weeks,O
Randomized,O
Treatment,O
Study,O
306,O
8,O
to,O
10,O
Weeks,O
Randomized,O
Treatment,O
Placebo,O
N,O
132,O
n,O
NORTHERA,O
N,O
131,O
n,O
Placebo,O
N,O
108,O
n,O
NORTHERA,O
N,O
114,O
n,O
Headache,AdverseReaction
4,O
3,O
0,O
8,O
6,O
1,O
8,O
7,O
4,O
15,O
13,O
2,O
Dizziness,AdverseReaction
2,O
1,O
5,O
5,O
3,O
8,O
5,O
4,O
6,O
11,O
9,O
6,O
Nausea,AdverseReaction
2,O
1,O
5,O
2,O
1,O
5,O
5,O
4,O
6,O
10,O
8,O
8,O
Hypertension,AdverseReaction
0,O
2,O
1,O
5,O
1,O
0,O
9,O
8,O
7,O
0,O
Note,O
n,O
number,O
of,O
patients,O
Table,O
displays,O
adverse,O
reactions,O
that,O
were,O
reported,O
in,O
greater,O
than,O
5,O
of,O
patients,O
in,O
the,O
NORTHERA,O
group,O
and,O
with,O
at,O
least,O
a,O
3,O
greater,O
incidence,O
in,O
the,O
NORTHERA,O
group,O
than,O
in,O
the,O
placebo,O
group,O
Long,O
Term,O
Open,O
Label,O
Trials,O
with,O
NORTHERA,O
In,O
the,O
long,O
term,O
open,O
label,O
extension,O
studies,O
a,O
total,O
of,O
422,O
patients,O
mean,O
age,O
65,O
years,O
were,O
treated,O
with,O
NORTHERA,O
for,O
a,O
mean,O
total,O
exposure,O
of,O
approximately,O
one,O
year,O
The,O
commonly,O
reported,O
adverse,O
events,O
were,O
falls,AdverseReaction
24,O
urinary tract infections,AdverseReaction
15,O
headache,AdverseReaction
13,O
syncope,AdverseReaction
13,O
and,O
dizziness,AdverseReaction
10,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Post Transplant Lymphoproliferative Disorder,AdverseReaction
PTLD,AdverseReaction
increased,O
risk,Factor
predominantly,O
involving,O
the,O
CNS,O
monitor,O
for,O
new,O
or,O
worsening,O
neurological,O
cognitive,O
or,O
behavioral,O
signs,O
and,O
symptoms,O
Boxed,O
Warning,O
4,O
5,O
1,O
5,O
6,O
Other,O
malignancies,AdverseReaction
increased,O
risk,O
with,O
all,O
immunosuppressants,DrugClass
appears,O
related,O
to,O
intensity,O
and,O
duration,O
of,O
use,O
Avoid,O
prolonged,O
exposure,O
to,O
UV,O
light,O
and,O
sunlight,O
5,O
3,O
Progressive Multifocal Leukoencephalopathy,AdverseReaction
PML,AdverseReaction
increased,O
risk,Factor
consider,O
in,O
the,O
diagnosis,O
of,O
patients,O
reporting,O
new,O
or,O
worsening,O
neurological,O
cognitive,O
or,O
behavioral,O
signs,O
and,O
symptoms,O
Recommended,O
doses,O
of,O
immunosuppressants,O
should,O
not,O
be,O
exceeded,O
5,O
4,O
Other,O
serious,Severity
infections,AdverseReaction
increased,O
risk,Factor
of,O
bacterial,AdverseReaction
viral,AdverseReaction
fungal,AdverseReaction
and,O
protozoal infections,AdverseReaction
including,O
opportunistic infections,AdverseReaction
and,O
tuberculosis,AdverseReaction
Some,O
infections,AdverseReaction
were,O
fatal,AdverseReaction
Polyoma virus associated nephropathy,AdverseReaction
can,Factor
lead,O
to,O
kidney graft loss,AdverseReaction
consider,O
reduction,O
in,O
immunosuppression,O
Evaluate,O
for,O
tuberculosis,O
and,O
initiate,O
treatment,O
for,O
latent,O
infection,O
prior,O
to,O
NULOJIX,O
use,O
Cytomegalovirus,O
and,O
pneumocystis,O
prophylaxis,O
are,O
recommended,O
after,O
transplantation,O
5,O
1,O
5,O
4,O
5,O
5,O
Liver,O
transplant,O
use,O
is,O
not,O
recommended,O
5,O
6,O
Acute Rejection,AdverseReaction
and,O
Graft Loss,AdverseReaction
with,O
Corticosteroid,O
Minimization,O
corticosteroid,O
utilization,O
should,O
be,O
consistent,O
with,O
the,O
NULOJIX,O
clinical,O
trial,O
experience,O
2,O
1,O
5,O
7,O
14,O
1,O
Immunizations,O
avoid,O
use,O
of,O
live,O
vaccines,O
during,O
treatment,O
5,O
8,O
5,O
1,O
Post,O
Transplant,O
Lymphoproliferative,O
Disorder,O
NULOJIX,O
treated,O
patients,O
have,O
an,O
increased,O
risk,Factor
for,O
developing,O
post transplant lymphoproliferative disorder,AdverseReaction
PTLD,AdverseReaction
predominantly,O
involving,O
the,O
CNS,O
compared,O
to,O
patients,O
on,O
a,O
cyclosporine,O
based,O
regimen,O
see,O
Adverse,O
Reactions,O
6,O
1,O
and,O
Table,O
2,O
As,O
the,O
total,O
burden,O
of,O
immunosuppression,O
is,O
a,O
risk,O
factor,O
for,O
PTLD,O
higher,O
than,O
the,O
recommended,O
doses,O
or,O
more,O
frequent,O
dosing,O
of,O
NULOJIX,O
and,O
higher,O
than,O
recommended,O
doses,O
of,O
concomitant,O
immunosuppressive,O
agents,O
are,O
not,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
and,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Physicians,O
should,O
consider,O
PTLD,O
in,O
patients,O
reporting,O
new,O
or,O
worsening,O
neurological,O
cognitive,O
or,O
behavioral,O
signs,O
or,O
symptoms,O
EBV,O
Serostatus,O
The,O
risk,Factor
of,O
PTLD,AdverseReaction
was,O
higher,O
in,O
EBV,O
seronegative,O
patients,O
compared,O
to,O
EBV,O
seropositive,O
patients,O
EBV,O
seropositive,O
patients,O
are,O
defined,O
as,O
having,O
evidence,O
of,O
acquired,O
immunity,O
shown,O
by,O
the,O
presence,O
of,O
IgG,O
antibodies,O
to,O
viral,O
capsid,O
antigen,O
VCA,O
and,O
EBV,O
nuclear,O
antigen,O
EBNA,O
Epstein,O
Barr,O
virus,O
serology,O
should,O
be,O
ascertained,O
before,O
starting,O
administration,O
of,O
NULOJIX,O
and,O
only,O
patients,O
who,O
are,O
EBV,O
seropositive,O
should,O
receive,O
NULOJIX,O
Transplant,O
recipients,O
who,O
are,O
EBV,O
seronegative,O
or,O
with,O
unknown,O
serostatus,O
should,O
not,O
receive,O
NULOJIX,O
see,O
Boxed,O
Warning,O
and,O
Contraindications,O
4,O
Other,O
Risk,O
Factors,O
Other,O
known,O
risk,O
factors,O
for,O
PTLD,O
include,O
cytomegalovirus,O
CMV,O
infection,O
and,O
T,O
cell,O
depleting,O
therapy,O
T,O
cell,O
depleting,O
therapies,O
to,O
treat,O
acute,O
rejection,O
should,O
be,O
used,O
cautiously,O
CMV,O
prophylaxis,O
is,O
recommended,O
for,O
at,O
least,O
3,O
months,O
after,O
transplantation,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Patients,O
who,O
are,O
EBV,O
seropositive,O
and,O
CMV,O
seronegative,O
may,O
be,O
at,O
increased,O
risk,O
for,O
PTLD,O
compared,O
to,O
patients,O
who,O
are,O
EBV,O
seropositive,O
and,O
CMV,O
seropositive,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Since,O
CMV,O
seronegative,O
patients,O
are,O
at,O
increased,O
risk,O
for,O
CMV,O
disease,O
a,O
known,O
risk,O
factor,O
for,O
PTLD,O
the,O
clinical,O
significance,O
of,O
CMV,O
serology,O
for,O
PTLD,O
remains,O
to,O
be,O
determined,O
however,O
these,O
findings,O
should,O
be,O
considered,O
when,O
prescribing,O
NULOJIX,O
5,O
2,O
Management,O
of,O
Immunosuppression,O
Only,O
physicians,O
experienced,O
in,O
management,O
of,O
systemic,O
immunosuppressant,O
therapy,O
in,O
transplantation,O
should,O
prescribe,O
NULOJIX,O
Patients,O
receiving,O
the,O
drug,O
should,O
be,O
managed,O
in,O
facilities,O
equipped,O
and,O
staffed,O
with,O
adequate,O
laboratory,O
and,O
supportive,O
medical,O
resources,O
The,O
physician,O
responsible,O
for,O
the,O
maintenance,O
therapy,O
should,O
have,O
complete,O
information,O
requisite,O
for,O
the,O
follow,O
up,O
of,O
the,O
patient,O
see,O
Boxed,O
Warning,O
5,O
3,O
Other,O
Malignancies,O
Patients,O
receiving,O
immunosuppressants,O
including,O
NULOJIX,O
are,O
at,O
increased,O
risk,O
of,O
developing,O
malignancies,AdverseReaction
in,O
addition,O
to,O
PTLD,AdverseReaction
including,O
the,O
skin,AdverseReaction
see,O
Boxed,O
Warning,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Exposure,O
to,O
sunlight,O
and,O
ultraviolet,O
UV,O
light,O
should,O
be,O
limited,O
by,O
wearing,O
protective,O
clothing,O
and,O
using,O
a,O
sunscreen,O
with,O
a,O
high,O
protection,O
factor,O
5,O
4,O
Progressive,O
Multifocal,O
Leukoencephalopathy,O
Progressive,O
multifocal,O
leukoencephalopathy,O
PML,O
is,O
an,O
often,O
rapidly,O
progressive,O
and,O
fatal,O
opportunistic,O
infection,O
of,O
the,O
CNS,O
that,O
is,O
caused,O
by,O
the,O
JC,O
virus,O
a,O
human,O
polyoma,O
virus,O
In,O
clinical,O
trials,O
with,O
NULOJIX,O
two,O
cases,O
of,O
PML,AdverseReaction
were,O
reported,O
in,O
patients,O
receiving,O
NULOJIX,O
at,O
higher,O
cumulative,O
doses,O
and,O
more,O
frequently,O
than,O
the,O
recommended,O
regimen,O
along,O
with,O
mycophenolate,O
mofetil,O
MMF,O
and,O
corticosteroids,O
one,O
case,O
occurred,O
in,O
a,O
kidney,O
transplant,O
recipient,O
and,O
the,O
second,O
case,O
occurred,O
in,O
a,O
liver,O
transplant,O
recipient,O
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
As,O
PML,O
has,O
been,O
associated,O
with,O
high,O
levels,O
of,O
overall,O
immunosuppression,O
the,O
recommended,O
doses,O
and,O
frequency,O
of,O
NULOJIX,O
and,O
concomitant,O
immunosuppressives,O
including,O
MMF,O
should,O
not,O
be,O
exceeded,O
Physicians,O
should,O
consider,O
PML,O
in,O
the,O
differential,O
diagnosis,O
in,O
patients,O
with,O
new,O
or,O
worsening,O
neurological,O
cognitive,O
or,O
behavioral,O
signs,O
or,O
symptoms,O
PML,O
is,O
usually,O
diagnosed,O
by,O
brain,O
imaging,O
cerebrospinal,O
fluid,O
CSF,O
testing,O
for,O
JC,O
viral,O
DNA,O
by,O
polymerase,O
chain,O
reaction,O
PCR,O
and,O
or,O
brain,O
biopsy,O
Consultation,O
with,O
a,O
specialist,O
e,O
g,O
neurologist,O
and,O
or,O
infectious,O
disease,O
should,O
be,O
considered,O
for,O
any,O
suspected,O
or,O
confirmed,O
cases,O
of,O
PML,O
If,O
PML,O
is,O
diagnosed,O
consideration,O
should,O
be,O
given,O
to,O
reduction,O
or,O
withdrawal,O
of,O
immunosuppression,O
taking,O
into,O
account,O
the,O
risk,O
to,O
the,O
allograft,O
5,O
5,O
Other,O
Serious,O
Infections,O
Patients,O
receiving,O
immunosuppressants,O
including,O
NULOJIX,O
are,O
at,O
increased,O
risk,Factor
of,O
developing,O
bacterial,AdverseReaction
viral,AdverseReaction
cytomegalovirus,AdverseReaction
CMV,AdverseReaction
and,O
herpes,AdverseReaction
fungal,AdverseReaction
and,O
protozoal infections,AdverseReaction
including,O
opportunistic infections,AdverseReaction
These,O
infections,AdverseReaction
may,O
lead,O
to,O
serious,Severity
including,O
fatal,AdverseReaction
outcomes,O
see,O
Boxed,O
Warning,O
and,O
Adverse,O
Reactions,O
6,O
1,O
Prophylaxis,O
for,O
cytomegalovirus,O
is,O
recommended,O
for,O
at,O
least,O
3,O
months,O
after,O
transplantation,O
Prophylaxis,O
for,O
Pneumocystis,O
jiroveci,O
is,O
recommended,O
after,O
transplantation,O
Tuberculosis,O
Tuberculosis,AdverseReaction
was,O
more,O
frequently,O
observed,O
in,O
patients,O
receiving,O
NULOJIX,O
than,O
cyclosporine,O
in,O
clinical,O
trials,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Patients,O
should,O
be,O
evaluated,O
for,O
tuberculosis,O
and,O
tested,O
for,O
latent,O
infection,O
prior,O
to,O
initiating,O
NULOJIX,O
Treatment,O
of,O
latent,O
tuberculosis,O
infection,O
should,O
be,O
initiated,O
prior,O
to,O
NULOJIX,O
use,O
Polyoma,O
Virus,O
Nephropathy,O
In,O
addition,O
to,O
cases,O
of,O
JC virus,AdverseReaction
associated,O
PML,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
cases,O
of,O
polyoma virus associated nephropathy,AdverseReaction
PVAN,AdverseReaction
mostly,O
due,O
to,O
BK virus infection,AdverseReaction
have,O
been,O
reported,O
PVAN,AdverseReaction
is,O
associated,O
with,O
serious,O
outcomes,O
including,O
deteriorating renal function,AdverseReaction
and,O
kidney graft loss,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
Patient,O
monitoring,O
may,O
help,O
detect,O
patients,O
at,O
risk,O
for,O
PVAN,O
Reductions,O
in,O
immunosuppression,O
should,O
be,O
considered,O
for,O
patients,O
who,O
develop,O
evidence,O
of,O
PVAN,O
Physicians,O
should,O
also,O
consider,O
the,O
risk,O
that,O
reduced,O
immunosuppression,O
represents,O
to,O
the,O
functioning,O
allograft,O
5,O
6,O
Liver,O
Transplant,O
Use,O
of,O
NULOJIX,O
in,O
liver,O
transplant,O
patients,O
is,O
not,O
recommended,O
see,O
Boxed,O
Warning,O
In,O
a,O
clinical,O
trial,O
of,O
liver,O
transplant,O
patients,O
use,O
of,O
NULOJIX,O
regimens,O
with,O
more,O
frequent,O
administration,O
of,O
belatacept,O
than,O
any,O
of,O
those,O
studied,O
in,O
kidney,O
transplant,O
along,O
with,O
mycophenolate,O
mofetil,O
MMF,O
and,O
corticosteroids,O
was,O
associated,O
with,O
a,O
higher,O
rate,O
of,O
graft loss,AdverseReaction
and,O
death,AdverseReaction
compared,O
to,O
the,O
tacrolimus,O
control,O
arms,O
In,O
addition,O
two,O
cases,O
of,O
PTLD,AdverseReaction
involving,O
the,O
liver,O
allograft,O
one,O
fatal,AdverseReaction
and,O
one,O
fatal,AdverseReaction
case,O
of,O
PML,AdverseReaction
were,O
observed,O
among,O
the,O
147,O
patients,O
randomized,O
to,O
NULOJIX,O
The,O
two,O
cases,O
of,O
PTLD,AdverseReaction
were,O
reported,O
among,O
the,O
140,O
EBV,O
seropositive,O
patients,O
1,O
4,O
The,O
fatal,AdverseReaction
case,O
of,O
PML,AdverseReaction
was,O
reported,O
in,O
a,O
patient,O
receiving,O
higher,O
than,O
recommended,O
doses,O
of,O
NULOJIX,O
and,O
MMF,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
5,O
7,O
Acute,O
Rejection,O
and,O
Graft,AdverseReaction
Loss,O
with,O
Corticosteroid,O
Minimization,O
In,O
postmarketing,O
experience,O
use,O
of,O
NULOJIX,O
in,O
conjunction,O
with,O
basiliximab,O
induction,O
MMF,O
and,O
corticosteroid,O
minimization,O
to,O
5,O
mg,O
per,O
day,O
between,O
Day,O
3,O
and,O
Week,O
6,O
post transplant transplant,AdverseReaction
was,O
associated,O
with,O
an,O
increased,O
rate,O
and,O
grade,O
of,O
acute rejection rejection,AdverseReaction
particularly,O
Grade III,Severity
rejection,O
These,O
Grade III,Severity
rejections,AdverseReaction
occurred,O
in,O
patients,O
with,O
4,O
to,O
6,O
HLA,O
mismatches,O
Graft loss,AdverseReaction
was,O
a,O
consequence,O
of,O
Grade III,Severity
rejection,AdverseReaction
in,O
some,O
patients,O
Corticosteroid,O
utilization,O
should,O
be,O
consistent,O
with,O
the,O
NULOJIX,O
clinical,O
trial,O
experience,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
and,O
Clinical,O
Studies,O
14,O
1,O
5,O
8,O
Immunizations,O
The,O
use,O
of,O
live,O
vaccines,O
should,O
be,O
avoided,O
during,O
treatment,O
with,O
NULOJIX,O
including,O
but,O
not,O
limited,O
to,O
the,O
following,O
intranasal,O
influenza,O
measles,O
mumps,O
rubella,O
oral,O
polio,O
BCG,O
yellow,O
fever,O
varicella,O
and,O
TY21a,O
typhoid,O
vaccines,O
""
BOXED,O
WARNING,O
WARNING,O
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,AdverseReaction
OTHER,O
MALIGNANCIES,AdverseReaction
AND,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
WARNING,O
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,AdverseReaction
OTHER,O
MALIGNANCIES,AdverseReaction
AND,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
Increased,O
risk,Factor
for,O
developing,O
post transplant lymphoproliferative disorder,AdverseReaction
PTLD,AdverseReaction
predominantly,O
involving,O
the,O
central,O
nervous,O
system,O
CNS,O
Recipients,O
without,O
immunity,O
to,O
Epstein,O
Barr,O
virus,O
EBV,O
are,O
at,O
a,O
particularly,O
increased,O
risk,O
therefore,O
use,O
in,O
EBV,O
seropositive,O
patients,O
only,O
Do,O
not,O
use,O
NULOJIX,O
in,O
transplant,O
recipients,O
who,O
are,O
EBV,O
seronegative,O
or,O
with,O
unknown,O
EBV,O
serostatus,O
see,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Only,O
physicians,O
experienced,O
in,O
immunosuppressive,O
therapy,O
and,O
management,O
of,O
kidney,O
transplant,O
patients,O
should,O
prescribe,O
NULOJIX,O
Patients,O
receiving,O
the,O
drug,O
should,O
be,O
managed,O
in,O
facilities,O
equipped,O
and,O
staffed,O
with,O
adequate,O
laboratory,O
and,O
supportive,O
medical,O
resources,O
The,O
physician,O
responsible,O
for,O
maintenance,O
therapy,O
should,O
have,O
complete,O
information,O
requisite,O
for,O
the,O
follow,O
up,O
of,O
the,O
patient,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Increased susceptibility to infection,AdverseReaction
and,O
the,O
possible,O
development,O
of,O
malignancies,AdverseReaction
may,Factor
result,O
from,O
immunosuppression,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
3,O
5,O
4,O
5,O
5,O
Use,O
in,O
liver,O
transplant,O
patients,O
is,O
not,O
recommended,O
due,O
to,O
an,O
increased,O
risk,O
of,O
graft,O
loss,O
and,O
death,O
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
EXCERPT,O
WARNING,O
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,AdverseReaction
OTHER,O
MALIGNANCIES,AdverseReaction
AND,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Increased,O
risk,Factor
for,O
developing,O
post transplant lymphoproliferative disorder,AdverseReaction
PTLD,AdverseReaction
predominantly,O
involving,O
the,O
central,O
nervous,O
system,O
CNS,O
Recipients,O
without,O
immunity,O
to,O
Epstein,O
Barr,O
virus,O
EBV,O
are,O
at,O
a,O
particularly,O
increased,O
risk,O
therefore,O
use,O
in,O
EBV,O
seropositive,O
patients,O
only,O
Do,O
not,O
use,O
NULOJIX,O
in,O
transplant,O
recipients,O
who,O
are,O
EBV,O
seronegative,O
or,O
with,O
unknown,O
serostatus,O
4,O
5,O
1,O
Only,O
physicians,O
experienced,O
in,O
immunosuppressive,O
therapy,O
and,O
management,O
of,O
kidney,O
transplant,O
patients,O
should,O
prescribe,O
NULOJIX,O
5,O
2,O
Increased susceptibility to infection,AdverseReaction
and,O
the,O
possible,O
development,O
of,O
malignancies,AdverseReaction
may,Factor
result,O
from,O
immunosuppression,O
5,O
1,O
5,O
3,O
5,O
4,O
5,O
5,O
Use,O
in,O
liver,O
transplant,O
patients,O
is,O
not,O
recommended,O
due,O
to,O
an,O
increased,O
risk,O
of,O
graft,O
loss,O
and,O
death,O
5,O
6,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
most,O
serious,O
adverse,O
reactions,O
reported,O
with,O
NULOJIX,O
are,O
PTLD,AdverseReaction
predominantly,O
CNS PTLD,AdverseReaction
and,O
other,O
malignancies,AdverseReaction
see,O
Boxed,O
Warning,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
3,O
Serious,Severity
infections,AdverseReaction
including,O
JC virus,AdverseReaction
associated,O
PML,AdverseReaction
and,O
polyoma virus nephropathy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
5,O
5,O
5,O
6,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
20,O
on,O
NULOJIX,O
treatment,O
are,O
anemia,AdverseReaction
diarrhea,AdverseReaction
urinary tract infection,AdverseReaction
peripheral edema,AdverseReaction
constipation,AdverseReaction
hypertension,AdverseReaction
pyrexia,AdverseReaction
graft dysfunction,AdverseReaction
cough,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
headache,AdverseReaction
hypokalemia,AdverseReaction
hyperkalemia,AdverseReaction
and,O
leukopenia,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Bristol,O
Myers,O
Squibb,O
at,O
1,O
800,O
721,O
5072,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
The,O
data,O
described,O
below,O
primarily,O
derive,O
from,O
two,O
randomized,O
active,O
controlled,O
three,O
year,O
trials,O
of,O
NULOJIX,O
in,O
de,O
novo,O
kidney,O
transplant,O
patients,O
In,O
Study,O
1,O
and,O
Study,O
2,O
NULOJIX,O
was,O
studied,O
at,O
the,O
recommended,O
dose,O
and,O
frequency,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
in,O
a,O
total,O
of,O
401,O
patients,O
compared,O
to,O
a,O
cyclosporine,O
control,O
regimen,O
in,O
a,O
total,O
of,O
405,O
patients,O
These,O
two,O
trials,O
also,O
included,O
a,O
total,O
of,O
403,O
patients,O
treated,O
with,O
a,O
NULOJIX,O
regimen,O
of,O
higher,O
cumulative,O
dose,O
and,O
more,O
frequent,O
dosing,O
than,O
recommended,O
see,O
Clinical,O
Studies,O
14,O
1,O
All,O
patients,O
also,O
received,O
basiliximab,O
induction,O
mycophenolate,O
mofetil,O
and,O
corticosteroids,O
Patients,O
were,O
treated,O
and,O
followed,O
for,O
3,O
years,O
CNS PTLD,AdverseReaction
PML,AdverseReaction
and,O
other,O
CNS infections,AdverseReaction
were,O
more,O
frequently,O
observed,O
in,O
association,O
with,O
a,O
NULOJIX,O
regimen,O
of,O
higher,O
cumulative,O
dose,O
and,O
more,O
frequent,O
dosing,O
compared,O
to,O
the,O
recommended,O
regimen,O
therefore,O
administration,O
of,O
higher,O
than,O
the,O
recommended,O
doses,O
and,O
or,O
more,O
frequent,O
dosing,O
of,O
NULOJIX,O
is,O
not,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
The,O
average,O
age,O
of,O
patients,O
in,O
Studies,O
1,O
and,O
2,O
in,O
the,O
NULOJIX,O
recommended,O
dose,O
and,O
cyclosporine,O
control,O
regimens,O
was,O
49,O
years,O
ranging,O
from,O
18,O
to,O
79,O
years,O
Approximately,O
70,O
of,O
patients,O
were,O
male,O
67,O
were,O
white,O
11,O
were,O
black,O
and,O
22,O
other,O
races,O
About,O
25,O
of,O
patients,O
were,O
from,O
the,O
United,O
States,O
and,O
75,O
from,O
other,O
countries,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
the,O
adverse,O
reaction,O
rates,O
observed,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
other,O
trials,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
occurring,O
in,O
20,O
of,O
patients,O
treated,O
with,O
the,O
recommended,O
dose,O
and,O
frequency,O
of,O
NULOJIX,O
were,O
anemia,AdverseReaction
diarrhea,AdverseReaction
urinary tract infection,AdverseReaction
peripheral edema,AdverseReaction
constipation,AdverseReaction
hypertension,AdverseReaction
pyrexia,AdverseReaction
graft dysfunction,AdverseReaction
cough,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
headache,AdverseReaction
hypokalemia,AdverseReaction
hyperkalemia,AdverseReaction
and,O
leukopenia,AdverseReaction
The,O
proportion,O
of,O
patients,O
who,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reactions,O
was,O
13,O
for,O
the,O
recommended,O
NULOJIX,O
regimen,O
and,O
19,O
for,O
the,O
cyclosporine,O
control,O
arm,O
through,O
three,O
years,O
of,O
treatment,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
in,O
NULOJIX,O
treated,O
patients,O
were,O
cytomegalovirus infection,AdverseReaction
1,O
5,O
and,O
complications of transplanted kidney,AdverseReaction
1,O
5,O
Information,O
on,O
selected,O
significant,O
adverse,O
reactions,O
observed,O
during,O
clinical,O
trials,O
is,O
summarized,O
below,O
Post,O
Transplant,O
Lymphoproliferative,O
Disorder,O
Reported,O
cases,O
of,O
post transplant lymphoproliferative disorder,AdverseReaction
PTLD,AdverseReaction
up,O
to,O
36,O
months,O
post,O
transplant,O
were,O
obtained,O
for,O
NULOJIX,O
by,O
pooling,O
both,O
dosage,O
regimens,O
of,O
NULOJIX,O
in,O
Studies,O
1,O
and,O
2,O
804,O
patients,O
with,O
data,O
from,O
a,O
third,O
study,O
in,O
kidney,O
transplantation,O
Study,O
3,O
145,O
patients,O
which,O
evaluated,O
two,O
NULOJIX,O
dosage,O
regimens,O
similar,O
but,O
slightly,O
different,O
from,O
those,O
of,O
Studies,O
1,O
and,O
2,O
see,O
Table,O
2,O
The,O
total,O
number,O
of,O
NULOJIX,O
patients,O
from,O
these,O
three,O
studies,O
949,O
was,O
compared,O
to,O
the,O
pooled,O
cyclosporine,O
control,O
groups,O
from,O
all,O
three,O
studies,O
476,O
patients,O
Among,O
401,O
patients,O
in,O
Studies,O
1,O
and,O
2,O
treated,O
with,O
the,O
recommended,O
regimen,O
of,O
NULOJIX,O
and,O
the,O
71,O
patients,O
in,O
Study,O
3,O
treated,O
with,O
a,O
very,O
similar,O
but,O
non,O
identical,O
NULOJIX,O
regimen,O
there,O
were,O
5,O
cases,O
of,O
PTLD,AdverseReaction
3,O
in,O
EBV,O
seropositive,O
patients,O
and,O
2,O
in,O
EBV,O
seronegative,O
patients,O
Two,O
of,O
the,O
5,O
cases,O
presented,O
with,O
CNS,O
involvement,O
Among,O
the,O
477,O
patients,O
in,O
Studies,O
1,O
2,O
and,O
3,O
treated,O
with,O
the,O
NULOJIX,O
regimen,O
of,O
higher,O
cumulative,O
dose,O
and,O
more,O
frequent,O
dosing,O
than,O
recommended,O
there,O
were,O
8,O
cases,O
of,O
PTLD,AdverseReaction
2,O
in,O
EBV,O
seropositive,O
patients,O
and,O
6,O
in,O
EBV,O
seronegative,O
or,O
serostatus,O
unknown,O
patients,O
Six,O
of,O
the,O
8,O
cases,O
presented,O
with,O
CNS,O
involvement,O
Therefore,O
administration,O
of,O
higher,O
than,O
the,O
recommended,O
doses,O
or,O
more,O
frequent,O
dosing,O
of,O
NULOJIX,O
is,O
not,O
recommended,O
See,O
Dosage,O
and,O
Administration,O
2,O
1,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
One,O
of,O
the,O
476,O
patients,O
treated,O
with,O
cyclosporine,O
developed,O
PTLD,AdverseReaction
without,O
CNS,O
involvement,O
All,O
cases,O
of,O
PTLD,AdverseReaction
reported,O
up,O
to,O
36,O
months,O
post,O
transplant,O
in,O
NULOJIX,O
or,O
cyclosporine,O
treated,O
patients,O
presented,O
within,O
18,O
months,O
of,O
transplantation,O
Overall,O
the,O
rate,O
of,O
PTLD,AdverseReaction
in,O
949,O
patients,O
treated,O
with,O
any,O
of,O
the,O
NULOJIX,O
regimens,O
was,O
9,O
fold,O
higher,O
in,O
those,O
who,O
were,O
EBV,O
seronegative,O
or,O
EBV,O
serostatus,O
unknown,O
8,O
139,O
compared,O
to,O
those,O
who,O
were,O
EBV,O
seropositive,O
5,O
810,O
patients,O
Therefore,O
NULOJIX,O
is,O
recommended,O
for,O
use,O
only,O
in,O
patients,O
who,O
are,O
EBV,O
seropositive,O
see,O
Boxed,O
Warning,O
and,O
Contraindications,O
4,O
Table,O
2,O
Summary,O
of,O
PTLD,AdverseReaction
Reported,O
in,O
Studies,O
1,O
2,O
and,O
3,O
Through,O
Three,O
Years,O
of,O
Treatment,O
NULOJIX,O
Non,O
Recommended,O
Regimen,O
N,O
477,O
NULOJIX,O
Recommended,O
Regimen,O
N,O
472,O
Cyclosporine,O
N,O
476,O
Trial,O
EBV,O
Positive,O
n,O
406,O
EBV,O
Negative,O
n,O
43,O
EBV,O
Unknown,O
n,O
28,O
EBV,O
Positive,O
n,O
404,O
EBV,O
Negative,O
n,O
48,O
EBV,O
Unknown,O
n,O
20,O
EBV,O
Positive,O
n,O
399,O
EBV,O
Negative,O
n,O
57,O
EBV,O
Unknown,O
n,O
20,O
Regimen,O
with,O
higher,O
cumulative,O
dose,O
and,O
more,O
frequent,O
dosing,O
than,O
the,O
recommended,O
NULOJIX,O
regimen,O
In,O
Studies,O
1,O
and,O
2,O
the,O
NULOJIX,O
regimen,O
is,O
identical,O
to,O
the,O
recommended,O
regimen,O
but,O
is,O
slightly,O
different,O
in,O
Study,O
3,O
Study,O
1,O
CNS PTLD,AdverseReaction
1,O
1,O
Non CNSPTLD,AdverseReaction
1,O
2,O
1,O
Study,O
2,O
CNS PTLD,AdverseReaction
1,O
1,O
1,O
1,O
Non CNSPTLD,AdverseReaction
1,O
Study,O
3,O
CNS PTLD,AdverseReaction
2,O
Non CNSPTLD,AdverseReaction
1,O
Total,O
2,O
0,O
5,O
5,O
11,O
6,O
1,O
3,O
6,O
3,O
0,O
7,O
2,O
4,O
1,O
0,O
0,O
1,O
1,O
8,O
0,O
EBV,O
Seropositive,O
Subpopulation,O
Among,O
the,O
806,O
EBV,O
seropositive,O
patients,O
with,O
known,O
CMV,O
serostatus,O
treated,O
with,O
either,O
NULOJIX,O
regimen,O
in,O
Studies,O
1,O
2,O
and,O
3,O
two,O
percent,O
2,O
4,O
210,O
of,O
CMV,O
seronegative,O
patients,O
developed,O
PTLD,AdverseReaction
compared,O
to,O
0,O
2,O
1,O
596,O
of,O
CMV,O
seropositive,O
patients,O
Among,O
the,O
404,O
EBV,O
seropositive,O
recipients,O
treated,O
with,O
the,O
recommended,O
dosage,O
regimen,O
of,O
NULOJIX,O
three,O
PTLD,AdverseReaction
cases,O
were,O
detected,O
among,O
99,O
CMV,O
seronegative,O
patients,O
3,O
and,O
there,O
was,O
no,O
case,O
detected,O
among,O
303,O
CMV,O
seropositive,O
patients,O
The,O
clinical,O
significance,O
of,O
CMV,O
serology,O
as,O
a,O
risk,O
factor,O
for,O
PTLD,AdverseReaction
remains,O
to,O
be,O
determined,O
however,O
these,O
findings,O
should,O
be,O
considered,O
when,O
prescribing,O
NULOJIX,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Other,O
Malignancies,O
Malignancies,AdverseReaction
excluding,Negation
non melanoma skin cancer,AdverseReaction
and,O
PTLD,AdverseReaction
were,O
reported,O
in,O
Study,O
1,O
and,O
Study,O
2,O
in,O
3,O
5,O
14,O
401,O
of,O
patients,O
treated,O
with,O
the,O
recommended,O
NULOJIX,O
regimen,O
and,O
3,O
7,O
15,O
405,O
of,O
patients,O
treated,O
with,O
the,O
cyclosporine,O
control,O
regimen,O
Non melanoma skin cancer,AdverseReaction
was,O
reported,O
in,O
1,O
5,O
6,O
401,O
of,O
patients,O
treated,O
with,O
the,O
recommended,O
NULOJIX,O
regimen,O
and,O
in,O
3,O
7,O
15,O
405,O
of,O
patients,O
treated,O
with,O
cyclosporine,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Progressive,O
Multifocal,O
Leukoencephalopathy,O
Two,O
fatal,AdverseReaction
cases,O
of,O
progressive multifocal leukoencephalopathy,AdverseReaction
PML,AdverseReaction
have,O
been,O
reported,O
among,O
1096,O
patients,O
treated,O
with,O
a,O
NULOJIX,O
containing,O
regimen,O
one,O
patient,O
in,O
clinical,O
trials,O
of,O
kidney,O
transplant,O
Studies,O
1,O
2,O
and,O
3,O
described,O
above,O
and,O
one,O
patient,O
in,O
a,O
trial,O
of,O
liver,O
transplant,O
trial,O
of,O
250,O
patients,O
No,Negation
cases,O
of,O
PML,AdverseReaction
were,O
reported,O
in,O
patients,O
treated,O
with,O
the,O
recommended,O
NULOJIX,O
regimen,O
or,O
the,O
control,O
regimen,O
in,O
these,O
trials,O
The,O
kidney,O
transplant,O
recipient,O
was,O
treated,O
with,O
the,O
NULOJIX,O
regimen,O
of,O
higher,O
cumulative,O
dose,O
and,O
more,O
frequent,O
dosing,O
than,O
recommended,O
mycophenolate,O
mofetil,O
MMF,O
and,O
corticosteroids,O
for,O
2,O
years,O
The,O
liver,O
transplant,O
recipient,O
was,O
treated,O
with,O
6,O
months,O
of,O
a,O
NULOJIX,O
dosage,O
regimen,O
that,O
was,O
more,O
intensive,O
than,O
that,O
studied,O
in,O
kidney,O
transplant,O
recipients,O
MMF,O
at,O
doses,O
higher,O
than,O
the,O
recommended,O
dose,O
and,O
corticosteroids,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Bacterial,O
Mycobacterial,O
Viral,O
and,O
Fungal,O
Infections,O
Adverse,O
reactions,O
of,O
infectious etiology,AdverseReaction
were,O
reported,O
based,O
on,O
clinical,O
assessment,O
by,O
physicians,O
The,O
causative,O
organisms,O
for,O
these,O
reactions,O
are,O
identified,O
when,O
provided,O
by,O
the,O
physician,O
The,O
overall,O
number,O
of,O
infections,AdverseReaction
serious,Severity
infections,AdverseReaction
and,O
select,O
infections,AdverseReaction
with,O
identified,O
etiology,O
reported,O
in,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
or,O
the,O
cyclosporine,O
control,O
in,O
Studies,O
1,O
and,O
2,O
are,O
shown,O
in,O
Table,O
3,O
Fungal infections,AdverseReaction
were,O
reported,O
in,O
18,O
of,O
patients,O
receiving,O
NULOJIX,O
compared,O
to,O
22,O
receiving,O
cyclosporine,O
primarily,O
due,O
to,O
skin,AdverseReaction
and,O
mucocutaneous fungal infections infections,AdverseReaction
Tuberculosis,AdverseReaction
and,O
herpes infections,AdverseReaction
were,O
reported,O
more,O
frequently,O
in,O
patients,O
receiving,O
NULOJIX,O
than,O
cyclosporine,O
Of,O
the,O
patients,O
who,O
developed,O
tuberculosis,AdverseReaction
through,O
3,O
years,O
all,O
but,O
one,O
NULOJIX,O
patient,O
lived,O
in,O
countries,O
with,O
a,O
high,O
prevalence,O
of,O
tuberculosis,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Table,O
3,O
Overall,O
Infections,AdverseReaction
and,O
Select,O
Infections,AdverseReaction
with,O
Identified,O
Etiology,O
by,O
Treatment,O
Group,O
following,O
One,O
and,O
Three,O
Years,O
of,O
Treatment,O
in,O
Studies,O
1,O
and,O
2,O
Up,O
to,O
Year,O
1,O
Up,O
to,O
Year,O
3,O
NULOJIX,O
Recommended,O
Regimen,O
N,O
401,O
n,O
Cyclosporine,O
N,O
405,O
n,O
NULOJIX,O
Recommended,O
Regimen,O
N,O
401,O
n,O
Cyclosporine,O
N,O
405,O
n,O
Studies,O
1,O
and,O
2,O
were,O
not,O
designed,O
to,O
support,O
comparative,O
claims,O
for,O
NULOJIX,O
for,O
the,O
adverse,O
reactions,O
reported,O
in,O
this,O
table,O
Median,O
exposure,O
in,O
days,O
for,O
pooled,O
studies,O
1203,O
for,O
NULOJIX,O
recommended,O
regimen,O
and,O
1163,O
for,O
cyclosporine,O
in,O
Studies,O
1,O
and,O
2,O
All,O
infections,AdverseReaction
include,O
bacterial,AdverseReaction
viral,AdverseReaction
fungal,AdverseReaction
and,O
other,O
organisms,O
For,O
infectious adverse reactions,AdverseReaction
the,O
causative,O
organism,O
is,O
reported,O
if,O
specified,O
by,O
the,O
physician,O
in,O
the,O
clinical,O
trials,O
S,O
A,O
medically,O
important,O
event,O
that,O
may,O
be,O
life,O
threatening,O
or,O
result,O
in,O
death,AdverseReaction
or,O
hospitalization,O
or,O
prolongation,O
of,O
existing,O
hospitalization,O
Infections,AdverseReaction
not,O
meeting,O
these,O
criteria,O
are,O
considered,O
non,O
serious,O
BK virus associated nephropathy,AdverseReaction
was,O
reported,O
in,O
6,O
NULOJIX,O
patients,O
4,O
of,O
which,O
resulted,O
in,O
graft,O
loss,O
and,O
6,O
cyclosporine,O
patients,O
none,O
of,O
which,O
resulted,O
in,O
graft,O
loss,O
by,O
Year,O
3,O
Most,O
herpes infections infections,AdverseReaction
were,O
non serious,Severity
and,O
1,O
led,O
to,O
treatment,O
discontinuation,O
All,O
infections,AdverseReaction
287,O
72,O
299,O
74,O
329,O
82,O
327,O
81,O
Serious,Severity
infectionsS,O
98,O
24,O
113,O
28,O
144,O
36,O
157,O
39,O
CMV,AdverseReaction
44,O
11,O
52,O
13,O
53,O
13,O
56,O
14,O
Polyoma virus,AdverseReaction
10,O
3,O
23,O
6,O
17,O
4,O
27,O
7,O
Herpes,AdverseReaction
27,O
7,O
26,O
6,O
55,O
14,O
46,O
11,O
Tuberculosis,AdverseReaction
2,O
1,O
1,O
1,O
6,O
2,O
1,O
1,O
Infections,O
Reported,O
in,O
the,O
CNS,O
Following,O
three,O
years,O
of,O
treatment,O
in,O
Studies,O
1,O
and,O
2,O
cryptococcal meningitis,AdverseReaction
was,O
reported,O
in,O
one,O
patient,O
out,O
of,O
401,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
0,O
2,O
and,O
one,O
patient,O
out,O
of,O
the,O
405,O
treated,O
with,O
the,O
cyclosporine,O
control,O
0,O
2,O
Six,O
patients,O
out,O
of,O
the,O
403,O
who,O
were,O
treated,O
with,O
the,O
NULOJIX,O
regimen,O
of,O
higher,O
cumulative,O
dose,O
and,O
more,O
frequent,O
dosing,O
than,O
recommended,O
in,O
Studies,O
1,O
and,O
2,O
1,O
5,O
were,O
reported,O
to,O
have,O
developed,O
CNS infections,AdverseReaction
including,O
2,O
cases,O
of,O
cryptococcal meningitis,AdverseReaction
one,O
case,O
of,O
Chagas encephalitis,AdverseReaction
with,O
cryptococcal meningitis,AdverseReaction
one,O
case,O
of,O
cerebral aspergillosis,AdverseReaction
one,O
case,O
of,O
West Nile encephalitis,AdverseReaction
and,O
one,O
case,O
of,O
PML,AdverseReaction
discussed,O
above,O
Infusion,O
Reactions,O
There,O
were,O
no,Negation
reports,O
of,O
anaphylaxis,AdverseReaction
or,O
drug hypersensitivity,AdverseReaction
in,O
patients,O
treated,O
with,O
NULOJIX,O
in,O
Studies,O
1,O
and,O
2,O
through,O
three,O
years,O
Infusion related reactions,AdverseReaction
within,O
one,O
hour,O
of,O
infusion,O
were,O
reported,O
in,O
5,O
of,O
patients,O
treated,O
with,O
the,O
recommended,O
dose,O
of,O
NULOJIX,O
similar,O
to,O
the,O
placebo,O
rate,O
No,O
serious,O
events,O
were,O
reported,O
through,O
Year,O
3,O
The,O
most,O
frequent,O
reactions,O
were,O
hypotension,AdverseReaction
and,O
hypertension,AdverseReaction
Proteinuria,O
At,O
Month,O
1,O
after,O
transplantation,O
in,O
Studies,O
1,O
and,O
2,O
the,O
frequency,O
of,O
2,Severity
proteinuria,AdverseReaction
on,O
urine,O
dipstick,O
in,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
was,O
33,O
130,O
390,O
and,O
28,O
107,O
384,O
in,O
patients,O
treated,O
with,O
the,O
cyclosporine,O
control,O
regimen,O
The,O
frequency,O
of,O
2,Severity
proteinuria,AdverseReaction
was,O
similar,O
between,O
the,O
two,O
treatment,O
groups,O
between,O
one,O
and,O
three,O
years,O
after,O
transplantation,O
10,O
in,O
both,O
studies,O
There,O
were,O
no,O
differences,O
in,O
the,O
occurrence,O
of,O
3,Severity
proteinuria,AdverseReaction
4,O
in,O
both,O
studies,O
at,O
any,O
time,O
point,O
and,O
no,Negation
patients,O
experienced,O
4,Severity
proteinuria,AdverseReaction
The,O
clinical,O
significance,O
of,O
this,O
increase,O
in,O
early proteinuria,AdverseReaction
is,O
unknown,O
Immunogenicity,O
Antibodies,O
directed,O
against,O
the,O
belatacept,O
molecule,O
were,O
assessed,O
in,O
398,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
in,O
Studies,O
1,O
and,O
2,O
212,O
of,O
these,O
patients,O
were,O
treated,O
for,O
at,O
least,O
2,O
years,O
Of,O
the,O
372,O
patients,O
with,O
immunogenicity,O
assessment,O
at,O
baseline,O
prior,O
to,O
receiving,O
belatacept,O
treatment,O
29,O
patients,O
tested,O
positive,O
for,O
anti,O
belatacept,O
antibodies,O
13,O
of,O
these,O
patients,O
had,O
antibodies,O
to,O
the,O
modified,O
cytotoxic,O
T,O
lymphocyte,O
associated,O
antigen,O
4,O
CTLA,O
4,O
Anti,O
belatacept,O
antibody,O
titers,O
did,O
not,O
increase,O
during,O
treatment,O
in,O
these,O
29,O
patients,O
Eight,O
2,O
patients,O
developed,O
antibodies,O
during,O
treatment,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
In,O
the,O
patients,O
who,O
developed,O
antibodies,O
during,O
treatment,O
the,O
median,O
titer,O
by,O
dilution,O
method,O
was,O
8,O
with,O
a,O
range,O
of,O
5,O
to,O
80,O
Of,O
56,O
patients,O
who,O
tested,O
negative,O
for,O
antibodies,O
during,O
treatment,O
and,O
reassessed,O
approximately,O
7,O
half,O
lives,O
after,O
discontinuation,O
of,O
NULOJIX,O
1,O
tested,O
antibody,O
positive,O
Anti,O
belatacept,O
antibody,O
development,O
was,O
not,O
associated,O
with,O
altered,O
clearance,O
of,O
belatacept,O
Samples,O
from,O
6,O
patients,O
with,O
confirmed,O
binding,O
activity,O
to,O
the,O
modified,O
cytotoxic,O
T,O
lymphocyte,O
associated,O
antigen,O
4,O
CTLA,O
4,O
region,O
of,O
the,O
belatacept,O
molecule,O
were,O
assessed,O
by,O
an,O
in,O
vitro,O
bioassay,O
for,O
the,O
presence,O
of,O
neutralizing,O
antibodies,O
Three,O
of,O
these,O
6,O
patients,O
tested,O
positive,O
for,O
neutralizing,O
antibodies,O
However,O
the,O
development,O
of,O
neutralizing,O
antibodies,O
may,O
be,O
underreported,O
due,O
to,O
lack,O
of,O
assay,O
sensitivity,O
The,O
clinical,O
impact,O
of,O
anti,O
belatacept,O
antibodies,O
including,O
neutralizing,O
anti,O
belatacept,O
antibodies,O
could,O
not,O
be,O
determined,O
in,O
the,O
studies,O
The,O
data,O
reflect,O
the,O
percentage,O
of,O
patients,O
whose,O
test,O
results,O
were,O
positive,O
for,O
antibodies,O
to,O
belatacept,O
in,O
specific,O
assays,O
The,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
sensitivity,O
and,O
specificity,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
belatacept,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
New,O
Onset,O
Diabetes,O
After,O
Transplantation,O
The,O
incidence,O
of,O
new onset diabetes after transplantation,AdverseReaction
NODAT,AdverseReaction
was,O
defined,O
in,O
Studies,O
1,O
and,O
2,O
as,O
use,O
of,O
an,O
antidiabetic,O
agent,O
for,O
30,O
days,O
or,O
2,O
fasting,O
plasma,O
glucose,O
values,O
126,O
mg,O
dL,O
7,O
0,O
mmol,O
L,O
post,O
transplantation,O
Of,O
the,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
5,O
14,O
304,O
developed,O
NODAT,AdverseReaction
by,O
the,O
end,O
of,O
one,O
year,O
compared,O
to,O
10,O
27,O
280,O
of,O
patients,O
on,O
the,O
cyclosporine,O
control,O
regimen,O
However,O
by,O
the,O
end,O
of,O
the,O
third,O
year,O
the,O
cumulative,O
incidence,O
of,O
NODAT,AdverseReaction
was,O
8,O
24,O
304,O
in,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
and,O
10,O
29,O
280,O
in,O
patients,O
treated,O
with,O
the,O
cyclosporine,O
regimen,O
Hypertension,O
Blood,O
pressure,O
and,O
use,O
of,O
antihypertensive,O
medications,O
were,O
reported,O
in,O
Studies,O
1,O
and,O
2,O
By,O
Year,O
3,O
one,O
or,O
more,O
antihypertensive,O
medications,O
were,O
used,O
in,O
85,O
of,O
NULOJIX,O
treated,O
patients,O
and,O
92,O
of,O
cyclosporine,O
treated,O
patients,O
At,O
one,O
year,O
after,O
transplantation,O
systolic,O
blood,O
pressures,O
were,O
8,O
mmHg,O
lower,O
and,O
diastolic,O
blood,O
pressures,O
were,O
3,O
mmHg,O
lower,O
in,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
compared,O
to,O
the,O
cyclosporine,O
control,O
regimen,O
At,O
three,O
years,O
after,O
transplantation,O
systolic,O
blood,O
pressures,O
were,O
6,O
mmHg,O
lower,O
and,O
diastolic,O
blood,O
pressures,O
were,O
3,O
mmHg,O
lower,O
in,O
NULOJIX,O
treated,O
patients,O
compared,O
to,O
cyclosporine,O
treated,O
patients,O
Hypertension,AdverseReaction
was,O
reported,O
as,O
an,O
adverse,O
reaction,O
in,O
32,O
of,O
NULOJIX,O
treated,O
patients,O
and,O
37,O
of,O
cyclosporine,O
treated,O
patients,O
see,O
Table,O
4,O
Dyslipidemia,O
Mean,O
values,O
of,O
total,O
cholesterol,O
HDL,O
LDL,O
and,O
triglycerides,O
were,O
reported,O
in,O
Studies,O
1,O
and,O
2,O
At,O
one,O
year,O
after,O
transplantation,O
these,O
values,O
were,O
183,O
mg,O
dL,O
50,O
mg,O
dL,O
102,O
mg,O
dL,O
and,O
151,O
mg,O
dL,O
respectively,O
in,O
401,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
and,O
196,O
mg,O
dL,O
48,O
mg,O
dL,O
108,O
mg,O
dL,O
and,O
195,O
mg,O
dL,O
respectively,O
in,O
405,O
patients,O
treated,O
with,O
the,O
cyclosporine,O
control,O
regimen,O
At,O
three,O
years,O
after,O
transplantation,O
the,O
total,O
cholesterol,O
HDL,O
LDL,O
and,O
triglycerides,O
were,O
176,O
mg,O
dL,O
49,O
mg,O
dL,O
100,O
mg,O
dL,O
and,O
141,O
mg,O
dL,O
respectively,O
in,O
NULOJIX,O
treated,O
patients,O
compared,O
to,O
193,O
mg,O
dL,O
48,O
mg,O
dL,O
106,O
mg,O
dL,O
and,O
180,O
mg,O
dL,O
in,O
cyclosporine,O
treated,O
patients,O
The,O
clinical,O
significance,O
of,O
the,O
lower,O
mean,O
triglyceride,O
values,O
in,O
NULOJIX,O
treated,O
patients,O
at,O
one,O
and,O
three,O
years,O
is,O
unknown,O
Other,O
Adverse,O
Reactions,O
Adverse,O
reactions,O
that,O
occurred,O
at,O
a,O
frequency,O
of,O
10,O
in,O
patients,O
treated,O
with,O
the,O
NULOJIX,O
recommended,O
regimen,O
or,O
cyclosporine,O
control,O
regimen,O
in,O
Studies,O
1,O
and,O
2,O
through,O
three,O
years,O
are,O
summarized,O
by,O
preferred,O
term,O
in,O
decreasing,O
order,O
of,O
frequency,O
within,O
Table,O
4,O
Table,O
4,O
Adverse,O
Reactions,O
Reported,O
by,O
10,O
of,O
Patients,O
Treated,O
with,O
Either,O
the,O
NULOJIX,O
Recommended,O
Regimen,O
or,O
Control,O
in,O
Studies,O
1,O
and,O
2,O
Through,O
Three,O
Years,O
Adverse,O
Reaction,O
NULOJIX,O
Recommended,O
Regimen,O
N,O
401,O
Cyclosporine,O
N,O
405,O
All,O
randomized,O
and,O
transplanted,O
patients,O
in,O
Studies,O
1,O
and,O
2,O
Studies,O
1,O
and,O
2,O
were,O
not,O
designed,O
to,O
support,O
comparative,O
claims,O
for,O
NULOJIX,O
for,O
the,O
adverse,O
reactions,O
reported,O
in,O
this,O
table,O
Infections,O
and,O
Infestations,O
Urinary tract infection,AdverseReaction
37,O
36,O
Upper respiratory infection,AdverseReaction
15,O
16,O
Nasopharyngitis,AdverseReaction
13,O
16,O
Cytomegalovirus infection,AdverseReaction
12,O
12,O
Influenza,AdverseReaction
11,O
8,O
Bronchitis,AdverseReaction
10,O
7,O
Gastrointestinal,O
Disorders,O
Diarrhea,AdverseReaction
39,O
36,O
Constipation,AdverseReaction
33,O
35,O
Nausea,AdverseReaction
24,O
27,O
Vomiting,AdverseReaction
22,O
20,O
Abdominal pain,AdverseReaction
19,O
16,O
Abdominal pain upper,AdverseReaction
9,O
10,O
Metabolism,O
and,O
Nutrition,O
Disorders,O
Hyperkalemia,AdverseReaction
20,O
20,O
Hypokalemia,AdverseReaction
21,O
14,O
Hypophosphatemia,AdverseReaction
19,O
13,O
Dyslipidemia,AdverseReaction
19,O
24,O
Hyperglycemia,AdverseReaction
16,O
17,O
Hypocalcemia,AdverseReaction
13,O
11,O
Hypercholesterolemia,AdverseReaction
11,O
11,O
Hypomagnesemia,AdverseReaction
7,O
10,O
Hyperuricemia,AdverseReaction
5,O
12,O
Procedural,O
Complications,O
Graft dysfunction,AdverseReaction
25,O
34,O
General,O
Disorders,O
Peripheral edema,AdverseReaction
34,O
42,O
Pyrexia,AdverseReaction
28,O
26,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
Anemia,AdverseReaction
45,O
44,O
Leukopenia,AdverseReaction
20,O
23,O
Renal,O
and,O
Urinary,O
Disorders,O
Hematuria,AdverseReaction
16,O
18,O
Proteinuria,AdverseReaction
16,O
12,O
Dysuria,AdverseReaction
11,O
11,O
Renal tubular necrosis,AdverseReaction
9,O
13,O
Vascular,O
Disorders,O
Hypertension,AdverseReaction
32,O
37,O
Hypotension,AdverseReaction
18,O
12,O
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Cough,AdverseReaction
24,O
18,O
Dyspnea,AdverseReaction
12,O
15,O
Investigations,O
Blood creatinine increased,AdverseReaction
15,O
20,O
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Arthralgia,AdverseReaction
17,O
13,O
Back pain,AdverseReaction
13,O
13,O
Nervous,O
System,O
Disorders,O
Headache,AdverseReaction
21,O
18,O
Dizziness,AdverseReaction
9,O
10,O
Tremor,AdverseReaction
8,O
17,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Acne,AdverseReaction
8,O
11,O
Psychiatric,O
Disorders,O
Insomnia,AdverseReaction
15,O
18,O
Anxiety,AdverseReaction
10,O
11,O
Selected,O
adverse,O
reactions,O
occurring,O
in,O
10,O
from,O
NULOJIX,O
treated,O
patients,O
in,O
either,O
regimen,O
through,O
three,O
years,O
in,O
Studies,O
1,O
and,O
2,O
are,O
listed,O
below,O
Immune,O
System,O
Disorders,O
Guillain Barre syndrome,AdverseReaction
Infections,O
and,O
Infestations,O
see,O
Table,O
3,O
Gastrointestinal,O
Disorders,O
stomatitis,AdverseReaction
including,O
aphthous stomatitis,AdverseReaction
Injury,O
Poisoning,O
and,O
Procedural,O
Complications,O
chronic allograft nephropathy,AdverseReaction
complications of transplanted kidney,AdverseReaction
including,O
wound dehiscence,AdverseReaction
arteriovenous fistula thrombosis,AdverseReaction
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
neutropenia,AdverseReaction
Renal,O
and,O
Urinary,O
Disorders,O
renal impairment,AdverseReaction
including,O
acute renal failure,AdverseReaction
renal artery stenosis,AdverseReaction
urinary incontinence,AdverseReaction
hydronephrosis,AdverseReaction
Vascular,O
Disorders,O
hematoma,AdverseReaction
lymphocele,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
musculoskeletal pain,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
alopecia,AdverseReaction
hyperhidrosis,AdverseReaction
Cardiac,O
Disorders,O
atrial fibrillation,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Somnolence,AdverseReaction
or,O
Sedation,AdverseReaction
Monitor,O
for,O
central,O
nervous,O
system,O
CNS,O
depression,O
Risk,O
may,O
be,O
increased,O
with,O
concomitant,O
use,O
of,O
other,O
CNS,O
depressants,O
5,O
1,O
5,O
2,O
Withdrawal,O
Symptoms,O
may,O
occur,O
with,O
rapid,O
dose,O
reduction,O
or,O
discontinuation,O
Discontinue,O
ONFI,O
gradually,O
5,O
3,O
Serious,Severity
Dermatological Reactions,AdverseReaction
including,O
Stevens Johnson syndrome,AdverseReaction
and,O
toxic epidermal necrolysis,AdverseReaction
Discontinue,O
ONFI,O
at,O
first,O
sign,O
of,O
rash,O
unless,O
the,O
rash,O
is,O
clearly,O
not,O
drug,O
related,O
5,O
4,O
Physical,AdverseReaction
and,O
Psychological Dependence,AdverseReaction
Monitor,O
patients,O
with,O
a,O
history,O
of,O
substance,O
abuse,O
for,O
signs,O
of,O
habituation,O
and,O
dependence,O
5,O
5,O
9,O
Suicidal Behavior,AdverseReaction
and,O
Ideation,AdverseReaction
Monitor,O
for,O
suicidal,O
thoughts,O
or,O
behaviors,O
5,O
6,O
5,O
1,O
Somnolence,O
or,O
Sedation,O
ONFI,O
causes,O
somnolence,AdverseReaction
and,O
sedation,AdverseReaction
In,O
clinical,O
trials,O
somnolence,AdverseReaction
or,O
sedation,AdverseReaction
was,O
reported,O
at,O
all,O
effective,O
doses,O
and,O
was,O
dose,O
related,O
In,O
general,O
somnolence,AdverseReaction
and,O
sedation,AdverseReaction
begin,O
within,O
the,O
first,O
month,O
of,O
treatment,O
and,O
may,O
diminish,O
with,O
continued,O
treatment,O
Prescribers,O
should,O
monitor,O
patients,O
for,O
somnolence,O
and,O
sedation,O
particularly,O
with,O
concomitant,O
use,O
of,O
other,O
central,O
nervous,O
system,O
depressants,O
Prescribers,O
should,O
caution,O
patients,O
against,O
engaging,O
in,O
hazardous,O
activities,O
requiring,O
mental,O
alertness,O
such,O
as,O
operating,O
dangerous,O
machinery,O
or,O
motor,O
vehicles,O
until,O
the,O
effect,O
of,O
ONFI,O
is,O
known,O
5,O
2,O
Potentiation,O
of,O
Sedation,O
from,O
Concomitant,O
Use,O
with,O
Central,O
Nervous,O
System,O
Depressants,O
Since,O
ONFI,O
has,O
a,O
central,O
nervous,O
system,O
CNS,O
depressant,O
effect,O
patients,O
or,O
their,O
caregivers,O
should,O
be,O
cautioned,O
against,O
simultaneous,O
use,O
with,O
other,O
CNS,O
depressant,O
drugs,O
or,O
alcohol,O
and,O
cautioned,O
that,O
the,O
effects,O
of,O
other,O
CNS,O
depressant,O
drugs,O
or,O
alcohol,O
may,O
be,O
potentiated,O
5,O
3,O
Withdrawal,O
Symptoms,O
Abrupt,O
discontinuation,O
of,O
ONFI,O
should,O
be,O
avoided,O
ONFI,O
should,O
be,O
tapered,O
by,O
decreasing,O
the,O
dose,O
every,O
week,O
by,O
5,O
10,O
mg,O
day,O
until,O
discontinuation,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Withdrawal,O
symptoms,O
occurred,O
following,O
abrupt,O
discontinuation,O
of,O
ONFI,O
the,O
risk,O
of,O
withdrawal,O
symptoms,O
is,O
greater,O
with,O
higher,O
doses,O
As,O
with,O
all,O
antiepileptic,O
drugs,O
ONFI,O
should,O
be,O
withdrawn,O
gradually,O
to,O
minimize,O
the,O
risk,O
of,O
precipitating,O
seizures,O
seizure,O
exacerbation,O
or,O
status,O
epilepticus,O
Withdrawal,O
symptoms,O
e,O
g,O
convulsions,O
psychosis,O
hallucinations,O
behavioral,O
disorder,O
tremor,O
and,O
anxiety,O
have,O
been,O
reported,O
following,O
abrupt,O
discontinuance,O
of,O
benzodiazepines,O
The,O
more,O
severe,O
withdrawal,O
symptoms,O
have,O
usually,O
been,O
limited,O
to,O
patients,O
who,O
received,O
excessive,O
doses,O
over,O
an,O
extended,O
period,O
of,O
time,O
followed,O
by,O
an,O
abrupt,O
discontinuation,O
Generally,O
milder,O
withdrawal,O
symptoms,O
e,O
g,O
dysphoria,O
anxiety,O
and,O
insomnia,O
have,O
been,O
reported,O
following,O
abrupt,O
discontinuance,O
of,O
benzodiazepines,O
taken,O
continuously,O
at,O
therapeutic,O
doses,O
for,O
several,O
months,O
5,O
4,O
Serious,O
Dermatological,O
Reactions,O
Serious,Severity
skin reactions,AdverseReaction
including,O
Stevens Johnson syndrome,AdverseReaction
SJS,AdverseReaction
and,O
toxic epidermal necrolysis,AdverseReaction
TEN,AdverseReaction
have,O
been,O
reported,O
with,O
ONFI,O
in,O
both,O
children,O
and,O
adults,O
during,O
the,O
post,O
marketing,O
period,O
Patients,O
should,O
be,O
closely,O
monitored,O
for,O
signs,O
or,O
symptoms,O
of,O
SJS,O
TEN,O
especially,O
during,O
the,O
first,O
8,O
weeks,O
of,O
treatment,O
initiation,O
or,O
when,O
re,O
introducing,O
therapy,O
ONFI,O
should,O
be,O
discontinued,O
at,O
the,O
first,O
sign,O
of,O
rash,O
unless,O
the,O
rash,O
is,O
clearly,O
not,O
drug,O
related,O
If,O
signs,O
or,O
symptoms,O
suggest,O
SJS,O
TEN,O
use,O
of,O
this,O
drug,O
should,O
not,O
be,O
resumed,O
and,O
alternative,O
therapy,O
should,O
be,O
considered,O
see,O
Contraindications,O
4,O
5,O
5,O
Physical,O
and,O
Psychological,O
Dependence,O
Patients,O
with,O
a,O
history,O
of,O
substance,O
abuse,O
should,O
be,O
under,O
careful,O
surveillance,O
when,O
receiving,O
ONFI,O
or,O
other,O
psychotropic,O
agents,O
because,O
of,O
the,O
predisposition,O
of,O
such,O
patients,O
to,O
habituation,O
and,O
dependence,O
see,O
Drug,O
Abuse,O
and,O
Dependence,O
9,O
5,O
6,O
Suicidal,O
Behavior,O
and,O
Ideation,O
Antiepileptic,O
drugs,O
AEDs,O
including,O
ONFI,O
increase,O
the,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
in,O
patients,O
taking,O
these,O
drugs,O
for,O
any,O
indication,O
Patients,O
treated,O
with,O
any,O
AED,O
for,O
any,O
indication,O
should,O
be,O
monitored,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
depression,O
suicidal,O
thoughts,O
or,O
behavior,O
and,O
or,O
any,O
unusual,O
changes,O
in,O
mood,O
or,O
behavior,O
Pooled,O
analyses,O
of,O
199,O
placebo,O
controlled,O
clinical,O
trials,O
mono,O
and,O
adjunctive,O
therapy,O
of,O
11,O
different,O
AEDs,DrugClass
showed,O
that,O
patients,O
randomized,O
to,O
one,O
of,O
the,O
AEDs,O
had,O
approximately,O
twice,O
the,O
risk,O
adjusted,O
relative,O
risk,O
1,O
8,O
95,O
confidence,O
interval,O
CI,O
1,O
2,O
2,O
7,O
of,O
suicidal thinking,AdverseReaction
or,O
behavior,AdverseReaction
compared,O
to,O
patients,O
randomized,O
to,O
placebo,O
In,O
these,O
trials,O
which,O
had,O
a,O
median,O
treatment,O
duration,O
of,O
12,O
weeks,O
the,O
estimated,O
incidence,O
rate,O
of,O
suicidal behavior,AdverseReaction
or,O
ideation,AdverseReaction
among,O
27,O
863,O
AED,DrugClass
treated,O
patients,O
was,O
0,O
43,O
compared,O
to,O
0,O
24,O
among,O
16,O
029,O
placebo,O
treated,O
patients,O
representing,O
an,O
increase,O
of,O
approximately,O
one,O
case,O
of,O
suicidal thinking,AdverseReaction
or,O
behavior,AdverseReaction
for,O
every,O
530,O
patients,O
treated,O
There,O
were,O
four,O
suicides,AdverseReaction
in,O
drug,O
treated,O
patients,O
in,O
the,O
trials,O
and,O
none,O
in,O
placebo,O
treated,O
patients,O
but,O
the,O
number,O
is,O
too,O
small,O
to,O
allow,O
any,O
conclusion,O
about,O
drug,O
effect,O
on,O
suicide,AdverseReaction
The,O
increased,O
risk,O
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
with,O
AEDs,DrugClass
was,O
observed,O
as,O
early,O
as,O
one,O
week,O
after,O
starting,O
drug,O
treatment,O
with,O
AEDs,O
and,O
persisted,O
for,O
the,O
duration,O
of,O
treatment,O
assessed,O
Because,O
most,O
trials,O
included,O
in,O
the,O
analysis,O
did,O
not,O
extend,O
beyond,O
24,O
weeks,O
the,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
beyond,O
24,O
weeks,O
could,O
not,O
be,O
assessed,O
The,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
was,O
generally,O
consistent,O
among,O
drugs,O
in,O
the,O
data,O
analyzed,O
The,O
finding,O
of,O
increased,O
risk,O
with,O
AEDs,O
of,O
varying,O
mechanisms,O
of,O
action,O
and,O
across,O
a,O
range,O
of,O
indications,O
suggests,O
that,O
the,O
risk,O
applies,O
to,O
all,O
AEDs,O
used,O
for,O
any,O
indication,O
The,O
risk,O
did,O
not,O
vary,O
substantially,O
by,O
age,O
5,O
100,O
years,O
in,O
the,O
clinical,O
trials,O
analyzed,O
Table,O
2,O
shows,O
absolute,O
and,O
relative,O
risk,O
by,O
indication,O
for,O
all,O
evaluated,O
AEDs,O
Table,O
2,O
Risk,O
by,O
Indication,O
for,O
Antiepileptic,O
Drugs,O
in,O
the,O
Pooled,O
Analysis,O
Indication,O
Placebo,O
Patients,O
with,O
Events,O
per,O
1000,O
Patients,O
Drug,O
Patients,O
with,O
Events,O
per,O
1000,O
Patients,O
Relative,O
Risk,O
Incidence,O
of,O
Drug,O
Events,O
in,O
Drug,O
Patients,O
Incidencein,O
Placebo,O
Patients,O
Risk,O
Difference,O
Additional,O
Drug,O
Patients,O
with,O
Events,O
per,O
1000,O
Patients,O
Epilepsy,O
1,O
0,O
3,O
4,O
3,O
5,O
2,O
4,O
Psychiatric,O
5,O
7,O
8,O
5,O
1,O
5,O
2,O
9,O
Other,O
1,O
0,O
1,O
8,O
1,O
9,O
0,O
9,O
Total,O
2,O
4,O
4,O
3,O
1,O
8,O
1,O
9,O
The,O
relative,O
risk,Factor
for,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
was,O
higher,O
in,O
clinical,O
trials,O
for,O
epilepsy,O
than,O
in,O
clinical,O
trials,O
for,O
psychiatric,O
or,O
other,O
conditions,O
but,O
the,O
absolute,O
risk,O
differences,O
were,O
similar,O
for,O
the,O
epilepsy,O
and,O
psychiatric,O
indications,O
Anyone,O
considering,O
prescribing,O
ONFI,O
or,O
any,O
other,O
AED,O
must,O
balance,O
the,O
risk,O
of,O
suicidal,O
thoughts,O
or,O
behavior,O
with,O
the,O
risk,O
of,O
untreated,O
illness,O
Epilepsy,O
and,O
many,O
other,O
illnesses,O
for,O
which,O
AEDs,O
are,O
prescribed,O
are,O
themselves,O
associated,O
with,O
morbidity,O
and,O
mortality,O
and,O
an,O
increased,O
risk,O
of,O
suicidal,O
thoughts,O
and,O
behavior,O
Should,O
suicidal,O
thoughts,O
and,O
behavior,O
emerge,O
during,O
treatment,O
the,O
prescriber,O
needs,O
to,O
consider,O
whether,O
the,O
emergence,O
of,O
these,O
symptoms,O
in,O
any,O
given,O
patient,O
may,O
be,O
related,O
to,O
the,O
illness,O
being,O
treated,O
Patients,O
their,O
caregivers,O
and,O
families,O
should,O
be,O
informed,O
that,O
AEDs,O
increase,O
the,O
risk,O
of,O
suicidal,O
thoughts,O
and,O
behavior,O
and,O
should,O
be,O
advised,O
of,O
the,O
need,O
to,O
be,O
alert,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
depression,O
any,O
unusual,O
changes,O
in,O
mood,O
or,O
behavior,O
or,O
the,O
emergence,O
of,O
suicidal,O
thoughts,O
behavior,O
or,O
thoughts,O
about,O
self,O
harm,O
Behaviors,O
of,O
concern,O
should,O
be,O
reported,O
immediately,O
to,O
healthcare,O
providers,O
""
6,O
ADVERSE,O
REACTIONS,O
Clinically,O
significant,O
adverse,O
reactions,O
that,O
appear,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
include,O
the,O
following,O
Somnolence,AdverseReaction
or,O
Sedation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Potentiation of Sedation,AdverseReaction
from,O
Concomitant,O
Use,O
with,O
Central,O
Nervous,O
System,O
Depressants,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Withdrawal,O
Symptoms,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Serious,Severity
Dermatological Reactions,AdverseReaction
see,O
Contraindications,O
4,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Physical,AdverseReaction
and,O
Psychological Dependence,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Suicidal Behavior,AdverseReaction
and,O
Ideation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
EXCERPT,O
Adverse,O
reactions,O
that,O
occurred,O
at,O
least,O
10,O
more,O
frequently,O
than,O
placebo,O
in,O
any,O
ONFI,O
dose,O
included,O
constipation,AdverseReaction
somnolence,AdverseReaction
or,O
sedation,AdverseReaction
pyrexia,AdverseReaction
lethargy,AdverseReaction
and,O
drooling,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Lundbeck,O
at,O
1,O
800,O
455,O
1141,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
During,O
its,O
development,O
for,O
the,O
adjunctive,O
treatment,O
of,O
seizures,O
associated,O
with,O
LGS,O
ONFI,O
was,O
administered,O
to,O
333,O
healthy,O
volunteers,O
and,O
300,O
patients,O
with,O
a,O
current,O
or,O
prior,O
diagnosis,O
of,O
LGS,O
including,O
197,O
patients,O
treated,O
for,O
12,O
months,O
or,O
more,O
The,O
conditions,O
and,O
duration,O
of,O
exposure,O
varied,O
greatly,O
and,O
included,O
single,O
and,O
multiple,O
dose,O
clinical,O
pharmacology,O
studies,O
in,O
healthy,O
volunteers,O
and,O
two,O
double,O
blind,O
studies,O
in,O
patients,O
with,O
LGS,O
Study,O
1,O
and,O
2,O
see,O
Clinical,O
Studies,O
14,O
Only,O
Study,O
1,O
included,O
a,O
placebo,O
group,O
allowing,O
comparison,O
of,O
adverse,O
reaction,O
rates,O
on,O
ONFI,O
at,O
several,O
doses,O
to,O
placebo,O
Adverse,O
Reactions,O
Leading,O
to,O
Discontinuation,O
in,O
an,O
LGS,O
Placebo,O
Controlled,O
Clinical,O
Trial,O
Study,O
1,O
The,O
adverse,O
reactions,O
associated,O
with,O
ONFI,O
treatment,O
discontinuation,O
in,O
1,O
of,O
patients,O
in,O
decreasing,O
order,O
of,O
frequency,O
included,O
lethargy,AdverseReaction
somnolence,AdverseReaction
ataxia,AdverseReaction
aggression,AdverseReaction
fatigue,AdverseReaction
and,O
insomnia,AdverseReaction
Most,O
Common,O
Adverse,O
Reactions,O
in,O
an,O
LGS,O
Placebo,O
Controlled,O
Clinical,O
Trial,O
Study,O
1,O
Table,O
3,O
lists,O
the,O
adverse,O
reactions,O
that,O
occurred,O
in,O
5,O
of,O
ONFI,O
treated,O
patients,O
at,O
any,O
dose,O
and,O
at,O
a,O
rate,O
greater,O
than,O
placebo,O
treated,O
patients,O
in,O
the,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
parallel,O
group,O
clinical,O
study,O
of,O
adjunctive,O
AED,O
therapy,O
for,O
15,O
weeks,O
Study,O
1,O
Table,O
3,O
Adverse,O
Reactions,O
Reported,O
for,O
5,O
of,O
Patients,O
and,O
More,O
Frequently,O
than,O
Placebo,O
in,O
Any,O
Treatment,O
Group,O
a,O
Maximum,O
daily,O
dose,O
of,O
5,O
mg,O
for,O
30,O
kg,O
body,O
weight,O
10,O
mg,O
for,O
30,O
kg,O
body,O
weight,O
b,O
Maximum,O
daily,O
dose,O
of,O
10,O
mg,O
for,O
30,O
kg,O
body,O
weight,O
20,O
mg,O
for,O
30,O
kg,O
body,O
weight,O
c,O
Maximum,O
daily,O
dose,O
of,O
20,O
mg,O
for,O
30,O
kg,O
body,O
weight,O
40,O
mg,O
for,O
30,O
kg,O
body,O
weight,O
Placebo,O
N,O
59,O
ONFI,O
Dose,O
Level,O
All,O
ONFI,O
N,O
179,O
Low,O
a,O
N,O
58,O
Medium,O
b,O
N,O
62,O
High,O
c,O
N,O
59,O
Gastrointestinal,O
Disorders,O
Vomiting,AdverseReaction
5,O
9,O
5,O
7,O
7,O
Constipation,AdverseReaction
0,O
2,O
2,O
10,O
5,O
Dysphagia,AdverseReaction
0,O
0,O
0,O
5,O
2,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Pyrexia,AdverseReaction
3,O
17,O
10,O
12,O
13,O
Irritability,AdverseReaction
5,O
3,O
11,O
5,O
7,O
Fatigue,AdverseReaction
2,O
5,O
5,O
3,O
5,O
Infections,O
and,O
Infestations,O
Upper respiratory tract infection,AdverseReaction
10,O
10,O
13,O
14,O
12,O
Pneumonia,AdverseReaction
2,O
3,O
3,O
7,O
4,O
Urinary tract infection,AdverseReaction
0,O
2,O
5,O
5,O
4,O
Bronchitis,AdverseReaction
0,O
2,O
0,O
5,O
2,O
Metabolism,O
and,O
Nutrition,O
Disorders,O
Decreased appetite,AdverseReaction
3,O
3,O
0,O
7,O
3,O
Increased appetite,AdverseReaction
0,O
2,O
3,O
5,O
3,O
Nervous,O
System,O
Disorders,O
Somnolence,AdverseReaction
or,O
Sedation,AdverseReaction
15,O
17,O
27,O
32,O
26,O
Somnolence,AdverseReaction
12,O
16,O
24,O
25,O
22,O
Sedation,AdverseReaction
3,O
2,O
3,O
9,O
5,O
Lethargy,AdverseReaction
5,O
10,O
5,O
15,O
10,O
Drooling,AdverseReaction
3,O
0,O
13,O
14,O
9,O
Ataxia,AdverseReaction
3,O
3,O
2,O
10,O
5,O
Psychomotor hyperactivity,AdverseReaction
3,O
3,O
3,O
5,O
4,O
Dysarthria,AdverseReaction
0,O
2,O
2,O
5,O
3,O
Psychiatric,O
Disorders,O
Aggression,AdverseReaction
5,O
3,O
8,O
14,O
8,O
Insomnia,AdverseReaction
2,O
2,O
5,O
7,O
5,O
Respiratory,O
Disorders,O
Cough,AdverseReaction
0,O
3,O
5,O
7,O
5,O
6,O
2,O
Post,O
Marketing,O
Experience,O
These,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
therefore,O
it,O
is,O
not,O
possible,O
to,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Adverse,O
reactions,O
are,O
categorized,O
by,O
system,O
organ,O
class,O
Blood,O
Disorders,O
Anemia,AdverseReaction
eosinophilia,AdverseReaction
leukopenia,AdverseReaction
thrombocytopenia,AdverseReaction
Eye,O
Disorders,O
Diplopia,AdverseReaction
vision blurred,AdverseReaction
Gastrointestinal,O
Disorders,O
Abdominal distention,AdverseReaction
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Hypothermia,AdverseReaction
Investigations,O
Hepatic enzyme increased,AdverseReaction
Musculoskeletal,O
Muscle spasms,AdverseReaction
Psychiatric,O
Disorders,O
Agitation,AdverseReaction
anxiety,AdverseReaction
apathy,AdverseReaction
confusional state,AdverseReaction
depression,AdverseReaction
delirium,AdverseReaction
delusion,AdverseReaction
hallucination,AdverseReaction
Renal,O
and,O
Urinary,O
Disorders,O
Urinary retention,AdverseReaction
Respiratory,O
Disorders,O
Aspiration,AdverseReaction
respiratory depression,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Rash,AdverseReaction
urticaria,AdverseReaction
angioedema,AdverseReaction
and,O
facial,AdverseReaction
and,O
lip edema,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Depression,AdverseReaction
Advise,O
patients,O
their,O
caregivers,O
and,O
families,O
to,O
be,O
alert,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
depression,O
suicidal,O
thoughts,O
or,O
other,O
mood,O
changes,O
and,O
if,O
such,O
changes,O
occur,O
to,O
contact,O
their,O
healthcare,O
provider,O
Carefully,O
weigh,O
risks,O
and,O
benefits,O
of,O
treatment,O
with,O
OTEZLA,O
in,O
patients,O
with,O
a,O
history,O
of,O
depression,O
and,O
or,O
suicidal,O
thoughts,O
or,O
behavior,O
5,O
1,O
Weight Decrease,AdverseReaction
Monitor,O
weight,O
regularly,O
If,O
unexplained,O
or,O
clinically,O
significant,O
weight,O
loss,O
occurs,O
evaluate,O
weight,O
loss,O
and,O
consider,O
discontinuation,O
of,O
OTEZLA,O
5,O
2,O
Drug,O
Interactions,O
Use,O
with,O
strong,O
cytochrome,O
P450,O
enzyme,O
inducers,O
e,O
g,O
rifampin,O
phenobarbital,O
carbamazepine,O
phenytoin,O
is,O
not,O
recommended,O
because,O
loss,O
of,O
efficacy,O
may,O
occur,O
5,O
3,O
7,O
1,O
5,O
1,O
Depression,O
Treatment,O
with,O
OTEZLA,O
is,O
associated,O
with,O
an,O
increase,O
in,O
adverse,O
reactions,O
of,O
depression,AdverseReaction
Before,O
using,O
OTEZLA,O
in,O
patients,O
with,O
a,O
history,O
of,O
depression,O
and,O
or,O
suicidal,O
thoughts,O
or,O
behavior,O
prescribers,O
should,O
carefully,O
weigh,O
the,O
risks,O
and,O
benefits,O
of,O
treatment,O
with,O
OTEZLA,O
in,O
such,O
patients,O
Patients,O
their,O
caregivers,O
and,O
families,O
should,O
be,O
advised,O
of,O
the,O
need,O
to,O
be,O
alert,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
depression,O
suicidal,O
thoughts,O
or,O
other,O
mood,O
changes,O
and,O
if,O
such,O
changes,O
occur,O
to,O
contact,O
their,O
healthcare,O
provider,O
Prescribers,O
should,O
carefully,O
evaluate,O
the,O
risks,O
and,O
benefits,O
of,O
continuing,O
treatment,O
with,O
OTEZLA,O
if,O
such,O
events,O
occur,O
Psoriatic,O
arthritis,O
During,O
the,O
0,O
to,O
16,O
week,O
placebo,O
controlled,O
period,O
of,O
the,O
3,O
controlled,O
clinical,O
trials,O
1,O
0,O
10,O
998,O
of,O
subjects,O
treated,O
with,O
OTEZLA,O
reported,O
depression,AdverseReaction
or,O
depressed mood,AdverseReaction
compared,O
to,O
0,O
8,O
4,O
495,O
treated,O
with,O
placebo,O
During,O
the,O
clinical,O
trials,O
0,O
3,O
4,O
1441,O
of,O
subjects,O
treated,O
with,O
OTEZLA,O
discontinued,O
treatment,O
due,O
to,O
depression,AdverseReaction
or,O
depressed mood,AdverseReaction
compared,O
with,O
none,O
in,O
placebo,O
treated,O
subjects,O
0,O
495,O
Depression,AdverseReaction
was,O
reported,O
as,O
serious,Severity
in,O
0,O
2,O
3,O
1441,O
of,O
subjects,O
exposed,O
to,O
OTEZLA,O
compared,O
to,O
none,O
in,O
placebo,O
treated,O
subjects,O
0,O
495,O
Instances,O
of,O
suicidal ideation,AdverseReaction
and,O
behavior,AdverseReaction
have,O
been,O
observed,O
in,O
0,O
2,O
3,O
1441,O
of,O
subjects,O
while,O
receiving,O
OTEZLA,O
compared,O
to,O
none,O
in,O
placebo,O
treated,O
subjects,O
0,O
495,O
In,O
the,O
clinical,O
trials,O
2,O
subjects,O
who,O
received,O
placebo,O
committed,O
suicide,AdverseReaction
compared,O
to,O
none,Negation
in,O
OTEZLA,O
treated,O
subjects,O
Psoriasis,O
During,O
the,O
0,O
to,O
16,O
week,O
placebo,O
controlled,O
period,O
of,O
the,O
3,O
controlled,O
clinical,O
trials,O
1,O
3,O
12,O
920,O
of,O
subjects,O
treated,O
with,O
OTEZLA,O
reported,O
depression,AdverseReaction
compared,O
to,O
0,O
4,O
2,O
506,O
treated,O
with,O
placebo,O
During,O
the,O
clinical,O
trials,O
0,O
1,O
1,O
1308,O
of,O
subjects,O
treated,O
with,O
OTEZLA,O
discontinued,O
treatment,O
due,O
to,O
depression,AdverseReaction
compared,O
with,O
none,O
in,O
placebo,O
treated,O
subjects,O
0,O
506,O
Depression,AdverseReaction
was,O
reported,O
as,O
serious,Severity
in,O
0,O
1,O
1,O
1308,O
of,O
subjects,O
exposed,O
to,O
OTEZLA,O
compared,O
to,O
none,O
in,O
placebo,O
treated,O
subjects,O
0,O
506,O
Instances,O
of,O
suicidal behavior,AdverseReaction
have,O
been,O
observed,O
in,O
0,O
1,O
1,O
1308,O
of,O
subjects,O
while,O
receiving,O
OTEZLA,O
compared,O
to,O
0,O
2,O
1,O
506,O
in,O
placebo,O
treated,O
subjects,O
In,O
the,O
clinical,O
trials,O
one,O
subject,O
treated,O
with,O
OTEZLA,O
attempted suicide,AdverseReaction
while,O
one,O
who,O
received,O
placebo,Factor
committed,O
suicide,AdverseReaction
5,O
2,O
Weight,O
Decrease,O
During,O
the,O
controlled,O
period,O
of,O
the,O
studies,O
in,O
psoriatic,O
arthritis,O
PsA,O
weight decrease,AdverseReaction
between,O
5,O
10,O
of,O
body,O
weight,O
was,O
reported,O
in,O
10,O
49,O
497,O
of,O
subjects,O
treated,O
with,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
compared,O
to,O
3,O
3,O
16,O
495,O
treated,O
with,O
placebo,O
see,O
Adverse,O
Reactions,O
6,O
1,O
During,O
the,O
controlled,O
period,O
of,O
the,O
trials,O
in,O
psoriasis,O
weight decrease,AdverseReaction
between 5 10 of body weight,Severity
occurred,O
in,O
12,O
96,O
784,O
of,O
subjects,O
treated,O
with,O
OTEZLA,O
compared,O
to,O
5,O
19,O
382,O
treated,O
with,O
placebo,O
Weight decrease,AdverseReaction
of,O
10 of body weight,Severity
occurred,O
in,O
2,O
16,O
784,O
of,O
subjects,O
treated,O
with,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
compared,O
to,O
1,O
3,O
382,O
subjects,O
treated,O
with,O
placebo,O
Patients,O
treated,O
with,O
OTEZLA,O
should,O
have,O
their,O
weight,O
monitored,O
regularly,O
If,O
unexplained,O
or,O
clinically,O
significant,O
weight,O
loss,O
occurs,O
weight,O
loss,O
should,O
be,O
evaluated,O
and,O
discontinuation,O
of,O
OTEZLA,O
should,O
be,O
considered,O
5,O
3,O
Drug,O
Interactions,O
Co,O
administration,O
of,O
strong,O
cytochrome,O
P450,O
enzyme,O
inducer,O
rifampin,O
resulted,O
in,O
a,O
reduction,O
of,O
systemic,O
exposure,O
of,O
apremilast,O
which,O
may,O
result,O
in,O
a,O
loss,O
of,O
efficacy,O
of,O
OTEZLA,O
Therefore,O
the,O
use,O
of,O
cytochrome,O
P450,O
enzyme,O
inducers,O
e,O
g,O
rifampin,O
phenobarbital,O
carbamazepine,O
phenytoin,O
with,O
OTEZLA,O
is,O
not,O
recommended,O
see,O
Drug,O
Interactions,O
7,O
1,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Psoriatic,O
Arthritis,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
are,O
diarrhea,AdverseReaction
nausea,AdverseReaction
and,O
headache,AdverseReaction
6,O
1,O
Psoriasis,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
are,O
diarrhea,AdverseReaction
nausea,AdverseReaction
upper respiratory tract infection,AdverseReaction
and,O
headache,AdverseReaction
including,O
tension headache,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Celgene,O
Corporation,O
at,O
1,O
888,O
423,O
5436,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trial,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Psoriatic,O
Arthritis,O
Clinical,O
Trials,O
OTEZLA,O
was,O
evaluated,O
in,O
3,O
multicenter,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
trials,O
Studies,O
PsA,O
1,O
PsA,O
2,O
and,O
PsA,O
3,O
of,O
similar,O
design,O
in,O
adult,O
patients,O
with,O
active,O
psoriatic,O
arthritis,O
see,O
Clinical,O
Studies,O
14,O
1,O
Across,O
the,O
3,O
studies,O
there,O
were,O
1493,O
patients,O
randomized,O
equally,O
to,O
placebo,O
OTEZLA,O
20,O
mg,O
twice,O
daily,O
or,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
Titration,O
was,O
used,O
over,O
the,O
first,O
5,O
days,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
Placebo,O
patients,O
whose,O
tender,O
and,O
swollen,O
joint,O
counts,O
had,O
not,O
improved,O
by,O
at,O
least,O
20,O
were,O
re,O
randomized,O
1,O
1,O
in,O
a,O
blinded,O
fashion,O
to,O
either,O
OTEZLA,O
20,O
mg,O
twice,O
daily,O
or,O
30,O
mg,O
twice,O
daily,O
at,O
week,O
16,O
while,O
OTEZLA,O
patients,O
remained,O
on,O
their,O
initial,O
treatment,O
Patients,O
ranged,O
in,O
age,O
from,O
18,O
to,O
83,O
years,O
with,O
an,O
overall,O
median,O
age,O
of,O
51,O
years,O
The,O
majority,O
of,O
the,O
most,O
common,O
adverse,O
reactions,O
presented,O
inTable,O
2occurred,O
within,O
the,O
first,O
2,O
weeks,O
of,O
treatment,O
and,O
tended,O
to,O
resolve,O
over,O
time,O
with,O
continued,O
dosing,O
Diarrhea,AdverseReaction
headache,AdverseReaction
and,O
nausea,AdverseReaction
were,O
the,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
for,O
patients,O
taking,O
OTEZLA,O
were,O
nausea,AdverseReaction
1,O
8,O
diarrhea,AdverseReaction
1,O
8,O
and,O
headache,AdverseReaction
1,O
2,O
The,O
proportion,O
of,O
patients,O
with,O
psoriatic,O
arthritis,O
who,O
discontinued,O
treatment,O
due,O
to,O
any,O
adverse,O
reaction,O
was,O
4,O
6,O
for,O
patients,O
taking,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
and,O
1,O
2,O
for,O
placebo,O
treated,O
patients,O
Table,O
2,O
Adverse,O
Reactions,O
Reported,O
in,O
2,O
of,O
Patients,O
on,O
OTEZLA,O
30,O
mg,O
Twice,O
Daily,O
and,O
1,O
Than,O
That,O
Observed,O
in,O
Patients,O
on,O
Placebo,O
for,O
up,O
to,O
Day,O
112,O
Week,O
16,O
a,O
Of,O
the,O
reported,O
gastrointestinal adverse reactions,AdverseReaction
1,O
subject,O
experienced,O
a,O
serious,Severity
adverse,O
reaction,O
of,O
nausea,AdverseReaction
and,O
vomiting,AdverseReaction
in,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
1,O
subject,O
treated,O
with,O
OTEZLA,O
20,O
mg,O
twice,O
daily,O
experienced,O
a,O
serious,Severity
adverse,O
reaction,O
of,O
diarrhea,AdverseReaction
1,O
patient,O
treated,O
with,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
experienced,O
a,O
serious,Severity
adverse,O
reaction,O
of,O
headache,AdverseReaction
b,O
Of,O
the,O
reported,O
adverse,O
drug,O
reactions,O
none,O
were,O
serious,O
c,O
n,O
indicates,O
number,O
of,O
patients,O
and,O
percent,O
Placebo,O
OTEZLA,O
30,O
mg,O
BID,O
Preferred,O
Term,O
Day,O
1,O
to,O
5,O
N,O
495,O
n,O
c,O
Day,O
6,O
to,O
Day,O
112,O
N,O
490,O
n,O
Day,O
1,O
to,O
5,O
N,O
497,O
n,O
Day,O
6,O
to,O
Day,O
112,O
N,O
493,O
n,O
Diarrhea,AdverseReaction
a,O
6,O
1,O
2,O
8,O
1,O
6,O
46,O
9,O
3,O
38,O
7,O
7,O
Nausea,AdverseReaction
a,O
7,O
1,O
4,O
15,O
3,O
1,O
37,O
7,O
4,O
44,O
8,O
9,O
Headache,AdverseReaction
a,O
9,O
1,O
8,O
11,O
2,O
2,O
24,O
4,O
8,O
29,O
5,O
9,O
Upper respiratory tractinfection,AdverseReaction
b,O
3,O
0,O
6,O
9,O
1,O
8,O
3,O
0,O
6,O
19,O
3,O
9,O
Vomiting,AdverseReaction
a,O
2,O
0,O
4,O
2,O
0,O
4,O
4,O
0,O
8,O
16,O
3,O
2,O
Nasopharyngitis,AdverseReaction
b,O
1,O
0,O
2,O
8,O
1,O
6,O
1,O
0,O
2,O
13,O
2,O
6,O
Abdominal pain upper,AdverseReaction
b,O
0,O
0,O
0,O
1,O
0,O
2,O
3,O
0,O
6,O
10,O
2,O
0,O
Other,O
adverse,O
reactions,O
reported,O
in,O
patients,O
on,O
OTEZLA,O
in,O
clinical,O
studies,O
including,O
extension,O
studies,O
Immune,O
system,O
disorders,O
Hypersensitivity,AdverseReaction
Investigations,O
Weight decrease,AdverseReaction
Gastrointestinal,O
Disorders,O
Frequent bowel movement,AdverseReaction
gastroesophageal reflux disease,AdverseReaction
dyspepsia,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorders,O
Decreased appetite,AdverseReaction
Nervous,O
System,O
Disorders,O
Migraine,AdverseReaction
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Cough,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Rash,AdverseReaction
1,O
patient,O
treated,O
with,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
experienced,O
a,O
serious,O
adverse,O
reaction,O
Psoriasis,O
Clinical,O
Trials,O
The,O
safety,O
of,O
OTEZLA,O
r,O
was,O
assessed,O
in,O
1426,O
subjects,O
in,O
3,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
trials,O
in,O
adult,O
subjects,O
with,O
moderate,O
to,O
severe,O
plaque,O
psoriasis,O
who,O
were,O
candidates,O
for,O
phototherapy,O
or,O
systemic,O
therapy,O
Subjects,O
were,O
randomized,O
to,O
receive,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
or,O
placebo,O
twice,O
daily,O
Titration,O
was,O
used,O
over,O
the,O
first,O
5,O
days,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
Subjects,O
ranged,O
in,O
age,O
from,O
18,O
to,O
83,O
years,O
with,O
an,O
overall,O
median,O
age,O
of,O
46,O
years,O
Diarrhea,AdverseReaction
nausea,AdverseReaction
and,O
upper respiratory tract infection,AdverseReaction
were,O
the,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
for,O
subjects,O
taking,O
OTEZLA,O
were,O
nausea,AdverseReaction
1,O
6,O
diarrhea,AdverseReaction
1,O
0,O
and,O
headache,AdverseReaction
0,O
8,O
The,O
proportion,O
of,O
subjects,O
with,O
psoriasis,O
who,O
discontinued,O
treatment,O
due,O
to,O
any,O
adverse,O
reaction,O
was,O
6,O
1,O
for,O
subjects,O
treated,O
with,O
OTEZLA,O
30,O
mg,O
twice,O
daily,O
and,O
4,O
1,O
for,O
placebo,O
treated,O
subjects,O
Table,O
3,O
Adverse,O
Reactions,O
Reported,O
in,O
1,O
of,O
Subjects,O
on,O
OTEZLA,O
and,O
With,O
Greater,O
Frequency,O
Than,O
in,O
Subjects,O
on,O
Placebo,O
up,O
to,O
Day,O
112,O
Week,O
16,O
Two,O
subjects,O
treated,O
with,O
OTEZLA,O
experienced,O
serious,Severity
adverse,O
reaction,O
of,O
abdominal pain,AdverseReaction
Preferred,O
Term,O
Placebo,O
N,O
506,O
n,O
OTEZLA,O
30,O
mg,O
BID,O
N,O
920,O
n,O
Diarrhea,AdverseReaction
32,O
6,O
160,O
17,O
Nausea,AdverseReaction
35,O
7,O
155,O
17,O
Upper respiratory tract infection,AdverseReaction
31,O
6,O
84,O
9,O
Tension headache,AdverseReaction
21,O
4,O
75,O
8,O
Headache,AdverseReaction
19,O
4,O
55,O
6,O
Abdominal pain,AdverseReaction
11,O
2,O
39,O
4,O
Vomiting,AdverseReaction
8,O
2,O
35,O
4,O
Fatigue,AdverseReaction
9,O
2,O
29,O
3,O
Dyspepsia,AdverseReaction
6,O
1,O
29,O
3,O
Decrease appetite,AdverseReaction
5,O
1,O
26,O
3,O
Insomnia,AdverseReaction
4,O
1,O
21,O
2,O
Back pain,AdverseReaction
4,O
1,O
20,O
2,O
Migraine,AdverseReaction
5,O
1,O
19,O
2,O
Frequent bowel movements,AdverseReaction
1,O
0,O
17,O
2,O
Depression,AdverseReaction
2,O
0,O
12,O
1,O
Bronchitis,AdverseReaction
2,O
0,O
12,O
1,O
Tooth abscess,AdverseReaction
0,O
0,O
10,O
1,O
Folliculitis,AdverseReaction
0,O
0,O
9,O
1,O
Sinus headache,AdverseReaction
0,O
0,O
9,O
1,O
Severe,O
worsening,O
of,O
psoriasis,O
rebound,O
occurred,O
in,O
0,O
3,O
4,O
1184,O
subjects,O
following,O
discontinuation,O
of,O
treatment,O
with,O
OTEZLA,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Avoid,O
treatment,O
in,O
the,O
periocular,O
area,O
Eye disorders,AdverseReaction
including,O
severe,Severity
eye pain,AdverseReaction
chemical conjunctivitis,AdverseReaction
corneal burn,AdverseReaction
eyelid edema,AdverseReaction
eyelid ptosis,AdverseReaction
periorbital edema,AdverseReaction
can,Factor
occur,O
after,O
exposure,O
Avoid,O
accidental,O
transfer,O
of,O
the,O
drug,O
into,O
the,O
eyes,O
and,O
to,O
the,O
periocular,O
area,O
If,O
accidental,O
exposure,O
occurs,O
flush,O
eyes,O
with,O
water,O
and,O
seek,O
medical,O
care,O
5,O
1,O
Local skin reactions skin skin skin skin,AdverseReaction
can,Factor
occur,O
including,O
severe,Severity
reactions,O
e,O
g,O
vesiculation,AdverseReaction
pustulation,AdverseReaction
erosion,AdverseReaction
ulceration,AdverseReaction
Administration,O
of,O
Picato,O
r,O
gel,O
is,O
not,O
recommended,O
until,O
skin,O
is,O
healed,O
from,O
any,O
previous,O
drug,O
or,O
surgical,O
treatment,O
5,O
3,O
5,O
1,O
Ophthalmic,O
Adverse,O
Reactions,O
Avoid,O
treatment,O
in,O
the,O
periocular,O
area,O
Eye disorders,AdverseReaction
including,O
severe,Severity
eye pain,AdverseReaction
chemical conjunctivitis,AdverseReaction
corneal burn,AdverseReaction
eyelid edema,AdverseReaction
eyelid ptosis,AdverseReaction
periorbital edema,AdverseReaction
can,Factor
occur,O
after,O
exposure,O
see,O
Adverse,O
Reactions,O
6,O
To,O
avoid,O
transfer,O
of,O
the,O
drug,O
into,O
the,O
eyes,O
and,O
to,O
the,O
periocular,O
area,O
during,O
and,O
after,O
application,O
patients,O
should,O
wash,O
hands,O
well,O
after,O
applying,O
Picato,O
r,O
gel,O
If,O
accidental,O
exposure,O
occurs,O
the,O
area,O
should,O
be,O
flushed,O
with,O
water,O
and,O
the,O
patient,O
should,O
seek,O
medical,O
care,O
as,O
soon,O
as,O
possible,O
5,O
2,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
and,O
allergic contact dermatitis,AdverseReaction
have,O
been,O
reported,O
post,O
marketing,O
see,O
Adverse,O
Reactions,O
6,O
2,O
If,O
anaphylactic,O
or,O
other,O
clinically,O
significant,O
hypersensitivity,O
reactions,O
occur,O
discontinue,O
Picato,O
r,O
immediately,O
and,O
institute,O
appropriate,O
medical,O
therapy,O
5,O
3,O
Local,O
Skin,O
Reactions,O
Severe,Severity
skin reactions in the treated area reactions in the treated area reactions in the treated area reactions in the treated area reactions in the treated area reactions in the treated area reactions in the treated area reactions in the treated area,AdverseReaction
including,O
erythema,AdverseReaction
crusting,AdverseReaction
swelling,AdverseReaction
vesiculation,AdverseReaction
postulation,AdverseReaction
and,O
erosion,AdverseReaction
ulceration,AdverseReaction
can,Factor
occur,O
after,O
topical,O
application,O
of,O
Picato,O
r,O
gel,O
see,O
Adverse,O
Reactions,O
6,O
Administration,O
of,O
Picato,O
r,O
gel,O
is,O
not,O
recommended,O
until,O
the,O
skin,O
is,O
healed,O
from,O
any,O
previous,O
drug,O
or,O
surgical,O
treatment,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
in,O
more,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Ophthalmic Adverse Reaction,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hypersensitivity Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
2,O
are,O
local skin reactions,AdverseReaction
application site pain,AdverseReaction
application site pruritus,AdverseReaction
application site irritation,AdverseReaction
application site infection,AdverseReaction
periorbital edema,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
headache,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
LEO,O
Pharma,O
Inc,O
at,O
1,O
877,O
494,O
4536,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
Picato,O
r,O
gel,O
in,O
499,O
subjects,O
with,O
actinic,O
keratosis,O
including,O
274,O
subjects,O
exposed,O
to,O
Picato,O
r,O
gel,O
field,O
treatment,O
skin,O
area,O
of,O
25,O
cm,O
2,O
in,O
the,O
face,O
or,O
scalp,O
regions,O
at,O
a,O
concentration,O
of,O
0,O
015,O
once,O
daily,O
for,O
3,O
consecutive,O
days,O
and,O
225,O
subjects,O
exposed,O
to,O
Picato,O
r,O
gel,O
field,O
treatment,O
skin,O
area,O
of,O
25,O
cm,O
2,O
in,O
the,O
trunk,O
or,O
extremities,O
regions,O
at,O
a,O
concentration,O
of,O
0,O
05,O
once,O
daily,O
for,O
2,O
consecutive,O
days,O
Local skin reactions skin skin skin skin skin skin skin skin skin,AdverseReaction
including,O
erythema,AdverseReaction
flaking,AdverseReaction
scaling,AdverseReaction
crusting,AdverseReaction
swelling,AdverseReaction
vesiculation,AdverseReaction
pustulation,AdverseReaction
and,O
erosion,AdverseReaction
ulceration,AdverseReaction
were,O
assessed,O
within,O
the,O
selected,O
treatment,O
area,O
and,O
graded,O
by,O
the,O
investigator,O
on,O
a,O
scale,O
of,O
0,O
to,O
4,O
A,O
grade,O
of,O
0,O
represented,O
no,O
reaction,O
present,O
in,O
the,O
treated,O
area,O
and,O
a,O
grade,O
of,O
4,O
indicated,O
a,O
marked,O
and,O
severe,O
skin,O
reaction,O
that,O
extended,O
beyond,O
the,O
treated,O
area,O
Table,O
1,O
Investigator,O
Assessment,O
of,O
Maximal,O
Local Skin Reactions,AdverseReaction
in,O
the,O
Treatment,O
Area,O
during,O
the,O
57,O
Days,O
Post,O
Treatment,O
Period,O
face,O
scalp,O
trials,O
Face,O
and,O
Scalp,O
n,O
545,O
Picato,O
r,O
gel,O
0,O
015,O
once,O
daily,O
for,O
3,O
days,O
Skin,AdverseReaction
reactions,O
Any,O
Gradea,O
Baseline,O
Grade,O
4,O
Picato,O
r,O
gel,O
n,O
274,O
Vehicle,O
n,O
271,O
Picato,O
r,O
gel,O
n,O
274,O
Vehicle,O
n,O
271,O
Erythema,AdverseReaction
258,O
94,O
69,O
25,O
66,O
24,O
0,O
0,O
Flaking,AdverseReaction
Scaling,AdverseReaction
233,O
85,O
67,O
25,O
25,O
9,O
0,O
0,O
Crusting,AdverseReaction
220,O
80,O
46,O
17,O
16,O
6,O
0,O
0,O
Swelling,AdverseReaction
217,O
79,O
11,O
4,O
14,O
5,O
0,O
0,O
Vesiculation,AdverseReaction
Pustulation,AdverseReaction
154,O
56,O
1,O
0,O
15,O
5,O
0,O
0,O
Erosion,AdverseReaction
Ulceration,AdverseReaction
87,O
32,O
3,O
1,O
1,O
0,O
0,O
0,O
a,O
Mild,O
grade,O
1,O
Moderate,O
grade,O
2,O
3,O
or,O
Severe,O
grade,O
4,O
Table,O
2,O
Investigator,O
Assessment,O
of,O
Maximal,O
Local Skin Reactions,AdverseReaction
in,O
the,O
Treatment,O
Area,O
during,O
the,O
57,O
Days,O
Post,O
Treatment,O
Period,O
trunk,O
extremities,O
trials,O
Trunk,O
and,O
Extremities,O
n,O
457,O
Picato,O
r,O
gel,O
0,O
05,O
once,O
daily,O
for,O
2,O
days,O
Skin,AdverseReaction
reactions,O
Any,O
Gradea,O
Baseline,O
Grade,O
4,O
Picato,O
r,O
gel,O
n,O
225,O
Vehicle,O
n,O
232,O
Picato,O
r,O
gel,O
n,O
225,O
Vehicle,O
n,O
232,O
Erythema,AdverseReaction
207,O
92,O
43,O
19,O
34,O
15,O
0,O
0,O
Flaking,AdverseReaction
Scaling,AdverseReaction
203,O
90,O
44,O
19,O
18,O
8,O
0,O
0,O
Crusting,AdverseReaction
167,O
74,O
23,O
10,O
8,O
4,O
0,O
0,O
Swelling,AdverseReaction
143,O
64,O
13,O
6,O
7,O
3,O
0,O
0,O
Vesiculation,AdverseReaction
Pustulation,AdverseReaction
98,O
44,O
2,O
1,O
3,O
1,O
0,O
0,O
Erosion,AdverseReaction
Ulceration,AdverseReaction
58,O
26,O
6,O
3,O
2,O
1,O
0,O
0,O
a,O
Mild,O
grade,O
1,O
Moderate,O
grade,O
2,O
3,O
or,O
Severe,O
grade,O
4,O
Local skin reactions,AdverseReaction
typically,O
occurred,O
within,O
1,O
day,O
of,O
treatment,O
initiation,O
peaked,O
in,O
intensity,O
up,O
to,O
1,O
week,O
following,O
completion,O
of,O
treatment,O
and,O
resolved,O
within,O
2,O
weeks,O
for,O
areas,O
treated,O
on,O
the,O
face,O
and,O
scalp,O
and,O
within,O
4,O
weeks,O
for,O
areas,O
treated,O
on,O
the,O
trunk,O
and,O
extremities,O
Adverse,O
reactions,O
that,O
occurred,O
in,O
2,O
of,O
subjects,O
treated,O
with,O
Picato,O
r,O
gel,O
and,O
at,O
a,O
higher,O
frequency,O
than,O
the,O
vehicle,O
are,O
presented,O
in,O
Table,O
3,O
and,O
Table,O
4,O
Table,O
3,O
Adverse,O
reactions,O
occurring,O
in,O
2,O
of,O
subjects,O
treated,O
with,O
Picato,O
r,O
gel,O
and,O
at,O
higher,O
frequency,O
than,O
vehicle,O
face,O
scalp,O
trials,O
Face,O
Scalp,O
Adverse,O
Reactions,O
Picato,O
r,O
gel,O
0,O
015,O
N,O
274,O
Vehicle,O
N,O
271,O
Application Site Pain,AdverseReaction
42,O
15,O
1,O
0,O
Application Site Pruritus,AdverseReaction
22,O
8,O
3,O
1,O
Application Site Infection,AdverseReaction
7,O
3,O
0,O
0,O
Periorbital Edema,AdverseReaction
7,O
3,O
0,O
0,O
Headache,AdverseReaction
6,O
2,O
3,O
1,O
Table,O
4,O
Adverse,O
reactions,O
occurring,O
in,O
2,O
of,O
subjects,O
treated,O
with,O
Picato,O
r,O
gel,O
and,O
at,O
higher,O
frequency,O
than,O
vehicle,O
trunk,O
extremities,O
trials,O
Trunk,O
Extremities,O
Adverse,O
Reactions,O
Picato,O
r,O
gel,O
0,O
05,O
N,O
225,O
Vehicle,O
N,O
232,O
Application Site Pruritus,AdverseReaction
18,O
8,O
0,O
0,O
Application Site Irritation,AdverseReaction
8,O
4,O
1,O
0,O
Nasopharyngitis,AdverseReaction
4,O
2,O
2,O
1,O
Application Site Pain,AdverseReaction
5,O
2,O
0,O
0,O
Less,O
common,O
adverse,O
reactions,O
in,O
subjects,O
treated,O
with,O
Picato,O
r,O
included,O
eyelid edema,AdverseReaction
eye pain,AdverseReaction
conjunctivitis,AdverseReaction
A,O
total,O
of,O
108,O
subjects,O
treated,O
with,O
Picato,O
r,O
gel,O
on,O
the,O
face,O
scalp,O
and,O
38,O
subjects,O
treated,O
on,O
the,O
trunk,O
extremities,O
were,O
followed,O
for,O
12,O
months,O
Results,O
from,O
these,O
studies,O
did,O
not,O
change,O
the,O
safety,O
profile,O
of,O
Picato,O
r,O
gel,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
Picato,O
r,O
ingenol,O
mebutate,O
gel,O
0,O
015,O
and,O
0,O
05,O
hypersensitivity,AdverseReaction
allergic contact dermatitis,AdverseReaction
herpes zoster,AdverseReaction
chemical conjunctivitis,AdverseReaction
and,O
corneal burn,AdverseReaction
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Urinary retention,AdverseReaction
Patients,O
should,O
be,O
carefully,O
monitored,O
for,O
urologic,O
symptoms,O
5,O
2,O
POTIGA,O
can,Factor
cause,O
skin discoloration,AdverseReaction
If,O
a,O
patient,O
develops,O
skin,O
discoloration,O
serious,O
consideration,O
should,O
be,O
given,O
to,O
an,O
alternative,O
treatment,O
5,O
3,O
Neuropsychiatric symptoms,AdverseReaction
Monitor,O
for,O
confusional,O
state,O
psychotic,O
symptoms,O
and,O
hallucinations,O
5,O
4,O
Monitor,O
for,O
dizziness,O
and,O
somnolence,O
5,O
5,O
QT prolongation,AdverseReaction
QT,O
interval,O
should,O
be,O
monitored,O
in,O
patients,O
taking,O
concomitant,O
medications,O
known,O
to,O
increase,O
the,O
QT,O
interval,O
or,O
with,O
certain,O
heart,O
conditions,O
5,O
6,O
Monitor,O
for,O
suicidal,O
thoughts,O
or,O
behaviors,O
5,O
7,O
5,O
1,O
Retinal,O
Abnormalities,O
and,O
Potential,O
Vision,O
Loss,O
POTIGA,O
can,Factor
cause,O
abnormalities of the retina,AdverseReaction
The,O
abnormalities,O
seen,O
in,O
patients,O
treated,O
with,O
POTIGA,O
have,O
funduscopic features similar to,AdverseReaction
those,O
seen,O
in,O
retinal pigment dystrophies,AdverseReaction
that,O
are,O
known,O
to,O
result,O
in,O
damage to photoreceptors,AdverseReaction
and,O
vision loss,AdverseReaction
The,O
retinal abnormalities,AdverseReaction
observed,O
with,O
POTIGA,O
have,O
been,O
reported,O
in,O
patients,O
who,O
were,O
originally,O
enrolled,O
in,O
clinical,O
trials,O
with,O
POTIGA,O
and,O
who,O
have,O
generally,O
taken,O
the,O
drug,O
for,O
a,O
long,O
period,O
of,O
time,O
in,O
2,O
ongoing,O
extension,O
trials,O
Approximately,O
one,O
third,O
of,O
the,O
patients,O
who,O
had,O
eye,O
examinations,O
performed,O
after,O
approximately,O
4,O
years,O
of,O
treatment,O
were,O
found,O
to,O
have,O
retinal pigmentary abnormalities,AdverseReaction
However,O
an,O
earlier,O
onset,O
cannot,O
be,O
ruled,O
out,O
and,O
it,O
is,O
possible,O
that,O
retinal abnormalities,AdverseReaction
were,O
present,O
earlier,O
in,O
the,O
course,O
of,O
exposure,O
to,O
POTIGA,O
POTIGA,O
causes,O
skin,AdverseReaction
scleral,AdverseReaction
nail,AdverseReaction
and,O
mucous membrane discoloration,AdverseReaction
and,O
it,O
is,O
not,O
clear,O
whether,O
this,O
discoloration,AdverseReaction
is,O
related,O
to,O
retinal abnormalities,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Approximately,O
15,O
of,O
patients,O
with,O
retinal pigmentary abnormalities,AdverseReaction
had,O
no,Negation
such,O
discoloration,AdverseReaction
Funduscopic abnormalities,AdverseReaction
have,O
most,O
commonly,O
been,O
described,O
as,O
perivascular pigmentation pigmentation,AdverseReaction
bone spicule pattern,AdverseReaction
in the retinal periphery the retinal periphery,AdverseReaction
and,O
or,O
as,O
areas,O
of,O
focal retinal pigment epithelium clumping,AdverseReaction
Although,O
some,O
of,O
the,O
patients,O
with,O
retinal abnormalities,AdverseReaction
have,O
been,O
found,O
to,O
have,O
abnormal visual acuity,AdverseReaction
it,O
is,O
not,O
possible,O
to,O
assess,O
whether,Factor
POTIGA,O
caused,O
their,O
decreased visual acuity,AdverseReaction
as,O
baseline,O
assessments,O
are,O
not,O
available,O
for,O
these,O
patients,O
Two,O
patients,O
with,O
retinal abnormalities,AdverseReaction
have,O
had,O
more,O
extensive,O
diagnostic,O
retinal,O
evaluations,O
The,O
results,O
of,O
these,O
evaluations,O
were,O
consistent,O
with,O
a,O
retinal dystrophy,AdverseReaction
including,O
abnormalities in the electroretinogram in,AdverseReaction
and,O
electrooculogram,AdverseReaction
of,O
both,O
patients,O
with,O
abnormal fluorescein angiography,AdverseReaction
and,O
diminished sensitivity on visual field,AdverseReaction
testing,O
in,O
one,O
patient,O
The,O
rate,O
of,O
progression,O
of,O
retinal abnormalities,AdverseReaction
and,O
the,O
reversibility,O
after,O
drug,O
discontinuation,O
are,O
unknown,O
Because,Factor
of,O
the,O
observed,O
ophthalmologic,O
adverse,O
reactions,O
POTIGA,O
should,O
only,O
be,O
used,O
in,O
patients,O
who,O
have,O
responded,O
inadequately,O
to,O
several,O
alternative,O
treatments,O
and,O
for,O
whom,O
the,O
benefits,O
outweigh,O
the,O
risk,O
of,O
retinal,O
abnormalities,O
and,O
potential,O
vision,O
loss,O
Patients,O
who,O
fail,O
to,O
show,O
substantial,O
clinical,O
benefit,O
after,O
adequate,O
titration,O
should,O
be,O
discontinued,O
from,O
POTIGA,O
Patients,O
should,O
have,O
baseline,O
ophthalmologic,O
testing,O
by,O
an,O
ophthalmic,O
professional,O
and,O
follow,O
up,O
testing,O
every,O
6,O
months,O
The,O
best,O
method,O
of,O
detection,O
of,O
these,O
abnormalities,O
and,O
the,O
optimal,O
frequency,O
of,O
periodic,O
ophthalmologic,O
monitoring,O
are,O
unknown,O
Patients,O
who,O
cannot,O
be,O
monitored,O
should,O
usually,O
not,O
be,O
treated,O
with,O
POTIGA,O
The,O
ophthalmologic,O
monitoring,O
program,O
should,O
include,O
visual,O
acuity,O
testing,O
and,O
dilated,O
fundus,O
photography,O
Additional,O
testing,O
may,O
include,O
fluorescein,O
angiograms,O
FA,O
optical,O
coherence,O
tomography,O
OCT,O
perimetry,O
and,O
electroretinograms,O
ERG,O
If,O
retinal,O
pigmentary,O
abnormalities,O
or,O
vision,O
changes,O
are,O
detected,O
POTIGA,O
should,O
be,O
discontinued,O
unless,O
no,O
other,O
suitable,O
treatment,O
options,O
are,O
available,O
and,O
the,O
benefits,O
of,O
treatment,O
outweigh,O
the,O
potential,O
risk,O
of,O
vision,O
loss,Factor
5,O
2,O
Urinary,O
Retention,O
POTIGA,O
caused,O
urinary retention,AdverseReaction
in,O
clinical,O
trials,O
Urinary retention,AdverseReaction
was,O
generally,O
reported,O
within,O
the,O
first,O
6,O
months,O
of,O
treatment,O
but,O
was,O
also,O
observed,O
later,O
Urinary retention,AdverseReaction
was,O
reported,O
as,O
an,O
adverse,O
event,O
in,O
29,O
of,O
1,O
365,O
approximately,O
2,O
patients,O
treated,O
with,O
POTIGA,O
in,O
the,O
open,O
label,O
and,O
placebo,O
controlled,O
epilepsy,O
database,O
see,O
Clinical,O
Studies,O
14,O
Of,O
these,O
29,O
patients,O
5,O
17,O
required,O
catheterization,O
with,O
post,O
voiding,O
residuals,O
of,O
up,O
to,O
1,O
500,O
mL,O
POTIGA,O
was,O
discontinued,O
in,O
3,O
of,O
the,O
5,O
patients,O
who,O
required,O
catheterization,O
and,O
all,O
were,O
able,O
to,O
void,O
spontaneously,O
however,O
1,O
of,O
the,O
3,O
patients,O
continued,O
intermittent,O
self,O
catheterization,O
Two,O
patients,O
continued,O
treatment,O
with,O
POTIGA,O
and,O
were,O
able,O
to,O
void,O
spontaneously,O
after,O
catheter,O
removal,O
Hydronephrosis,AdverseReaction
occurred,O
in,O
2,O
patients,O
one,O
of,O
whom,O
had,O
associated,O
renal function impairment,AdverseReaction
that,O
resolved,O
upon,O
discontinuation,O
of,O
POTIGA,O
Hydronephrosis,AdverseReaction
was,O
not,Negation
reported,O
in,O
placebo,Factor
patients,O
In,O
the,O
placebo,O
controlled,O
epilepsy,O
trials,O
urinary retention,AdverseReaction
urinary hesitation,AdverseReaction
and,O
dysuria,AdverseReaction
were,O
reported,O
in,O
0,O
9,O
2,O
2,O
and,O
2,O
3,O
of,O
patients,O
on,O
POTIGA,O
respectively,O
and,O
in,O
0,O
5,O
0,O
9,O
and,O
0,O
7,O
of,O
patients,O
on,O
placebo,O
respectively,O
Because,Factor
of,O
the,O
increased,O
risk,O
of,O
urinary,O
retention,O
on,O
POTIGA,O
urologic,O
symptoms,O
should,O
be,O
carefully,O
monitored,O
Closer,O
monitoring,O
is,O
recommended,O
for,O
patients,O
who,O
have,O
other,O
risk,O
factors,O
for,O
urinary,O
retention,O
e,O
g,O
benign,O
prostatic,O
hyperplasia,O
BPH,O
patients,O
who,O
are,O
unable,O
to,O
communicate,O
clinical,O
symptoms,O
e,O
g,O
cognitively,O
impaired,O
patients,O
or,O
patients,O
who,O
use,O
concomitant,O
medications,O
that,O
may,O
affect,O
voiding,O
e,O
g,O
anticholinergics,O
In,O
these,O
patients,O
a,O
comprehensive,O
evaluation,O
of,O
urologic,O
symptoms,O
prior,O
to,O
and,O
during,O
treatment,O
with,O
POTIGA,O
may,O
be,O
appropriate,Factor
5,O
3,O
Skin,O
Discoloration,O
POTIGA,O
can,Factor
cause,O
skin discoloration,AdverseReaction
The,O
skin discoloration,AdverseReaction
is,O
generally,O
described,O
as,O
blue,O
but,O
has,O
also,O
been,O
described,O
as,O
grey,O
blue,O
or,O
brown,O
It,O
is,O
predominantly,O
on,O
or,O
around,O
the,O
lips,O
or,O
in,O
the,O
nail,O
beds,O
of,O
the,O
fingers,O
or,O
toes,O
but,O
more,O
widespread,O
involvement,O
of,O
the,O
face,O
and,O
legs,O
has,O
also,O
been,O
reported,O
Discoloration of the palate of the of the,AdverseReaction
sclera,AdverseReaction
and,O
conjunctiva,AdverseReaction
has,O
also,O
been,O
reported,O
Approximately,O
10,O
of,O
patients,O
in,O
long,O
term,O
clinical,O
trials,O
developed,O
skin discoloration,AdverseReaction
generally,O
after,O
2,O
or,O
more,O
years,O
of,O
treatment,O
and,O
at,O
higher,O
doses,O
900,O
mg,O
or,O
greater,O
of,O
POTIGA,O
Among,O
patients,O
in,O
whom,O
the,O
status,O
of,O
both,O
skin,AdverseReaction
nail,AdverseReaction
lip,AdverseReaction
or,O
mucous membrane discoloration,AdverseReaction
and,O
retinal pigmentary abnormalities,AdverseReaction
are,O
reported,O
approximately,O
a,O
quarter,O
of,O
those,O
with,O
skin,AdverseReaction
nail,AdverseReaction
lip,AdverseReaction
or,O
mucous membrane discoloration,AdverseReaction
had,O
concurrent,O
retinal pigmentary abnormalities,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Information,O
on,O
the,O
consequences,O
reversibility,O
time,O
to,O
onset,O
and,O
pathophysiology,O
of,O
the,O
skin abnormalities,AdverseReaction
remains,O
incomplete,O
The,O
possibility,O
of,O
more,O
extensive,O
systemic,O
involvement,O
has,O
not,O
been,O
excluded,O
If,O
a,O
patient,O
develops,O
skin,O
discoloration,O
serious,O
consideration,O
should,O
be,O
given,O
to,O
changing,O
to,O
an,O
alternate,O
medication,O
5,O
4,O
Neuropsychiatric,O
Symptoms,O
Confusional state,AdverseReaction
psychotic symptoms,AdverseReaction
and,O
hallucinations,AdverseReaction
were,O
reported,O
more,O
frequently,O
as,O
adverse,O
reactions,O
in,O
patients,O
treated,O
with,O
POTIGA,O
than,O
in,O
those,O
treated,O
with,O
placebo,O
in,O
placebo,O
controlled,O
epilepsy,O
trials,O
see,O
Table,O
2,O
Discontinuations,O
resulting,O
from,O
these,O
reactions,O
were,O
more,O
common,O
in,O
the,O
drug,O
treated,O
group,O
see,O
Table,O
2,O
These,O
effects,O
were,O
dose,O
related,O
and,O
generally,O
appeared,O
within,O
the,O
first,O
8,O
weeks,O
of,O
treatment,O
Half,O
of,O
the,O
patients,O
in,O
the,O
controlled,O
trials,O
who,O
discontinued,O
POTIGA,O
due,O
to,O
hallucinations,AdverseReaction
or,O
psychosis,AdverseReaction
required,O
hospitalization,O
Approximately,O
two,O
thirds,O
of,O
patients,O
with,O
psychosis,AdverseReaction
in,O
controlled,O
trials,O
had,O
no,O
prior,O
psychiatric,O
history,O
The,O
psychiatric symptoms,AdverseReaction
in,O
the,O
vast,O
majority,O
of,O
patients,O
in,O
both,O
controlled,O
and,O
open,O
label,O
trials,O
resolved,O
within,O
7,O
days,O
of,O
discontinuation,O
of,O
POTIGA,O
Rapid,O
titration,O
at,O
greater,O
than,O
the,O
recommended,O
doses,O
appeared,O
to,O
increase,O
the,O
risk,Factor
of,O
psychosis,AdverseReaction
and,O
hallucinations,AdverseReaction
Table,O
2,O
Major,O
Neuropsychiatric Symptoms,AdverseReaction
in,O
Placebo,O
Controlled,O
Epilepsy,O
Trials,O
Adverse,O
Reaction,O
Number,O
with,O
Adverse,O
Reaction,O
Number,O
Discontinuing,O
POTIGA,O
n,O
813,O
Placebo,O
n,O
427,O
POTIGA,O
n,O
813,O
Placebo,O
n,O
427,O
Confusional state,AdverseReaction
75,O
9,O
11,O
3,O
32,O
4,O
4,O
1,O
Psychosis,AdverseReaction
9,O
1,O
0,O
6,O
1,O
0,O
Hallucinationsa,O
14,O
2,O
2,O
1,O
6,O
1,O
0,O
a,O
Hallucinations,AdverseReaction
includes,O
visual,AdverseReaction
auditory,AdverseReaction
and,O
mixed hallucinations,AdverseReaction
5,O
5,O
Dizziness,O
and,O
Somnolence,O
POTIGA,O
causes,O
dose,O
related,O
increases,O
in,O
dizziness,AdverseReaction
and,O
somnolence,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
In,O
placebo,O
controlled,O
trials,O
in,O
patients,O
with,O
epilepsy,O
dizziness,AdverseReaction
was,O
reported,O
in,O
23,O
of,O
patients,O
treated,O
with,O
POTIGA,O
and,O
9,O
of,O
patients,O
treated,O
with,O
placebo,O
Somnolence,AdverseReaction
was,O
reported,O
in,O
22,O
of,O
patients,O
treated,O
with,O
POTIGA,O
and,O
12,O
of,O
patients,O
treated,O
with,O
placebo,O
In,O
these,O
trials,O
6,O
of,O
patients,O
on,O
POTIGA,O
and,O
1,O
2,O
on,O
placebo,O
discontinued,O
treatment,O
because,O
of,O
dizziness,AdverseReaction
3,O
of,O
patients,O
on,O
POTIGA,O
and,O
1,O
0,O
on,O
placebo,O
discontinued,O
because,O
of,O
somnolence,AdverseReaction
Most,O
of,O
these,O
adverse,O
reactions,O
were,O
mild,O
to,O
moderate,O
in,O
intensity,O
and,O
occurred,O
during,O
the,O
titration,O
phase,O
For,O
those,O
patients,O
continued,O
on,O
POTIGA,O
dizziness,AdverseReaction
and,O
somnolence,AdverseReaction
appeared,O
to,O
diminish,O
with,O
continued,O
use,O
5,O
6,O
QT,O
Interval,O
Effect,O
A,O
study,O
of,O
cardiac,O
conduction,O
showed,O
that,O
POTIGA,O
produced,O
a,O
mean,O
7 7 msec,Severity
QT prolongation,AdverseReaction
in,O
healthy,O
volunteers,O
titrated,O
to,O
400,O
mg,O
3,O
times,O
daily,O
The,O
QT prolonging,AdverseReaction
effect,O
occurred,O
within,O
3,O
hours,O
The,O
QT,O
interval,O
should,O
be,O
monitored,O
when,O
POTIGA,O
is,O
prescribed,O
with,O
medicines,O
known,O
to,O
increase,O
QT,O
interval,O
and,O
in,O
patients,O
with,O
known,O
prolonged,O
QT,O
interval,O
congestive,O
heart,O
failure,O
ventricular,O
hypertrophy,O
hypokalemia,O
or,O
hypomagnesemia,O
see,O
Clinical,O
Pharmacology,O
12,O
2,O
5,O
7,O
Suicidal,O
Behavior,O
and,O
Ideation,O
Antiepileptic,O
drugs,O
AEDs,O
including,O
POTIGA,O
increase,O
the,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
in,O
patients,O
taking,O
these,O
drugs,O
for,O
any,O
indication,O
Patients,O
treated,O
with,O
any,O
AED,O
for,O
any,O
indication,O
should,O
be,O
monitored,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
depression,O
suicidal,O
thoughts,O
or,O
behavior,O
and,O
or,O
any,O
unusual,O
changes,O
in,O
mood,O
or,O
behavior,O
Pooled,O
analyses,O
of,O
199,O
placebo,O
controlled,O
clinical,O
trials,O
mono,O
and,O
adjunctive,O
therapy,O
of,O
11,O
different,O
AEDs,O
showed,O
that,O
patients,O
randomized,O
to,O
one,O
of,O
the,O
AEDs,O
had,O
approximately,O
twice,O
the,O
risk,Factor
adjusted,O
relative,O
risk,O
1,O
8,O
95,O
confidence,O
interval,O
CI,O
1,O
2,O
2,O
7,O
of,O
suicidal thinking,AdverseReaction
or,O
behavior,AdverseReaction
compared,O
with,O
patients,O
randomized,O
to,O
placebo,O
In,O
these,O
trials,O
which,O
had,O
a,O
median,O
treatment,O
duration,O
of,O
12,O
weeks,O
the,O
estimated,O
incidence,O
of,O
suicidal behavior,AdverseReaction
or,O
ideation,AdverseReaction
among,O
27,O
863,O
AED,O
treated,O
patients,O
was,O
0,O
43,O
compared,O
with,O
0,O
24,O
among,O
16,O
029,O
placebo,O
treated,O
patients,O
representing,O
an,O
increase,O
of,O
approximately,O
1,O
case,O
of,O
suicidal thinking,AdverseReaction
or,O
behavior,AdverseReaction
for,O
every,O
530,O
patients,O
treated,O
There,O
were,O
4,O
suicides,AdverseReaction
in,O
drug,O
treated,O
patients,O
in,O
the,O
trials,O
and,O
none,O
in,O
placebo,O
treated,O
patients,O
but,O
the,O
number is too small,Factor
to,O
allow,O
any,O
conclusion,O
about,O
drug,O
effect,O
on,O
suicide,AdverseReaction
The,O
increased,O
risk,O
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
with,O
AEDs,DrugClass
was,O
observed,O
as,O
early,O
as,O
1,O
week,O
after,O
starting,O
treatment,O
with,O
AEDs,O
and,O
persisted,O
for,O
the,O
duration,O
of,O
treatment,O
assessed,O
Because,O
most,O
trials,O
included,O
in,O
the,O
analysis,O
did,O
not,O
extend,O
beyond,O
24,O
weeks,O
the,O
risk,O
of,O
suicidal,O
thoughts,O
or,O
behavior,O
beyond,O
24,O
weeks,O
could,O
not,O
be,O
assessed,O
The,O
risk,Factor
of,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
was,O
generally,O
consistent,O
among,O
drugs,O
in,O
the,O
data,O
analyzed,O
The,O
finding,O
of,O
increased,O
risk,O
with,O
AEDs,O
of,O
varying,O
mechanism,O
of,O
action,O
and,O
across,O
a,O
range,O
of,O
indications,O
suggests,O
that,O
the,O
risk,O
applies,O
to,O
all,O
AEDs,O
used,O
for,O
any,O
indication,O
The,O
risk,O
did,O
not,O
vary,O
substantially,O
by,O
age,O
5,O
to,O
100,O
years,O
in,O
the,O
clinical,O
trials,O
analyzed,O
Table,O
3,O
shows,O
absolute,O
and,O
relative,O
risk,O
by,O
indication,O
for,O
all,O
evaluated,O
AEDs,O
Table,O
3,O
Risk,Factor
of,O
Suicidal Thoughts,AdverseReaction
or,O
Behaviors,AdverseReaction
by,O
Indication,O
for,O
Antiepileptic,O
Drugs,O
in,O
the,O
Pooled,O
Analysis,O
Indication,O
Placebo,O
Patients,O
with,O
Events,O
per,O
1,O
000,O
Patients,O
Drug,O
Patients,O
with,O
Events,O
per,O
1,O
000,O
Patients,O
Relative,O
Risk,O
Incidence,O
of,O
Events,O
in,O
Drug,O
Patients,O
Incidence,O
in,O
Placebo,O
Patients,O
Risk,O
Difference,O
Additional,O
Drug,O
Patients,O
with,O
Events,O
per,O
1,O
000,O
Patients,O
Epilepsy,O
1,O
0,O
3,O
4,O
3,O
5,O
2,O
4,O
Psychiatric,O
5,O
7,O
8,O
5,O
1,O
5,O
2,O
9,O
Other,O
1,O
0,O
1,O
8,O
1,O
9,O
0,O
9,O
Total,O
2,O
4,O
4,O
3,O
1,O
8,O
1,O
9,O
The,O
relative,O
risk,Factor
for,O
suicidal thoughts,AdverseReaction
or,O
behavior,AdverseReaction
was,O
higher,O
in,O
clinical,O
trials,O
in,O
patients,O
with,O
epilepsy,O
than,O
in,O
clinical,O
trials,O
in,O
patients,O
with,O
psychiatric,O
or,O
other,O
conditions,O
but,O
the,O
absolute,O
risk,O
differences,O
were,O
similar,O
for,O
epilepsy,O
and,O
psychiatric,O
indications,O
Anyone,O
considering,O
prescribing,O
POTIGA,O
or,O
any,O
other,O
AED,O
must,O
balance,O
this,O
risk,O
with,O
the,O
risk,O
of,O
untreated,O
illness,O
Epilepsy,O
and,O
many,O
other,O
illnesses,O
for,O
which,O
AEDs,O
are,O
prescribed,O
are,O
themselves,O
associated,O
with,O
morbidity,O
and,O
mortality,O
and,O
an,O
increased,O
risk,O
of,O
suicidal,O
thoughts,O
and,O
behavior,O
Should,O
suicidal,O
thoughts,O
and,O
behavior,O
emerge,O
during,O
treatment,O
the,O
prescriber,O
needs,O
to,O
consider,O
whether,O
the,O
emergence,O
of,O
these,O
symptoms,O
in,O
any,O
given,O
patient,O
may,O
be,O
related,O
to,O
the,O
illness,O
being,O
treated,O
Patients,O
their,O
caregivers,O
and,O
families,O
should,O
be,O
informed,O
that,O
AEDs,O
increase,O
the,O
risk,O
of,O
suicidal,O
thoughts,O
and,O
behavior,O
and,O
should,O
be,O
advised,O
of,O
the,O
need,O
to,O
be,O
alert,O
for,O
the,O
emergence,O
or,O
worsening,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
depression,O
any,O
unusual,O
changes,O
in,O
mood,O
or,O
behavior,O
or,O
the,O
emergence,O
of,O
suicidal,O
thoughts,O
behavior,O
or,O
thoughts,O
about,O
self,O
harm,O
Behaviors,O
of,O
concern,O
should,O
be,O
reported,O
immediately,O
to,O
healthcare,O
providers,O
5,O
8,O
Withdrawal,O
Seizures,O
As,O
with,O
all,O
AEDs,O
when,O
POTIGA,O
is,O
discontinued,O
it,O
should,O
be,O
withdrawn,O
gradually,O
when,O
possible,O
to,O
minimize,O
the,O
potential,O
of,O
increased,O
seizure,O
frequency,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
The,O
dosage,O
of,O
POTIGA,O
should,O
be,O
reduced,O
over,O
a,O
period,O
of,O
at,O
least,O
3,O
weeks,O
unless,O
safety,O
concerns,O
require,O
abrupt,O
withdrawal,O
""
BOXED,O
WARNING,O
WARNING,O
RETINAL ABNORMALITIES,AdverseReaction
AND,O
POTENTIAL,Factor
VISION LOSS,AdverseReaction
WARNING,O
RETINAL ABNORMALITIES,AdverseReaction
AND,O
POTENTIAL,Factor
VISION LOSS,AdverseReaction
POTIGA,O
can,Factor
cause,O
retinal abnormalities abnormalities,AdverseReaction
with,O
funduscopic,O
features,O
similar to,AdverseReaction
those,O
seen,O
in,O
retinal pigment dystrophies,AdverseReaction
which,O
are,O
known,O
to,O
result,O
in,O
damage to the photoreceptors,AdverseReaction
and,O
vision loss,AdverseReaction
Some,O
patients,O
with,O
retinal abnormalities,AdverseReaction
have,O
been,O
found,O
to,O
have,O
abnormal visual acuity,AdverseReaction
It,O
is,O
not possible to determine,Factor
whether,O
POTIGA,O
caused,O
this,O
decreased visual acuity,AdverseReaction
as,O
baseline,O
assessments,O
are,O
not,O
available,O
for,O
these,O
patients,O
Approximately,O
one,O
third,O
of,O
the,O
patients,O
who,O
had,O
eye,O
examinations,O
performed,O
after,O
approximately,O
4,O
years,O
of,O
treatment,O
were,O
found,O
to,O
have,O
retinal pigmentary abnormalities,AdverseReaction
An,O
earlier,O
onset,O
cannot,O
be,O
ruled,O
out,O
and,O
it,O
is,O
possible,O
that,O
retinal abnormalities,AdverseReaction
were,O
present,O
earlier,O
in,O
the,O
course,O
of,O
exposure,O
to,O
POTIGA,O
The,O
rate,O
of,O
progression,O
of,O
retinal abnormalities,AdverseReaction
and,O
their,O
reversibility,O
are,O
unknown,O
POTIGA,O
should,O
only,O
be,O
used,O
in,O
patients,O
who,O
have,O
responded,O
inadequately,O
to,O
several,O
alternative,O
treatments,O
and,O
for,O
whom,O
the,O
benefits,O
outweigh,O
the,O
potential,O
risk,O
of,O
vision,O
loss,O
Patients,O
who,O
fail,O
to,O
show,O
substantial,O
clinical,O
benefit,O
after,O
adequate,O
titration,O
should,O
be,O
discontinued,O
from,O
POTIGA,O
All,O
patients,O
taking,O
POTIGA,O
should,O
have,O
baseline,O
and,O
periodic,O
every,O
6,O
months,O
systematic,O
visual,O
monitoring,O
by,O
an,O
ophthalmic,O
professional,O
Testing,O
should,O
include,O
visual,O
acuity,O
and,O
dilated,O
fundus,O
photography,O
Additional,O
testing,O
may,O
include,O
fluorescein,O
angiograms,O
FA,O
optical,O
coherence,O
tomography,O
OCT,O
perimetry,O
and,O
electroretinograms,O
ERG,O
If,O
retinal,O
pigmentary,O
abnormalities,O
or,O
vision,O
changes,O
are,O
detected,O
POTIGA,O
should,O
be,O
discontinued,O
unless,O
no,O
other,O
suitable,O
treatment,O
options,O
are,O
available,O
and,O
the,O
benefits,O
of,O
treatment,O
outweigh,O
the,O
potential,O
risk,O
of,O
vision,O
loss,O
EXCERPT,O
WARNING,O
RETINAL ABNORMALITIES,AdverseReaction
AND,O
POTENTIAL,Factor
VISION LOSS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
POTIGA,O
can,O
cause,O
retinal abnormalities abnormalities,AdverseReaction
with,O
funduscopic,O
features,O
similar to,AdverseReaction
those,O
seen,O
in,O
retinal,O
pigment dystrophies,AdverseReaction
which,O
are,O
known,O
to,O
result,O
in,O
damage to the photoreceptors,AdverseReaction
and,O
vision loss,AdverseReaction
5,O
1,O
Some,O
patients,O
with,O
retinal,O
abnormalities,O
have,O
been,O
found,O
to,O
have,O
abnormal,O
visual,O
acuity,O
It,O
is,O
not possible to determine,Factor
whether,O
POTIGA,O
caused,O
this,O
decreased visual acuity,AdverseReaction
5,O
1,O
The,O
rate,O
of,O
progression,O
of,O
retinal,O
abnormalities,O
and,O
their,O
reversibility,O
are,O
unknown,O
5,O
1,O
Patients,O
who,O
fail,O
to,O
show,O
substantial,O
clinical,O
benefit,O
after,O
adequate,O
titration,O
should,O
be,O
discontinued,O
from,O
POTIGA,O
5,O
1,O
All,O
patients,O
taking,O
POTIGA,O
should,O
have,O
baseline,O
and,O
periodic,O
every,O
6,O
months,O
systematic,O
visual,O
monitoring,O
by,O
an,O
ophthalmic,O
professional,O
Testing,O
should,O
include,O
visual,O
acuity,O
and,O
dilated,O
fundus,O
photography,O
5,O
1,O
If,O
retinal,O
pigmentary,O
abnormalities,O
or,O
vision,O
changes,O
are,O
detected,O
POTIGA,O
should,O
be,O
discontinued,O
unless,O
no,O
other,O
suitable,O
treatment,O
options,O
are,O
available,O
and,O
the,O
benefits,O
of,O
treatment,O
outweigh,O
the,O
potential,O
risk,O
of,O
vision,O
loss,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
described,O
in,O
more,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
of,O
the,O
label,O
Retinal abnormalities,AdverseReaction
and,O
potential,Factor
vision loss,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Urinary retention,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Skin discoloration,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Neuropsychiatric symptoms,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Dizziness,AdverseReaction
and,O
somnolence,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
QT interval effect,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Suicidal behavior,AdverseReaction
and,O
ideation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Withdrawal seizures,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
4,O
and,O
twice,O
placebo,O
were,O
dizziness,AdverseReaction
somnolence,AdverseReaction
fatigue,AdverseReaction
confusional state,AdverseReaction
vertigo,AdverseReaction
tremor,AdverseReaction
abnormal coordination,AdverseReaction
diplopia,AdverseReaction
disturbance in attention,AdverseReaction
memory impairment,AdverseReaction
asthenia,AdverseReaction
blurred vision,AdverseReaction
gait disturbance,AdverseReaction
aphasia,AdverseReaction
dysarthria,AdverseReaction
and,O
balance disorder,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GlaxoSmithKline,O
at,O
1,O
888,O
825,O
5249,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
POTIGA,O
was,O
administered,O
as,O
adjunctive,O
therapy,O
to,O
1,O
365,O
patients,O
with,O
epilepsy,O
in,O
all,O
controlled,O
and,O
uncontrolled,O
clinical,O
studies,O
during,O
the,O
premarketing,O
development,O
A,O
total,O
of,O
801,O
patients,O
were,O
treated,O
for,O
at,O
least,O
6,O
months,O
585,O
patients,O
were,O
treated,O
for,O
1,O
year,O
or,O
longer,O
and,O
311,O
patients,O
were,O
treated,O
for,O
at,O
least,O
2,O
years,O
Adverse,O
Reactions,O
Leading,O
to,O
Discontinuation,O
in,O
All,O
Controlled,O
Clinical,O
Studies,O
In,O
the,O
3,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
studies,O
199,O
of,O
813,O
patients,O
25,O
receiving,O
POTIGA,O
and,O
45,O
of,O
427,O
patients,O
11,O
receiving,O
placebo,O
discontinued,O
treatment,O
because,O
of,O
adverse,O
reactions,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
withdrawal,O
in,O
patients,O
receiving,O
POTIGA,O
were,O
dizziness,AdverseReaction
6,O
confusional state,AdverseReaction
4,O
fatigue,AdverseReaction
3,O
and,O
somnolence,AdverseReaction
3,O
Common,O
Adverse,O
Reactions,O
in,O
All,O
Controlled,O
Clinical,O
Studies,O
Overall,O
the,O
most,O
frequently,O
reported,O
adverse,O
reactions,O
in,O
patients,O
receiving,O
POTIGA,O
4,O
and,O
occurring,O
approximately,O
twice,O
the,O
placebo,O
rate,O
were,O
dizziness,AdverseReaction
23,O
somnolence,AdverseReaction
22,O
fatigue,AdverseReaction
15,O
confusional state,AdverseReaction
9,O
vertigo,AdverseReaction
8,O
tremor,AdverseReaction
8,O
abnormal coordination,AdverseReaction
7,O
diplopia,AdverseReaction
7,O
disturbance in attention,AdverseReaction
6,O
memory impairment,AdverseReaction
6,O
asthenia,AdverseReaction
5,O
blurred vision,AdverseReaction
5,O
gait disturbance,AdverseReaction
4,O
aphasia,AdverseReaction
4,O
dysarthria,AdverseReaction
4,O
and,O
balance disorder,AdverseReaction
4,O
see,O
Table,O
4,O
In,O
most,O
cases,O
the,O
reactions,O
were,O
of,O
mild,O
or,O
moderate,O
intensity,O
Table,O
4,O
Adverse,O
Reactions,O
Incidence,O
in,O
Placebo,O
Controlled,O
Adjunctive,O
Trials,O
in,O
Adult,O
Patients,O
with,O
Partial,O
Onset,O
Seizures,O
Adverse,O
reactions,O
in,O
at,O
least,O
2,O
of,O
patients,O
treated,O
with,O
POTIGA,O
in,O
any,O
treatment,O
group,O
and,O
numerically,O
more,O
frequent,O
than,O
in,O
the,O
placebo,O
group,O
Body,O
System,O
Adverse,O
Reaction,O
Placebo,O
POTIGA,O
600,O
mg,O
day,O
900,O
mg,O
day,O
1,O
200,O
mg,O
day,O
All,O
N,O
427,O
n,O
281,O
n,O
273,O
n,O
259,O
N,O
813,O
Eye,O
Diplopia,AdverseReaction
2,O
8,O
6,O
7,O
7,O
Blurred vision,AdverseReaction
2,O
2,O
4,O
10,O
5,O
Gastrointestinal,O
Nausea,AdverseReaction
5,O
6,O
6,O
9,O
7,O
Constipation,AdverseReaction
1,O
1,O
4,O
5,O
3,O
Dyspepsia,AdverseReaction
2,O
3,O
2,O
3,O
2,O
General,O
Fatigue,AdverseReaction
6,O
16,O
15,O
13,O
15,O
Asthenia,AdverseReaction
2,O
4,O
6,O
4,O
5,O
Infections,O
and,O
infestations,O
Influenza,AdverseReaction
2,O
4,O
1,O
5,O
3,O
Investigations,O
Weight increased,AdverseReaction
1,O
2,O
3,O
3,O
3,O
Nervous,O
system,O
Dizziness,AdverseReaction
9,O
15,O
23,O
32,O
23,O
Somnolence,AdverseReaction
12,O
15,O
25,O
27,O
22,O
Memory impairment,AdverseReaction
3,O
3,O
6,O
9,O
6,O
Tremor,AdverseReaction
3,O
3,O
10,O
12,O
8,O
Vertigo,AdverseReaction
2,O
8,O
8,O
9,O
8,O
Abnormal coordination,AdverseReaction
3,O
5,O
5,O
12,O
7,O
Disturbance in attention,AdverseReaction
1,O
6,O
6,O
7,O
6,O
Gait disturbance,AdverseReaction
1,O
2,O
5,O
6,O
4,O
Aphasia,AdverseReaction
1,O
1,O
3,O
7,O
4,O
Dysarthria,AdverseReaction
1,O
4,O
2,O
8,O
4,O
Balance disorder,AdverseReaction
1,O
3,O
3,O
5,O
4,O
Paresthesia,AdverseReaction
2,O
3,O
2,O
5,O
3,O
Amnesia,AdverseReaction
1,O
1,O
3,O
3,O
2,O
Dysphasia,AdverseReaction
1,O
1,O
1,O
3,O
2,O
Psychiatric,O
Confusional state,AdverseReaction
3,O
4,O
8,O
16,O
9,O
Anxiety,AdverseReaction
2,O
3,O
2,O
5,O
3,O
Disorientation,AdverseReaction
1,O
1,O
1,O
5,O
2,O
Psychotic disorder,AdverseReaction
0,O
0,O
1,O
2,O
1,O
Renal,O
and,O
urinary,O
Dysuria,AdverseReaction
1,O
1,O
2,O
4,O
2,O
Urinary hesitation,AdverseReaction
1,O
2,O
1,O
4,O
2,O
Hematuria,AdverseReaction
1,O
2,O
1,O
2,O
2,O
Chromaturia,AdverseReaction
1,O
1,O
2,O
3,O
2,O
Other,O
adverse,O
reactions,O
reported,O
in,O
these,O
3,O
studies,O
in,O
2,O
of,O
patients,O
treated,O
with,O
POTIGA,O
and,O
numerically,O
greater,O
than,O
placebo,O
were,O
increased appetite,AdverseReaction
hallucinations,AdverseReaction
myoclonus,AdverseReaction
peripheral edema,AdverseReaction
hypokinesia,AdverseReaction
dry mouth,AdverseReaction
dysphagia,AdverseReaction
hyperhydrosis,AdverseReaction
urinary retention,AdverseReaction
malaise,AdverseReaction
and,O
increased liver enzymes,AdverseReaction
Most,O
of,O
the,O
adverse,O
reactions,O
appear,O
to,O
be,O
dose,O
related,O
especially,O
those,O
classified,O
as,O
psychiatric,O
and,O
nervous,O
system,O
symptoms,O
including,O
dizziness,AdverseReaction
somnolence,AdverseReaction
confusional state,AdverseReaction
tremor,AdverseReaction
abnormal coordination,AdverseReaction
memory impairment,AdverseReaction
blurred vision,AdverseReaction
gait disturbance,AdverseReaction
aphasia,AdverseReaction
balance disorder,AdverseReaction
constipation,AdverseReaction
dysuria,AdverseReaction
and,O
chromaturia,AdverseReaction
POTIGA,O
was,O
associated,O
with,O
dose,O
related,O
weight gain,AdverseReaction
with,O
mean,O
weight increasing,AdverseReaction
by,O
0,O
2,O
kg,O
1,O
2,O
kg,O
1,O
6,O
kg,O
and,O
2,O
7,O
kg,O
in,O
the,O
placebo,O
600,O
mg,O
per,O
day,O
900,O
mg,O
per,O
day,O
and,O
1,O
200,O
mg,O
per,O
day,O
groups,O
respectively,O
Additional,O
Adverse,O
Reactions,O
Observed,O
during,O
All,O
Phase,O
2,O
and,O
3,O
Clinical,O
Trials,O
Following,O
is,O
a,O
list,O
of,O
adverse,O
reactions,O
reported,O
by,O
patients,O
treated,O
with,O
POTIGA,O
during,O
all,O
clinical,O
trials,O
rash,AdverseReaction
nystagmus,AdverseReaction
dyspnea,AdverseReaction
leukopenia,AdverseReaction
muscle spasms,AdverseReaction
alopecia,AdverseReaction
nephrolithiasis,AdverseReaction
syncope,AdverseReaction
neutropenia,AdverseReaction
thrombocytopenia,AdverseReaction
euphoric mood,AdverseReaction
renal colic,AdverseReaction
coma,AdverseReaction
encephalopathy,AdverseReaction
Comparison,O
of,O
Gender,O
Age,O
and,O
Race,O
The,O
overall,O
adverse,O
reaction,O
profile,O
of,O
POTIGA,O
was,O
similar,O
for,O
females,O
and,O
males,O
There,O
are,O
insufficient,O
data,O
to,O
support,O
meaningful,O
analyses,O
of,O
adverse,O
reactions,O
by,O
age,O
or,O
race,O
Approximately,O
86,O
of,O
the,O
population,O
studied,O
was,O
Caucasian,O
and,O
0,O
8,O
of,O
the,O
population,O
was,O
aged,O
65,O
years,O
or,O
older,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Bleeding,AdverseReaction
PRADAXA,O
can,Factor
cause,O
serious,Severity
and,O
fatal,AdverseReaction
bleeding,AdverseReaction
5,O
2,O
Bioprosthetic,O
heart,O
valves,O
PRADAXA,O
use,O
not,O
recommended,O
5,O
4,O
5,O
1,O
Increased,O
Risk,O
of,O
Thrombotic,O
Events,O
after,O
Premature,O
Discontinuation,O
Premature,O
discontinuation,O
of,O
any,O
oral,O
anticoagulant,O
including,O
PRADAXA,O
in,O
the,O
absence,O
of,O
adequate,O
alternative,O
anticoagulation,O
increases,O
the,O
risk,O
of,O
thrombotic,O
events,O
If,O
PRADAXA,O
is,O
discontinued,O
for,O
a,O
reason,O
other,O
than,O
pathological,O
bleeding,O
or,O
completion,O
of,O
a,O
course,O
of,O
therapy,O
consider,O
coverage,O
with,O
another,O
anticoagulant,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
2,O
5,O
2,O
6,O
5,O
2,O
Risk,O
of,O
Bleeding,O
PRADAXA,O
increases,O
the,O
risk,Factor
of,O
bleeding,AdverseReaction
and,O
can,Factor
cause,O
significant,Severity
and,O
sometimes,O
fatal,AdverseReaction
bleeding,AdverseReaction
Promptly,O
evaluate,O
any,O
signs,O
or,O
symptoms,O
of,O
blood,O
loss,O
e,O
g,O
a,O
drop,O
in,O
hemoglobin,O
and,O
or,O
hematocrit,O
or,O
hypotension,O
Discontinue,O
PRADAXA,O
in,O
patients,O
with,O
active,O
pathological,O
bleeding,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Risk,O
factors,O
for,O
bleeding,O
include,O
the,O
concomitant,O
use,O
of,O
other,O
drugs,O
that,O
increase,O
the,O
risk,O
of,O
bleeding,O
e,O
g,O
anti,O
platelet,O
agents,O
heparin,O
fibrinolytic,O
therapy,O
and,O
chronic,O
use,O
of,O
NSAIDs,O
PRADAXA,O
s,O
anticoagulant,O
activity,O
and,O
half,O
life,O
are,O
increased,O
in,O
patients,O
with,O
renal,O
impairment,O
see,O
Clinical,O
Pharmacology,O
12,O
2,O
Reversal,O
of,O
Anticoagulant,O
Effect,O
A,O
specific,O
reversal,O
agent,O
for,O
dabigatran,O
is,O
not,O
available,O
Hemodialysis,O
can,O
remove,O
dabigatran,O
however,O
the,O
clinical,O
experience,O
supporting,O
the,O
use,O
of,O
hemodialysis,O
as,O
a,O
treatment,O
for,O
bleeding,O
is,O
limited,O
see,O
Overdosage,O
10,O
Activated,O
prothrombin,O
complex,O
concentrates,O
aPCCs,O
e,O
g,O
FEIBA,O
or,O
recombinant,O
Factor,O
VIIa,O
or,O
concentrates,O
of,O
coagulation,O
factors,O
II,O
IX,O
or,O
X,O
may,O
be,O
considered,O
but,O
their,O
use,O
has,O
not,O
been,O
evaluated,O
in,O
clinical,O
trials,O
Protamine,O
sulfate,O
and,O
vitamin,O
K,O
are,O
not,O
expected,O
to,O
affect,O
the,O
anticoagulant,O
activity,O
of,O
dabigatran,O
Consider,O
administration,O
of,O
platelet,O
concentrates,O
in,O
cases,O
where,O
thrombocytopenia,O
is,O
present,O
or,O
long,O
acting,O
antiplatelet,O
drugs,O
have,O
been,O
used,O
5,O
3,O
Spinal,O
Epidural,O
Anesthesia,O
or,O
Puncture,O
When,O
neuraxial,O
anesthesia,O
spinal,O
epidural,O
anesthesia,O
or,O
spinal,O
puncture,O
is,O
employed,O
patients,O
treated,O
with,O
anticoagulant agents,DrugClass
are,O
at,O
risk,O
of,O
developing,O
an,O
epidural,AdverseReaction
or,O
spinal hematoma,AdverseReaction
which,O
can,O
result,O
in,O
long,O
term,O
or,O
permanent paralysis,AdverseReaction
paralysis,AdverseReaction
see,O
Boxed,O
Warning,O
To,O
reduce,O
the,O
potential,O
risk,O
of,O
bleeding,O
associated,O
with,O
the,O
concurrent,O
use,O
of,O
dabigatran,O
and,O
epidural,O
or,O
spinal,O
anesthesia,O
analgesia,O
or,O
spinal,O
puncture,O
consider,O
the,O
pharmacokinetic,O
profile,O
of,O
dabigatran,O
see,O
Clinical,O
Pharmacology,O
12,O
3,O
Placement,O
or,O
removal,O
of,O
an,O
epidural,O
catheter,O
or,O
lumbar,O
puncture,O
is,O
best,O
performed,O
when,O
the,O
anticoagulant,O
effect,O
of,O
dabigatran,O
is,O
low,O
however,O
the,O
exact,O
timing,O
to,O
reach,O
a,O
sufficiently,O
low,O
anticoagulant,O
effect,O
in,O
each,O
patient,O
is,O
not,O
known,O
Should,O
the,O
physician,O
decide,O
to,O
administer,O
anticoagulation,O
in,O
the,O
context,O
of,O
epidural,O
or,O
spinal,O
anesthesia,O
analgesia,O
or,O
lumbar,O
puncture,O
monitor,O
frequently,O
to,O
detect,O
any,O
signs,O
or,O
symptoms,O
of,O
neurological,O
impairment,O
such,O
as,O
midline,O
back,O
pain,O
sensory,O
and,O
motor,O
deficits,O
numbness,O
tingling,O
or,O
weakness,O
in,O
lower,O
limbs,O
bowel,O
and,O
or,O
bladder,O
dysfunction,O
Instruct,O
patients,O
to,O
immediately,O
report,O
if,O
they,O
experience,O
any,O
of,O
the,O
above,O
signs,O
or,O
symptoms,O
If,O
signs,O
or,O
symptoms,O
of,O
spinal,O
hematoma,O
are,O
suspected,O
initiate,O
urgent,O
diagnosis,O
and,O
treatment,O
including,O
consideration,O
for,O
spinal,O
cord,O
decompression,O
even,O
though,O
such,O
treatment,O
may,O
not,O
prevent,O
or,O
reverse,O
neurological,O
sequelae,O
5,O
4,O
Thromboembolic,O
and,O
Bleeding,O
Events,O
in,O
Patients,O
with,O
Prosthetic Heart,AdverseReaction
Valves,O
The,O
safety,O
and,O
efficacy,O
of,O
PRADAXA,O
in,O
patients,O
with,O
bileaflet,O
mechanical,O
prosthetic,O
heart,O
valves,O
was,O
evaluated,O
in,O
the,O
RE,O
ALIGN,O
trial,O
in,O
which,O
patients,O
with,O
bileaflet,O
mechanical,O
prosthetic,O
heart,O
valves,O
recently,O
implanted,O
or,O
implanted,O
more,O
than,O
three,O
months,O
prior,O
to,O
enrollment,O
were,O
randomized,O
to,O
dose,O
adjusted,O
warfarin,O
or,O
150,O
220,O
or,O
300,O
mg,O
of,O
PRADAXA,O
twice,O
a,O
day,O
RE,O
ALIGN,O
was,O
terminated,O
early,O
due,O
to,O
the,O
occurrence,O
of,O
significantly,O
more,O
thromboembolic events,AdverseReaction
valve thrombosis,AdverseReaction
stroke,AdverseReaction
transient ischemic attack,AdverseReaction
and,O
myocardial infarction,AdverseReaction
and,O
an,O
excess,O
of,O
major,Severity
bleeding,AdverseReaction
predominantly,O
post,O
operative,O
pericardial effusions,AdverseReaction
requiring,O
intervention,O
for,O
hemodynamic,O
compromise,O
in,O
the,O
PRADAXA,O
treatment,O
arm,O
as,O
compared,O
to,O
the,O
warfarin,O
treatment,O
arm,O
These,O
bleeding,AdverseReaction
and,O
thromboembolic events,AdverseReaction
were,O
seen,O
both,O
in,O
patients,O
who,O
were,O
initiated,O
on,O
PRADAXA,O
post,O
operatively,O
within,O
three,O
days,O
of,O
mechanical,O
bileaflet,O
valve,O
implantation,O
as,O
well,O
as,O
in,O
patients,O
whose,O
valves,O
had,O
been,O
implanted,O
more,O
than,O
three,O
months,O
prior,O
to,O
enrollment,O
Therefore,O
the,O
use,O
of,O
PRADAXA,O
is,O
contraindicated,O
in,O
patients,O
with,O
mechanical,O
prosthetic,O
valves,O
see,O
Contraindications,O
4,O
The,O
use,O
of,O
PRADAXA,O
for,O
the,O
prophylaxis,O
of,O
thromboembolic,O
events,O
in,O
patients,O
with,O
atrial,O
fibrillation,O
in,O
the,O
setting,O
of,O
other,O
forms,O
of,O
valvular,O
heart,O
disease,O
including,O
the,O
presence,O
of,O
a,O
bioprosthetic,O
heart,O
valve,O
has,O
not,O
been,O
studied,O
and,O
is,O
not,O
recommended,O
5,O
5,O
Effect,O
of,O
P,O
gp,O
Inducers,O
and,O
Inhibitors,O
on,O
Dabigatran,O
Exposure,O
The,O
concomitant,O
use,O
of,O
PRADAXA,O
with,O
P,O
gp,O
inducers,O
e,O
g,O
rifampin,O
reduces,O
exposure,O
to,O
dabigatran,O
and,O
should,O
generally,O
be,O
avoided,O
see,O
Clinical,O
Pharmacology,O
12,O
3,O
P,O
gp,O
inhibition,O
and,O
impaired,O
renal,O
function,O
are,O
the,O
major,O
independent,O
factors,O
that,O
result,O
in,O
increased,O
exposure,O
to,O
dabigatran,O
see,O
Clinical,O
Pharmacology,O
12,O
3,O
Concomitant,O
use,O
of,O
P,O
gp,O
inhibitors,O
in,O
patients,O
with,O
renal,O
impairment,O
is,O
expected,O
to,O
produce,O
increased,O
exposure,O
of,O
dabigatran,O
compared,O
to,O
that,O
seen,O
with,O
either,O
factor,O
alone,O
Reduction,O
of,O
Risk,O
of,O
Stroke,O
and,O
Systemic,O
Embolism,O
in,O
Non,O
valvular,O
Atrial,O
Fibrillation,O
Reduce,O
the,O
dose,O
of,O
PRADAXA,O
to,O
75,O
mg,O
twice,O
daily,O
when,O
dronedarone,O
or,O
systemic,O
ketoconazole,O
is,O
coadministered,O
with,O
PRADAXA,O
in,O
patients,O
with,O
moderate,O
renal,O
impairment,O
CrCl,O
30,O
50,O
mL,O
min,O
Avoid,O
use,O
of,O
PRADAXA,O
and,O
P,O
gp,O
inhibitors,O
in,O
patients,O
with,O
severe,O
renal,O
impairment,O
CrCl,O
15,O
30,O
mL,O
min,O
see,O
Drug,O
Interactions,O
7,O
1,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
Treatment,O
and,O
Reduction,O
in,O
the,O
Risk,O
of,O
Recurrence,O
of,O
Deep,O
Venous,O
Thrombosis,O
and,O
Pulmonary,O
Embolism,O
Avoid,O
use,O
of,O
PRADAXA,O
and,O
concomitant,O
P,O
gp,O
inhibitors,O
in,O
patients,O
with,O
CrCl,O
50,O
mL,O
min,O
see,O
Drug,O
Interactions,O
7,O
2,O
and,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
""
BOXED,O
WARNING,O
WARNING,O
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
PRADAXA,O
INCREASES,O
THE,O
RISK,O
OF,O
THROMBOTIC,O
EVENTS,O
B,O
SPINAL,AdverseReaction
EPIDURAL HEMATOMA,AdverseReaction
WARNING,O
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
PRADAXA,O
INCREASES,O
THE,O
RISK,O
OF,O
THROMBOTIC,O
EVENTS,O
B,O
SPINAL,AdverseReaction
EPIDURAL HEMATOMA,AdverseReaction
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
PRADAXA,O
INCREASES,O
THE,O
RISK,O
OF,O
THROMBOTIC,O
EVENTSPremature,O
discontinuation,O
of,O
any,O
oral,O
anticoagulant,O
including,O
PRADAXA,O
increases,O
the,O
risk,O
of,O
thrombotic,O
events,O
If,O
anticoagulation,O
with,O
PRADAXA,O
is,O
discontinued,O
for,O
a,O
reason,O
other,O
than,O
pathological,O
bleeding,O
or,O
completion,O
of,O
a,O
course,O
of,O
therapy,O
consider,O
coverage,O
with,O
another,O
anticoagulant,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
2,O
5,O
2,O
6,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
B,O
SPINAL,O
EPIDURAL,O
HEMATOMAEpidural,O
or,O
spinal hematomas,AdverseReaction
may,Factor
occur,O
in,O
patients,O
treated,O
with,O
PRADAXA,O
who,O
are,O
receiving,O
neuraxial,O
anesthesia,O
or,O
undergoing,O
spinal,O
puncture,O
These,O
hematomas,AdverseReaction
may,Factor
result,O
in,O
long term,AdverseReaction
or,O
permanent paralysis,AdverseReaction
Consider,O
these,O
risks,O
when,O
scheduling,O
patients,O
for,O
spinal,O
procedures,O
Factors,O
that,O
can,O
increase,O
the,O
risk,O
of,O
developing,O
epidural,O
or,O
spinal,O
hematomas,O
in,O
these,O
patients,O
include,O
use,O
of,O
indwelling,O
epidural,O
catheters,O
concomitant,O
use,O
of,O
other,O
drugs,O
that,O
affect,O
hemostasis,O
such,O
as,O
non,O
steroidal,O
anti,O
inflammatory,O
drugs,O
NSAIDs,O
platelet,O
inhibitors,O
other,O
anticoagulants,O
a,O
history,O
of,O
traumatic,O
or,O
repeated,O
epidural,O
or,O
spinal,O
punctures,O
a,O
history,O
of,O
spinal,O
deformity,O
or,O
spinal,O
surgery,O
optimal,O
timing,O
between,O
the,O
administration,O
of,O
PRADAXA,O
and,O
neuraxial,O
procedures,O
is,O
not,O
known,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Monitor,O
patients,O
frequently,O
for,O
signs,O
and,O
symptoms,O
of,O
neurological,O
impairment,O
If,O
neurological,O
compromise,O
is,O
noted,O
urgent,O
treatment,O
is,O
necessary,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Consider,O
the,O
benefits,O
and,O
risks,O
before,O
neuraxial,O
intervention,O
in,O
patients,O
anticoagulated,O
or,O
to,O
be,O
anticoagulated,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
EXCERPT,O
WARNING,O
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
PRADAXA,O
INCREASES,O
THE,O
RISK,O
OF,O
THROMBOTIC,O
EVENTS,O
and,O
B,O
SPINAL,AdverseReaction
EPIDURAL HEMATOMA,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
A,O
PREMATURE,O
DISCONTINUATION,O
OF,O
PRADAXA,O
INCREASES,O
THE,O
RISK,O
OF,O
THROMBOTIC,O
EVENTS,O
Premature,O
discontinuation,O
of,O
any,O
oral,O
anticoagulant,O
including,O
PRADAXA,O
increases,O
the,O
risk,O
of,O
thrombotic,O
events,O
To,O
reduce,O
this,O
risk,O
consider,O
coverage,O
with,O
another,O
anticoagulant,O
if,O
PRADAXA,O
is,O
discontinued,O
for,O
a,O
reason,O
other,O
than,O
pathological,O
bleeding,O
or,O
completion,O
of,O
a,O
course,O
of,O
therapy,O
2,O
4,O
2,O
5,O
2,O
6,O
5,O
1,O
B,O
SPINAL,O
EPIDURAL,O
HEMATOMA,O
Epidural,AdverseReaction
or,O
spinal hematomas,AdverseReaction
may,Factor
occur,O
in,O
patients,O
treated,O
with,O
PRADAXA,O
who,O
are,O
receiving,O
neuraxial,O
anesthesia,O
or,O
undergoing,O
spinal,O
puncture,O
These,O
hematomas,AdverseReaction
may,Factor
result,O
in,O
long term,AdverseReaction
or,O
permanent paralysis,AdverseReaction
5,O
3,O
Monitor,O
patients,O
frequently,O
for,O
signs,O
and,O
symptoms,O
of,O
neurological,O
impairment,O
and,O
if,O
observed,O
treat,O
urgently,O
Consider,O
the,O
benefits,O
and,O
risks,O
before,O
neuraxial,O
intervention,O
in,O
patients,O
who,O
are,O
or,O
who,O
need,O
to,O
be,O
anticoagulated,O
5,O
3,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
most,O
serious,O
adverse,O
reactions,O
reported,O
with,O
PRADAXA,O
were,O
related,O
to,O
bleeding,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
15,O
are,O
gastritis,AdverseReaction
like,O
symptoms,O
and,O
bleeding,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Boehringer,O
Ingelheim,O
Pharmaceuticals,O
Inc,O
at,O
800,O
542,O
6257,O
or,O
800,O
459,O
9906,O
TTY,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reactions,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Reduction,O
of,O
Risk,O
of,O
Stroke,O
and,O
Systemic,O
Embolism,O
in,O
Non,O
valvular,O
Atrial,O
Fibrillation,O
The,O
RE,O
LY,O
Randomized,O
Evaluation,O
of,O
Long,O
term,O
Anticoagulant,O
Therapy,O
study,O
provided,O
safety,O
information,O
on,O
the,O
use,O
of,O
two,O
doses,O
of,O
PRADAXA,O
and,O
warfarin,O
see,O
Clinical,O
Studies,O
14,O
1,O
The,O
numbers,O
of,O
patients,O
and,O
their,O
exposures,O
are,O
described,O
in,O
Table,O
1,O
Limited,O
information,O
is,O
presented,O
on,O
the,O
110,O
mg,O
dosing,O
arm,O
because,O
this,O
dose,O
is,O
not,O
approved,O
Table,O
1,O
Summary,O
of,O
Treatment,O
Exposure,O
in,O
RE,O
LY,O
PRADAXA,O
110,O
mg,O
twice,O
daily,O
PRADAXA,O
150,O
mg,O
twice,O
daily,O
Warfarin,O
Total,O
number,O
treated,O
5983,O
6059,O
5998,O
Exposure,O
12,O
months,O
4936,O
4939,O
5193,O
24,O
months,O
2387,O
2405,O
2470,O
Mean,O
exposure,O
months,O
20,O
5,O
20,O
3,O
21,O
3,O
Total,O
patient,O
years,O
10,O
242,O
10,O
261,O
10,O
659,O
Drug,O
Discontinuation,O
in,O
RE,O
LY,O
The,O
rates,O
of,O
adverse,O
reactions,O
leading,O
to,O
treatment,O
discontinuation,O
were,O
21,O
for,O
PRADAXA,O
150,O
mg,O
and,O
16,O
for,O
warfarin,O
The,O
most,O
frequent,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
of,O
PRADAXA,O
were,O
bleeding,AdverseReaction
and,O
gastrointestinal events,AdverseReaction
i,O
e,O
dyspepsia,AdverseReaction
nausea,AdverseReaction
upper abdominal pain,AdverseReaction
gastrointestinal hemorrhage,AdverseReaction
and,O
diarrhea,AdverseReaction
Bleeding,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Table,O
2,O
shows,O
the,O
number,O
of,O
adjudicated,O
major,Severity
bleeding,AdverseReaction
events,O
during,O
the,O
treatment,O
period,O
in,O
the,O
RE,O
LY,O
study,O
with,O
the,O
bleeding,AdverseReaction
rate,O
per,O
100,O
subject,O
years,O
Major,Severity
bleeding,AdverseReaction
is,O
defined,O
as,O
bleeding,AdverseReaction
accompanied,O
by,O
one,O
or,O
more,O
of,O
the,O
following,O
a,O
decrease in hemoglobin,AdverseReaction
of,O
2 g dL,Severity
a,O
transfusion,O
of,O
2,O
units,O
of,O
packed,O
red,O
blood,O
cells,O
bleeding at a critical site,AdverseReaction
or,O
with,O
a,O
fatal,AdverseReaction
outcome,O
Intracranial hemorrhage,AdverseReaction
included,O
intracerebral,AdverseReaction
hemorrhagic stroke,AdverseReaction
subarachnoid,AdverseReaction
and,O
subdural bleeds,AdverseReaction
Table,O
2,O
Adjudicated,O
Major,Severity
Bleeding,AdverseReaction
Events,O
in,O
Treated,O
Patientsa,O
aPatients,O
during,O
treatment,O
or,O
within,O
2,O
days,O
of,O
stopping,O
study,O
treatment,O
Major,Severity
bleeding,AdverseReaction
events,O
within,O
each,O
subcategory,O
were,O
counted,O
once,O
per,O
patient,O
but,O
patients,O
may,O
have,O
contributed,O
events,O
to,O
multiple,O
subcategories,O
bAnnual,O
event,O
rate,O
per,O
100,O
pt,O
years,O
100,O
number,O
of,O
subjects,O
with,O
event,O
subject,O
years,O
Subject,O
years,O
is,O
defined,O
as,O
cumulative,O
number,O
of,O
days,O
from,O
first,O
drug,O
intake,O
to,O
event,O
date,O
date,O
of,O
last,O
drug,O
intake,O
2,O
death,O
date,O
whatever,O
occurred,O
first,O
across,O
all,O
treated,O
subjects,O
divided,O
by,O
365,O
25,O
In,O
case,O
of,O
recurrent,O
events,O
of,O
the,O
same,O
category,O
the,O
first,O
event,O
was,O
considered,O
cDefined,O
as,O
bleeding,AdverseReaction
accompanied,O
by,O
one,O
or,O
more,O
of,O
the,O
following,O
a,O
decrease in hemoglobin,AdverseReaction
of,O
2 g dL,Severity
a,O
transfusion,O
of,O
2,O
or,O
more,O
units,O
of,O
packed,O
red,O
blood,O
cells,O
bleeding at a critical site,AdverseReaction
or,O
with,O
fatal,AdverseReaction
outcome,O
dIntracranial,O
bleed,O
included,O
intracerebral,AdverseReaction
hemorrhagic stroke,AdverseReaction
subarachnoid,AdverseReaction
and,O
subdural bleeds,AdverseReaction
eOn,O
treatment,O
analysis,O
based,O
on,O
the,O
safety,O
population,O
compared,O
to,O
ITT,O
analysis,O
presented,O
in,O
Section,O
14,O
Clinical,O
Studies,O
fFatal,O
bleed,AdverseReaction
Adjudicated,O
major,Severity
bleed,AdverseReaction
as,O
defined,O
above,O
with,O
investigator,O
reported,O
fatal,AdverseReaction
outcome,O
and,O
adjudicated,O
death,AdverseReaction
with,O
primary,O
cause,O
from,O
bleeding,AdverseReaction
gNon,O
intracranial,O
fatal,AdverseReaction
bleed,AdverseReaction
Adjudicated,O
major,Severity
bleed,AdverseReaction
as,O
defined,O
above,O
and,O
adjudicated,O
death,AdverseReaction
with,O
primary,O
cause,O
from,O
bleeding,AdverseReaction
but,O
without,Negation
symptomatic intracranial bleed,AdverseReaction
based,O
on,O
investigator,O
s,O
clinical,O
assessment,O
Event,O
PRADAXA,O
150,O
mgN,O
6059n,O
year,O
b,O
WarfarinN,O
5998n,O
year,O
b,O
PRADAXA,O
150,O
mgvs,O
WarfarinHR,O
95,O
CI,O
Major,Severity
Bleeding,AdverseReaction
c,O
350,O
3,O
47,O
374,O
3,O
58,O
0,O
97,O
0,O
84,O
1,O
12,O
Intracranial Hemorrhage,AdverseReaction
ICH,AdverseReaction
d,O
23,O
0,O
22,O
82,O
0,O
77,O
0,O
29,O
0,O
18,O
0,O
46,O
Hemorrhagic Stroke,AdverseReaction
e,O
6,O
0,O
06,O
40,O
0,O
37,O
0,O
16,O
0,O
07,O
0,O
37,O
Other,O
ICH,AdverseReaction
17,O
0,O
17,O
46,O
0,O
43,O
0,O
38,O
0,O
22,O
0,O
67,O
Gastrointestinal,O
162,O
1,O
59,O
111,O
1,O
05,O
1,O
51,O
1,O
19,O
1,O
92,O
Fatal,AdverseReaction
Bleeding,AdverseReaction
f,O
7,O
0,O
07,O
16,O
0,O
15,O
0,O
45,O
0,O
19,O
1,O
10,O
ICH,AdverseReaction
3,O
0,O
03,O
9,O
0,O
08,O
0,O
35,O
0,O
09,O
1,O
28,O
Non,O
intracranial,O
g,O
4,O
0,O
04,O
7,O
0,O
07,O
0,O
59,O
0,O
17,O
2,O
02,O
There,O
was,O
a,O
higher,O
rate,O
of,O
any,O
gastrointestinal bleeds,AdverseReaction
in,O
patients,O
receiving,O
PRADAXA,O
150,O
mg,O
than,O
in,O
patients,O
receiving,O
warfarin,O
6,O
6,O
vs,O
4,O
2,O
respectively,O
The,O
risk,Factor
of,O
major,Severity
bleeds,AdverseReaction
was,O
similar,O
with,O
PRADAXA,O
150,O
mg,O
and,O
warfarin,O
across,O
major,O
subgroups,O
defined,O
by,O
baseline,O
characteristics,O
see,O
Figure,O
1,O
with,O
the,O
exception,O
of,O
age,O
where,O
there,O
was,O
a,O
trend,O
towards,O
a,O
higher,O
incidence,O
of,O
major,Severity
bleeding,AdverseReaction
on,O
PRADAXA,O
hazard,O
ratio,O
1,O
2,O
95,O
CI,O
1,O
0,O
to,O
1,O
5,O
for,O
patients,O
75,O
years,O
of,O
age,O
Figure,O
1,O
Adjudicated,O
Major,Severity
Bleeding,AdverseReaction
by,O
Baseline,O
Characteristics,O
Including,O
Hemorrhagic,O
Stroke,O
Treated,O
Patients,O
Note,O
The,O
figure,O
above,O
presents,O
effects,O
in,O
various,O
subgroups,O
all,O
of,O
which,O
are,O
baseline,O
characteristics,O
and,O
all,O
of,O
which,O
were,O
pre,O
specified,O
The,O
95,O
confidence,O
limits,O
that,O
are,O
shown,O
do,O
not,O
take,O
into,O
account,O
how,O
many,O
comparisons,O
were,O
made,O
nor,O
do,O
they,O
reflect,O
the,O
effect,O
of,O
a,O
particular,O
factor,O
after,O
adjustment,O
for,O
all,O
other,O
factors,O
Apparent,O
homogeneity,O
or,O
heterogeneity,O
among,O
groups,O
should,O
not,O
be,O
over,O
interpreted,O
Figure,O
1,O
Gastrointestinal,O
Adverse,O
Reactions,O
Patients,O
on,O
PRADAXA,O
150,O
mg,O
had,O
an,O
increased,O
incidence,O
of,O
gastrointestinal adverse reactions,AdverseReaction
35,O
vs,O
24,O
on,O
warfarin,O
These,O
were,O
commonly,O
dyspepsia,AdverseReaction
including,O
abdominal pain upper,AdverseReaction
abdominal pain,AdverseReaction
abdominal discomfort,AdverseReaction
and,O
epigastric discomfort,AdverseReaction
and,O
gastritis,AdverseReaction
like,O
symptoms,O
including,O
GERD,AdverseReaction
esophagitis,AdverseReaction
erosive gastritis,AdverseReaction
gastric hemorrhage,AdverseReaction
hemorrhagic gastritis,AdverseReaction
hemorrhagic erosive gastritis,AdverseReaction
and,O
gastrointestinal ulcer,AdverseReaction
Hypersensitivity,O
Reactions,O
In,O
the,O
RE,O
LY,O
study,O
drug,O
hypersensitivity,AdverseReaction
including,O
urticaria,AdverseReaction
rash,AdverseReaction
and,O
pruritus,AdverseReaction
allergic edema,AdverseReaction
anaphylactic reaction,AdverseReaction
and,O
anaphylactic shock,AdverseReaction
were,O
reported,O
in,O
0,O
1,O
of,O
patients,O
receiving,O
PRADAXA,O
Treatment,O
and,O
Reduction,O
in,O
the,O
Risk,O
of,O
Recurrence,O
of,O
Deep,O
Venous,O
Thrombosis,O
and,O
Pulmonary,O
Embolism,O
PRADAXA,O
was,O
studied,O
in,O
4387,O
patients,O
in,O
4,O
pivotal,O
parallel,O
randomized,O
double,O
blind,O
trials,O
Three,O
of,O
these,O
trials,O
were,O
active,O
controlled,O
warfarin,O
RE,O
COVER,O
RE,O
COVER,O
II,O
and,O
RE,O
MEDY,O
and,O
one,O
study,O
RE,O
SONATE,O
was,O
placebo,O
controlled,O
The,O
demographic,O
characteristics,O
were,O
similar,O
among,O
the,O
4,O
pivotal,O
studies,O
and,O
between,O
the,O
treatment,O
groups,O
within,O
these,O
studies,O
Approximately,O
60,O
of,O
the,O
treated,O
patients,O
were,O
male,O
with,O
a,O
mean,O
age,O
of,O
55,O
1,O
years,O
The,O
majority,O
of,O
the,O
patients,O
were,O
white,O
87,O
7,O
10,O
3,O
were,O
Asian,O
and,O
1,O
9,O
were,O
black,O
with,O
a,O
mean,O
CrCl,O
of,O
105,O
6,O
mL,O
min,O
Bleeding,AdverseReaction
events,O
for,O
the,O
4,O
pivotal,O
studies,O
were,O
classified,O
as,O
major,Severity
bleeding,AdverseReaction
events,O
if,O
at,O
least,O
one,O
of,O
the,O
following,O
criteria,O
applied,O
fatal,AdverseReaction
bleeding,AdverseReaction
symptomatic bleeding in a critical area bleeding in a critical,AdverseReaction
bleeding,AdverseReaction
or,O
organ,AdverseReaction
intraocular,AdverseReaction
intracranial,AdverseReaction
intraspinal,AdverseReaction
or,O
intramuscular,AdverseReaction
with,O
compartment syndrome,AdverseReaction
retroperitoneal bleeding,AdverseReaction
intra articular bleeding,AdverseReaction
or,O
pericardial bleeding,AdverseReaction
bleeding,AdverseReaction
causing,O
a,O
fall in hemoglobin level,AdverseReaction
of,O
2 0 g dL,Severity
1,O
24,O
mmol,O
L,O
or,O
more,O
or,O
leading,O
to,O
transfusion,O
of,O
2,O
or,O
more,O
units,O
of,O
whole,O
blood,O
or,O
red,O
cells,O
RE,O
COVER,O
and,O
RE,O
COVER,O
II,O
studies,O
compared,O
PRADAXA,O
150,O
mg,O
twice,O
daily,O
and,O
warfarin,O
for,O
the,O
treatment,O
of,O
deep,O
vein,O
thrombosis,O
and,O
pulmonary,O
embolism,O
Patients,O
received,O
5,O
10,O
days,O
of,O
an,O
approved,O
parenteral,O
anticoagulant,O
therapy,O
followed,O
by,O
6,O
months,O
with,O
mean,O
exposure,O
of,O
164,O
days,O
of,O
oral,O
only,O
treatment,O
warfarin,O
was,O
overlapped,O
with,O
parenteral,O
therapy,O
Table,O
3,O
shows,O
the,O
number,O
of,O
patients,O
experiencing,O
bleeding,AdverseReaction
events,O
in,O
the,O
pooled,O
analysis,O
of,O
RE,O
COVER,O
and,O
RE,O
COVER,O
II,O
studies,O
during,O
the,O
full,O
treatment,O
including,O
parenteral,O
and,O
oral,O
only,O
treatment,O
periods,O
after,O
randomization,O
Table,O
3,O
Bleeding,AdverseReaction
Events,O
in,O
RE,O
COVER,O
and,O
RE,O
COVER,O
II,O
Treated,O
Patients,O
Note,O
MBE,AdverseReaction
can,O
belong,O
to,O
more,O
than,O
one,O
criterion,O
a,O
Patients,O
with,O
at,O
least,O
one,O
MBE,AdverseReaction
b,O
Bleeding,AdverseReaction
site,O
based,O
on,O
investigator,O
assessment,O
Patients,O
can,O
have,O
more,O
than,O
one,O
site,O
of,O
bleeding,AdverseReaction
c,O
Confidence,O
interval,O
Patients,O
Major,Severity
bleeding,AdverseReaction
event,O
a,O
Bleeding,AdverseReaction
sites,O
for,O
MBE,AdverseReaction
b,O
Clinically,O
relevant,O
non major,Severity
bleeding,AdverseReaction
Any,O
bleeding,AdverseReaction
The,O
rate,O
of,O
any,O
gastrointestinal bleeds,AdverseReaction
in,O
patients,O
receiving,O
PRADAXA,O
150,O
mg,O
in,O
the,O
full,O
treatment,O
period,O
was,O
3,O
1,O
2,O
4,O
on,O
warfarin,O
The,O
RE,O
MEDY,O
and,O
RE,O
SONATE,O
studies,O
provided,O
safety,O
information,O
on,O
the,O
use,O
of,O
PRADAXA,O
for,O
the,O
reduction,O
in,O
the,O
risk,O
of,O
recurrence,O
of,O
deep,O
vein,O
thrombosis,O
and,O
pulmonary,O
embolism,O
RE,O
MEDY,O
was,O
an,O
active,O
controlled,O
study,O
warfarin,O
in,O
which,O
1430,O
patients,O
received,O
PRADAXA,O
150,O
mg,O
twice,O
daily,O
following,O
3,O
to,O
12,O
months,O
of,O
oral,O
anticoagulant,O
regimen,O
Patients,O
in,O
the,O
treatment,O
studies,O
who,O
rolled,O
over,O
into,O
the,O
RE,O
MEDY,O
study,O
had,O
a,O
combined,O
treatment,O
duration,O
of,O
up,O
to,O
more,O
than,O
3,O
years,O
with,O
mean,O
exposure,O
of,O
473,O
days,O
Table,O
4,O
shows,O
the,O
number,O
of,O
patients,O
experiencing,O
bleeding,AdverseReaction
events,O
in,O
the,O
study,O
Table,O
4,O
Bleeding,AdverseReaction
Events,O
in,O
RE,O
MEDY,O
Treated,O
Patients,O
Note,O
MBE,AdverseReaction
can,O
belong,O
to,O
more,O
than,O
one,O
criterion,O
a,O
Patients,O
with,O
at,O
least,O
one,O
MBE,AdverseReaction
b,O
Bleeding,AdverseReaction
site,O
based,O
on,O
investigator,O
assessment,O
Patients,O
can,O
have,O
more,O
than,O
one,O
site,O
of,O
bleeding,AdverseReaction
c,O
Confidence,O
interval,O
Patients,O
Major,Severity
bleeding,AdverseReaction
event,O
a,O
Bleeding,AdverseReaction
sites,O
for,O
MBE,AdverseReaction
b,O
Clinically,O
relevant,O
non major,Severity
bleeding,AdverseReaction
Any,O
bleeding,AdverseReaction
In,O
the,O
RE,O
MEDY,O
study,O
the,O
rate,O
of,O
any,O
gastrointestinal bleeds,AdverseReaction
in,O
patients,O
receiving,O
PRADAXA,O
150,O
mg,O
was,O
3,O
1,O
2,O
2,O
on,O
warfarin,O
RE,O
SONATE,O
was,O
a,O
placebo,O
controlled,O
study,O
in,O
which,O
684,O
patients,O
received,O
PRADAXA,O
150,O
mg,O
twice,O
daily,O
following,O
6,O
to,O
18,O
months,O
of,O
oral,O
anticoagulant,O
regimen,O
Patients,O
in,O
the,O
treatment,O
studies,O
who,O
rolled,O
over,O
into,O
the,O
RE,O
SONATE,O
study,O
had,O
combined,O
treatment,O
duration,O
up,O
to,O
9,O
months,O
with,O
mean,O
exposure,O
of,O
165,O
days,O
Table,O
5,O
shows,O
the,O
number,O
of,O
patients,O
experiencing,O
bleeding,AdverseReaction
events,O
in,O
the,O
study,O
Table,O
5,O
Bleeding,AdverseReaction
Events,O
in,O
RE,O
SONATE,O
Treated,O
Patients,O
Note,O
MBE,AdverseReaction
can,O
belong,O
to,O
more,O
than,O
one,O
criterion,O
a,O
Patients,O
with,O
at,O
least,O
one,O
MBE,AdverseReaction
b,O
Bleeding,AdverseReaction
site,O
based,O
on,O
investigator,O
assessment,O
Patients,O
can,O
have,O
more,O
than,O
one,O
site,O
of,O
bleeding,AdverseReaction
c,O
Confidence,O
interval,O
Patients,O
Major,Severity
bleeding,AdverseReaction
event,O
a,O
Clinically,O
relevant,O
non major,Severity
bleeding,AdverseReaction
Any,O
bleeding,AdverseReaction
In,O
the,O
RE,O
SONATE,O
study,O
the,O
rate,O
of,O
any,O
gastrointestinal bleeds,AdverseReaction
in,O
patients,O
receiving,O
PRADAXA,O
150,O
mg,O
was,O
0,O
7,O
0,O
3,O
on,O
placebo,O
Clinical,O
Myocardial,O
Infarction,O
Events,O
In,O
the,O
active,O
controlled,O
VTE,O
studies,O
a,O
higher,O
rate,O
of,O
clinical,O
myocardial infarction,AdverseReaction
was,O
reported,O
in,O
patients,O
who,O
received,O
PRADAXA,O
20,O
0,O
66,O
per,O
100,O
patient,O
years,O
than,O
in,O
those,O
who,O
received,O
warfarin,O
5,O
0,O
17,O
per,O
100,O
patient,O
years,O
In,O
the,O
placebo,O
controlled,O
study,O
a,O
similar,O
rate,O
of,O
non fatal,Severity
and,O
fatal,AdverseReaction
clinical,O
myocardial infarction infarction,AdverseReaction
was,O
reported,O
in,O
patients,O
who,O
received,O
PRADAXA,O
1,O
0,O
32,O
per,O
100,O
patient,O
years,O
and,O
in,O
those,O
who,O
received,O
placebo,O
1,O
0,O
34,O
per,O
100,O
patient,O
years,O
Gastrointestinal,O
Adverse,O
Reactions,O
In,O
the,O
four,O
pivotal,O
studies,O
patients,O
on,O
PRADAXA,O
150,O
mg,O
had,O
a,O
similar,O
incidence,O
of,O
gastrointestinal adverse reactions,AdverseReaction
24,O
7,O
vs,O
22,O
7,O
on,O
warfarin,O
Dyspepsia,AdverseReaction
including,O
abdominal pain upper,AdverseReaction
abdominal pain,AdverseReaction
abdominal discomfort,AdverseReaction
and,O
epigastric discomfort,AdverseReaction
occurred,O
in,O
patients,O
on,O
PRADAXA,O
in,O
7,O
5,O
vs,O
5,O
5,O
on,O
warfarin,O
and,O
gastritis,AdverseReaction
like,O
symptoms,O
including,O
gastritis,AdverseReaction
GERD,AdverseReaction
esophagitis,AdverseReaction
erosive gastritis,AdverseReaction
and,O
gastric hemorrhage,AdverseReaction
occurred,O
at,O
3,O
0,O
vs,O
1,O
7,O
respectively,O
Hypersensitivity,O
Reactions,O
In,O
the,O
4,O
pivotal,O
studies,O
drug,O
hypersensitivity,AdverseReaction
including,O
urticaria,AdverseReaction
rash,AdverseReaction
and,O
pruritus,AdverseReaction
allergic edema,AdverseReaction
anaphylactic reaction,AdverseReaction
and,O
anaphylactic shock,AdverseReaction
were,O
reported,O
in,O
0,O
1,O
of,O
patients,O
receiving,O
PRADAXA,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
PRADAXA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
PRADAXA,O
angioedema,AdverseReaction
thrombocytopenia,AdverseReaction
esophageal ulcer,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Clinical Worsening,AdverseReaction
Suicide Risk,AdverseReaction
Monitor,O
for,O
clinical,O
worsening,O
and,O
suicide,O
risk,O
5,O
1,O
Serotonin Syndrome,AdverseReaction
Serotonin syndrome,AdverseReaction
has,O
been,O
reported,O
with,O
SSRIs,O
and,O
SNRIs,O
including,O
with,O
PRISTIQ,O
both,O
when,O
taken,O
alone,O
but,O
especially,O
when,O
co,O
administered,O
with,O
other,O
serotonergic,O
agents,O
including,O
triptans,O
tricyclic,O
antidepressants,O
fentanyl,O
lithium,O
tramadol,O
tryptophan,O
buspirone,O
and,O
St,O
John,O
s,O
Wort,O
If,O
such,O
symptoms,O
occur,O
discontinue,O
PRISTIQ,O
and,O
initiate,O
supportive,O
treatment,O
If,O
concomitant,O
use,O
of,O
PRISTIQ,O
with,O
other,O
serotonergic,O
drugs,O
is,O
clinically,O
warranted,O
patients,O
should,O
be,O
made,O
aware,O
of,O
a,O
potential,O
increased,O
risk,O
for,O
serotonin,O
syndrome,O
particularly,O
during,O
treatment,O
initiation,O
and,O
dose,O
increases,O
5,O
2,O
Elevated Blood Pressure,AdverseReaction
Control,O
hypertension,O
before,O
initiating,O
treatment,O
Monitor,O
blood,O
pressure,O
regularly,O
during,O
treatment,O
5,O
3,O
Abnormal Bleeding,AdverseReaction
PRISTIQ,O
may,Factor
increase,O
risk,O
of,O
bleeding,AdverseReaction
events,O
Caution,O
patients,O
about,O
risk,O
of,O
bleeding,O
associated,O
with,O
concomitant,O
use,O
of,O
PRISTIQ,O
and,O
NSAIDs,O
aspirin,O
or,O
other,O
drugs,O
that,O
affect,O
coagulation,O
5,O
4,O
Angle Closure Glaucoma,AdverseReaction
Angle closure glaucoma,AdverseReaction
has,O
occurred,O
in,O
patients,O
with,O
untreated,O
anatomically,O
narrow,O
angles,O
treated,O
with,O
antidepressants,DrugClass
5,O
5,O
Activation of Mania of,AdverseReaction
Hypomania,AdverseReaction
Use,O
cautiously,O
in,O
patients,O
with,O
Bipolar,O
Disorder,O
Caution,O
patients,O
about,O
risk,O
of,O
activation,O
of,O
mania,O
hypomania,O
5,O
6,O
Discontinuation Syndrome,AdverseReaction
Taper,O
dose,O
when,O
possible,O
and,O
monitor,O
for,O
discontinuation,O
symptoms,O
5,O
7,O
Seizure,AdverseReaction
Can,O
occur,O
Use,O
cautiously,O
in,O
patients,O
with,O
seizure,O
disorder,O
5,O
8,O
Hyponatremia,AdverseReaction
Can,O
occur,O
in,O
association,O
with,O
SIADH,O
5,O
9,O
Interstitial Lung Disease,AdverseReaction
and,O
Eosinophilic Pneumonia,AdverseReaction
Can,O
occur,O
5,O
10,O
5,O
1,O
Suicidal,O
Thoughts,O
and,O
Behaviors,O
in,O
Children,O
Adolescents,O
and,O
Young,O
Adults,O
Patients,O
with,O
major,O
depressive,O
disorder,O
MDD,O
both,O
adult,O
and,O
pediatric,O
may,O
experience,O
worsening,O
of,O
their,O
depression,O
and,O
or,O
the,O
emergence,O
of,O
suicidal,O
ideation,O
and,O
behavior,O
suicidality,O
or,O
unusual,O
changes,O
in,O
behavior,O
whether,O
or,O
not,O
they,O
are,O
taking,O
antidepressant,O
medications,O
and,O
this,O
risk,O
may,O
persist,O
until,O
significant,O
remission,O
occurs,O
Suicide,O
is,O
a,O
known,O
risk,O
of,O
depression,O
and,O
certain,O
other,O
psychiatric,O
disorders,O
and,O
these,O
disorders,O
themselves,O
are,O
the,O
strongest,O
predictors,O
of,O
suicide,O
There,O
has,O
been,O
a,O
long,O
standing,O
concern,O
however,O
that,O
antidepressants,DrugClass
may,O
have,O
a,O
role,O
in,O
inducing,O
worsening of depression,AdverseReaction
and,O
the,O
emergence,O
of,O
suicidality,AdverseReaction
in,O
certain,O
patients,O
during,O
the,O
early,O
phases,O
of,O
treatment,O
Pooled,O
analyses,O
of,O
short,O
term,O
placebo,O
controlled,O
studies,O
of,O
antidepressant drugs,DrugClass
SSRIs,O
and,O
others,O
showed,O
that,O
these,O
drugs,O
increase,O
the,O
risk,O
of,O
suicidal thinking,AdverseReaction
and,O
behavior,AdverseReaction
suicidality,AdverseReaction
in,O
children,O
adolescents,O
and,O
young,O
adults,O
ages,O
18,O
to,O
24,O
with,O
major,O
depressive,O
disorder,O
MDD,O
and,O
other,O
psychiatric,O
disorders,O
Short,O
term,O
studies,O
did,O
not,Negation
show,O
an,O
increase,O
in,O
the,O
risk,O
of,O
suicidality,AdverseReaction
with,O
antidepressants,O
compared,O
to,O
placebo,O
in,O
adults,O
beyond,O
age,O
24,O
there,O
was,O
a,O
reduction,O
with,O
antidepressants,O
compared,O
to,O
placebo,O
in,O
adults,O
aged,O
65,O
and,O
older,O
The,O
pooled,O
analyses,O
of,O
placebo,O
controlled,O
studies,O
in,O
children,O
and,O
adolescents,O
with,O
MDD,O
obsessive,O
compulsive,O
disorder,O
OCD,O
or,O
other,O
psychiatric,O
disorders,O
included,O
a,O
total,O
of,O
24,O
short,O
term,O
studies,O
of,O
9,O
antidepressant,O
drugs,O
in,O
over,O
4,O
400,O
patients,O
The,O
pooled,O
analyses,O
of,O
placebo,O
controlled,O
studies,O
in,O
adults,O
with,O
MDD,O
or,O
other,O
psychiatric,O
disorders,O
included,O
a,O
total,O
of,O
295,O
short,O
term,O
studies,O
median,O
duration,O
of,O
2,O
months,O
of,O
11,O
antidepressant,O
drugs,O
in,O
over,O
77,O
000,O
patients,O
There,O
was,O
considerable,O
variation,O
in,O
risk,O
of,O
suicidality,AdverseReaction
among,O
drugs,DrugClass
but,O
a,O
tendency,O
toward,O
an,O
increase,O
in,O
the,O
younger,O
patients,O
for,O
almost,O
all,O
drugs,O
studied,O
There,O
were,O
differences,O
in,O
absolute,O
risk,O
of,O
suicidality,AdverseReaction
across,O
the,O
different,O
indications,O
with,O
the,O
highest,O
incidence,O
in,O
MDD,O
The,O
risk,O
differences,O
drug,O
vs,O
placebo,O
however,O
were,O
relatively,O
stable,O
within,O
age,O
strata,O
and,O
across,O
indications,O
These,O
risk,O
differences,O
drug,O
placebo,O
difference,O
in,O
the,O
number,O
of,O
cases,O
of,O
suicidality,AdverseReaction
per,O
1,O
000,O
patients,O
treated,O
are,O
provided,O
in,O
Table,O
1,O
Table,O
1,O
Age,O
Range,O
Drug,O
Placebo,O
Difference,O
in,O
Number,O
of,O
Cases,O
of,O
Suicidality,AdverseReaction
per,O
1,O
000,O
Patients,O
Treated,O
Increases,O
Compared,O
to,O
Placebo,O
18,O
14,O
additional,O
cases,O
18,O
to,O
24,O
5,O
additional,O
cases,O
Decreases,O
Compared,O
to,O
Placebo,O
25,O
to,O
64,O
1,O
fewer,O
case,O
65,O
6,O
fewer,O
cases,O
No,Negation
suicides,AdverseReaction
occurred,O
in,O
any,O
of,O
the,O
pediatric,O
studies,O
There,O
were,O
suicides,AdverseReaction
in,O
the,O
adult,O
studies,O
but,O
the,O
number,O
was,O
not,O
sufficient,O
to,O
reach,O
any,O
conclusion,O
about,O
drug,O
effect,O
on,O
suicide,O
It,O
is,O
unknown,O
whether,O
the,O
suicidality,AdverseReaction
risk,Factor
extends,O
to,O
longer,O
term,O
use,O
i,O
e,O
beyond,O
several,O
months,O
However,O
there,O
is,O
substantial,O
evidence,O
from,O
placebo,O
controlled,O
maintenance,O
studies,O
in,O
adults,O
with,O
depression,O
that,O
the,O
use,O
of,O
antidepressants,O
can,O
delay,O
the,O
recurrence,O
of,O
depression,O
All,O
patients,O
being,O
treated,O
with,O
antidepressants,O
for,O
any,O
indication,O
should,O
be,O
monitored,O
appropriately,O
and,O
observed,O
closely,O
for,O
clinical,O
worsening,O
suicidality,O
and,O
unusual,O
changes,O
in,O
behavior,O
especially,O
during,O
the,O
initial,O
few,O
months,O
of,O
a,O
course,O
of,O
drug,O
therapy,O
or,O
at,O
times,O
of,O
dose,O
changes,O
either,O
increases,O
or,O
decreases,O
The,O
following,O
symptoms,O
anxiety,AdverseReaction
agitation,AdverseReaction
panic attacks,AdverseReaction
insomnia,AdverseReaction
irritability,AdverseReaction
hostility,AdverseReaction
aggressiveness,AdverseReaction
impulsivity,AdverseReaction
akathisia,AdverseReaction
psychomotor restlessness,AdverseReaction
hypomania,AdverseReaction
and,O
mania,AdverseReaction
have,O
been,O
reported,O
in,O
adult,O
and,O
pediatric,O
patients,O
being,O
treated,O
with,O
antidepressants,DrugClass
for,O
major,O
depressive,O
disorder,O
as,O
well,O
as,O
for,O
other,O
indications,O
both,O
psychiatric,O
and,O
nonpsychiatric,O
Although,O
a,O
causal,O
link,O
between,O
the,O
emergence,O
of,O
such,O
symptoms,O
and,O
either,O
the,O
worsening of depression,AdverseReaction
and,O
or,O
the,O
emergence,O
of,O
suicidal impulses,AdverseReaction
has,O
not been established,Negation
there,O
is,O
concern,O
that,O
such,O
symptoms,O
may,Factor
represent,O
precursors,O
to,O
emerging,O
suicidality,AdverseReaction
Consideration,O
should,O
be,O
given,O
to,O
changing,O
the,O
therapeutic,O
regimen,O
including,O
possibly,O
discontinuing,O
the,O
medication,O
in,O
patients,O
whose,O
depression,O
is,O
persistently,O
worse,O
or,O
who,O
are,O
experiencing,O
emergent,O
suicidality,O
or,O
symptoms,O
that,O
might,O
be,O
precursors,O
to,O
worsening,O
depression,O
or,O
suicidality,O
especially,O
if,O
these,O
symptoms,O
are,O
severe,O
abrupt,O
in,O
onset,O
or,O
were,O
not,O
part,O
of,O
the,O
patient,O
s,O
presenting,O
symptoms,O
If,O
the,O
decision,O
has,O
been,O
made,O
to,O
discontinue,O
treatment,O
medication,O
should,O
be,O
tapered,O
as,O
rapidly,O
as,O
is,O
feasible,O
but,O
with,O
recognition,O
that,O
abrupt,O
discontinuation,O
can,O
be,O
associated,O
with,O
certain,O
symptoms,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
7,O
for,O
a,O
description,O
of,O
the,O
risks,O
of,O
discontinuation,O
of,O
PRISTIQ,O
Families,O
and,O
caregivers,O
of,O
patients,O
being,O
treated,O
with,O
antidepressants,O
for,O
major,O
depressive,O
disorder,O
or,O
other,O
indications,O
both,O
psychiatric,O
and,O
nonpsychiatric,O
should,O
be,O
alerted,O
about,O
the,O
need,O
to,O
monitor,O
patients,O
for,O
the,O
emergence,O
of,O
agitation,O
irritability,O
unusual,O
changes,O
in,O
behavior,O
and,O
the,O
other,O
symptoms,O
described,O
above,O
as,O
well,O
as,O
the,O
emergence,O
of,O
suicidality,O
and,O
to,O
report,O
such,O
symptoms,O
immediately,O
to,O
healthcare,O
providers,O
Such,O
monitoring,O
should,O
include,O
daily,O
observation,O
by,O
families,O
and,O
caregivers,O
Prescriptions,O
for,O
PRISTIQ,O
should,O
be,O
written,O
for,O
the,O
smallest,O
quantity,O
of,O
tablets,O
consistent,O
with,O
good,O
patient,O
management,O
in,O
order,O
to,O
reduce,O
the,O
risk,O
of,O
overdose,O
Screening,O
patients,O
for,O
bipolar,O
disorder,O
A,O
major,O
depressive,O
episode,O
may,O
be,O
the,O
initial,O
presentation,O
of,O
bipolar,O
disorder,O
It,O
is,O
generally,O
believed,O
though,O
not,O
established,O
in,O
controlled,O
studies,O
that,O
treating,O
such,O
an,O
episode,O
with,O
an,O
antidepressant,DrugClass
alone,O
may,O
increase,O
the,O
likelihood,O
of,O
precipitation of a of a mixed,AdverseReaction
manic episode,AdverseReaction
episode,AdverseReaction
in,O
patients,O
at,O
risk,O
for,O
bipolar,O
disorder,O
Whether,O
any,O
of,O
the,O
symptoms,O
described,O
above,O
represent,O
such,O
a,O
conversion,O
is,O
unknown,O
However,O
prior,O
to,O
initiating,O
treatment,O
with,O
an,O
antidepressant,O
patients,O
with,O
depressive,O
symptoms,O
should,O
be,O
adequately,O
screened,O
to,O
determine,O
if,O
they,O
are,O
at,O
risk,O
for,O
bipolar,O
disorder,O
such,O
screening,O
should,O
include,O
a,O
detailed,O
psychiatric,O
history,O
including,O
a,O
family,O
history,O
of,O
suicide,O
bipolar,O
disorder,O
and,O
depression,O
It,O
should,O
be,O
noted,O
that,O
PRISTIQ,O
is,O
not,O
approved,O
for,O
use,O
in,O
treating,O
bipolar,O
depression,O
5,O
2,O
Serotonin,O
Syndrome,O
The,O
development,O
of,O
a,O
potentially,Factor
life threatening,Severity
serotonin syndrome,AdverseReaction
has,O
been,O
reported,O
with,O
SNRIs,O
and,O
SSRIs,O
including,O
PRISTIQ,O
alone,O
but,O
particularly,O
with,O
concomitant,O
use,O
of,O
other,O
serotonergic,O
drugs,O
including,O
triptans,O
tricyclic,O
antidepressants,O
fentanyl,O
lithium,O
tramadol,O
tryptophan,O
buspirone,O
and,O
St,O
John,O
s,O
Wort,O
and,O
with,O
drugs,O
that,O
impair,O
metabolism,O
of,O
serotonin,O
in,O
particular,O
MAOIs,O
both,O
those,O
intended,O
to,O
treat,O
psychiatric,O
disorders,O
and,O
also,O
others,O
such,O
as,O
linezolid,O
and,O
intravenous,O
methylene,O
blue,O
Serotonin syndrome,AdverseReaction
symptoms,O
may,Factor
include,O
mental status changes,AdverseReaction
e,O
g,O
agitation,AdverseReaction
hallucinations,AdverseReaction
delirium,AdverseReaction
and,O
coma,AdverseReaction
autonomic instability,AdverseReaction
e,O
g,O
tachycardia,AdverseReaction
labile blood pressure,AdverseReaction
dizziness,AdverseReaction
diaphoresis,AdverseReaction
flushing,AdverseReaction
hyperthermia,AdverseReaction
neuromuscular symptoms,AdverseReaction
e,O
g,O
tremor,AdverseReaction
rigidity,AdverseReaction
myoclonus,AdverseReaction
hyperreflexia,AdverseReaction
incoordination,AdverseReaction
seizures,AdverseReaction
and,O
or,O
gastrointestinal symptoms,AdverseReaction
e,O
g,O
nausea,AdverseReaction
vomiting,AdverseReaction
diarrhea,AdverseReaction
Patients,O
should,O
be,O
monitored,O
for,O
the,O
emergence,O
of,O
serotonin,O
syndrome,O
The,O
concomitant,O
use,O
of,O
PRISTIQ,O
with,O
MAOIs,O
intended,O
to,O
treat,O
psychiatric,O
disorders,O
is,O
contraindicated,O
PRISTIQ,O
should,O
also,O
not,O
be,O
started,O
in,O
a,O
patient,O
who,O
is,O
being,O
treated,O
with,O
MAOIs,O
such,O
as,O
linezolid,O
or,O
intravenous,O
methylene,O
blue,O
All,O
reports,O
with,O
methylene,O
blue,O
that,O
provided,O
information,O
on,O
the,O
route,O
of,O
administration,O
involved,O
intravenous,O
administration,O
in,O
the,O
dose,O
range,O
of,O
1,O
mg,O
kg,O
to,O
8,O
mg,O
kg,O
No,O
reports,O
involved,O
the,O
administration,O
of,O
methylene,O
blue,O
by,O
other,O
routes,O
such,O
as,O
oral,O
tablets,O
or,O
local,O
tissue,O
injection,O
or,O
at,O
lower,O
doses,O
There,O
may,O
be,O
circumstances,O
when,O
it,O
is,O
necessary,O
to,O
initiate,O
treatment,O
with,O
a,O
MAOI,O
such,O
as,O
linezolid,O
or,O
intravenous,O
methylene,O
blue,O
in,O
a,O
patient,O
taking,O
PRISTIQ,O
PRISTIQ,O
should,O
be,O
discontinued,O
before,O
initiating,O
treatment,O
with,O
the,O
MAOI,O
see,O
Contraindications,O
4,O
2,O
and,O
Dosage,O
and,O
Administration,O
2,O
6,O
If,O
concomitant,O
use,O
of,O
PRISTIQ,O
with,O
other,O
serotonergic,O
drugs,O
including,O
triptans,O
tricyclic,O
antidepressants,O
fentanyl,O
lithium,O
tramadol,O
buspirone,O
tryptophan,O
and,O
St,O
John,O
s,O
Wort,O
is,O
clinically,O
warranted,O
patients,O
should,O
be,O
made,O
aware,O
of,O
a,O
potential,O
increased,O
risk,O
for,O
serotonin,O
syndrome,O
particularly,O
during,O
treatment,O
initiation,O
and,O
dose,O
increases,O
Treatment,O
with,O
PRISTIQ,O
and,O
any,O
concomitant,O
serotonergic,O
agents,O
should,O
be,O
discontinued,O
immediately,O
if,O
the,O
above,O
events,O
occur,O
and,O
supportive,O
symptomatic,O
treatment,O
should,O
be,O
initiated,O
5,O
3,O
Elevated,O
Blood,O
Pressure,O
Patients,O
receiving,O
PRISTIQ,O
should,O
have,O
regular,O
monitoring,O
of,O
blood,O
pressure,O
since,O
increases in blood pressure,AdverseReaction
were,O
observed,O
in,O
clinical,O
studies,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Pre,O
existing,O
hypertension,O
should,O
be,O
controlled,O
before,O
initiating,O
treatment,O
with,O
PRISTIQ,O
Caution,O
should,O
be,O
exercised,O
in,O
treating,O
patients,O
with,O
pre,O
existing,O
hypertension,O
cardiovascular,O
or,O
cerebrovascular,O
conditions,O
that,O
might,O
be,O
compromised,O
by,O
increases,O
in,O
blood,O
pressure,O
Cases,O
of,O
elevated blood pressure,AdverseReaction
requiring,O
immediate,O
treatment,O
have,O
been,O
reported,O
with,O
PRISTIQ,O
Sustained,Severity
blood pressure increases,AdverseReaction
could,O
have,O
adverse,O
consequences,O
For,O
patients,O
who,O
experience,O
a,O
sustained,O
increase,O
in,O
blood,O
pressure,O
while,O
receiving,O
PRISTIQ,O
either,O
dose,O
reduction,O
or,O
discontinuation,O
should,O
be,O
considered,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
4,O
Abnormal,O
Bleeding,O
SSRIs,O
and,O
SNRIs,O
including,O
PRISTIQ,O
may,O
increase,O
the,O
risk,Factor
of,O
bleeding,AdverseReaction
events,O
Concomitant,O
use,O
of,O
aspirin,O
nonsteroidal,O
anti,O
inflammatory,O
drugs,O
warfarin,O
and,O
other,O
anticoagulants,O
may,O
add,O
to,O
this,O
risk,O
Case,O
reports,O
and,O
epidemiological,O
studies,O
case,O
control,O
and,O
cohort,O
design,O
have,O
demonstrated,O
an,O
association,O
between,O
use,O
of,O
drugs that interfere with serotonin reuptake,DrugClass
and,O
the,O
occurrence,O
of,O
gastrointestinal bleeding,AdverseReaction
Bleeding,AdverseReaction
events,O
related,O
to,O
SSRIs,O
and,O
SNRIs,DrugClass
have,O
ranged,O
from,O
ecchymosis,AdverseReaction
hematoma,AdverseReaction
epistaxis,AdverseReaction
and,O
petechiae,AdverseReaction
to,O
life threatening,Severity
hemorrhages,AdverseReaction
Patients,O
should,O
be,O
cautioned,O
about,O
the,O
risk,O
of,O
bleeding,O
associated,O
with,O
the,O
concomitant,O
use,O
of,O
PRISTIQ,O
and,O
NSAIDs,O
aspirin,O
or,O
other,O
drugs,O
that,O
affect,O
coagulation,O
or,O
bleeding,O
5,O
5,O
Angle,O
Closure,O
Glaucoma,O
Angle Closure Glaucoma,AdverseReaction
The,O
pupillary,O
dilation,O
that,O
occurs,O
following,O
use,O
of,O
many,O
antidepressant,O
drugs,O
including,O
Pristiq,O
may,Factor
trigger,O
an,O
angle closure attack,AdverseReaction
in,O
a,O
patient,O
with,O
anatomically,O
narrow,O
angles,O
who,O
does,O
not,O
have,O
a,O
patent,O
iridectomy,O
5,O
6,O
Activation,O
of,O
Mania,O
Hypomania,O
During,O
all,O
MDD,O
phase,O
2,O
and,O
phase,O
3,O
studies,O
mania,AdverseReaction
was,O
reported,O
for,O
approximately,O
0,O
02,O
of,O
patients,O
treated,O
with,O
PRISTIQ,O
Activation of mania of,AdverseReaction
hypomania,AdverseReaction
has,O
also,O
been,O
reported,O
in,O
a,O
small,O
proportion,O
of,O
patients,O
with,O
major,O
affective,O
disorder,O
who,O
were,O
treated,O
with,O
other,O
marketed,O
antidepressants,DrugClass
As,O
with,O
all,O
antidepressants,O
PRISTIQ,O
should,O
be,O
used,O
cautiously,O
in,O
patients,O
with,O
a,O
history,O
or,O
family,O
history,O
of,O
mania,O
or,O
hypomania,O
5,O
7,O
Discontinuation,O
Syndrome,O
Discontinuation,O
symptoms,O
have,O
been,O
systematically,O
and,O
prospectively,O
evaluated,O
in,O
patients,O
treated,O
with,O
PRISTIQ,O
during,O
clinical,O
studies,O
in,O
Major,O
Depressive,O
Disorder,O
Abrupt,O
discontinuation,O
or,O
dose,O
reduction,O
has,O
been,O
associated,O
with,O
the,O
appearance,O
of,O
new,O
symptoms,O
that,O
include,O
dizziness,AdverseReaction
nausea,AdverseReaction
headache,AdverseReaction
irritability,AdverseReaction
insomnia,AdverseReaction
diarrhea,AdverseReaction
anxiety,AdverseReaction
fatigue,AdverseReaction
abnormal dreams,AdverseReaction
and,O
hyperhidrosis,AdverseReaction
In,O
general,O
discontinuation,O
events,O
occurred,O
more,O
frequently,O
with,O
longer,O
duration,O
of,O
therapy,O
During,O
marketing,O
of,O
SNRIs,O
Serotonin,O
and,O
Norepinephrine,O
Reuptake,O
Inhibitors,O
and,O
SSRIs,O
Selective,O
Serotonin,O
Reuptake,O
Inhibitors,O
there,O
have,O
been,O
spontaneous,O
reports,O
of,O
adverse,O
events,O
occurring,O
upon,O
discontinuation,O
of,O
these,O
drugs,O
particularly,O
when,O
abrupt,O
including,O
the,O
following,O
dysphoric,O
mood,O
irritability,O
agitation,O
dizziness,O
sensory,O
disturbances,O
e,O
g,O
paresthesia,O
such,O
as,O
electric,O
shock,O
sensations,O
anxiety,O
confusion,O
headache,O
lethargy,O
emotional,O
lability,O
insomnia,O
hypomania,O
tinnitus,O
and,O
seizures,O
While,O
these,O
events,O
are,O
generally,O
self,O
limiting,O
there,O
have,O
been,O
reports,O
of,O
serious,O
discontinuation,O
symptoms,O
Patients,O
should,O
be,O
monitored,O
for,O
these,O
symptoms,O
when,O
discontinuing,O
treatment,O
with,O
PRISTIQ,O
A,O
gradual,O
reduction,O
in,O
the,O
dose,O
rather,O
than,O
abrupt,O
cessation,O
is,O
recommended,O
whenever,O
possible,O
If,O
intolerable,O
symptoms,O
occur,O
following,O
a,O
decrease,O
in,O
the,O
dose,O
or,O
upon,O
discontinuation,O
of,O
treatment,O
then,O
resuming,O
the,O
previously,O
prescribed,O
dose,O
may,O
be,O
considered,O
Subsequently,O
the,O
physician,O
may,O
continue,O
decreasing,O
the,O
dose,O
but,O
at,O
a,O
more,O
gradual,O
rate,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
and,O
Adverse,O
Reactions,O
6,O
1,O
5,O
8,O
Seizure,O
Cases,O
of,O
seizure,AdverseReaction
have,O
been,O
reported,O
in,O
pre,O
marketing,O
clinical,O
studies,O
with,O
PRISTIQ,O
PRISTIQ,O
has,O
not,O
been,O
systematically,O
evaluated,O
in,O
patients,O
with,O
a,O
seizure,O
disorder,O
Patients,O
with,O
a,O
history,O
of,O
seizures,O
were,O
excluded,O
from,O
pre,O
marketing,O
clinical,O
studies,O
PRISTIQ,O
should,O
be,O
prescribed,O
with,O
caution,O
in,O
patients,O
with,O
a,O
seizure,O
disorder,O
5,O
9,O
Hyponatremia,O
Hyponatremia,AdverseReaction
may,Factor
occur,O
as,O
a,O
result,O
of,O
treatment,O
with,O
SSRIs,O
and,O
SNRIs,O
including,O
PRISTIQ,O
In,O
many,O
cases,O
this,O
hyponatremia,AdverseReaction
appears,O
to,O
be,O
the,O
result,O
of,O
the,O
syndrome of inappropriate antidiuretic hormone secretion,AdverseReaction
SIADH,AdverseReaction
Cases,O
with,O
serum sodium lower than 110 mmol L,AdverseReaction
have,O
been,O
reported,O
Elderly,O
patients,O
may,O
be,O
at,O
greater,O
risk,O
of,O
developing,O
hyponatremia,AdverseReaction
with,O
SSRIs,O
and,O
SNRIs,DrugClass
Also,O
patients,O
taking,O
diuretics,O
or,O
who,O
are,O
otherwise,O
volume,O
depleted,O
can,O
be,O
at,O
greater,O
risk,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
5,O
and,O
Clinical,O
Pharmacology,O
12,O
6,O
Discontinuation,O
of,O
PRISTIQ,O
should,O
be,O
considered,O
in,O
patients,O
with,O
symptomatic,O
hyponatremia,O
and,O
appropriate,O
medical,O
intervention,O
should,O
be,O
instituted,O
Signs,O
and,O
symptoms,O
of,O
hyponatremia,AdverseReaction
include,O
headache,AdverseReaction
difficulty concentrating,AdverseReaction
memory impairment,AdverseReaction
confusion,AdverseReaction
weakness,AdverseReaction
and,O
unsteadiness,AdverseReaction
which,O
can,Factor
lead,O
to,O
falls,AdverseReaction
Signs,O
and,O
symptoms,O
associated,O
with,O
more,O
severe,O
and,O
or,O
acute,O
cases,O
have,O
included,O
hallucination,AdverseReaction
syncope,AdverseReaction
seizure,AdverseReaction
coma,AdverseReaction
respiratory arrest,AdverseReaction
and,O
death,AdverseReaction
5,O
10,O
Interstitial,O
Lung,O
Disease,O
and,O
Eosinophilic,O
Pneumonia,O
Interstitial lung disease,AdverseReaction
and,O
eosinophilic pneumonia,AdverseReaction
associated,O
with,O
venlafaxine,DrugClass
the,O
parent,O
drug,O
of,O
PRISTIQ,O
therapy,O
have,O
been,O
rarely,O
reported,O
The,O
possibility,O
of,O
these,O
adverse,O
events,O
should,O
be,O
considered,O
in,O
patients,O
treated,O
with,O
PRISTIQ,O
who,O
present,O
with,O
progressive,O
dyspnea,O
cough,O
or,O
chest,O
discomfort,O
Such,O
patients,O
should,O
undergo,O
a,O
prompt,O
medical,O
evaluation,O
and,O
discontinuation,O
of,O
PRISTIQ,O
should,O
be,O
considered,O
""
BOXED,O
WARNING,O
WARNING,O
SUICIDAL THOUGHTS,AdverseReaction
AND,O
BEHAVIORS,AdverseReaction
WARNING,O
SUICIDAL THOUGHTS,AdverseReaction
AND,O
BEHAVIORS,AdverseReaction
Antidepressants,DrugClass
increased,O
the,O
risk,O
of,O
suicidal thoughts,AdverseReaction
and,O
behavior,AdverseReaction
in,O
children,O
adolescents,O
and,O
young,O
adults,O
in,O
short,O
term,O
studies,O
These,O
studies,O
did,O
not,Negation
show,O
an,O
increase,O
in,O
the,O
risk,O
of,O
suicidal thoughts,AdverseReaction
and,O
behavior,AdverseReaction
with,O
antidepressant,O
use,O
in,O
patients,O
over,O
age,O
24,O
there,O
was,O
a,O
reduction,O
in,O
risk,O
with,O
antidepressant,O
use,O
in,O
patients,O
aged,O
65,O
and,O
older,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
In,O
patients,O
of,O
all,O
ages,O
who,O
are,O
started,O
on,O
antidepressant,O
therapy,O
monitor,O
closely,O
for,O
worsening,O
and,O
for,O
emergence,O
of,O
suicidal,O
thoughts,O
and,O
behaviors,O
Advise,O
families,O
and,O
caregivers,O
of,O
the,O
need,O
for,O
close,O
observation,O
and,O
communication,O
with,O
the,O
prescriber,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
PRISTIQ,O
is,O
not,O
approved,O
for,O
use,O
in,O
pediatric,O
patients,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
4,O
EXCERPT,O
WARNING,O
SUICIDAL THOUGHTS,AdverseReaction
AND,O
BEHAVIORS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Increased,O
risk,O
of,O
suicidal thinking,AdverseReaction
and,O
behavior,AdverseReaction
in,O
children,O
adolescents,O
and,O
young,O
adults,O
taking,O
antidepressants,DrugClass
5,O
1,O
Monitor,O
for,O
worsening,O
and,O
emergence,O
of,O
suicidal,O
thoughts,O
and,O
behaviors,O
5,O
1,O
PRISTIQ,O
is,O
not,O
approved,O
for,O
use,O
in,O
pediatric,O
patients,O
8,O
4,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
label,O
Hypersensitivity,AdverseReaction
see,O
Contraindications,O
4,O
Suicidal Thoughts,AdverseReaction
and,O
Behaviors,AdverseReaction
in,O
Adolescents,O
and,O
Young,O
Adults,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Serotonin Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Elevated Blood Pressure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Abnormal Bleeding,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Angle Closure Glaucoma,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Activation,O
of,O
Mania,AdverseReaction
Hypomania,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Discontinuation Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Seizure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Hyponatremia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
Interstitial Lung Disease,AdverseReaction
and,O
Eosinophilic Pneumonia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
10,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
5,O
and,O
twice,O
the,O
rate,O
of,O
placebo,O
in,O
the,O
50,O
or,O
100,O
mg,O
dose,O
groups,O
were,O
nausea,AdverseReaction
dizziness,AdverseReaction
insomnia,AdverseReaction
hyperhidrosis,AdverseReaction
constipation,AdverseReaction
somnolence,AdverseReaction
decreased appetite,AdverseReaction
anxiety,AdverseReaction
and,O
specific,O
male sexual function disorders,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Wyeth,O
Pharmaceuticals,O
Inc,O
a,O
subsidiary,O
of,O
Pfizer,O
Inc,O
at,O
1,O
800,O
438,O
1985,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
studies,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Patient,O
exposure,O
PRISTIQ,O
was,O
evaluated,O
for,O
safety,O
in,O
8,O
394,O
patients,O
diagnosed,O
with,O
major,O
depressive,O
disorder,O
who,O
participated,O
in,O
multiple,O
dose,O
pre,O
marketing,O
studies,O
representing,O
2,O
784,O
patient,O
years,O
of,O
exposure,O
Of,O
the,O
total,O
8,O
394,O
patients,O
exposed,O
to,O
at,O
least,O
one,O
dose,O
of,O
PRISTIQ,O
2,O
116,O
were,O
exposed,O
to,O
PRISTIQ,O
for,O
6,O
months,O
representing,O
1,O
658,O
patient,O
years,O
of,O
exposure,O
and,O
421,O
were,O
exposed,O
for,O
one,O
year,O
representing,O
416,O
patient,O
years,O
of,O
exposure,O
Adverse,O
reactions,O
reported,O
as,O
reasons,O
for,O
discontinuation,O
of,O
treatment,O
In,O
the,O
pre,O
marketing,O
pooled,O
8,O
week,O
placebo,O
controlled,O
studies,O
in,O
patients,O
with,O
MDD,O
1,O
834,O
patients,O
were,O
exposed,O
to,O
PRISTIQ,O
50,O
to,O
400,O
mg,O
Of,O
the,O
1,O
834,O
patients,O
12,O
discontinued,O
treatment,O
due,O
to,O
an,O
adverse,O
reaction,O
compared,O
with,O
3,O
of,O
the,O
1,O
116,O
placebo,O
treated,O
patients,O
At,O
the,O
recommended,O
dose,O
of,O
50,O
mg,O
the,O
discontinuation,O
rate,O
due,O
to,O
an,O
adverse,O
reaction,O
for,O
PRISTIQ,O
4,O
1,O
was,O
similar,O
to,O
the,O
rate,O
for,O
placebo,O
3,O
8,O
For,O
the,O
100,O
mg,O
dose,O
of,O
PRISTIQ,O
the,O
discontinuation,O
rate,O
due,O
to,O
an,O
adverse,O
reaction,O
was,O
8,O
7,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
in,O
at,O
least,O
2,O
and,O
at,O
a,O
rate,O
greater,O
than,O
placebo,O
of,O
the,O
PRISTIQ,O
treated,O
patients,O
in,O
the,O
short,O
term,O
studies,O
up,O
to,O
8,O
weeks,O
were,O
nausea,AdverseReaction
4,O
dizziness,AdverseReaction
headache,AdverseReaction
and,O
vomiting,AdverseReaction
2,O
each,O
In,O
a,O
longer,O
term,O
study,O
up,O
to,O
9,O
months,O
the,O
most,O
common,O
was,O
vomiting,AdverseReaction
2,O
Common,O
adverse,O
reactions,O
in,O
placebo,O
controlled,O
MDD,O
studies,O
The,O
most,O
commonly,O
observed,O
adverse,O
reactions,O
in,O
PRISTIQ,O
treated,O
MDD,O
patients,O
in,O
pre,O
marketing,O
pooled,O
8,O
week,O
placebo,O
controlled,O
fixed,O
dose,O
studies,O
incidence,O
5,O
and,O
at,O
least,O
twice,O
the,O
rate,O
of,O
placebo,O
in,O
the,O
50,O
or,O
100,O
mg,O
dose,O
groups,O
were,O
nausea,AdverseReaction
dizziness,AdverseReaction
insomnia,AdverseReaction
hyperhidrosis,AdverseReaction
constipation,AdverseReaction
somnolence,AdverseReaction
decreased appetite,AdverseReaction
anxiety,AdverseReaction
and,O
specific,O
male sexual function disorders,AdverseReaction
Table,O
2,O
shows,O
the,O
incidence,O
of,O
common,O
adverse,O
reactions,O
that,O
occurred,O
in,O
2,O
of,O
PRISTIQ,O
treated,O
MDD,O
patients,O
and,O
twice,O
the,O
rate,O
of,O
placebo,O
at,O
any,O
dose,O
in,O
the,O
pre,O
marketing,O
pooled,O
8,O
week,O
placebo,O
controlled,O
fixed,O
dose,O
clinical,O
studies,O
Table,O
2,O
Common,O
Adverse,O
Reactions,O
2,O
in,O
any,O
Fixed,O
Dose,O
Group,O
and,O
Twice,O
the,O
Rate,O
of,O
Placebo,O
in,O
Pre,O
marketing,O
Pooled,O
MDD,O
8,O
Week,O
Placebo,O
Controlled,O
Studies,O
Percentage,O
of,O
Patients,O
Reporting,O
Reaction,O
PRISTIQ,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
Placebo,O
n,O
636,O
50,O
mg,O
n,O
317,O
100,O
mg,O
n,O
424,O
200,O
mg,O
n,O
307,O
400,O
mg,O
n,O
317,O
Cardiac,O
disorders,O
Blood pressure increased,AdverseReaction
1,O
1,O
1,O
2,O
2,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
10,O
22,O
26,O
36,O
41,O
Dry mouth,AdverseReaction
9,O
11,O
17,O
21,O
25,O
Constipation,AdverseReaction
4,O
9,O
9,O
10,O
14,O
Vomiting,AdverseReaction
3,O
3,O
4,O
6,O
9,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
4,O
7,O
7,O
10,O
11,O
Chills,AdverseReaction
1,O
1,O
1,O
3,O
4,O
Feeling jittery,AdverseReaction
1,O
1,O
2,O
3,O
3,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
2,O
5,O
8,O
10,O
10,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
5,O
13,O
10,O
15,O
16,O
Somnolence,AdverseReaction
4,O
4,O
9,O
12,O
12,O
Tremor,AdverseReaction
2,O
2,O
3,O
9,O
9,O
Disturbance in attention,AdverseReaction
1,O
1,O
1,O
2,O
1,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
6,O
9,O
12,O
14,O
15,O
Anxiety,AdverseReaction
2,O
3,O
5,O
4,O
4,O
Nervousness,AdverseReaction
1,O
1,O
1,O
2,O
2,O
Abnormal dreams,AdverseReaction
1,O
2,O
3,O
2,O
4,O
Renal,O
and,O
urinary,O
disorders,O
Urinary hesitation,AdverseReaction
0,O
1,O
1,O
2,O
2,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Yawning,AdverseReaction
1,O
1,O
1,O
4,O
3,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Hyperhidrosis,AdverseReaction
4,O
10,O
11,O
18,O
21,O
Special,O
Senses,O
Vision blurred,AdverseReaction
1,O
3,O
4,O
4,O
4,O
Mydriasis,AdverseReaction
1,O
2,O
2,O
6,O
6,O
Vertigo,AdverseReaction
1,O
2,O
1,O
5,O
3,O
Tinnitus,AdverseReaction
1,O
2,O
1,O
1,O
2,O
Dysgeusia,AdverseReaction
1,O
1,O
1,O
1,O
2,O
Vascular,O
disorders,O
Hot flush,AdverseReaction
1,O
1,O
1,O
2,O
2,O
Sexual,O
function,O
adverse,O
reactions,O
Table,O
3,O
shows,O
the,O
incidence,O
of,O
sexual function adverse reactions,AdverseReaction
that,O
occurred,O
in,O
2,O
of,O
PRISTIQ,O
treated,O
MDD,O
patients,O
in,O
any,O
fixed,O
dose,O
group,O
pre,O
marketing,O
pooled,O
8,O
week,O
placebo,O
controlled,O
fixed,O
dose,O
clinical,O
studies,O
Table,O
3,O
Sexual Function Adverse Reactions,AdverseReaction
2,O
in,O
Men,O
or,O
Women,O
in,O
any,O
PRISTIQ,O
Group,O
During,O
the,O
On,O
Therapy,O
Period,O
PRISTIQ,O
Placebo,O
n,O
239,O
50,O
mg,O
n,O
108,O
100,O
mg,O
n,O
157,O
200,O
mg,O
n,O
131,O
400,O
mg,O
n,O
154,O
Men,O
only,O
Anorgasmia,AdverseReaction
0,O
0,O
3,O
5,O
8,O
Libido decreased,AdverseReaction
1,O
4,O
5,O
6,O
3,O
Orgasm abnormal,AdverseReaction
0,O
0,O
1,O
2,O
3,O
Ejaculation delayed,AdverseReaction
1,O
1,O
5,O
7,O
6,O
Erectile dysfunction,AdverseReaction
1,O
3,O
6,O
8,O
11,O
Ejaculation disorder,AdverseReaction
0,O
0,O
1,O
2,O
5,O
Ejaculation failure,AdverseReaction
0,O
1,O
0,O
2,O
2,O
Sexual dysfunction,AdverseReaction
0,O
1,O
0,O
0,O
2,O
PRISTIQ,O
Placebo,O
n,O
397,O
50,O
mg,O
n,O
209,O
100,O
mg,O
n,O
267,O
200,O
mg,O
n,O
176,O
400,O
mg,O
n,O
163,O
Women,O
only,O
Anorgasmia,AdverseReaction
0,O
1,O
1,O
0,O
3,O
Other,O
adverse,O
reactions,O
observed,O
in,O
premarketing,O
and,O
postmarketing,O
clinical,O
studies,O
Other,O
infrequent,O
adverse,O
reactions,O
not,O
described,O
elsewhere,O
in,O
the,O
label,O
occurring,O
at,O
an,O
incidence,O
of,O
2,O
in,O
MDD,O
patients,O
treated,O
with,O
PRISTIQ,O
were,O
Cardiac,O
disorders,O
Tachycardia,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Asthenia,AdverseReaction
Investigations,O
Weight increased,AdverseReaction
liver function test abnormal,AdverseReaction
blood prolactin increased,AdverseReaction
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Musculoskeletal stiffness,AdverseReaction
Nervous,O
system,O
disorders,O
Syncope,AdverseReaction
convulsion,AdverseReaction
dystonia,AdverseReaction
Psychiatric,O
disorders,O
Depersonalization,AdverseReaction
bruxism,AdverseReaction
Renal,O
and,O
urinary,O
disorders,O
Urinary retention,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
alopecia,AdverseReaction
photosensitivity,AdverseReaction
reaction,O
angioedema,AdverseReaction
In,O
clinical,O
studies,O
there,O
were,O
uncommon,O
reports,O
of,O
ischemic cardiac adverse reactions,AdverseReaction
including,O
myocardial ischemia,AdverseReaction
myocardial infarction,AdverseReaction
and,O
coronary occlusion,AdverseReaction
requiring,O
revascularization,O
these,O
patients,O
had,O
multiple,O
underlying,O
cardiac,O
risk,O
factors,O
More,O
patients,O
experienced,O
these,O
events,O
during,O
PRISTIQ,O
treatment,O
as,O
compared,O
to,O
placebo,O
Laboratory,O
ECG,O
and,O
vital,O
sign,O
changes,O
observed,O
in,O
MDD,O
clinical,O
studies,O
The,O
following,O
changes,O
were,O
observed,O
in,O
pre,O
marketing,O
placebo,O
controlled,O
short,O
term,O
MDD,O
studies,O
with,O
PRISTIQ,O
Lipids,O
Elevations in fasting serum total cholesterol in fasting serum in fasting serum in fasting serum in fasting serum,AdverseReaction
LDL,AdverseReaction
low density lipoproteins,AdverseReaction
cholesterol,AdverseReaction
and,O
triglycerides,AdverseReaction
occurred,O
in,O
the,O
controlled,O
studies,O
Some,O
of,O
these,O
abnormalities,O
were,O
considered,O
potentially,O
clinically,O
significant,O
The,O
percentage,O
of,O
patients,O
who,O
exceeded,O
a,O
predetermined,O
threshold,O
value,O
is,O
shown,O
in,O
Table,O
4,O
Table,O
4,O
Incidence,O
of,O
Patients,O
With,O
Lipid Abnormalities,AdverseReaction
of,O
Potential,O
Clinical,O
Significance,O
PRISTIQ,O
Placebo,O
50,O
mg,O
100,O
mg,O
200,O
mg,O
400,O
mg,O
Total Cholesterol,AdverseReaction
Increase,O
of,O
50,O
mg,O
dl,O
and,O
an,O
absolute,O
value,O
of,O
261,O
mg,O
dl,O
2,O
3,O
4,O
4,O
10,O
LDL Cholesterol,AdverseReaction
Increase,O
50,O
mg,O
dl,O
and,O
an,O
absolute,O
value,O
of,O
190,O
mg,O
dl,O
0,O
1,O
0,O
1,O
2,O
Triglycerides fasting,AdverseReaction
Fasting,O
327,O
mg,O
dl,O
3,O
2,O
1,O
4,O
6,O
Proteinuria,O
Proteinuria,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
trace,O
was,O
observed,O
in,O
the,O
pre,O
marketing,O
fixed,O
dose,O
controlled,O
studies,O
see,O
Table,O
5,O
This,O
proteinuria,AdverseReaction
was,O
not,Negation
associated,O
with,O
increases in BUN,AdverseReaction
or,O
creatinine,AdverseReaction
and,O
was,O
generally,O
transient,Severity
Table,O
5,O
Incidence,O
of,O
Patients,O
with,O
Proteinuria,AdverseReaction
in,O
the,O
Fixed,O
dose,O
Clinical,O
Studies,O
PRISTIQ,O
Placebo,O
50,O
mg,O
100,O
mg,O
200,O
mg,O
400,O
mg,O
Proteinuria,AdverseReaction
4,O
6,O
8,O
5,O
7,O
Vital,O
sign,O
changes,O
Table,O
6,O
summarizes,O
the,O
changes,O
that,O
were,O
observed,O
in,O
placebo,O
controlled,O
short,O
term,O
pre,O
marketing,O
studies,O
with,O
PRISTIQ,O
in,O
patients,O
with,O
MDD,O
doses,O
50,O
to,O
400,O
mg,O
Table,O
6,O
Mean,O
Changes,O
in,O
Vital,O
Signs,O
at,O
Final,O
on,O
Therapy,O
for,O
All,O
Short,O
term,O
Fixed,O
dose,O
Controlled,O
Studies,O
PRISTIQ,O
Placebo,O
50,O
mg,O
100,O
mg,O
200,O
mg,O
400,O
mg,O
Blood,O
pressure,O
Supine,O
systolic,O
bp,O
mm,O
Hg,O
1,O
4,O
1,O
2,O
2,O
0,O
2,O
5,O
2,O
1,O
Supine,O
diastolic,O
bp,O
mm,O
Hg,O
0,O
6,O
0,O
7,O
0,O
8,O
1,O
8,O
2,O
3,O
Pulse,O
rate,O
Supine,O
pulse,O
bpm,O
0,O
3,O
1,O
3,O
1,O
3,O
0,O
9,O
4,O
1,O
Weight,O
kg,O
0,O
0,O
0,O
4,O
0,O
6,O
0,O
9,O
1,O
1,O
Treatment,O
with,O
PRISTIQ,O
at,O
all,O
doses,O
from,O
50,O
mg,O
per,O
day,O
to,O
400,O
mg,O
per,O
day,O
in,O
controlled,O
studies,O
was,O
associated,O
with,O
sustained,Severity
hypertension,AdverseReaction
defined,O
as,O
treatment,O
emergent,O
supine diastolic blood pressure,AdverseReaction
SDBP,O
90,O
mm,O
Hg,O
and,O
10,O
mm,O
Hg,O
above,O
baseline,O
for,O
3,O
consecutive,O
on,O
therapy,O
visits,O
see,O
Table,O
7,O
Analyses,O
of,O
patients,O
in,O
PRISTIQ,O
pre,O
marketing,O
short,O
term,O
controlled,O
studies,O
who,O
met,O
criteria,O
for,O
sustained,Severity
hypertension,AdverseReaction
revealed,O
a,O
consistent,O
increase,O
in,O
the,O
proportion,O
of,O
patients,O
who,O
developed,O
sustained,Severity
hypertension,AdverseReaction
This,O
was,O
seen,O
at,O
all,O
doses,O
with,O
a,O
suggestion,O
of,O
a,O
higher,O
rate,O
at,O
400,O
mg,O
per,O
day,O
Table,O
7,O
Proportion,O
of,O
Patients,O
with,O
Sustained,Severity
Elevation of Supine Diastolic Blood Pressure,AdverseReaction
Treatment,O
Group,O
Proportion,O
of,O
Patients,O
with,O
Sustained,O
Hypertension,O
Placebo,O
0,O
5,O
PRISTIQ,O
50,O
mg,O
per,O
day,O
1,O
3,O
PRISTIQ,O
100,O
mg,O
per,O
day,O
0,O
7,O
PRISTIQ,O
200,O
mg,O
per,O
day,O
1,O
1,O
PRISTIQ,O
400,O
mg,O
per,O
day,O
2,O
3,O
Orthostatic,O
hypotension,O
In,O
the,O
pre,O
marketing,O
short,O
term,O
placebo,O
controlled,O
clinical,O
studies,O
with,O
doses,O
of,O
50,O
to,O
400,O
mg,O
systolic orthostatic hypotension,AdverseReaction
decrease,O
30,O
mm,O
Hg,O
from,O
supine,O
to,O
standing,O
position,O
occurred,O
more,O
frequently,O
in,O
patients,O
65,O
years,O
of,O
age,O
receiving,O
PRISTIQ,O
8,O
7,O
87,O
versus,O
placebo,O
2,O
5,O
1,O
40,O
compared,O
to,O
patients,O
65,O
years,O
of,O
age,O
receiving,O
PRISTIQ,O
0,O
9,O
18,O
1,O
937,O
versus,O
placebo,O
0,O
7,O
8,O
1,O
218,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reaction,O
has,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
PRISTIQ,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Stevens Johnson syndrome,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Same,O
Active,O
Ingredient,O
Patients,O
receiving,O
Prolia,O
should,O
not,O
receive,O
XGEVA,O
r,O
5,O
1,O
Hypersensitivity,AdverseReaction
including,O
anaphylactic reactions,AdverseReaction
may,O
occur,O
Discontinue,O
permanently,O
if,O
a,O
clinically,O
significant,O
reaction,O
occurs,O
5,O
2,O
Hypocalcemia,AdverseReaction
Must,O
be,O
corrected,O
before,O
initiating,O
Prolia,O
May,O
worsen,O
especially,O
in,O
patients,O
with,O
renal,O
impairment,O
Adequately,O
supplement,O
patients,O
with,O
calcium,O
and,O
vitamin,O
D,O
5,O
3,O
Osteonecrosis of the jaw,AdverseReaction
Has,O
been,O
reported,O
with,O
Prolia,O
Monitor,O
for,O
symptoms,O
5,O
4,O
Atypical femoral fractures,AdverseReaction
Have,O
been,O
reported,O
Evaluate,O
patients,O
with,O
thigh,O
or,O
groin,O
pain,O
to,O
rule,O
out,O
a,O
femoral,O
fracture,O
5,O
5,O
Serious,Severity
infections,AdverseReaction
including,O
skin infections,AdverseReaction
May,O
occur,O
including,O
those,O
leading,O
to,O
hospitalization,O
Advise,O
patients,O
to,O
seek,O
prompt,O
medical,O
attention,O
if,O
they,O
develop,O
signs,O
or,O
symptoms,O
of,O
infection,O
including,O
cellulitis,O
5,O
6,O
Dermatologic reactions,AdverseReaction
Dermatitis,AdverseReaction
rashes,AdverseReaction
and,O
eczema,AdverseReaction
have,O
been,O
reported,O
Consider,O
discontinuing,O
Prolia,O
if,O
severe,O
symptoms,O
develop,O
5,O
7,O
Severe,Severity
Bone,AdverseReaction
Joint,AdverseReaction
Muscle Pain,AdverseReaction
may,O
occur,O
Discontinue,O
use,O
if,O
severe,O
symptoms,O
develop,O
5,O
8,O
Suppression of bone turnover,AdverseReaction
Significant,O
suppression,O
has,O
been,O
demonstrated,O
Monitor,O
for,O
consequences,O
of,O
bone,O
oversuppression,O
5,O
9,O
5,O
1,O
Drug,O
Products,O
with,O
Same,O
Active,O
Ingredient,O
Prolia,O
contains,O
the,O
same,O
active,O
ingredient,O
denosumab,O
found,O
in,O
Xgeva,O
Patients,O
receiving,O
Prolia,O
should,O
not,O
receive,O
Xgeva,O
5,O
2,O
Hypersensitivity,O
Clinically,O
significant,O
hypersensitivity,AdverseReaction
including,O
anaphylaxis,AdverseReaction
has,O
been,O
reported,O
with,O
Prolia,O
Symptoms,O
have,O
included,O
hypotension,AdverseReaction
dyspnea,AdverseReaction
throat tightness,AdverseReaction
facial,AdverseReaction
and,O
upper airway edema,AdverseReaction
pruritus,AdverseReaction
and,O
urticaria,AdverseReaction
If,O
an,O
anaphylactic,O
or,O
other,O
clinically,O
significant,O
allergic,O
reaction,O
occurs,O
initiate,O
appropriate,O
therapy,O
and,O
discontinue,O
further,O
use,O
of,O
Prolia,O
see,O
Contraindications,O
4,O
3,O
Adverse,O
Reactions,O
6,O
2,O
5,O
3,O
Hypocalcemia,O
and,O
Mineral,O
Metabolism,O
Hypocalcemia,AdverseReaction
may,Factor
be,O
exacerbated,AdverseReaction
by,O
the,O
use,O
of,O
Prolia,O
Pre,O
existing,O
hypocalcemia,O
must,O
be,O
corrected,O
prior,O
to,O
initiating,O
therapy,O
with,O
Prolia,O
In,O
patients,O
predisposed,O
to,O
hypocalcemia,O
and,O
disturbances,O
of,O
mineral,O
metabolism,O
e,O
g,O
history,O
of,O
hypoparathyroidism,O
thyroid,O
surgery,O
parathyroid,O
surgery,O
malabsorption,O
syndromes,O
excision,O
of,O
small,O
intestine,O
severe,O
renal,O
impairment,O
creatinine,O
clearance,O
30,O
mL,O
min,O
or,O
receiving,O
dialysis,O
clinical,O
monitoring,O
of,O
calcium,O
and,O
mineral,O
levels,O
phosphorus,O
and,O
magnesium,O
is,O
highly,O
recommended,O
within,O
14,O
days,O
of,O
Prolia,O
injection,O
In,O
some,O
postmarketing,O
cases,O
hypocalcemia,AdverseReaction
persisted,O
for,O
weeks,O
or,O
months,O
and,O
required,O
frequent,O
monitoring,O
and,O
intravenous,O
and,O
or,O
oral,O
calcium,O
replacement,O
with,O
or,O
without,O
vitamin,O
D,O
Hypocalcemia,AdverseReaction
following,O
Prolia,O
administration,O
is,O
a,O
significant,O
risk,O
in,O
patients,O
with,O
severe,O
renal,O
impairment,O
creatinine,O
clearance,O
30,O
mL,O
min,O
or,O
receiving,O
dialysis,O
These,O
patients,O
may,Factor
also,O
develop,O
marked,Severity
elevations of serum parathyroid hormone,AdverseReaction
PTH,O
Instruct,O
all,O
patients,O
with,O
severe,O
renal,O
impairment,O
including,O
those,O
receiving,O
dialysis,O
about,O
the,O
symptoms,O
of,O
hypocalcemia,O
and,O
the,O
importance,O
of,O
maintaining,O
calcium,O
levels,O
with,O
adequate,O
calcium,O
and,O
vitamin,O
D,O
supplementation,O
Adequately,O
supplement,O
all,O
patients,O
with,O
calcium,O
and,O
vitamin,O
D,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
Contraindications,O
4,O
1,O
Adverse,O
Reactions,O
6,O
1,O
and,O
Patient,O
Counseling,O
Information,O
17,O
3,O
5,O
4,O
Osteonecrosis,O
of,O
the,O
Jaw,O
Osteonecrosis,O
of,O
the,O
jaw,O
ONJ,O
which,O
can,O
occur,O
spontaneously,O
is,O
generally,O
associated,O
with,O
tooth,O
extraction,O
and,O
or,O
local,O
infection,O
with,O
delayed,O
healing,O
ONJ,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
receiving,O
denosumab,O
see,O
Adverse,O
Reactions,O
6,O
1,O
A,O
routine,O
oral,O
exam,O
should,O
be,O
performed,O
by,O
the,O
prescriber,O
prior,O
to,O
initiation,O
of,O
Prolia,O
treatment,O
A,O
dental,O
examination,O
with,O
appropriate,O
preventive,O
dentistry,O
is,O
recommended,O
prior,O
to,O
treatment,O
with,O
Prolia,O
in,O
patients,O
with,O
risk,O
factors,O
for,O
ONJ,O
such,O
as,O
invasive,O
dental,O
procedures,O
e,O
g,O
tooth,O
extraction,O
dental,O
implants,O
oral,O
surgery,O
diagnosis,O
of,O
cancer,O
concomitant,O
therapies,O
e,O
g,O
chemotherapy,O
corticosteroids,O
angiogenesis,O
inhibitors,O
poor,O
oral,O
hygiene,O
and,O
co,O
morbid,O
disorders,O
e,O
g,O
periodontal,O
and,O
or,O
other,O
pre,O
existing,O
dental,O
disease,O
anemia,O
coagulopathy,O
infection,O
ill,O
fitting,O
dentures,O
Good,O
oral,O
hygiene,O
practices,O
should,O
be,O
maintained,O
during,O
treatment,O
with,O
Prolia,O
Concomitant,O
administration,O
of,O
drugs,O
associated,O
with,O
ONJ,O
may,O
increase,O
the,O
risk,O
of,O
developing,O
ONJ,O
For,O
patients,O
requiring,O
invasive,O
dental,O
procedures,O
clinical,O
judgment,O
of,O
the,O
treating,O
physician,O
and,O
or,O
oral,O
surgeon,O
should,O
guide,O
the,O
management,O
plan,O
of,O
each,O
patient,O
based,O
on,O
individual,O
benefit,O
risk,O
assessment,O
Patients,O
who,O
are,O
suspected,O
of,O
having,O
or,O
who,O
develop,O
ONJ,O
while,O
on,O
Prolia,O
should,O
receive,O
care,O
by,O
a,O
dentist,O
or,O
an,O
oral,O
surgeon,O
In,O
these,O
patients,O
extensive,O
dental,O
surgery,O
to,O
treat,O
ONJ,O
may,O
exacerbate,O
the,O
condition,O
Discontinuation,O
of,O
Prolia,O
therapy,O
should,O
be,O
considered,O
based,O
on,O
individual,O
benefit,O
risk,O
assessment,O
5,O
5,O
Atypical,O
Subtrochanteric,O
and,O
Diaphyseal,O
Femoral,AdverseReaction
Fractures,O
Atypical,AdverseReaction
low,O
energy,O
or,O
low,O
trauma,O
fractures of the shaft,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
receiving,O
Prolia,O
see,O
Adverse,O
Reactions,O
6,O
1,O
These,O
fractures,AdverseReaction
can,O
occur,O
anywhere,O
in the femoral shaft,AdverseReaction
from,O
just,O
below,O
the,O
lesser,O
trochanter,O
to,O
above,O
the,O
supracondylar,O
flare,O
and,O
are,O
transverse,O
or,O
short,O
oblique,O
in,O
orientation,O
without,O
evidence,O
of,O
comminution,O
Causality,O
has,O
not,O
been,O
established,O
as,O
these,O
fractures,O
also,O
occur,O
in,O
osteoporotic,O
patients,O
who,O
have,O
not,O
been,O
treated,O
with,O
anti,O
resorptive,O
agents,O
Atypical femoral fractures,AdverseReaction
most,O
commonly,O
occur,O
with,O
minimal,O
or,O
no,O
trauma,O
to,O
the,O
affected,O
area,O
They,O
may,O
be,O
bilateral,O
and,O
many,O
patients,O
report,O
prodromal,O
pain,O
in,O
the,O
affected,O
area,O
usually,O
presenting,O
as,O
dull,O
aching,O
thigh pain,AdverseReaction
weeks,O
to,O
months,O
before,O
a,O
complete,O
fracture,O
occurs,O
A,O
number,O
of,O
reports,O
note,O
that,O
patients,O
were,O
also,O
receiving,O
treatment,O
with,O
glucocorticoids,O
e,O
g,O
prednisone,O
at,O
the,O
time,O
of,O
fracture,O
During,O
Prolia,O
treatment,O
patients,O
should,O
be,O
advised,O
to,O
report,O
new,O
or,O
unusual,O
thigh,O
hip,O
or,O
groin,O
pain,O
Any,O
patient,O
who,O
presents,O
with,O
thigh,O
or,O
groin,O
pain,O
should,O
be,O
suspected,O
of,O
having,O
an,O
atypical,O
fracture,O
and,O
should,O
be,O
evaluated,O
to,O
rule,O
out,O
an,O
incomplete,O
femur,O
fracture,O
Patient,O
presenting,O
with,O
an,O
atypical,O
femur,O
fracture,O
should,O
also,O
be,O
assessed,O
for,O
symptoms,O
and,O
signs,O
of,O
fracture,O
in,O
the,O
contralateral,O
limb,O
Interruption,O
of,O
Prolia,O
therapy,O
should,O
be,O
considered,O
pending,O
a,O
risk,O
benefit,O
assessment,O
on,O
an,O
individual,O
basis,O
5,O
6,O
Serious,O
Infections,O
In,O
a,O
clinical,O
trial,O
of,O
over,O
7800,O
women,O
with,O
postmenopausal,O
osteoporosis,O
serious,Severity
infections,AdverseReaction
leading,O
to,O
hospitalization,O
were,O
reported,O
more,O
frequently,O
in,O
the,O
Prolia,O
group,O
than,O
in,O
the,O
placebo,O
group,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Serious,Severity
skin infections,AdverseReaction
as,O
well,O
as,O
infections of the abdomen of the of the,AdverseReaction
urinary tract,AdverseReaction
and,O
ear,AdverseReaction
were,O
more,O
frequent,O
in,O
patients,O
treated,O
with,O
Prolia,O
Endocarditis,AdverseReaction
was,O
also,O
reported,O
more,O
frequently,O
in,O
Prolia,O
treated,O
patients,O
The,O
incidence,O
of,O
opportunistic infections,AdverseReaction
was,O
similar,O
between,O
placebo,O
and,O
Prolia,O
groups,O
and,O
the,O
overall,O
incidence,O
of,O
infections,AdverseReaction
was,O
similar,O
between,O
the,O
treatment,O
groups,O
Advise,O
patients,O
to,O
seek,O
prompt,O
medical,O
attention,O
if,O
they,O
develop,O
signs,O
or,O
symptoms,O
of,O
severe,O
infection,O
including,O
cellulitis,O
Patients,O
on,O
concomitant,O
immunosuppressant,O
agents,O
or,O
with,O
impaired,O
immune,O
systems,O
may,Factor
be,O
at,O
increased,O
risk,O
for,O
serious,Severity
infections,AdverseReaction
Consider,O
the,O
benefit,O
risk,O
profile,O
in,O
such,O
patients,O
before,O
treating,O
with,O
Prolia,O
In,O
patients,O
who,O
develop,O
serious,O
infections,O
while,O
on,O
Prolia,O
prescribers,O
should,O
assess,O
the,O
need,O
for,O
continued,O
Prolia,O
therapy,O
5,O
7,O
Dermatologic,O
Adverse,O
Reactions,O
In,O
a,O
large,O
clinical,O
trial,O
of,O
over,O
7800,O
women,O
with,O
postmenopausal,O
osteoporosis,O
epidermal,AdverseReaction
and,O
dermal adverse events events,AdverseReaction
such,O
as,O
dermatitis,AdverseReaction
eczema,AdverseReaction
and,O
rashes,AdverseReaction
occurred,O
at,O
a,O
significantly,O
higher,O
rate,O
in,O
the,O
Prolia,O
group,O
compared,O
to,O
the,O
placebo,O
group,O
Most,O
of,O
these,O
events,O
were,O
not,O
specific,O
to,O
the,O
injection,O
site,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Consider,O
discontinuing,O
Prolia,O
if,O
severe,O
symptoms,O
develop,O
5,O
8,O
Musculoskeletal,O
Pain,O
In,O
post,O
marketing,O
experience,O
severe,Severity
and,O
occasionally,O
incapacitating,Severity
bone,AdverseReaction
joint,AdverseReaction
and,O
or,O
muscle pain,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
taking,O
Prolia,O
see,O
Adverse,O
Reactions,O
6,O
2,O
The,O
time,O
to,O
onset,O
of,O
symptoms,O
varied,O
from,O
one,O
day,O
to,O
several,O
months,O
after,O
starting,O
Prolia,O
Consider,O
discontinuing,O
use,O
if,O
severe,O
symptoms,O
develop,O
see,O
Patient,O
Counseling,O
Information,O
17,O
8,O
5,O
9,O
Suppression,O
of,O
Bone,O
Turnover,O
In,O
clinical,O
trials,O
in,O
women,O
with,O
postmenopausal,O
osteoporosis,O
treatment,O
with,O
Prolia,O
resulted,O
in,O
significant,O
suppression of bone remodeling,AdverseReaction
as,O
evidenced,O
by,O
markers,O
of,O
bone,O
turnover,O
and,O
bone,O
histomorphometry,O
see,O
Clinical,O
Pharmacology,O
12,O
2,O
and,O
Clinical,O
Studies,O
14,O
1,O
The,O
significance,O
of,O
these,O
findings,O
and,O
the,O
effect,O
of,O
long,O
term,O
treatment,O
with,O
Prolia,O
are,O
unknown,O
The,O
long,O
term,O
consequences,O
of,O
the,O
degree,O
of,O
suppression of bone remodeling,AdverseReaction
observed,O
with,O
Prolia,O
may,Factor
contribute,O
to,O
adverse,O
outcomes,O
such,O
as,O
osteonecrosis of the jaw,AdverseReaction
atypical fractures,AdverseReaction
and,O
delayed fracture healing,AdverseReaction
Monitor,O
patients,O
for,O
these,O
consequences,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
below,O
and,O
also,O
elsewhere,O
in,O
the,O
labeling,O
Hypocalcemia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Serious,Severity
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Dermatologic Adverse Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Osteonecrosis of the Jaw,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Atypical Subtrochanteric,AdverseReaction
and,O
Diaphyseal Femoral Fractures Fractures,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
The,O
most,O
common,O
adverse,O
reactions,O
reported,O
with,O
Prolia,O
in,O
patients,O
with,O
postmenopausal,O
osteoporosis,O
are,O
back pain,AdverseReaction
pain in extremity,AdverseReaction
musculoskeletal pain,AdverseReaction
hypercholesterolemia,AdverseReaction
and,O
cystitis,AdverseReaction
The,O
most,O
common,O
adverse,O
reactions,O
reported,O
with,O
Prolia,O
in,O
men,O
with,O
osteoporosis,O
are,O
back pain,AdverseReaction
arthralgia,AdverseReaction
and,O
nasopharyngitis,AdverseReaction
The,O
most,O
common,O
per,O
patient,O
incidence,O
10,O
adverse,O
reactions,O
reported,O
with,O
Prolia,O
in,O
patients,O
with,O
bone,O
loss,O
receiving,O
androgen,O
deprivation,O
therapy,O
for,O
prostate,O
cancer,O
or,O
adjuvant,O
aromatase,O
inhibitor,O
therapy,O
for,O
breast,O
cancer,O
are,O
arthralgia,AdverseReaction
and,O
back pain,AdverseReaction
Pain in extremity,AdverseReaction
and,O
musculoskeletal pain,AdverseReaction
have,O
also,O
been,O
reported,O
in,O
clinical,O
trials,O
The,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
of,O
Prolia,O
in,O
patients,O
with,O
postmenopausal,O
osteoporosis,O
are,O
back pain,AdverseReaction
and,O
constipation,AdverseReaction
The,O
Prolia,O
Postmarketing,O
Active,O
Safety,O
Surveillance,O
Program,O
is,O
available,O
to,O
collect,O
information,O
from,O
prescribers,O
on,O
specific,O
adverse,O
events,O
Please,O
see,O
www,O
proliasafety,O
com,O
or,O
call,O
1,O
800,O
772,O
6436,O
for,O
more,O
information,O
about,O
this,O
program,O
EXCERPT,O
Postmenopausal,O
osteoporosis,O
Most,O
common,O
adverse,O
reactions,O
5,O
and,O
more,O
common,O
than,O
placebo,O
were,O
back pain,AdverseReaction
pain in extremity,AdverseReaction
hypercholesterolemia,AdverseReaction
musculoskeletal pain,AdverseReaction
and,O
cystitis,AdverseReaction
Pancreatitis,AdverseReaction
has,O
been,O
reported,O
in,O
clinical,O
trials,O
6,O
1,O
Male,O
Osteoporosis,O
Most,O
common,O
adverse,O
reactions,O
5,O
and,O
more,O
common,O
than,O
placebo,O
were,O
back pain,AdverseReaction
arthralgia,AdverseReaction
and,O
nasopharyngitis,AdverseReaction
6,O
1,O
Bone,O
loss,O
due,O
to,O
hormone,O
ablation,O
for,O
cancer,O
Most,O
common,O
adverse,O
reactions,O
10,O
and,O
more,O
common,O
than,O
placebo,O
were,O
arthralgia,AdverseReaction
and,O
back pain,AdverseReaction
Pain in extremity,AdverseReaction
and,O
musculoskeletal pain,AdverseReaction
have,O
also,O
been,O
reported,O
in,O
clinical,O
trials,O
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Amgen,O
Inc,O
at,O
1,O
800,O
77,O
AMGEN,O
1,O
800,O
772,O
6436,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
studies,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
studies,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
studies,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Treatment,O
of,O
Postmenopausal,O
Women,O
with,O
Osteoporosis,O
The,O
safety,O
of,O
Prolia,O
in,O
the,O
treatment,O
of,O
postmenopausal,O
osteoporosis,O
was,O
assessed,O
in,O
a,O
3,O
year,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
multinational,O
study,O
of,O
7808,O
postmenopausal,O
women,O
aged,O
60,O
to,O
91,O
years,O
A,O
total,O
of,O
3876,O
women,O
were,O
exposed,O
to,O
placebo,O
and,O
3886,O
women,O
were,O
exposed,O
to,O
Prolia,O
administered,O
subcutaneously,O
once,O
every,O
6,O
months,O
as,O
a,O
single,O
60,O
mg,O
dose,O
All,O
women,O
were,O
instructed,O
to,O
take,O
at,O
least,O
1000,O
mg,O
of,O
calcium,O
and,O
400,O
IU,O
of,O
vitamin,O
D,O
supplementation,O
per,O
day,O
The,O
incidence,O
of,O
all,O
cause,O
mortality,AdverseReaction
was,O
2,O
3,O
n,O
90,O
in,O
the,O
placebo,O
group,O
and,O
1,O
8,O
n,O
70,O
in,O
the,O
Prolia,O
group,O
The,O
incidence,O
of,O
nonfatal,O
serious,O
adverse,O
events,O
was,O
24,O
2,O
in,O
the,O
placebo,O
group,O
and,O
25,O
0,O
in,O
the,O
Prolia,O
group,O
The,O
percentage,O
of,O
patients,O
who,O
withdrew,O
from,O
the,O
study,O
due,O
to,O
adverse,O
events,O
was,O
2,O
1,O
and,O
2,O
4,O
for,O
the,O
placebo,O
and,O
Prolia,O
groups,O
respectively,O
Adverse,O
reactions,O
reported,O
in,O
2,O
of,O
postmenopausal,O
women,O
with,O
osteoporosis,O
and,O
more,O
frequently,O
in,O
the,O
Prolia,O
treated,O
women,O
than,O
in,O
the,O
placebo,O
treated,O
women,O
are,O
shown,O
in,O
the,O
table,O
below,O
Table,O
1,O
Adverse,O
Reactions,O
Occurring,O
in,O
2,O
of,O
Patients,O
with,O
Osteoporosis,O
and,O
More,O
Frequently,O
than,O
in,O
Placebo,O
treated,O
Patients,O
SYSTEM,O
ORGAN,O
CLASS,O
Preferred,O
Term,O
Prolia,O
N,O
3886,O
n,O
Placebo,O
N,O
3876,O
n,O
BLOOD,O
AND,O
LYMPHATIC,O
SYSTEM,O
DISORDERS,O
Anemia,AdverseReaction
129,O
3,O
3,O
107,O
2,O
8,O
CARDIAC,O
DISORDERS,O
Angina pectoris,AdverseReaction
101,O
2,O
6,O
87,O
2,O
2,O
Atrial fibrillation,AdverseReaction
79,O
2,O
0,O
77,O
2,O
0,O
EAR,O
AND,O
LABYRINTH,O
DISORDERS,O
Vertigo,AdverseReaction
195,O
5,O
0,O
187,O
4,O
8,O
GASTROINTESTINAL,O
DISORDERS,O
Abdominal pain upper,AdverseReaction
129,O
3,O
3,O
111,O
2,O
9,O
Flatulence,AdverseReaction
84,O
2,O
2,O
53,O
1,O
4,O
Gastroesophageal reflux disease,AdverseReaction
80,O
2,O
1,O
66,O
1,O
7,O
GENERAL,O
DISORDERS,O
AND,O
ADMINISTRATION,O
SITE,O
CONDITIONS,O
Edema peripheral,AdverseReaction
189,O
4,O
9,O
155,O
4,O
0,O
Asthenia,AdverseReaction
90,O
2,O
3,O
73,O
1,O
9,O
INFECTIONS,O
AND,O
INFESTATIONS,O
Cystitis,AdverseReaction
228,O
5,O
9,O
225,O
5,O
8,O
Upper respiratory tract infection,AdverseReaction
190,O
4,O
9,O
167,O
4,O
3,O
Pneumonia,AdverseReaction
152,O
3,O
9,O
150,O
3,O
9,O
Pharyngitis,AdverseReaction
91,O
2,O
3,O
78,O
2,O
0,O
Herpes zoster,AdverseReaction
79,O
2,O
0,O
72,O
1,O
9,O
METABOLISM,O
AND,O
NUTRITION,O
DISORDERS,O
Hypercholesterolemia,AdverseReaction
280,O
7,O
2,O
236,O
6,O
1,O
MUSCULOSKELETAL,O
AND,O
CONNECTIVE,O
TISSUE,O
DISORDERS,O
Back pain,AdverseReaction
1347,O
34,O
7,O
1340,O
34,O
6,O
Pain in extremity,AdverseReaction
453,O
11,O
7,O
430,O
11,O
1,O
Musculoskeletal pain,AdverseReaction
297,O
7,O
6,O
291,O
7,O
5,O
Bone pain,AdverseReaction
142,O
3,O
7,O
117,O
3,O
0,O
Myalgia,AdverseReaction
114,O
2,O
9,O
94,O
2,O
4,O
Spinal osteoarthritis,AdverseReaction
82,O
2,O
1,O
64,O
1,O
7,O
NERVOUS,O
SYSTEM,O
DISORDERS,O
Sciatica,AdverseReaction
178,O
4,O
6,O
149,O
3,O
8,O
PSYCHIATRIC,O
DISORDERS,O
Insomnia,AdverseReaction
126,O
3,O
2,O
122,O
3,O
1,O
SKIN,O
AND,O
SUBCUTANEOUS,O
TISSUE,O
DISORDERS,O
Rash,AdverseReaction
96,O
2,O
5,O
79,O
2,O
0,O
Pruritus,AdverseReaction
87,O
2,O
2,O
82,O
2,O
1,O
Hypocalcemia,AdverseReaction
Decreases in serum calcium levels,AdverseReaction
to,O
less,O
than,O
8,O
5,O
mg,O
dL,O
at,O
any,O
visit,O
were,O
reported,O
in,O
0,O
4,O
women,O
in,O
the,O
placebo,O
group,O
and,O
1,O
7,O
women,O
in,O
the,O
Prolia,O
group,O
The,O
nadir,O
in,O
serum,O
calcium,O
level,O
occurs,O
at,O
approximately,O
day,O
10,O
after,O
Prolia,O
dosing,O
in,O
subjects,O
with,O
normal,O
renal,O
function,O
In,O
clinical,O
studies,O
subjects,O
with,O
impaired,O
renal,O
function,O
were,O
more,O
likely,O
to,O
have,O
greater,O
reductions,O
in,O
serum,O
calcium,O
levels,O
compared,O
to,O
subjects,O
with,O
normal,O
renal,O
function,O
In,O
a,O
study,O
of,O
55,O
subjects,O
with,O
varying,O
degrees,O
of,O
renal,O
function,O
serum,O
calcium,O
levels,O
7,O
5,O
mg,O
dL,O
or,O
symptomatic hypocalcemia,AdverseReaction
were,O
observed,O
in,O
5,O
subjects,O
These,O
included,O
no,O
subjects,O
in,O
the,O
normal,O
renal,O
function,O
group,O
10,O
of,O
subjects,O
in,O
the,O
creatinine,O
clearance,O
50,O
to,O
80,O
mL,O
min,O
group,O
29,O
of,O
subjects,O
in,O
the,O
creatinine,O
clearance,O
30,O
mL,O
min,O
group,O
and,O
29,O
of,O
subjects,O
in,O
the,O
hemodialysis,O
group,O
These,O
subjects,O
did,O
not,O
receive,O
calcium,O
and,O
vitamin,O
D,O
supplementation,O
In,O
a,O
study,O
of,O
4550,O
postmenopausal,O
women,O
with,O
osteoporosis,O
the,O
mean,O
change,O
from,O
baseline,O
in,O
serum,O
calcium,O
level,O
10,O
days,O
after,O
Prolia,O
dosing,O
was,O
5,O
5,O
in,O
subjects,O
with,O
creatinine,O
clearance,O
30,O
mL,O
min,O
vs,O
3,O
1,O
in,O
subjects,O
with,O
creatinine,O
clearance,O
30,O
mL,O
min,O
Serious,O
Infections,O
Receptor,O
activator,O
of,O
nuclear,O
factor,O
kappa,O
B,O
ligand,O
RANKL,O
is,O
expressed,O
on,O
activated,O
T,O
and,O
B,O
lymphocytes,O
and,O
in,O
lymph,O
nodes,O
Therefore,O
a,O
RANKL,O
inhibitor,O
such,O
as,O
Prolia,O
may,O
increase,O
the,O
risk,Factor
of,O
infection,AdverseReaction
In,O
the,O
clinical,O
study,O
of,O
7808,O
postmenopausal,O
women,O
with,O
osteoporosis,O
the,O
incidence,O
of,O
infections,AdverseReaction
resulting,O
in,O
death,AdverseReaction
was,O
0,O
2,O
in,O
both,O
placebo,O
and,O
Prolia,O
treatment,O
groups,O
However,O
the,O
incidence,O
of,O
nonfatal,O
serious,Severity
infections,AdverseReaction
was,O
3,O
3,O
in,O
the,O
placebo,O
and,O
4,O
0,O
in,O
the,O
Prolia,O
groups,O
Hospitalizations,O
due,O
to,O
serious,Severity
infections in the abdomen in the in the,AdverseReaction
0,O
7,O
placebo,O
vs,O
0,O
9,O
Prolia,O
urinary tract,AdverseReaction
0,O
5,O
placebo,O
vs,O
0,O
7,O
Prolia,O
and,O
ear,AdverseReaction
0,O
0,O
placebo,O
vs,O
0,O
1,O
Prolia,O
were,O
reported,O
Endocarditis,AdverseReaction
was,O
reported,O
in,O
no,O
placebo,O
patients,O
and,O
3,O
patients,O
receiving,O
Prolia,O
Skin infections,AdverseReaction
including,O
erysipelas,AdverseReaction
and,O
cellulitis,AdverseReaction
leading,O
to,O
hospitalization,O
were,O
reported,O
more,O
frequently,O
in,O
patients,O
treated,O
with,O
Prolia,O
0,O
1,O
placebo,O
vs,O
0,O
4,O
Prolia,O
The,O
incidence,O
of,O
opportunistic infections,AdverseReaction
was,O
similar,O
to,O
that,O
reported,O
with,O
placebo,O
Dermatologic,O
Reactions,O
A,O
significantly,O
higher,O
number,O
of,O
patients,O
treated,O
with,O
Prolia,O
developed,O
epidermal,AdverseReaction
and,O
dermal adverse events events,AdverseReaction
such,O
as,O
dermatitis,AdverseReaction
eczema,AdverseReaction
and,O
rashes,AdverseReaction
with,O
these,O
events,O
reported,O
in,O
8,O
2,O
of,O
the,O
placebo,O
and,O
10,O
8,O
of,O
the,O
Prolia,O
groups,O
p,O
0,O
0001,O
Most,O
of,O
these,O
events,O
were,O
not,O
specific,O
to,O
the,O
injection,O
site,O
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Osteonecrosis of the Jaw,AdverseReaction
ONJ,AdverseReaction
has,O
been,O
reported,O
in,O
the,O
osteoporosis,O
clinical,O
trial,O
program,O
in,O
patients,O
treated,O
with,O
Prolia,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Atypical,O
Subtrochanteric,O
and,O
Diaphyseal,O
Fractures,O
In,O
the,O
osteoporosis,O
clinical,O
trial,O
program,O
atypical femoral fractures,AdverseReaction
were,O
reported,O
in,O
patients,O
treated,O
with,O
Prolia,O
The,O
duration,O
of,O
Prolia,O
exposure,O
to,O
time,O
of,O
atypical femoral fracture,AdverseReaction
diagnosis,O
was,O
as,O
early,O
as,O
21,O
2,O
years,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Pancreatitis,O
Pancreatitis,AdverseReaction
was,O
reported,O
in,O
4,O
patients,O
0,O
1,O
in,O
the,O
placebo,O
and,O
8,O
patients,O
0,O
2,O
in,O
the,O
Prolia,O
groups,O
Of,O
these,O
reports,O
1,O
patient,O
in,O
the,O
placebo,O
group,O
and,O
all,O
8,O
patients,O
in,O
the,O
Prolia,O
group,O
had,O
serious,O
events,O
including,O
one,O
death,AdverseReaction
in,O
the,O
Prolia,O
group,O
Several,O
patients,O
had,O
a,O
prior,O
history,O
of,O
pancreatitis,O
The,O
time,O
from,O
product,O
administration,O
to,O
event,O
occurrence,O
was,O
variable,O
New,O
Malignancies,O
The,O
overall,O
incidence,O
of,O
new,O
malignancies,AdverseReaction
was,O
4,O
3,O
in,O
the,O
placebo,O
and,O
4,O
8,O
in,O
the,O
Prolia,O
groups,O
New,O
malignancies,AdverseReaction
related,O
to the breast the the,AdverseReaction
0,O
7,O
placebo,O
vs,O
0,O
9,O
Prolia,O
reproductive system,AdverseReaction
0,O
2,O
placebo,O
vs,O
0,O
5,O
Prolia,O
and,O
gastrointestinal system,AdverseReaction
0,O
6,O
placebo,O
vs,O
0,O
9,O
Prolia,O
were,O
reported,O
A,O
causal,O
relationship,O
to,O
drug,O
exposure,O
has,O
not,O
been,O
established,O
Treatment,O
to,O
Increase,O
Bone,O
Mass,O
in,O
Men,O
with,O
Osteoporosis,O
The,O
safety,O
of,O
Prolia,O
in,O
the,O
treatment,O
of,O
men,O
with,O
osteoporosis,O
was,O
assessed,O
in,O
a,O
1,O
year,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
study,O
A,O
total,O
of,O
120,O
men,O
were,O
exposed,O
to,O
placebo,O
and,O
120,O
men,O
were,O
exposed,O
to,O
Prolia,O
administered,O
subcutaneously,O
once,O
every,O
6,O
months,O
as,O
a,O
single,O
60,O
mg,O
dose,O
All,O
men,O
were,O
instructed,O
to,O
take,O
at,O
least,O
1000,O
mg,O
of,O
calcium,O
and,O
800,O
IU,O
of,O
vitamin,O
D,O
supplementation,O
per,O
day,O
The,O
incidence,O
of,O
all,O
cause,O
mortality,AdverseReaction
was,O
0,O
8,O
n,O
1,O
in,O
the,O
placebo,O
group,O
and,O
0,O
8,O
n,O
1,O
in,O
the,O
Prolia,O
group,O
The,O
incidence,O
of,O
nonfatal,O
serious,O
adverse,O
events,O
was,O
7,O
5,O
in,O
the,O
placebo,O
group,O
and,O
8,O
3,O
in,O
the,O
Prolia,O
group,O
The,O
percentage,O
of,O
patients,O
who,O
withdrew,O
from,O
the,O
study,O
due,O
to,O
adverse,O
events,O
was,O
0,O
and,O
2,O
5,O
for,O
the,O
placebo,O
and,O
Prolia,O
groups,O
respectively,O
Adverse,O
reactions,O
reported,O
in,O
5,O
of,O
men,O
with,O
osteoporosis,O
and,O
more,O
frequently,O
with,O
Prolia,O
than,O
in,O
the,O
placebo,O
treated,O
patients,O
were,O
back pain,AdverseReaction
6,O
7,O
placebo,O
vs,O
8,O
3,O
Prolia,O
arthralgia,AdverseReaction
5,O
8,O
placebo,O
vs,O
6,O
7,O
Prolia,O
and,O
nasopharyngitis,AdverseReaction
5,O
8,O
placebo,O
vs,O
6,O
7,O
Prolia,O
Serious,O
Infections,O
S erious,Severity
infection,AdverseReaction
was,O
reported,O
in,O
1,O
patient,O
0,O
8,O
in,O
the,O
placebo,O
group,O
and,O
no,Negation
patients,O
in,O
the,O
Prolia,O
group,O
Dermatologic,O
Reactions,O
Epidermal,AdverseReaction
and,O
dermal adverse events events,AdverseReaction
such,O
as,O
dermatitis,AdverseReaction
eczema,AdverseReaction
and,O
rashes,AdverseReaction
were,O
reported,O
in,O
4,O
patients,O
3,O
3,O
in,O
the,O
placebo,O
group,O
and,O
5,O
patients,O
4,O
2,O
in,O
the,O
Prolia,O
group,O
Osteonecrosis,O
of,O
the,O
Jaw,O
No,Negation
cases,O
of,O
ONJ,AdverseReaction
were,O
reported,O
Pancreatitis,O
Pancreatitis,AdverseReaction
was,O
reported,O
in,O
1,O
patient,O
0,O
8,O
in,O
the,O
placebo,O
group,O
and,O
1,O
patient,O
0,O
8,O
in,O
the,O
Prolia,O
group,O
New,O
Malignancies,O
New,O
malignancies,AdverseReaction
were,O
reported,O
in,O
no,O
patients,O
in,O
the,O
placebo,O
group,O
and,O
4,O
3,O
3,O
patients,O
3,O
prostate cancers,AdverseReaction
1,O
basal cell carcinoma,AdverseReaction
in,O
the,O
Prolia,O
group,O
Treatment,O
of,O
Bone,O
Loss,O
in,O
Patients,O
Receiving,O
Androgen,O
Deprivation,O
Therapy,O
for,O
Prostate,O
Cancer,O
or,O
Adjuvant,O
Aromatase,O
Inhibitor,O
Therapy,O
for,O
Breast,O
Cancer,O
The,O
safety,O
of,O
Prolia,O
in,O
the,O
treatment,O
of,O
bone,O
loss,O
in,O
men,O
with,O
nonmetastatic,O
prostate,O
cancer,O
receiving,O
androgen,O
deprivation,O
therapy,O
ADT,O
was,O
assessed,O
in,O
a,O
3,O
year,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
multinational,O
study,O
of,O
1468,O
men,O
aged,O
48,O
to,O
97,O
years,O
A,O
total,O
of,O
725,O
men,O
were,O
exposed,O
to,O
placebo,O
and,O
731,O
men,O
were,O
exposed,O
to,O
Prolia,O
administered,O
once,O
every,O
6,O
months,O
as,O
a,O
single,O
60,O
mg,O
subcutaneous,O
dose,O
All,O
men,O
were,O
instructed,O
to,O
take,O
at,O
least,O
1000,O
mg,O
of,O
calcium,O
and,O
400,O
IU,O
of,O
vitamin,O
D,O
supplementation,O
per,O
day,O
The,O
incidence,O
of,O
serious,O
adverse,O
events,O
was,O
30,O
6,O
in,O
the,O
placebo,O
group,O
and,O
34,O
6,O
in,O
the,O
Prolia,O
group,O
The,O
percentage,O
of,O
patients,O
who,O
withdrew,O
from,O
the,O
study,O
due,O
to,O
adverse,O
events,O
was,O
6,O
1,O
and,O
7,O
0,O
for,O
the,O
placebo,O
and,O
Prolia,O
groups,O
respectively,O
The,O
safety,O
of,O
Prolia,O
in,O
the,O
treatment,O
of,O
bone,O
loss,O
in,O
women,O
with,O
nonmetastatic,O
breast,O
cancer,O
receiving,O
aromatase,O
inhibitor,O
AI,O
therapy,O
was,O
assessed,O
in,O
a,O
2,O
year,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
multinational,O
study,O
of,O
252,O
postmenopausal,O
women,O
aged,O
35,O
to,O
84,O
years,O
A,O
total,O
of,O
120,O
women,O
were,O
exposed,O
to,O
placebo,O
and,O
129,O
women,O
were,O
exposed,O
to,O
Prolia,O
administered,O
once,O
every,O
6,O
months,O
as,O
a,O
single,O
60,O
mg,O
subcutaneous,O
dose,O
All,O
women,O
were,O
instructed,O
to,O
take,O
at,O
least,O
1000,O
mg,O
of,O
calcium,O
and,O
400,O
IU,O
of,O
vitamin,O
D,O
supplementation,O
per,O
day,O
The,O
incidence,O
of,O
serious,O
adverse,O
events,O
was,O
9,O
2,O
in,O
the,O
placebo,O
group,O
and,O
14,O
7,O
in,O
the,O
Prolia,O
group,O
The,O
percentage,O
of,O
patients,O
who,O
withdrew,O
from,O
the,O
study,O
due,O
to,O
adverse,O
events,O
was,O
4,O
2,O
and,O
0,O
8,O
for,O
the,O
placebo,O
and,O
Prolia,O
groups,O
respectively,O
Adverse,O
reactions,O
reported,O
in,O
10,O
of,O
Prolia,O
treated,O
patients,O
receiving,O
ADT,O
for,O
prostate,O
cancer,O
or,O
adjuvant,O
AI,O
therapy,O
for,O
breast,O
cancer,O
and,O
more,O
frequently,O
than,O
in,O
the,O
placebo,O
treated,O
patients,O
were,O
arthralgia,AdverseReaction
13,O
0,O
placebo,O
vs,O
14,O
3,O
Prolia,O
and,O
back pain,AdverseReaction
10,O
5,O
placebo,O
vs,O
11,O
5,O
Prolia,O
Pain in extremity,AdverseReaction
7,O
7,O
placebo,O
vs,O
9,O
9,O
Prolia,O
and,O
musculoskeletal pain,AdverseReaction
3,O
8,O
placebo,O
vs,O
6,O
0,O
Prolia,O
have,O
also,O
been,O
reported,O
in,O
clinical,O
trials,O
Additionally,O
in,O
Prolia,O
treated,O
men,O
with,O
nonmetastatic,O
prostate,O
cancer,O
receiving,O
ADT,O
a,O
greater,O
incidence,O
of,O
cataracts,AdverseReaction
was,O
observed,O
1,O
2,O
placebo,O
vs,O
4,O
7,O
Prolia,O
Hypocalcemia,AdverseReaction
serum,O
calcium,O
8,O
4,O
mg,O
dL,O
was,O
reported,O
only,O
in,O
Prolia,O
treated,O
patients,O
2,O
4,O
vs,O
0,O
at,O
the,O
month,O
1,O
visit,O
6,O
2,O
Postmarketing,O
Experience,O
Because,O
postmarketing,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
Prolia,O
Drug,O
related,O
hypersensitivity reactions,AdverseReaction
anaphylaxis,AdverseReaction
rash,AdverseReaction
urticaria,AdverseReaction
facial swelling,AdverseReaction
and,O
erythema,AdverseReaction
Hypocalcemia,AdverseReaction
severe,Severity
symptomatic hypocalcemia,AdverseReaction
hypocalcemia,AdverseReaction
Musculoskeletal pain,AdverseReaction
including,O
severe,Severity
cases,O
Parathyroid,O
Hormone,O
PTH,O
Marked,Severity
elevation in serum PTH,AdverseReaction
in,O
patients,O
with,O
severe,O
renal,O
impairment,O
creatinine,O
clearance,O
30,O
mL,O
min,O
or,O
receiving,O
dialysis,O
6,O
3,O
Immunogenicity,O
Denosumab,O
is,O
a,O
human,O
monoclonal,O
antibody,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
potential,O
for,O
immunogenicity,O
Using,O
an,O
electrochemiluminescent,O
bridging,O
immunoassay,O
less,O
than,O
1,O
55,O
out,O
of,O
8113,O
of,O
patients,O
treated,O
with,O
Prolia,O
for,O
up,O
to,O
5,O
years,O
tested,O
positive,O
for,O
binding,O
antibodies,O
including,O
pre,O
existing,O
transient,O
and,O
developing,O
antibodies,O
None,O
of,O
the,O
patients,O
tested,O
positive,O
for,O
neutralizing,O
antibodies,O
as,O
was,O
assessed,O
using,O
a,O
chemiluminescent,O
cell,O
based,O
in,O
vitro,O
biological,O
assay,O
No,Negation
evidence,O
of,O
altered,O
pharmacokinetic,O
profile,O
toxicity,AdverseReaction
profile,O
or,O
clinical,O
response,O
was,O
associated,O
with,O
binding,O
antibody,O
development,O
The,O
incidence,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
a,O
positive,O
antibody,O
including,O
neutralizing,O
antibody,O
test,O
result,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
antibodies,O
to,O
denosumab,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hepatotoxicity,AdverseReaction
Monitor,O
liver,O
function,O
before,O
and,O
during,O
therapy,O
5,O
2,O
Thrombotic,AdverseReaction
Thromboembolic Complications,AdverseReaction
Portal vein thrombosis,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
with,O
chronic,O
liver,O
disease,O
receiving,O
PROMACTA,O
Monitor,O
platelet,O
counts,O
regularly,O
5,O
3,O
5,O
1,O
Hepatic,O
Decompensation,O
in,O
Patients,O
with,O
Chronic,O
Hepatitis,O
C,O
In,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
PROMACTA,O
in,O
combination,O
with,O
interferon,O
and,O
ribavirin,O
may,O
increase,O
the,O
risk,Factor
of,O
hepatic decompensation,AdverseReaction
In,O
two,O
controlled,O
clinical,O
trials,O
in,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
and,O
thrombocytopenia,O
ascites,AdverseReaction
and,O
encephalopathy,AdverseReaction
occurred,O
more,O
frequently,O
on,O
the,O
arm,O
receiving,O
treatment,O
with,O
PROMACTA,O
plus,O
antivirals,O
7,O
than,O
the,O
placebo,O
plus,O
antivirals,O
arm,O
4,O
Patients,O
with,O
low,O
albumin,O
levels,O
less,O
than,O
3,O
5,O
g,O
dL,O
or,O
Model,O
for,O
End,O
Stage,O
Liver,O
Disease,O
MELD,O
score,O
greater,O
than,O
or,O
equal,O
to,O
10,O
at,O
baseline,O
had,O
a,O
greater,O
risk,Factor
for,O
hepatic decompensation,AdverseReaction
on,O
the,O
arm,O
receiving,O
treatment,O
with,O
PROMACTA,O
plus,O
antivirals,O
Discontinue,O
PROMACTA,O
if,O
antiviral,O
therapy,O
is,O
discontinued,O
5,O
2,O
Hepatotoxicity,O
PROMACTA,O
can,Factor
cause,O
liver enzyme elevations,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
1,O
Measure,O
serum,O
ALT,O
AST,O
and,O
bilirubin,O
prior,O
to,O
initiation,O
of,O
PROMACTA,O
every,O
2,O
weeks,O
during,O
the,O
dose,O
adjustment,O
phase,O
and,O
monthly,O
following,O
establishment,O
of,O
a,O
stable,O
dose,O
PROMACTA,O
inhibits,O
UDP,O
glucuronosyltransferase,O
UGT,O
1A1,O
and,O
organic,O
anion,O
transporting,O
polypeptide,O
OATP,O
1B1,O
which,O
may,Factor
lead,O
to,O
indirect hyperbilirubinemia,AdverseReaction
If,O
bilirubin,O
is,O
elevated,O
perform,O
fractionation,O
Evaluate,O
abnormal,O
serum,O
liver,O
tests,O
with,O
repeat,O
testing,O
within,O
3,O
to,O
5,O
days,O
If,O
the,O
abnormalities,O
are,O
confirmed,O
monitor,O
serum,O
liver,O
tests,O
weekly,O
until,O
resolved,O
or,O
stabilized,O
Discontinue,O
PROMACTA,O
if,O
ALT,O
levels,O
increase,O
to,O
greater,O
than,O
or,O
equal,O
to,O
3,O
x,O
ULN,O
in,O
patients,O
with,O
normal,O
liver,O
function,O
or,O
greater,O
than,O
or,O
equal,O
to,O
3,O
x,O
baseline,O
in,O
patients,O
with,O
pre,O
treatment,O
elevations,O
in,O
transaminases,O
and,O
are,O
progressively,O
increasing,O
or,O
persistent,O
for,O
greater,O
than,O
or,O
equal,O
to,O
4,O
weeks,O
or,O
accompanied,O
by,O
increased,O
direct,O
bilirubin,O
or,O
accompanied,O
by,O
clinical,O
symptoms,O
of,O
liver,O
injury,O
or,O
evidence,O
for,O
hepatic,O
decompensation,O
If,O
the,O
potential,O
benefit,O
for,O
reinitiating,O
treatment,O
with,O
PROMACTA,O
is,O
considered,O
to,O
outweigh,O
the,O
risk,O
for,O
hepatotoxicity,O
then,O
consider,O
cautiously,O
reintroducing,O
PROMACTA,O
and,O
measure,O
serum,O
liver,O
tests,O
weekly,O
during,O
the,O
dose,O
adjustment,O
phase,O
Hepatotoxicity,AdverseReaction
may,Factor
reoccur,O
if,O
PROMACTA,O
is,O
reinitiated,O
If,O
liver,O
test,O
abnormalities,O
persist,O
worsen,O
or,O
recur,O
then,O
permanently,O
discontinue,O
PROMACTA,O
5,O
3,O
Thrombotic,O
Thromboembolic,O
Complications,O
In,O
two,O
controlled,O
clinical,O
trials,O
in,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
and,O
thrombocytopenia,O
3,O
31,O
955,O
treated,O
with,O
PROMACTA,O
experienced,O
a,O
thrombotic event,AdverseReaction
compared,O
with,O
1,O
5,O
484,O
on,O
placebo,O
The,O
majority,O
of,O
events,AdverseReaction
were,O
of the portal venous system,AdverseReaction
1,O
in,O
patients,O
treated,O
with,O
PROMACTA,O
versus,O
less,O
than,O
1,O
for,O
placebo,O
Thrombotic,AdverseReaction
thromboembolic complications,AdverseReaction
may,Factor
result,O
from,O
increases in platelet counts,AdverseReaction
with,O
PROMACTA,O
Reported,O
thrombotic,AdverseReaction
thromboembolic complications,AdverseReaction
included,O
both,O
venous,AdverseReaction
and,O
arterial events events,AdverseReaction
and,O
were,O
observed,O
at,O
low,O
and,O
at,O
normal,O
platelet,O
counts,O
Consider,O
the,O
potential,O
for,O
an,O
increased,O
risk,O
of,O
thromboembolism,O
when,O
administering,O
PROMACTA,O
to,O
patients,O
with,O
known,O
risk,O
factors,O
for,O
thromboembolism,O
e,O
g,O
Factor,O
V,O
Leiden,O
ATIII,O
deficiency,O
antiphospholipid,O
syndrome,O
chronic,O
liver,O
disease,O
To,O
minimize,O
the,O
risk,O
for,O
thrombotic,O
thromboembolic,O
complications,O
do,O
not,O
use,O
PROMACTA,O
in,O
an,O
attempt,O
to,O
normalize,O
platelet,O
counts,O
Follow,O
the,O
dose,O
adjustment,O
guidelines,O
to,O
achieve,O
and,O
maintain,O
target,O
platelet,O
counts,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
2,O
2,O
2,O
3,O
In,O
a,O
controlled,O
trial,O
in,O
patients,O
with,O
chronic,O
liver,O
disease,O
and,O
thrombocytopenia,O
not,O
related,O
to,O
ITP,O
undergoing,O
elective,O
invasive,O
procedures,O
N,O
292,O
the,O
risk,Factor
of,O
thrombotic events,AdverseReaction
was,O
increased,O
in,O
patients,O
treated,O
with,O
75,O
mg,O
of,O
PROMACTA,O
once,O
daily,O
Seven,O
thrombotic complications,AdverseReaction
six,O
patients,O
were,O
reported,O
in,O
the,O
group,O
that,O
received,O
PROMACTA,O
and,O
three,O
thrombotic complications,AdverseReaction
were,O
reported,O
in,O
the,O
placebo,Factor
group,O
two,O
patients,O
All,O
of,O
the,O
thrombotic complications,AdverseReaction
reported,O
in,O
the,O
group,O
that,O
received,O
PROMACTA,O
were,O
portal vein thrombosis,AdverseReaction
PVT,AdverseReaction
Symptoms,O
of,O
PVT,AdverseReaction
included,O
abdominal pain,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
and,O
diarrhea,AdverseReaction
Five,O
of,O
the,O
six,O
patients,O
in,O
the,O
group,O
that,O
received,O
PROMACTA,O
experienced,O
a,O
thrombotic complication,AdverseReaction
within,O
30,O
days,O
of,O
completing,O
treatment,O
with,O
PROMACTA,O
and,O
at,O
a,O
platelet,O
count,O
above,O
200,O
x,O
10,O
9,O
L,O
The,O
risk,Factor
of,O
portal venous thrombosis,AdverseReaction
was,O
increased,O
in,O
thrombocytopenic,O
patients,O
with,O
chronic,O
liver,O
disease,O
treated,O
with,O
75,O
mg,O
of,O
PROMACTA,O
once,O
daily,O
for,O
2,O
weeks,O
in,O
preparation,O
for,O
invasive,O
procedures,O
5,O
4,O
Cataracts,O
In,O
the,O
three,O
controlled,O
clinical,O
trials,O
in,O
adults,O
with,O
chronic,O
ITP,O
cataracts,AdverseReaction
developed,O
or,O
worsened,O
in,O
15,O
7,O
patients,O
who,O
received,O
50,O
mg,O
of,O
PROMACTA,O
daily,O
and,O
8,O
7,O
placebo,O
group,O
patients,O
In,O
the,O
extension,O
trial,O
cataracts,AdverseReaction
developed,O
or,O
worsened,O
in,O
4,O
of,O
patients,O
who,O
underwent,O
ocular,O
examination,O
prior,O
to,O
therapy,O
with,O
PROMACTA,O
In,O
the,O
two,O
controlled,O
clinical,O
trials,O
in,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
and,O
thrombocytopenia,O
cataracts,AdverseReaction
developed,O
or,O
worsened,O
in,O
8,O
patients,O
treated,O
with,O
PROMACTA,O
and,O
5,O
patients,O
treated,O
with,O
placebo,O
Cataracts,AdverseReaction
were,O
observed,O
in,O
toxicology,O
studies,O
of,O
eltrombopag,O
in,O
rodents,Animal
see,O
Nonclinical,O
Toxicology,O
13,O
2,O
Perform,O
a,O
baseline,O
ocular,O
examination,O
prior,O
to,O
administration,O
of,O
PROMACTA,O
and,O
during,O
therapy,O
with,O
PROMACTA,O
regularly,O
monitor,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
cataracts,O
""
BOXED,O
WARNING,O
WARNING,O
RISK,Factor
FOR,O
HEPATIC DECOMPENSATION,AdverseReaction
IN,O
PATIENTS,O
WITH,O
CHRONIC,O
HEPATITIS,O
C,O
WARNING,O
RISK,Factor
FOR,O
HEPATIC DECOMPENSATION,AdverseReaction
IN,O
PATIENTS,O
WITH,O
CHRONIC,O
HEPATITIS,O
C,O
In,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
PROMACTA,O
r,O
in,O
combination,O
with,O
interferon,O
and,O
ribavirin,O
may,O
increase,O
the,O
risk,Factor
of,O
hepatic decompensation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
RISK,Factor
FOR,O
HEPATIC DECOMPENSATION,AdverseReaction
IN,O
PATIENTS,O
WITH,O
CHRONIC,O
HEPATITIS,O
C,O
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
In,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
PROMACTA,O
in,O
combination,O
with,O
interferon,O
and,O
ribavirin,O
may,O
increase,O
the,O
risk,Factor
of,O
hepatic decompensation,AdverseReaction
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
associated,O
with,O
PROMACTA,O
are,O
described,O
in,O
other,O
sections,O
Hepatic Decompensation,AdverseReaction
in,O
Patients,O
with,O
Chronic,O
Hepatitis,O
C,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hepatotoxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Thrombotic,AdverseReaction
Thromboembolic Complications,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Cataracts,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
In,O
adult,O
patients,O
with,O
ITP,O
the,O
most,O
common,O
adverse,O
reactions,O
greater,O
than,O
or,O
equal,O
to,O
5,O
and,O
greater,O
than,O
placebo,O
were,O
nausea,AdverseReaction
diarrhea,AdverseReaction
upper respiratory tract infection,AdverseReaction
vomiting,AdverseReaction
increased ALT,AdverseReaction
myalgia,AdverseReaction
and,O
urinary tract infection,AdverseReaction
6,O
1,O
In,O
pediatric,O
patients,O
age,O
6,O
years,O
and,O
older,O
with,O
ITP,O
the,O
most,O
common,O
adverse,O
reactions,O
greater,O
than,O
or,O
equal,O
to,O
10,O
and,O
greater,O
than,O
placebo,O
were,O
upper respiratory tract infection,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
rhinitis,AdverseReaction
6,O
1,O
In,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
associated,O
thrombocytopenia,O
the,O
most,O
common,O
adverse,O
reactions,O
greater,O
than,O
or,O
equal,O
to,O
10,O
and,O
greater,O
than,O
placebo,O
were,O
anemia,AdverseReaction
pyrexia,AdverseReaction
fatigue,AdverseReaction
headache,AdverseReaction
nausea,AdverseReaction
diarrhea,AdverseReaction
decreased appetite,AdverseReaction
influenza like illness,AdverseReaction
asthenia,AdverseReaction
insomnia,AdverseReaction
cough,AdverseReaction
pruritus,AdverseReaction
chills,AdverseReaction
myalgia,AdverseReaction
alopecia,AdverseReaction
and,O
peripheral edema,AdverseReaction
6,O
1,O
In,O
patients,O
with,O
severe,O
aplastic,O
anemia,O
the,O
most,O
common,O
adverse,O
reactions,O
greater,O
than,O
or,O
equal,O
to,O
20,O
were,O
nausea,AdverseReaction
fatigue,AdverseReaction
cough,AdverseReaction
diarrhea,AdverseReaction
and,O
headache,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GlaxoSmithKline,O
at,O
1,O
888,O
825,O
5249,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Chronic,O
Immune,O
Idiopathic,O
Thrombocytopenia,O
Adults,O
In,O
clinical,O
trials,O
hemorrhage,AdverseReaction
was,O
the,O
most,O
common,O
serious,O
adverse,O
reaction,O
and,O
most,O
hemorrhagic reactions,AdverseReaction
followed,O
discontinuation,O
of,O
PROMACTA,O
Other,O
serious,O
adverse,O
reactions,O
included,O
thrombotic,AdverseReaction
thromboembolic complications,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
of,O
PROMACTA,O
to,O
446,O
patients,O
with,O
chronic,O
ITP,O
aged,O
18,O
to,O
85,O
years,O
of,O
whom,O
65,O
were,O
female,O
across,O
the,O
ITP,O
clinical,O
development,O
program,O
including,O
three,O
placebo,O
controlled,O
trials,O
PROMACTA,O
was,O
administered,O
to,O
277,O
patients,O
for,O
at,O
least,O
6,O
months,O
and,O
202,O
patients,O
for,O
at,O
least,O
1,O
year,O
Table,O
4,O
presents,O
the,O
most,O
common,O
adverse,O
drug,O
reactions,O
experienced,O
by,O
greater,O
than,O
or,O
equal,O
to,O
3,O
of,O
patients,O
receiving,O
PROMACTA,O
from,O
the,O
three,O
placebo,O
controlled,O
trials,O
with,O
a,O
higher,O
incidence,O
in,O
PROMACTA,O
versus,O
placebo,O
Table,O
4,O
Adverse,O
Reactions,O
3,O
from,O
Three,O
Placebo,O
controlled,O
Trials,O
in,O
Adults,O
with,O
Chronic,O
Immune,O
Idiopathic,O
Thrombocytopenia,O
Adverse,O
Reaction,O
PROMACTA,O
50,O
mg,O
n,O
241,O
Placebo,O
n,O
128,O
Nausea,AdverseReaction
9,O
3,O
Diarrhea,AdverseReaction
9,O
7,O
Upper respiratory tract infection,AdverseReaction
7,O
6,O
Vomiting,AdverseReaction
6,O
1,O
Increased ALT,AdverseReaction
5,O
3,O
Myalgia,AdverseReaction
5,O
2,O
Urinary tract infection,AdverseReaction
5,O
3,O
Oropharyngeal pain,AdverseReaction
4,O
3,O
Increased AST,AdverseReaction
4,O
2,O
Pharyngitis,AdverseReaction
4,O
2,O
Back pain,AdverseReaction
3,O
2,O
Influenza,AdverseReaction
3,O
2,O
Paresthesia,AdverseReaction
3,O
2,O
Rash,AdverseReaction
3,O
2,O
In,O
the,O
three,O
controlled,O
clinical,O
chronic,O
ITP,O
trials,O
alopecia,AdverseReaction
musculoskeletal pain,AdverseReaction
blood alkaline phosphatase increased,AdverseReaction
and,O
dry mouth,AdverseReaction
were,O
the,O
adverse,O
reactions,O
reported,O
in,O
2,O
of,O
patients,O
treated,O
with,O
PROMACTA,O
and,O
in,O
no,O
patients,O
who,O
received,O
placebo,O
Among,O
299,O
patients,O
with,O
chronic,O
ITP,O
who,O
received,O
PROMACTA,O
in,O
the,O
single,O
arm,O
extension,O
trial,O
the,O
adverse,O
reactions,O
occurred,O
in,O
a,O
pattern,O
similar,O
to,O
that,O
seen,O
in,O
the,O
placebo,O
controlled,O
trials,O
Table,O
5,O
presents,O
the,O
most,O
common,O
treatment,O
related,O
adverse,O
reactions,O
experienced,O
by,O
greater,O
than,O
or,O
equal,O
to,O
3,O
of,O
patients,O
receiving,O
PROMACTA,O
from,O
the,O
extension,O
trial,O
Table,O
5,O
Treatment,O
related,O
Adverse,O
Reactions,O
3,O
from,O
Extension,O
Trial,O
in,O
Adults,O
with,O
Chronic,O
Immune,O
Idiopathic,O
Thrombocytopenia,O
Adverse,O
Reaction,O
PROMACTA,O
50,O
mg,O
n,O
299,O
Headache,AdverseReaction
10,O
Hyperbilirubinemia,AdverseReaction
6,O
ALT increased,AdverseReaction
6,O
Cataract,AdverseReaction
5,O
AST increased,AdverseReaction
4,O
Fatigue,AdverseReaction
4,O
Nausea,AdverseReaction
4,O
In,O
the,O
three,O
controlled,O
chronic,O
ITP,O
trials,O
serum liver test abnormalities liver test abnormalities,AdverseReaction
predominantly,O
Grade 2,Severity
or,O
less,O
in,O
severity,O
were,O
reported,O
in,O
11,O
and,O
7,O
of,O
patients,O
for,O
PROMACTA,O
and,O
placebo,O
respectively,O
Four,O
patients,O
1,O
treated,O
with,O
PROMACTA,O
and,O
three,O
patients,O
in,O
the,O
placebo,O
group,O
2,O
discontinued,O
treatment,O
due,O
to,O
hepatobiliary laboratory abnormalities,AdverseReaction
Seven,O
of,O
the,O
patients,O
treated,O
with,O
PROMACTA,O
in,O
the,O
controlled,O
trials,O
with,O
hepatobiliary laboratory abnormalities,AdverseReaction
were,O
re,O
exposed,O
to,O
PROMACTA,O
in,O
the,O
extension,O
trial,O
Six,O
of,O
these,O
patients,O
again,O
experienced,O
liver test abnormalities test abnormalities,AdverseReaction
predominantly,O
Grade 1,Severity
resulting,O
in,O
discontinuation,O
of,O
PROMACTA,O
in,O
one,O
patient,O
In,O
the,O
extension,O
chronic,O
ITP,O
trial,O
one,O
additional,O
patient,O
had,O
PROMACTA,O
discontinued,O
due,O
to,O
liver test abnormalities test abnormalities,AdverseReaction
less,O
than,O
or,O
equal,O
to,O
Grade 3,Severity
In,O
a,O
placebo,O
controlled,O
trial,O
of,O
PROMACTA,O
in,O
patients,O
with,O
chronic,O
liver,O
diseaseand,O
thrombocytopenia,O
not,O
related,O
to,O
ITP,O
six,O
patients,O
treated,O
with,O
PROMACTA,O
and,O
one,O
patient,O
in,O
the,O
placebo,O
group,O
developed,O
portal vein thromboses,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Pediatric,O
Patients,O
The,O
data,O
described,O
below,O
reflect,O
median,O
exposure,O
to,O
PROMACTA,O
of,O
91,O
days,O
for,O
82,O
pediatric,O
patients,O
aged,O
6,O
to,O
17,O
years,O
with,O
chronic,O
ITP,O
of,O
whom,O
52,O
were,O
female,O
across,O
the,O
randomized,O
phase,O
of,O
two,O
placebo,O
controlled,O
trials,O
Table,O
6,O
presents,O
the,O
most,O
common,O
adverse,O
drug,O
reactions,O
experienced,O
by,O
greater,O
than,O
or,O
equal,O
to,O
3,O
of,O
pediatric,O
patients,O
6,O
years,O
and,O
older,O
receiving,O
PROMACTA,O
across,O
the,O
two,O
placebo,O
controlled,O
trials,O
with,O
a,O
higher,O
incidence,O
for,O
PROMACTA,O
versus,O
placebo,O
Table,O
6,O
Adverse,O
Reactions,O
3,O
with,O
a,O
Higher,O
Incidence,O
for,O
PROMACTA,O
versus,O
Placebo,O
from,O
Two,O
Placebo,O
controlled,O
Trials,O
in,O
Pediatric,O
Patients,O
6,O
Years,O
and,O
Older,O
with,O
Chronic,O
Immune,O
Idiopathic,O
Thrombocytopenia,O
PROMACTA,O
Placebo,O
n,O
82,O
n,O
40,O
Adverse,O
Reaction,O
Upper respiratory tract infection,AdverseReaction
16,O
5,O
Nasopharyngitis,AdverseReaction
12,O
5,O
Rhinitis,AdverseReaction
11,O
8,O
Abdominal pain,AdverseReaction
9,O
5,O
Cough,AdverseReaction
9,O
0,O
Oropharyngeal pain,AdverseReaction
9,O
3,O
Toothache,AdverseReaction
6,O
0,O
AST increased,AdverseReaction
5,O
0,O
Diarrhea,AdverseReaction
5,O
3,O
Rash,AdverseReaction
5,O
3,O
ALT,O
increaseda,O
6,O
0,O
Vitamin D deficiency,AdverseReaction
4,O
0,O
a,O
Includes,O
adverse,O
reactions,O
or,O
laboratory,O
abnormalities,O
3,O
x,O
ULN,O
Chronic,O
Hepatitis,O
C,O
associated,O
Thrombocytopenia,O
In,O
the,O
two,O
placebo,O
controlled,O
trials,O
955,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
associated,O
thrombocytopenia,O
received,O
PROMACTA,O
Table,O
7,O
presents,O
the,O
most,O
common,O
adverse,O
drug,O
reactions,O
experienced,O
by,O
greater,O
than,O
or,O
equal,O
to,O
10,O
of,O
patients,O
receiving,O
PROMACTA,O
compared,O
with,O
placebo,O
Table,O
7,O
Adverse,O
Reactions,O
10,O
and,O
Greater,O
than,O
Placebo,O
from,O
Two,O
Placebo,O
controlled,O
Trials,O
in,O
Adults,O
with,O
Chronic,O
Hepatitis,O
C,O
Adverse,O
Reaction,O
PROMACTA,O
Peginterferon,O
Ribavirin,O
n,O
955,O
Placebo,O
Peginterferon,O
Ribavirin,O
n,O
484,O
Anemia,AdverseReaction
40,O
35,O
Pyrexia,AdverseReaction
30,O
24,O
Fatigue,AdverseReaction
28,O
23,O
Headache,AdverseReaction
21,O
20,O
Nausea,AdverseReaction
19,O
14,O
Diarrhea,AdverseReaction
19,O
11,O
Decreased appetite,AdverseReaction
18,O
14,O
Influenza like illness,AdverseReaction
18,O
16,O
Asthenia,AdverseReaction
16,O
13,O
Insomnia,AdverseReaction
16,O
15,O
Cough,AdverseReaction
15,O
12,O
Pruritus,AdverseReaction
15,O
13,O
Chills,AdverseReaction
14,O
9,O
Myalgia,AdverseReaction
12,O
10,O
Alopecia,AdverseReaction
10,O
6,O
Peripheral edema,AdverseReaction
10,O
5,O
In,O
the,O
two,O
controlled,O
clinical,O
trials,O
in,O
patients,O
with,O
chronic,O
hepatitis,O
C,O
hyperbilirubinemia,AdverseReaction
was,O
reported,O
in,O
8,O
of,O
patients,O
receiving,O
PROMACTA,O
compared,O
with,O
3,O
for,O
placebo,O
Total bilirubin greater than or equal to 1 5 x ULN,AdverseReaction
was,O
reported,O
in,O
76,O
and,O
50,O
of,O
patients,O
receiving,O
PROMACTA,O
and,O
placebo,O
respectively,O
ALT,AdverseReaction
or,O
AST greater than or equal to 3 x ULN than or equal to 3 x ULN,AdverseReaction
was,O
reported,O
in,O
34,O
and,O
38,O
of,O
patients,O
for,O
PROMACTA,O
and,O
placebo,O
respectively,O
Severe,O
Aplastic,O
Anemia,O
In,O
the,O
single,O
arm,O
open,O
label,O
trial,O
43,O
patients,O
with,O
severe,O
aplastic,O
anemia,O
received,O
PROMACTA,O
Eleven,O
patients,O
26,O
were,O
treated,O
for,O
greater,O
than,O
6,O
months,O
and,O
7,O
patients,O
16,O
were,O
treated,O
for,O
greater,O
than,O
1,O
year,O
The,O
most,O
common,O
adverse,O
reactions,O
greater,O
than,O
or,O
equal,O
to,O
20,O
were,O
nausea,AdverseReaction
fatigue,AdverseReaction
cough,AdverseReaction
diarrhea,AdverseReaction
and,O
headache,AdverseReaction
Table,O
8,O
Adverse,O
Reactions,O
10,O
from,O
One,O
Open,O
label,O
Trial,O
in,O
Adults,O
with,O
Severe,O
Aplastic,O
Anemia,O
Adverse,O
Reaction,O
PROMACTA,O
n,O
43,O
Nausea,AdverseReaction
33,O
Fatigue,AdverseReaction
28,O
Cough,AdverseReaction
23,O
Diarrhea,AdverseReaction
21,O
Headache,AdverseReaction
21,O
Pain in extremity,AdverseReaction
19,O
Dyspnea,AdverseReaction
14,O
Pyrexia,AdverseReaction
14,O
Dizziness,AdverseReaction
14,O
Oropharyngeal pain,AdverseReaction
14,O
Febrile neutropenia,AdverseReaction
14,O
Abdominal pain,AdverseReaction
12,O
Ecchymosis,AdverseReaction
12,O
Muscle spasms,AdverseReaction
12,O
Transaminases increased,AdverseReaction
12,O
Arthralgia,AdverseReaction
12,O
Rhinorrhea,AdverseReaction
12,O
In,O
this,O
trial,O
patients,O
had,O
bone,O
marrow,O
aspirates,O
evaluated,O
for,O
cytogenetic,O
abnormalities,O
Eight,O
patients,O
had,O
a,O
new,O
cytogenetic abnormality,AdverseReaction
reported,O
on,O
therapy,O
including,O
5,O
patients,O
who,O
had,O
complex,O
changes in chromosome 7,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
PROMACTA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
the,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Vascular,O
Disorders,O
Thrombotic microangiopathy,AdverseReaction
with,O
acute renal failure,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Do,O
not,O
use,O
near,O
eyes,O
or,O
mucous,O
membranes,O
5,O
1,O
Inhalation,O
of,O
airborne,O
capsaicin,O
can,Factor
result,O
in,O
coughing,AdverseReaction
or,O
sneezing,AdverseReaction
5,O
2,O
If,O
irritation,O
of,O
eyes,O
or,O
airway,O
occurs,O
remove,O
the,O
affected,O
individual,O
from,O
the,O
vicinity,O
of,O
Qutenza,O
and,O
flush,O
the,O
mucous,O
membranes,O
or,O
eyes,O
with,O
water,O
If,O
skin,O
not,O
intended,O
to,O
be,O
treated,O
comes,O
into,O
contact,O
with,O
Qutenza,O
apply,O
Cleansing,O
Gel,O
and,O
then,O
wipe,O
off,O
with,O
dry,O
gauze,O
5,O
2,O
5,O
3,O
Transient,Severity
increases in blood pressure,AdverseReaction
may,Factor
occur,O
in,O
patients,O
during,O
and,O
shortly,O
after,O
the,O
Qutenza,O
treatment,O
Monitor,O
blood,O
pressure,O
during,O
and,O
following,O
the,O
treatment,O
procedure,O
For,O
those,O
patients,O
who,O
require,O
the,O
use,O
of,O
opioids,O
to,O
treat,O
pain,O
during,O
or,O
following,O
the,O
procedure,O
their,O
ability,O
to,O
perform,O
potentially,O
hazardous,O
activities,O
such,O
as,O
driving,O
or,O
operating,O
machinery,O
may,O
be,O
affected,O
5,O
4,O
5,O
5,O
5,O
1,O
Eye,O
and,O
Mucous,O
Membrane,O
Exposure,O
Do,O
not,O
apply,O
Qutenza,O
to,O
the,O
face,O
or,O
scalp,O
to,O
avoid,O
risk,O
of,O
exposure,O
to,O
the,O
eyes,O
or,O
mucous,O
membranes,O
5,O
2,O
Aerosolization,O
of,O
Capsaicin,O
Aerosolization,O
of,O
capsaicin,O
can,O
occur,O
upon,O
rapid,O
removal,O
of,O
Qutenza,O
patches,O
Therefore,O
remove,O
Qutenza,O
patches,O
gently,O
and,O
slowly,O
by,O
rolling,O
the,O
adhesive,O
side,O
inward,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
If,O
irritation,O
of,O
eyes,O
or,O
airways,O
occurs,O
remove,O
the,O
affected,O
individual,O
from,O
the,O
vicinity,O
of,O
Qutenza,O
Flush,O
eyes,O
and,O
mucous,O
membranes,O
with,O
cool,O
water,O
Inhalation,O
of,O
airborne,O
capsaicin,O
can,Factor
result,O
in,O
coughing,AdverseReaction
or,O
sneezing,AdverseReaction
Provide,O
supportive,O
medical,O
care,O
if,O
shortness,O
of,O
breath,O
develops,O
5,O
3,O
Unintended,O
Skin,O
Exposure,O
If,O
skin,O
not,O
intended,O
to,O
be,O
treated,O
comes,O
in,O
contact,O
with,O
Qutenza,O
apply,O
Cleansing,O
Gel,O
for,O
one,O
minute,O
and,O
wipe,O
off,O
with,O
dry,O
gauze,O
After,O
the,O
Cleansing,O
Gel,O
has,O
been,O
wiped,O
off,O
wash,O
the,O
area,O
with,O
soap,O
and,O
water,O
5,O
4,O
Application,O
Associated,O
Pain,O
Even,O
following,O
use,O
of,O
a,O
local,O
anesthetic,O
prior,O
to,O
administration,O
of,O
Qutenza,O
patients,O
may,Factor
experience,O
substantial,Severity
procedural pain,AdverseReaction
Prepare,O
to,O
treat,O
acute,O
pain,O
during,O
and,O
following,O
the,O
application,O
procedure,O
with,O
local,O
cooling,O
such,O
as,O
an,O
ice,O
pack,O
and,O
or,O
appropriate,O
analgesic,O
medication,O
such,O
as,O
opioids,O
Opioids,O
may,O
affect,O
the,O
ability,O
to,O
perform,O
potentially,O
hazardous,O
activities,O
such,O
as,O
driving,O
or,O
operating,O
machinery,O
5,O
5,O
Increase,O
in,O
Blood,O
Pressure,O
In,O
clinical,O
trials,O
increases in blood pressure,AdverseReaction
occurred,O
during,O
or,O
shortly,O
after,O
exposure,O
to,O
Qutenza,O
The,O
changes,O
averaged,O
less,O
than,O
10,O
mm,O
Hg,O
although,O
some,O
patients,O
had,O
greater,O
increases,O
and,O
these,O
changes,O
lasted,O
for,O
approximately,O
two,O
hours,O
after,O
patch,O
removal,O
Increases in blood pressure,AdverseReaction
were,O
unrelated,O
to,O
the,O
pretreatment,O
blood,O
pressure,O
but,O
were,O
related,O
to,O
treatment,O
related,O
increases in pain,AdverseReaction
Monitor,O
blood,O
pressure,O
periodically,O
during,O
the,O
treatment,O
and,O
provide,O
adequate,O
support,O
for,O
treatment,O
related,O
pain,O
Patients,O
with,O
unstable,O
or,O
poorly,O
controlled,O
hypertension,O
a,O
recent,O
history,O
of,O
cardiovascular,O
or,O
cerebrovascular,O
events,O
may,O
be,O
at,O
an,O
increased,O
risk,Factor
of,O
adverse cardiovascular effects,AdverseReaction
Consider,O
these,O
factors,O
prior,O
to,O
initiating,O
Qutenza,O
treatment,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
elsewhere,O
in,O
the,O
labeling,O
Application Associated Pain,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Increase in Blood Pressure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
and,O
greater,O
than,O
control,O
are,O
application site erythema,AdverseReaction
application site pain,AdverseReaction
application site pruritus,AdverseReaction
and,O
application site papules,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Acorda,O
Therapeutics,O
at,O
1,O
877,O
900,O
6479,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
other,O
drugs,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Across,O
all,O
controlled,O
and,O
uncontrolled,O
trials,O
more,O
than,O
1,O
600,O
patients,O
have,O
received,O
Qutenza,O
A,O
total,O
of,O
394,O
patients,O
received,O
more,O
than,O
one,O
treatment,O
application,O
and,O
274,O
patients,O
were,O
followed,O
for,O
48,O
weeks,O
or,O
longer,O
In,O
controlled,O
clinical,O
studies,O
98,O
of,O
patients,O
completed,O
90,O
of,O
the,O
intended,O
patch,O
application,O
duration,O
Among,O
patients,O
treated,O
with,O
Qutenza,O
1,O
discontinued,O
prematurely,O
due,O
to,O
an,O
adverse,O
event,O
Controlled,O
Clinical,O
Studies,O
Common,O
Adverse,O
Reactions,O
Adverse,O
reactions,O
occurring,O
in,O
5,O
of,O
patients,O
in,O
the,O
Qutenza,O
group,O
and,O
at,O
an,O
incidence,O
greater,O
than,O
in,O
the,O
control,O
group,O
were,O
application site erythema,AdverseReaction
application site pain,AdverseReaction
application site pruritus,AdverseReaction
and,O
application site papules,AdverseReaction
Table,O
1,O
summarizes,O
all,O
adverse,O
reactions,O
regardless,O
of,O
causality,O
occurring,O
in,O
1,O
of,O
patients,O
with,O
postherpetic,O
neuralgia,O
in,O
the,O
Qutenza,O
group,O
for,O
which,O
the,O
incidence,O
was,O
greater,O
than,O
in,O
the,O
control,O
group,O
The,O
majority,O
of,O
application site reactions site reactions,AdverseReaction
were,O
transient,Severity
and,O
self,O
limited,O
Transient,Severity
increases in pain,AdverseReaction
were,O
commonly,O
observed,O
on,O
the,O
day,O
of,O
treatment,O
in,O
patients,O
treated,O
with,O
Qutenza,O
Pain increases,AdverseReaction
occurring,O
during,O
patch,O
application,O
usually,O
began,O
to,O
resolve,O
after,O
patch,O
removal,O
On,O
average,O
pain,O
scores,O
returned,O
to,O
baseline,O
by,O
the,O
end,O
of,O
the,O
treatment,O
day,O
and,O
then,O
remained,O
at,O
or,O
below,O
baseline,O
levels,O
A,O
majority,O
of,O
Qutenza,O
treated,O
patients,O
in,O
clinical,O
studies,O
had,O
adverse,O
reactions,O
with,O
a,O
maximum,O
intensity,O
of,O
mild,O
or,O
moderate,O
TABLE,O
1,O
Treatment,O
emergent,O
adverse,O
reaction,O
incidence,O
in,O
controlled,O
trials,O
in,O
Postherpetic,O
Neuralgia,O
Events,O
in,O
1,O
of,O
Qutenza,O
treated,O
patients,O
and,O
at,O
least,O
1,O
greater,O
in,O
the,O
Qutenza,O
group,O
than,O
in,O
the,O
Control,O
group,O
Body,O
SystemPreferred,O
Term,O
Qutenza60,O
minutes,O
N,O
622,O
Control60,O
minutes,O
N,O
495,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Application Site Erythema,AdverseReaction
63,O
54,O
Application Site Pain,AdverseReaction
42,O
21,O
Application Site Pruritus,AdverseReaction
6,O
4,O
Application Site Papules,AdverseReaction
6,O
3,O
Application Site Edema,AdverseReaction
4,O
1,O
Application Site Swelling,AdverseReaction
2,O
1,O
Application Site Dryness,AdverseReaction
2,O
1,O
Infections,O
and,O
Infestations,O
Nasopharyngitis,AdverseReaction
4,O
2,O
Bronchitis,AdverseReaction
2,O
1,O
Sinusitis,AdverseReaction
3,O
1,O
Gastrointestinal,O
Disorders,O
Nausea,AdverseReaction
5,O
2,O
Vomiting,AdverseReaction
3,O
1,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorder,O
Pruritus,AdverseReaction
2,O
1,O
Vascular,O
Disorders,O
Hypertension,AdverseReaction
2,O
1,O
Other,O
Adverse,O
Reactions,O
Observed,O
During,O
the,O
Clinical,O
Studies,O
of,O
Qutenza,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Application site urticaria,AdverseReaction
Application site paresthesia,AdverseReaction
Application site dermatitis,AdverseReaction
Application site hyperesthesia,AdverseReaction
Application site excoriation,AdverseReaction
Application site warmth,AdverseReaction
Application site anesthesia,AdverseReaction
Application site bruising,AdverseReaction
Application site inflammation,AdverseReaction
Application site exfoliation,AdverseReaction
Peripheral edema,AdverseReaction
Nervous,O
System,O
Disorders,O
Headache,AdverseReaction
Burning sensation,AdverseReaction
Peripheral sensory neuropathy,AdverseReaction
Dizziness,AdverseReaction
Dysgeusia,AdverseReaction
Hyperesthesia,AdverseReaction
Hypoesthesia,AdverseReaction
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Cough,AdverseReaction
Throat irritation,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Abnormal skin odor,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Cerebrovascular Adverse Events,AdverseReaction
An,O
increased,O
incidence,O
of,O
cerebrovascular adverse events,AdverseReaction
e,O
g,O
stroke,AdverseReaction
transient ischemic attack,AdverseReaction
has,O
been,O
seen,O
in,O
elderly,O
patients,O
with,O
dementia,O
related,O
psychoses,O
treated,O
with,O
atypical antipsychotic drugs,DrugClass
5,O
2,O
Neuroleptic Malignant Syndrome,AdverseReaction
Manage,O
with,O
immediate,O
discontinuation,O
and,O
close,O
monitoring,O
5,O
3,O
Tardive Dyskinesia,AdverseReaction
Discontinue,O
if,O
clinically,O
appropriate,O
5,O
4,O
dispatch,O
unexpected,O
key,O
list,O
in,O
dispatch,O
table,O
caption,O
function,O
print_caption,O
at,O
0x1c6c8c0,O
text,O
function,O
print_text,O
at,O
0x1c6c500,O
Metabolic Changes,AdverseReaction
Atypical antipsychotic drugs,DrugClass
have,O
been,O
associated,O
with,O
metabolic changes,AdverseReaction
that,O
may,O
increase,O
cardiovascular,AdverseReaction
cerebrovascular risk,AdverseReaction
These,O
metabolic changes,AdverseReaction
include,O
hyperglycemia,AdverseReaction
dyslipidemia,AdverseReaction
and,O
weight gain,AdverseReaction
5,O
5,O
Hypersensitivity Reactions,AdverseReaction
Hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
and,O
angioedema,AdverseReaction
have,O
been,O
observed,O
5,O
6,O
Orthostatic Hypotension,AdverseReaction
Syncope,AdverseReaction
and,O
Other,O
Hemodynamic Effects,AdverseReaction
Dizziness,AdverseReaction
tachycardia,AdverseReaction
or,O
bradycardia,AdverseReaction
and,O
syncope,AdverseReaction
may,Factor
occur,O
especially,O
early,O
in,O
treatment,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
known,O
cardiovascular,O
or,O
cerebrovascular,O
disease,O
and,O
in,O
antipsychotic,O
naive,O
patients,O
5,O
7,O
Leukopenia,AdverseReaction
Neutropenia,AdverseReaction
and,O
Agranulocytosis,AdverseReaction
have,O
been,O
reported,O
with,O
antipsychotics,DrugClass
Patients,O
with,O
a,O
pre,O
existing,O
low,O
white,O
blood,O
cell,O
count,O
WBC,O
or,O
a,O
history,O
of,O
leukopenia,O
neutropenia,O
should,O
have,O
their,O
complete,O
blood,O
count,O
CBC,O
monitored,O
frequently,O
during,O
the,O
first,O
few,O
months,O
of,O
therapy,O
and,O
SAPHRIS,O
should,O
be,O
discontinued,O
at,O
the,O
first,O
sign,O
of,O
a,O
decline,O
in,O
WBC,O
in,O
the,O
absence,O
of,O
other,O
causative,O
factors,O
5,O
8,O
QT Prolongation,AdverseReaction
Increases in QT interval,AdverseReaction
avoid,O
use,O
with,O
drugs,O
that,O
also,O
increase,O
the,O
QT,O
interval,O
and,O
in,O
patients,O
with,O
risk,O
factors,O
for,O
prolonged,O
QT,O
interval,O
5,O
9,O
Seizures,AdverseReaction
Use,O
cautiously,O
in,O
patients,O
with,O
a,O
history,O
of,O
seizures,O
or,O
with,O
conditions,O
that,O
lower,O
the,O
seizure,O
threshold,O
5,O
11,O
Potential,Factor
for,O
Cognitive,AdverseReaction
and,O
Motor Impairment,AdverseReaction
Use,O
caution,O
when,O
operating,O
machinery,O
5,O
12,O
Suicide,AdverseReaction
The,O
possibility,O
of,O
a,O
suicide,O
attempt,O
is,O
inherent,O
in,O
schizophrenia,O
and,O
bipolar,O
disorder,O
Closely,O
supervise,O
high,O
risk,O
patients,O
5,O
14,O
5,O
1,O
Increased,O
Mortality,O
in,O
Elderly,O
Patients,O
with,O
Dementia,O
Related,O
Psychosis,O
Elderly,O
patients,O
with,O
dementia,O
related,O
psychosis,O
treated,O
with,O
antipsychotic drugs,DrugClass
are,O
at,O
an,O
increased,O
risk,O
of,O
death,AdverseReaction
Analyses,O
of,O
17,O
placebo,O
controlled,O
trials,O
modal,O
duration,O
of,O
10,O
weeks,O
largely,O
in,O
patients,O
taking,O
atypical antipsychotic drugs,DrugClass
revealed,O
a,O
risk,O
of,O
death,AdverseReaction
in,O
the,O
drug,O
treated,O
patients,O
of,O
between,O
1,O
6,O
to,O
1,O
7,O
times,O
that,O
seen,O
in,O
placebo,O
treated,O
patients,O
Over,O
the,O
course,O
of,O
a,O
typical,O
10,O
week,O
controlled,O
trial,O
the,O
rate,O
of,O
death,AdverseReaction
in,O
drug,O
treated,O
patients,O
was,O
about,O
4,O
5,O
compared,O
to,O
a,O
rate,O
of,O
about,O
2,O
6,O
in,O
the,O
placebo,O
group,O
Although,O
the,O
causes,O
of,O
death,AdverseReaction
were,O
varied,O
most,O
of,O
the,O
deaths,AdverseReaction
appeared,O
to,O
be,O
either,O
cardiovascular,O
e,O
g,O
heart failure,AdverseReaction
sudden death,AdverseReaction
or,O
infectious,O
e,O
g,O
pneumonia,AdverseReaction
in,O
nature,O
Observational,O
studies,O
suggest,O
that,O
similar,O
to,O
atypical,O
antipsychotic,O
drugs,O
treatment,O
with,O
conventional,O
antipsychotic,O
drugs,O
may,O
increase,O
mortality,O
The,O
extent,O
to,O
which,O
the,O
findings,O
of,O
increased mortality,AdverseReaction
in,O
observational,O
studies,O
may,O
be,O
attributed,O
to,O
the,O
antipsychotic drug,DrugClass
as,O
opposed,O
to,O
some,O
characteristic,O
s,O
of,O
the,O
patients,O
is,O
not,O
clear,O
SAPHRIS,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
dementia,O
related,O
psychosis,O
seeBoxed,O
Warningand,O
Warnings,O
and,O
Precautions,O
5,O
2,O
5,O
2,O
Cerebrovascular,O
Adverse,O
Events,O
Including,O
Stroke,O
In,O
Elderly,O
Patients,O
with,O
Dementia,O
Related,O
Psychosis,O
In,O
placebo,O
controlled,O
trials,O
with,O
risperidone,DrugClass
aripiprazole,DrugClass
and,O
olanzapine,DrugClass
in,O
elderly,O
subjects,O
with,O
dementia,O
there,O
was,O
a,O
higher,O
incidence,O
of,O
cerebrovascular adverse reactions,AdverseReaction
cerebrovascular accidents,AdverseReaction
and,O
transient ischemic attacks,AdverseReaction
including,O
fatalities,AdverseReaction
compared,O
to,O
placebo,O
treated,O
subjects,O
SAPHRIS,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
dementia,O
related,O
psychosis,O
see,O
alsoBoxed,O
Warningand,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
3,O
Neuroleptic,O
Malignant,O
Syndrome,O
A,O
potentially,Factor
fatal,AdverseReaction
symptom,O
complex,O
sometimes,O
referred,O
to,O
as,O
Neuroleptic Malignant Syndrome,AdverseReaction
NMS,AdverseReaction
has,O
been,O
reported,O
in,O
association,O
with,O
administration,O
of,O
antipsychotic,O
drugs,O
including,O
SAPHRIS,O
Clinical,O
manifestations,O
of,O
NMS,AdverseReaction
are,O
hyperpyrexia,AdverseReaction
muscle rigidity,AdverseReaction
altered mental status,AdverseReaction
and,O
evidence,O
of,O
autonomic instability,AdverseReaction
irregular pulse,AdverseReaction
or,O
blood pressure,AdverseReaction
tachycardia,AdverseReaction
diaphoresis,AdverseReaction
and,O
cardiac dysrhythmia,AdverseReaction
Additional,O
signs,O
may,Factor
include,O
elevated creatine phosphokinase,AdverseReaction
myoglobinuria,AdverseReaction
rhabdomyolysis,AdverseReaction
and,O
acute renal failure,AdverseReaction
The,O
diagnostic,O
evaluation,O
of,O
patients,O
with,O
this,O
syndrome,O
is,O
complicated,O
It,O
is,O
important,O
to,O
exclude,O
cases,O
where,O
the,O
clinical,O
presentation,O
includes,O
both,O
serious,O
medical,O
illness,O
e,O
g,O
pneumonia,O
systemic,O
infection,O
and,O
untreated,O
or,O
inadequately,O
treated,O
extrapyramidal,O
signs,O
and,O
symptoms,O
EPS,O
Other,O
important,O
considerations,O
in,O
the,O
differential,O
diagnosis,O
include,O
central,O
anticholinergic,O
toxicity,O
heat,O
stroke,O
drug,O
fever,O
and,O
primary,O
central,O
nervous,O
system,O
pathology,O
The,O
management,O
of,O
NMS,O
should,O
include,O
1,O
immediate,O
discontinuation,O
of,O
antipsychotic,O
drugs,O
and,O
other,O
drugs,O
not,O
essential,O
to,O
concurrent,O
therapy,O
2,O
intensive,O
symptomatic,O
treatment,O
and,O
medical,O
monitoring,O
and,O
3,O
treatment,O
of,O
any,O
concomitant,O
serious,O
medical,O
problems,O
for,O
which,O
specific,O
treatments,O
are,O
available,O
There,O
is,O
no,O
general,O
agreement,O
about,O
specific,O
pharmacological,O
treatment,O
regimens,O
for,O
NMS,O
If,O
a,O
patient,O
requires,O
antipsychotic,O
drug,O
treatment,O
after,O
recovery,O
from,O
NMS,O
the,O
potential,O
reintroduction,O
of,O
drug,O
therapy,O
should,O
be,O
carefully,O
considered,O
The,O
patient,O
should,O
be,O
carefully,O
monitored,O
since,O
recurrences,O
of,O
NMS,O
have,O
been,O
reported,O
5,O
4,O
Tardive,O
Dyskinesia,O
A,O
syndrome,O
of,O
potentially irreversible,Severity
involuntary dyskinetic movements,AdverseReaction
can,O
develop,O
in,O
patients,O
treated,O
with,O
antipsychotic drugs,DrugClass
Although,O
the,O
prevalence,O
of,O
the,O
syndrome,O
appears,O
to,O
be,O
highest,O
among,O
the,O
elderly,O
especially,O
elderly,O
women,O
it,O
is,O
impossible,O
to,O
rely,O
upon,O
prevalence,O
estimates,O
to,O
predict,O
at,O
the,O
inception,O
of,O
antipsychotic,O
treatment,O
which,O
patients,O
are,O
likely,O
to,O
develop,O
the,O
syndrome,O
Whether,O
antipsychotic drug,DrugClass
products,O
differ,O
in,O
their,O
potential,O
to,O
cause,O
Tardive Dyskinesia,AdverseReaction
TD,AdverseReaction
is,O
unknown,O
The,O
risk,O
of,O
developing,O
TD,AdverseReaction
and,O
the,O
likelihood,O
that,O
it,O
will,O
become,O
irreversible,Severity
are,O
believed,O
to,O
increase,O
as,O
the,O
duration,O
of,O
treatment,O
and,O
the,O
total,O
cumulative,O
dose,O
of,O
antipsychotic drugs,DrugClass
administered,O
to,O
the,O
patient,O
increase,O
However,O
the,O
syndrome,O
can,O
develop,O
although,O
much,O
less,O
commonly,O
after,O
relatively,O
brief,O
treatment,O
periods,O
at,O
low,O
doses,O
There,O
is,O
no,O
known,O
treatment,O
for,O
established,O
cases,O
of,O
TD,O
although,O
the,O
syndrome,O
may,O
remit,O
partially,O
or,O
completely,O
if,O
antipsychotic,O
treatment,O
is,O
withdrawn,O
Antipsychotic,O
treatment,O
itself,O
however,O
may,O
suppress,O
or,O
partially,O
suppress,O
the,O
signs,O
and,O
symptoms,O
of,O
the,O
syndrome,O
and,O
thereby,O
may,O
possibly,O
mask,O
the,O
underlying,O
process,O
The,O
effect,O
that,O
symptomatic,O
suppression,O
has,O
upon,O
the,O
long,O
term,O
course,O
of,O
the,O
syndrome,O
is,O
unknown,O
Given,O
these,O
considerations,O
SAPHRIS,O
should,O
be,O
prescribed,O
in,O
a,O
manner,O
that,O
is,O
most,O
likely,O
to,O
minimize,O
the,O
occurrence,O
of,O
TD,O
Chronic,O
antipsychotic,O
treatment,O
should,O
generally,O
be,O
reserved,O
for,O
patients,O
who,O
suffer,O
from,O
a,O
chronic,O
illness,O
that,O
1,O
is,O
known,O
to,O
respond,O
to,O
antipsychotic,O
drugs,O
and,O
2,O
for,O
whom,O
alternative,O
equally,O
effective,O
but,O
potentially,O
less,O
harmful,O
treatments,O
are,O
not,O
available,O
or,O
appropriate,O
In,O
patients,O
who,O
do,O
require,O
chronic,O
treatment,O
the,O
smallest,O
dose,O
and,O
the,O
shortest,O
duration,O
of,O
treatment,O
producing,O
a,O
satisfactory,O
clinical,O
response,O
should,O
be,O
sought,O
The,O
need,O
for,O
continued,O
treatment,O
should,O
be,O
reassessed,O
periodically,O
If,O
signs,O
and,O
symptoms,O
of,O
TD,O
appear,O
in,O
a,O
patient,O
on,O
SAPHRIS,O
drug,O
discontinuation,O
should,O
be,O
considered,O
However,O
some,O
patients,O
may,O
require,O
treatment,O
with,O
SAPHRIS,O
despite,O
the,O
presence,O
of,O
the,O
syndrome,O
5,O
5,O
Metabolic,O
Changes,O
Atypical antipsychotic drugs,DrugClass
have,O
been,O
associated,O
with,O
metabolic changes,AdverseReaction
that,O
may,O
increase cardiovascular,AdverseReaction
cerebrovascular risk,AdverseReaction
These,O
metabolic changes,AdverseReaction
include,O
hyperglycemia,AdverseReaction
dyslipidemia,AdverseReaction
and,O
body weight gain,AdverseReaction
While,O
all,O
of,O
the,O
drugs in the class,DrugClass
have,O
been,O
shown,O
to,O
produce,O
some,O
metabolic changes,AdverseReaction
each,O
drug,O
has,O
its,O
own,O
specific,O
risk,O
profile,O
Hyperglycemia,O
and,O
Diabetes,O
Mellitus,O
Hyperglycemia,AdverseReaction
in,O
some,O
cases,O
extreme,Severity
and,O
associated,O
with,O
ketoacidosis,AdverseReaction
or,O
hyperosmolar coma,AdverseReaction
or,O
death,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
atypical antipsychotics,DrugClass
Assessment,O
of,O
the,O
relationship,O
between,O
atypical,O
antipsychotic,O
use,O
and,O
glucose,O
abnormalities,O
is,O
complicated,O
by,O
the,O
possibility,O
of,O
an,O
increased,O
background,O
risk,O
of,O
diabetes,O
mellitus,O
in,O
patients,O
with,O
schizophrenia,O
and,O
the,O
increasing,O
incidence,O
of,O
diabetes,O
mellitus,O
in,O
the,O
general,O
population,O
Given,O
these,O
confounders,O
the,O
relationship,O
between,O
atypical antipsychotic,DrugClass
use,O
and,O
hyperglycemia,AdverseReaction
related,O
adverse,O
reactions,O
is,O
not,O
completely,O
understood,O
However,O
epidemiological,O
studies,O
suggest,O
an,O
increased,O
risk,O
of,O
treatment,O
emergent,O
hyperglycemia,AdverseReaction
related,O
adverse,O
events,O
in,O
patients,O
treated,O
with,O
the,O
atypical antipsychotics,DrugClass
included,O
in,O
these,O
studies,O
Precise,O
risk,O
estimates,O
for,O
hyperglycemia,AdverseReaction
related,O
adverse,O
events,O
in,O
patients,O
treated,O
with,O
atypical antipsychotics,DrugClass
are,O
not,O
available,O
Patients,O
with,O
an,O
established,O
diagnosis,O
of,O
diabetes,O
mellitus,O
who,O
are,O
started,O
on,O
atypical,O
antipsychotics,O
should,O
be,O
monitored,O
regularly,O
for,O
worsening,O
of,O
glucose,O
control,O
Patients,O
with,O
risk,O
factors,O
for,O
diabetes,O
mellitus,O
e,O
g,O
obesity,O
family,O
history,O
of,O
diabetes,O
who,O
are,O
starting,O
treatment,O
with,O
atypical,O
antipsychotics,O
should,O
undergo,O
fasting,O
blood,O
glucose,O
testing,O
at,O
the,O
beginning,O
of,O
treatment,O
and,O
periodically,O
during,O
treatment,O
Any,O
patient,O
treated,O
with,O
atypical,O
antipsychotics,O
should,O
be,O
monitored,O
for,O
symptoms,O
of,O
hyperglycemia,O
including,O
polydipsia,O
polyuria,O
polyphagia,O
and,O
weakness,O
Patients,O
who,O
develop,O
symptoms,O
of,O
hyperglycemia,O
during,O
treatment,O
with,O
atypical,O
antipsychotics,O
should,O
undergo,O
fasting,O
blood,O
glucose,O
testing,O
In,O
some,O
cases,O
hyperglycemia,O
has,O
resolved,O
when,O
the,O
atypical,O
antipsychotic,O
was,O
discontinued,O
however,O
some,O
patients,O
required,O
continuation,O
of,O
anti,O
diabetic,O
treatment,O
despite,O
discontinuation,O
of,O
the,O
antipsychotic,O
drug,O
Adult,O
Patients,O
Pooled,O
data,O
from,O
the,O
short,O
term,O
placebo,O
controlled,O
schizophrenia,O
and,O
bipolar,O
mania,O
trials,O
are,O
presented,O
in,O
Table,O
1,O
TABLE,O
1,O
Changes,O
in,O
Fasting,O
Glucose,O
in,O
Adult,O
Patients,O
N,O
Number,O
of,O
patients,O
who,O
had,O
assessments,O
at,O
both,O
Baseline,O
and,O
Endpoint,O
N,O
Number,O
of,O
patients,O
at,O
risk,O
at,O
Baseline,O
with,O
assessments,O
at,O
both,O
Baseline,O
and,O
Endpoint,O
S,O
Includes,O
patients,O
treated,O
with,O
flexible,O
dose,O
of,O
SAPHRIS,O
5,O
or,O
10,O
mg,O
twice,O
daily,O
N,O
90,O
SAPHRIS,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
with,O
flexible,O
dosing,O
Schizophrenia,O
6,O
weeks,O
Bipolar,O
3,O
weeks,O
Placebo,O
SAPHRIS,O
Placebo,O
SAPHRIS5,O
or,O
10,O
mgtwice,O
daily,O
5,O
mgtwice,O
daily,O
10,O
mgtwice,O
daily,O
5,O
or,O
10,O
mgtwice,O
daily,O
S,O
Mean,O
Change,O
from,O
Baseline,O
in,O
Fasting,O
Glucose,O
at,O
Endpoint,O
Change,O
from,O
Baseline,O
mg,O
dL,O
N,O
0,O
2,O
232,O
3,O
8,O
158,O
1,O
1,O
153,O
3,O
2,O
377,O
0,O
6,O
89,O
0,O
6,O
156,O
Proportion,O
of,O
Patients,O
with,O
Shifts,O
from,O
Baseline,O
to,O
Endpoint,O
Normal,O
to,O
High,O
100,O
to,O
126,O
mg,O
dL,O
4,O
1,O
4,O
5,O
4,O
5,O
5,O
0,O
3,O
3,O
2,O
7,O
n,O
N,O
7,O
170,O
5,O
111,O
5,O
111,O
13,O
262,O
2,O
61,O
3,O
111,O
Borderline,O
to,O
High,O
100,O
and,O
126to,O
126,O
mg,O
dL,O
5,O
9,O
6,O
8,O
6,O
3,O
10,O
5,O
0,O
0,O
11,O
4,O
n,O
N,O
3,O
51,O
3,O
44,O
2,O
32,O
10,O
95,O
0,O
23,O
4,O
35,O
In,O
a,O
52,O
week,O
double,O
blind,O
comparator,O
controlled,O
trial,O
that,O
included,O
primarily,O
patients,O
with,O
schizophrenia,O
the,O
mean,O
increase,AdverseReaction
from,O
baseline,O
of fasting glucose,AdverseReaction
was,O
2,O
4,O
mg,O
dL,O
Pediatric,O
Patients,O
Data,O
from,O
the,O
short,O
term,O
placebo,O
controlled,O
trial,O
in,O
pediatric,O
patients,O
with,O
bipolar,O
I,O
disorder,O
are,O
shown,O
in,O
Table,O
2,O
TABLE,O
2,O
Changes,O
in,O
Fasting,O
Glucose,O
in,O
Pediatric,O
Subjects,O
Bipolar,O
I,O
Disorder,O
3,O
weeks,O
Placebo,O
SAPHRIS2,O
5,O
mgtwice,O
daily,O
SAPHRIS5,O
mgtwice,O
daily,O
SAPHRIS10,O
mgtwice,O
daily,O
Mean,O
Change,O
from,O
Baseline,O
in,O
Fasting,O
Glucose,O
at,O
Endpoint,O
Change,O
from,O
Baseline,O
mg,O
dL,O
N,O
2,O
24,O
56,O
1,O
43,O
51,O
0,O
45,O
57,O
0,O
34,O
52,O
Proportion,O
of,O
Subjects,O
with,O
Shifts,O
from,O
Baseline,O
to,O
Endpoint,O
Normal,O
to,O
High,O
45,O
100,O
to,O
126,O
mg,O
dL,O
0,O
0,O
1,O
8,O
0,O
n,O
N,O
0,O
56,O
0,O
51,O
1,O
57,O
0,O
52,O
Dyslipidemia,AdverseReaction
Undesirable alterations in lipids,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
treated,O
with,O
atypical antipsychotics,DrugClass
Adult,O
Patients,O
Pooled,O
data,O
from,O
the,O
short,O
term,O
placebo,O
controlled,O
schizophrenia,O
and,O
bipolar,O
mania,O
trials,O
are,O
presented,O
in,O
Table,O
3,O
TABLE,O
3,O
Changes,O
in,O
Lipids,O
in,O
Adult,O
Patients,O
N,O
Number,O
of,O
subjects,O
who,O
had,O
assessments,O
at,O
both,O
Baseline,O
and,O
Endpoint,O
S,O
Includes,O
subjects,O
treated,O
with,O
flexible,O
dose,O
of,O
SAPHRIS,O
5,O
or,O
10,O
mg,O
twice,O
daily,O
N,O
90,O
SAPHRIS,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
with,O
flexible,O
dosing,O
Schizophrenia,O
6,O
weeks,O
Bipolar,O
3,O
weeks,O
Placebo,O
SAPHRIS,O
Placebo,O
SAPHRIS5,O
or,O
10,O
mgtwice,O
daily,O
5,O
mgtwice,O
daily,O
10,O
mgtwice,O
daily,O
5,O
or,O
10,O
mgtwice,O
daily,O
S,O
Mean,O
Change,O
from,O
Baseline,O
mg,O
dL,O
Total,O
cholesterol,O
N,O
2,O
2,O
351,O
2,O
4,O
258,O
3,O
3,O
199,O
0,O
4,O
539,O
1,O
5,O
163,O
1,O
1,O
322,O
LDL,O
N,O
0,O
1,O
285,O
0,O
2,O
195,O
2,O
6,O
195,O
1,O
3,O
465,O
1,O
9,O
158,O
1,O
6,O
304,O
HDL,O
N,O
0,O
5,O
290,O
0,O
4,O
199,O
1,O
0,O
199,O
0,O
5,O
480,O
0,O
0,O
163,O
0,O
9,O
322,O
Fasting,O
triglycerides,O
N,O
7,O
6,O
233,O
1,O
9,O
159,O
0,O
1,O
154,O
3,O
8,O
380,O
17,O
9,O
129,O
3,O
5,O
237,O
Proportion,O
of,O
Patients,O
with,O
Shifts,O
from,O
Baseline,O
to,O
Endpoint,O
Total,O
cholesterolNormal,O
to,O
High,O
200,O
to,O
240,O
mg,O
dL,O
n,O
N,O
1,O
3,O
3,O
225,O
0,O
6,O
1,O
161,O
2,O
2,O
3,O
134,O
1,O
7,O
6,O
343,O
1,O
1,O
1,O
95,O
2,O
5,O
5,O
204,O
LDLNormal,O
to,O
High,O
100,O
to,O
160,O
mg,O
dL,O
n,O
N,O
1,O
7,O
2,O
117,O
0,O
0,O
0,O
80,O
1,O
2,O
1,O
86,O
1,O
0,O
2,O
196,O
1,O
9,O
1,O
53,O
0,O
0,O
0,O
141,O
HDLNormal,O
to,O
Low,O
40,O
to,O
40,O
mg,O
dL,O
n,O
N,O
10,O
7,O
21,O
196,O
13,O
3,O
18,O
135,O
14,O
7,O
20,O
136,O
14,O
0,O
45,O
322,O
7,O
4,O
9,O
122,O
8,O
7,O
21,O
242,O
Fasting,O
triglyceridesNormal,O
to,O
High,O
150,O
to,O
200,O
mg,O
dL,O
n,O
N,O
2,O
4,O
4,O
167,O
7,O
0,O
8,O
115,O
8,O
3,O
9,O
108,O
7,O
7,O
20,O
260,O
5,O
1,O
4,O
78,O
7,O
4,O
11,O
148,O
In,O
short,O
term,O
schizophrenia,O
trials,O
the,O
proportion,O
of,O
patients,O
with,O
total cholesterol elevations,AdverseReaction
240 mg dL,Severity
at,O
Endpoint,O
was,O
8,O
3,O
for,O
SAPHRIS,O
treated,O
patients,O
versus,O
7,O
for,O
placebo,O
treated,O
patients,O
The,O
proportion,O
of,O
patients,O
with,O
elevations in triglycerides,AdverseReaction
200 mg dL,Severity
at,O
Endpoint,O
was,O
13,O
2,O
for,O
SAPHRIS,O
treated,O
patients,O
versus,O
10,O
5,O
for,O
placebo,O
treated,O
patients,O
In,O
short,O
term,O
placebo,O
controlled,O
bipolar,O
mania,O
trials,O
the,O
proportion,O
of,O
patients,O
with,O
total cholesterol elevations,AdverseReaction
240 mg dL,Severity
at,O
Endpoint,O
was,O
8,O
7,O
for,O
SAPHRIS,O
treated,O
patients,O
versus,O
8,O
6,O
for,O
placebo,O
treated,O
patients,O
The,O
proportion,O
of,O
patients,O
with,O
elevations in triglycerides,AdverseReaction
200 mg dL,Severity
at,O
Endpoint,O
was,O
15,O
2,O
for,O
SAPHRIS,O
treated,O
patients,O
versus,O
11,O
4,O
for,O
placebo,O
treated,O
patients,O
In,O
a,O
52,O
week,O
double,O
blind,O
comparator,O
controlled,O
trial,O
that,O
included,O
primarily,O
patients,O
with,O
schizophrenia,O
the,O
mean,O
decrease,O
from,O
baseline,O
of,O
total,O
cholesterol,O
was,O
6,O
mg,O
dL,O
and,O
the,O
mean,O
decrease,O
from,O
baseline,O
of,O
fasting,O
triglycerides,O
was,O
9,O
8,O
mg,O
dL,O
Pediatric,O
Patients,O
Data,O
from,O
the,O
short,O
term,O
placebo,O
controlled,O
bipolar,O
mania,O
trial,O
are,O
presented,O
in,O
Table,O
4,O
TABLE,O
4,O
Changes,O
in,O
Fasting,O
Lipids,O
in,O
Pediatric,O
Subjects,O
N,O
Number,O
of,O
patients,O
who,O
had,O
assessments,O
at,O
both,O
Baseline,O
and,O
Endpoint,O
Bipolar,O
I,O
Disorder,O
3,O
weeks,O
Placebo,O
SAPHRIS2,O
5,O
mgtwice,O
daily,O
SAPHRIS5,O
mgtwice,O
daily,O
SAPHRIS10,O
mgtwice,O
daily,O
Mean,O
Change,O
from,O
Baseline,O
mg,O
dL,O
Total,O
fasting,O
cholesterol,O
N,O
2,O
3,O
57,O
3,O
7,O
50,O
7,O
2,O
57,O
9,O
3,O
52,O
Fasting,O
LDL,O
N,O
2,O
5,O
57,O
0,O
2,O
50,O
3,O
0,O
57,O
4,O
9,O
51,O
Fasting,O
HDL,O
N,O
1,O
6,O
57,O
2,O
3,O
50,O
1,O
5,O
57,O
1,O
7,O
52,O
Fasting,O
triglycerides,O
N,O
6,O
6,O
57,O
8,O
7,O
50,O
13,O
4,O
57,O
14,O
7,O
52,O
Proportion,O
of,O
Subjects,O
with,O
Shifts,O
from,O
Baseline,O
to,O
Endpoint,O
Total,O
fasting,O
cholesterolNormal,O
to,O
High,O
170,O
to,O
200,O
mg,O
dL,O
n,O
N,O
1,O
8,O
1,O
57,O
0,O
0,O
50,O
1,O
8,O
1,O
57,O
0,O
0,O
52,O
Fasting,O
LDLNormal,O
to,O
High,O
110,O
to,O
130,O
n,O
N,O
1,O
8,O
1,O
57,O
2,O
0,O
1,O
50,O
1,O
8,O
1,O
57,O
0,O
0,O
51,O
Fasting,O
HDLNormal,O
to,O
Low,O
40,O
to,O
40,O
mg,O
dL,O
n,O
N,O
3,O
5,O
2,O
57,O
6,O
0,O
3,O
50,O
3,O
5,O
2,O
57,O
9,O
6,O
5,O
52,O
Fasting,O
triglyceridesNormal,O
to,O
High,O
150,O
to,O
200,O
mg,O
dL,O
n,O
N,O
0,O
0,O
57,O
4,O
0,O
2,O
50,O
3,O
5,O
2,O
57,O
1,O
9,O
1,O
52,O
Weight,O
Gain,O
Increases in weight,AdverseReaction
have,O
been,O
observed,O
in,O
pre,O
marketing,O
clinical,O
trials,O
with,O
SAPHRIS,O
Patients,O
receiving,O
SAPHRIS,O
should,O
receive,O
regular,O
monitoring,O
of,O
weight,O
see,O
Patient,O
Counseling,O
Information,O
17,O
Adult,O
Patients,O
Pooled,O
data,O
on,O
mean,O
changes,O
in,O
body,O
weight,O
and,O
the,O
proportion,O
of,O
subjects,O
meeting,O
a,O
weight gain,AdverseReaction
criterion,O
of,O
7,O
of,O
body,O
weight,O
from,O
the,O
short,O
term,O
placebo,O
controlled,O
schizophrenia,O
and,O
bipolar,O
mania,O
trials,O
are,O
presented,O
in,O
Table,O
5,O
Table,O
5,O
Change,O
in,O
Body,O
Weight,O
in,O
Adult,O
Patients,O
from,O
Baseline,O
N,O
Number,O
of,O
subjects,O
who,O
had,O
assessments,O
at,O
both,O
Baseline,O
and,O
Endpoint,O
S,O
Includes,O
subjects,O
treated,O
with,O
flexible,O
dose,O
of,O
SAPHRIS,O
5,O
or,O
10,O
mg,O
twice,O
daily,O
N,O
90,O
SAPHRIS,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
with,O
flexible,O
dosing,O
Schizophrenia,O
6,O
weeks,O
Bipolar,O
3,O
weeks,O
Placebo,O
SAPHRIS,O
Placebo,O
SAPHRIS5,O
or,O
10,O
mgtwice,O
daily,O
5,O
mgtwice,O
daily,O
10,O
mgtwice,O
daily,O
5,O
or,O
10,O
mgtwice,O
daily,O
S,O
Change,O
from,O
Baseline,O
kg,O
N,O
0,O
0,O
348,O
1,O
0,O
251,O
0,O
9,O
200,O
1,O
1,O
532,O
0,O
2,O
171,O
1,O
3,O
336,O
Proportion,O
of,O
Patients,O
with,O
a,O
7,O
Increase in Body Weight,AdverseReaction
with,O
7,O
increase in body weight,AdverseReaction
1,O
6,O
4,O
4,O
4,O
8,O
4,O
9,O
0,O
5,O
5,O
8,O
Adult,O
Patients,O
In,O
a,O
52,O
week,O
double,O
blind,O
comparator,O
controlled,O
adult,O
trial,O
that,O
included,O
primarily,O
patients,O
with,O
schizophrenia,O
the,O
mean,O
weight gain,AdverseReaction
from,O
baseline,O
was,O
0,O
9,O
kg,O
The,O
proportion,O
of,O
patients,O
with,O
a,O
7,O
increase in body weight,AdverseReaction
at,O
Endpoint,O
was,O
14,O
7,O
Table,O
5provides,O
the,O
mean,O
weight change,AdverseReaction
from,O
baseline,O
and,O
the,O
proportion,O
of,O
patients,O
with,O
a,O
weight gain,AdverseReaction
of,O
7,O
categorized,O
by,O
Body,O
Mass,O
Index,O
BMI,O
at,O
baseline,O
Table,O
6,O
Weight,O
Change,O
Results,O
Categorized,O
by,O
BMI,O
at,O
Baseline,O
Comparator,O
Controlled,O
52,O
Week,O
Study,O
in,O
Adults,O
with,O
Schizophrenia,O
BMI,O
23,O
SAPHRIS,O
N,O
295,O
BMI,O
23,O
27,O
SAPHRIS,O
N,O
290,O
BMI,O
27,O
SAPHRIS,O
N,O
302,O
Mean,O
change,O
from,O
Baseline,O
kg,O
1,O
7,O
1,O
0,O
with,O
7,O
increase in body weight,AdverseReaction
22,O
13,O
9,O
Pediatric,O
Patients,O
Data,O
on,O
mean,O
changes in body weight,AdverseReaction
and,O
the,O
proportion,O
of,O
pediatric,O
patients,O
meeting,O
a,O
weight gain,AdverseReaction
criterion,O
of,O
7,O
of,O
body,O
weight,O
from,O
the,O
short,O
term,O
placebo,O
controlled,O
bipolar,O
mania,O
trial,O
are,O
presented,O
in,O
Table,O
7,O
To,O
adjust,O
for,O
normal,O
growth,O
z,O
scores,O
were,O
derived,O
measured,O
in,O
standard,O
deviations,O
SD,O
which,O
normalize,O
for,O
the,O
natural,O
growth,O
of,O
pediatric,O
patients,O
by,O
comparisons,O
to,O
age,O
and,O
sex,O
matched,O
population,O
standards,O
The,O
distance,O
of,O
a,O
z,O
score,O
from,O
0,O
represents,O
the,O
distance,O
of,O
a,O
percentile,O
from,O
the,O
median,O
measured,O
in,O
standard,O
deviations,O
SD,O
After,O
adjusting,O
for,O
age,O
and,O
sex,O
the,O
mean,O
change,O
from,O
baseline,O
to,O
endpoint,O
in,O
weight,O
z,O
score,O
for,O
SAPHRS,O
2,O
5,O
mg,O
5,O
mg,O
and,O
10,O
mg,O
twice,O
daily,O
was,O
0,O
11,O
0,O
08,O
and,O
0,O
09,O
SD,O
versus,O
0,O
02,O
SD,O
for,O
placebo,O
respectively,O
When,O
treating,O
pediatric,O
patients,O
weight,O
gain,O
should,O
be,O
monitored,O
and,O
assessed,O
against,O
that,O
expected,O
for,O
normal,O
growth,O
Table,O
7,O
Change,O
in,O
Body,O
Weight,O
in,O
Pediatric,O
Subjects,O
from,O
Baseline,O
N,O
Number,O
of,O
subjects,O
who,O
had,O
assessments,O
at,O
both,O
Baseline,O
and,O
Endpoint,O
Bipolar,O
I,O
Disorder,O
3,O
weeks,O
Placebo,O
SAPHRIS2,O
5,O
mgtwice,O
daily,O
SAPHRIS5,O
mgtwice,O
daily,O
SAPHRIS10,O
mgtwice,O
daily,O
Change,O
from,O
Baseline,O
kg,O
N,O
0,O
5,O
89,O
1,O
7,O
92,O
1,O
6,O
90,O
1,O
4,O
87,O
Proportion,O
of,O
Subjects,O
with,O
a,O
7,O
Increase in Body Weight,AdverseReaction
with,O
7,O
increase in body weight,AdverseReaction
1,O
1,O
12,O
0,O
8,O
9,O
8,O
0,O
5,O
6,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
treated,O
with,O
SAPHRIS,O
In,O
several,O
cases,O
these,O
reactions,O
occurred,O
after,O
the,O
first,O
dose,O
These,O
hypersensitivity reactions,AdverseReaction
included,O
anaphylaxis,AdverseReaction
angioedema,AdverseReaction
hypotension,AdverseReaction
tachycardia,AdverseReaction
swollen tongue,AdverseReaction
dyspnea,AdverseReaction
wheezing,AdverseReaction
and,O
rash,AdverseReaction
5,O
7,O
Orthostatic,O
Hypotension,O
Syncope,O
and,O
Other,O
Hemodynamic,O
Effects,O
SAPHRIS,O
may,Factor
induce,O
orthostatic hypotension,AdverseReaction
and,O
syncope,AdverseReaction
in,O
some,O
patients,O
especially,O
early,O
in,O
treatment,O
because,O
of,O
its,O
alpha1,O
adrenergic,O
antagonist,O
activity,O
In,O
short,O
term,O
schizophrenia,O
adult,O
trials,O
syncope,AdverseReaction
was,O
reported,O
in,O
0,O
2,O
1,O
572,O
of,O
patients,O
treated,O
with,O
therapeutic,O
doses,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
of,O
SAPHRIS,O
compared,O
to,O
0,O
3,O
1,O
378,O
of,O
patients,O
treated,O
with,O
placebo,O
In,O
short,O
term,O
bipolar,O
mania,O
adult,O
trials,O
syncope,AdverseReaction
was,O
reported,O
in,O
0,O
3,O
1,O
379,O
of,O
patients,O
treated,O
with,O
therapeutic,O
doses,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
of,O
SAPHRIS,O
compared,O
to,O
0,O
0,O
203,O
of,O
patients,O
treated,O
with,O
placebo,O
During,O
adult,O
pre,O
marketing,O
clinical,O
trials,O
with,O
SAPHRIS,O
including,O
long,O
term,O
trials,O
without,O
comparison,O
to,O
placebo,O
syncope,AdverseReaction
was,O
reported,O
in,O
0,O
6,O
11,O
1953,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
In,O
a,O
3,O
week,O
bipolar,O
mania,O
pediatric,O
trial,O
syncope,AdverseReaction
was,O
reported,O
in,O
1,O
1,O
104,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
2,O
5,O
mg,O
twice,O
daily,O
1,O
1,O
99,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
and,O
0,O
0,O
99,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
compared,O
to,O
0,O
0,O
101,O
for,O
patients,O
treated,O
with,O
placebo,O
Patients,O
should,O
be,O
instructed,O
about,O
non,O
pharmacologic,O
interventions,O
that,O
help,O
to,O
reduce,O
the,O
occurrence,O
of,O
orthostatic,O
hypotension,O
e,O
g,O
sitting,O
on,O
the,O
edge,O
of,O
the,O
bed,O
for,O
several,O
minutes,O
before,O
attempting,O
to,O
stand,O
in,O
the,O
morning,O
and,O
slowly,O
rising,O
from,O
a,O
seated,O
position,O
SAPHRIS,O
should,O
be,O
used,O
with,O
caution,O
in,O
1,O
patients,O
with,O
known,O
cardiovascular,O
disease,O
history,O
of,O
myocardial,O
infarction,O
or,O
ischemic,O
heart,O
disease,O
heart,O
failure,O
or,O
conduction,O
abnormalities,O
cerebrovascular,O
disease,O
or,O
conditions,O
which,O
would,O
predispose,O
patients,O
to,O
hypotension,O
dehydration,O
hypovolemia,O
and,O
treatment,O
with,O
antihypertensive,O
medications,O
and,O
2,O
in,O
the,O
elderly,O
SAPHRIS,O
should,O
be,O
used,O
cautiously,O
when,O
treating,O
patients,O
who,O
receive,O
treatment,O
with,O
other,O
drugs,O
that,O
can,O
induce,O
hypotension,O
bradycardia,O
respiratory,O
or,O
central,O
nervous,O
system,O
depression,O
see,O
Drug,O
Interactions,O
7,O
1,O
Monitoring,O
of,O
orthostatic,O
vital,O
signs,O
should,O
be,O
considered,O
in,O
all,O
such,O
patients,O
and,O
a,O
dose,O
reduction,O
should,O
be,O
considered,O
if,O
hypotension,O
occurs,O
5,O
8,O
Leukopenia,O
Neutropenia,O
and,O
Agranulocytosis,O
In,O
clinical,O
trial,O
and,O
postmarketing,O
experience,O
leukopenia,AdverseReaction
and,O
neutropenia,AdverseReaction
have,O
been,O
reported,O
temporally,O
related,O
to,O
antipsychotic,O
agents,O
including,O
SAPHRIS,O
Agranulocytosis,AdverseReaction
including,O
fatal,AdverseReaction
cases,O
has,O
been,O
reported,O
with,O
other agents in the class,DrugClass
Possible,O
risk,O
factors,O
for,O
leukopenia,O
neutropenia,O
include,O
pre,O
existing,O
low,O
white,O
blood,O
cell,O
count,O
WBC,O
absolute,O
neutrophil,O
count,O
ANC,O
and,O
history,O
of,O
drug,O
induced,O
leukopenia,O
neutropenia,O
In,O
patients,O
with,O
a,O
pre,O
existing,O
low,O
WBC,O
ANC,O
or,O
drug,O
induced,O
leukopenia,O
neutropenia,O
perform,O
a,O
complete,O
blood,O
count,O
CBC,O
frequently,O
during,O
the,O
first,O
few,O
months,O
of,O
therapy,O
In,O
such,O
patients,O
consider,O
discontinuation,O
of,O
SAPHRIS,O
at,O
the,O
first,O
sign,O
of,O
a,O
clinically,O
significant,O
decline,O
in,O
WBC,O
in,O
the,O
absence,O
of,O
other,O
causative,O
factors,O
Monitor,O
patients,O
with,O
clinically,O
significant,O
neutropenia,O
for,O
fever,O
or,O
other,O
symptoms,O
or,O
signs,O
of,O
infection,O
and,O
treat,O
promptly,O
if,O
such,O
symptoms,O
or,O
signs,O
occur,O
Discontinue,O
SAPHRIS,O
in,O
patients,O
with,O
severe,O
neutropenia,O
absolute,O
neutrophil,O
count,O
1000,O
mm,O
3,O
and,O
follow,O
their,O
WBC,O
until,O
recovery,O
5,O
9,O
QT,O
Prolongation,O
The,O
effects,O
of,O
SAPHRIS,O
on,O
the,O
QT,O
QTc,O
interval,O
were,O
evaluated,O
in,O
a,O
dedicated,O
adult,O
QT,O
study,O
This,O
trial,O
involved,O
SAPHRIS,O
doses,O
of,O
5,O
mg,O
10,O
mg,O
15,O
mg,O
and,O
20,O
mg,O
twice,O
daily,O
and,O
placebo,O
and,O
was,O
conducted,O
in,O
151,O
clinically,O
stable,O
patients,O
with,O
schizophrenia,O
with,O
electrocardiographic,O
assessments,O
throughout,O
the,O
dosing,O
interval,O
at,O
baseline,O
and,O
steady,O
state,O
At,O
these,O
doses,O
SAPHRIS,O
was,O
associated,O
with,O
increases in QTc interval,AdverseReaction
ranging,O
from,O
2 to 5 msec,Severity
5 msec,Severity
compared,O
to,O
placebo,O
No,Negation
patients,O
treated,O
with,O
SAPHRIS,O
experienced,O
QTc increases,AdverseReaction
60 msec,Severity
from,O
baseline,O
measurements,O
nor,Negation
did,O
any,O
patient,O
experience,O
a,O
QTc of 500 msec,AdverseReaction
Electrocardiogram,O
ECG,O
measurements,O
were,O
taken,O
at,O
various,O
time,O
points,O
during,O
the,O
SAPHRIS,O
clinical,O
trial,O
program,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
doses,O
Post,O
baseline,O
QT prolongations,AdverseReaction
exceeding,O
500 msec,Severity
were,O
reported,O
at,O
comparable,O
rates,O
for,O
SAPHRIS,O
and,O
placebo,O
in,O
these,O
short,O
term,O
trials,O
There,O
were,O
no,Negation
reports,O
of,O
Torsade de Pointes,AdverseReaction
or,O
any,O
other,O
adverse,O
reactions,O
associated,O
with,O
delayed ventricular repolarization,AdverseReaction
The,O
use,O
of,O
SAPHRIS,O
should,O
be,O
avoided,O
in,O
combination,O
with,O
other,O
drugs,O
known,O
to,O
prolong,O
QTc,O
including,O
Class,O
1A,O
antiarrhythmics,O
e,O
g,O
quinidine,O
procainamide,O
or,O
Class,O
3,O
antiarrhythmics,O
e,O
g,O
amiodarone,O
sotalol,O
antipsychotic,O
medications,O
e,O
g,O
ziprasidone,O
chlorpromazine,O
thioridazine,O
and,O
antibiotics,O
e,O
g,O
gatifloxacin,O
moxifloxacin,O
SAPHRIS,O
should,O
also,O
be,O
avoided,O
in,O
patients,O
with,O
a,O
history,O
of,O
cardiac,O
arrhythmias,O
and,O
in,O
other,O
circumstances,O
that,O
may,O
increase,O
the,O
risk,O
of,O
the,O
occurrence,O
of,O
torsade,O
de,O
pointes,O
and,O
or,O
sudden,O
death,O
in,O
association,O
with,O
the,O
use,O
of,O
drugs,O
that,O
prolong,O
the,O
QTc,O
interval,O
including,O
bradycardia,O
hypokalemia,O
or,O
hypomagnesemia,O
and,O
presence,O
of,O
congenital,O
prolongation,O
of,O
the,O
QT,O
interval,O
5,O
10,O
Hyperprolactinemia,O
Like,O
other,O
drugs,O
that,O
antagonize,O
dopamine,O
D2receptors,O
SAPHRIS,O
can,Factor
elevate prolactin levels,AdverseReaction
and,O
the,O
elevation,O
can,O
persist,O
during,O
chronic,O
administration,O
Hyperprolactinemia,AdverseReaction
may,Factor
suppress hypothalamic GnRH,AdverseReaction
resulting,O
in,O
reduced pituitary gonadotropin secretion,AdverseReaction
This,O
in,O
turn,O
may,Factor
inhibit reproductive function,AdverseReaction
by,O
impairing gonadal steroidogenesis,AdverseReaction
in,O
both,O
female,O
and,O
male,O
patients,O
Galactorrhea,AdverseReaction
amenorrhea,AdverseReaction
gynecomastia,AdverseReaction
and,O
impotence,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
receiving,O
prolactin elevating compounds,DrugClass
Long,O
standing,O
hyperprolactinemia,AdverseReaction
when,O
associated,O
with,O
hypogonadism,AdverseReaction
may,Factor
lead,O
to,O
decreased bone density,AdverseReaction
in,O
both,O
female,O
and,O
male,O
subjects,O
In,O
SAPHRIS,O
adult,O
clinical,O
trials,O
the,O
incidences,O
of,O
adverse,O
events,O
related,O
to,O
abnormal prolactin levels,AdverseReaction
were,O
0,O
4,O
versus,O
0,O
for,O
placebo,O
In,O
a,O
3,O
week,O
bipolar,O
mania,O
pediatric,O
trial,O
the,O
incidence,O
of,O
adverse,O
events,O
related,O
to,O
abnormal prolactin levels,AdverseReaction
were,O
0,O
in,O
the,O
SAPHRIS,O
2,O
5,O
mg,O
twice,O
daily,O
treatment,O
group,O
2,O
in,O
the,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
treatment,O
group,O
and,O
1,O
in,O
the,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
treatment,O
group,O
versus,O
to,O
1,O
for,O
patients,O
treated,O
with,O
placebo,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Tissue,O
culture,O
experiments,O
indicate,O
that,O
approximately,O
one,O
third,O
of,O
human,O
breast,O
cancers,O
are,O
prolactin,O
dependent,O
in,O
vitro,O
a,O
factor,O
of,O
potential,O
importance,O
if,O
the,O
prescription,O
of,O
these,O
drugs,O
is,O
considered,O
in,O
a,O
patient,O
with,O
previously,O
detected,O
breast,O
cancer,O
Neither,Negation
clinical,O
studies,O
nor,Negation
epidemiologic,O
studies,O
conducted,O
to,O
date,O
have,O
shown,O
an,O
association,O
between,O
chronic,O
administration,O
of,O
this,O
class,O
of,O
drugs,O
and,O
tumorigenesis,AdverseReaction
in,O
humans,O
but,O
the,O
available,O
evidence,O
is,O
too,O
limited,O
to,O
be,O
conclusive,O
5,O
11,O
Seizures,O
Seizures,AdverseReaction
were,O
reported,O
in,O
0,O
and,O
0,O
3,O
0,O
572,O
1,O
379,O
of,O
adult,O
patients,O
treated,O
with,O
doses,O
of,O
5,O
mg,O
and,O
10,O
mg,O
twice,O
daily,O
of,O
SAPHRIS,O
respectively,O
compared,O
to,O
0,O
0,O
503,O
0,O
203,O
of,O
patients,O
treated,O
with,O
placebo,O
in,O
short,O
term,O
schizophrenia,O
and,O
bipolar,O
mania,O
trials,O
respectively,O
During,O
adult,O
pre,O
marketing,O
clinical,O
trials,O
with,O
SAPHRIS,O
including,O
long,O
term,O
trials,O
without,O
comparison,O
to,O
placebo,O
seizures,AdverseReaction
were,O
reported,O
in,O
0,O
3,O
5,O
1953,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
There,O
were,O
no,Negation
reports,O
of,O
seizures,AdverseReaction
in,O
pediatric,O
patients,O
treated,O
with,O
SAPHRIS,O
in,O
a,O
3,O
week,O
term,O
bipolar,O
mania,O
trial,O
As,O
with,O
other,O
antipsychotic,O
drugs,O
SAPHRIS,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
a,O
history,O
of,O
seizures,O
or,O
with,O
conditions,O
that,O
potentially,O
lower,O
the,O
seizure,O
threshold,O
Conditions,O
that,O
lower,O
the,O
seizure,O
threshold,O
may,O
be,O
more,O
prevalent,O
in,O
patients,O
65,O
years,O
or,O
older,O
5,O
12,O
Potential,O
for,O
Cognitive,O
and,O
Motor,O
Impairment,O
Somnolence,AdverseReaction
was,O
reported,O
in,O
patients,O
treated,O
with,O
SAPHRIS,O
It,O
was,O
usually,O
transient,O
with,O
the,O
highest,O
incidence,O
reported,O
during,O
the,O
first,O
week,O
of,O
treatment,O
In,O
short,O
term,O
fixed,O
dose,O
placebo,O
controlled,O
schizophrenia,O
adult,O
trials,O
somnolence,AdverseReaction
was,O
reported,O
in,O
15,O
41,O
274,O
of,O
patients,O
on,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
and,O
in,O
13,O
26,O
208,O
of,O
patients,O
on,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
compared,O
to,O
7,O
26,O
378,O
of,O
placebo,O
patients,O
In,O
short,O
term,O
placebo,O
controlled,O
bipolar,O
mania,O
adult,O
trials,O
of,O
therapeutic,O
doses,O
5,O
10,O
mg,O
twice,O
daily,O
somnolence,AdverseReaction
was,O
reported,O
in,O
24,O
90,O
379,O
of,O
patients,O
on,O
SAPHRIS,O
compared,O
to,O
6,O
13,O
203,O
of,O
placebo,O
patients,O
During,O
adult,O
pre,O
marketing,O
clinical,O
trials,O
with,O
SAPHRIS,O
including,O
long,O
term,O
trials,O
without,O
comparison,O
to,O
placebo,O
somnolence,AdverseReaction
was,O
reported,O
in,O
18,O
358,O
1953,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
Somnolence,AdverseReaction
including,O
sedation,AdverseReaction
led,O
to,O
discontinuation,O
in,O
0,O
6,O
12,O
1953,O
of,O
patients,O
in,O
short,O
term,O
placebo,O
controlled,O
trials,O
In,O
a,O
3,O
week,O
placebo,O
controlled,O
bipolar,O
I,O
pediatric,O
trial,O
the,O
incidence,O
of,O
somnolence,AdverseReaction
including,O
sedation,AdverseReaction
and,O
hypersomnia,AdverseReaction
for,O
placebo,O
SAPHRIS,O
2,O
5,O
mg,O
twice,O
daily,O
5,O
mg,O
twice,O
daily,O
and,O
10,O
mg,O
twice,O
daily,O
was,O
12,O
12,O
101,O
46,O
48,O
104,O
53,O
52,O
99,O
and,O
49,O
49,O
99,O
respectively,O
Somnolence,AdverseReaction
led,O
to,O
discontinuation,O
in,O
0,O
3,O
1,O
and,O
2,O
of,O
patients,O
treated,O
with,O
placebo,O
and,O
SAPHRIS,O
2,O
5,O
mg,O
twice,O
daily,O
5,O
mg,O
twice,O
daily,O
and,O
10,O
mg,O
twice,O
daily,O
respectively,O
Patients,O
should,O
be,O
cautioned,O
about,O
performing,O
activities,O
requiring,O
mental,O
alertness,O
such,O
as,O
operating,O
hazardous,O
machinery,O
or,O
operating,O
a,O
motor,O
vehicle,O
until,O
they,O
are,O
reasonably,O
certain,O
that,O
SAPHRIS,O
therapy,O
does,O
not,O
affect,O
them,O
adversely,O
5,O
13,O
Body,O
Temperature,O
Regulation,O
Disruption of the body s ability to reduce core body temperature,AdverseReaction
has,O
been,O
attributed,O
to,O
antipsychotic agents,DrugClass
In,O
the,O
short,O
term,O
placebo,O
controlled,O
trials,O
for,O
both,O
schizophrenia,O
and,O
acute,O
bipolar,O
disorder,O
the,O
incidence,O
of,O
adverse,O
reactions,O
suggestive,O
of,O
body temperature increases,AdverseReaction
was,O
low,O
1,O
and,O
comparable,O
to,O
placebo,O
0,O
During,O
clinical,O
trials,O
with,O
SAPHRIS,O
including,O
long,O
term,O
trials,O
without,O
comparison,O
to,O
placebo,O
the,O
incidence,O
of,O
adverse,O
reactions,O
suggestive,O
of,O
body temperature increases,AdverseReaction
pyrexia,AdverseReaction
and,O
feeling hot,AdverseReaction
was,O
1,O
Appropriate,O
care,O
is,O
advised,O
when,O
prescribing,O
SAPHRIS,O
for,O
patients,O
who,O
will,O
be,O
experiencing,O
conditions,O
that,O
may,O
contribute,O
to,O
an,O
elevation,O
in,O
core,O
body,O
temperature,O
e,O
g,O
exercising,O
strenuously,O
exposure,O
to,O
extreme,O
heat,O
receiving,O
concomitant,O
medication,O
with,O
anticholinergic,O
activity,O
or,O
being,O
subject,O
to,O
dehydration,O
5,O
14,O
Suicide,O
The,O
possibility,O
of,O
a,O
suicide,O
attempt,O
is,O
inherent,O
in,O
psychotic,O
illnesses,O
and,O
bipolar,O
disorder,O
and,O
close,O
supervision,O
of,O
high,O
risk,O
patients,O
should,O
accompany,O
drug,O
therapy,O
Prescriptions,O
for,O
SAPHRIS,O
should,O
be,O
written,O
for,O
the,O
smallest,O
quantity,O
of,O
tablets,O
consistent,O
with,O
good,O
patient,O
management,O
in,O
order,O
to,O
reduce,O
the,O
risk,O
of,O
overdose,O
5,O
15,O
Dysphagia,O
Esophageal dysmotility,AdverseReaction
and,O
aspiration,AdverseReaction
have,O
been,O
associated,O
with,O
antipsychotic drug,DrugClass
use,O
Dysphagia,AdverseReaction
was,O
reported,O
in,O
0,O
2,O
and,O
0,O
1,O
572,O
0,O
379,O
of,O
patients,O
treated,O
with,O
therapeutic,O
doses,O
5,O
10,O
mg,O
twice,O
daily,O
of,O
SAPHRIS,O
as,O
compared,O
to,O
0,O
0,O
378,O
0,O
203,O
of,O
patients,O
treated,O
with,O
placebo,O
in,O
short,O
term,O
schizophrenia,O
and,O
bipolar,O
mania,O
adult,O
trials,O
respectively,O
During,O
adult,O
pre,O
marketing,O
clinical,O
trials,O
with,O
SAPHRIS,O
including,O
long,O
term,O
trials,O
without,O
comparison,O
to,O
placebo,O
dysphagia,AdverseReaction
was,O
reported,O
in,O
0,O
1,O
2,O
1953,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
Aspiration,O
pneumonia,O
is,O
a,O
common,O
cause,O
of,O
morbidity,O
and,O
mortality,O
in,O
elderly,O
patients,O
in,O
particular,O
those,O
with,O
advanced,O
Alzheimer,O
s,O
dementia,O
SAPHRIS,O
is,O
not,O
indicated,O
for,O
the,O
treatment,O
of,O
dementia,O
related,O
psychosis,O
and,O
should,O
not,O
be,O
used,O
in,O
patients,O
at,O
risk,O
for,O
aspiration,O
pneumonia,O
see,O
also,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
16,O
Use,O
in,O
Patients,O
with,O
Concomitant,O
Illness,O
Clinical,O
experience,O
with,O
SAPHRIS,O
in,O
patients,O
with,O
certain,O
concomitant,O
systemic,O
illnesses,O
is,O
limited,O
see,O
Clinical,O
Pharmacology,O
12,O
3,O
SAPHRIS,O
has,O
not,O
been,O
evaluated,O
in,O
patients,O
with,O
a,O
recent,O
history,O
of,O
myocardial,O
infarction,O
or,O
unstable,O
heart,O
disease,O
Patients,O
with,O
these,O
diagnoses,O
were,O
excluded,O
from,O
pre,O
marketing,O
clinical,O
trials,O
Because,O
of,O
the,O
risk,O
of,O
orthostatic,O
hypotension,O
with,O
SAPHRIS,O
caution,O
should,O
be,O
observed,O
in,O
cardiac,O
patients,O
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
""
BOXED,O
WARNING,O
WARNING,O
INCREASED MORTALITY,AdverseReaction
IN,O
ELDERLY,O
PATIENTS,O
WITH,O
DEMENTIA,O
RELATED,O
PSYCHOSIS,O
WARNING,O
INCREASED MORTALITY,AdverseReaction
IN,O
ELDERLY,O
PATIENTS,O
WITH,O
DEMENTIA,O
RELATED,O
PSYCHOSIS,O
Elderly,O
patients,O
with,O
dementia,O
related,O
psychosis,O
treated,O
with,O
antipsychotic drugs,DrugClass
are,O
at,O
an,O
increased,O
risk,Factor
of,O
death,AdverseReaction
SAPHRIS,O
r,O
asenapine,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
dementia,O
related,O
psychosis,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
2,O
WARNING,O
INCREASED MORTALITY,AdverseReaction
IN,O
ELDERLY,O
PATIENTS,O
WITH,O
DEMENTIA,O
RELATED,O
PSYCHOSIS,O
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Elderly,O
patients,O
with,O
dementia,O
related,O
psychosis,O
treated,O
with,O
antipsychotic drugs,DrugClass
are,O
at,O
an,O
increased,O
risk,O
of,O
death,AdverseReaction
SAPHRIS,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
dementia,O
related,O
psychosis,O
5,O
1,O
5,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
more,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Use,O
in,O
Elderly,O
Patients,O
with,O
Dementia,O
Related,O
Psychosis,O
seeBoxed,O
Warningand,O
Warnings,O
and,O
Precautions,O
5,O
1and5,O
2,O
Neuroleptic Malignant Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Tardive Dyskinesia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Metabolic Changes,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Hypersensitivity Reactions,AdverseReaction
see,O
Contraindications,O
Warnings,O
and,O
Precautions,O
5,O
6,O
and,O
Patient,O
Counseling,O
Information,O
17,O
Application site reactions site site site site site,AdverseReaction
including,O
oral ulcers,AdverseReaction
blisters,AdverseReaction
peeling,AdverseReaction
sloughing,AdverseReaction
and,O
inflammation,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
2,O
Orthostatic Hypotension,AdverseReaction
Syncope,AdverseReaction
and,O
other,O
Hemodynamic Effects,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Leukopenia,AdverseReaction
Neutropenia,AdverseReaction
and,O
Agranulocytosis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
QT Interval Prolongation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
Hyperprolactinemia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
10,O
Seizures,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
11,O
Potential,Factor
for,O
Cognitive,AdverseReaction
and,O
Motor Impairment,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
12,O
Body,O
Temperature,O
Regulation,O
see,O
Warnings,O
and,O
Precautions,O
5,O
13,O
Suicide,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
14,O
Dysphagia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
15,O
Use,O
in,O
Patients,O
with,O
Concomitant,O
Illness,O
see,O
Warnings,O
and,O
Precautions,O
5,O
16,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
and,O
at,O
least,O
twice,O
the,O
rate,O
of,O
placebo,O
reported,O
with,O
acute,O
treatment,O
in,O
adults,O
with,O
schizophrenia,O
were,O
akathisia,AdverseReaction
oral hypoesthesia,AdverseReaction
and,O
somnolence,AdverseReaction
The,O
safety,O
profile,O
of,O
SAPHRIS,O
in,O
the,O
maintenance,O
treatment,O
of,O
schizophrenia,O
in,O
adults,O
was,O
similar,O
to,O
that,O
seen,O
with,O
acute,O
treatment,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
and,O
at,O
least,O
twice,O
the,O
rate,O
of,O
placebo,O
reported,O
with,O
acute,O
monotherapy,O
treatment,O
of,O
manic,O
or,O
mixed,O
episodes,O
associated,O
with,O
bipolar,O
I,O
disorder,O
in,O
adults,O
were,O
somnolence,AdverseReaction
dizziness,AdverseReaction
extrapyramidal symptoms,AdverseReaction
other than,Factor
akathisia,AdverseReaction
and,O
increased weight,AdverseReaction
and,O
during,O
the,O
adjunctive,O
therapy,O
trial,O
in,O
bipolar,O
I,O
disorder,O
in,O
adults,O
were,O
somnolence,AdverseReaction
and,O
oral hypoesthesia,AdverseReaction
The,O
adult,O
information,O
below,O
is,O
derived,O
from,O
a,O
clinical,O
trial,O
database,O
for,O
SAPHRIS,O
consisting,O
of,O
over,O
4565,O
patients,O
and,O
or,O
healthy,O
subjects,O
exposed,O
to,O
one,O
or,O
more,O
sublingual,O
doses,O
of,O
SAPHRIS,O
A,O
total,O
of,O
1314,O
SAPHRIS,O
treated,O
patients,O
were,O
treated,O
for,O
at,O
least,O
24,O
weeks,O
and,O
785,O
SAPHRIS,O
treated,O
patients,O
had,O
at,O
least,O
52,O
weeks,O
of,O
exposure,O
at,O
therapeutic,O
doses,O
In,O
a,O
3,O
week,O
monotherapy,O
trial,O
the,O
most,O
common,O
adverse,O
reactions,O
5,O
and,O
at,O
least,O
twice,O
the,O
rate,O
of,O
placebo,O
reported,O
in,O
pediatric,O
patients,O
with,O
bipolar,O
I,O
disorder,O
treated,O
with,O
SAPHRIS,O
were,O
somnolence,AdverseReaction
dizziness,AdverseReaction
dysgeusia,AdverseReaction
oral paresthesia,AdverseReaction
nausea,AdverseReaction
increased appetite,AdverseReaction
fatigue,AdverseReaction
and,O
increased weight,AdverseReaction
No,O
new,O
major,O
safety,O
findings,O
were,O
reported,O
from,O
a,O
50,O
week,O
open,O
label,O
uncontrolled,O
safety,O
trial,O
A,O
total,O
of,O
651,O
pediatric,O
patients,O
were,O
treated,O
with,O
SAPHRIS,O
Of,O
these,O
patients,O
352,O
pediatric,O
patients,O
were,O
treated,O
with,O
SAPHRIS,O
for,O
at,O
least,O
180,O
days,O
and,O
58,O
pediatric,O
patients,O
treated,O
with,O
SAPHRIS,O
had,O
at,O
least,O
1,O
year,O
of,O
exposure,O
The,O
safety,O
of,O
SAPHRIS,O
was,O
evaluated,O
in,O
403,O
pediatric,O
patients,O
with,O
bipolar,O
I,O
disorder,O
who,O
participated,O
in,O
a,O
3,O
week,O
placebo,O
controlled,O
double,O
blind,O
trial,O
of,O
whom,O
302,O
patients,O
received,O
SAPHRIS,O
at,O
fixed,O
doses,O
ranging,O
from,O
2,O
5,O
mg,O
to,O
10,O
mg,O
twice,O
daily,O
The,O
stated,O
frequencies,O
of,O
adverse,O
reactions,O
represent,O
the,O
proportion,O
of,O
individuals,O
who,O
experienced,O
a,O
treatment,O
emergent,O
adverse,O
event,O
of,O
the,O
type,O
listed,O
A,O
reaction,O
was,O
considered,O
treatment,O
emergent,O
if,O
it,O
occurred,O
for,O
the,O
first,O
time,O
or,O
worsened,O
while,O
receiving,O
therapy,O
following,O
baseline,O
evaluation,O
EXCERPT,O
Commonly,O
observed,O
adverse,O
reactions,O
incidence,O
5,O
and,O
at,O
least,O
twice,O
that,O
for,O
placebo,O
were,O
6,O
1,O
Schizophrenia,O
Adults,O
akathisia,AdverseReaction
oral hypoesthesia,AdverseReaction
somnolence,AdverseReaction
Bipolar,O
Disorder,O
Adults,O
Monotherapy,O
somnolence,AdverseReaction
dizziness,AdverseReaction
extrapyramidal symptoms,AdverseReaction
other than,Factor
akathisia,AdverseReaction
increased weight,AdverseReaction
Bipolar,O
Disorder,O
Pediatric,O
Patients,O
Monotherapy,O
somnolence,AdverseReaction
dizziness,AdverseReaction
dysgeusia,AdverseReaction
oral paresthesia,AdverseReaction
nausea,AdverseReaction
increased appetite,AdverseReaction
fatigue,AdverseReaction
increased weight,AdverseReaction
Bipolar,O
Disorder,O
Adults,O
Adjunctive,O
somnolence,AdverseReaction
oral hypoesthesia,AdverseReaction
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Forest,O
Laboratories,O
LLC,O
at,O
1,O
800,O
678,O
1605,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Adult,O
Patients,O
with,O
Schizophrenia,O
The,O
following,O
findings,O
are,O
based,O
on,O
the,O
short,O
term,O
placebo,O
controlled,O
pre,O
marketing,O
trials,O
for,O
schizophrenia,O
a,O
pool,O
of,O
three,O
6,O
week,O
fixed,O
dose,O
trials,O
and,O
one,O
6,O
week,O
flexible,O
dose,O
trial,O
in,O
which,O
sublingual,O
SAPHRIS,O
was,O
administered,O
in,O
doses,O
ranging,O
from,O
5,O
to,O
10,O
mg,O
twice,O
daily,O
Adverse,O
Reactions,O
Associated,O
with,O
Discontinuation,O
of,O
Treatment,O
A,O
total,O
of,O
9,O
of,O
SAPHRIS,O
treated,O
patients,O
and,O
10,O
of,O
placebo,O
treated,O
patients,O
discontinued,O
due,O
to,O
adverse,O
reactions,O
There,O
were,O
no,O
drug,O
related,O
adverse,O
reactions,O
associated,O
with,O
discontinuation,O
in,O
patients,O
treated,O
with,O
SAPHRIS,O
at,O
the,O
rate,O
of,O
at,O
least,O
1,O
and,O
at,O
least,O
twice,O
the,O
placebo,O
rate,O
Adverse,O
Reactions,O
Occurring,O
at,O
an,O
Incidence,O
of,O
2,O
or,O
More,O
in,O
SAPHRIS,O
Treated,O
Patients,O
with,O
Schizophrenia,O
Adverse,O
reactions,O
associated,O
with,O
the,O
use,O
of,O
SAPHRIS,O
incidence,O
of,O
2,O
or,O
greater,O
rounded,O
to,O
the,O
nearest,O
percent,O
and,O
SAPHRIS,O
incidence,O
greater,O
than,O
placebo,O
that,O
occurred,O
during,O
acute,O
therapy,O
up,O
to,O
6,O
weeks,O
in,O
patients,O
with,O
schizophrenia,O
are,O
shown,O
in,O
Table,O
8,O
Table,O
8,O
Adverse,O
Reactions,O
Reported,O
in,O
2,O
or,O
More,O
of,O
Adult,O
Patients,O
in,O
Any,O
SAPHRIS,O
Dose,O
Group,O
and,O
Which,O
Occurred,O
at,O
Greater,O
Incidence,O
Than,O
in,O
the,O
Placebo,O
Group,O
in,O
6,O
Week,O
Schizophrenia,O
Trials,O
Akathisia,AdverseReaction
includes,O
akathisia,AdverseReaction
and,O
hyperkinesia,AdverseReaction
Extrapyramidal symptoms,AdverseReaction
included,O
dystonia,AdverseReaction
oculogyration,AdverseReaction
dyskinesia,AdverseReaction
tardive dyskinesia,AdverseReaction
muscle rigidity,AdverseReaction
parkinsonism,AdverseReaction
tremor,AdverseReaction
and,O
extrapyramidal disorder,AdverseReaction
excluding,Negation
akathisia,AdverseReaction
Somnolence,AdverseReaction
includes,O
the,O
following,O
events,O
somnolence,AdverseReaction
sedation,AdverseReaction
and,O
hypersomnia,AdverseReaction
S,O
Also,O
includes,O
the,O
Flexible,O
dose,O
trial,O
N,O
90,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
Placebo,O
N,O
378,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
N,O
274,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
N,O
208,O
All,O
SAPHRIS,O
S,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
N,O
572,O
Gastrointestinal,O
disorders,O
Constipation,AdverseReaction
6,O
7,O
4,O
5,O
Dry mouth,AdverseReaction
1,O
3,O
1,O
2,O
Oral hypoesthesia,AdverseReaction
1,O
6,O
7,O
5,O
Salivary hypersecretion,AdverseReaction
0,O
1,O
4,O
2,O
Stomach discomfort,AdverseReaction
1,O
1,O
3,O
2,O
Vomiting,AdverseReaction
5,O
4,O
7,O
5,O
General,O
disorders,O
Fatigue,AdverseReaction
3,O
4,O
3,O
3,O
Irritability,AdverseReaction
1,O
2,O
1,O
2,O
Investigations,O
Increased weight,AdverseReaction
1,O
2,O
2,O
3,O
Metabolism,O
disorders,O
Increased appetite,AdverseReaction
1,O
3,O
0,O
2,O
Nervous,O
system,O
disorders,O
Akathisia,AdverseReaction
3,O
4,O
11,O
6,O
Dizziness,AdverseReaction
4,O
7,O
3,O
5,O
Extrapyramidal symptoms,AdverseReaction
excluding,Negation
akathisia,AdverseReaction
7,O
9,O
12,O
10,O
Somnolence,AdverseReaction
7,O
15,O
13,O
13,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
13,O
16,O
15,O
15,O
Vascular,O
disorders,O
Hypertension,AdverseReaction
2,O
2,O
3,O
2,O
Dose,O
Related,O
Adverse,O
Reactions,O
In,O
the,O
short,O
term,O
schizophrenia,O
trials,O
the,O
incidence,O
of,O
akathisia,AdverseReaction
appeared,O
to,O
be,O
dose,O
related,O
seeTable,O
8,O
Monotherapy,O
in,O
Adult,O
Patients,O
with,O
Bipolar,O
Mania,O
The,O
following,O
findings,O
are,O
based,O
on,O
the,O
short,O
term,O
placebo,O
controlled,O
trials,O
for,O
bipolar,O
mania,O
a,O
pool,O
of,O
two,O
3,O
week,O
flexible,O
dose,O
trials,O
in,O
which,O
sublingual,O
SAPHRIS,O
was,O
administered,O
in,O
doses,O
of,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
Adverse,O
Reactions,O
Associated,O
with,O
Discontinuation,O
of,O
Treatment,O
Approximately,O
10,O
38,O
379,O
of,O
SAPHRIS,O
treated,O
patients,O
in,O
short,O
term,O
placebo,O
controlled,O
trials,O
discontinued,O
treatment,O
due,O
to,O
an,O
adverse,O
reaction,O
compared,O
with,O
about,O
6,O
12,O
203,O
on,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
associated,O
with,O
discontinuation,O
in,O
patients,O
treated,O
with,O
SAPHRIS,O
rates,O
at,O
least,O
1,O
and,O
at,O
least,O
twice,O
the,O
placebo,O
rate,O
were,O
anxiety,AdverseReaction
1,O
1,O
and,O
oral hypoesthesia,AdverseReaction
1,O
1,O
compared,O
to,O
placebo,O
0,O
Adverse,O
Reactions,O
Occurring,O
at,O
an,O
Incidence,O
of,O
2,O
or,O
More,O
Among,O
SAPHRIS,O
Treated,O
Monotherapy,O
patients,O
with,O
Bipolar,O
I,O
Disorder,O
Adverse,O
reactions,O
associated,O
with,O
the,O
use,O
of,O
SAPHRIS,O
incidence,O
of,O
2,O
or,O
greater,O
rounded,O
to,O
the,O
nearest,O
percent,O
and,O
SAPHRIS,O
incidence,O
greater,O
than,O
placebo,O
that,O
occurred,O
during,O
acute,O
monotherapy,O
up,O
to,O
3,O
weeks,O
in,O
patients,O
with,O
bipolar,O
mania,O
are,O
shown,O
in,O
Table,O
9,O
Table,O
9,O
Adverse,O
Reactions,O
Reported,O
in,O
2,O
or,O
More,O
of,O
Adult,O
Patients,O
in,O
Any,O
SAPHRIS,O
Dose,O
Group,O
and,O
Which,O
Occurred,O
at,O
Greater,O
Incidence,O
Than,O
in,O
the,O
Placebo,O
Group,O
in,O
3,O
Week,O
Bipolar,O
Mania,O
Trials,O
SAPHRIS,O
5,O
mg,O
to,O
10,O
mg,O
twice,O
daily,O
with,O
flexible,O
dosing,O
Extrapyramidal symptoms,AdverseReaction
included,O
dystonia,AdverseReaction
blepharospasm,AdverseReaction
torticollis,AdverseReaction
dyskinesia,AdverseReaction
tardive dyskinesia,AdverseReaction
muscle rigidity,AdverseReaction
parkinsonism,AdverseReaction
gait disturbance,AdverseReaction
masked facies,AdverseReaction
and,O
tremor,AdverseReaction
excluding,Negation
akathisia,AdverseReaction
Somnolence,AdverseReaction
includes,O
the,O
following,O
events,O
somnolence,AdverseReaction
sedation,AdverseReaction
and,O
hypersomnia,AdverseReaction
System,O
Organ,O
Class,O
Preferred,O
Term,O
Placebo,O
N,O
203,O
SAPHRIS,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
N,O
379,O
Gastrointestinal,O
disorders,O
Dry mouth,AdverseReaction
1,O
3,O
Dyspepsia,AdverseReaction
2,O
4,O
Oral hypoesthesia,AdverseReaction
1,O
4,O
Toothache,AdverseReaction
2,O
3,O
General,O
disorders,O
Fatigue,AdverseReaction
2,O
4,O
Investigations,O
Increased weight,AdverseReaction
1,O
5,O
Metabolism,O
disorders,O
Increased appetite,AdverseReaction
1,O
4,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
1,O
3,O
Pain in extremity,AdverseReaction
1,O
2,O
Nervous,O
system,O
disorders,O
Akathisia,AdverseReaction
2,O
4,O
Dizziness,AdverseReaction
3,O
11,O
Dysgeusia,AdverseReaction
1,O
3,O
Headache,AdverseReaction
11,O
12,O
Other,O
extrapyramidal symptoms,AdverseReaction
excluding,Negation
akathisia,AdverseReaction
2,O
7,O
Somnolence,AdverseReaction
6,O
24,O
Psychiatric,O
disorders,O
Anxiety,AdverseReaction
2,O
4,O
Depression,AdverseReaction
1,O
2,O
Insomnia,AdverseReaction
5,O
6,O
Monotherapy,O
in,O
Pediatric,O
Patients,O
with,O
Bipolar,O
Mania,O
The,O
following,O
findings,O
are,O
based,O
on,O
a,O
3,O
week,O
placebo,O
controlled,O
trial,O
for,O
bipolar,O
mania,O
in,O
which,O
SAPHRIS,O
was,O
administered,O
at,O
doses,O
of,O
2,O
5,O
mg,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
Adverse,O
Reactions,O
Leading,O
to,O
Discontinuation,O
of,O
Treatment,O
A,O
total,O
of,O
6,O
7,O
7,O
104,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
2,O
5,O
mg,O
twice,O
daily,O
5,O
1,O
5,O
99,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
and,O
5,O
1,O
5,O
99,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reactions,O
compared,O
to,O
4,O
4,O
101,O
on,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
that,O
led,O
to,O
discontinuation,O
in,O
pediatric,O
patients,O
treated,O
with,O
SAPHRIS,O
rates,O
at,O
least,O
2,O
in,O
any,O
SAPHRIS,O
arm,O
and,O
at,O
least,O
twice,O
the,O
placebo,O
rate,O
were,O
somnolence,AdverseReaction
3,O
in,O
the,O
2,O
5mg,O
twice,O
daily,O
group,O
1,O
in,O
the,O
5mg,O
twice,O
daily,O
group,O
and,O
2,O
in,O
the,O
10mg,O
twice,O
daily,O
group,O
abdominal pain,AdverseReaction
2,O
in,O
the,O
10mg,O
twice,O
daily,O
group,O
and,O
nausea,AdverseReaction
2,O
in,O
the,O
10mg,O
twice,O
daily,O
group,O
No,O
placebo,O
treated,O
patients,O
dropped,O
out,O
for,O
these,O
events,O
Adverse,O
Reactions,O
Occurring,O
with,O
SAPHRIS,O
at,O
an,O
Incidence,O
of,O
2,O
or,O
More,O
in,O
SAPHRIS,O
treated,O
Bipolar,O
Patients,O
Adverse,O
reactions,O
associated,O
with,O
the,O
use,O
of,O
SAPHRIS,O
incidence,O
of,O
2,O
in,O
any,O
SAPHRIS,O
dose,O
group,O
and,O
greater,O
than,O
placebo,O
that,O
occurred,O
during,O
acute,O
therapy,O
are,O
shown,O
in,O
Table,O
10,O
Table,O
10,O
Adverse,O
Reactions,O
Reported,O
in,O
2,O
or,O
More,O
of,O
Pediatric,O
Patients,O
Ages,O
10,O
to,O
17,O
Years,O
in,O
Any,O
SAPHRIS,O
Dose,O
Group,O
and,O
Which,O
Occurred,O
at,O
Greater,O
Incidence,O
Than,O
in,O
the,O
Placebo,O
Group,O
in,O
a,O
3,O
Week,O
Bipolar,O
Mania,O
Trial,O
1Includes,O
the,O
preferred,O
terms,O
tachycardia,AdverseReaction
and,O
heart rate increased,AdverseReaction
2Includes,O
the,O
preferred,O
terms,O
oral hypoesthesia,AdverseReaction
oral paresthesia,AdverseReaction
and,O
oral dysesthesia,AdverseReaction
3Includes,O
the,O
preferred,O
terms,O
abdominal pain,AdverseReaction
abdominal pain upper,AdverseReaction
abdominal pain lower,AdverseReaction
and,O
abdominal discomfort,AdverseReaction
4Includes,O
the,O
preferred,O
terms,O
fatigue,AdverseReaction
and,O
lethargy,AdverseReaction
5Includes,O
the,O
preferred,O
terms,O
hyperinsulinemia,AdverseReaction
and,O
blood insulin increased,AdverseReaction
6Includes,O
the,O
preferred,O
terms,O
somnolence,AdverseReaction
sedation,AdverseReaction
and,O
hypersomnia,AdverseReaction
System,O
Organ,O
Class,O
AE,O
Preferred,O
Term,O
Placebo,O
N,O
101,O
Placebo,O
SAPHRIS,O
2,O
5,O
mg,O
twice,O
daily,O
N,O
104,O
2,O
5mg,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
N,O
99,O
5mg,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
N,O
99,O
10mg,O
All,O
SAPHRIS,O
2,O
5,O
5,O
and,O
10,O
mg,O
N,O
101,O
N,O
104,O
N,O
99,O
N,O
99,O
N,O
302,O
Cardiac,O
Disorders,O
Tachycardia,AdverseReaction
1,O
0,O
3,O
0,O
1,O
1,O
Gastrointestinal,O
Disorders,O
Oral paraesthesia,AdverseReaction
2,O
4,O
25,O
25,O
30,O
27,O
Nausea,AdverseReaction
3,O
6,O
6,O
6,O
6,O
Vomiting,AdverseReaction
3,O
4,O
4,O
4,O
4,O
Abdominal pain,AdverseReaction
3,O
7,O
9,O
3,O
5,O
6,O
Glossodynia,AdverseReaction
0,O
0,O
2,O
0,O
1,O
General,O
Disorders,O
and,O
Administrative,O
Site,O
Disorders,O
Fatigue,AdverseReaction
4,O
5,O
4,O
8,O
14,O
9,O
Irritability,AdverseReaction
1,O
1,O
1,O
2,O
1,O
Injury,O
Poisoning,O
and,O
Procedural,O
Complications,O
Muscle strain,AdverseReaction
0,O
0,O
0,O
2,O
1,O
Investigations,O
Increased weight,AdverseReaction
0,O
6,O
2,O
2,O
3,O
Hyperinsulinemia,AdverseReaction
5,O
0,O
1,O
3,O
1,O
2,O
ALT increased,AdverseReaction
0,O
0,O
0,O
2,O
1,O
AST increased,AdverseReaction
0,O
0,O
0,O
2,O
1,O
Metabolism,O
and,O
Nutrition,O
Disorders,O
Increased appetite,AdverseReaction
2,O
10,O
9,O
6,O
8,O
Dehydration,AdverseReaction
1,O
0,O
2,O
0,O
1,O
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Myalgia,AdverseReaction
0,O
0,O
2,O
1,O
1,O
Nervous,O
System,O
Disorders,O
Somnolence,AdverseReaction
6,O
12,O
46,O
53,O
49,O
49,O
Headache,AdverseReaction
6,O
8,O
11,O
9,O
9,O
Dizziness,AdverseReaction
3,O
6,O
10,O
5,O
7,O
Dysgeusia,AdverseReaction
2,O
4,O
5,O
9,O
6,O
Akathisia,AdverseReaction
0,O
2,O
2,O
1,O
2,O
Parkinsonism,AdverseReaction
0,O
1,O
0,O
2,O
1,O
Psychiatric,O
Disorders,O
Insomnia,AdverseReaction
3,O
3,O
4,O
3,O
3,O
Suicidal ideation,AdverseReaction
1,O
4,O
1,O
3,O
3,O
Anger,AdverseReaction
0,O
0,O
0,O
2,O
1,O
Reproductive,O
System,O
and,O
Breast,O
Disorders,O
Dysmenorrhea,AdverseReaction
1,O
0,O
2,O
0,O
1,O
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Oropharyngeal pain,AdverseReaction
2,O
0,O
3,O
1,O
1,O
Nasal congestion,AdverseReaction
1,O
0,O
2,O
0,O
1,O
Dyspnea,AdverseReaction
0,O
0,O
2,O
0,O
1,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Rash,AdverseReaction
1,O
0,O
1,O
2,O
1,O
Dose,O
Related,O
Adverse,O
Reactions,O
In,O
the,O
short,O
term,O
pediatric,O
bipolar,O
trials,O
the,O
incidence,O
of,O
fatigue,AdverseReaction
appeared,O
to,O
be,O
dose,O
related,O
see,O
Table,O
10,O
Adjunctive,O
Therapy,O
in,O
Adult,O
Patients,O
with,O
Bipolar,O
Mania,O
The,O
following,O
findings,O
are,O
based,O
on,O
a,O
12,O
week,O
placebo,O
controlled,O
trial,O
with,O
a,O
3,O
week,O
efficacy,O
endpoint,O
in,O
adult,O
patients,O
with,O
bipolar,O
mania,O
in,O
which,O
sublingual,O
SAPHRIS,O
was,O
administered,O
in,O
doses,O
of,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
as,O
adjunctive,O
therapy,O
with,O
lithium,O
or,O
valproate,O
Adverse,O
Reactions,O
Associated,O
with,O
Discontinuation,O
of,O
Treatment,O
Approximately,O
16,O
25,O
158,O
of,O
SAPHRIS,O
treated,O
patients,O
discontinued,O
treatment,O
due,O
to,O
an,O
adverse,O
reaction,O
compared,O
with,O
about,O
11,O
18,O
166,O
on,O
placebo,O
The,O
most,O
common,O
adverse,O
reactions,O
associated,O
with,O
discontinuation,O
in,O
subjects,O
treated,O
with,O
SAPHRIS,O
rates,O
at,O
least,O
1,O
and,O
at,O
least,O
twice,O
the,O
placebo,O
rate,O
were,O
depression,AdverseReaction
2,O
5,O
suicidal ideation,AdverseReaction
2,O
5,O
bipolar I disorder,AdverseReaction
1,O
9,O
insomnia,AdverseReaction
1,O
9,O
and,O
depressive symptoms,AdverseReaction
1,O
3,O
Adverse,O
Reactions,O
Occurring,O
at,O
an,O
Incidence,O
of,O
2,O
or,O
More,O
Among,O
SAPHRIS,O
Treated,O
Adjunctive,O
Bipolar,O
Patients,O
Adverse,O
reactions,O
associated,O
with,O
the,O
use,O
of,O
SAPHRIS,O
incidence,O
of,O
2,O
or,O
greater,O
rounded,O
to,O
the,O
nearest,O
percent,O
and,O
SAPHRIS,O
incidence,O
greater,O
than,O
placebo,O
that,O
occurred,O
during,O
acute,O
adjunctive,O
therapy,O
at,O
3,O
weeks,O
a,O
time,O
when,O
most,O
of,O
the,O
patients,O
were,O
still,O
participating,O
in,O
the,O
trial,O
are,O
shown,O
in,O
Table,O
11,O
Table,O
11,O
Adverse,O
Reactions,O
Reported,O
in,O
2,O
or,O
More,O
of,O
Adult,O
Patients,O
In,O
Any,O
SAPHRIS,O
Dose,O
Group,O
and,O
Which,O
Occurred,O
at,O
Greater,O
Incidence,O
Than,O
in,O
the,O
Placebo,O
Group,O
at,O
3,O
Weeks,O
in,O
Adjunctive,O
Bipolar,O
Mania,O
Trials,O
SAPHRIS,O
5,O
mg,O
to,O
10,O
mg,O
twice,O
daily,O
with,O
flexible,O
dosing,O
Extrapyramidal symptoms,AdverseReaction
included,O
dystonia,AdverseReaction
parkinsonism,AdverseReaction
oculogyration,AdverseReaction
and,O
tremor,AdverseReaction
excluding,Negation
akathisia,AdverseReaction
Somnolence,AdverseReaction
includes,O
the,O
following,O
events,O
somnolence,AdverseReaction
and,O
sedation,AdverseReaction
System,O
Organ,O
Class,O
Preferred,O
Term,O
Placebo,O
N,O
166,O
SAPHRIS,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
N,O
158,O
Gastrointestinal,O
disorders,O
Dyspepsia,AdverseReaction
2,O
3,O
Oral hypoesthesia,AdverseReaction
0,O
5,O
General,O
disorders,O
Fatigue,AdverseReaction
2,O
4,O
Edema peripheral,AdverseReaction
1,O
3,O
Investigations,O
Increased weight,AdverseReaction
0,O
3,O
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
2,O
4,O
Other,O
extrapyramidal symptoms,AdverseReaction
excluding,Negation
akathisia,AdverseReaction
5,O
6,O
Somnolence,AdverseReaction
10,O
22,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
8,O
10,O
Vascular,O
disorders,O
Hypertension,AdverseReaction
1,O
3,O
Dystonia,O
Symptoms,O
of,O
dystonia,AdverseReaction
prolonged abnormal contractions of muscle groups,AdverseReaction
may,Factor
occur,O
in,O
susceptible,O
individuals,O
during,O
the,O
first,O
few,O
days,O
of,O
treatment,O
Dystonic symptoms,AdverseReaction
include,O
spasm of the neck muscles,AdverseReaction
sometimes,O
progressing,O
to,O
tightness of the throat,AdverseReaction
swallowing difficulty,AdverseReaction
difficulty breathing,AdverseReaction
and,O
or,O
protrusion of the tongue,AdverseReaction
While,O
these,O
symptoms,O
can,O
occur,O
at,O
low,O
doses,O
they,O
occur,O
more,O
frequently,O
and,O
with,O
greater,O
severity,O
with,O
high,O
potency,O
and,O
at,O
higher,O
doses,O
of,O
first,O
generation,O
antipsychotic,O
drugs,O
An,O
elevated,O
risk,Factor
of,O
acute dystonia,AdverseReaction
is,O
observed,O
in,O
males,O
and,O
younger,O
age,O
groups,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Use,O
in,O
Specific,O
Populations,O
8,O
4,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
Extrapyramidal,O
Symptoms,O
In,O
the,O
short,O
term,O
placebo,O
controlled,O
schizophrenia,O
and,O
bipolar,O
mania,O
adult,O
trials,O
data,O
was,O
objectively,O
collected,O
on,O
the,O
Simpson,O
Angus,O
Rating,O
Scale,O
for,O
extrapyramidal symptoms,AdverseReaction
EPS,AdverseReaction
the,O
Barnes,O
Akathisia,O
Scale,O
for,O
akathisia,AdverseReaction
and,O
the,O
Assessments,O
of,O
Involuntary,O
Movement,O
Scales,O
for,O
dyskinesias,AdverseReaction
The,O
mean,O
change,O
from,O
baseline,O
for,O
the,O
all,O
SAPHRIS,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
treated,O
group,O
was,O
comparable,O
to,O
placebo,O
in,O
each,O
of,O
the,O
rating,O
scale,O
scores,O
In,O
the,O
short,O
term,O
placebo,O
controlled,O
schizophrenia,O
adult,O
trials,O
the,O
incidence,O
of,O
reported,O
EPS related events,AdverseReaction
excluding,Negation
events,O
related,O
to,O
akathisia,AdverseReaction
for,O
SAPHRIS,O
treated,O
patients,O
was,O
10,O
versus,O
7,O
for,O
placebo,O
and,O
the,O
incidence,O
of,O
akathisia,AdverseReaction
related,O
events,O
for,O
SAPHRIS,O
treated,O
patients,O
was,O
6,O
versus,O
3,O
for,O
placebo,O
In,O
short,O
term,O
placebo,O
controlled,O
bipolar,O
mania,O
adult,O
trials,O
the,O
incidence,O
of,O
EPS related events,AdverseReaction
excluding,Negation
events,O
related,O
to,O
akathisia,AdverseReaction
for,O
SAPHRIS,O
treated,O
patients,O
was,O
7,O
versus,O
2,O
for,O
placebo,O
and,O
the,O
incidence,O
of,O
akathisia,AdverseReaction
related,O
events,O
for,O
SAPHRIS,O
treated,O
patients,O
was,O
4,O
versus,O
2,O
for,O
placebo,O
In,O
a,O
3,O
week,O
placebo,O
controlled,O
pediatric,O
trial,O
with,O
bipolar,O
I,O
disorder,O
the,O
incidences,O
of,O
EPS related events,AdverseReaction
excluding,Negation
events,O
related,O
to,O
akathisia,AdverseReaction
were,O
4,O
3,O
and,O
5,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
2,O
5,O
mg,O
5,O
mg,O
and,O
10,O
mg,O
twice,O
daily,O
respectively,O
as,O
compared,O
to,O
3,O
for,O
placebo,O
treated,O
patients,O
EPS related events,AdverseReaction
include,O
bradykinesia,AdverseReaction
dyskinesia,AdverseReaction
dystonia,AdverseReaction
oromandibular dystonia,AdverseReaction
muscle contractions involuntary,AdverseReaction
muscle twitching,AdverseReaction
musculoskeletal stiffness,AdverseReaction
parkinsonism,AdverseReaction
protrusion tongue,AdverseReaction
resting tremor,AdverseReaction
and,O
tremor,AdverseReaction
For,O
events,O
of,O
akathisia,AdverseReaction
incidences,O
were,O
2,O
2,O
and,O
1,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
2,O
5,O
mg,O
5,O
mg,O
and,O
10,O
mg,O
twice,O
daily,O
respectively,O
as,O
compared,O
to,O
0,O
for,O
placebo,O
treated,O
patients,O
Other,O
Findings,O
Oral hypoesthesia,AdverseReaction
and,O
or,O
oral paresthesia,AdverseReaction
may,O
occur,O
directly,O
after,O
administration,O
of,O
SAPHRIS,O
and,O
usually,O
resolves,O
within,O
1,O
hour,O
Laboratory,O
Test,O
Abnormalities,O
Transaminases,O
Transient,O
elevations in serum transaminases in,AdverseReaction
primarily,O
ALT,AdverseReaction
in,O
the,O
short,O
term,O
schizophrenia,O
and,O
bipolar,O
mania,O
adult,O
trials,O
were,O
more,O
common,O
in,O
treated,O
patients,O
In,O
short,O
term,O
placebo,O
controlled,O
schizophrenia,O
adult,O
trials,O
the,O
mean,O
increase in transaminase levels,AdverseReaction
for,O
SAPHRIS,O
treated,O
patients,O
was,O
1,O
6,O
units,O
L,O
compared,O
to,O
a,O
decrease,O
of,O
0,O
4,O
units,O
L,O
for,O
placebo,O
treated,O
patients,O
The,O
proportion,O
of,O
patients,O
with,O
transaminase elevations,AdverseReaction
3 times ULN,Severity
at,O
Endpoint,O
was,O
0,O
9,O
for,O
SAPHRIS,O
treated,O
patients,O
versus,O
1,O
3,O
for,O
placebo,O
treated,O
patients,O
In,O
short,O
term,O
placebo,O
controlled,O
bipolar,O
adult,O
mania,O
trials,O
the,O
mean,O
increase in transaminase levels,AdverseReaction
for,O
SAPHRIS,O
treated,O
patients,O
was,O
8,O
9,O
units,O
L,O
compared,O
to,O
a,O
decrease,O
of,O
4,O
9,O
units,O
L,O
in,O
placebo,O
treated,O
patients,O
The,O
proportion,O
of,O
patients,O
with,O
transaminase elevations,AdverseReaction
3,O
times,O
upper,O
limit,O
of,O
normal,O
ULN,O
at,O
Endpoint,O
was,O
2,O
5,O
for,O
SAPHRIS,O
treated,O
patients,O
versus,O
0,O
6,O
for,O
placebo,O
treated,O
patients,O
In,O
a,O
52,O
week,O
double,O
blind,O
comparator,O
controlled,O
trial,O
that,O
included,O
primarily,O
adult,O
patients,O
with,O
schizophrenia,O
the,O
mean,O
increase,AdverseReaction
from,O
baseline,O
of ALT,AdverseReaction
was,O
1 7 units L,Severity
In,O
a,O
3,O
week,O
placebo,O
controlled,O
pediatric,O
trial,O
with,O
bipolar,O
I,O
disorder,O
transient,O
elevations in serum transaminases in,AdverseReaction
primarily,O
ALT,AdverseReaction
were,O
more,O
common,O
in,O
treated,O
patients,O
The,O
proportion,O
of,O
pediatric,O
patients,O
with,O
ALT elevations,AdverseReaction
3,O
times,O
upper,O
limit,O
of,O
normal,O
ULN,O
was,O
2,O
4,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
versus,O
none,O
for,O
the,O
other,O
SAPHRIS,O
dose,O
groups,O
and,O
placebo,O
treated,O
patients,O
Prolactin,O
In,O
short,O
term,O
placebo,O
controlled,O
adult,O
schizophrenia,O
trials,O
the,O
mean,O
decreases in prolactin levels,AdverseReaction
were,O
6,O
5,O
ng,O
mL,O
for,O
SAPHRIS,O
treated,O
patients,O
compared,O
to,O
10,O
7,O
ng,O
mL,O
for,O
placebo,O
treated,O
patients,O
The,O
proportion,O
of,O
patients,O
with,O
prolactin elevations,AdverseReaction
4 times ULN,Severity
at,O
Endpoint,O
were,O
2,O
6,O
for,O
SAPHRIS,O
treated,O
patients,O
versus,O
0,O
6,O
for,O
placebo,O
treated,O
patients,O
In,O
short,O
term,O
placebo,O
controlled,O
bipolar,O
mania,O
adult,O
trials,O
the,O
mean,O
increase in prolactin levels,AdverseReaction
was,O
4,O
9,O
ng,O
mL,O
for,O
SAPHRIS,O
treated,O
patients,O
compared,O
to,O
a,O
decrease,O
of,O
0,O
2,O
ng,O
mL,O
for,O
placebo,O
treated,O
patients,O
The,O
proportion,O
of,O
patients,O
with,O
prolactin elevations,AdverseReaction
4 times ULN,Severity
at,O
Endpoint,O
were,O
2,O
3,O
for,O
SAPHRIS,O
treated,O
patients,O
versus,O
0,O
7,O
for,O
placebo,O
treated,O
patients,O
In,O
a,O
long,O
term,O
52,O
week,O
double,O
blind,O
comparator,O
controlled,O
adult,O
trial,O
that,O
included,O
primarily,O
patients,O
with,O
schizophrenia,O
the,O
mean,O
decrease in prolactin,AdverseReaction
from,O
baseline,O
for,O
SAPHRIS,O
treated,O
patients,O
was,O
26,O
9,O
ng,O
mL,O
In,O
a,O
3,O
week,O
placebo,O
controlled,O
pediatric,O
trial,O
with,O
bipolar,O
I,O
disorder,O
the,O
mean,O
increases,AdverseReaction
at,O
Endpoint,O
in prolactin levels,AdverseReaction
were,O
3,O
2,O
ng,O
mL,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
2,O
5,O
mg,O
twice,O
daily,O
2,O
1,O
ng,O
mL,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
and,O
6,O
4,O
ng,O
mL,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
compared,O
to,O
an,O
increase,O
of,O
2,O
5,O
ng,O
mL,O
for,O
placebo,O
treated,O
patients,O
There,O
were,O
no,Negation
reports,O
of,O
prolactin elevations,AdverseReaction
4 times ULN,Severity
at,O
Endpoint,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
or,O
placebo,O
Galactorrhea,AdverseReaction
or,O
dysmenorrhea,AdverseReaction
were,O
reported,O
in,O
0,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
2,O
5,O
mg,O
twice,O
daily,O
2,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
and,O
1,O
of,O
patients,O
treated,O
with,O
SAPHRIS,O
10,O
mg,O
twice,O
daily,O
compared,O
to,O
1,O
of,O
placebo,O
treated,O
patients,O
There,O
were,O
no,Negation
reports,O
of,O
gynecomastia,AdverseReaction
in,O
this,O
trial,O
Creatine,O
Kinase,O
CK,O
The,O
proportion,O
of,O
adult,O
patients,O
with,O
CK elevations,AdverseReaction
3 times ULN,Severity
at,O
any,O
time,O
were,O
6,O
4,O
and,O
11,O
1,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
5,O
mg,O
twice,O
daily,O
and,O
10,O
mg,O
twice,O
daily,O
respectively,O
as,O
compared,O
to,O
6,O
7,O
for,O
placebo,O
treated,O
patients,O
in,O
short,O
term,O
fixed,O
dose,O
trials,O
in,O
schizophrenia,O
and,O
bipolar,O
mania,O
The,O
clinical,O
relevance,O
of,O
this,O
finding,O
is,O
unknown,O
The,O
proportion,O
of,O
patients,O
with,O
CK elevations,AdverseReaction
3 times ULN,Severity
during,O
a,O
3,O
week,O
trial,O
in,O
pediatric,O
bipolar,O
I,O
disorder,O
at,O
any,O
time,O
were,O
1,O
0,O
and,O
1,O
for,O
patients,O
treated,O
with,O
SAPHRIS,O
2,O
5,O
mg,O
5,O
mg,O
and,O
10,O
mg,O
twice,O
daily,O
respectively,O
versus,O
3,O
for,O
placebo,O
treated,O
patients,O
Other,O
Adverse,O
Reactions,O
Observed,O
During,O
the,O
Premarketing,O
Evaluation,O
of,O
SAPHRIS,O
Following,O
is,O
a,O
list,O
of,O
MedDRA,O
terms,O
that,O
reflect,O
adverse,O
reactions,O
reported,O
by,O
patients,O
treated,O
with,O
sublingual,O
SAPHRIS,O
at,O
multiple,O
doses,O
of,O
5,O
mg,O
twice,O
daily,O
during,O
any,O
phase,O
of,O
a,O
trial,O
within,O
the,O
database,O
of,O
adult,O
patients,O
The,O
reactions,O
listed,O
are,O
those,O
that,O
could,O
be,O
of,O
clinical,O
importance,O
as,O
well,O
as,O
reactions,O
that,O
are,O
plausibly,O
drug,O
related,O
on,O
pharmacologic,O
or,O
other,O
grounds,O
Reactions,O
already,O
listed,O
for,O
either,O
adults,O
or,O
pediatric,O
patients,O
in,O
other,O
parts,O
of,O
Adverse,O
Reactions,O
6,O
or,O
those,O
considered,O
in,O
Contraindications,O
4,O
Warnings,O
and,O
Precautions,O
5,O
or,O
Overdosage,O
10,O
are,O
not,O
included,O
Reactions,O
are,O
further,O
categorized,O
by,O
MedDRA,O
system,O
organ,O
class,O
and,O
listed,O
in,O
order,O
of,O
decreasing,O
frequency,O
according,O
to,O
the,O
following,O
definitions,O
those,O
occurring,O
in,O
at,O
least,O
1,O
100,O
patients,O
frequent,O
only,O
those,O
not,O
already,O
listed,O
in,O
the,O
tabulated,O
results,O
from,O
placebo,O
controlled,O
trials,O
appear,O
in,O
this,O
listing,O
those,O
occurring,O
in,O
1,O
100,O
to,O
1,O
1000,O
patients,O
infrequent,O
and,O
those,O
occurring,O
in,O
fewer,O
than,O
1,O
1000,O
patients,O
rare,O
Blood,O
and,O
lymphatic,O
disorders,O
infrequent,O
anemia,AdverseReaction
rare,O
thrombocytopenia,AdverseReaction
Cardiac,O
disorders,O
infrequent,O
temporary bundle branch block,AdverseReaction
Eye,O
disorders,O
infrequent,O
accommodation disorder,AdverseReaction
Gastrointestinal,O
disorders,O
infrequent,O
swollen tongue,AdverseReaction
General,O
disorders,O
rare,O
idiosyncratic drug reaction,AdverseReaction
Investigations,O
infrequent,O
hyponatremia,AdverseReaction
Nervous,O
system,O
disorders,O
infrequent,O
dysarthria,AdverseReaction
Following,O
is,O
a,O
list,O
of,O
MedDRA,O
terms,O
not,O
already,O
listed,O
either,O
for,O
adults,O
or,O
pediatric,O
patients,O
in,O
other,O
parts,O
of,O
Adverse,O
Reactions,O
6,O
or,O
those,O
considered,O
in,O
Contraindications,O
4,O
Warnings,O
and,O
Precautions,O
5,O
or,O
Overdosage,O
10,O
that,O
reflect,O
adverse,O
reactions,O
reported,O
by,O
pediatric,O
patients,O
Ages,O
10,O
to,O
17,O
years,O
treated,O
with,O
sublingual,O
SAPHRIS,O
at,O
doses,O
of,O
2,O
5,O
mg,O
5,O
mg,O
or,O
10,O
mg,O
twice,O
daily,O
during,O
any,O
phase,O
of,O
a,O
trial,O
within,O
the,O
database,O
of,O
pediatric,O
patients,O
Eye,O
disorders,O
infrequent,O
diplopia,AdverseReaction
vision blurred,AdverseReaction
Gastrointestinal,O
disorders,O
infrequent,O
gastroesophageal reflux disease,AdverseReaction
Injury,O
Poisoning,O
and,O
Procedural,O
Complications,O
infrequent,O
fall,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
infrequent,O
photosensitivity reaction,AdverseReaction
Renal,O
and,O
urinary,O
disorders,O
infrequent,O
enuresis,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
SAPHRIS,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
In,O
many,O
cases,O
the,O
occurrence,O
of,O
these,O
adverse,O
reactions,O
led,O
to,O
discontinuation,O
of,O
therapy,O
Application site reactions site reactions,AdverseReaction
primarily,O
in,O
the,O
sublingual area,AdverseReaction
have,O
been,O
reported,O
These,O
application site reactions site site site site site,AdverseReaction
included,O
oral ulcers,AdverseReaction
blisters,AdverseReaction
peeling,AdverseReaction
sloughing,AdverseReaction
and,O
inflammation,AdverseReaction
Choking,AdverseReaction
has,O
been,O
reported,O
by,O
patients,O
some,O
of,O
whom,O
may,Factor
have,O
also,O
experienced,O
oropharyngeal muscular dysfunction,AdverseReaction
or,O
hypoesthesia,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Serious,Severity
infections,AdverseReaction
Do,O
not,O
start,O
SIMPONI,O
ARIA,O
during,O
an,O
active,O
infection,O
If,O
an,O
infection,O
develops,O
monitor,O
carefully,O
and,O
stop,O
SIMPONI,O
ARIA,O
if,O
infection,O
becomes,O
serious,O
5,O
1,O
Invasive fungal infections,AdverseReaction
For,O
patients,O
who,O
develop,O
a,O
systemic,O
illness,O
on,O
SIMPONI,O
ARIA,O
consider,O
empiric,O
antifungal,O
therapy,O
for,O
those,O
who,O
reside,O
in,O
or,O
travel,O
to,O
regions,O
where,O
mycoses,O
are,O
endemic,O
5,O
1,O
Hepatitis B reactivation,AdverseReaction
Monitor,O
HBV,O
carriers,O
during,O
and,O
several,O
months,O
after,O
therapy,O
If,O
reactivation,O
occurs,O
stop,O
SIMPONI,O
ARIA,O
and,O
begin,O
anti,O
viral,O
therapy,O
5,O
1,O
Malignancies,AdverseReaction
More,O
cases,O
of,O
lymphoma,AdverseReaction
have,O
been,O
observed,O
among,O
patients,O
receiving,O
TNF,O
blockers,O
compared,O
with,O
patients,O
in,O
the,O
control,O
groups,O
Cases,O
of,O
other,O
malignancies,AdverseReaction
have,O
been,O
observed,O
among,O
patients,O
receiving,O
TNF,O
blockers,O
5,O
2,O
Heart failure failure failure,AdverseReaction
Worsening,AdverseReaction
or,O
new onset,AdverseReaction
may,Factor
occur,O
Stop,O
SIMPONI,O
ARIA,O
if,O
new,O
or,O
worsening,O
symptoms,O
occur,O
5,O
3,O
Demyelinating disease disease disease,AdverseReaction
exacerbation,AdverseReaction
or,O
new onset,AdverseReaction
may,Factor
occur,O
5,O
4,O
Hypersensitivity reactions,AdverseReaction
Serious,Severity
systemic hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
may,Factor
occur,O
5,O
10,O
5,O
1,O
Serious,O
Infections,O
Patients,O
treated,O
with,O
SIMPONI,O
ARIA,O
are,O
at,O
increased,O
risk,Factor
for,O
developing,O
serious,Severity
infections,AdverseReaction
involving,O
various,O
organ,O
systems,O
and,O
sites,O
that,O
may,Factor
lead,O
to,O
hospitalization,O
or,O
death,AdverseReaction
Opportunistic infections infections infections infections infections infections,AdverseReaction
due,O
to,O
bacterial,AdverseReaction
mycobacterial,AdverseReaction
invasive fungal,AdverseReaction
viral,AdverseReaction
or,O
parasitic,AdverseReaction
organisms,O
including,O
aspergillosis,AdverseReaction
blastomycosis,AdverseReaction
candidiasis,AdverseReaction
coccidioidomycosis,AdverseReaction
histoplasmosis,AdverseReaction
legionellosis,AdverseReaction
listeriosis,AdverseReaction
pneumocystosis,AdverseReaction
and,O
tuberculosis,AdverseReaction
have,O
been,O
reported,O
with,O
TNF blockers,DrugClass
Patients,O
have,O
frequently,O
presented,O
with,O
disseminated,O
rather,O
than,O
localized,O
disease,O
The,O
concomitant,O
use,O
of,O
a,O
TNF,O
blocker,O
and,O
abatacept,O
or,O
anakinra,O
was,O
associated,O
with,O
a,O
higher,O
risk,O
of,O
serious,O
infections,O
therefore,O
the,O
concomitant,O
use,O
of,O
SIMPONI,O
ARIA,O
and,O
these,O
biologic,O
products,O
is,O
not,O
recommended,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
5,O
6,O
and,O
Drug,O
Interactions,O
7,O
2,O
Treatment,O
with,O
SIMPONI,O
ARIA,O
should,O
not,O
be,O
initiated,O
in,O
patients,O
with,O
an,O
active,O
infection,O
including,O
clinically,O
important,O
localized,O
infections,O
Patients,O
greater,O
than,O
65,O
years,O
of,O
age,O
patients,O
with,O
co,O
morbid,O
conditions,O
and,O
or,O
patients,O
taking,O
concomitant,O
immunosuppressants,O
such,O
as,O
corticosteroids,O
or,O
methotrexate,O
may,O
be,O
at,O
greater,O
risk,O
of,O
infection,O
Consider,O
the,O
risks,O
and,O
benefits,O
of,O
treatment,O
prior,O
to,O
initiating,O
SIMPONI,O
ARIA,O
in,O
patients,O
with,O
chronic,O
or,O
recurrent,O
infection,O
who,O
have,O
been,O
exposed,O
to,O
tuberculosis,O
with,O
a,O
history,O
of,O
an,O
opportunistic,O
infection,O
who,O
have,O
resided,O
or,O
traveled,O
in,O
areas,O
of,O
endemic,O
tuberculosis,O
or,O
endemic,O
mycoses,O
such,O
as,O
histoplasmosis,O
coccidioidomycosis,O
or,O
blastomycosis,O
or,O
with,O
underlying,O
conditions,O
that,O
may,O
predispose,O
them,O
to,O
infection,O
Monitoring,O
Closely,O
monitor,O
patients,O
for,O
the,O
development,O
of,O
signs,O
and,O
symptoms,O
of,O
infection,O
during,O
and,O
after,O
treatment,O
with,O
SIMPONI,O
ARIA,O
Discontinue,O
SIMPONI,O
ARIA,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
an,O
opportunistic,O
infection,O
or,O
sepsis,O
For,O
patients,O
who,O
develop,O
a,O
new,O
infection,O
during,O
treatment,O
with,O
SIMPONI,O
ARIA,O
perform,O
a,O
prompt,O
and,O
complete,O
diagnostic,O
workup,O
appropriate,O
for,O
an,O
immunocompromised,O
patient,O
and,O
initiate,O
appropriate,O
antimicrobial,O
therapy,O
and,O
closely,O
monitor,O
them,O
Tuberculosis,O
Cases,O
of,O
reactivation of tuberculosis,AdverseReaction
or,O
new tuberculosis infections,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
receiving,O
TNF,O
blockers,O
including,O
patients,O
who,O
have,O
previously,O
received,O
treatment,O
for,O
latent,O
or,O
active,O
tuberculosis,O
Evaluate,O
patients,O
for,O
tuberculosis,O
risk,O
factors,O
and,O
test,O
for,O
latent,O
infection,O
prior,O
to,O
initiating,O
SIMPONI,O
ARIA,O
and,O
periodically,O
during,O
therapy,O
Treatment,O
of,O
latent,O
tuberculosis,O
infection,O
prior,O
to,O
therapy,O
with,O
TNF,O
blockers,O
has,O
been,O
shown,O
to,O
reduce,O
the,O
risk,O
of,O
tuberculosis,O
reactivation,O
during,O
therapy,O
Prior,O
to,O
initiating,O
SIMPONI,O
ARIA,O
assess,O
if,O
treatment,O
for,O
latent,O
tuberculosis,O
is,O
needed,O
An,O
induration,O
of,O
5,O
mm,O
or,O
greater,O
is,O
a,O
positive,O
tuberculin,O
skin,O
test,O
even,O
for,O
patients,O
previously,O
vaccinated,O
with,O
Bacille,O
Calmette,O
Guerin,O
BCG,O
Consider,O
anti,O
tuberculosis,O
therapy,O
prior,O
to,O
initiation,O
of,O
SIMPONI,O
ARIA,O
in,O
patients,O
with,O
a,O
past,O
history,O
of,O
latent,O
or,O
active,O
tuberculosis,O
in,O
whom,O
an,O
adequate,O
course,O
of,O
treatment,O
cannot,O
be,O
confirmed,O
and,O
for,O
patients,O
with,O
a,O
negative,O
test,O
for,O
latent,O
tuberculosis,O
but,O
having,O
risk,O
factors,O
for,O
tuberculosis,O
infection,O
Consultation,O
with,O
a,O
physician,O
with,O
expertise,O
in,O
the,O
treatment,O
of,O
tuberculosis,O
is,O
recommended,O
to,O
aid,O
in,O
the,O
decision,O
whether,O
initiating,O
anti,O
tuberculosis,O
therapy,O
is,O
appropriate,O
for,O
an,O
individual,O
patient,O
Cases,O
of,O
active,O
tuberculosis,O
have,O
occurred,O
in,O
patients,O
treated,O
with,O
the,O
subcutaneous,O
formulation,O
of,O
golimumab,O
during,O
and,O
after,O
treatment,O
for,O
latent,O
tuberculosis,O
Monitor,O
patients,O
for,O
the,O
development,O
of,O
signs,O
and,O
symptoms,O
of,O
tuberculosis,O
including,O
patients,O
who,O
tested,O
negative,O
for,O
latent,O
tuberculosis,O
infection,O
prior,O
to,O
initiating,O
therapy,O
patients,O
who,O
are,O
on,O
treatment,O
for,O
latent,O
tuberculosis,O
or,O
patients,O
who,O
were,O
previously,O
treated,O
for,O
tuberculosis,O
infection,O
Consider,O
tuberculosis,O
in,O
the,O
differential,O
diagnosis,O
in,O
patients,O
who,O
develop,O
a,O
new,O
infection,O
during,O
SIMPONI,O
ARIA,O
treatment,O
especially,O
in,O
patients,O
who,O
have,O
previously,O
or,O
recently,O
traveled,O
to,O
countries,O
with,O
a,O
high,O
prevalence,O
of,O
tuberculosis,O
or,O
who,O
have,O
had,O
close,O
contact,O
with,O
a,O
person,O
with,O
active,O
tuberculosis,O
Invasive,O
Fungal,O
Infections,O
If,O
patients,O
develop,O
a,O
serious,O
systemic,O
illness,O
and,O
they,O
reside,O
or,O
travel,O
in,O
regions,O
where,O
mycoses,O
are,O
endemic,O
consider,O
invasive,O
fungal,O
infection,O
in,O
the,O
differential,O
diagnosis,O
Consider,O
appropriate,O
empiric,O
antifungal,O
therapy,O
and,O
take,O
into,O
account,O
both,O
the,O
risk,O
for,O
severe,O
fungal,O
infection,O
and,O
the,O
risks,O
of,O
antifungal,O
therapy,O
while,O
a,O
diagnostic,O
workup,O
is,O
being,O
performed,O
Antigen,O
and,O
antibody,O
testing,O
for,O
histoplasmosis,O
may,O
be,O
negative,O
in,O
some,O
patients,O
with,O
active,O
infection,O
To,O
aid,O
in,O
the,O
management,O
of,O
such,O
patients,O
consider,O
consultation,O
with,O
a,O
physician,O
with,O
expertise,O
in,O
the,O
diagnosis,O
and,O
treatment,O
of,O
invasive,O
fungal,O
infections,O
Hepatitis,O
B,O
Virus,O
Reactivation,O
The,O
use,O
of,O
TNF,O
blockers,O
of,O
which,O
SIMPONI,O
ARIA,O
is,O
a,O
member,O
has,O
been,O
associated,O
with,O
reactivation of hepatitis B virus of,AdverseReaction
HBV,AdverseReaction
in,O
patients,O
who,O
are,O
chronic,O
hepatitis,O
B,O
carriers,O
i,O
e,O
surface,O
antigen,O
positive,O
In,O
some,O
instances,O
HBV reactivation,AdverseReaction
occurring,O
in,O
conjunction,O
with,O
TNF,O
blocker,O
therapy,O
has,O
been,O
fatal,AdverseReaction
The,O
majority,O
of,O
these,O
reports,O
have,O
occurred,O
in,O
patients,O
who,O
received,O
concomitant,O
immunosuppressants,O
All,O
patients,O
should,O
be,O
tested,O
for,O
HBV,O
infection,O
before,O
initiating,O
TNF,O
blocker,O
therapy,O
For,O
patients,O
who,O
test,O
positive,O
for,O
hepatitis,O
B,O
surface,O
antigen,O
consultation,O
with,O
a,O
physician,O
with,O
expertise,O
in,O
the,O
treatment,O
of,O
hepatitis,O
B,O
is,O
recommended,O
before,O
initiating,O
TNF,O
blocker,O
therapy,O
The,O
risks,O
and,O
benefits,O
of,O
treatment,O
should,O
be,O
considered,O
prior,O
to,O
prescribing,O
TNF,O
blockers,O
including,O
SIMPONI,O
ARIA,O
to,O
patients,O
who,O
are,O
carriers,O
of,O
HBV,O
Adequate,O
data,O
are,O
not,O
available,O
on,O
whether,O
anti,O
viral,O
therapy,O
can,O
reduce,O
the,O
risk,O
of,O
HBV,O
reactivation,O
in,O
HBV,O
carriers,O
who,O
are,O
treated,O
with,O
TNF,O
blockers,O
Patients,O
who,O
are,O
carriers,O
of,O
HBV,O
and,O
require,O
treatment,O
with,O
TNF,O
blockers,O
should,O
be,O
closely,O
monitored,O
for,O
clinical,O
and,O
laboratory,O
signs,O
of,O
active,O
HBV,O
infection,O
throughout,O
therapy,O
and,O
for,O
several,O
months,O
following,O
termination,O
of,O
therapy,O
In,O
patients,O
who,O
develop,O
HBV,O
reactivation,O
TNF,O
blockers,O
should,O
be,O
stopped,O
and,O
antiviral,O
therapy,O
with,O
appropriate,O
supportive,O
treatment,O
should,O
be,O
initiated,O
The,O
safety,O
of,O
resuming,O
TNF,O
blockers,O
after,O
HBV,O
reactivation,O
has,O
been,O
controlled,O
is,O
not,O
known,O
Therefore,O
prescribers,O
should,O
exercise,O
caution,O
when,O
considering,O
resumption,O
of,O
TNF,O
blockers,O
in,O
this,O
situation,O
and,O
monitor,O
patients,O
closely,O
5,O
2,O
Malignancies,O
Malignancies,O
in,O
Pediatric,O
Patients,O
Malignancies,AdverseReaction
some,O
fatal,AdverseReaction
have,O
been,O
reported,O
among,O
children,O
adolescents,O
and,O
young,O
adults,O
who,O
received,O
treatment,O
with,O
TNF,O
blocking,O
agents,O
initiation,O
of,O
therapy,O
18,O
years,O
of,O
age,O
of,O
which,O
SIMPONI,O
ARIA,O
is,O
a,O
member,O
Approximately,O
half,O
the,O
cases,O
were,O
lymphomas,AdverseReaction
including,O
Hodgkin s,AdverseReaction
and,O
non Hodgkin s lymphoma,AdverseReaction
The,O
other,O
cases,O
represented,O
a,O
variety,O
of,O
malignancies,AdverseReaction
including,O
rare malignancies,AdverseReaction
that,O
are,O
usually,O
associated,O
with,O
immunosuppression,AdverseReaction
and,O
malignancies,O
that,O
are,O
not,O
usually,O
observed,O
in,O
children,O
and,O
adolescents,O
The,O
malignancies,O
occurred,O
after,O
a,O
median,O
of,O
30,O
months,O
range,O
1,O
to,O
84,O
months,O
after,O
the,O
first,O
dose,O
of,O
TNF,O
blocker,O
therapy,O
Most,O
of,O
the,O
patients,O
were,O
receiving,O
concomitant,O
immunosuppressants,O
These,O
cases,O
were,O
reported,O
post,O
marketing,O
and,O
are,O
derived,O
from,O
a,O
variety,O
of,O
sources,O
including,O
registries,O
and,O
spontaneous,O
post,O
marketing,O
reports,O
Use,O
of,O
SIMPONI,O
ARIA,O
in,O
patients,O
under,O
18,O
years,O
of,O
age,O
has,O
not,O
been,O
established,O
Malignancies,O
in,O
Adult,O
Patients,O
The,O
risks,O
and,O
benefits,O
of,O
TNF,O
blocker,O
treatment,O
including,O
SIMPONI,O
ARIA,O
should,O
be,O
considered,O
prior,O
to,O
initiating,O
therapy,O
in,O
patients,O
with,O
a,O
known,O
malignancy,O
other,O
than,O
a,O
successfully,O
treated,O
non,O
melanoma,O
skin,O
cancer,O
NMSC,O
or,O
when,O
considering,O
continuing,O
a,O
TNF,O
blocker,O
in,O
patients,O
who,O
develop,O
a,O
malignancy,O
In,O
the,O
controlled,O
portions,O
of,O
clinical,O
trials,O
of,O
TNF,O
blockers,O
including,O
the,O
subcutaneous,O
formulation,O
of,O
golimumab,O
more,O
cases,O
of,O
lymphoma,AdverseReaction
have,O
been,O
observed,O
among,O
patients,O
receiving,O
anti,O
TNF,O
treatment,O
compared,O
with,O
patients,O
in,O
the,O
control,O
groups,O
Patients,O
with,O
RA,O
and,O
other,O
chronic,O
inflammatory,O
diseases,O
particularly,O
patients,O
with,O
highly,O
active,O
disease,O
and,O
or,O
chronic,O
exposure,O
to,O
immunosuppressant,O
therapies,O
may,O
be,O
at,O
higher,O
risk,Factor
up,O
to,O
several,O
fold,O
than,O
the,O
general,O
population,O
for,O
the,O
development,O
of,O
lymphoma,AdverseReaction
even,O
in,O
the,O
absence,O
of,O
TNF,O
blocking,O
therapy,O
Cases,O
of,O
acute,AdverseReaction
and,O
chronic leukemia,AdverseReaction
have,O
been,O
reported,O
with,O
post,O
marketing,O
TNF,O
blocker,O
use,O
in,O
rheumatoid,O
arthritis,O
and,O
other,O
indications,O
Even,O
in,O
the,O
absence,O
of,O
TNF,O
blocker,O
therapy,O
patients,O
with,O
rheumatoid,O
arthritis,O
may,O
be,O
at,O
a,O
higher,O
risk,O
approximately,O
2,O
fold,O
than,O
the,O
general,O
population,O
for,O
the,O
development,O
of,O
leukemia,O
Rare,O
post,O
marketing,O
cases,O
of,O
hepatosplenic T cell lymphoma,AdverseReaction
HSTCL,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
TNF,O
blocking,O
agents,O
This,O
rare type of T cell lymphoma,AdverseReaction
has,O
a,O
very,O
aggressive,O
disease,O
course,O
and,O
is,O
usually,O
fatal,AdverseReaction
Nearly,O
all,O
of,O
the,O
reported,O
TNF,O
blocker,O
associated,O
cases,O
have,O
occurred,O
in,O
patients,O
with,O
Crohn,O
s,O
disease,O
or,O
ulcerative,O
colitis,O
The,O
majority,O
were,O
in,O
adolescent,O
and,O
young,O
adult,O
males,O
Almost,O
all,O
these,O
patients,O
had,O
received,O
treatment,O
with,O
azathioprine,O
AZA,O
or,O
6,O
mercaptopurine,O
6,O
MP,O
concomitantly,O
with,O
a,O
TNF,O
blocker,O
at,O
or,O
prior,O
to,O
diagnosis,O
A,O
risk,O
for,O
the,O
development,O
for,O
hepatosplenic,O
T,O
cell,O
lymphoma,O
in,O
patients,O
treated,O
with,O
TNF,O
blockers,O
cannot,O
be,O
excluded,O
Melanoma,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
TNF,O
blocking,O
agents,O
including,O
the,O
subcutaneous,O
formulation,O
of,O
golimumab,O
Merkel cell carcinoma,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
TNF,O
blocking,O
agents,O
Periodic,O
skin,O
examination,O
is,O
recommended,O
for,O
all,O
patients,O
particularly,O
those,O
with,O
risk,O
factors,O
for,O
skin,O
cancer,O
In,O
controlled,O
trials,O
of,O
other,O
TNF,O
blockers,O
in,O
patients,O
at,O
higher,O
risk,O
for,O
malignancies,O
e,O
g,O
patients,O
with,O
COPD,O
patients,O
with,O
Wegener,O
s,O
granulomatosis,O
treated,O
with,O
concomitant,O
cyclophosphamide,O
a,O
greater,O
portion,O
of,O
malignancies,AdverseReaction
occurred,O
in,O
the,O
TNF,O
blocker,O
group,O
compared,O
to,O
the,O
controlled,O
group,O
In,O
an,O
exploratory,O
clinical,O
trial,O
evaluating,O
the,O
use,O
of,O
the,O
subcutaneous,O
formulation,O
of,O
golimumab,O
in,O
patients,O
with,O
severe,O
persistent,O
asthma,O
more,O
patients,O
treated,O
with,O
golimumab,O
reported,O
malignancies,AdverseReaction
compared,O
with,O
control,O
patients,O
The,O
significance,O
of,O
this,O
finding,O
is,O
unknown,O
During,O
the,O
controlled,O
portion,O
of,O
the,O
Phase,O
3,O
trial,O
in,O
RA,O
for,O
SIMPONI,O
ARIA,O
the,O
incidence,O
of,O
malignancies,AdverseReaction
other,O
than,O
lymphoma,O
and,O
NMSC,O
per,O
100,O
patient,O
years,O
of,O
follow,O
up,O
was,O
0,O
56,O
95,O
CI,O
0,O
01,O
3,O
11,O
in,O
the,O
SIMPONI,O
ARIA,O
group,O
compared,O
with,O
an,O
incidence,O
of,O
0,O
95,O
CI,O
0,O
00,O
3,O
79,O
in,O
the,O
placebo,O
group,O
5,O
3,O
Congestive,O
Heart,O
Failure,O
Cases,O
of,O
worsening congestive heart failure,AdverseReaction
CHF,AdverseReaction
and,O
new onset CHF,AdverseReaction
have,O
been,O
reported,O
with,O
TNF,O
blockers,O
including,O
SIMPONI,O
ARIA,O
In,O
several,O
exploratory,O
trials,O
of,O
other,O
TNF,O
blockers,O
in,O
the,O
treatment,O
of,O
CHF,O
there,O
were,O
greater,O
proportions,O
of,O
TNF,O
blocker,O
treated,O
patients,O
who,O
had,O
CHF exacerbations,AdverseReaction
requiring,O
hospitalization,O
or,O
increased mortality,AdverseReaction
SIMPONI,O
ARIA,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
a,O
history,O
of,O
CHF,O
and,O
SIMPONI,O
ARIA,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
CHF,O
If,O
a,O
decision,O
is,O
made,O
to,O
administer,O
SIMPONI,O
ARIA,O
to,O
RA,O
patients,O
with,O
CHF,O
these,O
patients,O
should,O
be,O
closely,O
monitored,O
during,O
therapy,O
and,O
SIMPONI,O
ARIA,O
should,O
be,O
discontinued,O
if,O
new,O
or,O
worsening,O
symptoms,O
of,O
CHF,O
appear,O
5,O
4,O
Demyelinating,O
Disorders,O
Use,O
of,O
TNF,O
blockers,O
of,O
which,O
SIMPONI,O
ARIA,O
is,O
a,O
member,O
has,O
been,O
associated,O
with,O
rare,O
cases,O
of,O
new onset onset,AdverseReaction
or,O
exacerbation of central nervous system nervous system of,AdverseReaction
CNS,AdverseReaction
demyelinating disorders disorders disorders disorders,AdverseReaction
including,O
multiple sclerosis,AdverseReaction
MS,AdverseReaction
and,O
peripheral demyelinating disorders,AdverseReaction
including,O
Guillain Barre syndrome,AdverseReaction
Cases,O
of,O
central demyelination,AdverseReaction
MS,AdverseReaction
optic neuritis,AdverseReaction
and,O
peripheral demyelinating polyneuropathy,AdverseReaction
have,O
rarely,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
the,O
subcutaneous,O
formulation,O
of,O
golimumab,O
Prescribers,O
should,O
exercise,O
caution,O
in,O
considering,O
the,O
use,O
of,O
TNF,O
blockers,O
including,O
SIMPONI,O
ARIA,O
in,O
patients,O
with,O
central,O
or,O
peripheral,O
nervous,O
system,O
demyelinating,O
disorders,O
Discontinuation,O
of,O
SIMPONI,O
ARIA,O
should,O
be,O
considered,O
if,O
these,O
disorders,O
develop,O
5,O
5,O
Use,O
with,O
Abatacept,O
In,O
controlled,O
trials,O
the,O
concurrent,O
administration,O
of,O
another,O
TNF,O
blocker,O
and,O
abatacept,O
was,O
associated,O
with,O
a,O
greater,O
proportion,O
of,O
serious,O
infections,O
than,O
the,O
use,O
of,O
a,O
TNF,O
blocker,O
alone,O
and,O
the,O
combination,O
therapy,O
compared,O
to,O
the,O
use,O
of,O
a,O
TNF,O
blocker,O
alone,O
has,O
not,O
demonstrated,O
improved,O
clinical,O
benefit,O
in,O
the,O
treatment,O
of,O
RA,O
Therefore,O
the,O
combination,O
of,O
TNF,O
blockers,O
including,O
SIMPONI,O
ARIA,O
and,O
abatacept,O
is,O
not,O
recommended,O
see,O
Drug,O
Interactions,O
7,O
2,O
5,O
6,O
Use,O
with,O
Anakinra,O
Concurrent,O
administration,O
of,O
anakinra,O
an,O
interleukin,O
1,O
antagonist,O
and,O
another,O
TNF,O
blocker,O
was,O
associated,O
with,O
a,O
greater,O
portion,O
of,O
serious,O
infections,O
and,O
neutropenia,O
and,O
no,O
additional,O
benefits,O
compared,O
with,O
the,O
TNF,O
blocker,O
alone,O
Therefore,O
the,O
combination,O
of,O
anakinra,O
with,O
TNF,O
blockers,O
including,O
SIMPONI,O
ARIA,O
is,O
not,O
recommended,O
see,O
Drug,O
Interactions,O
7,O
2,O
5,O
7,O
Switching,O
Between,O
Biological,O
Disease,O
Modifying,O
Antirheumatic,O
Drugs,O
DMARDs,O
Care,O
should,O
be,O
taken,O
when,O
switching,O
from,O
one,O
biologic,O
product,O
to,O
another,O
biologic,O
product,O
since,O
overlapping,O
biological,O
activity,O
may,O
further,O
increase,O
the,O
risk,O
of,O
infection,O
5,O
8,O
Hematologic,O
Cytopenias,O
There,O
have,O
been,O
post,O
marketing,O
reports,O
of,O
pancytopenia,AdverseReaction
leukopenia,AdverseReaction
neutropenia,AdverseReaction
aplastic anemia,AdverseReaction
and,O
thrombocytopenia,AdverseReaction
in,O
patients,O
receiving,O
TNF,O
blockers,O
In,O
clinical,O
studies,O
cases,O
of,O
pancytopenia,AdverseReaction
leukopenia,AdverseReaction
neutropenia,AdverseReaction
and,O
thrombocytopenia,AdverseReaction
have,O
also,O
occurred,O
in,O
SIMPONI,O
ARIA,O
treated,O
patients,O
Caution,O
should,O
be,O
exercised,O
when,O
using,O
TNF,O
blockers,O
including,O
SIMPONI,O
ARIA,O
in,O
patients,O
who,O
have,O
or,O
have,O
had,O
significant,O
cytopenias,O
5,O
9,O
Vaccinations,O
Therapeutic,O
Infectious,O
Agents,O
Live,O
Vaccines,O
Patients,O
treated,O
with,O
SIMPONI,O
ARIA,O
may,O
receive,O
vaccinations,O
except,O
for,O
live,O
vaccines,O
In,O
patients,O
receiving,O
anti,O
TNF,O
therapy,O
limited,O
data,O
are,O
available,O
on,O
the,O
response,O
to,O
live,O
vaccination,O
or,O
on,O
the,O
secondary,O
transmission,O
of,O
infection,O
by,O
live,O
vaccines,O
Use,O
of,O
live,O
vaccines,O
could,O
result,O
in,O
clinical,O
infections,O
including,O
disseminated,O
infections,O
Therapeutic,O
Infectious,O
Agents,O
Other,O
uses,O
of,O
therapeutic,O
infectious,O
agents,O
such,O
as,O
live,O
attenuated,O
bacteria,O
e,O
g,O
BCG,O
bladder,O
instillation,O
for,O
the,O
treatment,O
of,O
cancer,O
could,O
result,O
in,O
clinical,O
infections,O
including,O
disseminated,O
infections,O
It,O
is,O
recommended,O
that,O
therapeutic,O
infectious,O
agents,O
not,O
be,O
given,O
concurrently,O
with,O
SIMPONI,O
ARIA,O
5,O
10,O
Hypersensitivity,O
Reactions,O
In,O
post,O
marketing,O
experience,O
serious,Severity
systemic,O
hypersensitivity reactions,AdverseReaction
including,O
anaphylactic reaction,AdverseReaction
have,O
been,O
reported,O
following,O
administration,O
of,O
the,O
subcutaneous,O
formulation,O
of,O
golimumab,O
Some,O
of,O
these,O
reactions,O
occurred,O
after,O
the,O
first,O
administration,O
of,O
golimumab,O
If,O
an,O
anaphylactic,O
or,O
other,O
serious,O
allergic,O
reaction,O
occurs,O
administration,O
of,O
SIMPONI,O
ARIA,O
should,O
be,O
discontinued,O
immediately,O
and,O
appropriate,O
therapy,O
instituted,O
""
BOXED,O
WARNING,O
WARNING,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
AND,O
MALIGNANCY,AdverseReaction
WARNING,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
AND,O
MALIGNANCY,AdverseReaction
EXCERPT,O
WARNING,O
SERIOUS,Severity
INFECTIONS,AdverseReaction
AND,O
MALIGNANCY,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Serious,Severity
infections,AdverseReaction
leading,O
to,O
hospitalization,O
or,O
death,AdverseReaction
including,O
tuberculosis,AdverseReaction
TB,AdverseReaction
bacterial sepsis,AdverseReaction
invasive fungal,AdverseReaction
such,O
as,O
histoplasmosis,AdverseReaction
and,O
other,O
opportunistic infections,AdverseReaction
have,O
occurred,O
in,O
patients,O
receiving,O
SIMPONI,O
ARIA,O
5,O
1,O
Discontinue,O
SIMPONI,O
ARIA,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
or,O
sepsis,O
5,O
1,O
Perform,O
test,O
for,O
latent,O
TB,O
if,O
positive,O
start,O
treatment,O
for,O
TB,O
prior,O
to,O
starting,O
SIMPONI,O
ARIA,O
5,O
1,O
Monitor,O
all,O
patients,O
for,O
active,O
TB,O
during,O
treatment,O
even,O
if,O
initial,O
latent,O
TB,O
test,O
is,O
negative,O
5,O
1,O
Lymphoma,AdverseReaction
and,O
other,O
malignancies,AdverseReaction
some,O
fatal,AdverseReaction
have,O
been,O
reported,O
in,O
children,O
and,O
adolescent,O
patients,O
treated,O
with,O
TNF,O
blockers,O
of,O
which,O
SIMPONI,O
ARIA,O
is,O
a,O
member,O
5,O
2,O
SERIOUS,O
INFECTIONS,O
Patients,O
treated,O
with,O
SIMPONI,O
ARIA,O
are,O
at,O
increased,O
risk,Factor
for,O
developing,O
serious,Severity
infections,AdverseReaction
that,O
may,Factor
lead,O
to,O
hospitalization,O
or,O
death,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Most,O
patients,O
who,O
developed,O
these,O
infections,AdverseReaction
were,O
taking,O
concomitant,O
immunosuppressants,O
such,O
as,O
methotrexate,O
or,O
corticosteroids,O
Discontinue,O
SIMPONI,O
ARIA,O
if,O
a,O
patient,O
develops,O
a,O
serious,O
infection,O
Reported,O
infections,O
with,O
TNF,O
blockers,O
of,O
which,O
SIMPONI,O
ARIA,O
is,O
a,O
member,O
include,O
Active tuberculosis,AdverseReaction
including,O
reactivation of latent tuberculosis,AdverseReaction
Patients,O
with,O
tuberculosis,AdverseReaction
have,O
frequently,O
presented,O
with,O
disseminated,AdverseReaction
or,O
extrapulmonary,AdverseReaction
disease,O
Test,O
patients,O
for,O
latent,O
tuberculosis,O
before,O
SIMPONI,O
ARIA,O
use,O
and,O
during,O
therapy,O
Initiate,O
treatment,O
for,O
latent,O
tuberculosis,O
prior,O
to,O
SIMPONI,O
ARIA,O
use,O
Invasive fungal infections,AdverseReaction
including,O
histoplasmosis,AdverseReaction
coccidioidomycosis,AdverseReaction
candidiasis,AdverseReaction
aspergillosis,AdverseReaction
blastomycosis,AdverseReaction
and,O
pneumocystosis,AdverseReaction
Patients,O
with,O
histoplasmosis,O
or,O
other,O
invasive,O
fungal,O
infections,O
may,O
present,O
with,O
disseminated,O
rather,O
than,O
localized,O
disease,O
Antigen,O
and,O
antibody,O
testing,O
for,O
histoplasmosis,O
may,O
be,O
negative,O
in,O
some,O
patients,O
with,O
active,O
infection,O
Consider,O
empiric,O
anti,O
fungal,O
therapy,O
in,O
patients,O
at,O
risk,O
for,O
invasive,O
fungal,O
infections,O
who,O
develop,O
severe,O
systemic,O
illness,O
Bacterial,AdverseReaction
viral,AdverseReaction
and,O
other,O
infections due to opportunistic pathogens,AdverseReaction
including,O
Legionella,AdverseReaction
and,O
Listeria,AdverseReaction
Consider,O
the,O
risks,O
and,O
benefits,O
of,O
treatment,O
with,O
SIMPONI,O
ARIA,O
prior,O
to,O
initiating,O
therapy,O
in,O
patients,O
with,O
chronic,O
or,O
recurrent,O
infection,O
Monitor,O
patients,O
closely,O
for,O
the,O
development,O
of,O
signs,O
and,O
symptoms,O
of,O
infection,O
during,O
and,O
after,O
treatment,O
with,O
SIMPONI,O
ARIA,O
including,O
the,O
possible,O
development,O
of,O
tuberculosis,O
in,O
patients,O
who,O
tested,O
negative,O
for,O
latent,O
tuberculosis,O
infection,O
prior,O
to,O
initiating,O
therapy,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
MALIGNANCY,O
Lymphoma,AdverseReaction
and,O
other,O
malignancies,AdverseReaction
some,O
fatal,AdverseReaction
have,O
been,O
reported,O
in,O
children,O
and,O
adolescent,O
patients,O
treated,O
with,O
TNF,O
blockers,O
of,O
which,O
SIMPONI,O
ARIA,O
is,O
a,O
member,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
most,O
serious,O
adverse,O
reactions,O
were,O
Serious,Severity
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Malignancies,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
3,O
are,O
upper respiratory tract infection,AdverseReaction
viral infection,AdverseReaction
bronchitis,AdverseReaction
hypertension,AdverseReaction
and,O
rash,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contactJanssen,O
Biotech,O
Inc,O
at,O
1,O
800,O
JANSSEN,O
1,O
800,O
526,O
7736,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
safety,O
data,O
described,O
below,O
are,O
based,O
on,O
one,O
randomized,O
double,O
blind,O
controlled,O
Phase,O
3,O
trial,O
in,O
patients,O
with,O
RA,O
receiving,O
SIMPONI,O
ARIA,O
by,O
intravenous,O
infusion,O
Trial,O
1,O
The,O
protocol,O
included,O
provisions,O
for,O
patients,O
taking,O
placebo,O
to,O
receive,O
treatment,O
with,O
SIMPONI,O
ARIA,O
at,O
Week,O
16,O
or,O
Week,O
24,O
either,O
by,O
patient,O
response,O
based,O
on,O
uncontrolled,O
disease,O
activity,O
or,O
by,O
design,O
so,O
that,O
adverse,O
events,O
cannot,O
always,O
be,O
unambiguously,O
attributed,O
to,O
a,O
given,O
treatment,O
Comparisons,O
between,O
placebo,O
and,O
SIMPONI,O
ARIA,O
were,O
based,O
on,O
the,O
first,O
24,O
weeks,O
of,O
exposure,O
Trial,O
1,O
included,O
197,O
control,O
treated,O
patients,O
and,O
463,O
SIMPONI,O
ARIA,O
treated,O
patients,O
which,O
includes,O
control,O
treated,O
patients,O
who,O
switched,O
to,O
SIMPONI,O
ARIA,O
at,O
Week,O
16,O
The,O
proportion,O
of,O
patients,O
who,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reactions,O
in,O
the,O
controlled,O
phase,O
of,O
Trial,O
1,O
through,O
Week,O
24,O
was,O
3,O
5,O
for,O
SIMPONI,O
ARIA,O
treated,O
patients,O
and,O
0,O
5,O
for,O
placebo,O
treated,O
patients,O
Upper respiratory tract infection,AdverseReaction
was,O
the,O
most,O
common,O
adverse,O
reaction,O
reported,O
in,O
the,O
trial,O
through,O
Week,O
24,O
occurring,O
in,O
6,O
5,O
of,O
SIMPONI,O
ARIA,O
treated,O
patients,O
as,O
compared,O
with,O
7,O
6,O
of,O
control,O
treated,O
patients,O
respectively,O
Infections,O
Serious,Severity
infections,AdverseReaction
observed,O
in,O
SIMPONI,O
ARIA,O
treated,O
patients,O
included,O
sepsis,AdverseReaction
pneumonia,AdverseReaction
cellulitis,AdverseReaction
abscess,AdverseReaction
opportunistic infections,AdverseReaction
tuberculosis,AdverseReaction
TB,AdverseReaction
and,O
invasive fungal infections,AdverseReaction
Cases,O
of,O
TB,AdverseReaction
included,O
pulmonary,AdverseReaction
and,O
extrapulmonary TB,AdverseReaction
The,O
majority,O
of,O
the,O
TB,AdverseReaction
cases,O
occurred,O
in,O
countries,O
with,O
a,O
high,O
incidence,O
rate,O
of,O
TB,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
In,O
the,O
controlled,O
phase,O
of,O
Trial,O
1,O
through,O
Week,O
24,O
infections,AdverseReaction
were,O
observed,O
in,O
27,O
of,O
SIMPONI,O
ARIA,O
treated,O
patients,O
compared,O
with,O
24,O
of,O
control,O
treated,O
patients,O
and,O
serious,Severity
infections,AdverseReaction
were,O
observed,O
in,O
0,O
9,O
of,O
SIMPONI,O
ARIA,O
treated,O
patients,O
and,O
0,O
0,O
of,O
control,O
treated,O
patients,O
Through,O
Week,O
24,O
the,O
incidence,O
of,O
serious,Severity
infections,AdverseReaction
per,O
100,O
patient,O
years,O
of,O
follow,O
up,O
was,O
2,O
2,O
95,O
CI,O
0,O
61,O
5,O
71,O
for,O
the,O
SIMPONI,O
ARIA,O
group,O
and,O
0,O
0,O
00,O
3,O
79,O
for,O
the,O
placebo,O
group,O
In,O
the,O
controlled,O
and,O
uncontrolled,O
portions,O
of,O
Trial,O
1,O
958,O
total,O
patient,O
years,O
of,O
follow,O
up,O
with,O
a,O
median,O
follow,O
up,O
of,O
approximately,O
92,O
weeks,O
the,O
incidence,O
per,O
100,O
patient,O
years,O
of,O
all,O
serious,Severity
infections,AdverseReaction
was,O
4,O
07,O
CI,O
2,O
90,O
5,O
57,O
in,O
patients,O
receiving,O
SIMPONI,O
ARIA,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
In,O
the,O
controlled,O
and,O
uncontrolled,O
portions,O
of,O
Trial,O
1,O
in,O
SIMPONI,O
ARIA,O
treated,O
patients,O
the,O
incidence,O
of,O
active TB,AdverseReaction
per,O
100,O
patient,O
years,O
was,O
0,O
31,O
95,O
CI,O
0,O
06,O
0,O
92,O
and,O
the,O
incidence,O
of,O
other,O
opportunistic infections,AdverseReaction
per,O
100,O
patient,O
years,O
was,O
0,O
42,O
95,O
CI,O
0,O
11,O
1,O
07,O
Malignancies,O
One,O
case,O
of,O
malignancy,AdverseReaction
other,O
than,O
lymphoma,AdverseReaction
and,O
NMSC,AdverseReaction
with,O
SIMPONI,O
ARIA,O
was,O
reported,O
through,O
Week,O
24,O
during,O
the,O
controlled,O
phase,O
of,O
Trial,O
1,O
In,O
the,O
controlled,O
and,O
uncontrolled,O
portions,O
through,O
approximately,O
92,O
weeks,O
the,O
incidence,O
of,O
malignancies,AdverseReaction
per,O
100,O
patient,O
years,O
other,O
than,O
lymphoma,AdverseReaction
and,O
NMSC,AdverseReaction
in,O
SIMPONI,O
ARIA,O
treated,O
patients,O
was,O
0,O
31,O
CI,O
0,O
06,O
0,O
92,O
and,O
the,O
incidence,O
of,O
NMSC,AdverseReaction
was,O
0,O
1,O
95,O
CI,O
0,O
00,O
0,O
58,O
Liver,O
Enzyme,O
Elevations,O
There,O
have,O
been,O
reports,O
of,O
severe,Severity
hepatic reactions,AdverseReaction
including,O
acute liver failure,AdverseReaction
in,O
patients,O
receiving,O
TNF blockers,DrugClass
In,O
the,O
controlled,O
phase,O
of,O
Trial,O
1,O
through,O
Week,O
24,O
ALT elevations,AdverseReaction
5 ULN,Severity
occurred,O
in,O
0,O
8,O
of,O
SIMPONI,O
ARIA,O
treated,O
patients,O
and,O
0,O
of,O
control,O
treated,O
patients,O
and,O
ALT elevations,AdverseReaction
3 ULN,Severity
occurred,O
in,O
2,O
3,O
of,O
SIMPONI,O
ARIA,O
treated,O
patients,O
and,O
2,O
5,O
of,O
control,O
treated,O
patients,O
Since,O
many,O
of,O
the,O
patients,O
in,O
the,O
Phase,O
3,O
trial,O
were,O
also,O
taking,O
medications,O
that,O
cause,O
liver,O
enzyme,O
elevations,O
e,O
g,O
nonsteroidal,O
anti,O
inflammatory,O
drugs,O
NSAIDs,O
methotrexate,O
MTX,O
or,O
isoniazid,O
prophylaxis,O
the,O
relationship,O
between,O
SIMPONI,O
ARIA,O
and,O
liver,O
enzyme,O
elevation,O
is,O
not,O
clear,O
Autoimmune,O
Disorders,O
and,O
Autoantibodies,O
The,O
use,O
of,O
TNF blockers,DrugClass
of,O
which,O
SIMPONI,O
ARIA,O
is,O
a,O
member,O
has,O
been,O
associated,O
with,O
the,O
formation of autoantibodies,AdverseReaction
and,O
rarely,O
with,O
the,O
development,O
of,O
a,O
lupus like syndrome,AdverseReaction
At,O
Week,O
20,O
in,O
Trial,O
1,O
17,O
of,O
SIMPONI,O
ARIA,O
treated,O
patients,O
and,O
13,O
of,O
control,O
patients,O
were,O
newly ANA positive,AdverseReaction
at titers of 1 160,Severity
or,O
greater,O
Of,O
these,O
patients,O
one,O
SIMPONI,O
ARIA,O
treated,O
patient,O
and,O
no,Negation
control,O
treated,O
patients,O
had,O
newly positive anti dsDNA antibodies,AdverseReaction
Administration,O
Reactions,O
In,O
the,O
controlled,O
phase,O
of,O
Trial,O
1,O
through,O
Week,O
24,O
1,O
1,O
of,O
SIMPONI,O
ARIA,O
infusions,O
were,O
associated,O
with,O
an,O
infusion reaction,AdverseReaction
compared,O
with,O
0,O
2,O
of,O
infusions,O
in,O
the,O
control,O
group,O
The,O
most,O
common,O
infusion,O
reaction,O
in,O
SIMPONI,O
ARIA,O
treated,O
patients,O
was,O
rash,AdverseReaction
No,Negation
serious,Severity
infusion reactions,AdverseReaction
were,O
reported,O
Immunogenicity,O
Antibodies,O
to,O
SIMPONI,O
ARIA,O
were,O
detected,O
in,O
13,O
3,O
golimumab,O
treated,O
patients,O
following,O
IV,O
administration,O
of,O
SIMPONI,O
ARIA,O
in,O
combination,O
with,O
MTX,O
through,O
Week,O
24,O
of,O
Trial,O
1,O
All,O
patients,O
who,O
were,O
positive,O
for,O
antibodies,O
to,O
golimumab,O
had,O
neutralizing,O
antibodies,O
based,O
on,O
an,O
in,O
vitro,O
cell,O
based,O
assay,O
The,O
small,O
number,O
of,O
patients,O
positive,O
for,O
antibodies,O
to,O
SIMPONI,O
ARIA,O
limits,O
the,O
ability,O
to,O
draw,O
definitive,O
conclusions,O
regarding,O
the,O
relationship,O
between,O
antibodies,O
to,O
golimumab,O
and,O
clinical,O
efficacy,O
or,O
safety,O
measures,O
The,O
data,O
above,O
reflect,O
the,O
percentage,O
of,O
patients,O
whose,O
test,O
results,O
were,O
considered,O
positive,O
for,O
antibodies,O
to,O
SIMPONI,O
ARIA,O
in,O
an,O
ELISA,O
assay,O
The,O
ELISA,O
assay,O
is,O
subject,O
to,O
interference,O
by,O
co,O
present,O
golimumab,O
and,O
thus,O
the,O
results,O
are,O
an,O
underestimate,O
of,O
the,O
rate,O
of,O
product,O
immunogenicity,O
and,O
are,O
in,O
addition,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
SIMPONI,O
ARIA,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
Other,O
Adverse,O
Reactions,O
Table,O
1,O
summarizes,O
the,O
adverse,O
drug,O
reactions,O
that,O
occurred,O
at,O
a,O
rate,O
of,O
at,O
least,O
1,O
in,O
the,O
SIMPONI,O
ARIA,O
MTX,O
group,O
with,O
a,O
higher,O
incidence,O
than,O
in,O
the,O
placebo,O
MTX,O
group,O
during,O
the,O
controlled,O
period,O
of,O
Trial,O
1,O
through,O
Week,O
24,O
Table,O
1,O
Adverse,O
Drug,O
Reactions,O
Reported,O
by,O
1,O
of,O
SIMPONI,O
ARIA,O
Treated,O
Patients,O
and,O
with,O
a,O
Higher,O
Incidence,O
than,O
Placebo,O
Treated,O
Patients,O
in,O
Trial,O
1,O
through,O
Week,O
24,O
Placebo,O
MTX,O
SIMPONI,O
ARIA,O
MTX,O
Patients,O
treated,O
197,O
463,O
Adverse,O
Reaction,O
Infections,O
and,O
Infestations,O
Upper respiratory tract infection,AdverseReaction
such,O
as,O
upper respiratory tract infection,AdverseReaction
nasopharyngitis,AdverseReaction
pharyngitis,AdverseReaction
laryngitis,AdverseReaction
and,O
rhinitis,AdverseReaction
12,O
13,O
Viral infections,AdverseReaction
such,O
as,O
influenza,AdverseReaction
and,O
herpes,AdverseReaction
3,O
4,O
Bacterial infections,AdverseReaction
0,O
1,O
Bronchitis,AdverseReaction
1,O
3,O
Vascular disorders,AdverseReaction
Hypertension,AdverseReaction
2,O
3,O
Skin,O
and,O
subcutaneous,O
disorders,O
Rash,AdverseReaction
1,O
3,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Pyrexia,AdverseReaction
1,O
2,O
Blood,AdverseReaction
and,O
lymphatic disorders,AdverseReaction
Leukopenia,AdverseReaction
0,O
1,O
Other,O
and,O
less,O
common,O
clinical,O
trial,O
adverse,O
drug,O
reactions,O
Adverse,O
drug,O
reactions,O
that,O
do,O
not,O
appear,O
in,O
Table,O
1,O
or,O
that,O
occurred,O
1,O
in,O
SIMPONI,O
ARIA,O
treated,O
patients,O
during,O
Trial,O
1,O
through,O
Week,O
24,O
that,O
do,O
not,O
appear,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
included,O
the,O
following,O
events,O
listed,O
by,O
system,O
organ,O
class,O
Infections,O
and,O
Infestations,O
Superficial fungal infection,AdverseReaction
sinusitis,AdverseReaction
abscess,AdverseReaction
lower respiratory tract infection,AdverseReaction
pneumonia,AdverseReaction
pyelonephritis,AdverseReaction
Investigations,O
Alanine aminotransferase increased,AdverseReaction
aspartate aminotransferase increased,AdverseReaction
neutrophil count decreased,AdverseReaction
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
paresthesia,AdverseReaction
Gastrointestinal,O
disorders,O
Constipation,AdverseReaction
6,O
2,O
Post,O
marketing,O
Experience,O
There,O
is,O
no,O
post,O
marketing,O
experience,O
available,O
for,O
SIMPONI,O
ARIA,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
the,O
subcutaneous,O
formulation,O
of,O
golimumab,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
golimumab,O
exposure,O
Neoplasm,O
Benign,O
and,O
Malignant,O
Melanoma,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Immune,O
System,O
Disorders,O
Serious,Severity
systemic hypersensitivity reactions,AdverseReaction
including,O
anaphylactic reaction,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
10,O
sarcoidosis,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Interstitial lung disease,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Skin exfoliation,AdverseReaction
bullous skin reactions,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
QT prolongation,AdverseReaction
can,Factor
occur,O
with,O
SIRTURO,O
Monitor,O
ECGs,O
and,O
discontinue,O
SIRTURO,O
if,O
significant,O
ventricular,O
arrhythmia,O
or,O
QTcF,O
interval,O
500,O
ms,O
develops,O
5,O
2,O
Hepatotoxicity,AdverseReaction
may,Factor
occur,O
with,O
use,O
of,O
SIRTURO,O
Monitor,O
liver,O
related,O
laboratory,O
tests,O
Discontinue,O
if,O
evidence,O
of,O
liver,O
injury,O
5,O
3,O
5,O
1,O
Increased,O
Mortality,O
An,O
increased,O
risk,Factor
of,O
death,AdverseReaction
was,O
seen,O
in,O
the,O
SIRTURO,O
treatment,O
group,O
9,O
79,O
11,O
4,O
compared,O
to,O
the,O
placebo,O
treatment,O
group,O
2,O
81,O
2,O
5,O
in,O
one,O
placebo,O
controlled,O
trial,O
based,O
on,O
the,O
120,O
week,O
visit,O
window,O
One,O
death,AdverseReaction
occurred,O
during,O
the,O
24,O
weeks,O
of,O
administration,O
of,O
SIRTURO,O
The,O
imbalance,O
in,O
deaths,AdverseReaction
is,O
unexplained,O
No,O
discernible,O
pattern,O
between,O
death,AdverseReaction
and,O
sputum,O
culture,O
conversion,O
relapse,O
sensitivity,O
to,O
other,O
drugs,O
used,O
to,O
treat,O
tuberculosis,O
HIV,O
status,O
or,O
severity,O
of,O
disease,O
could,O
be,O
observed,O
Only,O
use,O
SIRTURO,O
when,O
an,O
effective,O
treatment,O
regimen,O
cannot,O
otherwise,O
be,O
provided,O
see,O
Adverse,O
Reactions,O
6,O
5,O
2,O
QT,O
Prolongation,O
SIRTURO,O
prolongs the QT interval,AdverseReaction
Obtain,O
an,O
ECG,O
before,O
initiation,O
of,O
treatment,O
and,O
at,O
least,O
2,O
12,O
and,O
24,O
weeks,O
after,O
starting,O
treatment,O
with,O
SIRTURO,O
Obtain,O
serum,O
potassium,O
calcium,O
and,O
magnesium,O
at,O
baseline,O
and,O
correct,O
if,O
abnormal,O
Monitor,O
electrolytes,O
if,O
QT,O
prolongation,O
is,O
detected,O
see,O
Adverse,O
Reactions,O
6,O
1,O
and,O
Drug,O
Interactions,O
7,O
4,O
SIRTURO,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
ventricular,O
arrhythmias,O
or,O
recent,O
myocardial,O
infarction,O
The,O
following,O
may,O
increase,O
the,O
risk,Factor
for,O
QT prolongation,AdverseReaction
when,O
patients,O
are,O
receiving,O
SIRTURO,O
use,O
with,O
other,O
QT,O
prolonging,O
drugs,O
including,O
fluoroquinolones,O
and,O
macrolide,O
antibacterial,O
drugs,O
and,O
the,O
antimycobacterial,O
drug,O
clofazimine,O
a,O
history,O
of,O
Torsade,O
de,O
Pointes,O
a,O
history,O
of,O
congenital,O
long,O
QT,O
syndrome,O
a,O
history,O
of,O
or,O
ongoing,O
hypothyroidism,O
a,O
history,O
of,O
or,O
ongoing,O
bradyarrhythmias,O
a,O
history,O
of,O
uncompensated,O
heart,O
failure,O
serum,O
calcium,O
magnesium,O
or,O
potassium,O
levels,O
below,O
the,O
lower,O
limits,O
of,O
normal,O
If,O
necessary,O
bedaquiline,O
treatment,O
initiation,O
could,O
be,O
considered,O
in,O
these,O
patients,O
after,O
a,O
favorable,O
benefit,O
risk,O
assessment,O
and,O
with,O
frequent,O
ECG,O
monitoring,O
Discontinue,O
SIRTURO,O
and,O
all,O
other,O
QT,O
prolonging,O
drugs,O
if,O
the,O
patient,O
develops,O
Clinically,O
significant,O
ventricular,O
arrhythmia,O
A,O
QTcF,O
interval,O
of,O
greater,O
than,O
500,O
ms,O
confirmed,O
by,O
repeat,O
ECG,O
If,O
syncope,O
occurs,O
obtain,O
an,O
ECG,O
to,O
detect,O
QT,O
prolongation,O
5,O
3,O
Hepatotoxicity,O
More,O
hepatic related adverse reactions,AdverseReaction
were,O
reported,O
with,O
the,O
use,O
of,O
SIRTURO,O
plus,O
other,O
drugs,O
used,O
to,O
treat,O
tuberculosis,O
compared,O
to,O
other,O
drugs,O
used,O
to,O
treat,O
tuberculosis,O
without,O
the,O
addition,O
of,O
SIRTURO,O
Alcohol,O
and,O
other,O
hepatotoxic,O
drugs,O
should,O
be,O
avoided,O
while,O
on,O
SIRTURO,O
especially,O
in,O
patients,O
with,O
impaired,O
hepatic,O
function,O
Monitor,O
symptoms,O
such,O
as,O
fatigue,O
anorexia,O
nausea,O
jaundice,O
dark,O
urine,O
liver,O
tenderness,O
and,O
hepatomegaly,O
and,O
laboratory,O
tests,O
ALT,O
AST,O
alkaline,O
phosphatase,O
and,O
bilirubin,O
at,O
baseline,O
monthly,O
while,O
on,O
treatment,O
and,O
as,O
needed,O
Test,O
for,O
viral,O
hepatitis,O
and,O
discontinue,O
other,O
hepatotoxic,O
medications,O
if,O
evidence,O
of,O
new,O
or,O
worsening,O
liver,O
dysfunction,O
occurs,O
Discontinue,O
SIRTURO,O
if,O
aminotransferase,O
elevations,O
are,O
accompanied,O
by,O
total,O
bilirubin,O
elevation,O
greater,O
than,O
two,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
aminotransferase,O
elevations,O
are,O
greater,O
than,O
eight,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
aminotransferase,O
elevations,O
are,O
greater,O
than,O
five,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
and,O
persist,O
beyond,O
two,O
weeks,O
5,O
4,O
Drug,O
Interactions,O
CYP3A4,O
inducers,O
inhibitors,O
Bedaquiline,O
is,O
metabolized,O
by,O
CYP3A4,O
and,O
its,O
systemic,O
exposure,O
and,O
therapeutic,O
effect,O
may,O
therefore,O
be,O
reduced,O
during,O
co,O
administration,O
with,O
inducers,O
of,O
CYP3A4,O
Avoid,O
co,O
administration,O
of,O
strong,O
CYP3A4,O
inducers,O
such,O
as,O
rifamycins,O
i,O
e,O
rifampin,O
rifapentine,O
and,O
rifabutin,O
or,O
moderate,O
CYP3A4,O
inducers,O
such,O
as,O
efavirenz,O
during,O
treatment,O
with,O
SIRTURO,O
see,O
Drug,O
Interactions,O
7,O
1,O
Co,O
administration,O
of,O
SIRTURO,O
with,O
strong,O
CYP3A4,O
inhibitors,O
may,O
increase,O
the,O
systemic,O
exposure,O
to,O
bedaquiline,O
which,O
could,O
potentially,O
increase,O
the,O
risk,O
of,O
adverse,O
reactions,O
Therefore,O
avoid,O
the,O
use,O
of,O
strong,O
CYP3A4,O
inhibitors,O
for,O
more,O
than,O
14,O
consecutive,O
days,O
while,O
on,O
SIRTURO,O
unless,O
the,O
benefit,O
of,O
treatment,O
with,O
the,O
drug,O
combination,O
outweighs,O
the,O
risk,O
see,O
Drug,O
Interactions,O
7,O
1,O
Appropriate,O
clinical,O
monitoring,O
for,O
SIRTURO,O
related,O
adverse,O
reactions,O
is,O
recommended,O
""
BOXED,O
WARNING,O
WARNINGS,O
INCREASED MORTALITY,AdverseReaction
QT PROLONGATION,AdverseReaction
WARNINGS,O
INCREASED MORTALITY,AdverseReaction
QT PROLONGATION,AdverseReaction
EXCERPT,O
WARNINGS,O
INCREASED MORTALITY,AdverseReaction
QT PROLONGATION,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Increased,O
Mortality,O
An,O
increased,O
risk,Factor
of,O
death,AdverseReaction
was,O
seen,O
in,O
the,O
SIRTURO,O
treatment,O
group,O
9,O
79,O
11,O
4,O
compared,O
to,O
the,O
placebo,O
treatment,O
group,O
2,O
81,O
2,O
5,O
in,O
one,O
placebo,O
controlled,O
trial,O
Only,O
use,O
SIRTURO,O
when,O
an,O
effective,O
treatment,O
regimen,O
cannot,O
otherwise,O
be,O
provided,O
5,O
1,O
QT,O
Prolongation,O
QT prolongation,AdverseReaction
can,Factor
occur,O
with,O
SIRTURO,O
Use,O
with,O
drugs,O
that,O
prolong,O
the,O
QT,O
interval,O
may,Factor
cause,O
additive,O
QT prolongation,AdverseReaction
Monitor,O
ECGs,O
Discontinue,O
SIRTURO,O
if,O
significant,O
ventricular,O
arrhythmia,O
or,O
QTcF,O
interval,O
500,O
ms,O
develops,O
5,O
2,O
Increased,O
Mortality,O
An,O
increased,O
risk,Factor
of,O
death,AdverseReaction
was,O
seen,O
in,O
the,O
SIRTURO,O
treatment,O
group,O
9,O
79,O
11,O
4,O
compared,O
to,O
the,O
placebo,O
treatment,O
group,O
2,O
81,O
2,O
5,O
in,O
one,O
placebo,O
controlled,O
trial,O
Only,O
use,O
SIRTURO,O
when,O
an,O
effective,O
treatment,O
regimen,O
cannot,O
otherwise,O
be,O
provided,O
see,O
Indications,O
and,O
Usage,O
1,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
QT,O
Prolongation,O
QT prolongation,AdverseReaction
can,Factor
occur,O
with,O
SIRTURO,O
Use,O
with,O
drugs,O
that,O
prolong,O
the,O
QT,O
interval,O
may,Factor
cause,O
additive QT prolongation,AdverseReaction
Monitor,O
ECGs,O
Discontinue,O
SIRTURO,O
if,O
significant,O
ventricular,O
arrhythmia,O
or,O
if,O
QTcF,O
interval,O
prolongation,O
of,O
greater,O
than,O
500,O
ms,O
develops,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
discussed,O
elsewhere,O
in,O
the,O
labeling,O
Increased mortality,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
QT Prolongation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
and,O
Clinical,O
Pharmacology,O
12,O
2,O
Hepatotoxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Drug,O
Interactions,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
The,O
most,O
common,O
adverse,O
reactions,O
reported,O
in,O
10,O
or,O
more,O
of,O
patients,O
treated,O
with,O
SIRTURO,O
were,O
nausea,AdverseReaction
arthralgia,AdverseReaction
headache,AdverseReaction
hemoptysis,AdverseReaction
and,O
chest pain,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Janssen,O
Therapeutics,O
Division,O
of,O
Janssen,O
Products,O
LP,O
at,O
1,O
800,O
JANSSEN,O
1,O
800,O
526,O
7736,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
Because,O
clinical,O
studies,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
studies,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
the,O
rates,O
in,O
the,O
clinical,O
studies,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Adverse,O
drug,O
reactions,O
for,O
SIRTURO,O
were,O
identified,O
from,O
the,O
pooled,O
safety,O
data,O
from,O
335,O
SIRTURO,O
exposed,O
patients,O
who,O
received,O
8,O
weeks,O
Study,O
2,O
and,O
24,O
weeks,O
Studies,O
1,O
and,O
3,O
at,O
the,O
proposed,O
dose,O
Studies,O
1,O
and,O
2,O
were,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
trial,O
in,O
newly,O
diagnosed,O
patients,O
with,O
pulmonary,O
MDR,O
TB,O
In,O
both,O
treatment,O
arms,O
patients,O
received,O
SIRTURO,O
or,O
placebo,O
in,O
combination,O
with,O
other,O
drugs,O
used,O
to,O
treat,O
MDR,O
TB,O
Study,O
3,O
was,O
an,O
open,O
label,O
noncomparative,O
study,O
with,O
SIRTURO,O
administered,O
as,O
part,O
of,O
an,O
individualized,O
pulmonary,O
MDR,O
TB,O
treatment,O
regimen,O
in,O
previously,O
treated,O
patients,O
In,O
Study,O
1,O
35,O
were,O
Black,O
17,O
5,O
were,O
Hispanic,O
12,O
5,O
were,O
White,O
9,O
4,O
were,O
Asian,O
and,O
25,O
6,O
were,O
of,O
another,O
race,O
Eight,O
of,O
79,O
10,O
1,O
patients,O
in,O
the,O
SIRTURO,O
group,O
and,O
16,O
of,O
81,O
19,O
8,O
patients,O
in,O
the,O
placebo,O
treatment,O
group,O
were,O
HIV,O
infected,O
Seven,O
8,O
9,O
SIRTURO,O
treated,O
patients,O
and,O
six,O
7,O
4,O
placebo,O
treated,O
patients,O
discontinued,O
Study,O
1,O
because,O
of,O
an,O
adverse,O
reaction,O
Table,O
1,O
Select,O
Adverse,O
Reactions,O
from,O
Study,O
1,O
That,O
Occurred,O
More,O
Frequently,O
Than,O
Placebo,O
During,O
Treatment,O
with,O
SIRTURO,O
Adverse,O
Reactions,O
SIRTURO,O
Treatment,O
GroupN,O
79n,O
Placebo,O
Treatment,O
GroupN,O
81n,O
Nausea,AdverseReaction
30,O
38,O
26,O
32,O
Arthralgia,AdverseReaction
26,O
33,O
18,O
22,O
Headache,AdverseReaction
22,O
28,O
10,O
12,O
Hemoptysis,AdverseReaction
14,O
18,O
9,O
11,O
Chest Pain,AdverseReaction
9,O
11,O
6,O
7,O
Anorexia,AdverseReaction
7,O
9,O
3,O
4,O
Transaminases Increased,AdverseReaction
7,O
9,O
1,O
1,O
Rash,AdverseReaction
6,O
8,O
3,O
4,O
Blood Amylase Increased,AdverseReaction
2,O
3,O
1,O
1,O
No,O
additional,O
unique,O
Adverse,O
Reactions,O
were,O
identified,O
from,O
the,O
uncontrolled,O
Study,O
3,O
In,O
both,O
Studies,O
1,O
and,O
2,O
aminotransferase elevations,AdverseReaction
of,O
at,O
least,O
3 times the upper limit of normal,Severity
developed,O
more,O
frequently,O
in,O
the,O
SIRTURO,O
treatment,O
group,O
11,O
102,O
10,O
8,O
vs,O
6,O
105,O
5,O
7,O
than,O
in,O
the,O
placebo,O
treatment,O
group,O
In,O
Study,O
3,O
22,O
230,O
9,O
6,O
patients,O
had,O
alanine aminotransferase,AdverseReaction
or,O
aspartate aminotransferase,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
3 times the upper limit of normal times the upper limit of normal,AdverseReaction
during,O
the,O
overall,O
treatment,O
period,O
Increased,O
Mortality,O
In,O
Study,O
1,O
there,O
was,O
a,O
statistically,O
significant,O
increased mortality,AdverseReaction
risk,Factor
by,O
Week,O
120,O
in,O
the,O
SIRTURO,O
treatment,O
group,O
compared,O
to,O
the,O
placebo,O
treatment,O
group,O
9,O
79,O
11,O
4,O
versus,O
2,O
81,O
2,O
5,O
p,O
value,O
0,O
03,O
an,O
exact,O
95,O
confidence,O
interval,O
of,O
the,O
difference,O
1,O
1,O
18,O
2,O
Five,O
of,O
the,O
9,O
SIRTURO,O
deaths,AdverseReaction
and,O
the,O
2,O
placebo,Factor
deaths,AdverseReaction
were,O
tuberculosis,O
related,O
One,O
death,AdverseReaction
occurred,O
during,O
the,O
24,O
week,O
SIRTURO,O
treatment,O
period,O
The,O
median,O
time,O
to,O
death,AdverseReaction
for,O
the,O
remaining,O
eight,O
subjects,O
in,O
the,O
SIRTURO,O
treatment,O
group,O
was,O
329,O
days,O
after,O
last,O
intake,O
of,O
SIRTURO,O
The,O
imbalance,O
in,O
deaths,AdverseReaction
is,O
unexplained,O
no,O
discernible,O
pattern,O
between,O
death,AdverseReaction
and,O
sputum,O
conversion,O
relapse,O
sensitivity,O
to,O
other,O
drugs,O
used,O
to,O
treat,O
tuberculosis,O
HIV,O
status,O
and,O
severity,O
of,O
disease,O
was,O
observed,O
In,O
the,O
open,O
label,O
Study,O
3,O
6,O
9,O
16,O
233,O
subjects,O
died,AdverseReaction
The,O
most,O
common,O
cause,O
of,O
death,AdverseReaction
as,O
reported,O
by,O
the,O
investigator,O
was,O
TB,O
9,O
subjects,O
All,O
but,O
one,O
subject,O
who,O
died,AdverseReaction
of,O
TB,O
had,O
not,O
converted,O
or,O
had,O
relapsed,O
The,O
causes,O
of,O
death,AdverseReaction
in,O
the,O
remaining,O
subjects,O
varied,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
Evaluation,O
of,O
erectile,O
dysfunction,O
ED,O
should,O
include,O
an,O
appropriate,O
medical,O
assessment,O
to,O
identify,O
potential,O
underlying,O
causes,O
as,O
well,O
as,O
treatment,O
options,O
Before,O
prescribing,O
STENDRA,O
it,O
is,O
important,O
to,O
note,O
the,O
following,O
EXCERPT,O
Patients,O
should,O
not,O
use,O
STENDRA,O
if,O
sexual,O
activity,O
is,O
inadvisable,O
due,O
to,O
cardiovascular,O
status,O
or,O
any,O
other,O
reason,O
5,O
1,O
Use,O
of,O
STENDRA,O
with,O
alpha,O
blockers,O
other,O
antihypertensives,O
or,O
substantial,O
amounts,O
of,O
alcohol,O
greater,O
than,O
3,O
units,O
may,O
lead,O
to,O
hypotension,AdverseReaction
2,O
3,O
5,O
6,O
5,O
7,O
Patients,O
should,O
seek,O
emergency,O
treatment,O
if,O
an,O
erection,O
lasts,O
greater,O
than,O
4,O
hours,O
5,O
3,O
Patients,O
should,O
stop,O
STENDRA,O
and,O
seek,O
medical,O
care,O
if,O
a,O
sudden,O
loss,O
of,O
vision,O
occurs,O
in,O
one,O
or,O
both,O
eyes,O
which,O
could,O
be,O
a,O
sign,O
of,O
Non,O
Arteritic,O
Ischemic,O
Optic,O
Neuropathy,O
NAION,O
STENDRA,O
should,O
be,O
used,O
with,O
caution,O
and,O
only,O
when,O
the,O
anticipated,O
benefits,O
outweigh,O
the,O
risks,O
in,O
patients,O
with,O
a,O
history,O
of,O
NAION,O
Patients,O
with,O
a,O
crowded,O
optic,O
disc,O
may,O
also,O
be,O
at,O
an,O
increased,O
risk,O
of,O
NAION,O
5,O
4,O
6,O
2,O
Patients,O
should,O
stop,O
taking,O
STENDRA,O
and,O
seek,O
prompt,O
medical,O
attention,O
in,O
the,O
event,O
of,O
sudden,O
decrease,O
or,O
loss,O
of,O
hearing,O
5,O
5,O
5,O
1,O
Cardiovascular,O
Risks,O
There,O
is,O
a,O
potential,Factor
for,O
cardiac risk,AdverseReaction
during,O
sexual,O
activity,O
in,O
patients,O
with,O
pre,O
existing,O
cardiovascular,O
disease,O
Therefore,O
treatments,O
for,O
ED,O
including,O
STENDRA,O
should,O
not,O
be,O
used,O
in,O
men,O
for,O
whom,O
sexual,O
activity,O
is,O
inadvisable,O
because,O
of,O
their,O
underlying,O
cardiovascular,O
status,O
Patients,O
with,O
left,O
ventricular,O
outflow,O
obstruction,O
e,O
g,O
aortic,O
stenosis,O
idiopathic,O
hypertrophic,O
subaortic,O
stenosis,O
and,O
those,O
with,O
severely,O
impaired,O
autonomic,O
control,O
of,O
blood,O
pressure,O
can,O
be,O
particularly,O
sensitive,O
to,O
the,O
actions,O
of,O
vasodilators,O
including,O
STENDRA,O
The,O
following,O
groups,O
of,O
patients,O
were,O
not,O
included,O
in,O
clinical,O
safety,O
and,O
efficacy,O
trials,O
for,O
STENDRA,O
and,O
therefore,O
until,O
further,O
information,O
is,O
available,O
STENDRA,O
is,O
not,O
recommended,O
for,O
the,O
following,O
groups,O
Patients,O
who,O
have,O
suffered,O
a,O
myocardial,O
infarction,O
stroke,O
life,O
threatening,O
arrhythmia,O
or,O
coronary,O
revascularization,O
within,O
the,O
last,O
6,O
months,O
Patients,O
with,O
resting,O
hypotension,O
blood,O
pressure,O
less,O
than,O
90,O
50,O
mmHg,O
or,O
hypertension,O
blood,O
pressure,O
greater,O
than,O
170,O
100,O
mmHg,O
Patients,O
with,O
unstable,O
angina,O
angina,O
with,O
sexual,O
intercourse,O
or,O
New,O
York,O
Heart,O
Association,O
Class,O
2,O
or,O
greater,O
congestive,O
heart,O
failure,O
As,O
with,O
other,O
PDE5,O
inhibitors,O
STENDRA,O
has,O
systemic,O
vasodilatory,O
properties,O
and,O
may,O
augment,O
the,O
blood,O
pressure,O
lowering,O
effect,O
of,O
other,O
anti,O
hypertensive,O
medications,O
STENDRA,O
200,O
mg,O
resulted,O
in,O
transient decreases in sitting blood pressure,AdverseReaction
in,O
healthy,O
volunteers,O
of,O
8 0 mmHg systolic and 3 3 mmHg diastolic,Severity
seeClinical,O
Pharmacology,O
12,O
2,O
with,O
the,O
maximum,O
decrease,O
observed,O
at,O
1,O
hour,O
after,O
dosing,O
While,O
this,O
normally,O
would,O
be,O
expected,O
to,O
be,O
of,O
little,O
consequence,O
in,O
most,O
patients,O
prior,O
to,O
prescribing,O
STENDRA,O
physicians,O
should,O
carefully,O
consider,O
whether,O
patients,O
with,O
underlying,O
cardiovascular,O
disease,O
could,O
be,O
affected,O
adversely,O
by,O
such,O
vasodilatory,O
effects,O
especially,O
in,O
combination,O
with,O
sexual,O
activity,O
5,O
2,O
Concomitant,O
Use,O
of,O
CYP3A4,O
Inhibitors,O
STENDRA,O
metabolism,O
is,O
principally,O
mediated,O
by,O
the,O
CYP450,O
isoform,O
3A4,O
CYP3A4,O
Inhibitors,O
of,O
CYP3A4,O
may,O
reduce,O
STENDRA,O
clearance,O
and,O
increase,O
plasma,O
concentrations,O
of,O
avanafil,O
For,O
patients,O
taking,O
concomitant,O
strong,O
CYP3A4,O
inhibitors,O
including,O
ketoconazole,O
ritonavir,O
atazanavir,O
clarithromycin,O
indinavir,O
itraconazole,O
nefazodone,O
nelfinavir,O
saquinavir,O
and,O
telithromycin,O
do,O
not,O
use,O
STENDRA,O
seeDrug,O
Interactions,O
7,O
2,O
For,O
patients,O
taking,O
concomitant,O
moderate,O
CYP3A4,O
inhibitors,O
including,O
erythromycin,O
amprenavir,O
aprepitant,O
diltiazem,O
fluconazole,O
fosamprenavir,O
and,O
verapamil,O
the,O
maximum,O
recommended,O
dose,O
of,O
STENDRA,O
is,O
50,O
mg,O
not,O
to,O
exceed,O
once,O
every,O
24,O
hours,O
seeDrug,O
Interactions,O
7,O
2,O
5,O
3,O
Prolonged,O
Erection,O
Prolonged erection,AdverseReaction
greater,O
than,O
4 hours,Severity
and,O
priapism,AdverseReaction
painful erections,AdverseReaction
greater,O
than,O
6 hours,Severity
in,O
duration,O
have,O
been,O
reported,O
with,O
other,O
PDE5 inhibitors,DrugClass
In,O
the,O
event,O
of,O
an,O
erection,O
that,O
persists,O
longer,O
than,O
4,O
hours,O
the,O
patient,O
should,O
seek,O
immediate,O
medical,O
assistance,O
If,O
not,O
treated,O
immediately,O
penile,O
tissue,O
damage,O
and,O
permanent,O
loss,O
of,O
potency,O
could,O
result,O
STENDRA,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
anatomical,O
deformation,O
of,O
the,O
penis,O
such,O
as,O
angulation,O
cavernosal,O
fibrosis,O
or,O
Peyronie,O
s,O
disease,O
or,O
in,O
patients,O
who,O
have,O
conditions,O
which,O
may,O
predispose,O
them,O
to,O
priapism,O
such,O
as,O
sickle,O
cell,O
anemia,O
multiple,O
myeloma,O
or,O
leukemia,O
5,O
4,O
Effects,O
on,O
Eye,O
Physicians,O
should,O
advise,O
patients,O
to,O
stop,O
use,O
of,O
all,O
PDE5,O
inhibitors,O
including,O
STENDRA,O
and,O
seek,O
medical,O
attention,O
in,O
the,O
event,O
of,O
a,O
sudden,O
loss,O
of,O
vision,O
in,O
one,O
or,O
both,O
eyes,O
Such,O
an,O
event,O
may,O
be,O
a,O
sign,O
of,O
non arteritic anterior ischemic optic neuropathy,AdverseReaction
NAION,AdverseReaction
a,O
rare,O
condition,O
and,O
a,O
cause,O
of,O
decreased vision,AdverseReaction
including,O
permanent loss of vision,AdverseReaction
that,O
has,O
been,O
reported,O
rarely,O
postmarketing,O
in,O
temporal,O
association,O
with,O
the,O
use,O
of,O
all,O
PDE5 inhibitors,DrugClass
Based,O
on,O
published,O
literature,O
the,O
annual,O
incidence,O
of,O
NAION,O
is,O
2,O
5,O
11,O
8,O
cases,O
per,O
100,O
000,O
in,O
males,O
aged,O
50,O
An,O
observational,O
study,O
evaluated,O
whether,O
recent,O
use,O
of,O
PDE5 inhibitors,DrugClass
as,O
a,O
class,O
was,O
associated,O
with,O
acute,O
onset,O
of,O
NAION,AdverseReaction
The,O
results,O
suggest,O
an,O
approximate,O
2,O
fold,O
increase,O
in,O
the,O
risk,O
of,O
NAION,AdverseReaction
within,O
5,O
half,O
lives,O
of,O
PDE5 inhibitor,DrugClass
use,O
From,O
this,O
information,O
it,O
is,O
not,O
possible,O
to,O
determine,O
whether,O
these,O
events,O
are,O
related,O
directly,O
to,O
the,O
use,O
of,O
PDE5,O
inhibitors,O
or,O
to,O
other,O
factors,O
seeAdverse,O
Reactions,O
6,O
2,O
Physicians,O
should,O
consider,O
whether,O
their,O
patients,O
with,O
underlying,O
NAION,O
risk,O
factors,O
could,O
be,O
adversely,O
affected,O
by,O
use,O
of,O
PDE5,O
inhibitors,O
Individuals,O
who,O
have,O
already,O
experienced,O
NAION,O
are,O
at,O
increased,O
risk,O
of,O
NAION,O
recurrence,O
Therefore,O
PDE5,O
inhibitors,O
including,O
STENDRA,O
should,O
be,O
used,O
with,O
caution,O
in,O
these,O
patients,O
and,O
only,O
when,O
the,O
anticipated,O
benefits,O
outweigh,O
the,O
risks,O
Individuals,O
with,O
crowded,O
optic,O
disc,O
are,O
also,O
considered,O
at,O
greater,O
risk,O
for,O
NAION,O
compared,O
to,O
the,O
general,O
population,O
however,O
evidence,O
is,O
insufficient,O
to,O
support,O
screening,O
of,O
prospective,O
users,O
of,O
PDE5,O
inhibitors,O
including,O
STENDRA,O
for,O
this,O
uncommon,O
condition,O
5,O
5,O
Sudden,O
Hearing,O
Loss,O
Use,O
of,O
PDE5 inhibitors,DrugClass
has,O
been,O
associated,O
with,O
sudden decrease,AdverseReaction
or,O
loss of hearing hearing,AdverseReaction
which,O
may,O
be,O
accompanied,O
by,O
tinnitus,AdverseReaction
or,O
dizziness,AdverseReaction
It,O
is,O
not,O
possible,O
to,O
determine,O
whether,O
these,O
events,O
are,O
related,O
directly,O
to,O
the,O
use,O
of,O
PDE5,O
inhibitors,O
or,O
to,O
other,O
factors,O
seeAdverse,O
Reactions,O
6,O
Patients,O
experiencing,O
these,O
symptoms,O
should,O
be,O
advised,O
to,O
stop,O
taking,O
STENDRA,O
and,O
seek,O
prompt,O
medical,O
attention,O
5,O
6,O
Alpha,O
Blockers,O
and,O
Other,O
Antihypertensives,O
Physicians,O
should,O
discuss,O
with,O
patients,O
the,O
potential,O
for,O
STENDRA,O
to,O
augment,O
the,O
blood,O
pressure,O
lowering,O
effect,O
of,O
alpha,O
blockers,O
and,O
other,O
antihypertensive,O
medications,O
seeDrug,O
Interactions,O
7,O
1,O
andClinical,O
Pharmacology,O
12,O
2,O
Caution,O
is,O
advised,O
when,O
PDE5,O
inhibitors,O
are,O
co,O
administered,O
with,O
alpha,O
blockers,O
Phosphodiesterase,O
type,O
5,O
inhibitors,O
including,O
STENDRA,O
and,O
alpha,O
adrenergic,O
blocking,O
agents,O
are,O
both,O
vasodilators,O
with,O
blood,O
pressure,O
lowering,O
effects,O
When,O
vasodilators,O
are,O
used,O
in,O
combination,O
an,O
additive,O
effect,O
on,O
blood,O
pressure,O
may,O
be,O
anticipated,O
In,O
some,O
patients,O
concomitant,O
use,O
of,O
these,O
two,O
drug,O
classes,O
can,Factor
lower,O
blood,O
pressure,O
significantly,O
leading,O
to,O
symptomatic hypotension,AdverseReaction
e,O
g,O
dizziness,AdverseReaction
lightheadedness,AdverseReaction
fainting,AdverseReaction
Consideration,O
should,O
be,O
given,O
to,O
the,O
following,O
Patients,O
should,O
be,O
stable,O
on,O
alpha,O
blocker,O
therapy,O
prior,O
to,O
initiating,O
treatment,O
with,O
a,O
PDE5,O
inhibitor,O
Patients,O
who,O
demonstrate,O
hemodynamic,O
instability,O
on,O
alpha,O
blocker,O
therapy,O
alone,O
are,O
at,O
increased,O
risk,O
of,O
symptomatic hypotension,AdverseReaction
with,O
concomitant,O
use,O
of,O
PDE5 inhibitors,DrugClass
In,O
those,O
patients,O
who,O
are,O
stable,O
on,O
alpha,O
blocker,O
therapy,O
PDE5,O
inhibitors,O
should,O
be,O
initiated,O
at,O
the,O
lowest,O
dose,O
STENDRA,O
50,O
mg,O
In,O
those,O
patients,O
already,O
taking,O
an,O
optimized,O
dose,O
of,O
a,O
PDE5,O
inhibitor,O
alpha,O
blocker,O
therapy,O
should,O
be,O
initiated,O
at,O
the,O
lowest,O
dose,O
Stepwise,O
increase,O
in,O
alpha,O
blocker,O
dose,O
may,O
be,O
associated,O
with,O
further,O
lowering,O
of,O
blood,O
pressure,O
when,O
taking,O
a,O
PDE5,O
inhibitor,O
Safety,O
of,O
combined,O
use,O
of,O
PDE5,O
inhibitors,O
and,O
alpha,O
blockers,O
may,O
be,O
affected,O
by,O
other,O
variables,O
including,O
intravascular,O
volume,O
depletion,O
and,O
other,O
anti,O
hypertensive,O
drugs,O
see,O
Dosage,O
and,O
Administration,O
2,O
and,O
Drug,O
Interactions,O
7,O
1,O
5,O
7,O
Alcohol,O
Patients,O
should,O
be,O
made,O
aware,O
that,O
both,O
alcohol,O
and,O
PDE5,O
inhibitors,O
including,O
STENDRA,O
act,O
as,O
vasodilators,O
When,O
vasodilators,O
are,O
taken,O
in,O
combination,O
blood,O
pressure,O
lowering,O
effects,O
of,O
each,O
individual,O
compound,O
may,O
be,O
increased,O
Therefore,O
physicians,O
should,O
inform,O
patients,O
that,O
substantial,O
consumption,O
of,O
alcohol,O
e,O
g,O
greater,O
than,O
3,O
units,O
in,O
combination,O
with,O
STENDRA,O
may,O
increase,O
the,O
potential,O
for,O
orthostatic,O
signs,O
and,O
symptoms,O
including,O
increase,O
in,O
heart,O
rate,O
decrease,O
in,O
standing,O
blood,O
pressure,O
dizziness,O
and,O
headache,O
seeDrug,O
Interactions,O
7,O
1,O
andClinical,O
Pharmacology,O
12,O
2,O
5,O
8,O
Combination,O
with,O
Other,O
PDE5,O
Inhibitors,O
or,O
Erectile,O
Dysfunction,O
Therapies,O
The,O
safety,O
and,O
efficacy,O
of,O
combinations,O
of,O
STENDRA,O
with,O
other,O
treatments,O
for,O
ED,O
has,O
not,O
been,O
studied,O
Therefore,O
the,O
use,O
of,O
such,O
combinations,O
is,O
not,O
recommended,O
5,O
9,O
Effects,O
on,O
Bleeding,O
The,O
safety,O
of,O
STENDRA,O
is,O
unknown,O
in,O
patients,O
with,O
bleeding,O
disorders,O
and,O
patients,O
with,O
active,O
peptic,O
ulceration,O
In vitro studies,Factor
with,O
human,O
platelets,O
indicate,O
that,O
STENDRA,O
potentiates the anti aggregatory effect of sodium nitroprusside,AdverseReaction
a,O
nitric,O
oxide,O
NO,O
donor,O
5,O
10,O
Counseling,O
Patients,O
about,O
Sexually,O
Transmitted,O
Diseases,O
The,O
use,O
of,O
STENDRA,O
offers,O
no,O
protection,O
against,O
sexually,O
transmitted,O
diseases,O
Counseling,O
patients,O
about,O
the,O
protective,O
measures,O
necessary,O
to,O
guard,O
against,O
sexually,O
transmitted,O
diseases,O
including,O
Human,O
Immunodeficiency,O
Virus,O
HIV,O
should,O
be,O
considered,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
greater,O
than,O
or,O
equal,O
to,O
2,O
include,O
headache,AdverseReaction
flushing,AdverseReaction
nasal congestion,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
back pain,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
1,O
877,O
663,O
0412,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
STENDRA,O
was,O
administered,O
to,O
2215,O
men,O
during,O
clinical,O
trials,O
In,O
trials,O
of,O
STENDRA,O
for,O
use,O
as,O
needed,O
a,O
total,O
of,O
493,O
patients,O
were,O
exposed,O
for,O
greater,O
than,O
or,O
equal,O
to,O
6,O
months,O
and,O
153,O
patients,O
were,O
treated,O
for,O
greater,O
than,O
or,O
equal,O
to,O
12,O
months,O
In,O
three,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
trials,O
lasting,O
up,O
to,O
3,O
months,O
in,O
duration,O
the,O
mean,O
age,O
of,O
patients,O
was,O
56,O
4,O
years,O
range,O
from,O
23,O
to,O
88,O
years,O
83,O
9,O
of,O
patients,O
were,O
White,O
13,O
8,O
were,O
Black,O
1,O
4,O
Asian,O
and,O
1,O
Hispanic,O
41,O
1,O
were,O
current,O
or,O
previous,O
smokers,O
30,O
6,O
had,O
diabetes,O
mellitus,O
The,O
discontinuation,O
rate,O
due,O
to,O
adverse,O
reactions,O
for,O
patients,O
treated,O
with,O
STENDRA,O
50,O
mg,O
100,O
mg,O
or,O
200,O
mg,O
was,O
1,O
4,O
2,O
0,O
and,O
2,O
0,O
respectively,O
compared,O
to,O
1,O
7,O
for,O
placebo,O
treated,O
patients,O
Table,O
1,O
presents,O
the,O
adverse,O
reactions,O
reported,O
when,O
STENDRA,O
was,O
taken,O
as,O
recommended,O
on,O
an,O
as,O
needed,O
basis,O
from,O
these,O
3,O
clinical,O
trials,O
Table,O
1,O
Adverse,O
Reactions,O
Reported,O
by,O
Greater,O
Than,O
or,O
Equal,O
to,O
2,O
of,O
Patients,O
Treated,O
with,O
STENDRA,O
From,O
3,O
Placebo,O
Controlled,O
Clinical,O
Trials,O
Lasting,O
3,O
Months,O
for,O
STENDRA,O
Use,O
as,O
Needed,O
Adverse,O
Reaction,O
Placebo,O
N,O
349,O
STENDRA,O
50,O
mg,O
N,O
217,O
STENDRA,O
100,O
mg,O
N,O
349,O
STENDRA,O
200,O
mg,O
N,O
352,O
Headache,AdverseReaction
1,O
7,O
5,O
1,O
6,O
9,O
10,O
5,O
Flushing,AdverseReaction
0,O
0,O
3,O
2,O
4,O
3,O
4,O
0,O
Nasal congestion,AdverseReaction
1,O
1,O
1,O
8,O
2,O
9,O
2,O
0,O
Nasopharyngitis,AdverseReaction
2,O
9,O
0,O
9,O
2,O
6,O
3,O
4,O
Back pain,AdverseReaction
1,O
1,O
3,O
2,O
2,O
0,O
1,O
1,O
Adverse,O
reactions,O
reported,O
by,O
greater,O
than,O
or,O
equal,O
to,O
1,O
but,O
less,O
than,O
2,O
of,O
patients,O
in,O
any,O
STENDRA,O
dose,O
group,O
and,O
greater,O
than,O
placebo,O
included,O
upper respiratory infection,AdverseReaction
URI,AdverseReaction
bronchitis,AdverseReaction
influenza,AdverseReaction
sinusitis,AdverseReaction
sinus congestion,AdverseReaction
hypertension,AdverseReaction
dyspepsia,AdverseReaction
nausea,AdverseReaction
constipation,AdverseReaction
and,O
rash,AdverseReaction
In,O
an,O
open,O
label,O
long,O
term,O
extension,O
study,O
of,O
two,O
of,O
these,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
trials,O
the,O
total,O
duration,O
of,O
treatment,O
was,O
up,O
to,O
52,O
weeks,O
Among,O
the,O
712,O
patients,O
who,O
participated,O
in,O
this,O
open,O
label,O
extension,O
study,O
the,O
mean,O
age,O
of,O
the,O
population,O
was,O
56,O
4,O
years,O
range,O
from,O
23,O
to,O
88,O
years,O
The,O
discontinuation,O
rate,O
due,O
to,O
adverse,O
reactions,O
for,O
patients,O
treated,O
with,O
STENDRA,O
50,O
mg,O
100,O
mg,O
or,O
200,O
mg,O
was,O
2,O
8,O
In,O
this,O
extension,O
trial,O
all,O
eligible,O
patients,O
were,O
initially,O
assigned,O
to,O
STENDRA,O
100,O
mg,O
At,O
any,O
point,O
during,O
the,O
trial,O
patients,O
could,O
request,O
to,O
have,O
their,O
dose,O
of,O
STENDRA,O
increased,O
to,O
200,O
mg,O
or,O
decreased,O
to,O
50,O
mg,O
based,O
on,O
their,O
individual,O
response,O
to,O
treatment,O
In,O
total,O
536,O
approximately,O
75,O
patients,O
increased,O
their,O
dose,O
to,O
200,O
mg,O
and,O
5,O
less,O
than,O
1,O
patients,O
reduced,O
their,O
dose,O
to,O
50,O
mg,O
Table,O
2,O
presents,O
the,O
adverse,O
reactions,O
reported,O
when,O
STENDRA,O
was,O
taken,O
as,O
recommended,O
on,O
an,O
as,O
needed,O
basis,O
in,O
this,O
open,O
label,O
extension,O
trial,O
Table,O
2,O
Adverse,O
Reactions,O
Reported,O
by,O
Greater,O
Than,O
or,O
Equal,O
to,O
2,O
of,O
Patients,O
Treated,O
With,O
STENDRA,O
in,O
an,O
Open,O
Label,O
Extension,O
Trial,O
Adverse,O
Reaction,O
STENDRA,O
N,O
711,O
Headache,AdverseReaction
5,O
6,O
Flushing,AdverseReaction
3,O
5,O
Nasopharyngitis,AdverseReaction
3,O
4,O
Nasal congestion,AdverseReaction
2,O
1,O
Adverse,O
reactions,O
reported,O
by,O
greater,O
than,O
or,O
equal,O
to,O
1,O
but,O
less,O
than,O
2,O
of,O
patients,O
in,O
the,O
open,O
label,O
extension,O
study,O
included,O
upper respiratory infection,AdverseReaction
URI,AdverseReaction
influenza,AdverseReaction
sinusitis,AdverseReaction
bronchitis,AdverseReaction
dizziness,AdverseReaction
back pain,AdverseReaction
arthralgia,AdverseReaction
hypertension,AdverseReaction
and,O
diarrhea,AdverseReaction
The,O
following,O
events,O
occurred,O
in,O
less,O
than,O
1,O
of,O
patients,O
in,O
the,O
three,O
placebo,O
controlled,O
3,O
month,O
clinical,O
trials,O
and,O
or,O
the,O
open,O
label,O
long,O
term,O
extension,O
study,O
lasting,O
12,O
months,O
A,O
causal,O
relationship,O
to,O
STENDRA,O
is,O
uncertain,O
Excluded,O
from,O
this,O
list,O
are,O
those,O
events,O
that,O
were,O
minor,O
those,O
with,O
no,O
plausible,O
relation,O
to,O
drug,O
use,O
and,O
reports,O
too,O
imprecise,O
to,O
be,O
meaningful,O
Body,O
as,O
a,O
whole,O
edema peripheral,AdverseReaction
fatigue,AdverseReaction
Cardiovascular,O
angina,AdverseReaction
unstable angina,AdverseReaction
deep vein thrombosis,AdverseReaction
palpitations,AdverseReaction
Digestive,O
gastritis,AdverseReaction
gastroesophageal reflux disease,AdverseReaction
hypoglycemia,AdverseReaction
blood glucose increased,AdverseReaction
alanine aminotransferase increased,AdverseReaction
oropharyngeal pain,AdverseReaction
stomach discomfort,AdverseReaction
vomiting,AdverseReaction
Musculoskeletal,O
muscle spasms,AdverseReaction
musculoskeletal pain,AdverseReaction
myalgia,AdverseReaction
pain in extremity,AdverseReaction
Nervous,O
depression,AdverseReaction
insomnia,AdverseReaction
somnolence,AdverseReaction
vertigo,AdverseReaction
Respiratory,O
cough,AdverseReaction
dyspnea exertional,AdverseReaction
epistaxis,AdverseReaction
wheezing,AdverseReaction
Skin,O
and,O
Appendages,O
pruritus,AdverseReaction
Urogenital,O
balanitis,AdverseReaction
erection increased,AdverseReaction
hematuria,AdverseReaction
nephrolithiasis,AdverseReaction
pollakiuria,AdverseReaction
urinary tract infection,AdverseReaction
In,O
an,O
additional,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
study,O
lasting,O
up,O
to,O
3,O
months,O
in,O
298,O
men,O
who,O
had,O
undergone,O
bilateral,O
nerve,O
sparing,O
radical,O
prostatectomy,O
for,O
prostate,O
cancer,O
the,O
mean,O
age,O
of,O
patients,O
was,O
58,O
4,O
years,O
range,O
40,O
70,O
Table,O
3,O
presents,O
the,O
adverse,O
reactions,O
reported,O
in,O
this,O
study,O
Table,O
3,O
Adverse,O
Reactions,O
Reported,O
by,O
Greater,O
than,O
or,O
Equal,O
to,O
2,O
of,O
Patients,O
Treated,O
with,O
STENDRA,O
in,O
a,O
Placebo,O
Controlled,O
Clinical,O
Trial,O
Lasting,O
3,O
Months,O
in,O
Patients,O
Who,O
Underwent,O
Bilateral,O
Nerve,O
Sparing,O
Radical,O
Prostatectomy,O
Adverse,O
Reaction,O
Placebo,O
N,O
100,O
STENDRA,O
100,O
mg,O
N,O
99,O
STENDRA,O
200,O
mg,O
N,O
99,O
Headache,AdverseReaction
1,O
0,O
8,O
1,O
12,O
1,O
Flushing,AdverseReaction
0,O
0,O
5,O
1,O
10,O
1,O
Nasopharyngitis,AdverseReaction
0,O
0,O
3,O
0,O
5,O
1,O
Upper respiratory infection,AdverseReaction
0,O
0,O
2,O
0,O
3,O
0,O
Nasal congestion,AdverseReaction
1,O
0,O
3,O
0,O
1,O
0,O
Back pain,AdverseReaction
1,O
0,O
3,O
0,O
2,O
0,O
Electrocardiogram abnormal,AdverseReaction
0,O
0,O
1,O
0,O
3,O
0,O
Dizziness,AdverseReaction
0,O
0,O
1,O
0,O
2,O
0,O
A,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
2,O
months,O
study,O
was,O
conducted,O
in,O
435,O
subjects,O
with,O
a,O
mean,O
age,O
of,O
58,O
2,O
years,O
range,O
24,O
to,O
86,O
years,O
to,O
determine,O
the,O
time,O
to,O
onset,O
of,O
effect,O
of,O
STENDRA,O
defined,O
as,O
the,O
time,O
to,O
the,O
first,O
occurrence,O
of,O
an,O
erection,O
sufficient,O
for,O
sexual,O
intercourse,O
Table,O
4,O
presents,O
the,O
adverse,O
reactions,O
occurring,O
in,O
2,O
of,O
subjects,O
treated,O
with,O
STENDRA,O
Table,O
4,O
Adverse,O
Reactions,O
Reported,O
by,O
2,O
of,O
Patients,O
Treated,O
with,O
STENDRA,O
in,O
a,O
Placebo,O
Controlled,O
Clinical,O
Trial,O
Lasting,O
2,O
Months,O
to,O
Determine,O
the,O
Time,O
to,O
Onset,O
of,O
Effect,O
Study,O
3,O
Adverse,O
Reaction,O
Placebon,O
143,O
STENDRA,O
100,O
mgn,O
146,O
STENDRA,O
200,O
mgn,O
146,O
Headache,AdverseReaction
0,O
7,O
1,O
4,O
8,O
9,O
Nasal congestion,AdverseReaction
0,O
0,O
0,O
7,O
4,O
1,O
Gastroenteritis viral,AdverseReaction
0,O
0,O
0,O
0,O
2,O
1,O
Across,O
all,O
trials,O
with,O
any,O
STENDRA,O
dose,O
1,O
subject,O
reported,O
a,O
change in color vision,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
Ophthalmologic,O
Non arteritic anterior ischemic optic neuropathy,AdverseReaction
NAION,AdverseReaction
a,O
cause,O
of,O
decreased vision,AdverseReaction
including,O
permanent loss of vision,AdverseReaction
has,O
been,O
reported,O
rarely,O
post,O
marketing,O
in,O
temporal,O
association,O
with,O
the,O
use,O
of,O
phosphodiesterase type 5 PDE5 inhibitors,DrugClass
Most,O
but,O
not,O
all,O
of,O
these,O
patients,O
had,O
underlying,O
anatomic,O
or,O
vascular,O
risk,O
factors,O
for,O
developing,O
NAION,O
including,O
but,O
not,O
necessarily,O
limited,O
to,O
low,O
cup,O
to,O
disc,O
ratio,O
crowded,O
disc,O
age,O
over,O
50,O
diabetes,O
hypertension,O
coronary,O
artery,O
disease,O
hyperlipidemia,O
and,O
smoking,O
It,O
is,O
not,O
possible,O
to,O
determine,O
whether,O
these,O
events,O
are,O
related,O
directly,O
to,O
the,O
use,O
of,O
PDE5,O
inhibitors,O
to,O
the,O
patient,O
s,O
underlying,O
vascular,O
risk,O
factors,O
or,O
anatomical,O
defects,O
to,O
a,O
combination,O
of,O
these,O
factors,O
or,O
to,O
other,O
factors,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
andPatient,O
Counseling,O
Information,O
17,O
6,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
New onset,AdverseReaction
or,O
worsening renal impairment impairment,AdverseReaction
Can,Factor
include,O
acute renal failure,AdverseReaction
and,O
Fanconi syndrome,AdverseReaction
Assess,O
creatinine,O
clearance,O
CLcr,O
urine,O
glucose,O
and,O
urine,O
protein,O
before,O
initiating,O
treatment,O
with,O
STRIBILD,O
Monitor,O
CLcr,O
urine,O
glucose,O
and,O
urine,O
protein,O
in,O
all,O
patients,O
Monitor,O
serum,O
phosphorus,O
in,O
patients,O
at,O
risk,O
for,O
renal,O
impairment,O
Avoid,O
administering,O
STRIBILD,O
with,O
concurrent,O
or,O
recent,O
use,O
of,O
nephrotoxic,O
drugs,O
5,O
3,O
Avoid,O
coadministration,O
with,O
other,O
anti,O
retroviral,O
products,O
Do,O
not,O
use,O
with,O
products,O
containing,O
any,O
of,O
the,O
components,O
of,O
STRIBILD,O
cobicistat,O
elvitegravir,O
emtricitabine,O
and,O
tenofovir,O
disoproxil,O
fumarate,O
including,O
ATRIPLA,O
COMPLERA,O
EMTRIVA,O
TRUVADA,O
TYBOST,O
VIREAD,O
or,O
VITEKTA,O
with,O
drugs,O
containing,O
lamivudine,O
or,O
with,O
drugs,O
or,O
regimens,O
containing,O
ritonavir,O
Do,O
not,O
administer,O
in,O
combination,O
with,O
HEPSERA,O
5,O
4,O
Risk,O
of,O
adverse,O
reactions,O
or,O
loss,O
of,O
virologic,O
response,O
due,O
to,O
drug,O
interactions,O
The,O
concomitant,O
use,O
of,O
STRIBILD,O
and,O
other,O
drugs,O
may,O
result,O
in,O
known,O
or,O
potentially,O
significant,O
drug,O
interactions,O
some,O
of,O
which,O
may,O
lead,O
to,O
loss,O
of,O
therapeutic,O
effect,O
of,O
STRIBILD,O
and,O
possible,O
development,O
of,O
resistance,O
and,O
possible,O
clinically,O
significant,O
adverse,O
reactions,O
from,O
greater,O
exposures,O
of,O
concomitant,O
drugs,O
5,O
5,O
Decreases in bone mineral density in,AdverseReaction
BMD,AdverseReaction
Consider,O
monitoring,O
BMD,O
in,O
patients,O
with,O
a,O
history,O
of,O
pathologic,O
fracture,O
or,O
other,O
risk,O
factors,O
of,O
osteoporosis,O
or,O
bone,O
loss,O
5,O
6,O
Redistribution,AdverseReaction
accumulation of body fat body fat,AdverseReaction
Observed,O
in,O
patients,O
receiving,O
antiretroviral,O
therapy,O
5,O
7,O
Immune reconstitution syndrome,AdverseReaction
May,O
necessitate,O
further,O
evaluation,O
and,O
treatment,O
5,O
8,O
5,O
1,O
Lactic,O
Acidosis,O
Severe,O
Hepatomegaly,O
with,O
Steatosis,O
Lactic acidosis,AdverseReaction
and,O
severe,Severity
hepatomegaly,AdverseReaction
with,O
steatosis,AdverseReaction
including,O
fatal,AdverseReaction
cases,O
have,O
been,O
reported,O
with,O
the,O
use,O
of,O
nucleoside,O
analogs,O
including,O
tenofovir,O
DF,O
a,O
component,O
of,O
STRIBILD,O
in,O
combination,O
with,O
other,O
antiretrovirals,O
A,O
majority,O
of,O
these,O
cases,O
have,O
been,O
in,O
women,O
Obesity,O
and,O
prolonged,O
nucleoside,O
exposure,O
may,O
be,O
risk,O
factors,O
Particular,O
caution,O
should,O
be,O
exercised,O
when,O
administering,O
nucleoside,O
analogs,O
to,O
any,O
patient,O
with,O
known,O
risk,O
factors,O
for,O
liver,O
disease,O
however,O
cases,O
have,O
also,O
been,O
reported,O
in,O
patients,O
with,O
no,O
known,O
risk,O
factors,O
Treatment,O
with,O
STRIBILD,O
should,O
be,O
suspended,O
in,O
any,O
patient,O
who,O
develops,O
clinical,O
or,O
laboratory,O
findings,O
suggestive,O
of,O
lactic,O
acidosis,O
or,O
pronounced,O
hepatotoxicity,O
which,O
may,O
include,O
hepatomegaly,O
and,O
steatosis,O
even,O
in,O
the,O
absence,O
of,O
marked,O
transaminase,O
elevations,O
5,O
2,O
Patients,O
Coinfected,O
with,O
HIV,O
1,O
and,O
HBV,O
It,O
is,O
recommended,O
that,O
all,O
patients,O
with,O
HIV,O
1,O
be,O
tested,O
for,O
the,O
presence,O
of,O
chronic,O
hepatitis,O
B,O
virus,O
HBV,O
before,O
initiating,O
antiretroviral,O
therapy,O
STRIBILD,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
chronic,O
HBV,O
infection,O
and,O
the,O
safety,O
and,O
efficacy,O
of,O
STRIBILD,O
have,O
not,O
been,O
established,O
in,O
patients,O
coinfected,O
with,O
HBV,O
and,O
HIV,O
1,O
Severe,O
acute,O
exacerbations,O
of,O
hepatitis,O
B,O
have,O
been,O
reported,O
in,O
patients,O
who,O
are,O
coinfected,O
with,O
HBV,O
and,O
HIV,O
1,O
and,O
have,O
discontinued,O
emtricitabine,O
or,O
tenofovir,O
DF,O
two,O
of,O
the,O
components,O
of,O
STRIBILD,O
In,O
some,O
patients,O
infected,O
with,O
HBV,O
and,O
treated,O
with,O
EMTRIVA,O
the,O
exacerbations of hepatitis B,AdverseReaction
were,O
associated,O
with,O
liver decompensation,AdverseReaction
and,O
liver failure,AdverseReaction
Patients,O
who,O
are,O
coinfected,O
with,O
HIV,O
1,O
and,O
HBV,O
should,O
be,O
closely,O
monitored,O
with,O
both,O
clinical,O
and,O
laboratory,O
follow,O
up,O
for,O
at,O
least,O
several,O
months,O
after,O
stopping,O
treatment,O
with,O
STRIBILD,O
If,O
appropriate,O
initiation,O
of,O
anti,O
hepatitis,O
B,O
therapy,O
may,O
be,O
warranted,O
5,O
3,O
New,O
Onset,O
or,O
Worsening,O
Renal,O
Impairment,O
Renal impairment,AdverseReaction
including,O
cases,O
of,O
acute renal failure,AdverseReaction
and,O
Fanconi syndrome,AdverseReaction
renal tubular injury,AdverseReaction
with,O
severe,Severity
hypophosphatemia,AdverseReaction
has,O
been,O
reported,O
with,O
the,O
use,O
of,O
tenofovir,O
DF,O
a,O
component,O
of,O
STRIBILD,O
and,O
with,O
the,O
use,O
of,O
STRIBILD,O
see,O
Adverse,O
Reactions,O
6,O
2,O
In,O
the,O
clinical,O
trials,O
of,O
STRIBILD,O
over,O
144,O
weeks,O
13,O
1,O
9,O
subjects,O
in,O
the,O
STRIBILD,O
group,O
N,O
701,O
8,O
2,O
3,O
subjects,O
in,O
the,O
ATV,O
RTV,O
TRUVADA,O
group,O
N,O
355,O
and,O
no,O
subjects,O
in,O
the,O
ATRIPLA,O
group,O
N,O
352,O
discontinued,O
study,O
drug,O
due,O
to,O
a,O
renal adverse reaction,AdverseReaction
Of,O
these,O
discontinuations,O
8,O
in,O
the,O
STRIBILD,O
group,O
and,O
1,O
in,O
the,O
ATV,O
RTV,O
TRUVADA,O
group,O
occurred,O
during,O
the,O
first,O
48,O
weeks,O
Four,O
0,O
6,O
subjects,O
who,O
received,O
STRIBILD,O
developed,O
laboratory,O
findings,O
consistent,O
with,O
proximal renal tubular dysfunction,AdverseReaction
leading,O
to,O
discontinuation,O
of,O
STRIBILD,O
during,O
the,O
first,O
48,O
weeks,O
of,O
treatment,O
Two,O
of,O
the,O
four,O
subjects,O
had,O
renal,O
impairment,O
i,O
e,O
estimated,O
creatinine,O
clearance,O
less,O
than,O
70,O
mL,O
per,O
minute,O
at,O
baseline,O
The,O
laboratory,O
findings,O
in,O
these,O
4,O
subjects,O
improved,O
but,O
did,O
not,O
completely,O
resolve,O
in,O
all,O
subjects,O
upon,O
discontinuation,O
of,O
STRIBILD,O
Renal,O
replacement,O
therapy,O
was,O
not,O
required,O
for,O
these,O
subjects,O
One,O
0,O
3,O
subject,O
who,O
received,O
ATV,O
RTV,O
TRUVADA,O
developed,O
laboratory,O
findings,O
consistent,O
with,O
proximal renal tubular dysfunction,AdverseReaction
leading,O
to,O
discontinuation,O
of,O
ATV,O
RTV,O
TRUVADA,O
after,O
Week,O
96,O
STRIBILD,O
should,O
be,O
avoided,O
with,O
concurrent,O
or,O
recent,O
use,O
of,O
a,O
nephrotoxic,O
agent,O
e,O
g,O
high,O
dose,O
or,O
multiple,O
non,O
steroidal,O
anti,O
inflammatory,O
drugs,O
NSAIDs,O
see,O
Drug,O
Interactions,O
7,O
4,O
Cases,O
of,O
acute,O
renal,O
failure,O
after,O
initiation,O
of,O
high,O
dose,O
or,O
multiple,O
NSAIDs,O
have,O
been,O
reported,O
in,O
HIV,O
infected,O
patients,O
with,O
risk,O
factors,O
for,O
renal,O
dysfunction,O
who,O
appeared,O
stable,O
on,O
tenofovir,O
DF,O
Some,O
patients,O
required,O
hospitalization,O
and,O
renal,O
replacement,O
therapy,O
Alternatives,O
to,O
NSAIDs,O
should,O
be,O
considered,O
if,O
needed,O
in,O
patients,O
at,O
risk,O
for,O
renal,O
dysfunction,O
Persistent,O
or,O
worsening,O
bone,O
pain,O
pain,O
in,O
extremities,O
fractures,O
and,O
or,O
muscular,O
pain,O
or,O
weakness,O
may,O
be,O
manifestations,O
of,O
proximal,O
renal,O
tubulopathy,O
and,O
should,O
prompt,O
an,O
evaluation,O
of,O
renal,O
function,O
in,O
at,O
risk,O
patients,O
Estimated,O
creatinine,O
clearance,O
urine,O
glucose,O
and,O
urine,O
protein,O
should,O
be,O
documented,O
in,O
all,O
patients,O
prior,O
to,O
initiating,O
therapy,O
Initiation,O
of,O
STRIBILD,O
in,O
patients,O
with,O
estimated,O
creatinine,O
clearance,O
below,O
70,O
mL,O
per,O
minute,O
is,O
not,O
recommended,O
Routine,O
monitoring,O
of,O
estimated,O
creatinine,O
clearance,O
urine,O
glucose,O
and,O
urine,O
protein,O
should,O
be,O
performed,O
during,O
STRIBILD,O
therapy,O
in,O
all,O
patients,O
Additionally,O
serum,O
phosphorus,O
should,O
be,O
measured,O
in,O
patients,O
at,O
risk,O
for,O
renal,O
impairment,O
Although,O
cobicistat,O
a,O
component,O
of,O
STRIBILD,O
may,Factor
cause,O
modest,Severity
increases in serum creatinine,AdverseReaction
and,O
modest,Severity
declines in estimated creatinine clearance,AdverseReaction
without,O
affecting,O
renal,O
glomerular,O
function,O
see,O
Adverse,O
Reactions,O
6,O
1,O
patients,O
who,O
experience,O
a,O
confirmed,O
increase,O
in,O
serum,O
creatinine,O
of,O
greater,O
than,O
0,O
4,O
mg,O
per,O
dL,O
from,O
baseline,O
should,O
be,O
closely,O
monitored,O
for,O
renal,O
safety,O
The,O
emtricitabine,O
and,O
tenofovir,O
DF,O
components,O
of,O
STRIBILD,O
are,O
primarily,O
excreted,O
by,O
the,O
kidney,O
STRIBILD,O
should,O
be,O
discontinued,O
if,O
estimated,O
creatinine,O
clearance,O
declines,O
below,O
50,O
mL,O
per,O
minute,O
as,O
dose,O
interval,O
adjustment,O
required,O
for,O
emtricitabine,O
and,O
tenofovir,O
DF,O
cannot,O
be,O
achieved,O
with,O
the,O
fixed,O
dose,O
combination,O
tablet,O
5,O
4,O
Avoid,O
Use,O
with,O
Other,O
Antiretroviral,O
Products,O
STRIBILD,O
is,O
indicated,O
for,O
use,O
as,O
a,O
complete,O
regimen,O
for,O
the,O
treatment,O
of,O
HIV,O
1,O
infection,O
and,O
coadministration,O
with,O
other,O
antiretroviral,O
products,O
is,O
not,O
recommended,O
STRIBILD,O
is,O
not,O
recommended,O
for,O
coadministration,O
with,O
the,O
following,O
cobicistat,O
TYBOST,O
elvitegravir,O
VITEKTA,O
products,O
containing,O
emtricitabine,O
or,O
tenofovir,O
DF,O
ATRIPLA,O
COMPLERA,O
EMTRIVA,O
TRUVADA,O
VIREAD,O
products,O
containing,O
lamivudine,O
COMBIVIR,O
EPIVIR,O
EPIVIR,O
HBV,O
EPZICOM,O
TRIUMEQ,O
TRIZIVIR,O
adefovir,O
dipivoxil,O
HEPSERA,O
products,O
containing,O
ritonavir,O
NORVIR,O
KALETRA,O
5,O
5,O
Risk,O
of,O
Adverse,O
Reactions,O
or,O
Loss,O
of,O
Virologic,O
Response,O
Due,O
to,O
Drug,O
Interactions,O
The,O
concomitant,O
use,O
of,O
STRIBILD,O
and,O
other,O
drugs,O
may,O
result,O
in,O
known,O
or,O
potentially,O
significant,O
drug,O
interactions,O
some,O
of,O
which,O
may,O
lead,O
to,O
see,O
Contraindications,O
4,O
Drug,O
Interactions,O
7,O
5,O
Loss,O
of,O
therapeutic,O
effect,O
of,O
STRIBILD,O
and,O
possible,O
development,O
of,O
resistance,O
Possible,O
clinically,O
significant,O
adverse,O
reactions,O
from,O
greater,O
exposures,O
of,O
concomitant,O
drugs,O
See,O
Table,O
6,O
for,O
steps,O
to,O
prevent,O
or,O
manage,O
these,O
possible,O
and,O
known,O
significant,O
drug,O
interactions,O
including,O
dosing,O
recommendations,O
see,O
Drug,O
Interactions,O
7,O
5,O
Consider,O
the,O
potential,O
for,O
drug,O
interactions,O
prior,O
to,O
and,O
during,O
STRIBILD,O
therapy,O
review,O
concomitant,O
medications,O
during,O
STRIBILD,O
therapy,O
and,O
monitor,O
for,O
the,O
adverse,O
reactions,O
associated,O
with,O
the,O
concomitant,O
drugs,O
5,O
6,O
Bone,O
Effects,O
of,O
Tenofovir,O
DF,O
Bone,O
Mineral,O
Density,O
In,O
clinical,O
trials,O
in,O
HIV,O
1,O
infected,O
adults,O
tenofovir,O
DF,O
a,O
component,O
of,O
STRIBILD,O
was,O
associated,O
with,O
slightly,O
greater,O
decreases in bone mineral density in,AdverseReaction
BMD,AdverseReaction
and,O
increases in biochemical markers of bone metabolism,AdverseReaction
suggesting,O
increased bone turnover,AdverseReaction
relative,O
to,O
comparators,O
Serum,O
parathyroid,O
hormone,O
levels,O
and,O
1,O
25,O
Vitamin,O
D,O
levels,O
were,O
also,O
higher,O
in,O
subjects,O
receiving,O
tenofovir,O
DF,O
For,O
additional,O
information,O
see,O
Adverse,O
Reactions,O
6,O
1,O
and,O
consult,O
the,O
VIREAD,O
prescribing,O
information,O
The,O
effects,O
of,O
tenofovir,O
DF,O
associated,O
changes,O
in,O
BMD,O
and,O
biochemical,O
markers,O
on,O
long,O
term,O
bone,O
health,O
and,O
future,O
fracture,O
risk,O
are,O
unknown,O
Assessment,O
of,O
BMD,O
should,O
be,O
considered,O
for,O
HIV,O
1,O
infected,O
patients,O
who,O
have,O
a,O
history,O
of,O
pathologic,O
bone,O
fracture,O
or,O
other,O
risk,O
factors,O
for,O
osteoporosis,O
or,O
bone,O
loss,O
Although,O
the,O
effect,O
of,O
supplementation,O
with,O
calcium,O
and,O
vitamin,O
D,O
was,O
not,O
studied,O
such,O
supplementation,O
may,O
be,O
beneficial,O
in,O
all,O
patients,O
If,O
bone,O
abnormalities,O
are,O
suspected,O
then,O
appropriate,O
consultation,O
should,O
be,O
obtained,O
Mineralization,O
Defects,O
Cases,O
of,O
osteomalacia,AdverseReaction
associated,O
with,O
proximal renal tubulopathy,AdverseReaction
manifested,O
as,O
bone pain,AdverseReaction
or,O
pain in extremities,AdverseReaction
and,O
which,O
may,Factor
contribute,O
to,O
fractures,AdverseReaction
have,O
been,O
reported,O
in,O
association,O
with,O
the,O
use,O
of,O
tenofovir,O
DF,O
see,O
Adverse,O
Reactions,O
6,O
2,O
Arthralgias,AdverseReaction
and,O
muscle pain,AdverseReaction
or,O
weakness,AdverseReaction
have,O
also,O
been,O
reported,O
in,O
cases,O
of,O
proximal renal tubulopathy,AdverseReaction
Hypophosphatemia,O
and,O
osteomalacia,O
secondary,O
to,O
proximal,O
renal,O
tubulopathy,O
should,O
be,O
considered,O
in,O
patients,O
at,O
risk,O
of,O
renal,O
dysfunction,O
who,O
present,O
with,O
persistent,O
or,O
worsening,O
bone,O
or,O
muscle,O
symptoms,O
while,O
receiving,O
products,O
containing,O
tenofovir,O
DF,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
5,O
7,O
Fat,O
Redistribution,O
Redistribution,AdverseReaction
accumulation of body fat body fat,AdverseReaction
body fat,AdverseReaction
including,O
central obesity,AdverseReaction
dorsocervical fat enlargement,AdverseReaction
buffalo hump,AdverseReaction
peripheral wasting,AdverseReaction
facial wasting,AdverseReaction
breast enlargement,AdverseReaction
and,O
cushingoid appearance,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
receiving,O
antiretroviral,O
therapy,O
The,O
mechanism,O
and,O
long,O
term,O
consequences,O
of,O
these,O
events,O
are,O
currently,O
unknown,O
A,O
causal,O
relationship,O
has,O
not,O
been,O
established,O
5,O
8,O
Immune,O
Reconstitution,O
Syndrome,O
Immune reconstitution syndrome,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
combination,O
antiretroviral,O
therapy,O
including,O
STRIBILD,O
During,O
the,O
initial,O
phase,O
of,O
combination,O
antiretroviral,O
treatment,O
patients,O
whose,O
immune,O
system,O
responds,O
may,Factor
develop,O
an,O
inflammatory,O
response,O
to,O
indolent,O
or,O
residual opportunistic infections,AdverseReaction
such,O
as,O
Mycobacterium avium infection,AdverseReaction
cytomegalovirus,AdverseReaction
Pneumocystis jirovecii pneumonia,AdverseReaction
PCP,AdverseReaction
or,O
tuberculosis,AdverseReaction
which,O
may,O
necessitate,O
further,O
evaluation,O
and,O
treatment,O
Autoimmune disorders,AdverseReaction
such,O
as,O
Graves disease,AdverseReaction
polymyositis,AdverseReaction
and,O
Guillain Barre syndrome,AdverseReaction
have,O
also,O
been,O
reported,O
to,O
occur,O
in,O
the,O
setting,O
of,O
immune,O
reconstitution,O
however,O
the,O
time,O
to,O
onset,O
is,O
more,O
variable,O
and,O
can,O
occur,O
many,O
months,O
after,O
initiation,O
of,O
treatment,O
""
BOXED,O
WARNING,O
WARNING,O
LACTIC ACIDOSIS,AdverseReaction
SEVERE,Severity
HEPATOMEGALY,AdverseReaction
WITH,O
STEATOSIS,AdverseReaction
and,O
POST,O
TREATMENT,O
ACUTE EXACERBATION OF HEPATITIS B,AdverseReaction
WARNING,O
LACTIC ACIDOSIS,AdverseReaction
SEVERE,Severity
HEPATOMEGALY,AdverseReaction
WITH,O
STEATOSIS,AdverseReaction
and,O
POST,O
TREATMENT,O
ACUTE EXACERBATION OF HEPATITIS B,AdverseReaction
Lactic acidosis,AdverseReaction
and,O
severe,Severity
hepatomegaly,AdverseReaction
with,O
steatosis,AdverseReaction
including,O
fatal,AdverseReaction
cases,O
have,O
been,O
reported,O
with,O
the,O
use,O
of,O
nucleoside,O
analogs,O
including,O
tenofovir,O
disoproxil,O
fumarate,O
a,O
component,O
of,O
STRIBILD,O
in,O
combination,O
with,O
other,O
antiretrovirals,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
STRIBILD,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
chronic,O
hepatitis,O
B,O
virus,O
HBV,O
infection,O
and,O
the,O
safety,O
and,O
efficacy,O
of,O
STRIBILD,O
have,O
not,O
been,O
established,O
in,O
patients,O
coinfected,O
with,O
HBV,O
and,O
HIV,O
1,O
Severe,Severity
acute exacerbations of hepatitis B,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
who,O
are,O
coinfected,O
with,O
HBV,O
and,O
human,O
immunodeficiency,O
virus,O
1,O
HIV,O
1,O
and,O
have,O
discontinued,O
EMTRIVA,O
or,O
VIREAD,O
which,O
are,O
components,O
of,O
STRIBILD,O
Hepatic,O
function,O
should,O
be,O
monitored,O
closely,O
with,O
both,O
clinical,O
and,O
laboratory,O
follow,O
up,O
for,O
at,O
least,O
several,O
months,O
in,O
patients,O
who,O
are,O
coinfected,O
with,O
HIV,O
1,O
and,O
HBV,O
and,O
discontinue,O
STRIBILD,O
If,O
appropriate,O
initiation,O
of,O
anti,O
hepatitis,O
B,O
therapy,O
may,O
be,O
warranted,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
WARNING,O
LACTIC ACIDOSIS,AdverseReaction
SEVERE,Severity
HEPATOMEGALY,AdverseReaction
WITH,O
STEATOSIS,AdverseReaction
and,O
POST,O
TREATMENT,O
ACUTE EXACERBATION OF HEPATITIS B,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Lactic acidosis,AdverseReaction
and,O
severe,Severity
hepatomegaly,AdverseReaction
with,O
steatosis,AdverseReaction
including,O
fatal,AdverseReaction
cases,O
have,O
been,O
reported,O
with,O
the,O
use,O
of,O
nucleoside,O
analogs,O
including,O
tenofovir,O
disoproxil,O
fumarate,O
DF,O
a,O
component,O
of,O
STRIBILD,O
5,O
1,O
STRIBILD,O
is,O
not,O
approved,O
for,O
the,O
treatment,O
of,O
chronic,O
hepatitis,O
B,O
virus,O
HBV,O
infection,O
Severe,Severity
acute exacerbations of hepatitis B,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
coinfected,O
with,O
HIV,O
1,O
and,O
HBV,O
who,O
have,O
discontinued,O
EMTRIVA,O
or,O
VIREAD,O
two,O
of,O
the,O
components,O
of,O
STRIBILD,O
Hepatic,O
function,O
should,O
be,O
monitored,O
closely,O
in,O
these,O
patients,O
If,O
appropriate,O
initiation,O
of,O
anti,O
hepatitis,O
B,O
therapy,O
may,O
be,O
warranted,O
5,O
2,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
drug,O
reactions,O
are,O
discussed,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Lactic Acidosis,AdverseReaction
Severe,Severity
Hepatomegaly,AdverseReaction
with,O
Steatosis,AdverseReaction
see,O
Boxed,O
Warning,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Severe,Severity
Acute Exacerbations of Hepatitis B,AdverseReaction
see,O
Boxed,O
Warning,O
Warnings,O
and,O
Precautions,O
5,O
2,O
New Onset,AdverseReaction
or,O
Worsening Renal Impairment Impairment,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Bone Effects,AdverseReaction
of,O
Tenofovir,O
DF,O
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Immune Reconstitution Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
EXCERPT,O
Most,O
common,O
adverse,O
drug,O
reactions,O
to,O
STRIBILD,O
incidence,O
greater,O
than,O
or,O
equal,O
to,O
10,O
all,O
grades,O
are,O
nausea,AdverseReaction
and,O
diarrhea,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Gilead,O
Sciences,O
Inc,O
at,O
1,O
800,O
GILEAD,O
5,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Adverse,O
Reactions,O
from,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
In,O
HIV,O
1,O
Infected,O
Subjects,O
With,O
No,O
Antiretroviral,O
Treatment,O
History,O
The,O
safety,O
assessment,O
of,O
STRIBILD,O
is,O
based,O
on,O
the,O
Week,O
144,O
pooled,O
data,O
from,O
1408,O
subjects,O
in,O
two,O
randomized,O
double,O
blind,O
active,O
controlled,O
clinical,O
trials,O
Study,O
102,O
and,O
Study,O
103,O
in,O
antiretroviral,O
treatment,O
naive,O
HIV,O
1,O
infected,O
adult,O
subjects,O
see,O
Clinical,O
Studies,O
14,O
A,O
total,O
of,O
701,O
subjects,O
received,O
STRIBILD,O
once,O
daily,O
in,O
these,O
two,O
studies,O
The,O
proportion,O
of,O
subjects,O
who,O
discontinued,O
treatment,O
with,O
STRIBILD,O
elvitegravir,O
150,O
mg,O
cobicistat,O
150,O
mg,O
emtricitabine,O
200,O
mg,O
tenofovir,O
DF,O
300,O
mg,O
ATRIPLA,O
efavirenz,O
600,O
mg,O
emtricitabine,O
200,O
mg,O
tenofovir,O
DF,O
300,O
mg,O
or,O
atazanavir,O
ATV,O
ritonavir,O
RTV,O
TRUVADA,O
emtricitabine,O
200,O
mg,O
tenofovir,O
DF,O
300,O
mg,O
due,O
to,O
adverse,O
events,O
regardless,O
of,O
severity,O
was,O
6,O
0,O
7,O
4,O
and,O
8,O
5,O
respectively,O
Table,O
2,O
displays,O
the,O
frequency,O
of,O
adverse,O
drug,O
reactions,O
greater,O
than,O
or,O
equal,O
to,O
5,O
of,O
subjects,O
in,O
any,O
treatment,O
arm,O
Table,O
2,O
Adverse,O
Drug,O
ReactionsFrequencies,O
of,O
adverse,O
reactions,O
are,O
based,O
on,O
all,O
treatment,O
emergent,O
adverse,O
events,O
attributed,O
to,O
study,O
drugs,O
all,O
grades,O
Reported,O
in,O
5,O
of,O
Subjects,O
in,O
Any,O
Treatment,O
Arm,O
in,O
Studies,O
102,O
and,O
103,O
Week,O
144,O
analysis,O
STRIBILDN,O
701,O
ATRIPLAN,O
352,O
ATV,O
RTV,O
TRUVADAN,O
355,O
EYE,O
DISORDERS,O
Ocular icterus,AdverseReaction
1,O
0,O
13,O
GASTROINTESTINAL,O
DISORDERS,O
Diarrhea,AdverseReaction
12,O
11,O
17,O
Flatulence,AdverseReaction
2,O
1,O
8,O
Nausea,AdverseReaction
16,O
9,O
14,O
GENERAL,O
DISORDERS,O
AND,O
ADMINISTRATION,O
SITE,O
CONDITIONS,O
Fatigue,AdverseReaction
4,O
8,O
6,O
HEPATOBILIARY,O
DISORDERS,O
Jaundice,AdverseReaction
0,O
1,O
9,O
NERVOUS,O
SYSTEM,O
DISORDERS,O
Somnolence,AdverseReaction
1,O
7,O
1,O
Headache,AdverseReaction
7,O
4,O
6,O
Dizziness,AdverseReaction
3,O
21,O
5,O
PSYCHIATRIC,O
DISORDERS,O
Insomnia,AdverseReaction
3,O
9,O
1,O
Abnormal dreams,AdverseReaction
9,O
27,O
4,O
SKIN,O
AND,O
SUBCUTANEOUS,O
TISSUE,O
DISORDERS,O
Rash,AdverseReaction
4,O
15,O
6,O
See,O
Warnings,O
and,O
Precautions,O
5,O
3,O
for,O
a,O
discussion,O
of,O
renal adverse reactions,AdverseReaction
from,O
clinical,O
trials,O
experience,O
with,O
STRIBILD,O
Additional,O
adverse,O
drug,O
reactions,O
observed,O
with,O
STRIBILD,O
included,O
suicidal ideation,AdverseReaction
and,O
suicide attempt,AdverseReaction
0,O
3,O
all,O
in,O
subjects,O
with,O
a,O
pre,O
existing,O
history,O
of,O
depression,O
or,O
psychiatric,O
illness,O
In,O
Virologically,O
Suppressed,O
HIV,O
1,O
Infected,O
Subjects,O
No,O
new,O
adverse,O
reactions,O
to,O
STRIBILD,O
through,O
Week,O
48,O
were,O
identified,O
in,O
584,O
virologically,O
stably,O
suppressed,O
subjects,O
switching,O
to,O
STRIBILD,O
from,O
a,O
regimen,O
containing,O
a,O
RTV,O
boosted,O
protease,O
inhibitor,O
PI,O
or,O
a,O
non,O
nucleoside,O
reverse,O
transcriptase,O
inhibitor,O
NNRTI,O
In,O
a,O
combined,O
analysis,O
of,O
Studies,O
115,O
and,O
121,O
the,O
frequency,O
of,O
adverse,O
reactions,O
all,O
grades,O
was,O
24,O
in,O
subjects,O
switching,O
to,O
STRIBILD,O
compared,O
to,O
6,O
of,O
subjects,O
in,O
either,O
group,O
who,O
stayed,O
on,O
their,O
baseline,O
antiretroviral,O
regimen,O
RTV,O
boosted,O
PI,O
TRUVADA,O
or,O
NNRTI,O
TRUVADA,O
Common,O
adverse,O
reactions,O
that,O
occurred,O
in,O
greater,O
than,O
or,O
equal,O
to,O
2,O
of,O
subjects,O
switching,O
to,O
STRIBILD,O
were,O
nausea,AdverseReaction
4,O
flatulence,AdverseReaction
2,O
and,O
headache,AdverseReaction
2,O
The,O
proportion,O
of,O
subjects,O
who,O
discontinued,O
treatment,O
with,O
STRIBILD,O
the,O
RTV,O
boosted,O
PI,O
or,O
the,O
NNRTI,O
due,O
to,O
adverse,O
events,O
was,O
2,O
3,O
and,O
1,O
respectively,O
Adverse,O
Reactions,O
from,O
Clinical,O
Trials,O
of,O
the,O
Components,O
of,O
STRIBILD,O
Emtricitabine,O
and,O
Tenofovir,O
Disoproxil,O
Fumarate,O
In,O
addition,O
to,O
the,O
adverse,O
reactions,O
observed,O
with,O
STRIBILD,O
the,O
following,O
adverse,O
reactions,O
occurred,O
in,O
at,O
least,O
5,O
of,O
treatment,O
experienced,O
or,O
treatment,O
naive,O
subjects,O
receiving,O
emtricitabine,O
or,O
tenofovir,O
DF,O
with,O
other,O
antiretroviral,O
agents,O
in,O
other,O
clinical,O
trials,O
depression,AdverseReaction
abdominal pain,AdverseReaction
dyspepsia,AdverseReaction
vomiting,AdverseReaction
fever,AdverseReaction
pain,AdverseReaction
nasopharyngitis,AdverseReaction
pneumonia,AdverseReaction
sinusitis,AdverseReaction
upper respiratory tract infection,AdverseReaction
arthralgia,AdverseReaction
back pain,AdverseReaction
myalgia,AdverseReaction
paresthesia,AdverseReaction
peripheral neuropathy,AdverseReaction
including,O
peripheral neuritis,AdverseReaction
and,O
neuropathy,AdverseReaction
anxiety,AdverseReaction
increased cough,AdverseReaction
and,O
rhinitis,AdverseReaction
Skin discoloration,AdverseReaction
has,O
been,O
reported,O
with,O
higher,O
frequency,O
among,O
emtricitabine,O
treated,O
subjects,O
it,O
was,O
manifested,O
by,O
hyperpigmentation on the palms on the,AdverseReaction
and,O
or,O
soles,AdverseReaction
and,O
was,O
generally,O
mild,Severity
and,O
asymptomatic,O
The,O
mechanism,O
and,O
clinical,O
significance,O
are,O
unknown,O
Laboratory,O
Abnormalities,O
The,O
frequency,O
of,O
laboratory,O
abnormalities,O
Grades,O
3,O
4,O
occurring,O
in,O
at,O
least,O
2,O
of,O
subjects,O
receiving,O
STRIBILD,O
in,O
Studies,O
102,O
and,O
103,O
are,O
presented,O
in,O
Table,O
3,O
Table,O
3,O
Laboratory,O
Abnormalities,O
Grades,O
3,O
4,O
Reported,O
in,O
2,O
of,O
Subjects,O
Receiving,O
STRIBILD,O
in,O
Studies,O
102,O
and,O
103,O
Week,O
144,O
analysis,O
STRIBILD,O
ATRIPLA,O
ATV,O
RTV,O
TRUVADA,O
Laboratory,O
Parameter,O
Abnormality,O
N,O
701,O
N,O
352,O
N,O
355,O
AST,AdverseReaction
5,O
0,O
ULN,O
3,O
6,O
6,O
ALT,AdverseReaction
3,O
0,O
ULN,O
2,O
5,O
4,O
Amylase,AdverseReaction
2,O
0,O
ULN,O
3,O
3,O
5,O
Creatine Kinase,AdverseReaction
10,O
0,O
ULN,O
8,O
15,O
11,O
Urine RBC,AdverseReaction
Hematuria,AdverseReaction
75,O
RBC,O
HPF,O
4,O
2,O
4,O
In,O
Study,O
103,O
BMD,O
was,O
assessed,O
by,O
DEXA,O
in,O
a,O
non,O
random,O
subset,O
of,O
120,O
subjects,O
STRIBILD,O
group,O
N,O
54,O
ATV,O
RTV,O
TRUVADA,O
group,O
N,O
66,O
Mean,O
percentage,O
decreases in BMD,AdverseReaction
from,O
baseline,O
to,O
Week,O
144,O
in,O
the,O
STRIBILD,O
group,O
were,O
comparable,O
to,O
the,O
ATV,O
RTV,O
TRUVADA,O
group,O
at,O
the,O
lumbar,O
spine,O
1,O
43,O
versus,O
3,O
68,O
respectively,O
and,O
at,O
the,O
hip,O
2,O
83,O
versus,O
3,O
77,O
respectively,O
In,O
Studies,O
102,O
and,O
103,O
bone fractures,AdverseReaction
occurred,O
in,O
27,O
subjects,O
3,O
9,O
in,O
the,O
STRIBILD,O
group,O
8,O
subjects,O
2,O
3,O
in,O
the,O
ATRIPLA,O
group,O
and,O
19,O
subjects,O
5,O
4,O
in,O
the,O
ATV,O
RTV,O
TRUVADA,O
group,O
These,O
findings,O
were,O
consistent,O
with,O
data,O
from,O
an,O
earlier,O
144,O
week,O
trial,O
of,O
treatment,O
naive,O
subjects,O
receiving,O
tenofovir,O
DF,O
lamivudine,O
efavirenz,O
Proteinuria,AdverseReaction
all,O
grades,O
occurred,O
in,O
52,O
of,O
subjects,O
receiving,O
STRIBILD,O
41,O
of,O
subjects,O
receiving,O
ATRIPLA,O
and,O
42,O
of,O
subjects,O
receiving,O
ATV,O
RTV,O
TRUVADA,O
The,O
cobicistat,O
component,O
of,O
STRIBILD,O
has,O
been,O
shown,O
to,O
increase serum creatinine,AdverseReaction
and,O
decrease estimated creatinine clearance,AdverseReaction
due,O
to,O
inhibition,O
of,O
tubular,O
secretion,O
of,O
creatinine,O
without,Negation
affecting renal glomerular function,AdverseReaction
In,O
Studies,O
102,O
and,O
103,O
increases in serum creatinine,AdverseReaction
and,O
decreases in estimated creatinine clearance,AdverseReaction
occurred,O
early,O
in,O
treatment,O
with,O
STRIBILD,O
after,O
which,O
they,O
stabilized,O
Table,O
4,O
displays,O
the,O
mean,O
changes,O
in,O
serum,O
creatinine,O
and,O
eGFR,O
levels,O
at,O
Week,O
144,O
and,O
the,O
percentage,O
of,O
subjects,O
with,O
elevations in serum creatinine,AdverseReaction
All,O
Grades,O
Table,O
4,O
Change,O
from,O
Baseline,O
in,O
Serum,O
Creatinine,O
and,O
eGFR,O
and,O
Incidence,O
of,O
Elevated Serum Creatinine,AdverseReaction
All,O
Grades,O
in,O
Studies,O
102,O
and,O
103,O
at,O
Week,O
144,O
STRIBILD,O
N,O
701,O
ATRIPLA,O
N,O
352,O
ATV,O
RTV,O
TRUVADA,O
N,O
355,O
Serum,O
Creatinine,O
mg,O
dL,O
0,O
14,O
0,O
14,O
0,O
01,O
0,O
12,O
0,O
09,O
0,O
15,O
eGFR,O
by,O
Cockcroft,O
Gault,O
mL,O
minute,O
14,O
0,O
16,O
6,O
1,O
9,O
17,O
9,O
9,O
8,O
19,O
4,O
Subjects,O
with,O
Elevations in Serum Creatinine,AdverseReaction
All,O
Grades,O
12,O
2,O
6,O
Emtricitabine,O
or,O
Tenofovir,O
DF,O
In,O
addition,O
to,O
the,O
laboratory,O
abnormalities,O
observed,O
with,O
STRIBILD,O
the,O
following,O
laboratory,O
abnormalities,O
have,O
been,O
previously,O
reported,O
in,O
subjects,O
treated,O
with,O
emtricitabine,O
or,O
tenofovir,O
DF,O
with,O
other,O
antiretroviral,O
agents,O
in,O
other,O
clinical,O
trials,O
Grade 3,Severity
or,O
4,Severity
laboratory,O
abnormalities of ALT of of of of of of of,AdverseReaction
M,O
greater,O
than,O
215 U per L,Severity
F,O
greater,O
than,O
170 U per L,Severity
alkaline phosphatase,AdverseReaction
greater,O
than,O
550 U per L,Severity
bilirubin,AdverseReaction
greater,O
than,O
2 5 ULN,Severity
serum glucose,AdverseReaction
less,O
than,O
40,Severity
or,O
greater,O
than,O
250 mg per dL per dL,Severity
glycosuria,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
3,O
neutrophils,AdverseReaction
less,O
than,O
750 per mm 3,Severity
fasting cholesterol,AdverseReaction
greater,O
than,O
240 mg per dL,Severity
and,O
fasting triglycerides,AdverseReaction
greater,O
than,O
750 mg per dL,Severity
Serum,O
Lipids,O
In,O
the,O
clinical,O
trials,O
of,O
STRIBILD,O
a,O
similar,O
percentage,O
of,O
subjects,O
receiving,O
STRIBILD,O
ATRIPLA,O
and,O
ATV,O
RTV,O
TRUVADA,O
were,O
on,O
lipid,O
lowering,O
agents,O
at,O
baseline,O
12,O
12,O
and,O
13,O
respectively,O
While,O
receiving,O
study,O
drug,O
through,O
Week,O
144,O
an,O
additional,O
11,O
of,O
STRIBILD,O
subjects,O
were,O
started,O
on,O
lipid,O
lowering,O
agents,O
compared,O
to,O
13,O
of,O
ATRIPLA,O
and,O
12,O
of,O
ATV,O
RTV,O
TRUVADA,O
subjects,O
Changes,O
from,O
baseline,O
in,O
total,O
cholesterol,O
HDL,O
cholesterol,O
LDL,O
cholesterol,O
and,O
triglycerides,O
are,O
presented,O
in,O
Table,O
5,O
Table,O
5,O
Lipid,O
Values,O
Mean,O
Change,O
from,O
Baseline,O
at,O
Week,O
144,O
in,O
Subjects,O
Receiving,O
STRIBILD,O
or,O
Comparator,O
in,O
Studies,O
102,O
and,O
103,O
STRIBILDN,O
701,O
ATRIPLAN,O
352,O
ATV,O
RTV,O
TRUVADAN,O
355,O
Baseline,O
Week,O
144,O
Baseline,O
Week,O
144,O
Baseline,O
Week,O
144,O
mg,O
dL,O
Change,O
mg,O
dL,O
Change,O
mg,O
dL,O
Change,O
Total,O
Cholesterol,O
fasted,O
166,O
N,O
675,O
17,O
N,O
535,O
161,O
N,O
343,O
22,O
N,O
262,O
168,O
N,O
337,O
16,O
N,O
243,O
HDL,O
cholesterol,O
fasted,O
43,O
N,O
675,O
7,O
N,O
535,O
43,O
N,O
343,O
9,O
N,O
262,O
42,O
N,O
335,O
7,O
N,O
242,O
LDL,O
cholesterol,O
fasted,O
100,O
N,O
675,O
15,O
N,O
535,O
97,O
N,O
343,O
19,O
N,O
262,O
101,O
N,O
337,O
18,O
N,O
242,O
Triglycerides,O
fasted,O
122,O
N,O
675,O
12,O
N,O
535,O
121,O
N,O
343,O
5,O
N,O
262,O
132,O
N,O
337,O
22,O
N,O
242,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
tenofovir,O
DF,O
Because,O
postmarketing,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
No,O
additional,O
postmarketing,O
adverse,O
reactions,O
specific,O
for,O
emtricitabine,O
have,O
been,O
identified,O
Immune,O
System,O
Disorders,O
allergic reaction,AdverseReaction
including,O
angioedema,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorders,O
lactic acidosis,AdverseReaction
hypokalemia,AdverseReaction
hypophosphatemia,AdverseReaction
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
dyspnea,AdverseReaction
Gastrointestinal,O
Disorders,O
pancreatitis,AdverseReaction
increased amylase,AdverseReaction
abdominal pain,AdverseReaction
Hepatobiliary,O
Disorders,O
hepatic steatosis,AdverseReaction
hepatitis,AdverseReaction
increased liver enzymes,AdverseReaction
most,O
commonly,O
AST,AdverseReaction
ALT,AdverseReaction
gamma GT,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
rash,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
rhabdomyolysis,AdverseReaction
osteomalacia,AdverseReaction
manifested,O
as,O
bone pain,AdverseReaction
and,O
which,O
may,O
contribute,O
to,O
fractures,AdverseReaction
muscular weakness,AdverseReaction
myopathy,AdverseReaction
Renal,O
and,O
Urinary,O
Disorders,O
acute renal failure,AdverseReaction
renal failure,AdverseReaction
acute tubular necrosis,AdverseReaction
Fanconi syndrome,AdverseReaction
proximal renal tubulopathy,AdverseReaction
interstitial nephritis nephritis,AdverseReaction
including,O
acute,AdverseReaction
cases,O
nephrogenic diabetes insipidus,AdverseReaction
renal insufficiency,AdverseReaction
increased creatinine,AdverseReaction
proteinuria,AdverseReaction
polyuria,AdverseReaction
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
asthenia,AdverseReaction
The,O
following,O
adverse,O
reactions,O
listed,O
under,O
the,O
body,O
system,O
headings,O
above,O
may,O
occur,O
as,O
a,O
consequence,O
of,O
proximal renal tubulopathy,AdverseReaction
rhabdomyolysis,AdverseReaction
osteomalacia,AdverseReaction
hypokalemia,AdverseReaction
muscular weakness,AdverseReaction
myopathy,AdverseReaction
hypophosphatemia,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
Review,O
the,O
Full,O
Prescribing,O
Information,O
for,O
trametinib,O
prior,O
to,O
initiation,O
of,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
The,O
following,O
serious,O
adverse,O
reactions,O
of,O
trametinib,O
as,O
a,O
single,O
agent,O
which,O
may,O
occur,O
when,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
are,O
not,O
described,O
in,O
the,O
Full,O
Prescribing,O
Information,O
for,O
TAFINLAR,O
Retinal vein occlusion,AdverseReaction
Interstitial lung disease,AdverseReaction
New,O
primary malignancies cutaneous malignancies,AdverseReaction
and,O
non cutaneous,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
administered,O
as,O
a,O
single,O
agent,O
or,O
in,O
combination,O
with,O
trametinib,O
Monitor,O
patients,O
for,O
new,O
malignancies,O
prior,O
to,O
initiation,O
of,O
therapy,O
while,O
on,O
therapy,O
and,O
following,O
discontinuation,O
of,O
TAFINLAR,O
or,O
the,O
combination,O
therapy,O
5,O
1,O
2,O
3,O
Tumor Promotion in BRAF Wild Type Melanoma,AdverseReaction
Increased cell proliferation,AdverseReaction
can,O
occur,O
with,O
BRAF inhibitors,DrugClass
5,O
2,O
Hemorrhage,AdverseReaction
Major,Severity
hemorrhagic events,AdverseReaction
can,Factor
occur,O
in,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
of,O
bleeding,O
5,O
3,O
Venous Thromboembolism,AdverseReaction
Deep vein thrombosis,AdverseReaction
and,O
pulmonary embolism,AdverseReaction
can,Factor
occur,O
in,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
5,O
4,O
2,O
3,O
Cardiomyopathy,AdverseReaction
Assess,O
LVEF,O
before,O
treatment,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
after,O
one,O
month,O
of,O
treatment,O
then,O
every,O
2,O
to,O
3,O
months,O
thereafter,O
5,O
5,O
2,O
3,O
Ocular Toxicities,AdverseReaction
Perform,O
ophthalmologic,O
evaluation,O
for,O
any,O
visual,O
disturbances,O
5,O
6,O
2,O
3,O
Serious,Severity
Febrile Reactions,AdverseReaction
Incidence,O
and,O
severity,O
of,O
pyrexia,AdverseReaction
are,O
increased,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
5,O
7,O
2,O
3,O
Serious,Severity
Skin Toxicity,AdverseReaction
Monitor,O
for,O
skin,O
toxicities,O
and,O
for,O
secondary,O
infections,O
Discontinue,O
for,O
intolerable,O
Grade,O
2,O
or,O
Grade,O
3,O
or,O
4,O
rash,O
not,O
improving,O
within,O
3,O
weeks,O
despite,O
interruption,O
of,O
TAFINLAR,O
5,O
8,O
2,O
3,O
Hyperglycemia,AdverseReaction
Monitor,O
serum,O
glucose,O
levels,O
in,O
patients,O
with,O
pre,O
existing,O
diabetes,O
or,O
hyperglycemia,O
5,O
9,O
Glucose 6 Phosphate Dehydrogenase Deficiency,AdverseReaction
Closely,O
monitor,O
for,O
hemolytic,O
anemia,O
5,O
10,O
Embryofetal Toxicity,AdverseReaction
Can,Factor
cause,O
fetal harm,AdverseReaction
Advise,O
females,O
of,O
reproductive,O
potential,O
of,O
potential,O
risk,O
to,O
a,O
fetus,O
TAFINLAR,O
may,O
render,O
hormonal,O
contraceptives,O
less,O
effective,O
and,O
an,O
alternative,O
method,O
of,O
contraception,O
should,O
be,O
used,O
5,O
11,O
8,O
1,O
EXCERPT,O
5,O
1,O
New,O
Primary,O
Malignancies,O
New,O
primary malignancies cutaneous malignancies,AdverseReaction
and,O
non cutaneous,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
administered,O
as,O
a,O
single,O
agent,O
or,O
when,O
used,O
in,O
combination,O
with,O
trametinib,O
Cutaneous,O
Malignancies,O
TAFINLAR,O
results,O
in,O
an,O
increased,O
incidence,O
of,O
cutaneous squamous cell carcinoma,AdverseReaction
keratoacanthoma,AdverseReaction
and,O
melanoma,AdverseReaction
TAFINLAR,O
when,O
used,O
in,O
combination,O
with,O
trametinib,O
results,O
in,O
an,O
increased,O
incidence,O
of,O
basal cell carcinoma,AdverseReaction
In,O
Trial,O
1,O
cutaneous squamous cell carcinomas,AdverseReaction
and,O
keratoacanthomas,AdverseReaction
cuSCC,AdverseReaction
occurred,O
in,O
7,O
14,O
187,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
and,O
in,O
none,O
of,O
the,O
patients,O
treated,O
with,O
dacarbazine,O
Across,O
clinical,O
trials,O
of,O
TAFINLAR,O
N,O
586,O
the,O
incidence,O
of,O
cuSCC,AdverseReaction
was,O
11,O
The,O
median,O
time,O
to,O
first,O
cuSCC,AdverseReaction
was,O
9,O
weeks,O
range,O
1,O
to,O
53,O
weeks,O
Of,O
those,O
patients,O
who,O
developed,O
new,O
cuSCC,AdverseReaction
approximately,O
33,O
developed,O
one,O
or,O
more,O
cuSCC,AdverseReaction
with,O
continued,O
administration,O
of,O
TAFINLAR,O
The,O
median,O
time,O
between,O
diagnosis,O
of,O
the,O
first,O
cuSCC,AdverseReaction
and,O
the,O
second,O
cuSCC,AdverseReaction
was,O
6,O
weeks,O
In,O
Trial,O
1,O
the,O
incidence,O
of,O
new,O
primary malignant melanomas,AdverseReaction
was,O
2,O
3,O
187,O
for,O
patients,O
receiving,O
TAFINLAR,O
while,O
no,O
dacarbazine,O
treated,O
patient,O
was,O
diagnosed,O
with,O
new,O
primary,O
malignant,O
melanoma,O
In,O
Trial,O
2,O
the,O
incidence,O
of,O
basal cell carcinoma,AdverseReaction
was,O
increased,O
in,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
9,O
5,O
55,O
of,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
compared,O
with,O
2,O
1,O
53,O
of,O
patients,O
receiving,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
The,O
range,O
of,O
time,O
to,O
diagnosis,O
of,O
basal cell carcinoma,AdverseReaction
was,O
28,O
to,O
249,O
days,O
in,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
and,O
was,O
197,O
days,O
for,O
the,O
patient,O
receiving,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
Cutaneous squamous cell carcinoma,AdverseReaction
SCC,AdverseReaction
including,O
keratoacanthoma,AdverseReaction
occurred,O
in,O
7,O
of,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
and,O
19,O
of,O
patients,O
receiving,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
The,O
range,O
of,O
time,O
to,O
diagnosis,O
of,O
cuSCC,AdverseReaction
was,O
136,O
to197,O
days,O
in,O
the,O
combination,O
arm,O
and,O
was,O
9,O
to,O
197,O
days,O
in,O
the,O
arm,O
receiving,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
New,O
primary melanoma,AdverseReaction
occurred,O
in,O
2,O
1,O
53,O
of,O
patients,O
receiving,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
and,O
in,O
none,O
of,O
the,O
55,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Perform,O
dermatologic,O
evaluations,O
prior,O
to,O
initiation,O
of,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
or,O
in,O
combination,O
with,O
trametinib,O
every,O
2,O
months,O
while,O
on,O
therapy,O
and,O
for,O
up,O
to,O
6,O
months,O
following,O
discontinuation,O
of,O
TAFINLAR,O
No,O
dose,O
modifications,O
of,O
TAFINLAR,O
or,O
trametinib,O
are,O
required,O
in,O
patients,O
who,O
develop,O
new,O
primary,O
cutaneous,O
malignancies,O
Non,O
cutaneous,O
Malignancies,O
Based,O
on,O
its,O
mechanism,O
of,O
action,O
TAFINLAR,O
may,Factor
promote,O
the,O
growth,O
and,O
development,O
of,O
malignancies,AdverseReaction
with,O
activation,O
of,O
RAS,O
through,O
mutation,O
or,O
other,O
mechanisms,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
In,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
four,O
cases,O
of,O
non cutaneous malignancies,AdverseReaction
were,O
identified,O
KRAS mutation positive pancreatic adenocarcinoma,AdverseReaction
n,O
1,O
recurrent NRAS mutation positive colorectal carcinoma,AdverseReaction
n,O
1,O
head and neck carcinoma,AdverseReaction
n,O
1,O
and,O
glioblastoma,AdverseReaction
n,O
1,O
Monitor,O
patients,O
receiving,O
the,O
combination,O
closely,O
for,O
signs,O
or,O
symptoms,O
of,O
non,O
cutaneous,O
malignancies,O
Permanently,O
discontinue,O
TAFINLAR,O
for,O
RAS,O
mutation,O
positive,O
non,O
cutaneous,O
malignancies,O
If,O
used,O
in,O
combination,O
with,O
trametinib,O
no,O
dose,O
modification,O
of,O
trametinib,O
is,O
required,O
for,O
patients,O
who,O
develop,O
non,O
cutaneous,O
malignancies,O
5,O
2,O
Tumor,O
Promotion,O
in,O
BRAF,O
Wild,O
Type,O
Melanoma,O
In,O
vitro,O
experiments,O
have,O
demonstrated,O
paradoxical,O
activation,O
of,O
MAP,O
kinase,O
signaling,O
and,O
increased cell proliferation,AdverseReaction
in,O
BRAF,O
wild,O
type,O
cells,O
which,O
are,O
exposed,O
to,O
BRAF inhibitors,DrugClass
Confirm,O
evidence,O
of,O
BRAF,O
V600E,O
or,O
V600K,O
mutation,O
status,O
prior,O
to,O
initiation,O
of,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
or,O
combination,O
therapy,O
see,O
Indications,O
and,O
Usage,O
1,O
Dosage,O
and,O
Administration,O
2,O
1,O
5,O
3,O
Hemorrhage,O
Hemorrhages,AdverseReaction
including,O
major,Severity
hemorrhages,AdverseReaction
defined,O
as,O
symptomatic bleeding,AdverseReaction
in,O
a,O
critical,O
area,O
or,O
organ,O
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
In,O
Trial,O
2,O
treatment,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
resulted,O
in,O
an,O
increased,O
incidence,O
and,O
severity,O
of,O
any,O
hemorrhagic event,AdverseReaction
16,O
9,O
55,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
compared,O
with,O
2,O
1,O
53,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
The,O
major,Severity
hemorrhagic events,AdverseReaction
of,O
intracranial,AdverseReaction
or,O
gastric hemorrhage,AdverseReaction
occurred,O
in,O
5,O
3,O
55,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
compared,O
with,O
none,O
of,O
the,O
53,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
Intracranial hemorrhage,AdverseReaction
was,O
fatal,AdverseReaction
in,O
4,O
2,O
55,O
of,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Permanently,O
discontinue,O
TAFINLAR,O
and,O
trametinib,O
for,O
all,O
Grade,O
4,O
hemorrhagic,O
events,O
and,O
for,O
any,O
Grade,O
3,O
hemorrhagic,O
events,O
that,O
do,O
not,O
improve,O
Withhold,O
TAFINLAR,O
for,O
Grade,O
3,O
hemorrhagic,O
events,O
if,O
improved,O
resume,O
at,O
a,O
lower,O
dose,O
level,O
Withhold,O
trametinib,O
for,O
up,O
to,O
3,O
weeks,O
for,O
Grade,O
3,O
hemorrhagic,O
events,O
if,O
improved,O
resume,O
at,O
a,O
lower,O
dose,O
level,O
5,O
4,O
Venous,O
Thromboembolism,O
Venous thromboembolism,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
In,O
Trial,O
2,O
treatment,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
resulted,O
in,O
an,O
increased,O
incidence,O
of,O
deep venous thrombosis,AdverseReaction
DVT,AdverseReaction
and,O
pulmonary embolism,AdverseReaction
PE,AdverseReaction
7,O
4,O
55,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
compared,O
with,O
none,O
of,O
the,O
53,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
Pulmonary embolism,AdverseReaction
was,O
fatal,AdverseReaction
in,O
2,O
1,O
55,O
of,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Advise,O
patients,O
to,O
immediately,O
seek,O
medical,O
care,O
if,O
they,O
develop,O
symptoms,O
of,O
DVT,O
or,O
PE,O
such,O
as,O
shortness,O
of,O
breath,O
chest,O
pain,O
or,O
arm,O
or,O
leg,O
swelling,O
Permanently,O
discontinue,O
TAFINLAR,O
and,O
trametinib,O
for,O
life,O
threatening,O
PE,O
Withhold,O
trametinib,O
and,O
continue,O
TAFINLAR,O
at,O
the,O
same,O
dose,O
for,O
uncomplicated,O
DVT,O
or,O
PE,O
if,O
improved,O
within,O
3,O
weeks,O
trametinib,O
may,O
be,O
resumed,O
at,O
a,O
lower,O
dose,O
level,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
5,O
Cardiomyopathy,O
Cardiomyopathy,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
and,O
with,O
trametinib,O
as,O
a,O
single,O
agent,O
refer,O
to,O
Full,O
Prescribing,O
Information,O
for,O
trametinib,O
In,O
Trial,O
2,O
cardiomyopathy,AdverseReaction
occurred,O
in,O
9,O
5,O
55,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
and,O
in,O
none,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
The,O
median,O
time,O
to,O
onset,O
of,O
cardiomyopathy,AdverseReaction
in,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
was,O
86,O
days,O
range,O
27,O
to,O
253,O
days,O
Cardiomyopathy,AdverseReaction
was,O
identified,O
within,O
the,O
first,O
month,O
of,O
treatment,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
in,O
two,O
of,O
five,O
patients,O
Development,O
of,O
cardiomyopathy,AdverseReaction
resolved,O
in,O
all,O
five,O
patients,O
following,O
dose,O
reduction,O
4,O
55,O
and,O
or,O
dose,O
interruption,O
1,O
55,O
Across,O
clinical,O
trials,O
of,O
TAFINLAR,O
administered,O
in,O
combination,O
with,O
trametinib,O
N,O
202,O
8,O
of,O
patients,O
developed,O
evidence,O
of,O
cardiomyopathy,AdverseReaction
decrease in LVEF,AdverseReaction
below,O
institutional lower limits of normal,Severity
with,O
an,O
absolute decrease in LVEF,AdverseReaction
10 below baseline,Severity
Two,O
percent,O
demonstrated,O
a,O
decrease in LVEF,AdverseReaction
below,O
institutional lower limits of normal,Severity
with,O
an,O
absolute decrease in LVEF,AdverseReaction
of,O
20 below baseline,Severity
Assess,O
LVEF,O
by,O
echocardiogram,O
or,O
multigated,O
acquisition,O
MUGA,O
scan,O
before,O
initiation,O
of,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
one,O
month,O
after,O
initiation,O
and,O
then,O
at,O
2,O
to,O
3,O
month,O
intervals,O
while,O
on,O
treatment,O
with,O
the,O
combination,O
Withhold,O
treatment,O
with,O
trametinib,O
and,O
continue,O
TAFINLAR,O
at,O
the,O
same,O
dose,O
if,O
absolute,O
LVEF,O
value,O
decreases,O
by,O
10,O
from,O
pretreatment,O
values,O
and,O
is,O
less,O
than,O
the,O
lower,O
limit,O
of,O
normal,O
For,O
symptomatic,O
cardiomyopathy,O
or,O
persistent,O
asymptomatic,O
LV,O
dysfunction,O
that,O
does,O
not,O
resolve,O
within,O
4,O
weeks,O
permanently,O
discontinue,O
trametinib,O
and,O
withhold,O
TAFINLAR,O
Resume,O
TAFINLAR,O
at,O
the,O
same,O
dose,O
level,O
upon,O
recovery,O
of,O
cardiac,O
function,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
6,O
Ocular,O
Toxicities,O
Retinal,O
Pigment,O
Epithelial,O
Detachment,O
RPED,O
Retinal pigment epithelial detachments,AdverseReaction
RPED,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
and,O
with,O
trametinib,O
as,O
a,O
single,O
agent,O
refer,O
to,O
Full,O
Prescribing,O
Information,O
for,O
trametinib,O
Retinal detachments,AdverseReaction
resulting,O
from,O
trametinib,O
are,O
often,O
bilateral,O
and,O
multifocal,O
occurring,O
in,O
the,O
macular,O
region,O
of,O
the,O
retina,O
In,O
Trial,O
2,O
ophthalmologic,O
examinations,O
including,O
retinal,O
evaluation,O
were,O
performed,O
pretreatment,O
and,O
at,O
regular,O
intervals,O
during,O
treatment,O
RPED,AdverseReaction
occurred,O
in,O
2,O
1,O
55,O
of,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Across,O
clinical,O
trials,O
of,O
TAFINLAR,O
administered,O
in,O
combination,O
with,O
trametinib,O
N,O
202,O
the,O
incidence,O
of,O
RPED,AdverseReaction
was,O
1,O
2,O
202,O
Perform,O
ophthalmological,O
evaluation,O
at,O
any,O
time,O
a,O
patient,O
reports,O
visual,O
disturbances,O
and,O
compare,O
with,O
baseline,O
if,O
available,O
If,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
do,O
not,O
modify,O
the,O
dose,O
of,O
TAFINLAR,O
Withhold,O
trametinib,O
if,O
RPED,O
is,O
diagnosed,O
If,O
resolution,O
of,O
the,O
RPED,O
is,O
documented,O
on,O
repeat,O
ophthalmological,O
evaluation,O
within,O
3,O
weeks,O
resume,O
trametinib,O
at,O
a,O
lower,O
dose,O
level,O
Discontinue,O
trametinib,O
if,O
no,O
improvement,O
after,O
3,O
weeks,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Uveitis,O
and,O
Iritis,O
Uveitis,AdverseReaction
and,O
iritis,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
administered,O
as,O
a,O
single,O
agent,O
or,O
when,O
used,O
in,O
combination,O
with,O
trametinib,O
Uveitis,AdverseReaction
including,O
iritis,AdverseReaction
occurred,O
in,O
1,O
6,O
586,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
and,O
uveitis,AdverseReaction
occurred,O
in,O
1,O
2,O
202,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Symptomatic,O
treatment,O
employed,O
in,O
clinical,O
trials,O
included,O
steroid,O
and,O
mydriatic,O
ophthalmic,O
drops,O
Monitor,O
patients,O
for,O
visual,O
signs,O
and,O
symptoms,O
of,O
uveitis,O
e,O
g,O
change,O
in,O
vision,O
photophobia,O
eye,O
pain,O
If,O
diagnosed,O
withhold,O
TAFINLAR,O
for,O
up,O
to,O
6,O
weeks,O
until,O
uveitis,O
iritis,O
resolves,O
to,O
Grade,O
0,O
1,O
If,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
do,O
not,O
modify,O
the,O
dose,O
of,O
trametinib,O
5,O
7,O
Serious,O
Febrile,O
Reactions,O
Serious,Severity
febrile reactions,AdverseReaction
and,O
fever,AdverseReaction
of,O
any,O
severity,O
complicated,O
by,O
hypotension,AdverseReaction
rigors,AdverseReaction
or,O
chills,AdverseReaction
dehydration,AdverseReaction
or,O
renal failure,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
administered,O
as,O
a,O
single,O
agent,O
or,O
when,O
used,O
in,O
combination,O
with,O
trametinib,O
The,O
incidence,O
and,O
severity,O
of,O
pyrexia,AdverseReaction
are,O
increased,O
when,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
compared,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
see,O
Adverse,O
Reactions,O
6,O
1,O
In,O
Trial,O
1,O
the,O
incidence,O
of,O
fever,AdverseReaction
serious,Severity
and,O
non,O
serious,O
was,O
28,O
in,O
patients,O
treated,O
with,O
TAFINLAR,O
and,O
10,O
in,O
patients,O
treated,O
with,O
dacarbazine,O
In,O
patients,O
treated,O
with,O
TAFINLAR,O
the,O
median,O
time,O
to,O
initial,O
onset,O
of,O
fever,AdverseReaction
any,O
severity,O
was,O
11,O
days,O
range,O
1,O
to,O
202,O
days,O
and,O
the,O
median,O
duration,O
of,O
fever,AdverseReaction
was,O
3,O
days,O
range,O
1,O
to,O
129,O
days,O
Serious,Severity
febrile reactions,AdverseReaction
and,O
fever,AdverseReaction
of,O
any,O
severity,O
complicated,O
by,O
hypotension,AdverseReaction
rigors,AdverseReaction
or,O
chills,AdverseReaction
occurred,O
in,O
3,O
7,O
7,O
187,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
and,O
in,O
none,O
of,O
the,O
59,O
patients,O
treated,O
with,O
dacarbazine,O
In,O
Trial,O
2,O
the,O
incidence,O
of,O
fever,AdverseReaction
serious,Severity
and,O
non,O
serious,O
was,O
71,O
39,O
55,O
in,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
and,O
26,O
14,O
53,O
in,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
Serious,Severity
febrile reactions,AdverseReaction
and,O
fever,AdverseReaction
of,O
any,O
severity,O
complicated,O
by,O
hypotension,AdverseReaction
rigors,AdverseReaction
or,O
chills,AdverseReaction
occurred,O
in,O
25,O
14,O
55,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
compared,O
with,O
2,O
1,O
53,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
Fever,AdverseReaction
was,O
complicated,O
with,O
chills,AdverseReaction
rigors,AdverseReaction
in,O
51,O
28,O
55,O
dehydration,AdverseReaction
in,O
9,O
5,O
55,O
renal failure,AdverseReaction
in,O
4,O
2,O
55,O
and,O
syncope,AdverseReaction
in,O
4,O
2,O
55,O
of,O
patients,O
in,O
Trial,O
2,O
In,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
the,O
median,O
time,O
to,O
initial,O
onset,O
of,O
fever,AdverseReaction
was,O
30,O
days,O
compared,O
with,O
19,O
days,O
in,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
the,O
median,O
duration,O
of,O
fever,AdverseReaction
was,O
6,O
days,O
with,O
the,O
combination,O
compared,O
with,O
4,O
days,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
Across,O
clinical,O
trials,O
of,O
TAFINLAR,O
administered,O
in,O
combination,O
with,O
trametinib,O
N,O
202,O
the,O
incidence,O
of,O
pyrexia,AdverseReaction
was,O
57,O
116,O
202,O
Withhold,O
TAFINLAR,O
for,O
fever,O
of,O
101,O
3oF,O
or,O
higher,O
Withhold,O
trametinib,O
for,O
any,O
fever,O
higher,O
than,O
104oF,O
Withhold,O
TAFINLAR,O
and,O
trametinib,O
if,O
used,O
in,O
combination,O
for,O
any,O
serious,O
febrile,O
reaction,O
or,O
fever,O
complicated,O
by,O
hypotension,O
rigors,O
or,O
chills,O
dehydration,O
or,O
renal,O
failure,O
and,O
evaluate,O
for,O
signs,O
and,O
symptoms,O
of,O
infection,O
Refer,O
to,O
Table,O
2,O
for,O
recommended,O
dose,O
modifications,O
for,O
adverse,O
reactions,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Prophylaxis,O
with,O
antipyretics,O
may,O
be,O
required,O
when,O
resuming,O
TAFINLAR,O
or,O
trametinib,O
5,O
8,O
Serious,O
Skin,O
Toxicity,O
Serious,Severity
skin toxicity,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
used,O
in,O
combination,O
with,O
trametinib,O
and,O
with,O
trametinib,O
as,O
a,O
single,O
agent,O
refer,O
to,O
Full,O
Prescribing,O
Information,O
for,O
trametinib,O
In,O
Trial,O
2,O
the,O
incidence,O
of,O
any,O
skin toxicity,AdverseReaction
was,O
similar,O
for,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
65,O
36,O
55,O
compared,O
with,O
patients,O
receiving,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
68,O
36,O
53,O
The,O
median,O
time,O
to,O
onset,O
of,O
skin toxicity,AdverseReaction
in,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
was,O
37,O
days,O
range,O
1,O
to,O
225,O
days,O
and,O
median,O
time,O
to,O
resolution,O
of,O
skin toxicity,AdverseReaction
was,O
33,O
days,O
range,O
3,O
to,O
421,O
days,O
No,O
patient,O
required,O
dose,O
reduction,O
or,O
permanent,O
discontinuation,O
of,O
TAFINLAR,O
or,O
trametinib,O
for,O
skin,O
toxicity,O
Across,O
clinical,O
trials,O
of,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
N,O
202,O
severe,Severity
skin toxicity,AdverseReaction
and,O
secondary infections of the skin,AdverseReaction
requiring,O
hospitalization,O
occurred,O
in,O
2,O
5,O
5,O
202,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Withhold,O
TAFINLAR,O
and,O
trametinib,O
if,O
used,O
in,O
combination,O
for,O
intolerable,O
or,O
severe,O
skin,O
toxicity,O
TAFINLAR,O
and,O
trametinib,O
may,O
be,O
resumed,O
at,O
lower,O
dose,O
levels,O
in,O
patients,O
with,O
improvement,O
or,O
recovery,O
from,O
skin,O
toxicity,O
within,O
3,O
weeks,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
5,O
9,O
Hyperglycemia,O
Hyperglycemia,AdverseReaction
can,Factor
occur,O
when,O
TAFINLAR,O
is,O
administered,O
as,O
a,O
single,O
agent,O
or,O
when,O
used,O
in,O
combination,O
with,O
trametinib,O
In,O
Trial,O
1,O
5,O
of,O
12,O
patients,O
with,O
a,O
history,O
of,O
diabetes,O
required,O
more,O
intensive,O
hypoglycemic,O
therapy,O
while,O
taking,O
TAFINLAR,O
The,O
incidence,O
of,O
Grade 3,Severity
hyperglycemia,AdverseReaction
based,O
on,O
laboratory,O
values,O
was,O
6,O
12,O
187,O
in,O
patients,O
treated,O
with,O
TAFINLAR,O
compared,O
with,O
none,O
of,O
the,O
dacarbazine,O
treated,O
patients,O
In,O
Trial,O
2,O
the,O
incidence,O
of,O
Grade 3,Severity
hyperglycemia,AdverseReaction
based,O
on,O
laboratory,O
values,O
was,O
5,O
3,O
55,O
in,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
compared,O
with,O
2,O
1,O
53,O
in,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
Monitor,O
serum,O
glucose,O
levels,O
as,O
clinically,O
appropriate,O
when,O
TAFINLAR,O
is,O
administered,O
as,O
a,O
single,O
agent,O
or,O
when,O
used,O
in,O
combination,O
with,O
trametinib,O
in,O
patients,O
with,O
pre,O
existing,O
diabetes,O
or,O
hyperglycemia,O
Advise,O
patients,O
to,O
report,O
symptoms,O
of,O
severe,O
hyperglycemia,O
such,O
as,O
excessive,O
thirst,O
or,O
any,O
increase,O
in,O
the,O
volume,O
or,O
frequency,O
of,O
urination,O
5,O
10,O
Glucose,O
6,O
Phosphate,O
Dehydrogenase,O
Deficiency,O
TAFINLAR,O
which,O
contains,O
a,O
sulfonamide,O
moiety,O
confers,O
a,O
potential,O
risk,Factor
of,O
hemolytic anemia,AdverseReaction
in,O
patients,O
with,O
glucose,O
6,O
phosphate,O
dehydrogenase,O
G6PD,O
deficiency,O
Closely,O
observe,O
patients,O
with,O
G6PD,O
deficiency,O
for,O
signs,O
of,O
hemolytic,O
anemia,O
5,O
11,O
Embryofetal,O
Toxicity,O
Based,O
on,O
its,O
mechanism,O
of,O
action,O
TAFINLAR,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Dabrafenib,O
was,O
teratogenic,AdverseReaction
and,O
embryotoxic,AdverseReaction
in,O
rats,Animal
at,O
doses,O
three,O
times,O
greater,O
than,O
the,O
human,O
exposure,O
at,O
the,O
recommended,O
clinical,O
dose,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
a,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
Advise,O
female,O
patients,O
of,O
reproductive,O
potential,O
to,O
use,O
a,O
highly,O
effective,O
non,O
hormonal,O
method,O
of,O
contraception,O
since,O
TAFINLAR,O
can,O
render,O
hormonal,O
contraceptives,O
ineffective,O
during,O
treatment,O
and,O
for,O
at,O
least,O
2,O
weeks,O
after,O
treatment,O
with,O
TAFINLAR,O
or,O
for,O
4,O
months,O
after,O
treatment,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Advise,O
patients,O
to,O
contact,O
their,O
healthcare,O
provider,O
if,O
they,O
become,O
pregnant,O
or,O
if,O
pregnancy,O
is,O
suspected,O
while,O
taking,O
TAFINLAR,O
see,O
Drug,O
Interactions,O
7,O
2,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
another,O
section,O
of,O
the,O
label,O
New,O
Primary Malignancies,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Tumor Promotion in BRAF Wild Type Melanoma,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hemorrhage,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Venous Thromboembolism,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Cardiomyopathy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Ocular Toxicities,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Serious,Severity
Febrile Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Serious,Severity
Skin Toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
8,O
Hyperglycemia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
9,O
Glucose 6 Phosphate Dehydrogenase Deficiency,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
10,O
Most,O
common,O
adverse,O
reactions,O
20,O
for,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
are,O
hyperkeratosis,AdverseReaction
headache,AdverseReaction
pyrexia,AdverseReaction
arthralgia,AdverseReaction
papilloma,AdverseReaction
alopecia,AdverseReaction
and,O
palmar plantar erythrodysesthesia syndrome,AdverseReaction
6,O
1,O
Most,O
common,O
adverse,O
reactions,O
20,O
for,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
are,O
pyrexia,AdverseReaction
chills,AdverseReaction
fatigue,AdverseReaction
rash,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
diarrhea,AdverseReaction
abdominal pain,AdverseReaction
peripheral edema,AdverseReaction
cough,AdverseReaction
headache,AdverseReaction
arthralgia,AdverseReaction
night sweats,AdverseReaction
decreased appetite,AdverseReaction
constipation,AdverseReaction
and,O
myalgia,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GlaxoSmithKline,O
at,O
1,O
888,O
825,O
5249,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
data,O
described,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
and,O
below,O
reflect,O
exposure,O
to,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
and,O
in,O
combination,O
with,O
trametinib,O
BRAF,O
V600E,O
Unresectable,O
or,O
Metastatic,O
Melanoma,O
The,O
safety,O
of,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
was,O
evaluated,O
in,O
586,O
patients,O
with,O
BRAF,O
V600,O
mutation,O
positive,O
unresectable,O
or,O
metastatic,O
melanoma,O
previously,O
treated,O
or,O
untreated,O
who,O
received,O
TAFINLAR,O
150,O
mg,O
orally,O
twice,O
daily,O
until,O
disease,O
progression,O
or,O
unacceptable,O
toxicity,O
including,O
181,O
patients,O
treated,O
for,O
at,O
least,O
6,O
months,O
and,O
86,O
additional,O
patients,O
treated,O
for,O
more,O
than,O
12,O
months,O
TAFINLAR,O
was,O
studied,O
in,O
open,O
label,O
single,O
arm,O
trials,O
and,O
in,O
an,O
open,O
label,O
randomized,O
active,O
controlled,O
trial,O
The,O
median,O
daily,O
dose,O
of,O
TAFINLAR,O
was,O
300,O
mg,O
range,O
118,O
to,O
300,O
mg,O
Table,O
3,O
and,O
Table,O
4,O
present,O
adverse,O
drug,O
reactions,O
and,O
laboratory,O
abnormalities,O
identified,O
from,O
analyses,O
of,O
Trial,O
1,O
see,O
Clinical,O
Studies,O
14,O
1,O
Trial,O
1,O
a,O
multicenter,O
international,O
open,O
label,O
randomized,O
3,O
1,O
controlled,O
trial,O
allocated,O
250,O
patients,O
with,O
unresectable,O
or,O
metastatic,O
BRAF,O
V600E,O
mutation,O
positive,O
melanoma,O
to,O
receive,O
TAFINLAR,O
150,O
mg,O
orally,O
twice,O
daily,O
n,O
187,O
or,O
dacarbazine,O
1,O
000,O
mg,O
m,O
2,O
intravenously,O
every,O
3,O
weeks,O
n,O
63,O
The,O
trial,O
excluded,O
patients,O
with,O
abnormal,O
left,O
ventricular,O
ejection,O
fraction,O
or,O
cardiac,O
valve,O
morphology,O
Grade,O
2,O
corrected,O
QT,O
interval,O
480,O
milliseconds,O
on,O
electrocardiogram,O
or,O
a,O
known,O
history,O
of,O
glucose,O
6,O
phosphate,O
dehydrogenase,O
deficiency,O
The,O
median,O
duration,O
on,O
treatment,O
was,O
4,O
9,O
months,O
for,O
patients,O
treated,O
with,O
TAFINLAR,O
and,O
2,O
8,O
months,O
for,O
dacarbazine,O
treated,O
patients,O
The,O
population,O
exposed,O
to,O
TAFINLAR,O
was,O
60,O
male,O
99,O
white,O
and,O
had,O
a,O
median,O
age,O
of,O
53,O
years,O
The,O
most,O
commonly,O
occurring,O
adverse,O
reactions,O
20,O
in,O
patients,O
treated,O
with,O
TAFINLAR,O
were,O
in,O
order,O
of,O
decreasing,O
frequency,O
hyperkeratosis,AdverseReaction
headache,AdverseReaction
pyrexia,AdverseReaction
arthralgia,AdverseReaction
papilloma,AdverseReaction
alopecia,AdverseReaction
and,O
palmar plantar erythrodysesthesia syndrome,AdverseReaction
PPES,AdverseReaction
The,O
incidence,O
of,O
adverse,O
events,O
resulting,O
in,O
permanent,O
discontinuation,O
of,O
study,O
medication,O
in,O
Trial,O
1,O
was,O
3,O
for,O
patients,O
treated,O
with,O
TAFINLAR,O
and,O
3,O
for,O
patients,O
treated,O
with,O
dacarbazine,O
The,O
most,O
frequent,O
2,O
adverse,O
reactions,O
leading,O
to,O
dose,O
reduction,O
of,O
TAFINLAR,O
were,O
pyrexia,AdverseReaction
9,O
PPES,AdverseReaction
3,O
chills,AdverseReaction
3,O
fatigue,AdverseReaction
2,O
and,O
headache,AdverseReaction
2,O
Table,O
3,O
Selected,O
Common,O
Adverse,O
Reactions,O
Occurring,O
in,O
10,O
All,O
Grades,O
or,O
2,O
Grades,O
3,O
or,O
4,O
of,O
Patients,O
Treated,O
With,O
TAFINLARa,O
TAFINLARN,O
187,O
Dacarbazine,O
N,O
59,O
Primary,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
All,O
Grades,O
Grades,O
3,O
and,O
4b,O
All,O
Grades,O
Grades,O
3,O
and,O
4,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Hyperkeratosis,AdverseReaction
37,O
1,O
0,O
0,O
Alopecia,AdverseReaction
22,O
NAf,O
2,O
NAf,O
Palmar plantar erythrodysesthesia syndrome,AdverseReaction
20,O
2,O
2,O
0,O
Rash,AdverseReaction
17,O
0,O
0,O
0,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
32,O
0,O
8,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Pyrexia,AdverseReaction
28,O
3,O
10,O
0,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Arthralgia,AdverseReaction
27,O
1,O
2,O
0,O
Back pain,AdverseReaction
12,O
3,O
7,O
0,O
Myalgia,AdverseReaction
11,O
0,O
0,O
0,O
Neoplasms,O
benign,O
malignant,O
and,O
unspecified,O
including,O
cysts,O
and,O
polyps,O
Papilloma,AdverseReaction
c,O
27,O
0,O
2,O
0,O
cuSCC,AdverseReaction
d,O
e,O
7,O
4,O
0,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
12,O
0,O
5,O
0,O
Gastrointestinal,O
disorders,O
Constipation,AdverseReaction
11,O
2,O
14,O
0,O
Infections,O
and,O
infestations,O
Nasopharyngitis,AdverseReaction
10,O
0,O
3,O
0,O
a,O
Adverse,O
drug,O
reactions,O
reported,O
using,O
MedDRA,O
and,O
graded,O
using,O
CTCAE,O
version,O
4,O
0,O
for,O
assessment,O
of,O
toxicity,O
b,O
Grade 4,Severity
adverse,O
reactions,O
limited,O
to,O
hyperkeratosis,AdverseReaction
n,O
1,O
and,O
constipation,AdverseReaction
n,O
1,O
c,O
Includes,O
skin papilloma,AdverseReaction
and,O
papilloma,AdverseReaction
d,O
Includes,O
squamous cell carcinoma of the skin,AdverseReaction
and,O
keratoacanthoma,AdverseReaction
e,O
Cases,O
of,O
cutaneous squamous cell carcinoma,AdverseReaction
were,O
required,O
to,O
be,O
reported,O
as,O
Grade 3,Severity
per,O
protocol,O
f,O
NA,O
not,O
applicable,O
Table,O
4,O
Incidence,O
of,O
Laboratory,O
Abnormalities,O
Increased,O
From,O
Baseline,O
Occurring,O
at,O
a,O
Higher,O
Incidence,O
in,O
Patients,O
Treated,O
With,O
TAFINLAR,O
in,O
Trial,O
1,O
Between,O
Arm,O
Difference,O
of,O
5,O
All,O
Grades,O
or,O
2,O
Grades,O
3,O
or,O
4,O
Test,O
TAFINLAR,O
N,O
187,O
DTIC,O
N,O
59,O
All,O
Grades,O
Grades,O
3,O
and,O
4,O
All,O
Grades,O
Grades,O
3,O
and,O
4,O
Hyperglycemia,AdverseReaction
50,O
6,O
43,O
0,O
Hypophosphatemia,AdverseReaction
37,O
6a,O
14,O
2,O
Increased alkaline phosphatase,AdverseReaction
19,O
0,O
14,O
2,O
Hyponatremia,AdverseReaction
8,O
2,O
3,O
0,O
a,O
Grade 4,Severity
laboratory,O
abnormality,O
limited,O
to,O
hypophosphatemia,AdverseReaction
n,O
1,O
Other,O
clinically,O
important,O
adverse,O
reactions,O
observed,O
in,O
10,O
of,O
patients,O
N,O
586,O
treated,O
with,O
TAFINLAR,O
were,O
Gastrointestinal,O
Disorders,O
Pancreatitis,AdverseReaction
Immune,O
System,O
Disorders,O
Hypersensitivity,AdverseReaction
manifesting,O
as,O
bullous rash,AdverseReaction
Renal,O
and,O
Urinary,O
Disorders,O
Interstitial nephritis,AdverseReaction
BRAF,O
V600E,O
or,O
V600K,O
Unresectable,O
or,O
Metastatic,O
Melanoma,O
The,O
safety,O
of,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
was,O
evaluated,O
in,O
Trial,O
2,O
and,O
other,O
trials,O
consisting,O
of,O
a,O
total,O
of,O
202,O
patients,O
with,O
BRAF,O
V600,O
mutation,O
positive,O
unresectable,O
or,O
metastatic,O
melanoma,O
who,O
received,O
TAFINLAR,O
150,O
mg,O
orally,O
twice,O
daily,O
in,O
combination,O
with,O
trametinib,O
2,O
mg,O
orally,O
once,O
daily,O
until,O
disease,O
progression,O
or,O
unacceptable,O
toxicity,O
Among,O
these,O
202,O
patients,O
66,O
33,O
were,O
exposed,O
to,O
TAFINLAR,O
and,O
68,O
34,O
were,O
exposed,O
to,O
trametinib,O
for,O
greater,O
than,O
6,O
to,O
12,O
months,O
while,O
40,O
20,O
were,O
exposed,O
to,O
TAFINLAR,O
and,O
36,O
18,O
were,O
exposed,O
to,O
trametinib,O
for,O
greater,O
than,O
one,O
year,O
The,O
median,O
age,O
was,O
54,O
years,O
57,O
were,O
male,O
and,O
99,O
were,O
white,O
Table,O
5,O
presents,O
adverse,O
reactions,O
from,O
Trial,O
2,O
a,O
multicenter,O
open,O
label,O
randomized,O
trial,O
of,O
162,O
patients,O
with,O
BRAF,O
V600E,O
or,O
V600K,O
mutation,O
positive,O
melanoma,O
receiving,O
TAFINLAR,O
150,O
mg,O
twice,O
daily,O
in,O
combination,O
with,O
trametinib,O
2,O
mg,O
orally,O
once,O
daily,O
n,O
55,O
TAFINLAR,O
150,O
mg,O
orally,O
twice,O
daily,O
in,O
combination,O
with,O
trametinib,O
1,O
mg,O
once,O
daily,O
n,O
54,O
and,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
150,O
mg,O
orally,O
twice,O
daily,O
n,O
53,O
see,O
Clinical,O
Studies,O
14,O
2,O
Patients,O
with,O
abnormal,O
LVEF,O
history,O
of,O
acute,O
coronary,O
syndrome,O
within,O
6,O
months,O
current,O
evidence,O
of,O
Class,O
II,O
or,O
greater,O
congestive,O
heart,O
failure,O
New,O
York,O
Heart,O
Association,O
history,O
RVO,O
or,O
RPED,O
QTc,O
interval,O
480,O
msec,O
treatment,O
refractory,O
hypertension,O
uncontrolled,O
arrhythmias,O
history,O
of,O
pneumonitis,O
or,O
interstitial,O
lung,O
disease,O
or,O
a,O
known,O
history,O
of,O
G6PD,O
deficiency,O
were,O
excluded,O
The,O
median,O
duration,O
of,O
treatment,O
was,O
10,O
9,O
months,O
for,O
both,O
TAFINLAR,O
and,O
trametinib,O
2,O
mg,O
orally,O
once,O
daily,O
treatment,O
group,O
when,O
used,O
in,O
combination,O
10,O
6,O
months,O
for,O
both,O
TAFINLAR,O
and,O
trametinib,O
1,O
mg,O
orally,O
once,O
daily,O
treatment,O
group,O
when,O
used,O
in,O
combination,O
and,O
6,O
1,O
months,O
for,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
In,O
Trial,O
2,O
13,O
of,O
patients,O
receiving,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
experienced,O
adverse,O
reactions,O
resulting,O
in,O
permanent,O
discontinuation,O
of,O
trial,O
medication,O
s,O
The,O
most,O
common,O
adverse,O
reaction,O
resulting,O
in,O
permanent,O
discontinuation,O
was,O
pyrexia,AdverseReaction
4,O
Adverse,O
reactions,O
led,O
to,O
dose,O
reductions,O
in,O
49,O
and,O
dose,O
interruptions,O
in,O
67,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
Pyrexia,AdverseReaction
chills,AdverseReaction
and,O
nausea,AdverseReaction
were,O
the,O
most,O
common,O
reasons,O
cited,O
for,O
dose,O
reductions,O
and,O
pyrexia,AdverseReaction
chills,AdverseReaction
and,O
decreased ejection fraction,AdverseReaction
were,O
the,O
most,O
common,O
reasons,O
cited,O
for,O
dose,O
interruptions,O
of,O
TAFINLAR,O
and,O
trametinib,O
when,O
used,O
in,O
combination,O
Table,O
5,O
Common,O
Adverse,O
Drug,O
Reactions,O
Occurring,O
in,O
10,O
at,O
All,O
Grades,O
or,O
5,O
Grades,O
3,O
or,O
4,O
of,O
Patients,O
Treated,O
With,O
TAFINLAR,O
in,O
Combination,O
With,O
Trametinib,O
in,O
Trial,O
2,O
Adverse,O
Reactions,O
TAFINLAR,O
plus,O
Trametinib,O
2,O
mg,O
N,O
55,O
TAFINLAR,O
plus,O
Trametinib,O
1,O
mg,O
N,O
54,O
TAFINLAR,O
N,O
53,O
All,O
Gradesa,O
Grades,O
3,O
and,O
4,O
All,O
Gradesa,O
Grades,O
3,O
and,O
4,O
All,O
Gradesa,O
Grades,O
3,O
and,O
4,O
General,O
disorders,O
and,O
administrative,O
site,O
conditions,O
Pyrexia,AdverseReaction
71,O
5,O
69,O
9,O
26,O
0,O
Chills,AdverseReaction
58,O
2,O
50,O
2,O
17,O
0,O
Fatigue,AdverseReaction
53,O
4,O
57,O
2,O
40,O
6,O
Edema peripheral,AdverseReaction
b,O
31,O
0,O
28,O
0,O
17,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
c,O
45,O
0,O
43,O
2,O
53,O
0,O
Night Sweats,AdverseReaction
24,O
0,O
15,O
0,O
6,O
0,O
Dry skin,AdverseReaction
18,O
0,O
9,O
0,O
6,O
0,O
Dermatitis acneiform,AdverseReaction
16,O
0,O
11,O
0,O
4,O
0,O
Actinic keratosis,AdverseReaction
15,O
0,O
7,O
0,O
9,O
0,O
Erythema,AdverseReaction
15,O
0,O
6,O
0,O
2,O
0,O
Pruritus,AdverseReaction
11,O
0,O
11,O
0,O
13,O
0,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
44,O
2,O
46,O
6,O
21,O
0,O
Vomiting,AdverseReaction
40,O
2,O
43,O
4,O
15,O
0,O
Diarrhea,AdverseReaction
36,O
2,O
26,O
0,O
28,O
0,O
Abdominal pain,AdverseReaction
d,O
33,O
2,O
24,O
2,O
21,O
2,O
Constipation,AdverseReaction
22,O
0,O
17,O
2,O
11,O
0,O
Dry mouth,AdverseReaction
11,O
0,O
11,O
0,O
6,O
0,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
29,O
0,O
37,O
2,O
28,O
0,O
Dizziness,AdverseReaction
16,O
0,O
13,O
0,O
9,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
29,O
0,O
11,O
0,O
21,O
0,O
Oropharyngeal pain,AdverseReaction
13,O
0,O
7,O
0,O
0,O
0,O
Musculoskeletal,O
connective,O
tissue,O
and,O
bone,O
disorders,O
Arthralgia,AdverseReaction
27,O
0,O
44,O
0,O
34,O
0,O
Myalgia,AdverseReaction
22,O
2,O
24,O
0,O
23,O
2,O
Back pain,AdverseReaction
18,O
5,O
11,O
0,O
11,O
2,O
Muscle spasms,AdverseReaction
16,O
0,O
2,O
0,O
4,O
0,O
Pain in extremity,AdverseReaction
16,O
0,O
11,O
2,O
19,O
0,O
Metabolism,O
and,O
nutritional,O
disorders,O
Decreased appetite,AdverseReaction
22,O
0,O
30,O
0,O
19,O
0,O
Dehydration,AdverseReaction
11,O
0,O
6,O
2,O
2,O
0,O
Psychiatric,O
Disorders,O
Insomnia,AdverseReaction
18,O
0,O
11,O
0,O
8,O
2,O
Vascular,O
disorders,O
Hemorrhage,AdverseReaction
e,O
16,O
5,O
11,O
0,O
2,O
0,O
Infections,O
and,O
infestations,O
Urinary tract infection,AdverseReaction
13,O
2,O
6,O
0,O
9,O
2,O
Renal,O
and,O
urinary,O
disorders,O
Renal failure,AdverseReaction
f,O
7,O
7,O
2,O
0,O
0,O
0,O
a,O
National,O
Cancer,O
Institute,O
Common,O
Terminology,O
Criteria,O
for,O
Adverse,O
Events,O
version,O
4,O
b,O
Includes,O
the,O
following,O
terms,O
peripheral edema,AdverseReaction
edema,AdverseReaction
and,O
lymphedema,AdverseReaction
c,O
Includes,O
the,O
following,O
terms,O
rash,AdverseReaction
rash generalized,AdverseReaction
rash pruritic,AdverseReaction
rash erythematous,AdverseReaction
rash papular,AdverseReaction
rash vesicular,AdverseReaction
rash macular,AdverseReaction
and,O
rash maculo papular,AdverseReaction
d,O
Includes,O
the,O
following,O
terms,O
abdominal pain,AdverseReaction
abdominal pain upper,AdverseReaction
abdominal pain lower,AdverseReaction
and,O
abdominal discomfort,AdverseReaction
e,O
Includes,O
the,O
following,O
terms,O
brain stem hemorrhage,AdverseReaction
cerebral hemorrhage,AdverseReaction
gastric hemorrhage,AdverseReaction
epistaxis,AdverseReaction
gingival hemorrhage,AdverseReaction
hematuria,AdverseReaction
vaginal hemorrhage,AdverseReaction
hemorrhage intracranial,AdverseReaction
eye hemorrhage,AdverseReaction
and,O
vitreous hemorrhage,AdverseReaction
f,O
Includes,O
the,O
following,O
terms,O
renal failure,AdverseReaction
and,O
renal failure acute,AdverseReaction
Other,O
clinically,O
important,O
adverse,O
reactions,O
N,O
202,O
observed,O
in,O
10,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
were,O
Eye,O
Disorders,O
Vision blurred,AdverseReaction
transient blindness,AdverseReaction
Gastrointestinal,O
Disorders,O
Stomatitis,AdverseReaction
pancreatitis,AdverseReaction
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Asthenia,AdverseReaction
Infections,O
and,O
Infestations,O
Cellulitis,AdverseReaction
folliculitis,AdverseReaction
paronychia,AdverseReaction
rash pustular,AdverseReaction
Neoplasms,O
Benign,O
Malignant,O
and,O
Unspecified,O
including,O
cysts,O
and,O
polyps,O
Skin papilloma,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Palmar plantar erythrodysesthesia syndrome,AdverseReaction
hyperkeratosis,AdverseReaction
hyperhidrosis,AdverseReaction
Vascular,O
Disorders,O
Hypertension,AdverseReaction
Table,O
6,O
Treatment,O
Emergent,O
Laboratory,O
Abnormalities,O
Occurring,O
at,O
10,O
All,O
Grades,O
or,O
2,O
Grades,O
3,O
or,O
4,O
of,O
Patients,O
Treated,O
With,O
TAFINLAR,O
in,O
Combination,O
With,O
Trametinib,O
in,O
Trial,O
2,O
Tests,O
TAFINLAR,O
plus,O
Trametinib,O
2,O
mg,O
N,O
55,O
TAFINLAR,O
plus,O
Trametinib,O
1,O
mg,O
N,O
54,O
TAFINLAR,O
N,O
53,O
All,O
Grades,O
Grades,O
3,O
and,O
4,O
All,O
Grades,O
Grades,O
3,O
and,O
4,O
All,O
Grades,O
Grades,O
3,O
and,O
4a,O
Hematology,O
Leukopenia,AdverseReaction
62,O
5,O
46,O
4,O
21,O
0,O
Lymphopenia,AdverseReaction
55,O
22,O
59,O
19,O
40,O
6,O
Neutropenia,AdverseReaction
55,O
13,O
37,O
2,O
9,O
2,O
Anemia,AdverseReaction
55,O
4,O
46,O
7,O
28,O
0,O
Thrombocytopenia,AdverseReaction
31,O
4,O
31,O
2,O
8,O
0,O
Liver,O
Function,O
Tests,O
Increased AST,AdverseReaction
60,O
5,O
54,O
0,O
15,O
0,O
Increased alkaline phosphatase,AdverseReaction
60,O
2,O
67,O
6,O
26,O
2,O
Increased ALT,AdverseReaction
42,O
4,O
35,O
4,O
11,O
0,O
Hyperbilirubinemia,AdverseReaction
15,O
0,O
7,O
4,O
0,O
0,O
Chemistry,O
Hyperglycemia,AdverseReaction
58,O
5,O
67,O
6,O
49,O
2,O
Increased GGT,AdverseReaction
56,O
11,O
54,O
17,O
38,O
2,O
Hyponatremia,AdverseReaction
55,O
11,O
48,O
15,O
36,O
2,O
Hypoalbuminemia,AdverseReaction
53,O
0,O
43,O
2,O
23,O
0,O
Hypophosphatemia,AdverseReaction
47,O
5,O
41,O
11,O
40,O
0,O
Hypokalemia,AdverseReaction
29,O
2,O
15,O
2,O
23,O
6,O
Increased creatinine,AdverseReaction
24,O
5,O
20,O
2,O
9,O
0,O
Hypomagnesemia,AdverseReaction
18,O
2,O
2,O
0,O
6,O
0,O
Hyperkalemia,AdverseReaction
18,O
0,O
22,O
0,O
15,O
4,O
Hypercalcemia,AdverseReaction
15,O
0,O
19,O
2,O
4,O
0,O
Hypocalcemia,AdverseReaction
13,O
0,O
20,O
0,O
9,O
0,O
a,O
No,O
Grade,O
4,O
events,O
were,O
reported,O
in,O
patients,O
receiving,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
ALT,O
Alanine,O
aminotransferase,O
AST,O
Aspartate,O
aminotransferase,O
GGT,O
Gamma,O
glutamyltransferase,O
QT,O
Prolongation,O
In,O
Trial,O
2,O
QTcF prolongation,AdverseReaction
to,O
500 msec,Severity
occurred,O
in,O
4,O
2,O
55,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
and,O
in,O
2,O
1,O
53,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
The,O
QTcF was increased,AdverseReaction
more,O
than,O
60 msec from baseline,Severity
in,O
13,O
7,O
55,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
in,O
combination,O
with,O
trametinib,O
and,O
2,O
1,O
53,O
of,O
patients,O
treated,O
with,O
TAFINLAR,O
as,O
a,O
single,O
agent,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Thyroid C cell Tumors,AdverseReaction
See,O
Boxed,O
Warning,O
5,O
1,O
Pancreatitis,AdverseReaction
Discontinue,O
promptly,O
if,O
suspected,O
Do,O
not,O
restart,O
if,O
confirmed,O
Consider,O
other,O
antidiabetic,O
therapies,O
in,O
patients,O
with,O
a,O
history,O
of,O
pancreatitis,O
5,O
2,O
Hypoglycemia,AdverseReaction
Can,O
occur,O
when,O
used,O
in,O
combination,O
with,O
insulin,O
secretagogues,O
e,O
g,O
sulfonylureas,O
or,O
insulin,O
Consider,O
lowering,O
sulfonylurea,O
or,O
insulin,O
dosage,O
when,O
starting,O
TANZEUM,O
5,O
3,O
Hypersensitivity Reactions,AdverseReaction
Discontinue,O
TANZEUM,O
if,O
suspected,O
Monitor,O
and,O
treat,O
promptly,O
per,O
standard,O
of,O
care,O
until,O
signs,O
and,O
symptoms,O
resolve,O
5,O
4,O
Renal Impairment,AdverseReaction
Monitor,O
renal,O
function,O
in,O
patients,O
with,O
renal,O
impairment,O
reporting,O
severe,O
adverse,O
gastrointestinal,O
reactions,O
5,O
5,O
Macrovascular,O
Outcomes,O
There,O
have,O
been,O
no,O
clinical,O
trials,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
TANZEUM,O
or,O
any,O
other,O
antidiabetic,O
drug,O
5,O
6,O
5,O
1,O
Risk,O
of,O
Thyroid,O
C,O
cell,O
Tumors,O
Carcinogenicity,O
of,O
albiglutide,O
could,O
not,O
be,O
assessed,O
in,O
rodents,O
due,O
to,O
the,O
rapid,O
development,O
of,O
drug,O
clearing,O
anti,O
drug,O
antibodies,O
see,O
Nonclinical,O
Toxicology,O
13,O
1,O
Other,O
GLP 1 receptor agonists,DrugClass
have,O
caused,O
dose,O
related,O
and,O
treatment,O
duration,O
dependent,O
thyroid C cell tumors C cell C cell,AdverseReaction
adenomas,AdverseReaction
or,O
carcinomas,AdverseReaction
in,O
rodents,Animal
Human,O
relevance,O
of,O
GLP 1 receptor agonist,DrugClass
induced,O
C cell tumors,AdverseReaction
in,O
rodents,Animal
has,O
not,O
been,O
determined,O
It,O
is,O
unknown,Factor
whether,O
TANZEUM,O
causes,O
thyroid C cell tumors,AdverseReaction
including,O
MTC,AdverseReaction
in,O
humans,O
see,O
Boxed,O
Warning,O
Contraindications,O
4,O
1,O
Across,O
8,O
Phase,O
III,O
clinical,O
trials,O
see,O
Clinical,O
Studies,O
14,O
MTC,AdverseReaction
was,O
diagnosed,O
in,O
1,O
patient,O
receiving,O
TANZEUM,O
and,O
1,O
patient,O
receiving,O
placebo,O
Both,O
patients,O
had,O
markedly,O
elevated,O
serum,O
calcitonin,O
levels,O
at,O
baseline,O
Cases,O
of,O
MTC,AdverseReaction
in,O
patients,O
treated,O
with,O
liraglutide,DrugClass
another,O
GLP,O
1,O
receptor,O
agonist,O
have,O
been,O
reported,O
in,O
the,O
postmarketing,O
period,O
the,O
data,O
in,O
these,O
reports,O
are,O
insufficient,O
to,O
establish,O
or,O
exclude,O
a,O
causal,O
relationship,O
between,O
MTC,AdverseReaction
and,O
GLP 1 receptor agonist,DrugClass
use,O
in,O
humans,O
TANZEUM,O
is,O
contraindicated,O
in,O
patients,O
with,O
a,O
personal,O
or,O
family,O
history,O
of,O
MTC,O
or,O
in,O
patients,O
with,O
MEN,O
2,O
Counsel,O
patients,O
regarding,O
the,O
potential,O
risk,O
for,O
MTC,O
with,O
the,O
use,O
of,O
TANZEUM,O
and,O
inform,O
them,O
of,O
symptoms,O
of,O
thyroid,O
tumors,O
e,O
g,O
a,O
mass,O
in,O
the,O
neck,O
dysphagia,O
dyspnea,O
or,O
persistent,O
hoarseness,O
Routine,O
monitoring,O
of,O
serum,O
calcitonin,O
or,O
using,O
thyroid,O
ultrasound,O
is,O
of,O
uncertain,O
value,O
for,O
early,O
detection,O
of,O
MTC,O
in,O
patients,O
treated,O
with,O
TANZEUM,O
Such,O
monitoring,O
may,O
increase,O
the,O
risk,O
of,O
unnecessary,O
procedures,O
due,O
to,O
the,O
low,O
specificity,O
of,O
serum,O
calcitonin,O
testing,O
for,O
MTC,O
and,O
a,O
high,O
background,O
incidence,O
of,O
thyroid,O
disease,O
Significantly,O
elevated,O
serum,O
calcitonin,O
may,O
indicate,O
MTC,O
and,O
patients,O
with,O
MTC,O
usually,O
have,O
calcitonin,O
values,O
50,O
ng,O
L,O
If,O
serum,O
calcitonin,O
is,O
measured,O
and,O
found,O
to,O
be,O
elevated,O
the,O
patient,O
should,O
be,O
further,O
evaluated,O
Patients,O
with,O
thyroid,O
nodules,O
noted,O
on,O
physical,O
examination,O
or,O
neck,O
imaging,O
should,O
also,O
be,O
further,O
evaluated,O
5,O
2,O
Acute,O
Pancreatitis,O
In,O
clinical,O
trials,O
acute pancreatitis,AdverseReaction
has,O
been,O
reported,O
in,O
association,O
with,O
TANZEUM,O
Across,O
8,O
Phase,O
III,O
clinical,O
trials,O
see,O
Clinical,O
Studies,O
14,O
pancreatitis,AdverseReaction
adjudicated,O
as,O
likely,O
related,O
to,O
therapy,O
occurred,O
more,O
frequently,O
in,O
patients,O
receiving,O
TANZEUM,O
6,O
of,O
2,O
365,O
0,O
3,O
than,O
in,O
patients,O
receiving,O
placebo,O
0,O
of,O
468,O
0,O
or,O
active,O
comparators,O
2,O
of,O
2,O
065,O
0,O
1,O
After,O
initiation,O
of,O
TANZEUM,O
observe,O
patients,O
carefully,O
for,O
signs,O
and,O
symptoms,O
of,O
pancreatitis,O
including,O
persistent,O
severe,O
abdominal,O
pain,O
sometimes,O
radiating,O
to,O
the,O
back,O
and,O
which,O
may,O
or,O
may,O
not,O
be,O
accompanied,O
by,O
vomiting,O
If,O
pancreatitis,O
is,O
suspected,O
promptly,O
discontinue,O
TANZEUM,O
If,O
pancreatitis,O
is,O
confirmed,O
TANZEUM,O
should,O
not,O
be,O
restarted,O
TANZEUM,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
a,O
history,O
of,O
pancreatitis,O
to,O
determine,O
whether,O
these,O
patients,O
are,O
at,O
increased,O
risk,O
for,O
pancreatitis,O
Consider,O
other,O
antidiabetic,O
therapies,O
in,O
patients,O
with,O
a,O
history,O
of,O
pancreatitis,O
5,O
3,O
Hypoglycemia,O
with,O
Concomitant,O
Use,O
of,O
Insulin,O
Secretagogues,O
or,O
Insulin,O
The,O
risk,Factor
of,O
hypoglycemia,AdverseReaction
is,O
increased,O
when,O
TANZEUM,O
is,O
used,O
in,O
combination,O
with,O
insulin,O
secretagogues,O
e,O
g,O
sulfonylureas,O
or,O
insulin,O
Therefore,O
patients,O
may,O
require,O
a,O
lower,O
dose,O
of,O
sulfonylurea,O
or,O
insulin,O
to,O
reduce,O
the,O
risk,Factor
of,O
hypoglycemia,AdverseReaction
in,O
this,O
setting,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Adverse,O
Reactions,O
6,O
1,O
5,O
4,O
Hypersensitivity,O
Reactions,O
Across,O
8,O
Phase,O
III,O
clinical,O
trials,O
see,O
Clinical,O
Studies,O
14,O
a,O
serious,Severity
hypersensitivity reaction,AdverseReaction
with,O
pruritus,AdverseReaction
rash,AdverseReaction
and,O
dyspnea,AdverseReaction
occurred,O
in,O
a,O
patient,O
treated,O
with,O
TANZEUM,O
If,O
hypersensitivity,O
reactions,O
occur,O
discontinue,O
use,O
of,O
TANZEUM,O
treat,O
promptly,O
per,O
standard,O
of,O
care,O
and,O
monitor,O
until,O
signs,O
and,O
symptoms,O
resolve,O
see,O
Contraindications,O
4,O
2,O
5,O
5,O
Renal,O
Impairment,O
In,O
patients,O
treated,O
with,O
GLP 1 receptor agonists,DrugClass
there,O
have,O
been,O
postmarketing,O
reports,O
of,O
acute renal failure,AdverseReaction
and,O
worsening of chronic renal failure,AdverseReaction
which,O
may,O
sometimes,O
require,O
hemodialysis,O
Some,O
of,O
these,O
events,O
were,O
reported,O
in,O
patients,O
without,O
known,O
underlying,O
renal,O
disease,O
A,O
majority,O
of,O
reported,O
events,O
occurred,O
in,O
patients,O
who,O
had,O
experienced,O
nausea,AdverseReaction
vomiting,AdverseReaction
diarrhea,AdverseReaction
or,O
dehydration,AdverseReaction
In,O
a,O
trial,O
of,O
TANZEUM,O
in,O
patients,O
with,O
renal,O
impairment,O
see,O
Clinical,O
Studies,O
14,O
3,O
the,O
frequency,O
of,O
such,O
gastrointestinal reactions,AdverseReaction
increased,O
as,O
renal function declined,AdverseReaction
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
Because,O
these,O
reactions,O
may,O
worsen,O
renal,O
function,O
use,O
caution,O
when,O
initiating,O
or,O
escalating,O
doses,O
of,O
TANZEUM,O
in,O
patients,O
with,O
renal,O
impairment,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
5,O
6,O
Macrovascular,O
Outcomes,O
There,O
have,O
been,O
no,O
clinical,O
trials,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
TANZEUM,O
or,O
any,O
other,O
antidiabetic,O
drug,O
""
BOXED,O
WARNING,O
WARNING,O
RISK,Factor
OF,O
THYROID C CELL TUMORS,AdverseReaction
WARNING,O
RISK,Factor
OF,O
THYROID C CELL TUMORS,AdverseReaction
Carcinogenicity,O
of,O
albiglutide,O
could,O
not,O
be,O
assessed,O
in,O
rodents,O
but,O
other,O
glucagon like peptide 1 GLP 1 receptor agonists,DrugClass
have,O
caused,O
thyroid C cell tumors,AdverseReaction
in,O
rodents,Animal
at,O
clinically,O
relevant,O
exposures,O
Human,O
relevance,O
of,O
GLP 1 receptor agonist,DrugClass
induced,O
C cell tumors,AdverseReaction
in,O
rodents,Animal
has,O
not,O
been,O
determined,O
It,O
is,O
unknown,Factor
whether,O
TANZEUM,O
r,O
causes,O
thyroid C cell tumors,AdverseReaction
including,O
medullary thyroid carcinoma,AdverseReaction
MTC,AdverseReaction
in,O
humans,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Nonclinical,O
Toxicology,O
13,O
1,O
TANZEUM,O
is,O
contraindicated,O
in,O
patients,O
with,O
a,O
personal,O
or,O
family,O
history,O
of,O
MTC,O
or,O
in,O
patients,O
with,O
Multiple,O
Endocrine,O
Neoplasia,O
syndrome,O
type,O
2,O
MEN,O
2,O
Counsel,O
patients,O
regarding,O
the,O
potential,O
risk,O
of,O
MTC,O
with,O
the,O
use,O
of,O
TANZEUM,O
and,O
inform,O
them,O
of,O
the,O
symptoms,O
of,O
thyroid,O
tumors,O
e,O
g,O
mass,O
in,O
the,O
neck,O
dysphagia,O
dyspnea,O
persistent,O
hoarseness,O
Routine,O
monitoring,O
of,O
serum,O
calcitonin,O
or,O
using,O
thyroid,O
ultrasound,O
monitoring,O
is,O
of,O
uncertain,O
value,O
for,O
early,O
detection,O
of,O
MTC,O
in,O
patients,O
treated,O
with,O
TANZEUM,O
see,O
Contraindications,O
4,O
1,O
Warnings,O
and,O
Precautions,O
5,O
1,O
WARNING,O
RISK,Factor
OF,O
THYROID C CELL TUMORS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Carcinogenicity,O
of,O
albiglutide,O
could,O
not,O
be,O
assessed,O
in,O
rodents,O
but,O
other,O
glucagon like peptide 1 GLP 1 receptor agonists,DrugClass
have,O
caused,O
thyroid C cell tumors,AdverseReaction
in,O
rodents,Animal
at,O
clinically,O
relevant,O
exposures,O
Human,O
relevance,O
of,O
GLP 1 receptor agonist,DrugClass
induced,O
C cell tumors,AdverseReaction
in,O
rodents,Animal
has,O
not,O
been,O
determined,O
It,O
is,O
unknown,Factor
whether,O
TANZEUM,O
causes,O
thyroid C cell tumors,AdverseReaction
including,O
medullary thyroid carcinoma,AdverseReaction
MTC,AdverseReaction
in,O
humans,O
5,O
1,O
13,O
1,O
TANZEUM,O
is,O
contraindicated,O
in,O
patients,O
with,O
a,O
personal,O
or,O
family,O
history,O
of,O
MTC,O
or,O
in,O
patients,O
with,O
Multiple,O
Endocrine,O
Neoplasia,O
syndrome,O
type,O
2,O
MEN,O
2,O
Counsel,O
patients,O
regarding,O
the,O
potential,O
risk,O
of,O
MTC,O
and,O
symptoms,O
of,O
thyroid,O
tumors,O
4,O
1,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
reactions,O
are,O
described,O
below,O
or,O
elsewhere,O
in,O
the,O
prescribing,O
information,O
Risk,Factor
of,O
Thyroid C cell Tumors,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Acute Pancreatitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hypoglycemia,AdverseReaction
with,O
Concomitant,O
Use,O
of,O
Insulin,O
Secretagogues,O
or,O
Insulin,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Hypersensitivity Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Renal Impairment,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
EXCERPT,O
Adverse,O
reactions,O
reported,O
in,O
5,O
of,O
patients,O
treated,O
with,O
TANZEUM,O
and,O
more,O
frequently,O
than,O
in,O
patients,O
on,O
placebo,O
were,O
upper respiratory tract infection,AdverseReaction
diarrhea,AdverseReaction
nausea,AdverseReaction
injection site reaction,AdverseReaction
cough,AdverseReaction
back pain,AdverseReaction
arthralgia,AdverseReaction
sinusitis,AdverseReaction
and,O
influenza,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GlaxoSmithKline,O
at,O
1,O
888,O
825,O
5249,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Pool,O
of,O
Placebo,O
Controlled,O
Trials,O
The,O
data,O
in,O
Table,O
1,O
are,O
derived,O
from,O
4,O
placebo,O
controlled,O
trials,O
TANZEUM,O
was,O
used,O
as,O
monotherapy,O
in,O
1,O
trial,O
and,O
as,O
add,O
on,O
therapy,O
in,O
3,O
trials,O
see,O
Clinical,O
Studies,O
14,O
These,O
data,O
reflect,O
exposure,O
of,O
923,O
patients,O
to,O
TANZEUM,O
and,O
a,O
mean,O
duration,O
of,O
exposure,O
to,O
TANZEUM,O
of,O
93,O
weeks,O
The,O
mean,O
age,O
of,O
participants,O
was,O
55,O
years,O
1,O
of,O
participants,O
were,O
75,O
years,O
or,O
older,O
and,O
53,O
of,O
participants,O
were,O
male,O
The,O
population,O
in,O
these,O
studies,O
was,O
48,O
white,O
13,O
African,O
African,O
American,O
7,O
Asian,O
and,O
29,O
Hispanic,O
Latino,O
At,O
baseline,O
the,O
population,O
had,O
type,O
2,O
diabetes,O
for,O
an,O
average,O
of,O
7,O
years,O
and,O
had,O
a,O
mean,O
HbA1c,O
of,O
8,O
1,O
At,O
baseline,O
17,O
of,O
the,O
population,O
in,O
these,O
studies,O
reported,O
peripheral,O
neuropathy,O
and,O
4,O
reported,O
retinopathy,O
Baseline,O
estimated,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
eGFR,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
in,O
91,O
of,O
the,O
study,O
population,O
and,O
moderately,O
impaired,O
eGFR,O
30,O
to,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
in,O
9,O
Table,O
1,O
shows,O
common,O
adverse,O
reactions,O
excluding,O
hypoglycemia,AdverseReaction
associated,O
with,O
the,O
use,O
of,O
TANZEUM,O
in,O
the,O
pool,O
of,O
placebo,O
controlled,O
trials,O
These,O
adverse,O
reactions,O
were,O
not,O
present,O
at,O
baseline,O
occurred,O
more,O
commonly,O
on,O
TANZEUM,O
than,O
on,O
placebo,O
and,O
occurred,O
in,O
at,O
least,O
5,O
of,O
patients,O
treated,O
with,O
TANZEUM,O
Table,O
1,O
Adverse,O
Reactions,O
in,O
Placebo,O
controlled,O
Trials,O
Reported,O
in,O
5,O
of,O
Patients,O
Treated,O
with,O
TANZEUM,O
a,O
Adverse,O
Reaction,O
Placebo,O
N,O
468,O
TANZEUM,O
N,O
923,O
Upper respiratory tract infection,AdverseReaction
13,O
0,O
14,O
2,O
Diarrhea,AdverseReaction
10,O
5,O
13,O
1,O
Nausea,AdverseReaction
9,O
6,O
11,O
1,O
Injection,O
site,O
reactionb,O
2,O
1,O
10,O
5,O
Cough,AdverseReaction
6,O
2,O
6,O
9,O
Back pain,AdverseReaction
5,O
8,O
6,O
7,O
Arthralgia,AdverseReaction
6,O
4,O
6,O
6,O
Sinusitis,AdverseReaction
5,O
8,O
6,O
2,O
Influenza,AdverseReaction
3,O
2,O
5,O
2,O
a,O
Adverse,O
reactions,O
reported,O
includes,O
adverse,O
reactions,O
occurring,O
with,O
the,O
use,O
of,O
glycemic,O
rescue,O
medications,O
which,O
included,O
metformin,O
17,O
for,O
placebo,O
and,O
10,O
for,O
TANZEUM,O
and,O
insulin,O
24,O
for,O
placebo,O
and,O
14,O
for,O
TANZEUM,O
b,O
See,O
below,O
for,O
other,O
events,O
of,O
injection site reactions,AdverseReaction
reported,O
Gastrointestinal,O
Adverse,O
Reactions,O
In,O
the,O
pool,O
of,O
placebo,O
controlled,O
trials,O
gastrointestinal complaints,AdverseReaction
occurred,O
more,O
frequently,O
among,O
patients,O
receiving,O
TANZEUM,O
39,O
than,O
patients,O
receiving,O
placebo,O
33,O
In,O
addition,O
to,O
diarrhea,AdverseReaction
and,O
nausea,AdverseReaction
see,O
Table,O
1,O
the,O
following,O
gastrointestinal adverse reactions,AdverseReaction
also,O
occurred,O
more,O
frequently,O
in,O
patients,O
receiving,O
TANZEUM,O
vomiting,AdverseReaction
2,O
6,O
versus,O
4,O
2,O
for,O
placebo,O
versus,O
TANZEUM,O
gastroesophageal reflux disease,AdverseReaction
1,O
9,O
versus,O
3,O
5,O
for,O
placebo,O
versus,O
TANZEUM,O
and,O
dyspepsia,AdverseReaction
2,O
8,O
versus,O
3,O
4,O
for,O
placebo,O
versus,O
TANZEUM,O
Constipation,AdverseReaction
also,O
contributed,O
to,O
the,O
frequently,O
reported,O
reactions,O
In,O
the,O
group,O
treated,O
with,O
TANZEUM,O
investigators,O
graded,O
the,O
severity,O
of,O
GI reactions,AdverseReaction
as,O
mild,Severity
in,O
56,O
of,O
cases,O
moderate,Severity
in,O
37,O
of,O
cases,O
and,O
severe,Severity
in,O
7,O
of,O
cases,O
Discontinuation,O
due,O
to,O
GI adverse reactions,AdverseReaction
occurred,O
in,O
2,O
of,O
individuals,O
on,O
TANZEUM,O
or,O
placebo,O
Injection,O
Site,O
Reactions,O
In,O
the,O
pool,O
of,O
placebo,O
controlled,O
trials,O
injection site reactions,AdverseReaction
occurred,O
more,O
frequently,O
on,O
TANZEUM,O
18,O
than,O
on,O
placebo,O
8,O
In,O
addition,O
to,O
the,O
term,O
injection site reaction,AdverseReaction
see,O
Table,O
1,O
the,O
following,O
other,O
types,O
of,O
injection site reactions,AdverseReaction
also,O
occurred,O
more,O
frequently,O
on,O
TANZEUM,O
injection site hematoma,AdverseReaction
1,O
9,O
versus,O
2,O
1,O
for,O
placebo,O
versus,O
TANZEUM,O
injection site erythema,AdverseReaction
0,O
4,O
versus,O
1,O
7,O
for,O
placebo,O
versus,O
TANZEUM,O
injection site rash,AdverseReaction
0,O
versus,O
1,O
4,O
for,O
placebo,O
versus,O
TANZEUM,O
injection site hypersensitivity,AdverseReaction
0,O
versus,O
0,O
8,O
for,O
placebo,O
versus,O
TANZEUM,O
and,O
injection site hemorrhage,AdverseReaction
0,O
6,O
versus,O
0,O
7,O
for,O
placebo,O
versus,O
TANZEUM,O
Injection site pruritus,AdverseReaction
also,O
contributed,O
to,O
the,O
frequently,O
reported,O
reactions,O
The,O
majority,O
of,O
injection site reactions site reactions,AdverseReaction
were,O
judged,O
as,O
mild,Severity
by,O
investigators,O
in,O
both,O
groups,O
73,O
for,O
TANZEUM,O
versus,O
94,O
for,O
placebo,O
More,O
patients,O
on,O
TANZEUM,O
than,O
on,O
placebo,O
discontinued,O
due,O
to,O
an,O
injection site reaction,AdverseReaction
2,O
versus,O
0,O
2,O
experienced,O
more,O
than,O
2,O
reactions,O
38,O
versus,O
20,O
had,O
a,O
reaction,O
judged,O
by,O
investigators,O
to,O
be,O
moderate,O
or,O
severe,O
27,O
versus,O
6,O
and,O
required,O
local,O
or,O
systemic,O
treatment,O
for,O
the,O
reactions,O
36,O
versus,O
11,O
Pool,O
of,O
Placebo,O
and,O
Active,O
controlled,O
Trials,O
The,O
occurrence,O
of,O
adverse,O
reactions,O
was,O
also,O
evaluated,O
in,O
a,O
larger,O
pool,O
of,O
patients,O
with,O
type,O
2,O
diabetes,O
participating,O
in,O
7,O
placebo,O
and,O
active,O
controlled,O
trials,O
These,O
trials,O
evaluated,O
the,O
use,O
of,O
TANZEUM,O
as,O
monotherapy,O
and,O
as,O
add,O
on,O
therapy,O
to,O
oral,O
antidiabetic,O
agents,O
and,O
as,O
add,O
on,O
therapy,O
to,O
basal,O
insulin,O
see,O
Clinical,O
Studies,O
14,O
In,O
this,O
pool,O
a,O
total,O
of,O
2,O
116,O
patients,O
with,O
type,O
2,O
diabetes,O
were,O
treated,O
with,O
TANZEUM,O
for,O
a,O
mean,O
duration,O
of,O
75,O
weeks,O
The,O
mean,O
age,O
of,O
patients,O
treated,O
with,O
TANZEUM,O
was,O
55,O
years,O
1,O
5,O
of,O
the,O
population,O
in,O
these,O
studies,O
was,O
75,O
years,O
or,O
older,O
and,O
51,O
of,O
participants,O
were,O
male,O
Forty,O
eight,O
percent,O
of,O
patients,O
were,O
white,O
15,O
African,O
African,O
American,O
9,O
Asian,O
and,O
26,O
were,O
Hispanic,O
Latino,O
At,O
baseline,O
the,O
population,O
had,O
diabetes,O
for,O
an,O
average,O
of,O
8,O
years,O
and,O
had,O
a,O
mean,O
HbA1c,O
of,O
8,O
2,O
At,O
baseline,O
21,O
of,O
the,O
population,O
reported,O
peripheral,O
neuropathy,O
and,O
5,O
reported,O
retinopathy,O
Baseline,O
estimated,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
eGFR,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
in,O
92,O
of,O
the,O
population,O
and,O
moderately,O
impaired,O
eGFR,O
30,O
to,O
60,O
mL,O
min,O
1,O
73,O
m,O
2,O
in,O
8,O
of,O
the,O
population,O
In,O
the,O
pool,O
of,O
placebo,O
and,O
active,O
controlled,O
trials,O
the,O
types,O
and,O
frequency,O
of,O
common,O
adverse,O
reactions,O
excluding,O
hypoglycemia,AdverseReaction
were,O
similar,O
to,O
those,O
listed,O
in,O
Table,O
1,O
Other,O
Adverse,O
Reactions,O
Hypoglycemia,O
The,O
proportion,O
of,O
patients,O
experiencing,O
at,O
least,O
one,O
documented,O
symptomatic,Severity
hypoglycemic episode,AdverseReaction
on,O
TANZEUM,O
and,O
the,O
proportion,O
of,O
patients,O
experiencing,O
at,O
least,O
one,O
severe,Severity
hypoglycemic episode,AdverseReaction
on,O
TANZEUM,O
in,O
clinical,O
trials,O
see,O
Clinical,O
Studies,O
14,O
is,O
shown,O
in,O
Table,O
2,O
Hypoglycemia,AdverseReaction
was,O
more,O
frequent,O
when,O
TANZEUM,O
was,O
added,O
to,O
sulfonylurea,O
or,O
insulin,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Table,O
2,O
Incidence,O
of,O
Hypoglycemia,O
in,O
Clinical,O
Trials,O
of,O
TANZEUM,O
a,O
TANZEUM,O
Monotherapyb,O
Placebo,O
30,O
mg,O
Weekly,O
52,O
Weeks,O
N,O
101,O
N,O
101,O
Documented,O
symptomaticc,O
2,O
2,O
Severed,O
In,O
Combination,O
with,O
Metformin,O
Trial,O
Placebo,O
TANZEUM,O
104,O
Weeks,O
e,O
N,O
101,O
N,O
302,O
Documented,O
symptomatic,O
4,O
3,O
Severe,O
In,O
Combination,O
with,O
Pioglitazone,O
Placebo,O
TANZEUM,O
Metformin,O
52,O
Weeks,O
N,O
151,O
N,O
150,O
Documented,O
symptomatic,O
1,O
3,O
Severe,O
1,O
In,O
Combination,O
with,O
Metformin,O
and,O
Placebo,O
TANZEUM,O
Sulfonylurea,O
52,O
Weeks,O
N,O
115,O
N,O
271,O
Documented,O
symptomatic,O
7,O
13,O
Severe,O
0,O
4,O
In,O
Combination,O
with,O
Insulin,O
Lispro,O
TANZEUM,O
Insulin,O
Glargine,O
26,O
Weeks,O
N,O
281,O
N,O
285,O
Documented,O
symptomatic,O
30,O
16,O
Severe,O
0,O
7,O
In,O
Combination,O
with,O
Insulin,O
Glargine,O
TANZEUM,O
Metformin,O
Sulfonylurea,O
52,O
Weeks,O
N,O
241,O
N,O
504,O
Documented,O
symptomatic,O
27,O
17,O
Severe,O
0,O
4,O
0,O
4,O
In,O
Combination,O
with,O
OADs,O
in,O
Renal,O
Sitagliptin,O
TANZEUM,O
Impairment,O
26,O
Weeks,O
N,O
246,O
N,O
249,O
Documented,O
symptomatic,O
6,O
10,O
Severe,O
0,O
8,O
OAD,O
Oral,O
antidiabetic,O
agents,O
a,O
Data,O
presented,O
are,O
to,O
the,O
primary,O
endpoint,O
and,O
include,O
only,O
events,O
occurring,O
on,O
therapy,O
with,O
randomized,O
medications,O
and,O
excludes,O
events,O
occurring,O
after,O
use,O
of,O
glycemic,O
rescue,O
medications,O
i,O
e,O
primarily,O
metformin,O
or,O
insulin,O
b,O
In,O
this,O
trial,O
no,Negation
documented,O
symptomatic,Severity
or,O
severe,Severity
hypoglycemia,AdverseReaction
were,O
reported,O
for,O
TANZEUM,O
50,O
mg,O
and,O
these,O
data,O
are,O
omitted,O
from,O
the,O
table,O
c,O
Plasma glucose concentration 70 mg dL,AdverseReaction
and,O
presence,O
of,O
hypoglycemic symptoms,AdverseReaction
d,O
Event,O
requiring,O
another,O
person,O
to,O
administer,O
a,O
resuscitative,O
action,O
e,O
Rate,O
of,O
documented,O
symptomatic,Severity
hypoglycemia,AdverseReaction
for,O
active,O
controls,O
18,O
glimepiride,O
and,O
2,O
sitagliptin,O
Pneumonia,O
In,O
the,O
pool,O
of,O
7,O
placebo,O
and,O
active,O
controlled,O
trials,O
the,O
adverse,O
reaction,O
of,O
pneumonia,AdverseReaction
was,O
reported,O
more,O
frequently,O
in,O
patients,O
receiving,O
TANZEUM,O
1,O
8,O
than,O
in,O
patients,O
in,O
the,O
all,O
comparators,O
group,O
0,O
8,O
More,O
cases,O
of,O
pneumonia,AdverseReaction
in,O
the,O
group,O
receiving,O
TANZEUM,O
were,O
serious,Severity
0,O
4,O
for,O
TANZEUM,O
versus,O
0,O
1,O
for,O
all,O
comparators,O
Atrial,O
Fibrillation,O
Flutte,O
r,O
In,O
the,O
pool,O
of,O
7,O
placebo,O
and,O
active,O
controlled,O
trials,O
adverse,O
reactions,O
of,O
atrial fibrillation,AdverseReaction
1,O
0,O
and,O
atrial flutter,AdverseReaction
0,O
2,O
were,O
reported,O
more,O
frequently,O
for,O
TANZEUM,O
than,O
for,O
all,O
comparators,O
0,O
5,O
and,O
0,O
respectively,O
In,O
both,O
groups,O
patients,O
with,O
events,O
were,O
generally,O
male,O
older,O
and,O
had,O
underlying,O
renal,O
impairment,O
or,O
cardiac,O
disease,O
e,O
g,O
history,O
of,O
arrhythmia,O
palpitations,O
congestive,O
heart,O
failure,O
cardiomyopathy,O
etc,O
Appendicitis,O
In,O
the,O
pool,O
of,O
placebo,O
and,O
active,O
controlled,O
trials,O
serious,Severity
events,O
of,O
appendicitis,AdverseReaction
occurred,O
in,O
0,O
3,O
of,O
patients,O
treated,O
with,O
TANZEUM,O
compared,O
with,O
0,O
among,O
all,O
comparators,O
Immunogenicity,O
In,O
the,O
pool,O
of,O
7,O
placebo,O
and,O
active,O
controlled,O
trials,O
116,O
5,O
5,O
of,O
2,O
098,O
patients,O
exposed,O
to,O
TANZEUM,O
tested,O
positive,O
for,O
anti,O
albiglutide,O
antibodies,O
at,O
any,O
time,O
during,O
the,O
trials,O
None,O
of,O
these,O
antibodies,O
were,O
shown,O
to,O
neutralize,O
the,O
activity,O
of,O
albiglutide,O
in,O
an,O
in,O
vitro,O
bioassay,O
Presence,O
of,O
antibody,O
did,O
not,O
correlate,O
with,O
reduced,O
efficacy,O
as,O
measured,O
by,O
HbA1c,O
and,O
fasting,O
plasma,O
glucose,O
or,O
specific,O
adverse,O
reactions,O
Consistent,O
with,O
the,O
high,O
homology,O
of,O
albiglutide,O
with,O
human,O
GLP,O
1,O
the,O
majority,O
of,O
patients,O
approximately,O
79,O
with,O
anti,O
albiglutide,O
antibodies,O
also,O
tested,O
positive,O
for,O
anti,O
GLP,O
1,O
antibodies,O
none,O
were,O
neutralizing,O
A,O
minority,O
of,O
patients,O
approximately,O
17,O
who,O
tested,O
positive,O
for,O
anti,O
albiglutide,O
antibodies,O
also,O
transiently,O
tested,O
positive,O
for,O
antibodies,O
to,O
human,O
albumin,O
The,O
detection,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
the,O
incidence,O
of,O
antibodies,O
to,O
albiglutide,O
cannot,O
be,O
directly,O
compared,O
with,O
the,O
incidence,O
of,O
antibodies,O
of,O
other,O
products,O
Liver,O
Enzyme,O
Abnormalities,O
In,O
the,O
pool,O
of,O
placebo,O
and,O
active,O
controlled,O
trials,O
a,O
similar,O
proportion,O
of,O
patients,O
experienced,O
at,O
least,O
one,O
event,O
of,O
alanine aminotransferase,AdverseReaction
ALT,AdverseReaction
increase,AdverseReaction
of,O
3,O
fold,O
or,O
greater,O
above,O
the,O
upper,O
limit,O
of,O
normal,O
0,O
9,O
and,O
0,O
9,O
for,O
all,O
comparators,O
versus,O
TANZEUM,O
Three,O
subjects,O
on,O
TANZEUM,O
and,O
one,O
subject,O
in,O
the,O
all,O
comparator,O
group,O
experienced,O
at,O
least,O
one,O
event,O
of,O
ALT increase,AdverseReaction
of,O
10,O
fold,O
or,O
greater,O
above,O
the,O
upper,O
limit,O
of,O
normal,O
In,O
one,O
of,O
the,O
3,O
cases,O
an,O
alternate etiology,Negation
was,O
identified,O
to,O
explain,O
the,O
rise in liver enzyme,AdverseReaction
acute,O
viral,O
hepatitis,O
In,O
one,O
case,O
insufficient,O
information,O
was,O
obtained,O
to,O
establish,O
or,O
refute,O
a,O
drug,O
related,O
causality,O
In,O
the,O
third,O
case,O
elevation in ALT,AdverseReaction
10 times the upper limit of normal,Severity
was,O
accompanied,O
by,O
an,O
increase in total bilirubin,AdverseReaction
4 times the upper limit of normal,Severity
and,O
occurred,O
8,O
days,O
after,O
the,O
first,O
dose,O
of,O
TANZEUM,O
The,O
etiology,O
of,O
hepatocellular injury,AdverseReaction
was,O
possibly,O
related,O
to,O
TANZEUM,O
but,O
direct,O
attribution,O
to,O
TANZEUM,O
was,O
confounded,O
by,O
the,O
presence,O
of,O
gallstone,O
disease,O
diagnosed,O
on,O
ultrasound,O
3,O
weeks,O
after,O
the,O
event,O
Gamma,O
Glutamyltransferase,O
GGT,O
Increase,O
In,O
the,O
pool,O
of,O
placebo,O
controlled,O
trials,O
the,O
adverse,O
event,O
of,O
increased GGT,AdverseReaction
occurred,O
more,O
frequently,O
in,O
the,O
group,O
treated,O
with,O
TANZEUM,O
0,O
9,O
and,O
1,O
5,O
for,O
placebo,O
versus,O
TANZEUM,O
Heart,O
Rate,O
Increase,O
In,O
the,O
pool,O
of,O
placebo,O
controlled,O
trials,O
mean heart rate,AdverseReaction
in,O
patients,O
treated,O
with,O
TANZEUM,O
was,O
higher by an average of 1 to 2 bpm,AdverseReaction
compared,O
with,O
mean,O
heart,O
rate,O
in,O
patients,O
treated,O
with,O
placebo,O
across,O
study,O
visits,O
The,O
long,O
term,O
clinical,O
effects,O
of,O
the,O
increase in heart rate,AdverseReaction
have,O
not,O
been,O
established,O
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Anaphylaxis,AdverseReaction
and,O
angioedema,AdverseReaction
Discontinue,O
and,O
do,O
not,O
restart,O
TECFIDERA,O
if,O
these,O
occur,O
5,O
1,O
Progressive multifocal leukoencephalopathy,AdverseReaction
PML,AdverseReaction
Withhold,O
TECFIDERA,O
at,O
the,O
first,O
sign,O
or,O
symptom,O
suggestive,O
of,O
PML,O
5,O
2,O
Lymphopenia,AdverseReaction
Obtain,O
a,O
CBC,O
including,O
lymphocyte,O
count,O
before,O
initiating,O
TECFIDERA,O
after,O
6,O
months,O
and,O
every,O
6,O
to,O
12,O
months,O
thereafter,O
Consider,O
interruption,O
of,O
TECFIDERA,O
if,O
lymphocyte,O
counts,O
0,O
5,O
x,O
10,O
9,O
L,O
persist,O
for,O
more,O
than,O
six,O
months,O
5,O
3,O
5,O
1,O
Anaphylaxis,O
and,O
Angioedema,O
TECFIDERA,O
can,Factor
cause,O
anaphylaxis,AdverseReaction
and,O
angioedema,AdverseReaction
after,O
the,O
first,O
dose,O
or,O
at,O
any,O
time,O
during,O
treatment,O
Signs,O
and,O
symptoms,O
have,O
included,O
difficulty breathing,AdverseReaction
urticaria,AdverseReaction
and,O
swelling of the throat of the,AdverseReaction
and,O
tongue,AdverseReaction
Patients,O
should,O
be,O
instructed,O
to,O
discontinue,O
TECFIDERA,O
and,O
seek,O
immediate,O
medical,O
care,O
should,O
they,O
experience,O
signs,O
and,O
symptoms,O
of,O
anaphylaxis,O
or,O
angioedema,O
5,O
2,O
Progressive,O
Multifocal,O
Leukoencephalopathy,O
A,O
fatal,AdverseReaction
case,O
of,O
progressive multifocal leukoencephalopathy,AdverseReaction
PML,AdverseReaction
occurred,O
in,O
a,O
patient,O
with,O
MS,O
who,O
received,O
TECFIDERA,O
for,O
4,O
years,O
while,O
enrolled,O
in,O
a,O
clinical,O
trial,O
PML,O
is,O
an,O
opportunistic,O
viral,O
infection,O
of,O
the,O
brain,O
caused,O
by,O
the,O
JC,O
virus,O
JCV,O
that,O
typically,O
only,O
occurs,O
in,O
patients,O
who,O
are,O
immunocompromised,O
and,O
that,O
usually,O
leads,O
to,O
death,O
or,O
severe,O
disability,O
During,O
the,O
clinical,O
trial,O
the,O
patient,O
experienced,O
prolonged,Severity
lymphopenia,AdverseReaction
lymphocyte,O
counts,O
predominantly,O
0,O
5x10,O
9,O
L,O
for,O
3,O
5,O
years,O
while,O
taking,O
TECFIDERA,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
The,O
role,O
of,O
lymphopenia,AdverseReaction
in,O
this,O
case,O
is,O
unknown,O
The,O
patient,O
had,O
no,O
other,O
identified,O
systemic,O
medical,O
conditions,O
resulting,O
in,O
compromised,O
immune,O
system,O
function,O
and,O
had,O
not,O
previously,O
been,O
treated,O
with,O
natalizumab,O
which,O
has,O
a,O
known,O
association,O
with,O
PML,O
The,O
patient,O
was,O
also,O
not,O
taking,O
any,O
immunosuppressive,O
or,O
immunomodulatory,O
medications,O
concomitantly,O
At,O
the,O
first,O
sign,O
or,O
symptom,O
suggestive,O
of,O
PML,O
withhold,O
TECFIDERA,O
and,O
perform,O
an,O
appropriate,O
diagnostic,O
evaluation,O
Typical,O
symptoms,O
associated,O
with,O
PML,O
are,O
diverse,O
progress,O
over,O
days,O
to,O
weeks,O
and,O
include,O
progressive,O
weakness,O
on,O
one,O
side,O
of,O
the,O
body,O
or,O
clumsiness,O
of,O
limbs,O
disturbance,O
of,O
vision,O
and,O
changes,O
in,O
thinking,O
memory,O
and,O
orientation,O
leading,O
to,O
confusion,O
and,O
personality,O
changes,O
5,O
3,O
Lymphopenia,O
TECFIDERA,O
may,Factor
decrease lymphocyte counts,AdverseReaction
In,O
the,O
MS,O
placebo,O
controlled,O
trials,O
mean,O
lymphocyte counts decreased,AdverseReaction
by,O
approximately,O
30,O
during,O
the,O
first,O
year,O
of,O
treatment,O
with,O
TECFIDERA,O
and,O
then,O
remained,O
stable,O
Four,O
weeks,O
after,O
stopping,O
TECFIDERA,O
mean,O
lymphocyte,O
counts,O
increased,O
but,O
did,O
not,O
return,O
to,O
baseline,O
Six,O
percent,O
6,O
of,O
TECFIDERA,O
patients,O
and,O
1,O
of,O
placebo,O
patients,O
experienced,O
lymphocyte counts 0 5x10 9 L,AdverseReaction
lower,O
limit,O
of,O
normal,O
0,O
91x10,O
9,O
L,O
The,O
incidence,O
of,O
infections,AdverseReaction
60,O
vs,O
58,O
and,O
serious,Severity
infections,AdverseReaction
2,O
vs,O
2,O
was,O
similar,O
in,O
patients,O
treated,O
with,O
TECFIDERA,O
or,O
placebo,O
respectively,O
There,O
was,O
no,Negation
increased,AdverseReaction
incidence,O
of,O
serious,Severity
infections,AdverseReaction
observed,O
in,O
patients,O
with,O
lymphocyte,O
counts,O
0,O
8x10,O
9,O
L,O
or,O
0,O
5x10,O
9,O
L,O
in,O
controlled,O
trials,O
although,O
one,O
patient,O
in,O
an,O
extension,O
study,O
developed,O
PML,AdverseReaction
in,O
the,O
setting,O
of,O
prolonged lymphopenia,AdverseReaction
lymphocyte,O
counts,O
predominantly,O
0,O
5x10,O
9,O
L,O
for,O
3,O
5,O
years,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
In,O
controlled,O
and,O
uncontrolled,O
clinical,O
trials,O
2,O
of,O
patients,O
experienced,O
lymphocyte counts 0 5 x 10 9 L,AdverseReaction
for,O
at,O
least,O
six,O
months,O
In,O
these,O
patients,O
the,O
majority,O
of,O
lymphocyte counts,AdverseReaction
remained,O
0,O
5x10,O
9,O
L,O
with,O
continued,O
therapy,O
TECFIDERA,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
pre,O
existing,O
low,O
lymphocyte,O
counts,O
Before,O
initiating,O
treatment,O
with,O
TECFIDERA,O
a,O
CBC,O
including,O
lymphocyte,O
count,O
should,O
be,O
obtained,O
A,O
CBC,O
including,O
lymphocyte,O
count,O
should,O
also,O
be,O
obtained,O
after,O
6,O
months,O
of,O
treatment,O
every,O
6,O
to,O
12,O
months,O
thereafter,O
and,O
as,O
clinically,O
indicated,O
Consider,O
interruption,O
of,O
TECFIDERA,O
in,O
patients,O
with,O
lymphocyte,O
counts,O
0,O
5,O
x,O
10,O
9,O
L,O
persisting,O
for,O
more,O
than,O
six,O
months,O
Given,O
the,O
potential,O
for,O
delay,O
in,O
lymphocyte,O
recovery,O
after,O
discontinuation,O
of,O
TECFIDERA,O
consider,O
following,O
lymphocyte,O
counts,O
until,O
lymphopenia,O
is,O
resolved,O
Withholding,O
treatment,O
should,O
be,O
considered,O
in,O
patients,O
with,O
serious,O
infections,O
until,O
the,O
infection,O
s,O
is,O
resolved,O
Decisions,O
about,O
whether,O
or,O
not,O
to,O
restart,O
TECFIDERA,O
should,O
be,O
individualized,O
based,O
on,O
clinical,O
circumstances,O
5,O
4,O
Flushing,O
TECFIDERA,O
may,O
cause,O
flushing,AdverseReaction
e,O
g,O
warmth,AdverseReaction
redness,AdverseReaction
itching,AdverseReaction
and,O
or,O
burning sensation,AdverseReaction
In,O
clinical,O
trials,O
40,O
of,O
TECFIDERA,O
treated,O
patients,O
experienced,O
flushing,AdverseReaction
Flushing,AdverseReaction
symptoms,O
generally,O
began,O
soon,O
after,O
initiating,O
TECFIDERA,O
and,O
usually,O
improved,O
or,O
resolved,O
over,O
time,O
In,O
the,O
majority,O
of,O
patients,O
who,O
experienced,O
flushing,AdverseReaction
it,O
was,O
mild,Severity
or,O
moderate,Severity
in,O
severity,O
Three,O
percent,O
3,O
of,O
patients,O
discontinued,O
TECFIDERA,O
for,O
flushing,AdverseReaction
and,O
1,O
had,O
serious,Severity
flushing,AdverseReaction
symptoms,O
that,O
were,O
not life threatening,Severity
but,O
led,O
to,O
hospitalization,O
Administration,O
of,O
TECFIDERA,O
with,O
food,O
may,O
reduce,O
the,O
incidence,O
of,O
flushing,AdverseReaction
Alternatively,O
administration,O
of,O
non,O
enteric,O
coated,O
aspirin,O
up,O
to,O
a,O
dose,O
of,O
325,O
mg,O
30,O
minutes,O
prior,O
to,O
TECFIDERA,O
dosing,O
may,O
reduce,O
the,O
incidence,O
or,O
severity,O
of,O
flushing,AdverseReaction
see,O
Dosing,O
and,O
Administration,O
2,O
1,O
and,O
Clinical,O
Pharmacology,O
12,O
3,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
important,O
adverse,O
reactions,O
are,O
described,O
elsewhere,O
in,O
labeling,O
Anaphylaxis,AdverseReaction
and,O
Angioedema,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Progressive multifocal leukoencephalopathy,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Lymphopenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Flushing,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
incidence,O
10,O
and,O
2,O
placebo,O
were,O
flushing,AdverseReaction
abdominal pain,AdverseReaction
diarrhea,AdverseReaction
and,O
nausea,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Biogen,O
at,O
1,O
800,O
456,O
2255,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
10,O
and,O
2,O
more,O
than,O
placebo,O
for,O
TECFIDERA,O
were,O
flushing,AdverseReaction
abdominal pain,AdverseReaction
diarrhea,AdverseReaction
and,O
nausea,AdverseReaction
Adverse,O
Reactions,O
in,O
Placebo,O
Controlled,O
Trials,O
In,O
the,O
two,O
well,O
controlled,O
studies,O
demonstrating,O
effectiveness,O
1529,O
patients,O
received,O
TECFIDERA,O
with,O
an,O
overall,O
exposure,O
of,O
2244,O
person,O
years,O
see,O
Clinical,O
Studies,O
14,O
The,O
adverse,O
reactions,O
presented,O
in,O
the,O
table,O
below,O
are,O
based,O
on,O
safety,O
information,O
from,O
769,O
patients,O
treated,O
with,O
TECFIDERA,O
240,O
mg,O
twice,O
a,O
day,O
and,O
771,O
placebo,O
treated,O
patients,O
Table,O
1,O
Adverse,O
Reactions,O
in,O
Study,O
1,O
and,O
2,O
reported,O
for,O
TECFIDERA,O
240,O
mg,O
BID,O
at,O
2,O
higher,O
incidence,O
than,O
placebo,O
TECFIDERA,O
N,O
769,O
Placebo,O
N,O
771,O
Flushing,AdverseReaction
40,O
6,O
Abdominal pain,AdverseReaction
18,O
10,O
Diarrhea,AdverseReaction
14,O
11,O
Nausea,AdverseReaction
12,O
9,O
Vomiting,AdverseReaction
9,O
5,O
Pruritus,AdverseReaction
8,O
4,O
Rash,AdverseReaction
8,O
3,O
Albumin urine present,AdverseReaction
6,O
4,O
Erythema,AdverseReaction
5,O
1,O
Dyspepsia,AdverseReaction
5,O
3,O
Aspartate aminotransferase increased,AdverseReaction
4,O
2,O
Lymphopenia,AdverseReaction
2,O
1,O
Gastrointestinal,O
TECFIDERA,O
caused,O
GI events,AdverseReaction
e,O
g,O
nausea,AdverseReaction
vomiting,AdverseReaction
diarrhea,AdverseReaction
abdominal pain,AdverseReaction
and,O
dyspepsia,AdverseReaction
The,O
incidence,O
of,O
GI events,AdverseReaction
was,O
higher,O
early,O
in,O
the,O
course,O
of,O
treatment,O
primarily,O
in,O
month,O
1,O
and,O
usually,O
decreased,O
over,O
time,O
in,O
patients,O
treated,O
with,O
TECFIDERA,O
compared,O
with,O
placebo,O
Four,O
percent,O
4,O
of,O
patients,O
treated,O
with,O
TECFIDERA,O
and,O
less,O
than,O
1,O
of,O
placebo,O
patients,O
discontinued,O
due,O
to,O
gastrointestinal events,AdverseReaction
The,O
incidence,O
of,O
serious,Severity
GI events,AdverseReaction
was,O
1,O
in,O
patients,O
treated,O
with,O
TECFIDERA,O
Hepatic,O
Transaminases,O
An,O
increased,O
incidence,O
of,O
elevations of hepatic transaminases,AdverseReaction
in,O
patients,O
treated,O
with,O
TECFIDERA,O
was,O
seen,O
primarily,O
during,O
the,O
first,O
six,O
months,O
of,O
treatment,O
and,O
most,O
patients,O
with,O
elevations,O
had,O
levels,O
3,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
ULN,O
Elevations of alanine aminotransferase of,AdverseReaction
and,O
aspartate aminotransferase,AdverseReaction
to,O
3,O
times,O
the,O
ULN,O
occurred,O
in,O
a,O
small,O
number,O
of,O
patients,O
treated,O
with,O
both,O
TECFIDERA,O
and,O
placebo,O
and,O
were,O
balanced,O
between,O
groups,O
There,O
were,O
no,Negation
elevations in transaminases,AdverseReaction
3 times the ULN,Severity
with,O
concomitant,O
elevations in total bilirubin,AdverseReaction
2 times the ULN,Severity
Discontinuations,O
due,O
to,O
elevated hepatic transaminases,AdverseReaction
were,O
1,O
and,O
were,O
similar,O
in,O
patients,O
treated,O
with,O
TECFIDERA,O
or,O
placebo,O
Eosinophilia,O
A,O
transient,Severity
increase in mean eosinophil counts,AdverseReaction
was,O
seen,O
during,O
the,O
first,O
2,O
months,O
of,O
therapy,O
Adverse,O
Reactions,O
in,O
Placebo,O
Controlled,O
and,O
Uncontrolled,O
Studies,O
In,O
placebo,O
controlled,O
and,O
uncontrolled,O
clinical,O
studies,O
a,O
total,O
of,O
2513,O
patients,O
have,O
received,O
TECFIDERA,O
and,O
been,O
followed,O
for,O
periods,O
up,O
to,O
4,O
years,O
with,O
an,O
overall,O
exposure,O
of,O
4603,O
person,O
years,O
Approximately,O
1162,O
patients,O
have,O
received,O
more,O
than,O
2,O
years,O
of,O
treatment,O
with,O
TECFIDERA,O
The,O
adverse,O
reaction,O
profile,O
of,O
TECFIDERA,O
in,O
the,O
uncontrolled,O
clinical,O
studies,O
was,O
consistent,O
with,O
the,O
experience,O
in,O
the,O
placebo,O
controlled,O
clinical,O
trials,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Serious,Severity
hypersensitivity,AdverseReaction
anaphylactic,AdverseReaction
reactions,AdverseReaction
have,O
been,O
reported,O
with,O
beta,O
lactam,O
antibacterial,O
drugs,O
including,O
Teflaro,O
If,O
a,O
hypersensitivity,O
reaction,O
occurs,O
discontinue,O
Teflaro,O
5,O
1,O
Clostridium difficile associated diarrhea,AdverseReaction
CDAD,AdverseReaction
has,O
been,O
reported,O
with,O
nearly,O
all,O
systemic,O
antibacterial,O
agents,O
including,O
Teflaro,O
Evaluate,O
if,O
diarrhea,O
occurs,O
5,O
2,O
Direct Coombs test seroconversion,AdverseReaction
has,O
been,O
reported,O
with,O
Teflaro,O
If,O
anemia,O
develops,O
during,O
or,O
after,O
therapy,O
a,O
diagnostic,O
workup,O
for,O
drug,O
induced,O
hemolytic,O
anemia,O
should,O
be,O
performed,O
and,O
consideration,O
given,O
to,O
discontinuation,O
of,O
Teflaro,O
5,O
3,O
5,O
1,O
Hypersensitivity,O
Reactions,O
Serious,Severity
and,O
occasionally,O
fatal,AdverseReaction
hypersensitivity,AdverseReaction
anaphylactic,AdverseReaction
reactions,AdverseReaction
and,O
serious,Severity
skin reactions,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
receiving,O
beta lactam antibacterial drugs,DrugClass
Before,O
therapy,O
with,O
Teflaro,O
is,O
instituted,O
careful,O
inquiry,O
about,O
previous,O
hypersensitivity,O
reactions,O
to,O
other,O
cephalosporins,O
penicillins,O
or,O
carbapenems,O
should,O
be,O
made,O
Maintain,O
clinical,O
supervision,O
if,O
this,O
product,O
is,O
to,O
be,O
given,O
to,O
a,O
penicillin,O
or,O
other,O
beta,O
lactam,O
allergic,O
patient,O
because,O
cross,O
sensitivity,O
among,O
beta,O
lactam,O
antibacterial,O
agents,O
has,O
been,O
clearly,O
established,O
If,O
an,O
allergic,O
reaction,O
to,O
Teflaro,O
occurs,O
discontinue,O
Teflaro,O
and,O
institute,O
appropriate,O
treatment,O
and,O
supportive,O
measures,O
5,O
2,O
Clostridium,O
difficile,O
Associated,O
Diarrhea,O
Clostridium difficile associated diarrhea,AdverseReaction
CDAD,AdverseReaction
has,O
been,O
reported,O
for,O
nearly,O
all,O
systemic,O
antibacterial,O
agents,O
including,O
Teflaro,O
and,O
may,O
range,O
in,O
severity,O
from,O
mild,Severity
diarrhea,AdverseReaction
to,O
fatal,AdverseReaction
colitis,AdverseReaction
Treatment,O
with,O
antibacterial,O
agents,O
alters,O
the,O
normal,O
flora,O
of,O
the,O
colon,O
and,O
may,O
permit,O
overgrowth,O
of,O
C,O
difficile,O
C,O
difficile,O
produces,O
toxins,O
A,O
and,O
B,O
which,O
contribute,O
to,O
the,O
development,O
of,O
CDAD,O
Hypertoxin,O
producing,O
strains,O
of,O
C,O
difficile,O
cause,O
increased,O
morbidity,O
and,O
mortality,O
as,O
these,O
infections,O
can,O
be,O
refractory,O
to,O
antimicrobial,O
therapy,O
and,O
may,O
require,O
colectomy,O
CDAD,O
must,O
be,O
considered,O
in,O
all,O
patients,O
who,O
present,O
with,O
diarrhea,O
following,O
antibiotic,O
use,O
Careful,O
medical,O
history,O
is,O
necessary,O
because,O
CDAD,O
has,O
been,O
reported,O
to,O
occur,O
more,O
than,O
2,O
months,O
after,O
the,O
administration,O
of,O
antibacterial,O
agents,O
If,O
CDAD,O
is,O
suspected,O
or,O
confirmed,O
antibacterials,O
not,O
directed,O
against,O
C,O
difficile,O
should,O
be,O
discontinued,O
if,O
possible,O
Appropriate,O
fluid,O
and,O
electrolyte,O
management,O
protein,O
supplementation,O
antibiotic,O
treatment,O
of,O
C,O
difficile,O
and,O
surgical,O
evaluation,O
should,O
be,O
instituted,O
as,O
clinically,O
indicated,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
3,O
Direct,O
Coombs,O
Test,O
Seroconversion,O
Seroconversion from a negative to a positive direct Coombs test result,AdverseReaction
occurred,O
in,O
120,O
1114,O
10,O
8,O
of,O
patients,O
receiving,O
Teflaro,O
and,O
49,O
1116,O
4,O
4,O
of,O
patients,O
receiving,O
comparator,O
drugs,O
in,O
the,O
four,O
pooled,O
Phase,O
3,O
trials,O
In,O
the,O
pooled,O
Phase,O
3,O
CABP,O
trials,O
51,O
520,O
9,O
8,O
of,O
Teflaro,O
treated,O
patients,O
compared,O
to,O
24,O
534,O
4,O
5,O
of,O
ceftriaxone,O
treated,O
patients,O
seroconverted from a negative to a positive direct Coombs test result,AdverseReaction
No,Negation
adverse,O
reactions,O
representing,O
hemolytic anemia,AdverseReaction
were,O
reported,O
in,O
any,O
treatment,O
group,O
If,O
anemia,O
develops,O
during,O
or,O
after,O
treatment,O
with,O
Teflaro,O
drug,O
induced,O
hemolytic,O
anemia,O
should,O
be,O
considered,O
Diagnostic,O
studies,O
including,O
a,O
direct,O
Coombs,O
test,O
should,O
be,O
performed,O
If,O
drug,O
induced,O
hemolytic,O
anemia,O
is,O
suspected,O
discontinuation,O
of,O
Teflaro,O
should,O
be,O
considered,O
and,O
supportive,O
care,O
should,O
be,O
administered,O
to,O
the,O
patient,O
i,O
e,O
transfusion,O
if,O
clinically,O
indicated,O
5,O
4,O
Development,O
of,O
Drug,O
Resistant,O
Bacteria,O
Prescribing,O
Teflaro,O
in,O
the,O
absence,O
of,O
a,O
proven,O
or,O
strongly,O
suspected,O
bacterial,O
infection,O
is,O
unlikely,O
to,O
provide,O
benefit,O
to,O
the,O
patient,O
and,O
increases,O
the,O
risk,O
of,O
the,O
development,O
of,O
drug,O
resistant,O
bacteria,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
described,O
in,O
greater,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
Hypersensitivity Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Clostridium difficile Associated diarrhea,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Direct Coombs Test Seroconversion,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
occurring,O
in,O
2,O
of,O
patients,O
are,O
diarrhea,AdverseReaction
nausea,AdverseReaction
and,O
rash,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Forest,O
Laboratories,O
LLC,O
at,O
1,O
800,O
678,O
1605,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
compared,O
directly,O
to,O
rates,O
from,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
rates,O
observed,O
in,O
practice,O
Teflaro,O
was,O
evaluated,O
in,O
four,O
controlled,O
comparative,O
Phase,O
3,O
clinical,O
trials,O
two,O
in,O
ABSSSI,O
and,O
two,O
in,O
CABP,O
which,O
included,O
1300,O
adult,O
patients,O
treated,O
with,O
Teflaro,O
600,O
mg,O
administered,O
by,O
IV,O
over,O
1,O
hour,O
every,O
12h,O
and,O
1297,O
patients,O
treated,O
with,O
comparator,O
vancomycin,O
plus,O
aztreonam,O
or,O
ceftriaxone,O
for,O
a,O
treatment,O
period,O
up,O
to,O
21,O
days,O
The,O
median,O
age,O
of,O
patients,O
treated,O
with,O
Teflaro,O
was,O
54,O
years,O
ranging,O
between,O
18,O
and,O
99,O
years,O
old,O
Patients,O
treated,O
with,O
Teflaro,O
were,O
predominantly,O
male,O
63,O
and,O
Caucasian,O
82,O
Serious,O
Adverse,O
Reactions,O
and,O
Adverse,O
Reactions,O
Leading,O
to,O
Discontinuation,O
In,O
the,O
four,O
pooled,O
Phase,O
3,O
clinical,O
trials,O
serious,O
adverse,O
reactions,O
SARs,O
occurred,O
in,O
98,O
1300,O
7,O
5,O
of,O
patients,O
receiving,O
Teflaro,O
and,O
100,O
1297,O
7,O
7,O
of,O
patients,O
receiving,O
comparator,O
drugs,O
Treatment,O
discontinuation,O
due,O
to,O
adverse,O
reactions,O
occurred,O
in,O
35,O
1300,O
2,O
7,O
of,O
patients,O
receiving,O
Teflaro,O
and,O
48,O
1297,O
3,O
7,O
of,O
patients,O
receiving,O
comparator,O
drugs,O
with,O
the,O
most,O
common,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
being,O
hypersensitivity,AdverseReaction
for,O
both,O
treatment,O
groups,O
at,O
a,O
rate,O
of,O
0,O
3,O
in,O
the,O
Teflaro,O
group,O
and,O
0,O
5,O
in,O
comparator,O
group,O
Most,O
Common,O
Adverse,O
Reactions,O
No,O
adverse,O
reactions,O
occurred,O
in,O
greater,O
than,O
5,O
of,O
patients,O
receiving,O
Teflaro,O
The,O
most,O
common,O
adverse,O
reactions,O
occurring,O
in,O
2,O
of,O
patients,O
receiving,O
Teflaro,O
in,O
the,O
pooled,O
phase,O
3,O
clinical,O
trials,O
were,O
diarrhea,AdverseReaction
nausea,AdverseReaction
and,O
rash,AdverseReaction
Table,O
4,O
lists,O
adverse,O
reactions,O
occurring,O
in,O
2,O
of,O
patients,O
receiving,O
Teflaro,O
in,O
the,O
pooled,O
Phase,O
3,O
clinical,O
trials,O
Table,O
4,O
Adverse,O
Reactions,O
Occurring,O
in,O
2,O
of,O
Patients,O
Receiving,O
Teflaro,O
in,O
the,O
Pooled,O
Phase,O
3,O
Clinical,O
Trials,O
a,O
Comparators,O
included,O
vancomycin,O
1,O
gram,O
IV,O
every,O
12h,O
plus,O
aztreonam,O
1,O
gram,O
IV,O
every,O
12h,O
in,O
the,O
Phase,O
3,O
ABSSSI,O
trials,O
and,O
ceftriaxone,O
1,O
gram,O
IV,O
every,O
24h,O
in,O
the,O
Phase,O
3,O
CABP,O
trials,O
Adverse,O
Reactions,O
Pooled,O
Phase,O
3,O
Clinical,O
Trials,O
four,O
trials,O
two,O
in,O
ABSSSI,O
and,O
two,O
in,O
CABP,O
Teflaro,O
N,O
1300,O
Pooled,O
Comparators,O
a,O
N,O
1297,O
Gastrointestinal,O
Disorders,O
Diarrhea,AdverseReaction
5,O
3,O
Nausea,AdverseReaction
4,O
4,O
Constipation,AdverseReaction
2,O
2,O
Vomiting,AdverseReaction
2,O
2,O
Laboratory,O
Investigations,O
Increased transaminases,AdverseReaction
2,O
3,O
Metabolism,O
and,O
Nutrition,O
disorders,O
Hypokalemia,AdverseReaction
2,O
3,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Rash,AdverseReaction
3,O
2,O
Vascular,O
Disorders,O
Phlebitis,AdverseReaction
2,O
1,O
Other,O
Adverse,O
Reactions,O
Observed,O
During,O
Clinical,O
Trials,O
of,O
Teflaro,O
Following,O
is,O
a,O
list,O
of,O
additional,O
adverse,O
reactions,O
reported,O
by,O
the,O
1740,O
patients,O
who,O
received,O
Teflaro,O
in,O
any,O
clinical,O
trial,O
with,O
incidences,O
less,O
than,O
2,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Anemia,AdverseReaction
Eosinophilia,AdverseReaction
Neutropenia,AdverseReaction
Thrombocytopenia,AdverseReaction
Cardiac,O
disorders,O
Bradycardia,AdverseReaction
Palpitations,AdverseReaction
Gastrointestinal,O
disorders,O
Abdominal pain,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Pyrexia,AdverseReaction
Hepatobiliary,O
disorders,O
Hepatitis,AdverseReaction
Immune,O
system,O
disorders,O
Hypersensitivity,AdverseReaction
Anaphylaxis,AdverseReaction
Infections,O
and,O
infestations,O
Clostridium difficile colitis,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorders,O
Hyperglycemia,AdverseReaction
Hyperkalemia,AdverseReaction
Nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
Convulsion,AdverseReaction
Renal,O
and,O
urinary,O
disorders,O
Renal failure,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Urticaria,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reaction,O
has,O
been,O
identified,O
during,O
postapproval,O
use,O
of,O
Teflaro,O
Because,O
this,O
adverse,O
reaction,O
was,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
possible,O
to,O
estimate,O
its,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Blood,O
and,O
lymphatic,O
system,O
disorders,O
Agranulocytosis,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypersensitivity reactions,AdverseReaction
characterized,O
by,O
rash,AdverseReaction
constitutional,O
findings,O
and,O
sometimes,O
organ dysfunction,AdverseReaction
including,O
liver injury,AdverseReaction
have,O
been,O
reported,O
Discontinue,O
TIVICAY,O
and,O
other,O
suspect,O
agents,O
immediately,O
if,O
signs,O
or,O
symptoms,O
of,O
hypersensitivity,O
reactions,O
develop,O
as,O
a,O
delay,O
in,O
stopping,O
treatment,O
may,O
result,O
in,O
a,O
life,O
threatening,O
reaction,O
5,O
1,O
Patients,O
with,O
underlying,O
hepatitis,O
B,O
or,O
C,O
may,O
be,O
at,O
increased,O
risk,Factor
for,O
worsening,O
or,O
development,O
of,O
transaminase elevations,AdverseReaction
with,O
use,O
of,O
TIVICAY,O
Appropriate,O
laboratory,O
testing,O
prior,O
to,O
initiating,O
therapy,O
and,O
monitoring,O
for,O
hepatotoxicity,O
during,O
therapy,O
with,O
TIVICAY,O
is,O
recommended,O
in,O
patients,O
with,O
underlying,O
hepatic,O
disease,O
such,O
as,O
hepatitis,O
B,O
or,O
C,O
5,O
2,O
Redistribution,AdverseReaction
accumulation of body fat body fat,AdverseReaction
and,O
immune reconstitution syndrome,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
combination antiretroviral therapy,DrugClass
5,O
3,O
5,O
4,O
5,O
1,O
Hypersensitivity,O
Reactions,O
Hypersensitivity,AdverseReaction
reactions,O
have,O
been,O
reported,O
and,O
were,O
characterized,O
by,O
rash,AdverseReaction
constitutional,O
findings,O
and,O
sometimes,O
organ dysfunction,AdverseReaction
including,O
liver injury,AdverseReaction
The,O
events,O
were,O
reported,O
in,O
less,O
than,O
1,O
of,O
subjects,O
receiving,O
TIVICAY,O
in,O
Phase,O
3,O
clinical,O
trials,O
Discontinue,O
TIVICAY,O
and,O
other,O
suspect,O
agents,O
immediately,O
if,O
signs,O
or,O
symptoms,O
of,O
hypersensitivity,O
reactions,O
develop,O
including,O
but,O
not,O
limited,O
to,O
severe,O
rash,O
or,O
rash,O
accompanied,O
by,O
fever,O
general,O
malaise,O
fatigue,O
muscle,O
or,O
joint,O
aches,O
blisters,O
or,O
peeling,O
of,O
the,O
skin,O
oral,O
blisters,O
or,O
lesions,O
conjunctivitis,O
facial,O
edema,O
hepatitis,O
eosinophilia,O
angioedema,O
difficulty,O
breathing,O
Clinical,O
status,O
including,O
liver,O
aminotransferases,O
should,O
be,O
monitored,O
and,O
appropriate,O
therapy,O
initiated,O
Delay,O
in,O
stopping,O
treatment,O
with,O
TIVICAY,O
or,O
other,O
suspect,O
agents,O
after,O
the,O
onset,O
of,O
hypersensitivity,O
may,O
result,O
in,O
a,O
life,O
threatening,O
reaction,O
TIVICAY,O
is,O
contraindicated,O
in,O
patients,O
who,O
have,O
experienced,O
a,O
previous,O
hypersensitivity,O
reaction,O
to,O
dolutegravir,O
5,O
2,O
Effects,O
on,O
Serum,O
Liver,O
Biochemistries,O
in,O
Patients,O
with,O
Hepatitis,O
B,O
or,O
C,O
Co,O
infection,O
Patients,O
with,O
underlying,O
hepatitis,O
B,O
or,O
C,O
may,O
be,O
at,O
increased,O
risk,Factor
for,O
worsening,O
or,O
development,O
of,O
transaminase elevations,AdverseReaction
with,O
use,O
of,O
TIVICAY,O
see,O
Adverse,O
Reactions,O
6,O
1,O
In,O
some,O
cases,O
the,O
elevations in transaminases,AdverseReaction
were,O
consistent,O
with,O
immune reconstitution syndrome,AdverseReaction
or,O
hepatitis B reactivation,AdverseReaction
particularly,O
in,O
the,O
setting,O
where,O
anti,O
hepatitis,O
therapy,O
was,O
withdrawn,O
Appropriate,O
laboratory,O
testing,O
prior,O
to,O
initiating,O
therapy,O
and,O
monitoring,O
for,O
hepatotoxicity,O
during,O
therapy,O
with,O
TIVICAY,O
are,O
recommended,O
in,O
patients,O
with,O
underlying,O
hepatic,O
disease,O
such,O
as,O
hepatitis,O
B,O
or,O
C,O
5,O
3,O
Fat,O
Redistribution,O
Redistribution,AdverseReaction
accumulation of body fat body fat,AdverseReaction
body fat,AdverseReaction
including,O
central obesity,AdverseReaction
dorsocervical fat enlargement,AdverseReaction
buffalo hump,AdverseReaction
peripheral wasting,AdverseReaction
facial wasting,AdverseReaction
breast enlargement,AdverseReaction
and,O
cushingoid appearance,AdverseReaction
have,O
been,O
observed,O
in,O
patients,O
receiving,O
antiretroviral therapy,DrugClass
The,O
mechanism,O
and,O
long,O
term,O
consequences,O
of,O
these,O
events,O
are,O
currently,O
unknown,O
A,O
causal,O
relationship,O
has,O
not,O
been,O
established,O
5,O
4,O
Immune,O
Reconstitution,O
Syndrome,O
Immune reconstitution syndrome,AdverseReaction
has,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
combination,O
antiretroviral,O
therapy,O
including,O
TIVICAY,O
During,O
the,O
initial,O
phase,O
of,O
combination,O
antiretroviral,O
treatment,O
patients,O
whose,O
immune,O
systems,O
respond,O
may,Factor
develop,O
an,O
inflammatory response,AdverseReaction
to,O
indolent,O
or,O
residual opportunistic infections,AdverseReaction
such,O
as,O
Mycobacterium avium infection,AdverseReaction
cytomegalovirus,AdverseReaction
Pneumocystis jirovecii pneumonia,AdverseReaction
PCP,AdverseReaction
or,O
tuberculosis,AdverseReaction
which,O
may,O
necessitate,O
further,O
evaluation,O
and,O
treatment,O
Autoimmune disorders,AdverseReaction
such,O
as,O
Graves disease,AdverseReaction
polymyositis,AdverseReaction
and,O
Guillain Barre syndrome,AdverseReaction
have,O
also,O
been,O
reported,O
to,O
occur,O
in,O
the,O
setting,O
of,O
immune,O
reconstitution,O
however,O
the,O
time,O
to,O
onset,O
is,O
more,O
variable,O
and,O
can,O
occur,O
many,O
months,O
after,O
initiation,O
of,O
treatment,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
drug,O
reactions,O
adverse,O
events,O
assessed,O
as,O
causally,O
related,O
by,O
the,O
investigator,O
or,O
ADRs,O
are,O
discussed,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Hypersensitivity,AdverseReaction
reactions,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Effects,O
on,O
serum,O
liver,O
biochemistries,O
in,O
patients,O
with,O
hepatitis,O
B,O
or,O
C,O
co,O
infection,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Fat Redistribution,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Immune Reconstitution Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
of,O
moderate,Severity
to,O
severe,Severity
intensity,O
and,O
incidence,O
at,O
least,O
2,O
in,O
those,O
receiving,O
TIVICAY,O
in,O
any,O
one,O
adult,O
trial,O
are,O
insomnia,AdverseReaction
fatigue,AdverseReaction
and,O
headache,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
ViiV,O
Healthcare,O
at,O
1,O
877,O
844,O
8872,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
in,O
Adult,O
Subjects,O
Treatment,O
emergent,O
Adverse,O
Drug,O
Reactions,O
ADRs,O
Treatment,O
naive,O
Subjects,O
The,O
safety,O
assessment,O
of,O
TIVICAY,O
in,O
HIV,O
1,O
infected,O
treatment,O
naive,O
subjects,O
is,O
based,O
on,O
the,O
analyses,O
of,O
96,O
week,O
data,O
from,O
2,O
international,O
multicenter,O
double,O
blind,O
trials,O
SPRING,O
2,O
ING113086,O
and,O
SINGLE,O
ING114467,O
and,O
48,O
week,O
data,O
from,O
the,O
international,O
multicenter,O
open,O
label,O
FLAMINGO,O
ING114915,O
trial,O
In,O
SPRING,O
2,O
822,O
subjects,O
were,O
randomized,O
and,O
received,O
at,O
least,O
1,O
dose,O
of,O
either,O
TIVICAY,O
50,O
mg,O
once,O
daily,O
or,O
raltegravir,O
400,O
mg,O
twice,O
daily,O
both,O
in,O
combination,O
with,O
fixed,O
dose,O
dual,O
nucleoside,O
reverse,O
transcriptase,O
inhibitor,O
NRTI,O
treatment,O
either,O
abacavir,O
sulfate,O
and,O
lamivudine,O
EPZICOM,O
r,O
or,O
emtricitabine,O
tenofovir,O
TRUVADA,O
r,O
There,O
were,O
808,O
subjects,O
included,O
in,O
the,O
efficacy,O
and,O
safety,O
analyses,O
Through,O
96,O
weeks,O
the,O
rate,O
of,O
adverse,O
events,O
leading,O
to,O
discontinuation,O
was,O
2,O
in,O
both,O
treatment,O
arms,O
In,O
SINGLE,O
833,O
subjects,O
were,O
randomized,O
and,O
received,O
at,O
least,O
1,O
dose,O
of,O
either,O
TIVICAY,O
50,O
mg,O
with,O
fixed,O
dose,O
abacavir,O
sulfate,O
and,O
lamivudine,O
EPZICOM,O
once,O
daily,O
or,O
fixed,O
dose,O
efavirenz,O
emtricitabine,O
tenofovir,O
ATRIPLA,O
r,O
once,O
daily,O
Through,O
96,O
weeks,O
the,O
rates,O
of,O
adverse,O
events,O
leading,O
to,O
discontinuation,O
were,O
3,O
in,O
subjects,O
receiving,O
TIVICAY,O
50,O
mg,O
once,O
daily,O
EPZICOM,O
and,O
12,O
in,O
subjects,O
receiving,O
ATRIPLA,O
once,O
daily,O
Treatment,O
emergent,O
ADRs,O
of,O
moderate,O
to,O
severe,O
intensity,O
observed,O
in,O
at,O
least,O
2,O
of,O
subjects,O
in,O
either,O
treatment,O
arm,O
in,O
SPRING,O
2,O
and,O
SINGLE,O
trials,O
are,O
provided,O
in,O
Table,O
2,O
Side,O
by,O
side,O
tabulation,O
is,O
to,O
simplify,O
presentation,O
direct,O
comparisons,O
across,O
trials,O
should,O
not,O
be,O
made,O
due,O
to,O
differing,O
trial,O
designs,O
Table,O
2,O
Treatment,O
emergent,O
Adverse,O
Drug,O
Reactions,O
of,O
at,O
Least,O
Moderate,O
Intensity,O
Grades,O
2,O
to,O
4,O
and,O
at,O
Least,O
2,O
Frequency,O
in,O
Treatment,O
naive,O
Subjects,O
in,O
SPRING,O
2,O
and,O
SINGLE,O
Trials,O
Week,O
96,O
Analysis,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
SPRING,O
2,O
SINGLE,O
TIVICAY,O
50,O
mg,O
Once,O
Daily,O
2,O
NRTIs,O
n,O
403,O
Raltegravir,O
400,O
mg,O
Twice,O
Daily,O
2,O
NRTIs,O
n,O
405,O
TIVICAY,O
50,O
mg,O
EPZICOM,O
Once,O
Daily,O
n,O
414,O
ATRIPLA,O
Once,O
Daily,O
n,O
419,O
Psychiatric,O
Insomnia,AdverseReaction
1,O
1,O
3,O
2,O
Depression,AdverseReaction
1,O
1,O
1,O
2,O
Abnormal dreams,AdverseReaction
1,O
1,O
1,O
2,O
Nervous,O
System,O
Dizziness,AdverseReaction
1,O
1,O
1,O
5,O
Headache,AdverseReaction
1,O
1,O
2,O
2,O
Gastrointestinal,O
Nausea,AdverseReaction
1,O
1,O
1,O
3,O
Diarrhea,AdverseReaction
1,O
1,O
1,O
2,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Rasha,O
0,O
1,O
1,O
6,O
General,O
Disorders,O
Fatigue,AdverseReaction
1,O
1,O
2,O
2,O
Ear,O
and,O
Labyrinth,O
Vertigo,AdverseReaction
0,O
1,O
0,O
2,O
a,O
Includes,O
pooled,O
terms,O
rash,AdverseReaction
rash generalized,AdverseReaction
rash macular,AdverseReaction
rash maculo papular,AdverseReaction
rash pruritic,AdverseReaction
and,O
drug eruption,AdverseReaction
In,O
addition,O
Grade 1,Severity
insomnia,AdverseReaction
was,O
reported,O
by,O
1,O
and,O
less,O
than,O
1,O
of,O
subjects,O
receiving,O
TIVICAY,O
and,O
raltegravir,O
respectively,O
in,O
SPRING,O
2,O
whereas,O
in,O
SINGLE,O
the,O
rates,O
were,O
7,O
and,O
4,O
for,O
TIVICAY,O
and,O
ATRIPLA,O
respectively,O
These,O
events,O
were,O
not,O
treatment,O
limiting,O
In,O
a,O
multicenter,O
open,O
label,O
trial,O
FLAMINGO,O
243,O
subjects,O
received,O
TIVICAY,O
50,O
mg,O
once,O
daily,O
versus,O
242,O
subjects,O
who,O
received,O
darunavir,O
800,O
mg,O
ritonavir,O
100,O
mg,O
once,O
daily,O
both,O
in,O
combination,O
with,O
investigator,O
selected,O
NRTI,O
background,O
regimen,O
either,O
EPZICOM,O
or,O
TRUVADA,O
There,O
were,O
484,O
subjects,O
included,O
in,O
the,O
efficacy,O
and,O
safety,O
analyses,O
Through,O
48,O
weeks,O
the,O
rates,O
of,O
adverse,O
events,O
leading,O
to,O
discontinuation,O
were,O
2,O
in,O
subjects,O
receiving,O
TIVICAY,O
and,O
4,O
in,O
subjects,O
receiving,O
darunavir,O
ritonavir,O
The,O
ADRs,O
observed,O
in,O
FLAMINGO,O
were,O
generally,O
consistent,O
with,O
those,O
seen,O
in,O
SPRING,O
2,O
and,O
SINGLE,O
Treatment,O
experienced,O
Integrase,O
Strand,O
Transfer,O
Inhibitor,O
naive,O
Subjects,O
In,O
an,O
international,O
multicenter,O
double,O
blind,O
trial,O
ING111762,O
SAILING,O
719,O
HIV,O
1,O
infected,O
antiretroviral,O
treatment,O
experienced,O
adults,O
were,O
randomized,O
and,O
received,O
either,O
TIVICAY,O
50,O
mg,O
once,O
daily,O
or,O
raltegravir,O
400,O
mg,O
twice,O
daily,O
with,O
investigator,O
selected,O
background,O
regimen,O
consisting,O
of,O
up,O
to,O
2,O
agents,O
including,O
at,O
least,O
one,O
fully,O
active,O
agent,O
At,O
48,O
weeks,O
the,O
rates,O
of,O
adverse,O
events,O
leading,O
to,O
discontinuation,O
were,O
3,O
in,O
subjects,O
receiving,O
TIVICAY,O
50,O
mg,O
once,O
daily,O
background,O
regimen,O
and,O
4,O
in,O
subjects,O
receiving,O
raltegravir,O
400,O
mg,O
twice,O
daily,O
background,O
regimen,O
The,O
only,O
treatment,O
emergent,O
ADR,O
of,O
moderate,Severity
to,O
severe,Severity
intensity,O
with,O
at,O
least,O
2,O
frequency,O
in,O
either,O
treatment,O
group,O
was,O
diarrhea,AdverseReaction
2,O
6,O
of,O
354,O
in,O
subjects,O
receiving,O
TIVICAY,O
50,O
mg,O
once,O
daily,O
background,O
regimen,O
and,O
1,O
5,O
of,O
361,O
in,O
subjects,O
receiving,O
raltegravir,O
400,O
mg,O
twice,O
daily,O
background,O
regimen,O
Treatment,O
experienced,O
Integrase,O
Strand,O
Transfer,O
Inhibitor,O
experienced,O
Subjects,O
In,O
a,O
multicenter,O
open,O
label,O
single,O
arm,O
trial,O
ING112574,O
VIKING,O
3,O
183,O
HIV,O
1,O
infected,O
antiretroviral,O
treatment,O
experienced,O
adults,O
with,O
virological,O
failure,O
and,O
current,O
or,O
historical,O
evidence,O
of,O
raltegravir,O
and,O
or,O
elvitegravir,O
resistance,O
received,O
TIVICAY,O
50,O
mg,O
twice,O
daily,O
with,O
the,O
current,O
failing,O
background,O
regimen,O
for,O
7,O
days,O
and,O
with,O
optimized,O
background,O
therapy,O
from,O
Day,O
8,O
The,O
rate,O
of,O
adverse,O
events,O
leading,O
to,O
discontinuation,O
was,O
4,O
of,O
subjects,O
at,O
Week,O
48,O
Treatment,O
emergent,O
ADRs,O
in,O
VIKING,O
3,O
were,O
generally,O
similar,O
compared,O
with,O
observations,O
with,O
the,O
50,O
mg,O
once,O
daily,O
dose,O
in,O
adult,O
Phase,O
3,O
trials,O
Less,O
Common,O
Adverse,O
Reactions,O
Observed,O
in,O
Treatment,O
naive,O
and,O
Treatment,O
experienced,O
Trials,O
The,O
following,O
ADRs,O
occurred,O
in,O
less,O
than,O
2,O
of,O
treatment,O
naive,O
or,O
treatment,O
experienced,O
subjects,O
receiving,O
TIVICAY,O
in,O
a,O
combination,O
regimen,O
in,O
any,O
one,O
trial,O
These,O
events,O
have,O
been,O
included,O
because,O
of,O
their,O
seriousness,O
and,O
assessment,O
of,O
potential,O
causal,O
relationship,O
Gastrointestinal,O
Disorders,O
Abdominal pain,AdverseReaction
abdominal discomfort,AdverseReaction
flatulence,AdverseReaction
upper abdominal pain,AdverseReaction
vomiting,AdverseReaction
Hepatobiliary,O
Disorders,O
Hepatitis,AdverseReaction
Musculoskeletal,O
Disorders,O
Myositis,AdverseReaction
Psychiatric,O
Disorders,O
Suicidal ideation,AdverseReaction
attempt,AdverseReaction
behavior,AdverseReaction
or,O
completion,AdverseReaction
These,O
events,O
were,O
observed,O
primarily,O
in,O
subjects,O
with,O
a,O
pre,O
existing,O
history,O
of,O
depression,O
or,O
other,O
psychiatric,O
illness,O
Renal,O
and,O
Urinary,O
Disorders,O
Renal impairment,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Pruritus,AdverseReaction
Laboratory,O
Abnormalities,O
Treatment,O
naive,O
Subjects,O
Selected,O
laboratory,O
abnormalities,O
Grades,O
2,O
to,O
4,O
with,O
a,O
worsening,O
grade,O
from,O
baseline,O
and,O
representing,O
the,O
worst,O
grade,O
toxicity,O
in,O
at,O
least,O
2,O
of,O
subjects,O
are,O
presented,O
in,O
Table,O
3,O
The,O
mean,O
change,O
from,O
baseline,O
observed,O
for,O
selected,O
lipid,O
values,O
is,O
presented,O
in,O
Table,O
4,O
Side,O
by,O
side,O
tabulation,O
is,O
to,O
simplify,O
presentation,O
direct,O
comparisons,O
across,O
trials,O
should,O
not,O
be,O
made,O
due,O
to,O
differing,O
trial,O
designs,O
Table,O
3,O
Selected,O
Laboratory,O
Abnormalities,O
Grades,O
2,O
to,O
4,O
in,O
Treatment,O
naive,O
Subjects,O
in,O
SPRING,O
2,O
and,O
SINGLE,O
Trials,O
Week,O
96,O
Analysis,O
Laboratory,O
Parameter,O
Preferred,O
Term,O
SPRING,O
2,O
SINGLE,O
TIVICAY,O
50,O
mg,O
Once,O
Daily,O
2,O
NRTIs,O
n,O
403,O
Raltegravir,O
400,O
mg,O
Twice,O
Daily,O
2,O
NRTIs,O
n,O
405,O
TIVICAY,O
50,O
mg,O
EPZICOM,O
Once,O
Daily,O
n,O
414,O
ATRIPLA,O
Once,O
Daily,O
n,O
419,O
ALT,O
4,O
4,O
2,O
5,O
2,O
2,O
1,O
1,O
AST,O
5,O
3,O
3,O
3,O
3,O
2,O
1,O
3,O
3,O
2,O
1,O
0,O
1,O
1,O
1,O
0,O
Creatine,O
kinase,O
2,O
5,O
4,O
1,O
7,O
4,O
5,O
7,O
Hyperglycemia,AdverseReaction
6,O
6,O
7,O
5,O
1,O
2,O
2,O
1,O
Lipase,O
7,O
7,O
9,O
9,O
2,O
5,O
4,O
3,O
Total,O
neutrophils,O
4,O
3,O
3,O
5,O
2,O
2,O
2,O
3,O
ULN,O
Upper,O
limit,O
of,O
normal,O
Table,O
4,O
Mean,O
Change,O
from,O
Baseline,O
in,O
Fasted,O
Lipid,O
Values,O
in,O
Treatment,O
naive,O
Subjects,O
in,O
SPRING,O
2,O
and,O
SINGLE,O
Trials,O
Week,O
96,O
Analysisa,O
Laboratory,O
Parameter,O
Preferred,O
Term,O
SPRING,O
2,O
SINGLE,O
TIVICAY,O
50,O
mg,O
Once,O
Daily,O
2,O
NRTIs,O
n,O
403,O
Raltegravir,O
400,O
mg,O
Twice,O
Daily,O
2,O
NRTIs,O
n,O
405,O
TIVICAY,O
50,O
mg,O
EPZICOM,O
Once,O
Daily,O
n,O
414,O
ATRIPLA,O
Once,O
Daily,O
n,O
419,O
Cholesterol,O
mg,O
dL,O
8,O
1,O
10,O
1,O
23,O
2,O
28,O
0,O
HDL,O
cholesterol,O
mg,O
dL,O
2,O
0,O
2,O
3,O
5,O
2,O
7,O
4,O
LDL,O
cholesterol,O
mg,O
dL,O
5,O
1,O
6,O
1,O
14,O
5,O
18,O
0,O
Triglycerides,O
mg,O
dL,O
6,O
7,O
6,O
6,O
17,O
2,O
17,O
4,O
a,O
Subjects,O
on,O
lipid,O
lowering,O
agents,O
at,O
baseline,O
were,O
excluded,O
from,O
these,O
analyses,O
19,O
subjects,O
in,O
each,O
arm,O
in,O
SPRING,O
2,O
and,O
in,O
SINGLE,O
TIVICAY,O
n,O
30,O
and,O
ATRIPLA,O
n,O
27,O
Seventy,O
seven,O
subjects,O
initiated,O
a,O
lipid,O
lowering,O
agent,O
post,O
baseline,O
their,O
last,O
fasted,O
on,O
treatment,O
values,O
prior,O
to,O
starting,O
the,O
agent,O
were,O
used,O
regardless,O
if,O
they,O
discontinued,O
the,O
agent,O
SPRING,O
2,O
TIVICAY,O
n,O
9,O
raltegravir,O
n,O
13,O
SINGLE,O
TIVICAY,O
n,O
25,O
and,O
ATRIPLA,O
n,O
30,O
Laboratory,O
abnormalities,O
observed,O
in,O
the,O
FLAMINGO,O
trial,O
were,O
generally,O
consistent,O
with,O
observations,O
in,O
SPRING,O
2,O
and,O
SINGLE,O
Treatment,O
experienced,O
Integrase,O
Strand,O
Transfer,O
Inhibitor,O
naive,O
Subjects,O
Laboratory,O
abnormalities,O
observed,O
in,O
SAILING,O
were,O
generally,O
similar,O
compared,O
with,O
observations,O
seen,O
in,O
the,O
treatment,O
naive,O
SPRING,O
2,O
and,O
SINGLE,O
trials,O
Treatment,O
experienced,O
Integrase,O
Strand,O
Transfer,O
Inhibitor,O
experienced,O
Subjects,O
The,O
most,O
common,O
treatment,O
emergent,O
laboratory,O
abnormalities,O
greater,O
than,O
5,O
for,O
Grades,O
2,O
to,O
4,O
combined,O
observed,O
in,O
VIKING,O
3,O
at,O
Week,O
48,O
were,O
elevated ALT,AdverseReaction
9,O
AST,O
8,O
cholesterol,AdverseReaction
10,O
creatine kinase,AdverseReaction
6,O
hyperglycemia,AdverseReaction
14,O
and,O
lipase,AdverseReaction
10,O
Two,O
percent,O
4,O
of,O
183,O
of,O
subjects,O
had,O
a,O
Grade,O
3,O
to,O
4,O
treatment,O
emergent,O
hematology,O
laboratory,O
abnormality,O
with,O
neutropenia,AdverseReaction
2,O
3,O
of,O
183,O
being,O
the,O
most,O
frequently,O
reported,O
Hepatitis,O
B,O
and,O
or,O
Hepatitis,O
C,O
Virus,O
Co,O
infection,O
In,O
Phase,O
3,O
trials,O
subjects,O
with,O
hepatitis,O
B,O
and,O
or,O
C,O
virus,O
co,O
infection,O
were,O
permitted,O
to,O
enroll,O
provided,O
that,O
baseline,O
liver,O
chemistry,O
tests,O
did,O
not,O
exceed,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
Overall,O
the,O
safety,O
profile,O
in,O
subjects,O
with,O
hepatitis,O
B,O
and,O
or,O
C,O
virus,O
co,O
infection,O
was,O
similar,O
to,O
that,O
observed,O
in,O
subjects,O
without,O
hepatitis,O
B,O
or,O
C,O
co,O
infection,O
although,O
the,O
rates,O
of,O
AST,AdverseReaction
and,O
ALT abnormalities,AdverseReaction
were,O
higher,O
in,O
the,O
subgroup,O
with,O
hepatitis,O
B,O
and,O
or,O
C,O
virus,O
co,O
infection,O
for,O
all,O
treatment,O
groups,O
Grades 2 to 4,Severity
ALT abnormalities,AdverseReaction
in,O
hepatitis,O
B,O
and,O
or,O
C,O
co,O
infected,O
compared,O
with,O
HIV,O
mono,O
infected,O
subjects,O
receiving,O
TIVICAY,O
were,O
observed,O
in,O
18,O
vs,O
3,O
with,O
the,O
50,O
mg,O
once,O
daily,O
dose,O
and,O
13,O
vs,O
8,O
with,O
the,O
50,O
mg,O
twice,O
daily,O
dose,O
Liver chemistry elevations,AdverseReaction
consistent,O
with,O
immune reconstitution syndrome,AdverseReaction
were,O
observed,O
in,O
some,O
subjects,O
with,O
hepatitis,O
B,O
and,O
or,O
C,O
at,O
the,O
start,O
of,O
therapy,O
with,O
TIVICAY,O
particularly,O
in,O
the,O
setting,O
where,O
anti,O
hepatitis,O
therapy,O
was,O
withdrawn,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Changes,O
in,O
Serum,O
Creatinine,O
Dolutegravir,O
has,O
been,O
shown,O
to,O
increase serum creatinine,AdverseReaction
due,O
to,O
inhibition,O
of,O
tubular,O
secretion,O
of,O
creatinine,O
without,O
affecting,O
renal,O
glomerular,O
function,O
see,O
Clinical,O
Pharmacology,O
12,O
2,O
Increases in serum creatinine,AdverseReaction
occurred,O
within,O
the,O
first,O
4,O
weeks,O
of,O
treatment,O
and,O
remained,O
stable,O
through,O
48,O
to,O
96,O
weeks,O
In,O
treatment,O
naive,O
subjects,O
a,O
mean,O
change,O
from,O
baseline,O
of,O
0,O
15,O
mg,O
per,O
dL,O
range,O
0,O
32,O
mg,O
per,O
dL,O
to,O
0,O
65,O
mg,O
per,O
dL,O
was,O
observed,O
after,O
96,O
weeks,O
of,O
treatment,O
Creatinine increases,AdverseReaction
were,O
comparable,O
by,O
background,O
NRTIs,O
and,O
were,O
similar,O
in,O
treatment,O
experienced,O
subjects,O
6,O
2,O
Clinical,O
Trials,O
Experience,O
in,O
Pediatric,O
Subjects,O
IMPAACT,O
P1093,O
is,O
an,O
ongoing,O
multicenter,O
open,O
label,O
non,O
comparative,O
trial,O
of,O
approximately,O
160,O
HIV,O
1,O
infected,O
pediatric,O
subjects,O
aged,O
6,O
weeks,O
to,O
less,O
than,O
18,O
years,O
of,O
which,O
23,O
treatment,O
experienced,O
INSTI,O
naive,O
subjects,O
aged,O
12,O
to,O
less,O
than,O
18,O
years,O
were,O
enrolled,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
4,O
Clinical,O
Studies,O
14,O
2,O
The,O
adverse,O
reaction,O
profile,O
was,O
similar,O
to,O
that,O
for,O
adults,O
Grade 2,Severity
ADRs,O
reported,O
in,O
at,O
least,O
1,O
subject,O
were,O
rash,AdverseReaction
n,O
1,O
abdominal pain,AdverseReaction
n,O
1,O
and,O
diarrhea,AdverseReaction
n,O
1,O
No,O
Grade,O
3,O
or,O
4,O
ADRs,O
were,O
reported,O
The,O
Grade 3,Severity
laboratory,O
abnormalities,O
were,O
elevated total bilirubin total,AdverseReaction
and,O
lipase,AdverseReaction
reported,O
in,O
1,O
subject,O
each,O
No,O
Grade,O
4,O
laboratory,O
abnormalities,O
were,O
reported,O
The,O
changes,O
in,O
mean,O
serum,O
creatinine,O
were,O
similar,O
to,O
those,O
observed,O
in,O
adults,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Angioedema of the face of the of the of the,AdverseReaction
lips,AdverseReaction
tongue,AdverseReaction
and,O
or,O
larynx,AdverseReaction
has,O
been,O
reported,O
with,O
fesoterodine,O
5,O
1,O
Toviaz,O
should,O
be,O
administered,O
with,O
caution,O
to,O
patients,O
with,O
clinically,O
significant,O
bladder,O
outlet,O
obstruction,O
because,O
of,O
the,O
risk,O
of,O
urinary,O
retention,O
5,O
2,O
Toviaz,O
like,O
other,O
antimuscarinic,O
drugs,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
decreased,O
gastrointestinal,O
motility,O
such,O
as,O
those,O
with,O
severe,O
constipation,O
5,O
3,O
Toviaz,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
being,O
treated,O
for,O
narrow,O
angle,O
glaucoma,O
and,O
only,O
where,O
the,O
potential,O
benefits,O
outweigh,O
the,O
risks,O
5,O
4,O
Central Nervous System Effects,AdverseReaction
Somnolence,AdverseReaction
has,O
been,O
reported,O
with,O
Toviaz,O
Advise,O
patients,O
not,O
to,O
drive,O
or,O
operate,O
heavy,O
machinery,O
until,O
they,O
know,O
how,O
Toviaz,O
affects,O
them,O
5,O
5,O
Toviaz,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
myasthenia,O
gravis,O
a,O
disease,O
characterized,O
by,O
decreased,O
cholinergic,O
activity,O
at,O
the,O
neuromuscular,O
junction,O
5,O
9,O
5,O
1,O
Angioedema,O
Angioedema of the face of the of the of the,AdverseReaction
lips,AdverseReaction
tongue,AdverseReaction
and,O
or,O
larynx,AdverseReaction
has,O
been,O
reported,O
with,O
fesoterodine,O
In,O
some,O
cases,O
angioedema,O
occurred,O
after,O
the,O
first,O
dose,O
Angioedema,AdverseReaction
associated,O
with,O
upper airway swelling,AdverseReaction
may,Factor
be,O
life threatening,Severity
If,O
involvement,O
of,O
the,O
tongue,O
hypopharynx,O
or,O
larynx,O
occurs,O
fesoterodine,O
should,O
be,O
promptly,O
discontinued,O
and,O
appropriate,O
therapy,O
and,O
or,O
measures,O
to,O
ensure,O
a,O
patent,O
airway,O
should,O
be,O
promptly,O
provided,O
5,O
2,O
Bladder,O
Outlet,O
Obstruction,O
Toviaz,O
should,O
be,O
administered,O
with,O
caution,O
to,O
patients,O
with,O
clinically,O
significant,O
bladder,O
outlet,O
obstruction,O
because,O
of,O
the,O
risk,O
of,O
urinary,O
retention,O
see,O
Contraindications,O
4,O
5,O
3,O
Decreased,O
Gastrointestinal,O
Motility,O
Toviaz,O
like,O
other,O
antimuscarinic,O
drugs,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
decreased,O
gastrointestinal,O
motility,O
such,O
as,O
those,O
with,O
severe,O
constipation,O
5,O
4,O
Controlled,O
Narrow,O
Angle,O
Glaucoma,O
Toviaz,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
being,O
treated,O
for,O
narrow,O
angle,O
glaucoma,O
and,O
only,O
where,O
the,O
potential,O
benefits,O
outweigh,O
the,O
risks,O
see,O
Contraindications,O
4,O
5,O
5,O
Central,O
Nervous,O
System,O
Effects,O
Toviaz,O
is,O
associated,O
with,O
anticholinergic central nervous sytem,AdverseReaction
CNS,AdverseReaction
effects,AdverseReaction
see,O
Adverse,O
Reactions,O
6,O
2,O
A,O
variety,O
of,O
CNS anticholinergic effects,AdverseReaction
have,O
been,O
reported,O
including,O
headache,AdverseReaction
dizziness,AdverseReaction
and,O
somnolence,AdverseReaction
Patients,O
should,O
be,O
monitored,O
for,O
signs,O
of,O
anticholinergic,O
CNS,O
effects,O
particularly,O
after,O
beginning,O
treatment,O
or,O
increasing,O
the,O
dose,O
Advise,O
patients,O
not,O
to,O
drive,O
or,O
operate,O
heavy,O
machinery,O
until,O
they,O
know,O
how,O
Toviaz,O
affects,O
them,O
If,O
a,O
patient,O
experiences,O
anticholinergic,O
CNS,O
effects,O
dose,O
reduction,O
or,O
drug,O
discontinuation,O
should,O
be,O
considered,O
5,O
6,O
Hepatic,O
Impairment,O
Toviaz,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
severe,O
hepatic,O
impairment,O
and,O
therefore,O
is,O
not,O
recommended,O
for,O
use,O
in,O
this,O
patient,O
population,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
7,O
and,O
Dosage,O
and,O
Administration,O
2,O
5,O
7,O
Renal,O
Impairment,O
Doses,O
of,O
Toviaz,O
greater,O
than,O
4,O
mg,O
are,O
not,O
recommended,O
in,O
patients,O
with,O
severe,O
renal,O
impairment,O
see,O
Use,O
In,O
Specific,O
Populations,O
8,O
6,O
and,O
Dosage,O
and,O
Administration,O
2,O
5,O
8,O
Concomitant,O
Administration,O
with,O
CYP3A4,O
Inhibitors,O
Doses,O
of,O
Toviaz,O
greater,O
than,O
4,O
mg,O
are,O
not,O
recommended,O
in,O
patients,O
taking,O
a,O
potent,O
CYP3A4,O
inhibitor,O
e,O
g,O
ketoconazole,O
itraconazole,O
clarithromycin,O
No,O
dosing,O
adjustments,O
are,O
recommended,O
in,O
the,O
presence,O
of,O
moderate,O
CYP3A4,O
inhibitors,O
e,O
g,O
erythromycin,O
fluconazole,O
diltiazem,O
verapamil,O
and,O
grapefruit,O
juice,O
While,O
the,O
effect,O
of,O
weak,O
CYP3A4,O
inhibitors,O
e,O
g,O
cimetidine,O
was,O
not,O
examined,O
by,O
clinical,O
study,O
some,O
pharmacokinetic,O
interaction,O
is,O
expected,O
albeit,O
less,O
than,O
that,O
observed,O
with,O
moderate,O
CYP3A4,O
inhibitors,O
see,O
Drug,O
Interactions,O
7,O
2,O
and,O
Dosage,O
and,O
Administration,O
2,O
5,O
9,O
Myasthenia,O
Gravis,O
Toviaz,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
myasthenia,O
gravis,O
a,O
disease,O
characterized,O
by,O
decreased,O
cholinergic,O
activity,O
at,O
the,O
neuromuscular,O
junction,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
The,O
most,O
frequently,O
reported,O
adverse,O
events,O
4,O
for,O
Toviaz,O
were,O
dry mouth,AdverseReaction
placebo,O
7,O
Toviaz,O
4,O
mg,O
19,O
Toviaz,O
8,O
mg,O
35,O
and,O
constipation,AdverseReaction
placebo,O
2,O
Toviaz,O
4,O
mg,O
4,O
Toviaz,O
8,O
mg,O
6,O
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Pfizer,O
Inc,O
at,O
1,O
800,O
438,O
1985,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
The,O
safety,O
of,O
Toviaz,O
was,O
evaluated,O
in,O
Phase,O
2,O
and,O
3,O
controlled,O
trials,O
in,O
a,O
total,O
of,O
2859,O
patients,O
with,O
overactive,O
bladder,O
of,O
which,O
2288,O
were,O
treated,O
with,O
fesoterodine,O
Of,O
this,O
total,O
782,O
received,O
Toviaz,O
4,O
mg,O
day,O
and,O
785,O
received,O
Toviaz,O
8,O
mg,O
day,O
in,O
Phase,O
2,O
or,O
3,O
studies,O
with,O
treatment,O
periods,O
of,O
8,O
or,O
12,O
weeks,O
Approximately,O
80,O
of,O
these,O
patients,O
had,O
10,O
weeks,O
exposure,O
to,O
Toviaz,O
in,O
these,O
trials,O
A,O
total,O
of,O
1964,O
patients,O
participated,O
in,O
two,O
12,O
week,O
Phase,O
3,O
efficacy,O
and,O
safety,O
studies,O
and,O
subsequent,O
open,O
label,O
extension,O
studies,O
In,O
these,O
two,O
studies,O
combined,O
554,O
patients,O
received,O
Toviaz,O
4,O
mg,O
day,O
and,O
566,O
patients,O
received,O
Toviaz,O
8,O
mg,O
day,O
In,O
Phase,O
2,O
and,O
3,O
placebo,O
controlled,O
trials,O
combined,O
the,O
incidences,O
of,O
serious,O
adverse,O
events,O
in,O
patients,O
receiving,O
placebo,O
Toviaz,O
4,O
mg,O
and,O
Toviaz,O
8,O
mg,O
were,O
1,O
9,O
3,O
5,O
and,O
2,O
9,O
respectively,O
All,O
serious,O
adverse,O
events,O
were,O
judged,O
to,O
be,O
not,O
related,O
or,O
unlikely,O
to,O
be,O
related,O
to,O
study,O
medication,O
by,O
the,O
investigator,O
except,O
for,O
four,O
patients,O
receiving,O
Toviaz,O
who,O
reported,O
one,O
serious,O
adverse,O
event,O
each,O
angina,AdverseReaction
chest pain,AdverseReaction
gastroenteritis,AdverseReaction
and,O
QT prolongation,AdverseReaction
on,O
ECG,O
The,O
most,O
commonly,O
reported,O
adverse,O
event,O
in,O
patients,O
treated,O
with,O
Toviaz,O
was,O
dry mouth,AdverseReaction
The,O
incidence,O
of,O
dry mouth,AdverseReaction
was,O
higher,O
in,O
those,O
taking,O
8,O
mg,O
day,O
35,O
and,O
in,O
those,O
taking,O
4,O
mg,O
day,O
19,O
as,O
compared,O
to,O
placebo,O
7,O
Dry mouth,AdverseReaction
led,O
to,O
discontinuation,O
in,O
0,O
4,O
0,O
4,O
and,O
0,O
8,O
of,O
patients,O
receiving,O
placebo,O
Toviaz,O
4,O
mg,O
and,O
Toviaz,O
8,O
mg,O
respectively,O
For,O
those,O
patients,O
who,O
reported,O
dry mouth,AdverseReaction
most,O
had,O
their,O
first,O
occurrence,O
of,O
the,O
event,O
within,O
the,O
first,O
month,O
of,O
treatment,O
The,O
second,O
most,O
commonly,O
reported,O
adverse,O
event,O
was,O
constipation,AdverseReaction
The,O
incidence,O
of,O
constipation,AdverseReaction
was,O
2,O
in,O
those,O
taking,O
placebo,O
4,O
in,O
those,O
taking,O
4,O
mg,O
day,O
and,O
6,O
in,O
those,O
taking,O
8,O
mg,O
day,O
Table,O
1,O
lists,O
adverse,O
events,O
regardless,O
of,O
causality,O
that,O
were,O
reported,O
in,O
the,O
combined,O
Phase,O
3,O
randomized,O
placebo,O
controlled,O
trials,O
at,O
an,O
incidence,O
greater,O
than,O
placebo,O
and,O
in,O
1,O
or,O
more,O
of,O
patients,O
treated,O
with,O
Toviaz,O
4,O
or,O
8,O
mg,O
once,O
daily,O
for,O
up,O
to,O
12,O
weeks,O
Table,O
1,O
Adverse,O
events,O
with,O
an,O
incidence,O
exceeding,O
the,O
placebo,O
rate,O
and,O
reported,O
by,O
1,O
of,O
patients,O
from,O
double,O
blind,O
placebo,O
controlled,O
Phase,O
3,O
trials,O
of,O
12,O
weeks,O
treatment,O
duration,O
System,O
organ,O
class,O
Preferred,O
term,O
Placebo,O
N,O
554,O
Toviaz,O
4,O
mg,O
day,O
N,O
554,O
Toviaz,O
8,O
mg,O
day,O
N,O
566,O
ALT,O
alanine,O
aminotransferase,O
GGT,O
gamma,O
glutamyltransferase,O
Gastrointestinal,O
disorders,O
Dry mouth,AdverseReaction
7,O
0,O
18,O
8,O
34,O
6,O
Constipation,AdverseReaction
2,O
0,O
4,O
2,O
6,O
0,O
Dyspepsia,AdverseReaction
0,O
5,O
1,O
6,O
2,O
3,O
Nausea,AdverseReaction
1,O
3,O
0,O
7,O
1,O
9,O
Abdominal pain upper,AdverseReaction
0,O
5,O
1,O
1,O
0,O
5,O
Infections,O
Urinary tract infection,AdverseReaction
3,O
1,O
3,O
2,O
4,O
2,O
Upper respiratory tract infection,AdverseReaction
2,O
2,O
2,O
5,O
1,O
8,O
Eye,O
disorders,O
Dry eyes,AdverseReaction
0,O
1,O
4,O
3,O
7,O
Renal,O
and,O
urinary,O
disorders,O
Dysuria,AdverseReaction
0,O
7,O
1,O
3,O
1,O
6,O
Urinary retention,AdverseReaction
0,O
2,O
1,O
1,O
1,O
4,O
Respiratory,O
disorders,O
Cough,AdverseReaction
0,O
5,O
1,O
6,O
0,O
9,O
Dry throat,AdverseReaction
0,O
4,O
0,O
9,O
2,O
3,O
General,O
disorders,O
Edema peripheral,AdverseReaction
0,O
7,O
0,O
7,O
1,O
2,O
Musculoskeletal,O
disorders,O
Back pain,AdverseReaction
0,O
4,O
2,O
0,O
0,O
9,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
0,O
5,O
1,O
3,O
0,O
4,O
Investigations,O
ALT increased,AdverseReaction
0,O
9,O
0,O
5,O
1,O
2,O
GGT increased,AdverseReaction
0,O
4,O
0,O
4,O
1,O
2,O
Skin,O
disorders,O
Rash,AdverseReaction
0,O
5,O
0,O
7,O
1,O
1,O
Patients,O
also,O
received,O
Toviaz,O
for,O
up,O
to,O
three,O
years,O
in,O
open,O
label,O
extension,O
phases,O
of,O
one,O
Phase,O
2,O
and,O
two,O
Phase,O
3,O
controlled,O
trials,O
In,O
all,O
open,O
label,O
trials,O
combined,O
857,O
701,O
529,O
and,O
105,O
patients,O
received,O
Toviaz,O
for,O
at,O
least,O
6,O
months,O
1,O
year,O
2,O
years,O
and,O
3,O
years,O
respectively,O
The,O
adverse,O
events,O
observed,O
during,O
long,O
term,O
open,O
label,O
studies,O
were,O
similar,O
to,O
those,O
observed,O
in,O
the,O
12,O
week,O
placebo,O
controlled,O
studies,O
and,O
included,O
dry mouth,AdverseReaction
constipation,AdverseReaction
dry eyes,AdverseReaction
dyspepsia,AdverseReaction
and,O
abdominal pain,AdverseReaction
Similar,O
to,O
the,O
controlled,O
studies,O
most,O
adverse,O
events,O
of,O
dry mouth,AdverseReaction
and,O
constipation,AdverseReaction
were,O
mild to moderate,Severity
moderate,Severity
in,O
intensity,O
Serious,O
adverse,O
events,O
judged,O
to,O
be,O
at,O
least,O
possibly,O
related,O
to,O
study,O
medication,O
by,O
the,O
investigator,O
and,O
reported,O
more,O
than,O
once,O
during,O
the,O
open,O
label,O
treatment,O
period,O
of,O
up,O
to,O
3,O
years,O
included,O
urinary retention,AdverseReaction
3,O
cases,O
diverticulitis,AdverseReaction
3,O
cases,O
constipation,AdverseReaction
2,O
cases,O
irritable bowel syndrome,AdverseReaction
2,O
cases,O
and,O
electrocardiogram,O
QT corrected interval prolongation,AdverseReaction
2,O
cases,O
6,O
2,O
Post,O
marketing,O
Experience,O
The,O
following,O
events,O
have,O
been,O
reported,O
in,O
association,O
with,O
fesoterodine,O
use,O
in,O
worldwide,O
post,O
marketing,O
experience,O
Eye,O
disorders,O
Blurred vision,AdverseReaction
Cardiac,O
disorders,O
Palpitations,AdverseReaction
General,O
disorders,O
and,O
administrative,O
site,O
conditions,O
Hypersensitivity reactions,AdverseReaction
including,O
angioedema,AdverseReaction
with,O
airway obstruction,AdverseReaction
face edema,AdverseReaction
Central,O
nervous,O
system,O
disorders,O
Dizziness,AdverseReaction
headache,AdverseReaction
somnolence,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Urticaria,AdverseReaction
pruritus,AdverseReaction
Because,O
these,O
spontaneously,O
reported,O
events,O
are,O
from,O
the,O
worldwide,O
post,O
marketing,O
experience,O
the,O
frequency,O
of,O
events,O
and,O
the,O
role,O
of,O
fesoterodine,O
in,O
their,O
causation,O
cannot,O
be,O
reliably,O
determined,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Myelosuppression,AdverseReaction
Delay,O
or,O
reduce,O
dose,O
Restart,O
treatment,O
based,O
on,O
ANC,O
and,O
platelet,O
count,O
recovery,O
2,O
2,O
Complications,O
of,O
myelosuppression,AdverseReaction
may,Factor
lead,O
to,O
death,AdverseReaction
5,O
1,O
Infections,AdverseReaction
Monitor,O
for,O
fever,O
and,O
other,O
signs,O
of,O
infection,O
and,O
treat,O
promptly,O
5,O
2,O
Anaphylaxis,AdverseReaction
and,O
Infusion Reactions,AdverseReaction
Severe,O
and,O
anaphylactic reactions,AdverseReaction
have,O
occurred,O
monitor,O
clinically,O
and,O
discontinue,O
TREANDA,O
Pre,O
medicate,O
in,O
subsequent,O
cycles,O
for,O
milder,O
reactions,O
5,O
3,O
Tumor Lysis Syndrome,AdverseReaction
Acute renal failure,AdverseReaction
and,O
death,AdverseReaction
anticipate,O
and,O
use,O
supportive,O
measures,O
5,O
4,O
Skin Reactions,AdverseReaction
Discontinue,O
for,O
severe,O
skin,O
reactions,O
Cases,O
of,O
SJS,AdverseReaction
and,O
TEN,AdverseReaction
some,O
fatal,AdverseReaction
have,O
been,O
reported,O
when,O
TREANDA,O
was,O
administered,O
concomitantly,O
with,O
allopurinol,O
and,O
other,O
medications,O
known,O
to,O
cause,O
these,O
syndromes,O
5,O
5,O
Other,O
Malignancies,AdverseReaction
Pre malignant,AdverseReaction
and,O
malignant diseases,AdverseReaction
have,O
been,O
reported,O
5,O
6,O
Extravasation,AdverseReaction
Assure,O
good,O
venous,O
access,O
and,O
monitor,O
infusion,O
site,O
during,O
and,O
after,O
administration,O
5,O
7,O
Embryo fetal toxicity,AdverseReaction
Fetal harm,AdverseReaction
can,Factor
occur,O
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Women,O
should,O
be,O
advised,O
to,O
avoid,O
becoming,O
pregnant,O
when,O
receiving,O
TREANDA,O
5,O
8,O
8,O
1,O
5,O
1,O
Myelosuppression,O
TREANDA,O
caused,O
severe,Severity
myelosuppression,AdverseReaction
Grade 3 3 4,Severity
in,O
98,O
of,O
patients,O
in,O
the,O
two,O
NHL,O
studies,O
see,O
Table,O
4,O
Three,O
patients,O
2,O
died,AdverseReaction
from,O
myelosuppression related adverse reactions,AdverseReaction
one,O
each,O
from,O
neutropenic sepsis,AdverseReaction
diffuse alveolar hemorrhage,AdverseReaction
with,O
Grade,Severity
3,O
thrombocytopenia,AdverseReaction
and,O
pneumonia,AdverseReaction
from,O
an,O
opportunistic infection,AdverseReaction
infection,AdverseReaction
CMV,AdverseReaction
In,O
the,O
event,O
of,O
treatment,O
related,O
myelosuppression,O
monitor,O
leukocytes,O
platelets,O
hemoglobin,O
Hgb,O
and,O
neutrophils,O
frequently,O
In,O
the,O
clinical,O
trials,O
blood,O
counts,O
were,O
monitored,O
every,O
week,O
initially,O
Hematologic,O
nadirs,O
were,O
observed,O
predominantly,O
in,O
the,O
third,O
week,O
of,O
therapy,O
Myelosuppression,O
may,O
require,O
dose,O
delays,O
and,O
or,O
subsequent,O
dose,O
reductions,O
if,O
recovery,O
to,O
the,O
recommended,O
values,O
has,O
not,O
occurred,O
by,O
the,O
first,O
day,O
of,O
the,O
next,O
scheduled,O
cycle,O
Prior,O
to,O
the,O
initiation,O
of,O
the,O
next,O
cycle,O
of,O
therapy,O
the,O
ANC,O
should,O
be,O
1,O
x,O
10,O
9,O
L,O
and,O
the,O
platelet,O
count,O
should,O
be,O
75,O
x,O
10,O
9,O
L,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
2,O
3,O
5,O
2,O
Infections,O
Infection,AdverseReaction
including,O
pneumonia,AdverseReaction
sepsis,AdverseReaction
septic shock,AdverseReaction
and,O
death,AdverseReaction
have,O
occurred,O
in,O
adult,O
and,O
pediatric,O
patients,O
in,O
clinical,O
trials,O
and,O
in,O
postmarketing,O
reports,O
Patients,O
with,O
myelosuppression,AdverseReaction
following,O
treatment,O
with,O
TREANDA,O
are,O
more,O
susceptible,Factor
to,O
infections,AdverseReaction
Advise,O
patients,O
with,O
myelosuppression,O
following,O
TREANDA,O
treatment,O
to,O
contact,O
a,O
physician,O
if,O
they,O
have,O
symptoms,O
or,O
signs,O
of,O
infection,O
5,O
3,O
Anaphylaxis,O
and,O
Infusion,O
Reactions,O
Infusion reactions,AdverseReaction
to,O
TREANDA,O
have,O
occurred,O
commonly,O
in,O
clinical,O
trials,O
Symptoms,O
include,O
fever,AdverseReaction
chills,AdverseReaction
pruritus,AdverseReaction
and,O
rash,AdverseReaction
In,O
rare,O
instances,O
severe,Severity
anaphylactic,AdverseReaction
and,O
anaphylactoid reactions,AdverseReaction
have,O
occurred,O
particularly,O
in,O
the,O
second,O
and,O
subsequent,O
cycles,O
of,O
therapy,O
Monitor,O
clinically,O
and,O
discontinue,O
drug,O
for,O
severe,O
reactions,O
Ask,O
patients,O
about,O
symptoms,O
suggestive,O
of,O
infusion,O
reactions,O
after,O
their,O
first,O
cycle,O
of,O
therapy,O
Patients,O
who,O
experience,O
Grade,O
3,O
or,O
worse,O
allergic,O
type,O
reactions,O
should,O
not,O
be,O
rechallenged,O
Consider,O
measures,O
to,O
prevent,O
severe,O
reactions,O
including,O
antihistamines,O
antipyretics,O
and,O
corticosteroids,O
in,O
subsequent,O
cycles,O
in,O
patients,O
who,O
have,O
experienced,O
Grade,O
1,O
or,O
2,O
infusion,O
reactions,O
Discontinue,O
TREANDA,O
for,O
patients,O
with,O
Grade,O
4,O
infusion,O
reactions,O
Consider,O
discontinuation,O
for,O
Grade,O
3,O
infusions,O
reactions,O
as,O
clinically,O
appropriate,O
considering,O
individual,O
benefits,O
risks,O
and,O
supportive,O
care,O
5,O
4,O
Tumor,O
Lysis,O
Syndrome,O
Tumor lysis syndrome,AdverseReaction
associated,O
with,O
TREANDA,O
treatment,O
has,O
occurred,O
in,O
patients,O
in,O
clinical,O
trials,O
and,O
in,O
postmarketing,O
reports,O
The,O
onset,O
tends,O
to,O
be,O
within,O
the,O
first,O
treatment,O
cycle,O
of,O
TREANDA,O
and,O
without,O
intervention,O
may,Factor
lead,O
to,O
acute renal failure,AdverseReaction
and,O
death,AdverseReaction
Preventive,O
measures,O
include,O
vigorous,O
hydration,O
and,O
close,O
monitoring,O
of,O
blood,O
chemistry,O
particularly,O
potassium,O
and,O
uric,O
acid,O
levels,O
Allopurinol,O
has,O
also,O
been,O
used,O
during,O
the,O
beginning,O
of,O
TREANDA,O
therapy,O
However,O
there,O
may,O
be,O
an,O
increased,O
risk,Factor
of,O
severe,Severity
skin toxicity,AdverseReaction
when,O
TREANDA,O
and,O
allopurinol,O
are,O
administered,O
concomitantly,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
5,O
5,O
Skin,O
Reactions,O
Skin reactions,AdverseReaction
have,O
been,O
reported,O
with,O
TREANDA,O
treatment,O
in,O
clinical,O
trials,O
and,O
postmarketing,O
safety,O
reports,O
including,O
rash,AdverseReaction
toxic skin reactions,AdverseReaction
and,O
bullous exanthema,AdverseReaction
Some,O
events,O
occurred,O
when,O
TREANDA,O
was,O
given,O
in,O
combination,O
with,O
other,O
anticancer,O
agents,O
In,O
a,O
study,O
of,O
TREANDA,O
90,O
mg,O
m,O
2,O
in,O
combination,O
with,O
rituximab,O
one,O
case,O
of,O
toxic epidermal necrolysis,AdverseReaction
TEN,AdverseReaction
occurred,O
TEN,O
has,O
been,O
reported,O
for,O
rituximab,O
see,O
rituximab,O
package,O
insert,O
Cases,O
of,O
Stevens Johnson syndrome,AdverseReaction
SJS,AdverseReaction
and,O
TEN,AdverseReaction
some,O
fatal,AdverseReaction
have,O
been,O
reported,O
when,O
TREANDA,O
was,O
administered,O
concomitantly,O
with,O
allopurinol,O
and,O
other,O
medications,O
known,O
to,O
cause,O
these,O
syndromes,O
The,O
relationship,O
to,O
TREANDA,O
cannot,O
be,O
determined,O
Where,O
skin reactions,AdverseReaction
occur,O
they,O
may,O
be,O
progressive,O
and,O
increase,O
in,O
severity,O
with,O
further,O
treatment,O
Monitor,O
patients,O
with,O
skin,O
reactions,O
closely,O
If,O
skin,O
reactions,O
are,O
severe,O
or,O
progressive,O
withhold,O
or,O
discontinue,O
TREANDA,O
5,O
6,O
Other,O
Malignancies,O
There,O
are,O
reports,O
of,O
pre malignant,AdverseReaction
and,O
malignant diseases,AdverseReaction
that,O
have,O
developed,O
in,O
patients,O
who,O
have,O
been,O
treated,O
with,O
TREANDA,O
including,O
myelodysplastic syndrome,AdverseReaction
myeloproliferative disorders,AdverseReaction
acute myeloid leukemia,AdverseReaction
and,O
bronchial carcinoma,AdverseReaction
The,O
association,O
with,O
TREANDA,O
therapy,O
has,O
not,O
been,O
determined,O
5,O
7,O
Extravasation,O
Injury,O
TREANDA,O
extravasations,AdverseReaction
have,O
been,O
reported,O
in,O
post,O
marketing,O
resulting,O
in,O
hospitalizations,O
from,O
erythema,AdverseReaction
marked,Severity
swelling,AdverseReaction
and,O
pain,AdverseReaction
Assure,O
good,O
venous,O
access,O
prior,O
to,O
starting,O
TREANDA,O
infusion,O
and,O
monitor,O
the,O
intravenous,O
infusion,O
site,O
for,O
redness,O
swelling,O
pain,O
infection,O
and,O
necrosis,O
during,O
and,O
after,O
administration,O
of,O
TREANDA,O
5,O
8,O
Embryo,O
fetal,O
Toxicity,O
TREANDA,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Single,O
intraperitoneal,O
doses,O
of,O
bendamustine,O
in,O
mice,Animal
and,O
rats,Animal
administered,O
during,O
organogenesis,O
caused,O
an,O
increase in resorptions,AdverseReaction
skeletal,AdverseReaction
and,O
visceral malformations,AdverseReaction
and,O
decreased fetal body weights,AdverseReaction
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
have,O
been,O
associated,O
with,O
TREANDA,O
in,O
clinical,O
trials,O
and,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
label,O
Myelosuppression,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Infections,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Anaphylaxis,AdverseReaction
and,O
Infusion Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Tumor Lysis Syndrome,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Skin Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Other,O
Malignancies,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Extravasation injury,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Most,O
common,O
non,O
hematologic,O
adverse,O
reactions,O
for,O
CLL,O
frequency,O
15,O
are,O
pyrexia,AdverseReaction
nausea,AdverseReaction
and,O
vomiting,AdverseReaction
6,O
1,O
Most,O
common,O
non,O
hematologic,O
adverse,O
reactions,O
for,O
NHL,O
frequency,O
15,O
are,O
nausea,AdverseReaction
fatigue,AdverseReaction
vomiting,AdverseReaction
diarrhea,AdverseReaction
pyrexia,AdverseReaction
constipation,AdverseReaction
anorexia,AdverseReaction
cough,AdverseReaction
headache,AdverseReaction
weight decreased,AdverseReaction
dyspnea,AdverseReaction
rash,AdverseReaction
and,O
stomatitis,AdverseReaction
6,O
1,O
Most,O
common,O
hematologic abnormalities,AdverseReaction
for,O
both,O
indications,O
frequency,O
15,O
are,O
lymphopenia,AdverseReaction
anemia,AdverseReaction
leukopenia,AdverseReaction
thrombocytopenia,AdverseReaction
and,O
neutropenia,AdverseReaction
6,O
1,O
EXCERPT,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Teva,O
Pharmaceuticals,O
at,O
1,O
800,O
896,O
5855,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Chronic,O
Lymphocytic,O
Leukemia,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
TREANDA,O
in,O
153,O
patients,O
with,O
CLL,O
studied,O
in,O
an,O
active,O
controlled,O
randomized,O
trial,O
The,O
population,O
was,O
45,O
77,O
years,O
of,O
age,O
63,O
male,O
100,O
white,O
and,O
were,O
treatment,O
naive,O
All,O
patients,O
started,O
the,O
study,O
at,O
a,O
dose,O
of,O
100,O
mg,O
m,O
2,O
intravenously,O
over,O
30,O
minutes,O
on,O
Days,O
1,O
and,O
2,O
every,O
28,O
days,O
Adverse,O
reactions,O
were,O
reported,O
according,O
to,O
NCI,O
CTC,O
v,O
2,O
0,O
Non,O
hematologic,O
adverse,O
reactions,O
any,O
grade,O
in,O
the,O
TREANDA,O
group,O
that,O
occurred,O
with,O
a,O
frequency,O
greater,O
than,O
15,O
were,O
pyrexia,AdverseReaction
24,O
nausea,AdverseReaction
20,O
and,O
vomiting,AdverseReaction
16,O
Other,O
adverse,O
reactions,O
seen,O
frequently,O
in,O
one,O
or,O
more,O
studies,O
included,O
asthenia,AdverseReaction
fatigue,AdverseReaction
malaise,AdverseReaction
and,O
weakness,AdverseReaction
dry mouth,AdverseReaction
somnolence,AdverseReaction
cough,AdverseReaction
constipation,AdverseReaction
headache,AdverseReaction
mucosal inflammation,AdverseReaction
and,O
stomatitis,AdverseReaction
Worsening hypertension,AdverseReaction
was,O
reported,O
in,O
4,O
patients,O
treated,O
with,O
TREANDA,O
in,O
the,O
CLL,O
trial,O
and,O
in,O
none,O
treated,O
with,O
chlorambucil,O
Three,O
of,O
these,O
4,O
adverse,O
reactions,O
were,O
described,O
as,O
a,O
hypertensive crisis,AdverseReaction
and,O
were,O
managed,O
with,O
oral,O
medications,O
and,O
resolved,O
The,O
most,O
frequent,O
adverse,O
reactions,O
leading,O
to,O
study,O
withdrawal,O
for,O
patients,O
receiving,O
TREANDA,O
were,O
hypersensitivity,AdverseReaction
2,O
and,O
pyrexia,AdverseReaction
1,O
Table,O
1,O
contains,O
the,O
treatment,O
emergent,O
adverse,O
reactions,O
regardless,O
of,O
attribution,O
that,O
were,O
reported,O
in,O
5,O
of,O
patients,O
in,O
either,O
treatment,O
group,O
in,O
the,O
randomized,O
CLL,O
clinical,O
study,O
Table,O
1,O
Non,O
Hematologic,O
Adverse,O
Reactions,O
Occurring,O
in,O
Randomized,O
CLL,O
Clinical,O
Study,O
in,O
at,O
Least,O
5,O
of,O
Patients,O
Number,O
of,O
patients,O
TREANDA,O
N,O
153,O
Chlorambucil,O
N,O
143,O
System,O
organ,O
class,O
Preferred,O
term,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
Total,O
number,O
of,O
patients,O
with,O
at,O
least,O
1,O
adverse,O
reaction,O
121,O
79,O
52,O
34,O
96,O
67,O
25,O
17,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
31,O
20,O
1,O
1,O
21,O
15,O
1,O
1,O
Vomiting,AdverseReaction
24,O
16,O
1,O
1,O
9,O
6,O
0,O
Diarrhea,AdverseReaction
14,O
9,O
2,O
1,O
5,O
3,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Pyrexia,AdverseReaction
36,O
24,O
6,O
4,O
8,O
6,O
2,O
1,O
Fatigue,AdverseReaction
14,O
9,O
2,O
1,O
8,O
6,O
0,O
Asthenia,AdverseReaction
13,O
8,O
0,O
6,O
4,O
0,O
Chills,AdverseReaction
9,O
6,O
0,O
1,O
1,O
0,O
Immune,O
system,O
disorders,O
Hypersensitivity,AdverseReaction
7,O
5,O
2,O
1,O
3,O
2,O
0,O
Infections,O
and,O
infestations,O
Nasopharyngitis,AdverseReaction
10,O
7,O
0,O
12,O
8,O
0,O
Infection,AdverseReaction
9,O
6,O
3,O
2,O
1,O
1,O
1,O
1,O
Herpes simplex,AdverseReaction
5,O
3,O
0,O
7,O
5,O
0,O
Investigations,O
Weight decreased,AdverseReaction
11,O
7,O
0,O
5,O
3,O
0,O
Metabolism,O
and,O
nutrition,O
disorders,O
Hyperuricemia,AdverseReaction
11,O
7,O
3,O
2,O
2,O
1,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
6,O
4,O
1,O
1,O
7,O
5,O
1,O
1,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
12,O
8,O
4,O
3,O
7,O
5,O
3,O
2,O
Pruritus,AdverseReaction
8,O
5,O
0,O
2,O
1,O
0,O
The,O
Grade,O
3,O
and,O
4,O
hematology,O
laboratory,O
test,O
values,O
by,O
treatment,O
group,O
in,O
the,O
randomized,O
CLL,O
clinical,O
study,O
are,O
described,O
in,O
Table,O
2,O
These,O
findings,O
confirm,O
the,O
myelosuppressive effects,AdverseReaction
seen,O
in,O
patients,O
treated,O
with,O
TREANDA,O
Red,O
blood,O
cell,O
transfusions,O
were,O
administered,O
to,O
20,O
of,O
patients,O
receiving,O
TREANDA,O
compared,O
with,O
6,O
of,O
patients,O
receiving,O
chlorambucil,O
Table,O
2,O
Incidence,O
of,O
Hematology,O
Laboratory,O
Abnormalities,O
in,O
Patients,O
Who,O
Received,O
TREANDA,O
or,O
Chlorambucil,O
in,O
the,O
Randomized,O
CLL,O
Clinical,O
Study,O
TREANDA,O
N,O
150,O
ChlorambucilN,O
141,O
Laboratory,O
Abnormality,O
All,O
Gradesn,O
Grade,O
3,O
4n,O
All,O
Gradesn,O
Grade,O
3,O
4n,O
Hemoglobin Decreased,AdverseReaction
134,O
89,O
20,O
13,O
115,O
82,O
12,O
9,O
Platelets Decreased,AdverseReaction
116,O
77,O
16,O
11,O
110,O
78,O
14,O
10,O
Leukocytes Decreased,AdverseReaction
92,O
61,O
42,O
28,O
26,O
18,O
4,O
3,O
Lymphocytes Decreased,AdverseReaction
102,O
68,O
70,O
47,O
27,O
19,O
6,O
4,O
Neutrophils Decreased,AdverseReaction
113,O
75,O
65,O
43,O
86,O
61,O
30,O
21,O
In,O
the,O
CLL,O
trial,O
34,O
of,O
patients,O
had,O
bilirubin elevations,AdverseReaction
some,O
without,Negation
associated,O
significant,Severity
elevations in AST in AST in in,AdverseReaction
and,O
ALT,AdverseReaction
Grade 3,Severity
or,O
4,Severity
increased bilirubin,AdverseReaction
occurred,O
in,O
3,O
of,O
patients,O
Increases in AST in,AdverseReaction
and,O
ALT,AdverseReaction
of,O
Grade 3,Severity
or,O
4,Severity
were,O
limited,O
to,O
1,O
and,O
3,O
of,O
patients,O
respectively,O
Patients,O
treated,O
with,O
TREANDA,O
may,Factor
also,O
have,O
changes in,AdverseReaction
their,O
creatinine levels,AdverseReaction
If,O
abnormalities,O
are,O
detected,O
monitoring,O
of,O
these,O
parameters,O
should,O
be,O
continued,O
to,O
ensure,O
that,O
further,O
deterioration,O
does,O
not,O
occur,O
Non,O
Hodgkin,O
Lymphoma,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
TREANDA,O
in,O
176,O
patients,O
with,O
indolent,O
B,O
cell,O
NHL,O
treated,O
in,O
two,O
single,O
arm,O
studies,O
The,O
population,O
was,O
31,O
84,O
years,O
of,O
age,O
60,O
male,O
and,O
40,O
female,O
The,O
race,O
distribution,O
was,O
89,O
White,O
7,O
Black,O
3,O
Hispanic,O
1,O
other,O
and,O
1,O
Asian,O
These,O
patients,O
received,O
TREANDA,O
at,O
a,O
dose,O
of,O
120,O
mg,O
m,O
2,O
intravenously,O
on,O
Days,O
1,O
and,O
2,O
for,O
up,O
to,O
eight,O
21,O
day,O
cycles,O
The,O
adverse,O
reactions,O
occurring,O
in,O
at,O
least,O
5,O
of,O
the,O
NHL,O
patients,O
regardless,O
of,O
severity,O
are,O
shown,O
in,O
Table,O
3,O
The,O
most,O
common,O
non,O
hematologic,O
adverse,O
reactions,O
30,O
were,O
nausea,AdverseReaction
75,O
fatigue,AdverseReaction
57,O
vomiting,AdverseReaction
40,O
diarrhea,AdverseReaction
37,O
and,O
pyrexia,AdverseReaction
34,O
The,O
most,O
common,O
non,O
hematologic,O
Grade,O
3,O
or,O
4,O
adverse,O
reactions,O
5,O
were,O
fatigue,AdverseReaction
11,O
febrile neutropenia,AdverseReaction
6,O
and,O
pneumonia,AdverseReaction
hypokalemia,AdverseReaction
and,O
dehydration,AdverseReaction
each,O
reported,O
in,O
5,O
of,O
patients,O
Table,O
3,O
Non,O
Hematologic,O
Adverse,O
Reactions,O
Occurring,O
in,O
at,O
Least,O
5,O
of,O
NHL,O
Patients,O
Treated,O
with,O
TREANDA,O
by,O
System,O
Organ,O
Class,O
and,O
Preferred,O
Term,O
N,O
176,O
System,O
organ,O
class,O
Number,O
of,O
patients,O
Preferred,O
term,O
All,O
Grades,O
Grade,O
3,O
4,O
Total,O
number,O
of,O
patients,O
with,O
at,O
least,O
1,O
adverse,O
reaction,O
176,O
100,O
94,O
53,O
Cardiac,O
disorders,O
Tachycardia,AdverseReaction
13,O
7,O
0,O
Gastrointestinal,O
disorders,O
Nausea,AdverseReaction
132,O
75,O
7,O
4,O
Vomiting,AdverseReaction
71,O
40,O
5,O
3,O
Diarrhea,AdverseReaction
65,O
37,O
6,O
3,O
Constipation,AdverseReaction
51,O
29,O
1,O
1,O
Stomatitis,AdverseReaction
27,O
15,O
1,O
1,O
Abdominal pain,AdverseReaction
22,O
13,O
2,O
1,O
Dyspepsia,AdverseReaction
20,O
11,O
0,O
Gastroesophageal reflux disease,AdverseReaction
18,O
10,O
0,O
Dry mouth,AdverseReaction
15,O
9,O
1,O
1,O
Abdominal pain upper,AdverseReaction
8,O
5,O
0,O
Abdominal distension,AdverseReaction
8,O
5,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
101,O
57,O
19,O
11,O
Pyrexia,AdverseReaction
59,O
34,O
3,O
2,O
Chills,AdverseReaction
24,O
14,O
0,O
Edema peripheral,AdverseReaction
23,O
13,O
1,O
1,O
Asthenia,AdverseReaction
19,O
11,O
4,O
2,O
Chest pain,AdverseReaction
11,O
6,O
1,O
1,O
Infusion site pain,AdverseReaction
11,O
6,O
0,O
Pain,AdverseReaction
10,O
6,O
0,O
Catheter site pain,AdverseReaction
8,O
5,O
0,O
Infections,O
and,O
infestations,O
Herpes zoster,AdverseReaction
18,O
10,O
5,O
3,O
Upper respiratory tract infection,AdverseReaction
18,O
10,O
0,O
Urinary tract infection,AdverseReaction
17,O
10,O
4,O
2,O
Sinusitis,AdverseReaction
15,O
9,O
0,O
Pneumonia,AdverseReaction
14,O
8,O
9,O
5,O
Febrile neutropenia,AdverseReaction
11,O
6,O
11,O
6,O
Oral candidiasis,AdverseReaction
11,O
6,O
2,O
1,O
Nasopharyngitis,AdverseReaction
11,O
6,O
0,O
Investigations,O
Weight decreased,AdverseReaction
31,O
18,O
3,O
2,O
Metabolism,O
and,O
nutrition,O
disorders,O
Anorexia,AdverseReaction
40,O
23,O
3,O
2,O
Dehydration,AdverseReaction
24,O
14,O
8,O
5,O
Decreased appetite,AdverseReaction
22,O
13,O
1,O
1,O
Hypokalemia,AdverseReaction
15,O
9,O
9,O
5,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Back pain,AdverseReaction
25,O
14,O
5,O
3,O
Arthralgia,AdverseReaction
11,O
6,O
0,O
Pain in extremity,AdverseReaction
8,O
5,O
2,O
1,O
Bone pain,AdverseReaction
8,O
5,O
0,O
Nervous,O
system,O
disorders,O
Headache,AdverseReaction
36,O
21,O
0,O
Dizziness,AdverseReaction
25,O
14,O
0,O
Dysgeusia,AdverseReaction
13,O
7,O
0,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
23,O
13,O
0,O
Anxiety,AdverseReaction
14,O
8,O
1,O
1,O
Depression,AdverseReaction
10,O
6,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
38,O
22,O
1,O
1,O
Dyspnea,AdverseReaction
28,O
16,O
3,O
2,O
Pharyngolaryngeal pain,AdverseReaction
14,O
8,O
1,O
1,O
Wheezing,AdverseReaction
8,O
5,O
0,O
Nasal congestion,AdverseReaction
8,O
5,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
28,O
16,O
1,O
1,O
Pruritus,AdverseReaction
11,O
6,O
0,O
Dry skin,AdverseReaction
9,O
5,O
0,O
Night sweats,AdverseReaction
9,O
5,O
0,O
Hyperhidrosis,AdverseReaction
8,O
5,O
0,O
Vascular,O
disorders,O
Hypotension,AdverseReaction
10,O
6,O
2,O
1,O
Patients,O
may,O
have,O
reported,O
more,O
than,O
1,O
adverse,O
reaction,O
NOTE,O
Patients,O
counted,O
only,O
once,O
in,O
each,O
preferred,O
term,O
category,O
and,O
once,O
in,O
each,O
system,O
organ,O
class,O
category,O
Hematologic toxicities,AdverseReaction
based,O
on,O
laboratory,O
values,O
and,O
CTC,O
grade,O
in,O
NHL,O
patients,O
treated,O
in,O
both,O
single,O
arm,O
studies,O
combined,O
are,O
described,O
in,O
Table,O
4,O
Clinically,O
important,O
chemistry,O
laboratory,O
values,O
that,O
were,O
new,O
or,O
worsened,O
from,O
baseline,O
and,O
occurred,O
in,O
1,O
of,O
patients,O
at,O
Grade,O
3,O
or,O
4,O
in,O
NHL,O
patients,O
treated,O
in,O
both,O
single,O
arm,O
studies,O
combined,O
were,O
hyperglycemia,AdverseReaction
3,O
elevated creatinine,AdverseReaction
2,O
hyponatremia,AdverseReaction
2,O
and,O
hypocalcemia,AdverseReaction
2,O
Table,O
4,O
Incidence,O
of,O
Hematology,O
Laboratory,O
Abnormalities,O
in,O
Patients,O
Who,O
Received,O
TREANDA,O
in,O
the,O
NHL,O
Studies,O
Percent,O
of,O
patients,O
Hematology,O
variable,O
All,O
Grades,O
Grades,O
3,O
4,O
Lymphocytes Decreased,AdverseReaction
99,O
94,O
Leukocytes Decreased,AdverseReaction
94,O
56,O
Hemoglobin Decreased,AdverseReaction
88,O
11,O
Neutrophils Decreased,AdverseReaction
86,O
60,O
Platelets Decreased,AdverseReaction
86,O
25,O
In,O
both,O
studies,O
serious,O
adverse,O
reactions,O
regardless,O
of,O
causality,O
were,O
reported,O
in,O
37,O
of,O
patients,O
receiving,O
TREANDA,O
The,O
most,O
common,O
serious,O
adverse,O
reactions,O
occurring,O
in,O
5,O
of,O
patients,O
were,O
febrile neutropenia,AdverseReaction
and,O
pneumonia,AdverseReaction
Other,O
important,O
serious,O
adverse,O
reactions,O
reported,O
in,O
clinical,O
trials,O
and,O
or,O
postmarketing,O
experience,O
were,O
acute renal failure,AdverseReaction
cardiac failure,AdverseReaction
hypersensitivity,AdverseReaction
skin reactions,AdverseReaction
pulmonary fibrosis,AdverseReaction
and,O
myelodysplastic syndrome,AdverseReaction
Serious,O
drug,O
related,O
adverse,O
reactions,O
reported,O
in,O
clinical,O
trials,O
included,O
myelosuppression,AdverseReaction
infection,AdverseReaction
pneumonia,AdverseReaction
tumor lysis syndrome,AdverseReaction
and,O
infusion reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
Adverse,O
reactions,O
occurring,O
less,O
frequently,O
but,O
possibly,Factor
related,O
to,O
TREANDA,O
treatment,O
were,O
hemolysis,AdverseReaction
dysgeusia,AdverseReaction
taste disorder,AdverseReaction
atypical pneumonia,AdverseReaction
sepsis,AdverseReaction
herpes zoster,AdverseReaction
erythema,AdverseReaction
dermatitis,AdverseReaction
and,O
skin necrosis,AdverseReaction
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
TREANDA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
anaphylaxis,AdverseReaction
and,O
injection,AdverseReaction
or,O
infusion site reactions reactions site reactions site reactions site reactions site reactions site reactions,AdverseReaction
including,O
phlebitis,AdverseReaction
pruritus,AdverseReaction
irritation,AdverseReaction
pain,AdverseReaction
and,O
swelling,AdverseReaction
pneumocystis jiroveci pneumonia,AdverseReaction
and,O
pneumonitis,AdverseReaction
Skin reactions,AdverseReaction
including,O
SJS,AdverseReaction
and,O
TEN,AdverseReaction
have,O
occurred,O
when,O
TREANDA,O
was,O
administered,O
concomitantly,O
with,O
allopurinol,O
and,O
other,O
medications,O
known,O
to,O
cause,O
these,O
syndromes,O
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Thyroid C cell Tumors,AdverseReaction
See,O
Boxed,O
Warning,O
5,O
1,O
Pancreatitis,AdverseReaction
Has,O
been,O
reported,O
in,O
clinical,O
trials,O
Discontinue,O
promptly,O
if,O
pancreatitis,O
is,O
suspected,O
Do,O
not,O
restart,O
if,O
pancreatitis,O
is,O
confirmed,O
Consider,O
other,O
antidiabetic,O
therapies,O
in,O
patients,O
with,O
history,O
of,O
pancreatitis,O
5,O
2,O
Hypoglycemia,AdverseReaction
When,O
TRULICITY,O
is,O
used,O
with,O
an,O
insulin,O
secretagogue,O
e,O
g,O
a,O
sulfonylurea,O
or,O
insulin,O
consider,O
lowering,O
the,O
dose,O
of,O
the,O
sulfonylurea,O
or,O
insulin,O
to,O
reduce,O
the,O
risk,O
of,O
hypoglycemia,O
5,O
3,O
Hypersensitivity,AdverseReaction
Reactions,O
Discontinue,O
TRULICITY,O
if,O
suspected,O
Monitor,O
and,O
treat,O
promptly,O
per,O
standard,O
of,O
care,O
until,O
signs,O
and,O
symptoms,O
resolve,O
5,O
4,O
Renal Impairment,AdverseReaction
Monitor,O
renal,O
function,O
in,O
patients,O
with,O
renal,O
impairment,O
reporting,O
severe,O
adverse,O
gastrointestinal,O
reactions,O
5,O
5,O
Macrovascular,O
outcomes,O
There,O
have,O
been,O
no,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
TRULICITY,O
or,O
any,O
other,O
antidiabetic,O
drug,O
5,O
7,O
5,O
1,O
Risk,O
of,O
Thyroid,O
C,O
cell,O
Tumors,O
In,O
male,O
and,O
female,O
rats,Animal
dulaglutide,O
causes,O
a,O
dose,O
related,O
and,O
treatment,O
duration,O
dependent,O
increase,O
in,O
the,O
incidence,O
of,O
thyroid C cell tumors C cell C cell,AdverseReaction
adenomas,AdverseReaction
and,O
carcinomas,AdverseReaction
after,O
lifetime,O
exposure,O
see,O
Nonclinical,O
Toxicology,O
13,O
1,O
Glucagon,O
like,O
peptide,O
GLP,O
1,O
receptor,O
agonists,O
have,O
induced,O
thyroid C cell adenomas C cell,AdverseReaction
and,O
carcinomas,AdverseReaction
in,O
mice,Animal
and,O
rats,Animal
at,O
clinically,O
relevant,O
exposures,O
It,O
is,O
unknown,Factor
whether,O
TRULICITY,O
will,O
cause,O
thyroid C cell tumors,AdverseReaction
including,O
medullary thyroid carcinoma,AdverseReaction
MTC,AdverseReaction
in,O
humans,O
as,O
the,O
human,O
relevance,O
of,O
dulaglutide,O
induced,O
rodent,Animal
thyroid C cell tumors,AdverseReaction
has,O
not,O
been,O
determined,O
One,O
case,O
of,O
MTC,AdverseReaction
was,O
reported,O
in,O
a,O
patient,O
treated,O
with,O
TRULICITY,O
This,O
patient,O
had,O
pretreatment,O
calcitonin,O
levels,O
approximately,O
8,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
ULN,O
Cases,O
of,O
MTC,AdverseReaction
in,O
patients,O
treated,O
with,O
liraglutide,O
another,O
GLP 1 receptor agonist,DrugClass
have,O
been,O
reported,O
in,O
the,O
postmarketing,O
period,O
the,O
data,O
in,O
these,O
reports,O
are,O
insufficient,O
to,O
establish,O
or,O
exclude,O
a,O
causal,O
relationship,O
between,O
MTC,AdverseReaction
and,O
GLP,O
1,O
receptor,O
agonist,O
use,O
in,O
humans,O
TRULICITY,O
is,O
contraindicated,O
in,O
patients,O
with,O
a,O
personal,O
or,O
family,O
history,O
of,O
MTC,O
or,O
in,O
patients,O
with,O
MEN,O
2,O
Counsel,O
patients,O
regarding,O
the,O
potential,O
risk,O
for,O
MTC,O
with,O
the,O
use,O
of,O
TRULICITY,O
and,O
inform,O
them,O
of,O
symptoms,O
of,O
thyroid,O
tumors,O
e,O
g,O
a,O
mass,O
in,O
the,O
neck,O
dysphagia,O
dyspnea,O
persistent,O
hoarseness,O
Routine,O
monitoring,O
of,O
serum,O
calcitonin,O
or,O
using,O
thyroid,O
ultrasound,O
is,O
of,O
uncertain,O
value,O
for,O
early,O
detection,O
of,O
MTC,O
in,O
patients,O
treated,O
with,O
TRULICITY,O
Such,O
monitoring,O
may,O
increase,O
the,O
risk,O
of,O
unnecessary,O
procedures,O
due,O
to,O
the,O
low,O
test,O
specificity,O
for,O
serum,O
calcitonin,O
and,O
a,O
high,O
background,O
incidence,O
of,O
thyroid,O
disease,O
Significantly,O
elevated,O
serum,O
calcitonin,O
value,O
may,O
indicate,O
MTC,O
and,O
patients,O
with,O
MTC,O
usually,O
have,O
calcitonin,O
values,O
50,O
ng,O
L,O
If,O
serum,O
calcitonin,O
is,O
measured,O
and,O
found,O
to,O
be,O
elevated,O
the,O
patient,O
should,O
be,O
further,O
evaluated,O
Patients,O
with,O
thyroid,O
nodules,O
noted,O
on,O
physical,O
examination,O
or,O
neck,O
imaging,O
should,O
also,O
be,O
further,O
evaluated,O
5,O
2,O
Pancreatitis,O
In,O
Phase,O
2,O
and,O
Phase,O
3,O
clinical,O
studies,O
12,O
3,O
4,O
cases,O
per,O
1000,O
patient,O
years,O
pancreatitis,AdverseReaction
related,O
adverse,O
reactions,O
were,O
reported,O
in,O
patients,O
exposed,O
to,O
TRULICITY,O
versus,O
3,O
in,O
non,O
incretin,O
comparators,O
2,O
7,O
cases,O
per,O
1000,O
patient,O
years,O
An,O
analyses,O
of,O
adjudicated,O
events,O
revealed,O
5,O
cases,O
of,O
confirmed,O
pancreatitis,AdverseReaction
in,O
patients,O
exposed,O
to,O
TRULICITY,O
1,O
4,O
cases,O
per,O
1000,O
patient,O
years,O
versus,O
1,O
case,O
in,O
non,O
incretin,O
comparators,O
0,O
88,O
cases,O
per,O
1000,O
patient,O
years,O
After,O
initiation,O
of,O
TRULICITY,O
observe,O
patients,O
carefully,O
for,O
signs,O
and,O
symptoms,O
of,O
pancreatitis,O
including,O
persistent,O
severe,O
abdominal,O
pain,O
If,O
pancreatitis,O
is,O
suspected,O
promptly,O
discontinue,O
TRULICITY,O
If,O
pancreatitis,O
is,O
confirmed,O
TRULICITY,O
should,O
not,O
be,O
restarted,O
TRULICITY,O
has,O
not,O
been,O
evaluated,O
in,O
patients,O
with,O
a,O
prior,O
history,O
of,O
pancreatitis,O
Consider,O
other,O
antidiabetic,O
therapies,O
in,O
patients,O
with,O
a,O
history,O
of,O
pancreatitis,O
5,O
3,O
Hypoglycemia,O
with,O
Concomitant,O
Use,O
of,O
Insulin,O
Secretagogues,O
or,O
Insulin,O
The,O
risk,Factor
of,O
hypoglycemia,AdverseReaction
is,O
increased,O
when,O
TRULICITY,O
is,O
used,O
in,O
combination,O
with,O
insulin,O
secretagogues,O
e,O
g,O
sulfonylureas,O
or,O
insulin,O
Patients,O
may,O
require,O
a,O
lower,O
dose,O
of,O
sulfonylurea,O
or,O
insulin,O
to,O
reduce,O
the,O
risk,O
of,O
hypoglycemia,O
in,O
this,O
setting,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
4,O
Hypersensitivity,O
Reactions,O
Systemic hypersensitivity,AdverseReaction
reactions,O
were,O
observed,O
in,O
patients,O
receiving,O
TRULICITY,O
in,O
clinical,O
trials,O
see,O
Adverse,O
Reactions,O
6,O
1,O
If,O
a,O
hypersensitivity,O
reaction,O
occurs,O
the,O
patient,O
should,O
discontinue,O
TRULICITY,O
and,O
promptly,O
seek,O
medical,O
advice,O
5,O
5,O
Renal,O
Impairment,O
In,O
patients,O
treated,O
with,O
GLP 1 receptor agonists,DrugClass
there,O
have,O
been,O
postmarketing,O
reports,O
of,O
acute renal failure,AdverseReaction
and,O
worsening,O
of,O
chronic renal failure,AdverseReaction
which,O
may,O
sometimes,O
require,O
hemodialysis,O
Some,O
of,O
these,O
events,O
were,O
reported,O
in,O
patients,O
without,O
known,O
underlying,O
renal,O
disease,O
A,O
majority,O
of,O
reported,O
events,O
occurred,O
in,O
patients,O
who,O
had,O
experienced,O
nausea,AdverseReaction
vomiting,AdverseReaction
diarrhea,AdverseReaction
or,O
dehydration,AdverseReaction
Because,O
these,O
reactions,O
may,O
worsen,O
renal,O
function,O
use,O
caution,O
when,O
initiating,O
or,O
escalating,O
doses,O
of,O
TRULICITY,O
in,O
patients,O
with,O
renal,O
impairment,O
Monitor,O
renal,O
function,O
in,O
patients,O
with,O
renal,O
impairment,O
reporting,O
severe,O
adverse,O
gastrointestinal,O
reactions,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Use,O
in,O
Specific,O
Populations,O
8,O
7,O
5,O
6,O
Severe,O
Gastrointestinal,O
Disease,O
Use,O
of,O
TRULICITY,O
may,O
be,O
associated,O
with,O
gastrointestinal adverse reactions adverse reactions,AdverseReaction
sometimes,O
severe,Severity
see,O
Adverse,O
Reactions,O
6,O
1,O
TRULICITY,O
has,O
not,O
been,O
studied,O
in,O
patients,O
with,O
severe,O
gastrointestinal,O
disease,O
including,O
severe,O
gastroparesis,O
and,O
is,O
therefore,O
not,O
recommended,O
in,O
these,O
patients,O
5,O
7,O
Macrovascular,O
Outcomes,O
There,O
have,O
been,O
no,O
clinical,O
studies,O
establishing,O
conclusive,O
evidence,O
of,O
macrovascular,O
risk,O
reduction,O
with,O
TRULICITY,O
or,O
any,O
other,O
antidiabetic,O
drug,O
""
BOXED,O
WARNING,O
WARNING,O
RISK,Factor
OF,O
THYROID C CELL TUMORS,AdverseReaction
WARNING,O
RISK,Factor
OF,O
THYROID C CELL TUMORS,AdverseReaction
In,O
male,O
and,O
female,O
rats,Animal
dulaglutide,O
causes,O
a,O
dose,O
related,O
and,O
treatment,O
duration,O
dependent,O
increase,O
in,O
the,O
incidence,O
of,O
thyroid C cell tumors C cell C cell,AdverseReaction
adenomas,AdverseReaction
and,O
carcinomas,AdverseReaction
after,O
lifetime,O
exposure,O
It,O
is,O
unknown,Factor
whether,O
TRULICITY,O
causes,O
thyroid C cell tumors,AdverseReaction
including,O
medullary thyroid carcinoma,AdverseReaction
MTC,AdverseReaction
in,O
humans,O
as,O
human,O
relevance,O
of,O
dulaglutide,O
induced,O
rodent,Animal
thyroid C cell tumors,AdverseReaction
has,O
not,O
been,O
determined,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Nonclinical,O
Toxicology,O
13,O
1,O
TRULICITY,O
is,O
contraindicated,O
in,O
patients,O
with,O
a,O
personal,O
or,O
family,O
history,O
of,O
MTC,O
and,O
in,O
patients,O
with,O
Multiple,O
Endocrine,O
Neoplasia,O
syndrome,O
type,O
2,O
MEN,O
2,O
Counsel,O
patients,O
regarding,O
the,O
potential,O
risk,O
of,O
MTC,O
with,O
use,O
of,O
TRULICITY,O
and,O
inform,O
them,O
of,O
symptoms,O
of,O
thyroid,O
tumors,O
e,O
g,O
mass,O
in,O
the,O
neck,O
dysphagia,O
dyspnea,O
persistent,O
hoarseness,O
Routine,O
monitoring,O
of,O
serum,O
calcitonin,O
or,O
using,O
thyroid,O
ultrasound,O
is,O
of,O
uncertain,O
value,O
for,O
early,O
detection,O
of,O
MTC,O
in,O
patients,O
treated,O
with,O
TRULICITY,O
see,O
Contraindications,O
4,O
1,O
and,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
RISK,Factor
OF,O
THYROID C CELL TUMORS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Dulaglutide,O
causes,O
thyroid C cell tumors,AdverseReaction
in,O
rats,Animal
It,O
is,O
unknown,Factor
whether,O
TRULICITY,O
causes,O
thyroid C cell tumors,AdverseReaction
including,O
medullary thyroid carcinoma,AdverseReaction
MTC,AdverseReaction
in,O
humans,O
as,O
the,O
human,O
relevance,O
of,O
dulaglutide,O
induced,O
rodent,Animal
thyroid C cell tumors,AdverseReaction
has,O
not,O
been,O
determined,O
5,O
1,O
13,O
1,O
TRULICITY,O
is,O
contraindicated,O
in,O
patients,O
with,O
a,O
personal,O
or,O
family,O
history,O
of,O
MTC,O
and,O
in,O
patients,O
with,O
Multiple,O
Endocrine,O
Neoplasia,O
syndrome,O
type,O
2,O
MEN,O
2,O
Counsel,O
patients,O
regarding,O
the,O
potential,O
risk,O
of,O
MTC,O
and,O
symptoms,O
of,O
thyroid,O
tumors,O
4,O
1,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
reactions,O
are,O
described,O
below,O
or,O
elsewhere,O
in,O
the,O
prescribing,O
information,O
Risk,Factor
of,O
Thyroid C cell Tumors,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Pancreatitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Hypoglycemia,AdverseReaction
with,O
Concomitant,O
Use,O
of,O
Insulin,O
Secretagogues,O
or,O
Insulin,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Hypersensitivity,AdverseReaction
reactions,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Renal impairment,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Severe,Severity
Gastrointestinal Disease,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
reported,O
in,O
5,O
of,O
patients,O
treated,O
with,O
TRULICITY,O
are,O
nausea,AdverseReaction
diarrhea,AdverseReaction
vomiting,AdverseReaction
abdominal pain,AdverseReaction
and,O
decreased appetite,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Eli,O
Lilly,O
and,O
Company,O
at,O
1,O
800,O
LillyRx,O
1,O
800,O
545,O
5979,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
Because,O
clinical,O
studies,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
studies,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
studies,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Pool,O
of,O
Placebo,O
controlled,O
Trials,O
The,O
data,O
in,O
Table,O
1,O
are,O
derived,O
from,O
the,O
placebo,O
controlled,O
trials,O
see,O
Clinical,O
Studies,O
14,O
These,O
data,O
reflect,O
exposure,O
of,O
1670,O
patients,O
to,O
TRULICITY,O
and,O
a,O
mean,O
duration,O
of,O
exposure,O
to,O
TRULICITY,O
of,O
23,O
8,O
weeks,O
Across,O
the,O
treatment,O
arms,O
the,O
mean,O
age,O
of,O
patients,O
was,O
56,O
years,O
1,O
were,O
75,O
years,O
or,O
older,O
and,O
53,O
were,O
male,O
The,O
population,O
in,O
these,O
studies,O
was,O
69,O
White,O
7,O
Black,O
or,O
African,O
American,O
13,O
Asian,O
30,O
were,O
of,O
Hispanic,O
or,O
Latino,O
ethnicity,O
At,O
baseline,O
the,O
population,O
had,O
diabetes,O
for,O
an,O
average,O
of,O
8,O
0,O
years,O
and,O
had,O
a,O
mean,O
HbA1c,O
of,O
8,O
0,O
At,O
baseline,O
2,O
5,O
of,O
the,O
population,O
reported,O
retinopathy,O
Baseline,O
estimated,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
eGFR,O
60mL,O
min,O
1,O
73,O
m,O
2,O
in,O
96,O
0,O
of,O
the,O
pooled,O
study,O
populations,O
Table,O
1,O
shows,O
common,O
adverse,O
reactions,O
excluding,O
hypoglycemia,AdverseReaction
associated,O
with,O
the,O
use,O
of,O
TRULICITY,O
in,O
the,O
pool,O
of,O
placebo,O
controlled,O
trials,O
These,O
adverse,O
reactions,O
were,O
not,O
present,O
at,O
baseline,O
occurred,O
more,O
commonly,O
on,O
TRULICITY,O
than,O
on,O
placebo,O
and,O
occurred,O
in,O
at,O
least,O
5,O
of,O
patients,O
treated,O
with,O
TRULICITY,O
Table,O
1,O
Adverse,O
Reactions,O
in,O
Placebo,O
Controlled,O
Trials,O
Reported,O
in,O
5,O
of,O
TRULICITY,O
Treated,O
Patients,O
a,O
Includes,O
diarrhea,AdverseReaction
fecal volume increased,AdverseReaction
frequent bowel movements,AdverseReaction
b,O
Includes,O
retching,AdverseReaction
vomiting,AdverseReaction
vomiting projectile,AdverseReaction
c,O
Includes,O
abdominal discomfort,AdverseReaction
abdominal pain,AdverseReaction
abdominal pain lower,AdverseReaction
abdominal pain upper,AdverseReaction
abdominal tenderness,AdverseReaction
gastrointestinal pain,AdverseReaction
d,O
Includes,O
fatigue,AdverseReaction
asthenia,AdverseReaction
malaise,AdverseReaction
Note,O
Percentages,O
reflect,O
the,O
number,O
of,O
patients,O
that,O
reported,O
at,O
least,O
1,O
treatment,O
emergent,O
occurrence,O
of,O
the,O
adverse,O
reaction,O
Adverse,O
Reaction,O
Placebo,O
N,O
568,O
Trulicity,O
0,O
75,O
mg,O
N,O
836,O
Trulicity,O
1,O
5,O
mg,O
N,O
834,O
Nausea,AdverseReaction
5,O
3,O
12,O
4,O
21,O
1,O
Diarrhea,AdverseReaction
a,O
6,O
7,O
8,O
9,O
12,O
6,O
Vomiting,AdverseReaction
b,O
2,O
3,O
6,O
0,O
12,O
7,O
Abdominal Pain,AdverseReaction
c,O
4,O
9,O
6,O
5,O
9,O
4,O
Decreased Appetite,AdverseReaction
1,O
6,O
4,O
9,O
8,O
6,O
Dyspepsia,AdverseReaction
2,O
3,O
4,O
1,O
5,O
8,O
Fatigue,AdverseReaction
d,O
2,O
6,O
4,O
2,O
5,O
6,O
Gastrointestinal,O
Adverse,O
Reactions,O
In,O
the,O
pool,O
of,O
placebo,O
controlled,O
trials,O
gastrointestinal adverse reactions,AdverseReaction
occurred,O
more,O
frequently,O
among,O
patients,O
receiving,O
TRULICITY,O
than,O
placebo,O
placebo,O
21,O
3,O
0,O
75,O
mg,O
31,O
6,O
1,O
5,O
mg,O
41,O
0,O
More,O
patients,O
receiving,O
TRULICITY,O
0,O
75,O
mg,O
1,O
3,O
and,O
TRULICITY,O
1,O
5,O
mg,O
3,O
5,O
discontinued,O
treatment,O
due,O
to,O
gastrointestinal adverse reactions,AdverseReaction
than,O
patients,O
receiving,O
placebo,O
0,O
2,O
Investigators,O
graded,O
the,O
severity,O
of,O
gastrointestinal adverse reactions,AdverseReaction
occurring,O
on,O
0,O
75,O
mg,O
and,O
1,O
5,O
mg,O
of,O
TRULICITY,O
as,O
mild,Severity
in,O
58,O
and,O
48,O
of,O
cases,O
respectively,O
moderate,Severity
in,O
35,O
and,O
42,O
of,O
cases,O
respectively,O
or,O
severe,Severity
in,O
7,O
and,O
11,O
of,O
cases,O
respectively,O
In,O
addition,O
to,O
the,O
reactions,O
in,O
Table,O
1,O
the,O
following,O
adverse,O
reactions,O
were,O
reported,O
more,O
frequently,O
in,O
TRULICITY,O
treated,O
patients,O
than,O
placebo,O
frequencies,O
listed,O
respectively,O
as,O
placebo,O
0,O
75,O
mg,O
1,O
5,O
mg,O
constipation,AdverseReaction
0,O
7,O
3,O
9,O
3,O
7,O
flatulence,AdverseReaction
1,O
4,O
1,O
4,O
3,O
4,O
abdominal distension,AdverseReaction
0,O
7,O
2,O
9,O
2,O
3,O
gastroesophageal reflux disease,AdverseReaction
0,O
5,O
1,O
7,O
2,O
0,O
and,O
eructation,AdverseReaction
0,O
2,O
0,O
6,O
1,O
6,O
Pool,O
of,O
Placebo,O
and,O
Active,O
Controlled,O
Trials,O
The,O
occurrence,O
of,O
adverse,O
reactions,O
was,O
also,O
evaluated,O
in,O
a,O
larger,O
pool,O
of,O
patients,O
with,O
type,O
2,O
diabetes,O
participating,O
in,O
6,O
placebo,O
and,O
active,O
controlled,O
trials,O
evaluating,O
the,O
use,O
of,O
TRULICITY,O
as,O
monotherapy,O
and,O
add,O
on,O
therapy,O
to,O
oral,O
medications,O
or,O
insulin,O
see,O
Clinical,O
Studies,O
14,O
In,O
this,O
pool,O
a,O
total,O
of,O
3342,O
patients,O
with,O
type,O
2,O
diabetes,O
were,O
treated,O
with,O
TRULICITY,O
for,O
a,O
mean,O
duration,O
of,O
52,O
weeks,O
The,O
mean,O
age,O
of,O
patients,O
was,O
56,O
years,O
2,O
were,O
75,O
years,O
or,O
older,O
and,O
51,O
were,O
male,O
The,O
population,O
in,O
these,O
studies,O
was,O
71,O
White,O
7,O
Black,O
or,O
African,O
American,O
11,O
Asian,O
32,O
were,O
of,O
Hispanic,O
or,O
Latino,O
ethnicity,O
At,O
baseline,O
the,O
population,O
had,O
diabetes,O
for,O
an,O
average,O
of,O
8,O
2,O
years,O
and,O
had,O
a,O
mean,O
HbA1c,O
of,O
7,O
6,O
8,O
5,O
At,O
baseline,O
5,O
2,O
of,O
the,O
population,O
reported,O
retinopathy,O
Baseline,O
estimated,O
renal,O
function,O
was,O
normal,O
or,O
mildly,O
impaired,O
eGFR,O
60,O
ml,O
min,O
1,O
73,O
m2,O
in,O
95,O
7,O
of,O
the,O
TRULICITY,O
population,O
In,O
the,O
pool,O
of,O
placebo,O
and,O
active,O
controlled,O
trials,O
the,O
types,O
and,O
frequency,O
of,O
common,O
adverse,O
reactions,O
excluding,O
hypoglycemia,AdverseReaction
were,O
similar,O
to,O
those,O
listed,O
in,O
Table,O
1,O
Other,O
Adverse,O
Reactions,O
Hypoglycemia,O
Table,O
2,O
summarizes,O
the,O
incidence,O
of,O
documented,O
symptomatic,AdverseReaction
70,O
mg,O
dL,O
glucose,O
threshold,O
and,O
severe,Severity
hypoglycemia,AdverseReaction
in,O
the,O
placebo,O
controlled,O
clinical,O
studies,O
Table,O
2,O
Incidence,O
of,O
Documented,O
Symptomatic,AdverseReaction
and,O
Severe,Severity
Hypoglycemia,AdverseReaction
Adverse,O
Reactions,O
in,O
Placebo,O
Controlled,O
Trials,O
Placebo,O
TRULICITY,O
0,O
75,O
mg,O
TRULICITY,O
1,O
5,O
mg,O
Add,O
on,O
to,O
Metformin,O
26,O
weeks,O
N,O
177,O
N,O
302,O
N,O
304,O
Documented,O
symptomatic,O
1,O
1,O
2,O
6,O
5,O
6,O
Severe,O
0,O
0,O
0,O
Add,O
on,O
to,O
Metformin,O
Pioglitazone,O
26,O
weeks,O
N,O
141,O
N,O
280,O
N,O
279,O
Documented,O
symptomatic,O
1,O
4,O
4,O
6,O
5,O
0,O
Severe,O
0,O
0,O
0,O
Hypoglycemia,AdverseReaction
was,O
more,O
frequent,O
when,O
TRULICITY,O
was,O
used,O
in,O
combination,O
with,O
a,O
sulfonylurea,O
or,O
insulin,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Documented,O
symptomatic hypoglycemia,AdverseReaction
occurred,O
in,O
39,O
and,O
40,O
of,O
patients,O
when,O
TRULICITY,O
0,O
75,O
mg,O
and,O
1,O
5,O
mg,O
respectively,O
was,O
co,O
administered,O
with,O
a,O
sulfonylurea,O
Severe,Severity
hypoglycemia,AdverseReaction
occurred,O
in,O
0,O
and,O
0,O
7,O
of,O
patients,O
when,O
TRULICITY,O
0,O
75,O
mg,O
and,O
1,O
5,O
mg,O
respectively,O
was,O
co,O
administered,O
with,O
a,O
sulfonylurea,O
Documented,O
symptomatic hypoglycemia,AdverseReaction
occurred,O
in,O
85,O
and,O
80,O
of,O
patients,O
when,O
TRULICITY,O
0,O
75,O
mg,O
and,O
1,O
5,O
mg,O
respectively,O
was,O
co,O
administered,O
with,O
prandial,O
insulin,O
Severe,Severity
hypoglycemia,AdverseReaction
occurred,O
in,O
2,O
4,O
and,O
3,O
4,O
of,O
patients,O
when,O
TRULICITY,O
0,O
75,O
mg,O
and,O
1,O
5,O
mg,O
respectively,O
was,O
co,O
administered,O
with,O
prandial,O
insulin,O
Heart,O
Rate,O
Increase,O
and,O
Tachycardia,O
Related,O
Adverse,O
Reactions,O
TRULICITY,O
0,O
75,O
mg,O
and,O
1,O
5,O
mg,O
resulted,O
in,O
a,O
mean,O
increase in heart rate in,AdverseReaction
HR,AdverseReaction
of,O
2,O
4,O
beats,O
per,O
minute,O
bpm,O
The,O
long,O
term,O
clinical,O
effects,O
of,O
the,O
increase in HR,AdverseReaction
have,O
not,O
been,O
established,O
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
Adverse,O
reactions,O
of,O
sinus tachycardia,AdverseReaction
were,O
reported,O
more,O
frequently,O
in,O
patients,O
exposed,O
to,O
TRULICITY,O
Sinus tachycardia,AdverseReaction
was,O
reported,O
in,O
3,O
0,O
2,O
8,O
and,O
5,O
6,O
of,O
patient,O
treated,O
with,O
placebo,O
TRULICITY,O
0,O
75,O
mg,O
and,O
TRULICITY,O
1,O
5,O
mg,O
respectively,O
Persistence of sinus tachycardia,AdverseReaction
reported,O
at,O
more,O
than,O
2,O
visits,O
was,O
reported,O
in,O
0,O
2,O
0,O
4,O
and,O
1,O
6,O
of,O
patients,O
treated,O
with,O
placebo,O
TRULICITY,O
0,O
75,O
mg,O
and,O
TRULICITY,O
1,O
5,O
mg,O
respectively,O
Episodes,O
of,O
sinus tachycardia,AdverseReaction
associated,O
with,O
a,O
concomitant,O
increase,AdverseReaction
from,O
baseline,O
in heart rate,AdverseReaction
of,O
15,O
beats,O
per,O
minute,O
were,O
reported,O
in,O
0,O
7,O
1,O
3,O
and,O
2,O
2,O
of,O
patient,O
treated,O
with,O
placebo,O
TRULICITY,O
0,O
75,O
mg,O
and,O
TRULICITY,O
1,O
5,O
mg,O
respectively,O
Immunogenicity,O
Across,O
four,O
Phase,O
2,O
and,O
five,O
Phase,O
3,O
clinical,O
studies,O
64,O
1,O
6,O
TRULICITY,O
treated,O
patients,O
developed,O
anti,O
drug,O
antibodies,O
ADAs,O
to,O
the,O
active,O
ingredient,O
in,O
TRULICITY,O
i,O
e,O
dulaglutide,O
Of,O
the,O
64,O
dulaglutide,O
treated,O
patients,O
that,O
developed,O
dulaglutide,O
ADAs,O
34,O
patients,O
0,O
9,O
of,O
the,O
overall,O
population,O
had,O
dulaglutide,O
neutralizing,O
antibodies,O
and,O
36,O
patients,O
0,O
9,O
of,O
the,O
overall,O
population,O
developed,O
antibodies,O
against,O
native,O
GLP,O
1,O
The,O
detection,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
the,O
incidence,O
of,O
antibodies,O
to,O
dulaglutide,O
cannot,O
be,O
directly,O
compared,O
with,O
the,O
incidence,O
of,O
antibodies,O
of,O
other,O
products,O
Hypersensitivity,O
Systemic hypersensitivity hypersensitivity,AdverseReaction
adverse,O
reactions,O
sometimes,O
severe,Severity
e,O
g,O
severe,Severity
urticaria,AdverseReaction
systemic rash,AdverseReaction
facial edema,AdverseReaction
lip swelling,AdverseReaction
occurred,O
in,O
0,O
5,O
of,O
patients,O
on,O
TRULICITY,O
in,O
the,O
four,O
Phase,O
2,O
and,O
five,O
Phase,O
3,O
studies,O
Injection,O
site,O
Reactions,O
In,O
the,O
placebo,O
controlled,O
studies,O
injection site reactions site,AdverseReaction
e,O
g,O
injection site rash,AdverseReaction
erythema,AdverseReaction
were,O
reported,O
in,O
0,O
5,O
of,O
TRULICITY,O
treated,O
patients,O
and,O
in,O
0,O
0,O
of,O
placebo,O
treated,O
patients,O
PR,O
Interval,O
Prolongation,O
and,O
Adverse,O
Reactions,O
of,O
First,O
Degree,O
Atrioventricular,O
AV,O
Block,O
A,O
mean,O
increase,AdverseReaction
from,O
baseline,O
in,O
PR interval,AdverseReaction
of,O
2,O
3,O
milliseconds,O
was,O
observed,O
in,O
TRULICITY,O
treated,O
patients,O
in,O
contrast,O
to,O
a,O
mean,O
decrease,O
of,O
0,O
9,O
millisecond,O
in,O
placebo,O
treated,O
patients,O
The,O
adverse,O
reaction,O
of,O
first degree AV block,AdverseReaction
occurred,O
more,O
frequently,O
in,O
patients,O
treated,O
with,O
TRULICITY,O
than,O
placebo,O
0,O
9,O
1,O
7,O
and,O
2,O
3,O
for,O
placebo,O
TRULICITY,O
0,O
75,O
mg,O
and,O
TRULICITY,O
1,O
5,O
mg,O
respectively,O
On,O
electrocardiograms,O
a,O
PR interval increase,AdverseReaction
to,O
at,O
least,O
220,O
milliseconds,O
was,O
observed,O
in,O
0,O
7,O
2,O
5,O
and,O
3,O
2,O
of,O
patients,O
treated,O
with,O
placebo,O
TRULICITY,O
0,O
75,O
mg,O
and,O
TRULICITY,O
1,O
5,O
mg,O
respectively,O
Amylase,O
and,O
Lipase,O
Increase,O
Patients,O
exposed,O
to,O
TRULICITY,O
had,O
mean,O
increases,AdverseReaction
from,O
baseline,O
in lipase,AdverseReaction
and,O
or,O
pancreatic amylase,AdverseReaction
of,O
14,O
to,O
20,O
while,O
placebo,O
treated,O
patients,O
had,O
mean,O
increases,O
of,O
up,O
to,O
3,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Not,O
for,O
acute,O
use,O
Not,O
for,O
use,O
as,O
a,O
rescue,O
medication,O
5,O
1,O
Paradoxical bronchospasm,AdverseReaction
Discontinue,O
TUDORZA,O
PRESSAIR,O
and,O
consider,O
other,O
treatments,O
if,O
paradoxical,O
bronchospasm,O
occurs,O
5,O
2,O
Worsening of narrow angle glaucoma,AdverseReaction
may,Factor
occur,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
narrow,O
angle,O
glaucoma,O
and,O
instruct,O
patients,O
to,O
consult,O
a,O
physician,O
immediately,O
if,O
this,O
occurs,O
5,O
3,O
Worsening of urinary retention,AdverseReaction
may,Factor
occur,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
prostatic,O
hyperplasia,O
or,O
bladder,O
neck,O
obstruction,O
and,O
instruct,O
patients,O
to,O
consult,O
a,O
physician,O
immediately,O
if,O
this,O
occurs,O
5,O
4,O
Immediate,O
hypersensitivity reactions,AdverseReaction
Discontinue,O
TUDORZA,O
PRESSAIR,O
at,O
once,O
and,O
consider,O
alternatives,O
if,O
immediate,O
hypersensitivity,O
reactions,O
including,O
angioedema,O
bronchospasm,O
or,O
anaphylaxis,O
occur,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
severe,O
hypersensitivity,O
to,O
milk,O
proteins,O
5,O
5,O
5,O
1,O
Not,O
for,O
Acute,O
Use,O
TUDORZA,O
PRESSAIR,O
is,O
intended,O
as,O
a,O
twice,O
daily,O
maintenance,O
treatment,O
for,O
COPD,O
and,O
is,O
not,O
indicated,O
for,O
the,O
initial,O
treatment,O
of,O
acute,O
episodes,O
of,O
bronchospasm,O
i,O
e,O
rescue,O
therapy,O
5,O
2,O
Paradoxical,O
Bronchospasm,O
Inhaled,O
medicines,O
including,O
TUDORZA,O
PRESSAIR,O
may,Factor
cause,O
paradoxical bronchospasm,AdverseReaction
If,O
this,O
occurs,O
treatment,O
with,O
TUDORZA,O
PRESSAIR,O
should,O
be,O
stopped,O
and,O
other,O
treatments,O
considered,O
5,O
3,O
Worsening,O
of,O
Narrow,O
Angle,O
Glaucoma,O
TUDORZA,O
PRESSAIR,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
narrow,O
angle,O
glaucoma,O
Prescribers,O
and,O
patients,O
should,O
be,O
alert,O
for,O
signs,O
and,O
symptoms,O
of,O
acute,O
narrow,O
angle,O
glaucoma,O
e,O
g,O
eye,O
pain,O
or,O
discomfort,O
blurred,O
vision,O
visual,O
halos,O
or,O
colored,O
images,O
in,O
association,O
with,O
red,O
eyes,O
from,O
conjunctival,O
congestion,O
and,O
corneal,O
edema,O
Instruct,O
patients,O
to,O
consult,O
a,O
physician,O
immediately,O
should,O
any,O
of,O
these,O
signs,O
or,O
symptoms,O
develop,O
5,O
4,O
Worsening,O
of,O
Urinary,O
Retention,O
TUDORZA,O
PRESSAIR,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
urinary,O
retention,O
Prescribers,O
and,O
patients,O
should,O
be,O
alert,O
for,O
signs,O
and,O
symptoms,O
of,O
prostatic,O
hyperplasia,O
or,O
bladder,O
neck,O
obstruction,O
e,O
g,O
difficulty,O
passing,O
urine,O
painful,O
urination,O
Instruct,O
patients,O
to,O
consult,O
a,O
physician,O
immediately,O
should,O
any,O
of,O
these,O
signs,O
or,O
symptoms,O
develop,O
5,O
5,O
Immediate,O
Hypersensitivity,O
Reactions,O
Immediate hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
angioedema,AdverseReaction
including,O
swelling of the lips of the of the,AdverseReaction
tongue,AdverseReaction
or,O
throat,AdverseReaction
urticaria,AdverseReaction
rash,AdverseReaction
bronchospasm,AdverseReaction
or,O
itching,AdverseReaction
have,O
occurred,O
after,O
administration,O
of,O
TUDORZA,O
PRESSAIR,O
If,O
such,O
a,O
reaction,O
occurs,O
therapy,O
with,O
TUDORZA,O
PRESSAIR,O
should,O
be,O
stopped,O
at,O
once,O
and,O
alternative,O
treatments,O
should,O
be,O
considered,O
Given,O
the,O
similar,O
structural,O
formula,O
of,O
atropine,O
to,O
aclidinium,O
patients,O
with,O
a,O
history,O
of,O
hypersensitivity,O
reactions,O
to,O
atropine,O
should,O
be,O
closely,O
monitored,O
for,O
similar,O
hypersensitivity,O
reactions,O
to,O
TUDORZA,O
PRESSAIR,O
In,O
addition,O
TUDORZA,O
PRESSAIR,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
with,O
severe,O
hypersensitivity,O
to,O
milk,O
proteins,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
described,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
Paradoxical bronchospasm,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Worsening of narrow angle glaucoma,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Worsening of urinary retention,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Immediate Hypersensitivity Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
3,O
incidence,O
and,O
greater,O
than,O
placebo,O
are,O
headache,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
cough,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
Contact,O
AstraZeneca,O
at,O
1,O
800,O
236,O
9933,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
3,O
Month,O
and,O
6,O
Month,O
Trials,O
TUDORZA,O
PRESSAIR,O
was,O
studied,O
in,O
two,O
3,O
month,O
Trials,O
B,O
and,O
C,O
and,O
one,O
6,O
month,O
Trial,O
D,O
placebo,O
controlled,O
trials,O
in,O
patients,O
with,O
COPD,O
In,O
these,O
trials,O
636,O
patients,O
were,O
treated,O
with,O
TUDORZA,O
PRESSAIR,O
at,O
the,O
recommended,O
dose,O
of,O
400,O
mcg,O
twice,O
daily,O
The,O
population,O
had,O
a,O
mean,O
age,O
of,O
64,O
years,O
ranging,O
from,O
40,O
to,O
89,O
years,O
with,O
58,O
males,O
94,O
Caucasian,O
and,O
had,O
COPD,O
with,O
a,O
mean,O
pre,O
bronchodilator,O
forced,O
expiratory,O
volume,O
in,O
one,O
second,O
FEV1,O
percent,O
predicted,O
of,O
48,O
Patients,O
with,O
unstable,O
cardiac,O
disease,O
narrow,O
angle,O
glaucoma,O
or,O
symptomatic,O
prostatic,O
hypertrophy,O
or,O
bladder,O
outlet,O
obstruction,O
were,O
excluded,O
from,O
these,O
trials,O
Table,O
1shows,O
all,O
adverse,O
reactions,O
that,O
occurred,O
with,O
a,O
frequency,O
of,O
greater,O
than,O
or,O
equal,O
to,O
1,O
in,O
the,O
TUDORZA,O
PRESSAIR,O
group,O
in,O
the,O
two,O
3,O
month,O
and,O
one,O
6,O
month,O
placebo,O
controlled,O
trials,O
where,O
the,O
rates,O
in,O
the,O
TUDORZA,O
PRESSAIR,O
group,O
exceeded,O
placebo,O
Table,O
1,O
Adverse,O
Reactions,O
Patients,O
in,O
Placebo,O
Controlled,O
Clinical,O
Trials,O
Treatment,O
Adverse,O
Reactions,O
TUDORZA,O
PRESSAIR,O
Placebo,O
Preferred,O
Term,O
N,O
636,O
N,O
640,O
n,O
n,O
Headache,AdverseReaction
42,O
6,O
6,O
32,O
5,O
0,O
Nasopharyngitis,AdverseReaction
35,O
5,O
5,O
25,O
3,O
9,O
Cough,AdverseReaction
19,O
3,O
0,O
14,O
2,O
2,O
Diarrhea,AdverseReaction
17,O
2,O
7,O
9,O
1,O
4,O
Sinusitis,AdverseReaction
11,O
1,O
7,O
5,O
0,O
8,O
Rhinitis,AdverseReaction
10,O
1,O
6,O
8,O
1,O
2,O
Toothache,AdverseReaction
7,O
1,O
1,O
5,O
0,O
8,O
Fall,AdverseReaction
7,O
1,O
1,O
3,O
0,O
5,O
Vomiting,AdverseReaction
7,O
1,O
1,O
3,O
0,O
5,O
In,O
addition,O
among,O
the,O
adverse,O
reactions,O
observed,O
in,O
the,O
clinical,O
trials,O
with,O
an,O
incidence,O
of,O
less,O
than,O
1,O
were,O
diabetes mellitus,AdverseReaction
dry mouth,AdverseReaction
1st degree,Severity
AV block,AdverseReaction
osteoarthritis,AdverseReaction
cardiac failure,AdverseReaction
and,O
cardio respiratory arrest,AdverseReaction
Long,O
term,O
Safety,O
Trials,O
TUDORZA,O
PRESSAIR,O
was,O
studied,O
in,O
three,O
long,O
term,O
safety,O
trials,O
two,O
double,O
blind,O
and,O
one,O
open,O
label,O
ranging,O
from,O
40,O
to,O
52,O
weeks,O
in,O
patients,O
with,O
moderate,O
to,O
severe,O
COPD,O
Two,O
of,O
these,O
trials,O
were,O
extensions,O
of,O
the,O
3,O
month,O
trials,O
and,O
one,O
was,O
a,O
dedicated,O
long,O
term,O
safety,O
trial,O
In,O
these,O
trials,O
891,O
patients,O
were,O
treated,O
with,O
TUDORZA,O
PRESSAIR,O
at,O
the,O
recommended,O
dose,O
of,O
400,O
mcg,O
twice,O
daily,O
The,O
demographic,O
and,O
baseline,O
characteristics,O
of,O
the,O
long,O
term,O
safety,O
trials,O
were,O
similar,O
to,O
those,O
of,O
the,O
placebo,O
controlled,O
trials,O
The,O
adverse,O
events,O
reported,O
in,O
the,O
long,O
term,O
safety,O
trials,O
were,O
similar,O
to,O
those,O
occurring,O
in,O
the,O
placebo,O
controlled,O
trials,O
of,O
3,O
to,O
6,O
months,O
No,O
new,O
safety,O
findings,O
were,O
reported,O
compared,O
to,O
the,O
placebo,O
controlled,O
trials,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
postapproval,O
use,O
of,O
drug,O
TUDORZA,O
PRESSAIR,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
In,O
postmarketing,O
experience,O
with,O
TUDORZA,O
PRESSAIR,O
immediate hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
angioedema,AdverseReaction
including,O
swelling of the lips of the of the,AdverseReaction
tongue,AdverseReaction
or,O
throat,AdverseReaction
urticaria,AdverseReaction
rash,AdverseReaction
bronchospasm,AdverseReaction
or,O
itching,AdverseReaction
have,O
been,O
reported,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Neonatal toxicity,AdverseReaction
Risk,Factor
of,O
gasping syndrome,AdverseReaction
if,O
benzyl,O
alcohol,O
is,O
used,O
in,O
neonates,O
5,O
1,O
Eye irritation,AdverseReaction
Avoid,O
eye,O
exposure,O
Flush,O
immediately,O
with,O
water,O
if,O
ULESFIA,O
r,O
Lotion,O
comes,O
into,O
contact,O
with,O
eyes,O
5,O
2,O
Contact dermatitis,AdverseReaction
May,Factor
occur,O
with,O
ULESFIA,O
r,O
Lotion,O
5,O
3,O
Use,O
in,O
children,O
ULESFIA,O
r,O
Lotion,O
should,O
only,O
be,O
used,O
on,O
children,O
under,O
the,O
direct,O
supervision,O
of,O
an,O
adult,O
Keep,O
out,O
of,O
reach,O
of,O
children,O
5,O
4,O
5,O
1,O
Neonatal,O
Toxicity,O
Intravenous,O
administration,O
of,O
products,O
containing,O
benzyl,O
alcohol,O
has,O
been,O
associated,O
with,O
neonatal gasping syndrome,AdverseReaction
consisting,O
of,O
severe,Severity
metabolic acidosis,AdverseReaction
gasping respirations,AdverseReaction
progressive hypotension,AdverseReaction
seizures,AdverseReaction
central nervous system depression,AdverseReaction
intraventricular hemorrhage,AdverseReaction
and,O
death,AdverseReaction
in,O
preterm,O
low,O
birth,O
weight,O
infants,O
Neonates,O
i,O
e,O
patients,O
less,O
than,O
1,O
month,O
of,O
age,O
or,O
preterm,O
infants,O
with,O
a,O
corrected,O
age,O
of,O
less,O
than,O
44,O
weeks,O
could,O
be,O
at,O
risk,Factor
for,O
gasping syndrome,AdverseReaction
if,O
treated,O
with,O
ULESFIA,O
r,O
Lotion,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
4,O
5,O
2,O
Eye,O
Irritation,O
Avoid,O
eye,O
exposure,O
ULESFIA,O
r,O
Lotion,O
may,Factor
cause,O
eye irritation,AdverseReaction
If,O
ULESFIA,O
r,O
Lotion,O
comes,O
in,O
contact,O
with,O
the,O
eyes,O
flush,O
them,O
immediately,O
with,O
water,O
If,O
irritation,O
persists,O
consult,O
a,O
physician,O
5,O
3,O
Contact,O
Dermatitis,O
ULESFIA,O
r,O
Lotion,O
may,Factor
cause,O
allergic,AdverseReaction
or,O
irritant dermatitis,AdverseReaction
5,O
4,O
Use,O
in,O
Children,O
ULESFIA,O
r,O
Lotion,O
should,O
only,O
be,O
used,O
on,O
children,O
6,O
months,O
of,O
age,O
and,O
older,O
under,O
the,O
direct,O
supervision,O
of,O
an,O
adult,O
Keep,O
out,O
of,O
reach,O
of,O
children,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
1,O
and,O
more,O
common,O
than,O
with,O
placebo,O
ocular irritation,AdverseReaction
application site irritation,AdverseReaction
and,O
application site anesthesia site,AdverseReaction
and,O
hypoesthesia,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Zylera,O
Pharmaceuticals,O
LLC,O
at,O
1,O
866,O
416,O
9637,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
rates,O
of,O
adverse,O
reactions,O
below,O
were,O
derived,O
from,O
two,O
randomized,O
multi,O
center,O
vehicle,O
controlled,O
clinical,O
trials,O
and,O
one,O
open,O
label,O
study,O
in,O
subjects,O
with,O
head,O
lice,O
infestation,O
Skin,O
scalp,O
and,O
ocular,O
irritation,O
were,O
monitored,O
in,O
the,O
clinical,O
trials,O
All,O
subjects,O
were,O
queried,O
about,O
the,O
presence,O
of,O
skin,O
and,O
scalp,O
symptoms,O
the,O
results,O
are,O
presented,O
in,O
Table,O
2,O
Table,O
2,O
Monitored,O
Adverse,O
Reactions,O
Application,O
Site,O
Symptoms,O
Event,O
ULESFIA,O
r,O
Lotion,O
Vehicle,O
Application site Irritation,AdverseReaction
2,O
11,O
478,O
1,O
2,O
336,O
Application site anesthesia site,AdverseReaction
hypoesthesia,AdverseReaction
2,O
10,O
478,O
0,O
0,O
336,O
Pain,AdverseReaction
1,O
5,O
478,O
0,O
1,O
336,O
The,O
subset,O
of,O
subjects,O
who,O
did,O
not,O
have,O
pruritus,O
erythema,O
edema,O
or,O
pyoderma,O
of,O
skin,O
and,O
scalp,O
or,O
ocular,O
irritation,O
prior,O
to,O
treatment,O
were,O
assessed,O
for,O
these,O
signs,O
and,O
symptoms,O
after,O
treatment,O
the,O
results,O
are,O
presented,O
in,O
Table,O
3,O
Table,O
3,O
Monitored,O
Adverse,O
Reactions,O
Pruritus,AdverseReaction
Erythema,AdverseReaction
Pyoderma,AdverseReaction
and,O
Ocular Irritation,AdverseReaction
with,O
Onset,O
After,O
Treatment,O
Signs,O
Symptoms,O
ULESFIA,O
r,O
Lotion,O
Vehicle,O
Pruritus,AdverseReaction
12,O
14,O
116,O
4,O
3,O
67,O
Erythema,AdverseReaction
10,O
32,O
309,O
9,O
19,O
217,O
Pyoderma,AdverseReaction
7,O
22,O
308,O
4,O
10,O
230,O
Ocular irritation,AdverseReaction
6,O
26,O
428,O
1,O
3,O
313,O
Other,O
less,O
common,O
reactions,O
less,O
than,O
1,O
but,O
more,O
than,O
0,O
1,O
were,O
in,O
decreasing,O
order,O
of,O
incidence,O
application site dryness,AdverseReaction
application site excoriation,AdverseReaction
paraesthesia,AdverseReaction
application site dermatitis,AdverseReaction
excoriation,AdverseReaction
thermal burn,AdverseReaction
dandruff,AdverseReaction
erythema,AdverseReaction
rash,AdverseReaction
and,O
skin exfoliation,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Gout Flare,AdverseReaction
An,O
increase,O
in,O
gout flares,AdverseReaction
is,O
frequently,O
observed,O
during,O
initiation,O
of,O
anti,O
hyperuricemic,O
agents,O
including,O
ULORIC,O
If,O
a,O
gout,O
flare,O
occurs,O
during,O
treatment,O
ULORIC,O
need,O
not,O
be,O
discontinued,O
Prophylactic,O
therapy,O
i,O
e,O
non,O
steroidal,O
anti,O
inflammatory,O
drug,O
NSAID,O
or,O
colchicine,O
upon,O
initiation,O
of,O
treatment,O
may,O
be,O
beneficial,O
for,O
up,O
to,O
six,O
months,O
2,O
4,O
5,O
1,O
Cardiovascular Events,AdverseReaction
A,O
higher,O
rate,O
of,O
cardiovascular thromboembolic events,AdverseReaction
was,O
observed,O
in,O
patients,O
treated,O
with,O
ULORIC,O
than,O
allopurinol,O
in,O
clinical,O
trials,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
of,O
MI,O
and,O
stroke,O
5,O
2,O
Hepatic Effects,AdverseReaction
Postmarketing,O
reports,O
of,O
hepatic failure,AdverseReaction
sometimes,O
fatal,AdverseReaction
Causality,O
cannot,O
be,O
excluded,O
If,O
liver,O
injury,O
is,O
detected,O
promptly,O
interrupt,O
ULORIC,O
and,O
assess,O
patient,O
for,O
probable,O
cause,O
then,O
treat,O
cause,O
if,O
possible,O
to,O
resolution,O
or,O
stabilization,O
Do,O
not,O
restart,O
ULORIC,O
if,O
liver,O
injury,O
is,O
confirmed,O
and,O
no,O
alternate,O
etiology,O
can,O
be,O
found,O
5,O
3,O
5,O
1,O
Gout,O
Flare,O
After,O
initiation,O
of,O
ULORIC,O
an,O
increase,O
in,O
gout flares,AdverseReaction
is,O
frequently,O
observed,O
This,O
increase,O
is,O
due,O
to,O
reduction,O
in,O
serum,O
uric,O
acid,O
levels,O
resulting,O
in,O
mobilization,O
of,O
urate,O
from,O
tissue,O
deposits,O
In,O
order,O
to,O
prevent,O
gout,O
flares,O
when,O
ULORIC,O
is,O
initiated,O
concurrent,O
prophylactic,O
treatment,O
with,O
an,O
NSAID,O
or,O
colchicine,O
is,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
4,O
5,O
2,O
Cardiovascular,O
Events,O
In,O
the,O
randomized,O
controlled,O
studies,O
there,O
was,O
a,O
higher,O
rate,O
of,O
cardiovascular thromboembolic events,AdverseReaction
cardiovascular deaths,AdverseReaction
non fatal,Severity
myocardial infarctions,AdverseReaction
and,O
non fatal,Severity
strokes,AdverseReaction
in,O
patients,O
treated,O
with,O
ULORIC,O
0,O
74,O
per,O
100,O
P,O
Y,O
95,O
Confidence,O
Interval,O
CI,O
0,O
36,O
1,O
37,O
than,O
allopurinol,O
0,O
60,O
per,O
100,O
P,O
Y,O
95,O
CI,O
0,O
16,O
1,O
53,O
see,O
Adverse,O
Reactions,O
6,O
1,O
A,O
causal,O
relationship,O
with,O
ULORIC,O
has,O
not,O
been,O
established,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
of,O
myocardial,O
infarction,O
MI,O
and,O
stroke,O
5,O
3,O
Hepatic,O
Effects,O
There,O
have,O
been,O
postmarketing,O
reports,O
of,O
fatal,AdverseReaction
and,O
non,O
fatal,O
hepatic failure,AdverseReaction
in,O
patients,O
taking,O
ULORIC,O
although,O
the,O
reports,O
contain,O
insufficient,O
information,O
necessary,O
to,O
establish,O
the,O
probable,O
cause,O
During,O
randomized,O
controlled,O
studies,O
transaminase elevations,AdverseReaction
greater,O
than,O
three times the upper limit of normal,Severity
ULN,O
were,O
observed,O
AST,O
2,O
2,O
and,O
ALT,O
3,O
2,O
in,O
ULORIC,O
and,O
allopurinol,O
treated,O
patients,O
respectively,O
No,O
dose,O
effect,O
relationship,O
for,O
these,O
transaminase,O
elevations,O
was,O
noted,O
see,O
Clinical,O
Pharmacology,O
12,O
3,O
Obtain,O
a,O
liver,O
test,O
panel,O
serum,O
alanine,O
aminotransferase,O
ALT,O
aspartate,O
aminotransferase,O
AST,O
alkaline,O
phosphatase,O
and,O
total,O
bilirubin,O
as,O
a,O
baseline,O
before,O
initiating,O
ULORIC,O
Measure,O
liver,O
tests,O
promptly,O
in,O
patients,O
who,O
report,O
symptoms,O
that,O
may,O
indicate,O
liver,O
injury,O
including,O
fatigue,O
anorexia,O
right,O
upper,O
abdominal,O
discomfort,O
dark,O
urine,O
or,O
jaundice,O
In,O
this,O
clinical,O
context,O
if,O
the,O
patient,O
is,O
found,O
to,O
have,O
abnormal,O
liver,O
tests,O
ALT,O
greater,O
than,O
three,O
times,O
the,O
upper,O
limit,O
of,O
the,O
reference,O
range,O
ULORIC,O
treatment,O
should,O
be,O
interrupted,O
and,O
investigation,O
done,O
to,O
establish,O
the,O
probable,O
cause,O
ULORIC,O
should,O
not,O
be,O
restarted,O
in,O
these,O
patients,O
without,O
another,O
explanation,O
for,O
the,O
liver,O
test,O
abnormalities,O
Patients,O
who,O
have,O
serum,O
ALT,O
greater,O
than,O
three,O
times,O
the,O
reference,O
range,O
with,O
serum,O
total,O
bilirubin,O
greater,O
than,O
two,O
times,O
the,O
reference,O
range,O
without,O
alternative,O
etiologies,O
are,O
at,O
risk,O
for,O
severe,O
drug,O
induced,O
liver,O
injury,O
and,O
should,O
not,O
be,O
restarted,O
on,O
ULORIC,O
For,O
patients,O
with,O
lesser,O
elevations,O
of,O
serum,O
ALT,O
or,O
bilirubin,O
and,O
with,O
an,O
alternate,O
probable,O
cause,O
treatment,O
with,O
ULORIC,O
can,O
be,O
used,O
with,O
caution,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Adverse,O
reactions,O
occurring,O
in,O
at,O
least,O
1,O
of,O
ULORIC,O
treated,O
patients,O
and,O
at,O
least,O
0,O
5,O
greater,O
than,O
placebo,O
are,O
liver function abnormalities,AdverseReaction
nausea,AdverseReaction
arthralgia,AdverseReaction
and,O
rash,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Takeda,O
Pharmaceuticals,O
at,O
1,O
877,O
TAKEDA,O
7,O
1,O
877,O
825,O
3327,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
A,O
total,O
of,O
2757,O
subjects,O
with,O
hyperuricemia,O
and,O
gout,O
were,O
treated,O
with,O
ULORIC,O
40,O
mg,O
or,O
80,O
mg,O
daily,O
in,O
clinical,O
studies,O
For,O
ULORIC,O
40,O
mg,O
559,O
patients,O
were,O
treated,O
for,O
6,O
months,O
For,O
ULORIC,O
80,O
mg,O
1377,O
subjects,O
were,O
treated,O
for,O
6,O
months,O
674,O
patients,O
were,O
treated,O
for,O
1,O
year,O
and,O
515,O
patients,O
were,O
treated,O
for,O
2,O
years,O
Most,O
Common,O
Adverse,O
Reactions,O
In,O
three,O
randomized,O
controlled,O
clinical,O
studies,O
Studies,O
1,O
2,O
and,O
3,O
which,O
were,O
six,O
to,O
12,O
months,O
in,O
duration,O
the,O
following,O
adverse,O
reactions,O
were,O
reported,O
by,O
the,O
treating,O
physician,O
as,O
related,O
to,O
study,O
drug,O
Table,O
1,O
summarizes,O
adverse,O
reactions,O
reported,O
at,O
a,O
rate,O
of,O
at,O
least,O
1,O
in,O
ULORIC,O
treatment,O
groups,O
and,O
at,O
least,O
0,O
5,O
greater,O
than,O
placebo,O
Table,O
1,O
Adverse,O
Reactions,O
Occurring,O
in,O
1,O
of,O
ULORIC,O
Treated,O
Patients,O
and,O
at,O
Least,O
0,O
5,O
Greater,O
than,O
Seen,O
in,O
Patients,O
Receiving,O
Placebo,O
in,O
Controlled,O
Studies,O
Adverse,O
Reactions,O
Placebo,O
ULORIC,O
allopurinolOf,O
the,O
subjects,O
who,O
received,O
allopurinol,O
10,O
received,O
100,O
mg,O
145,O
received,O
200,O
mg,O
and,O
1122,O
received,O
300,O
mg,O
based,O
on,O
level,O
of,O
renal,O
impairment,O
N,O
134,O
40,O
mg,O
daily,O
N,O
757,O
80,O
mg,O
daily,O
N,O
1279,O
N,O
1277,O
Liver Function Abnormalities,AdverseReaction
0,O
7,O
6,O
6,O
4,O
6,O
4,O
2,O
Nausea,AdverseReaction
0,O
7,O
1,O
1,O
1,O
3,O
0,O
8,O
Arthralgia,AdverseReaction
0,O
1,O
1,O
0,O
7,O
0,O
7,O
Rash,AdverseReaction
0,O
7,O
0,O
5,O
1,O
6,O
1,O
6,O
The,O
most,O
common,O
adverse,O
reaction,O
leading,O
to,O
discontinuation,O
from,O
therapy,O
was,O
liver function abnormalities,AdverseReaction
in,O
1,O
8,O
of,O
ULORIC,O
40,O
mg,O
1,O
2,O
of,O
ULORIC,O
80,O
mg,O
and,O
in,O
0,O
9,O
of,O
allopurinol,O
treated,O
subjects,O
In,O
addition,O
to,O
the,O
adverse,O
reactions,O
presented,O
in,O
Table,O
1,O
dizziness,AdverseReaction
was,O
reported,O
in,O
more,O
than,O
1,O
of,O
ULORIC,O
treated,O
subjects,O
although,O
not,O
at,O
a,O
rate,O
more,O
than,O
0,O
5,O
greater,O
than,O
placebo,O
Less,O
Common,O
Adverse,O
Reactions,O
In,O
Phase,O
2,O
and,O
3,O
clinical,O
studies,O
the,O
following,O
adverse,O
reactions,O
occurred,O
in,O
less,O
than,O
1,O
of,O
subjects,O
and,O
in,O
more,O
than,O
one,O
subject,O
treated,O
with,O
doses,O
ranging,O
from,O
40,O
mg,O
to,O
240,O
mg,O
of,O
ULORIC,O
This,O
list,O
also,O
includes,O
adverse,O
reactions,O
less,O
than,O
1,O
of,O
subjects,O
associated,O
with,O
organ,O
systems,O
from,O
Warnings,O
and,O
Precautions,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
anemia,AdverseReaction
idiopathic thrombocytopenic purpura,AdverseReaction
leukocytosis,AdverseReaction
leukopenia,AdverseReaction
neutropenia,AdverseReaction
pancytopenia,AdverseReaction
splenomegaly,AdverseReaction
thrombocytopenia,AdverseReaction
Cardiac,O
Disorders,O
angina pectoris,AdverseReaction
atrial fibrillation,AdverseReaction
flutter,AdverseReaction
cardiac murmur,AdverseReaction
ECG abnormal,AdverseReaction
palpitations,AdverseReaction
sinus bradycardia,AdverseReaction
tachycardia,AdverseReaction
Ear,O
and,O
Labyrinth,O
Disorders,O
deafness,AdverseReaction
tinnitus,AdverseReaction
vertigo,AdverseReaction
Eye,O
Disorders,O
vision blurred,AdverseReaction
Gastrointestinal,O
Disorders,O
abdominal distention,AdverseReaction
abdominal pain,AdverseReaction
constipation,AdverseReaction
dry mouth,AdverseReaction
dyspepsia,AdverseReaction
flatulence,AdverseReaction
frequent stools,AdverseReaction
gastritis,AdverseReaction
gastroesophageal reflux disease,AdverseReaction
gastrointestinal discomfort,AdverseReaction
gingival pain,AdverseReaction
haematemesis,AdverseReaction
hyperchlorhydria,AdverseReaction
hematochezia,AdverseReaction
mouth ulceration,AdverseReaction
pancreatitis,AdverseReaction
peptic ulcer,AdverseReaction
vomiting,AdverseReaction
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
asthenia,AdverseReaction
chest pain,AdverseReaction
discomfort,AdverseReaction
edema,AdverseReaction
fatigue,AdverseReaction
feeling abnormal,AdverseReaction
gait disturbance,AdverseReaction
influenza like symptoms,AdverseReaction
mass,AdverseReaction
pain,AdverseReaction
thirst,AdverseReaction
Hepatobiliary,O
Disorders,O
cholelithiasis,AdverseReaction
cholecystitis,AdverseReaction
hepatic steatosis,AdverseReaction
hepatitis,AdverseReaction
hepatomegaly,AdverseReaction
Immune,O
System,O
Disorder,O
hypersensitivity,AdverseReaction
Infections,O
and,O
Infestations,O
herpes zoster,AdverseReaction
Procedural,O
Complications,O
contusion,AdverseReaction
Metabolism,O
and,O
Nutrition,O
Disorders,O
anorexia,AdverseReaction
appetite decreased,AdverseReaction
increased,AdverseReaction
dehydration,AdverseReaction
diabetes mellitus,AdverseReaction
hypercholesterolemia,AdverseReaction
hyperglycemia,AdverseReaction
hyperlipidemia,AdverseReaction
hypertriglyceridemia,AdverseReaction
hypokalemia,AdverseReaction
weight decreased,AdverseReaction
increased,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
arthritis,AdverseReaction
joint stiffness,AdverseReaction
joint swelling,AdverseReaction
muscle spasms,AdverseReaction
twitching,AdverseReaction
tightness,AdverseReaction
weakness,AdverseReaction
musculoskeletal pain,AdverseReaction
stiffness,AdverseReaction
myalgia,AdverseReaction
Nervous,O
System,O
Disorders,O
altered taste,AdverseReaction
balance disorder,AdverseReaction
cerebrovascular accident,AdverseReaction
Guillain Barre syndrome,AdverseReaction
headache,AdverseReaction
hemiparesis,AdverseReaction
hypoesthesia,AdverseReaction
hyposmia,AdverseReaction
lacunar infarction,AdverseReaction
lethargy,AdverseReaction
mental impairment,AdverseReaction
migraine,AdverseReaction
paresthesia,AdverseReaction
somnolence,AdverseReaction
transient ischemic attack,AdverseReaction
tremor,AdverseReaction
Psychiatric,O
Disorders,O
agitation,AdverseReaction
anxiety,AdverseReaction
depression,AdverseReaction
insomnia,AdverseReaction
irritability,AdverseReaction
libido decreased,AdverseReaction
nervousness,AdverseReaction
panic attack,AdverseReaction
personality change,AdverseReaction
Renal,O
and,O
Urinary,AdverseReaction
Disorders,O
hematuria,AdverseReaction
nephrolithiasis,AdverseReaction
pollakiuria,AdverseReaction
proteinuria,AdverseReaction
renal failure,AdverseReaction
renal insufficiency,AdverseReaction
urgency,AdverseReaction
incontinence,AdverseReaction
Reproductive,O
System,O
and,O
Breast,O
Changes,O
breast pain,AdverseReaction
erectile dysfunction,AdverseReaction
gynecomastia,AdverseReaction
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
bronchitis,AdverseReaction
cough,AdverseReaction
dyspnea,AdverseReaction
epistaxis,AdverseReaction
nasal dryness,AdverseReaction
paranasal sinus hypersecretion,AdverseReaction
pharyngeal edema,AdverseReaction
respiratory tract congestion,AdverseReaction
sneezing,AdverseReaction
throat irritation,AdverseReaction
upper respiratory tract infection,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
alopecia,AdverseReaction
angio edema,AdverseReaction
dermatitis,AdverseReaction
dermographism,AdverseReaction
ecchymosis,AdverseReaction
eczema,AdverseReaction
hair color changes,AdverseReaction
hair growth abnormal,AdverseReaction
hyperhidrosis,AdverseReaction
peeling skin,AdverseReaction
petechiae,AdverseReaction
photosensitivity,AdverseReaction
pruritus,AdverseReaction
purpura,AdverseReaction
skin discoloration,AdverseReaction
altered pigmentation,AdverseReaction
skin lesion,AdverseReaction
skin odor abnormal,AdverseReaction
urticaria,AdverseReaction
Vascular,O
Disorders,O
flushing,AdverseReaction
hot flush,AdverseReaction
hypertension,AdverseReaction
hypotension,AdverseReaction
Laboratory,O
Parameters,O
activated partial thromboplastin time prolonged,AdverseReaction
creatine increased,AdverseReaction
bicarbonate decreased,AdverseReaction
sodium increased,AdverseReaction
EEG abnormal,AdverseReaction
glucose increased,AdverseReaction
cholesterol increased,AdverseReaction
triglycerides increased,AdverseReaction
amylase increased,AdverseReaction
potassium increased,AdverseReaction
TSH increased,AdverseReaction
platelet count decreased,AdverseReaction
hematocrit decreased,AdverseReaction
hemoglobin decreased,AdverseReaction
MCV increased,AdverseReaction
RBC decreased,AdverseReaction
creatinine increased,AdverseReaction
blood urea increased,AdverseReaction
BUN creatinine ratio increased,AdverseReaction
creatine phosphokinase,AdverseReaction
CPK,AdverseReaction
increased,AdverseReaction
alkaline phosphatase increased,AdverseReaction
LDH increased,AdverseReaction
PSA increased,AdverseReaction
urine output increased output,AdverseReaction
decreased,AdverseReaction
lymphocyte count decreased,AdverseReaction
neutrophil count decreased,AdverseReaction
WBC increased,AdverseReaction
decreased,AdverseReaction
coagulation test abnormal,AdverseReaction
low density lipoprotein,AdverseReaction
LDL,AdverseReaction
increased,AdverseReaction
prothrombin time prolonged,AdverseReaction
urinary casts,AdverseReaction
urine positive for white blood cells positive for,AdverseReaction
and,O
protein,AdverseReaction
Cardiovascular,O
Safety,O
Cardiovascular events,AdverseReaction
and,O
deaths,AdverseReaction
were,O
adjudicated,O
to,O
one,O
of,O
the,O
pre,O
defined,O
endpoints,O
from,O
the,O
Anti,O
Platelet,O
Trialists,O
Collaborations,O
APTC,O
cardiovascular death,AdverseReaction
non fatal,Severity
myocardial infarction,AdverseReaction
and,O
non fatal,Severity
stroke,AdverseReaction
in,O
the,O
randomized,O
controlled,O
and,O
long,O
term,O
extension,O
studies,O
In,O
the,O
Phase,O
3,O
randomized,O
controlled,O
studies,O
the,O
incidences,O
of,O
adjudicated,O
APTC,O
events,O
per,O
100,O
patient,O
years,O
of,O
exposure,O
were,O
Placebo,O
0,O
95,O
CI,O
0,O
00,O
6,O
16,O
ULORIC,O
40,O
mg,O
0,O
95,O
CI,O
0,O
00,O
1,O
08,O
ULORIC,O
80,O
mg,O
1,O
09,O
95,O
CI,O
0,O
44,O
2,O
24,O
and,O
allopurinol,O
0,O
60,O
95,O
CI,O
0,O
16,O
1,O
53,O
In,O
the,O
long,O
term,O
extension,O
studies,O
the,O
incidences,O
of,O
adjudicated,O
APTC,O
events,O
were,O
ULORIC,O
80,O
mg,O
0,O
97,O
95,O
CI,O
0,O
57,O
1,O
56,O
and,O
allopurinol,O
0,O
58,O
95,O
CI,O
0,O
02,O
3,O
24,O
Overall,O
a,O
higher,O
rate,O
of,O
APTC,O
events,O
was,O
observed,O
in,O
ULORIC,O
than,O
in,O
allopurinol,O
treated,O
patients,O
A,O
causal,O
relationship,O
with,O
ULORIC,O
has,O
not,O
been,O
established,O
Monitor,O
for,O
signs,O
and,O
symptoms,O
of,O
MI,O
and,O
stroke,O
6,O
2,O
Postmarketing,O
Experience,O
Adverse,O
reactions,O
have,O
been,O
identified,O
during,O
postapproval,O
use,O
of,O
ULORIC,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
Hepatobiliary,O
Disorders,O
hepatic failure,AdverseReaction
some,O
fatal,AdverseReaction
jaundice,AdverseReaction
serious,Severity
cases,O
of,O
abnormal liver function,AdverseReaction
test,O
results,O
liver disorder,AdverseReaction
Immune,O
System,O
Disorders,O
anaphylaxis,AdverseReaction
anaphylactic reaction,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
rhabdomyolysis,AdverseReaction
Psychiatric,O
Disorders,O
psychotic behavior,AdverseReaction
including,O
aggressive thoughts,AdverseReaction
Renal,O
and,O
Urinary,O
Disorders,O
tubulointerstitial nephritis,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
generalized rash,AdverseReaction
Stevens Johnson Syndrome,AdverseReaction
hypersensitivity skin reactions,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Use,O
of,O
VICTRELIS,O
with,O
Ribavirin,O
and,O
Peginterferon,O
alfa,O
Embryofetal Toxicity,AdverseReaction
Use,O
with,O
Ribavirin,O
and,O
Peginterferon,O
Alfa,O
Ribavirin,O
may,Factor
cause,O
birth defects,AdverseReaction
and,O
fetal death,AdverseReaction
avoid,O
pregnancy,O
in,O
female,O
patients,O
and,O
female,O
partners,O
of,O
male,O
patients,O
Patients,O
must,O
have,O
a,O
negative,O
pregnancy,O
test,O
prior,O
to,O
therapy,O
use,O
two,O
or,O
more,O
forms,O
of,O
contraception,O
and,O
have,O
monthly,O
pregnancy,O
tests,O
5,O
1,O
Anemia,AdverseReaction
The,O
addition,O
of,O
VICTRELIS,O
to,O
peginterferon,O
alfa,O
and,O
ribavirin,O
is,O
associated,O
with,O
an,O
additional,O
decrease in hemoglobin concentrations,AdverseReaction
compared,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
alone,O
5,O
2,O
Neutropenia,AdverseReaction
The,O
addition,O
of,O
VICTRELIS,O
to,O
peginterferon,O
alfa,O
and,O
ribavirin,O
may,Factor
result,O
in,O
worsening of neutropenia,AdverseReaction
associated,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
therapy,O
alone,O
5,O
3,O
Hypersensitivity,AdverseReaction
Serious,Severity
acute hypersensitivity reactions,AdverseReaction
e,O
g,O
urticaria,AdverseReaction
angioedema,AdverseReaction
have,O
been,O
observed,O
during,O
combination,O
therapy,O
with,O
VICTRELIS,O
peginterferon,O
alfa,O
and,O
ribavirin,O
5,O
5,O
5,O
1,O
Embryofetal,O
Toxicity,O
Use,O
with,O
Ribavirin,O
and,O
Peginterferon,O
Alfa,O
Ribavirin,O
may,Factor
cause,O
birth defects,AdverseReaction
and,O
or,O
death of the exposed fetus,AdverseReaction
Extreme,O
care,O
must,O
be,O
taken,O
to,O
avoid,O
pregnancy,O
in,O
female,O
patients,O
and,O
in,O
female,O
partners,O
of,O
male,O
patients,O
Ribavirin,O
therapy,O
should,O
not,O
be,O
started,O
unless,O
a,O
report,O
of,O
a,O
negative,O
pregnancy,O
test,O
has,O
been,O
obtained,O
immediately,O
prior,O
to,O
initiation,O
of,O
therapy,O
Refer,O
to,O
the,O
prescribing,O
information,O
for,O
ribavirin,O
for,O
additional,O
information,O
Women,O
of,O
childbearing,O
potential,O
and,O
men,O
must,O
use,O
at,O
least,O
two,O
forms,O
of,O
effective,O
contraception,O
during,O
treatment,O
and,O
for,O
at,O
least,O
6,O
months,O
after,O
treatment,O
has,O
concluded,O
One,O
of,O
these,O
forms,O
of,O
contraception,O
can,O
be,O
a,O
combined,O
oral,O
contraceptive,O
product,O
containing,O
at,O
least,O
1,O
mg,O
of,O
norethindrone,O
Oral,O
contraceptives,O
containing,O
lower,O
doses,O
of,O
norethindrone,O
and,O
other,O
forms,O
of,O
hormonal,O
contraception,O
have,O
not,O
been,O
studied,O
or,O
are,O
contraindicated,O
Routine,O
monthly,O
pregnancy,O
tests,O
must,O
be,O
performed,O
during,O
this,O
time,O
see,O
Contraindications,O
4,O
and,O
Drug,O
Interactions,O
7,O
5,O
2,O
Anemia,O
Use,O
with,O
Ribavirin,O
and,O
Peginterferon,O
Alfa,O
Anemia,AdverseReaction
has,O
been,O
reported,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
therapy,O
The,O
addition,O
of,O
VICTRELIS,O
to,O
peginterferon,O
alfa,O
and,O
ribavirin,O
is,O
associated,O
with,O
an,O
additional decrease in hemoglobin concentrations,AdverseReaction
Complete,O
blood,O
counts,O
with,O
white,O
blood,O
cell,O
differential,O
counts,O
should,O
be,O
obtained,O
pretreatment,O
and,O
at,O
Treatment,O
Weeks,O
2,O
4,O
8,O
and,O
12,O
and,O
should,O
be,O
monitored,O
closely,O
at,O
other,O
time,O
points,O
as,O
clinically,O
appropriate,O
If,O
hemoglobin,O
is,O
less,O
than,O
10,O
g,O
per,O
dL,O
a,O
decrease,O
in,O
dosage,O
of,O
ribavirin,O
is,O
recommended,O
and,O
if,O
hemoglobin,O
is,O
less,O
than,O
8,O
5,O
g,O
per,O
dL,O
discontinuation,O
of,O
ribavirin,O
is,O
recommended,O
see,O
Adverse,O
Reactions,O
6,O
1,O
and,O
Clinical,O
Studies,O
14,O
If,O
ribavirin,O
is,O
permanently,O
discontinued,O
for,O
management,O
of,O
anemia,O
then,O
peginterferon,O
alfa,O
and,O
VICTRELIS,O
must,O
also,O
be,O
discontinued,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Refer,O
to,O
the,O
prescribing,O
information,O
for,O
ribavirin,O
for,O
additional,O
information,O
regarding,O
dose,O
reduction,O
and,O
or,O
discontinuation,O
In,O
clinical,O
trials,O
with,O
VICTRELIS,O
the,O
proportion,O
of,O
subjects,O
who,O
experienced,O
hemoglobin values less than 10 g per dL values,AdverseReaction
and,O
less than 8 5 g per dL,AdverseReaction
was,O
higher,O
in,O
subjects,O
treated,O
with,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
r,O
REBETOL,O
r,O
than,O
in,O
those,O
treated,O
with,O
PegIntron,O
REBETOL,O
alone,O
see,O
Table,O
4,O
With,O
the,O
interventions,O
used,O
for,O
anemia,O
management,O
in,O
the,O
clinical,O
trials,O
the,O
average,O
additional,O
decrease,O
of,O
hemoglobin,O
was,O
approximately,O
1,O
g,O
per,O
dL,O
In,O
clinical,O
trials,O
the,O
median,O
time,O
to,O
onset,O
of,O
hemoglobin less than 10 g per dL,AdverseReaction
from,O
the,O
initiation,O
of,O
therapy,O
was,O
similar,O
among,O
subjects,O
treated,O
with,O
the,O
combination,O
of,O
VICTRELIS,O
and,O
PegIntron,O
REBETOL,O
71,O
days,O
with,O
a,O
range,O
of,O
15,O
337,O
days,O
compared,O
to,O
those,O
who,O
received,O
PegIntron,O
REBETOL,O
71,O
days,O
with,O
a,O
range,O
of,O
8,O
337,O
days,O
Certain,O
adverse,O
reactions,O
consistent,O
with,O
symptoms,O
of,O
anemia,AdverseReaction
such,O
as,O
dyspnea,AdverseReaction
exertional dyspnea,AdverseReaction
dizziness,AdverseReaction
and,O
syncope,AdverseReaction
were,O
reported,O
more,O
frequently,O
in,O
subjects,O
who,O
received,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
than,O
in,O
those,O
treated,O
with,O
PegIntron,O
REBETOL,O
alone,O
see,O
Adverse,O
Reactions,O
6,O
1,O
In,O
clinical,O
trials,O
with,O
VICTRELIS,O
dose,O
modifications,O
generally,O
of,O
PegIntron,O
REBETOL,O
due,O
to,O
anemia,AdverseReaction
occurred,O
twice,O
as,O
often,O
in,O
subjects,O
treated,O
with,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
26,O
compared,O
to,O
PegIntron,O
REBETOL,O
13,O
The,O
proportion,O
of,O
subjects,O
who,O
discontinued,O
study,O
drug,O
due,O
to,O
anemia,AdverseReaction
was,O
1,O
in,O
subjects,O
treated,O
with,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
and,O
1,O
in,O
subjects,O
who,O
received,O
PegIntron,O
REBETOL,O
The,O
use,O
of,O
erythropoiesis,O
stimulating,O
agents,O
ESAs,O
was,O
permitted,O
for,O
management,O
of,O
anemia,O
at,O
the,O
investigator,O
s,O
discretion,O
with,O
or,O
without,O
ribavirin,O
dose,O
reduction,O
in,O
the,O
Phase,O
2,O
and,O
3,O
clinical,O
trials,O
The,O
proportion,O
of,O
subjects,O
who,O
received,O
an,O
ESA,O
was,O
43,O
in,O
those,O
treated,O
with,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
compared,O
to,O
24,O
in,O
those,O
treated,O
with,O
PegIntron,O
REBETOL,O
alone,O
The,O
proportion,O
of,O
subjects,O
who,O
received,O
a,O
transfusion,O
for,O
the,O
management,O
of,O
anemia,O
was,O
3,O
of,O
subjects,O
treated,O
with,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
compared,O
to,O
less,O
than,O
1,O
in,O
subjects,O
who,O
received,O
PegIntron,O
REBETOL,O
alone,O
Thromboembolic,O
events,O
have,O
been,O
associated,O
with,O
ESA,O
use,O
in,O
other,O
disease,O
states,O
and,O
have,O
also,O
been,O
reported,O
with,O
peginterferon,O
alfa,O
use,O
in,O
hepatitis,O
C,O
patients,O
Thromboembolic events,AdverseReaction
were,O
reported,O
in,O
clinical,O
trials,O
with,O
VICTRELIS,O
among,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
and,O
among,O
those,O
receiving,O
PegIntron,O
REBETOL,O
alone,O
regardless,O
of,O
ESA,O
use,O
No,O
definite,O
causality,O
assessment,O
or,O
benefit,O
risk,O
assessment,O
could,O
be,O
made,O
for,O
these,O
events,O
due,O
to,O
the,O
presence,O
of,O
confounding,O
factors,O
and,O
lack,O
of,O
randomization,O
of,O
ESA,O
use,O
A,O
randomized,O
parallel,O
arm,O
open,O
label,O
clinical,O
trial,O
was,O
conducted,O
in,O
previously,O
untreated,O
CHC,O
subjects,O
with,O
genotype,O
1,O
infection,O
to,O
compare,O
use,O
of,O
an,O
ESA,O
versus,O
ribavirin,O
dose,O
reduction,O
for,O
initial,O
management,O
of,O
anemia,O
during,O
therapy,O
with,O
VICTRELIS,O
in,O
combination,O
with,O
peginterferon,O
alfa,O
2b,O
and,O
ribavirin,O
Similar,O
SVR,O
rates,O
were,O
reported,O
in,O
subjects,O
who,O
were,O
randomized,O
to,O
receive,O
ribavirin,O
dose,O
reduction,O
compared,O
to,O
subjects,O
who,O
were,O
randomized,O
to,O
receive,O
an,O
ESA,O
In,O
this,O
trial,O
use,O
of,O
ESAs,O
was,O
associated,O
with,O
an,O
increased,O
risk,O
of,O
thromboembolic,O
events,O
including,O
pulmonary,O
embolism,O
acute,O
myocardial,O
infarction,O
cerebrovascular,O
accident,O
and,O
deep,O
vein,O
thrombosis,O
compared,O
to,O
ribavirin,O
dose,O
reduction,O
alone,O
The,O
treatment,O
discontinuation,O
rate,O
due,O
to,O
anemia,AdverseReaction
was,O
similar,O
in,O
subjects,O
randomized,O
to,O
receive,O
ribavirin,O
dose,O
reduction,O
compared,O
to,O
subjects,O
randomized,O
to,O
receive,O
ESA,O
2,O
in,O
each,O
group,O
The,O
transfusion,O
rate,O
was,O
4,O
in,O
subjects,O
randomized,O
to,O
receive,O
ribavirin,O
dose,O
reduction,O
and,O
2,O
in,O
subjects,O
randomized,O
to,O
receive,O
ESA,O
Ribavirin,O
dose,O
reduction,O
is,O
recommended,O
for,O
the,O
initial,O
management,O
of,O
anemia,O
5,O
3,O
Neutropenia,O
Use,O
with,O
Ribavirin,O
and,O
Peginterferon,O
Alfa,O
In,O
Phase,O
2,O
and,O
3,O
clinical,O
trials,O
seven,O
percent,O
of,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
had,O
neutrophil counts of less than 0 5 10 9 per L,AdverseReaction
compared,O
to,O
4,O
of,O
subjects,O
receiving,O
PegIntron,O
REBETOL,O
alone,O
see,O
Table,O
4,O
Three,O
subjects,O
experienced,O
severe,Severity
or,O
life threatening,Severity
infections,AdverseReaction
associated,O
with,O
neutropenia,AdverseReaction
and,O
two,O
subjects,O
experienced,O
life threatening,Severity
neutropenia,AdverseReaction
while,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
Complete,O
blood,O
counts,O
with,O
white,O
blood,O
cell,O
differential,O
counts,O
should,O
be,O
obtained,O
at,O
pretreatment,O
and,O
at,O
Treatment,O
Weeks,O
2,O
4,O
8,O
and,O
12,O
and,O
should,O
be,O
monitored,O
closely,O
at,O
other,O
time,O
points,O
as,O
clinically,O
appropriate,O
Decreases,O
in,O
neutrophil,O
counts,O
may,O
require,O
dose,O
reduction,O
or,O
discontinuation,O
of,O
peginterferon,O
alfa,O
and,O
ribavirin,O
If,O
peginterferon,O
alfa,O
and,O
ribavirin,O
are,O
permanently,O
discontinued,O
then,O
VICTRELIS,O
must,O
also,O
be,O
discontinued,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Refer,O
to,O
the,O
prescribing,O
information,O
for,O
peginterferon,O
alfa,O
and,O
ribavirin,O
for,O
additional,O
information,O
regarding,O
dose,O
reduction,O
or,O
discontinuation,O
5,O
4,O
Pancytopenia,O
Use,O
with,O
Ribavirin,O
and,O
Peginterferon,O
Alfa,O
Serious,Severity
cases,O
of,O
pancytopenia,AdverseReaction
have,O
been,O
reported,O
postmarketing,O
in,O
patients,O
receiving,O
VICTRELIS,O
in,O
combination,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
Complete,O
blood,O
counts,O
with,O
white,O
blood,O
cell,O
differential,O
counts,O
should,O
be,O
obtained,O
at,O
pretreatment,O
and,O
at,O
Treatment,O
Weeks,O
2,O
4,O
8,O
and,O
12,O
and,O
should,O
be,O
monitored,O
closely,O
at,O
other,O
time,O
points,O
as,O
clinically,O
appropriate,O
Refer,O
to,O
the,O
prescribing,O
information,O
for,O
ribavirin,O
and,O
peginterferon,O
alfa,O
for,O
guidelines,O
for,O
discontinuation,O
of,O
therapy,O
based,O
on,O
laboratory,O
parameters,O
5,O
5,O
Hypersensitivity,O
Serious,Severity
acute hypersensitivity reactions,AdverseReaction
e,O
g,O
urticaria,AdverseReaction
angioedema,AdverseReaction
have,O
been,O
observed,O
during,O
combination,O
therapy,O
with,O
VICTRELIS,O
peginterferon,O
alfa,O
and,O
ribavirin,O
If,O
such,O
an,O
acute,O
reaction,O
occurs,O
combination,O
therapy,O
should,O
be,O
discontinued,O
and,O
appropriate,O
medical,O
therapy,O
immediately,O
instituted,O
see,O
Contraindications,O
4,O
and,O
Adverse,O
Reactions,O
6,O
2,O
5,O
6,O
Drug,O
Interactions,O
See,O
Table,O
2,O
for,O
a,O
listing,O
of,O
drugs,O
that,O
are,O
contraindicated,O
for,O
use,O
with,O
VICTRELIS,O
due,O
to,O
potentially,O
life,O
threatening,O
adverse,O
events,O
significant,O
drug,O
interactions,O
or,O
loss,O
of,O
virologic,O
activity,O
see,O
Contraindications,O
4,O
Please,O
refer,O
to,O
Table,O
5,O
for,O
established,O
and,O
other,O
potentially,O
significant,O
drug,O
interactions,O
see,O
Drug,O
Interactions,O
7,O
3,O
5,O
7,O
Laboratory,O
Tests,O
HCV,O
RNA,O
levels,O
should,O
be,O
monitored,O
at,O
Treatment,O
Weeks,O
4,O
8,O
12,O
and,O
24,O
at,O
the,O
end,O
of,O
treatment,O
during,O
treatment,O
follow,O
up,O
and,O
for,O
other,O
time,O
points,O
as,O
clinically,O
indicated,O
Use,O
of,O
a,O
sensitive,O
real,O
time,O
reverse,O
transcription,O
polymerase,O
chain,O
reaction,O
RT,O
PCR,O
assay,O
for,O
monitoring,O
HCV,O
RNA,O
levels,O
during,O
treatment,O
is,O
recommended,O
The,O
assay,O
should,O
have,O
a,O
lower,O
limit,O
of,O
HCV,O
RNA,O
quantification,O
of,O
equal,O
to,O
or,O
less,O
than,O
25,O
IU,O
per,O
mL,O
and,O
a,O
limit,O
of,O
HCV,O
RNA,O
detection,O
of,O
approximately,O
10,O
to,O
15,O
IU,O
per,O
mL,O
For,O
the,O
purposes,O
of,O
assessing,O
Response,O
Guided,O
Therapy,O
milestones,O
a,O
confirmed,O
detectable,O
but,O
below,O
limit,O
of,O
quantification,O
HCV,O
RNA,O
result,O
should,O
not,O
be,O
considered,O
equivalent,O
to,O
an,O
undetectable,O
HCV,O
RNA,O
result,O
reported,O
as,O
Target,O
Not,O
Detected,O
or,O
HCV,O
RNA,O
Not,O
Detected,O
Complete,O
blood,O
count,O
with,O
white,O
blood,O
cell,O
differential,O
counts,O
should,O
be,O
obtained,O
at,O
pretreatment,O
and,O
at,O
Treatment,O
Weeks,O
2,O
4,O
8,O
and,O
12,O
and,O
should,O
be,O
monitored,O
closely,O
at,O
other,O
time,O
points,O
as,O
clinically,O
appropriate,O
Refer,O
to,O
the,O
prescribing,O
information,O
for,O
peginterferon,O
alfa,O
and,O
ribavirin,O
for,O
pre,O
treatment,O
on,O
treatment,O
and,O
post,O
treatment,O
laboratory,O
testing,O
recommendations,O
including,O
hematology,O
biochemistry,O
including,O
hepatic,O
function,O
tests,O
and,O
pregnancy,O
testing,O
requirements,O
""
6,O
ADVERSE,O
REACTIONS,O
See,O
the,O
peginterferon,O
alfa,O
and,O
ribavirin,O
prescribing,O
information,O
for,O
description,O
of,O
adverse,O
reactions,O
associated,O
with,O
their,O
use,O
EXCERPT,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
greater,O
than,O
35,O
of,O
subjects,O
in,O
clinical,O
trials,O
in,O
adult,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
and,O
REBETOL,O
were,O
fatigue,AdverseReaction
anemia,AdverseReaction
nausea,AdverseReaction
headache,AdverseReaction
and,O
dysgeusia,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Merck,O
Sharp,O
Dohme,O
Corp,O
a,O
subsidiary,O
of,O
Merck,O
Co,O
Inc,O
at,O
1,O
877,O
888,O
4231,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
clinical,O
trials,O
of,O
VICTRELIS,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
following,O
serious,O
and,O
otherwise,O
important,O
adverse,O
drug,O
reactions,O
ADRs,O
are,O
discussed,O
in,O
detail,O
in,O
another,O
section,O
of,O
the,O
labeling,O
Anemia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Neutropenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Pancytopenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Hypersensitivity,AdverseReaction
see,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
5,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
more,O
than,O
35,O
of,O
subjects,O
regardless,O
of,O
investigator,O
s,O
causality,O
assessment,O
in,O
adult,O
subjects,O
were,O
fatigue,AdverseReaction
anemia,AdverseReaction
nausea,AdverseReaction
headache,AdverseReaction
and,O
dysgeusia,AdverseReaction
when,O
VICTRELIS,O
was,O
used,O
in,O
combination,O
with,O
PegIntron,O
and,O
REBETOL,O
The,O
safety,O
of,O
the,O
combination,O
of,O
VICTRELIS,O
800,O
mg,O
three,O
times,O
daily,O
with,O
PegIntron,O
REBETOL,O
was,O
assessed,O
in,O
2095,O
subjects,O
with,O
chronic,O
hepatitis,O
C,O
in,O
one,O
Phase,O
2,O
open,O
label,O
trial,O
and,O
two,O
Phase,O
3,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
clinical,O
trials,O
SPRINT,O
1,O
subjects,O
who,O
were,O
previously,O
untreated,O
evaluated,O
the,O
use,O
of,O
VICTRELIS,O
in,O
combination,O
with,O
PegIntron,O
REBETOL,O
with,O
or,O
without,O
a,O
four,O
week,O
lead,O
in,O
period,O
with,O
PegIntron,O
REBETOL,O
compared,O
to,O
PegIntron,O
REBETOL,O
alone,O
SPRINT,O
2,O
subjects,O
who,O
were,O
previously,O
untreated,O
and,O
RESPOND,O
2,O
subjects,O
who,O
had,O
failed,O
previous,O
therapy,O
evaluated,O
the,O
use,O
of,O
VICTRELIS,O
800,O
mg,O
three,O
times,O
daily,O
in,O
combination,O
with,O
PegIntron,O
REBETOL,O
with,O
a,O
four,O
week,O
lead,O
in,O
period,O
with,O
PegIntron,O
REBETOL,O
compared,O
to,O
PegIntron,O
REBETOL,O
alone,O
see,O
Clinical,O
Studies,O
14,O
The,O
population,O
studied,O
had,O
a,O
mean,O
age,O
of,O
49,O
years,O
3,O
of,O
subjects,O
were,O
older,O
than,O
65,O
years,O
of,O
age,O
39,O
were,O
female,O
82,O
were,O
white,O
and,O
15,O
were,O
black,O
During,O
the,O
four,O
week,O
lead,O
in,O
period,O
with,O
PegIntron,O
REBETOL,O
in,O
subjects,O
treated,O
with,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
28,O
1263,O
2,O
subjects,O
experienced,O
adverse,O
reactions,O
leading,O
to,O
discontinuation,O
of,O
treatment,O
During,O
the,O
entire,O
course,O
of,O
treatment,O
the,O
proportion,O
of,O
subjects,O
who,O
discontinued,O
treatment,O
due,O
to,O
adverse,O
reactions,O
was,O
13,O
for,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
and,O
12,O
for,O
subjects,O
receiving,O
PegIntron,O
REBETOL,O
alone,O
Events,O
resulting,O
in,O
discontinuation,O
were,O
similar,O
to,O
those,O
seen,O
in,O
previous,O
studies,O
with,O
PegIntron,O
REBETOL,O
Only,O
anemia,AdverseReaction
and,O
fatigue,AdverseReaction
were,O
reported,O
as,O
events,O
that,O
led,O
to,O
discontinuation,O
in,O
more,O
than,O
1,O
of,O
subjects,O
in,O
any,O
arm,O
Adverse,O
reactions,O
that,O
led,O
to,O
dose,O
modifications,O
of,O
any,O
drug,O
primarily,O
PegIntron,O
and,O
REBETOL,O
occurred,O
in,O
39,O
of,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
compared,O
to,O
24,O
of,O
subjects,O
receiving,O
PegIntron,O
REBETOL,O
alone,O
The,O
most,O
common,O
reason,O
for,O
dose,O
reduction,O
was,O
anemia,AdverseReaction
which,O
occurred,O
more,O
frequently,O
in,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
than,O
in,O
subjects,O
receiving,O
PegIntron,O
REBETOL,O
alone,O
Serious,O
adverse,O
events,O
were,O
reported,O
in,O
11,O
of,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
and,O
in,O
8,O
of,O
subjects,O
receiving,O
PegIntron,O
REBETOL,O
Adverse,O
events,O
regardless,O
of,O
investigator,O
s,O
causality,O
assessment,O
reported,O
in,O
greater,O
than,O
or,O
equal,O
to,O
10,O
of,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
and,O
reported,O
at,O
a,O
rate,O
of,O
greater,O
than,O
or,O
equal,O
to,O
5,O
than,O
PegIntron,O
REBETOL,O
alone,O
in,O
SPRINT,O
1,O
SPRINT,O
2,O
and,O
RESPOND,O
2,O
are,O
presented,O
in,O
Table,O
3,O
Table,O
3,O
Adverse,O
Events,O
Reported,O
in,O
10,O
of,O
Subjects,O
Receiving,O
the,O
Combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
and,O
Reported,O
at,O
a,O
Rate,O
of,O
5,O
than,O
PegIntron,O
REBETOL,O
alone,O
Adverse,O
Events,O
Previously,O
Untreated,O
SPRINT,O
1,O
and,O
SPRINT,O
2,O
Previous,O
Treatment,O
Failures,O
RESPOND,O
2,O
Percentage,O
of,O
Subjects,O
Reporting,O
Adverse,O
Events,O
Percentage,O
of,O
Subjects,O
Reporting,O
Adverse,O
Events,O
Body,O
System,O
Organ,O
Class,O
VICTRELIS,O
PegIntron,O
REBETOL,O
n,O
1225,O
PegIntron,O
REBETOL,O
n,O
467,O
VICTRELIS,O
PegIntron,O
REBETOL,O
n,O
323,O
PegIntron,O
REBETOL,O
n,O
80,O
Median,O
Exposure,O
days,O
197,O
216,O
253,O
104,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
Anemia,AdverseReaction
50,O
30,O
45,O
20,O
Neutropenia,AdverseReaction
25,O
19,O
14,O
10,O
Gastrointestinal,O
Disorders,O
Nausea,AdverseReaction
46,O
42,O
43,O
38,O
Dysgeusia,AdverseReaction
35,O
16,O
44,O
11,O
Diarrhea,AdverseReaction
25,O
22,O
24,O
16,O
Vomiting,AdverseReaction
20,O
13,O
15,O
8,O
Dry Mouth,AdverseReaction
11,O
10,O
15,O
9,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Fatigue,AdverseReaction
58,O
59,O
55,O
50,O
Chills,AdverseReaction
34,O
29,O
33,O
30,O
Asthenia,AdverseReaction
15,O
18,O
21,O
16,O
Metabolism,O
and,O
Nutrition,O
Disorders,O
Decreased Appetite,AdverseReaction
25,O
24,O
26,O
16,O
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Arthralgia,AdverseReaction
19,O
19,O
23,O
16,O
Nervous,O
System,O
Disorders,O
Dizziness,AdverseReaction
19,O
16,O
16,O
10,O
Psychiatric,O
Disorders,O
Insomnia,AdverseReaction
34,O
34,O
30,O
24,O
Irritability,AdverseReaction
22,O
23,O
21,O
13,O
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Dyspnea Exertional,AdverseReaction
8,O
8,O
11,O
5,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Alopecia,AdverseReaction
27,O
27,O
22,O
16,O
Dry Skin,AdverseReaction
18,O
18,O
22,O
9,O
Rash,AdverseReaction
17,O
19,O
16,O
6,O
Other,O
Important,O
Adverse,O
Reactions,O
Reported,O
in,O
Clinical,O
Trials,O
Among,O
subjects,O
previously,O
untreated,O
subjects,O
or,O
those,O
who,O
failed,O
previous,O
therapy,O
who,O
received,O
VICTRELIS,O
in,O
combination,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
the,O
following,O
adverse,O
drug,O
reactions,O
were,O
reported,O
These,O
events,O
are,O
notable,O
because,O
of,O
their,O
seriousness,O
severity,O
or,O
increased,O
frequency,O
in,O
subjects,O
who,O
received,O
VICTRELIS,O
in,O
combination,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
compared,O
with,O
subjects,O
who,O
received,O
only,O
peginterferon,O
alfa,O
and,O
ribavirin,O
Gastrointestinal,O
Disorders,O
Dysgeusia,AdverseReaction
alteration of taste,AdverseReaction
was,O
an,O
adverse,O
event,O
reported,O
at,O
an,O
increased,O
frequency,O
in,O
subjects,O
receiving,O
VICTRELIS,O
in,O
combination,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
compared,O
with,O
subjects,O
receiving,O
peginterferon,O
alfa,O
and,O
ribavirin,O
alone,O
Table,O
3,O
Adverse,O
events,O
such,O
as,O
dry mouth,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
and,O
diarrhea,AdverseReaction
were,O
also,O
reported,O
at,O
an,O
increased,O
frequency,O
in,O
subjects,O
receiving,O
VICTRELIS,O
in,O
combination,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
Laboratory,O
Values,O
Changes,O
in,O
selected,O
hematological,O
parameters,O
during,O
treatment,O
of,O
adult,O
subjects,O
with,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
and,O
REBETOL,O
are,O
described,O
in,O
Table,O
4,O
Hemoglobin,O
Decreases,O
in,O
hemoglobin,O
may,O
require,O
a,O
decrease,O
in,O
dosage,O
or,O
discontinuation,O
of,O
ribavirin,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
and,O
Clinical,O
Studies,O
14,O
see,O
prescribing,O
information,O
for,O
ribavirin,O
If,O
ribavirin,O
is,O
permanently,O
discontinued,O
then,O
peginterferon,O
alfa,O
and,O
VICTRELIS,O
must,O
also,O
be,O
discontinued,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Neutrophils,O
and,O
Platelets,O
The,O
proportion,O
of,O
subjects,O
with,O
decreased neutrophil,AdverseReaction
and,O
platelet counts,AdverseReaction
was,O
higher,O
in,O
subjects,O
treated,O
with,O
VICTRELIS,O
in,O
combination,O
with,O
PegIntron,O
REBETOL,O
compared,O
to,O
subjects,O
receiving,O
PegIntron,O
REBETOL,O
alone,O
Three,O
percent,O
of,O
subjects,O
receiving,O
the,O
combination,O
of,O
VICTRELIS,O
with,O
PegIntron,O
REBETOL,O
had,O
platelet counts of less than 50 10 9 per L,AdverseReaction
compared,O
to,O
1,O
of,O
subjects,O
receiving,O
PegIntron,O
REBETOL,O
alone,O
Decreases,O
in,O
neutrophils,O
or,O
platelets,O
may,O
require,O
a,O
decrease,O
in,O
dosage,O
or,O
interruption,O
of,O
peginterferon,O
alfa,O
or,O
discontinuation,O
of,O
therapy,O
see,O
prescribing,O
information,O
for,O
peginterferon,O
alfa,O
and,O
ribavirin,O
If,O
peginterferon,O
alfa,O
is,O
permanently,O
discontinued,O
then,O
ribavirin,O
and,O
VICTRELIS,O
must,O
also,O
be,O
discontinued,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Table,O
4,O
Selected,O
Hematological,O
Parameters,O
Previously,O
Untreated,O
SPRINT,O
1,O
and,O
SPRINT,O
2,O
Previous,O
Treatment,O
Failures,O
RESPOND,O
2,O
Percentage,O
of,O
Subjects,O
Reporting,O
Selected,O
Hematological,O
Parameters,O
Percentage,O
of,O
Subjects,O
Reporting,O
Selected,O
Hematological,O
Parameters,O
Hematological,O
Parameters,O
VICTRELIS,O
PegIntron,O
REBETOL,O
n,O
1225,O
PegIntron,O
REBETOL,O
n,O
467,O
VICTRELIS,O
PegIntron,O
REBETOL,O
n,O
323,O
PegIntron,O
REBETOL,O
n,O
80,O
Hemoglobin g dL 10,AdverseReaction
49,O
29,O
49,O
25,O
8,O
5,O
6,O
3,O
10,O
1,O
Neutrophils 10 9 L 0 75,AdverseReaction
31,O
18,O
26,O
13,O
0,O
5,O
8,O
4,O
7,O
4,O
Platelets 10 9 L 50,AdverseReaction
3,O
1,O
4,O
0,O
25,O
1,O
0,O
0,O
0,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
VICTRELIS,O
in,O
combination,O
with,O
peginterferon,O
alfa,O
and,O
ribavirin,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Blood,O
and,O
Lymphatic,O
System,O
Disorders,O
agranulocytosis,AdverseReaction
pancytopenia,AdverseReaction
thrombocytopenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Gastrointestinal,O
Disorders,O
mouth ulceration,AdverseReaction
stomatitis,AdverseReaction
Infections,O
and,O
Infestations,O
pneumonia,AdverseReaction
sepsis,AdverseReaction
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
angioedema,AdverseReaction
urticaria,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
drug rash with eosinophilia and systemic symptoms,AdverseReaction
DRESS,AdverseReaction
syndrome,AdverseReaction
exfoliative rash,AdverseReaction
exfoliative dermatitis,AdverseReaction
Stevens Johnson syndrome,AdverseReaction
toxic skin eruption,AdverseReaction
toxicoderma,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Anaphylaxis,AdverseReaction
and,O
Hypersensitivity Reactions,AdverseReaction
Life threatening,Severity
anaphylaxis,AdverseReaction
and,O
hypersensitivity,AdverseReaction
reactions,O
have,O
been,O
observed,O
in,O
some,O
patients,O
during,O
treatment,O
with,O
Vimizim,O
If,O
anaphylaxis,O
or,O
severe,O
hypersensitivity,O
reactions,O
occur,O
immediately,O
stop,O
the,O
infusion,O
and,O
initiate,O
appropriate,O
medical,O
treatment,O
Pre,O
treatment,O
with,O
antihistamines,O
with,O
or,O
without,O
antipyretics,O
is,O
recommended,O
prior,O
to,O
the,O
start,O
of,O
infusion,O
5,O
1,O
Risk,Factor
of,O
Acute Respiratory Complications,AdverseReaction
Patients,O
with,O
acute,O
febrile,O
or,O
respiratory,O
illness,O
may,O
be,O
at,O
higher,O
risk,O
of,O
life threatening,Severity
complications,O
from,O
hypersensitivity reactions,AdverseReaction
Careful,O
consideration,O
should,O
be,O
given,O
to,O
the,O
patient,O
s,O
clinical,O
status,O
prior,O
to,O
administration,O
of,O
Vimizim,O
and,O
consider,O
delaying,O
the,O
Vimizim,O
infusion,O
5,O
2,O
5,O
1,O
Anaphylaxis,O
and,O
Hypersensitivity,O
Reactions,O
Anaphylaxis,AdverseReaction
and,O
hypersensitivity,AdverseReaction
reactions,O
have,O
been,O
reported,O
in,O
patients,O
treated,O
with,O
Vimizim,O
In,O
premarketing,O
clinical,O
trials,O
18,O
of,O
235,O
7,O
7,O
patients,O
treated,O
with,O
Vimizim,O
experienced,O
signs,O
and,O
symptoms,O
consistent,O
with,O
anaphylaxis,AdverseReaction
These,O
18,O
patients,O
experienced,O
26,O
anaphylactic reactions,AdverseReaction
during,O
infusion,O
with,O
signs,O
and,O
symptoms,O
including,O
cough,AdverseReaction
erythema,AdverseReaction
throat tightness,AdverseReaction
urticaria,AdverseReaction
flushing,AdverseReaction
cyanosis,AdverseReaction
hypotension,AdverseReaction
rash,AdverseReaction
dyspnea,AdverseReaction
chest discomfort,AdverseReaction
and,O
gastrointestinal symptoms,AdverseReaction
e,O
g,O
nausea,AdverseReaction
abdominal pain,AdverseReaction
retching,AdverseReaction
and,O
vomiting,AdverseReaction
in,O
conjunction,O
with,O
urticaria,AdverseReaction
These,O
cases,O
of,O
anaphylaxis,AdverseReaction
occurred,O
as,O
early,O
as,O
30,O
minutes,O
from,O
the,O
start,O
of,O
infusion,O
and,O
up,O
to,O
three,O
hours,O
after,O
infusion,O
Anaphylaxis,AdverseReaction
occurred,O
as,O
late,O
into,O
treatment,O
as,O
the,O
47,O
th,O
infusion,O
In,O
clinical,O
trials,O
with,O
Vimizim,O
44,O
of,O
235,O
18,O
7,O
patients,O
experienced,O
hypersensitivity,AdverseReaction
reactions,O
including,O
anaphylaxis,AdverseReaction
Hypersensitivity,AdverseReaction
reactions,O
have,O
occurred,O
as,O
early,O
as,O
30,O
minutes,O
from,O
the,O
start,O
of,O
infusion,O
but,O
as,O
late,O
as,O
six,O
days,O
after,O
infusion,O
Frequent,O
symptoms,O
of,O
hypersensitivity,AdverseReaction
reactions,O
occurring,O
in,O
more,O
than,O
2,O
patients,O
included,O
anaphylactic reactions,AdverseReaction
urticaria,AdverseReaction
peripheral edema,AdverseReaction
cough,AdverseReaction
dyspnea,AdverseReaction
and,O
flushing,AdverseReaction
Due,O
to,O
the,O
potential,O
for,O
anaphylaxis,O
appropriate,O
medical,O
support,O
should,O
be,O
readily,O
available,O
when,O
Vimizim,O
is,O
administered,O
Observe,O
patients,O
closely,O
for,O
an,O
appropriate,O
period,O
of,O
time,O
after,O
administration,O
of,O
Vimizim,O
taking,O
into,O
account,O
the,O
time,O
to,O
onset,O
of,O
anaphylaxis,O
seen,O
in,O
premarketing,O
clinical,O
trials,O
Inform,O
patients,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
anaphylaxis,O
and,O
instruct,O
them,O
to,O
seek,O
immediate,O
medical,O
care,O
should,O
signs,O
and,O
symptoms,O
occur,O
Because,O
of,O
the,O
potential,O
for,O
hypersensitivity,O
reactions,O
administer,O
antihistamines,O
with,O
or,O
without,O
antipyretics,O
prior,O
to,O
infusion,O
Management,O
of,O
hypersensitivity,O
reactions,O
should,O
be,O
based,O
on,O
the,O
severity,O
of,O
the,O
reaction,O
and,O
include,O
slowing,O
or,O
temporary,O
interruption,O
of,O
the,O
infusion,O
and,O
or,O
administration,O
of,O
additional,O
antihistamines,O
antipyretics,O
and,O
or,O
corticosteroids,O
for,O
mild,O
reactions,O
However,O
if,O
severe,O
hypersensitivity,O
reactions,O
occur,O
immediately,O
stop,O
the,O
infusion,O
of,O
Vimizim,O
and,O
initiate,O
appropriate,O
treatment,O
Consider,O
the,O
risks,O
and,O
benefits,O
of,O
re,O
administering,O
Vimizim,O
following,O
a,O
severe,O
reaction,O
5,O
2,O
Risk,O
of,O
Acute,O
Respiratory,O
Complications,O
Patients,O
with,O
acute,O
febrile,O
or,O
respiratory,O
illness,O
at,O
the,O
time,O
of,O
Vimizim,O
infusion,O
may,O
be,O
at,O
higher,O
risk,Factor
of,O
life threatening,Severity
complications,O
from,O
hypersensitivity reactions,AdverseReaction
Careful,O
consideration,O
should,O
be,O
given,O
to,O
the,O
patient,O
s,O
clinical,O
status,O
prior,O
to,O
administration,O
of,O
Vimizim,O
and,O
consider,O
delaying,O
the,O
Vimizim,O
infusion,O
Sleep,O
apnea,O
is,O
common,O
in,O
MPS,O
IVA,O
patients,O
Evaluation,O
of,O
airway,O
patency,O
should,O
be,O
considered,O
prior,O
to,O
initiation,O
of,O
treatment,O
with,O
Vimizim,O
Patients,O
using,O
supplemental,O
oxygen,O
or,O
continuous,O
positive,O
airway,O
pressure,O
CPAP,O
during,O
sleep,O
should,O
have,O
these,O
treatments,O
readily,O
available,O
during,O
infusion,O
in,O
the,O
event,O
of,O
an,O
acute,O
reaction,O
or,O
extreme,O
drowsiness,O
sleep,O
induced,O
by,O
antihistamine,O
use,O
5,O
3,O
Spinal,O
or,O
Cervical,O
Cord,O
Compression,O
Spinal,O
or,O
cervical,O
cord,O
compression,O
SCC,O
is,O
a,O
known,O
and,O
serious,O
complication,O
of,O
MPS,O
IVA,O
and,O
may,O
occur,O
as,O
part,O
of,O
the,O
natural,O
history,O
of,O
the,O
disease,O
In,O
clinical,O
trials,O
SCC,O
was,O
observed,O
both,O
in,O
patients,O
receiving,O
Vimizim,O
and,O
patients,O
receiving,O
placebo,O
Patients,O
with,O
MPS,O
IVA,O
should,O
be,O
monitored,O
for,O
signs,O
and,O
symptoms,O
of,O
SCC,O
including,O
back,O
pain,O
paralysis,O
of,O
limbs,O
below,O
the,O
level,O
of,O
compression,O
urinary,O
and,O
fecal,O
incontinence,O
and,O
given,O
appropriate,O
clinical,O
care,O
""
BOXED,O
WARNING,O
WARNING,O
RISK,Factor
OF,O
ANAPHYLAXIS,AdverseReaction
WARNING,O
RISK,Factor
OF,O
ANAPHYLAXIS,AdverseReaction
Life threatening,Severity
anaphylactic reactions,AdverseReaction
have,O
occurred,O
in,O
some,O
patients,O
during,O
Vimizim,O
infusions,O
Anaphylaxis,AdverseReaction
presenting,O
as,O
cough,AdverseReaction
erythema,AdverseReaction
throat tightness,AdverseReaction
urticaria,AdverseReaction
flushing,AdverseReaction
cyanosis,AdverseReaction
hypotension,AdverseReaction
rash,AdverseReaction
dyspnea,AdverseReaction
chest discomfort,AdverseReaction
and,O
gastrointestinal symptoms,AdverseReaction
e,O
g,O
nausea,AdverseReaction
abdominal pain,AdverseReaction
retching,AdverseReaction
and,O
vomiting,AdverseReaction
in,O
conjunction,O
with,O
urticaria,AdverseReaction
have,O
been,O
reported,O
to,O
occur,O
during,O
Vimizim,O
infusions,O
regardless,O
of,O
duration,O
of,O
the,O
course,O
of,O
treatment,O
Closely,O
observe,O
patients,O
during,O
and,O
after,O
Vimizim,O
administration,O
and,O
be,O
prepared,O
to,O
manage,O
anaphylaxis,O
Inform,O
patients,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
anaphylaxis,O
and,O
have,O
them,O
seek,O
immediate,O
medical,O
care,O
should,O
symptoms,O
occur,O
Patients,O
with,O
acute,O
respiratory,O
illness,O
may,O
be,O
at,O
risk,O
of,O
serious,O
acute,O
exacerbation,O
of,O
their,O
respiratory,O
compromise,O
due,O
to,O
hypersensitivity,O
reactions,O
and,O
require,O
additional,O
monitoring,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
2,O
and,O
Adverse,O
Reactions,O
6,O
EXCERPT,O
WARNING,O
RISK,Factor
OF,O
ANAPHYLAXIS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Life threatening,Severity
anaphylactic reactions,AdverseReaction
have,O
occurred,O
in,O
some,O
patients,O
during,O
Vimizim,O
infusions,O
Anaphylaxis,AdverseReaction
presenting,O
as,O
cough,AdverseReaction
erythema,AdverseReaction
throat tightness,AdverseReaction
urticaria,AdverseReaction
flushing,AdverseReaction
cyanosis,AdverseReaction
hypotension,AdverseReaction
rash,AdverseReaction
dyspnea,AdverseReaction
chest discomfort,AdverseReaction
and,O
gastrointestinal symptoms,AdverseReaction
in,O
conjunction,O
with,O
urticaria,AdverseReaction
have,O
been,O
reported,O
to,O
occur,O
during,O
infusions,O
regardless,O
of,O
duration,O
of,O
the,O
course,O
of,O
treatment,O
Closely,O
observe,O
patients,O
during,O
and,O
after,O
Vimizim,O
administration,O
and,O
be,O
prepared,O
to,O
manage,O
anaphylaxis,O
Inform,O
patients,O
of,O
the,O
signs,O
and,O
symptoms,O
of,O
anaphylaxis,O
and,O
have,O
them,O
seek,O
immediate,O
medical,O
care,O
should,O
symptoms,O
occur,O
Patients,O
with,O
acute,O
respiratory,O
illness,O
may,O
be,O
at,O
risk,O
of,O
serious,O
acute,O
exacerbation,O
of,O
their,O
respiratory,O
compromise,O
due,O
to,O
hypersensitivity,O
reactions,O
and,O
require,O
additional,O
monitoring,O
5,O
1,O
5,O
2,O
6,O
""
6,O
ADVERSE,O
REACTIONS,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
following,O
serious,O
adverse,O
reactions,O
are,O
described,O
below,O
and,O
elsewhere,O
in,O
the,O
labeling,O
Anaphylaxis,AdverseReaction
and,O
hypersensitivity reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
The,O
most,O
common,O
adverse,O
reactions,O
10,O
observed,O
across,O
pre,O
marketing,O
clinical,O
trials,O
were,O
similar,O
in,O
type,O
and,O
frequency,O
as,O
those,O
observed,O
in,O
the,O
placebo,O
controlled,O
trial,O
see,O
Table1,O
The,O
acute,O
reactions,O
requiring,O
intervention,O
were,O
managed,O
by,O
either,O
temporarily,O
interrupting,O
or,O
discontinuing,O
infusion,O
and,O
administering,O
additional,O
antihistamine,O
antipyretics,O
or,O
corticosteroids,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
10,O
in,O
Vimizim,O
patients,O
and,O
occurring,O
at,O
a,O
higher,O
incidence,O
than,O
placebo,O
treated,O
patients,O
were,O
pyrexia,AdverseReaction
vomiting,AdverseReaction
headache,AdverseReaction
nausea,AdverseReaction
abdominal pain,AdverseReaction
chills,AdverseReaction
and,O
fatigue,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
BioMarin,O
at,O
1,O
866,O
906,O
6100,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
A,O
24,O
week,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
clinical,O
trial,O
of,O
Vimizim,O
was,O
conducted,O
in,O
176,O
patients,O
with,O
MPS,O
IVA,O
ages,O
5,O
to,O
57,O
years,O
old,O
Approximately,O
half,O
of,O
the,O
patients,O
49,O
were,O
male,O
Of,O
the,O
176,O
patients,O
65,O
were,O
White,O
23,O
Asian,O
3,O
Black,O
and,O
10,O
Other,O
race,O
The,O
majority,O
of,O
patients,O
78,O
were,O
non,O
Hispanic,O
Patients,O
were,O
randomized,O
to,O
three,O
treatment,O
groups,O
Vimizim,O
2,O
mg,O
kg,O
once,O
per,O
week,O
n,O
58,O
Vimizim,O
2,O
mg,O
kg,O
once,O
every,O
other,O
week,O
n,O
59,O
or,O
placebo,O
n,O
59,O
All,O
patients,O
were,O
treated,O
with,O
antihistamines,O
prior,O
to,O
each,O
infusion,O
Table,O
1,O
summarizes,O
the,O
most,O
common,O
adverse,O
reactions,O
that,O
occurred,O
in,O
the,O
placebo,O
controlled,O
trial,O
with,O
an,O
incidence,O
of,O
10,O
in,O
patients,O
treated,O
with,O
Vimizim,O
2,O
mg,O
kg,O
once,O
per,O
week,O
and,O
with,O
a,O
higher,O
incidence,O
than,O
in,O
the,O
placebo,O
treated,O
patients,O
Table,O
1,O
Adverse,O
Reactions,O
That,O
Occurred,O
in,O
the,O
Placebo,O
Controlled,O
Trial,O
in,O
At,O
Least,O
10,O
of,O
Patients,O
in,O
the,O
Vimizim,O
2,O
mg,O
kg,O
Once,O
Per,O
Week,O
Group,O
and,O
with,O
a,O
Higher,O
Incidence,O
than,O
in,O
the,O
Placebo,O
Group,O
Adverse,O
Reaction,O
Vimizim,O
2,O
mg,O
kg,O
once,O
per,O
week,O
Placebo,O
N,O
58n,O
N,O
59,O
n,O
Pyrexia,AdverseReaction
19,O
33,O
8,O
14,O
Vomiting,AdverseReaction
18,O
31,O
4,O
7,O
Headache,AdverseReaction
15,O
26,O
9,O
15,O
Nausea,AdverseReaction
14,O
24,O
4,O
7,O
Abdominal pain,AdverseReaction
12,O
21,O
1,O
1,O
7,O
Chills,AdverseReaction
6,O
10,O
3,O
1,O
1,O
7,O
Fatigue,AdverseReaction
6,O
10,O
3,O
2,O
3,O
4,O
Extension,O
Trial,O
An,O
open,O
label,O
extension,O
trial,O
was,O
conducted,O
in,O
173,O
patients,O
who,O
completed,O
the,O
placebo,O
controlled,O
trial,O
see,O
Clinical,O
Studies,O
14,O
No,O
new,O
adverse,O
reactions,O
were,O
reported,O
6,O
2,O
Immunogenicity,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
potential,O
for,O
immunogenicity,O
All,O
patients,O
treated,O
with,O
Vimizim,O
2,O
mg,O
kg,O
once,O
per,O
week,O
in,O
the,O
placebo,O
controlled,O
trial,O
developed,O
anti,O
drug,O
antibodies,O
by,O
Week,O
4,O
Anti,O
drug,O
antibody,O
titers,O
were,O
sustained,O
or,O
increased,O
for,O
the,O
duration,O
of,O
Vimizim,O
treatment,O
Because,O
all,O
patients,O
developed,O
anti,O
drug,O
antibodies,O
associations,O
between,O
antibody,O
titers,O
and,O
reductions,O
in,O
treatment,O
effect,O
or,O
the,O
occurrence,O
of,O
anaphylaxis,O
or,O
other,O
hypersensitivity,O
reactions,O
could,O
not,O
be,O
determined,O
All,O
patients,O
treated,O
with,O
Vimizim,O
2,O
mg,O
kg,O
once,O
per,O
week,O
tested,O
positive,O
for,O
neutralizing,O
antibodies,O
capable,O
of,O
inhibiting,O
the,O
drug,O
from,O
binding,O
to,O
the,O
mannose,O
6,O
phosphate,O
receptor,O
at,O
least,O
once,O
during,O
the,O
trial,O
Binding,O
to,O
this,O
receptor,O
is,O
required,O
for,O
Vimizim,O
to,O
be,O
taken,O
into,O
cells,O
where,O
it,O
is,O
active,O
Neutralizing,O
antibody,O
titers,O
were,O
not,O
determined,O
in,O
the,O
patients,O
Therefore,O
the,O
possibility,O
of,O
an,O
association,O
between,O
neutralizing,O
antibody,O
titer,O
and,O
treatment,O
effect,O
cannot,O
be,O
assessed,O
Assessment,O
of,O
the,O
incidence,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
to,O
Vimizim,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hypersensitivity reactions,AdverseReaction
Ask,O
patients,O
about,O
prior,O
reactions,O
to,O
Vizamyl,O
Observe,O
for,O
hypersensitivity,O
signs,O
and,O
symptoms,O
following,O
Vizamyl,O
administration,O
Have,O
resuscitation,O
equipment,O
and,O
trained,O
personnel,O
available,O
at,O
time,O
of,O
Vizamyl,O
administration,O
5,O
1,O
Image,O
interpretation,O
errors,O
especially,O
false,O
positives,O
have,O
been,O
observed,O
5,O
2,O
Radiation risk,AdverseReaction
Vizamyl,O
similar,O
to,O
all,O
radiopharmaceuticals,O
contributes,O
to,O
a,O
patient,O
s,O
long term cumulative radiation exposure,AdverseReaction
Ensure,O
safe,O
handling,O
to,O
protect,O
patients,O
and,O
health,O
care,O
workers,O
from,O
unintentional,O
radiation,O
exposure,O
2,O
1,O
5,O
3,O
5,O
1,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
such,O
as,O
flushing,AdverseReaction
and,O
dyspnea,AdverseReaction
have,O
been,O
observed,O
within,O
minutes,O
following,O
Vizamyl,O
administration,O
These,O
reactions,O
may,O
occur,O
in,O
patients,O
with,O
no,O
history,O
of,O
prior,O
exposure,O
to,O
Vizamyl,O
Before,O
administering,O
Vizamyl,O
ask,O
patients,O
about,O
prior,O
reactions,O
to,O
drugs,O
especially,O
those,O
containing,O
polysorbate,O
80,O
Have,O
resuscitation,O
equipment,O
and,O
trained,O
personnel,O
immediately,O
available,O
at,O
the,O
time,O
of,O
Vizamyl,O
administration,O
see,O
Contraindications,O
4,O
5,O
2,O
Risk,O
for,O
Image,O
Misinterpretation,O
and,O
Other,O
Errors,O
Errors,O
may,O
occur,O
while,O
using,O
Vizamyl,O
PET,O
images,O
to,O
estimate,O
brain,O
neuritic,O
plaque,O
density,O
see,O
Clinical,O
Studies,O
14,O
Image,O
interpretation,O
is,O
performed,O
independently,O
of,O
the,O
patient,O
s,O
clinical,O
information,O
The,O
use,O
of,O
clinical,O
information,O
in,O
the,O
interpretation,O
of,O
Vizamyl,O
images,O
has,O
not,O
been,O
evaluated,O
and,O
may,O
lead,O
to,O
errors,O
Extensive,O
brain,O
atrophy,O
may,O
limit,O
the,O
ability,O
to,O
distinguish,O
grey,O
and,O
white,O
matter,O
on,O
a,O
Vizamyl,O
scan,O
see,O
Dosage,O
and,O
Administration,O
2,O
5,O
Motion,O
artifacts,O
may,O
distort,O
the,O
image,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
Vizamyl,O
scan,O
results,O
are,O
indicative,O
of,O
the,O
brain,O
neuritic,O
amyloid,O
plaque,O
content,O
only,O
at,O
the,O
time,O
of,O
image,O
acquisition,O
and,O
a,O
negative,O
scan,O
result,O
does,O
not,O
preclude,O
the,O
development,O
of,O
brain,O
amyloid,O
in,O
the,O
future,O
5,O
3,O
Radiation,O
Risk,O
Vizamyl,O
similar,O
to,O
other,O
radiopharmaceuticals,O
contributes,O
to,O
a,O
patient,O
s,O
overall,O
long term cumulative radiation exposure,AdverseReaction
Long term cumulative radiation exposure,AdverseReaction
is,O
associated,O
with,O
an,O
increased,O
risk,Factor
of,O
cancer,AdverseReaction
Ensure,O
safe,O
handling,O
to,O
protect,O
patients,O
and,O
health,O
care,O
workers,O
from,O
unintentional,O
radiation,O
exposure,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
EXCERPT,O
Most,O
commonly,O
reported,O
adverse,O
reactions,O
were,O
flushing,AdverseReaction
2,O
headache,AdverseReaction
1,O
increased blood pressure,AdverseReaction
2,O
nausea,AdverseReaction
1,O
and,O
dizziness,AdverseReaction
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
GE,O
Healthcare,O
at,O
1,O
800,O
654,O
0118,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
and,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
Vizamyl,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
In,O
clinical,O
trials,O
761,O
adults,O
367,O
men,O
and,O
394,O
women,O
91,O
Caucasian,O
with,O
a,O
mean,O
age,O
of,O
62,O
years,O
range,O
18,O
93,O
years,O
received,O
Vizamyl,O
Most,O
subjects,O
530,O
70,O
received,O
a,O
dose,O
of,O
185,O
MBq,O
5,O
mCi,O
One,O
subject,O
out,O
of,O
761,O
administered,O
Vizamyl,O
experienced,O
a,O
serious,Severity
hypersensitivity reaction,AdverseReaction
with,O
flushing,AdverseReaction
dyspnea,AdverseReaction
and,O
chest pressure,AdverseReaction
within,O
minutes,O
following,O
Vizamyl,O
administration,O
and,O
recovered,O
with,O
treatment,O
Most,O
adverse,O
reactions,O
were,O
mild,O
to,O
moderate,O
in,O
intensity,O
and,O
resolved,O
spontaneously,O
The,O
most,O
commonly,O
reported,O
adverse,O
reactions,O
occurring,O
in,O
at,O
least,O
1,O
of,O
subjects,O
in,O
Vizamyl,O
treated,O
subjects,O
are,O
shown,O
in,O
Table,O
2,O
Table,O
2,O
Adverse,O
Reactions,O
Reported,O
in,O
Clinical,O
Trials,O
of,O
Vizamyl,O
N,O
761,O
subjects,O
Adverse,O
Reaction,O
N,O
percent,O
of,O
patients,O
Flushing,AdverseReaction
16,O
2,O
Increased blood pressure,AdverseReaction
13,O
2,O
Headache,AdverseReaction
10,O
1,O
Nausea,AdverseReaction
8,O
1,O
Dizziness,AdverseReaction
8,O
1,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Serious,Severity
allergic reactions,AdverseReaction
including,O
anaphylactic reactions,AdverseReaction
may,Factor
occur,O
5,O
1,O
Measurement,O
of,O
methotrexate,O
using,O
immunoassays,O
is,O
unreliable,O
for,O
samples,O
collected,O
within,O
48,O
hours,O
following,O
VORAXAZE,O
administration,O
5,O
2,O
Continue,O
therapy,O
with,O
leucovorin,O
until,O
the,O
methotrexate,O
concentration,O
has,O
been,O
maintained,O
below,O
the,O
leucovorin,O
treatment,O
threshold,O
for,O
a,O
minimum,O
of,O
3,O
days,O
5,O
3,O
Do,O
not,O
administer,O
leucovorin,O
within,O
2,O
hours,O
before,O
or,O
after,O
a,O
dose,O
of,O
VORAXAZE,O
5,O
3,O
For,O
48,O
hours,O
after,O
VORAXAZE,O
administration,O
determine,O
the,O
leucovorin,O
dose,O
based,O
on,O
the,O
patient,O
s,O
pre,O
VORAXAZE,O
methotrexate,O
concentration,O
5,O
3,O
Continue,O
hydration,O
and,O
alkalinization,O
of,O
the,O
urine,O
as,O
indicated,O
5,O
3,O
5,O
1,O
Serious,O
Allergic,O
Reactions,O
Serious,Severity
allergic reactions,AdverseReaction
occurred,O
in,O
less,O
than,O
1,O
of,O
patients,O
see,O
Adverse,O
Reactions,O
6,O
1,O
5,O
2,O
Monitoring,O
Methotrexate,O
Concentration,O
Interference,O
with,O
Assay,O
Methotrexate,O
concentrations,O
within,O
48,O
hours,O
following,O
administration,O
of,O
VORAXAZE,O
can,O
only,O
be,O
reliably,O
measured,O
by,O
a,O
chromatographic,O
method,O
DAMPA,O
4,O
deoxy,O
4,O
amino,O
N,O
10,O
methylpteroic,O
acid,O
is,O
an,O
inactive,O
metabolite,O
of,O
methotrexate,O
resulting,O
from,O
treatment,O
with,O
VORAXAZE,O
DAMPA,O
interferes,O
with,O
the,O
measurement,O
of,O
methotrexate,O
concentration,O
using,O
immunoassays,O
resulting,O
in,O
an,O
erroneous,O
measurement,O
which,O
overestimates,O
the,O
methotrexate,O
concentration,O
Due,O
to,O
the,O
long,O
half,O
life,O
of,O
DAMPA,O
t1,O
2of,O
approximately,O
9,O
hours,O
measurement,O
of,O
methotrexate,O
using,O
immunoassays,O
is,O
unreliable,O
for,O
samples,O
collected,O
within,O
48,O
hours,O
following,O
VORAXAZE,O
administration,O
see,O
Clinical,O
Pharmacology,O
12,O
1,O
5,O
3,O
Continuation,O
and,O
Timing,O
of,O
Leucovorin,O
Rescue,O
Continue,O
to,O
administer,O
leucovorin,O
after,O
VORAXAZE,O
Do,O
not,O
administer,O
leucovorin,O
within,O
2,O
hours,O
before,O
or,O
after,O
a,O
dose,O
of,O
VORAXAZE,O
because,O
leucovorin,O
is,O
a,O
substrate,O
for,O
VORAXAZE,O
see,O
Drug,O
Interactions,O
7,O
1,O
For,O
the,O
first,O
48,O
hours,O
after,O
VORAXAZE,O
administer,O
the,O
same,O
leucovorin,O
dose,O
as,O
given,O
prior,O
to,O
VORAXAZE,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Beyond,O
48,O
hours,O
after,O
VORAXAZE,O
administer,O
leucovorin,O
based,O
on,O
the,O
measured,O
methotrexate,O
concentration,O
Do,O
not,O
discontinue,O
therapy,O
with,O
leucovorin,O
based,O
on,O
the,O
determination,O
of,O
a,O
single,O
methotrexate,O
concentration,O
below,O
the,O
leucovorin,O
treatment,O
threshold,O
Therapy,O
with,O
leucovorin,O
should,O
be,O
continued,O
until,O
the,O
methotrexate,O
concentration,O
has,O
been,O
maintained,O
below,O
the,O
leucovorin,O
treatment,O
threshold,O
for,O
a,O
minimum,O
of,O
3,O
days,O
Continue,O
hydration,O
and,O
alkalinization,O
of,O
the,O
urine,O
as,O
indicated,O
""
6,O
ADVERSE,O
REACTIONS,O
Serious,Severity
allergic reactions,AdverseReaction
including,O
anaphylactic reactions,AdverseReaction
may,Factor
occur,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
1,O
with,O
VORAXAZE,O
are,O
paraesthesias,AdverseReaction
flushing,AdverseReaction
nausea,AdverseReaction
and,O
or,O
vomiting,AdverseReaction
hypotension,AdverseReaction
and,O
headache,AdverseReaction
EXCERPT,O
In,O
clinical,O
trials,O
the,O
most,O
common,O
related,O
adverse,O
events,O
occurring,O
in,O
1,O
of,O
patients,O
were,O
paraesthesia,AdverseReaction
flushing,AdverseReaction
nausea,AdverseReaction
and,O
or,O
vomiting,AdverseReaction
hypotension,AdverseReaction
and,O
headache,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
call,O
877,O
377,O
3784,O
or,O
contact,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
controlled,O
but,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
clinical,O
trials,O
of,O
VORAXAZE,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
other,O
drugs,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
evaluation,O
of,O
adverse,O
reactions,O
in,O
patients,O
treated,O
with,O
VORAXAZE,O
is,O
confounded,O
by,O
the,O
population,O
in,O
which,O
it,O
was,O
studied,O
patients,O
with,O
toxic,O
plasma,O
methotrexate,O
levels,O
due,O
to,O
impaired,O
renal,O
function,O
Adverse,O
reactions,O
related,O
to,O
toxic,O
methotrexate,O
levels,O
due,O
to,O
prolonged,O
methotrexate,O
clearance,O
include,O
myelosuppression,O
mucositis,O
acute,O
hepatitis,O
and,O
renal,O
dysfunction,O
and,O
failure,O
The,O
safety,O
of,O
VORAXAZE,O
is,O
based,O
on,O
data,O
from,O
290,O
patients,O
who,O
were,O
treated,O
in,O
2,O
single,O
arm,O
open,O
label,O
multicenter,O
trials,O
enrolling,O
patients,O
who,O
had,O
markedly,O
delayed,O
methotrexate,O
clearance,O
secondary,O
to,O
renal,O
dysfunction,O
Patients,O
with,O
osteosarcoma,O
were,O
eligible,O
for,O
these,O
studies,O
if,O
the,O
plasma,O
methotrexate,O
concentration,O
was,O
greater,O
than,O
50,O
mumol,O
L,O
at,O
24,O
hours,O
greater,O
that,O
5,O
mumol,O
L,O
at,O
48,O
hours,O
or,O
greater,O
than,O
2,O
standard,O
deviations,O
above,O
the,O
mean,O
methotrexate,O
elimination,O
curve,O
at,O
least,O
12,O
hours,O
after,O
methotrexate,O
administration,O
and,O
there,O
was,O
a,O
2,O
fold,O
or,O
greater,O
increase,O
in,O
serum,O
creatinine,O
above,O
baseline,O
All,O
other,O
patients,O
were,O
eligible,O
for,O
these,O
studies,O
if,O
the,O
plasma,O
methotrexate,O
level,O
was,O
greater,O
than,O
10,O
mumol,O
L,O
more,O
than,O
42,O
hours,O
after,O
the,O
start,O
of,O
the,O
methotrexate,O
or,O
the,O
plasma,O
level,O
was,O
greater,O
than,O
2,O
standard,O
deviations,O
above,O
the,O
mean,O
methotrexate,O
excretion,O
curve,O
at,O
least,O
12,O
hours,O
following,O
methotrexate,O
and,O
the,O
serum,O
creatinine,O
was,O
greater,O
than,O
1,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
or,O
the,O
creatinine,O
clearance,O
was,O
less,O
than,O
60,O
mL,O
min,O
at,O
least,O
12,O
hours,O
following,O
methotrexate,O
administration,O
Study,O
1,O
conducted,O
by,O
the,O
National,O
Cancer,O
Institute,O
NCI,O
enrolled,O
184,O
patients,O
safety,O
information,O
is,O
available,O
for,O
149,O
patients,O
VORAXAZE,O
was,O
given,O
at,O
a,O
dose,O
of,O
50,O
Units,O
kg,O
as,O
an,O
intravenous,O
injection,O
over,O
5,O
minutes,O
Patients,O
with,O
pre,O
VORAXAZE,O
methotrexate,O
concentrations,O
100,O
mumol,O
L,O
were,O
to,O
receive,O
a,O
second,O
dose,O
of,O
VORAXAZE,O
48,O
hours,O
after,O
the,O
first,O
dose,O
The,O
protocol,O
specified,O
that,O
patients,O
continue,O
receiving,O
intravenous,O
hydration,O
urinary,O
alkalinization,O
and,O
leucovorin,O
and,O
that,O
leucovorin,O
administration,O
be,O
adjusted,O
to,O
ensure,O
that,O
it,O
was,O
not,O
administered,O
within,O
two,O
hours,O
before,O
or,O
after,O
VORAXAZE,O
In,O
Study,O
1,O
VORAXAZE,O
related,O
adverse,O
reactions,O
were,O
collected,O
on,O
a,O
flow,O
sheet,O
with,O
a,O
daily,O
log,O
of,O
adverse,O
reactions,O
characterized,O
as,O
glucarpidase,O
toxicity,O
Additional,O
safety,O
information,O
was,O
collected,O
from,O
clinical,O
records,O
submitted,O
by,O
treating,O
physicians,O
This,O
information,O
was,O
abstracted,O
and,O
categorized,O
using,O
the,O
National,O
Cancer,O
Institute,O
NCI,O
Common,O
Terminology,O
Criteria,O
for,O
Adverse,O
Events,O
CTCAE,O
version,O
3,O
scale,O
The,O
Study,O
1,O
population,O
enrolled,O
patients,O
with,O
a,O
median,O
age,O
of,O
18,O
years,O
1,O
month,O
to,O
85,O
years,O
63,O
were,O
male,O
and,O
the,O
underlying,O
malignancies,O
were,O
osteosarcoma,O
sarcomas,O
in,O
32,O
and,O
leukemia,O
or,O
lymphoma,O
in,O
63,O
of,O
patients,O
One,O
n,O
106,O
or,O
2,O
n,O
30,O
doses,O
of,O
VORAXAZE,O
were,O
administered,O
intravenously,O
the,O
number,O
of,O
doses,O
was,O
not,O
specified,O
in,O
13,O
patients,O
Doses,O
ranged,O
from,O
18,O
to,O
98,O
Units,O
kg,O
with,O
a,O
median,O
dose,O
of,O
49,O
Units,O
kg,O
Study,O
2,O
is,O
an,O
ongoing,O
expanded,O
access,O
program,O
At,O
the,O
time,O
of,O
data,O
cut,O
off,O
243,O
patients,O
were,O
enrolled,O
and,O
safety,O
data,O
was,O
available,O
for,O
141,O
patients,O
VORAXAZE,O
was,O
given,O
at,O
a,O
dose,O
of,O
50,O
Units,O
kg,O
as,O
an,O
intravenous,O
injection,O
over,O
5,O
minutes,O
The,O
criterion,O
for,O
allowing,O
patients,O
to,O
receive,O
a,O
second,O
glucarpidase,O
dose,O
was,O
not,O
specified,O
in,O
the,O
protocol,O
The,O
protocol,O
specified,O
that,O
patients,O
continue,O
receiving,O
intravenous,O
hydration,O
urinary,O
alkalinization,O
and,O
leucovorin,O
and,O
that,O
leucovorin,O
administration,O
be,O
adjusted,O
to,O
ensure,O
that,O
it,O
was,O
not,O
administered,O
within,O
two,O
hours,O
before,O
or,O
after,O
VORAXAZE,O
Study,O
2,O
enrolled,O
patients,O
with,O
a,O
median,O
age,O
of,O
17,O
years,O
6,O
months,O
to,O
85,O
years,O
64,O
were,O
male,O
and,O
the,O
underlying,O
malignancies,O
were,O
osteogenic,O
sarcoma,O
in,O
32,O
and,O
leukemia,O
or,O
lymphoma,O
in,O
62,O
of,O
patients,O
One,O
n,O
122,O
or,O
2,O
n,O
18,O
doses,O
of,O
VORAXAZE,O
were,O
administered,O
intravenously,O
the,O
number,O
of,O
doses,O
was,O
not,O
specified,O
for,O
1,O
patient,O
Doses,O
ranged,O
from,O
6,O
to,O
189,O
Units,O
kg,O
with,O
a,O
median,O
dose,O
of,O
50,O
Units,O
kg,O
In,O
Study,O
2,O
only,O
VORAXAZE,O
related,O
adverse,O
reactions,O
were,O
collected,O
and,O
severity,O
was,O
graded,O
according,O
to,O
NCI,O
CTCAE,O
version,O
3,O
Among,O
the,O
290,O
patients,O
included,O
in,O
the,O
safety,O
evaluation,O
of,O
VORAXAZE,O
there,O
were,O
8,O
deaths,AdverseReaction
within,O
30,O
days,O
of,O
VORAXAZE,O
exposure,O
that,O
were,O
not,O
related,O
to,O
progressive,O
disease,O
Twenty,O
one,O
of,O
290,O
patients,O
7,O
experienced,O
adverse,O
reactions,O
that,O
were,O
assessed,O
as,O
related,O
to,O
VORAXAZE,O
Most,O
were,O
Grade,O
1,O
or,O
2,O
events,O
One,O
patient,O
experienced,O
related,O
Grade 3,Severity
flushing,AdverseReaction
The,O
most,O
common,O
related,O
adverse,O
reactions,O
that,O
were,O
not,O
hematologic,O
hepatic,O
or,O
renal,O
events,O
were,O
paresthesia,AdverseReaction
flushing,AdverseReaction
and,O
nausea,AdverseReaction
and,O
or,O
vomiting,AdverseReaction
which,O
each,O
occurred,O
in,O
2,O
of,O
patients,O
Table,O
1,O
Table,O
1,O
Per,O
Patient,O
Incidence,O
of,O
Grade,O
1,O
and,O
2,O
Adverse,O
Reactions,O
Assessed,O
as,O
Possibly,O
Probably,O
or,O
Definitely,O
Related,O
to,O
VORAXAZE,O
Excluding,O
Hematologic,O
Hepatic,O
or,O
Renal,O
Adverse,O
Reactions,O
1,O
This,O
incidence,O
includes,O
the,O
following,O
terms,O
flushing,AdverseReaction
feeling hot,AdverseReaction
burning sensation,AdverseReaction
2,O
One,O
of,O
these,O
reactions,O
was,O
classified,O
as,O
Grade,O
3,O
in,O
severity,O
Adverse,O
Reaction,O
N,O
290n,O
Paresthesias,AdverseReaction
7,O
2,O
Flushing,AdverseReaction
1,O
2,O
5,O
2,O
Nausea,AdverseReaction
Vomiting,AdverseReaction
5,O
2,O
Headache,AdverseReaction
2,O
1,O
Hypotension,AdverseReaction
2,O
1,O
Blurred Vision,AdverseReaction
1,O
1,O
Diarrhea,AdverseReaction
1,O
1,O
Hypersensitivity,AdverseReaction
1,O
1,O
Hypertension,AdverseReaction
1,O
1,O
Rash,AdverseReaction
1,O
1,O
Throat irritation,AdverseReaction
Throat tightness,AdverseReaction
1,O
1,O
Tremor,AdverseReaction
1,O
1,O
6,O
2,O
Immunogenicity,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
potential,O
for,O
immunogenicity,O
In,O
clinical,O
trials,O
121,O
patients,O
who,O
received,O
one,O
n,O
99,O
two,O
n,O
21,O
or,O
three,O
n,O
1,O
doses,O
of,O
VORAXAZE,O
were,O
evaluated,O
for,O
anti,O
glucarpidase,O
antibodies,O
Twenty,O
five,O
of,O
these,O
121,O
patients,O
21,O
had,O
detectable,O
anti,O
glucarpidase,O
antibodies,O
following,O
VORAXAZE,O
administration,O
of,O
which,O
19,O
received,O
a,O
single,O
dose,O
of,O
VORAXAZE,O
and,O
6,O
received,O
two,O
doses,O
of,O
VORAXAZE,O
Antibody,O
titers,O
were,O
determined,O
using,O
a,O
bridging,O
enzyme,O
linked,O
immunosorbent,O
assay,O
ELISA,O
for,O
anti,O
glucarpidase,O
antibodies,O
Neutralizing,O
antibodies,O
were,O
detected,O
in,O
11,O
of,O
the,O
25,O
patients,O
who,O
tested,O
positive,O
for,O
anti,O
glucarpidase,O
binding,O
antibodies,O
Eight,O
of,O
these,O
11,O
patients,O
had,O
received,O
a,O
single,O
dose,O
of,O
VORAXAZE,O
However,O
the,O
development,O
of,O
neutralizing,O
antibodies,O
may,O
be,O
underreported,O
due,O
to,O
lack,O
of,O
assay,O
sensitivity,O
The,O
detection,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
Additionally,O
the,O
observed,O
incidence,O
of,O
antibody,O
including,O
neutralizing,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
incidence,O
of,O
antibodies,O
to,O
VORAXAZE,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Hepatotoxicity,AdverseReaction
Fatal,AdverseReaction
hepatotoxicity,AdverseReaction
occurred,O
in,O
0,O
1,O
of,O
patients,O
Monitor,O
with,O
periodic,O
liver,O
testing,O
Temporarily,O
suspend,O
dose,O
reduce,O
or,O
permanently,O
discontinue,O
XALKORI,O
5,O
1,O
Interstitial Lung Disease,AdverseReaction
ILD,AdverseReaction
Pneumonitis,AdverseReaction
Occurred,O
in,O
2,O
9,O
of,O
patients,O
Permanently,O
discontinue,O
in,O
patients,O
with,O
ILD,O
pneumonitis,O
5,O
2,O
QT Interval Prolongation,AdverseReaction
Occurred,O
in,O
2,O
1,O
of,O
patients,O
Monitor,O
with,O
electrocardiograms,O
and,O
electrolytes,O
in,O
patients,O
who,O
have,O
a,O
history,O
of,O
or,O
predisposition,O
for,O
QTc,O
prolongation,O
or,O
who,O
are,O
taking,O
medications,O
that,O
prolong,O
QT,O
Temporarily,O
suspend,O
dose,O
reduce,O
or,O
permanently,O
discontinue,O
XALKORI,O
5,O
3,O
Bradycardia,AdverseReaction
XALKORI,O
can,Factor
cause,O
bradycardia,AdverseReaction
Monitor,O
heart,O
rate,O
and,O
blood,O
pressure,O
regularly,O
Temporarily,O
suspend,O
dose,O
reduce,O
or,O
permanently,O
discontinue,O
XALKORI,O
5,O
4,O
Severe,Severity
Visual Loss,AdverseReaction
Reported,O
in,O
0,O
2,O
of,O
patients,O
Discontinue,O
XALKORI,O
in,O
patients,O
with,O
severe,O
visual,O
loss,O
Perform,O
an,O
ophthalmological,O
evaluation,O
5,O
5,O
Embryofetal Toxicity,AdverseReaction
Can,Factor
cause,O
fetal harm,AdverseReaction
Advise,O
females,O
of,O
reproductive,O
potential,O
of,O
the,O
potential,O
risk,O
to,O
a,O
fetus,O
and,O
use,O
of,O
effective,O
contraception,O
5,O
6,O
8,O
1,O
8,O
3,O
5,O
1,O
Hepatotoxicity,O
Drug,O
induced,O
hepatotoxicity,AdverseReaction
with,O
fatal,AdverseReaction
outcome,O
occurred,O
in,O
2,O
0,O
1,O
of,O
the,O
1669,O
patients,O
treated,O
with,O
XALKORI,O
across,O
clinical,O
trials,O
in,O
patients,O
with,O
NSCLC,O
Concurrent,O
elevations in alanine aminotransferase in in in,AdverseReaction
ALT,AdverseReaction
or,O
aspartate aminotransferase,AdverseReaction
AST,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
three,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
ULN,O
and,O
total bilirubin,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
two times the ULN,AdverseReaction
with,O
normal,O
alkaline,O
phosphatase,O
occurred,O
in,O
10,O
patients,O
0,O
6,O
treated,O
with,O
XALKORI,O
Additionally,O
elevations in ALT in,AdverseReaction
or,O
AST,AdverseReaction
greater,O
than,O
five times the ULN,Severity
occurred,O
in,O
184,O
11,O
and,O
93,O
5,O
7,O
patients,O
respectively,O
Seventeen,O
patients,O
1,O
0,O
required,O
permanent,O
discontinuation,O
due,O
to,O
elevated transaminases,AdverseReaction
Transaminase elevations,AdverseReaction
generally,O
occurred,O
within,O
the,O
first,O
2,O
months,O
of,O
treatment,O
Monitor,O
with,O
liver,O
function,O
tests,O
including,O
ALT,O
and,O
total,O
bilirubin,O
every,O
2,O
weeks,O
during,O
the,O
first,O
2,O
months,O
of,O
treatment,O
then,O
once,O
a,O
month,O
and,O
as,O
clinically,O
indicated,O
with,O
more,O
frequent,O
repeat,O
testing,O
for,O
increased,O
liver,O
transaminases,O
alkaline,O
phosphatase,O
or,O
total,O
bilirubin,O
in,O
patients,O
who,O
develop,O
transaminase,O
elevations,O
Temporarily,O
suspend,O
dose,O
reduce,O
or,O
permanently,O
discontinue,O
XALKORI,O
as,O
described,O
in,O
Table,O
2,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Adverse,O
Reactions,O
6,O
5,O
2,O
Interstitial,O
Lung,O
Disease,O
Pneumonitis,O
Severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
interstitial lung disease lung disease,AdverseReaction
ILD,AdverseReaction
pneumonitis,AdverseReaction
can,Factor
occur,O
in,O
patients,O
treated,O
with,O
XALKORI,O
Across,O
clinical,O
trials,O
n,O
1669,O
49,O
XALKORI,O
treated,O
patients,O
2,O
9,O
had,O
ILD,AdverseReaction
of,O
any,O
grade,O
18,O
patients,O
1,O
1,O
had,O
Grade 3,Severity
or,O
4,Severity
ILD,AdverseReaction
and,O
8,O
patients,O
0,O
5,O
had,O
fatal,AdverseReaction
ILD,AdverseReaction
These,O
cases,O
generally,O
occurred,O
within,O
3,O
months,O
after,O
the,O
initiation,O
of,O
XALKORI,O
Monitor,O
patients,O
for,O
pulmonary,O
symptoms,O
indicative,O
of,O
ILD,O
pneumonitis,O
Exclude,O
other,O
potential,O
causes,O
of,O
ILD,O
pneumonitis,O
and,O
permanently,O
discontinue,O
XALKORI,O
in,O
patients,O
diagnosed,O
with,O
drug,O
related,O
ILD,O
pneumonitis,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Adverse,O
Reactions,O
6,O
5,O
3,O
QT,O
Interval,O
Prolongation,O
QTc prolongation,AdverseReaction
can,Factor
occur,O
in,O
patients,O
treated,O
with,O
XALKORI,O
Across,O
clinical,O
trials,O
32,O
of,O
1560,O
patients,O
2,O
1,O
had,O
QTcF,AdverseReaction
corrected,O
QT,O
by,O
the,O
Fridericia,O
method,O
greater than or equal to 500 ms,AdverseReaction
and,O
76,O
of,O
1520,O
patients,O
5,O
0,O
had,O
an,O
increase,AdverseReaction
from,O
baseline,O
QTcF,AdverseReaction
greater,O
than,O
or,O
equal,O
to,O
60 ms,Severity
by,O
automated,O
machine,O
read,O
evaluation,O
of,O
ECG,O
Avoid,O
use,O
of,O
XALKORI,O
in,O
patients,O
with,O
congenital,O
long,O
QT,O
syndrome,O
Consider,O
periodic,O
monitoring,O
with,O
electrocardiograms,O
ECGs,O
and,O
electrolytes,O
in,O
patients,O
with,O
congestive,O
heart,O
failure,O
bradyarrhythmias,O
electrolyte,O
abnormalities,O
or,O
who,O
are,O
taking,O
medications,O
that,O
are,O
known,O
to,O
prolong,O
the,O
QT,O
interval,O
Permanently,O
discontinue,O
XALKORI,O
in,O
patients,O
who,O
develop,O
QTc,O
greater,O
than,O
500,O
ms,O
or,O
greater,O
than,O
or,O
equal,O
to,O
60,O
ms,O
change,O
from,O
baseline,O
with,O
Torsade,O
de,O
pointes,O
or,O
polymorphic,O
ventricular,O
tachycardia,O
or,O
signs,O
symptoms,O
of,O
serious,O
arrhythmia,O
Withhold,O
XALKORI,O
in,O
patients,O
who,O
develop,O
QTc,O
greater,O
than,O
500,O
ms,O
on,O
at,O
least,O
2,O
separate,O
ECGs,O
until,O
recovery,O
to,O
a,O
QTc,O
less,O
than,O
or,O
equal,O
to,O
480,O
ms,O
then,O
resume,O
XALKORI,O
at,O
a,O
reduced,O
dose,O
as,O
described,O
in,O
Table,O
2,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Clinical,O
Pharmacology,O
12,O
2,O
5,O
4,O
Bradycardia,O
Symptomatic bradycardia,AdverseReaction
can,O
occur,O
in,O
patients,O
receiving,O
XALKORI,O
Across,O
clinical,O
trials,O
bradycardia,AdverseReaction
occurred,O
in,O
205,O
12,O
3,O
of,O
1669,O
patients,O
treated,O
with,O
XALKORI,O
A,O
total,O
of,O
242,O
14,O
9,O
patients,O
had,O
a,O
heart rate less than 50 beats per minute,AdverseReaction
In,O
Studies,O
1,O
and,O
2,O
Grade 3,Severity
syncope,AdverseReaction
occurred,O
in,O
2,O
0,O
of,O
XALKORI,O
treated,O
patients,O
and,O
in,O
0,O
6,O
of,O
the,O
chemotherapy,O
treated,O
patients,O
Avoid,O
using,O
XALKORI,O
in,O
combination,O
with,O
other,O
agents,O
known,O
to,O
cause,O
bradycardia,O
e,O
g,O
beta,O
blockers,O
non,O
dihydropyridine,O
calcium,O
channel,O
blockers,O
clonidine,O
and,O
digoxin,O
to,O
the,O
extent,O
possible,O
Monitor,O
heart,O
rate,O
and,O
blood,O
pressure,O
regularly,O
In,O
cases,O
of,O
symptomatic,O
bradycardia,O
that,O
is,O
not,O
life,O
threatening,O
hold,O
XALKORI,O
until,O
recovery,O
to,O
asymptomatic,O
bradycardia,O
or,O
to,O
a,O
heart,O
rate,O
of,O
60,O
bpm,O
or,O
above,O
re,O
evaluate,O
the,O
use,O
of,O
concomitant,O
medications,O
and,O
adjust,O
the,O
dose,O
of,O
XALKORI,O
Permanently,O
discontinue,O
for,O
life,O
threatening,O
bradycardia,O
due,O
to,O
XALKORI,O
however,O
if,O
associated,O
with,O
concomitant,O
medications,O
known,O
to,O
cause,O
bradycardia,O
or,O
hypotension,O
hold,O
XALKORI,O
until,O
recovery,O
to,O
asymptomatic,O
bradycardia,O
or,O
to,O
a,O
heart,O
rate,O
of,O
60,O
bpm,O
or,O
above,O
and,O
if,O
concomitant,O
medications,O
can,O
be,O
adjusted,O
or,O
discontinued,O
restart,O
XALKORI,O
at,O
250,O
mg,O
once,O
daily,O
with,O
frequent,O
monitoring,O
see,O
Dosage,O
and,O
Administration,O
2,O
3,O
and,O
Adverse,O
Reactions,O
6,O
5,O
5,O
Severe,O
Visual,O
Loss,O
Across,O
all,O
clinical,O
trials,O
the,O
incidence,O
of,O
Grade 4,Severity
visual field defect,AdverseReaction
with,O
vision loss,AdverseReaction
was,O
0,O
2,O
4,O
1669,O
Optic atrophy,AdverseReaction
and,O
optic nerve disorder,AdverseReaction
have,O
been,O
reported,O
as,O
potential,Factor
causes,O
of,O
vision loss,AdverseReaction
Discontinue,O
XALKORI,O
in,O
patients,O
with,O
new,O
onset,O
of,O
severe,O
visual,O
loss,O
best,O
corrected,O
vision,O
less,O
than,O
20,O
200,O
in,O
one,O
or,O
both,O
eyes,O
Perform,O
an,O
ophthalmological,O
evaluation,O
consisting,O
of,O
best,O
corrected,O
visual,O
acuity,O
retinal,O
photographs,O
visual,O
fields,O
optical,O
coherence,O
tomography,O
OCT,O
and,O
other,O
evaluations,O
as,O
appropriate,O
for,O
new,O
onset,O
of,O
severe,O
visual,O
loss,O
There,O
is,O
insufficient,O
information,O
to,O
characterize,O
the,O
risks,O
of,O
resumption,O
of,O
XALKORI,O
in,O
patients,O
with,O
a,O
severe,O
visual,O
loss,O
a,O
decision,O
to,O
resume,O
XALKORI,O
should,O
consider,O
the,O
potential,O
benefits,O
to,O
the,O
patient,O
5,O
6,O
Embryofetal,O
Toxicity,O
Based,O
on,O
its,O
mechanism,O
of,O
action,O
XALKORI,O
can,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
In,O
animal,O
reproduction,O
studies,O
oral,O
administration,O
of,O
crizotinib,O
in,O
pregnant,O
rats,Animal
during,O
organogenesis,O
at,O
exposures,O
similar,O
to,O
those,O
observed,O
with,O
the,O
maximum,O
recommended,O
human,O
dose,O
resulted,O
in,O
embryotoxicity,AdverseReaction
and,O
fetotoxicity,AdverseReaction
Advise,O
pregnant,O
women,O
of,O
the,O
potential,O
risk,O
to,O
a,O
fetus,O
Advise,O
females,O
of,O
reproductive,O
potential,O
to,O
use,O
effective,O
contraception,O
during,O
treatment,O
with,O
XALKORI,O
and,O
for,O
at,O
least,O
45,O
days,O
following,O
the,O
final,O
dose,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
8,O
3,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Hepatotoxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Interstitial Lung Disease,AdverseReaction
Pneumonitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
QT Interval Prolongation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Bradycardia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Severe,Severity
Visual Loss,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
25,O
are,O
vision disorders,AdverseReaction
diarrhea,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
constipation,AdverseReaction
edema,AdverseReaction
elevated transaminases,AdverseReaction
upper respiratory infection,AdverseReaction
decreased appetite,AdverseReaction
and,O
dysgeusia,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Pfizer,O
Inc,O
at,O
1,O
800,O
438,O
1985,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
safety,O
of,O
XALKORI,O
is,O
based,O
primarily,O
on,O
343,O
patients,O
with,O
ALK,O
positive,O
metastatic,O
NSCLC,O
who,O
received,O
XALKORI,O
250,O
mg,O
twice,O
daily,O
in,O
two,O
open,O
label,O
randomized,O
active,O
controlled,O
trials,O
Studies,O
1,O
and,O
2,O
This,O
is,O
supplemented,O
with,O
information,O
on,O
adverse,O
drug,O
reactions,O
in,O
1326,O
patients,O
with,O
ALK,O
positive,O
metastatic,O
NSCLC,O
who,O
received,O
XALKORI,O
250,O
mg,O
twice,O
daily,O
across,O
clinical,O
trials,O
for,O
a,O
total,O
of,O
1669,O
patients,O
across,O
all,O
clinical,O
studies,O
The,O
most,O
common,O
adverse,O
reactions,O
25,O
of,O
XALKORI,O
in,O
Studies,O
1,O
and,O
2,O
are,O
vision disorders,AdverseReaction
diarrhea,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
constipation,AdverseReaction
edema,AdverseReaction
elevated transaminases,AdverseReaction
upper respiratory infection,AdverseReaction
decreased appetite,AdverseReaction
and,O
dysgeusia,AdverseReaction
Previously,O
Untreated,O
ALK,O
Positive,O
Metastatic,O
NSCLC,O
Study,O
1,O
The,O
data,O
in,O
Table,O
3,O
are,O
derived,O
from,O
340,O
patients,O
with,O
ALK,O
positive,O
metastatic,O
NSCLC,O
who,O
had,O
not,O
received,O
previous,O
systemic,O
treatment,O
for,O
advanced,O
disease,O
who,O
received,O
treatment,O
in,O
a,O
randomized,O
multicenter,O
open,O
label,O
active,O
controlled,O
trial,O
Study,O
1,O
Patients,O
in,O
the,O
XALKORI,O
arm,O
n,O
171,O
received,O
XALKORI,O
250,O
mg,O
orally,O
twice,O
daily,O
until,O
documented,O
disease,O
progression,O
intolerance,O
to,O
therapy,O
or,O
the,O
investigator,O
determined,O
that,O
the,O
patient,O
was,O
no,O
longer,O
experiencing,O
clinical,O
benefit,O
A,O
total,O
of,O
169,O
patients,O
in,O
the,O
chemotherapy,O
arm,O
received,O
pemetrexed,O
500,O
mg,O
m,O
2,O
in,O
combination,O
with,O
cisplatin,O
75,O
mg,O
m,O
2,O
n,O
91,O
or,O
carboplatin,O
at,O
a,O
dose,O
calculated,O
to,O
produce,O
an,O
area,O
under,O
the,O
concentration,O
time,O
curve,O
AUC,O
of,O
5,O
or,O
6,O
mg,O
min,O
mL,O
n,O
78,O
Chemotherapy,O
was,O
given,O
by,O
intravenous,O
infusion,O
every,O
3,O
weeks,O
for,O
up,O
to,O
6,O
cycles,O
in,O
the,O
absence,O
of,O
dose,O
limiting,O
chemotherapy,O
related,O
toxicities,O
After,O
6,O
cycles,O
patients,O
remained,O
on,O
study,O
with,O
no,O
additional,O
anticancer,O
treatment,O
and,O
tumor,O
assessments,O
continued,O
until,O
documented,O
disease,O
progression,O
The,O
median,O
duration,O
of,O
study,O
treatment,O
was,O
10,O
9,O
months,O
for,O
patients,O
in,O
the,O
XALKORI,O
arm,O
and,O
4,O
1,O
months,O
for,O
patients,O
in,O
the,O
chemotherapy,O
arm,O
Median,O
duration,O
of,O
treatment,O
was,O
5,O
2,O
months,O
for,O
patients,O
who,O
received,O
XALKORI,O
after,O
cross,O
over,O
from,O
chemotherapy,O
Across,O
the,O
340,O
patients,O
who,O
were,O
treated,O
in,O
Study,O
1,O
the,O
median,O
age,O
was,O
53,O
years,O
16,O
of,O
patients,O
were,O
older,O
than,O
65,O
years,O
A,O
total,O
of,O
62,O
of,O
patients,O
were,O
female,O
and,O
46,O
were,O
Asian,O
Serious,O
adverse,O
events,O
were,O
reported,O
in,O
58,O
patients,O
34,O
treated,O
with,O
XALKORI,O
The,O
most,O
frequent,O
serious,O
adverse,O
events,O
reported,O
in,O
patients,O
treated,O
with,O
XALKORI,O
were,O
dyspnea,AdverseReaction
4,O
1,O
and,O
pulmonary embolism,AdverseReaction
2,O
9,O
Fatal,AdverseReaction
adverse,O
events,O
in,O
XALKORI,O
treated,O
patients,O
occurred,O
in,O
2,O
3,O
patients,O
consisting,O
of,O
septic shock,AdverseReaction
acute respiratory failure,AdverseReaction
and,O
diabetic ketoacidosis,AdverseReaction
Dose,O
reductions,O
due,O
to,O
adverse,O
reactions,O
were,O
required,O
in,O
6,O
4,O
of,O
XALKORI,O
treated,O
patients,O
The,O
most,O
frequent,O
adverse,O
reactions,O
that,O
led,O
to,O
dose,O
reduction,O
in,O
these,O
patients,O
were,O
nausea,AdverseReaction
1,O
8,O
and,O
elevated transaminases,AdverseReaction
1,O
8,O
Permanent,O
discontinuation,O
of,O
XALKORI,O
treatment,O
for,O
adverse,O
reactions,O
was,O
8,O
2,O
The,O
most,O
frequent,O
adverse,O
reactions,O
that,O
led,O
to,O
permanent,O
discontinuation,O
in,O
XALKORI,O
treated,O
patients,O
were,O
elevated transaminases,AdverseReaction
1,O
2,O
hepatotoxicity,AdverseReaction
1,O
2,O
and,O
ILD,AdverseReaction
1,O
2,O
Tables,O
3,O
and,O
4,O
summarize,O
common,O
adverse,O
reactions,O
and,O
laboratory,O
abnormalities,O
in,O
XALKORI,O
treated,O
patients,O
Table,O
3,O
Adverse,O
Reactions,O
Reported,O
at,O
a,O
Higher,O
Incidence,O
5,O
Higher,O
for,O
All,O
Grades,O
or,O
2,O
Higher,O
for,O
Grades,O
3,O
4,O
with,O
XALKORI,O
than,O
Chemotherapy,O
in,O
Study,O
1,O
Adverse,O
Reaction,O
XALKORI,O
N,O
171,O
Chemotherapy,O
Pemetrexed,O
Cisplatin,O
or,O
Pemetrexed,O
Carboplatin,O
N,O
169,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
Includes,O
cases,O
reported,O
within,O
the,O
clustered,O
terms,O
Cardiac,O
Disorders,O
Electrocardiogram QT prolonged,AdverseReaction
6,O
2,O
2,O
0,O
Bradycardia,AdverseReaction
14,O
1,O
1,O
0,O
Eye,O
Disorders,O
Vision disorder,AdverseReaction
71,O
1,O
10,O
0,O
Gastrointestinal,O
Disorders,O
Vomiting,AdverseReaction
46,O
2,O
36,O
3,O
Diarrhea,AdverseReaction
61,O
2,O
13,O
1,O
Constipation,AdverseReaction
43,O
2,O
30,O
0,O
Dyspepsia,AdverseReaction
14,O
0,O
2,O
0,O
Dysphagia,AdverseReaction
10,O
1,O
2,O
1,O
Abdominal pain,AdverseReaction
26,O
0,O
12,O
0,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Edema,AdverseReaction
49,O
1,O
12,O
1,O
Pyrexia,AdverseReaction
19,O
0,O
11,O
1,O
Infections,O
and,O
Infestations,O
Upper respiratory infection,AdverseReaction
32,O
0,O
12,O
1,O
Investigations,O
Weight increased,AdverseReaction
8,O
1,O
2,O
0,O
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
Pain in extremity,AdverseReaction
16,O
0,O
7,O
0,O
Muscle spasm,AdverseReaction
8,O
0,O
2,O
1,O
Nervous,O
System,O
Disorder,O
Dizziness,AdverseReaction
18,O
0,O
10,O
1,O
Dysgeusia,AdverseReaction
26,O
0,O
5,O
0,O
Headache,AdverseReaction
22,O
1,O
15,O
0,O
Additional,O
adverse,O
reactions,O
occurring,O
at,O
an,O
overall,O
incidence,O
between,O
1,O
and,O
60,O
in,O
patients,O
treated,O
with,O
XALKORI,O
included,O
nausea,AdverseReaction
56,O
decreased appetite,AdverseReaction
30,O
fatigue,AdverseReaction
29,O
neuropathy,AdverseReaction
21,O
which,O
included,O
gait disturbance,AdverseReaction
hypoaesthesia,AdverseReaction
muscular weakness,AdverseReaction
neuralgia,AdverseReaction
neuropathy peripheral,AdverseReaction
paraesthesia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
polyneuropathy,AdverseReaction
sensory disturbance,AdverseReaction
rash,AdverseReaction
11,O
renal cyst,AdverseReaction
5,O
ILD,AdverseReaction
1,O
ILD,AdverseReaction
pneumonitis,AdverseReaction
and,O
syncope,AdverseReaction
1,O
Table,O
4,O
Summary,O
of,O
Treatment,O
Emergent,O
Laboratory,O
Abnormalities,O
with,O
Grade,O
3,O
or,O
4,O
Incidence,O
of,O
4,O
in,O
XALKORI,O
Treated,O
Patients,O
in,O
Study,O
1,O
Laboratory,O
Abnormality,O
XALKORI,O
Chemotherapy,O
Any,O
Grade,O
Grade,O
3,O
4,O
Any,O
Grade,O
Grade,O
3,O
4,O
Hematology,O
Neutropenia,AdverseReaction
52,O
11,O
59,O
16,O
Lymphopenia,AdverseReaction
48,O
7,O
53,O
13,O
Chemistry,O
ALT elevation,AdverseReaction
79,O
15,O
33,O
2,O
AST elevation,AdverseReaction
66,O
8,O
28,O
1,O
Hypophosphatemia,AdverseReaction
32,O
10,O
21,O
6,O
Previously,O
Treated,O
ALK,O
Positive,O
Metastatic,O
NSCLC,O
Study,O
2,O
The,O
data,O
in,O
Table,O
5,O
are,O
derived,O
from,O
343,O
patients,O
with,O
ALK,O
positive,O
metastatic,O
NSCLC,O
enrolled,O
in,O
a,O
randomized,O
multicenter,O
active,O
controlled,O
open,O
label,O
trial,O
Study,O
2,O
Patients,O
in,O
the,O
XALKORI,O
arm,O
n,O
172,O
received,O
XALKORI,O
250,O
mg,O
orally,O
twice,O
daily,O
until,O
documented,O
disease,O
progression,O
intolerance,O
to,O
therapy,O
or,O
the,O
investigator,O
determined,O
that,O
the,O
patient,O
was,O
no,O
longer,O
experiencing,O
clinical,O
benefit,O
A,O
total,O
of,O
171,O
patients,O
in,O
the,O
chemotherapy,O
arm,O
received,O
pemetrexed,O
500,O
mg,O
m,O
2,O
n,O
99,O
or,O
docetaxel,O
75,O
mg,O
m,O
2,O
n,O
72,O
by,O
intravenous,O
infusion,O
every,O
three,O
weeks,O
until,O
documented,O
disease,O
progression,O
intolerance,O
to,O
therapy,O
or,O
the,O
investigator,O
determined,O
that,O
the,O
patient,O
was,O
no,O
longer,O
experiencing,O
clinical,O
benefit,O
Patients,O
in,O
the,O
chemotherapy,O
arm,O
received,O
pemetrexed,O
unless,O
they,O
had,O
received,O
pemetrexed,O
as,O
part,O
of,O
first,O
line,O
or,O
maintenance,O
treatment,O
The,O
median,O
duration,O
of,O
study,O
treatment,O
was,O
7,O
1,O
months,O
for,O
patients,O
who,O
received,O
XALKORI,O
and,O
2,O
8,O
months,O
for,O
patients,O
who,O
received,O
chemotherapy,O
Across,O
the,O
347,O
patients,O
who,O
were,O
randomized,O
to,O
study,O
treatment,O
343,O
received,O
at,O
least,O
one,O
dose,O
of,O
study,O
treatment,O
the,O
median,O
age,O
was,O
50,O
years,O
14,O
of,O
patients,O
were,O
older,O
than,O
65,O
years,O
A,O
total,O
of,O
56,O
of,O
patients,O
were,O
female,O
and,O
45,O
of,O
patients,O
were,O
Asian,O
Serious,O
adverse,O
reactions,O
were,O
reported,O
in,O
64,O
patients,O
37,O
2,O
treated,O
with,O
XALKORI,O
and,O
40,O
patients,O
23,O
4,O
in,O
the,O
chemotherapy,O
arm,O
The,O
most,O
frequent,O
serious,O
adverse,O
reactions,O
reported,O
in,O
patients,O
treated,O
with,O
XALKORI,O
were,O
pneumonia,AdverseReaction
4,O
1,O
pulmonary embolism,AdverseReaction
3,O
5,O
dyspnea,AdverseReaction
2,O
3,O
and,O
ILD,AdverseReaction
2,O
9,O
Fatal,AdverseReaction
adverse,O
reactions,O
in,O
XALKORI,O
treated,O
patients,O
in,O
Study,O
2,O
occurred,O
in,O
9,O
5,O
patients,O
consisting,O
of,O
acute respiratory distress syndrome,AdverseReaction
arrhythmia,AdverseReaction
dyspnea,AdverseReaction
pneumonia,AdverseReaction
pneumonitis,AdverseReaction
pulmonary embolism,AdverseReaction
ILD,AdverseReaction
respiratory failure,AdverseReaction
and,O
sepsis,AdverseReaction
Dose,O
reductions,O
due,O
to,O
adverse,O
reactions,O
were,O
required,O
in,O
16,O
of,O
XALKORI,O
treated,O
patients,O
The,O
most,O
frequent,O
adverse,O
reactions,O
that,O
led,O
to,O
dose,O
reduction,O
in,O
the,O
patients,O
treated,O
with,O
XALKORI,O
were,O
alanine aminotransferase,AdverseReaction
ALT,AdverseReaction
elevation,AdverseReaction
7,O
6,O
including,O
some,O
patients,O
with,O
concurrent,O
aspartate aminotransferase,AdverseReaction
AST,AdverseReaction
elevation,AdverseReaction
QTc prolongation,AdverseReaction
2,O
9,O
and,O
neutropenia,AdverseReaction
2,O
3,O
XALKORI,O
was,O
discontinued,O
for,O
adverse,O
reactions,O
in,O
15,O
of,O
patients,O
The,O
most,O
frequent,O
adverse,O
reactions,O
that,O
led,O
to,O
discontinuation,O
of,O
XALKORI,O
were,O
ILD,AdverseReaction
1,O
7,O
ALT,AdverseReaction
and,O
AST elevation,AdverseReaction
1,O
2,O
dyspnea,AdverseReaction
1,O
2,O
and,O
pulmonary embolism,AdverseReaction
1,O
2,O
Tables,O
5,O
and,O
6,O
summarize,O
common,O
adverse,O
reactions,O
and,O
laboratory,O
abnormalities,O
in,O
XALKORI,O
treated,O
patients,O
Table,O
5,O
Adverse,O
Reactions,O
Reported,O
at,O
a,O
Higher,O
Incidence,O
5,O
Higher,O
for,O
All,O
Grades,O
or,O
2,O
Higher,O
for,O
Grades,O
3,O
4,O
with,O
XALKORI,O
than,O
Chemotherapy,O
in,O
Study,O
2,O
Adverse,O
Reaction,O
XALKORI,O
N,O
172,O
Chemotherapy,O
Pemetrexed,O
or,O
Docetaxel,O
N,O
171,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
Includes,O
cases,O
reported,O
within,O
the,O
clustered,O
terms,O
Nervous,O
System,O
Disorder,O
Dizziness,AdverseReaction
22,O
1,O
8,O
0,O
Dysgeusia,AdverseReaction
26,O
0,O
9,O
0,O
Syncope,AdverseReaction
3,O
3,O
0,O
0,O
Eye,O
Disorders,O
Vision disorder,AdverseReaction
60,O
0,O
9,O
0,O
Cardiac,O
Disorders,O
Electrocardiogram QT prolonged,AdverseReaction
5,O
3,O
0,O
0,O
Bradycardia,AdverseReaction
5,O
0,O
0,O
0,O
Investigations,O
Weight decreased,AdverseReaction
10,O
1,O
4,O
0,O
Gastrointestinal,O
Disorders,O
Vomiting,AdverseReaction
47,O
1,O
18,O
0,O
Nausea,AdverseReaction
55,O
1,O
37,O
1,O
Diarrhea,AdverseReaction
60,O
0,O
19,O
1,O
Constipation,AdverseReaction
42,O
2,O
23,O
0,O
Dyspepsia,AdverseReaction
8,O
0,O
3,O
0,O
Infections,O
and,O
Infestations,O
Upper respiratory infection,AdverseReaction
26,O
0,O
13,O
1,O
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
Pulmonary embolism,AdverseReaction
6,O
5,O
2,O
2,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Edema,AdverseReaction
31,O
0,O
16,O
0,O
Additional,O
adverse,O
reactions,O
occurring,O
at,O
an,O
overall,O
incidence,O
between,O
1,O
and,O
30,O
in,O
patients,O
treated,O
with,O
XALKORI,O
included,O
fatigue,AdverseReaction
27,O
neuropathy,AdverseReaction
19,O
dysesthesia,AdverseReaction
gait disturbance,AdverseReaction
hypoesthesia,AdverseReaction
muscular weakness,AdverseReaction
neuralgia,AdverseReaction
peripheral neuropathy,AdverseReaction
parasthesia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
polyneuropathy,AdverseReaction
burning sensation in skin,AdverseReaction
rash,AdverseReaction
9,O
ILD,AdverseReaction
4,O
acute respiratory distress syndrome,AdverseReaction
ILD,AdverseReaction
pneumonitis,AdverseReaction
renal cyst,AdverseReaction
4,O
and,O
hepatic failure,AdverseReaction
1,O
Table,O
6,O
Summary,O
of,O
Treatment,O
Emergent,O
Laboratory,O
Abnormalities,O
with,O
Grade,O
3,O
or,O
4,O
Incidence,O
of,O
4,O
in,O
XALKORI,O
Treated,O
Patients,O
in,O
Study,O
2,O
Laboratory,O
Abnormality,O
XALKORI,O
Chemotherapy,O
Any,O
Grade,O
Grade,O
3,O
4,O
Any,O
Grade,O
Grade,O
3,O
4,O
Hematology,O
Neutropenia,AdverseReaction
49,O
12,O
28,O
12,O
Lymphopenia,AdverseReaction
51,O
9,O
60,O
25,O
Chemistry,O
ALT elevation,AdverseReaction
76,O
17,O
38,O
4,O
AST elevation,AdverseReaction
61,O
9,O
33,O
0,O
Hypokalemia,AdverseReaction
18,O
4,O
10,O
1,O
Hypophosphatemia,AdverseReaction
28,O
5,O
25,O
6,O
Description,O
of,O
Selected,O
Adverse,O
Drug,O
Reactions,O
Vision,O
disorders,O
Vision disorders,AdverseReaction
most,O
commonly,O
visual impairment,AdverseReaction
photopsia,AdverseReaction
blurred vision,AdverseReaction
or,O
vitreous floaters,AdverseReaction
occurred,O
in,O
1038,O
62,O
of,O
1669,O
patients,O
The,O
majority,O
95,O
of,O
these,O
patients,O
had,O
Grade 1,Severity
visual adverse reactions,AdverseReaction
There,O
were,O
13,O
0,O
8,O
patients,O
with,O
Grade 3,Severity
and,O
4,Severity
0,O
2,O
patients,O
with,O
Grade 4,Severity
visual impairment impairment,AdverseReaction
Based,O
on,O
the,O
Visual,O
Symptom,O
Assessment,O
Questionnaire,O
VSAQ,O
ALK,O
patients,O
treated,O
with,O
XALKORI,O
in,O
Studies,O
1,O
and,O
2,O
reported,O
a,O
higher,O
incidence,O
of,O
visual disturbances,AdverseReaction
compared,O
to,O
patients,O
treated,O
with,O
chemotherapy,O
The,O
onset,O
of,O
vision disorder,AdverseReaction
generally,O
was,O
within,O
the,O
first,O
week,O
of,O
drug,O
administration,O
The,O
majority,O
of,O
patients,O
on,O
the,O
XALKORI,O
arms,O
in,O
Studies,O
1,O
and,O
2,O
50,O
reported,O
visual disturbances,AdverseReaction
which,O
occurred,O
at,O
a,O
frequency,O
of,O
4,O
7,O
days,O
each,O
week,O
lasted,O
up,O
to,O
1,O
minute,O
and,O
had,O
mild,O
or,O
no,O
impact,O
scores,O
0,O
to,O
3,O
out,O
of,O
a,O
maximum,O
score,O
of,O
10,O
on,O
daily,O
activities,O
as,O
captured,O
in,O
the,O
VSAQ,O
ALK,O
questionnaire,O
Neuropathy,O
Neuropathy,AdverseReaction
most,O
commonly,O
sensory,AdverseReaction
in,O
nature,O
occurred,O
in,O
419,O
25,O
of,O
1669,O
patients,O
Most,O
events,O
95,O
were,O
Grade,O
1,O
or,O
Grade,O
2,O
in,O
severity,O
Renal,O
Cysts,O
Renal cysts,AdverseReaction
were,O
experienced,O
by,O
50,O
3,O
of,O
1669,O
patients,O
Renal cysts,AdverseReaction
occurred,O
in,O
8,O
5,O
patients,O
treated,O
with,O
XALKORI,O
and,O
1,O
1,O
patient,O
treated,O
with,O
chemotherapy,O
in,O
Study,O
1,O
Renal cysts,AdverseReaction
occurred,O
in,O
8,O
5,O
patients,O
treated,O
with,O
XALKORI,O
and,O
1,O
1,O
patient,O
treated,O
with,O
chemotherapy,O
in,O
Study,O
2,O
The,O
majority,O
of,O
renal cysts cysts,AdverseReaction
in,O
XALKORI,O
treated,O
patients,O
were,O
complex,AdverseReaction
Local cystic invasion beyond the kidney,AdverseReaction
occurred,O
in,O
some,O
cases,O
with,O
imaging,O
characteristics,O
suggestive,Factor
of,O
abscess,AdverseReaction
formation,O
However,O
across,O
clinical,O
trials,O
no,Negation
renal abscesses,AdverseReaction
were,O
confirmed,O
by,O
microbiology,O
tests,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
For,O
All,O
Indications,O
The,O
potency,O
Units,O
of,O
XEOMIN,O
are,O
not,O
interchangeable,O
with,O
other,O
preparations,O
of,O
botulinum,O
toxin,O
products,O
Therefore,O
Units,O
of,O
biological,O
activity,O
of,O
XEOMIN,O
cannot,O
be,O
compared,O
to,O
or,O
converted,O
into,O
Units,O
of,O
any,O
other,O
botulinum,O
toxin,O
products,O
5,O
2,O
Immediate,O
medical,O
attention,O
may,O
be,O
required,O
in,O
cases,O
of,O
respiratory,O
speech,O
or,O
swallowing,O
difficulties,O
5,O
1,O
5,O
4,O
Use,O
with,O
caution,O
in,O
patients,O
with,O
compromised,O
respiratory,O
function,O
or,O
dysphagia,O
5,O
4,O
Concomitant,O
neuromuscular,O
disorders,O
may,O
exacerbate,O
clinical,O
effects,O
of,O
treatment,O
5,O
5,O
Cervical,O
Dystonia,O
5,O
4,O
Patients,O
with,O
smaller,O
neck,O
muscle,O
mass,O
and,O
patients,O
who,O
require,O
bilateral,O
injections,O
into,O
the,O
sternocleidomastoid,O
muscles,O
are,O
at,O
greater,O
risk,Factor
of,O
dysphagia,AdverseReaction
Limiting,O
the,O
dose,O
injected,O
into,O
the,O
sternocleidomastoid,O
muscle,O
may,O
decrease,O
the,O
occurrence,O
of,O
dysphagia,O
Blepharospasm,O
5,O
6,O
Corneal exposure,AdverseReaction
and,O
ulceration,AdverseReaction
Injection,O
of,O
XEOMIN,O
into,O
the,O
orbicularis,O
oculi,O
muscle,O
may,Factor
lead,O
to,O
reduced blinking,AdverseReaction
and,O
corneal exposure,AdverseReaction
with,O
possible,Factor
ulceration,AdverseReaction
or,O
perforation,AdverseReaction
Lower,O
lid,O
injections,O
should,O
not,O
be,O
repeated,O
if,O
diplopia,O
occurred,O
with,O
previous,O
botulinum,O
toxin,O
injections,O
Glabellar,O
Lines,O
5,O
7,O
Risk,Factor
of,O
ptosis,AdverseReaction
5,O
7,O
5,O
1,O
Spread,O
of,O
Toxin,O
Effect,O
Postmarketing,O
safety,O
data,O
from,O
XEOMIN,O
and,O
other,O
approved,O
botulinum,O
toxins,O
suggest,O
that,O
botulinum,O
toxin effects,AdverseReaction
may,Factor
in,O
some,O
cases,O
be,O
observed,O
beyond the site of local injection,AdverseReaction
The,O
symptoms,O
are,O
consistent,O
with,O
the,O
mechanism,O
of,O
action,O
of,O
botulinum,O
toxin,O
and,O
may,O
include,O
asthenia,AdverseReaction
generalized muscle weakness,AdverseReaction
diplopia,AdverseReaction
blurred vision,AdverseReaction
ptosis,AdverseReaction
dysphagia,AdverseReaction
dysphonia,AdverseReaction
dysarthria,AdverseReaction
urinary incontinence,AdverseReaction
and,O
breathing difficulties,AdverseReaction
These,O
symptoms,O
have,O
been,O
reported,O
hours,O
to,O
weeks,O
after,O
injection,O
Swallowing,AdverseReaction
and,O
breathing difficulties,AdverseReaction
can,Factor
be,O
life threatening,Severity
and,O
there,O
have,O
been,O
reports,O
of,O
death,AdverseReaction
related,O
to,O
the,O
spread of toxin effects,AdverseReaction
The,O
risk,O
of,O
symptoms,O
is,O
probably,O
greatest,O
in,O
children,O
treated,O
for,O
spasticity,O
but,O
symptoms,O
can,O
occur,O
in,O
adults,O
treated,O
for,O
spasticity,O
and,O
other,O
conditions,O
and,O
particularly,O
in,O
those,O
patients,O
who,O
have,O
underlying,O
conditions,O
that,O
would,O
predispose,O
them,O
to,O
these,O
symptoms,O
In,O
unapproved,O
uses,O
including,O
spasticity,O
in,O
children,O
and,O
adults,O
and,O
in,O
approved,O
indications,O
symptoms,O
consistent,O
with,O
spread of toxin effect,AdverseReaction
have,O
been,O
reported,O
at,O
doses,O
comparable,O
to,O
or,O
lower,O
than,O
doses,O
used,O
to,O
treat,O
cervical,O
dystonia,O
Patients,O
or,O
caregivers,O
should,O
be,O
advised,O
to,O
seek,O
immediate,O
medical,O
care,O
if,O
swallowing,O
speech,O
or,O
respiratory,O
disorders,O
occur,O
5,O
2,O
Lack,O
of,O
Interchangeability,O
between,O
Botulinum,O
Toxin,O
Products,O
The,O
potency,O
Units,O
of,O
XEOMIN,O
are,O
specific,O
to,O
the,O
preparation,O
and,O
assay,O
method,O
utilized,O
They,O
are,O
not,O
interchangeable,O
with,O
the,O
other,O
preparations,O
of,O
botulinum,O
toxin,O
products,O
and,O
therefore,O
Units,O
of,O
biological,O
activity,O
of,O
XEOMIN,O
cannot,O
be,O
compared,O
to,O
or,O
converted,O
into,O
Units,O
of,O
any,O
other,O
botulinum,O
toxin,O
products,O
assessed,O
with,O
any,O
other,O
specific,O
assay,O
method,O
see,O
Description,O
11,O
5,O
3,O
Hypersensitivity,O
Reactions,O
Hypersensitivity reactions,AdverseReaction
have,O
been,O
reported,O
with,O
botulinum toxin products,DrugClass
anaphylaxis,AdverseReaction
serum sickness,AdverseReaction
urticaria,AdverseReaction
soft tissue edema,AdverseReaction
and,O
dyspnea,AdverseReaction
If,O
serious,O
and,O
or,O
immediate,O
hypersensitivity,O
reactions,O
occur,O
further,O
injection,O
of,O
XEOMIN,O
should,O
be,O
discontinued,O
and,O
appropriate,O
medical,O
therapy,O
immediately,O
instituted,O
5,O
4,O
Dysphagia,O
and,O
Breathing,O
Difficulties,O
in,O
Treatment,O
of,O
Cervical,O
Dystonia,O
Treatment,O
with,O
XEOMIN,O
and,O
other,O
botulinum,O
toxin,O
products,O
can,Factor
result,O
in,O
swallowing,AdverseReaction
or,O
breathing difficulties,AdverseReaction
Patients,O
with,O
pre,O
existing,O
swallowing,O
or,O
breathing,O
difficulties,O
may,O
be,O
more,O
susceptible,O
to,O
these,O
complications,O
In,O
most,O
cases,O
this,O
is,O
a,O
consequence,O
of,O
weakening,O
of,O
muscles,O
in,O
the,O
area,O
of,O
injection,O
that,O
are,O
involved,O
in,O
breathing,O
or,O
swallowing,O
When,O
distant,O
effects,O
occur,O
additional,O
respiratory,O
muscles,O
may,O
be,O
involved,O
See,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Deaths,AdverseReaction
as,O
a,O
complication,O
of,O
severe,Severity
dysphagia,AdverseReaction
have,O
been,O
reported,O
after,O
treatment,O
with,O
botulinum toxin,DrugClass
Dysphagia,AdverseReaction
may,O
persist,O
for,O
several,O
months,O
and,O
require,O
use,O
of,O
a,O
feeding,O
tube,O
to,O
maintain,O
adequate,O
nutrition,O
and,O
hydration,O
Aspiration,AdverseReaction
may,Factor
result,O
from,O
severe,Severity
dysphagia,AdverseReaction
and,O
is,O
a,O
particular,O
risk,O
when,O
treating,O
patients,O
in,O
whom,O
swallowing,O
or,O
respiratory,O
function,O
is,O
already,O
compromised,O
Treatment,O
of,O
cervical,O
dystonia,O
with,O
botulinum toxins,DrugClass
may,O
weaken neck muscles,AdverseReaction
that,O
serve,O
as,O
accessory,O
muscles,O
of,O
ventilation,O
This,O
may,Factor
result,O
in,O
critical,Severity
loss of breathing capacity,AdverseReaction
in,O
patients,O
with,O
respiratory,O
disorders,O
who,O
may,O
have,O
become,O
dependent,O
upon,O
these,O
accessory,O
muscles,O
There,O
have,O
been,O
post,O
marketing,O
reports,O
of,O
serious,Severity
breathing difficulties,AdverseReaction
including,O
respiratory failure,AdverseReaction
in,O
patients,O
with,O
cervical,O
dystonia,O
treated,O
with,O
botulinum toxin products,DrugClass
Patients,O
with,O
smaller,O
neck,O
muscle,O
mass,O
and,O
patients,O
who,O
require,O
bilateral,O
injections,O
into,O
the,O
sternocleidomastoid,O
muscles,O
have,O
been,O
reported,O
to,O
be,O
at,O
greater,O
risk,Factor
of,O
dysphagia,AdverseReaction
In,O
general,O
limiting,O
the,O
dose,O
injected,O
into,O
the,O
sternocleidomastoid,O
muscle,O
may,O
decrease,O
the,O
occurrence,O
of,O
dysphagia,O
Patients,O
treated,O
with,O
botulinum,O
toxin,O
may,O
require,O
immediate,O
medical,O
attention,O
should,O
they,O
develop,O
problems,O
with,O
swallowing,O
speech,O
or,O
respiratory,O
disorders,O
These,O
reactions,O
can,O
occur,O
within,O
hours,O
to,O
weeks,O
after,O
injection,O
with,O
botulinum,O
toxin,O
See,O
Warnings,O
and,O
Precautions,O
5,O
1,O
and,O
Adverse,O
Reactions,O
6,O
1,O
5,O
5,O
Pre,O
existing,O
Neuromuscular,O
Disorders,O
and,O
other,O
Special,O
Populations,O
Individuals,O
with,O
peripheral,O
motor,O
neuropathic,O
diseases,O
amyotrophic,O
lateral,O
sclerosis,O
or,O
neuromuscular,O
junctional,O
disorders,O
e,O
g,O
myasthenia,O
gravis,O
or,O
Lambert,O
Eaton,O
syndrome,O
should,O
be,O
monitored,O
particularly,O
closely,O
when,O
given,O
botulinum,O
toxin,O
Patients,O
with,O
neuromuscular,O
disorders,O
may,O
be,O
at,O
increased,O
risk,Factor
of,O
clinically,O
significant,O
effects,O
including,O
severe,Severity
dysphagia,AdverseReaction
and,O
respiratory compromise,AdverseReaction
from,O
typical,O
doses,O
of,O
XEOMIN,O
See,O
Adverse,O
Reactions,O
6,O
1,O
5,O
6,O
Corneal,O
Exposure,O
Corneal,O
Ulceration,O
and,O
Ectropion,O
in,O
Patients,O
Treated,O
with,O
XEOMIN,O
for,O
Blepharospasm,O
Reduced blinking,AdverseReaction
from,O
injection,O
of,O
botulinum toxin products,DrugClass
in,O
the,O
orbicularis,O
muscle,O
can,O
lead,O
to,O
corneal exposure,AdverseReaction
persistent epithelial defect,AdverseReaction
and,O
corneal ulceration,AdverseReaction
especially,O
in,O
patients,O
with,O
VII,O
nerve,O
disorders,O
Careful,O
testing,O
of,O
corneal,O
sensation,O
in,O
eyes,O
previously,O
operated,O
upon,O
avoidance,O
of,O
injection,O
into,O
the,O
lower,O
lid,O
area,O
to,O
avoid,O
ectropion,O
and,O
vigorous,O
treatment,O
of,O
any,O
epithelial,O
defect,O
should,O
be,O
employed,O
This,O
may,O
require,O
protective,O
drops,O
ointment,O
therapeutic,O
soft,O
contact,O
lenses,O
or,O
closure,O
of,O
the,O
eye,O
by,O
patching,O
or,O
other,O
means,O
Because,O
of,O
its,O
anticholinergic,O
effects,O
XEOMIN,O
should,O
be,O
used,O
with,O
caution,O
in,O
patients,O
at,O
risk,O
of,O
developing,O
narrow,O
angle,O
glaucoma,O
To,O
prevent,O
ectropion,O
botulinum,O
toxin,O
products,O
should,O
not,O
be,O
injected,O
into,O
the,O
medial,O
lower,O
eyelid,O
area,O
Ecchymosis,O
easily,O
occurs,O
in,O
the,O
soft,O
tissues,O
of,O
the,O
eyelid,O
Immediate,O
gentle,O
pressure,O
at,O
the,O
injection,O
site,O
can,O
limit,O
that,O
risk,O
5,O
7,O
Risk,O
of,O
Ptosis,O
in,O
Patients,O
Treated,O
with,O
XEOMIN,O
for,O
Glabellar,O
Lines,O
Do,O
not,O
exceed,O
the,O
recommended,O
dosage,O
and,O
frequency,O
of,O
administration,O
of,O
XEOMIN,O
In,O
order,O
to,O
reduce,O
the,O
complication,O
of,O
ptosis,O
the,O
following,O
steps,O
should,O
be,O
taken,O
Avoid,O
injection,O
near,O
the,O
levator,O
palpebrae,O
superioris,O
particularly,O
in,O
patients,O
with,O
larger,O
brow,O
depressor,O
complexes,O
Corrugator,O
injections,O
should,O
be,O
placed,O
at,O
least,O
1,O
cm,O
above,O
the,O
bony,O
supraorbital,O
ridge,O
5,O
8,O
Human,O
Albumin,O
and,O
Transmission,O
of,O
Viral,O
Diseases,O
This,O
product,O
contains,O
albumin,O
a,O
derivative,O
of,O
human,O
blood,O
Based,O
on,O
effective,O
donor,O
screening,O
and,O
product,O
manufacturing,O
processes,O
it,O
carries,O
an,O
extremely,O
remote,O
risk,Factor
for,O
transmission of viral diseases,AdverseReaction
A,O
theoretical,O
risk,Factor
for,O
transmission,O
of,O
Creutzfeldt Jakob disease,AdverseReaction
CJD,AdverseReaction
is,O
also,O
considered,O
extremely,O
remote,O
No,O
cases,O
of,O
transmission,O
of,O
viral,O
diseases,O
or,O
CJD,O
have,O
ever,O
been,O
reported,O
for,O
albumin,O
""
BOXED,O
WARNING,O
WARNING,O
DISTANT SPREAD OF TOXIN EFFECT,AdverseReaction
WARNING,O
DISTANT SPREAD OF TOXIN EFFECT,AdverseReaction
Postmarketing,O
reports,O
indicate,O
that,O
the,O
effects,O
of,O
XEOMIN,O
and,O
all,O
botulinum,O
toxin,O
products,O
may,Factor
spread from the area of injection,AdverseReaction
to,O
produce,O
symptoms,O
consistent,O
with,O
botulinum,O
toxin effects,AdverseReaction
These,O
may,Factor
include,O
asthenia,AdverseReaction
generalized muscle weakness,AdverseReaction
diplopia,AdverseReaction
blurred vision,AdverseReaction
ptosis,AdverseReaction
dysphagia,AdverseReaction
dysphonia,AdverseReaction
dysarthria,AdverseReaction
urinary incontinence,AdverseReaction
and,O
breathing difficulties,AdverseReaction
These,O
symptoms,O
have,O
been,O
reported,O
hours,O
to,O
weeks,O
after,O
injection,O
Swallowing,AdverseReaction
and,O
breathing difficulties difficulties,AdverseReaction
can,O
be,O
life threatening,Severity
and,O
there,O
have,O
been,O
reports,O
of,O
death,AdverseReaction
The,O
risk,O
of,O
symptoms,O
is,O
probably,O
greatest,O
in,O
children,O
treated,O
for,O
spasticity,O
but,O
symptoms,O
can,O
also,O
occur,O
in,O
adults,O
treated,O
for,O
spasticity,O
and,O
other,O
conditions,O
particularly,O
in,O
those,O
patients,O
who,O
have,O
underlying,O
conditions,O
that,O
would,O
predispose,O
them,O
to,O
these,O
symptoms,O
In,O
unapproved,O
uses,O
including,O
spasticity,O
in,O
children,O
and,O
adults,O
and,O
in,O
approved,O
indications,O
cases,O
of,O
spread of effect,AdverseReaction
have,O
been,O
reported,O
at,O
doses,O
comparable,O
to,O
those,O
used,O
to,O
treat,O
cervical,O
dystonia,O
and,O
at,O
lower,O
doses,O
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
WARNING,O
DISTANT SPREAD OF TOXIN EFFECT,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
The,O
effects,O
of,O
XEOMIN,O
and,O
all,O
botulinum,O
toxin,O
products,O
may,Factor
spread from the area of injection,AdverseReaction
to,O
produce,O
symptoms,O
consistent,O
with,O
botulinum,O
toxin effects,AdverseReaction
These,O
symptoms,O
have,O
been,O
reported,O
hours,O
to,O
weeks,O
after,O
injection,O
Swallowing,AdverseReaction
and,O
breathing difficulties,AdverseReaction
can,Factor
be,O
life threatening,Severity
and,O
there,O
have,O
been,O
reports,O
of,O
death,AdverseReaction
The,O
risk,O
of,O
symptoms,O
is,O
probably,O
greatest,O
in,O
children,O
treated,O
for,O
spasticity,O
but,O
symptoms,O
can,O
also,O
occur,O
in,O
adults,O
particularly,O
in,O
those,O
patients,O
who,O
have,O
underlying,O
conditions,O
that,O
would,O
predispose,O
them,O
to,O
these,O
symptoms,O
5,O
1,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
to,O
XEOMIN,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Hypersensitivity,AdverseReaction
see,O
Contraindications,O
4,O
and,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Dysphagia,AdverseReaction
and,O
Breathing Difficulties,AdverseReaction
in,O
Treatment,O
of,O
cervical,O
dystonia,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Spread of Effects from Toxin,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
Cervical,O
Dystonia,O
The,O
most,O
commonly,O
observed,O
adverse,O
reactions,O
5,O
of,O
patients,O
and,O
placebo,O
are,O
dysphagia,AdverseReaction
neck pain,AdverseReaction
muscle weakness,AdverseReaction
injection site pain,AdverseReaction
and,O
musculoskeletal pain,AdverseReaction
6,O
1,O
Blepharospasm,O
The,O
most,O
commonly,O
observed,O
adverse,O
reactions,O
5,O
of,O
patients,O
and,O
placebo,O
are,O
eyelid ptosis,AdverseReaction
dry eye,AdverseReaction
dry mouth,AdverseReaction
diarrhea,AdverseReaction
headache,AdverseReaction
visual impairment,AdverseReaction
dyspnea,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
respiratory tract infection,AdverseReaction
6,O
1,O
Glabellar,O
Lines,O
The,O
most,O
commonly,O
observed,O
adverse,O
reaction,O
1,O
of,O
patients,O
and,O
placebo,O
is,O
headache,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Merz,O
Pharmaceuticals,O
LLC,O
at,O
888,O
493,O
6646,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Cervical,O
Dystonia,O
The,O
data,O
described,O
below,O
reflect,O
exposure,O
to,O
a,O
single,O
intramuscular,O
dose,O
of,O
XEOMIN,O
in,O
a,O
placebo,O
controlled,O
Phase,O
3,O
trial,O
in,O
patients,O
with,O
cervical,O
dystonia,O
see,O
Clinical,O
Studies,O
14,O
1,O
In,O
this,O
study,O
159,O
patients,O
received,O
XEOMIN,O
78,O
were,O
randomized,O
to,O
receive,O
a,O
total,O
dose,O
of,O
120,O
Units,O
and,O
81,O
were,O
randomized,O
to,O
receive,O
a,O
total,O
dose,O
of,O
240,O
Units,O
XEOMIN,O
treated,O
patients,O
were,O
18,O
to,O
79,O
years,O
old,O
mean,O
53,O
years,O
and,O
were,O
predominantly,O
female,O
66,O
and,O
Caucasian,O
91,O
At,O
study,O
baseline,O
approximately,O
25,O
had,O
mild,O
50,O
had,O
moderate,O
and,O
25,O
had,O
severe,O
cervical,O
dystonia,O
Approximately,O
61,O
of,O
XEOMIN,O
treated,O
patients,O
had,O
previously,O
received,O
another,O
botulinum,O
toxin,O
type,O
A,O
product,O
Common,O
adverse,O
events,O
5,O
in,O
any,O
XEOMIN,O
treatment,O
group,O
observed,O
in,O
patients,O
who,O
received,O
XEOMIN,O
120,O
Units,O
or,O
240,O
Units,O
included,O
dysphagia,AdverseReaction
neck pain,AdverseReaction
muscle weakness,AdverseReaction
injection site pain,AdverseReaction
and,O
musculoskeletal pain,AdverseReaction
Table,O
2,O
Most,O
Common,O
TEAEs,O
5,O
and,O
Greater,O
than,O
Placebo,O
Double,O
Blind,O
Phase,O
of,O
Clinical,O
Trial,O
Double,O
Blind,O
Phase,O
System,O
Organ,O
ClassPreferred,O
Term,O
XEOMIN,O
120,O
Units,O
N,O
77,O
XEOMIN,O
240,O
Units,O
N,O
82,O
Placebo,O
N,O
74,O
Any,O
TEAEs,O
57,O
55,O
42,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
23,O
32,O
11,O
Neck pain,AdverseReaction
7,O
15,O
4,O
Muscular weakness,AdverseReaction
7,O
11,O
1,O
Musculoskeletal pain,AdverseReaction
7,O
4,O
1,O
Gastrointestinal,O
disorders,O
18,O
24,O
4,O
Dysphagia,AdverseReaction
13,O
18,O
3,O
Nervous,O
system,O
disorders,O
16,O
17,O
7,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
16,O
11,O
11,O
Injection site pain,AdverseReaction
9,O
4,O
7,O
Infections,O
and,O
infestations,O
14,O
13,O
11,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
13,O
10,O
3,O
Blepharospasm,O
In,O
the,O
placebo,O
controlled,O
Phase,O
3,O
trial,O
in,O
patients,O
with,O
blepharospasm,AdverseReaction
previously,O
treated,O
with,O
onabotulinumtoxinA,O
Botox,O
see,O
Clinical,O
Studies,O
14,O
2,O
74,O
patients,O
received,O
XEOMIN,O
at,O
a,O
mean,O
dose,O
of,O
approximately,O
33,O
Units,O
per,O
eye,O
minimum,O
10,O
Units,O
maximum,O
50,O
Units,O
XEOMIN,O
treated,O
patients,O
were,O
22,O
to,O
79,O
years,O
of,O
age,O
mean,O
62,O
years,O
predominantly,O
female,O
65,O
Caucasian,O
79,O
and,O
had,O
a,O
mean,O
time,O
since,O
diagnosis,O
of,O
approximately,O
5,O
years,O
The,O
adverse,O
events,O
occurring,O
in,O
5,O
of,O
XEOMIN,O
treated,O
patients,O
and,O
greater,O
than,O
placebo,O
in,O
the,O
Phase,O
3,O
study,O
were,O
eyelid ptosis,AdverseReaction
dry eye,AdverseReaction
dry mouth,AdverseReaction
diarrhea,AdverseReaction
headache,AdverseReaction
visual impairment,AdverseReaction
dyspnea,AdverseReaction
nasopharyngitis,AdverseReaction
and,O
respiratory tract infection,AdverseReaction
No,O
serious,O
adverse,O
events,O
occurred,O
in,O
patients,O
who,O
received,O
XEOMIN,O
one,O
placebo,Factor
treated,O
patient,O
experienced,O
a,O
serious,Severity
adverse,O
event,O
dyspnea,AdverseReaction
Table,O
3,O
Most,O
Common,O
TEAEs,O
5,O
and,O
Greater,O
than,O
Placebo,O
Double,O
Blind,O
Phase,O
of,O
Clinical,O
Trial,O
Double,O
Blind,O
Phase,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
XEOMIN,O
N,O
74,O
Placebo,O
N,O
34,O
Subjects,O
with,O
TEAEs,O
70,O
62,O
Eye,O
disorders,O
38,O
21,O
Eyelid ptosis,AdverseReaction
19,O
9,O
Dry eye,AdverseReaction
16,O
12,O
Visual impairment,AdverseReaction
12,O
6,O
Gastrointestinal,O
disorders,O
30,O
15,O
Dry mouth,AdverseReaction
16,O
3,O
Diarrhoea,AdverseReaction
8,O
Infections,O
and,O
infestations,O
20,O
15,O
Nasopharyngitis,AdverseReaction
5,O
3,O
Respiratory tract infection,AdverseReaction
5,O
3,O
Nervous,O
system,O
disorders,O
14,O
9,O
Headache,AdverseReaction
7,O
3,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
11,O
9,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
11,O
3,O
Dyspnoea,AdverseReaction
5,O
3,O
Glabellar,O
Lines,O
In,O
three,O
placebo,O
controlled,O
trials,O
in,O
803,O
subjects,O
with,O
glabellar,O
lines,O
535,O
subjects,O
received,O
a,O
single,O
dose,O
of,O
20,O
Units,O
XEOMIN,O
and,O
268,O
subjects,O
received,O
placebo,O
XEOMIN,O
treated,O
subjects,O
were,O
24,O
to,O
74,O
years,O
old,O
and,O
were,O
predominantly,O
female,O
88,O
The,O
most,O
frequent,O
adverse,O
reactions,O
in,O
XEOMIN,O
treated,O
subjects,O
were,O
headache,AdverseReaction
29,O
5,O
4,O
facial paresis,AdverseReaction
4,O
0,O
7,O
injection site hematoma,AdverseReaction
3,O
0,O
6,O
and,O
eyelid edema,AdverseReaction
2,O
0,O
4,O
Four,O
serious,O
adverse,O
events,O
occurred,O
in,O
two,O
placebo,O
treated,O
subjects,O
Six,O
XEOMIN,O
treated,O
subjects,O
experienced,O
six,O
serious,O
adverse,O
events,O
All,O
serious,O
adverse,O
events,O
were,O
assessed,O
as,O
unrelated,O
to,O
study,O
drug,O
The,O
adverse,O
reactions,O
below,O
reflect,O
exposure,O
to,O
XEOMIN,O
with,O
glabellar,O
lines,O
in,O
placebo,O
controlled,O
studies,O
Adverse,O
reactions,O
are,O
adverse,O
events,O
in,O
which,O
there,O
is,O
some,O
basis,O
to,O
believe,O
there,O
is,O
a,O
causal,O
relationship,O
between,O
the,O
drug,O
and,O
the,O
occurrence,O
of,O
the,O
adverse,O
event,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Table,O
4,O
Adverse,O
Reactions,O
in,O
Placebo,O
Controlled,O
Trials,O
Adverse,O
reactions,O
XEOMIN,O
N,O
535,O
Placebo,O
N,O
268,O
Nervous,O
system,O
disorders,O
33,O
6,O
1,O
6,O
2,O
2,O
Headache,AdverseReaction
1,O
29,O
5,O
4,O
6,O
2,O
2,O
Facial paresis,AdverseReaction
brow ptosis,AdverseReaction
4,O
0,O
7,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
5,O
0,O
9,O
2,O
0,O
7,O
Injection site hematoma,AdverseReaction
3,O
0,O
6,O
0,O
Injection site pain,AdverseReaction
1,O
0,O
2,O
0,O
Facial pain,AdverseReaction
1,O
0,O
2,O
0,O
Injection site swelling,AdverseReaction
0,O
1,O
0,O
4,O
Sensation of pressure,AdverseReaction
0,O
1,O
0,O
4,O
Eye,O
disorders,O
5,O
0,O
9,O
0,O
Eyelid edema,AdverseReaction
2,O
0,O
4,O
0,O
Blepharospasm,AdverseReaction
1,O
0,O
2,O
0,O
Eye disorder,AdverseReaction
1,O
0,O
2,O
0,O
Eyelid ptosis,AdverseReaction
1,O
0,O
2,O
0,O
In,O
open,O
label,O
multiple,O
dose,O
trials,O
adverse,O
reactions,O
were,O
reported,O
for,O
105,O
of,O
the,O
800,O
subjects,O
13,O
1,O
Headache,AdverseReaction
was,O
the,O
most,O
common,O
adverse,O
reaction,O
reported,O
for,O
57,O
subjects,O
7,O
1,O
followed,O
by,O
injection site hematoma,AdverseReaction
in,O
8,O
subjects,O
1,O
0,O
Adverse,O
reactions,O
reported,O
in,O
less,O
than,O
1,O
of,O
subjects,O
were,O
facial paresis,AdverseReaction
brow ptosis,AdverseReaction
muscle disorder,AdverseReaction
elevation of eyebrow,AdverseReaction
injection site pain,AdverseReaction
and,O
eyelid edema,AdverseReaction
6,O
2,O
Immunogenicity,O
As,O
with,O
all,O
therapeutic,O
proteins,O
there,O
is,O
a,O
potential,O
for,O
immunogenicity,O
The,O
incidence,O
of,O
antibody,O
formation,O
is,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
In,O
addition,O
the,O
observed,O
incidence,O
of,O
antibody,O
positivity,O
in,O
an,O
assay,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
the,O
incidence,O
of,O
antibodies,O
across,O
products,O
in,O
this,O
class,O
may,O
be,O
misleading,O
6,O
3,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
reported,O
during,O
post,O
approval,O
use,O
with,O
XEOMIN,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
eye swelling,AdverseReaction
eyelid edema,AdverseReaction
dysphagia,AdverseReaction
nausea,AdverseReaction
flu like symptoms,AdverseReaction
injection site pain,AdverseReaction
injection site reaction,AdverseReaction
allergic dermatitis,AdverseReaction
localized allergic reactions,AdverseReaction
like,O
swelling,AdverseReaction
edema,AdverseReaction
erythema,AdverseReaction
pruritus,AdverseReaction
or,O
rash,AdverseReaction
herpes zoster,AdverseReaction
muscular weakness,AdverseReaction
muscle spasm,AdverseReaction
dysarthria,AdverseReaction
myalgia,AdverseReaction
and,O
hypersensitivity,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Tendon rupture,AdverseReaction
or,O
serious,Severity
injury to the injected finger to the injected,AdverseReaction
hand,AdverseReaction
Avoid,O
injecting,O
XIAFLEX,O
into,O
tendons,O
nerves,O
blood,O
vessels,O
or,O
other,O
collagen,O
containing,O
structure,O
of,O
the,O
hand,O
Injection,O
into,O
these,O
structures,O
may,O
result,O
in,O
possible,O
permanent,O
injury,O
such,O
as,O
tendon,O
rupture,O
or,O
ligament,O
damage,O
or,O
skin,O
laceration,O
5,O
1,O
Corporal rupture,AdverseReaction
penile fracture,AdverseReaction
or,O
other,O
serious,Severity
injury to the penis,AdverseReaction
Avoid,O
injecting,O
into,O
the,O
urethra,O
nerves,O
blood,O
vessels,O
corpora,O
cavernosa,O
or,O
other,O
collagen,O
containing,O
structures,O
of,O
the,O
penis,O
Injection,O
into,O
these,O
structures,O
may,Factor
result,O
in,O
possible,O
permanent injury,AdverseReaction
such,O
as,O
corporal rupture,AdverseReaction
penile fracture,AdverseReaction
5,O
2,O
Hypersensitivity reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
Healthcare,O
providers,O
should,O
be,O
prepared,O
to,O
address,O
hypersensitivity,O
reactions,O
including,O
anaphylaxis,O
following,O
XIAFLEX,O
injections,O
5,O
4,O
Patients,O
with,O
abnormal,O
coagulation,O
Use,O
with,O
caution,O
including,O
in,O
patients,O
who,O
have,O
received,O
anticoagulant,O
medications,O
other,O
than,O
low,O
dose,O
aspirin,O
within,O
7,O
days,O
of,O
the,O
injection,O
5,O
5,O
5,O
1,O
Tendon,O
Rupture,O
or,O
Other,O
Serious,O
Injury,O
to,O
the,O
Injected,O
Finger,O
Hand,O
in,O
the,O
Treatment,O
of,O
Dupuytren,O
s,O
Contracture,O
In,O
the,O
controlled,O
and,O
uncontrolled,O
portions,O
of,O
clinical,O
trials,O
in,O
Dupuytren,O
s,O
contracture,O
flexor tendon ruptures,AdverseReaction
occurred,O
after,O
XIAFLEX,O
injection,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Injection,O
of,O
XIAFLEX,O
into,O
collagen containing structures,AdverseReaction
such,O
as,O
tendons,AdverseReaction
or,O
ligaments of the hand the hand,AdverseReaction
may,Factor
result,O
in,O
damage,AdverseReaction
to,O
those,O
structures,O
and,O
possible,Factor
permanent injury,AdverseReaction
such,O
as,O
tendon rupture,AdverseReaction
or,O
ligament damage,AdverseReaction
Therefore,O
XIAFLEX,O
should,O
be,O
injected,O
only,O
into,O
the,O
collagen,O
cord,O
with,O
a,O
MP,O
or,O
PIP,O
joint,O
contracture,O
and,O
care,O
should,O
be,O
taken,O
to,O
avoid,O
injecting,O
into,O
tendons,O
nerves,O
blood,O
vessels,O
or,O
other,O
collagen,O
containing,O
structures,O
of,O
the,O
hand,O
When,O
injecting,O
a,O
cord,O
affecting,O
a,O
PIP,O
joint,O
of,O
the,O
fifth,O
finger,O
the,O
needle,O
insertion,O
should,O
not,O
be,O
more,O
than,O
2,O
to,O
3,O
mm,O
in,O
depth,O
and,O
avoid,O
injecting,O
more,O
than,O
4,O
mm,O
distal,O
to,O
the,O
palmar,O
digital,O
crease,O
see,O
Dosage,O
and,O
Administration,O
2,O
1,O
Other,O
XIAFLEX,O
associated,O
serious,O
local,O
adverse,O
reactions,O
included,O
pulley rupture,AdverseReaction
ligament injury,AdverseReaction
complex regional pain syndrome,AdverseReaction
CRPS,AdverseReaction
sensory abnormality of the hand,AdverseReaction
and,O
skin laceration,AdverseReaction
tear,AdverseReaction
In,O
a,O
historically,O
controlled,O
post,O
marketing,O
trial,O
the,O
incidence,O
of,O
skin laceration,AdverseReaction
22,O
was,O
higher,O
for,O
subjects,O
treated,O
with,O
two,O
concurrent,O
injections,O
of,O
XIAFLEX,O
compared,O
with,O
subjects,O
treated,O
with,O
up,O
to,O
three,O
single,O
injections,O
in,O
the,O
placebo,O
controlled,O
premarketing,O
trials,O
9,O
Cases,O
of,O
skin laceration,AdverseReaction
requiring,O
skin,O
graft,O
after,O
finger,O
extension,O
procedures,O
have,O
been,O
reported,O
post,O
marketing,O
Signs,O
or,O
symptoms,O
that,O
may,O
reflect,O
serious,O
injury,O
to,O
the,O
injected,O
finger,O
hand,O
should,O
be,O
promptly,O
evaluated,O
because,O
surgical,O
intervention,O
may,O
be,O
required,O
5,O
2,O
Corporal,O
Rupture,O
Penile,O
Fracture,O
or,O
Other,O
Serious,O
Injury,O
to,O
the,O
Penis,O
in,O
the,O
Treatment,O
of,O
Peyronie,O
s,O
Disease,O
Corporal rupture,AdverseReaction
was,O
reported,O
as,O
an,O
adverse,O
reaction,O
after,O
XIAFLEX,O
injections,O
in,O
5,O
of,O
1044,O
0,O
5,O
XIAFLEX,O
treated,O
patients,O
in,O
the,O
controlled,O
and,O
uncontrolled,O
clinical,O
trials,O
in,O
Peyronie,O
s,O
disease,O
In,O
other,O
XIAFLEX,O
treated,O
patients,O
9,O
of,O
1044,O
0,O
9,O
a,O
combination,O
of,O
penile ecchymoses,AdverseReaction
or,O
hematoma,AdverseReaction
sudden,O
penile detumescence,AdverseReaction
and,O
or,O
a,O
penile popping sound,AdverseReaction
or,O
sensation,AdverseReaction
was,O
reported,O
and,O
in,O
these,O
cases,O
a,O
diagnosis,O
of,O
corporal rupture,AdverseReaction
can not be excluded,Factor
These,O
patients,O
were,O
managed,O
without,O
surgical,O
intervention,O
but,O
the,O
long,O
term,O
consequences,O
are,O
unknown,O
Severe,Severity
penile hematoma,AdverseReaction
was,O
also,O
reported,O
as,O
an,O
adverse,O
reaction,O
in,O
39,O
of,O
1044,O
patients,O
3,O
7,O
in,O
the,O
controlled,O
and,O
uncontrolled,O
clinical,O
trials,O
in,O
Peyronie,O
s,O
disease,O
see,O
Adverse,O
Reactions,O
6,O
Signs,O
or,O
symptoms,O
that,O
may,O
reflect,O
serious,O
injury,O
to,O
the,O
penis,O
should,O
be,O
promptly,O
evaluated,O
in,O
order,O
to,O
assess,O
for,O
corporal,O
rupture,O
or,O
severe,O
penile,O
hematoma,O
which,O
may,O
require,O
surgical,O
intervention,O
Injection,O
of,O
XIAFLEX,O
into,O
collagen containing structures,AdverseReaction
such,O
as,O
the,O
corpora cavernosa of the penis,AdverseReaction
may,Factor
result,O
in,O
damage,AdverseReaction
to,O
those,O
structures,O
and,O
possible,Factor
injury,O
such,O
as,O
corporal rupture,AdverseReaction
penile fracture,AdverseReaction
Therefore,O
XIAFLEX,O
should,O
be,O
injected,O
only,O
into,O
the,O
Peyronie,O
s,O
plaque,O
and,O
care,O
should,O
be,O
taken,O
to,O
avoid,O
injecting,O
into,O
the,O
urethra,O
nerves,O
blood,O
vessels,O
corpora,O
cavernosa,O
or,O
other,O
collagen,O
containing,O
structures,O
of,O
the,O
penis,O
5,O
3,O
XIAFLEX,O
REMS,O
Program,O
Because,O
of,O
the,O
risks,O
of,O
corporal,O
rupture,O
penile,O
fracture,O
or,O
other,O
serious,O
penile,O
injury,O
in,O
the,O
treatment,O
of,O
Peyronie,O
s,O
disease,O
XIAFLEX,O
is,O
available,O
only,O
through,O
the,O
XIAFLEX,O
REMS,O
Program,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Required,O
components,O
of,O
the,O
XIAFLEX,O
REMS,O
Program,O
include,O
the,O
following,O
Prescribers,O
must,O
be,O
certified,O
with,O
the,O
program,O
by,O
enrolling,O
and,O
completing,O
training,O
in,O
the,O
administration,O
of,O
XIAFLEX,O
treatment,O
for,O
Peyronie,O
s,O
disease,O
Healthcare,O
sites,O
must,O
be,O
certified,O
with,O
the,O
program,O
and,O
ensure,O
that,O
XIAFLEX,O
is,O
only,O
dispensed,O
for,O
use,O
by,O
certified,O
prescribers,O
Further,O
information,O
is,O
available,O
at,O
www,O
XIAFLEXREMS,O
com,O
or,O
1,O
877,O
313,O
1235,O
5,O
4,O
Hypersensitivity,O
Reactions,O
Including,O
Anaphylaxis,O
In,O
the,O
controlled,O
portions,O
of,O
the,O
clinical,O
trials,O
in,O
Dupuytren,O
s,O
contracture,O
Studies,O
1,O
and,O
2,O
a,O
greater,O
proportion,O
of,O
XIAFLEX,O
treated,O
patients,O
15,O
compared,O
to,O
placebo,O
treated,O
patients,O
1,O
had,O
mild,Severity
allergic reactions,AdverseReaction
pruritus,AdverseReaction
after,O
up,O
to,O
3,O
injections,O
The,O
incidence,O
of,O
XIAFLEX,O
associated,O
pruritus,AdverseReaction
increased,O
after,O
more,O
XIAFLEX,O
injections,O
in,O
patients,O
with,O
Dupuytren,O
s,O
contracture,O
In,O
the,O
double,O
blind,O
placebo,O
controlled,O
portions,O
of,O
the,O
clinical,O
trials,O
in,O
Peyronie,O
s,O
disease,O
Studies,O
1,O
and,O
2,O
a,O
greater,O
proportion,O
of,O
XIAFLEX,O
treated,O
patients,O
4,O
compared,O
to,O
placebo,O
treated,O
patients,O
1,O
had,O
localized pruritus,AdverseReaction
after,O
up,O
to,O
4,O
treatment,O
cycles,O
involving,O
up,O
to,O
8,O
XIAFLEX,O
injection,O
procedures,O
The,O
incidence,O
of,O
XIAFLEX,O
associated,O
pruritus,AdverseReaction
was,O
similar,O
after,O
each,O
injection,O
regardless,O
of,O
the,O
number,O
of,O
injections,O
administered,O
Because,O
XIAFLEX,O
contains,O
foreign,O
proteins,O
severe,Severity
allergic reactions,AdverseReaction
to,O
XIAFLEX,O
can,Factor
occur,O
Anaphylaxis,AdverseReaction
was,O
reported,O
in,O
a,O
post,O
marketing,O
clinical,O
trial,O
Study,O
3,O
in,O
one,O
patient,O
who,O
had,O
previous,O
exposure,O
to,O
XIAFLEX,O
for,O
the,O
treatment,O
of,O
Dupuytren,O
s,O
contracture,O
Some,O
patients,O
with,O
Dupuytren,O
s,O
contracture,O
developed,O
IgE,O
anti,O
drug,O
antibodies,O
in,O
greater,O
proportions,O
and,O
higher,O
titers,O
with,O
successive,O
XIAFLEX,O
injections,O
Healthcare,O
providers,O
should,O
be,O
prepared,O
to,O
address,O
severe,O
allergic,O
reactions,O
following,O
XIAFLEX,O
injections,O
5,O
5,O
Risk,O
of,O
bleeding,O
in,O
Patients,O
with,O
Abnormal,O
Coagulation,O
In,O
the,O
XIAFLEX,O
trials,O
in,O
Dupuytren,O
s,O
contracture,O
Studies,O
1,O
and,O
2,O
70,O
and,O
38,O
of,O
XIAFLEX,O
treated,O
patients,O
developed,O
an,O
ecchymosis,AdverseReaction
contusion,AdverseReaction
or,O
an,O
injection site hemorrhage,AdverseReaction
respectively,O
see,O
Table,O
3,O
In,O
the,O
XIAFLEX,O
controlled,O
trials,O
in,O
Peyronie,O
s,O
disease,O
Studies,O
1,O
and,O
2,O
65,O
5,O
of,O
XIAFLEX,O
treated,O
patients,O
developed,O
penile hematoma,AdverseReaction
and,O
14,O
5,O
developed,O
penile ecchymosis,AdverseReaction
see,O
Table,O
4,O
Patients,O
with,O
abnormal,O
coagulation,O
except,O
for,O
patients,O
taking,O
low,O
dose,O
aspirin,O
e,O
g,O
up,O
to,O
150,O
mg,O
per,O
day,O
were,O
excluded,O
from,O
participating,O
in,O
these,O
studies,O
Therefore,O
the,O
efficacy,O
and,O
safety,O
of,O
XIAFLEX,O
in,O
patients,O
receiving,O
anticoagulant,O
medications,O
other,O
than,O
low,O
dose,O
aspirin,O
e,O
g,O
up,O
to,O
150,O
mg,O
per,O
day,O
within,O
7,O
days,O
prior,O
to,O
XIAFLEX,O
administration,O
is,O
not,O
known,O
In,O
addition,O
it,O
is,O
recommended,O
to,O
avoid,O
use,O
of,O
XIAFLEX,O
in,O
patients,O
with,O
coagulation,O
disorders,O
including,O
patients,O
receiving,O
concomitant,O
anticoagulants,O
except,O
for,O
low,O
dose,O
aspirin,O
""
BOXED,O
WARNING,O
WARNING,O
CORPORAL RUPTURE,AdverseReaction
PENILE FRACTURE,AdverseReaction
OR,O
OTHER,O
SERIOUS,Severity
PENILE INJURY,AdverseReaction
IN,O
THE,O
TREATMENT,O
OF,O
PEYRONIE,O
S,O
DISEASE,O
WARNING,O
CORPORAL RUPTURE,AdverseReaction
PENILE FRACTURE,AdverseReaction
OR,O
OTHER,O
SERIOUS,Severity
PENILE INJURY,AdverseReaction
IN,O
THE,O
TREATMENT,O
OF,O
PEYRONIE,O
S,O
DISEASE,O
Corporal rupture,AdverseReaction
penile fracture,AdverseReaction
was,O
reported,O
as,O
an,O
adverse,O
reaction,O
in,O
5,O
of,O
1044,O
0,O
5,O
XIAFLEX,O
treated,O
patients,O
in,O
clinical,O
studies,O
In,O
other,O
XIAFLEX,O
treated,O
patients,O
9,O
of,O
1044,O
0,O
9,O
a,O
combination,O
of,O
penile ecchymoses,AdverseReaction
or,O
hematoma,AdverseReaction
sudden,O
penile detumescence,AdverseReaction
and,O
or,O
a,O
penile popping sound,AdverseReaction
or,O
sensation,AdverseReaction
was,O
reported,O
and,O
in,O
these,O
cases,O
a,O
diagnosis,O
of,O
corporal rupture,AdverseReaction
cannot be excluded,Factor
Severe,Severity
penile hematoma,AdverseReaction
was,O
also,O
reported,O
as,O
an,O
adverse,O
reaction,O
in,O
39,O
of,O
1044,O
3,O
7,O
XIAFLEX,O
treated,O
patients,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Signs,O
or,O
symptoms,O
that,O
may,O
reflect,O
serious,O
penile,O
injury,O
should,O
be,O
promptly,O
evaluated,O
to,O
assess,O
for,O
corporal,O
rupture,O
or,O
severe,O
penile,O
hematoma,O
which,O
may,O
require,O
surgical,O
intervention,O
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Because,O
of,O
the,O
risks,Factor
of,O
corporal rupture,AdverseReaction
or,O
other,O
serious,Severity
penile injury,AdverseReaction
XIAFLEX,O
is,O
available,O
for,O
the,O
treatment,O
of,O
Peyronie,O
s,O
disease,O
only,O
through,O
a,O
restricted,O
program,O
under,O
a,O
Risk,O
Evaluation,O
and,O
Mitigation,O
Strategy,O
REMS,O
called,O
the,O
XIAFLEX,O
REMS,O
Program,O
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
EXCERPT,O
WARNING,O
CORPORAL RUPTURE,AdverseReaction
PENILE FRACTURE,AdverseReaction
OR,O
OTHER,O
SERIOUS,Severity
PENILE INJURY,AdverseReaction
IN,O
THE,O
TREATMENT,O
OF,O
PEYRONIE,O
S,O
DISEASE,O
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Corporal rupture,AdverseReaction
penile fracture,AdverseReaction
was,O
reported,O
as,O
an,O
adverse,O
reaction,O
in,O
5,O
of,O
1044,O
0,O
5,O
XIAFLEX,O
treated,O
patients,O
in,O
clinical,O
studies,O
In,O
other,O
XIAFLEX,O
treated,O
patients,O
9,O
of,O
1044,O
0,O
9,O
a,O
diagnosis,O
of,O
corporal rupture,AdverseReaction
cannot be excluded,Factor
Severe,Severity
penile hematoma,AdverseReaction
was,O
also,O
reported,O
as,O
an,O
adverse,O
reaction,O
in,O
39,O
of,O
1044,O
3,O
7,O
XIAFLEX,O
treated,O
patients,O
5,O
2,O
XIAFLEX,O
is,O
available,O
for,O
the,O
treatment,O
of,O
Peyronie,O
s,O
disease,O
only,O
through,O
a,O
restricted,O
program,O
called,O
the,O
XIAFLEX,O
REMS,O
Program,O
5,O
3,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
in,O
patients,O
with,O
Dupuytren,O
s,O
contracture,O
are,O
discussed,O
in,O
greater,O
detail,O
elsewhere,O
in,O
the,O
labeling,O
Tendon ruptures,AdverseReaction
or,O
other,O
serious,Severity
injury to the injected extremity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
The,O
following,O
serious,O
adverse,O
reactions,O
in,O
patients,O
with,O
Peyronie,O
s,O
disease,O
are,O
discussed,O
in,O
greater,O
detail,O
elsewhere,O
in,O
the,O
labeling,O
Corporal rupture,AdverseReaction
penile fracture,AdverseReaction
and,O
severe,Severity
penile hematoma,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
In,O
other,O
XIAFLEX,O
treated,O
patients,O
a,O
combination,O
of,O
penile ecchymoses,AdverseReaction
or,O
hematoma,AdverseReaction
sudden,O
penile detumescence,AdverseReaction
and,O
or,O
a,O
penile popping sound,AdverseReaction
or,O
sensation,AdverseReaction
was,O
reported,O
and,O
in,O
these,O
cases,O
a,O
diagnosis,O
of,O
corporal rupture,AdverseReaction
cannot be excluded,Factor
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
EXCERPT,O
Dupuytren,O
s,O
Contracture,O
6,O
1,O
The,O
most,O
common,O
adverse,O
reactions,O
reported,O
in,O
25,O
of,O
patients,O
treated,O
with,O
XIAFLEX,O
and,O
at,O
an,O
incidence,O
greater,O
than,O
placebo,O
were,O
edema peripheral,AdverseReaction
e,O
g,O
swelling of the injected hand,AdverseReaction
contusion,AdverseReaction
injection site hemorrhage,AdverseReaction
injection site reaction,AdverseReaction
and,O
pain in the injected extremity,AdverseReaction
Peyronie,O
s,O
Disease,O
6,O
2,O
The,O
most,O
frequently,O
reported,O
adverse,O
drug,O
reactions,O
reported,O
with,O
25,O
of,O
patients,O
treated,O
with,O
XIAFLEX,O
and,O
at,O
an,O
incidence,O
greater,O
than,O
placebo,O
were,O
penile hematoma,AdverseReaction
penile swelling,AdverseReaction
and,O
penile pain,AdverseReaction
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Auxilium,O
Pharmaceuticals,O
Inc,O
at,O
1,O
877,O
663,O
0412,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Studies,O
Experience,O
in,O
Patients,O
with,O
Dupuytren,O
s,O
Contracture,O
Because,O
clinical,O
studies,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
studies,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
studies,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Out,O
of,O
1082,O
patients,O
who,O
received,O
0,O
58,O
mg,O
of,O
XIAFLEX,O
in,O
the,O
controlled,O
and,O
uncontrolled,O
portions,O
of,O
the,O
XIAFLEX,O
studies,O
2630,O
XIAFLEX,O
injections,O
3,O
0,O
3,O
patients,O
had,O
a,O
flexor tendon rupture of the,AdverseReaction
treated,O
finger,AdverseReaction
within,O
7,O
days,O
of,O
the,O
injection,O
The,O
data,O
described,O
below,O
are,O
based,O
on,O
two,O
pooled,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
trials,O
through,O
Day,O
90,O
in,O
patients,O
with,O
Dupuytren,O
s,O
contracture,O
Studies,O
1,O
and,O
2,O
In,O
these,O
trials,O
patients,O
were,O
treated,O
with,O
up,O
to,O
3,O
injections,O
of,O
0,O
58,O
mg,O
of,O
XIAFLEX,O
or,O
placebo,O
with,O
approximately,O
4,O
week,O
intervals,O
between,O
injections,O
and,O
the,O
patients,O
had,O
finger,O
extension,O
procedures,O
the,O
day,O
after,O
injection,O
if,O
needed,O
to,O
facilitate,O
disruption,O
of,O
the,O
cord,O
see,O
Clinical,O
Studies,O
14,O
These,O
trials,O
were,O
comprised,O
of,O
374,O
patients,O
of,O
whom,O
249,O
and,O
125,O
received,O
0,O
58,O
mg,O
of,O
XIAFLEX,O
and,O
placebo,O
respectively,O
The,O
mean,O
age,O
was,O
63,O
years,O
80,O
were,O
male,O
and,O
20,O
were,O
female,O
and,O
100,O
were,O
white,O
In,O
the,O
placebo,O
controlled,O
portions,O
of,O
Studies,O
1,O
and,O
2,O
through,O
Day,O
90,O
98,O
and,O
51,O
of,O
XIAFLEX,O
treated,O
and,O
placebo,O
treated,O
patients,O
had,O
an,O
adverse,O
reaction,O
after,O
up,O
to,O
3,O
injections,O
respectively,O
Over,O
95,O
of,O
XIAFLEX,O
treated,O
patients,O
had,O
an,O
adverse reaction of the injected extremity,AdverseReaction
after,O
up,O
to,O
3,O
injections,O
Approximately,O
81,O
of,O
these,O
local,O
reactions,O
resolved,O
without,O
intervention,O
within,O
4,O
weeks,O
of,O
XIAFLEX,O
injections,O
The,O
adverse,O
reaction,O
profile,O
was,O
similar,O
for,O
each,O
injection,O
regardless,O
of,O
the,O
number,O
of,O
injections,O
administered,O
However,O
the,O
incidence,O
of,O
pruritus,AdverseReaction
increased,O
with,O
more,O
injections,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
The,O
most,O
frequently,O
reported,O
adverse,O
drug,O
reactions,O
25,O
in,O
the,O
XIAFLEX,O
clinical,O
trials,O
in,O
patients,O
with,O
Dupuytren,O
s,O
contracture,O
included,O
edema peripheral,AdverseReaction
mostly,O
swelling of the injected hand,AdverseReaction
contusion,AdverseReaction
injection site hemorrhage,AdverseReaction
injection site reaction,AdverseReaction
and,O
pain in the treated extremity,AdverseReaction
Table,O
3,O
shows,O
the,O
incidence,O
of,O
adverse,O
reactions,O
that,O
were,O
reported,O
in,O
greater,O
than,O
or,O
equal,O
to,O
5,O
of,O
XIAFLEX,O
treated,O
patients,O
and,O
at,O
a,O
frequency,O
greater,O
than,O
placebo,O
treated,O
patients,O
after,O
up,O
to,O
3,O
injections,O
in,O
the,O
pooled,O
placebo,O
controlled,O
trials,O
through,O
Day,O
90,O
Studies,O
1,O
and,O
2,O
Table,O
3,O
Adverse,O
Reactions,O
Occurring,O
in,O
5,O
of,O
XIAFLEX,O
Treated,O
Patients,O
with,O
Dupuytren,O
s,O
Contracture,O
and,O
at,O
a,O
Greater,O
Incidence,O
than,O
Placebo,O
in,O
the,O
Placebo,O
Controlled,O
Trials,O
Through,O
Day,O
90,O
After,O
Up,O
to,O
3,O
Injections,O
a,O
Most,O
of,O
these,O
events,O
were,O
swelling of the injected hand,AdverseReaction
b,O
Includes,O
the,O
terms,O
contusion,AdverseReaction
any,O
body,O
system,O
and,O
ecchymosis,AdverseReaction
c,O
Includes,O
the,O
terms,O
injection site reaction,AdverseReaction
injection site erythema,AdverseReaction
injection site inflammation,AdverseReaction
injection site irritation,AdverseReaction
injection site pain,AdverseReaction
and,O
injection site warmth,AdverseReaction
d,O
Includes,O
the,O
terms,O
injection site swelling,AdverseReaction
and,O
injection site edema,AdverseReaction
e,O
Includes,O
the,O
terms,O
pruritus,AdverseReaction
and,O
injection site pruritus,AdverseReaction
f,O
Includes,O
the,O
terms,O
lymphadenopathy,AdverseReaction
and,O
axillary mass,AdverseReaction
Adverse,O
Reaction,O
XIAFLEXN,O
249,O
PlaceboN,O
125,O
All,O
Adverse,O
Reactions,O
98,O
51,O
Edema Peripheral,AdverseReaction
a,O
73,O
5,O
Contusion,AdverseReaction
b,O
70,O
3,O
Injection Site Hemorrhage,AdverseReaction
38,O
3,O
Injection Site Reaction,AdverseReaction
c,O
35,O
6,O
Pain in Extremity,AdverseReaction
35,O
4,O
Tenderness,AdverseReaction
24,O
0,O
Injection Site Swelling,AdverseReaction
d,O
24,O
6,O
Pruritus,AdverseReaction
e,O
15,O
1,O
Lymphadenopathy,AdverseReaction
f,O
13,O
0,O
Skin Laceration,AdverseReaction
9,O
0,O
Lymph Node Pain,AdverseReaction
8,O
0,O
Erythema,AdverseReaction
6,O
0,O
Axillary Pain,AdverseReaction
6,O
0,O
Some,O
patients,O
developed,O
vasovagal syncope,AdverseReaction
after,O
finger,O
extension,O
procedures,O
The,O
safety,O
of,O
two,O
concurrent,O
injections,O
of,O
XIAFLEX,O
0,O
58,O
mg,O
into,O
Dupuytren,O
s,O
cords,O
in,O
the,O
same,O
hand,O
was,O
evaluated,O
in,O
a,O
historically,O
controlled,O
open,O
label,O
multi,O
center,O
trial,O
in,O
715,O
adult,O
subjects,O
with,O
Dupuytren,O
s,O
contracture,O
Study,O
3,O
In,O
Study,O
3,O
finger,O
extension,O
procedures,O
were,O
performed,O
approximately,O
24,O
to,O
72,O
hours,O
after,O
injection,O
The,O
patient,O
demographics,O
were,O
similar,O
to,O
Studies,O
1,O
and,O
2,O
Out,O
of,O
715,O
patients,O
who,O
received,O
two,O
concurrent,O
injections,O
of,O
XIAFLEX,O
0,O
58,O
mg,O
in,O
the,O
same,O
hand,O
1450,O
XIAFLEX,O
injections,O
in,O
Study,O
3,O
one,O
0,O
1,O
patient,O
experienced,O
a,O
tendon rupture of the,AdverseReaction
treated,O
finger,AdverseReaction
within,O
3,O
days,O
of,O
the,O
injection,O
Table,O
4,O
shows,O
the,O
incidence,O
of,O
adverse,O
reactions,O
that,O
were,O
reported,O
in,O
greater,O
than,O
or,O
equal,O
to,O
5,O
of,O
XIAFLEX,O
treated,O
patients,O
after,O
two,O
concurrent,O
injections,O
of,O
XIAFLEX,O
in,O
the,O
same,O
hand,O
through,O
Day,O
60,O
in,O
Study,O
3,O
Table,O
4,O
Adverse,O
Reactions,O
Occurring,O
in,O
5,O
0,O
of,O
Subjects,O
Who,O
Received,O
Two,O
Concurrent,O
Injections,O
of,O
XIAFLEX,O
in,O
Study,O
3,O
Adverse,O
Reaction,O
XIAFLEXN,O
715,O
Subjects,O
with,O
1,O
adverse,O
reaction,O
95,O
Edema peripheral,AdverseReaction
77,O
Contusion,AdverseReaction
59,O
Pain in extremity,AdverseReaction
51,O
Laceration,AdverseReaction
22,O
Pruritus,AdverseReaction
15,O
Injection site pain,AdverseReaction
14,O
Lymphadenopathy,AdverseReaction
13,O
Blood blister,AdverseReaction
12,O
Injection site hematoma,AdverseReaction
8,O
Axillary pain,AdverseReaction
7,O
Injection site hemorrhage,AdverseReaction
6,O
Injection site swelling,AdverseReaction
5,O
Ecchymosis,AdverseReaction
5,O
Safety,O
of,O
Retreatment,O
of,O
Recurrent,O
Contractures,O
An,O
observational,O
open,O
label,O
study,O
was,O
conducted,O
in,O
subjects,O
who,O
had,O
participated,O
in,O
XIAFLEX,O
clinical,O
trials,O
for,O
Dupuytren,O
s,O
contracture,O
Study,O
4,O
A,O
subset,O
of,O
patients,O
who,O
had,O
recurrence,O
of,O
contracture,O
in,O
a,O
joint,O
that,O
was,O
previously,O
successfully,O
treated,O
with,O
XIAFLEX,O
in,O
Study,O
4,O
were,O
retreated,O
Study,O
5,O
No,O
new,O
safety,O
signals,O
were,O
identified,O
among,O
subjects,O
who,O
were,O
retreated,O
with,O
XIAFLEX,O
6,O
2,O
Clinical,O
Studies,O
Experience,O
in,O
Patients,O
with,O
Peyronie,O
s,O
Disease,O
Because,O
clinical,O
studies,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
studies,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
studies,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
In,O
the,O
controlled,O
and,O
uncontrolled,O
clinical,O
studies,O
of,O
XIAFLEX,O
in,O
Peyronie,O
s,O
disease,O
1044,O
patients,O
received,O
a,O
total,O
of,O
7466,O
XIAFLEX,O
injections,O
Corporal,O
Rupture,O
and,O
Other,O
Serious,O
Penile,O
Injury,O
Corporal rupture,AdverseReaction
was,O
reported,O
as,O
an,O
adverse,O
reaction,O
after,O
XIAFLEX,O
injections,O
in,O
5,O
of,O
1044,O
0,O
5,O
XIAFLEX,O
treated,O
patients,O
In,O
other,O
XIAFLEX,O
treated,O
patients,O
9,O
of,O
1044,O
0,O
9,O
a,O
combination,O
of,O
penile ecchymoses,AdverseReaction
or,O
hematoma,AdverseReaction
sudden,O
penile detumescence,AdverseReaction
and,O
or,O
a,O
penile popping sound,AdverseReaction
or,O
sensation,AdverseReaction
was,O
reported,O
and,O
in,O
these,O
cases,O
a,O
diagnosis,O
of,O
corporal rupture,AdverseReaction
cannot be excluded,Factor
These,O
patients,O
were,O
managed,O
without,O
surgical,O
intervention,O
but,O
the,O
long,O
term,O
consequences,O
are,O
unknown,O
Severe,Severity
penile hematoma,AdverseReaction
was,O
also,O
reported,O
as,O
an,O
adverse,O
reaction,O
in,O
39,O
of,O
1044,O
patients,O
3,O
7,O
in,O
the,O
controlled,O
and,O
uncontrolled,O
clinical,O
trials,O
in,O
Peyronie,O
s,O
disease,O
see,O
Adverse,O
Reactions,O
6,O
The,O
data,O
described,O
below,O
are,O
based,O
on,O
two,O
identical,O
pooled,O
randomized,O
double,O
blind,O
placebo,O
controlled,O
multi,O
center,O
trials,O
through,O
Day,O
365,O
in,O
patients,O
with,O
Peyronie,O
s,O
disease,O
Studies,O
1,O
and,O
2,O
These,O
trials,O
included,O
832,O
patients,O
of,O
whom,O
551,O
and,O
281,O
received,O
XIAFLEX,O
and,O
placebo,O
respectively,O
In,O
these,O
trials,O
patients,O
were,O
given,O
up,O
to,O
4,O
treatment,O
cycles,O
of,O
XIAFLEX,O
or,O
placebo,O
In,O
each,O
cycle,O
two,O
injections,O
of,O
XIAFLEX,O
or,O
two,O
injections,O
of,O
placebo,O
were,O
administered,O
1,O
to,O
3,O
days,O
apart,O
A,O
penile,O
modeling,O
procedure,O
was,O
performed,O
at,O
the,O
study,O
site,O
on,O
patients,O
1,O
to,O
3,O
days,O
after,O
the,O
second,O
injection,O
of,O
the,O
cycle,O
The,O
treatment,O
cycle,O
was,O
repeated,O
at,O
approximately,O
6,O
week,O
intervals,O
up,O
to,O
three,O
additional,O
times,O
for,O
a,O
maximum,O
of,O
8,O
total,O
injection,O
procedures,O
and,O
4,O
total,O
modeling,O
procedures,O
see,O
Clinical,O
Studies,O
14,O
2,O
The,O
majority,O
of,O
Peyronie,O
s,O
patients,O
experienced,O
at,O
least,O
one,O
adverse,O
reaction,O
92,O
XIAFLEX,O
treated,O
patients,O
61,O
placebo,O
treated,O
Most,O
adverse reactions reactions reactions reactions,AdverseReaction
were,O
local,O
events,O
of the penis the penis the the,AdverseReaction
and,O
groin,AdverseReaction
and,O
the,O
majority,O
of,O
these,O
events,O
were,O
of,O
mild,Severity
or,O
moderate,Severity
severity,O
and,O
most,O
79,O
resolved,O
within,O
14,O
days,O
of,O
the,O
injection,O
The,O
adverse,O
reaction,O
profile,O
was,O
similar,O
after,O
each,O
injection,O
regardless,O
of,O
the,O
number,O
of,O
injections,O
administered,O
The,O
most,O
frequently,O
reported,O
adverse,O
drug,O
reactions,O
25,O
in,O
the,O
XIAFLEX,O
clinical,O
trials,O
in,O
patients,O
with,O
Peyronie,O
s,O
disease,O
were,O
penile hematoma,AdverseReaction
penile swelling,AdverseReaction
and,O
penile pain,AdverseReaction
Table,O
5,O
shows,O
the,O
incidence,O
of,O
adverse,O
reactions,O
that,O
were,O
reported,O
in,O
greater,O
than,O
or,O
equal,O
to,O
1,O
of,O
XIAFLEX,O
treated,O
patients,O
and,O
at,O
a,O
frequency,O
greater,O
than,O
placebo,O
treated,O
patients,O
after,O
up,O
to,O
8,O
injections,O
in,O
the,O
pooled,O
placebo,O
controlled,O
trials,O
through,O
Day,O
365,O
Table,O
5,O
Adverse,O
Reactions,O
Occurring,O
in,O
1,O
of,O
XIAFLEX,O
Treated,O
Patients,O
with,O
Peyronie,O
s,O
disease,O
and,O
at,O
a,O
Greater,O
Incidence,O
than,O
Placebo,O
After,O
Up,O
to,O
Four,O
Treatment,O
Cycles,O
in,O
Studies,O
1,O
and,O
2,O
Combined,O
a,O
Includes,O
injection site hematoma,AdverseReaction
and,O
penile hematoma,AdverseReaction
were,O
reported,O
with,O
the,O
verbatim,O
term,O
of,O
penile bruising,AdverseReaction
or,O
injection site bruising,AdverseReaction
in,O
87,O
of,O
subjects,O
b,O
Includes,O
injection site swelling,AdverseReaction
penile edema,AdverseReaction
penile swelling,AdverseReaction
local swelling,AdverseReaction
scrotal swelling,AdverseReaction
and,O
injection site edema,AdverseReaction
c,O
Includes,O
injection site pain,AdverseReaction
penile pain,AdverseReaction
and,O
injection site discomfort,AdverseReaction
d,O
Includes,O
contusion,AdverseReaction
ecchymoses,AdverseReaction
penile hemorrhage,AdverseReaction
and,O
injection site hemorrhage,AdverseReaction
Adverse,O
Reaction,O
XIAFLEXN,O
551,O
PlaceboN,O
281,O
All,O
Adverse,O
Reactions,O
84,O
2,O
36,O
3,O
Penile hematoma,AdverseReaction
a,O
65,O
5,O
19,O
2,O
Penile swelling,AdverseReaction
b,O
55,O
0,O
3,O
2,O
Penile pain,AdverseReaction
c,O
45,O
4,O
9,O
3,O
Penile ecchymoses,AdverseReaction
d,O
14,O
5,O
6,O
8,O
Blood blister,AdverseReaction
4,O
5,O
0,O
Penile blister,AdverseReaction
3,O
3,O
0,O
Pruritus genital,AdverseReaction
3,O
1,O
0,O
Painful erection,AdverseReaction
2,O
9,O
0,O
Erectile dysfunction,AdverseReaction
1,O
8,O
0,O
4,O
Skin discoloration,AdverseReaction
1,O
8,O
0,O
Procedural pain,AdverseReaction
1,O
6,O
0,O
7,O
Injection site vesicles,AdverseReaction
1,O
3,O
0,O
Localized edema,AdverseReaction
1,O
3,O
0,O
Dyspareunia,AdverseReaction
1,O
1,O
0,O
Injection site pruritus,AdverseReaction
1,O
1,O
0,O
Nodule,AdverseReaction
1,O
1,O
0,O
Suprapubic pain,AdverseReaction
1,O
1,O
0,O
Severe,Severity
penile hematoma,AdverseReaction
or,O
severe,Severity
injection site hematoma,AdverseReaction
were,O
reported,O
in,O
33,O
551,O
6,O
0,O
of,O
XIAFLEX,O
treated,O
patients,O
and,O
0,O
281,O
0,O
of,O
placebo,O
treated,O
patients,O
in,O
Studies,O
1,O
and,O
2,O
combined,O
Reports,O
of,O
penile,O
popping,O
sounds,O
or,O
sensations,O
A,O
popping noise,AdverseReaction
or,O
popping sensation in the penis the penis,AdverseReaction
penis,AdverseReaction
sometimes,O
described,O
as,O
snapping,AdverseReaction
or,O
cracking,AdverseReaction
and,O
sometimes,O
accompanied,O
by,O
detumescence,AdverseReaction
hematoma,AdverseReaction
and,O
or,O
pain,AdverseReaction
were,O
reported,O
in,O
73,O
551,O
13,O
2,O
XIAFLEX,O
treated,O
patients,O
and,O
1,O
281,O
0,O
3,O
placebo,O
treated,O
patients,O
There,O
were,O
no,O
clinically,O
meaningful,O
differences,O
in,O
the,O
incidence,O
of,O
adverse,O
events,O
following,O
treatment,O
with,O
XIAFLEX,O
based,O
on,O
the,O
severity,O
of,O
baseline,O
erectile,O
dysfunction,O
or,O
concomitant,O
phosphodiesterase,O
type,O
5,O
PDE5,O
inhibitor,O
use,O
XIAFLEX,O
was,O
not,Negation
associated,O
with,O
shortening of penile length,AdverseReaction
in,O
clinical,O
trials,O
in,O
the,O
treatment,O
of,O
Peyronie,O
s,O
disease,O
6,O
3,O
Immunogenicity,O
During,O
clinical,O
studies,O
in,O
Dupuytren,O
s,O
contracture,O
and,O
Peyronie,O
s,O
disease,O
patients,O
were,O
tested,O
at,O
multiple,O
time,O
points,O
for,O
antibodies,O
to,O
the,O
protein,O
components,O
of,O
XIAFLEX,O
AUX,O
I,O
and,O
AUX,O
II,O
In,O
the,O
Dupuytren,O
s,O
contracture,O
clinical,O
studies,O
Studies,O
1,O
and,O
2,O
at,O
30,O
days,O
post,O
the,O
first,O
injection,O
of,O
XIAFLEX,O
0,O
58,O
mg,O
92,O
of,O
patients,O
had,O
antibodies,O
against,O
AUX,O
I,O
detected,O
and,O
86,O
of,O
patients,O
had,O
antibodies,O
against,O
AUX,O
II,O
detected,O
After,O
the,O
fourth,O
injection,O
of,O
XIAFLEX,O
every,O
XIAFLEX,O
treated,O
patient,O
developed,O
high,O
titers,O
of,O
antibodies,O
to,O
both,O
AUX,O
I,O
and,O
AUX,O
II,O
After,O
five,O
years,O
more,O
than,O
90,O
percent,O
of,O
patients,O
remained,O
seropositive,O
for,O
anti,O
AUX,O
I,O
and,O
anti,O
AUX,O
II,O
antibody,O
Study,O
4,O
Neutralizing,O
antibodies,O
were,O
assayed,O
for,O
all,O
patients,O
204,O
in,O
Study,O
1,O
Neutralizing,O
antibodies,O
to,O
AUX,O
I,O
or,O
AUX,O
II,O
were,O
detected,O
in,O
10,O
and,O
21,O
respectively,O
of,O
patients,O
treated,O
with,O
XIAFLEX,O
Among,O
patients,O
in,O
Study,O
3,O
who,O
reported,O
no,O
prior,O
exposure,O
to,O
XIAFLEX,O
97,O
of,O
patients,O
had,O
antibodies,O
against,O
AUX,O
I,O
and,O
AUX,O
II,O
after,O
two,O
concurrent,O
doses,O
of,O
XIAFLEX,O
0,O
58,O
mg,O
total,O
dose,O
of,O
1,O
16,O
mg,O
in,O
the,O
same,O
hand,O
In,O
Study,O
5,O
treatment,O
of,O
recurrent,O
contractures,O
with,O
XIAFLEX,O
resulted,O
in,O
similar,O
immunogenicity,O
results,O
as,O
seen,O
in,O
Studies,O
1,O
and,O
2,O
In,O
the,O
Peyronie,O
s,O
disease,O
clinical,O
studies,O
at,O
6,O
weeks,O
after,O
the,O
first,O
treatment,O
cycle,O
of,O
XIAFLEX,O
0,O
58,O
mg,O
approximately,O
75,O
of,O
patients,O
had,O
antibodies,O
against,O
AUX,O
I,O
and,O
approximately,O
55,O
of,O
patients,O
had,O
antibodies,O
against,O
AUX,O
II,O
Six,O
weeks,O
after,O
the,O
eighth,O
injection,O
fourth,O
treatment,O
cycle,O
of,O
XIAFLEX,O
99,O
of,O
XIAFLEX,O
treated,O
patients,O
developed,O
high,O
titers,O
of,O
antibodies,O
to,O
both,O
AUX,O
I,O
and,O
AUX,O
II,O
Neutralizing,O
antibodies,O
were,O
assayed,O
for,O
a,O
subset,O
of,O
70,O
samples,O
selected,O
to,O
be,O
representative,O
of,O
high,O
and,O
low,O
titer,O
binding,O
antibody,O
responses,O
at,O
week,O
12,O
of,O
treatment,O
For,O
each,O
subject,O
in,O
whom,O
a,O
Week,O
12,O
sample,O
was,O
selected,O
the,O
corresponding,O
Week,O
6,O
18,O
24,O
and,O
52,O
samples,O
were,O
assayed,O
if,O
they,O
were,O
also,O
binding,O
antibody,O
positive,O
Neutralizing,O
antibodies,O
to,O
AUX,O
I,O
or,O
AUX,O
II,O
were,O
detected,O
in,O
60,O
and,O
51,O
8,O
respectively,O
of,O
patients,O
tested,O
In,O
patients,O
treated,O
for,O
these,O
two,O
indications,O
there,O
was,O
no,O
apparent,O
correlation,O
of,O
antibody,O
frequency,O
antibody,O
titers,O
or,O
neutralizing,O
status,O
to,O
clinical,O
response,O
or,O
adverse,O
reactions,O
Since,O
the,O
protein,O
components,O
in,O
XIAFLEX,O
AUX,O
I,O
and,O
AUX,O
II,O
have,O
some,O
sequence,O
homology,O
with,O
human,O
matrix,O
metalloproteinases,O
MMPs,O
anti,O
product,O
antibodies,O
could,O
theoretically,O
interfere,O
with,O
human,O
MMPs,O
In,O
vitro,O
studies,O
showed,O
no,O
evidence,O
of,O
cross,O
reactivity,O
between,O
anti,O
drug,O
antibody,O
positive,O
patient,O
sera,O
and,O
a,O
series,O
of,O
relevant,O
MMPs,O
In,O
addition,O
no,O
clinical,O
safety,O
concerns,O
related,O
to,O
the,O
inhibition,O
of,O
endogenous,O
MMPs,O
have,O
been,O
observed,O
Immunogenicity,O
assay,O
results,O
are,O
highly,O
dependent,O
on,O
the,O
sensitivity,O
and,O
specificity,O
of,O
the,O
assay,O
used,O
in,O
detection,O
and,O
may,O
be,O
influenced,O
by,O
several,O
factors,O
including,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
incidence,O
of,O
antibodies,O
to,O
collagenase,O
clostridium,O
histolyticum,O
with,O
the,O
incidence,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Seizure,AdverseReaction
occurred,O
in,O
0,O
9,O
of,O
patients,O
receiving,O
XTANDI,O
who,O
previously,O
received,O
docetaxel,O
and,O
in,O
0,O
1,O
of,O
patients,O
who,O
were,O
chemotherapy,O
naive,O
There,O
is,O
no,O
clinical,O
trial,O
experience,O
with,O
XTANDI,O
in,O
patients,O
who,O
have,O
had,O
a,O
seizure,O
Permanently,O
discontinue,O
XTANDI,O
in,O
patients,O
who,O
develop,O
a,O
seizure,O
during,O
treatment,O
5,O
1,O
5,O
1,O
Seizure,O
In,O
Study,O
1,O
which,O
enrolled,O
patients,O
who,O
previously,O
received,O
docetaxel,O
7,O
of,O
800,O
0,O
9,O
patients,O
treated,O
with,O
XTANDI,O
experienced,O
a,O
seizure,AdverseReaction
and,O
no,Negation
patients,O
treated,O
with,O
placebo,O
experienced,O
a,O
seizure,AdverseReaction
Seizure,AdverseReaction
occurred,O
from,O
31,O
to,O
603,O
days,O
after,O
initiation,O
of,O
XTANDI,O
In,O
Study,O
2,O
1,O
of,O
871,O
0,O
1,O
chemotherapy,O
naive,O
patients,O
treated,O
with,O
XTANDI,O
and,O
1,O
of,O
844,O
0,O
1,O
patients,O
treated,O
with,O
placebo,O
experienced,O
a,O
seizure,AdverseReaction
Patients,O
experiencing,O
seizure,AdverseReaction
were,O
permanently,O
discontinued,O
from,O
therapy,O
and,O
all,O
seizure,O
events,O
resolved,O
There,O
is,O
no,O
clinical,O
trial,O
experience,O
re,O
administering,O
XTANDI,O
to,O
patients,O
who,O
experienced,O
seizure,O
Limited,O
safety,O
data,O
are,O
available,O
in,O
patients,O
with,O
predisposing,O
factors,O
for,O
seizure,O
because,O
these,O
patients,O
were,O
generally,O
excluded,O
from,O
the,O
trials,O
These,O
exclusion,O
criteria,O
included,O
a,O
history,O
of,O
seizure,O
underlying,O
brain,O
injury,O
with,O
loss,O
of,O
consciousness,O
transient,O
ischemic,O
attack,O
within,O
the,O
past,O
12,O
months,O
cerebral,O
vascular,O
accident,O
brain,O
metastases,O
and,O
brain,O
arteriovenous,O
malformation,O
Study,O
1,O
excluded,O
the,O
use,O
of,O
concomitant,O
medications,O
that,O
may,O
lower,O
the,O
seizure,O
threshold,O
whereas,O
Study,O
2,O
permitted,O
the,O
use,O
of,O
these,O
medications,O
Because,O
of,O
the,O
risk,O
of,O
seizure,O
associated,O
with,O
XTANDI,O
use,O
patients,O
should,O
be,O
advised,O
of,O
the,O
risk,O
of,O
engaging,O
in,O
any,O
activity,O
where,O
sudden,O
loss,O
of,O
consciousness,O
could,O
cause,O
serious,O
harm,O
to,O
themselves,O
or,O
others,O
Permanently,O
discontinue,O
XTANDI,O
in,O
patients,O
who,O
develop,O
a,O
seizure,O
during,O
treatment,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
is,O
discussed,O
in,O
more,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Seizure,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
10,O
are,O
asthenia,AdverseReaction
fatigue,AdverseReaction
back pain,AdverseReaction
decreased appetite,AdverseReaction
constipation,AdverseReaction
arthralgia,AdverseReaction
diarrhea,AdverseReaction
hot flush,AdverseReaction
upper respiratory tract infection,AdverseReaction
peripheral edema,AdverseReaction
dyspnea,AdverseReaction
musculoskeletal pain,AdverseReaction
weight decreased,AdverseReaction
headache,AdverseReaction
hypertension,AdverseReaction
and,O
dizziness,AdverseReaction
vertigo,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Astellas,O
Pharma,O
US,O
Inc,O
at,O
1,O
800,O
727,O
7003,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Two,O
randomized,O
clinical,O
trials,O
enrolled,O
patients,O
with,O
metastatic,O
prostate,O
cancer,O
that,O
has,O
progressed,O
on,O
androgen,O
deprivation,O
therapy,O
GnRH,O
therapy,O
or,O
bilateral,O
orchiectomy,O
a,O
disease,O
setting,O
that,O
is,O
also,O
defined,O
as,O
metastatic,O
CRPC,O
In,O
both,O
studies,O
patients,O
received,O
XTANDI,O
160,O
mg,O
orally,O
once,O
daily,O
in,O
the,O
active,O
treatment,O
arm,O
or,O
placebo,O
in,O
the,O
control,O
arm,O
All,O
patients,O
continued,O
androgen,O
deprivation,O
therapy,O
Patients,O
were,O
allowed,O
but,O
not,O
required,O
to,O
take,O
glucocorticoids,O
The,O
most,O
common,O
adverse,O
reactions,O
10,O
that,O
occurred,O
more,O
commonly,O
2,O
over,O
placebo,O
in,O
the,O
XTANDI,O
treated,O
patients,O
from,O
the,O
two,O
randomized,O
clinical,O
trials,O
were,O
asthenia,AdverseReaction
fatigue,AdverseReaction
back pain,AdverseReaction
decreased appetite,AdverseReaction
constipation,AdverseReaction
arthralgia,AdverseReaction
diarrhea,AdverseReaction
hot flush,AdverseReaction
upper respiratory tract infection,AdverseReaction
peripheral edema,AdverseReaction
dyspnea,AdverseReaction
musculoskeletal pain,AdverseReaction
weight decreased,AdverseReaction
headache,AdverseReaction
hypertension,AdverseReaction
and,O
dizziness,AdverseReaction
vertigo,AdverseReaction
Study,O
1,O
Metastatic,O
Castration,O
Resistant,O
Prostate,O
Cancer,O
Following,O
Chemotherapy,O
Study,O
1,O
enrolled,O
1199,O
patients,O
with,O
metastatic,O
CRPC,O
who,O
had,O
previously,O
received,O
docetaxel,O
The,O
median,O
duration,O
of,O
treatment,O
was,O
8,O
3,O
months,O
with,O
XTANDI,O
and,O
3,O
0,O
months,O
with,O
placebo,O
During,O
the,O
trial,O
48,O
of,O
patients,O
on,O
the,O
XTANDI,O
arm,O
and,O
46,O
of,O
patients,O
on,O
the,O
placebo,O
arm,O
received,O
glucocorticoids,O
Grade,O
3,O
and,O
higher,O
adverse,O
reactions,O
were,O
reported,O
among,O
47,O
of,O
XTANDI,O
treated,O
patients,O
and,O
53,O
of,O
placebo,O
treated,O
patients,O
Discontinuations,O
due,O
to,O
adverse,O
events,O
were,O
reported,O
for,O
16,O
of,O
XTANDI,O
treated,O
patients,O
and,O
18,O
of,O
placebo,O
treated,O
patients,O
The,O
most,O
common,O
adverse,O
reaction,O
leading,O
to,O
treatment,O
discontinuation,O
was,O
seizure,AdverseReaction
which,O
occurred,O
in,O
0,O
9,O
of,O
the,O
XTANDI,O
treated,O
patients,O
compared,O
to,O
none,O
0,O
of,O
the,O
placebo,O
treated,O
patients,O
Table,O
1,O
shows,O
adverse,O
reactions,O
reported,O
in,O
Study,O
1,O
that,O
occurred,O
at,O
a,O
2,O
higher,O
frequency,O
in,O
the,O
XTANDI,O
arm,O
compared,O
to,O
the,O
placebo,O
arm,O
Table,O
1,O
Adverse,O
Reactions,O
in,O
Study,O
1,O
XTANDI,O
N,O
800,O
Placebo,O
N,O
399,O
Grade,O
1,O
4a,O
Grade,O
3,O
4,O
Grade,O
1,O
4,O
Grade,O
3,O
4,O
General,O
Disorders,O
Asthenic,O
Conditionsb,O
50,O
6,O
9,O
0,O
44,O
4,O
9,O
3,O
Peripheral Edema,AdverseReaction
15,O
4,O
1,O
0,O
13,O
3,O
0,O
8,O
Musculoskeletal,O
And,O
Connective,O
Tissue,O
Disorders,O
Back Pain,AdverseReaction
26,O
4,O
5,O
3,O
24,O
3,O
4,O
0,O
Arthralgia,AdverseReaction
20,O
5,O
2,O
5,O
17,O
3,O
1,O
8,O
Musculoskeletal Pain,AdverseReaction
15,O
0,O
1,O
3,O
11,O
5,O
0,O
3,O
Muscular Weakness,AdverseReaction
9,O
8,O
1,O
5,O
6,O
8,O
1,O
8,O
Musculoskeletal Stiffness,AdverseReaction
2,O
6,O
0,O
3,O
0,O
3,O
0,O
0,O
Gastrointestinal,O
Disorders,O
Diarrhea,AdverseReaction
21,O
8,O
1,O
1,O
17,O
5,O
0,O
3,O
Vascular,O
Disorders,O
Hot Flush,AdverseReaction
20,O
3,O
0,O
0,O
10,O
3,O
0,O
0,O
Hypertension,AdverseReaction
6,O
4,O
2,O
1,O
2,O
8,O
1,O
3,O
Nervous,O
System,O
Disorders,O
Headache,AdverseReaction
12,O
1,O
0,O
9,O
5,O
5,O
0,O
0,O
Dizzinessc,O
9,O
5,O
0,O
5,O
7,O
5,O
0,O
5,O
Spinal Cord Compression,AdverseReaction
and,O
Cauda Equina Syndrome,AdverseReaction
7,O
4,O
6,O
6,O
4,O
5,O
3,O
8,O
Paresthesia,AdverseReaction
6,O
6,O
0,O
0,O
4,O
5,O
0,O
0,O
Mental,O
Impairment,O
Disordersd,O
4,O
3,O
0,O
3,O
1,O
8,O
0,O
0,O
Hypoesthesia,AdverseReaction
4,O
0,O
0,O
3,O
1,O
8,O
0,O
0,O
Infections,O
And,O
Infestations,O
Upper,O
Respiratory,O
Tract,O
Infectione,O
10,O
9,O
0,O
0,O
6,O
5,O
0,O
3,O
Lower Respiratory Tract,AdverseReaction
And,O
Lung,O
Infectionf,O
8,O
5,O
2,O
4,O
4,O
8,O
1,O
3,O
Psychiatric,O
Disorders,O
Insomnia,AdverseReaction
8,O
8,O
0,O
0,O
6,O
0,O
0,O
5,O
Anxiety,AdverseReaction
6,O
5,O
0,O
3,O
4,O
0,O
0,O
0,O
Renal,O
And,O
Urinary,O
Disorders,O
Hematuria,AdverseReaction
6,O
9,O
1,O
8,O
4,O
5,O
1,O
0,O
Pollakiuria,AdverseReaction
4,O
8,O
0,O
0,O
2,O
5,O
0,O
0,O
Injury,O
Poisoning,O
And,O
Procedural,O
Complications,O
Fall,AdverseReaction
4,O
6,O
0,O
3,O
1,O
3,O
0,O
0,O
Non pathologic Fractures,AdverseReaction
4,O
0,O
1,O
4,O
0,O
8,O
0,O
3,O
Skin,O
And,O
Subcutaneous,O
Tissue,O
Disorders,O
Pruritus,AdverseReaction
3,O
8,O
0,O
0,O
1,O
3,O
0,O
0,O
Dry Skin,AdverseReaction
3,O
5,O
0,O
0,O
1,O
3,O
0,O
0,O
Respiratory,O
Disorders,O
Epistaxis,AdverseReaction
3,O
3,O
0,O
1,O
1,O
3,O
0,O
3,O
a,O
CTCAE,O
v4b,O
Includes,O
asthenia,AdverseReaction
and,O
fatigue,AdverseReaction
c,O
Includes,O
dizziness,AdverseReaction
and,O
vertigo,AdverseReaction
d,O
Includes,O
amnesia,AdverseReaction
memory impairment,AdverseReaction
cognitive disorder,AdverseReaction
and,O
disturbance in attention,AdverseReaction
e,O
Includes,O
nasopharyngitis,AdverseReaction
upper respiratory tract infection,AdverseReaction
sinusitis,AdverseReaction
rhinitis,AdverseReaction
pharyngitis,AdverseReaction
and,O
laryngitis,AdverseReaction
f,O
Includes,O
pneumonia,AdverseReaction
lower respiratory tract infection,AdverseReaction
bronchitis,AdverseReaction
and,O
lung infection,AdverseReaction
Study,O
2,O
Chemotherapy,O
naive,O
Metastatic,O
Castration,O
Resistant,O
Prostate,O
Cancer,O
Study,O
2,O
enrolled,O
1717,O
patients,O
with,O
metastatic,O
CRPC,O
who,O
had,O
not,O
received,O
prior,O
cytotoxic,O
chemotherapy,O
of,O
whom,O
1715,O
received,O
at,O
least,O
one,O
dose,O
of,O
study,O
drug,O
The,O
median,O
duration,O
of,O
treatment,O
was,O
17,O
5,O
months,O
with,O
XTANDI,O
and,O
4,O
6,O
months,O
with,O
placebo,O
Grade,O
3,O
4,O
adverse,O
reactions,O
were,O
reported,O
in,O
44,O
of,O
XTANDI,O
treated,O
patients,O
and,O
37,O
of,O
placebo,O
treated,O
patients,O
Discontinuations,O
due,O
to,O
adverse,O
events,O
were,O
reported,O
for,O
6,O
of,O
XTANDI,O
treated,O
patients,O
and,O
6,O
of,O
placebo,O
treated,O
patients,O
The,O
most,O
common,O
adverse,O
reaction,O
leading,O
to,O
treatment,O
discontinuation,O
was,O
fatigue,AdverseReaction
asthenia,AdverseReaction
which,O
occurred,O
in,O
1,O
of,O
patients,O
on,O
each,O
treatment,O
arm,O
Table,O
2,O
includes,O
adverse,O
reactions,O
reported,O
in,O
Study,O
2,O
that,O
occurred,O
at,O
a,O
2,O
higher,O
frequency,O
in,O
the,O
XTANDI,O
arm,O
compared,O
to,O
the,O
placebo,O
arm,O
Table,O
2,O
Adverse,O
Reactions,O
in,O
Study,O
2,O
XTANDI,O
N,O
871,O
Placebo,O
N,O
844,O
Grade,O
1,O
4,O
a,O
Grade,O
3,O
4,O
Grade,O
1,O
4,O
Grade,O
3,O
4,O
General,O
Disorders,O
Asthenic,O
Conditionsb,O
46,O
9,O
3,O
4,O
33,O
0,O
2,O
8,O
Peripheral Edema,AdverseReaction
11,O
5,O
0,O
2,O
8,O
2,O
0,O
4,O
Musculoskeletal,O
And,O
Connective,O
Tissue,O
Disorders,O
Back Pain,AdverseReaction
28,O
6,O
2,O
5,O
22,O
4,O
3,O
0,O
Arthralgia,AdverseReaction
21,O
4,O
1,O
6,O
16,O
1,O
1,O
1,O
Gastrointestinal,O
Disorders,O
Constipation,AdverseReaction
23,O
2,O
0,O
7,O
17,O
3,O
0,O
4,O
Diarrhea,AdverseReaction
16,O
8,O
0,O
3,O
14,O
3,O
0,O
4,O
Vascular,O
Disorders,O
Hot Flush,AdverseReaction
18,O
0,O
0,O
1,O
7,O
8,O
0,O
0,O
Hypertension,AdverseReaction
14,O
2,O
7,O
2,O
4,O
1,O
2,O
3,O
Nervous,O
System,O
Disorders,O
Dizzinessc,O
11,O
3,O
0,O
3,O
7,O
1,O
0,O
0,O
Headache,AdverseReaction
11,O
0,O
0,O
2,O
7,O
0,O
0,O
4,O
Dysgeusia,AdverseReaction
7,O
6,O
0,O
1,O
3,O
7,O
0,O
0,O
Mental,O
Impairment,O
Disordersd,O
5,O
7,O
0,O
0,O
1,O
3,O
0,O
1,O
Restless Legs Syndrome,AdverseReaction
2,O
1,O
0,O
1,O
0,O
4,O
0,O
0,O
Respiratory,O
Disorders,O
Dyspneae,AdverseReaction
11,O
0,O
0,O
6,O
8,O
5,O
0,O
6,O
Infections,O
And,O
Infestations,O
Upper,O
Respiratory,O
Tract,O
Infectionf,O
16,O
4,O
0,O
0,O
10,O
5,O
0,O
0,O
Lower Respiratory Tract,AdverseReaction
And,O
Lung,O
Infectiong,O
7,O
9,O
1,O
5,O
4,O
7,O
1,O
1,O
Psychiatric,O
Disorders,O
Insomnia,AdverseReaction
8,O
2,O
0,O
1,O
5,O
7,O
0,O
0,O
Renal,O
And,O
Urinary,O
Disorders,O
Hematuria,AdverseReaction
8,O
8,O
1,O
3,O
5,O
8,O
1,O
3,O
Injury,O
Poisoning,O
And,O
Procedural,O
Complications,O
Fall,AdverseReaction
12,O
7,O
1,O
6,O
5,O
3,O
0,O
7,O
Non Pathological Fracture,AdverseReaction
8,O
8,O
2,O
1,O
3,O
0,O
1,O
1,O
Metabolism,O
and,O
Nutrition,O
Disorders,O
Decreased Appetite,AdverseReaction
18,O
9,O
0,O
3,O
16,O
4,O
0,O
7,O
Investigations,O
Weight Decreased,AdverseReaction
12,O
4,O
0,O
8,O
8,O
5,O
0,O
2,O
Reproductive,O
System,O
and,O
Breast,O
disorders,O
Gynecomastia,AdverseReaction
3,O
4,O
0,O
0,O
1,O
4,O
0,O
0,O
a,O
CTCAE,O
v4b,O
Includes,O
asthenia,AdverseReaction
and,O
fatigue,AdverseReaction
c,O
Includes,O
dizziness,AdverseReaction
and,O
vertigo,AdverseReaction
d,O
Includes,O
amnesia,AdverseReaction
memory impairment,AdverseReaction
cognitive disorder,AdverseReaction
and,O
disturbance in attention,AdverseReaction
e,O
Includes,O
dyspnea,AdverseReaction
exertional dyspnea,AdverseReaction
and,O
dyspnea at rest,AdverseReaction
f,O
Includes,O
nasopharyngitis,AdverseReaction
upper respiratory tract infection,AdverseReaction
sinusitis,AdverseReaction
rhinitis,AdverseReaction
pharyngitis,AdverseReaction
and,O
laryngitis,AdverseReaction
g,O
Includes,O
pneumonia,AdverseReaction
lower respiratory tract infection,AdverseReaction
bronchitis,AdverseReaction
and,O
lung infection,AdverseReaction
Laboratory,O
Abnormalities,O
In,O
the,O
two,O
randomized,O
clinical,O
trials,O
Grade 1 1 4,Severity
neutropenia,AdverseReaction
occurred,O
in,O
15,O
of,O
patients,O
treated,O
with,O
XTANDI,O
1,O
Grade,O
3,O
4,O
and,O
in,O
6,O
of,O
patients,O
treated,O
with,O
placebo,O
0,O
5,O
Grade,O
3,O
4,O
The,O
incidence,O
of,O
Grade 1 1 4,Severity
4,Severity
thrombocytopenia,AdverseReaction
was,O
6,O
of,O
patients,O
treated,O
with,O
XTANDI,O
0,O
3,O
Grade,O
3,O
4,O
and,O
5,O
of,O
patients,O
treated,O
with,O
placebo,O
0,O
5,O
Grade,O
3,O
4,O
Grade 1 1 4,Severity
4,Severity
elevations in ALT in ALT in ALT,AdverseReaction
occurred,O
in,O
10,O
of,O
patients,O
treated,O
with,O
XTANDI,O
0,O
2,O
Grade,O
3,O
4,O
and,O
16,O
of,O
patients,O
treated,O
with,O
placebo,O
0,O
2,O
Grade,O
3,O
4,O
Grade 1 1 4,Severity
4,Severity
elevations in bilirubin in bilirubin in bilirubin,AdverseReaction
occurred,O
in,O
3,O
of,O
patients,O
treated,O
with,O
XTANDI,O
0,O
1,O
Grade,O
3,O
4,O
and,O
2,O
of,O
patients,O
treated,O
with,O
placebo,O
no,O
Grade,O
3,O
4,O
Infections,O
In,O
Study,O
1,O
1,O
of,O
patients,O
treated,O
with,O
XTANDI,O
compared,O
to,O
0,O
3,O
of,O
patients,O
treated,O
with,O
placebo,O
died,AdverseReaction
from,O
infections,AdverseReaction
or,O
sepsis,AdverseReaction
In,O
Study,O
2,O
1,O
patient,O
in,O
each,O
treatment,O
group,O
0,O
1,O
had,O
an,O
infection,AdverseReaction
resulting,O
in,O
death,AdverseReaction
Falls,O
and,O
Fall,O
related,O
Injuries,O
In,O
the,O
two,O
randomized,O
clinical,O
trials,O
falls,AdverseReaction
including,O
fall related injuries,AdverseReaction
occurred,O
in,O
9,O
of,O
patients,O
treated,O
with,O
XTANDI,O
compared,O
to,O
4,O
of,O
patients,O
treated,O
with,O
placebo,O
Falls,AdverseReaction
were,O
not,Negation
associated,O
with,O
loss of consciousness,AdverseReaction
or,O
seizure,AdverseReaction
Fall related injuries,AdverseReaction
were,O
more,O
severe,O
in,O
patients,O
treated,O
with,O
XTANDI,O
and,O
included,O
non pathologic fractures,AdverseReaction
joint injuries,AdverseReaction
and,O
hematomas,AdverseReaction
Hypertension,AdverseReaction
In,O
the,O
two,O
randomized,O
trials,O
hypertension,AdverseReaction
was,O
reported,O
in,O
11,O
of,O
patients,O
receiving,O
XTANDI,O
and,O
4,O
of,O
patients,O
receiving,O
placebo,O
No,Negation
patients,O
experienced,O
hypertensive crisis,AdverseReaction
Medical,O
history,O
of,O
hypertension,O
was,O
balanced,O
between,O
arms,O
Hypertension,AdverseReaction
led,O
to,O
study,O
discontinuation,O
in,O
1,O
of,O
patients,O
in,O
each,O
arm,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
YERVOY,O
can,Factor
result,O
in,O
severe,Severity
and,O
fatal,AdverseReaction
immune mediated reactions,AdverseReaction
due,O
to,O
T,O
cell,O
activation,O
and,O
proliferation,O
See,O
Boxed,O
Warning,O
EXCERPT,O
Immune mediated adverse reactions,AdverseReaction
Permanently,O
discontinue,O
for,O
severe,O
reactions,O
Withhold,O
dose,O
for,O
moderate,O
immune,O
mediated,O
adverse,O
reactions,O
until,O
return,O
to,O
baseline,O
improvement,O
to,O
mild,O
severity,O
or,O
complete,O
resolution,O
and,O
patient,O
is,O
receiving,O
less,O
than,O
7,O
5,O
mg,O
prednisone,O
or,O
equivalent,O
per,O
day,O
Administer,O
systemic,O
high,O
dose,O
corticosteroids,O
for,O
severe,O
persistent,O
or,O
recurring,O
immune,O
mediated,O
reactions,O
5,O
1,O
5,O
2,O
5,O
3,O
5,O
4,O
5,O
5,O
Immune mediated hepatitis,AdverseReaction
Evaluate,O
liver,O
function,O
tests,O
before,O
each,O
dose,O
of,O
YERVOY,O
5,O
2,O
Immune mediated endocrinopathies,AdverseReaction
Monitor,O
thyroid,O
function,O
tests,O
and,O
clinical,O
chemistries,O
prior,O
to,O
each,O
dose,O
Evaluate,O
at,O
each,O
visit,O
for,O
signs,O
and,O
symptoms,O
of,O
endocrinopathy,O
Institute,O
hormone,O
replacement,O
therapy,O
as,O
needed,O
5,O
5,O
5,O
1,O
Immune,O
mediated,O
Enterocolitis,O
In,O
Study,O
1,O
severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
diarrhea,AdverseReaction
of,O
7 or more stools above baseline,Severity
fever,AdverseReaction
ileus,AdverseReaction
peritoneal signs,AdverseReaction
Grade 3 3 5,Severity
immune mediated enterocolitis,AdverseReaction
occurred,O
in,O
34,O
7,O
YERVOY,O
treated,O
patients,O
and,O
moderate,Severity
diarrhea,AdverseReaction
with,O
up to 6 stools above baseline,Severity
abdominal pain,AdverseReaction
mucus,AdverseReaction
or,O
blood in stool stool,AdverseReaction
Grade 2,Severity
enterocolitis,AdverseReaction
occurred,O
in,O
28,O
5,O
YERVOY,O
treated,O
patients,O
Across,O
all,O
YERVOY,O
treated,O
patients,O
n,O
511,O
5,O
1,O
patients,O
developed,O
intestinal perforation,AdverseReaction
4,O
0,O
8,O
patients,O
died,AdverseReaction
as,O
a,O
result,O
of,O
complications,O
and,O
26,O
5,O
patients,O
were,O
hospitalized,O
for,O
severe,Severity
enterocolitis,AdverseReaction
The,O
median,O
time,O
to,O
onset,O
was,O
7,O
4,O
weeks,O
range,O
1,O
6,O
13,O
4,O
and,O
6,O
3,O
weeks,O
range,O
0,O
3,O
18,O
9,O
after,O
the,O
initiation,O
of,O
YERVOY,O
for,O
patients,O
with,O
Grade 3 3 5,Severity
enterocolitis,AdverseReaction
and,O
with,O
Grade 2,Severity
enterocolitis,AdverseReaction
respectively,O
Twenty,O
nine,O
patients,O
85,O
with,O
Grade 3 3 5,Severity
enterocolitis,AdverseReaction
were,O
treated,O
with,O
high,O
dose,O
40,O
mg,O
prednisone,O
equivalent,O
per,O
day,O
corticosteroids,O
with,O
a,O
median,O
dose,O
of,O
80,O
mg,O
day,O
of,O
prednisone,O
or,O
equivalent,O
the,O
median,O
duration,O
of,O
treatment,O
was,O
2,O
3,O
weeks,O
ranging,O
up,O
to,O
13,O
9,O
weeks,O
followed,O
by,O
corticosteroid,O
taper,O
Of,O
the,O
28,O
patients,O
with,O
moderate,Severity
enterocolitis,AdverseReaction
46,O
were,O
not,O
treated,O
with,O
systemic,O
corticosteroids,O
29,O
were,O
treated,O
with,O
40,O
mg,O
prednisone,O
or,O
equivalent,O
per,O
day,O
for,O
a,O
median,O
duration,O
of,O
5,O
1,O
weeks,O
and,O
25,O
were,O
treated,O
with,O
high,O
dose,O
corticosteroids,O
for,O
a,O
median,O
duration,O
of,O
10,O
days,O
prior,O
to,O
corticosteroid,O
taper,O
Infliximab,O
was,O
administered,O
to,O
5,O
of,O
the,O
62,O
patients,O
8,O
with,O
moderate,Severity
severe,Severity
or,O
life threatening,Severity
immune mediated enterocolitis,AdverseReaction
following,O
inadequate,O
response,O
to,O
corticosteroids,O
Of,O
the,O
34,O
patients,O
with,O
Grade 3 3 5,Severity
5,Severity
enterocolitis,AdverseReaction
74,O
experienced,O
complete,O
resolution,O
3,O
experienced,O
improvement,O
to,O
Grade,O
2,O
severity,O
and,O
24,O
did,O
not,O
improve,O
Among,O
the,O
28,O
patients,O
with,O
Grade 2,Severity
enterocolitis,AdverseReaction
79,O
experienced,O
complete,O
resolution,O
11,O
improved,O
and,O
11,O
did,O
not,O
improve,O
Monitor,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
enterocolitis,O
such,O
as,O
diarrhea,O
abdominal,O
pain,O
mucus,O
or,O
blood,O
in,O
stool,O
with,O
or,O
without,O
fever,O
and,O
of,O
bowel,O
perforation,O
such,O
as,O
peritoneal,O
signs,O
and,O
ileus,O
In,O
symptomatic,O
patients,O
rule,O
out,O
infectious,O
etiologies,O
and,O
consider,O
endoscopic,O
evaluation,O
for,O
persistent,O
or,O
severe,O
symptoms,O
Permanently,O
discontinue,O
YERVOY,O
in,O
patients,O
with,O
severe,O
enterocolitis,O
and,O
initiate,O
systemic,O
corticosteroids,O
at,O
a,O
dose,O
of,O
1,O
to,O
2,O
mg,O
kg,O
day,O
of,O
prednisone,O
or,O
equivalent,O
Upon,O
improvement,O
to,O
Grade,O
1,O
or,O
less,O
initiate,O
corticosteroid,O
taper,O
and,O
continue,O
to,O
taper,O
over,O
at,O
least,O
1,O
month,O
In,O
clinical,O
trials,O
rapid,O
corticosteroid,O
tapering,O
resulted,O
in,O
recurrence,O
or,O
worsening,O
symptoms,O
of,O
enterocolitis,O
in,O
some,O
patients,O
Withhold,O
YERVOY,O
dosing,O
for,O
moderate,O
enterocolitis,O
administer,O
anti,O
diarrheal,O
treatment,O
and,O
if,O
persistent,O
for,O
more,O
than,O
1,O
week,O
initiate,O
systemic,O
corticosteroids,O
at,O
a,O
dose,O
of,O
0,O
5,O
mg,O
kg,O
day,O
prednisone,O
or,O
equivalent,O
See,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
2,O
Immune,O
mediated,O
Hepatitis,O
In,O
Study,O
1,O
severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
hepatotoxicity,AdverseReaction
AST,AdverseReaction
or,O
ALT elevations,AdverseReaction
of,O
more,O
than,O
5 times the upper limit of normal,Severity
or,O
total bilirubin elevations,AdverseReaction
more,O
than,O
3 times the upper limit of normal,Severity
Grade 3 3 5,Severity
5,Severity
occurred,O
in,O
8,O
2,O
YERVOY,O
treated,O
patients,O
with,O
fatal,AdverseReaction
hepatic failure,AdverseReaction
in,O
0,O
2,O
and,O
hospitalization,O
in,O
0,O
4,O
of,O
YERVOY,O
treated,O
patients,O
An,O
additional,O
13,O
2,O
5,O
patients,O
experienced,O
moderate,Severity
hepatotoxicity,AdverseReaction
manifested,O
by,O
liver function test abnormalities,AdverseReaction
AST,AdverseReaction
or,O
ALT elevations,AdverseReaction
of,O
more,O
than,O
2 5 times but not more than 5 times the upper limit of normal,Severity
or,O
total bilirubin elevation,AdverseReaction
of,O
more,O
than,O
1 5 times but not more than 3 times the upper limit of normal,Severity
Grade 2,Severity
The,O
underlying,O
pathology,O
was,O
not,O
ascertained,O
in,O
all,O
patients,O
but,O
in,O
some,O
instances,O
included,O
immune mediated hepatitis,AdverseReaction
There,O
were,O
insufficient,O
numbers,O
of,O
patients,O
with,O
biopsy,O
proven,O
hepatitis,O
to,O
characterize,O
the,O
clinical,O
course,O
of,O
this,O
event,O
Monitor,O
liver,O
function,O
tests,O
hepatic,O
transaminase,O
and,O
bilirubin,O
levels,O
and,O
assess,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
hepatotoxicity,O
before,O
each,O
dose,O
of,O
YERVOY,O
In,O
patients,O
with,O
hepatotoxicity,O
rule,O
out,O
infectious,O
or,O
malignant,O
causes,O
and,O
increase,O
frequency,O
of,O
liver,O
function,O
test,O
monitoring,O
until,O
resolution,O
Permanently,O
discontinue,O
YERVOY,O
in,O
patients,O
with,O
Grade,O
3,O
5,O
hepatotoxicity,O
and,O
administer,O
systemic,O
corticosteroids,O
at,O
a,O
dose,O
of,O
1,O
to,O
2,O
mg,O
kg,O
day,O
of,O
prednisone,O
or,O
equivalent,O
When,O
liver,O
function,O
tests,O
show,O
sustained,O
improvement,O
or,O
return,O
to,O
baseline,O
initiate,O
corticosteroid,O
tapering,O
and,O
continue,O
to,O
taper,O
over,O
1,O
month,O
Across,O
the,O
clinical,O
development,O
program,O
for,O
YERVOY,O
mycophenolate,O
treatment,O
has,O
been,O
administered,O
in,O
patients,O
who,O
have,O
persistent,O
severe,O
hepatitis,O
despite,O
high,O
dose,O
corticosteroids,O
Withhold,O
YERVOY,O
in,O
patients,O
with,O
Grade,O
2,O
hepatotoxicity,O
See,O
Dosage,O
and,O
Administration,O
2,O
2,O
Concurrent,O
Administration,O
with,O
Vemurafenib,O
In,O
a,O
dose,O
finding,O
trial,O
Grade 3,Severity
increases in transaminases,AdverseReaction
with,O
or,O
without,O
concomitant,O
increases in total bilirubin,AdverseReaction
occurred,O
in,O
6,O
of,O
10,O
patients,O
who,O
received,O
concurrent,O
YERVOY,O
3,O
mg,O
kg,O
and,O
vemurafenib,O
960,O
mg,O
BID,O
or,O
720,O
mg,O
BID,O
5,O
3,O
Immune,O
mediated,O
Dermatitis,O
In,O
Study,O
1,O
severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
immune mediated dermatitis,AdverseReaction
eg,O
Stevens Johnson syndrome,AdverseReaction
toxic epidermal necrolysis,AdverseReaction
or,O
rash,AdverseReaction
complicated,O
by,O
full,O
thickness,O
dermal ulceration,AdverseReaction
or,O
necrotic,AdverseReaction
bullous,AdverseReaction
or,O
hemorrhagic manifestations,AdverseReaction
Grade 3 3 5,Severity
occurred,O
in,O
13,O
2,O
5,O
YERVOY,O
treated,O
patients,O
One,O
0,O
2,O
patient,O
died,AdverseReaction
as,O
a,O
result,O
of,O
toxic epidermal necrolysis,AdverseReaction
and,O
one,O
additional,O
patient,O
required,O
hospitalization,O
for,O
severe,Severity
dermatitis,AdverseReaction
There,O
were,O
63,O
12,O
patients,O
with,O
moderate,Severity
Grade 2,Severity
dermatitis,AdverseReaction
The,O
median,O
time,O
to,O
onset,O
of,O
moderate,Severity
severe,Severity
or,O
life threatening,Severity
immune mediated dermatitis,AdverseReaction
was,O
3,O
1,O
weeks,O
and,O
ranged,O
up,O
to,O
17,O
3,O
weeks,O
from,O
the,O
initiation,O
of,O
YERVOY,O
Seven,O
54,O
YERVOY,O
treated,O
patients,O
with,O
severe,Severity
dermatitis,AdverseReaction
received,O
high,O
dose,O
corticosteroids,O
median,O
dose,O
60,O
mg,O
prednisone,O
day,O
or,O
equivalent,O
for,O
up,O
to,O
14,O
9,O
weeks,O
followed,O
by,O
corticosteroid,O
taper,O
Of,O
these,O
7,O
patients,O
6,O
had,O
complete,O
resolution,O
time,O
to,O
resolution,O
ranged,O
up,O
to,O
15,O
6,O
weeks,O
Of,O
the,O
63,O
patients,O
with,O
moderate,Severity
dermatitis,AdverseReaction
25,O
40,O
were,O
treated,O
with,O
systemic,O
corticosteroids,O
median,O
of,O
60,O
mg,O
day,O
of,O
prednisone,O
or,O
equivalent,O
for,O
a,O
median,O
of,O
2,O
1,O
weeks,O
7,O
11,O
were,O
treated,O
with,O
only,O
topical,O
corticosteroids,O
and,O
31,O
49,O
did,O
not,O
receive,O
systemic,O
or,O
topical,O
corticosteroids,O
Forty,O
four,O
70,O
patients,O
with,O
moderate,Severity
dermatitis,AdverseReaction
were,O
reported,O
to,O
have,O
complete,O
resolution,O
7,O
11,O
improved,O
to,O
mild,O
Grade,O
1,O
severity,O
and,O
12,O
19,O
had,O
no,O
reported,O
improvement,O
Monitor,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
dermatitis,O
such,O
as,O
rash,O
and,O
pruritus,O
Unless,O
an,O
alternate,O
etiology,O
has,O
been,O
identified,O
signs,O
or,O
symptoms,O
of,O
dermatitis,O
should,O
be,O
considered,O
immune,O
mediated,O
Permanently,O
discontinue,O
YERVOY,O
in,O
patients,O
with,O
Stevens,O
Johnson,O
syndrome,O
toxic,O
epidermal,O
necrolysis,O
or,O
rash,O
complicated,O
by,O
full,O
thickness,O
dermal,O
ulceration,O
or,O
necrotic,O
bullous,O
or,O
hemorrhagic,O
manifestations,O
Administer,O
systemic,O
corticosteroids,O
at,O
a,O
dose,O
of,O
1,O
to,O
2,O
mg,O
kg,O
day,O
of,O
prednisone,O
or,O
equivalent,O
When,O
dermatitis,O
is,O
controlled,O
corticosteroid,O
tapering,O
should,O
occur,O
over,O
a,O
period,O
of,O
at,O
least,O
1,O
month,O
Withhold,O
YERVOY,O
dosing,O
in,O
patients,O
with,O
moderate,O
to,O
severe,O
signs,O
and,O
symptoms,O
See,O
Dosage,O
and,O
Administration,O
2,O
2,O
For,O
mild,O
to,O
moderate,O
dermatitis,O
such,O
as,O
localized,O
rash,O
and,O
pruritus,O
treat,O
symptomatically,O
Administer,O
topical,O
or,O
systemic,O
corticosteroids,O
if,O
there,O
is,O
no,O
improvement,O
of,O
symptoms,O
within,O
1,O
week,O
5,O
4,O
Immune,O
mediated,O
Neuropathies,O
In,O
Study,O
1,O
1,O
case,O
of,O
fatal,AdverseReaction
Guillain Barre syndrome,AdverseReaction
and,O
1,O
case,O
of,O
severe,Severity
Grade 3,Severity
peripheral motor neuropathy,AdverseReaction
were,O
reported,O
Across,O
the,O
clinical,O
development,O
program,O
of,O
YERVOY,O
myasthenia gravis,AdverseReaction
and,O
additional,O
cases,O
of,O
Guillain Barre syndrome,AdverseReaction
have,O
been,O
reported,O
Monitor,O
for,O
symptoms,O
of,O
motor,O
or,O
sensory,O
neuropathy,O
such,O
as,O
unilateral,O
or,O
bilateral,O
weakness,O
sensory,O
alterations,O
or,O
paresthesia,O
Permanently,O
discontinue,O
YERVOY,O
in,O
patients,O
with,O
severe,O
neuropathy,O
interfering,O
with,O
daily,O
activities,O
such,O
as,O
Guillain,O
Barre,O
like,O
syndromes,O
Institute,O
medical,O
intervention,O
as,O
appropriate,O
for,O
management,O
of,O
severe,O
neuropathy,O
Consider,O
initiation,O
of,O
systemic,O
corticosteroids,O
at,O
a,O
dose,O
of,O
1,O
to,O
2,O
mg,O
kg,O
day,O
prednisone,O
or,O
equivalent,O
for,O
severe,O
neuropathies,O
Withhold,O
YERVOY,O
dosing,O
in,O
patients,O
with,O
moderate,O
neuropathy,O
not,O
interfering,O
with,O
daily,O
activities,O
See,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
5,O
Immune,O
mediated,O
Endocrinopathies,O
In,O
Study,O
1,O
severe,Severity
to,O
life threatening,Severity
immune mediated endocrinopathies,AdverseReaction
requiring,O
hospitalization,O
urgent,O
medical,O
intervention,O
or,O
interfering,O
with,O
activities,O
of,O
daily,O
living,O
Grade 3 3 4,Severity
4,Severity
occurred,O
in,O
9,O
1,O
8,O
YERVOY,O
treated,O
patients,O
All,O
9,O
patients,O
had,O
hypopituitarism,AdverseReaction
and,O
some,O
had,O
additional,O
concomitant,O
endocrinopathies,AdverseReaction
such,O
as,O
adrenal insufficiency,AdverseReaction
hypogonadism,AdverseReaction
and,O
hypothyroidism,AdverseReaction
Six,O
of,O
the,O
9,O
patients,O
were,O
hospitalized,O
for,O
severe,Severity
endocrinopathies,AdverseReaction
Moderate,Severity
endocrinopathy,AdverseReaction
requiring,O
hormone,O
replacement,O
or,O
medical,O
intervention,O
Grade 2,Severity
occurred,O
in,O
12,O
2,O
3,O
patients,O
and,O
consisted,O
of,O
hypothyroidism,AdverseReaction
adrenal insufficiency,AdverseReaction
hypopituitarism,AdverseReaction
and,O
1,O
case,O
each,O
of,O
hyperthyroidism,AdverseReaction
and,O
Cushing s syndrome,AdverseReaction
The,O
median,O
time,O
to,O
onset,O
of,O
moderate,Severity
to,O
severe,Severity
immune mediated endocrinopathy,AdverseReaction
was,O
11,O
weeks,O
and,O
ranged,O
up,O
to,O
19,O
3,O
weeks,O
after,O
the,O
initiation,O
of,O
YERVOY,O
Of,O
the,O
21,O
patients,O
with,O
moderate,Severity
to,O
life threatening,Severity
endocrinopathy,AdverseReaction
17,O
patients,O
required,O
long,O
term,O
hormone,O
replacement,O
therapy,O
including,O
most,O
commonly,O
adrenal,O
hormones,O
n,O
10,O
and,O
thyroid,O
hormones,O
n,O
13,O
Monitor,O
patients,O
for,O
clinical,O
signs,O
and,O
symptoms,O
of,O
hypophysitis,O
adrenal,O
insufficiency,O
including,O
adrenal,O
crisis,O
and,O
hyper,O
or,O
hypothyroidism,O
Patients,O
may,O
present,O
with,O
fatigue,O
headache,O
mental,O
status,O
changes,O
abdominal,O
pain,O
unusual,O
bowel,O
habits,O
and,O
hypotension,O
or,O
nonspecific,O
symptoms,O
which,O
may,O
resemble,O
other,O
causes,O
such,O
as,O
brain,O
metastasis,O
or,O
underlying,O
disease,O
Unless,O
an,O
alternate,O
etiology,O
has,O
been,O
identified,O
signs,O
or,O
symptoms,O
of,O
endocrinopathies,O
should,O
be,O
considered,O
immune,O
mediated,O
Monitor,O
thyroid,O
function,O
tests,O
and,O
clinical,O
chemistries,O
at,O
the,O
start,O
of,O
treatment,O
before,O
each,O
dose,O
and,O
as,O
clinically,O
indicated,O
based,O
on,O
symptoms,O
In,O
a,O
limited,O
number,O
of,O
patients,O
hypophysitis,AdverseReaction
was,O
diagnosed,O
by,O
imaging,O
studies,O
through,O
enlargement,O
of,O
the,O
pituitary,O
gland,O
Withhold,O
YERVOY,O
dosing,O
in,O
symptomatic,O
patients,O
Initiate,O
systemic,O
corticosteroids,O
at,O
a,O
dose,O
of,O
1,O
to,O
2,O
mg,O
kg,O
day,O
of,O
prednisone,O
or,O
equivalent,O
and,O
initiate,O
appropriate,O
hormone,O
replacement,O
therapy,O
See,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
6,O
Other,O
Immune,O
mediated,O
Adverse,O
Reactions,O
Including,O
Ocular,O
Manifestations,O
The,O
following,O
clinically,O
significant,O
immune mediated adverse reactions,AdverseReaction
were,O
seen,O
in,O
less,O
than,O
1,O
of,O
YERVOY,O
treated,O
patients,O
in,O
Study,O
1,O
nephritis,AdverseReaction
pneumonitis,AdverseReaction
meningitis,AdverseReaction
pericarditis,AdverseReaction
uveitis,AdverseReaction
iritis,AdverseReaction
and,O
hemolytic anemia,AdverseReaction
Across,O
the,O
clinical,O
development,O
program,O
for,O
YERVOY,O
the,O
following,O
likely,O
immune mediated adverse reactions,AdverseReaction
were,O
also,O
reported,O
with,O
less,O
than,O
1,O
incidence,O
myocarditis,AdverseReaction
angiopathy,AdverseReaction
temporal arteritis,AdverseReaction
vasculitis,AdverseReaction
polymyalgia rheumatica,AdverseReaction
conjunctivitis,AdverseReaction
blepharitis,AdverseReaction
episcleritis,AdverseReaction
scleritis,AdverseReaction
leukocytoclastic vasculitis,AdverseReaction
erythema multiforme,AdverseReaction
psoriasis,AdverseReaction
pancreatitis,AdverseReaction
arthritis,AdverseReaction
autoimmune thyroiditis,AdverseReaction
sarcoidosis,AdverseReaction
neurosensory hypoacusis,AdverseReaction
autoimmune central neuropathy,AdverseReaction
encephalitis,AdverseReaction
myositis,AdverseReaction
polymyositis,AdverseReaction
and,O
ocular myositis,AdverseReaction
Permanently,O
discontinue,O
YERVOY,O
for,O
clinically,O
significant,O
or,O
severe,O
immune,O
mediated,O
adverse,O
reactions,O
Initiate,O
systemic,O
corticosteroids,O
at,O
a,O
dose,O
of,O
1,O
to,O
2,O
mg,O
kg,O
day,O
prednisone,O
or,O
equivalent,O
for,O
severe,O
immune,O
mediated,O
adverse,O
reactions,O
Administer,O
corticosteroid,O
eye,O
drops,O
to,O
patients,O
who,O
develop,O
uveitis,O
iritis,O
or,O
episcleritis,O
Permanently,O
discontinue,O
YERVOY,O
for,O
immune,O
mediated,O
ocular,O
disease,O
that,O
is,O
unresponsive,O
to,O
local,O
immunosuppressive,O
therapy,O
See,O
Dosage,O
and,O
Administration,O
2,O
2,O
""
BOXED,O
WARNING,O
WARNING,O
IMMUNE MEDIATED ADVERSE REACTIONS,AdverseReaction
WARNING,O
IMMUNE MEDIATED ADVERSE REACTIONS,AdverseReaction
YERVOY,O
can,Factor
result,O
in,O
severe,Severity
and,O
fatal,AdverseReaction
immune mediated adverse reactions,AdverseReaction
due,O
to,O
T,O
cell,O
activation,O
and,O
proliferation,O
These,O
immune mediated reactions,AdverseReaction
may,Factor
involve,O
any,O
organ,O
system,O
however,O
the,O
most,O
common,O
severe,Severity
immune mediated adverse reactions,AdverseReaction
are,O
enterocolitis,AdverseReaction
hepatitis,AdverseReaction
dermatitis,AdverseReaction
including,O
toxic epidermal necrolysis,AdverseReaction
neuropathy,AdverseReaction
and,O
endocrinopathy,AdverseReaction
The,O
majority,O
of,O
these,O
immune,O
mediated,O
reactions,O
initially,O
manifested,O
during,O
treatment,O
however,O
a,O
minority,O
occurred,O
weeks,O
to,O
months,O
after,O
discontinuation,O
of,O
YERVOY,O
Permanently,O
discontinue,O
YERVOY,O
and,O
initiate,O
systemic,O
high,O
dose,O
corticosteroid,O
therapy,O
for,O
severe,O
immune,O
mediated,O
reactions,O
See,O
Dosage,O
and,O
Administration,O
2,O
2,O
Assess,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
enterocolitis,O
dermatitis,O
neuropathy,O
and,O
endocrinopathy,O
and,O
evaluate,O
clinical,O
chemistries,O
including,O
liver,O
function,O
tests,O
and,O
thyroid,O
function,O
tests,O
at,O
baseline,O
and,O
before,O
each,O
dose,O
See,O
Warnings,O
and,O
Precautions,O
5,O
1,O
5,O
2,O
5,O
3,O
5,O
4,O
5,O
5,O
EXCERPT,O
WARNING,O
IMMUNE MEDIATED ADVERSE REACTIONS,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
YERVOY,O
can,Factor
result,O
in,O
severe,Severity
and,O
fatal,AdverseReaction
immune mediated adverse reactions,AdverseReaction
due,O
to,O
T,O
cell,O
activation,O
and,O
proliferation,O
These,O
immune,O
mediated,O
reactions,O
may,Factor
involve,O
any,O
organ,O
system,O
however,O
the,O
most,O
common,O
severe,Severity
immune mediated adverse reactions,AdverseReaction
are,O
enterocolitis,AdverseReaction
hepatitis,AdverseReaction
dermatitis,AdverseReaction
including,O
toxic epidermal necrolysis,AdverseReaction
neuropathy,AdverseReaction
and,O
endocrinopathy,AdverseReaction
The,O
majority,O
of,O
these,O
immune mediated reactions,AdverseReaction
initially,O
manifested,O
during,O
treatment,O
however,O
a,O
minority,O
occurred,O
weeks,O
to,O
months,O
after,O
discontinuation,O
of,O
YERVOY,O
Permanently,O
discontinue,O
YERVOY,O
and,O
initiate,O
systemic,O
high,O
dose,O
corticosteroid,O
therapy,O
for,O
severe,O
immune,O
mediated,O
reactions,O
2,O
2,O
Assess,O
patients,O
for,O
signs,O
and,O
symptoms,O
of,O
enterocolitis,O
dermatitis,O
neuropathy,O
and,O
endocrinopathy,O
and,O
evaluate,O
clinical,O
chemistries,O
including,O
liver,O
function,O
tests,O
and,O
thyroid,O
function,O
tests,O
at,O
baseline,O
and,O
before,O
each,O
dose,O
5,O
1,O
5,O
2,O
5,O
3,O
5,O
4,O
5,O
5,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Immune mediated enterocolitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Immune mediated hepatitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Immune mediated dermatitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Immune mediated neuropathies,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Immune mediated endocrinopathies,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Other,O
immune mediated adverse reactions,AdverseReaction
including,O
ocular manifestations,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
EXCERPT,O
Most,O
common,O
adverse,O
reactions,O
5,O
are,O
fatigue,AdverseReaction
diarrhea,AdverseReaction
pruritus,AdverseReaction
rash,AdverseReaction
and,O
colitis,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Bristol,O
Myers,O
Squibb,O
at,O
1,O
800,O
721,O
5072,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
the,O
adverse,O
reaction,O
rates,O
observed,O
cannot,O
be,O
directly,O
compared,O
with,O
rates,O
in,O
other,O
clinical,O
trials,O
or,O
experience,O
with,O
therapeutics,O
in,O
the,O
same,O
class,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
The,O
clinical,O
development,O
program,O
excluded,O
patients,O
with,O
active,O
autoimmune,O
disease,O
or,O
those,O
receiving,O
systemic,O
immunosuppression,O
for,O
organ,O
transplantation,O
Exposure,O
to,O
YERVOY,O
3,O
mg,O
kg,O
for,O
4,O
doses,O
given,O
by,O
intravenous,O
infusion,O
in,O
previously,O
treated,O
patients,O
with,O
unresectable,O
or,O
metastatic,O
melanoma,O
was,O
assessed,O
in,O
a,O
randomized,O
double,O
blind,O
clinical,O
study,O
Study,O
1,O
See,O
Clinical,O
Studies,O
14,O
One,O
hundred,O
thirty,O
one,O
patients,O
median,O
age,O
57,O
years,O
60,O
male,O
received,O
YERVOY,O
as,O
a,O
single,O
agent,O
380,O
patients,O
median,O
age,O
56,O
years,O
61,O
male,O
received,O
YERVOY,O
with,O
an,O
investigational,O
gp100,O
peptide,O
vaccine,O
gp100,O
and,O
132,O
patients,O
median,O
age,O
57,O
years,O
54,O
male,O
received,O
gp100,O
peptide,O
vaccine,O
alone,O
Patients,O
in,O
the,O
study,O
received,O
a,O
median,O
of,O
4,O
doses,O
range,O
1,O
4,O
doses,O
YERVOY,O
was,O
discontinued,O
for,O
adverse,O
reactions,O
in,O
10,O
of,O
patients,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
in,O
patients,O
who,O
received,O
YERVOY,O
at,O
3,O
mg,O
kg,O
were,O
fatigue,AdverseReaction
diarrhea,AdverseReaction
pruritus,AdverseReaction
rash,AdverseReaction
and,O
colitis,AdverseReaction
Table,O
1,O
presents,O
selected,O
adverse,O
reactions,O
from,O
Study,O
1,O
which,O
occurred,O
in,O
at,O
least,O
5,O
of,O
patients,O
in,O
the,O
YERVOY,O
containing,O
arms,O
and,O
with,O
at,O
least,O
5,O
increased,O
incidence,O
over,O
the,O
control,O
gp100,O
arm,O
for,O
all,O
grade,O
events,O
and,O
at,O
least,O
1,O
incidence,O
over,O
the,O
control,O
group,O
for,O
Grade,O
3,O
5,O
events,O
Table,O
1,O
Selected,O
Adverse,O
Reactions,O
in,O
Study,O
1,O
a,O
Incidences,O
presented,O
in,O
this,O
table,O
are,O
based,O
on,O
reports,O
of,O
adverse,O
events,O
regardless,O
of,O
causality,O
Percentage,O
of,O
Patientsa,O
YERVOY3,O
mg,O
kgn,O
131,O
YERVOY3,O
mg,O
kg,O
gp100n,O
380,O
gp100n,O
132,O
System,O
Organ,O
Class,O
Preferred,O
Term,O
AnyGrade,O
Grade3,O
5,O
AnyGrade,O
Grade3,O
5,O
AnyGrade,O
Grade3,O
5,O
Gastrointestinal,O
Disorders,O
Diarrhea,AdverseReaction
32,O
5,O
37,O
4,O
20,O
1,O
Colitis,AdverseReaction
8,O
5,O
5,O
3,O
2,O
0,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Pruritus,AdverseReaction
31,O
0,O
21,O
1,O
11,O
0,O
Rash,AdverseReaction
29,O
2,O
25,O
2,O
8,O
0,O
General,O
Disorders,O
and,O
Administration,O
Site,O
Conditions,O
Fatigue,AdverseReaction
41,O
7,O
34,O
5,O
31,O
3,O
Table,O
2,O
presents,O
the,O
per,O
patient,O
incidence,O
of,O
severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
immune mediated adverse reactions,AdverseReaction
from,O
Study,O
1,O
Table,O
2,O
Severe,Severity
to,O
Fatal,AdverseReaction
Immune mediated Adverse Reactions,AdverseReaction
in,O
Study,O
1,O
a,O
Including,O
fatal,AdverseReaction
outcome,O
b,O
Including,O
intestinal perforation,AdverseReaction
c,O
Underlying,O
etiology,O
not,O
established,O
Percentage,O
of,O
Patients,O
YERVOY3,O
mg,O
kgn,O
131,O
YERVOY3,O
mg,O
kg,O
gp100n,O
380,O
Any,O
Immune,O
mediated,O
Adverse,O
Reaction,O
15,O
12,O
Enterocolitisa,O
b,O
7,O
7,O
Hepatotoxicitya,O
1,O
2,O
Dermatitisa,O
2,O
3,O
Neuropathya,O
1,O
1,O
Endocrinopathy,AdverseReaction
4,O
1,O
Hypopituitarism,AdverseReaction
4,O
1,O
Adrenal insufficiency,AdverseReaction
0,O
1,O
Other,O
Pneumonitis,AdverseReaction
0,O
1,O
Meningitis,AdverseReaction
0,O
1,O
Nephritis,AdverseReaction
1,O
0,O
Eosinophiliac,O
1,O
0,O
Pericarditisa,O
c,O
0,O
1,O
Across,O
clinical,O
studies,O
that,O
utilized,O
YERVOY,O
doses,O
ranging,O
from,O
0,O
3,O
to,O
10,O
mg,O
kg,O
the,O
following,O
adverse,O
reactions,O
were,O
also,O
reported,O
incidence,O
less,O
than,O
1,O
unless,O
otherwise,O
noted,O
urticaria,AdverseReaction
2,O
large intestinal ulcer,AdverseReaction
esophagitis,AdverseReaction
acute respiratory distress syndrome,AdverseReaction
renal failure,AdverseReaction
and,O
infusion reaction,AdverseReaction
Based,O
on,O
the,O
experience,O
in,O
the,O
entire,O
clinical,O
program,O
for,O
melanoma,O
the,O
incidence,O
and,O
severity,O
of,O
enterocolitis,AdverseReaction
and,O
hepatitis,AdverseReaction
appear,O
to,O
be,O
dose,O
dependent,O
6,O
2,O
Postmarketing,O
Experience,O
The,O
following,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
postapproval,O
use,O
of,O
YERVOY,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Skin,O
and,O
Subcutaneous,O
Tissue,O
Disorders,O
Drug reaction with eosinophilia and systemic symptoms,AdverseReaction
DRESS syndrome,AdverseReaction
6,O
3,O
Immunogenicity,O
In,O
clinical,O
studies,O
1,O
1,O
of,O
1024,O
evaluable,O
patients,O
tested,O
positive,O
for,O
binding,O
antibodies,O
against,O
ipilimumab,O
in,O
an,O
electrochemiluminescent,O
ECL,O
based,O
assay,O
This,O
assay,O
has,O
substantial,O
limitations,O
in,O
detecting,O
anti,O
ipilimumab,O
antibodies,O
in,O
the,O
presence,O
of,O
ipilimumab,O
Infusion related,AdverseReaction
or,O
peri infusional reactions,AdverseReaction
consistent,O
with,O
hypersensitivity,AdverseReaction
or,O
anaphylaxis,AdverseReaction
were,O
not,Negation
reported,O
in,O
these,O
11,O
patients,O
nor,O
were,O
neutralizing,O
antibodies,O
against,O
ipilimumab,O
detected,O
Because,O
trough,O
levels,O
of,O
ipilimumab,O
interfere,O
with,O
the,O
ECL,O
assay,O
results,O
a,O
subset,O
analysis,O
was,O
performed,O
in,O
the,O
dose,O
cohort,O
with,O
the,O
lowest,O
trough,O
levels,O
In,O
this,O
analysis,O
6,O
9,O
of,O
58,O
evaluable,O
patients,O
who,O
were,O
treated,O
with,O
0,O
3,O
mg,O
kg,O
dose,O
tested,O
positive,O
for,O
binding,O
antibodies,O
against,O
ipilimumab,O
Immunogenicity,O
assay,O
results,O
are,O
highly,O
dependent,O
on,O
several,O
factors,O
including,O
assay,O
sensitivity,O
and,O
specificity,O
assay,O
methodology,O
sample,O
handling,O
timing,O
of,O
sample,O
collection,O
concomitant,O
medications,O
and,O
underlying,O
disease,O
For,O
these,O
reasons,O
comparison,O
of,O
incidence,O
of,O
antibodies,O
to,O
YERVOY,O
with,O
the,O
incidences,O
of,O
antibodies,O
to,O
other,O
products,O
may,O
be,O
misleading,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Decreased,O
efficacy,O
in,O
patients,O
with,O
baseline,O
CrCl,O
of,O
30,O
to,O
50,O
mL,O
min,O
Monitor,O
CrCl,O
at,O
least,O
daily,O
in,O
patients,O
with,O
changing,O
renal,O
function,O
and,O
adjust,O
the,O
dose,O
of,O
ZERBAXA,O
accordingly,O
5,O
1,O
Serious,Severity
hypersensitivity,AdverseReaction
anaphylactic,AdverseReaction
reactions,AdverseReaction
have,O
been,O
reported,O
with,O
beta lactam antibacterial drugs,DrugClass
Exercise,O
caution,O
in,O
patients,O
with,O
known,O
hypersensitivity,O
to,O
beta,O
lactam,O
antibacterial,O
drugs,O
5,O
2,O
Clostridium difficile associated diarrhea,AdverseReaction
CDAD,AdverseReaction
has,O
been,O
reported,O
with,O
nearly,O
all,O
systemic,O
antibacterial,O
agents,O
including,O
ZERBAXA,O
Evaluate,O
if,O
diarrhea,O
occurs,O
5,O
3,O
5,O
1,O
Decreased,O
Efficacy,O
in,O
Patients,O
with,O
Baseline,O
Creatinine,O
Clearance,O
of,O
30,O
to,O
50,O
mL,O
min,O
In,O
a,O
subgroup,O
analysis,O
of,O
a,O
Phase,O
3,O
cIAI,O
trial,O
clinical,O
cure,O
rates,O
were,O
lower,O
in,O
patients,O
with,O
baseline,O
creatinine,O
clearance,O
CrCl,O
of,O
30,O
to,O
50,O
mL,O
min,O
compared,O
to,O
those,O
with,O
CrCl,O
50,O
mL,O
min,O
Table,O
4,O
The,O
reduction,O
in,O
clinical,O
cure,O
rates,O
was,O
more,O
marked,O
in,O
the,O
ZERBAXA,O
plus,O
metronidazole,O
arm,O
compared,O
to,O
the,O
meropenem,O
arm,O
A,O
similar,O
trend,O
was,O
also,O
seen,O
in,O
the,O
cUTI,O
trial,O
Monitor,O
CrCl,O
at,O
least,O
daily,O
in,O
patients,O
with,O
changing,O
renal,O
function,O
and,O
adjust,O
the,O
dosage,O
of,O
ZERBAXA,O
accordingly,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Table,O
4,O
Clinical,O
Cure,O
Rates,O
in,O
a,O
Phase,O
3,O
Trial,O
of,O
cIAI,O
by,O
Baseline,O
Renal,O
Function,O
MITT,O
Population,O
Baseline,O
Renal,O
Function,O
ZERBAXA,O
plus,O
metronidazolen,O
N,O
Meropenemn,O
N,O
Normal,O
mild,O
impairment,O
CrCl,O
50,O
mL,O
min,O
312,O
366,O
85,O
2,O
355,O
404,O
87,O
9,O
Moderate,O
impairment,O
CrCl,O
30,O
to,O
50,O
mL,O
min,O
11,O
23,O
47,O
8,O
9,O
13,O
69,O
2,O
5,O
2,O
Hypersensitivity,O
Reactions,O
Serious,Severity
and,O
occasionally,O
fatal,AdverseReaction
hypersensitivity,AdverseReaction
anaphylactic,AdverseReaction
reactions,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
receiving,O
beta lactam antibacterial drugs,DrugClass
Before,O
initiating,O
therapy,O
with,O
ZERBAXA,O
make,O
careful,O
inquiry,O
about,O
previous,O
hypersensitivity,O
reactions,O
to,O
other,O
cephalosporins,O
penicillins,O
or,O
other,O
beta,O
lactams,O
If,O
this,O
product,O
is,O
to,O
be,O
given,O
to,O
a,O
patient,O
with,O
a,O
cephalosporin,O
penicillin,O
or,O
other,O
beta,O
lactam,O
allergy,O
exercise,O
caution,O
because,O
cross,O
sensitivity,O
has,O
been,O
established,O
If,O
an,O
anaphylactic,O
reaction,O
to,O
ZERBAXA,O
occurs,O
discontinue,O
the,O
drug,O
and,O
institute,O
appropriate,O
therapy,O
5,O
3,O
Clostridium,O
difficile,O
associated,O
Diarrhea,O
Clostridium difficile associated diarrhea,AdverseReaction
CDAD,AdverseReaction
has,O
been,O
reported,O
for,O
nearly,O
all,O
systemic,O
antibacterial,O
agents,O
including,O
ZERBAXA,O
and,O
may,O
range,O
in,O
severity,O
from,O
mild,Severity
diarrhea,AdverseReaction
to,O
fatal,AdverseReaction
colitis,AdverseReaction
Treatment,O
with,O
antibacterial,O
agents,O
alters,O
the,O
normal,O
flora,O
of,O
the,O
colon,O
and,O
may,O
permit,O
overgrowth,O
of,O
C,O
difficile,O
C,O
difficile,O
produces,O
toxins,O
A,O
and,O
B,O
which,O
contribute,O
to,O
the,O
development,O
of,O
CDAD,O
CDAD,O
must,O
be,O
considered,O
in,O
all,O
patients,O
who,O
present,O
with,O
diarrhea,O
following,O
antibacterial,O
use,O
Careful,O
medical,O
history,O
is,O
necessary,O
because,O
CDAD,O
has,O
been,O
reported,O
to,O
occur,O
more,O
than,O
2,O
months,O
after,O
the,O
administration,O
of,O
antibacterial,O
agents,O
If,O
CDAD,O
is,O
confirmed,O
discontinue,O
antibacterials,O
not,O
directed,O
against,O
C,O
difficile,O
if,O
possible,O
Manage,O
fluid,O
and,O
electrolyte,O
levels,O
as,O
appropriate,O
supplement,O
protein,O
intake,O
monitor,O
antibacterial,O
treatment,O
of,O
C,O
difficile,O
and,O
institute,O
surgical,O
evaluation,O
as,O
clinically,O
indicated,O
5,O
4,O
Development,O
of,O
Drug,O
Resistant,O
Bacteria,O
Prescribing,O
ZERBAXA,O
in,O
the,O
absence,O
of,O
a,O
proven,O
or,O
strongly,O
suspected,O
bacterial,O
infection,O
is,O
unlikely,O
to,O
provide,O
benefit,O
to,O
the,O
patient,O
and,O
risks,O
the,O
development,O
of,O
drug,O
resistant,O
bacteria,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
reactions,O
are,O
described,O
in,O
greater,O
detail,O
in,O
the,O
Warnings,O
and,O
Precautions,O
section,O
Hypersensitivity reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Clostridium difficile associated diarrhea,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
in,O
either,O
indication,O
are,O
nausea,AdverseReaction
diarrhea,AdverseReaction
headache,AdverseReaction
and,O
pyrexia,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Merck,O
Sharp,O
Dohme,O
Corp,O
a,O
subsidiary,O
of,O
Merck,O
Co,O
Inc,O
at,O
1,O
877,O
888,O
4231,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
also,O
may,O
not,O
reflect,O
rates,O
observed,O
in,O
practice,O
ZERBAXA,O
was,O
evaluated,O
in,O
Phase,O
3,O
comparator,O
controlled,O
clinical,O
trials,O
of,O
cIAI,O
and,O
cUTI,O
which,O
included,O
a,O
total,O
of,O
1015,O
patients,O
treated,O
with,O
ZERBAXA,O
and,O
1032,O
patients,O
treated,O
with,O
comparator,O
levofloxacin,O
750,O
mg,O
daily,O
in,O
cUTI,O
or,O
meropenem,O
1,O
g,O
every,O
8,O
hours,O
in,O
cIAI,O
for,O
up,O
to,O
14,O
days,O
The,O
mean,O
age,O
of,O
treated,O
patients,O
was,O
48,O
to,O
50,O
years,O
range,O
18,O
to,O
92,O
years,O
across,O
treatment,O
arms,O
and,O
indications,O
In,O
both,O
indications,O
about,O
25,O
of,O
the,O
subjects,O
were,O
65,O
years,O
of,O
age,O
or,O
older,O
Most,O
patients,O
75,O
enrolled,O
in,O
the,O
cUTI,O
trial,O
were,O
female,O
and,O
most,O
patients,O
58,O
enrolled,O
in,O
the,O
cIAI,O
trial,O
were,O
male,O
Most,O
patients,O
70,O
in,O
both,O
trials,O
were,O
enrolled,O
in,O
Eastern,O
Europe,O
and,O
were,O
White,O
The,O
most,O
common,O
adverse,O
reactions,O
5,O
or,O
greater,O
in,O
either,O
indication,O
occurring,O
in,O
patients,O
receiving,O
ZERBAXA,O
were,O
nausea,AdverseReaction
diarrhea,AdverseReaction
headache,AdverseReaction
and,O
pyrexia,AdverseReaction
Table,O
5,O
lists,O
adverse,O
reactions,O
occurring,O
in,O
1,O
or,O
greater,O
of,O
patients,O
receiving,O
ZERBAXA,O
in,O
Phase,O
3,O
clinical,O
trials,O
Table,O
5,O
Adverse,O
Reactions,O
Occurring,O
in,O
1,O
or,O
Greater,O
of,O
Patients,O
Receiving,O
ZERBAXA,O
in,O
Phase,O
3,O
Clinical,O
Trials,O
Preferred,O
Term,O
Complicated,O
Intra,O
abdominal,O
Infections,O
Complicated,O
Urinary,O
Tract,O
Infections,O
Including,O
Pyelonephritis,O
ZERBAXA,O
N,O
482,O
Meropenem,O
N,O
497,O
ZERBAXA,O
N,O
533,O
Levofloxacin,O
N,O
535,O
Nausea,AdverseReaction
38,O
7,O
9,O
29,O
5,O
8,O
15,O
2,O
8,O
9,O
1,O
7,O
Headache,AdverseReaction
12,O
2,O
5,O
9,O
1,O
8,O
31,O
5,O
8,O
26,O
4,O
9,O
Diarrhea,AdverseReaction
30,O
6,O
2,O
25,O
5,O
10,O
1,O
9,O
23,O
4,O
3,O
Pyrexia,AdverseReaction
27,O
5,O
6,O
20,O
4,O
9,O
1,O
7,O
5,O
0,O
9,O
Constipation,AdverseReaction
9,O
1,O
9,O
6,O
1,O
2,O
21,O
3,O
9,O
17,O
3,O
2,O
Insomnia,AdverseReaction
17,O
3,O
5,O
11,O
2,O
2,O
7,O
1,O
3,O
14,O
2,O
6,O
Vomiting,AdverseReaction
16,O
3,O
3,O
20,O
4,O
6,O
1,O
1,O
6,O
1,O
1,O
Hypokalemia,AdverseReaction
16,O
3,O
3,O
10,O
2,O
4,O
0,O
8,O
2,O
0,O
4,O
ALT increased,AdverseReaction
7,O
1,O
5,O
5,O
1,O
9,O
1,O
7,O
5,O
0,O
9,O
AST increased,AdverseReaction
5,O
1,O
3,O
0,O
6,O
9,O
1,O
7,O
5,O
0,O
9,O
Anemia,AdverseReaction
7,O
1,O
5,O
5,O
1,O
2,O
0,O
4,O
5,O
0,O
9,O
Thrombocytosis,AdverseReaction
9,O
1,O
9,O
5,O
1,O
2,O
0,O
4,O
2,O
0,O
4,O
Abdominal pain,AdverseReaction
6,O
1,O
2,O
2,O
0,O
4,O
4,O
0,O
8,O
2,O
0,O
4,O
Anxiety,AdverseReaction
9,O
1,O
9,O
7,O
1,O
4,O
1,O
0,O
2,O
4,O
0,O
7,O
Dizziness,AdverseReaction
4,O
0,O
8,O
5,O
1,O
6,O
1,O
1,O
1,O
0,O
2,O
Hypotension,AdverseReaction
8,O
1,O
7,O
4,O
0,O
8,O
2,O
0,O
4,O
1,O
0,O
2,O
Atrial fibrillation,AdverseReaction
6,O
1,O
2,O
3,O
0,O
6,O
1,O
0,O
2,O
0,O
Rash,AdverseReaction
8,O
1,O
7,O
7,O
1,O
4,O
5,O
0,O
9,O
2,O
0,O
4,O
Treatment,O
discontinuation,O
due,O
to,O
adverse,O
events,O
occurred,O
in,O
2,O
0,O
20,O
1015,O
of,O
patients,O
receiving,O
ZERBAXA,O
and,O
1,O
9,O
20,O
1032,O
of,O
patients,O
receiving,O
comparator,O
drugs,O
Renal impairment,AdverseReaction
including,O
the,O
terms,O
renal impairment,AdverseReaction
renal failure,AdverseReaction
and,O
renal failure acute,AdverseReaction
led,O
to,O
discontinuation,O
of,O
treatment,O
in,O
5,O
1015,O
0,O
5,O
subjects,O
receiving,O
ZERBAXA,O
and,O
none,O
in,O
the,O
comparator,O
arms,O
Increased,O
Mortality,O
In,O
the,O
cIAI,O
trials,O
Phase,O
2,O
and,O
3,O
death,AdverseReaction
occurred,O
in,O
2,O
5,O
14,O
564,O
of,O
patients,O
receiving,O
ZERBAXA,O
and,O
in,O
1,O
5,O
8,O
536,O
of,O
patients,O
receiving,O
meropenem,O
The,O
causes,O
of,O
death,AdverseReaction
varied,O
and,O
included,O
worsening,AdverseReaction
and,O
or,O
complications of infection,AdverseReaction
surgery,O
and,O
underlying,O
conditions,O
Less,O
Common,O
Adverse,O
Reactions,O
The,O
following,O
selected,O
adverse,O
reactions,O
were,O
reported,O
in,O
ZERBAXA,O
treated,O
subjects,O
at,O
a,O
rate,O
of,O
less,O
than,O
1,O
Cardiac,O
disorders,O
tachycardia,AdverseReaction
angina pectoris,AdverseReaction
Gastrointestinal,O
disorders,O
ileus,AdverseReaction
gastritis,AdverseReaction
abdominal distension,AdverseReaction
dyspepsia,AdverseReaction
flatulence,AdverseReaction
ileus paralytic,AdverseReaction
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
infusion site reactions,AdverseReaction
Infections,O
and,O
infestations,O
candidiasis,AdverseReaction
oropharyngeal,AdverseReaction
fungal urinary tract infection,AdverseReaction
Investigations,O
increased serum gamma glutamyl transpeptidase,AdverseReaction
GGT,O
increased serum alkaline phosphatase,AdverseReaction
positive Coombs test,AdverseReaction
Metabolism,O
and,O
nutrition,O
disorders,O
hyperglycemia,AdverseReaction
hypomagnesemia,AdverseReaction
hypophosphatemia,AdverseReaction
Nervous,O
system,O
disorders,O
ischemic stroke,AdverseReaction
Renal,O
and,O
urinary,O
system,O
renal impairment,AdverseReaction
renal failure,AdverseReaction
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
dyspnea,AdverseReaction
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
urticaria,AdverseReaction
Vascular,O
disorders,O
venous thrombosis,AdverseReaction
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Severe,Severity
cutaneous reactions,AdverseReaction
Monitor,O
patients,O
for,O
the,O
development,O
of,O
severe,O
cutaneous,O
reactions,O
and,O
discontinue,O
Zydelig,O
5,O
5,O
Anaphylaxis,AdverseReaction
Monitor,O
patients,O
for,O
anaphylaxis,O
and,O
discontinue,O
Zydelig,O
5,O
6,O
Neutropenia,AdverseReaction
monitor,O
blood,O
counts,O
5,O
7,O
Embryo fetal toxicity,AdverseReaction
may,Factor
cause,O
fetal harm,AdverseReaction
Advise,O
women,O
of,O
potential,O
risk,O
to,O
a,O
fetus,O
and,O
to,O
avoid,O
pregnancy,O
while,O
taking,O
Zydelig,O
5,O
8,O
5,O
1,O
Hepatotoxicity,O
Fatal,AdverseReaction
and,O
or,O
serious,Severity
hepatotoxicity,AdverseReaction
occurred,O
in,O
14,O
of,O
patients,O
treated,O
with,O
Zydelig,O
Elevations in ALT in,AdverseReaction
or,O
AST,AdverseReaction
greater,O
than,O
5 times the upper limit of normal,Severity
have,O
occurred,O
see,O
Adverse,O
Reactions,O
6,O
1,O
These,O
findings,O
were,O
generally,O
observed,O
within,O
the,O
first,O
12,O
weeks,O
of,O
treatment,O
and,O
were,O
reversible,O
with,O
dose,O
interruption,O
After,O
resumption,O
of,O
treatment,O
at,O
a,O
lower,O
dose,O
26,O
of,O
patients,O
had,O
recurrence,AdverseReaction
of,O
ALT,AdverseReaction
and,O
AST elevations,AdverseReaction
Discontinue,O
Zydelig,O
for,O
recurrent,O
hepatotoxicity,O
Avoid,O
concurrent,O
use,O
of,O
Zydelig,O
with,O
other,O
drugs,O
that,O
may,O
cause,O
liver,O
toxicity,O
Monitor,O
ALT,O
and,O
AST,O
in,O
all,O
patients,O
every,O
2,O
weeks,O
for,O
the,O
first,O
3,O
months,O
of,O
treatment,O
every,O
4,O
weeks,O
for,O
the,O
next,O
3,O
months,O
then,O
every,O
1,O
to,O
3,O
months,O
thereafter,O
Monitor,O
weekly,O
for,O
liver,O
toxicity,O
if,O
the,O
ALT,O
or,O
AST,O
rises,O
above,O
3,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
until,O
resolved,O
Withhold,O
Zydelig,O
if,O
the,O
ALT,O
or,O
AST,O
is,O
greater,O
than,O
5,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
and,O
continue,O
to,O
monitor,O
AST,O
ALT,O
and,O
total,O
bilirubin,O
weekly,O
until,O
the,O
abnormality,O
is,O
resolved,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
2,O
Severe,O
Diarrhea,O
or,O
Colitis,O
Severe,Severity
diarrhea,AdverseReaction
or,O
colitis,AdverseReaction
Grade 3,Severity
or,O
higher,O
occurred,O
in,O
14,O
of,O
Zydelig,O
treated,O
patients,O
across,O
clinical,O
trials,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Diarrhea,AdverseReaction
can,Factor
occur,O
at,O
any,O
time,O
Avoid,O
concurrent,O
use,O
of,O
Zydelig,O
and,O
other,O
drugs,O
that,O
cause,O
diarrhea,O
Diarrhea,AdverseReaction
due,O
to,O
Zydelig,O
responds,O
poorly,O
to,O
antimotility,O
agents,O
Median,O
time,O
to,O
resolution,O
ranged,O
between,O
1,O
week,O
and,O
1,O
month,O
across,O
trials,O
following,O
interruption,O
of,O
Zydelig,O
therapy,O
and,O
in,O
some,O
instances,O
use,O
of,O
corticosteroids,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
3,O
Pneumonitis,O
Fatal,AdverseReaction
and,O
serious,Severity
pneumonitis,AdverseReaction
occurred,O
in,O
patients,O
treated,O
with,O
Zydelig,O
Patients,O
taking,O
Zydelig,O
who,O
present,O
with,O
pulmonary,O
symptoms,O
such,O
as,O
cough,O
dyspnea,O
hypoxia,O
interstitial,O
infiltrates,O
on,O
a,O
radiologic,O
exam,O
or,O
a,O
decline,O
by,O
more,O
than,O
5,O
in,O
oxygen,O
saturation,O
should,O
be,O
evaluated,O
for,O
pneumonitis,O
If,O
pneumonitis,O
is,O
suspected,O
interrupt,O
Zydelig,O
until,O
the,O
etiology,O
of,O
the,O
pulmonary,O
symptoms,O
has,O
been,O
determined,O
Patients,O
with,O
pneumonitis,O
thought,O
to,O
be,O
caused,O
by,O
Zydelig,O
have,O
been,O
treated,O
with,O
discontinuation,O
of,O
Zydelig,O
and,O
administration,O
of,O
corticosteroids,O
5,O
4,O
Intestinal,O
Perforation,O
Fatal,AdverseReaction
and,O
serious,Severity
intestinal perforation,AdverseReaction
occurred,O
in,O
Zydelig,O
treated,O
patients,O
At,O
the,O
time,O
of,O
perforation,O
some,O
patients,O
had,O
moderate,Severity
to,O
severe,Severity
diarrhea,AdverseReaction
Advise,O
patients,O
to,O
promptly,O
report,O
any,O
new,O
or,O
worsening,O
abdominal,O
pain,O
chills,O
fever,O
nausea,O
or,O
vomiting,O
Discontinue,O
Zydelig,O
permanently,O
in,O
patients,O
who,O
experience,O
intestinal,O
perforation,O
5,O
5,O
Severe,O
Cutaneous,O
Reactions,O
One,O
case,O
of,O
toxic epidermal necrolysis,AdverseReaction
TEN,AdverseReaction
occurred,O
in,O
a,O
study,O
of,O
Zydelig,O
in,O
combination,O
with,O
rituximab,O
and,O
bendamustine,O
Other,O
severe,Severity
or,O
life threatening,Severity
Grade,Severity
3,Severity
cutaneous reactions,AdverseReaction
including,O
dermatitis exfoliative,AdverseReaction
rash,AdverseReaction
rash erythematous,AdverseReaction
rash generalized,AdverseReaction
rash macular,AdverseReaction
rash maculo papular,AdverseReaction
rash papular,AdverseReaction
rash pruritic,AdverseReaction
exfoliative rash,AdverseReaction
and,O
skin disorder,AdverseReaction
have,O
been,O
reported,O
in,O
Zydelig,O
treated,O
patients,O
Monitor,O
patients,O
for,O
the,O
development,O
of,O
severe,O
cutaneous,O
reactions,O
and,O
discontinue,O
Zydelig,O
5,O
6,O
Anaphylaxis,O
Serious,Severity
allergic reactions,AdverseReaction
including,O
anaphylaxis,AdverseReaction
have,O
been,O
reported,O
in,O
patients,O
on,O
Zydelig,O
In,O
patients,O
who,O
develop,O
serious,O
allergic,O
reactions,O
discontinue,O
Zydelig,O
permanently,O
and,O
institute,O
appropriate,O
supportive,O
measures,O
5,O
7,O
Neutropenia,O
Treatment,O
emergent,O
Grade 3,Severity
or,O
4,Severity
neutropenia,AdverseReaction
occurred,O
in,O
31,O
of,O
Zydelig,O
treated,O
patients,O
across,O
clinical,O
trials,O
see,O
Adverse,O
Reactions,O
6,O
1,O
Monitor,O
blood,O
counts,O
at,O
least,O
every,O
two,O
weeks,O
for,O
the,O
first,O
3,O
months,O
of,O
therapy,O
and,O
at,O
least,O
weekly,O
in,O
patients,O
while,O
neutrophil,O
counts,O
are,O
less,O
than,O
1,O
0,O
Gi,O
L,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
5,O
8,O
Embryo,O
fetal,O
Toxicity,O
Based,O
on,O
findings,O
in,O
animals,Animal
Zydelig,O
may,O
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
Idelalisib,O
is,O
teratogenic,AdverseReaction
in,O
rats,Animal
at,O
systemic,O
exposures,O
12,O
times,O
those,O
reported,O
in,O
patients,O
at,O
the,O
recommended,O
dose,O
of,O
150,O
mg,O
twice,O
daily,O
If,O
this,O
drug,O
is,O
used,O
during,O
pregnancy,O
or,O
if,O
the,O
patient,O
becomes,O
pregnant,O
while,O
taking,O
this,O
drug,O
the,O
patient,O
should,O
be,O
apprised,O
of,O
the,O
potential,O
hazard,O
to,O
a,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
Advise,O
females,O
of,O
reproductive,O
potential,O
to,O
avoid,O
becoming,O
pregnant,O
while,O
taking,O
Zydelig,O
If,O
contraceptive,O
methods,O
are,O
being,O
considered,O
use,O
effective,O
contraception,O
during,O
treatment,O
and,O
for,O
at,O
least,O
1,O
month,O
after,O
the,O
last,O
dose,O
of,O
Zydelig,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
6,O
""
BOXED,O
WARNING,O
WARNING,O
FATAL,AdverseReaction
AND,O
SERIOUS,Severity
TOXICITIES,AdverseReaction
HEPATIC,AdverseReaction
SEVERE,Severity
DIARRHEA,AdverseReaction
COLITIS,AdverseReaction
PNEUMONITIS,AdverseReaction
and,O
INTESTINAL PERFORATION,AdverseReaction
WARNING,O
FATAL,AdverseReaction
AND,O
SERIOUS,Severity
TOXICITIES,AdverseReaction
HEPATIC,AdverseReaction
SEVERE,Severity
DIARRHEA,AdverseReaction
COLITIS,AdverseReaction
PNEUMONITIS,AdverseReaction
and,O
INTESTINAL PERFORATION,AdverseReaction
Fatal,AdverseReaction
and,O
or,O
serious,Severity
hepatotoxicity,AdverseReaction
occurred,O
in,O
14,O
of,O
Zydelig,O
treated,O
patients,O
Monitor,O
hepatic,O
function,O
prior,O
to,O
and,O
during,O
treatment,O
Interrupt,O
and,O
then,O
reduce,O
or,O
discontinue,O
Zydelig,O
as,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Fatal,AdverseReaction
and,O
or,O
serious,Severity
and,O
severe,Severity
diarrhea,AdverseReaction
or,O
colitis,AdverseReaction
occurred,O
in,O
14,O
of,O
Zydelig,O
treated,O
patients,O
Monitor,O
for,O
the,O
development,O
of,O
severe,O
diarrhea,O
or,O
colitis,O
Interrupt,O
and,O
then,O
reduce,O
or,O
discontinue,O
Zydelig,O
as,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Fatal,AdverseReaction
and,O
serious,Severity
pneumonitis,AdverseReaction
can,O
occur,O
in,O
Zydelig,O
treated,O
patients,O
Monitor,O
for,O
pulmonary,O
symptoms,O
and,O
bilateral,O
interstitial,O
infiltrates,O
Interrupt,O
or,O
discontinue,O
Zydelig,O
as,O
recommended,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Fatal,AdverseReaction
and,O
serious,Severity
intestinal perforation,AdverseReaction
can,O
occur,O
in,O
Zydelig,O
treated,O
patients,O
across,O
clinical,O
trials,O
Discontinue,O
Zydelig,O
for,O
intestinal,O
perforation,O
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
EXCERPT,O
WARNING,O
FATAL,AdverseReaction
AND,O
SERIOUS,Severity
TOXICITIES,AdverseReaction
HEPATIC,AdverseReaction
SEVERE,Severity
DIARRHEA,AdverseReaction
COLITIS,AdverseReaction
PNEUMONITIS,AdverseReaction
and,O
INTESTINAL PERFORATION,AdverseReaction
See,O
full,O
prescribing,O
information,O
for,O
complete,O
boxed,O
warning,O
Fatal,AdverseReaction
and,O
or,O
serious,Severity
hepatotoxicity,AdverseReaction
occurred,O
in,O
14,O
of,O
Zydelig,O
treated,O
patients,O
Monitor,O
hepatic,O
function,O
prior,O
to,O
and,O
during,O
treatment,O
Interrupt,O
and,O
then,O
reduce,O
or,O
discontinue,O
Zydelig,O
5,O
1,O
Fatal,AdverseReaction
and,O
or,O
serious,Severity
and,O
severe,Severity
diarrhea,AdverseReaction
or,O
colitis,AdverseReaction
occurred,O
in,O
14,O
of,O
Zydelig,O
treated,O
patients,O
Monitor,O
for,O
the,O
development,O
of,O
severe,O
diarrhea,O
or,O
colitis,O
Interrupt,O
and,O
then,O
reduce,O
or,O
discontinue,O
Zydelig,O
5,O
2,O
Fatal,AdverseReaction
and,O
serious,Severity
pneumonitis,AdverseReaction
can,O
occur,O
in,O
Zydelig,O
treated,O
patients,O
Monitor,O
for,O
pulmonary,O
symptoms,O
and,O
bilateral,O
interstitial,O
infiltrates,O
Interrupt,O
or,O
discontinue,O
Zydelig,O
5,O
3,O
Fatal,AdverseReaction
and,O
serious,Severity
intestinal perforation,AdverseReaction
can,O
occur,O
in,O
Zydelig,O
treated,O
patients,O
across,O
clinical,O
trials,O
Discontinue,O
Zydelig,O
if,O
intestinal,O
perforation,O
is,O
suspected,O
5,O
4,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
serious,O
adverse,O
reactions,O
have,O
been,O
associated,O
with,O
Zydelig,O
in,O
clinical,O
trials,O
and,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
prescribing,O
information,O
Hepatotoxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Severe,Severity
Diarrhea,AdverseReaction
or,O
Colitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Pneumonitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
Intestinal Perforation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
Severe,Severity
Cutaneous Reactions,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Anaphylaxis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
Neutropenia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
20,O
are,O
diarrhea,AdverseReaction
pyrexia,AdverseReaction
fatigue,AdverseReaction
nausea,AdverseReaction
cough,AdverseReaction
pneumonia,AdverseReaction
abdominal pain,AdverseReaction
chills,AdverseReaction
and,O
rash,AdverseReaction
6,O
1,O
The,O
most,O
common,O
laboratory,O
abnormalities,O
incidence,O
30,O
are,O
neutropenia,AdverseReaction
hypertriglyceridemia,AdverseReaction
hyperglycemia,AdverseReaction
ALT elevations,AdverseReaction
and,O
AST elevations,AdverseReaction
6,O
1,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Gilead,O
Sciences,O
Inc,O
at,O
1,O
800,O
GILEAD,O
5,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
Summary,O
of,O
Clinical,O
Trials,O
in,O
Chronic,O
Lymphocytic,O
Leukemia,O
The,O
safety,O
data,O
reflect,O
subject,O
exposure,O
to,O
Zydelig,O
from,O
Study,O
1,O
in,O
which,O
218,O
subjects,O
with,O
relapsed,O
CLL,O
received,O
up,O
to,O
8,O
doses,O
of,O
rituximab,O
with,O
or,O
without,O
Zydelig,O
150,O
mg,O
twice,O
daily,O
The,O
median,O
duration,O
of,O
exposure,O
to,O
Zydelig,O
was,O
5,O
months,O
Serious,O
adverse,O
reactions,O
were,O
reported,O
in,O
54,O
49,O
subjects,O
treated,O
with,O
Zydelig,O
rituximab,O
The,O
most,O
frequent,O
2,O
serious,O
adverse,O
reactions,O
reported,O
for,O
subjects,O
treated,O
with,O
Zydelig,O
were,O
pneumonia,AdverseReaction
17,O
pyrexia,AdverseReaction
9,O
sepsis,AdverseReaction
8,O
febrile neutropenia,AdverseReaction
5,O
and,O
diarrhea,AdverseReaction
5,O
Adverse,O
reactions,O
that,O
led,O
to,O
discontinuation,O
of,O
Zydelig,O
occurred,O
in,O
11,O
10,O
subjects,O
The,O
most,O
common,O
adverse,O
reactions,O
that,O
led,O
to,O
treatment,O
discontinuations,O
were,O
hepatotoxicity,AdverseReaction
and,O
diarrhea,AdverseReaction
colitis,AdverseReaction
Thirty,O
nine,O
subjects,O
35,O
had,O
dose,O
interruptions,O
and,O
sixteen,O
subjects,O
15,O
had,O
dose,O
reductions,O
due,O
to,O
adverse,O
reactions,O
or,O
laboratory,O
abnormalities,O
The,O
most,O
common,O
reasons,O
for,O
dose,O
reductions,O
were,O
elevated transaminases,AdverseReaction
diarrhea,AdverseReaction
or,O
colitis,AdverseReaction
and,O
rash,AdverseReaction
Table,O
2,O
and,O
Table,O
3,O
summarize,O
common,O
adverse,O
reactions,O
and,O
laboratory,O
abnormalities,O
reported,O
for,O
Zydelig,O
rituximab,O
and,O
placebo,O
rituximab,O
arms,O
Table,O
2,O
Adverse,O
Reactions,O
Reported,O
in,O
5,O
of,O
CLL,O
Patients,O
and,O
Occurred,O
at,O
2,O
Higher,O
Incidence,O
in,O
Subjects,O
Receiving,O
Zydelig,O
Zydelig,O
RN,O
110,O
Placebo,O
RN,O
108,O
Adverse,O
Reaction,O
Any,O
Grade,O
Grade,O
3,O
Any,O
Grade,O
Grade,O
3,O
R,O
rituximab,O
Gastrointestinal,O
disorders,O
nausea,AdverseReaction
28,O
25,O
0,O
23,O
21,O
0,O
vomiting,AdverseReaction
14,O
13,O
0,O
9,O
8,O
0,O
diarrhea,AdverseReaction
23,O
21,O
6,O
5,O
17,O
16,O
0,O
gastroesophageal reflux disease,AdverseReaction
7,O
6,O
0,O
1,O
1,O
0,O
stomatitis,AdverseReaction
7,O
6,O
2,O
2,O
2,O
2,O
0,O
Nervous,O
system,O
disorders,O
headache,AdverseReaction
11,O
10,O
1,O
1,O
5,O
5,O
0,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
pyrexia,AdverseReaction
38,O
35,O
3,O
3,O
18,O
17,O
1,O
1,O
chills,AdverseReaction
23,O
21,O
2,O
2,O
17,O
16,O
0,O
pain,AdverseReaction
8,O
7,O
0,O
2,O
2,O
0,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
rash,AdverseReaction
20,O
18,O
4,O
4,O
7,O
6,O
1,O
1,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
pneumonia,AdverseReaction
25,O
23,O
18,O
16,O
19,O
18,O
14,O
13,O
nasal congestion,AdverseReaction
6,O
5,O
0,O
2,O
2,O
0,O
Infections,O
and,O
infestations,O
sepsis,AdverseReaction
9,O
8,O
8,O
7,O
4,O
4,O
4,O
4,O
bronchitis,AdverseReaction
7,O
6,O
1,O
1,O
3,O
3,O
1,O
1,O
sinusitis,AdverseReaction
9,O
8,O
0,O
4,O
4,O
0,O
urinary tract infection,AdverseReaction
6,O
5,O
0,O
3,O
3,O
2,O
2,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
arthralgia,AdverseReaction
8,O
7,O
1,O
1,O
4,O
4,O
1,O
1,O
Table,O
3,O
Treatment,O
emergent,O
Laboratory,O
Abnormalities,O
Reported,O
in,O
10,O
of,O
CLL,O
Patients,O
Occurring,O
at,O
a,O
5,O
Higher,O
Incidence,O
in,O
Subjects,O
Receiving,O
Zydelig,O
Zydelig,O
RN,O
110,O
Placebo,O
RN,O
108,O
Laboratory,O
Parameter,O
Any,O
Grade,O
Grade,O
3,O
4,O
Any,O
Grade,O
Grade,O
3,O
4,O
Grades,O
were,O
obtained,O
per,O
CTCAE,O
version,O
4,O
03,O
R,O
rituximab,O
Hematology,O
abnormalities,O
neutrophil count decreased,AdverseReaction
66,O
60,O
41,O
37,O
55,O
51,O
29,O
27,O
lymphocyte count decreased,AdverseReaction
22,O
20,O
10,O
9,O
13,O
12,O
4,O
4,O
lymphocyte count increased,AdverseReaction
27,O
25,O
20,O
18,O
10,O
9,O
5,O
5,O
Serum,O
chemistry,O
abnormalities,O
ALT increased,AdverseReaction
38,O
35,O
9,O
8,O
11,O
10,O
1,O
1,O
AST increased,AdverseReaction
27,O
25,O
6,O
5,O
15,O
14,O
0,O
GGT increased,AdverseReaction
29,O
26,O
2,O
2,O
15,O
14,O
3,O
3,O
triglycerides,O
hypertriglyceridemia,AdverseReaction
62,O
56,O
3,O
3,O
37,O
34,O
0,O
hyperglycemia,AdverseReaction
59,O
54,O
8,O
7,O
50,O
46,O
2,O
2,O
hypoglycemia,AdverseReaction
12,O
11,O
0,O
5,O
5,O
0,O
hyponatremia,AdverseReaction
22,O
20,O
2,O
2,O
16,O
15,O
7,O
6,O
Summary,O
of,O
Clinical,O
Trials,O
in,O
Indolent,O
Non,O
Hodgkin,O
Lymphoma,O
The,O
safety,O
data,O
reflect,O
exposure,O
to,O
Zydelig,O
in,O
146,O
adults,O
with,O
indolent,O
non,O
Hodgkin,O
lymphoma,O
treated,O
with,O
Zydelig,O
150,O
mg,O
twice,O
daily,O
in,O
clinical,O
trials,O
The,O
median,O
duration,O
of,O
exposure,O
was,O
6,O
1,O
months,O
range,O
0,O
3,O
to,O
26,O
4,O
months,O
Serious,O
adverse,O
reactions,O
were,O
reported,O
in,O
73,O
50,O
subjects,O
The,O
most,O
frequent,O
serious,O
adverse,O
reactions,O
that,O
occurred,O
were,O
pneumonia,AdverseReaction
15,O
diarrhea,AdverseReaction
11,O
and,O
pyrexia,AdverseReaction
9,O
Adverse,O
reactions,O
resulted,O
in,O
interruption,O
or,O
discontinuation,O
for,O
78,O
53,O
subjects,O
The,O
most,O
common,O
reasons,O
for,O
interruption,O
or,O
discontinuations,O
were,O
diarrhea,AdverseReaction
11,O
pneumonia,AdverseReaction
11,O
and,O
elevated transaminases,AdverseReaction
10,O
Table,O
4,O
provides,O
the,O
adverse,O
reactions,O
occurring,O
in,O
at,O
least,O
10,O
of,O
subjects,O
receiving,O
Zydelig,O
monotherapy,O
and,O
Table,O
5,O
provides,O
the,O
treatment,O
emergent,O
laboratory,O
abnormalities,O
Table,O
4,O
Adverse,O
Reactions,O
10,O
of,O
Subjects,O
in,O
Patients,O
with,O
Indolent,O
non,O
Hodgkin,O
Lymphoma,O
Treated,O
with,O
Zydelig,O
150,O
mg,O
BID,O
Zydelig,O
MonotherapyN,O
146,O
Adverse,O
Reaction,O
Any,O
Grade,O
Grade,O
3,O
Gastrointestinal,O
disorders,O
diarrhea,AdverseReaction
68,O
47,O
20,O
14,O
nausea,AdverseReaction
42,O
29,O
2,O
1,O
abdominal pain,AdverseReaction
38,O
26,O
3,O
2,O
vomiting,AdverseReaction
22,O
15,O
2,O
1,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
fatigue,AdverseReaction
44,O
30,O
2,O
1,O
pyrexia,AdverseReaction
41,O
28,O
3,O
2,O
asthenia,AdverseReaction
17,O
12,O
3,O
2,O
peripheral edema,AdverseReaction
15,O
10,O
3,O
2,O
Infections,O
and,O
infestations,O
upper respiratory tract infection,AdverseReaction
18,O
12,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
pneumonia,AdverseReaction
37,O
25,O
23,O
16,O
cough,AdverseReaction
42,O
29,O
1,O
1,O
dyspnea,AdverseReaction
25,O
17,O
6,O
4,O
Skin,O
and,O
subcutaneous,O
disorders,O
rash,AdverseReaction
31,O
21,O
4,O
3,O
night sweats,AdverseReaction
18,O
12,O
0,O
Nervous,O
system,O
disorders,O
headache,AdverseReaction
16,O
11,O
1,O
1,O
Metabolism,O
and,O
nutrition,O
disorders,O
decreased appetite,AdverseReaction
24,O
16,O
1,O
1,O
Psychiatric,O
disorders,O
insomnia,AdverseReaction
17,O
12,O
0,O
Table,O
5,O
Treatment,O
emergent,O
Laboratory,O
Abnormalities,O
in,O
Patients,O
with,O
Indolent,O
non,O
Hodgkin,O
Lymphoma,O
Treated,O
with,O
Zydelig,O
150,O
mg,O
BID,O
Zydelig,O
MonotherapyN,O
146,O
Laboratory,O
Abnormality,O
Any,O
Grade,O
Grade,O
3,O
Grade,O
4,O
Grades,O
were,O
obtained,O
per,O
CTCAE,O
version,O
4,O
03,O
Serum,O
chemistry,O
abnormalities,O
ALT increased,AdverseReaction
73,O
50,O
20,O
14,O
7,O
5,O
AST increased,AdverseReaction
60,O
41,O
12,O
8,O
6,O
4,O
Hematology,O
abnormalities,O
neutrophils decreased,AdverseReaction
78,O
53,O
20,O
14,O
16,O
11,O
hemoglobin decreased,AdverseReaction
41,O
28,O
3,O
2,O
0,O
platelets decreased,AdverseReaction
38,O
26,O
4,O
3,O
5,O
3,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Severe,O
or,O
Persistent,O
Gastrointestinal,O
Toxicity,O
Dose,O
modification,O
due,O
to,O
diarrhea,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
or,O
abdominal pain,AdverseReaction
occurred,O
in,O
38,O
of,O
patients,O
Withhold,O
if,O
not,O
responsive,O
to,O
anti,O
emetics,O
or,O
anti,O
diarrheals,O
then,O
dose,O
reduce,O
ZYKADIA,O
2,O
2,O
5,O
1,O
Hepatotoxicity,AdverseReaction
ZYKADIA,O
can,Factor
cause,O
hepatotoxicity,AdverseReaction
Monitor,O
liver,O
laboratory,O
tests,O
at,O
least,O
monthly,O
Withhold,O
then,O
dose,O
reduce,O
or,O
permanently,O
discontinue,O
ZYKADIA,O
2,O
2,O
5,O
2,O
Interstitial Lung Disease,AdverseReaction
ILD,AdverseReaction
Pneumonitis,AdverseReaction
Occurred,O
in,O
4,O
of,O
patients,O
Permanently,O
discontinue,O
ZYKADIA,O
in,O
patients,O
diagnosed,O
with,O
treatment,O
related,O
ILD,O
pneumonitis,O
2,O
2,O
5,O
3,O
QT Interval Prolongation,AdverseReaction
ZYKADIA,O
can,Factor
cause,O
QTc interval prolongation,AdverseReaction
Monitor,O
electrocardiograms,O
and,O
electrolytes,O
in,O
patients,O
with,O
congestive,O
heart,O
failure,O
bradyarrhythmias,O
electrolyte,O
abnormalities,O
or,O
those,O
who,O
are,O
taking,O
medications,O
that,O
are,O
known,O
to,O
prolong,O
the,O
QTc,O
interval,O
Withhold,O
then,O
dose,O
reduce,O
or,O
permanently,O
discontinue,O
ZYKADIA,O
2,O
2,O
5,O
4,O
Hyperglycemia,AdverseReaction
ZYKADIA,O
can,Factor
cause,O
hyperglycemia,AdverseReaction
Monitor,O
fasting,O
glucose,O
prior,O
to,O
treatment,O
and,O
periodically,O
thereafter,O
as,O
clinically,O
indicated,O
Initiate,O
or,O
optimize,O
anti,O
hyperglycemic,O
medications,O
as,O
indicated,O
Withhold,O
then,O
dose,O
reduce,O
or,O
permanently,O
discontinue,O
ZYKADIA,O
2,O
2,O
5,O
5,O
Bradycardia,AdverseReaction
ZYKADIA,O
can,Factor
cause,O
bradycardia,AdverseReaction
Monitor,O
heart,O
rate,O
and,O
blood,O
pressure,O
regularly,O
Withhold,O
then,O
dose,O
reduce,O
or,O
permanently,O
discontinue,O
ZYKADIA,O
2,O
2,O
5,O
6,O
Pancreatitis,AdverseReaction
Elevations of lipase of,AdverseReaction
and,O
or,O
amylase,AdverseReaction
and,O
pancreatitis,AdverseReaction
can,Factor
occur,O
Monitor,O
lipase,O
and,O
amylase,O
prior,O
to,O
treatment,O
and,O
periodically,O
thereafter,O
as,O
clinically,O
indicated,O
2,O
2,O
5,O
7,O
Embryofetal Toxicity,AdverseReaction
ZYKADIA,O
may,Factor
cause,O
fetal harm,AdverseReaction
Advise,O
females,O
of,O
reproductive,O
potential,O
of,O
the,O
potential,O
risk,O
to,O
a,O
fetus,O
5,O
8,O
8,O
1,O
8,O
7,O
5,O
1,O
Severe,O
or,O
Persistent,O
Gastrointestinal,O
Toxicity,O
Diarrhea,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
or,O
abdominal pain pain,AdverseReaction
occurred,O
in,O
96,O
of,O
255,O
patients,O
including,O
severe,Severity
cases,O
in,O
14,O
of,O
patients,O
treated,O
with,O
ZYKADIA,O
in,O
Study,O
1,O
Dose,O
modification,O
due,O
to,O
diarrhea,AdverseReaction
nausea,AdverseReaction
vomiting,AdverseReaction
or,O
abdominal pain,AdverseReaction
occurred,O
in,O
38,O
of,O
patients,O
Monitor,O
and,O
manage,O
patients,O
using,O
standards,O
of,O
care,O
including,O
anti,O
diarrheals,O
anti,O
emetics,O
or,O
fluid,O
replacement,O
as,O
indicated,O
Based,O
on,O
the,O
severity,O
of,O
the,O
adverse,O
drug,O
reaction,O
withhold,O
ZYKADIA,O
with,O
resumption,O
at,O
a,O
reduced,O
dose,O
as,O
described,O
in,O
Table,O
1,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
5,O
2,O
Hepatotoxicity,O
Drug,O
induced,O
hepatotoxicity,AdverseReaction
occurred,O
in,O
patients,O
treated,O
with,O
ZYKADIA,O
Elevations in alanine aminotransferase,AdverseReaction
ALT,O
greater,O
than,O
5 times the upper limit of normal,Severity
ULN,O
occurred,O
in,O
27,O
of,O
255,O
patients,O
in,O
Study,O
1,O
One,O
patient,O
0,O
4,O
required,O
permanent,O
discontinuation,O
due,O
to,O
elevated transaminases,AdverseReaction
and,O
jaundice,AdverseReaction
Concurrent,O
elevations in ALT,AdverseReaction
greater,O
than,O
3 times the ULN,Severity
and,O
total bilirubin,AdverseReaction
greater,O
than,O
2 times the ULN,AdverseReaction
with,O
normal,O
alkaline,O
phosphatase,O
occurred,O
in,O
less,O
than,O
1,O
of,O
patients,O
in,O
clinical,O
studies,O
Monitor,O
with,O
liver,O
laboratory,O
tests,O
including,O
ALT,O
aspartate,O
aminotransferase,O
AST,O
and,O
total,O
bilirubin,O
once,O
a,O
month,O
and,O
as,O
clinically,O
indicated,O
with,O
more,O
frequent,O
testing,O
in,O
patients,O
who,O
develop,O
transaminase,O
elevations,O
Based,O
on,O
the,O
severity,O
of,O
the,O
adverse,O
drug,O
reaction,O
withhold,O
ZYKADIA,O
with,O
resumption,O
at,O
a,O
reduced,O
dose,O
or,O
permanently,O
discontinue,O
ZYKADIA,O
as,O
described,O
in,O
Table,O
1,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
5,O
3,O
Interstitial,O
Lung,O
Disease,O
ILD,O
Pneumonitis,O
Severe,Severity
life threatening,Severity
or,O
fatal,AdverseReaction
ILD,AdverseReaction
pneumonitis,AdverseReaction
can,Factor
occur,O
in,O
patients,O
treated,O
with,O
ZYKADIA,O
In,O
Study,O
1,O
pneumonitis,AdverseReaction
was,O
reported,O
in,O
4,O
of,O
255,O
patients,O
treated,O
with,O
ZYKADIA,O
CTCAE,O
Grade 3,Severity
or,O
4,Severity
ILD,AdverseReaction
pneumonitis,AdverseReaction
was,O
reported,O
in,O
3,O
of,O
patients,O
and,O
fatal,AdverseReaction
ILD,AdverseReaction
pneumonitis,AdverseReaction
was,O
reported,O
in,O
1,O
patient,O
0,O
4,O
in,O
Study,O
1,O
One,O
percent,O
1,O
of,O
patients,O
discontinued,O
ZYKADIA,O
in,O
Study,O
1,O
due,O
to,O
ILD,AdverseReaction
pneumonitis,AdverseReaction
Monitor,O
patients,O
for,O
pulmonary,O
symptoms,O
indicative,O
of,O
ILD,O
pneumonitis,O
Exclude,O
other,O
potential,O
causes,O
of,O
ILD,O
pneumonitis,O
and,O
permanently,O
discontinue,O
ZYKADIA,O
in,O
patients,O
diagnosed,O
with,O
treatment,O
related,O
ILD,O
pneumonitis,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
5,O
4,O
QT,O
Interval,O
Prolongation,O
QTc interval prolongation,AdverseReaction
which,O
may,O
lead,O
to,O
an,O
increased,O
risk,Factor
for,O
ventricular tachyarrhythmias,AdverseReaction
e,O
g,O
Torsade de pointes,AdverseReaction
or,O
sudden death,AdverseReaction
occurred,O
in,O
patients,O
treated,O
with,O
ZYKADIA,O
in,O
clinical,O
trials,O
Three,O
percent,O
3,O
of,O
255,O
patients,O
experienced,O
a,O
QTc interval increase,AdverseReaction
over,O
baseline,O
greater,O
than,O
60 msec,Severity
in,O
Study,O
1,O
Across,O
the,O
development,O
program,O
of,O
ZYKADIA,O
one,O
of,O
304,O
patients,O
less,O
than,O
1,O
treated,O
with,O
ZYKADIA,O
doses,O
ranging,O
from,O
50,O
to,O
750,O
mg,O
was,O
found,O
to,O
have,O
a,O
QTc greater than 500 msec,AdverseReaction
and,O
3,O
of,O
patients,O
had,O
an,O
increase from baseline QTc,AdverseReaction
greater,O
than,O
60 msec,Severity
A,O
pharmacokinetic,O
analysis,O
suggested,Factor
that,O
ZYKADIA,O
causes,O
concentration,O
dependent,O
increases in the QTc interval,AdverseReaction
When,O
possible,O
avoid,O
use,O
of,O
ZYKADIA,O
in,O
patients,O
with,O
congenital,O
long,O
QT,O
syndrome,O
Conduct,O
periodic,O
monitoring,O
with,O
electrocardiograms,O
ECGs,O
and,O
electrolytes,O
in,O
patients,O
with,O
congestive,O
heart,O
failure,O
bradyarrhythmias,O
electrolyte,O
abnormalities,O
or,O
those,O
who,O
are,O
taking,O
medications,O
that,O
are,O
known,O
to,O
prolong,O
the,O
QTc,O
interval,O
Withhold,O
ZYKADIA,O
in,O
patients,O
who,O
develop,O
a,O
QTc,O
interval,O
greater,O
than,O
500,O
msec,O
on,O
at,O
least,O
2,O
separate,O
ECGs,O
until,O
the,O
QTc,O
interval,O
is,O
less,O
than,O
481,O
msec,O
or,O
recovery,O
to,O
baseline,O
if,O
the,O
QTc,O
interval,O
is,O
greater,O
than,O
or,O
equal,O
to,O
481,O
msec,O
then,O
resume,O
ZYKADIA,O
at,O
a,O
reduced,O
dose,O
as,O
described,O
in,O
Table,O
1,O
Permanently,O
discontinue,O
ZYKADIA,O
in,O
patients,O
who,O
develop,O
QTc,O
interval,O
prolongation,O
in,O
combination,O
with,O
Torsade,O
de,O
pointes,O
or,O
polymorphic,O
ventricular,O
tachycardia,O
or,O
signs,O
symptoms,O
of,O
serious,O
arrhythmia,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Clinical,O
Pharmacology,O
12,O
2,O
5,O
5,O
Hyperglycemia,O
Hyperglycemia,AdverseReaction
can,Factor
occur,O
in,O
patients,O
receiving,O
ZYKADIA,O
In,O
Study,O
1,O
CTCAE,O
Grade 3 3 4,Severity
hyperglycemia,AdverseReaction
based,O
on,O
laboratory,O
values,O
occurred,O
in,O
13,O
of,O
255,O
patients,O
There,O
was,O
a,O
6,O
fold,O
increase,O
in,O
the,O
risk,Factor
of,O
CTCAE,O
Grade 3 3 4,Severity
4,Severity
hyperglycemia,AdverseReaction
in,O
patients,O
with,O
diabetes,O
or,O
glucose,O
intolerance,O
and,O
a,O
2,O
fold,O
increase,O
in,O
patients,O
taking,O
corticosteroids,O
Monitor,O
fasting,O
serum,O
glucose,O
prior,O
to,O
the,O
start,O
of,O
ZYKADIA,O
treatment,O
and,O
periodically,O
thereafter,O
as,O
clinically,O
indicated,O
Initiate,O
or,O
optimize,O
anti,O
hyperglycemic,O
medications,O
as,O
indicated,O
Based,O
on,O
the,O
severity,O
of,O
the,O
adverse,O
drug,O
reaction,O
withhold,O
ZYKADIA,O
until,O
hyperglycemia,O
is,O
adequately,O
controlled,O
then,O
resume,O
ZYKADIA,O
at,O
a,O
reduced,O
dose,O
as,O
described,O
in,O
Table,O
1,O
If,O
adequate,O
hyperglycemic,O
control,O
cannot,O
be,O
achieved,O
with,O
optimal,O
medical,O
management,O
permanently,O
discontinue,O
ZYKADIA,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
5,O
6,O
Bradycardia,O
Bradycardia,AdverseReaction
can,Factor
occur,O
in,O
patients,O
receiving,O
ZYKADIA,O
In,O
Study,O
1,O
sinus bradycardia,AdverseReaction
defined,O
as,O
a,O
heart rate of less than 50 beats per minute,AdverseReaction
was,O
noted,O
as,O
a,O
new,O
finding,O
in,O
1,O
of,O
255,O
patients,O
Bradycardia,AdverseReaction
was,O
reported,O
as,O
an,O
adverse,O
drug,O
reaction,O
in,O
3,O
of,O
patients,O
in,O
Study,O
1,O
Avoid,O
using,O
ZYKADIA,O
in,O
combination,O
with,O
other,O
agents,O
known,O
to,O
cause,O
bradycardia,O
e,O
g,O
beta,O
blockers,O
non,O
dihydropyridine,O
calcium,O
channel,O
blockers,O
clonidine,O
and,O
digoxin,O
to,O
the,O
extent,O
possible,O
Monitor,O
heart,O
rate,O
and,O
blood,O
pressure,O
regularly,O
In,O
cases,O
of,O
symptomatic,O
bradycardia,O
that,O
is,O
not,O
life,O
threatening,O
withhold,O
ZYKADIA,O
until,O
recovery,O
to,O
asymptomatic,O
bradycardia,O
or,O
to,O
a,O
heart,O
rate,O
of,O
60,O
bpm,O
or,O
above,O
evaluate,O
the,O
use,O
of,O
concomitant,O
medications,O
and,O
adjust,O
the,O
dose,O
of,O
ZYKADIA,O
Permanently,O
discontinue,O
ZYKADIA,O
for,O
life,O
threatening,O
bradycardia,O
if,O
no,O
contributing,O
concomitant,O
medication,O
is,O
identified,O
however,O
if,O
associated,O
with,O
a,O
concomitant,O
medication,O
known,O
to,O
cause,O
bradycardia,O
or,O
hypotension,O
withhold,O
ZYKADIA,O
until,O
recovery,O
to,O
asymptomatic,O
bradycardia,O
or,O
to,O
a,O
heart,O
rate,O
of,O
60,O
bpm,O
or,O
above,O
and,O
if,O
the,O
concomitant,O
medication,O
can,O
be,O
adjusted,O
or,O
discontinued,O
resume,O
ZYKADIA,O
at,O
a,O
reduced,O
dose,O
as,O
described,O
in,O
Table,O
1,O
upon,O
recovery,O
to,O
asymptomatic,O
bradycardia,O
or,O
to,O
a,O
heart,O
rate,O
of,O
60,O
bpm,O
or,O
above,O
with,O
frequent,O
monitoring,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
5,O
7,O
Pancreatitis,O
Pancreatitis,AdverseReaction
including,O
one,O
fatality,AdverseReaction
has,O
been,O
reported,O
in,O
less,O
than,O
1,O
of,O
patients,O
receiving,O
ZYKADIA,O
in,O
clinical,O
trials,O
CTCAE,O
Grade 3 3 4,Severity
4,Severity
elevations of lipase of,AdverseReaction
and,O
or,O
amylase,AdverseReaction
occurred,O
in,O
15,O
of,O
patients,O
receiving,O
ZYKADIA,O
in,O
Study,O
1,O
Monitor,O
lipase,O
and,O
amylase,O
prior,O
to,O
the,O
start,O
of,O
ZYKADIA,O
treatment,O
and,O
periodically,O
thereafter,O
as,O
clinically,O
indicated,O
Based,O
on,O
the,O
severity,O
of,O
the,O
laboratory,O
abnormalities,O
withhold,O
ZYKADIA,O
with,O
resumption,O
at,O
a,O
reduced,O
dose,O
as,O
described,O
in,O
Table,O
1,O
see,O
Dosage,O
and,O
Administration,O
2,O
2,O
and,O
Adverse,O
Reactions,O
6,O
5,O
8,O
Embryofetal,O
Toxicity,O
Based,O
on,O
its,O
mechanism,O
of,O
action,O
ZYKADIA,O
may,Factor
cause,O
fetal harm,AdverseReaction
when,O
administered,O
to,O
a,O
pregnant,O
woman,O
In,O
animal,O
studies,O
administration,O
of,O
ceritinib,O
to,O
rats,O
and,O
rabbits,O
during,O
organogenesis,O
at,O
maternal,O
plasma,O
exposures,O
below,O
the,O
recommended,O
human,O
dose,O
of,O
750,O
mg,O
daily,O
caused,O
increases in skeletal anomalies,AdverseReaction
in,O
rats,Animal
and,O
rabbits,Animal
Apprise,O
women,O
of,O
reproductive,O
potential,O
of,O
the,O
potential,O
hazard,O
to,O
a,O
fetus,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
1,O
Advise,O
females,O
of,O
reproductive,O
potential,O
to,O
use,O
effective,O
contraception,O
during,O
treatment,O
with,O
ZYKADIA,O
and,O
for,O
at,O
least,O
2,O
weeks,O
following,O
completion,O
of,O
therapy,O
see,O
Use,O
in,O
Specific,O
Populations,O
8,O
7,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
adverse,O
reactions,O
are,O
discussed,O
in,O
greater,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Severe,Severity
or,O
Persistent,Severity
Gastrointestinal Toxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
1,O
Hepatotoxicity,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
2,O
Interstitial Lung Disease,AdverseReaction
Pneumonitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
3,O
QT Interval Prolongation,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
4,O
and,O
Clinical,O
Pharmacology,O
12,O
2,O
Hyperglycemia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
5,O
Bradycardia,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
6,O
and,O
Clinical,O
Pharmacology,O
12,O
2,O
Pancreatitis,AdverseReaction
see,O
Warnings,O
and,O
Precautions,O
5,O
7,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
incidence,O
of,O
at,O
least,O
25,O
are,O
diarrhea,AdverseReaction
nausea,AdverseReaction
elevated transaminases,AdverseReaction
vomiting,AdverseReaction
abdominal pain,AdverseReaction
fatigue,AdverseReaction
decreased appetite,AdverseReaction
and,O
constipation,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Novartis,O
Pharmaceuticals,O
Corporation,O
at,O
1,O
888,O
669,O
6682,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trials,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
practice,O
The,O
safety,O
evaluation,O
of,O
ZYKADIA,O
is,O
based,O
on,O
255,O
ALK,O
positive,O
patients,O
in,O
Study,O
1,O
246,O
patients,O
with,O
NSCLC,O
and,O
9,O
patients,O
with,O
other,O
cancers,O
who,O
received,O
ZYKADIA,O
at,O
a,O
dose,O
of,O
750,O
mg,O
daily,O
The,O
median,O
duration,O
of,O
exposure,O
to,O
ZYKADIA,O
was,O
6,O
months,O
The,O
study,O
population,O
characteristics,O
were,O
median,O
age,O
53,O
years,O
age,O
less,O
than,O
65,O
84,O
female,O
53,O
Caucasian,O
63,O
Asian,O
34,O
NSCLC,O
adenocarcinoma,O
histology,O
90,O
never,O
or,O
former,O
smoker,O
97,O
ECOG,O
PS,O
0,O
or,O
1,O
89,O
brain,O
metastasis,O
49,O
and,O
number,O
of,O
prior,O
therapies,O
2,O
or,O
more,O
67,O
Dose,O
reductions,O
due,O
to,O
adverse,O
reactions,O
occurred,O
in,O
59,O
of,O
patients,O
treated,O
with,O
ZYKADIA,O
The,O
most,O
frequent,O
adverse,O
reactions,O
reported,O
in,O
at,O
least,O
10,O
of,O
patients,O
that,O
led,O
to,O
dose,O
reductions,O
or,O
interruptions,O
were,O
increased ALT,AdverseReaction
29,O
nausea,AdverseReaction
20,O
increased AST,AdverseReaction
16,O
diarrhea,AdverseReaction
16,O
and,O
vomiting,AdverseReaction
16,O
Serious,O
adverse,O
drug,O
reactions,O
reported,O
in,O
2,O
or,O
more,O
of,O
patients,O
in,O
Study,O
1,O
were,O
convulsion,AdverseReaction
pneumonia,AdverseReaction
ILD,AdverseReaction
pneumonitis,AdverseReaction
dyspnea,AdverseReaction
dehydration,AdverseReaction
hyperglycemia,AdverseReaction
and,O
nausea,AdverseReaction
Fatal,AdverseReaction
adverse,O
reactions,O
in,O
patients,O
treated,O
with,O
ZYKADIA,O
occurred,O
in,O
5,O
of,O
patients,O
consisting,O
of,O
pneumonia,AdverseReaction
4,O
patients,O
respiratory failure,AdverseReaction
ILD,AdverseReaction
pneumonitis,AdverseReaction
pneumothorax,AdverseReaction
gastric hemorrhage,AdverseReaction
general physical health deterioration,AdverseReaction
pulmonary tuberculosis,AdverseReaction
cardiac tamponade,AdverseReaction
and,O
sepsis,AdverseReaction
1,O
patient,O
each,O
Discontinuation,O
of,O
therapy,O
due,O
to,O
adverse,O
reactions,O
occurred,O
in,O
10,O
of,O
patients,O
treated,O
with,O
ZYKADIA,O
The,O
most,O
frequent,O
adverse,O
drug,O
reactions,O
that,O
led,O
to,O
discontinuation,O
in,O
1,O
or,O
more,O
of,O
patients,O
in,O
Study,O
1,O
were,O
pneumonia,AdverseReaction
ILD,AdverseReaction
pneumonitis,AdverseReaction
and,O
decreased appetite,AdverseReaction
Tables,O
2,O
and,O
3,O
summarize,O
the,O
common,O
adverse,O
reactions,O
and,O
laboratory,O
abnormalities,O
observed,O
in,O
ZYKADIA,O
treated,O
patients,O
Table,O
2,O
Adverse,O
Reactions,O
10,O
for,O
All,O
NCI,O
CTCAE,O
Grades,O
or,O
2,O
for,O
Grades,O
3,O
4,O
in,O
ALK,O
Positive,O
Patients,O
Treated,O
with,O
ZYKADIA,O
in,O
Study,O
1,O
National,O
Cancer,O
Institute,O
Common,O
Terminology,O
Criteria,O
for,O
Adverse,O
Events,O
version,O
4,O
03,O
a,O
Abdominal pain,AdverseReaction
abdominal pain,AdverseReaction
upper abdominal pain,AdverseReaction
abdominal discomfort,AdverseReaction
epigastric discomfort,AdverseReaction
b,O
Esophageal disorder,AdverseReaction
dyspepsia,AdverseReaction
gastroesophageal reflux disease,AdverseReaction
dysphagia,AdverseReaction
c,O
Fatigue,AdverseReaction
fatigue,AdverseReaction
asthenia,AdverseReaction
d,O
Rash,AdverseReaction
rash,AdverseReaction
maculopapular rash,AdverseReaction
acneiform dermatitis,AdverseReaction
ZYKADIAN,O
255,O
All,O
Grades,O
Grade,O
3,O
4,O
Gastrointestinal,O
disorders,O
Diarrhea,AdverseReaction
86,O
6,O
Nausea,AdverseReaction
80,O
4,O
Vomiting,AdverseReaction
60,O
4,O
Abdominal pain,AdverseReaction
a,O
54,O
2,O
Constipation,AdverseReaction
29,O
0,O
Esophageal disorder,AdverseReaction
b,O
16,O
1,O
General,O
disorders,O
and,O
administration,O
site,O
conditions,O
Fatigue,AdverseReaction
c,O
52,O
5,O
Metabolism,O
and,O
nutrition,O
disorders,O
Decreased appetite,AdverseReaction
34,O
1,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
d,O
16,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Interstitial lung disease,AdverseReaction
pneumonitis,AdverseReaction
4,O
3,O
Additional,O
clinically,O
significant,O
adverse,O
reactions,O
occurring,O
in,O
2,O
or,O
more,O
of,O
patients,O
treated,O
with,O
ZYKADIA,O
included,O
neuropathy,AdverseReaction
17,O
comprised,O
of,O
paresthesia,AdverseReaction
muscular weakness,AdverseReaction
gait disturbance,AdverseReaction
peripheral neuropathy,AdverseReaction
hypoesthesia,AdverseReaction
peripheral sensory neuropathy,AdverseReaction
dysesthesia,AdverseReaction
neuralgia,AdverseReaction
peripheral motor neuropathy,AdverseReaction
hypotonia,AdverseReaction
or,O
polyneuropathy,AdverseReaction
vision disorder,AdverseReaction
9,O
comprised,O
of,O
vision impairment,AdverseReaction
blurred vision,AdverseReaction
photopsia,AdverseReaction
accommodation disorder,AdverseReaction
presbyopia,AdverseReaction
or,O
reduced visual acuity,AdverseReaction
prolonged QT interval,AdverseReaction
4,O
and,O
bradycardia,AdverseReaction
3,O
Table,O
3,O
Key,O
Laboratory,O
Abnormalities,O
Occurring,O
in,O
10,O
All,O
NCI,O
CTCAE,O
Grades,O
of,O
ALK,O
Positive,O
Patients,O
Treated,O
with,O
ZYKADIA,O
in,O
Study,O
1,O
ZYKADIAN,O
255,O
All,O
Grades,O
Grade,O
3,O
4,O
Hemoglobin decreased,AdverseReaction
84,O
5,O
Alanine transaminase,AdverseReaction
ALT,AdverseReaction
increased,AdverseReaction
80,O
27,O
Aspartate transaminase,AdverseReaction
AST,AdverseReaction
increased,AdverseReaction
75,O
13,O
Creatinine increased,AdverseReaction
58,O
2,O
Glucose increased,AdverseReaction
49,O
13,O
Phosphate decreased,AdverseReaction
36,O
7,O
Lipase increased,AdverseReaction
28,O
10,O
Bilirubin,AdverseReaction
total,AdverseReaction
increased,AdverseReaction
15,O
1,O
""
5,O
WARNINGS,O
AND,O
PRECAUTIONS,O
EXCERPT,O
Mineralocorticoid excess,AdverseReaction
Use,O
ZYTIGA,O
with,O
caution,O
in,O
patients,O
with,O
a,O
history,O
of,O
cardiovascular,O
disease,O
The,O
safety,O
of,O
ZYTIGA,O
in,O
patients,O
with,O
LVEF,O
50,O
or,O
NYHA,O
Class,O
III,O
or,O
IV,O
heart,O
failure,O
in,O
Study,O
1,O
or,O
LVEF,O
50,O
or,O
NYHA,O
Class,O
II,O
to,O
IV,O
heart,O
failure,O
in,O
Study,O
2,O
was,O
not,O
established,O
Control,O
hypertension,O
and,O
correct,O
hypokalemia,O
before,O
treatment,O
Monitor,O
blood,O
pressure,O
serum,O
potassium,O
and,O
symptoms,O
of,O
fluid,O
retention,O
at,O
least,O
monthly,O
5,O
1,O
Adrenocortical insufficiency,AdverseReaction
Monitor,O
for,O
symptoms,O
and,O
signs,O
of,O
adrenocortical,O
insufficiency,O
Increased,O
dosage,O
of,O
corticosteroids,O
may,O
be,O
indicated,O
before,O
during,O
and,O
after,O
stressful,O
situations,O
5,O
2,O
Hepatotoxicity,AdverseReaction
Increases in liver enzymes,AdverseReaction
have,O
led,O
to,O
drug,O
interruption,O
dose,O
modification,O
and,O
or,O
discontinuation,O
Monitor,O
liver,O
function,O
and,O
modify,O
interrupt,O
or,O
discontinue,O
ZYTIGA,O
dosing,O
as,O
recommended,O
5,O
3,O
5,O
1,O
Hypertension,O
Hypokalemia,O
and,O
Fluid,O
Retention,O
Due,O
to,O
Mineralocorticoid,O
Excess,O
ZYTIGA,O
may,Factor
cause,O
hypertension,AdverseReaction
hypokalemia,AdverseReaction
and,O
fluid retention,AdverseReaction
as,O
a,O
consequence,O
of,O
increased mineralocorticoid levels,AdverseReaction
resulting,O
from,O
CYP17,O
inhibition,O
seeClinical,O
Pharmacology,O
12,O
1,O
In,O
the,O
two,O
randomized,O
clinical,O
trials,O
grade 3 3 to 4,Severity
hypertension,AdverseReaction
occurred,O
in,O
2,O
of,O
patients,O
grade 3 3 to 4,Severity
hypokalemia,AdverseReaction
in,O
4,O
of,O
patients,O
and,O
grade 3 3 to 4,Severity
edema,AdverseReaction
in,O
1,O
of,O
patients,O
treated,O
with,O
ZYTIGA,O
seeAdverse,O
Reactions,O
6,O
Co,O
administration,O
of,O
a,O
corticosteroid,O
suppresses,O
adrenocorticotropic,O
hormone,O
ACTH,O
drive,O
resulting,O
in,O
a,O
reduction,O
in,O
the,O
incidence,O
and,O
severity,O
of,O
these,O
adverse,O
reactions,O
Use,O
caution,O
when,O
treating,O
patients,O
whose,O
underlying,O
medical,O
conditions,O
might,O
be,O
compromised,O
by,O
increases,O
in,O
blood,O
pressure,O
hypokalemia,O
or,O
fluid,O
retention,O
e,O
g,O
those,O
with,O
heart,O
failure,O
recent,O
myocardial,O
infarction,O
or,O
ventricular,O
arrhythmia,O
Use,O
ZYTIGA,O
with,O
caution,O
in,O
patients,O
with,O
a,O
history,O
of,O
cardiovascular,O
disease,O
The,O
safety,O
of,O
ZYTIGA,O
in,O
patients,O
with,O
left,O
ventricular,O
ejection,O
fraction,O
50,O
or,O
New,O
York,O
Heart,O
Association,O
NYHA,O
Class,O
III,O
or,O
IV,O
heart,O
failure,O
in,O
Study,O
1,O
or,O
NYHA,O
Class,O
II,O
to,O
IV,O
heart,O
failure,O
in,O
Study,O
2,O
was,O
not,O
established,O
because,O
these,O
patients,O
were,O
excluded,O
from,O
these,O
randomized,O
clinical,O
trials,O
seeClinical,O
Studies,O
14,O
Monitor,O
patients,O
for,O
hypertension,O
hypokalemia,O
and,O
fluid,O
retention,O
at,O
least,O
once,O
a,O
month,O
Control,O
hypertension,O
and,O
correct,O
hypokalemia,O
before,O
and,O
during,O
treatment,O
with,O
ZYTIGA,O
5,O
2,O
Adrenocortical,O
Insufficiency,O
Adrenal insufficiency,AdverseReaction
occurred,O
in,O
the,O
two,O
randomized,O
clinical,O
studies,O
in,O
0,O
5,O
of,O
patients,O
taking,O
ZYTIGA,O
and,O
in,O
0,O
2,O
of,O
patients,O
taking,O
placebo,O
Adrenocortical insufficiency,AdverseReaction
was,O
reported,O
in,O
patients,O
receiving,O
ZYTIGA,O
in,O
combination,O
with,O
prednisone,O
following,O
interruption,O
of,O
daily,O
steroids,O
and,O
or,O
with,O
concurrent,O
infection,O
or,O
stress,O
Use,O
caution,O
and,O
monitor,O
for,O
symptoms,O
and,O
signs,O
of,O
adrenocortical,O
insufficiency,O
particularly,O
if,O
patients,O
are,O
withdrawn,O
from,O
prednisone,O
have,O
prednisone,O
dose,O
reductions,O
or,O
experience,O
unusual,O
stress,O
Symptoms,O
and,O
signs,O
of,O
adrenocortical insufficiency,AdverseReaction
may,O
be,O
masked,O
by,O
adverse,O
reactions,O
associated,O
with,O
mineralocorticoid excess,AdverseReaction
seen,O
in,O
patients,O
treated,O
with,O
ZYTIGA,O
If,O
clinically,O
indicated,O
perform,O
appropriate,O
tests,O
to,O
confirm,O
the,O
diagnosis,O
of,O
adrenocortical,O
insufficiency,O
Increased,O
dosage,O
of,O
corticosteroids,O
may,O
be,O
indicated,O
before,O
during,O
and,O
after,O
stressful,O
situations,O
seeWarnings,O
and,O
Precautions,O
5,O
1,O
5,O
3,O
Hepatotoxicity,O
In,O
the,O
two,O
randomized,O
clinical,O
trials,O
grade 3,Severity
or,O
4,Severity
ALT,AdverseReaction
or,O
AST increases,AdverseReaction
at,O
least,O
5,O
ULN,O
were,O
reported,O
in,O
4,O
of,O
patients,O
who,O
received,O
ZYTIGA,O
typically,O
during,O
the,O
first,O
3,O
months,O
after,O
starting,O
treatment,O
Patients,O
whose,O
baseline,O
ALT,O
or,O
AST,O
were,O
elevated,O
were,O
more,O
likely,O
to,O
experience,O
liver test elevation,AdverseReaction
than,O
those,O
beginning,O
with,O
normal,O
values,O
Treatment,O
discontinuation,O
due,O
to,O
liver enzyme increases,AdverseReaction
occurred,O
in,O
1,O
of,O
patients,O
taking,O
ZYTIGA,O
No,Negation
deaths,AdverseReaction
clearly,O
related,O
to,O
ZYTIGA,O
were,O
reported,O
due,O
to,O
hepatotoxicity,AdverseReaction
events,O
Measure,O
serum,O
transaminases,O
ALT,O
and,O
AST,O
and,O
bilirubin,O
levels,O
prior,O
to,O
starting,O
treatment,O
with,O
ZYTIGA,O
every,O
two,O
weeks,O
for,O
the,O
first,O
three,O
months,O
of,O
treatment,O
and,O
monthly,O
thereafter,O
In,O
patients,O
with,O
baseline,O
moderate,O
hepatic,O
impairment,O
receiving,O
a,O
reduced,O
ZYTIGA,O
dose,O
of,O
250,O
mg,O
measure,O
ALT,O
AST,O
and,O
bilirubin,O
prior,O
to,O
the,O
start,O
of,O
treatment,O
every,O
week,O
for,O
the,O
first,O
month,O
every,O
two,O
weeks,O
for,O
the,O
following,O
two,O
months,O
of,O
treatment,O
and,O
monthly,O
thereafter,O
Promptly,O
measure,O
serum,O
total,O
bilirubin,O
AST,O
and,O
ALT,O
if,O
clinical,O
symptoms,O
or,O
signs,O
suggestive,O
of,O
hepatotoxicity,O
develop,O
Elevations,O
of,O
AST,O
ALT,O
or,O
bilirubin,O
from,O
the,O
patient,O
s,O
baseline,O
should,O
prompt,O
more,O
frequent,O
monitoring,O
If,O
at,O
any,O
time,O
AST,O
or,O
ALT,O
rise,O
above,O
five,O
times,O
the,O
ULN,O
or,O
the,O
bilirubin,O
rises,O
above,O
three,O
times,O
the,O
ULN,O
interrupt,O
ZYTIGA,O
treatment,O
and,O
closely,O
monitor,O
liver,O
function,O
Re,O
treatment,O
with,O
ZYTIGA,O
at,O
a,O
reduced,O
dose,O
level,O
may,O
take,O
place,O
only,O
after,O
return,O
of,O
liver,O
function,O
tests,O
to,O
the,O
patient,O
s,O
baseline,O
or,O
to,O
AST,O
and,O
ALT,O
less,O
than,O
or,O
equal,O
to,O
2,O
5,O
ULN,O
and,O
total,O
bilirubin,O
less,O
than,O
or,O
equal,O
to,O
1,O
5,O
ULN,O
seeDosage,O
and,O
Administration,O
2,O
2,O
The,O
safety,O
of,O
ZYTIGA,O
re,O
treatment,O
of,O
patients,O
who,O
develop,O
AST,O
or,O
ALT,O
greater,O
than,O
or,O
equal,O
to,O
20,O
ULN,O
and,O
or,O
bilirubin,O
greater,O
than,O
or,O
equal,O
to,O
10,O
ULN,O
is,O
unknown,O
""
6,O
ADVERSE,O
REACTIONS,O
The,O
following,O
are,O
discussed,O
in,O
more,O
detail,O
in,O
other,O
sections,O
of,O
the,O
labeling,O
Hypertension,AdverseReaction
Hypokalemia,AdverseReaction
and,O
Fluid Retention,AdverseReaction
due,O
to,O
Mineralocorticoid Excess,AdverseReaction
seeWarnings,O
and,O
Precautions,O
5,O
1,O
Adrenocortical Insufficiency,AdverseReaction
seeWarnings,O
and,O
Precautions,O
5,O
2,O
Hepatotoxicity,AdverseReaction
seeWarnings,O
and,O
Precautions,O
5,O
3,O
EXCERPT,O
The,O
most,O
common,O
adverse,O
reactions,O
10,O
are,O
fatigue,AdverseReaction
joint swelling,AdverseReaction
or,O
discomfort,AdverseReaction
edema,AdverseReaction
hot flush,AdverseReaction
diarrhea,AdverseReaction
vomiting,AdverseReaction
cough,AdverseReaction
hypertension,AdverseReaction
dyspnea,AdverseReaction
urinary tract infection,AdverseReaction
and,O
contusion,AdverseReaction
The,O
most,O
common,O
laboratory,O
abnormalities,O
20,O
are,O
anemia,AdverseReaction
elevated alkaline phosphatase,AdverseReaction
hypertriglyceridemia,AdverseReaction
lymphopenia,AdverseReaction
hypercholesterolemia,AdverseReaction
hyperglycemia,AdverseReaction
elevated AST,AdverseReaction
hypophosphatemia,AdverseReaction
elevated ALT,AdverseReaction
and,O
hypokalemia,AdverseReaction
6,O
To,O
report,O
SUSPECTED,O
ADVERSE,O
REACTIONS,O
contact,O
Janssen,O
Biotech,O
Inc,O
at,O
1,O
800,O
526,O
7736,O
1,O
800,O
JANSSEN,O
or,O
FDA,O
at,O
1,O
800,O
FDA,O
1088,O
or,O
www,O
fda,O
gov,O
medwatch,O
6,O
1,O
Clinical,O
Trial,O
Experience,O
Because,O
clinical,O
trials,O
are,O
conducted,O
under,O
widely,O
varying,O
conditions,O
adverse,O
reaction,O
rates,O
observed,O
in,O
the,O
clinical,O
trials,O
of,O
a,O
drug,O
cannot,O
be,O
directly,O
compared,O
to,O
rates,O
in,O
the,O
clinical,O
trials,O
of,O
another,O
drug,O
and,O
may,O
not,O
reflect,O
the,O
rates,O
observed,O
in,O
clinical,O
practice,O
Two,O
randomized,O
placebo,O
controlled,O
multicenter,O
clinical,O
trials,O
enrolled,O
patients,O
who,O
had,O
metastatic,O
castration,O
resistant,O
prostate,O
cancer,O
who,O
were,O
using,O
a,O
gonadotropin,O
releasing,O
hormone,O
GnRH,O
agonist,O
or,O
were,O
previously,O
treated,O
with,O
orchiectomy,O
In,O
both,O
Study,O
1,O
and,O
Study,O
2,O
ZYTIGA,O
was,O
administered,O
at,O
a,O
dose,O
of,O
1,O
000,O
mg,O
daily,O
in,O
combination,O
with,O
prednisone,O
5,O
mg,O
twice,O
daily,O
in,O
the,O
active,O
treatment,O
arms,O
Placebo,O
plus,O
prednisone,O
5,O
mg,O
twice,O
daily,O
was,O
given,O
to,O
control,O
patients,O
The,O
most,O
common,O
adverse,O
drug,O
reactions,O
10,O
reported,O
in,O
the,O
two,O
randomized,O
clinical,O
trials,O
that,O
occurred,O
more,O
commonly,O
2,O
in,O
the,O
abiraterone,O
acetate,O
arm,O
were,O
fatigue,AdverseReaction
joint swelling,AdverseReaction
or,O
discomfort,AdverseReaction
edema,AdverseReaction
hot flush,AdverseReaction
diarrhea,AdverseReaction
vomiting,AdverseReaction
cough,AdverseReaction
hypertension,AdverseReaction
dyspnea,AdverseReaction
urinary tract infection,AdverseReaction
and,O
contusion,AdverseReaction
The,O
most,O
common,O
laboratory,O
abnormalities,O
20,O
reported,O
in,O
the,O
two,O
randomized,O
clinical,O
trials,O
that,O
occurred,O
more,O
commonly,O
2,O
in,O
the,O
abiraterone,O
acetate,O
arm,O
were,O
anemia,AdverseReaction
elevated alkaline phosphatase,AdverseReaction
hypertriglyceridemia,AdverseReaction
lymphopenia,AdverseReaction
hypercholesterolemia,AdverseReaction
hyperglycemia,AdverseReaction
elevated AST,AdverseReaction
hypophosphatemia,AdverseReaction
elevated ALT,AdverseReaction
and,O
hypokalemia,AdverseReaction
Study,O
1,O
Metastatic,O
CRPC,O
Following,O
Chemotherapy,O
Study,O
1,O
enrolled,O
1195,O
patients,O
with,O
metastatic,O
CRPC,O
who,O
had,O
received,O
prior,O
docetaxel,O
chemotherapy,O
Patients,O
were,O
not,O
eligible,O
if,O
AST,O
and,O
or,O
ALT,O
2,O
5,O
ULN,O
in,O
the,O
absence,O
of,O
liver,O
metastases,O
Patients,O
with,O
liver,O
metastases,O
were,O
excluded,O
if,O
AST,O
and,O
or,O
ALT,O
5,O
ULN,O
Table,O
1,O
shows,O
adverse,O
reactions,O
on,O
the,O
ZYTIGA,O
arm,O
in,O
Study,O
1,O
that,O
occurred,O
with,O
a,O
2,O
absolute,O
increase,O
in,O
frequency,O
compared,O
to,O
placebo,O
or,O
were,O
events,O
of,O
special,O
interest,O
The,O
median,O
duration,O
of,O
treatment,O
with,O
ZYTIGA,O
was,O
8,O
months,O
Table,O
1,O
Adverse,O
Reactions,O
due,O
to,O
ZYTIGA,O
in,O
Study,O
1,O
ZYTIGA,O
with,O
Prednisone,O
N,O
791,O
Placebo,O
with,O
Prednisone,O
N,O
394,O
System,O
Organ,O
Class,O
Adverse,O
reaction,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Joint swelling,AdverseReaction
discomfort,AdverseReaction
29,O
5,O
4,O
2,O
23,O
4,O
4,O
1,O
Muscle discomfort,AdverseReaction
26,O
2,O
3,O
0,O
23,O
1,O
2,O
3,O
General,O
disorders,O
Edema,AdverseReaction
26,O
7,O
1,O
9,O
18,O
3,O
0,O
8,O
Vascular,O
disorders,O
Hot flush,AdverseReaction
19,O
0,O
0,O
3,O
16,O
8,O
0,O
3,O
Hypertension,AdverseReaction
8,O
5,O
1,O
3,O
6,O
9,O
0,O
3,O
Gastrointestinal,O
disorders,O
Diarrhea,AdverseReaction
17,O
6,O
0,O
6,O
13,O
5,O
1,O
3,O
Dyspepsia,AdverseReaction
6,O
1,O
0,O
3,O
3,O
0,O
Infections,O
and,O
infestations,O
Urinary tract infection,AdverseReaction
11,O
5,O
2,O
1,O
7,O
1,O
0,O
5,O
Upper respiratory tract infection,AdverseReaction
5,O
4,O
0,O
2,O
5,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
10,O
6,O
0,O
7,O
6,O
0,O
Renal,O
and,O
urinary,O
disorders,O
Urinary frequency,AdverseReaction
7,O
2,O
0,O
3,O
5,O
1,O
0,O
3,O
Nocturia,AdverseReaction
6,O
2,O
0,O
4,O
1,O
0,O
Injury,O
poisoning,O
and,O
procedural,O
complications,O
Fractures,AdverseReaction
5,O
9,O
1,O
4,O
2,O
3,O
0,O
Cardiac,O
disorders,O
Arrhythmia,AdverseReaction
7,O
2,O
1,O
1,O
4,O
6,O
1,O
0,O
Chest pain,AdverseReaction
or,O
chest discomfort,AdverseReaction
3,O
8,O
0,O
5,O
2,O
8,O
0,O
Cardiac failure,AdverseReaction
2,O
3,O
1,O
9,O
1,O
0,O
0,O
3,O
Table,O
2,O
shows,O
laboratory,O
abnormalities,O
of,O
interest,O
from,O
Study,O
1,O
Grade 3 3 4,Severity
low serum phosphorus,AdverseReaction
7,O
and,O
low potassium,AdverseReaction
5,O
occurred,O
at,O
a,O
greater,O
than,O
or,O
equal,O
to,O
5,O
rate,O
in,O
the,O
ZYTIGA,O
arm,O
Table,O
2,O
Laboratory,O
Abnormalities,O
of,O
Interest,O
in,O
Study,O
1,O
Abiraterone,O
N,O
791,O
Placebo,O
N,O
394,O
Laboratory,O
Abnormality,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
Hypertriglyceridemia,AdverseReaction
62,O
5,O
0,O
4,O
53,O
0,O
0,O
High AST,AdverseReaction
30,O
6,O
2,O
1,O
36,O
3,O
1,O
5,O
Hypokalemia,AdverseReaction
28,O
3,O
5,O
3,O
19,O
8,O
1,O
0,O
Hypophosphatemia,AdverseReaction
23,O
8,O
7,O
2,O
15,O
7,O
5,O
8,O
High ALT,AdverseReaction
11,O
1,O
1,O
4,O
10,O
4,O
0,O
8,O
High Total Bilirubin,AdverseReaction
6,O
6,O
0,O
1,O
4,O
6,O
0,O
Study,O
2,O
Metastatic,O
CRPC,O
Prior,O
to,O
Chemotherapy,O
Study,O
2,O
enrolled,O
1088,O
patients,O
with,O
metastatic,O
CRPC,O
who,O
had,O
not,O
received,O
prior,O
cytotoxic,O
chemotherapy,O
Patients,O
were,O
ineligible,O
if,O
AST,O
and,O
or,O
ALT,O
2,O
5,O
ULN,O
and,O
patients,O
were,O
excluded,O
if,O
they,O
had,O
liver,O
metastases,O
Table,O
3,O
shows,O
adverse,O
reactions,O
on,O
the,O
ZYTIGA,O
arm,O
in,O
Study,O
2,O
that,O
occurred,O
with,O
a,O
2,O
absolute,O
increase,O
in,O
frequency,O
compared,O
to,O
placebo,O
The,O
median,O
duration,O
of,O
treatment,O
with,O
ZYTIGA,O
was,O
13,O
8,O
months,O
Table,O
3,O
Adverse,O
Reactions,O
in,O
5,O
of,O
Patients,O
on,O
the,O
ZYTIGA,O
Arm,O
in,O
Study,O
2,O
ZYTIGA,O
with,O
Prednisone,O
N,O
542,O
Placebo,O
with,O
Prednisone,O
N,O
540,O
System,O
Organ,O
Class,O
Adverse,O
reaction,O
All,O
Grades,O
Grade,O
3,O
4,O
All,O
Grades,O
Grade,O
3,O
4,O
General,O
disorders,O
Fatigue,AdverseReaction
39,O
1,O
2,O
2,O
34,O
3,O
1,O
7,O
Edema,AdverseReaction
25,O
1,O
0,O
4,O
20,O
7,O
1,O
1,O
Pyrexia,AdverseReaction
8,O
7,O
0,O
6,O
5,O
9,O
0,O
2,O
Musculoskeletal,O
and,O
connective,O
tissue,O
disorders,O
Joint swelling,AdverseReaction
discomfort,AdverseReaction
30,O
3,O
2,O
0,O
25,O
2,O
2,O
0,O
Groin pain,AdverseReaction
6,O
6,O
0,O
4,O
4,O
1,O
0,O
7,O
Gastrointestinal,O
disorders,O
Constipation,AdverseReaction
23,O
1,O
0,O
4,O
19,O
1,O
0,O
6,O
Diarrhea,AdverseReaction
21,O
6,O
0,O
9,O
17,O
8,O
0,O
9,O
Dyspepsia,AdverseReaction
11,O
1,O
0,O
0,O
5,O
0,O
0,O
2,O
Vascular,O
disorders,O
Hot flush,AdverseReaction
22,O
3,O
0,O
2,O
18,O
1,O
0,O
0,O
Hypertension,AdverseReaction
21,O
6,O
3,O
9,O
13,O
1,O
3,O
0,O
Respiratory,O
thoracic,O
and,O
mediastinal,O
disorders,O
Cough,AdverseReaction
17,O
3,O
0,O
0,O
13,O
5,O
0,O
2,O
Dyspnea,AdverseReaction
11,O
8,O
2,O
4,O
9,O
6,O
0,O
9,O
Psychiatric,O
disorders,O
Insomnia,AdverseReaction
13,O
5,O
0,O
2,O
11,O
3,O
0,O
0,O
Injury,O
poisoning,O
and,O
procedural,O
complications,O
Contusion,AdverseReaction
13,O
3,O
0,O
0,O
9,O
1,O
0,O
0,O
Falls,AdverseReaction
5,O
9,O
0,O
0,O
3,O
3,O
0,O
0,O
Infections,O
and,O
infestations,O
Upper respiratory tract infection,AdverseReaction
12,O
7,O
0,O
0,O
8,O
0,O
0,O
0,O
Nasopharyngitis,AdverseReaction
10,O
7,O
0,O
0,O
8,O
1,O
0,O
0,O
Renal,O
and,O
urinary,O
disorders,O
Hematuria,AdverseReaction
10,O
3,O
1,O
3,O
5,O
6,O
0,O
6,O
Skin,O
and,O
subcutaneous,O
tissue,O
disorders,O
Rash,AdverseReaction
8,O
1,O
0,O
0,O
3,O
7,O
0,O
0,O
Table,O
4,O
shows,O
laboratory,O
abnormalities,O
that,O
occurred,O
in,O
greater,O
than,O
15,O
of,O
patients,O
and,O
more,O
frequently,O
5,O
in,O
the,O
ZYTIGA,O
arm,O
compared,O
to,O
placebo,O
in,O
Study,O
2,O
Grade 3 3 4,Severity
lymphopenia,AdverseReaction
9,O
hyperglycemia,AdverseReaction
7,O
and,O
high alanine aminotransferase,AdverseReaction
6,O
occurred,O
at,O
a,O
greater,O
than,O
5,O
rate,O
in,O
the,O
ZYTIGA,O
arm,O
Table,O
4,O
Laboratory,O
Abnormalities,O
in,O
15,O
of,O
Patients,O
in,O
the,O
ZYTIGA,O
Arm,O
of,O
Study,O
2,O
Abiraterone,O
N,O
542,O
Placebo,O
N,O
540,O
Laboratory,O
Abnormality,O
Grade,O
1,O
4,O
Grade,O
3,O
4,O
Grade,O
1,O
4,O
Grade,O
3,O
4,O
Hematology,O
Lymphopenia,AdverseReaction
38,O
2,O
8,O
7,O
31,O
7,O
7,O
4,O
Chemistry,O
Hyperglycemia,AdverseReaction
56,O
6,O
6,O
5,O
50,O
9,O
5,O
2,O
High ALT,AdverseReaction
41,O
9,O
6,O
1,O
29,O
1,O
0,O
7,O
High AST,AdverseReaction
37,O
3,O
3,O
1,O
28,O
7,O
1,O
1,O
Hypernatremia,AdverseReaction
32,O
8,O
0,O
4,O
25,O
0,O
0,O
2,O
Hypokalemia,AdverseReaction
17,O
2,O
2,O
8,O
10,O
2,O
1,O
7,O
Cardiovascular,O
Adverse,O
Reactions,O
In,O
the,O
combined,O
data,O
for,O
studies,O
1,O
and,O
2,O
cardiac failure,AdverseReaction
occurred,O
more,O
commonly,O
in,O
patients,O
treated,O
with,O
ZYTIGA,O
compared,O
to,O
patients,O
on,O
the,O
placebo,O
arm,O
2,O
1,O
versus,O
0,O
7,O
Grade 3 3 4,Severity
cardiac failure,AdverseReaction
occurred,O
in,O
1,O
6,O
of,O
patients,O
taking,O
ZYTIGA,O
and,O
led,O
to,O
5,O
treatment,O
discontinuations,O
and,O
2,O
deaths,AdverseReaction
Grade 3 3 4,Severity
cardiac failure,AdverseReaction
occurred,O
in,O
0,O
2,O
of,O
patients,O
taking,O
placebo,Factor
There,O
were,O
no,O
treatment,O
discontinuations,O
and,O
one,O
death,AdverseReaction
due,O
to,O
cardiac failure,AdverseReaction
in,O
the,O
placebo,Factor
group,O
In,O
Study,O
1,O
and,O
2,O
the,O
majority,O
of,O
arrhythmias,AdverseReaction
were,O
grade 1,Severity
or,O
2,Severity
There,O
was,O
one,O
death,AdverseReaction
associated,O
with,O
arrhythmia,AdverseReaction
and,O
one,O
patient,O
with,O
sudden death,AdverseReaction
in,O
the,O
ZYTIGA,O
arms,O
and,O
no,Negation
deaths,AdverseReaction
in,O
the,O
placebo,Factor
arms,O
There,O
were,O
7,O
0,O
5,O
deaths,AdverseReaction
due,O
to,O
cardiorespiratory arrest,AdverseReaction
in,O
the,O
ZYTIGA,O
arms,O
and,O
3,O
0,O
3,O
deaths,AdverseReaction
in,O
the,O
placebo,Factor
arms,O
Myocardial ischemia,AdverseReaction
or,O
myocardial infarction,AdverseReaction
led,O
to,O
death,AdverseReaction
in,O
3,O
patients,O
in,O
the,O
placebo,Factor
arms,O
and,O
2,O
deaths,AdverseReaction
in,O
the,O
ZYTIGA,O
arms,O
6,O
2,O
Post,O
Marketing,O
Experience,O
The,O
following,O
additional,O
adverse,O
reactions,O
have,O
been,O
identified,O
during,O
post,O
approval,O
use,O
of,O
ZYTIGA,O
Because,O
these,O
reactions,O
are,O
reported,O
voluntarily,O
from,O
a,O
population,O
of,O
uncertain,O
size,O
it,O
is,O
not,O
always,O
possible,O
to,O
reliably,O
estimate,O
their,O
frequency,O
or,O
establish,O
a,O
causal,O
relationship,O
to,O
drug,O
exposure,O
Respiratory,O
Thoracic,O
and,O
Mediastinal,O
Disorders,O
non infectious pneumonitis,AdverseReaction
Musculoskeletal,O
and,O
Connective,O
Tissue,O
Disorders,O
myopathy,AdverseReaction
including,O
rhabdomyolysis,AdverseReaction
""
